PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Miyagishi, M; Fujii, R; Hatta, M; Yoshida, E; Araya, N; Nagafuchi, A; Ishihara, S; Nakajima, T; Fukamizu, A				Miyagishi, M; Fujii, R; Hatta, M; Yoshida, E; Araya, N; Nagafuchi, A; Ishihara, S; Nakajima, T; Fukamizu, A			Regulation of Lef-mediated transcription and p53-dependent pathway by associating beta-catenin with CBP/p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING-PROTEIN; NF-KAPPA-B; DEPENDENT KINASES; COLON-CARCINOMA; CELL-ADHESION; CBP; P300; COACTIVATOR; MODULATION; ACTIVATION	CBP and its homologue p300 play significant roles in cell differentiation, cell cycle, and anti-oncogenesis, We demonstrated that beta -catenin, recently known as a potent oncogene; and CBP/p300 are associated through its CH3 region, which is a primary target of adenoviral oncoprotein E1A and various nuclear proteins, such as p53, cyclin E, and AP-1, and both are colocalized in the nuclear :bodies. CBP/p300 potentiated Lef-mediated transactivation of beta -catenin, and E1A, a potent inhibitor of CBP/p300, repressed its transactivation. Furthermore, overexpression of stable beta -catenin mutant competitively suppressed the p53-dependent pathway. These may be a key mechanism of beta -catenin involved in oncogenic events underlying disruption of tumor suppressor function through CBP/p300.	Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Kyoto Univ, Fac Med, Dept Cell Biol, Kyoto 6068501, Japan	University of Tsukuba; Kyoto University	Fukamizu, A (corresponding author), Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan.		fukamizu, akiyoshi/J-5350-2012; Miyagishi, Makoto/L-8174-2016	fukamizu, akiyoshi/0000-0002-8786-6020; Miyagishi, Makoto/0000-0001-7654-3616				Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muraoka M, 1996, ONCOGENE, V12, P1565; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Scolnick DM, 1997, CANCER RES, V57, P3693; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871; Yoshida Y, 1998, HUM GENE THER, V9, P2503, DOI 10.1089/hum.1998.9.17-2503	36	99	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35170	35175		10.1074/jbc.C000258200	http://dx.doi.org/10.1074/jbc.C000258200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10906119	hybrid			2022-12-25	WOS:000165422800047
J	Wu, H; Rao, GN; Dai, BS; Singh, P				Wu, H; Rao, GN; Dai, BS; Singh, P			Autocrine gastrins in colon cancer cells up-regulate cytochrome c oxidase Vb and down-regulate efflux of cytochrome c and activation of caspase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; DIFFERENT TISSUES; TRANSGENIC MICE; PROTEIN-KINASE; GROWTH-FACTOR; CARCINOMA; APOPTOSIS; INDUCTION; SUBUNIT; RELEASE	Suppression of the gastrin gene in human colon cancer cells by stably expressing antisense (AS) gastrin RNA results in significant growth suppression of AS cells. To understand mechanisms mediating the growth effects of autocrine gastrins, differential expression of transcripts by AS and control (C) clones of a representative cell line (HCT-116) was analyzed to identify target genes of autocrine gastrins, Six differentially expressed transcripts were confirmed and sequenced. Of these, the RNA and protein levels of cytochrome c oxidase (COX) Vb were significantly higher in C versus AS cells. The expression of COX Vb by colon cancer cells was proportional to the expression of gastrin. Higher levels of COX Vb coprecipitated with cytochrome c in the mitochondria of C versus AS cells. Treatment of mitochondria with digitonin resulted in a a-fold higher release of cytochrome c from AS versus C mitochondria. As a corollary, the cytosolic levels of cytochrome c were significantly higher in AS versus C cells, which correlated with similar to2- and similar to3-fold higher activation of caspase-9 and -3, respectively, in AS versus C cells in response to camptothecin. Thus, autocrine gastrins may support growth/ survival of cells by up-regulating COX Vb, which may decrease the sensitivity of the cancer cells to apoptotic stimuli by increasing retention of cytochrome c in mitochondria.	Univ Texas, Med Branch, Dept Anat & Neurosci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Singh, P (corresponding author), Univ Texas, Med Branch, Dept Anat & Neurosci, 301 Univ Blvd,Rte 1043, Galveston, TX 77555 USA.	posingh@utmb.edu			NCI NIH HHS [CA60087, CA72992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN LA, 1995, J BIOL CHEM, V270, P110, DOI 10.1074/jbc.270.1.110; Bachman NJ, 1996, ARCH BIOCHEM BIOPHYS, V333, P152, DOI 10.1006/abbi.1996.0376; BALDWIN GS, 1992, CANCER RES, V52, P2261; Basu A, 1997, J BIOL CHEM, V272, P5899, DOI 10.1074/jbc.272.9.5899; Bini L, 1997, ELECTROPHORESIS, V18, P2832, DOI 10.1002/elps.1150181519; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CAPALDI RA, 1990, ARCH BIOCHEM BIOPHYS, V280, P252, DOI 10.1016/0003-9861(90)90327-U; Capaldi RA, 1995, METHOD ENZYMOL, V260, P117, DOI 10.1016/0076-6879(95)60134-1; Dai BS, 1997, ENDOCRINOLOGY, V138, P332, DOI 10.1210/en.138.1.332; FINLEY GG, 1993, CANCER RES, V53, P2919; GOSHORN SC, 1991, J BIOL CHEM, V266, P2134; GUO YS, 1990, IN VITRO CELL DEV B, V26, P871; Heerdt BG, 1998, CANCER RES, V58, P2869; HIGUCHI E, 1999, HOKKAIDO MED SCI, V74, P23123; Hollande F, 1997, GASTROENTEROLOGY, V113, P1576, DOI 10.1053/gast.1997.v113.pm9352860; HOOSEIN NM, 1988, CANCER RES, V48, P7179; Jarvis WD, 1996, J BIOL CHEM, V271, P8275, DOI 10.1074/jbc.271.14.8275; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JEMMERSON R, 1991, EUR J IMMUNOL, V21, P143, DOI 10.1002/eji.1830210122; JOHNSON LR, 1981, PHYSL GASTROINTESTIN, P169; Johnson N, 1997, LEUKEMIA RES, V21, P961, DOI 10.1016/S0145-2126(97)00077-5; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kato MV, 1999, LEUKEMIA LYMPHOMA, V33, P181, DOI 10.3109/10428199909093740; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOCHMAN ML, 1992, BIOCHEM BIOPH RES CO, V189, P1165, DOI 10.1016/0006-291X(92)92326-S; Koh TJ, 1999, J CLIN INVEST, V103, P1119, DOI 10.1172/JCI4910; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; NEMETH J, 1993, GUT, V34, P90, DOI 10.1136/gut.34.1.90; Nobumoto M, 1998, J BIOCHEM, V123, P128; Papadopoulou LC, 1996, BIOCHEM PHARMACOL, V52, P713, DOI 10.1016/0006-2952(96)00349-8; Patel S, 1997, MOL MED, V3, P674, DOI 10.1007/BF03401706; POLLACK C, 1998, NAT GENET, V20, P291; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; Ragno S, 1998, INFECT IMMUN, V66, P3952, DOI 10.1128/IAI.66.8.3952-3958.1998; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rothenberg ML, 1997, ANN ONCOL, V8, P837, DOI 10.1023/A:1008270717294; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; SHARP MGF, 1992, J PATHOL, V168, P163, DOI 10.1002/path.1711680203; Shirafuji N, 1997, BLOOD, V90, P4567, DOI 10.1182/blood.V90.11.4567.4567_4567_4577; SINGH P, 1994, AM J PHYSIOL, V267, pG235, DOI 10.1152/ajpgi.1994.267.2.G235; SINGH P, 1986, CANCER RES, V46, P1612; SINGH P, 1994, AM J PHYSIOL, V266, pG459, DOI 10.1152/ajpgi.1994.266.3.G459; SINGH P, 1987, CANCER RES, V47, P5000; Singh P, 2000, CURR OPIN GASTROEN, V16, P68, DOI 10.1097/00001574-200001000-00013; Singh P, 2000, GASTROENTEROLOGY, V119, P162, DOI 10.1053/gast.2000.8527; Singh P, 1996, CANCER RES, V56, P4111; SINGH P, 1995, J BIOL CHEM, V270, P8429, DOI 10.1074/jbc.270.15.8429; Singh P, 2000, AM J PHYSIOL-GASTR L, V278, pG390, DOI 10.1152/ajpgi.2000.278.3.G390; SINGH P, 1994, AM J PHYSIOL-GASTR L, V267, pG608, DOI 10.1152/ajpgi.1994.267.4.G608; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SMITH JP, 1988, GASTROENTEROLOGY, V95, P1541; Taanman JW, 1996, BBA-MOL BASIS DIS, V1315, P199, DOI 10.1016/0925-4439(95)00127-1; Vijayasarathy C, 1998, BBA-BIOMEMBRANES, V1371, P71, DOI 10.1016/S0005-2736(97)00278-2; WALSH JH, 1994, GUT PEPTIDES BIOCH P, P75; Wang FL, 1996, CANCER RES, V56, P3634; Wang TC, 1999, AM J PHYSIOL-GASTR L, V277, pG6, DOI 10.1152/ajpgi.1999.277.1.G6; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; Watanabe T, 1998, MOL CELL BIOL, V18, P442, DOI 10.1128/MCB.18.1.442; WATSON SA, 1988, BRIT J SURG, V75, P342, DOI 10.1002/bjs.1800750416; XU ZD, 1994, LIFE SCI, V54, P671, DOI 10.1016/0024-3205(94)00550-8; Yang WL, 1998, BIOCHEMISTRY-US, V37, P14175, DOI 10.1021/bi981402a; 1998, APOPTOSIS APPL REAGE	66	53	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32491	32498		10.1074/jbc.M002458200	http://dx.doi.org/10.1074/jbc.M002458200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10915781	hybrid			2022-12-25	WOS:000090003800017
J	Chen, X; Liu, Z; Wang, JQ; Fang, JW; Fan, HN; Wang, PG				Chen, X; Liu, Z; Wang, JQ; Fang, JW; Fan, HN; Wang, PG			Changing the donor cofactor bovine alpha 1,3-galactosyltransferase by fusion with UDP-galactose 4-epimerase - More efficient biocatalysis for synthesis of alpha-Gal epitopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOENZYMATIC SYNTHESIS; ENZYME; OLIGOSACCHARIDES; SEQUENCES; BINDING; TRANSPLANTATION; IDENTIFICATION; REGENERATION; ANTIBODIES; XENOGRAFTS	Two fusion enzymes consisting of uridine diphosphogalactose 4-epimerase (UDP-galactose 4-epimerase, EC 5.1.3.2) and alpha 1,3-galactosyltransferase (EC 2.4.1.151) with an N-terminal His(6) tag and an intervening three-glycine linker were constructed by in-frame fusion of the Escherichia coli galE gene either to the 3' terminus (fl) or to the 5' terminus (f2) of a truncated bovine alpha 1,3-galactosyltransferase gene, respectively. Both fusion proteins were expressed in cell lysate as active, soluble forms as well as in inclusion bodies as improperly folded proteins. Both f1 and f2 were determined to be homodimers, based on a single band observed at about 67 kDa in SDS-polyacrylamide gel electrophoresis and on a single peak with a molecular mass around 140 kDa determined by gel filtration chromatography for each of the enzymes. Without altering the acceptor specificity of the transferase, the fusion with the epimerase changed the donor requirement of alpha 1,3-galactosyltransferase from UDP-galactose to UDP-glucose and decreased the cost for the synthesis of biomedically important Ga1 alpha 1, 3Gal-terminated oligosaccharides by more than 40-fold. For enzymatic synthesis of Ga1 alpha 1,3Gal beta 1,4Glc from UDP-glucose and lactose, the genetically fused enzymes fl and f2 exhibited kinetic advantages with overall reaction rates that were 300 and 50%, respectively, higher than that of the system containing equal amounts of epimerase and galactosyltransferase. These results indicated that the active sites of the epimerase and the transferase in fusion enzymes were in proximity. The kinetic parameters suggested a random mechanism for the substrate binding of the alpha 1,3-galactosyltransferase. This work demonstrated a general approach that fusion of a glycosyltransferase with an epimerase can change the required but expensive sugar nucleotide to a less expensive one.	Wayne State Univ, Dept Chem, Detroit, MI 48202 USA	Wayne State University	Wang, PG (corresponding author), Wayne State Univ, Dept Chem, Detroit, MI 48202 USA.		Chen, Xi/H-1811-2018	Chen, Xi/0000-0002-3160-614X	NIAID NIH HHS [AI44040] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044040] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUGE C, 1986, CARBOHYD RES, V151, P147, DOI 10.1016/S0008-6215(00)90336-7; BAYNA EM, 1988, CELL, V53, P145, DOI 10.1016/0092-8674(88)90496-5; BEYER TA, 1981, ADV ENZYMOL, V52, P24; BLANKEN WM, 1985, J BIOL CHEM, V260, P2927; BULOW L, 1991, TRENDS BIOTECHNOL, V9, P226, DOI 10.1016/0167-7799(91)90075-S; BURKE JR, 1993, BIOCHEMISTRY-US, V32, P13220, DOI 10.1021/bi00211a034; Chen X, 1999, CURR OPIN CHEM BIOL, V3, P650, DOI 10.1016/S1367-5931(99)00022-8; Chen X, 2000, BIOTECHNOL PROGR, V16, P595, DOI 10.1021/bp000052s; Chen X, 1999, BIOTECHNOL LETT, V21, P1131, DOI 10.1023/A:1005678225031; Fang JW, 1998, J AM CHEM SOC, V120, P6635, DOI 10.1021/ja9808898; Fang JW, 1999, J ORG CHEM, V64, P4089, DOI 10.1021/jo990159y; GALILI U, 1993, BLOOD, V82, P2485, DOI 10.1182/blood.V82.8.2485.bloodjournal8282485; GALILI U, 1991, P NATL ACAD SCI USA, V88, P7401, DOI 10.1073/pnas.88.16.7401; GOOD AH, 1992, TRANSPL P, V24, P559; Janczuk A, 1999, CURR MED CHEM, V6, P155; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; Kapitonov D, 1999, GLYCOBIOLOGY, V9, P961, DOI 10.1093/glycob/9.10.961; KOIKE K, 1987, CARBOHYD RES, V163, P189, DOI 10.1016/0008-6215(87)80181-7; LJUNGCRANTZ P, 1989, BIOCHEMISTRY-US, V28, P8786, DOI 10.1021/bi00448a016; Lougheed B, 1999, J BIOL CHEM, V274, P37717, DOI 10.1074/jbc.274.53.37717; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MATSUZAKI Y, 1993, TETRAHEDRON LETT, V34, P1061, DOI 10.1016/S0040-4039(00)77492-2; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; Parker W, 1996, IMMUNOL TODAY, V17, P373, DOI 10.1016/0167-5699(96)10028-1; REDDY GV, 1994, CARBOHYD RES, V263, P67, DOI 10.1016/0008-6215(94)00153-7; SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; Simon PM, 1998, TRANSPLANTATION, V65, P346, DOI 10.1097/00007890-199802150-00009; TAMADA Y, 1994, BIOCONJUGATE CHEM, V5, P660, DOI 10.1021/bc00030a023; THIEM J, 1992, SYNTHESIS STUTTGART, V1, P141; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Wang JQ, 1999, J AM CHEM SOC, V121, P8174, DOI 10.1021/ja990219h; WILSON DB, 1964, J BIOL CHEM, V239, P2469; WONG CH, 1992, J ORG CHEM, V57, P4343, DOI 10.1021/jo00042a008; WONG CH, 1982, J ORG CHEM, V47, P5416, DOI 10.1021/jo00148a045; Zhang W, 1999, CURR ORG CHEM, V3, P241; Zhang YN, 1999, GLYCOBIOLOGY, V9, P815, DOI 10.1093/glycob/9.8.815	38	30	32	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31594	31600		10.1074/jbc.M004005200	http://dx.doi.org/10.1074/jbc.M004005200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913140	hybrid			2022-12-25	WOS:000089858900008
J	Gonzalez-Barroso, MD; Pecqueur, C; Gelly, C; Sanchis, D; Alves-Guerra, MC; Bouillaud, F; Ricquier, D; Cassard-Doulcier, AM				Gonzalez-Barroso, MD; Pecqueur, C; Gelly, C; Sanchis, D; Alves-Guerra, MC; Bouillaud, F; Ricquier, D; Cassard-Doulcier, AM			Transcriptional activation of the human ucp1 gene in a rodent cell line - Synergism of retinoids, isoproterenol, and thiazolidinedione is mediated by a multipartite response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCOUPLING PROTEIN GENE; BROWN ADIPOSE-TISSUE; CIS-ACTING ELEMENTS; MESSENGER-RNA; PPAR-GAMMA; ADIPOCYTE DIFFERENTIATION; 5'-FLANKING REGION; HORMONE RECEPTOR; X-RECEPTOR; EXPRESSION	Uncoupling protein 1 (UCP1) is uniquely expressed in brown adipocytes and generates heat production by uncoupling respiration from ATP synthesis. The activatory effects of norepinephrine and retinoic acid (RA) on rodent ucp1 gene transcription have been well characterized. These effects are mediated by a 211-base pair (bp) enhancer which is also sufficient to restrict expression to brown adipose tissue. The molecular mechanisms controlling the transcription of the human ucp1 gene are unknown. In order to study the transcriptional regulation of the human gene, we set up chloramphenicol acetyltransferase constructs containing the entire or deleted 5' regions upstream of the transcriptional start site of the gene. These constructs were transiently transfected in a mouse cell line. A 350-bp hormone response region showing a significant homology with the rat ucp1 enhancer and located between the BclI polymorphic site and an AatII site (bp -3820/-3470) was detected. This region was sufficient to mediate the stimulation by RA and by combined treatments (RA + isoproterenol (ISO), RA + thiazolidinedione (TZD), or RA + ISO + TZD). The highest stimulation, a 26-fold increase in basal activity, was obtained by RA + ISO + TZD treatment. In contrast to the rodent gene, under our conditions, the effect of ISO and/or TZD is dependent on RA stimulation. Analysis of 105 bp inside the 350-bp element by site-directed mutagenesis and gel retardation experiments demonstrated that a multipartite response element mediates the drug stimulation. This region binds RARs and RXRs nuclear factors, CREB/ATF factors, and also PPAR gamma despite the absence of a consensus peroxisome-proliferator response element. The activation of the human ucp1 gene transcription by certain hormones or drugs, and the identification of the cis-elements involved, will help to identify new compounds activating fat oxidation and energy expenditure in humans.	CNRS, CEREMOD, Ctr Rech Endocrinol Mol & Dev, F-92190 Meudon, France	Centre National de la Recherche Scientifique (CNRS)	Cassard-Doulcier, AM (corresponding author), CNRS, CEREMOD, Ctr Rech Endocrinol Mol & Dev, 9 Rue Jules Hetzel, F-92190 Meudon, France.		CASSARD, Anne-Marie/B-6095-2019; Alves-Guerra, Marie-Clotilde/P-4356-2017; Pecqueur, Claire/L-3073-2015; Bouillaud, Frédéric R/L-3238-2017; Sanchis, Daniel/B-5644-2009; Sanchis, Daniel/C-8077-2009	CASSARD, Anne-Marie/0000-0002-1813-5128; Alves-Guerra, Marie-Clotilde/0000-0002-7918-1216; Pecqueur, Claire/0000-0002-7612-1672; Bouillaud, Frédéric R/0000-0002-7518-9237; Sanchis, Daniel/0000-0003-0047-8533; GONZALEZ BARROSO, MARIA DEL MAR/0000-0002-0278-8298				ALVAREZ R, 1995, J BIOL CHEM, V270, P5666, DOI 10.1074/jbc.270.10.5666; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; CASSARD AM, 1990, J CELL BIOCHEM, V43, P255, DOI 10.1002/jcb.240430306; Cassard-Doulcier AM, 1998, BIOCHEM J, V333, P243, DOI 10.1042/bj3330243; CassardDoulcier AM, 1996, INT J OBESITY, V20, P278; CASSARDDOULCIER AM, 1993, MOL ENDOCRINOL, V7, P497, DOI 10.1210/me.7.4.497; CASSARDDOULCIER AM, 1994, J BIOL CHEM, V269, P24335; CASTEILLA L, 1989, BIOCHEM J, V257, P665, DOI 10.1042/bj2570665; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Digby JE, 1998, DIABETES, V47, P138, DOI 10.2337/diabetes.47.1.138; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Finn D, 1998, CELL TISSUE RES, V294, P461, DOI 10.1007/s004410051197; FoellmiAdams LA, 1996, BIOCHEM PHARMACOL, V52, P693, DOI 10.1016/0006-2952(96)00345-0; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; GARRUTI G, 1992, INT J OBESITY, V16, P383; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; HIMMSHAGEN J, 1985, ANNU REV NUTR, V5, P69, DOI 10.1146/annurev.nu.05.070185.000441; HIMMSHAGEN J, 1999, HDB OBESITY, P415; HUTTUNEN P, 1981, EUR J APPL PHYSIOL O, V46, P339, DOI 10.1007/BF00422121; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; Jansa P, 1996, NUCLEIC ACIDS RES, V24, P694, DOI 10.1093/nar/24.4.694; KLAUS S, 1994, J CELL SCI, V107, P313; Kliewer SA, 1998, CURR OPIN GENET DEV, V8, P576, DOI 10.1016/S0959-437X(98)80014-2; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; KRIEF S, 1993, J CLIN INVEST, V91, P344, DOI 10.1172/JCI116191; Kumar MV, 1999, J LIPID RES, V40, P824; Larose M, 1996, J BIOL CHEM, V271, P31533, DOI 10.1074/jbc.271.49.31533; LEAN MEJ, 1986, CLIN SCI, V71, P291, DOI 10.1042/cs0710291; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Nagy L, 1996, J BIOL CHEM, V271, P4355; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; OPPERT JM, 1994, INT J OBESITY, V18, P526; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rabelo R, 1996, ENDOCRINOLOGY, V137, P3488, DOI 10.1210/en.137.8.3488; Rabelo R, 1997, ENDOCRINOLOGY, V138, P5325, DOI 10.1210/en.138.12.5325; RAISHER BD, 1992, J BIOL CHEM, V267, P20264; REHNMARK S, 1992, AM J PHYSIOL, V262, pE58, DOI 10.1152/ajpendo.1992.262.1.E58; RICQUIER D, 1982, J CLIN ENDOCR METAB, V54, P803; RICQUIER D, 1984, FEBS LETT, V178, P240, DOI 10.1016/0014-5793(84)80608-0; RICQUIER D, 1986, J BIOL CHEM, V261, P13905; Sears IB, 1996, MOL CELL BIOL, V16, P3410; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Serra F, 1999, INT J OBESITY, V23, P650, DOI 10.1038/sj.ijo.0800897; Silva JE, 1997, EUR J ENDOCRINOL, V136, P251, DOI 10.1530/eje.0.1360251; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510	53	49	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31722	31732		10.1074/jbc.M001678200	http://dx.doi.org/10.1074/jbc.M001678200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10921912	hybrid			2022-12-25	WOS:000089858900027
J	Corvera, S; DiBonaventura, C; Shpetner, HS				Corvera, S; DiBonaventura, C; Shpetner, HS			Cell confluence-dependent remodeling of endothelial membranes mediated by cholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANNEXIN-II TETRAMER; TYROSINE PHOSPHORYLATION; E-CADHERIN; GROWTH-FACTOR; ADHERENS JUNCTIONS; CRYSTAL-STRUCTURE; BETA-CATENIN; ADHESION; INHIBITION; BINDING	The plasma membranes of endothelial cells reaching confluence undergo profound structural and functional modifications, including the formation of adherens junctions, crucial for the regulation of vascular permeability and angiogenesis. Adherens junction formation is accompanied by the tyrosine dephosphorylation of adherens junctions proteins, which has been correlated with the strength and stability of adherens junctions. Here we show that cholesterol is a critical determinant of plasma membrane remodeling in cultures of growing cow pulmonary aortic endothelial cells. Membrane cholesterol increased dramatically at an early stage in the formation of confluent cow pulmonary aortic endothelial cell monolayers, prior to formation of intercellular junctions. This increase was accompanied by the redistribution of caveolin from a high density to a low density membrane compartment, previously shown to require cholesterol, and increased binding of the annexin II-pll complex to membranes, consistent with other studies indicating cholesterol-dependent binding of annexin II to membranes. Furthermore, partial depletion of cholesterol from confluent cells with methyl-P-cyclodextrin both induced tyrosine phosphorylation of multiple membrane proteins, including adherens junctions proteins, and disrupted adherens junctions. Both effects were dramatically reduced by prior complexing of methyl-P-cyclodextrin with cholesterol. Our results reveal a novel physiological role for cholesterol regulating the formation of adherens junctions and other plasma membrane remodeling events as endothelial cells reach confluence.	Univ Massachusetts, Med Ctr, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Dept Cell Biol, Sch Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Shpetner, HS (corresponding author), Univ Massachusetts, Med Ctr, Sch Med, Program Mol Med, 373 Plantat St,Suite 107, Worcester, MA 01605 USA.							AOKI J, 1991, J CELL BIOL, V115, P1751, DOI 10.1083/jcb.115.6.1751; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; Burger A, 1996, J MOL BIOL, V257, P839, DOI 10.1006/jmbi.1996.0205; Cansell M, 1997, LIPIDS, V32, P39, DOI 10.1007/s11745-997-0006-3; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; Duh E, 1999, DIABETES, V48, P1899, DOI 10.2337/diabetes.48.10.1899; ELIAS PM, 1978, J CELL BIOL, V78, P577, DOI 10.1083/jcb.78.2.577; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; GIROLDI LA, 1993, CANCER METAST REV, V12, P29, DOI 10.1007/BF00689788; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; JOHNSTONE SA, 1992, J BIOL CHEM, V267, P25976; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; Kandikonda S, 1996, CELL ADHES COMMUN, V4, P13, DOI 10.3109/15419069609010760; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Konig J, 1998, J BIOL CHEM, V273, P19679, DOI 10.1074/jbc.273.31.19679; Korlach J, 1999, P NATL ACAD SCI USA, V96, P8461, DOI 10.1073/pnas.96.15.8461; LANGE Y, 1989, J BIOL CHEM, V264, P3786; Levenberg S, 1999, ONCOGENE, V18, P869, DOI 10.1038/sj.onc.1202396; LUECKE H, 1995, NATURE, V378, P512, DOI 10.1038/378512a0; LUSCINSKAS FW, 1991, J IMMUNOL, V146, P1617; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; Moss SE, 1997, TRENDS CELL BIOL, V7, P87, DOI 10.1016/S0962-8924(96)10049-0; Oh P, 1999, J BIOL CHEM, V274, P23144, DOI 10.1074/jbc.274.33.23144; Park H, 1998, J BIOL CHEM, V273, P32304, DOI 10.1074/jbc.273.48.32304; PASSANTI A, 1989, J CELL SCI, V92, P287; PEARSE BMF, 1982, P NATL ACAD SCI-BIOL, V79, P451, DOI 10.1073/pnas.79.2.451; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; POMERANTZ KB, 1995, ADV EXP MED BIOL, V369, P49; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHNITZER JE, 1993, TRENDS CARDIOVAS MED, V3, P124, DOI 10.1016/1050-1738(93)90012-U; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Smith LEH, 1999, NAT MED, V5, P1390, DOI 10.1038/70963; SPRINGER TA, 1990, NATURE, V346, P426; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; STADDON JM, 1995, J CELL BIOL, V130, P369, DOI 10.1083/jcb.130.2.369; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Takahashi K, 1996, EXP CELL RES, V226, P214, DOI 10.1006/excr.1996.0221; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983; VANE JR, 1990, NEW ENGL J MED, V323, P27; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WIDENMANN B, 1985, J CELL BIOL, V101, P12; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; ZAKS WJ, 1991, BIOCHEMISTRY-US, V30, P9607, DOI 10.1021/bi00104a007; ZETTER BR, 1993, SEMIN CANCER BIOL, V4, P219	64	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31414	31421		10.1074/jbc.M001708200	http://dx.doi.org/10.1074/jbc.M001708200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10903311	hybrid			2022-12-25	WOS:000089762700094
J	Funari, SS; Rapp, G; Perbandt, M; Dierks, K; Vallazza, M; Betzel, C; Erdmann, VA; Svergun, DI				Funari, SS; Rapp, G; Perbandt, M; Dierks, K; Vallazza, M; Betzel, C; Erdmann, VA; Svergun, DI			Structure of free Thermus flavus 5 S rRNA at 1.3 nm resolution from synchrotron x-ray solution scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-ANGLE-SCATTERING; 50S RIBOSOMAL SUBUNITS; PRELIMINARY DIFFRACTION; BACILLUS-STEAROTHERMOPHILUS; BIOLOGICAL MACROMOLECULES; CRYSTAL-STRUCTURE; DOMAIN-E; RNA; PROTEIN; CRYSTALLIZATION	The shape of free Thermus flavus 5 S rRNA in solution at 1.3 nm resolution is restored from synchrotron x-ray scattering data using an ab initio simulated annealing algorithm. The free 5 S rRNA is a bent elongated molecule displaying a compact central region and two projecting arms, similar to those of the tRNA The atomic models of the 5 S rRNA domains A-D-E and B-C in the form of elongated helices can be well accommodated within the shape, yielding a tentative model of the structure of the free 5 S rRNA in solution. Its comparison with the recent protein-RNA map in the ribosome (Svergun, D. I., and Nierhaus, K. H. (2000) J. Biol. Chem. 275, 14432-14439) indicates that the 5 S rRNA becomes essentially more compact upon complex formation with specific ribosomal proteins, A conceivable conformational change involves rotation of the B-C domain toward the A-D-E domain. The model of free 5 S rRNA displays no interactions between domains E and C, but such interactions are possible in the bound molecule.	Deutsch Elekrtonen Synchrotron, Univ Hamburg Hosp, Inst Physiol Chem, D-22603 Hamburg, Germany; Dierks & Partner Syst Technol, D-20257 Hamburg, Germany; Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany; DESY, European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany; Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia	Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); University of Hamburg; University Medical Center Hamburg-Eppendorf; Free University of Berlin; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS	Betzel, C (corresponding author), Deutsch Elekrtonen Synchrotron, Univ Hamburg Hosp, Inst Physiol Chem, Bldg 22a,Notkestra 85, D-22603 Hamburg, Germany.	betzel@unisgi1.desy.de	Betzel, Christian/G-8105-2018; Perbandt, Markus/K-7603-2018	Betzel, Christian/0000-0002-3879-5019; Svergun, Dmitri/0000-0003-0830-5696				Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BETZEL C, 1994, FEBS LETT, V351, P159, DOI 10.1016/0014-5793(94)00834-5; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; Correll CC, 1997, CELL, V91, P705, DOI 10.1016/S0092-8674(00)80457-2; ERDMANN VA, 1971, P NATL ACAD SCI USA, V68, P2932, DOI 10.1073/pnas.68.12.2932; Feigin L.A., 1987, STRUCTURE ANAL SMALL; GABRIEL A, 1982, NUCL INSTRUM METHODS, V201, P223, DOI 10.1016/0167-5087(82)90031-X; HANCOCK J, 1982, NUCLEIC ACIDS RES, V10, P1257, DOI 10.1093/nar/10.4.1257; HARTMANN RK, 1988, NUCLEIC ACIDS RES, V16, P3511, DOI 10.1093/nar/16.8.3511; HORNE JR, 1972, MOL GEN GENET, V119, P337, DOI 10.1007/BF00272091; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Konig S, 1998, BIOCHEMISTRY-US, V37, P5329, DOI 10.1021/bi972125v; Kozin MB, 1997, J APPL CRYSTALLOGR, V30, P811, DOI 10.1107/S0021889897001830; LORENZ S, 1991, J MOL BIOL, V219, P399, DOI 10.1016/0022-2836(91)90181-5; Lorenz S, 2000, ACTA CRYSTALLOGR D, V56, P498, DOI 10.1107/S0907444900001736; LORENZ S, 1993, ACTA CRYSTALLOGR D, V49, P418, DOI 10.1107/S0907444993001520; Lu M, 2000, P NATL ACAD SCI USA, V97, P2023, DOI 10.1073/pnas.97.5.2023; MOORE PB, 1980, J APPL CRYSTALLOGR, V13, P168, DOI 10.1107/S002188988001179X; MULLER JJ, 1986, EUR BIOPHYS J BIOPHY, V13, P301, DOI 10.1007/BF00254212; NOLTE A, 1995, FEBS LETT, V374, P292, DOI 10.1016/0014-5793(95)01136-3; NOMURA M, 1970, NATURE, V228, P744, DOI 10.1038/228744a0; OSTERBERG R, 1976, EUR J BIOCHEM, V68, P481, DOI 10.1111/j.1432-1033.1976.tb10835.x; Perbandt M, 1998, FEBS LETT, V429, P211, DOI 10.1016/S0014-5793(98)00436-0; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; SCHULZE T, 1996, THESIS U HAMBURG HAM; Serdyuk I N, 1979, Methods Enzymol, V59, P750; Shannon C., 1964, MATH THEORY COMMUNIC; SPECHT T, 1990, NUCLEIC ACIDS RES, V18, P2215, DOI 10.1093/nar/18.suppl.2215; Stoldt M, 1999, EMBO J, V18, P6508, DOI 10.1093/emboj/18.22.6508; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 2000, J BIOL CHEM, V275, P4210, DOI 10.1074/jbc.275.6.4210; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; Svergun DI, 2000, J BIOL CHEM, V275, P14432, DOI 10.1074/jbc.275.19.14432; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 1996, ACTA CRYSTALLOGR A, V52, P419, DOI 10.1107/S0108767396000177; SVERGUN DI, 1993, J APPL CRYSTALLOGR, V26, P258, DOI 10.1107/S0021889892011828; WESTHOF E, 1989, J MOL BIOL, V207, P417, DOI 10.1016/0022-2836(89)90264-7	42	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31283	31288		10.1074/jbc.M004974200	http://dx.doi.org/10.1074/jbc.M004974200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896668	hybrid			2022-12-25	WOS:000089762700076
J	Mao, CG; Xu, RJ; Bielawska, A; Szulc, ZM; Obeid, LM				Mao, CG; Xu, RJ; Bielawska, A; Szulc, ZM; Obeid, LM			Cloning and characterization of a Saccharomyces cerevisiae alkaline ceramidase with specificity for dihydroceramide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-RESPONSE; SPHINGOLIPIDS; IDENTIFICATION; PROLIFERATION; METABOLISM; GROWTH	In a previous study, we reported that the Saccharomyces cerevisiae gene YPC1 encodes an alkaline ceramidase with a dual activity, catalyzing both hydrolysis and synthesis of yeast ceramide (Mao, C., Xu, R., Bielawska, A., and Obeid, L., M., (2000) J. Biol. Chem. 275, 6876-6884). In this study, we have identified a YPC1 homologue in S. cerevisiae that also encodes an alkaline ceramidase, We show that these two ceramidases have different substrate specificity, such that YPC1p preferentially hydrolyzes phytoceramide, whereas the new ceramidase YDC1p hydrolyzes dihydroceramide preferentially and phytoceramide only slightly. Neither enzyme hydrolyzes unsaturated mammalian-type ceramide. In contrast to YPC1p, YDC1p had only minor in vitro reverse activity of catalyzing dihydroceramide formation from a free fatty acid and dihydrosphingosine and no activity with phytosphingosine, Overexpression of YDC1p had no reverse activity in non-stressed yeast cells, but like YPC1p suppressed the inhibition of growth by fumonisin B1 albeit more modestly. Deletion of YDC1 and YPC1 or both did not apparently affect growth, suggesting neither gene is essential, However, the Delta ydc1 deletion mutant but not the Delta ypc1 deletion mutant was sensitive to heat stress, indicating a role for dihydroceramide but not phytoceramide in heat stress responses, and suggesting that the two enzymes have distinct physiological functions.	Ralph H Johnson Vet Affairs Hosp, Div Gen Internal Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem, Charleston, SC 29425 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina; Medical University of South Carolina	Obeid, LM (corresponding author), Ralph H Johnson Vet Affairs Hosp, Div Gen Internal Med, 114 Doughty St,Rm 604 STB,POB 250779, Charleston, SC 29425 USA.	obeidl@musc.edu	xu, rui/GRX-5734-2022	obeid, lina/0000-0002-0734-0847	NIA NIH HHS [AG12467, AG16583] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG016583, R29AG012467, R55AG012467] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bielawska A, 2000, METHOD ENZYMOL, V311, P499; Bielawska A, 2000, METHOD ENZYMOL, V311, P518; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; El Bawab S, 1999, J BIOL CHEM, V274, P27948, DOI 10.1074/jbc.274.39.27948; Grilley MM, 1998, J BIOL CHEM, V273, P11062, DOI 10.1074/jbc.273.18.11062; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hannun YA, 1997, ADV EXP MED BIOL, V400, P305; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 1997, ADV EXP MED BIOL, V407, P145; Hannun YA, 1997, BIOCHEM SOC T, V25, P1171, DOI 10.1042/bst0251171; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Luberto C, 1999, LIPIDS, V34, pS5, DOI 10.1007/BF02562221; Lucci A, 1999, INT J ONCOL, V15, P541; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; Mao CG, 2000, J BIOL CHEM, V275, P6876, DOI 10.1074/jbc.275.10.6876; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; Ohnishi Y, 1999, CLIN DIAGN LAB IMMUN, V6, P101, DOI 10.1128/CDLI.6.1.101-104.1999; Okino N, 1999, J BIOL CHEM, V274, P36616, DOI 10.1074/jbc.274.51.36616; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462; Wells GB, 1998, J BIOL CHEM, V273, P7235, DOI 10.1074/jbc.273.13.7235	28	114	131	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31369	31378		10.1074/jbc.M003683200	http://dx.doi.org/10.1074/jbc.M003683200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10900202	hybrid			2022-12-25	WOS:000089762700088
J	Meijer, HA; Dictus, WJAG; Keuning, ED; Thomas, AAM				Meijer, HA; Dictus, WJAG; Keuning, ED; Thomas, AAM			Translational control of the Xenopus laevis Connexin-41 5 '-untranslated region by three upstream open reading frames	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA SECONDARY STRUCTURE; MESSENGER-RNA; GAP-JUNCTIONS; 3'-UNTRANSLATED REGION; EUKARYOTIC RIBOSOMES; MOLECULAR-CLONING; GENE; EXPRESSION; TERMINATION; INITIATION	The Xenopus laevis Connexin-41 (Cx41) mRNA contains three upstream open reading frames (uORFs) in the 5'-untranslated region (UTR). We analyzed the translation efficiency of constructs containing the Cx41 5'-UTR linked to the green fluorescent protein reporter after injection of transcripts into one-cell stage Xenopus embryos. The translational efficiency of the wild-type Cx41 5'-UTR was only 2% compared with that of the beta-globin 5'-UTR. Mutation of each of the three uAUGs into AAG codons enhanced translation 82-, 9-, and 4-fold compared with the wild-type Cx41 5'-UTR. Based on these increased translation efficiencies, the percentages of ribosomes that recognized the uAUGs were calculated. Only 0.03% of the ribosomes that entered at the cap structure scanned the entire 5'-UTR and translated the main ORF. The results indicate that all uAUGs are recognized by the majority of the scanning ribosomes and that the three uAUGs strongly modulate translation efficiency in Xenopus laevis embryos. Based on these data, a model of ribosomal flow along the mRNA is postulated. We conclude that the three uORFs may play an important role in the regulation of Cx41 expression.	Univ Utrecht, Dept Dev Biol, NL-3584 CH Utrecht, Netherlands	Utrecht University	Thomas, AAM (corresponding author), Univ Utrecht, Dept Dev Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	A.A.M.Thomas@bio.uu.nl						ABASTADO JP, 1991, NEW BIOL, V3, P511; Beardslee MA, 1998, CIRC RES, V83, P629, DOI 10.1161/01.RES.83.6.629; Belluardo N, 1999, J NEUROSCI RES, V57, P740, DOI 10.1002/(SICI)1097-4547(19990901)57:5<740::AID-JNR16>3.0.CO;2-Z; BERNSTEIN J, 1995, J BIOL CHEM, V270, P10559, DOI 10.1074/jbc.270.18.10559; BROWN CM, 1993, NUCLEIC ACIDS RES, V21, P3119, DOI 10.1093/nar/21.13.3119; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Cao JH, 1996, MOL CELL BIOL, V16, P7109; Cao JH, 1998, RNA, V4, P181; GIMLICH RL, 1988, J CELL BIOL, V107, P1065, DOI 10.1083/jcb.107.3.1065; GIMLICH RL, 1990, J CELL BIOL, V110, P597, DOI 10.1083/jcb.110.3.597; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GREEN CR, 1998, PR MED BIOL, V11, P103; HENNEMANN H, 1992, EUR J CELL BIOL, V58, P81; HINNEBUSCH AG, 1988, P NATL ACAD SCI USA, V85, P7279, DOI 10.1073/pnas.85.19.7279; HOUTZAGER E, 1998, THESIS UTRECHT U UTR, P67; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Kumar NM, 1999, NOVART FDN SYMP, V219, P6; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Neve RL, 1999, MOL BRAIN RES, V65, P52, DOI 10.1016/S0169-328X(98)00337-4; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; O'Brien J, 1998, J NEUROSCI, V18, P7625; Ruan HJ, 1996, J BIOL CHEM, V271, P29576, DOI 10.1074/jbc.271.47.29576; Saez JC, 1998, BRAZ J MED BIOL RES, V31, P593, DOI 10.1590/S0100-879X1998000500001; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEPER GC, 1992, J BIOL CHEM, V267, P7269; Schiavi A, 1999, FEBS LETT, V464, P118, DOI 10.1016/S0014-5793(99)01699-3; Sohl G, 1996, EUR J CELL BIOL, V69, P267; Sosinsky G, 2000, CURR TOP MEMBR, V49, P1; SULLIVAN R, 1993, GENE, V130, P191, DOI 10.1016/0378-1119(93)90419-4; van der Heyden MAG, 1998, J CELL SCI, V111, P1741; van Oers MM, 1999, J GEN VIROL, V80, P2253, DOI 10.1099/0022-1317-80-8-2253; Wang LJ, 1998, PLANT CELL, V10, P1733, DOI 10.1105/tpc.10.10.1733; WU M, 1991, METHOD CELL BIOL, V36, P3; YOSHIZAKI G, 1995, MOL REPROD DEV, V42, P7, DOI 10.1002/mrd.1080420103; Zuker M, 1994, Methods Mol Biol, V25, P267	41	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30787	30793		10.1074/jbc.M005531200	http://dx.doi.org/10.1074/jbc.M005531200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896676	hybrid			2022-12-25	WOS:000089762700009
J	Morrow, G; Inaguma, Y; Kato, K; Tanguay, RM				Morrow, G; Inaguma, Y; Kato, K; Tanguay, RM			The small heat shock protein Hsp22 of Drosophila melanogaster is a mitochondrial protein displaying oligomeric organization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; OXIDATIVE STRESS; ALPHA-CRYSTALLIN; PROTECTIVE ACTIVITY; NEUROSPORA-CRASSA; GENE-CLUSTER; RODENT CELLS; EXPRESSION; LOCALIZATION; PHOSPHORYLATION	Drosophila melanogaster has four main small heat shock proteins (Hsps), D. melanogaster Hsp22 (DmHsp22), Hsp23 (DmHsp23), Hsp26 (DmHsp26), and Hsp27 (DmHsp27). These proteins, although they have high sequence homology, show distinct developmental expression patterns. The function(s) of each small heat shock protein is unknown. DmHsp22 is shown to localize in mitochondria both in D. melanogaster 52 cells and after heterologous expression in mammalian cells. Fractionation of mitochondria indicates that DmHsp22 resides in the mitochondrial matrix, where it is found in oligomeric complexes, as shown by sedimentation and gel filtration analysis and by cross-linking experiments. Deletion analysis using a DmHsp22-EGFP construct reveals that residues 1-17 and an unknown number of residues between 17-28 are necessary for import. Site-directed mutagenesis within a putative mitochondrial motif (WRMAEE) at positions 8-13 shows that the first four residues are necessary for mitochondrial localization. Immunoprecipitation results indicate that there is no interaction between DmHsp22 and the other small heat shock proteins. The mitochondrial localization of this small Hsp22 of Drosophila and its high level of expression in aging suggests a role for this small heat shock protein in protection against oxidative stress.	Univ Laval, Dept Med, Lab Genet Cellulaire & Dev, Ste Foy, PQ G1K 7P4, Canada; Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, Kasugai, Aichi 4800392, Japan	Laval University	Tanguay, RM (corresponding author), Univ Laval, Dept Med, Lab Genet Cellulaire & Dev, Pavillon Marchand, Ste Foy, PQ G1K 7P4, Canada.	Robert.Tanguay@rsvs.ulaval.ca						Arrigo A P, 1991, Results Probl Cell Differ, V17, P106; ARRIGO AP, 1988, EXP CELL RES, V175, P169, DOI 10.1016/0014-4827(88)90264-9; ARRIGO AP, 1981, MOL GEN GENET, V184, P73, DOI 10.1007/BF00271198; ARRIGO AP, 1987, DEV BIOL, V122, P39, DOI 10.1016/0012-1606(87)90330-7; Arrigo AP, 1998, BIOL CHEM, V379, P19; AYME A, 1985, EMBO J, V4, P2949, DOI 10.1002/j.1460-2075.1985.tb04028.x; Banzet N, 1998, PLANT J, V13, P519, DOI 10.1046/j.1365-313X.1998.00056.x; BEAULIEU JF, 1989, J CELL SCI, V92, P29; BERGER EM, 1983, EXP CELL RES, V147, P437, DOI 10.1016/0014-4827(83)90225-2; CARBAJAL EM, 1993, EXP CELL RES, V207, P300, DOI 10.1006/excr.1993.1197; Debel K, 1997, PLANTA, V201, P326, DOI 10.1007/s004250050074; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DUBAND JL, 1986, CAN J GENET CYTOL, V28, P1088, DOI 10.1139/g86-152; DUBROVSKY EB, 1994, J MOL BIOL, V241, P353, DOI 10.1006/jmbi.1994.1512; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; EHRNSPERGER M, 1997, MOL CHAPERONES LIFE, P533; ENRIQUEZ J, 1996, METHOD ENZYMOL, P183; FAURE R, 1995, J CELL BIOCHEM, V59, P389, DOI 10.1002/jcb.240590310; Felts SJ, 2000, J BIOL CHEM, V275, P3305, DOI 10.1074/jbc.275.5.3305; Gershon D, 1999, EXP GERONTOL, V34, P613, DOI 10.1016/S0531-5565(99)00010-8; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Joanisse DR, 1998, BIOCHEM BIOPH RES CO, V244, P102, DOI 10.1006/bbrc.1998.8214; King V, 1999, DEV BIOL, V207, P107, DOI 10.1006/dbio.1998.9147; KLEMENZ R, 1986, MOL CELL BIOL, V6, P2011, DOI 10.1128/MCB.6.6.2011; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; LaFayette PR, 1996, PLANT MOL BIOL, V30, P159, DOI 10.1007/BF00017810; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; Laplante AF, 1998, J HISTOCHEM CYTOCHEM, V46, P1291, DOI 10.1177/002215549804601109; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; LENNE C, 1995, BIOCHEM J, V311, P805, DOI 10.1042/bj3110805; Liu JA, 1999, PLANT CELL PHYSIOL, V40, P1297, DOI 10.1093/oxfordjournals.pcp.a029518; Marin R, 1996, CHROMOSOMA, V105, P142, DOI 10.1007/s004120050169; MARIN R, 1993, DEV GENET, V14, P69, DOI 10.1002/dvg.1020140109; MASON PJ, 1984, MOL GEN GENET, V194, P73, DOI 10.1007/BF00383500; MCEWEN CR, 1967, ANAL BIOCHEM, V20, P114, DOI 10.1016/0003-2697(67)90271-0; MCMULLIN TW, 1987, MOL CELL BIOL, V7, P4414, DOI 10.1128/MCB.7.12.4414; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Michaud S, 1997, J CELL SCI, V110, P1989; Michaud S, 1997, CELL MOL LIFE SCI, V53, P104, DOI 10.1007/PL00000572; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; PAULI D, 1990, J CELL BIOL, V111, P817, DOI 10.1083/jcb.111.3.817; PINELLI E, 1990, EUR J BIOCHEM, V194, P685, DOI 10.1111/j.1432-1033.1990.tb15669.x; Plesofsky N, 1999, BIOL CHEM, V380, P1231, DOI 10.1515/BC.1999.156; PLESOFSKYVIG N, 1990, J BIOL CHEM, V265, P15432; Preville X, 1998, J CELL BIOCHEM, V69, P436, DOI 10.1002/(SICI)1097-4644(19980615)69:4<436::AID-JCB5>3.0.CO;2-O; PUGSLEY AP, 1989, PROTEIN TARGETING, P139; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROLLET E, 1992, BIOCHEM BIOPH RES CO, V185, P116, DOI 10.1016/S0006-291X(05)80963-5; SCHNAITMAN C, 1967, J CELL BIOL, V32, P719, DOI 10.1083/jcb.32.3.719; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SIROTKIN K, 1982, DEV BIOL, V89, P196, DOI 10.1016/0012-1606(82)90307-4; SOUTHGATE R, 1983, J MOL BIOL, V165, P35, DOI 10.1016/S0022-2836(83)80241-1; THOMAS JO, 1975, P NATL ACAD SCI USA, V72, P2626, DOI 10.1073/pnas.72.7.2626; WHEELER JC, 1995, P NATL ACAD SCI USA, V92, P10408, DOI 10.1073/pnas.92.22.10408	63	65	66	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31204	31210		10.1074/jbc.M002960200	http://dx.doi.org/10.1074/jbc.M002960200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896659	hybrid			2022-12-25	WOS:000089762700065
J	Scott, S; Abul-Hamd, AT; Cooper, TG				Scott, S; Abul-Hamd, AT; Cooper, TG			Roles of the Dal82p domains in allophanate/oxalurate-dependent gene expression in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPSTREAM INDUCTION SEQUENCE; TRANSCRIPTION; PATHWAY; PROTEIN; YEAST; OPERATION; ELEMENTS; URE2P; SAGA; SPT	Allophanate/oxalurate-induced gene expression in Saccharomyces cerevisiae requires at least five transcription factors, four of which act positively (Gln3p, Gat1p, Dal81p, and Dal82p) and one negatively (Dal80p). Gln3p binds to and Gat1p is proposed to bind to single GATA sequences; Dal80p binds to pairs of specifically oriented and spaced GATA sequences, and Dal82p binds to a pathway-specific element, UISALL. Dal82p consists of at least three domains as follows: (i) UIS, DNA-binding, (ii) transcriptional activation, and (iii) coil(DAL82). Here we show that the coiled-coil(DAL82) domain possesses two demonstrable functions. (i) It prevents Dal82p-mediated transcription when inducer is absent. (ii) It is a major, although not exclusive, domain through which the inducer signal is received. Supporting the latter conclusion, a 38-amino acid fragment, containing little more than the coiled-coil(DAL82) domain, supports oxalurate-inducible, Dal81p-dependent, reporter gene transcription. Dal81p is required for inducer responsiveness of LexAp-Dal82p and LexAp coiled-coil(DAL82)-mediated transcription but isn't needed for inducer-dependent activation mediated by a Dal82p containing deletions in both the coiled-coil(DAL82), UISALL-binding domains. There may be an interaction between Dal81p and the coiled-coil(DAL82) domain since (i) Dal81p is required for transcription mediated by LexA-coiled-coil(DAL82)p and (ii) a Dal81p-Dal82p complex is detected by two-hybrid assay.	Univ Tennessee, Ctr Hlth Sci, Dept Microbiol & Immunol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Cooper, TG (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Microbiol & Immunol, Memphis, TN 38163 USA.			Cooper, Terrance G./0000-0002-7651-9963	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35642, R01 GM035642] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; BRICMONT PA, 1991, MOL CELL BIOL, V11, P1161, DOI 10.1128/MCB.11.2.1161; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Cooper TG, 1996, MYCOTA, V3, P139; Cox KH, 2000, J BIOL CHEM, V275, P17611, DOI 10.1074/jbc.M001648200; Cunningham TS, 2000, J BIOL CHEM, V275, P14408, DOI 10.1074/jbc.275.19.14408; DAUGHERTY JR, 1993, J BACTERIOL, V175, P64, DOI 10.1128/JB.175.1.64-73.1993; DORRINGTON RA, 1993, NUCLEIC ACIDS RES, V21, P3777, DOI 10.1093/nar/21.16.3777; Edskes HK, 2000, P NATL ACAD SCI USA, V97, P6625, DOI 10.1073/pnas.120168697; Edskes HK, 1999, GENETICS, V153, P585; Edskes HK, 1999, P NATL ACAD SCI USA, V96, P1498, DOI 10.1073/pnas.96.4.1498; GOLEMIS EA, 1996, CURRENT PROTOCOLS MO; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Miller J.H., 1972, EXPT MOL GENETICS; MINEHART PL, 1991, MOL CELL BIOL, V11, P6216, DOI 10.1128/MCB.11.12.6216; OLIVE MG, 1991, J BACTERIOL, V173, P255, DOI 10.1128/jb.173.1.255-261.1991; Park HD, 1999, J BACTERIOL, V181, P7052, DOI 10.1128/JB.181.22.7052-7064.1999; Rai R, 1999, J BIOL CHEM, V274, P28026, DOI 10.1074/jbc.274.39.28026; Roberts SM, 1997, GENETICS, V147, P451; Scott S, 2000, J BIOL CHEM, V275, P7198, DOI 10.1074/jbc.275.10.7198; SVETLOV V, 1997, THESIS U TENNESSEE M; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; VANVUUREN HJJ, 1991, J BACTERIOL, V173, P7186, DOI 10.1128/jb.173.22.7186-7195.1991; Winston F, 1998, COLD SPRING HARB SYM, V63, P553, DOI 10.1101/sqb.1998.63.553; YOO HS, 1989, MOL CELL BIOL, V9, P3231, DOI 10.1128/MCB.9.8.3231	28	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30886	30893		10.1074/jbc.M005624200	http://dx.doi.org/10.1074/jbc.M005624200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906145	Green Accepted, hybrid			2022-12-25	WOS:000089762700024
J	Trejo, J; Altschuler, Y; Fu, HW; Mostov, KE; Coughlin, SR				Trejo, J; Altschuler, Y; Fu, HW; Mostov, KE; Coughlin, SR			Protease-activated receptor-1 down-regulation - A mutant HeLa cell line suggests novel requirements for PAR1 phosphorylation and recruitment to clathrin-coated pits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE CASCADE; THROMBIN-RECEPTOR; COUPLED RECEPTOR; STRUCTURAL REQUIREMENTS; VESICLE FORMATION; BETA-ARRESTIN; SUBSTANCE-P; INTERNALIZATION; DYNAMIN; RESENSITIZATION	Protease-activated receptor-1 (PAR1), a G protein-coupled receptor (GPCR) for thrombin, is irreversibly activated by a proteolytic mechanism, then internalized and degraded in lysosomes. The latter is critical for temporal fidelity of thrombin signaling. Toward understanding PAR1 down-regulation, we first investigated the pathway of PAR1 internalization. Activated PAR1 was rapidly recruited to clathrin-coated pits, where it colocalized with transferrin receptor (TfnR). Dominant-negative dynamin and clathrin hub mutants both blocked PAR1 internalization, Blockade of PARI internalization with dynamin K44A also inhibited activation-dependent PAR1 degradation. Thus activated PAR1 internalizes via clathrin-coated pits together with receptors that recycle and is then sorted away from such receptors and delivered to lysosomes. In the course of these studies we identified a mutant HeLa cell line, designated JT1, that was defective in PAR1 internalization. PAR1 signaled robustly in JT1 cells but was not phosphorylated or recruited to clathrin-coated pits after activation. Internalization of TfnR was intact in JT1 cells and internalization of beta(2)-adrenergic receptor, a GPCR that internalizes and recycles, was present but perhaps reduced. Taken together, these studies suggest that PAR1 is internalized in a dynamin- and clathrin-dependent manner like TfnR and beta(2)-adrenergic receptor but requires a distinct gene product for recruitment into this pathway.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Coughlin, SR (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.			Fu, Hua-Wen/0000-0002-6346-2785; mostov, keith/0000-0002-8123-6247; TREJO, JOANN/0000-0003-4405-6228	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44907] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACTON SL, 1990, J CELL BIOL, V111, P1419, DOI 10.1083/jcb.111.4.1419; Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; CHEN J, 1994, J BIOL CHEM, V269, P16041; CHOI KY, 1994, CELL, V78, P499; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Glantz SA., 2012, PRIMER BIOSTATISTICS, V7; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; HEIN L, 1994, J BIOL CHEM, V269, P27719; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; ISHII K, 1994, J BIOL CHEM, V269, P1125; ISHII K, 1993, J BIOL CHEM, V268, P9780; Krueger KM, 1997, J BIOL CHEM, V272, P5; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lazari RDM, 1998, J BIOL CHEM, V273, P18316, DOI 10.1074/jbc.273.29.18316; LIU LW, 1991, J BIOL CHEM, V266, P16977; Liu SH, 1998, J CELL BIOL, V140, P1023, DOI 10.1083/jcb.140.5.1023; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P77622; MATHEWS II, 1994, BIOCHEMISTRTY, V33, P326; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PRINTEN JA, 1994, GENETICS, V138, P609; SANAN DA, 1991, J HISTOCHEM CYTOCHEM, V39, P1017, DOI 10.1177/39.8.1906908; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Shapiro MJ, 1998, J BIOL CHEM, V273, P29009, DOI 10.1074/jbc.273.44.29009; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	47	65	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31255	31265		10.1074/jbc.M003770200	http://dx.doi.org/10.1074/jbc.M003770200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10893235	hybrid			2022-12-25	WOS:000089762700072
J	Verrecchia, F; Pessah, M; Atfi, A; Mauviel, A				Verrecchia, F; Pessah, M; Atfi, A; Mauviel, A			Tumor necrosis factor-alpha inhibits transforming growth factor-beta/Smad signaling in human dermal fibroblasts via AP-1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE COL7A1 PROMOTER; FACTOR-KAPPA-B; TGF-BETA; TRANSCRIPTIONAL ACTIVATION; BINDING SEQUENCE; COACTIVATOR P300; DNA-BINDING; JUN FAMILY; C-JUN; SMAD3	Understanding the molecular mechanisms underlying the antagonistic activities of tumor necrosis factor-alpha (TNF-alpha) against transforming growth factor-beta (TGF-beta) is of utmost importance given the physiopathological implications of these cytokines. In this report, we demonstrate that TNF-alpha prevents TGF-beta-induced Smad-specific gene transactivation without inducing detectable levels of inhibitory Smad7 in human dermal fibroblasts. On the other hand, c-Jun and JunB, both induced by TNF-alpha, block Smad3-mediated transcription. Expression of antisense c-Jun mRNA prevents TNF-alpha inhibition of TGF-beta/Smad signaling whereas that of dominant-negative I kappa-B kinase-alpha or antisense Smad7 does not. We provide evidence for off-DNA interactions between Smad3 and both c-Jun and JunB accompanied with reduced Smad3-DNA interactions. Finally, we show that overexpression of the transcriptional co-activator p300 prevents TNF-alpha/AP-1 inhibition of TGF-beta/Smad signaling. These data suggest that TNF-alpha interferes with Smad signaling through the induction of AP-1 components, the latter forming off-DNA complexes with Smad3 and preventing its binding to specific cis element(s). In addition, Jun members compete with Smad3 for the common transcription co-activator p300. These two mechanisms are likely to act in concert to decrease Smad-specific transcription.	Hop St Louis, INSERM, U532, F-75010 Paris, France; Hop St Antoine, INSERM, U482, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Mauviel, A (corresponding author), Hop St Louis, Skin Res Inst, INSERM, U532, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.		MAUVIEL, Alain/F-6251-2013; Verrecchia, Franck/G-5535-2018	Verrecchia, Franck/0000-0003-4920-2554; Mauviel, Alain/0000-0002-0438-2793				Alevizopoulos A, 1996, J BIOL CHEM, V271, P29672, DOI 10.1074/jbc.271.47.29672; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141; Bitzer M, 2000, GENE DEV, V14, P187; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DeLuca C, 1999, CYTOKINE GROWTH F R, V10, P235, DOI 10.1016/S1359-6101(99)00015-5; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goldring MB, 1999, CONNECT TISSUE RES, V40, P1, DOI 10.3109/03008209909005273; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; Kon A, 1999, ONCOGENE, V18, P1837, DOI 10.1038/sj.onc.1202495; Kouba DJ, 1999, J IMMUNOL, V162, P4226; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Letterio JJ, 1997, CLIN IMMUNOL IMMUNOP, V84, P244, DOI 10.1006/clin.1997.4409; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Maggirwar SB, 2000, J NEUROCHEM, V74, P527, DOI 10.1046/j.1471-4159.2000.740527.x; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; MAUVIEL A, 1993, WOUNDS, V5, P137; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; Nagarajan RP, 2000, BIOCHEM J, V348, P591, DOI 10.1042/0264-6021:3480591; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	45	149	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30226	30231		10.1074/jbc.M005310200	http://dx.doi.org/10.1074/jbc.M005310200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10903323	hybrid			2022-12-25	WOS:000089577900044
J	Baugh, RJ; Dickinson, CD; Ruf, W; Krishnaswamy, S				Baugh, RJ; Dickinson, CD; Ruf, W; Krishnaswamy, S			Exosite interactions determine the affinity of factor X for the extrinsic Xase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR PATHWAY; FACTOR-FACTOR-VIIA; MACROMOLECULAR SUBSTRATE RECOGNITION; CATALYZED PROTEASE INACTIVATION; COAGULATION-FACTOR-VIIA; ACTIVE-SITE; CRYSTAL-STRUCTURE; PROTHROMBINASE COMPLEX; TRANSIENT KINETICS; BLOOD-COAGULATION	The initiation of coagulation results from the activation of factor X by an enzyme complex (Xase) composed of the trypsin-like serine proteinase, factor VIIa, bound to tissue factor (TF) on phospholipid membranes. We have investigated the basis for the protein substrate specificity of Xase using TF reconstituted into vesicles of phosphatidylcholine, phosphatidylserine, or pure phosphatidylcholine. We show that occupation of the active site of VIIa within Xase by a reversible inhibitor or an alternate peptidyl substrate is sufficient to exclude substrate interactions at the active site but does not alter the affinity of Xase for factor X, This is evident as classical competitive inhibition of peptidyl substrate cleavage but as classical noncompetitive inhibition of factor X activation by active site-directed ligands. This implies that the productive recognition of factor X by Xase arises from a multistep reaction requiring an initial interaction at sites on the enzyme complex distinct from the active site (exosites), followed by active site interactions and bond cleavage. Exosite interactions determine protein substrate affinity, whereas the second binding step influences the maximum catalytic rate for the reaction. We also show that competitive inhibition can be achieved by interfering with exosite binding using factor X derivatives that are expected to have limited or abrogated interactions with the active site of VIIa within Xase. Thus, substrate interactions at exosites, sites removed from the active site of VIIa within the enzyme complex, determine affinity and binding specificity in the productive recognition of factor X by the VIIa-TF complex. This may represent a prevalent strategy through which distinctive protein substrate specificities are achieved by the homologous enzymes of coagulation.	Childrens Hosp Philadelphia, Joseph Stokes Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Scripps Research Institute; Scripps Research Institute	Krishnaswamy, S (corresponding author), Childrens Hosp Philadelphia, Joseph Stokes Res Inst, 310 Abramson,3516 Civic Ctr Blvd, Philadelphia, PA 19104 USA.	skrishna@mail.med.upenn.edu	Krishnaswamy, Sriram/Z-4380-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047465, R01HL048752, R01HL062523] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48752, HL-62523, HL-47465] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Baugh RJ, 1998, J BIOL CHEM, V273, P4378, DOI 10.1074/jbc.273.8.4378; Baugh RJ, 1996, J BIOL CHEM, V271, P16126, DOI 10.1074/jbc.271.27.16126; Betz A, 1997, BIOCHEMISTRY-US, V36, P181, DOI 10.1021/bi962060g; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bevington P. R., 1992, DATA REDUCTION ERROR, P141; Bode W, 1997, THROMB HAEMOSTASIS, V78, P501; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; BROZE GJ, 1995, ANNU REV MED, V46, P103, DOI 10.1146/annurev.med.46.1.103; BUTENAS S, 1993, BIOCHEMISTRY-US, V32, P6531, DOI 10.1021/bi00077a006; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; Dickinson CD, 1998, J MOL BIOL, V277, P959, DOI 10.1006/jmbi.1998.1639; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; EVANS SA, 1982, J BIOL CHEM, V257, P3014; Huang QL, 1996, J BIOL CHEM, V271, P21752, DOI 10.1074/jbc.271.36.21752; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; Jencks W. P., 1987, CATALYSIS CHEM ENZYM; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1993, METHOD ENZYMOL, V222, P177; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; Leung D, 2000, J MED CHEM, V43, P305, DOI 10.1021/jm990412m; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; Nemerson Y, 1987, Adv Exp Med Biol, V214, P83; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; OLSON ST, 1988, J BIOL CHEM, V263, P1698; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; RAPAPORT SI, 1995, THROMB HAEMOSTASIS, V74, P7; RUF W, 1992, J BIOL CHEM, V267, P6375; Ruf W, 1999, BIOCHEMISTRY-US, V38, P1957, DOI 10.1021/bi982254r; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; RUF W, 1991, J BIOL CHEM, V266, P15719; RUF W, 1991, J BIOL CHEM, V266, P16256; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; Shobe J, 1999, J BIOL CHEM, V274, P24171, DOI 10.1074/jbc.274.34.24171; Shobe J, 1999, BIOCHEMISTRY-US, V38, P2745, DOI 10.1021/bi981951g; STRAUME M, 1992, METHOD ENZYMOL, V210, P87	51	83	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28826	28833		10.1074/jbc.M005266200	http://dx.doi.org/10.1074/jbc.M005266200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10889208	hybrid			2022-12-25	WOS:000089330700065
J	Ghosh, AK; Yuan, W; Mori, Y; Varga, J				Ghosh, AK; Yuan, W; Mori, Y; Varga, J			Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-beta involves functional cooperation with p300/CBP transcriptional coactivators	ONCOGENE			English	Article						type I collagen; transforming growth factor-beta; coactivators; p300/CBP; signal transduction; Smads	GROWTH-FACTOR-BETA; ADENOVIRAL ONCOPROTEIN E1A; HISTONE ACETYLTRANSFERASES; MOLECULAR-CLONING; TUMOR-SUPPRESSOR; BINDING-PROTEIN; RETINOIC ACID; DNA-BINDING; F9 CELLS; CBP	Transforming growth factor-beta (TGF-beta) stimulation of Type I collagen gene (COL1A2) transcription involves the Smad signal transduction pathway, but the mechanisms of Smad-mediated transcriptional activation are not fully understood. We now demonstrate that the ubiquitous transcriptional coactivators p300 and CREB-binding protein (CBP) enhanced basal as well as TGF-beta- or Smad3-induced COL1A2 promoter activity, and stimulated the expression of endogenous Type I collagen. The adenoviral E1A oncoprotein abrogated stimulation of COL1A2 activity in transfected fibroblasts, and reduced the basal level of collagen gene expression. This effect was due to specific interaction of E1A with cellular p300/CBP because (a) a mutant form of EIA defective in p300 binding failed to abrogate stimulation, and (b) forced expression of D300/CBP restored the ability of TGF-beta to stimulate COL1A2 promoter activity in the presence of EIA, The effect of p300 on COL1A2, transcription appeared to be due, in part, to its intrinsic acetyltransferase activity, as stimulation induced by a histone acetyltransferase-deficient mutant p300 was substantially reduced. Transactivation of COL1A2 by p300 involved the Smad signaling pathway, as Smad4-deficient cells failed to respond to p300, and stimulation nas rescued by overexpression of Smad4, Furthermore, minimal constructs containing only the Smad-binding CAGACA element of COL1A2 were transactivated by p300 in the presence of TGF-beta, These results indicate, for the first time, that the multifunctional p300/CBP coactivators play a major role in Smad-dependent TGF-beta stimulation of collagen gene expression in fibroblasts.	Univ Illinois, Coll Med, Sect Rheumatol MC733, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Varga, J (corresponding author), Univ Illinois, Coll Med, Sect Rheumatol MC733, 1158 Mol Biol Res Bldg,900 S Ashland Ave, Chicago, IL 60607 USA.				NIAMS NIH HHS [AR-42309, AR-46390] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR046390, R01AR042309] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; CHIRIVIA JC, 1993, NATURE, V365, P855; COUSSENS LM, 1994, J CELL PHYSIOL, V160, P435, DOI 10.1002/jcp.1041600306; Datto MB, 1997, MOL CELL BIOL, V17, P2030, DOI 10.1128/MCB.17.4.2030; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DYSON N, 1992, CANCER SURV, V12, P161; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kawabata M, 1999, J BIOCHEM, V125, P9, DOI 10.1093/oxfordjournals.jbchem.a022273; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Kon A, 1999, ONCOGENE, V18, P1837, DOI 10.1038/sj.onc.1202495; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; LI LY, 1995, GENE, V164, P229, DOI 10.1016/0378-1119(95)00508-4; Liu B, 1999, MOL CELL BIOL, V19, P424; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; Morozov A, 1997, J VIROL, V71, P3451, DOI 10.1128/JVI.71.5.3451-3457.1997; Muraoka M, 1996, ONCOGENE, V12, P1565; MYERS JC, 1981, P NATL ACAD SCI-BIOL, V78, P3516, DOI 10.1073/pnas.78.6.3516; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Padgett RW, 1998, BIOESSAYS, V20, P382, DOI 10.1002/(SICI)1521-1878(199805)20:5&lt;382::AID-BIES5&gt;3.0.CO;2-Q; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Schutte M, 1996, CANCER RES, V56, P2527; SOBULO OM, 1997, P NATL ACAD SCI USA, V94, P10215; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; VARGA J, 1987, BIOCHEM J, V247, P597, DOI 10.1042/bj2470597; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Waltzer L, 1999, EMBO J, V18, P1630, DOI 10.1093/emboj/18.6.1630; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	63	182	192	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3546	3555		10.1038/sj.onc.1203693	http://dx.doi.org/10.1038/sj.onc.1203693			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918613				2022-12-25	WOS:000088346500011
J	Loukinova, E; Dong, G; Enamorado-Ayalya, I; Thomas, GR; Chen, Z; Schreiber, H; Van Waes, C				Loukinova, E; Dong, G; Enamorado-Ayalya, I; Thomas, GR; Chen, Z; Schreiber, H; Van Waes, C			Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism	ONCOGENE			English	Article						GRO-alpha; KC; CXCR2; chemokines; squamous cell carcinoma	PROINFLAMMATORY CYTOKINE EXPRESSION; COLONY-STIMULATING FACTOR; FACTOR-KAPPA-B; CONSTITUTIVE ACTIVATION; ENVIRONMENT PROMOTES; CANCER-CELLS; NECK-CANCER; HUMAN HEAD; IN-VIVO; LINES	Growth Regulated Oncogene-alpha (GRO-alpha) is an autocrine growth factor in melanoma and is a member of the C-X-C family of chemokines which promote chemotaxis of granulocytes and endothelia through binding to CXC Receptor 2, We found previously that variants of murine squamous cell carcinoma PAM 212 which grow and metastasize more rapidly in vivo constitutively express increased levels of murine GRO-alpha, designated mGRO-alpha, or KC, We have examined the possible role of mGRO-alpha. expression in malignant progression of squamous cell carcinoma PAM 212 in homologous BALB/c and BALB CXC Receptor-2 deficient mice, Transfection of the PAM 212 cell line which exhibits low expression of GRO-alpha and malignant potential with a pActin-KC vector encoding mGRO-alpha enabled isolation of PAM-KC expressing cell lines, These PAM-KC transfectants displayed an increased rate of growth and metastasis in BALB/c mice, similar to the highly malignant phenotype observed in spontaneously occurring metastatic variants. Furthermore, the PAM-KC tumors showed an increase in infiltration of host leukocytes and CD31+ blood vessels, consistent with increased CXC chemokine activity. The increased growth of PAM-KC cells was attenuated in CXCR-2 deficient mice, indicating that the increased growth was dependent in part upon host cells responsive to the CXC chemokine, Together, these results show that a CXC chemokine such as GRO-alpha can promote malignant growth of murine squamous cell carcinoma by a host CXCR-2 dependent pathway.	Natl Inst Deafness & Other Commun Disorders, Tumor Biol Sect, Head & Neck Surg Branch, NIH, Bethesda, MD 20892 USA; Univ Chicago, Comm Immunol, Dept Pathol, Chicago, IL 60637 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); University of Chicago	Van Waes, C (corresponding author), Natl Inst Deafness & Other Commun Disorders, Tumor Biol Sect, Head & Neck Surg Branch, NIH, Bldg 10,Rm 5D55,MSC-1419, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [R37CA022677, R01CA022677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000016, ZIADC000016] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22677] Funding Source: Medline; NIDCD NIH HHS [Z01-DC-00016] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BALENTIEN E, 1991, ONCOGENE, V6, P1115; BOZIC CR, 1995, J IMMUNOL, V154, P6048; Chen Z, 1998, CANCER RES, V58, P3668; Chen Z, 1999, CLIN CANCER RES, V5, P1369; Chen Z, 1997, CLIN EXP METASTAS, V15, P527, DOI 10.1023/A:1018474910432; COHEN RF, 1995, ARCH OTOLARYNGOL, V121, P202; Dong G, 1999, CANCER RES, V59, P3495; Dong G, 1997, J CELL BIOCHEM, P90; Duffey DC, 1999, CANCER RES, V59, P3468; GASPARINI G, 1993, INT J CANCER, V55, P739, DOI 10.1002/ijc.2910550507; GUTMAN M, 1994, CANCER BIOTHERAPY, V9, P163, DOI 10.1089/cbr.1994.9.163; Moore BB, 1999, AM J PATHOL, V154, P1503, DOI 10.1016/S0002-9440(10)65404-1; Ondrey FG, 1999, MOL CARCINOGEN, V26, P119, DOI 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; PAK AS, 1995, CLIN CANCER RES, V1, P95; PEKAREK LA, 1995, J EXP MED, V181, P435, DOI 10.1084/jem.181.1.435; Schrieber H, 1999, INFLAMMATION BASIC P, P1117; SEUNG LP, 1995, CANCER RES, V55, P5094; Smith CW, 1998, CLIN EXP METASTAS, V16, P655, DOI 10.1023/A:1006559811429; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; Strieter RM, 1996, CHEMOKINES DIS, P195; VANWAES C, 2000, IN PRESS NEW FRONTIE; Weidner Noel, 1996, P167; Young MRI, 1997, INT J CANCER, V74, P69, DOI 10.1002/(SICI)1097-0215(19970220)74:1<69::AID-IJC12>3.0.CO;2-D; YUSPA SH, 1980, CANCER RES, V40, P4694	25	149	157	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3477	3486		10.1038/sj.onc.1203687	http://dx.doi.org/10.1038/sj.onc.1203687			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918606				2022-12-25	WOS:000088346500004
J	Aufurth, S; Schagger, H; Muller, V				Aufurth, S; Schagger, H; Muller, V			Identification of subunits a, b, and c(1) from Acetobacterium woodii Na+-F1F0-ATPase - Subunits c(1), c(2), and c(3) constitute a mixed c-oligomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-TRANSLOCATING F1F0-ATPASE; F1F0 ATP SYNTHASE; ESCHERICHIA-COLI; PROPIONIGENIUM-MODESTUM; ENERGY TRANSDUCTION; PURIFICATION; SEQUENCE; RECONSTITUTION; SPECIFICITY; DEPENDENCE	The Na+-F1F0-ATPase operon of Acetobacterium woodii was recently shown to contain, among eleven atp genes, those genes that encode subunit a and b, a gene encoding a 16-kDa proteolipid (subunit c(1)), and two genes encoding 8-kDa proteolipids (subunits c(2) and c(3)). Because subunits a, b, and c(1) were not found in previous enzyme preparations, we re-determined the subunit composition of the enzyme. The genes were overproduced, and specific antibodies were raised. Western blots revealed that subunits a, b, and c(1) are produced and localized in the cytoplasmic membrane. Membrane protein complexes were solubilized by dodecylmaltoside and separated by blue native-polyacrylamide gel electrophoresis, and the ATPase subunits were resolved by SDS-polyacrylamide gel electrophoresis. N-terminal sequence analyses revealed the presence of subunits a, c(2), c(3), b, delta, alpha, gamma, beta, and epsilon. Biochemical and immunological analyses revealed that subunits c(1), c(2), and c(3) are all part of the c-oligomer, the first of a F1F0-ATPase that contains 8- and 16-kDa proteolipids.	Univ Munich, Lehrstuhl Mikrobiol, D-80638 Munich, Germany; Univ Frankfurt Klinikum, Zentrum Biol Chem, D-60590 Frankfurt, Germany	University of Munich; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Muller, V (corresponding author), Univ Munich, Lehrstuhl Mikrobiol, Maria Ward Str 1a, D-80638 Munich, Germany.		Mueller, Volker/ABE-4305-2021	Mueller, Volker/0000-0001-7955-5508				AssadiPorter FM, 1995, BIOCHEMISTRY-US, V34, P16186, DOI 10.1021/bi00049a034; Beechey R B, 1979, Methods Enzymol, V55, P426; Das A, 1997, J BACTERIOL, V179, P3746, DOI 10.1128/jb.179.11.3746-3755.1997; Das A, 1997, J BACTERIOL, V179, P1714, DOI 10.1128/jb.179.5.1714-1720.1997; Dimroth P, 1999, P NATL ACAD SCI USA, V96, P4924, DOI 10.1073/pnas.96.9.4924; DMITRIEV OY, 1995, EUR J BIOCHEM, V233, P478, DOI 10.1111/j.1432-1033.1995.478_2.x; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; FILLINGAME RH, 1976, J BIOL CHEM, V251, P6630; FORSTER A, 1994, BIOCHIM BIOPHYS ACTA, V1229, P393; GERIKE U, 1993, FEBS LETT, V316, P89, DOI 10.1016/0014-5793(93)81742-I; GIRVIN ME, 1993, BIOCHEMISTRY-US, V32, P12167, DOI 10.1021/bi00096a029; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEISE R, 1991, FEBS LETT, V295, P119, DOI 10.1016/0014-5793(91)81400-3; HEISE R, 1993, FEMS MICROBIOL LETT, V112, P261, DOI 10.1111/j.1574-6968.1993.tb06460.x; HEISE R, 1989, J BACTERIOL, V171, P5473, DOI 10.1128/jb.171.10.5473-5478.1989; Kaim G, 1997, BIOCHEMISTRY-US, V36, P9185, DOI 10.1021/bi970831q; Muller V, 1995, ARCH MICROBIOL, V164, P363, DOI 10.1007/s002030050276; Muller V, 1999, J BIOENERG BIOMEMBR, V31, P15, DOI 10.1023/A:1005451311009; Muller V., 1994, ACETOGENESIS, P127; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; Rahlfs S, 1997, FEBS LETT, V404, P269, DOI 10.1016/S0014-5793(97)00088-4; Rahlfs S, 1999, FEBS LETT, V453, P35, DOI 10.1016/S0014-5793(99)00576-1; Rahlfs S, 1999, J BIOL CHEM, V274, P33999, DOI 10.1074/jbc.274.48.33999; REIDLINGER J, 1994, FEBS LETT, V356, P17, DOI 10.1016/0014-5793(94)01222-9; REIDLINGER J, 1994, EUR J BIOCHEM, V223, P275, DOI 10.1111/j.1432-1033.1994.tb18992.x; Ruppert C, 1999, J BIOL CHEM, V274, P25281, DOI 10.1074/jbc.274.36.25281; Sch?gger, 1994, PRACTICAL GUIDE MEMB, P81; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P369; Schemidt RA, 1998, J BACTERIOL, V180, P3205, DOI 10.1128/JB.180.12.3205-3208.1998; SPRUTH M, 1995, BBA-BIOENERGETICS, V1229, P96, DOI 10.1016/0005-2728(94)00192-8; TSCHECH A, 1984, ARCH MICROBIOL, V137, P163, DOI 10.1007/BF00414460; WALKER JE, 1983, METHOD ENZYMOL, V97, P195; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; ZHANG Y, 1995, J BIOL CHEM, V270, P87, DOI 10.1074/jbc.270.1.87	34	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33297	33301		10.1074/jbc.M005134200	http://dx.doi.org/10.1074/jbc.M005134200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10913149	hybrid			2022-12-25	WOS:000090104600019
J	McIntosh, JM; Corpuz, GO; Layer, RT; Garrett, JE; Wagstaff, JD; Bulaj, G; Vyazovkina, A; Yoshikami, D; Cruz, LJ; Olivera, BM				McIntosh, JM; Corpuz, GO; Layer, RT; Garrett, JE; Wagstaff, JD; Bulaj, G; Vyazovkina, A; Yoshikami, D; Cruz, LJ; Olivera, BM			Isolation and characterization of a novel Conus peptide with apparent antinociceptive activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL NERVOUS-SYSTEM; MUSCARINIC CHOLINERGIC RECEPTORS; RAT-BRAIN MEMBRANES; SEROTONIN UPTAKE; SODIUM-CHANNELS; 5-HT3 RECEPTORS; SCIATIC-NERVE; BINDING-SITES; MARINE SNAIL; MOUSE-BRAIN	Cone snails are tropical marine mollusks that envenomate prey with a complex mixture of neuropharmacologically active compounds. We report the discovery and biochemical characterization of a structurally unique peptide isolated from the venom of Conus marmoreus, The new peptide, mr10a, potently increased withdrawal latency in a hot plate assay (a test of analgesia) at intrathecal doses that do not produce motor impairment as measured by rotarod test. The sequence of mr10a is NGVCCGYKLCHOC, where O is 4-trans-hydroxyproline. This sequence is highly divergent from all other known conotoxins, Analysis of a cDNA clone encoding the toxin, however, indicates that it is a member of the recently described T-superfamily, Total chemical synthesis of the three possible disulfide arrangements of mr10a was achieved, acid elution studies indicate that the native form has a disulfide connectivity of Cys1-Cys4 and Cys2-Cys3, This disulfide linkage is unprecedented among conotoxins and defines a new family of Conus peptides.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Psychiat, Salt Lake City, UT 84112 USA; Cognetix Inc, Salt Lake City, UT 84108 USA; Univ Philippines, Inst Marine Sci, Quezon City 1101, Philippines	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of the Philippines System; University of the Philippines Diliman	McIntosh, JM (corresponding author), Univ Utah, Dept Biol, 257 South 1400 East, Salt Lake City, UT 84112 USA.	mcintosh@biology.utah.edu			NIGMS NIH HHS [GM48677] Funding Source: Medline; NIMH NIH HHS [MH53631] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH053631, R01MH053631] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adams DJ, 1999, DRUG DEVELOP RES, V46, P219; AKIYAMA K, 1985, P NATL ACAD SCI USA, V82, P2543, DOI 10.1073/pnas.82.8.2543; BROWN NL, 1986, EUR J PHARMACOL, V123, P161, DOI 10.1016/0014-2999(86)90700-4; Buchanan S, 1996, NEUROSCI LETT, V219, P131, DOI 10.1016/S0304-3940(96)13189-X; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; CHANG RSL, 1979, J NEUROCHEM, V32, P1653, DOI 10.1111/j.1471-4159.1979.tb02276.x; CLARK C, 1981, TOXICON, V19, P691, DOI 10.1016/0041-0101(81)90106-9; Craig AG, 1998, BIOCHEMISTRY-US, V37, P16019, DOI 10.1021/bi981690a; Craig AG, 1999, J BIOL CHEM, V274, P13752, DOI 10.1074/jbc.274.20.13752; CRUZ LJ, 1986, J BIOL CHEM, V261, P6230; DAMATO RJ, 1987, J PHARMACOL EXP THER, V242, P364; DODD J, 1983, J PHYSIOL-LONDON, V334, P255, DOI 10.1113/jphysiol.1983.sp014493; Ecker A., 1889, ANATOMY FROG; ENNA SJ, 1977, BRAIN RES, V124, P185, DOI 10.1016/0006-8993(77)90878-2; Erlanger J., 1937, AM J PSYCHIAT, V93, P1472, DOI [10.1176/AJP.93.6.1472-A, DOI 10.1176/AJP.93.6.1472-A]; FALCH E, 1986, J NEUROCHEM, V47, P898; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GILLAN MGC, 1982, BRIT J PHARMACOL, V77, P461, DOI 10.1111/j.1476-5381.1982.tb09319.x; GOEDERT M, 1984, BRAIN RES, V304, P71, DOI 10.1016/0006-8993(84)90862-X; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; GULLY D, 1993, P NATL ACAD SCI USA, V90, P65, DOI 10.1073/pnas.90.1.65; HAAKSMA EEJ, 1990, PHARMACOL THERAPEUT, V47, P73, DOI 10.1016/0163-7258(90)90046-5; HEADING C, 1999, CURR OPIN CPNS INVES, V1, P153; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; HOYER D, 1988, MOL PHARMACOL, V33, P303; HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4; JAVITCH JA, 1984, MOL PHARMACOL, V26, P35; Jones RM, 2000, CURR PHARM DESIGN, V6, P1249, DOI 10.2174/1381612003399653; KALARIA RN, 1989, J NEUROCHEM, V53, P1772, DOI 10.1111/j.1471-4159.1989.tb09242.x; KINOUCHI K, 1991, EUR J PHARM-MOLEC PH, V207, P135, DOI 10.1016/0922-4106(91)90088-Y; Kobayashi JI, 1996, NEUROSCI LETT, V221, P9, DOI 10.1016/S0304-3940(96)13269-9; LAHTI RA, 1985, EUR J PHARMACOL, V109, P281, DOI 10.1016/0014-2999(85)90431-5; LANGER SZ, 1981, EUR J PHARMACOL, V72, P423, DOI 10.1016/0014-2999(81)90592-6; LEHMANN J, 1988, J PHARMACOL EXP THER, V246, P65; Lu Y, 1998, J PHARMACOL EXP THER, V287, P648; LUMMIS SCR, 1990, EUR J PHARM-MOLEC PH, V189, P223, DOI 10.1016/0922-4106(90)90026-T; Luo SQ, 1998, J NEUROSCI, V18, P8571; LUTHIN GR, 1984, MOL PHARMACOL, V26, P164; LUTHIN GR, 1984, J PHARMACOL EXP THER, V228, P648; MADRAS BK, 1989, MOL PHARMACOL, V36, P518; MARTINEZMIR MI, 1990, BRAIN RES, V526, P322, DOI 10.1016/0006-8993(90)91240-H; McIntosh J M, 1999, Methods Enzymol, V294, P605; McIntosh JM, 2000, EUR J PHARMACOL, V393, P205, DOI 10.1016/S0014-2999(99)00887-0; MCINTOSH JM, 1995, J BIOL CHEM, V270, P16796, DOI 10.1074/jbc.270.28.16796; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; MINNEMAN KP, 1979, MOL PHARMACOL, V16, P34; MURPHY DE, 1987, J PHARMACOL EXP THER, V240, P778; Olivera BM, 2001, TOXICON, V39, P7, DOI 10.1016/S0041-0101(00)00157-4; OROURKE MF, 1994, J PHARMACOL EXP THER, V268, P1362; PABREZA LA, 1991, MOL PHARMACOL, V39, P9; RAISMAN R, 1982, EUR J PHARMACOL, V78, P345, DOI 10.1016/0014-2999(82)90036-X; READER TA, 1987, J NEURAL TRANSM, V68, P79, DOI 10.1007/BF01244641; Rigby AC, 1999, P NATL ACAD SCI USA, V96, P5758, DOI 10.1073/pnas.96.10.5758; Rockel D, 1995, MANUAL LIVING CONIDA; ROTHMAN RB, 1992, PEPTIDES, V13, P977, DOI 10.1016/0196-9781(92)90059-C; RUIZGOMEZ A, 1989, J NEUROCHEM, V52, P1775, DOI 10.1111/j.1471-4159.1989.tb07256.x; SOFUOGLU M, 1992, EUR J PHARMACOL, V216, P273, DOI 10.1016/0014-2999(92)90370-J; Terlau H, 1996, NATURE, V381, P148, DOI 10.1038/381148a0; TIMMERMANS PBMWM, 1981, MOL PHARMACOL, V20, P295; TYERS MB, 1991, THERAPIE, V46, P431; Walker CS, 1999, J BIOL CHEM, V274, P30664, DOI 10.1074/jbc.274.43.30664; YAMAMURA HI, 1974, P NATL ACAD SCI USA, V71, P1725, DOI 10.1073/pnas.71.5.1725; YOUNG AB, 1974, MOL PHARMACOL, V10, P790	65	88	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32391	32397		10.1074/jbc.M003619200	http://dx.doi.org/10.1074/jbc.M003619200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10900201	hybrid			2022-12-25	WOS:000090003800004
J	Smyth, EM; Austin, SC; Reilly, MP; FitzGeralds, GA				Smyth, EM; Austin, SC; Reilly, MP; FitzGeralds, GA			Internalization and sequestration of the human prostacyclin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; PROTEIN-KINASE-C; ANGIOTENSIN-II RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; BETA-ARRESTIN; PULMONARY-HYPERTENSION; PLATELET ACTIVATION; COUPLED RECEPTORS; PHOSPHORYLATION; DESENSITIZATION	Prostacyclin (PGI(2)), the major product of cyolooxygenase in macrovascular endothelium, mediates its biological effects through its cell surface G protein-coupled receptor, the IF. PKC-mediated phosphorylation of human (h) IP is a critical determinant of agonist-induced desensitization (Smyth, E. M., Hong Li, W., and FitzGerald, G. A. (1998) J. Biol. Chem. 273, 23258-23266). The regulatory events that follow desensitization are unclear. We have examined agonist-induced sequestration of hIP. Human IF, tagged at the N terminus with hemagglutinin (HA) and fused at the C terminus to the green fluorescent protein (GFP), was coupled to increased cAMP (EC50 = 0.39 +/- 0.09 nM) and inositol phosphate (EC50 = 86.6 +/- 18.3 nM) generation when overexpressed in HEK 293 cells. Iloprost-induced Sequestration of HA-hIP-GFP, followed in real time by confocal microscopy, was partially colocalized to clathrin-coated vesicles. Iloprost induced a time- and concentration-dependent loss of cell surface HA, indicating receptor internalization, which was prevented by inhibitors of clathrin-mediated trafficking and partially reduced by cotransfection of cells with a dynamin dominant negative mutant. Sequestration (EC50 = 27.6 +/- 5.7 nM) was evident at those concentrations of iloprost that induce PKC-dependent desensitization. Neither the PKC inhibitor GF109203X nor mutation of Ser-328, the site for PKC phosphorylation, altered receptor sequestration indicating that, unlike desensitization, internalization is PKC-independent. Deletion of the C terminus prevented iloprost-induced internalization, demonstrating the critical nature of this region for sequestration. Internalization was unaltered by cotransfection of cells with G;protein-coupled receptor kinases (GRK)-2, -3, -5, -6, arrestin-2, or an arrestin-2 dominant negative mutant, indicating that GRKs and arrestins do not play a role in hIP trafficking. The hip is sequestered in response to agonist activation via a PKC-independent pathway that is distinct from desensitization. Trafficking is dependent on determinants located in the C terminus, is GRK/arrestin-independent, and proceeds in part via a dynamin-dependent clathrin-coated vesicular endocytotic pathway although other dynamin-independent pathways may also be involved.	Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA	University of Pennsylvania	FitzGeralds, GA (corresponding author), Univ Penn, Ctr Expt Therapeut, 153 Johnson Pavil,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	garret@spirit.gcrc.upenn.edu		Reilly, Muredach/0000-0002-3035-9386	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057847, P01HL062250] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-57847, HL-62250] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Archer SL, 1996, CHEST, V109, P750, DOI 10.1378/chest.109.3.750; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BOIE Y, 1994, J BIOL CHEM, V269, P12173; Bunemann M, 1999, ANNU REV PHYSIOL, V61, P169, DOI 10.1146/annurev.physiol.61.1.169; Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FITZGERALD DJ, 1986, J CLIN INVEST, V77, P496, DOI 10.1172/JCI112329; FITZGERALD GA, 1984, NEW ENGL J MED, V310, P1065, DOI 10.1056/NEJM198404263101701; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Fukushima Y, 1997, J BIOL CHEM, V272, P19464, DOI 10.1074/jbc.272.31.19464; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Geraci MW, 1999, J CLIN INVEST, V103, P1509, DOI 10.1172/JCI5911; Giovanazzi S, 1997, BIOCHEM J, V325, P71, DOI 10.1042/bj3250071; Go WY, 1998, AM J PHYSIOL-GASTR L, V275, pG56, DOI 10.1152/ajpgi.1998.275.1.G56; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GOODMAN RP, 1982, AM J OBSTET GYNECOL, V142, P817, DOI 10.1016/S0002-9378(16)32525-X; Haga K, 1996, J BIOL CHEM, V271, P2776, DOI 10.1074/jbc.271.5.2776; Herschman HR, 1998, TRENDS CARDIOVAS MED, V8, P145, DOI 10.1016/S1050-1738(98)00004-8; ISHII K, 1994, J BIOL CHEM, V269, P1125; Iwai N, 1999, CIRCULATION, V100, P2231, DOI 10.1161/01.CIR.100.22.2231; Kallal L, 2000, TRENDS PHARMACOL SCI, V21, P175, DOI 10.1016/S0165-6147(00)01477-2; KRANE A, 1994, BIOCHEM PHARMACOL, V47, P953, DOI 10.1016/0006-2952(94)90405-7; Krueger KM, 1997, J BIOL CHEM, V272, P5; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; MATSUMURA K, 1995, NEUROSCIENCE, V65, P493, DOI 10.1016/0306-4522(94)00505-Y; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; McLaughlin VV, 1998, NEW ENGL J MED, V338, P273, DOI 10.1056/NEJM199801293380501; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; MONCADA S, 1981, CLIN SCI, V61, P369, DOI 10.1042/cs0610369; MOORE RH, 1995, J CELL SCI, V108, P2983; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; NAMBA T, 1994, J BIOL CHEM, V269, P9986; Neuschafer-Rube F, 1999, MOL PHARMACOL, V56, P419, DOI 10.1124/mol.56.2.419; OATES JA, 1988, NEW ENGL J MED, V319, P689, DOI 10.1056/NEJM198809153191106; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Schonbeck U, 1999, AM J PATHOL, V155, P1281, DOI 10.1016/S0002-9440(10)65230-3; Siegle I, 2000, J HISTOCHEM CYTOCHEM, V48, P631, DOI 10.1177/002215540004800507; Smyth EM, 1996, J BIOL CHEM, V271, P33698, DOI 10.1074/jbc.271.52.33698; Smyth EM, 1998, J BIOL CHEM, V273, P23258, DOI 10.1074/jbc.273.36.23258; THOMAS WG, 1995, J BIOL CHEM, V270, P22153, DOI 10.1074/jbc.270.38.22153; Todaka T, 1999, STROKE, V30, P419, DOI 10.1161/01.STR.30.2.419; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; VANE JR, 1995, AM J CARDIOL, V75, pA3, DOI 10.1016/S0002-9149(99)80377-4; VANE JR, 1969, BRIT J PHARMACOL, V35, P209, DOI 10.1111/j.1476-5381.1969.tb07982.x; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; Xiao Z, 1997, J CELL BIOL, V139, P365, DOI 10.1083/jcb.139.2.365; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; ZHAO J, 1999, BIOCHEM BIOPH RES CO, V238, P71; Zucker TP, 1998, EUR J PHARMACOL, V345, P213, DOI 10.1016/S0014-2999(98)00022-3	59	68	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32037	32045		10.1074/jbc.M003873200	http://dx.doi.org/10.1074/jbc.M003873200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10889200	hybrid			2022-12-25	WOS:000089858900067
J	Uttaro, AD; Altabe, SG; Rider, MH; Michels, PAM; Opperdoes, FR				Uttaro, AD; Altabe, SG; Rider, MH; Michels, PAM; Opperdoes, FR			A family of highly conserved glycosomal 2-hydroxyacid dehydrogenases from Phytomonas sp.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALATE-DEHYDROGENASE; TRYPANOSOMA-BRUCEI; MOLECULAR-CLONING; LACTATE-DEHYDROGENASE; EUPHORBIA-CHARACIAS; ESCHERICHIA-COLI; PROTEIN; MITOCHONDRIAL; EXPRESSION; METABOLISM	Phytomonas sp. contains two malate dehydrogenase isoforms, a mitochondrial isoenzyme with a high specificity for oxaloacetate and a glycosomal isozyme that acts on a broad range of substrates (Uttaro, A. D., and Opperdoes, F.R, (1997) Mol. Biochem. Parasitol. 89, 51-59). Here, we show that the low specificity of the latter isoenzyme is the result of a number of recent gene duplications that gave rise to a family of glycosomal 2-hydroxyacid dehydrogenase genes. Two of these genes were cloned, sequenced, and overexpressed in Escherichia coli. Although both gene products have 322 amino acids, share 90.4% identical residues, and have a similar hydrophobicity profile and net charge, their kinetic properties were strikingly different. One isoform behaved as a real malate dehydrogenase with a high specificity for oxaloacetate, whereas the other showed no activity with oxaloacetate but was able to reduce other oxoacids, such as phenyl pyruvate, 2-oxoisocaproate, 2-oxovalerate, 2-oxobutyrate, 2-oxo-4-methiolbutyrate, and pyruvate.	Christian de Duve Inst Cellular Pathol, ICP, Trop Dis Res Unit, B-1200 Brussels, Belgium; Catholic Univ Louvain, B-1200 Brussels, Belgium; Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Dept Microbiol, RA-2000 Rosario, Santa Fe, Argentina; Christian de Duve Inst Cellular Pathol, Hormone & Metab Res Unit, B-1200 Brussels, Belgium	Universite Catholique Louvain; National University of Rosario	Opperdoes, FR (corresponding author), Christian de Duve Inst Cellular Pathol, ICP, Trop Dis Res Unit, B-1200 Brussels, Belgium.	opperdoes@trop.ucl.ac.be	Opperdoes, Fred/N-9922-2019; Michels, Paul A/A-5637-2009; Opperdoes, Frederik R/C-8897-2018	Opperdoes, Fred/0000-0003-1984-3764; Michels, Paul A/0000-0003-3726-6104; Opperdoes, Frederik R/0000-0003-1984-3764				ALLERT S, 1991, EUR J BIOCHEM, V200, P19, DOI 10.1111/j.1432-1033.1991.tb21043.x; Anderson SA, 1998, EXP PARASITOL, V89, P63, DOI 10.1006/expr.1998.4260; Anderson SA, 1998, MOL BIOCHEM PARASIT, V96, P185, DOI 10.1016/S0166-6851(98)00116-9; BANASZAK LJ, 1975, ENZYMES, V11, P369; BIRKTOFT JJ, 1982, P NATL ACAD SCI-BIOL, V79, P6166, DOI 10.1073/pnas.79.20.6166; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUMONT F, 1994, MOL BIOCHEM PARASIT, V67, P321, DOI 10.1016/0166-6851(94)00141-3; Chua N. H, 1980, METHOD ENZYMOL, V69, P434; DOLLET M, 1982, CR ACAD SCI III-VIE, V295, P547; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; Hannaert V, 1998, J MOL EVOL, V47, P728, DOI 10.1007/PL00006432; Hunter GR, 2000, MOL BIOCHEM PARASIT, V105, P203, DOI 10.1016/S0166-6851(99)00176-0; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAKE JA, 1988, P NATL ACAD SCI USA, V85, P4779, DOI 10.1073/pnas.85.13.4779; Musrati RA, 1998, GEN PHYSIOL BIOPHYS, V17, P193; NICHOLLS DJ, 1992, BIOCHEM BIOPH RES CO, V189, P1057, DOI 10.1016/0006-291X(92)92311-K; PARK SJ, 1995, J BACTERIOL, V177, P6652, DOI 10.1128/jb.177.22.6652-6656.1995; RIDER MH, 1995, EUR J BIOCHEM, V230, P258; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANCHEZMORENO M, 1992, MOL BIOCHEM PARASIT, V54, P185, DOI 10.1016/0166-6851(92)90111-V; SMITH K, 1984, J BACTERIOL, V157, P684, DOI 10.1128/JB.157.2.684-687.1984; Stevens JR, 1999, PARASITOL TODAY, V15, P432, DOI 10.1016/S0169-4758(99)01532-X; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SUNDARAM TK, 1980, BIOCHEMISTRY-US, V19, P2017, DOI 10.1021/bi00551a002; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uttaro AD, 1997, MOL BIOCHEM PARASIT, V89, P51, DOI 10.1016/S0166-6851(97)00100-X; Uttaro AD, 1997, MOL BIOCHEM PARASIT, V90, P337, DOI 10.1016/S0166-6851(97)00142-4; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242	30	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31833	31837		10.1074/jbc.M006080200	http://dx.doi.org/10.1074/jbc.M006080200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10900211	hybrid			2022-12-25	WOS:000089858900042
J	Ishigaki, Y; Oikawa, S; Suzuki, T; Usui, S; Magoori, K; Kim, DH; Suzuki, H; Sasaki, J; Sasano, H; Okazaki, M; Toyota, T; Saito, T; Yamamoto, TT				Ishigaki, Y; Oikawa, S; Suzuki, T; Usui, S; Magoori, K; Kim, DH; Suzuki, H; Sasaki, J; Sasano, H; Okazaki, M; Toyota, T; Saito, T; Yamamoto, TT			Virus-mediated transduction of apolipoprotein E (ApoE)-Sendai develops lipoprotein glomerulopathy in ApoE-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID DELETION; MUTATION; RECEPTOR; GENE; HYPERCHOLESTEROLEMIA; ATHEROSCLEROSIS; PROTEIN	Lipoprotein glomerulopathy (LPG) is a unique renal disease characterized by thrombus-like substances in markedly dilated glomerular capillaries, dysbetalipoproteinemia, and elevated plasma concentrations of apoE, Recent studies identified several apoE mutations in patients with LPG, including apoE2(R145P) Sendai (apoE-Sendai). Virus-mediated transduction of apoE-Sendai in apoE-deficient hypercholesterolemic mice resulted in insufficient correction of hypercholesterolemia and a marked and temporal induction of plasma triglyceride levels. In vitro binding studies showed that apoE-Sendai has a reduced affinity for the low density lipoprotein receptor, suggesting that dysbetalipoproteinemia in LPG is caused by the apoE mutation. Furthermore, histological examination revealed marked intraglomerular depositions of apoE-containing lipoproteins in mice injected with apoE-Sendai virus. These LPG-like depositions were detected 6 days after virus injection and were sustained for at least 60 days. Our results demonstrated that apoE-Sendai is an etiological cause of LPG.	Tohoku Univ, Ctr Gene Res, Sendai, Miyagi 9818555, Japan; Tohoku Univ, Sch Med, Dept Pathol, Sendai, Miyagi 9808574, Japan; Tohoku Univ, Sch Med, Dept Internal Med 3, Sendai, Miyagi 9808574, Japan; Tokyo Med & Dent Univ, Coll Liberal Arts & Sci, Chem Lab, Chiba 2820827, Japan; Fukuoka Univ, Sch Med, Dept Internal Med, Fukuoka 8140180, Japan	Tohoku University; Tohoku University; Tohoku University; Tokyo Medical & Dental University (TMDU); Fukuoka University	Yamamoto, TT (corresponding author), Tohoku Univ, Ctr Gene Res, 1-1 Tsutsumidori Amamiya, Sendai, Miyagi 9818555, Japan.		USUI, Shinichi/B-1800-2011	USUI, Shinichi/0000-0002-9671-9866				Ando M, 1999, KIDNEY INT, V56, P1317, DOI 10.1046/j.1523-1755.1999.00677.x; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Boren J, 1998, J CLIN INVEST, V101, P2658, DOI 10.1172/JCI2265; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; Konishi K, 1999, NEPHRON, V83, P214, DOI 10.1159/000045513; MAHLEY RW, 1991, JAMA-J AM MED ASSOC, V265, P78, DOI 10.1001/jama.265.1.78; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Matsunaga A, 1999, KIDNEY INT, V56, P421, DOI 10.1046/j.1523-1755.1999.00572.x; Ogawa T, 2000, PEDIATR NEPHROL, V14, P149, DOI 10.1007/s004670050032; Oikawa S, 1997, J AM SOC NEPHROL, V8, P820; OIKAWA S, 1991, AM J KIDNEY DIS, V18, P553, DOI 10.1016/S0272-6386(12)80649-4; Okazaki M, 1998, J CHROMATOGR B, V709, P179, DOI 10.1016/S0378-4347(98)00064-4; OKAZAKI M, 2000, HDB LIPOPROTEIN TEST, P647; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; SAITO T, 1989, AM J KIDNEY DIS, V13, P148, DOI 10.1016/S0272-6386(89)80134-9; Saito T, 1999, NEPHRON, V83, P193, DOI 10.1159/000045511; SHIBUI T, 1991, J BIOTECHNOL, V17, P109, DOI 10.1016/0168-1656(91)90002-D; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; Tsukamoto K, 1997, J CLIN INVEST, V100, P107, DOI 10.1172/JCI119501; Usui S, 2000, CLIN CHEM, V46, P63; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	23	52	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31269	31273		10.1074/jbc.M005906200	http://dx.doi.org/10.1074/jbc.M005906200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10903326	hybrid			2022-12-25	WOS:000089762700074
J	Kishi, H; Ascoli, M				Kishi, H; Ascoli, M			Multiple distant amino acid residues present in the serpentine region of the follitropin receptor modulate the rate of agonist-induced internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; C-TERMINAL TAIL; LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; MUSCARINIC ACETYLCHOLINE-RECEPTOR; FOLLICLE-STIMULATING-HORMONE; LUTROPIN/CHORIOGONADOTROPIN RECEPTOR; INDUCED PHOSPHORYLATION; MEDIATED ENDOCYTOSIS; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING	The amino acid sequences of the human (h) and rat (r) follitropin receptors (FSHR) are similar to 89% identical, but the half-time of internalization of agonist mediated by the rFSHR is similar to 3 times faster than that of the hFSHR. Chimeras of the hFSHR and the rFSHR showed that this difference in rate is dictated mostly by the serpentine domain. Further analysis identified six residues, two non-contiguous residues in the transmembrane helix 4 (Leu/Thr in the rFSHR and Met/Ile in the hFSHR), three non-contiguous residues in the third intracellular loop (Thr/Thr/Lys in the rFSHR and Ile/Asn/Arg in the hFSHR), and one in transmembrane helix 7 (Tyr in the rFSHR and His in the hFSHR) that are fully responsible for the difference in the rates of internalization of the hFSHR and the rFSHR.	Univ Iowa, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa	Ascoli, M (corresponding author), Univ Iowa, Dept Pharmacol, 2-319B,51 Newton Rd, Iowa City, IA 52242 USA.		Kishi, Hiroko/AAR-9148-2021	Kishi, Hiroko/0000-0003-2896-7355	NICHD NIH HHS [HD-28962] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028962] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCOLI M, 1984, J CELL BIOL, V99, P1242, DOI 10.1083/jcb.99.4.1242; ASCOLI M, 1978, P NATL ACAD SCI USA, V75, P99, DOI 10.1073/pnas.75.1.99; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Baratti-Elbaz C, 1999, MOL ENDOCRINOL, V13, P1751, DOI 10.1210/me.13.10.1751; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Bunemann M, 1999, ANNU REV PHYSIOL, V61, P169, DOI 10.1146/annurev.physiol.61.1.169; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; CODINA J, 1994, J BIOL CHEM, V269, P29339; Fanelli F, 2000, J MOL BIOL, V296, P1333, DOI 10.1006/jmbi.2000.3516; Faussner A, 1998, J BIOL CHEM, V273, P2617, DOI 10.1074/jbc.273.5.2617; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; GOODMAN J, 1996, NATURE, V383, P447; Hauser F, 1997, J BIOL CHEM, V272, P1002, DOI 10.1074/jbc.272.2.1002; HIPKIN RW, 1995, J BIOL CHEM, V270, P26683, DOI 10.1074/jbc.270.44.26683; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1830, DOI 10.1210/me.12.12.1830; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lazari MDM, 1999, MOL ENDOCRINOL, V13, P866, DOI 10.1210/me.13.6.866; Lazari RDM, 1998, J BIOL CHEM, V273, P18316, DOI 10.1074/jbc.273.29.18316; Lee KB, 2000, J BIOL CHEM, V275, P9284, DOI 10.1074/jbc.275.13.9284; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; Martens JWM, 1998, MOL ENDOCRINOL, V12, P775, DOI 10.1210/me.12.6.775; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MINEGISH T, 1990, BIOCHEM BIOPH RES CO, V172, P1049, DOI 10.1016/0006-291X(90)91552-4; MINEGISH T, 1991, BIOCHEM BIOPH RES CO, V175, P1125, DOI 10.1016/0006-291X(91)91682-3; Mukherjee S, 1999, J BIOL CHEM, V274, P12984, DOI 10.1074/jbc.274.19.12984; Nakamura K, 1998, MOL ENDOCRINOL, V12, P580, DOI 10.1210/me.12.4.580; Nakamura K, 1999, J BIOL CHEM, V274, P25426, DOI 10.1074/jbc.274.36.25426; Nakamura K, 2000, J BIOL CHEM, V275, P241, DOI 10.1074/jbc.275.1.241; Nakamura K, 1999, MOL PHARMACOL, V56, P728; Nakamura K, 1999, MOL ENDOCRINOL, V13, P1295, DOI 10.1210/me.13.8.1295; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; NOTHACKER HP, 1993, BIOCHEM BIOPH RES CO, V197, P1062, DOI 10.1006/bbrc.1993.2586; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Rapoport B, 1998, ENDOCR REV, V19, P673, DOI 10.1210/er.19.6.673; Riezman H, 1997, CELL, V91, P731, DOI 10.1016/S0092-8674(00)80461-4; Schlador ML, 2000, J BIOL CHEM, V275, P23295, DOI 10.1074/jbc.M002380200; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; TENSEN CP, 1994, P NATL ACAD SCI USA, V91, P4816, DOI 10.1073/pnas.91.11.4816; WILEY HS, 1982, J BIOL CHEM, V257, P4222; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836	55	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31030	31037		10.1074/jbc.M005528200	http://dx.doi.org/10.1074/jbc.M005528200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10915803	hybrid			2022-12-25	WOS:000089762700043
J	Outten, FW; Outten, CE; Hale, J; O'Halloran, TV				Outten, FW; Outten, CE; Hale, J; O'Halloran, TV			Transcriptional activation of an Escherichia coli copper efflux regulon by the chromosomal MerR homologue, CueR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-GENETICS; RESISTANCE; REPRESSOR; TRANSPORT; PROTEIN	Because copper ions are both essential cofactors and cytotoxic agents, the net accumulation of this element in a cell must be carefully balanced. Depending upon the cellular copper status, copper ions must either be imported or ejected. CopA, the principal copper efflux ATPase in Escherichia coli, is induced by elevated copper in the medium, but the copper-sensing regulatory factor is unknown. Inspection of the copA promoter reveals signature elements of promoters controlled by metalloregulatory proteins in the MerR family. These same elements are also present upstream of yacK, which encodes a putative multi-copper oxidase. Homologues of YacK are found in copper resistance determinants that facilitate copper efflux. Here we show by targeted gene deletion and promoter fusion assays that both copA and yacK are regulated in a copper-responsive manner by the MerR homologue, ybbI. We have designated ybbI as cueR for the Cu efflux regulator. This represents the first example of a copper-responsive regulon on the E. coli chromosome and further extends the roles of MerR family members in prokaryotic stress response.	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University; Northwestern University	O'Halloran, TV (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.	t-ohalloran@northwestern.edu	O'Halloran, Thomas/ABE-6125-2021; Outten, Caryn E./I-9433-2019	O'Halloran, Thomas/0000-0001-8732-5059; Outten, Caryn E./0000-0003-0335-6531; Outten, Franklin/0000-0002-9095-0194	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038784, T32GM008061, R01GM054111, T32GM008382] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM08061, R01 GM38784, T32 GM08382, R01 GM054111] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI AZ, 1995, NATURE, V374, P371; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Brocklehurst KR, 1999, MOL MICROBIOL, V31, P893, DOI 10.1046/j.1365-2958.1999.01229.x; BROWN NL, 1995, MOL MICROBIOL, V17, P1153, DOI 10.1111/j.1365-2958.1995.mmi_17061153.x; Bryson J. W., 1993, BIOINORGANIC CHEM CO, P101; COOKSEY DA, 1994, FEMS MICROBIOL REV, V14, P381, DOI 10.1016/0168-6445(94)90056-6; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; De Wulf P, 1999, J BACTERIOL, V181, P6772, DOI 10.1128/JB.181.21.6772-6778.1999; FONG ST, 1995, MOL MICROBIOL, V15, P1127, DOI 10.1111/j.1365-2958.1995.tb02286.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LUND PA, 1989, J MOL BIOL, V205, P343, DOI 10.1016/0022-2836(89)90345-8; MELLANO MA, 1988, J BACTERIOL, V170, P2879, DOI 10.1128/jb.170.6.2879-2883.1988; MESSERSCHMIDT A, 1989, J MOL BIOL, V206, P513, DOI 10.1016/0022-2836(89)90498-1; Munson GP, 2000, J BACTERIOL, V182, P5864, DOI 10.1128/JB.182.20.5864-5871.2000; NUNOSHIBA T, 1992, J BACTERIOL, V174, P6054, DOI 10.1128/JB.174.19.6054-6060.1992; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; Outten CE, 1999, J BIOL CHEM, V274, P37517, DOI 10.1074/jbc.274.53.37517; Outten FW, 2000, BACTERIAL STRESS RESPONSES, P145; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; SAIER MH, 1994, MOL MICROBIOL, V11, P841, DOI 10.1111/j.1365-2958.1994.tb00362.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; Strausak D, 1997, J BIOL CHEM, V272, P8932	26	237	247	2	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31024	31029		10.1074/jbc.M006508200	http://dx.doi.org/10.1074/jbc.M006508200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10915804	Green Published, hybrid			2022-12-25	WOS:000089762700042
J	Weihofen, A; Lemberg, MK; Ploegh, HL; Bogyo, M; Martoglio, B				Weihofen, A; Lemberg, MK; Ploegh, HL; Bogyo, M; Martoglio, B			Release of signal peptide fragments into the cytosol requires cleavage in the transmembrane region by a protease activity that is specifically blocked by a novel cysteine protease inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-DERIVED PEPTIDES; HLA-E BINDS; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; ROUGH MICROSOMES; CATHEPSIN-K; TRANSLOCATION; MEMBRANE; SITE; TRANSCRIPTION	Signal peptides of secretory and membrane proteins are generated by proteolytic processing of precursor proteins after insertion into the endoplasmic reticulum membrane. Liberated signal peptides can be further processed, and the resulting N-terminal fragments are released toward the cytosol, where they may interact with target proteins like calmodulin. We show here that the processing of signal peptides requires a protease activity distinct from signal peptidase, This activity is inhibited specifically with a newly developed cysteine protease inhibitor, 1,3-di-(N-carboxybenzoyl-L-leucyl-L-leucyl)amino acetone ((Z-LL)(2) ketone). Inhibitor studies revealed that the final, (Z-LL)(2) ketone sensitive cleavage event occurs within the hydrophobic transmembrane region of the signal peptide, thus promoting the release of an N-terminal fragment into the cytosol.	ETH Zentrum, Inst Biochem, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Martoglio, B (corresponding author), ETH Zentrum, Inst Biochem, Universitatstr 16, CH-8092 Zurich, Switzerland.	bruno.martoglio@bc.biol.ethz.ch	Lemberg, Marius K/B-8881-2016; Weihofen, Andreas/A-1566-2011	Lemberg, Marius K/0000-0002-0996-1268; Weihofen, Andreas/0000-0001-6265-9087; Bogyo, Matthew/0000-0003-3753-4412				An FY, 1999, J BACTERIOL, V181, P5915, DOI 10.1128/JB.181.19.5915-5921.1999; Bai AL, 1997, J IMMUNOL, V159, P2139; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Borrego F, 1998, J EXP MED, V187, P813, DOI 10.1084/jem.187.5.813; Braud V, 1997, EUR J IMMUNOL, V27, P1164, DOI 10.1002/eji.1830270517; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; HAUSER S, 1995, EMBO J, V14, P5485, DOI 10.1002/j.1460-2075.1995.tb00235.x; HIGH S, 1993, J BIOL CHEM, V268, P26745; Klappa P, 1996, EUR J BIOCHEM, V239, P509, DOI 10.1111/j.1432-1033.1996.0509u.x; LYKO F, 1995, J BIOL CHEM, V270, P19873, DOI 10.1074/jbc.270.34.19873; Marquis RW, 1999, BIOORGAN MED CHEM, V7, P581, DOI 10.1016/S0968-0896(99)00011-5; Marquis RW, 1998, J MED CHEM, V41, P3563, DOI 10.1021/jm980295f; Martoglio B, 1999, PROTOPLASMA, V207, P141, DOI 10.1007/BF01282993; Martoglio B, 1997, EMBO J, V16, P6636, DOI 10.1093/emboj/16.22.6636; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; Martoglio B, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P265; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NILSSON I, 1993, J BIOL CHEM, V268, P5798; NOVAK P, 1988, J BACTERIOL, V170, P5067, DOI 10.1128/jb.170.11.5067-5075.1988; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rudner DZ, 1999, P NATL ACAD SCI USA, V96, P14765, DOI 10.1073/pnas.96.26.14765; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; Stroud RM, 1999, CURR OPIN STRUC BIOL, V9, P754, DOI 10.1016/S0959-440X(99)00040-8; van Klompenburg W, 1998, J MEMBRANE BIOL, V162, P1, DOI 10.1007/s002329900336; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332	33	100	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30951	30956		10.1074/jbc.M005980200	http://dx.doi.org/10.1074/jbc.M005980200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10921927	hybrid			2022-12-25	WOS:000089762700032
J	Chen, SY; Sarlis, NJ; Simons, SS				Chen, SY; Sarlis, NJ; Simons, SS			Evidence for a common step in three different processes for modulating the kinetic properties of glucocorticoid receptor-induced gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING-PROTEIN; TYROSINE AMINOTRANSFERASE GENE; THYROID-HORMONE RECEPTOR; ESTROGEN-REGULATED RNAS; NUCLEAR RECEPTORS; HISTONE ACETYLTRANSFERASE; PROMOTER-CONTEXT; AGONIST ACTIVITY; DEPENDENT TRANSCRIPTION; COACTIVATOR COMPLEXES	The dose-response curve of steroid hormones and the associated EC50 value are critical parameters both in the development of new pharmacologically active compounds and in the endocrine therapy of various disease states. We have recently described three different variables that can reposition the dose-response curve of agonist-bound glucocorticoid receptors (GRs): a 21-base pair sequence of the rat tyrosine aminotransferase gene called a glucocorticoid modulatory element (GME), GR concentration, and coactivator concentration, At the same time, each of these three components was found to influence the partial agonist activity of antiglucocorticoids. In an effort to determine whether these three processes proceed via independent pathways or a common intermediate, we have examined several mechanistic details. The effects of increasing concentrations of both GR and the coactivator TIF2 are found to be saturable. Furthermore, saturating levels of either GR or TIF2 inhibit the ability of each protein, and the GME, to affect further changes in the dose-response curve or partial agonist activity of antisteroids. This competitive inhibition suggests that all three modulators proceed through a common step involving a titratable factor. Support for this hypothesis comes from the observation that a fragment of the coactivator TIF2 retaining intrinsic transactivation activity is a dominant negative inhibitor of each component (GME, GR, and coactivator). This inhibition was not due to nonspecific effects on the general transcription machinery as the VP16 transactivation domain was inactive. The viral protein E1A also prevented the action of each of the three components in a manner that was independent of E1A's ability to block the histone acetyltransferase activity of CBP. Collectively, these results suggest that three different inputs (GME, GR, and coactivator) for perturbing the dose-response curve, and partial agonist activity, of GR-steroid complexes act by converging at a single step that involves a limiting factor prior to transcription initiation.	NIDDKD, Steroid Hormones Sect, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Simons, SS (corresponding author), NIDDKD, Steroid Hormones Sect, Mol & Cellular Biol Lab, NIH, Bldg 8,Rm B2A-07, Bethesda, MD 20892 USA.		Sarlis, Nicholas/AAN-9444-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK057800, ZIADK057800] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AMARA JF, 1987, ENDOCRINOLOGY, V120, P264, DOI 10.1210/endo-120-1-264; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BAXTER JD, 1971, P NATL ACAD SCI USA, V68, P932, DOI 10.1073/pnas.68.5.932; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Collier CD, 1996, MOL ENDOCRINOL, V10, P463, DOI 10.1210/me.10.5.463; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; EVANS MI, 1987, P NATL ACAD SCI USA, V84, P8493, DOI 10.1073/pnas.84.23.8493; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; Folkers GE, 1998, J BIOL CHEM, V273, P32200, DOI 10.1074/jbc.273.48.32200; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Freedman LP, 1999, TRENDS ENDOCRIN MET, V10, P403, DOI 10.1016/S1043-2760(99)00208-8; Gee AC, 1999, MOL ENDOCRINOL, V13, P1912, DOI 10.1210/me.13.11.1912; Glass CK, 2000, GENE DEV, V14, P121; Guido EC, 1996, MOL ENDOCRINOL, V10, P1178, DOI 10.1210/me.10.10.1178; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; Jackson DA, 1998, J STEROID BIOCHEM, V66, P79, DOI 10.1016/S0960-0760(98)00048-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kaul S, 2000, MOL ENDOCRINOL, V14, P1010, DOI 10.1210/me.14.7.1010; KAUL S, 1999, ENDOCR SOC P, V3, P284; Kino T, 1999, J STEROID BIOCHEM, V70, P15, DOI 10.1016/S0960-0760(99)00100-4; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Li Q, 1999, EMBO J, V18, P5634, DOI 10.1093/emboj/18.20.5634; Liu Z, 1999, P NATL ACAD SCI USA, V96, P9485, DOI 10.1073/pnas.96.17.9485; MAHLER HR, 1966, BIOL CHEM, P250; MAY FEB, 1988, J BIOL CHEM, V263, P12901; MERCIER L, 1983, ENDOCRINOLOGY, V112, P601, DOI 10.1210/endo-112-2-601; MERCIER L, 1986, J STEROID BIOCHEM, V25, P11, DOI 10.1016/0022-4731(86)90275-X; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; MUNCK A, 1984, J BIOL CHEM, V259, P820; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; OSHIMA H, 1995, J BIOL CHEM, V270, P21893, DOI 10.1074/jbc.270.37.21893; OSHIMA H, 1993, J BIOL CHEM, V268, P26858; OSHIMA H, 1992, MOL ENDOCRINOL, V6, P416, DOI 10.1210/me.6.3.416; OSHIMA H, 1992, ENDOCRINOLOGY, V130, P2106, DOI 10.1210/en.130.4.2106; Perissi V, 1999, P NATL ACAD SCI USA, V96, P3652, DOI 10.1073/pnas.96.7.3652; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; ROUSSEAU GG, 1977, J STEROID BIOCHEM, V8, P911, DOI 10.1016/0022-4731(77)90187-X; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Sarlis NJ, 1999, J STEROID BIOCHEM, V68, P89, DOI 10.1016/S0960-0760(99)00021-7; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; SIMONS SS, 1980, J ORG CHEM, V45, P3084, DOI 10.1021/jo01303a030; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; SISTARE FD, 1987, MOL ENDOCRINOL, V1, P648, DOI 10.1210/mend-1-9-648; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Szapary D, 1996, J BIOL CHEM, V271, P30576, DOI 10.1074/jbc.271.48.30576; Szapary D, 1999, MOL ENDOCRINOL, V13, P2108, DOI 10.1210/me.13.12.2108; SZAPARY D, 1992, ENDOCRINOLOGY, V130, P3492, DOI 10.1210/en.130.6.3492; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Thenot S, 1999, MOL ENDOCRINOL, V13, P2137, DOI 10.1210/me.13.12.2137; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TURCOTTE B, 1990, MOL CELL BIOL, V10, P5002, DOI 10.1128/MCB.10.9.5002; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WASNER G, 1988, MOL ENDOCRINOL, V2, P1009, DOI 10.1210/mend-2-11-1009; WESTLEY BR, 1989, J STEROID BIOCHEM, V32, P365, DOI 10.1016/0022-4731(89)90208-2; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Xu Y, 2000, MOL CELL BIOL, V20, P2138, DOI 10.1128/MCB.20.6.2138-2146.2000; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zeng HW, 2000, MOL CELL ENDOCRINOL, V162, P221, DOI 10.1016/S0303-7207(99)00208-7; Zeng HW, 1998, J BIOL CHEM, V273, P17756, DOI 10.1074/jbc.273.28.17756	82	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30106	30117		10.1074/jbc.M005418200	http://dx.doi.org/10.1074/jbc.M005418200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10899170	hybrid			2022-12-25	WOS:000089577900028
J	von der Haar, T; Ball, PD; McCarthy, JEG				von der Haar, T; Ball, PD; McCarthy, JEG			Stabilization of eukaryotic initiation factor 4E binding to the mRNA 5 '-cap by domains of eIF4G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSLATION INITIATION; MESSENGER-RNA 5'-CAP; FACTOR 4G EIF4G; FACTOR EIF-4E; CAP-AFFINITY; PROTEIN; YEAST; ANALOGS; SUBUNITS; P20	The eukaryotic cap-binding complex eIF4F is an essential component of the translational machinery. Recognition of the mRNA cap structure through its subunit eIF4E is a requirement for the recruitment of other translation initiation factors to the mRNA 5'-end and thereby for the attachment of the 40 S ribosomal subunit. In this study, we have investigated the mechanistic basis of the observation that eIF4E binding to the cap is enhanced in the presence of the large eIF4F subunit, eIF4G. We show that eIF4E requires access to both the mRNA 5'-cap and eIF4G to form stable complexes with short RNAs. This stabilization can be achieved using fragments of eIF4G that contain the eIF4E binding site but not the RNA recognition motifs. Full-length eIF4G is shown to induce increased eIF4E binding to cap analogues that do not contain an RNA body. Both results show that interaction of eIF4G with the mRNA is not necessary to enhance cap binding by eIF4E. Moreover, we show that the effect of binding of full-length eIF4G on the cap affinity of eIF4E can be further modulated through binding of Pab1 to eIF4G. These data are consistent with a model in which heterotropic cooperativity underlies eIF4F function.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Posttranscript Control Grp, Manchester M60 1QD, Lancs, England	University of Manchester	von der Haar, T (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Posttranscript Control Grp, POB 88, Manchester M60 1QD, Lancs, England.			von der Haar, Tobias/0000-0002-6031-9254				Altmann M, 1997, EMBO J, V16, P1114, DOI 10.1093/emboj/16.5.1114; CARBERRY SE, 1989, BIOCHEMISTRY-US, V28, P8078, DOI 10.1021/bi00446a017; EDERY I, 1987, TRANSLATIONAL REGULA, P335; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; Hershey PEC, 1999, J BIOL CHEM, V274, P21297, DOI 10.1074/jbc.274.30.21297; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LANG V, 1994, J BIOL CHEM, V269, P6117; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; MADER S, 1995, MOL CELL BIOL, V15, P4990; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; McCarthy JEG, 1998, MICROBIOL MOL BIOL R, V62, P1492, DOI 10.1128/MMBR.62.4.1492-1553.1998; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Morley SJ, 1997, RNA, V3, P1085; NIEDZWIECKAKORM.A, 1999, RNA; Ptushkina M, 1999, EMBO J, V18, P4068, DOI 10.1093/emboj/18.14.4068; Ptushkina M, 1998, EMBO J, V17, P4798, DOI 10.1093/emboj/17.16.4798; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SHA M, 1995, J BIOL CHEM, V270, P29904; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Vilela C, 2000, EMBO J, V19, P4372, DOI 10.1093/emboj/19.16.4372; Wei CC, 1998, BIOCHEMISTRY-US, V37, P1910, DOI 10.1021/bi9724570; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Wieczorek Z, 1999, Z NATURFORSCH C, V54, P278; YOUTANI T, 2000, BIOCHEM MOL BIOL INT, V49, P27	31	116	118	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30551	30555		10.1074/jbc.M004565200	http://dx.doi.org/10.1074/jbc.M004565200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10887196	hybrid			2022-12-25	WOS:000089577900087
J	Pector, V; Backmann, J; Maes, D; Vandenbranden, M; Ruysschaert, JM				Pector, V; Backmann, J; Maes, D; Vandenbranden, M; Ruysschaert, JM			Biophysical and structural properties of DNA center dot diC(14)-amidine complexes - Influence of the DNA/lipid ratio	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATIONIC LIPOSOME COMPLEXES; VIVO GENE-TRANSFER; IN-VIVO; DNA COMPLEXES; CRYOELECTRON MICROSCOPY; MAMMALIAN-CELLS; LIPID VESICLES; FUSION; DELIVERY; THERAPY	Cationic liposomes are used as vectors for gene delivery both in vitro and in vivo. Comprehension of both DNA/liposome interactions on a molecular level and a description of structural modifications involved, are prerequisites to an optimization of the transfection protocol and, thus, successful application in therapy. Formation and stability of a DNA/cationic liposome complex were investigated here at different DNA:lipid molar ratios (rho). Isothermal titration calorimetry (ITC) of cationic liposomes with plasmid DNA was used to characterize the DNA-lipid interaction. Two processes were shown to be involved in the complex formation. A fast exothermic process was attributed to the electrostatic binding of DNA to the liposome surface. A subsequent slower endothermic reaction is likely to be caused by the fusion of the two components and their rearrangement into a new structure. Fluorescence and differential scanning calorimetry confirmed this interpretation. A kinetic model analyzes the ITC profile in terms of DNA/cationic liposome interactions.	Free Univ Brussels, Chim Phys Macromol Interfaces Lab, B-1050 Brussels, Belgium; Free Univ Brussels, Dept Ultrastruct, B-1640 Rhode St Genese, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Pector, V (corresponding author), Free Univ Brussels, Chim Phys Macromol Interfaces Lab, Campus Plaine CP 206-2, B-1050 Brussels, Belgium.			Backmann, Jan/0000-0002-3323-8838				ALI M, 1994, GENE THER, V1, P367; Battersby BJ, 1998, BBA-BIOMEMBRANES, V1372, P379, DOI 10.1016/S0005-2736(98)00062-5; BEHR JP, 1994, BIOCONJUGATE CHEM, V5, P382, DOI 10.1021/bc00029a002; BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; DUZGUNES N, 1989, BIOCHEMISTRY-US, V28, P9179, DOI 10.1021/bi00449a033; DUZGUNES N, 1993, METHOD ENZYMOL, V220, P3, DOI 10.1016/0076-6879(93)20069-F; ElOuahabi A, 1996, FEBS LETT, V380, P108, DOI 10.1016/0014-5793(96)00038-5; ElOuahabi A, 1997, FEBS LETT, V414, P187, DOI 10.1016/S0014-5793(97)00973-3; EPAND RM, 1995, BIOSCIENCE REP, V15, P151, DOI 10.1007/BF01207455; Felgner JH, 1997, PHARMACEUT RES, V14, P1269, DOI 10.1023/A:1012131613160; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; Felgner PL, 1996, HUM GENE THER, V7, P1791, DOI 10.1089/hum.1996.7.15-1791; Ferrari ME, 1998, HUM GENE THER, V9, P341, DOI 10.1089/hum.1998.9.3-341; Fortunati E, 1996, BBA-GENE STRUCT EXPR, V1306, P55, DOI 10.1016/0167-4781(95)00217-0; Gao X, 1995, GENE THER, V2, P710; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; GUNZBURG WH, 1995, MOL MED TODAY, V1, P410, DOI 10.1016/S1357-4310(95)90771-8; Hirsch-Lemer D, 1998, BBA-BIOMEMBRANES, V1370, P17, DOI 10.1016/S0005-2736(97)00239-3; Huebner S, 1999, BIOPHYS J, V76, P3158, DOI 10.1016/S0006-3495(99)77467-9; KENNETH WCM, 1997, BIOPHYS J, V73, P2534; KERENZUR M, 1989, BIOCHIM BIOPHYS ACTA, V983, P253, DOI 10.1016/0005-2736(89)90241-1; Lasic DD, 1997, J AM CHEM SOC, V119, P832, DOI 10.1021/ja962713g; LEVENTIS R, 1990, BIOCHIM BIOPHYS ACTA, V1023, P124, DOI 10.1016/0005-2736(90)90017-I; Liu F, 1997, GENE THER, V4, P517, DOI 10.1038/sj.gt.3300424; NIEVA JL, 1994, EMBO J, V13, P2797, DOI 10.1002/j.1460-2075.1994.tb06573.x; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V394, P483, DOI 10.1016/0005-2736(75)90299-0; Pires P, 1999, BBA-BIOMEMBRANES, V1418, P71, DOI 10.1016/S0005-2736(99)00023-1; Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810; RUYSSCHAERT JM, 1994, BIOCHEM BIOPH RES CO, V203, P1622, DOI 10.1006/bbrc.1994.2372; SEELIG J, 1993, BIOCHEMISTRY-US, V32, P9714, DOI 10.1021/bi00088a025; Seelig J, 1997, BBA-REV BIOMEMBRANES, V1331, P103, DOI 10.1016/S0304-4157(97)00002-6; Sternberg B, 1998, BBA-BIOMEMBRANES, V1375, P23, DOI 10.1016/S0005-2736(98)00129-1; STERNBERG B, 1994, FEBS LETT, V356, P361, DOI 10.1016/0014-5793(94)01315-2; TAKEHARA T, 1995, HEPATOLOGY, V21, P746, DOI 10.1002/hep.1840210323; THOMAS PG, 1993, BIOCHEM J, V291, P397, DOI 10.1042/bj2910397; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Yang JP, 1998, GENE THER, V5, P380, DOI 10.1038/sj.gt.3300596; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073; Zuidam NJ, 1997, BBA-BIOMEMBRANES, V1329, P211, DOI 10.1016/S0005-2736(97)00110-7	39	47	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29533	29538		10.1074/jbc.M909996199	http://dx.doi.org/10.1074/jbc.M909996199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896680	hybrid			2022-12-25	WOS:000089439800048
J	Yamaguchi, H; Yamashita, H; Mori, H; Okazaki, I; Nomizu, M; Beck, K; Kitagawa, Y				Yamaguchi, H; Yamashita, H; Mori, H; Okazaki, I; Nomizu, M; Beck, K; Kitagawa, Y			High and low affinity heparin-binding sites in the G domain of the mouse laminin alpha 4 chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG ARM; BASEMENT-MEMBRANES; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; GAMMA-3 CHAIN; EXPRESSION; DYSTROGLYCAN; GLYCOPROTEIN; RECOMBINANT; PROTEINS	G domains of the mouse laminin alpha 1 and alpha 4 chains consisting of its five subdomains LG1-LG5 were overexpressed in Chinese hamster ovary cells and purified by heparin chromatography. alpha 1LG1-LG5 and alpha 4LG1-LG5 eluted at NaCl concentrations of 0.30 and 0.47 M, respectively. In solid phase binding assays with immobilized heparin, half-maximal concentrations of 14 (alpha 1LG1-LG5) and 1.4 nM (alpha 4LG1-LG5) were observed. N-Glycan cleavage of alpha 4LG1-LG5 did not affect affinity to heparin. The affinity of ru4LG1-LG5 was significantly reduced upon denaturation with 8 M urea but could be recovered by removing urea. Chymotrypsin digestion of alpha 4LG1-LG5 yielded high and low heparin affinity fragments containing either the alpha 4LG4-LG5 or alpha 4LG2-LG3 modules, respectively. Trypsin digestion of heparin-bound alpha 4LG1-LG5 yielded a high affinity fragment of about 190 residues corresponding to the alpha 4LG4 module indicating that the high affinity binding site is contained within alpha 4LG4. Competition for heparin binding of synthetic peptides covering the alpha 4LG4 region with complete alpha 4LG1-LG5 suggests that the sequence AHGRL1521 is crucial for high affinity binding. Introduction of mutation of H1518A or R1520A in glutathione S-transferase fusion protein of the alpha 4LG4 module produced in Escherichia coli markedly reduced heparin binding activity of the wild type. When compared with the known structure of alpha 2LG5, this sequence corresponds to the turn connecting strands E and F of the 14-stranded beta-sheet sandwich, which is opposite to the proposed binding sites for calcium ion, alpha-dystroglycan, and heparan sulfate.	Nagoya Univ, Grad Sch Bioagr Sci, Grad Course Regulat Biol Signals, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Biosci Ctr, Nagoya, Aichi 4648601, Japan; Hokkaido Univ, Grad Sch Environm Earth Sci, Sapporo, Hokkaido 0600810, Japan	Nagoya University; Nagoya University; Hokkaido University	Kitagawa, Y (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Grad Course Regulat Biol Signals, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.		Beck, Konrad/AAX-1351-2020	Beck, Konrad/0000-0001-5098-9484; Yamashita, Hironobu/0000-0003-2587-7100				Andac Z, 1999, J MOL BIOL, V287, P253, DOI 10.1006/jmbi.1999.2606; ARATANI Y, 1988, J BIOL CHEM, V263, P16163; AUMAILLEY M, 1989, EUR J BIOCHEM, V184, P241, DOI 10.1111/j.1432-1033.1989.tb15013.x; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; Colognato H, 1997, J BIOL CHEM, V272, P29330, DOI 10.1074/jbc.272.46.29330; Delacoux F, 1998, J BIOL CHEM, V273, P15069, DOI 10.1074/jbc.273.24.15069; ErsdalBadju E, 1997, J BIOL CHEM, V272, P19393, DOI 10.1074/jbc.272.31.19393; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Frieser M, 1997, EUR J BIOCHEM, V246, P727, DOI 10.1111/j.1432-1033.1997.t01-1-00727.x; GEE SH, 1993, J BIOL CHEM, V268, P14972; Hill JS, 1998, J BIOL CHEM, V273, P30979, DOI 10.1074/jbc.273.47.30979; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; Iivanainen A, 1999, J BIOL CHEM, V274, P14107, DOI 10.1074/jbc.274.20.14107; IIVANAINEN A, 1995, FEBS LETT, V365, P183, DOI 10.1016/0014-5793(95)00462-I; Iivanainen A, 1997, J BIOL CHEM, V272, P27862, DOI 10.1074/jbc.272.44.27862; Kapila YL, 1997, J BIOL CHEM, V272, P18932, DOI 10.1074/jbc.272.30.18932; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu JG, 1996, MATRIX BIOL, V15, P433, DOI 10.1016/S0945-053X(96)90162-6; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Nielsen PK, 2000, J BIOL CHEM, V275, P14517, DOI 10.1074/jbc.275.19.14517; Niimi T, 1997, FEBS LETT, V400, P71, DOI 10.1016/S0014-5793(96)01355-5; Niimi T, 1997, J BIOCHEM, V121, P854; Niimi T, 1997, MATRIX BIOL, V16, P223, DOI 10.1016/S0945-053X(97)90011-1; Nomizu M, 1998, J BIOL CHEM, V273, P32491, DOI 10.1074/jbc.273.49.32491; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; RYAN MC, 1994, J BIOL CHEM, V269, P22779; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SOROKIN L, 1994, EUR J BIOCHEM, V223, P603, DOI 10.1111/j.1432-1033.1994.tb19031.x; Sorokin LM, 1997, DEV BIOL, V189, P285, DOI 10.1006/dbio.1997.8668; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; Sung U, 1997, EUR J BIOCHEM, V250, P138, DOI 10.1111/j.1432-1033.1997.00138.x; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Talts JF, 1998, FEBS LETT, V426, P71, DOI 10.1016/S0014-5793(98)00312-3; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; TOKIDA Y, 1990, J BIOL CHEM, V265, P18123; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	46	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29458	29465		10.1074/jbc.M003103200	http://dx.doi.org/10.1074/jbc.M003103200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893232	hybrid, Green Accepted			2022-12-25	WOS:000089439800039
J	Hasegawa, J; Uchiyama, S; Tanimoto, Y; Mizutani, M; Kobayashi, Y; Sambongi, Y; Igarashi, Y				Hasegawa, J; Uchiyama, S; Tanimoto, Y; Mizutani, M; Kobayashi, Y; Sambongi, Y; Igarashi, Y			Selected mutations in a mesophilic cytochrome c confer the stability of a thermophilic counterpart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL SCANNING CALORIMETRY; HYDROGEN-OXIDIZING BACTERIUM; TRIPLE-RESONANCE NMR; LARGER PROTEINS; THERMOSTABILITY; SPECTRA; SPECTROSCOPY; RESOLUTION; H2O; H-1	Mesophilic cytochrome c(551) of Pseudomonas aeruginosa (PA c(551)) became as stable as its thermophilic counterpart, Hydrogenobacter thermophilus cytochrome c(552) (HT c(552)), through only five amino acid substitutions. The five residues, distributed in three spatially separated regions, were selected and mutated with reference to the corresponding residues in HT c(552) through careful structure comparison. Thermodynamic analysis indicated that the stability of the quintuple mutant of PA c(551) could be partly attained through an enthalpic factor. The solution structure of the mutant showed that, as in HT c(552), there were tighter side chain packings in the mutated regions. Furthermore, the mutant had an increased total accessible surface area, resulting in great negative hydration free energy. Our results provide a novel example of protein stabilization in that limited amino acid substitutions can confer the overall stability of a natural highly thermophilic protein upon a mesophilic molecule.	Daiichi Pharmaceut Co Ltd, Edogawa Ku, Tokyo 1348630, Japan; Osaka Univ, Fac Pharmaceut Sci, Suita, Osaka 5650871, Japan; Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1130032, Japan; Osaka Univ, Inst Sci & Ind Res, Ibaraki, Osaka 5670047, Japan	Daiichi Sankyo Company Limited; Osaka University; University of Tokyo; Osaka University	Hasegawa, J (corresponding author), Daiichi Pharmaceut Co Ltd, Edogawa Ku, Tokyo 1348630, Japan.		UCHIYAMA, Susumu/F-9590-2017	UCHIYAMA, Susumu/0000-0002-5181-179X				ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; Bogin O, 1998, PROTEIN SCI, V7, P1156, DOI 10.1002/pro.5560070509; Brunger A.T., 1993, X PLOR VERSION 3 1 S; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Eidsness MK, 1997, BIOCHEMISTRY-US, V36, P10406, DOI 10.1021/bi970110r; FREIRE E, 1994, METHOD ENZYMOL, V240, P502; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Gromiha MM, 1999, BIOPHYS CHEM, V82, P51, DOI 10.1016/S0301-4622(99)00103-9; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; Hasegawa J, 1999, J BIOL CHEM, V274, P37533, DOI 10.1074/jbc.274.53.37533; Hasegawa J, 1998, BIOCHEMISTRY-US, V37, P9641, DOI 10.1021/bi9803067; Hollien J, 1999, P NATL ACAD SCI USA, V96, P13674, DOI 10.1073/pnas.96.24.13674; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KAY LE, 1993, J AM CHEM SOC, V115, P2055, DOI 10.1021/ja00058a072; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KELLER RM, 1978, BIOCHIM BIOPHYS ACTA, V533, P195, DOI 10.1016/0005-2795(78)90564-0; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MAKHATADZE GI, 1992, J MOL BIOL, V226, P491, DOI 10.1016/0022-2836(92)90963-K; Malakauskas SM, 1998, NAT STRUCT BIOL, V5, P470, DOI 10.1038/nsb0698-470; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; MATSUURA Y, 1982, J MOL BIOL, V156, P389, DOI 10.1016/0022-2836(82)90335-7; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; OOBATAKE M, 1993, PROG BIOPHYS MOL BIO, V59, P237, DOI 10.1016/0079-6107(93)90002-2; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; Perl D, 2000, NAT STRUCT BIOL, V7, P380; Plotnikov VV, 1997, ANAL BIOCHEM, V250, P237, DOI 10.1006/abio.1997.2236; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; Sambongi Y, 1996, MOL MICROBIOL, V19, P1193, DOI 10.1111/j.1365-2958.1996.tb02465.x; SANBONGI Y, 1989, J BACTERIOL, V171, P65, DOI 10.1128/jb.171.1.65-69.1989; SANBONGI Y, 1989, BIOCHEMISTRY-US, V28, P9574, DOI 10.1021/bi00451a004; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SERRANO L, 1993, J MOL BIOL, V233, P305, DOI 10.1006/jmbi.1993.1508; STURTEVANT JM, 1987, ANNU REV PHYS CHEM, V38, P463, DOI 10.1146/annurev.pc.38.100187.002335; Vetriani C, 1998, P NATL ACAD SCI USA, V95, P12300, DOI 10.1073/pnas.95.21.12300; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	43	59	61	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37824	37828		10.1074/jbc.M005861200	http://dx.doi.org/10.1074/jbc.M005861200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10918067	hybrid, Green Published			2022-12-25	WOS:000165618700070
J	Montano, MM; Wittmann, BM; Bianco, NR				Montano, MM; Wittmann, BM; Bianco, NR			Identification and characterization of a novel factor that regulates quinone reductase gene transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; PLANAR AROMATIC-COMPOUNDS; HORMONE-BINDING DOMAIN; YA-SUBUNIT GENE; RESPONSIVE ELEMENT; INDUCIBLE EXPRESSION; MOLECULAR-CLONING; INDUCTION; ANTIESTROGENS; ELECTROPHILE	The regulation of the quinone reductase (QR) gene as well as other genes involved in detoxification is known to be mediated by an electrophile/antioxidant response element (EpRE/ARE). We have previously observed that QR is up-regulated by the antiestrogen trans-hydroxytamoxifen in breast cancer cells. QR gene regulation by the antiestrogen-occupied estrogen receptor (ER) is mediated by the EpRE-containing region of the human QR gene, and the ER is one of the complex of proteins that binds to the EpRE. In an effort to further understand the mechanism for ER regulation of QR gene we identified other protein factors that regulate QR gene transcriptional activity in breast cancer cells. One of these protein factors, hPMC2 (human homolog of Xenopus gene which prevents mitotic catastrophe), directly binds to the EpRE and interacts with the ER in yeast genetic screening and in vitro assays. Interestingly hPMC2 interacts more strongly to ER beta when compared with ER alpha. In transient transfection assays using reporter constructs containing the EpRE, hPMC2 alone can slightly activate reporter in ER-negative MDA-MB-231 breast cancer cells. The activation of QR gene activity by hPMC2 is enhanced in the presence of ER beta.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44122 USA	Case Western Reserve University	Montano, MM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, HG Wood Bldg W307,2109 Adelbert Rd, Cleveland, OH 44122 USA.	mxm126@po.cwru.edu			NCI NIH HHS [CA80959] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chusacultanachai S, 1999, J BIOL CHEM, V274, P23591, DOI 10.1074/jbc.274.33.23591; Crute BE, 1996, J BIOL CHEM, V271, P26251, DOI 10.1074/jbc.271.42.26251; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; JIN WD, 1994, MOL ENDOCRINOL, V8, P1377, DOI 10.1210/me.8.10.1377; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KRAUS WL, 1994, MOL ENDOCRINOL, V8, P952, DOI 10.1210/me.8.8.952; Kwiatkowska J, 1997, GENOMICS, V44, P350, DOI 10.1006/geno.1997.4874; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Montano MM, 1997, P NATL ACAD SCI USA, V94, P2581, DOI 10.1073/pnas.94.6.2581; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Montano MM, 1998, J BIOL CHEM, V273, P25443, DOI 10.1074/jbc.273.39.25443; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Pentecost BT, 1998, J STEROID BIOCHEM, V64, P25, DOI 10.1016/S0960-0760(97)00140-4; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; PRESTERA T, 1993, ADV ENZYME REGUL, V33, P281; Qiu XB, 1996, J BIOL CHEM, V271, P31915, DOI 10.1074/jbc.271.50.31915; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; REESE JC, 1991, J BIOL CHEM, V266, P10880; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SU JY, 1995, MOL GEN GENET, V246, P387, DOI 10.1007/BF00288613; TALALAY P, 1989, ADV ENZYME REGUL, V28, P237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; WRENN CK, 1993, J BIOL CHEM, V268, P24089; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XIE T, 1995, J BIOL CHEM, V270, P6894, DOI 10.1074/jbc.270.12.6894; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545	34	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34306	34313		10.1074/jbc.M003880200	http://dx.doi.org/10.1074/jbc.M003880200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10908561	hybrid			2022-12-25	WOS:000165095300043
J	Ferguson, KL; Callaghan, SM; O'Hare, MJ; Park, DS; Slack, RS				Ferguson, KL; Callaghan, SM; O'Hare, MJ; Park, DS; Slack, RS			The Rb-CDK4/6 signaling pathway is critical in neural precursor cell cycle regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE-ACTIVITY; RETINOBLASTOMA PROTEIN; CDK INHIBITORS; RESTRICTION POINT; NUCLEAR-PROTEIN; DISTINCT ROLES; GANGLION-CELLS; DIFFERENTIATION; PHASE; MOUSE	The tumor suppressor, retinoblastoma (Rb), is involved in both terminal mitosis and neuronal differentiation. We hypothesized that activation of the Rb pathway would induce cell cycle arrest in primary neural precursor cells, independent of the proposed function of cyclin-dependent kinases 4/6 (CDK4/6) to sequester the CIP/KIP CDK inhibitors (CKIs) p21 and p27 from CDK2, We expressed dominant negative adenovirus mutants of CDKs 2, 4, and 6 (dnCDK2, dnCDK4, and dnCDK6) in neural progenitor cells derived from E12.5 wild type and Rb-deficient mouse embryos. In contrast to previous studies, our results demonstrate that in addition to dnCDK2, the dnCDK4/6 mutants can induce growth arrest. Moreover, the dnCDK4/6-mediated inhibition is Rb-dependent. The dnCDK2 partially inhibited cell growth in Rb-deficient cells, suggesting that CDK2 may have additional targets, A previously proposed function of CDK4/6 is CKI sequestration, thereby preventing the resulting inhibition of CDK2, believed to be the key regulator of cell cycle. However, our immunoprecipitations revealed that the dominant negative CDK mutants could arrest cell growth despite their interaction with p21 and p27, Taken together, our results demonstrate that both CDK2 and CDK4/6 are crucial for cell cycle regulation. Furthermore, our data underscore the importance of the Rb regulatory pathway in neuronal development and cell cycle regulation, independent of CRI sequestration.	Univ Ottawa, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Slack, RS (corresponding author), Univ Ottawa, Neurosci Res Inst, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.			Slack, Ruth/0000-0002-1552-2835; Park, David/0000-0002-4490-3784				Callaghan DA, 1999, DEV BIOL, V207, P257, DOI 10.1006/dbio.1998.9162; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cregan SP, 2000, GENE THER, V7, P1200, DOI 10.1038/sj.gt.3301208; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ElShamy WM, 1998, NEURON, V21, P1003, DOI 10.1016/S0896-6273(00)80619-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GHOSH A, 1995, NEURON, V15, P89, DOI 10.1016/0896-6273(95)90067-5; Gill RM, 1998, EXP CELL RES, V244, P157, DOI 10.1006/excr.1998.4197; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; INO H, 1994, BRAIN RES, V661, P196, DOI 10.1016/0006-8993(94)91197-5; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KATO J, 1993, GENE DEV, V7, P331; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; MCLOON SC, 1989, J NEUROSCI, V9, P1424; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Park DS, 1997, J NEUROSCI, V17, P8975; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; SEWING A, 1993, J CELL SCI, V104, P545; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Slack RS, 1996, DEV GENET, V18, P81, DOI 10.1002/(SICI)1520-6408(1996)18:1<81::AID-DVG9>3.0.CO;2-Y; Slack RS, 1998, J CELL BIOL, V140, P1497, DOI 10.1083/jcb.140.6.1497; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VESCOVI AL, 1993, NEURON, V11, P951, DOI 10.1016/0896-6273(93)90124-A; WAID DK, 1995, NEURON, V14, P117, DOI 10.1016/0896-6273(95)90245-7	40	61	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33593	33600		10.1074/jbc.M004879200	http://dx.doi.org/10.1074/jbc.M004879200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10915795	hybrid			2022-12-25	WOS:000090104600059
J	Imokawa, G; Kobayasi, T; Miyagishi, M				Imokawa, G; Kobayasi, T; Miyagishi, M			Intracellular signaling mechanisms leading to synergistic effects of endothelin-1 and stem cell factor on proliferation of cultured human melanocytes - Cross-talk vla trans-activation of the tyrosine kinase c-kit receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE; WAARDENBURG-SYNDROME; HUMAN PIEBALDISM; BIOLOGICAL CHARACTERIZATION; HIRSCHSPRUNG DISEASE; DEPENDENT MECHANISM; LOCUS PROTEIN; RAF-1 KINASE; MAST-CELLS	We previously reported that activation of mitogen-activated protein kinase (MAPK) is involved in the mitogenic stimulation of normal human melanocytes (NHMC) by endothelin-l (ET-1). In the present study, we determined signaling mechanisms upstream of MAPK activation that are involved in ET-1 stimulation and their synergism with stem cell factor (SCF). Pretreatment of cultured NHMC with ETB receptor antagonists, pertussis toxin, a specific phospholipase C inhibitor (U73122), or a protein kinase C inhibitor (calphostine) blocked a transient tyrosine phosphorylation of MAPK induced by ET-1, whereas the addition of a calcium chelator (BAPTA) failed to inhibit that tyrosine phosphorylation of MAPK. Treatment with ET-1 and SCF together synergistically increased DNA synthesis, which was accompanied by synergism for MAPK phosphorylation. The time course of inositol 1,4,5-trisphosphate formation revealed that there is no difference in the level of inositol 1,4,5-trisphosphate stimulated by ET-1 + SCF or by ET-1 alone. Evaluations of the serine phosphorylation of MEK and Raf-l activity showed a synergistic effect in SCF + ET-l-treated NHMC. Stimulation with SCF + ET-1 induced a more rapid and stronger tyrosyl phosphorylation of proteins corresponding to p52 and p66 Shc than did stimulation with SCF only, and this was accompanied by a stronger association of tyrosine-phosphorylated Shc with Grb2. Interestingly, a more rapid and marked tyrosine phosphorylation of c-kit was also detected in NHMC-treated with SCF + ET-1 than NHMC treated with SCF only. These data indicate that the synergistic cross-talk between SCF and ET-1 signaling is initiated through the pathway of tyrosine phosphorylation of c-kit, which results in the enhanced formation of the Shc-Grb(2) complex which leads in turn to the synergistic activation of the Ras/Raf-1/MEK/MAP kinase loop.	Kao Biol Sci Labs, Haga, Tochigi 3213497, Japan		Imokawa, G (corresponding author), Kao Biol Sci Labs, 2606 Akabane, Haga, Tochigi 3213497, Japan.		Miyagishi, Makoto/L-8174-2016	Miyagishi, Makoto/0000-0001-7654-3616; Kobayashi, Takeshi/0000-0002-4372-5285				ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Amiel J, 1996, HUM MOL GENET, V5, P355, DOI 10.1093/hmg/5.3.355; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; Cacace AM, 1996, ONCOGENE, V13, P2517; CAZAUBON S, 1993, BIOCHEM J, V293, P381, DOI 10.1042/bj2930381; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; Dabrowski A, 1996, J BIOL CHEM, V271, P27125, DOI 10.1074/jbc.271.43.27125; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Edery P, 1996, NAT GENET, V12, P442, DOI 10.1038/ng0496-442; EZOE K, 1995, AM J HUM GENET, V56, P58; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; HORI Y, 1996, MELANOGENESIS MALIGN, P35; Imokawa G, 1998, BIOCHEM J, V330, P1235, DOI 10.1042/bj3301235; Imokawa G, 1996, BIOCHEM J, V314, P305, DOI 10.1042/bj3140305; Imokawa G, 1997, PIGM CELL RES, V10, P218, DOI 10.1111/j.1600-0749.1997.tb00488.x; IMOKAWA G, 1992, J BIOL CHEM, V267, P24675; Ito A, 1999, BLOOD, V93, P1189, DOI 10.1182/blood.V93.4.1189.404k32_1189_1196; Iwasaki H, 1999, ENDOCRINOLOGY, V140, P4659, DOI 10.1210/en.140.10.4659; KOBAYASHI T, 1994, EMBO J, V13, P5818, DOI 10.1002/j.1460-2075.1994.tb06925.x; KOBAYASHI T, 1994, J BIOL CHEM, V269, P29198; Kobayashi T, 1998, J BIOL CHEM, V273, P31801, DOI 10.1074/jbc.273.48.31801; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; LONGLEY BJ, 1993, NEW ENGL J MED, V328, P1302, DOI 10.1056/NEJM199305063281803; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; Read AP, 1997, J MED GENET, V34, P656, DOI 10.1136/jmg.34.8.656; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Sakai C, 1997, EMBO J, V16, P3544, DOI 10.1093/emboj/16.12.3544; SPRITZ RA, 1992, AM J HUM GENET, V50, P261; Sui XW, 1998, BLOOD, V92, P1142, DOI 10.1182/blood.V92.4.1142.416k42_1142_1149; Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996-50; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; Tsujimura T, 1996, BLOOD, V88, P1225, DOI 10.1182/blood.V88.4.1225.bloodjournal8841225; Ueffing M, 1997, ONCOGENE, V15, P2921, DOI 10.1038/sj.onc.1201477; VAN BT, 1995, NATURE, V376, P781; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; vanDijk MCM, 1997, BIOCHEM J, V325, P303, DOI 10.1042/bj3250303; YADA Y, 1991, J BIOL CHEM, V266, P18352; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	48	95	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33321	33328		10.1074/jbc.M004346200	http://dx.doi.org/10.1074/jbc.M004346200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10921922	hybrid			2022-12-25	WOS:000090104600023
J	Tipnis, SR; Hooper, NM; Hyde, R; Karran, E; Christie, G; Turner, AJ				Tipnis, SR; Hooper, NM; Hyde, R; Karran, E; Christie, G; Turner, AJ			A human homolog of angiotensin-converting enzyme - Cloning and functional expression as a captopril-insensitive carboxypeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL CARBOXYPEPTIDASE; MOLECULAR-CLONING; BLOOD-PRESSURE; PROTEINS; MEMBRANE; GENE; FERTILITY; FLUID; ACID; MICE	A novel human zinc metalloprotease that has considerable homology to human angiotensin-converting enzyme (ACE) (40% identity and 61% similarity) has been identified, This metalloprotease (angiotensin-converting enzyme homolog (ACEH)) contains a single HEXXH zinc-binding domain and conserves other critical residues typical of the ACE family. The predicted protein sequence consists of 805 amino acids, including a potential 17-amino acid N-terminal signal peptide sequence and a putative C-terminal membrane anchor. Expression in Chinese hamster ovary cells of a soluble, truncated form of ACEH, lacking the transmembrane and cytosolic domains, produces a glycoprotein of 120 kDa, which is able to cleave angiotensin I and angiotensin II but not bradykinin or Hip-His-Leu. In the hydrolysis of the angiotensins, ACEH functions exclusively as a carboxypeptidase, ACEH activity is inhibited by EDTA but not by classical ACE inhibitors such as captopril, lisinopril, or enalaprilat, Identification of the genomic sequence of ACEH has shown that the ACEH gene contains 18 exons, of which several have considerable size similarity with the first 17 exons of human ACE. The gene maps to chromosomal location Xp22, Northern blotting analysis has shown that the ACEH mRNA transcript is similar to3.4 kilobase pairs and is most highly expressed in testis, kidney, and heart. This is the first report of a mammalian homolog of ACE and has implications for our understanding of cardiovascular and renal function.	Univ Leeds, Sch Biochem & Mol Biol, Proteolysis Res Grp, Leeds LS2 9JT, W Yorkshire, England; SmithKline Beecham Pharmaceut, Neurosci Res, Harlow CM19 5AW, Essex, England	University of Leeds; GlaxoSmithKline	Tipnis, SR (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Proteolysis Res Grp, Leeds LS2 9JT, W Yorkshire, England.			Hooper, Nigel/0000-0002-5811-3484				BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CORNEL MJ, 1995, J BIOL CHEM, V270, P13613, DOI 10.1074/jbc.270.23.13613; CORVOL P, 1998, HDB PROTEOLYTIC ENZY, P1066; DAS M, 1977, J BIOL CHEM, V252, P1316; EHLERS MRW, 1989, P NATL ACAD SCI USA, V86, P7741, DOI 10.1073/pnas.86.20.7741; ELDORRY HA, 1983, BIOCHEM BIOPH RES CO, V115, P1096, DOI 10.1016/S0006-291X(83)80048-5; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Esther CR, 1996, LAB INVEST, V74, P953; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; HOOPER NM, 1987, BIOCHEM J, V247, P85, DOI 10.1042/bj2470085; Houard X, 1998, EUR J BIOCHEM, V257, P599, DOI 10.1046/j.1432-1327.1998.2570599.x; HUBERT C, 1991, J BIOL CHEM, V266, P15377; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANGO N, 1993, BIOCHEM SOC T, V21, P245; LATTION AL, 1989, FEBS LETT, V252, P99, DOI 10.1016/0014-5793(89)80897-X; OPPONG SY, 1993, BIOCHEM J, V292, P597, DOI 10.1042/bj2920597; RIEGER KJ, 1993, BIOCHEM J, V296, P373, DOI 10.1042/bj2960373; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; Sugimura K, 1998, BIOCHEM BIOPH RES CO, V247, P466, DOI 10.1006/bbrc.1998.8813; Taylor CAM, 1996, GENE, V181, P191, DOI 10.1016/S0378-1119(96)00503-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Turner AJ, 1997, FASEB J, V11, P355, DOI 10.1096/fasebj.11.5.9141502; Vendrell J, 2000, BBA-PROTEIN STRUCT M, V1477, P284, DOI 10.1016/S0167-4838(99)00280-0; WILLIAMS TA, 1994, J BIOL CHEM, V269, P29430; Woodman ZL, 2000, BIOCHEM J, V347, P711, DOI 10.1042/0264-6021:3470711; YANG HYT, 1970, BIOCHIM BIOPHYS ACTA, V214, P374, DOI 10.1016/0005-2795(70)90017-6; YASUI T, 1984, J LAB CLIN MED, V104, P741	31	1501	1662	4	61	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33238	33243		10.1074/jbc.M002615200	http://dx.doi.org/10.1074/jbc.M002615200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10924499	hybrid			2022-12-25	WOS:000090104600011
J	Ridgeway, AG; Petropoulos, H; Wilton, S; Skerjanc, IS				Ridgeway, AG; Petropoulos, H; Wilton, S; Skerjanc, IS			Wnt signaling regulates the function of MyoD and myogenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; MOUSE PARAXIAL MESODERM; BHLH GENE-EXPRESSION; DORSAL NEURAL-TUBE; TRANSCRIPTION FACTOR; MUSCLE DIFFERENTIATION; SKELETAL MYOGENESIS; BINDING-PROTEIN; SONIC HEDGEHOG; DNA-BINDING	The myogenic regulatory factors (MRFs), MyoD and myogenin, can induce myogenesis in a variety of cell lines but not efficiently in monolayer cultures of P19 embryonal carcinoma stem cells. Aggregation of cells expressing MRFs, termed P19[MRF] cells, results in an approximately 30-fold enhancement of myogenesis, Here we examine molecular events occurring during P19 cell aggregation to identify potential mechanisms regulating MRF activity. Although myogenin protein was continually present in the nuclei of >90% of P19[myogenin] cells, only a fraction of these cells differentiated. Consequently, it appears that post-translational regulation controls myogenin activity in a cell lineage-specific manner. A correlation was obtained between the expression of factors involved in somite patterning, including Wnt3a, Wnt5b, BMP-2/4, and Pax3, and the induction of myogenesis, Co-culturing P19[Wnt3a] cells with P19[MRF] cells in monolayer resulted in a 5- to 8-fold increase in myogenesis, Neither BMP-4 nor Pax3 was efficient in enhancing MRF activity in unaggregated P19 cultures. Furthermore, BMP-4 abrogated the enhanced myogenesis induced by Wnt signaling. Consequently, signaling events resulting from Wnt3a expression but not BMP-4 signaling or Pax3 expression, regulate MRF function. Therefore, the P19 cell culture system can be used to study the link between somite patterning events and myogenesis.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Skerjanc, IS (corresponding author), Univ Western Ontario, Dept Biochem, Med Sci Bldg, London, ON N6A 5C1, Canada.	skerjanc@julian.uwo.ca	Skerjanc, Ilona/AAN-3318-2020					ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Amthor H, 1999, DEVELOPMENT, V126, P1041; Angello JC, 1997, DEV BIOL, V192, P93, DOI 10.1006/dbio.1997.8722; Arias AM, 1999, CURR OPIN GENET DEV, V9, P447, DOI 10.1016/S0959-437X(99)80068-9; Armour C, 1999, EXP CELL RES, V251, P79, DOI 10.1006/excr.1999.4567; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Borycki AG, 1999, DEVELOPMENT, V126, P4053; Borycki AG, 1998, DEVELOPMENT, V125, P777; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUFFINGER N, 1995, DEV BIOL, V169, P96, DOI 10.1006/dbio.1995.1130; BUFFINGER N, 1994, DEVELOPMENT, V120, P1443; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cossu G, 1996, DEVELOPMENT, V122, P429; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; Cossu G, 1999, EMBO J, V18, P6867, DOI 10.1093/emboj/18.24.6867; Currie PD, 1998, MECH DEVELOP, V73, P3, DOI 10.1016/S0925-4773(98)00036-7; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; GARFINKEL LI, 1982, J BIOL CHEM, V257, P1078; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Gofflot F, 1997, DEV DYNAM, V210, P431, DOI 10.1002/(SICI)1097-0177(199712)210:4<431::AID-AJA7>3.0.CO;2-H; Gossler A, 1998, CURR TOP DEV BIOL, V38, P225; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HENTHORN P, 1990, NUCLEIC ACIDS RES, V18, P677, DOI 10.1093/nar/18.3.677; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; Ikeya M, 1998, DEVELOPMENT, V125, P4969; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Marcelle C, 1997, DEVELOPMENT, V124, P3955; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; MCBURNEY MW, 1994, SOMAT CELL MOLEC GEN, V20, P529, DOI 10.1007/BF02255843; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; MUNSTERBERG AE, 1995, DEVELOPMENT, V121, P651; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; MURRAY SS, 1993, J CELL BIOCHEM, V53, P51, DOI 10.1002/jcb.240530107; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAIDU PS, 1995, MOL CELL BIOL, V15, P2707; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; Petropoulos H, 2000, J BIOL CHEM, V275, P25095, DOI 10.1074/jbc.M004251200; Pourquie O, 1996, CELL, V84, P461, DOI 10.1016/S0092-8674(00)81291-X; PRUITT SC, 1992, DEVELOPMENT, V116, P573; Puri PL, 2000, GENE DEV, V14, P574; Reshef R, 1998, GENE DEV, V12, P290, DOI 10.1101/gad.12.3.290; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; Ridgeway AG, 1999, FEBS LETT, V456, P399, DOI 10.1016/S0014-5793(99)00993-X; Ridgeway AG, 2000, J BIOL CHEM, V275, P41, DOI 10.1074/jbc.275.1.41; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; RUDNICKI MA, 1990, DEV BIOL, V138, P348, DOI 10.1016/0012-1606(90)90202-T; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SHANI M, 1992, SYM SOC EXP BIOL, V46, P19; SKERJANC IS, 1994, MOL CELL BIOL, V14, P8451, DOI 10.1128/MCB.14.12.8451; Skerjanc IS, 1996, J BIOL CHEM, V271, P3555, DOI 10.1074/jbc.271.7.3555; Skerjanc IS, 1998, J BIOL CHEM, V273, P34904, DOI 10.1074/jbc.273.52.34904; Skerjanc IS, 1999, TRENDS CARDIOVAS MED, V9, P139, DOI 10.1016/S1050-1738(99)00017-1; STERN HM, 1995, DEVELOPMENT, V121, P3675; Tajbakhsh S, 1997, CURR OPIN GENET DEV, V7, P634, DOI 10.1016/S0959-437X(97)80011-1; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Tajbakhsh S, 1998, DEVELOPMENT, V125, P4155; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; Tremblay P, 1998, DEV BIOL, V203, P49, DOI 10.1006/dbio.1998.9041; VIDRICAIRE G, 1994, DEVELOPMENT, V120, P115; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; Wilton S, 1999, IN VITRO CELL DEV-AN, V35, P175; Wright WE, 1996, DEV GENET, V19, P131, DOI 10.1002/(SICI)1520-6408(1996)19:2<131::AID-DVG4>3.0.CO;2-A; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193	86	117	128	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32398	32405		10.1074/jbc.M004349200	http://dx.doi.org/10.1074/jbc.M004349200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10915791	hybrid			2022-12-25	WOS:000090003800005
J	Henklein, P; Bruns, K; Sherman, MP; Tessmer, U; Licha, K; Kopp, J; de Noronha, CMC; Greene, WC; Wray, V; Schubert, U				Henklein, P; Bruns, K; Sherman, MP; Tessmer, U; Licha, K; Kopp, J; de Noronha, CMC; Greene, WC; Wray, V; Schubert, U			Functional and structural characterization of synthetic HIV-1 Vpr that transduces cells, localizes to the nucleus, and induces G(2) cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; VIRAL PROTEIN-R; PREINTEGRATION COMPLEX; BIOLOGICAL FUNCTIONS; TERMINAL DOMAIN; GAG PRECURSOR; P6 DOMAIN; IN-VIVO; TYPE-1; INFECTION	Human immunodeficiency virus (HIV) Vpr contributes to nuclear import of the viral pre-integration complex and induces G(2), cell cycle arrest. We describe the production of synthetic Vpr that permitted the first studies on the structure and folding of the full-length protein. Vpr is unstructured at neutral pH whereas under acidic conditions or upon addition of trifluorethanol it adopts a-helical structures. Vpr forms dimers in aqueous trifluorethanol, whereas oligomers exist in pure water. H-1 NMR spectroscopy allows the signal assignment of N- and C-terminal amino acid residues; however, the central section of the molecule is obscured by self-association. These findings suggest that the in vivo folding of Vpr may require structure-stabilizing interacting factors such as previously described interacting cellular and viral proteins or nucleic acids. In biological studies we found that Vpr is efficiently taken up from the extracellular medium by cells in a process that occurs independent of other HIV-1 proteins and appears to be independent of cellular receptors. Following cellular uptake, Vpr is efficiently imported into the nucleus of transduced cells. Extracellular addition of Vpr induces G(2), cell cycle arrest in dividing cells. Together, these findings raise the possibility that circulating forms of Vpr observed in HIV-infected patients may exert biological effects on a broad range of host target cells.	NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; NIDDKD, Kidney Dis Sect, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; Humboldt Univ, Inst Biochem, D-10115 Berlin, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Gesell Biotechnol Forsch GmbH, Dept Mol Struct Res, D-38124 Braunschweig, Germany; Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA; Free Univ Berlin, Inst Diagnost Res GmbH, D-1000 Berlin, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Humboldt University of Berlin; Heinrich Pette Institute; University of Hamburg; Gesellschaft fur Biotechnologische Forschung mbH; University of California System; University of California San Francisco; The J David Gladstone Institutes; Free University of Berlin	Schubert, U (corresponding author), NIAID, Viral Dis Lab, NIH, Rm 205,Bldg 4,4 Ctr Dr,MSC 0440, Bethesda, MD 20892 USA.		Kopp, Jeffrey B/O-2681-2015	Kopp, Jeffrey B/0000-0001-9052-186X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045324, Z01AI000658, ZIAAI000658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK043308, Z01DK043308] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI45324] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Ayyavoo V, 1997, NAT MED, V3, P1117, DOI 10.1038/nm1097-1117; Bachand F, 1999, J BIOL CHEM, V274, P9083, DOI 10.1074/jbc.274.13.9083; Bukrinsky M, 1999, REV MED VIROL, V9, P39, DOI 10.1002/(SICI)1099-1654(199901/03)9:1<39::AID-RMV235>3.0.CO;2-3; CARPINO LA, 1993, J AM CHEM SOC, V115, P4397, DOI 10.1021/ja00063a082; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; Cornille F, 1999, J PEPT RES, V54, P427, DOI 10.1034/j.1399-3011.1999.00129.x; de Rocquigny H, 1997, J BIOL CHEM, V272, P30753, DOI 10.1074/jbc.272.49.30753; Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0; Felzien LK, 1998, P NATL ACAD SCI USA, V95, P5281, DOI 10.1073/pnas.95.9.5281; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GIBBS JS, 1995, J VIROL, V69, P2378, DOI 10.1128/JVI.69.4.2378-2383.1995; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; GRASMASSE H, 1990, INT J PEPT PROT RES, V36, P219; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Hrimech M, 1999, J VIROL, V73, P4101, DOI 10.1128/JVI.73.5.4101-4109.1999; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; Kino T, 1999, J EXP MED, V189, P51, DOI 10.1084/jem.189.1.51; KONDO E, 1995, J VIROL, V69, P2759, DOI 10.1128/JVI.69.5.2759-2764.1995; LANG SM, 1993, J VIROL, V67, P902, DOI 10.1128/JVI.67.2.902-912.1993; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; LEVY DN, 1995, J VIROL, V69, P1243, DOI 10.1128/JVI.69.2.1243-1252.1995; LEVY DN, 1994, P NATL ACAD SCI USA, V91, P10873, DOI 10.1073/pnas.91.23.10873; Lundgren S, 1997, J HISTOCHEM CYTOCHEM, V45, P383, DOI 10.1177/002215549704500306; Luo ZW, 1998, BIOCHEM BIOPH RES CO, V244, P732, DOI 10.1006/bbrc.1998.8330; Macreadie IG, 1996, MOL MICROBIOL, V19, P1185, DOI 10.1111/j.1365-2958.1996.tb02464.x; MACREADIE IG, 1995, P NATL ACAD SCI USA, V91, P27770; Moestrup SK, 1996, P NATL ACAD SCI USA, V93, P8612, DOI 10.1073/pnas.93.16.8612; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nie ZL, 1998, J VIROL, V72, P4104, DOI 10.1128/JVI.72.5.4104-4115.1998; Piller SC, 1996, P NATL ACAD SCI USA, V93, P111, DOI 10.1073/pnas.93.1.111; Piller SC, 1998, P NATL ACAD SCI USA, V95, P4595, DOI 10.1073/pnas.95.8.4595; Poon B, 1998, SCIENCE, V281, P266, DOI 10.1126/science.281.5374.266; Popov S, 1998, J BIOL CHEM, V273, P13347, DOI 10.1074/jbc.273.21.13347; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; Roques BP, 1997, BIOCHIMIE, V79, P673, DOI 10.1016/S0300-9084(97)83501-8; Schuler W, 1999, J MOL BIOL, V285, P2105, DOI 10.1006/jmbi.1998.2381; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Selig L, 1999, J VIROL, V73, P592, DOI 10.1128/JVI.73.1.592-600.1999; Stark LA, 1998, J VIROL, V72, P3037, DOI 10.1128/JVI.72.4.3037-3044.1998; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; Wang LL, 1996, GENE, V178, P7, DOI 10.1016/0378-1119(96)00312-5; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; Wecker K, 1999, EUR J BIOCHEM, V266, P359, DOI 10.1046/j.1432-1327.1999.00858.x; WRAY V, 1995, INT J PEPT PROT RES, V45, P35; Yao SG, 1998, PROTEIN PEPTIDE LETT, V5, P127; Zhang SG, 1998, GENE, V212, P157, DOI 10.1016/S0378-1119(98)00178-4; ZHAO LJ, 1994, J BIOL CHEM, V269, P32131	51	96	100	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32016	32026		10.1074/jbc.M004044200	http://dx.doi.org/10.1074/jbc.M004044200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10903315	hybrid			2022-12-25	WOS:000089858900065
J	Vuong, H; Patterson, T; Shapiro, P; Kalvakolanu, DV; Wu, R; Ma, WY; Dong, ZG; Kleeberger, SR; Reddy, SPM				Vuong, H; Patterson, T; Shapiro, P; Kalvakolanu, DV; Wu, R; Ma, WY; Dong, ZG; Kleeberger, SR; Reddy, SPM			Phorbol ester-induced expression of airway squamous cell differentiation marker, SPRR1B, is regulated by protein kinase C delta/Ras/MEKK1/MKK1-dependent/AP-1 signal transduction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH PROTEINS; BRONCHIAL EPITHELIAL-CELLS; C-DELTA; GENE-EXPRESSION; SPR1 GENE; KERATINOCYTE DIFFERENTIATION; MALIGNANT KERATINOCYTES; MEK KINASE; ACTIVATION; RAS	The transcriptional induction of SPRR1B by phorbol 12-myristate 13-acetate (PMA) is mainly mediated by the first -152-base pair 5'-flanking region containing two functional AP-1 sites. In this study, we have analyzed the signaling pathways that mediate the induction in tracheobronchial epithelial cells. PKC inhibitor ablated PMA-stimulated expression of endogenous SPRR1B and reporter gene expression driven by SPRR1B promoter. PKC activator promoted the transcription. The dominant negative protein kinase C delta (dn-PKC delta) and rottlerin (PKC delta inhibitor) completely suppressed PMA-stimulated promoter activity, dn-Ras or dn-MEKK1 inhibited PMA-stimulated promoter activity, while their corresponding constitutively active mutants augmented it. dn-c-Raf-1 did not have any effect on reporter gene expression. Since MEKK1 activates multiple parallel pathways, we examined involvement of JNK/SAPK, p38, and MKK1 in promoter regulation. Go-expression of the dominant negative forms of MKK4, MKK7, JNK/SAPK, MKK3, MKK6, or p38 alpha did not suppress PMA-stimulated reporter gene expression. However, MKK1 inhibitors UO126 and PD98095 suppressed gene expression. Consistent with this, expression of dn-MKK1 strongly suppressed PMA-stimulated promoter activity, while the constitutively active MKK1 augmented it. However, MKK1-mediated induction of SPRR1B probably does not depend on extracellular signal-regulated kinases 1 and 2, suggesting the requirement of another kinase(s). dnc-Jun mutants abolished PMA-stimulated expression supporting an important role for AP-l proteins in SPRR1B expression. Together, these results suggest that a PKC delta/Ras/MEKK1/MKK1-dependent/AP-1 pathway regulates the PMA-inducible expression of the SPRR1B in tracheobronchial epithelial cells.	Johns Hopkins Univ, Dept Environm Hlth Sci, Div Physiol, Sch Publ Hlth, Baltimore, MD 21205 USA; Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenbaum Canc Ctr, Baltimore, MD 21201 USA; Univ Calif Davis, Dept Internal Med, Sch Med, Davis, CA 95616 USA; Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of California System; University of California Davis; University of Minnesota System	Reddy, SPM (corresponding author), Johns Hopkins Univ, Dept Environm Hlth Sci, Div Physiol, Sch Publ Hlth, Rm W7006,615 N Wolfe St, Baltimore, MD 21205 USA.	sreddy@jhsph.edu	Kleeberger, Steven R/F-1807-2019	Kleeberger, Steven R/0000-0003-2948-8452	NCI NIH HHS [CA-71401] Funding Source: Medline; NHLBI NIH HHS [HL-58122] Funding Source: Medline; NIEHS NIH HHS [ES-06230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071401] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058122, R29HL058122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006230, Z01ES100513, Z01ES100512] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AN G, 1993, J CELL PHYSIOL, V157, P562, DOI 10.1002/jcp.1041570316; AN G, 1993, J BIOL CHEM, V268, P10977; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Anisowicz A, 1999, MOL MED, V5, P526, DOI 10.1007/BF03401980; BASBAUM C, 1990, AM J PHYSIOL, V259, pL38, DOI 10.1152/ajplung.1990.259.2.L38; BECCI PJ, 1978, J NATL CANCER I, V61, P577; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DeMuth JP, 1998, AM J RESP CELL MOL, V19, P25, DOI 10.1165/ajrcmb.19.1.3078; Deng J, 2000, AM J RESP CELL MOL, V22, P597, DOI 10.1165/ajrcmb.22.5.3520; Deng J, 2000, J BIOL CHEM, V275, P5739, DOI 10.1074/jbc.275.8.5739; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Eckert RL, 1996, MOL BIOL REP, V23, P59, DOI 10.1007/BF00357073; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Efimova T, 2000, J BIOL CHEM, V275, P1601, DOI 10.1074/jbc.275.3.1601; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GANDARILLAS A, 1995, MAMM GENOME, V6, P680, DOI 10.1007/BF00352383; GANG A, 1992, AM J RESP CELL MOL, V7, P104, DOI 10.1165/ajrcmb/7.1.104; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GIBBS S, 1993, GENOMICS, V16, P630, DOI 10.1006/geno.1993.1240; Griffiths G, 1996, BIOCHEM BIOPH RES CO, V222, P802, DOI 10.1006/bbrc.1996.0830; HARRIS CC, 1972, JNCI-J NATL CANCER I, V48, P743; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; Jetten A M, 1992, J Natl Cancer Inst Monogr, P93; Jetten Anton M., 1997, Journal of Dermatology (Tokyo), V24, P711; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; Koizumi H, 1996, BRIT J DERMATOL, V134, P686, DOI 10.1111/j.1365-2133.1996.tb06971.x; KUMAR CC, 1995, CANCER RES, V55, P5106; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; Lau D, 2000, AM J RESP CELL MOL, V22, P92, DOI 10.1165/ajrcmb.22.1.3637; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIEDTKE CM, 1995, AM J PHYSIOL-LUNG C, V268, pL414, DOI 10.1152/ajplung.1995.268.3.L414; Lohman FP, 1997, EXP CELL RES, V231, P141, DOI 10.1006/excr.1996.3458; Lohman FP, 1997, ONCOGENE, V14, P1623, DOI 10.1038/sj.onc.1200974; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; PFEIFER AMA, 1989, ENVIRON HEALTH PERSP, V80, P209, DOI 10.2307/3430746; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Reddy SPM, 1998, GENE, V224, P59, DOI 10.1016/S0378-1119(98)00507-1; REDDY SPM, 1995, J BIOL CHEM, V270, P26451, DOI 10.1074/jbc.270.44.26451; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Sark MWJ, 1999, EXP CELL RES, V250, P475, DOI 10.1006/excr.1999.4532; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; SEGER R, 1995, J BIOL CHEM, V270, P28325; Steinert PM, 1998, J STRUCT BIOL, V122, P76, DOI 10.1006/jsbi.1998.3957; Steinert PM, 1999, MOL BIOL CELL, V10, P4247, DOI 10.1091/mbc.10.12.4247; Tesfaigzi J, 1996, EXP CELL RES, V228, P277, DOI 10.1006/excr.1996.0327; Tesfaigzi J, 1996, J CELL PHYSIOL, V166, P480, DOI 10.1002/(SICI)1097-4652(199603)166:3<480::AID-JCP2>3.0.CO;2-L; Tesfaigzi J, 1996, AM J RESP CELL MOL, V14, P478, DOI 10.1165/ajrcmb.14.5.8624253; Tesfaigzi Johannes, 1999, Cell Biochemistry and Biophysics, V30, P243, DOI 10.1007/BF02738069; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tolwinski NS, 1999, J BIOL CHEM, V274, P6168, DOI 10.1074/jbc.274.10.6168; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Welter JF, 1995, ONCOGENE, V11, P2681; WILLEY JC, 1984, CANCER RES, V44, P5124; WILLEY JC, 1984, CARCINOGENESIS, V5, P209, DOI 10.1093/carcin/5.2.209; Wu R, 1997, EUR RESPIR J, V10, P2398, DOI 10.1183/09031936.97.10102398; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; YAAR M, 1995, EXP CELL RES, V217, P217, DOI 10.1006/excr.1995.1081; Yamamoto T, 1999, J BIOCHEM-TOKYO, V126, P799, DOI 10.1093/oxfordjournals.jbchem.a022519; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067; YUSPA SH, 1982, CANCER RES, V42, P2344; YUSPA SH, 1994, J INVEST DERMATOL, V103, pS90, DOI 10.1111/1523-1747.ep12399255	75	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32250	32259		10.1074/jbc.M005227200	http://dx.doi.org/10.1074/jbc.M005227200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10918063	hybrid			2022-12-25	WOS:000089858900096
J	Waltner-Law, M; Daniels, MC; Sutherland, C; Granner, DK				Waltner-Law, M; Daniels, MC; Sutherland, C; Granner, DK			NF-kappa B inhibits glucocorticoid and cAMP-mediated expression of the phosphoenolpyruvate carboxykinase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN; CULTURED RAT HEPATOCYTES; TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; RESPONSE ELEMENT; CAENORHABDITIS-ELEGANS; ACCESSORY FACTOR; PEPCK GENE; GTP GENE; PHOSPHATIDYLINOSITOL 3-KINASE	Transcription of the phosphoenolpyruvate carboxykinase (PEPCK) gene is regulated by a variety of agents. Glucocorticoids, retinoic acid, and glucagon (via its second messenger, cAMP) stimulate PEPCK gene transcription, whereas insulin, phorbol esters, cytokines, and oxidative stress have an opposing effect. Stimulation of PEPCK gene expression has been extensively studied, and a number of important DNA elements and binding proteins that regulate the transcription of this gene have been identified. However, the mechanisms utilized to turn off expression of this gene are not well-defined. Many of the negative regulators of PEPCK gene transcription also stimulate the nuclear localization and activation of the transcription factor NF-kappa B, so we hypothesized that this factor could be involved in the repression of PEPCK gene expression. We find that the p65 subunit of NF-kappa B represses the increase of PEPCK gene transcription mediated by glucocorticoids and cAMP in a concentration-dependent manner. The mutation of an NF-kappa B binding element identified in the PEPCK gene promoter fails to abrogate this repression. Further analysis suggests that p65 represses PEPCK gene transcription through a protein protein interaction with the coactivator, CREB binding protein.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Granner, DK (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 707 Light Hall, Nashville, TN 37232 USA.	daryl.granner@mcmail.vanderbilt.edu		Sutherland, Calum/0000-0003-4398-7434	NIDDK NIH HHS [DK35107, DK20593, DK07563] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, R01DK035107, P30DK020593, R37DK035107] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agati JM, 1998, J BIOL CHEM, V273, P18751, DOI 10.1074/jbc.273.30.18751; ANGRAND PO, 1994, CELL GROWTH DIFFER, V5, P957; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Bertrand F, 1998, J BIOL CHEM, V273, P2931, DOI 10.1074/jbc.273.5.2931; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; CHANG KSS, 1993, CANCER LETT, V74, P75, DOI 10.1016/0304-3835(93)90047-D; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; CHRIST B, 1994, HEPATOLOGY, V20, P1577, DOI 10.1002/hep.1840200629; Christ B, 1996, BIOCHEM J, V320, P161, DOI 10.1042/bj3200161; CHU DTW, 1987, MOL ENDOCRINOL, V1, P53, DOI 10.1210/mend-1-1-53; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HILL MR, 1992, INFECT IMMUN, V60, P4040, DOI 10.1128/IAI.60.10.4040-4050.1992; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; KIROV N, 1993, EMBO J, V12, P3193, DOI 10.1002/j.1460-2075.1993.tb05988.x; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; Liao JF, 1998, J BIOL CHEM, V273, P27320, DOI 10.1074/jbc.273.42.27320; LIU JS, 1991, J BIOL CHEM, V266, P19095; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OBRIEN RM, 1994, BIOCHEM J, V303, P737, DOI 10.1042/bj3030737; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1991, P NATL ACAD SCI USA, V88, P6580, DOI 10.1073/pnas.88.15.6580; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Park EA, 1999, J BIOL CHEM, V274, P211, DOI 10.1074/jbc.274.1.211; Parker D, 1996, MOL CELL BIOL, V16, P694; Parry GCN, 1997, J IMMUNOL, V159, P5450; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Scott DK, 1998, J BIOL CHEM, V273, P24145, DOI 10.1074/jbc.273.37.24145; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; Sutherland C, 1997, DIABETES, V46, P17, DOI 10.2337/diabetes.46.1.17; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	71	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31847	31856		10.1074/jbc.M003656200	http://dx.doi.org/10.1074/jbc.M003656200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913132	hybrid			2022-12-25	WOS:000089858900044
J	Garinot-Schneider, C; Lellouch, AC; Geremia, RA				Garinot-Schneider, C; Lellouch, AC; Geremia, RA			Identification of essential amino acid residues in the Sinorhizobium meliloti glucosyltransferase ExoM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; RHIZOBIUM-MELILOTI; SUCCINOGLYCAN BIOSYNTHESIS; EXOPOLYSACCHARIDE BIOSYNTHESIS; STRUCTURAL CHARACTERIZATION; GLYCOSYL TRANSFERASES; GENE-CLUSTER; ACTIVE-SITE; GLYCOSYLTRANSFERASES; ENZYME	ExoM is a beta(1-4)-glucosyltransferase involved in the assembly of the repeat unit of the exopolysaccharide succinoglycan from Sinorhizobium meliloti, By comparing the sequence of ExoM to those of other members of the Pfam Glyco Domain 2 family, most notably SpsA (Bacillus subtilis) for whom the three-dimensional structure has been resolved, three potentially important aspartic acid residues of ExoM were identified, Single substitutions of each of the Asp amino acids at positions 44, 96, and 187 with Ala resulted in the loss of mutant recombinant protein activity in vitro as well as the loss of succinoglycan production in an in vivo rescue assay. Mutants harboring Glu instead of Asp 44 or Asp-96 possessed no in vitro activity but could restore succinoglycan production in vivo. However, replacement of Asp-187 with Glu completely inactivated ExoM as judged by both the in vitro and in vivo assays. These results indicate that Asp-44, Asp-96, and Asp-187 are essential for the activity of ExoM. Furthermore, these data are consistent with the functions proposed for each of the analogous aspartic acids of SpsA based on the SpsA-UDP structure, namely, that Asp-44 and Asp-96 are involved in UDP substrate binding and that Asp-187 is the catalytic base in the glycosyltransferase reaction.	Univ Grenoble 1, Ctr Rech Macromol Vegetales, CNRS, F-38041 Grenoble 9, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Geremia, RA (corresponding author), CNRS, CERMAV, BP 53, Grenoble 9, France.		Lellouch, Annemarie/E-9905-2014; Geremia, Roberto A/A-7972-2010					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Becker A, 1995, MOL GEN GENET, V249, P487, DOI 10.1007/BF00290574; BECKER A, 1993, MOL GEN GENET, V241, P367, DOI 10.1007/BF00284690; BECKER A, 1993, MOL PLANT MICROBE IN, V6, P735, DOI 10.1094/MPMI-6-735; Breton C, 1998, J BIOCHEM, V123, P1000; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; Cheng HP, 1998, J BACTERIOL, V180, P5183, DOI 10.1128/JB.180.19.5183-5191.1998; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Edwards KJ, 1999, MICROBIOL-SGM, V145, P1499, DOI 10.1099/13500872-145-6-1499; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; GLUCKSMANN MA, 1993, J BACTERIOL, V175, P7033, DOI 10.1128/jb.175.21.7033-7044.1993; GLUCKSMANN MA, 1993, J BACTERIOL, V175, P7045, DOI 10.1128/jb.175.21.7045-7055.1993; Griffiths G, 1998, J BIOL CHEM, V273, P11752, DOI 10.1074/jbc.273.19.11752; Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797; HYNES MF, 1986, MOL GEN GENET, V202, P356, DOI 10.1007/BF00333262; Kapitonov D, 1999, GLYCOBIOLOGY, V9, P961, DOI 10.1093/glycob/9.10.961; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; Lellouch AC, 1999, J BACTERIOL, V181, P1141, DOI 10.1128/JB.181.4.1141-1148.1999; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; McCally Michael, 1994, Med Glob Surviv, V1, P4; REINHOLD BB, 1994, J BACTERIOL, V176, P1997, DOI 10.1128/jb.176.7.1997-2002.1994; REUBER TL, 1993, CELL, V74, P269, DOI 10.1016/0092-8674(93)90418-P; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; Wang LX, 1999, J BACTERIOL, V181, P6788, DOI 10.1128/JB.181.21.6788-6796.1999; WHITFIELD C, 1993, ADV MICROB PHYSIOL, V35, P135, DOI 10.1016/S0065-2911(08)60099-5; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; York GM, 1998, P NATL ACAD SCI USA, V95, P4912, DOI 10.1073/pnas.95.9.4912; Zhang YN, 1999, GLYCOBIOLOGY, V9, P815, DOI 10.1093/glycob/9.8.815	36	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31407	31413		10.1074/jbc.M004524200	http://dx.doi.org/10.1074/jbc.M004524200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10908566	hybrid			2022-12-25	WOS:000089762700093
J	Nagasawa, K; Kitamura, K; Yasui, A; Nimura, Y; Ikeda, K; Hirai, M; Matsukage, A; Nakanishi, M				Nagasawa, K; Kitamura, K; Yasui, A; Nimura, Y; Ikeda, K; Hirai, M; Matsukage, A; Nakanishi, M			Identification and characterization of human DNA polymerase beta 2, a DNA polymerase beta-related enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; OVARIAN-CANCER; LONG ARM; GENE; MUTATIONS; BRCA1; PROTEINS; RNA; CHROMOSOME-10; REQUIREMENT	The BRCA1 COOH terminus (BRCT) motif is present in many nuclear proteins that contribute to cell cycle regulation or DNA repair. Polymerase chain reaction-based screening with degenerate primers targeted to the BRCT motif resulted in the isolation of a human cDNA for a previously unidentified DNA polymerase (designated DNA polymerase beta 2) that is closely related to DNA polymerase beta (Pol beta). The predicted Pol beta 2 protein contains a BRCT motif in its NH2-terminal region; its COOH-terminal region exhibits 33% sequence identity to a corresponding region of human Pol beta. The Pol beta 2 gene is expressed in a tissue-specific manner, with transcripts being most abundant in testis. A fusion con struct comprising Pol beta 2 and green fluorescent protein exhibited a predominantly nuclear localization in transfected HeLa cells. Recombinant human Pol beta 2 from insect cells exhibited substantial DNA polymerase activity, but it did not possess terminal deoxyribonucleotidyl transferase activity. A truncated Pd beta 2 mutant lacking the BRCT motif retained substantial DNA polymerase activity, whereas a mutant Pol beta 2 with two alanine point mutations within the DNA polymerase active site did not. These results indicate that Pol beta 2 is a Pol beta-related DNA polymerase with a BRCT motif that is dispensable for its polymerase activity.	Nagoya City Univ, Sch Med, Dept Biochem, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Natl Inst Longev Sci, Dept Geriatr Res, Obu, Aichi 4748522, Japan; Natl Chubu Hosp, Dept Surg, Obu, Aichi 4748511, Japan; Nagoya Univ, Sch Med, Dept Surg, Nagoya, Aichi 4648550, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 113, Japan; Aichi Canc Ctr, Res Inst, Cell Biol Lab, Nagoya, Aichi 4648681, Japan	Nagoya City University; Nagoya University; University of Tokyo; Aichi Cancer Center	Nakanishi, M (corresponding author), Nagoya City Univ, Sch Med, Dept Biochem, Mizuho Ku, 1 Kawasumi, Nagoya, Aichi 4678601, Japan.	mkt-naka@med.nagoya-cu.ac.jp						Albarosa R, 1996, AM J HUM GENET, V58, P1260; Bhattacharyya N, 1999, DNA CELL BIOL, V18, P549, DOI 10.1089/104454999315097; Bienstock RJ, 1996, CANCER RES, V56, P2539; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; DATE T, 1991, BIOCHEMISTRY-US, V30, P5286, DOI 10.1021/bi00235a023; DOBASHI Y, 1994, CANCER RES, V54, P2827; Ford S, 1998, CANCER GENET CYTOGEN, V102, P6, DOI 10.1016/S0165-4608(97)00250-1; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; HAMMOND RA, 1990, BIOCHEMISTRY-US, V29, P286, DOI 10.1021/bi00453a039; HIRAI M, 1994, CYTOGENET CELL GENET, V66, P149, DOI 10.1159/000133687; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HORTON JK, 1995, NUCLEIC ACIDS RES, V23, P3810, DOI 10.1093/nar/23.19.3810; Iwanaga A, 1999, MUTAT RES-DNA REPAIR, V435, P121, DOI 10.1016/S0921-8777(99)00036-1; Kim SK, 1998, ONCOGENE, V17, P1749, DOI 10.1038/sj.onc.1202073; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; LARIMER FW, 1989, J BACTERIOL, V171, P230, DOI 10.1128/jb.171.1.230-237.1989; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Matsuzaki J, 1996, MOL CARCINOGEN, V15, P38, DOI 10.1002/(SICI)1098-2744(199601)15:1<38::AID-MC6>3.0.CO;2-O; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mizushina Y, 1998, BIOCHEM J, V330, P1325, DOI 10.1042/bj3301325; Oda N, 1996, J BIOL CHEM, V271, P13816, DOI 10.1074/jbc.271.23.13816; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; WANG LM, 1992, CANCER RES, V52, P4824; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WILSON S, 1988, BIOCHIM BIOPHYS ACTA, V949, P149, DOI 10.1016/0167-4781(88)90078-4; WILSON SH, 1992, DNA REPAIR MECH, V35, P343; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199; Yan ZJ, 1995, BIOCHEM MOL BIOL INT, V37, P175; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404	37	59	62	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31233	31238		10.1074/jbc.M004263200	http://dx.doi.org/10.1074/jbc.M004263200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10887191	hybrid			2022-12-25	WOS:000089762700069
J	Yu, WH; Yu, SSC; Meng, Q; Brew, K; Woessner, JF				Yu, WH; Yu, SSC; Meng, Q; Brew, K; Woessner, JF			TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TISSUE INHIBITOR; CHICKEN-EMBRYO FIBROBLASTS; TRANSFORMATION-SENSITIVE PROTEIN; SORSBYS-FUNDUS-DYSTROPHY; ONCOGENIC TRANSFORMATION; ACTIVE DOMAIN; CELL-DEATH; METALLOPROTEINASES; FAMILY; INVASION	Of the four known tissue inhibitors of metalloproteinases (TIMPs), TIMP-3 is distinguished by its tighter binding to the extracellular matrix. The present results show that glycosaminoglycans such as heparin, heparan sulfate, chondroitin sulfates A, B, and C, and sulfated compounds such as suramin and pentosan efficiently extract TIMP-3 from the postpartum rat uterus. Enzymatic treatment by heparinase III or chondroitinase ABC also releases TIMP-3, but neither one alone gives complete release. Confocal microscopy shows colocalization of heparan sulfate and TIMP-3 in the endometrium subjacent to the lumen of the uterus. Immunostaining of TIMP-3 is lost upon digestion of tissue sections with heparinase III and chondroitinase ABC. The N-terminal domain of human TIMP-3 was expressed and found to bind to heparin with affinity similar to that of full-length mouse TIMP-3. The A and B P-strands of the N-terminal domain of TIMP-3 contain two potential heparin-binding sequences rich in lysine and arginine; these strands should form a double track on the outer surface of TIMP-3. Synthetic peptides corresponding to segments of these two strands compete for heparin in the DNase II binding assay. TIMP-3 binding may be important for the cellular regulation of activity of the matrix metalloproteinases.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Woessner, JF (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, R-127,POB 106960, Miami, FL 33101 USA.		Brew, Keith/W-1643-2019; Yu, Wei Hsuan/AAF-7129-2021; Brew, Keith/A-6746-2009	Brew, Keith/0000-0003-1306-1032; YU, WEI-HSUAN/0000-0002-1782-3738	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR016940, R01AR040994, R01AR016940] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-40994, AR-16940] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahonen M, 1998, CANCER RES, V58, P2310; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; Andreu T, 1998, J BIOL CHEM, V273, P13848, DOI 10.1074/jbc.273.22.13848; APTE SS, 1994, DEV DYNAM, V200, P177, DOI 10.1002/aja.1002000302; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; BLENIS J, 1983, P NATL ACAD SCI-BIOL, V80, P770, DOI 10.1073/pnas.80.3.770; BLENIS J, 1984, J BIOL CHEM, V259, P1563; Borland G, 1999, J BIOL CHEM, V274, P2810, DOI 10.1074/jbc.274.5.2810; Breedveld FC, 1997, ARTHRITIS RHEUM, V40, P794, DOI 10.1002/art.1780400503; Burger D, 1998, ARTHRITIS RHEUM, V41, P1748, DOI 10.1002/1529-0131(199810)41:10<1748::AID-ART7>3.3.CO;2-V; Butler GS, 1999, J BIOL CHEM, V274, P10846, DOI 10.1074/jbc.274.16.10846; Douglas DA, 1997, J PROTEIN CHEM, V16, P237, DOI 10.1023/A:1026348808069; Elliot SJ, 1999, J AM SOC NEPHROL, V10, P62; Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Guo X, 1996, ANAL BIOCHEM, V235, P153, DOI 10.1006/abio.1996.0107; Hargreaves PG, 1998, BRIT J HAEMATOL, V101, P694, DOI 10.1046/j.1365-2141.1998.00754.x; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Murate T, 1999, PLATELETS, V10, P5, DOI 10.1080/09537109976293; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; Tuuttila A, 1998, J MOL BIOL, V284, P1133, DOI 10.1006/jmbi.1998.2223; WEEKS JG, 1976, BIOCHIM BIOPHYS ACTA, V445, P205, DOI 10.1016/0005-2744(76)90173-X; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; Williamson RA, 1996, EUR J BIOCHEM, V241, P476, DOI 10.1111/j.1432-1033.1996.00476.x; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; YANG TT, 1992, P NATL ACAD SCI USA, V89, P10676, DOI 10.1073/pnas.89.22.10676; Yu WH, 2000, J BIOL CHEM, V275, P4183, DOI 10.1074/jbc.275.6.4183	37	261	267	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31226	31232		10.1074/jbc.M000907200	http://dx.doi.org/10.1074/jbc.M000907200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10900194	hybrid			2022-12-25	WOS:000089762700068
J	Deng, H; Callender, R; Dale, GE				Deng, H; Callender, R; Dale, GE			A vibrational structure of 7,8-dihydrobiopterin bound to dihydroneopterin aldolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DIHYDROFOLATE-REDUCTASE; ESCHERICHIA-COLI; RAMAN DIFFERENCE; CRYSTAL-STRUCTURES; TRANSITION-STATE; MECHANISM; COMPLEX; BINDING; SPECTROSCOPY; SUBSTRATE	(D)ihydroneopterin aldolase (DHNA) catalyzes the conversion of 7,8-dihhydroneopterin to 6-hydroxymethyl-7,8-dihydropterin and glycolaldehyde. An inhibitor of the enzyme, 7,8-dihydrobiopterin, free in solution and bound in its complex with the enzyme has been studied by Raman difference spectroscopy. By using isotopically labeled 7,8-dihydrobiopterin and normal mode analyses based on ab initio quantum mechanic methods, we have positively identified some of the Raman bands in the enzyme-bound inhibitor, particularly the important N5=C6 stretch mode. The spectrum of the enzyme-bound inhibitor shows that the pK(alpha) of N5 is not significantly increased in the complex. This result suggests that N5 of 7,8-dihydroneopterin is not protonated before the bond cleavage of 7,8-dihydroneopterin during the DHNA-catalyzed reaction as has been suggested. Our results also show that the N5=C6 stretch mode of 7,8- dihydrobiopterin shifts 19 cm(-1) upon binding to DHNA. Various possibilities on how the enzyme can bring about such large frequency change of the N5=C6 stretch mode are discussed.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; F Hoffmann La Roche & Co Ltd, Preclin Res, CH-4070 Basel, Switzerland	Yeshiva University; Albert Einstein College of Medicine; Roche Holding	Callender, R (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NIGMS NIH HHS [GM35183] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035183] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENKOVIC SJ, 1988, SCIENCE, V239, P1105, DOI 10.1126/science.3125607; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; CALLENDER R, 1994, ANNU REV BIOPH BIOM, V23, P215, DOI 10.1146/annurev.bb.23.060194.001243; CHEN YQ, 1994, BIOCHEMISTRY-US, V33, P7021, DOI 10.1021/bi00189a001; Deng H, 1998, BIOCHEMISTRY-US, V37, P4968, DOI 10.1021/bi9727904; Deng H, 1998, BIOCHEMISTRY-US, V37, P10972, DOI 10.1021/bi980556n; Deng H, 1998, J AM CHEM SOC, V120, P7730, DOI 10.1021/ja9814974; FIERKE CA, 1987, BIOCHEMISTRY-US, V26, P4085, DOI 10.1021/bi00387a052; Hennig M, 1998, NAT STRUCT BIOL, V5, P357, DOI 10.1038/nsb0598-357; HOWELL EE, 1986, SCIENCE, V231, P1123, DOI 10.1126/science.3511529; KRAUT J, 1987, BIOL MACROMOL ASSEM, V3, P1; Lee H, 1996, BIOCHEMISTRY-US, V35, P7012, DOI 10.1021/bi960028g; MAHARAJ G, 1990, BIOCHEMISTRY-US, V29, P4554, DOI 10.1021/bi00471a008; MCTIGUE MA, 1992, BIOCHEMISTRY-US, V31, P7264, DOI 10.1021/bi00147a009; MORRISON JF, 1988, BIOCHEMISTRY-US, V27, P5499, DOI 10.1021/bi00415a017; STONE SR, 1984, BIOCHEMISTRY-US, V23, P2753, DOI 10.1021/bi00307a034; Wang JH, 1998, BIOCHEMISTRY-US, V37, P11106, DOI 10.1021/bi980471m	17	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30139	30143		10.1074/jbc.M004464200	http://dx.doi.org/10.1074/jbc.M004464200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10896664	hybrid			2022-12-25	WOS:000089577900032
J	Kan, HY; Georgopoulos, S; Zannis, V				Kan, HY; Georgopoulos, S; Zannis, V			A hormone response element in the human apolipoprotein CIII (ApoCIII) enhancer is essential for intestinal expression of the ApoA-I and ApoCIII genes and contributes to the hepatic expression of the two linked genes in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-III GENE; A-I; TRANSCRIPTIONAL REGULATION; MESSENGER-RNA; DENSITY LIPOPROTEIN; PROXIMAL PROMOTERS; RECEPTOR; REGION; CELLS; SITES	We have generated transgenic mice carrying wildtype promoters of the human apolipoprotein A-I (apoA-I)-apoCIII gene cluster or promoters mutated in their hormone response elements. The wild-type cluster directed high levels of apoA-I gene expression in liver and intestine, moderate expression in kidney, and low to minimal expression in other tissues. It also directed high levels of chloramphenicol acetyltransferase (CAT) expression (used as a reporter for the apoCIII gene) in liver, low levels in intestine and kidney, and no expression in other tissues. Mutations in the apoCIII promoter and enhancer abolished the intestinal and renal expression of the apoA-I gene, reduced hepatic apoA-I expression by 80%, and abolished CAT expression in all tissues. A similar pattern of expression was obtained by mutations in the apoCIII enhancer alone. Mutations in the proximal apoA-I promoter reduced by 85% hepatic and intestinal apoA-I expression and did not affect CAT expression, The findings suggest that a hormone response element within the apoCIII enhancer is essential for intestinal and renal expression of apoA-I and apoCIII genes and also enhances hepatic expression. The hormone response elements of the proximal apoA-I pro meter or the apoCIII enhancer can promote independently low levels of hepatic and intestinal expression of the apoA-I gene in vivo.	Boston Univ, Sch Med, Dept Med, Whitaker Cardiovasc Inst,Sect Mol Genet, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University; Boston University	Zannis, V (corresponding author), Boston Univ, Sch Med, Dept Med, Whitaker Cardiovasc Inst,Sect Mol Genet, Boston, MA 02118 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033952] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33952] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agarwal M, 1998, J VIROL, V72, P3720, DOI 10.1128/JVI.72.5.3720-3728.1998; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BISAHA JG, 1995, J BIOL CHEM, V270, P19979, DOI 10.1074/jbc.270.34.19979; BROWN WV, 1972, BIOCHEM BIOPH RES CO, V46, P375; CASTELLI WP, 1977, CIRCULATION, V55, P767, DOI 10.1161/01.CIR.55.5.767; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P8242, DOI 10.1073/pnas.82.23.8242; GE RW, 1994, J BIOL CHEM, V269, P13185; GINSBURG GS, 1995, J CLIN INVEST, V96, P528, DOI 10.1172/JCI118065; GLUECK CJ, 1976, J LAB CLIN MED, V88, P941; HEISS G, 1982, NIH831266 PUBL, P7; Herbert P. N., 1982, METABOLIC BASIS INHE, P589; HOGAN B, 1986, MANIPULATING MOUSE E; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; KADDA IA, 1986, J BIOL CHEM, V28, P13268; KARATHANASIS SK, 1983, P NATL ACAD SCI-BIOL, V80, P6147, DOI 10.1073/pnas.80.20.6147; KARATHANASIS SK, 1985, P NATL ACAD SCI USA, V82, P6374, DOI 10.1073/pnas.82.19.6374; KARATHANASIS SK, 1986, BIOCHEMISTRY-US, V25, P3962, DOI 10.1021/bi00361a034; Kardassis D, 1997, ARTERIOSCL THROM VAS, V17, P222, DOI 10.1161/01.ATV.17.1.222; Kardassis D, 1996, HYPERTENSION, V27, P980, DOI 10.1161/01.HYP.27.4.980; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LAUER SJ, 1991, CIRCULATION S2, V84, P17; Lavrentiadou SN, 1999, BIOCHEMISTRY-US, V38, P964, DOI 10.1021/bi981068i; Le Beyec J, 1999, J BIOL CHEM, V274, P4954, DOI 10.1074/jbc.274.8.4954; LENICH C, 1988, J LIPID RES, V29, P755; Li JX, 2000, GENE DEV, V14, P464; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; OGAMI K, 1990, J BIOL CHEM, V265, P9808; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; QUARFORDT SH, 1982, J BIOL CHEM, V257, P4642; REUE K, 1988, J BIOL CHEM, V263, P6857; ROGHANI A, 1988, BIOCHEMISTRY-US, V27, P7428, DOI 10.1021/bi00419a038; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; TALIANIDIS I, 1995, BIOCHEMISTRY-US, V34, P10298, DOI 10.1021/bi00032a025; Tzameli I, 1996, J BIOL CHEM, V271, P8402, DOI 10.1074/jbc.271.14.8402; WALSH A, 1993, J LIPID RES, V34, P617; WALSH A, 1989, J BIOL CHEM, V264, P6488; WINDLER E, 1980, J BIOL CHEM, V255, P5475; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028	44	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30423	30431		10.1074/jbc.M005641200	http://dx.doi.org/10.1074/jbc.M005641200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10893424	hybrid			2022-12-25	WOS:000089577900069
J	Wankhade, S; Yu, YH; Weinberg, J; Tainsky, MA; Kannan, P				Wankhade, S; Yu, YH; Weinberg, J; Tainsky, MA; Kannan, P			Characterization of the activation domains of AP-2 family transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; DNA-BINDING; MOUSE EMBRYOGENESIS; DROSOPHILA HOMOLOG; MAMMARY-CARCINOMA; DOWN-REGULATION; MESSENGER-RNA; HTLV-I; GROWTH; MELANOMA	Despite sequence variation, all AP-2 isotypes are capable of activating transcription, which indicates a functional conservation. We used this property to gain a unique insight into the structure and function of the activation motifs of AP-2 family transcription factors. We have precisely localized the activation motif of human AP-2 alpha to amino acids 52-108. Our experiments indicate that similar sequence of amino acids in all AP-2 isotypes except Drosophila AP-2 alpha harbor their activation motifs, Within this sequence, fewer than 36 residues are critical for transcription activation. Our comparison studies and site-directed mutagenic analyses show that these critical amino acids are strategically placed within this sequence. These residues are interspersed with nonessential and influential residues that vary in composition and length, indicating a structural flexibility. The Drosophila AP-2 alpha has its partly conserved activation motif in an extended region about twice the length of other AP-2 isotypes. Our results reveal essential elements of the amino acid composition of activators in general and shed new light on the mechanism of transcription activation.	Case Western Reserve Univ, Rammelkamp Ctr Educ & Res, Cleveland, OH 44109 USA; Wayne State Univ, Karmanos Canc Inst, Program Mol Biol & Genet, Detroit, MI 48201 USA	Case Western Reserve University; MetroHealth System; Barbara Ann Karmanos Cancer Institute; Wayne State University	Kannan, P (corresponding author), Case Western Reserve Univ, Rammelkamp Ctr Educ & Res, Metrohlth Campus,2500 Metrohlth Dr, Cleveland, OH 44109 USA.		Weinbaum, Justin S/C-3192-2009	Weinbaum, Justin S/0000-0002-0626-6083; Tainsky, Michael/0000-0002-0261-831X	NATIONAL CANCER INSTITUTE [R01CA053475, R29CA067036, R01CA084278] Funding Source: NIH RePORTER; NCI NIH HHS [CA67036, CA84278, CA53475] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BarEli M, 1997, J CELL PHYSIOL, V173, P275, DOI 10.1002/(SICI)1097-4652(199711)173:2<275::AID-JCP35>3.0.CO;2-C; Bauer R, 1998, ONCOGENE, V17, P1911, DOI 10.1038/sj.onc.1202114; Berk AJ, 1999, CURR OPIN CELL BIOL, V11, P330, DOI 10.1016/S0955-0674(99)80045-3; Bisgrove DA, 1999, DEV DYNAM, V214, P195, DOI 10.1002/(SICI)1097-0177(199903)214:3<195::AID-AJA3>3.0.CO;2-8; Bjorklund S, 1999, CELL, V96, P759, DOI 10.1016/S0092-8674(00)80586-3; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; Chazaud C, 1996, MECH DEVELOP, V54, P83, DOI 10.1016/0925-4773(95)00463-7; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRECO D, 1995, J NEUROCHEM, V65, P510; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang X, 1991, ADV APPL MATH, V12, P373; Huang YH, 1999, ARCH BIOCHEM BIOPHYS, V364, P241, DOI 10.1006/abbi.1999.1142; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Kannan F, 1999, MOL CELL BIOL, V19, P899; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P549; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; MILLER JH, 1979, J MOL BIOL, V131, P223, DOI 10.1016/0022-2836(79)90074-3; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Monge I, 1998, MECH DEVELOP, V76, P191, DOI 10.1016/S0925-4773(98)00125-7; MOSER M, 1993, NUCLEIC ACIDS RES, V21, P4844, DOI 10.1093/nar/21.20.4844; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; MOSER M, 1995, DEVELOPMENT, V121, P2779; MUCHARDT C, 1992, NEW BIOL, V4, P541; MUCHARDT C, 1992, EMBO J, V11, P2573, DOI 10.1002/j.1460-2075.1992.tb05322.x; PERKINS ND, 1994, J VIROL, V68, P6820, DOI 10.1128/JVI.68.10.6820-6823.1994; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; Shen H, 1997, DEV BIOL, V188, P248, DOI 10.1006/dbio.1997.8617; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Turner BC, 1998, CANCER RES, V58, P5466; Wang DY, 1997, J BIOL CHEM, V272, P14244, DOI 10.1074/jbc.272.22.14244; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WINNING RS, 1991, NUCLEIC ACIDS RES, V19, P3709, DOI 10.1093/nar/19.13.3709; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; ZEUTHEN J, 1980, INT J CANCER, V25, P19, DOI 10.1002/ijc.2910250104; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhang LJ, 1998, ONCOGENE, V17, P1261, DOI 10.1038/sj.onc.1202050	57	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29701	29708		10.1074/jbc.M000931200	http://dx.doi.org/10.1074/jbc.M000931200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10899156	hybrid			2022-12-25	WOS:000089439800070
J	Nyyssola, A; Kerovuo, J; Kaukinen, P; von Weymarn, N; Reinikainen, T				Nyyssola, A; Kerovuo, J; Kaukinen, P; von Weymarn, N; Reinikainen, T			Extreme halophiles synthesize betaine from glycine by methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDEHYDE DEHYDROGENASE GENE; COMPATIBLE SOLUTES; ESCHERICHIA-COLI; ECTOTHIORHODOSPIRA-HALOCHLORIS; N-METHYLTRANSFERASE; BACILLUS-SUBTILIS; STRESS TOLERANCE; CHOLINE OXIDASE; WATER-STRESS; RAT-LIVER	Glycine betaine is a compatible solute, which is able to restore and maintain osmotic balance of living cells. It is synthesized and accumulated in response to abiotic stress. Betaine acts also as a methyl group donor and has a number of important applications including its use as a feed additive. The known biosynthetic pathways of betaine are universal and very well characterized. A number of enzymes catalyzing the two-step oxidation of choline to betaine have been isolated. In this work we have studied a novel betaine biosynthetic pathway in two phylogenically distant extreme halophiles, Actinopolyspora halophila and Ectothiorhodospira halochloris. We have identified a three-step series of methylation reactions from glycine to betaine, which is catalyzed by two methyltransferases, glycine sarcosine methyltransferase and sarcosine dimethylglycine methyltransferase, with partially overlapping substrate specificity. The methyltransferases from the two organisms show high sequence homology. E. halochloris methyltransferase genes were successfully expressed in Escherichia coli, and betaine accumulation and improved salt tolerance were demonstrated.	Danisco Cultor Innovat, FIN-02460 Kantvik, Finland		Reinikainen, T (corresponding author), Danisco Cultor Innovat, Sokeritehtaantie 20, FIN-02460 Kantvik, Finland.			Nyyssola, Antti/0000-0002-8195-3967				Atkinson D, 1977, CELLULAR ENERGY META, P72; Ausubel FM., 2006, ENZYMATIC MANIPULATI; Boch J, 1996, J BACTERIOL, V178, P5121, DOI 10.1128/jb.178.17.5121-5129.1996; Bohnert HJ, 1996, TRENDS BIOTECHNOL, V14, P89, DOI 10.1016/0167-7799(96)80929-2; BORK P, 1992, PROTEIN SCI, V1, P1677, DOI 10.1002/pro.5560011216; Fu ZJ, 1996, BIOCHEMISTRY-US, V35, P11985, DOI 10.1021/bi961068n; GALINSKI EA, 1994, FEMS MICROBIOL REV, V15, P95, DOI 10.1111/j.1574-6976.1994.tb00128.x; GORHAM J, 1995, AMINO ACIDS THEIR DE, P170; Guo Y, 1997, SCI CHINA SER C, V40, P496, DOI 10.1007/BF03183588; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HANSON AD, 1985, P NATL ACAD SCI USA, V82, P3678, DOI 10.1073/pnas.82.11.3678; Hayashi H, 1997, PLANT J, V12, P133, DOI 10.1046/j.1365-313X.1997.12010133.x; HOLMBERG N, 1996, THESIS LUND U; IMHOFF JF, 1977, ARCH MICROBIOL, V114, P115, DOI 10.1007/BF00410772; ISHITANI M, 1993, PLANT CELL PHYSIOL, V34, P493; ISHITANI M, 1995, PLANT MOL BIOL, V27, P307, DOI 10.1007/BF00020185; JONES RGW, 1981, BETAINES PHYSL BIOCH, P171; Kerovuo J, 1998, APPL ENVIRON MICROB, V64, P2079; KISHITANI S, 1994, PLANT CELL ENVIRON, V17, P89, DOI 10.1111/j.1365-3040.1994.tb00269.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai MC, 1999, APPL ENVIRON MICROB, V65, P828; LAI MC, 1991, J BACTERIOL, V173, P5352, DOI 10.1128/jb.173.17.5352-5358.1991; LAMARK T, 1991, MOL MICROBIOL, V5, P1049, DOI 10.1111/j.1365-2958.1991.tb01877.x; Lilius G, 1996, BIO-TECHNOL, V14, P177, DOI 10.1038/nbt0296-177; MILLER JH, 1977, EXPT MOL GENETICS, P431; MORI N, 1992, J FERMENT BIOENG, V73, P352, DOI 10.1016/0922-338X(92)90277-2; Nakamura T, 1997, PLANT J, V11, P1115, DOI 10.1046/j.1365-313X.1997.11051115.x; NOMURA M, 1995, PLANT PHYSIOL, V107, P703, DOI 10.1104/pp.107.3.703; OGAWA H, 1993, COMP BIOCHEM PHYS B, V106, P601, DOI 10.1016/0305-0491(93)90137-T; OHTAFUKUYAMA M, 1980, J BIOCHEM-TOKYO, V88, P197; Pocard JA, 1997, MICROBIOL-SGM, V143, P1369, DOI 10.1099/00221287-143-4-1369; RAHA A, 1994, J BIOL CHEM, V269, P5750; RAJAKYLA E, 1983, J CHROMATOGR, V282, P595, DOI 10.1016/S0021-9673(00)91636-4; REED RH, 1986, FEMS MICROBIOL LETT, V39, P51; RHODES D, 1993, ANNU REV PLANT PHYS, V44, P385; ROBERTS MF, 1992, J BACTERIOL, V174, P6688, DOI 10.1128/JB.174.20.6688-6693.1992; Sambrook J., 1989, MOL CLONING, pA1; SEHGAL SN, 1960, CAN J MICROBIOL, V6, P165, DOI 10.1139/m60-018; SEVERIN J, 1992, J GEN MICROBIOL, V138, P1629, DOI 10.1099/00221287-138-8-1629; Sutherland IW, 1971, METHOD MICROBIOL, V5, P345, DOI [DOI 10.1016/S0580-9517(08)70642-1, 10.1016/S0580-9517(08)70642-1]; TAKUSAGAWA F, 1998, COMPREHENSIVE BIOL C, V1, P1; TANI Y, 1979, AGR BIOL CHEM TOKYO, V43, P815, DOI 10.1080/00021369.1979.10863527; TRUPER HG, 1990, FEMS MICROBIOL LETT, V75, P247; TSCHICHHOLZ I, 1990, FEMS MICROBIOL ECOL, V73, P181, DOI 10.1016/0378-1097(90)90728-9; Velasco-Garcia R, 1999, J BACTERIOL, V181, P1292; WERETILNYK EA, 1989, ARCH BIOCHEM BIOPHYS, V271, P56, DOI 10.1016/0003-9861(89)90255-5; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	47	127	141	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22196	22201		10.1074/jbc.M910111199	http://dx.doi.org/10.1074/jbc.M910111199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10896953	hybrid			2022-12-25	WOS:000088363800062
J	Sawada, M; Nakashima, S; Banno, Y; Yamakawa, H; Takenaka, K; Shinoda, J; Nishimura, Y; Sakai, N; Nozawa, Y				Sawada, M; Nakashima, S; Banno, Y; Yamakawa, H; Takenaka, K; Shinoda, J; Nishimura, Y; Sakai, N; Nozawa, Y			Influence of Bax or Bcl-2 overexpression on the ceramide-dependent apoptotic pathway in glioma cells	ONCOGENE			English	Article						anti-cancer agents; apoptosis; Bcl-2 family; ceramide; glioma cells; sphingomyelinase	DAUNORUBICIN-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; CYTOCHROME-C; DNA-DAMAGE; CHEMOTHERAPEUTIC-AGENTS; PERMEABILITY TRANSITION; ISOLATED-MITOCHONDRIA; FAMILY PROTEINS; T-CELLS; DEATH	Ceramide has recently been regarded as a potential mediator of apoptosis, In the present study, the effects of Bcl-2 and Bax on the ceramide-mediated apoptotic pathways mere examined in glioma cells overexpressing Bcl-2 or Bax. Etoposide, cisplatin and tumor necrosis factor-alpha induced apoptosis of C6 rat glioma cells which was associated with ceramide formation due to activation of neutral sphingomyelinase, followed by release of mitochondrial cytochrome c into the cytosol and activation of caspases-9 and -3, The growth of C6 cells stably overexpressing either Bcl-2 or Bax was almost equal to that of the vector-transfected cells. Bas overexpression enhanced etoposide-induced apoptosis through acceleration of cytochrome c release and caspases activation. However, Bax had no effect on ceramide formation, Similar findings mere obtained in C6 cells and U87-MG human glioblastoma cells which mere transiently overexpressed with Bax. In contrast, Bcl-2 overexpression resulted in a retardation of the apoptotic process via prevention of cytochrome c release and caspases activation, and ceramide formation was also blocked when Bcl-2 was highly overexpressed in glioma cells. Tn addition, transient overexpression of Bcl-xL also exerted inhibitory effects on ceramide formation and apoptotic cell death induced by etoposide, These results indicate that Bax promotes apoptosis regardless of ceramide formation and that Bcl-2 or Bcl-xL prevents ceramide formation by repressing neutral sphingomyelinase as well as ceramide-induced cytochrome c release.	Gifu Univ, Sch Med, Dept Neurosurg, Gifu 5008705, Japan; Gifu Univ, Sch Med, Dept Biochem, Gifu 5008705, Japan; Gifu Int Inst Biotechnol, Mitake, Gifu 5050116, Japan	Gifu University; Gifu University	Sawada, M (corresponding author), Gifu Univ, Sch Med, Dept Neurosurg, Tsukasamachi 40, Gifu 5008705, Japan.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Allouche M, 1997, ONCOGENE, V14, P1837, DOI 10.1038/sj.onc.1201023; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Decaudin D, 1997, CANCER RES, V57, P62; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hsu SC, 1998, BLOOD, V91, P2658, DOI 10.1182/blood.V91.8.2658.2658_2658_2663; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kim CN, 1997, CANCER RES, V57, P3115; KIM MY, 1991, J BIOL CHEM, V266, P484; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kobayashi T, 1998, ONCOGENE, V16, P1587, DOI 10.1038/sj.onc.1201681; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Sakakura C, 1997, SURG TODAY, V27, P676, DOI 10.1007/BF02388231; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SAWADA M, 2000, IN PRESS CELL DEATH; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 1996, CANCER RES, V56, P2161; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Sillence DJ, 1997, BIOCHEM J, V324, P29, DOI 10.1042/bj3240029; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Vogelbaum MA, 1998, J NEUROSURG, V88, P99, DOI 10.3171/jns.1998.88.1.0099; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Watts JD, 1999, TRENDS BIOCHEM SCI, V24, P228, DOI 10.1016/S0968-0004(99)01411-5; Watts JD, 1999, CELL DEATH DIFFER, V6, P105, DOI 10.1038/sj.cdd.4400472; Watts JD, 1997, P NATL ACAD SCI USA, V94, P7292, DOI 10.1073/pnas.94.14.7292; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin DX, 1996, P NATL ACAD SCI USA, V93, P3394, DOI 10.1073/pnas.93.8.3394; YIN DX, 1995, CANCER RES, V55, P4922; YIN XM, 1994, COLD SPRING HARB SYM, V59, P387, DOI 10.1101/SQB.1994.059.01.043; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Yoshimura S, 1997, J NEUROCHEM, V69, P713; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	64	81	85	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3508	3520		10.1038/sj.onc.1203699	http://dx.doi.org/10.1038/sj.onc.1203699			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918609				2022-12-25	WOS:000088346500007
J	Vinos, J; Freeman, M				Vinos, J; Freeman, M			Evidence that Argos is an antagonistic ligand of the EGF receptor	ONCOGENE			English	Article						Argos; EGF receptor; antagonist; receptor; tyrosine kinase; Drosophila; growth factor	DROSOPHILA EYE; ACTIVATION; INHIBITION; PATHWAY; LOOP	Argos, the inhibitor of the Drosophila epidermal growth factor (EGF) receptor, remains the only known extracellular inhibitor of this family of receptors in any organism. The functional domain of Argos includes an atypical EGF domain and it is not clear whether it binds to the EGF receptor or if it acts via a distinct receptor to reduce Egfr activity indirectly. Here we present two lines of evidence that strongly suggest that Argos directly interacts with the EGF receptor. First, Argos is unable to inhibit a chimeric receptor that contains an extracellular domain from an unrelated RTK, indicating the need for the EGF receptor extracellular domain. Second, Argos can inhibit the Drosophila EGF receptor even when expressed in human cells, implying that no other Drosophila protein is necessary for inhibition. We also report that Argos and the Drosophila activating ligand, Spitz, can influence mammalian RTK activation, albeit in a cell-type specific manner. This includes the first evidence that Argos can inhibit signalling in mammalian cells, raising the possibility of engineering an effective human EGF receptor/Erbs antagonist.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Freeman, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.			Freeman, Matthew/0000-0003-0410-5451				Casci T, 1999, CANCER METAST REV, V18, P181, DOI 10.1023/A:1006313122373; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; Golembo M, 1996, DEVELOPMENT, V122, P223; Howes R, 1998, J BIOL CHEM, V273, P4275, DOI 10.1074/jbc.273.7.4275; Lohmeyer M, 1997, INT J ONCOL, V10, P677; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; Stemerdink C, 1997, DEVELOPMENT, V124, P3787; vandePoll MLM, 1997, BIOCHEMISTRY-US, V36, P7425, DOI 10.1021/bi970227f	11	24	25	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3560	3562		10.1038/sj.onc.1203702	http://dx.doi.org/10.1038/sj.onc.1203702			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918615				2022-12-25	WOS:000088346500013
J	Arlt, DH; Baur, B; Wagner, B; Hoppner, W				Arlt, DH; Baur, B; Wagner, B; Hoppner, W			A novel type of mutation in the cysteine rich domain of the RET receptor causes ligand independent activation	ONCOGENE			English	Article						MEN 2; RET-proto-oncogene; additional cysteine 634; ligand independent dimerization	NEOPLASIA TYPE 2A; TYROSINE KINASE; PROTOONCOGENE; GDNF; EXPRESSION; NEURTURIN	Multiple endocrine neoplasia type 2A (MEN 2A) is a dominantly inherited canter syndrome, which involves the triad of MTC, pheochromocytoma, and hypcrparathyridism, Missense mutations in one of sis cysteine codons in the extracellular cysteine-rich domain of the RET proto-oncogene predispose to this disease. These mutations cause ligand-independent constitutive activation of the tyrosine kinase receptor by the formation of disulfide-bonded homodimers. We examined a different type of mutation, which results in an additional cysteine in the cysteine rich domain. A duplication of 9 bp in the first case resulted in an insertion of three amino acids between codon 633 and 634, In the second case a 12 bp duplication in exon 11 results in four additional amino acids between codon 634 and 635. Here we demonstrate that an additional cysteine causes a ligand independent dimerization of the RET receptor in transfected NIH3T3 cells, which results in an activation of the intracellular tyrosine kinase.	Univ Hamburg, Inst Hormone & Fertil Res, D-22529 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Dept Neurosci, D-20246 Hamburg, Germany	University of Hamburg; University of Hamburg	Hoppner, W (corresponding author), Univ Hamburg, Inst Hormone & Fertil Res, Grandweg 64, D-22529 Hamburg, Germany.							AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; Berndt I, 1998, J CLIN ENDOCR METAB, V83, P770, DOI 10.1210/jc.83.3.770; Bongarzone I, 1999, ONCOGENE, V18, P4833, DOI 10.1038/sj.onc.1202848; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; FATTORUSO O, 1998, HUM MUTAT S, V1, P167, DOI DOI 10.1002/HUMU.1380110156); Hoppner W, 1997, HUM MOL GENET, V6, P587, DOI 10.1093/hmg/6.4.587; Hoppner W, 1998, HUM MUTAT, pS128; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0	19	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2000	19	30					3445	3448		10.1038/sj.onc.1203688	http://dx.doi.org/10.1038/sj.onc.1203688			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918602				2022-12-25	WOS:000088198100013
J	Jo, EJ; McLaurin, J; Yip, CM; St George-Hyslop, P; Fraser, PE				Jo, EJ; McLaurin, J; Yip, CM; St George-Hyslop, P; Fraser, PE			alpha-synuclein membrane interactions and lipid specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; FAMILIAL PARKINSONS-DISEASE; A-BETA COMPONENT; ATOMIC-FORCE MICROSCOPY; CENTRAL-NERVOUS-SYSTEM; LEWY-BODY-DISEASE; NACP/ALPHA-SYNUCLEIN; NEURODEGENERATIVE DISORDERS; ALZHEIMERS-DISEASE; TAPPING-MODE	With the discovery of missense mutations (A53T and A30P) in alpha -synuclein (alpha -Syn) in several families with early onset familial Parkinson's disease, alpha -Syn aggregation and fibril formation have been thought to play a role in the pathogenesis of alpha -synucleinopathies, such as Parkinson's disease, dementia. with Lewy bodies, and multiple system atrophy. As previous reports have suggested that alpha -Syn plays a role in lipid transport and synaptic membrane biogenesis, we investigated whether alpha -Syn binds to a specific lipid ligand using thin layer chromatography overlay and examined the changes in its secondary structure using circular dichroism spectroscopy. alpha -Syn was found to bind to acidic phospholipid vesicles and this:binding was significantly augmented by the. presence of phosphatidylethanolamine, a neutral phospholipid. We further examined the interaction of alpha -Syn with lipids by in situ atomic force microscopy. The association of soluble wild-type alpha -Syn with planar lipid bilayers resulted in extensive bilayer disruption and the formation of amorphous aggregates and small fibrils. The A53T mutant alpha -Syn disrupted the Lipid bilayers in a similar fashion but at a slower rate. These results suggest that alpha -Syn membrane interactions are physiologically important and the lipid composition of the cellular membranes may affect these interactions in vivo.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Lab Med & Pathobiol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Chem Engn, Inst Biomat & Biomed Engn, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Biochem, Inst Biomat & Biomed Engn, Toronto, ON M5S 3H2, Canada; Univ Toronto, Univ Hlth Network, Dept Med Neurol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H2, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Jo, EJ (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, 6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.			Jo, Euijung/0000-0003-1131-2723; Yip, Christopher/0000-0003-4507-556X				Arai T, 1999, NEUROSCI LETT, V259, P83, DOI 10.1016/S0304-3940(98)00890-8; Arima K, 1998, ACTA NEUROPATHOL, V96, P439, DOI 10.1007/s004010050917; Arima K, 1998, BRAIN RES, V808, P93, DOI 10.1016/S0006-8993(98)00734-3; Baba M, 1998, AM J PATHOL, V152, P879; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BAZZI MD, 1992, BIOCHEMISTRY-US, V31, P1125, DOI 10.1021/bi00119a022; Borden KLB, 1998, ANN NEUROL, V44, pS65, DOI 10.1002/ana.410440711; Brandsch R, 1997, LANGMUIR, V13, P6349, DOI 10.1021/la970822i; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.3.CO;2-5; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Cleveland JP, 1998, APPL PHYS LETT, V72, P2613, DOI 10.1063/1.121434; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; El-Agnaf OMA, 1998, FEBS LETT, V440, P71, DOI 10.1016/S0014-5793(98)01418-5; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; EPAND RM, 1995, BIOPOLYMERS, V37, P319, DOI 10.1002/bip.360370504; Epand RM, 1993, AMPHIPATHIC HELIX; GANSER AL, 1988, DEV NEUROSCI-BASEL, V10, P99, DOI 10.1159/000111961; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Goedert M, 1998, MOL PSYCHIATR, V3, P462, DOI 10.1038/sj.mp.4000458; Goedert M, 1997, NATURE, V388, P232, DOI 10.1038/40767; Goedert M, 1998, BIOCHEM SOC T, V26, P463, DOI 10.1042/bst0260463; HAUSER H, 1981, BIOCHIM BIOPHYS ACTA, V650, P21, DOI 10.1016/0304-4157(81)90007-1; Hsu LJ, 1998, J NEUROCHEM, V71, P338; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; IWAI A, 1995, BIOCHEMISTRY-US, V34, P10139, DOI 10.1021/bi00032a006; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; Mezey E, 1998, MOL PSYCHIATR, V3, P493, DOI 10.1038/sj.mp.4000446; Mezey E, 1998, NAT MED, V4, P755, DOI 10.1038/nm0798-755; MICHAELSON DM, 1983, BIOCHEM J, V211, P155, DOI 10.1042/bj2110155; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; NAKAJO S, 1990, J NEUROCHEM, V55, P2031, DOI 10.1111/j.1471-4159.1990.tb05792.x; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Noy A, 1998, LANGMUIR, V14, P1508, DOI 10.1021/la970948f; Polymeropoulos MH, 1998, ANN NEUROL, V44, pS63, DOI 10.1002/ana.410440710; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Takeda A, 1998, AM J PATHOL, V152, P367; Trojanowski JQ, 1998, ARCH NEUROL-CHICAGO, V55, P151, DOI 10.1001/archneur.55.2.151; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; TYTLER EM, 1993, J BIOL CHEM, V268, P22112; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; Wakabayashi K, 1997, NEUROSCI LETT, V239, P45, DOI 10.1016/S0304-3940(97)00891-4; Wakabayashi K, 2000, ACTA NEUROPATHOL, V99, P14, DOI 10.1007/PL00007400; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Winkler RG, 1996, PHYS REV B, V54, P8908, DOI 10.1103/PhysRevB.54.8908; Withers GS, 1997, DEV BRAIN RES, V99, P87, DOI 10.1016/S0165-3806(96)00210-6; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; YIU SCK, 1992, ANAL BIOCHEM, V202, P188, DOI 10.1016/0003-2697(92)90226-W	61	468	481	0	62	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34328	34334		10.1074/jbc.M004345200	http://dx.doi.org/10.1074/jbc.M004345200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10915790	hybrid			2022-12-25	WOS:000165095300046
J	Berthet, V; Rigot, V; Champion, S; Secchi, J; Fouchier, F; Marvaldi, J; Luis, J				Berthet, V; Rigot, V; Champion, S; Secchi, J; Fouchier, F; Marvaldi, J; Luis, J			Role of endoproteolytic processing in the adhesive and signaling functions of alpha(v)beta(5) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PRECURSOR PROTEINS; CELL-ADHESION; SUBSTRATE-SPECIFICITY; SECRETORY PATHWAY; FURIN; CONVERTASE; CLEAVAGE; ACTIVATION; TRANSDUCTION	Some integrin alpha subunits undergo a post-translational cleavage in their extracellular domain. However, the role of this cleavage in integrin function is unclear. Enzymes involved in this maturation belong to the subtilisin-like endoprotease family (convertases). To understand the role of the alpha subunit cleavage in integrin function, we have designed stable transfectants (PDX39P cells) expressing alpha (1)-PDX, a convertase inhibitor. Immunoprecipitation of cell surface proteins from PDX39P showed that alpha (3), alpha (6) and alpha (v) integrins lack endoproteolytic cleavage. We have compared adhesion between PDX39P cells and mock-transfected cells on different extracellular matrix proteins. No difference in adhesion could be observed on laminin-l and type I collagen, while attachment of PDX39P cells to vitronectin (ligand of the alpha (v)beta (5) integrin) was dramatically reduced. The reduced adhesion of PDX39P cells was not due to changes in integrin affinity as determined by solid-phase receptor assay in a cell-free environment. Intracellular signaling pathways activated by alpha (v) integrin ligation were also affected in PDX39P cells. It thus seems that the absence of endoproteolytic cleavage of alpha (v) integrins has important consequences on signal transduction pathways leading to alterations in integrin function such as cell adhesion.	Fac Pharm Marseille, CNRS, UPRESA 6032, Biochim Cellulaire Lab, F-13385 Marseille 5, France	Centre National de la Recherche Scientifique (CNRS)	Luis, J (corresponding author), Fac Pharm Marseille, CNRS, UPRESA 6032, Biochim Cellulaire Lab, 27 Bd J Moulin, F-13385 Marseille 5, France.	jose.luis@pharmacie.univ-mrs.fr	LUIS, José/M-3071-2013					ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; Andre F, 1999, GASTROENTEROLOGY, V116, P64, DOI 10.1016/S0016-5085(99)70230-1; Aplin AE, 1998, PHARMACOL REV, V50, P197; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; Brown E, 1996, IMMUNOL LETT, V54, P189, DOI 10.1016/S0165-2478(96)02671-5; CHUN JS, 1993, MOL BIOL CELL, V4, P271; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; Decroly E, 1996, J BIOL CHEM, V271, P30442, DOI 10.1074/jbc.271.48.30442; Delwel GO, 1996, J BIOL CHEM, V271, P7293, DOI 10.1074/jbc.271.13.7293; DENAULT JB, 1995, J CARDIOVASC PHARM, V26, pS47; Denault JB, 1996, FEBS LETT, V379, P113, DOI 10.1016/0014-5793(95)01487-X; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HEMLER ME, 1991, RECEPTORS EXTRACELLU, P255; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; Kadi A, 1998, BIOCHEM BIOPH RES CO, V246, P690, DOI 10.1006/bbrc.1998.8536; KOLODZIEJ MA, 1991, J BIOL CHEM, V266, P23499; Lehmann M, 1996, BIOCHEM J, V317, P803, DOI 10.1042/bj3170803; LEHMANN M, 1994, CANCER RES, V54, P2102; Lissitzky JC, 2000, BIOCHEM J, V346, P133, DOI 10.1042/0264-6021:3460133; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; MATTHEWS DJ, 1994, PROTEIN SCI, V3, P1197, DOI 10.1002/pro.5560030805; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MOEHRING JM, 1993, J BIOL CHEM, V268, P2590; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; Rigot V, 1998, J CELL SCI, V111, P3119; Rigot V, 1999, EUR J BIOCHEM, V261, P659, DOI 10.1046/j.1432-1327.1999.00300.x; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; SHAW SK, 1994, J BIOL CHEM, V269, P6016; Steiner DF, 1996, DIABETES METAB, V22, P94; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; TEIXIDO J, 1992, J BIOL CHEM, V267, P1786; TIMPL R, 1979, J BIOL CHEM, V254, P9933; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	37	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33308	33313		10.1074/jbc.M004834200	http://dx.doi.org/10.1074/jbc.M004834200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10913146	hybrid			2022-12-25	WOS:000090104600021
J	Tanioka, T; Nakatani, Y; Semmyo, N; Murakami, M; Kudo, I				Tanioka, T; Nakatani, Y; Semmyo, N; Murakami, M; Kudo, I			Molecular identification of cytosolic prostaglandin E-2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E-2 biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PHOSPHOLIPASE A(2)S; ARACHIDONIC-ACID RELEASE; GLUCOCORTICOID RECEPTOR; H SYNTHASE-1; HUMAN-BRAIN; PROTEIN; IIA; PURIFICATION; EXPRESSION; GENERATION	Here we report the molecular identification of cytosolic glutathione (GSH)-dependent prostaglandin (PG) E-2 synthase (cPGES), a terminal enzyme of the cyclooxygenase (COX)-1-mediated PGE(2) biosynthetic pathway. GSH-dependent PGES activity in the cytosol of rat brains, but not of other tissues, increased 3-fold after lipopolysaccharide (LPS) challenge. Peptide microsequencing of purified enzyme revealed that it was identical to p23, which is reportedly the weakly bound component of the steroid hormone receptor/hsp90 complex. Recombinant p23 expressed in Escherichia coli and 293 cells exhibited all the features of PGES activity detected in rat brain cytosol. A tyrosine residue near the N terminus (Tyr(9)), which is known to be critical for the activity of cytosolic GSH S-transferases, was essential for PGES activity. The expression of cPGES/p23 was constitutive and was unaltered by proinflammatory stimuli in various cells and tissues, except that it was increased significantly in rat brain after LPS treatment, cPGES/p23 was functionally linked with COX-1 in marked preference to COX-2 to produce PGE(2) from exogenous and endogenous arachidonic acid, the latter being supplied by cytosolic phospholipase A(2) in the immediate response. Thus, functional coupling between COX-1 and cPGES/p23 may contribute to production of the PGE(2) that plays a role in maintenance of tissue homeostasis.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 142, Japan	Showa University	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 142, Japan.							Beuckmann CT, 1999, BIOCHEMISTRY-US, V38, P8006, DOI 10.1021/bi990261p; Bohen SP, 1998, MOL CELL BIOL, V18, P3330, DOI 10.1128/MCB.18.6.3330; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Fournier T, 1997, J BIOL CHEM, V272, P31065, DOI 10.1074/jbc.272.49.31065; Freeman BC, 2000, GENE DEV, V14, P422; Harada Y, 1996, PROSTAG OTH LIPID M, V51, P19, DOI 10.1016/0090-6980(95)00168-9; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; Jakobsson PJ, 1999, PROTEIN SCI, V8, P689, DOI 10.1110/ps.8.3.689; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Liou JY, 2000, J BIOL CHEM, V275, P15314, DOI 10.1074/jbc.275.20.15314; Morishima Y, 2000, J BIOL CHEM, V275, P6894, DOI 10.1074/jbc.275.10.6894; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; NAGATA A, 1991, P NATL ACAD SCI USA, V88, P4020, DOI 10.1073/pnas.88.9.4020; Nakatani Y, 2000, J BIOL CHEM, V275, P1161, DOI 10.1074/jbc.275.2.1161; Naraba H, 1998, J IMMUNOL, V160, P2974; OGOROCHI T, 1987, J NEUROCHEM, V48, P900, DOI 10.1111/j.1471-4159.1987.tb05602.x; PINZAR E, 2000, IN PRESS J BIOL CHEM, V275; Salinas AE, 1999, CURR MED CHEM, V6, P279; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Suzuki T, 1999, J BIOL CHEM, V274, P241, DOI 10.1074/jbc.274.1.241; Tanaka T, 1997, J BIOL CHEM, V272, P15789, DOI 10.1074/jbc.272.25.15789; TANAKA Y, 1987, J BIOL CHEM, V262, P1374; Watanabe K, 1999, BBA-MOL CELL BIOL L, V1439, P406, DOI 10.1016/S1388-1981(99)00084-0; WATANABE K, 1985, J BIOL CHEM, V260, P7035; Weaver AJ, 2000, J BIOL CHEM, V275, P23045, DOI 10.1074/jbc.M003410200	40	592	610	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32775	32782		10.1074/jbc.M003504200	http://dx.doi.org/10.1074/jbc.M003504200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10922363	hybrid			2022-12-25	WOS:000090003800056
J	Hellmich, MR; Rui, XL; Hellmich, HL; Fleming, RYD; Evers, BM; Townsend, CM				Hellmich, MR; Rui, XL; Hellmich, HL; Fleming, RYD; Evers, BM; Townsend, CM			Human colorectal cancers express a constitutively active cholecystokinin-B/gastrin receptor that stimulates cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HUMAN-COLON-CANCER; GASTRIN RECEPTORS; CARCINOMA; CLONING; ACTIVATION; MUTATION; SUBTYPES; TUMORS; KINASE	Although ectopic expression of the cholecystokinin B/gastrin receptor (CCK-BR) is widely reported in human colorectal cancers, its role in mediating the proliferative effects of gastrin1-17 (G-17) on these cancers is unknown. Here we report the isolation of a novel splice variant of CCK-BR that exhibits constitutive (ligand-independent) activation of pathways regulating intracellular free Ca2+ ([Ca2+](i)) and cell growth. The splice variant (designated CCK-BRi4sv for intron 4-containing splice variant) is expressed in colorectal cancers but not in normal colonic mucosa adjacent to the cancer. Balb3T3 cells expressing CCK-BRi4sv exhibited spontaneous, ligand-independent, oscillatory increases in [Ca2+](i), whereas cells expressing wild-type CCK-BR did not. Primary cultures of cells isolated from resected colorectal cancers also exhibited a similar pattern of spontaneous [Ca2+], oscillations. For both Balb3T3 and primary tumor cells, application of G-17 (10 and 200 nM, respectively) caused an increase in [Ca2+](i), Selective CCK-BR antagonists blocked the G-17-stimulated Ca2+ responses but not the spontaneous [Ca2+](i) oscillations. Cells expressing CCK-BRi4sv exhibited an increased growth rate (similar to 2.5-fold), in the absence of 6-17, compared with cells expressing wild-type CCK-BR, The selective pattern of expression, constitutive activity, and trophic action associated with CCK-BRi4sv suggest that this variant may regulate colorectal cancer cell proliferation though a gastrin-independent mechanism.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Hellmich, MR (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	mhellmic@utmb.edu			NIDDK NIH HHS [R01DK48345] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048345] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; BALDWIN GS, 1990, BIOCHEM BIOPH RES CO, V170, P691, DOI 10.1016/0006-291X(90)92146-Q; Baldwin GS, 1998, GUT, V42, P581, DOI 10.1136/gut.42.4.581; Beahrs O. H., 1992, AM JOINT COMMITTEE C; Bertagnolli MM, 1997, P SOC EXP BIOL MED, V216, P266; Biagini P, 1997, LIFE SCI, V61, P1009, DOI 10.1016/S0024-3205(97)00605-X; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; BORDI C, 1995, AM J SURG PATHOL, V19, pS8; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Davis LG, 1994, BASIC METHODS MOL BI; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; Hollande F, 1997, GASTROENTEROLOGY, V113, P1576, DOI 10.1053/gast.1997.v113.pm9352860; IMDAHL A, 1995, J CANCER RES CLIN, V121, P661, DOI 10.1007/BF01218524; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MCGREGOR DB, 1989, ARCH SURG-CHICAGO, V124, P470; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; REHFELD JF, 1993, TUMOR BIOL, V14, P174, DOI 10.1159/000217833; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; Smith JP, 1996, AM J PHYSIOL-REG I, V271, pR797, DOI 10.1152/ajpregu.1996.271.3.R797; SMITH JP, 1988, GASTROENTEROLOGY, V95, P1541; SONG I, 1993, P NATL ACAD SCI USA, V90, P9085, DOI 10.1073/pnas.90.19.9085; Stepan VM, 1999, MOL MED, V5, P147, DOI 10.1007/BF03402058; STEPHENS EV, 1993, ONCOGENE, V8, P19; TODISCO A, 1995, J BIOL CHEM, V270, P28337; UPP JR, 1989, CANCER RES, V49, P488; Walsh John H., 1994, P1; Wang HL, 1997, J NEUROCHEM, V68, P1728; WANK SA, 1994, ANN NY ACAD SCI, V713, P49, DOI 10.1111/j.1749-6632.1994.tb44052.x; WATSON SA, 1995, INT J CANCER, V61, P233, DOI 10.1002/ijc.2910610216; WINSETT OE, 1986, SURGERY, V99, P302	38	117	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32122	32128		10.1074/jbc.M005754200	http://dx.doi.org/10.1074/jbc.M005754200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913157	hybrid			2022-12-25	WOS:000089858900078
J	Ohkawa, H; Pakrasi, HB; Ogawa, T				Ohkawa, H; Pakrasi, HB; Ogawa, T			Two types of functionally distinct NAD(P)H dehydrogenases in Synechocystis sp strain PCC6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INORGANIC CARBON TRANSPORT; PHOTOSYSTEM-I; ANABAENA-VARIABILIS; CYANOBACTERIUM; GENE; IDENTIFICATION; MECHANISM; PCC-7942	The ndhD gene encodes a membrane protein component of NAD(P)H dehydrogenase. The genome of Synechocystis sp. PCC6803 contains 6 ndhD genes. Three mutants were constructed by disrupting highly homologous ndhD genes in pairs. Only the Delta ndhD1/Delta ndhD2 (Delta ndhD1/D2) mutant was unable to grow under photoheterotrophic conditions and exhibited low respiration rate, although the mutant grew normally under photoautotrophic conditions in air. The Delta ndhD3/Delta ndhD4 (Delta ndhD3/D4) mutant grew very slowly in air and did not take up CO2. The results demonstrated the presence of two types of functionally distinct NAD(P)H dehydrogenases in Synechocystis PCC6803 cells. The Delta ndhD5/Delta ndhD6 (Delta ndhD5/D6) mutant grew like the wild-type strain. Under far-red light (>710 nm), the level of P700(+) was high in Delta ndhD1/D2 and M55 (ndhB-less mutant) at low intensities. The capacity of Q(A) (tightly bound plastoquinone) reduction by plastoquinone pool, as measured by the fluorescence increase in darkness upon addition of KCN, was much less in Delta ndhD1/D2 and M55 than in Delta ndhD3/D4 and Delta ndhD5/D6. We conclude that electrons from NADPH are transferred to the plastoquinone pool mainly by the NdhD1 . NdhD2 type of NAD(P)H dehydrogenases.	Nagoya Univ, Biosci Ctr, Nagoya, Aichi 4648601, Japan; Washington Univ, Dept Biol, St Louis, MO 63130 USA	Nagoya University; Washington University (WUSTL)	Ogawa, T (corresponding author), Nagoya Univ, Biosci Ctr, Nagoya, Aichi 4648601, Japan.	h44975a@nucc.cc.nagoya-u.ac.jp						Cooley JW, 2000, J BACTERIOL, V182, P714, DOI 10.1128/JB.182.3.714-722.2000; Kaftan D, 1999, PLANT PHYSIOL, V120, P433, DOI 10.1104/pp.120.2.433; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; Kaplan A, 1999, ANNU REV PLANT PHYS, V50, P539, DOI 10.1146/annurev.arplant.50.1.539; Klughammer B, 1999, MOL MICROBIOL, V32, P1305, DOI 10.1046/j.1365-2958.1999.01457.x; MARCO E, 1993, PLANT PHYSIOL, V101, P1047, DOI 10.1104/pp.101.3.1047; MI H, 1994, PLANT CELL PHYSIOL, V35, P163; OGAWA T, 1983, BIOCHIM BIOPHYS ACTA, V724, P490, DOI 10.1016/0005-2728(83)90110-X; OGAWA T, 1992, PLANT PHYSIOL, V99, P1604, DOI 10.1104/pp.99.4.1604; OGAWA T, 1991, PLANT PHYSIOL, V96, P280, DOI 10.1104/pp.96.1.280; OGAWA T, 1985, BIOCHIM BIOPHYS ACTA, V808, P77, DOI 10.1016/0005-2728(85)90029-5; OGAWA T, 1991, P NATL ACAD SCI USA, V88, P4275, DOI 10.1073/pnas.88.10.4275; Ogawa T, 1998, STRESS RESPONSES OF PHOTOSYNTHETIC ORGANISMS, P181; OGAWA T, 1965, PHOTOCHEM PHOTOBIOL, V4, P193; OGAWA T, 1985, INORGANIC CARBON UPT, P287; Ohkawa H, 1998, CAN J BOT, V76, P1035, DOI 10.1139/b98-076; Ohkawa H, 2000, J BACTERIOL, V182, P2591, DOI 10.1128/JB.182.9.2591-2596.2000; Omata T, 1999, P NATL ACAD SCI USA, V96, P13571, DOI 10.1073/pnas.96.23.13571; Price GD, 1998, CAN J BOT, V76, P973, DOI 10.1139/b98-081; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmetterer G, 1994, MOL BIOL CYANOBACTER, P409, DOI DOI 10.1007/0-306-48205-3_13; SCHREIBER U, 1988, Z NATURFORSCH C, V43, P686; STANIER RY, 1971, BACTERIOL REV, V35, P171, DOI 10.1128/MMBR.35.2.171-205.1971; VOLOKITA M, 1984, PLANT PHYSIOL, V76, P599, DOI 10.1104/pp.76.3.599	24	167	173	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31630	31634		10.1074/jbc.M003706200	http://dx.doi.org/10.1074/jbc.M003706200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10906128	hybrid			2022-12-25	WOS:000089858900013
J	Wintrode, PL; Miyazaki, K; Arnold, FH				Wintrode, PL; Miyazaki, K; Arnold, FH			Cold adaptation of a mesophilic subtilisin-like protease by laboratory evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGLIN-C; PSYCHROPHILIC ENZYMES; STRUCTURAL-ANALYSIS; BACILLUS-SUBTILIS; THERMITASE; CARLSBERG; PROTEINS; SEQUENCE; TEMPERATURE; MUTAGENESIS	Enzymes isolated from organisms native to cold environments generally exhibit higher catalytic efficiency at low temperatures and greater thermosensitivity than their mesophilic counterparts. In an effort to understand the evolutionary process and the molecular basis of cold adaptation, we have used directed evolution to convert a mesophilic subtilisin-like protease from Bacillus sphaericus, SSII, into its psychrophilic counterpart. A single round of random mutagenesis followed by recombination of improved variants yielded a mutant, P3C9, with a catalytic rate constant (k(cat)) at 10 degrees C 6.6 times and a catalytic efficiency (k(cat)/K-M) 9.6 times that of wild type. Its half-life at 70 degrees C is 3.3 times less than wild type. Although there is a trend toward decreasing stability during the progression from mesophile to psychrophile, there is not a strict correlation between decreasing stability and increasing low temperature activity. A first generation mutant with a >2-fold increase in k(cat) is actually more stable than wild type. This suggests that the ultimate decrease in stability may be due to random drift rather than a physical incompatibility between low temperature activity and high temperature stability. SSII shares 77.4% identity with the naturally psychrophilic protease subtilisin S41, Although SSII and S41 differ at 85 positions, four amino acid substitutions were sufficient to generate an SSII whose low temperature activity is greater than that of S41. That none of the four are found in S41 indicates that there are multiple routes to cold adaptation.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology	Arnold, FH (corresponding author), CALTECH, Div Chem & Chem Engn, 210-41, Pasadena, CA 91125 USA.	frances@cheme.caltech.edu	Miyazaki, Kentaro/F-7022-2010	Miyazaki, Kentaro/0000-0002-4349-566X; Arnold, Frances H./0000-0002-4027-364X				BENNER SA, 1989, CHEM REV, V89, P789, DOI 10.1021/cr00094a004; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BETZEL C, 1990, PROTEIN ENG, V3, P161, DOI 10.1093/protein/3.3.161; BODE W, 1987, EUR J BIOCHEM, V166, P673, DOI 10.1111/j.1432-1033.1987.tb13566.x; DAVAIL S, 1994, J BIOL CHEM, V269, P17448; DELMAR EG, 1979, ANAL BIOCHEM, V99, P316, DOI 10.1016/S0003-2697(79)80013-5; Feller G, 1997, CELL MOL LIFE SCI, V53, P830, DOI 10.1007/s000180050103; FELLER G, 1994, EUR J BIOCHEM, V222, P441, DOI 10.1111/j.1432-1033.1994.tb18883.x; Fields PA, 1998, P NATL ACAD SCI USA, V95, P11476, DOI 10.1073/pnas.95.19.11476; Gerday C, 1997, BBA-PROTEIN STRUCT M, V1342, P119, DOI 10.1016/S0167-4838(97)00093-9; Giver L, 1998, P NATL ACAD SCI USA, V95, P12809, DOI 10.1073/pnas.95.22.12809; GROS P, 1989, J MOL BIOL, V210, P347, DOI 10.1016/0022-2836(89)90336-7; HOCHACHKA PW, 1984, BIOCHEMICAL ADAPTATI; JACOBS M, 1985, NUCLEIC ACIDS RES, V13, P8913, DOI 10.1093/nar/13.24.8913; JANEICKE R, 1990, PHILOS T R SOC LOND, V326, P535; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRISTJANSSON MM, 1997, FOOD PROTEINS LIPIDS; Lebbink JHG, 2000, BIOCHEMISTRY-US, V39, P3656, DOI 10.1021/bi991483q; LOW PS, 1973, P NATL ACAD SCI USA, V70, P430, DOI 10.1073/pnas.70.2.430; MCPHALEN CA, 1988, BIOCHEMISTRY-US, V27, P6582, DOI 10.1021/bi00417a058; MELOUN B, 1985, FEBS LETT, V183, P195, DOI 10.1016/0014-5793(85)80775-4; Merz A, 2000, BIOCHEMISTRY-US, V39, P880, DOI 10.1021/bi992333i; Miyazaki K, 1999, J MOL EVOL, V49, P716, DOI 10.1007/PL00006593; Miyazaki K, 2000, J MOL BIOL, V297, P1015, DOI 10.1006/jmbi.2000.3612; Narinx E, 1997, PROTEIN ENG, V10, P1271, DOI 10.1093/protein/10.11.1271; NARINX E, 1992, BIOCHIM BIOPHYS ACTA, V1131, P111, DOI 10.1016/0167-4781(92)90108-C; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PANTOLIANO MW, 1988, BIOCHEMISTRY-US, V27, P8311, DOI 10.1021/bi00422a004; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SOMERO GN, 1995, ANNU REV PHYSIOL, V57, P43, DOI 10.1146/annurev.ph.57.030195.000355; STAHL ML, 1984, J BACTERIOL, V158, P411, DOI 10.1128/JB.158.2.411-418.1984; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Taguchi S, 1999, J BIOCHEM, V126, P689, DOI 10.1093/oxfordjournals.jbchem.a022504; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VOLKOV A, 2000, IN PRESS METHODS ENZ; Wati MR, 1997, BBA-GENE STRUCT EXPR, V1352, P56, DOI 10.1016/S0167-4781(97)00023-7; WELLS JA, 1983, NUCLEIC ACIDS RES, V11, P7911, DOI 10.1093/nar/11.22.7911; Wintrode PL, 2001, ADV PROTEIN CHEM, V55, P161, DOI 10.1016/S0065-3233(01)55004-4; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258	39	109	114	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31635	31640		10.1074/jbc.M004503200	http://dx.doi.org/10.1074/jbc.M004503200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10906329	Green Accepted, hybrid			2022-12-25	WOS:000089858900014
J	Ding, JY; Takano, T; Gao, SY; Han, WH; Noda, C; Yanagi, S; Yamamura, H				Ding, JY; Takano, T; Gao, SY; Han, WH; Noda, C; Yanagi, S; Yamamura, H			Syk is required for the activation of Akt survival pathway in B cells exposed to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; NF-KAPPA-B; P56/P53(LYN) TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; HYDROGEN-PEROXIDE; HEAT-SHOCK; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; LYMPHOMA-CELLS	Syk has been demonstrated to play a crucial role in oxidative stress signaling in B cells. Here we report that Syk is required for the activation of the phosphatidylinositol (PI) 3-kinase-Akt survival pathway in B cells exposed to oxidative stress. Phosphorylation and activation of the serine-threonine kinase Akt were markedly increased in B cells treated with H2O2. In Syk-deficient DT40 cells treated with low doses of H2O2 (10-100 mu M), Akt activation was considerably reduced. Pretreatment with wortmannin, a PI 3-kinase-specific inhibitor, completely blocked the Syk-dependent Akt activation. Following stimulation by low doses of H2O2, a significant increase in PI 3-kinase activity was found in wild-type but not in Syk-deficient cells. These findings suggest that PI 3-kinase mediates Syk-dependent Akt activation pathway, Furthermore, viability of Syk-deficient cells, after exposure to H2O2, was dramatically decreased and caspase-9 activity was greatly increased compared with that of the wild-type cells. These results suggest that Syk is essential for the Akt survival pathway in B cells and enhances cellular resistance to oxidative stress-induced apoptosis.	Kobe Univ, Sch Med, Dept Biochem, Kobe, Hyogo 6500017, Japan; Hyogo Coll, Kakogawa 6750101, Japan	Kobe University; Hyogo College of Medicine	Yamamura, H (corresponding author), 7-5-1 Kusunokicho,Chuo Ku, Kobe, Hyogo 6500017, Japan.							AagaardTillery KM, 1996, J IMMUNOL, V156, P4543; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Beitz LO, 1999, J BIOL CHEM, V274, P32662, DOI 10.1074/jbc.274.46.32662; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gardner AM, 1997, FREE RADICAL BIO MED, V22, P73, DOI 10.1016/S0891-5849(96)00235-3; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kelley TW, 1999, J BIOL CHEM, V274, P26393, DOI 10.1074/jbc.274.37.26393; KHARBANDA S, 1994, ONCOGENE, V9, P3005; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; Konishi H, 1999, J BIOCHEM-TOKYO, V126, P1136, DOI 10.1093/oxfordjournals.jbchem.a022559; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Lee Y, 1999, J BIOL CHEM, V274, P19792, DOI 10.1074/jbc.274.28.19792; Lee YJ, 1997, BLOOD, V89, P4480, DOI 10.1182/blood.V89.12.4480; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Qin SF, 1997, J BIOL CHEM, V272, P2098; Qin SF, 1998, BIOCHEMISTRY-US, V37, P5481, DOI 10.1021/bi9729460; Qin SF, 1996, EUR J BIOCHEM, V236, P443, DOI 10.1111/j.1432-1033.1996.00443.x; SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; YANAGI S, 1994, EUR J BIOCHEM, V224, P329, DOI 10.1111/j.1432-1033.1994.00329.x; YANAGI S, 1995, CELL SIGNAL, V7, P185, DOI 10.1016/0898-6568(94)00088-S	32	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30873	30877		10.1074/jbc.M004813200	http://dx.doi.org/10.1074/jbc.M004813200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906139	hybrid			2022-12-25	WOS:000089762700022
J	Masuda, CA; Ramirez, J; Pena, A; Montero-Lomeli, M				Masuda, CA; Ramirez, J; Pena, A; Montero-Lomeli, M			Regulation of monovalent ion homeostasis and pH by the Ser-Thr protein phosphatase SIT4 in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST PLASMA-MEMBRANE; SALT TOLERANCE; TRANSDUCTION PATHWAYS; NHA1 ANTIPORTER; TOR PROTEINS; GENE; SODIUM; TRANSPORT; GLYCEROL; EFFLUX	A gene, SIT4, was identified as corresponding to a serine/threonine protein phosphatase and when overexpressed confers lithium tolerance in galactose medium to the budding yeast Saccharomyces cerevisiae, This gene has been previously identified as a regulator of the cell cycle and involved in nitrogen sensing. It is shown that the transcription levels of SIT4 are induced by low concentrations of Li+ in a time-dependent manner. Na+ and K+ at high concentrations, but not sorbitol, also induce transcription. As a response to Na+ or Li+ stress, yeast cells lower the intracellular K+ content. This effect is enhanced in cells overexpressing SIT4, which also increase Rb-86 efflux after the addition of Na+ or Lit to the extracellular medium. Another feature of SIT4-overexpressing cells is that they maintain a more alkaline pH of 6.64 compared with 6.17 in the wild type cells, It has been proposed that the main pathway of salt tolerance in yeast is mediated by a P-type ATPase, encoded by PMR2A/ENA1. However, our results show that in a sit4 strain, expression of ENA1 is still induced by mono valent cations, and overexpression of SIT4 does not alter the amount of ENA1 transcript. These results show that SIT4 acts in a parallel pathway not involving induction of transcription of ENA1 and suggest a novel function for SIT4 in response to salt stress.	Univ Fed Rio de Janeiro, CCS, ICB, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Univ Nacl Autonoma Mexico, IFC, Dept Mol Genet, Mexico City 04510, DF, Mexico	Universidade Federal do Rio de Janeiro; Universidad Nacional Autonoma de Mexico	Montero-Lomeli, M (corresponding author), Univ Fed Rio de Janeiro, CCS, ICB, Dept Bioquim Med, CP 68041, BR-21941590 Rio De Janeiro, Brazil.		Masuda, Claudio A/F-7214-2014; Montero-Lomeli, Monica/D-9885-2013	Masuda, Claudio A/0000-0002-0310-7108; 				ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; Banuelos MA, 1998, MICROBIOL-UK, V144, P2749, DOI 10.1099/00221287-144-10-2749; Bastians H, 1996, J CELL SCI, V109, P2865; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; BLOMBERG A, 1989, J BACTERIOL, V171, P1087, DOI 10.1128/jb.171.2.1087-1092.1989; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; Chen XJ, 2000, J BIOL CHEM, V275, P14865, DOI 10.1074/jbc.275.20.14865; de Nadal E, 1998, P NATL ACAD SCI USA, V95, P7357, DOI 10.1073/pnas.95.13.7357; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; FERRANDO A, 1995, MOL CELL BIOL, V15, P5470; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; Gomez MJ, 1996, FEMS MICROBIOL LETT, V135, P157, DOI 10.1016/0378-1097(95)00441-6; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Jope RS, 1999, MOL PSYCHIATR, V4, P117, DOI 10.1038/sj.mp.4000494; LIU HP, 1992, GENETICS, V132, P665; MANJI HK, 1995, ARCH GEN PSYCHIAT, V52, P531; Marquez JA, 1996, FEBS LETT, V382, P89, DOI 10.1016/0014-5793(96)00157-3; Masson JY, 1998, GENETICS, V149, P893; Masuda CA, 2000, BIOCHEM CELL BIOL, V78, P51, DOI 10.1139/bcb-78-1-51; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; Mulet JM, 1999, MOL CELL BIOL, V19, P3328; NORKRANS B, 1969, J BACTERIOL, V100, P836, DOI 10.1128/JB.100.2.836-845.1969; PENA A, 1984, ARCH BIOCHEM BIOPHYS, V231, P217, DOI 10.1016/0003-9861(84)90381-3; PENA A, 1995, J BACTERIOL, V177, P1017, DOI 10.1128/jb.177.4.1017-1022.1995; PENA A, 1991, BIOCHIM BIOPHYS ACTA, V1068, P237, DOI 10.1016/0005-2736(91)90214-S; POSAS F, 1995, J BIOL CHEM, V270, P13036, DOI 10.1074/jbc.270.22.13036; Prior C, 1996, FEBS LETT, V387, P89, DOI 10.1016/0014-5793(96)00470-X; Proft M, 1999, MOL CELL BIOL, V19, P537; Ramirez J, 1998, J BACTERIOL, V180, P5860; Ramirez J, 1996, BBA-BIOMEMBRANES, V1285, P175, DOI 10.1016/S0005-2736(96)00153-8; REED RH, 1987, APPL ENVIRON MICROB, V53, P2119, DOI 10.1128/AEM.53.9.2119-2123.1987; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHOU M, 1997, ARCH GEN PSYCHIAT, V4, P9; SKALA J, 1991, YEAST, V7, P651, DOI 10.1002/yea.320070614; Sunder S, 1996, MOL CELL BIOCHEM, V158, P121; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; Sychrova H, 1999, FEMS MICROBIOL LETT, V171, P167, DOI 10.1111/j.1574-6968.1999.tb13428.x; Varela JCS, 1996, MICROBIOL-SGM, V142, P721, DOI 10.1099/00221287-142-4-721; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WIELAND J, 1995, EMBO J, V14, P3870, DOI 10.1002/j.1460-2075.1995.tb00059.x	43	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30957	30961		10.1074/jbc.M004869200	http://dx.doi.org/10.1074/jbc.M004869200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10921924	hybrid			2022-12-25	WOS:000089762700033
J	Nardini, M; Lang, DA; Liebeton, K; Jaeger, KE; Dijkstra, BM				Nardini, M; Lang, DA; Liebeton, K; Jaeger, KE; Dijkstra, BM			Crystal structure of Pseudomonas aeruginosa lipase in the open conformation - The prototype for family I.1 of bacterial lipases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA/BETA-HYDROLASE FOLD; BIOTECHNOLOGICAL APPLICATIONS; TRIACYLGLYCEROL LIPASE; BIOCHEMICAL-PROPERTIES; EXTRACELLULAR LIPASE; PROTEIN STRUCTURES; ENZYMES; REVEALS; ERRORS	The x-ray structure of the lipase from Pseudomonas aeruginosa PAO1 has been determined at 2.54 Angstrom resolution. It is the first structure of a member of homology family I.1 of bacterial lipases. The structure shows a variant of the alpha/beta hydrolase fold, with Ser(82), Asp(229), and His(251) as the catalytic triad residues. Compared with the "canonical" alpha/beta hydrolase fold, the first two P-strands and one alpha-helix (alpha E) are not present. The absence of helix alpha E allows the formation of a stabilizing intramolecular disulfide bridge. The loop containing His251 is stabilized by an octahedrally coordinated calcium ion. On top of the active site a lid subdomain is in an open conformation, making the catalytic cleft accessible from the solvent region. A triacylglycerol analogue is covalently bound to Ser(82) in the active site, demonstrating the position of the oxyanion hole and of the three pockets that accommodate the sn-1, sn-2, and sn-3 fatty acid chains. The inhibited enzyme can be thought to mimic the structure of the tetrahedral intermediate that occurs during the acylation step of the reaction. Analysis of the binding mode of the inhibitor suggests that the size of the acyl pocket and the size and interactions of the sn-2 binding pocket are the predominant determinants of the regio- and enantio-preference of the enzyme.	Univ Groningen, Dept Chem, Biophys Chem Lab, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Chem, BIOSON Res Inst, NL-9747 AG Groningen, Netherlands; Ruhr Univ Bochum, Lehrstuhl Biol Mikroorganismen, D-44780 Bochum, Germany	University of Groningen; University of Groningen; Ruhr University Bochum	Dijkstra, BM (corresponding author), Univ Groningen, Dept Chem, Biophys Chem Lab, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	bauke@chem.rug.nl	Nardini, Marco/B-7842-2017; jaeger, karl/ABB-1955-2020	Nardini, Marco/0000-0002-3718-2165; 				Arpigny JL, 1999, BIOCHEM J, V343, P177, DOI 10.1042/0264-6021:3430177; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Borgstrom B, 1984, LIPASES; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cygler M, 1997, METHOD ENZYMOL, V284, P3; GILBERT EJ, 1993, ENZYME MICROB TECH, V15, P634, DOI 10.1016/0141-0229(93)90062-7; Heikinheimo P, 1999, STRUCTURE, V7, pR141, DOI 10.1016/S0969-2126(99)80079-3; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JAEGER KE, 1994, IMMUN INFEKT, V22, P177; JAEGER KE, 1994, FEMS MICROBIOL REV, V15, P29, DOI 10.1016/0168-6445(94)90025-6; Jaeger KE, 1999, ANNU REV MICROBIOL, V53, P315, DOI 10.1146/annurev.micro.53.1.315; Jaeger KE, 1998, TRENDS BIOTECHNOL, V16, P396, DOI 10.1016/S0167-7799(98)01195-0; JAEGER KE, 1992, BIOCHIM BIOPHYS ACTA, V1120, P315, DOI 10.1016/0167-4838(92)90254-B; Jaeger KE, 1997, J MOL CATAL B-ENZYM, V3, P3, DOI 10.1016/S1381-1177(96)00039-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kazlauskas RJ, 1998, CURR OPIN CHEM BIOL, V2, P121, DOI 10.1016/S1367-5931(98)80043-4; Kim KK, 1997, STRUCTURE, V5, P173, DOI 10.1016/S0969-2126(97)00177-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lang D, 1996, J MOL BIOL, V259, P704, DOI 10.1006/jmbi.1996.0352; Lang DA, 1998, EUR J BIOCHEM, V254, P333, DOI 10.1046/j.1432-1327.1998.2540333.x; Lang DA, 1998, CHEM PHYS LIPIDS, V93, P115, DOI 10.1016/S0009-3084(98)00035-8; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MANNESSE MLM, 1995, BBA-LIPID LIPID MET, V1259, P56, DOI 10.1016/0005-2760(95)00145-3; Nardini M, 1999, CURR OPIN STRUC BIOL, V9, P732, DOI 10.1016/S0959-440X(99)00037-8; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NOBLE MEM, 1993, FEBS LETT, V331, P123, DOI 10.1016/0014-5793(93)80310-Q; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; Schrag JD, 1997, METHOD ENZYMOL, V284, P85; Schrag JD, 1997, STRUCTURE, V5, P187, DOI 10.1016/S0969-2126(97)00178-0; STUER W, 1986, J BACTERIOL, V168, P1070, DOI 10.1128/jb.168.3.1070-1074.1986; SVENDSEN A, 1995, BBA-LIPID LIPID MET, V1259, P9, DOI 10.1016/0005-2760(95)00117-U; THEIL F, 1995, CHEM REV, V95, P2203, DOI 10.1021/cr00038a017; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	37	207	218	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31219	31225		10.1074/jbc.M003903200	http://dx.doi.org/10.1074/jbc.M003903200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10893416	Green Published, hybrid			2022-12-25	WOS:000089762700067
J	Bowers, RC; Hevko, J; Henson, PM; Murphy, RC				Bowers, RC; Hevko, J; Henson, PM; Murphy, RC			A novel glutathione containing eicosanoid (FOG(7)) chemotactic for human granulocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; PHORBOL-MYRISTATE ACETATE; 5-OXO-6,8,11,14-EICOSATETRAENOIC ACID; HUMAN EOSINOPHILS; HUMAN NEUTROPHILS; SUBSTANCE; CELLS	A biologically active glutathione adduct of the eicosanoid 5-oxo-eicosatetraenoic acid has been observed as a product formed within the murine peritoneal macrophage. This five-ore glutathione adduct (FOG(7)) was structurally characterized using electrospray tandem mass spectrometry as a 1,4 Michael addition product 5-oxo-7-glutathionyl-8,11,14-eicosatrienoic acid. FOG(7) was found to be highly potent in stimulating eosinophil as well as neutrophil chemotaxis, also capable of initiating actin polymerization, without elevating intracellular free calcium ion concentration within either the eosinophil or polymorphonuclear leukocyte. These biological responses suggest that either FOG(7) activates a subset of receptors mediating the broader biological activity of the parent eicosanoid 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) or that a receptor not activated by 5-oxo-ETE participates in the chemotactic activity of FOG(7). The only other known biologically active glutathione adduct has been leukotriene C-4 (LTC4), another eicosanoid that exerts potent effects through the Cys-LT receptor. The biochemical parallel between the formation of LTC4 and FOG(7) suggests an interesting mechanism by which biologically active eicosanoids derived from electrophilic intermediates may have unique distribution and prolonged efficacy in vivo.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA	National Jewish Health	Murphy, RC (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, 1400 Jackson St, Denver, CO 80206 USA.	murphyr@njc.org			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024444] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24444] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Blackburn ML, 1997, CHEM RES TOXICOL, V10, P1364, DOI 10.1021/tx970087a; BORGEAT P, 1976, J BIOL CHEM, V251, P7816; BUTTERFIELD JH, 1994, SAMTERS IMMUNOLOGIC, P501; Czech W, 1997, J INVEST DERMATOL, V108, P108, DOI 10.1111/1523-1747.ep12285653; FADOK VA, 1992, J IMMUNOL, V149, P4029; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; GELFAND EW, 1986, J BIOL CHEM, V261, P1520; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOWARD TH, 1985, J CELL BIOL, V101, P1078, DOI 10.1083/jcb.101.3.1078; Martin LB, 1996, INT ARCH ALLERGY IMM, V109, P207, DOI 10.1159/000237239; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; O'Flaherty JT, 2000, J IMMUNOL, V164, P3345, DOI 10.4049/jimmunol.164.6.3345; OFLAHERTY JT, 1993, BIOCHEM BIOPH RES CO, V192, P129, DOI 10.1006/bbrc.1993.1391; OFLAHERTY JT, 1994, BBA-GEN SUBJECTS, V1201, P505, DOI 10.1016/0304-4165(94)90083-3; POWELL WS, 1994, BIOCHEMISTRY-US, V33, P3927, DOI 10.1021/bi00179a019; POWELL WS, 1994, J BIOL CHEM, V269, P25373; Powell WS, 1999, AM J RESP CELL MOL, V20, P163, DOI 10.1165/ajrcmb.20.1.3141; POWELL WS, 1993, J BIOL CHEM, V268, P9280; POWELL WS, 1992, J BIOL CHEM, V267, P19233; RAFTERY MJ, 1990, BIOMED ENVIRON MASS, V19, P465, DOI 10.1002/bms.1200190804; Samuelsson B, 2000, AM J RESP CRIT CARE, V161, pS2, DOI 10.1164/ajrccm.161.supplement_1.ltta-1; TALALAY P, 1989, ADV ENZYME REGUL, V28, P237, DOI 10.1016/0065-2571(89)90074-5; Wheelan P, 1999, J PHARMACOL EXP THER, V288, P326; Zhang Y, 1996, J LEUKOCYTE BIOL, V59, P847, DOI 10.1002/jlb.59.6.847; ZIGMOND SH, 1988, METHOD ENZYMOL, V162, P65	26	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29931	29934		10.1074/jbc.C000502200	http://dx.doi.org/10.1074/jbc.C000502200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10924496	hybrid			2022-12-25	WOS:000089577900003
J	Wu, GY; Toyokawa, T; Hahn, H; Dorn, GW				Wu, GY; Toyokawa, T; Hahn, H; Dorn, GW			epsilon Protein kinase C in pathological myocardial hypertrophy - Analysis by combined transgenic expression of translocation modifiers and G alpha(q)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; GROWTH; MICE; OVEREXPRESSION; CARDIOMYOPATHY; HEART; RAT	The epsilon isoform of protein kinase C (PKC) has a critical cardiotrophic function in normal postnatal developing heart as demonstrated by cardiac-specific transgenic expression of epsilon PKC-selective translocation inhibitor (epsilon V1) and activator (psi epsilon RACK) peptides (Mochly-Rosen, D., Wu, G., Hahn, H., Osinska, H., Liron, T., Lorenz, J. N., Robbins, J., and Dorn, G. W., II (2000) Circ. Res. 86, 1173-1179), To define the role of epsilon PKC signaling in pathological myocardial hypertrophy, epsilon V1 or psi epsilon RACK were coexpressed in mouse hearts with G alpha(q), a PKC-linked hypertrophy signal transducer. Compared with G alpha(q) overexpression alone, co-expression of psi epsilon RACK with G alpha(q) increased epsilon PKC particulate partitioning by 30 +/- 2%, whereas co-expression of epsilon V1 with G alpha(q) reduced particulate-associated epsilon PKC by 22 +/- 1%. Facilitation of epsilon PKC translocation by psi epsilon RACK in G alpha(q) mice improved cardiac contractile function measured as left ventricular fractional shortening (30 +/- 3% G alpha(q) versus 43 +/- 2% psi epsilon RACK/ G alpha(q), p < 0.05). Conversely, inhibition of epsilon PKC by epsilon V1 modified the G alpha(q) nonfailing hypertrophy phenotype to that of a lethal dilated cardiomyopathy. These opposing effects of epsilon PKC translocation activation and inhibition in G alpha(q) -hypertrophy indicate that epsilon PKC signaling is a compensatory event in myocardial hypertrophy, rather than a pathological event, and support the possible therapeutic efficacy of selective epsilon PKC translocation enhancement in cardiac insufficiency.	Univ Cincinnati, Med Ctr, Div Cardiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Dorn, GW (corresponding author), Univ Cincinnati, Med Ctr, Div Cardiol, 231 Bethesda Ave, Cincinnati, OH 45267 USA.	dorngw@ucmail.uc.edu			NHLBI NIH HHS [HL52318, HL58010] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058010, P50HL052318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Bowman JC, 1997, J CLIN INVEST, V100, P2189, DOI 10.1172/JCI119755; Chen CH, 1999, P NATL ACAD SCI USA, V96, P12784, DOI 10.1073/pnas.96.22.12784; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Dorn GW, 2000, MOL PHARMACOL, V57, P278; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798; Fazio S, 1996, NEW ENGL J MED, V334, P809, DOI 10.1056/NEJM199603283341301; GU X, 1994, CIRC RES, V75, P926, DOI 10.1161/01.RES.75.5.926; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Mochly-Rosen D, 2000, CIRC RES, V86, P1173; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Qiu YM, 1998, J CLIN INVEST, V101, P2182, DOI 10.1172/JCI1258; Sakata Y, 1998, CIRCULATION, V97, P1488; SCHUNKERT H, 1995, CIRC RES, V76, P489, DOI 10.1161/01.RES.76.3.489; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320	17	66	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29927	29930		10.1074/jbc.C000380200	http://dx.doi.org/10.1074/jbc.C000380200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10899155	hybrid			2022-12-25	WOS:000089577900002
J	Ledoux, D; Papy-Garcia, D; Escartin, Q; Sagot, MA; Cao, YH; Barritault, D; Courtois, J; Hornebeck, W; Caruelle, JP				Ledoux, D; Papy-Garcia, D; Escartin, Q; Sagot, MA; Cao, YH; Barritault, D; Courtois, J; Hornebeck, W; Caruelle, JP			Human plasmin enzymatic activity is inhibited by chemically modified dextrans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTICOAGULANT ACTIVITY; DERIVATIZED DEXTRANS; HEPARIN; KINETICS; SULFATE; BINDING; ACID; REGENERATION; BENZYLAMIDE; ACTIVATION	Some synthetic dextran derivatives that mimic the action of heparin/heparan sulfate were shown to promote in vivo tissue repair when added alone to wounds. These biofunctional mimetics were therefore designated as "regenerating agents" in regard to their in vivo properties. In vitro, these biopolymers were able to protect various heparin-binding growth factors against proteolytic degradation as well as to inhibit the enzymatic activity of neutrophil elastase. In the present work, different dextran derivatives were tested for their capacity to inhibit the enzymatic activity of human plasmin. We show that dextran containing carboxymethyl, sulfate as well as benzylamide groups (RG1192 compound), was the most efficient inhibitor of plasmin amidolytic activity. The inhibition of plasmin by RG1192 can be classified as tight binding hyperbolic noncompetitive. One molecule of RG1192 bound 20 molecules of plasmin with a K-i of 2.8 x 10(-8) M. Analysis with an optical biosensor confirmed the high affinity of RG1192 for plasmin and revealed that this polymer equally binds plasminogen with a similar affinity (K-d = 3 x 10(-8) M), Competitive experiments carried out with 6-aminohexanoic acid and kringle proteolytic fragments identified the lysine-binding site domains of plasmin as the RG1192 binding sites. In addition, RG1192 blocked the generation of plasmin from Glu-plasminogen and inhibited the plasmin-mediated proteolysis of fibronectin and laminin, Data from the present in vitro investigation thus indicated that specific dextran derivatives can contribute to the regulation of plasmin activity by impeding the plasmin generation, as a result of their binding to plasminogen and also by directly affecting the catalytic activity of the enzyme.	Univ Paris 12, Lab CRRET, CNRS, UPRESA 7053, F-94010 Creteil, France; CEA Saclay, Lab Pharmacol & Immunol, F-91191 Gif Sur Yvette, France; Karolinska Inst, Dept Cell & Mol Biol, Lab Angiogenesis Res, S-17177 Stockholm, Sweden; IUT Amiens, Lab Biotechnol Microbienne, F-80025 Amiens 1, France; Univ Reims, Fac Med, IFR Biomol 53, Lab Biochim,CNRS,UPRESA 6021, F-51095 Reims, France	Centre National de la Recherche Scientifique (CNRS); Universite Gustave-Eiffel; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CEA; UDICE-French Research Universities; Universite Paris Saclay; Karolinska Institutet; Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne	Barritault, D (corresponding author), Univ Paris 12, Lab CRRET, CNRS, UPRESA 7053, Av Gen de Gaulle, F-94010 Creteil, France.			LEDOUX, DOMINIQUE/0000-0002-5886-2266				AKASHI H, 1994, BIOL PHARM BULL, V17, P446; Alexander CM, 1989, CURR OPIN CELL BIOL, V1, P974, DOI 10.1016/0955-0674(89)90068-9; ANDRADEGORDON P, 1986, BIOCHEMISTRY-US, V25, P4033, DOI 10.1021/bi00362a007; BAICI A, 1993, BIOCHEM PHARMACOL, V46, P1545, DOI 10.1016/0006-2952(93)90321-M; BIETH JG, 1995, METHOD ENZYMOL, V248, P59; Blanquaert F, 1995, BONE, V17, P499, DOI 10.1016/8756-3282(95)00402-5; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; Christensen U, 1996, FEBS LETT, V387, P58, DOI 10.1016/0014-5793(96)00429-2; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; Desgranges P, 1999, FASEB J, V13, P761, DOI 10.1096/fasebj.13.6.761; DEWIT P, 1988, RECL TRAV CHIM PAY B, V107, P668; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; FREDJREYGROBELLET D, 1994, OPHTHALMIC RES, V26, P325, DOI 10.1159/000267497; HIGAZI AA, 1990, BIOCHEM J, V269, P299, DOI 10.1042/bj2690299; HIGAZI AA, 1992, BIOCHEM J, V282, P863, DOI 10.1042/bj2820863; HIGAZI AAR, 1989, BIOCHEM J, V260, P609, DOI 10.1042/bj2600609; Krentsel L, 1997, CARBOHYD POLYM, V33, P63, DOI 10.1016/S0144-8617(96)00173-7; LEGRAS S, 1992, INT J BIOL MACROMOL, V14, P97, DOI 10.1016/0141-8130(92)90005-S; LERCH PG, 1980, EUR J BIOCHEM, V107, P7, DOI 10.1111/j.1432-1033.1980.tb04617.x; MaigaRevel O, 1997, CARBOHYD POLYM, V32, P89, DOI 10.1016/S0144-8617(96)00171-3; MAUZAC M, 1984, BIOMATERIALS, V5, P301, DOI 10.1016/0142-9612(84)90078-4; Meddahi A, 1996, J BIOMED MATER RES, V31, P293, DOI 10.1002/(SICI)1097-4636(199607)31:3<293::AID-JBM1>3.0.CO;2-H; Meddahi A, 1996, INT J BIOL MACROMOL, V18, P141, DOI 10.1016/0141-8130(95)01074-2; MEDDAHI A, 1994, PATHOL RES PRACT, V190, P923; MOSER TL, 1993, J BIOL CHEM, V268, P18917; NADKARNI VD, 1994, ANAL BIOCHEM, V222, P59, DOI 10.1006/abio.1994.1454; Okada Y, 2000, CHEM PHARM BULL, V48, P184; Sanders TC, 1999, J MED CHEM, V42, P2969, DOI 10.1021/jm990110k; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; SZEDLACSEK SE, 1988, BIOCHEM J, V254, P311, DOI 10.1042/bj2540311; TARDIEU M, 1992, J CELL PHYSIOL, V150, P194, DOI 10.1002/jcp.1041500126; THEWES T, 1990, J BIOL CHEM, V265, P3906; VANZONNEVELD AJ, 1986, J BIOL CHEM, V261, P14214; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WU HL, 1990, J BIOL CHEM, V265, P19658	36	55	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29383	29390		10.1074/jbc.M000837200	http://dx.doi.org/10.1074/jbc.M000837200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10889187	hybrid			2022-12-25	WOS:000089439800029
J	Sun, F; Hug, MJ; Lewarchik, CM; Yun, CHC; Bradbury, NA; Frizzell, RA				Sun, F; Hug, MJ; Lewarchik, CM; Yun, CHC; Bradbury, NA; Frizzell, RA			E3KARP mediates the association of ezrin and protein kinase A with the cystic fibrosis transmembrane conductance regulator in airway cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER NA+/H+ EXCHANGER; PLASMA-MEMBRANE; BETA(2)-ADRENERGIC RECEPTOR; PDZ DOMAINS; CFTR; CYTOSKELETON; BINDING; NHE3; RECOGNITION; INHIBITION	Although it is generally recognized that cystic fibrosis transmembrane conductance regulator (CFTR) contains a PSD-95/Disc-large/ZO-1 (PDZ)-binding motif at its COOH terminus, the identity of the PDZ domain protein(s) that interact with CFTR is uncertain, and the functional impact of this interaction is not fully understood. By using human airway epithelial cells, we show that CFTR associates with Na+/H+ exchanger (NHE) type 3 kinase A regulatory protein (E3KARP), an EBP50/ NHE regulatory factor (NHERF)-related PDZ domain protein. The PDZ binding motif located at the COOH terminus of CFTR interacts preferentially with the second PDZ domain of E3KARP, with nanomolar affinity. In contrast to EBP50/NHERF, E3KARP is predominantly localized (>95%) in the membrane fractions of Calu-3 and T84 cells, where CFTR is located. Moreover, confocal immunofluorescence microscopy of polarized Calu-3 monolayers shows that E3KARP and CFTR are co-localized at the apical membrane domain. We also found that ezrin associates with E3KARP in vivo. Go-expression of CFTR with E3KARP and ezrin in Xenopus oocytes potentiated cAMP-stimulated CFTR Cl- currents. These results support the concept that E3KARP functions as a scaffold protein that links CFTR to ezrin, Since ezrin has been shown previously to function as a protein kinase A anchoring protein, we suggest that one function served by the interaction of E3KARP with both ezrin and CFTR is to localize protein kinase A in the vicinity of the R-domain of CFTR. Since ezrin is also an actin-binding protein, the formation of a CFTR E3KARP ezrin complex may be important also in stabilizing CFTR at the apical membrane domain of airway cells.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21205 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University	Frizzell, RA (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, S362 BST,3500 Terrace St, Pittsburgh, PA 15261 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK056490, P01DK044484] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44484, DK56490] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; BRANT SR, 1995, AM J PHYSIOL-CELL PH, V269, pC198, DOI 10.1152/ajpcell.1995.269.1.C198; Cantiello HF, 1996, EXP PHYSIOL, V81, P505, DOI 10.1113/expphysiol.1996.sp003953; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; DEJONGE HR, 1975, BIOCHIM BIOPHYS ACTA, V381, P128, DOI 10.1016/0304-4165(75)90195-6; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Feliciello A, 1997, CURR BIOL, V7, P1011, DOI 10.1016/S0960-9822(06)00424-6; Gadsby David C., 1999, Physiological Reviews, V79, pS77; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; HAWS C, 1994, AM J PHYSIOL, V266, pL502, DOI 10.1152/ajplung.1994.266.5.L502; Huang P, 2000, AM J PHYSIOL-CELL PH, V278, pC417, DOI 10.1152/ajpcell.2000.278.2.C417; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; Loffing J, 1998, AM J PHYSIOL-CELL PH, V275, pC913, DOI 10.1152/ajpcell.1998.275.4.C913; Mickle JE, 1998, HUM MOL GENET, V7, P729, DOI 10.1093/hmg/7.4.729; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Peters KW, 1999, AM J PHYSIOL-CELL PH, V277, pC174, DOI 10.1152/ajpcell.1999.277.1.C174; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; PRAT AG, 1995, AM J PHYSIOL-CELL PH, V268, pC1552, DOI 10.1152/ajpcell.1995.268.6.C1552; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; Sheppard David N., 1999, Physiological Reviews, V79, pS23; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Weinman EJ, 2000, BIOCHEMISTRY-US, V39, P6123, DOI 10.1021/bi000064m; Weinman EJ, 1998, J CLIN INVEST, V101, P2199, DOI 10.1172/JCI204; Weixel KM, 2000, J BIOL CHEM, V275, P3655, DOI 10.1074/jbc.275.5.3655; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zerhusen B, 1999, J BIOL CHEM, V274, P7627, DOI 10.1074/jbc.274.12.7627	43	175	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29539	29546		10.1074/jbc.M004961200	http://dx.doi.org/10.1074/jbc.M004961200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893422	hybrid			2022-12-25	WOS:000089439800049
J	Togashi, H; Nagata, K; Takagishi, M; Saitoh, N; Inagaki, M				Togashi, H; Nagata, K; Takagishi, M; Saitoh, N; Inagaki, M			Functions of a Rho-specific guanine nucleotide exchange factor in neurite retraction - Possible role of a proline-rich motif of KIAA0380 in localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; STRESS FIBER FORMATION; SERUM RESPONSE ELEMENT; KINASE ROK-ALPHA; LYSOPHOSPHATIDIC ACID; MYOSIN PHOSPHATASE; FOCAL ADHESIONS; GDP/GTP-EXCHANGE; PHOSPHOLIPASE-D; ACTIVATION	The Rho/Rho kinase signaling pathway plays an essential role in neurite retraction and cell rounding in response to G(12/13)-coupled receptor activation in neuronal cells. The Rho guanine nucleotide exchange factor involved in these processes has not been identified. To monitor the activation state of Rho kinase, we developed a vimentin head/Rho kinase chimera, which is intramolecularly phosphorylated in a Rho-dependent manner at Ser(71) of the fused vimentin head. Using this system, we identified a clone termed KIAA0380, which contains the G alpha(12/13)-binding domain as well as a tandem of the Dbl homology/pleckstrin homology (DH/PH) domain, as an activator of Rho/Rho kinase signaling. Molecular dissection analyses revealed that a proline-rich motif C-terminally adjacent to DH/PH domain is essential for plasma membrane localization of KIAA0380 and cortical actin reorganization followed by cell rounding. In contrast, the DH/PH domain of KIAA0380 is localized in the cytoplasm, where it activates Rho/Rho kinase and induces stress fiber formation, consistent with results using p115 Rho guanine nucleotide exchange factor, which has a similar structure to KIAA0380 but lacks a proline-rich motif, These results suggest that upon stimulation, KIAA0380 translocates to the plasma membrane via the proline-rich motif and there activates Rho/Rho kinase signaling, In neuroblastoma Neuro2a cells, KIAA0380 was observed in the tips of neurites, a location where cortical actin reorganization is induced upon stimulation with lysophosphatidic acid. Ectopic expression of the N-terminal fragment inhibited lysophosphatidic acid-induced neurite retraction of Neuro2a cells. These results suggest that KIAA0380 plays an important role in neurite retraction through Rho-dependent signaling.	Aichi Canc Ctr, Res Inst, Div Biochem, Aichi 4648681, Japan; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Aichi 4648602, Japan; Nagoya City Univ, Fac Pharmaceut Sci, Dept Chem Hyg & Nutr, Mizuho Ku, Aichi 4678603, Japan	Aichi Cancer Center; Nagoya University; Nagoya City University	Nagata, K (corresponding author), Aichi Canc Ctr, Res Inst, Div Biochem, 1-1 Chikusa Ku, Aichi 4648681, Japan.	knagata@aichi-cc.pref.aichi.jp; minagaki@aichi-cc.pref.aichi.jp	Inagaki, Masaki/B-9920-2016					Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; GOTO H, 2000, IN PRESS MICROSC RES; HART CM, 1994, J MOL BIOL, V237, P255, DOI 10.1006/jmbi.1994.1229; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Inada H, 1999, J BIOL CHEM, V274, P34932, DOI 10.1074/jbc.274.49.34932; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; Katoh H, 1996, J BIOL CHEM, V271, P29780, DOI 10.1074/jbc.271.47.29780; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; Kosako H, 1999, ONCOGENE, V18, P2783, DOI 10.1038/sj.onc.1202633; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kranenburg O, 1997, J CELL SCI, V110, P2417; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Leung T, 1996, MOL CELL BIOL, V16, P5313; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; NAGATA KI, 1994, BRIT J HAEMATOL, V88, P706, DOI 10.1111/j.1365-2141.1994.tb05108.x; NISHIZAWA K, 1991, J BIOL CHEM, V266, P3074; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1991, NEW BIOL, V3, P372; Rumenapp U, 1999, FEBS LETT, V459, P313, DOI 10.1016/S0014-5793(99)01270-3; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Tigyi G, 1996, J NEUROCHEM, V66, P549; UEDA T, 1990, J BIOL CHEM, V265, P9373; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	59	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29570	29578		10.1074/jbc.M003726200	http://dx.doi.org/10.1074/jbc.M003726200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10900204	hybrid			2022-12-25	WOS:000089439800053
J	Chen, JW; Dodia, C; Feinstein, SI; Jain, MK; Fisher, AB				Chen, JW; Dodia, C; Feinstein, SI; Jain, MK; Fisher, AB			1-Cys peroxiredoxin, a bifunctional enzyme with glutathione peroxidase and phospholipase A2 activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; CRYSTAL-STRUCTURE; A(2); PROTEIN; LUNG; DEGRADATION; EXPRESSION	This report provides definitive evidence that the protein 1-Cys peroxiredoxin is a bifunctional ("moonlighting") enzyme with two distinct active sites. We have previously shown that human, rat, and bovine lungs contain an acidic Ca2+-independent phospholipase A(2) (aiPLA(2)). The cDNA encoding aiPLA(2) was found to be identical to that of a non-selenium glutathione peroxidase (NSGPx). Protein expressed using a previously reported E, coli construct which has a His-tag and 50 additional amino acids at the NH2 terminus, did not exhibit aiPLA(2) activity. A new construct which contains the His-tag plus two extra amino acids at the COOH terminus when expressed in Escherichia coli generated a protein that hydrolyzed the sn-2 acyl chain of phospholipids at pH 4, and exhibited NSGPx activity with H2O2 at pH 8. The expressed 1-Cys peroxiredoxin has identical functional properties to the native lung enzyme: aiPLA(2) activity is inhibited by the serine protease inhibitor, diethyl p-nitrophenyl phosphate, by the tetrahedral mimic 1-hexadecyl-3-trifluoroethylglycero-sn-2-phosphomethanol (MJ33), and by 1-Cys peroxiredoxin monoclonal antibody (mAb) 8H11 but these agents have no effect on NSGPx activity; NSGPx activity is inhibited by mercaptosuccinate and by 1-Cys peroxiredoxin mAb 8B3 antibody which have no effect on aiPLA(2) activity. Mutation of Ser(32) to Ala abolishes aiPLA(2) activity, yet the NSGPx activity remains unaffected; a Cys(47) to Ser mutant is devoid of peroxidase activity but aiPLA(2) activity remains intact. These results suggest that Ser32 in the GDSWG consensus sequence provides the catalytic nucleophile for the hydrolase activity of aiPLA(2) while Cys47 in the PVCTTE consensus sequence is at the active site for peroxidase activity. The bifunctional catalytic properties of 1-Cys peroxiredoxin are compatible with a simultaneous role for the protein in the regulation of phospholipid turnover as well as in protection against oxidative injury.	Univ Penn, Med Ctr, Inst Environm Med, Philadelphia, PA 19104 USA; Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA	University of Pennsylvania; University of Delaware	Fisher, AB (corresponding author), Univ Penn, Sch Med, Inst Environm Med, 1 John Morgan Bldg,3620 Hmailton Walk, Philadelphia, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019737] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL19737] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akiba S, 1998, COMP BIOCHEM PHYS B, V120, P393, DOI 10.1016/S0305-0491(98)10046-9; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; CHANDER A, 1986, J BIOL CHEM, V261, P6126; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; DEREWENDA ZS, 1993, TRENDS BIOCHEM SCI, V18, P20, DOI 10.1016/0968-0004(93)90082-X; FISHER AB, 1992, BIOCHEM J, V288, P407, DOI 10.1042/bj2880407; FISHER AB, 1994, AM J PHYSIOL, V267, pL335, DOI 10.1152/ajplung.1994.267.3.L335; Fisher AB, 1996, J LIPID RES, V37, P1057; Fisher AB, 1999, J BIOL CHEM, V274, P21326, DOI 10.1074/jbc.274.30.21326; FORMAN HJ, 1983, LAB INVEST, V49, P148; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P10256, DOI 10.1021/bi00106a025; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kim TS, 1998, AM J PHYSIOL-LUNG C, V274, pL750, DOI 10.1152/ajplung.1998.274.5.L750; Kim TS, 1997, J BIOL CHEM, V272, P2542; LEWIS SD, 1976, BIOCHEMISTRY-US, V15, P5009, DOI 10.1021/bi00668a010; MICHIELS C, 1994, FREE RADICAL BIO MED, V17, P235, DOI 10.1016/0891-5849(94)90079-5; PATHAK D, 1991, PROTEINS, V9, P267, DOI 10.1002/prot.340090405; Peshenko IV, 1996, FEBS LETT, V381, P12, DOI 10.1016/0014-5793(96)00071-3; Rice SQJ, 1998, BIOCHEM J, V330, P1309; Sato T, 1997, J BIOL CHEM, V272, P2192; SHICHI H, 1990, EXP EYE RES, V50, P513, DOI 10.1016/0014-4835(90)90040-2; Singh AK, 1998, J BIOL CHEM, V273, P26171, DOI 10.1074/jbc.273.40.26171; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; Wang AJ, 1997, J BIOL CHEM, V272, P12723, DOI 10.1074/jbc.272.19.12723	26	256	283	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28421	28427		10.1074/jbc.M005073200	http://dx.doi.org/10.1074/jbc.M005073200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893423	hybrid			2022-12-25	WOS:000089330700013
J	Das, SK; Tan, J; Raja, S; Halder, J; Paria, BC; Dey, SK				Das, SK; Tan, J; Raja, S; Halder, J; Paria, BC; Dey, SK			Estrogen targets genes involved in protein processing, calcium homeostasis, and Wnt signaling in the mouse uterus independent of estrogen receptor-alpha and -beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CALCIUM; EXPRESSION PATTERNS; ADENYLATE-CYCLASE; MOLECULAR-CLONING; DOWN-REGULATION; BINDING-SITES; RAT UTERUS; CELL; PROGESTERONE; STIMULATION	Estrogen actions in target organs are normally mediated via activation of nuclear estrogen receptors (ERs). By using mRNA differential display technique, we show, herein, that estradiol-17 beta (E-2) and its catechol metabolite 4-hydroxy-E-2 (4OHE(2)) can modulate uterine gene expression in ER alpha(-/-) mice. Whereas administration of E-2 or 4OHE(2) rapidly up-regulated (4-8-fold) the expression of immunoglobulin heavy chain binding protein (Bip), calpactin I (CalP), calmodulin (CalM), and Sih similar protein (Sik-SP) genes in ovariectomized wildtype or ER alpha(-/-) mice, the expression of secreted frizzled related protein-2 (SFRP-2) gene was down-regulated (4-fold). Bip, CalP, and CalM are calcium-binding proteins and implicated in calcium homeostasis, whereas SFRP-2 is a negative regulator of Wnt signaling. Bip and Sik-SP also possess chaperone-like functions, Administration of ICI-182,780 or cycloheximide failed to influence these estrogenic responses, demonstrating that these effects occur independent of ER alpha, ER beta, or protein synthesis. In situ hybridization showed differential cell-specific expression of these genes in wild-type and ER alpha(-/-) uteri, Although progesterone can antagonize or synergize estrogen actions, it had minimal effects on these estrogenic responses. Collectively, the results demonstrate that estrogens have a unique ability to influence specific genes in the uterus not involving classical nuclear ERs.	Univ Kansas, Med Ctr, Dept Obstet & Gynaecol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Ralph L Smith Res Ctr, Dept Pediat, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Das, SK (corresponding author), Univ Kansas, Med Ctr, Dept Obstet & Gynaecol, 3901 Rainbow Blvd,MRRC 37-3004, Kansas City, KS 66160 USA.				NICHD NIH HHS [HD-29968, HD-12304] Funding Source: Medline; NIEHS NIH HHS [ES-07814] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD012304, U01HD029968, R37HD012304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007814] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aarli A, 1998, SCAND J IMMUNOL, V48, P522; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; AURICCHIO F, 1984, J STEROID BIOCHEM, V20, P31, DOI 10.1016/0022-4731(84)90185-7; Batra S, 1998, LIFE SCI, V62, P2093, DOI 10.1016/S0024-3205(98)00184-2; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bevan C, 1999, EXP CELL RES, V253, P349, DOI 10.1006/excr.1999.4719; BOUHOUTE A, 1995, BIOCHEM BIOPH RES CO, V208, P748, DOI 10.1006/bbrc.1995.1401; Brewer J. W., 1997, MOL CHAPERONE PROTEI, P415; Bui TD, 1997, BRIT J CANCER, V75, P1131, DOI 10.1038/bjc.1997.195; Cardone A, 1998, GEN COMP ENDOCR, V110, P227, DOI 10.1006/gcen.1998.7063; CHEUNG WY, 1975, BIOCHEM BIOPH RES CO, V66, P1055, DOI 10.1016/0006-291X(75)90747-0; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; Dale TC, 1998, BIOCHEM J, V329, P209; Das SK, 1997, DEV BIOL, V190, P178, DOI 10.1006/dbio.1997.8694; Das SK, 1998, ENDOCRINOLOGY, V139, P2905, DOI 10.1210/en.139.6.2905; Das SK, 1997, P NATL ACAD SCI USA, V94, P12786, DOI 10.1073/pnas.94.24.12786; Das SK, 1999, J MOL ENDOCRINOL, V22, P91, DOI 10.1677/jme.0.0220091; DAS SK, 1995, MOL ENDOCRINOL, V9, P691, DOI 10.1210/me.9.6.691; Dey SK, 1996, REPROD ENDOCRINOLOGY, V1, P421; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; FERNANDEZ AI, 1992, GEN PHARMACOL, V23, P291, DOI 10.1016/0306-3623(92)90026-G; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GORSKI J, 1964, ARCH BIOCHEM BIOPHYS, V105, P517, DOI 10.1016/0003-9861(64)90045-1; HARRIS J, 1978, ENDOCRINOLOGY, V103, P204; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; JacquierSarlin MR, 1996, BIOCHEM BIOPH RES CO, V226, P166, DOI 10.1006/bbrc.1996.1327; JENSEN TS, 1995, APMIS, V103, P433, DOI 10.1111/j.1699-0463.1995.tb01129.x; KAKIUCHI S, 1970, BIOCHEM BIOPH RES CO, V41, P1104, DOI 10.1016/0006-291X(70)90199-3; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; Kelly MJ, 1999, TRENDS ENDOCRIN MET, V10, P369, DOI 10.1016/S1043-2760(99)00190-3; KIRKLAND JL, 1977, ENDOCRINOLOGY, V101, P403, DOI 10.1210/endo-101-2-403; KITAJEWSKI J, 1992, MOL CELL BIOL, V12, P784, DOI 10.1128/MCB.12.2.784; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Ladher RK, 2000, DEV BIOL, V218, P183, DOI 10.1006/dbio.1999.9586; Lammers CH, 1999, SYNAPSE, V34, P222, DOI 10.1002/(SICI)1098-2396(19991201)34:3<222::AID-SYN6>3.0.CO;2-J; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; Leimeister C, 1998, MECH DEVELOP, V75, P29, DOI 10.1016/S0925-4773(98)00072-0; LIANG P, 1994, NUCLEIC ACIDS RES, V22, P5763, DOI 10.1093/nar/22.25.5763; LIEBERHERR M, 1993, J BONE MINER RES, V8, P1365; Lim HJ, 1999, MOL ENDOCRINOL, V13, P1005, DOI 10.1210/me.13.6.1005; LOOSEMITCHELL DS, 1988, MOL ENDOCRINOL, V2, P946, DOI 10.1210/mend-2-10-946; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Ma L, 1998, DEV BIOL, V197, P141, DOI 10.1006/dbio.1998.8907; MATSUI K, 1983, J ENDOCRINOL, V97, P11, DOI 10.1677/joe.0.0970011; McDonnell D P, 1997, Osteoporos Int, V7 Suppl 1, pS29; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Miller C, 1998, MECH DEVELOP, V76, P91, DOI 10.1016/S0925-4773(98)00112-9; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Nickenig G, 1998, CIRCULATION, V97, P2197, DOI 10.1161/01.CIR.97.22.2197; PERSICO E, 1990, BIOCHEM BIOPH RES CO, V171, P287, DOI 10.1016/0006-291X(90)91390-E; Picotto G, 1996, MOL CELL ENDOCRINOL, V119, P129, DOI 10.1016/0303-7207(96)03799-9; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; SCHULMAN H, 1978, NATURE, V271, P478, DOI 10.1038/271478a0; Simmons DG, 2000, BIOL REPROD, V62, P1168, DOI 10.1095/biolreprod62.5.1168; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; Watson CS, 1999, P SOC EXP BIOL MED, V220, P9, DOI 10.1046/j.1525-1373.1999.d01-2.x; WEBERHALL SJ, 1994, DIFFERENTIATION, V57, P205, DOI 10.1046/j.1432-0436.1994.5730205.x; Yang RZ, 1998, CONTRACEPTION, V58, P315; Yang YF, 2000, MOL BIOL CELL, V11, P567, DOI 10.1091/mbc.11.2.567; YOSHIDA T, 1985, TOHOKU J EXP MED, V145, P381, DOI 10.1620/tjem.145.381	69	72	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28834	28842		10.1074/jbc.M003827200	http://dx.doi.org/10.1074/jbc.M003827200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893236	hybrid			2022-12-25	WOS:000089330700066
J	Tamrakar, S; Ludlow, JW				Tamrakar, S; Ludlow, JW			The carboxyl-terminal region of the retinoblastoma protein binds non-competitively to protein phosphatase type 1 alpha and inhibits catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; SV40 LARGE-T; RABBIT SKELETAL-MUSCLE; E2F TRANSCRIPTION FACTOR; GENE-PRODUCT; CELL-CYCLE; SUSCEPTIBILITY GENE; GROWTH SUPPRESSION; OKADAIC ACID; PRB	pRB, a negative-growth regulatory protein, is a demonstrated substrate for type 1 serine/threonine protein phosphatases (PP1), In a recent report from this laboratory, we demonstrated that select forms of phosphorylated as well as hypophosphorylated pRB can be found complexed with the alpha-isotype of PP1 (PP1 alpha). This complex can also be observed when PP1 is rendered catalytically dead by toxin inhibition. These data suggested to us that pRB may bind to PP1 at one or more sites other than the catalytically active one on the enzyme and that such binding may play a role other than bringing the substrate into contact with the enzyme to facilitate catalysis. To address this possibility we utilized a series of PRE deletion mutants and coprecipitation studies to map the pRB domain involved in binding to PP1. Together with competition assays using in vivo expression of SV40 T-antigen, we show here that the carboxyl-terminal region of PRE is both necessary and sufficient for physical interaction with PP1. Subsequent biochemical analyses demonstrated inhibition of PP1 catalytic activity toward the standard substrate phosphorylase a when this enzyme is bound to pRB containing this region. K-m and V-max calculations revealed that pRB binds to PP1 in a non-competitive manner. These data support the notion that pRB, in addition to being a substrate for PP1, also functions as a PP1 inhibitor. The significance of this finding with respect to the functional importance of this interaction is discussed.	Univ Rochester, Ctr Canc, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Ludlow, JW (corresponding author), Univ Rochester, Ctr Canc, Box 704,601 Elmwood Ave, Rochester, NY 14642 USA.							ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHRISHOLM AA, 1988, BIOCHIM BIOPHYS ACTA, V971, P163; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; GAVIN AC, 1991, EXP CELL RES, V192, P75, DOI 10.1016/0014-4827(91)90159-R; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KATO J, 1993, GENE DEV, V7, P331; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu CWY, 1999, J BIOL CHEM, V274, P29470, DOI 10.1074/jbc.274.41.29470; Ludlow JW, 1998, METH MOL B, V93, P137; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Nelson DA, 1997, ONCOGENE, V14, P2407, DOI 10.1038/sj.onc.1201081; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Siegert JL, 1999, MOL CELL BIOL, V19, P846; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; Tamrakar S, 1999, ONCOGENE, V18, P7803, DOI 10.1038/sj.onc.1203211; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Tognarini M, 1998, EUR J CELL BIOL, V76, P212, DOI 10.1016/S0171-9335(98)80036-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUNG HYL, 1984, EUR J BIOCHEM, V145, P57, DOI 10.1111/j.1432-1033.1984.tb08521.x; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x	52	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27784	27789						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10889204				2022-12-25	WOS:000089197100037
J	Cormier, RT; Bilger, A; Lillich, AJ; Halberg, RB; Hong, KH; Gould, KA; Borenstein, N; Lander, ES; Dove, WF				Cormier, RT; Bilger, A; Lillich, AJ; Halberg, RB; Hong, KH; Gould, KA; Borenstein, N; Lander, ES; Dove, WF			The Mom1(AKR) intestinal tumor resistance region consists of Pla2g2a and a locus distal to D4Mit64	ONCOGENE			English	Article						Mom1; tumor resistance; Apc; Min mouse; goblet cell; Pla2g2a	FAMILIAL ADENOMATOUS POLYPOSIS; SECRETORY PHOSPHOLIPASE A(2); NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CARCINOMA CELL-LINES; LOW-MOLECULAR-WEIGHT; COLON-CANCER CELLS; TRANSGENIC MICE; MURINE MODEL; MIN MOUSE; CHROMOSOME 1P35-36	The Mom1 (Modifier of Min-1) region of distal chromosome 4 was identified during a screen for polymorphic modifiers of intestinal tumorigenesis in Apc(Min/+) mice. Here, we demonstrate that the Mom1(AKR) allele consists of two genetic components. These include the secretory phospholipase Pla2g2a, whose candidacy as a Mom1 resistance modifier has now been tested with several transgenic Lines. A second region, distal to Pla2g2a, has also been identified using fine structure recombinants. Pla2g2a(AKR) transgenic mice demonstrate a modest resistance to tumorigenesis in the small intestine and a ver! robust resistance in the large intestine, Moreover, the tumor resistance in the colon of Pla2g2a(AKR) animals is dosage-dependent, a finding that is consistent with our observation that Pla2g2a is expressed in goblet cells, By contrast, mice carrying the distal Mom1 modifier demonstrate a modest tumor resistance that is confined to the small intestine. Thus. the phenotypes of these two modifier loci are complementary, both in their quantitative and regional effects. The additive effects and tight Linkage of these modifiers may have been necessary for the initial identification of the Mom1 region.	Univ Wisconsin, Mcardle Lab Canc Res, Madison, WI 53706 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Wisconsin System; University of Wisconsin Madison	Dove, WF (corresponding author), Univ Wisconsin, Mcardle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.				NCI NIH HHS [CA63677, CA50585, CA07075] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063677, R37CA063677] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; BeazerBarclay Y, 1996, CARCINOGENESIS, V17, P1757, DOI 10.1093/carcin/17.8.1757; Boolbol SK, 1996, CANCER RES, V56, P2556; Charalambous D, 1998, J GASTROEN HEPATOL, V13, P1195; Chiu CH, 1997, CANCER RES, V57, P4267; Cohn SM, 1997, J CLIN INVEST, V99, P1367, DOI 10.1172/JCI119296; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Dobbie Z, 1997, HUM GENET, V99, P653, DOI 10.1007/s004390050423; DOVE WF, 1994, COLD SPRING HARB SYM, V59, P501, DOI 10.1101/SQB.1994.059.01.055; Dragani TA, 1997, NAT GENET, V17, P7, DOI 10.1038/ng0997-7; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Engle SJ, 1999, CANCER RES, V59, P3379; Erickson BA, 1999, J SURG RES, V81, P101, DOI 10.1006/jsre.1998.5511; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Fukushima K, 1999, J GASTROENTEROL, V34, P54, DOI 10.1007/s005350050216; Garabedian EM, 1997, J BIOL CHEM, V272, P23729, DOI 10.1074/jbc.272.38.23729; Gould KA, 1997, P NATL ACAD SCI USA, V94, P5848, DOI 10.1073/pnas.94.11.5848; Gould KA, 1996, GENETICS, V144, P1769; Gould KA, 1996, GENETICS, V144, P1777; Gould KA, 1998, EXP LUNG RES, V24, P437, DOI 10.3109/01902149809087379; Gould KA, 1996, CELL GROWTH DIFFER, V7, P1361; Grass DS, 1996, J CLIN INVEST, V97, P2233, DOI 10.1172/JCI118664; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HALBERG R, 1992, J MOL BIOL, V228, P840, DOI 10.1016/0022-2836(92)90868-K; Halberg RB, 2000, P NATL ACAD SCI USA, V97, P3461, DOI 10.1073/pnas.050585597; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HERZOG CR, 1995, ONCOGENE, V11, P1811; Ikegami T, 1998, CANCER LETT, V134, P129, DOI 10.1016/S0304-3835(98)00248-1; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; Itoh H, 1999, J CLIN INVEST, V104, P1539, DOI 10.1172/JCI6211; Jacoby RF, 1996, CANCER RES, V56, P710; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Laine VJO, 1999, J IMMUNOL, V162, P7402; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Legare ME, 2000, GENOME RES, V10, P42; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Mahmoud NN, 1998, CARCINOGENESIS, V19, P87, DOI 10.1093/carcin/19.1.87; McCracken JD, 1996, J CLIN PHARMACOL, V36, P540, DOI 10.1002/j.1552-4604.1996.tb05043.x; Moorghen M, 1998, CELL PROLIFERAT, V31, P59, DOI 10.1046/j.1365-2184.1998.00111.x; Morel L, 1999, MAMM GENOME, V10, P176; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MULHERKAR R, 1991, HISTOCHEMISTRY, V96, P367, DOI 10.1007/BF00271358; MULHERKAR R, 1993, FEBS LETT, V317, P263, DOI 10.1016/0014-5793(93)81289-C; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Nakatsugi S, 1997, JPN J CANCER RES, V88, P1117, DOI 10.1111/j.1349-7006.1997.tb00337.x; Nevalainen TJ, 1997, J HISTOCHEM CYTOCHEM, V45, P1109, DOI 10.1177/002215549704500808; Newberry RD, 1999, NAT MED, V5, P900, DOI 10.1038/11341; Nimmrich I, 1997, HUM GENET, V100, P345, DOI 10.1007/s004390050514; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Ouellette AJ, 1997, GASTROENTEROLOGY, V113, P1779, DOI 10.1053/gast.1997.v113.pm9352884; PAULUS U, 1993, J CELL SCI, V106, P473; PIAZZA GA, 1995, CANCER RES, V55, P3110; Podolin PL, 1998, MAMM GENOME, V9, P283, DOI 10.1007/s003359900749; Podolin PL, 1997, J IMMUNOL, V159, P1835; POTTER M, 1994, CANCER RES, V54, P969; PRAML C, 1995, CANCER RES, V55, P5504; Praml C, 1998, ONCOGENE, V17, P2009, DOI 10.1038/sj.onc.1202121; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; Quesada CF, 1998, JPN J CANCER RES, V89, P392, DOI 10.1111/j.1349-7006.1998.tb00576.x; RAO CV, 1995, CANCER RES, V55, P1464; Rao CV, 1996, CANCER RES, V56, P532; Reddy BS, 1999, CANCER RES, V59, P3387; RIGGINS GJ, 1995, CANCER RES, V55, P5184; Ritland SR, 1999, CARCINOGENESIS, V20, P51, DOI 10.1093/carcin/20.1.51; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Shoemaker AR, 1997, BBA-REV CANCER, V1332, pF25, DOI 10.1016/S0304-419X(96)00041-8; Spirio LN, 1996, CANCER RES, V56, P955; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Taketo MM, 1998, INFLAMM RES, V47, pS112; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; Tomlinson IPM, 1996, ANN HUM GENET, V60, P369, DOI 10.1111/j.1469-1809.1996.tb00434.x; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Weinrauch Y, 1998, J CLIN INVEST, V102, P633, DOI 10.1172/JCI3121; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Yang ZY, 1998, CANCER LETT, V124, P187, DOI 10.1016/S0304-3835(97)00476-X; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	89	86	90	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 29	2000	19	28					3182	3192		10.1038/sj.onc.1203646	http://dx.doi.org/10.1038/sj.onc.1203646			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918573				2022-12-25	WOS:000088019200007
J	Maya, R; Oren, M				Maya, R; Oren, M			Unmasking of phosphorylation-sensitive epitopes on p53 and Mdm2 by a simple Western-phosphatase procedure	ONCOGENE			English	Article						p53; Mdm2; phosphatase; monoclonal antibodies; Western blot	PROTEIN-KINASE-C; DNA-BINDING FUNCTION; GROWTH ARREST; CELL-LINES; IN-VITRO; INDUCTION; DEPHOSPHORYLATION; SIGNALS	Monoclonal antibodies are widely used for the assessment of protein expression levels, protein-protein interactions and protein localization. Phosphorylation of one or more residues within an epitope recognized by a particular antibody may compromise the ability of that antibody to bind the target protein. Inhibition of immunoreactivity by phosphorylation has been reported for many antibody/protein pairs. Here me describe a simple convenient protocol for assessing the effect of phosphorylation on immunoreactivity? employing phosphatase treatment of Western blotted membranes. The efficacy of this protocol is demonstrated for p53 and for Mdm2. This method is useful for obtaining more uniform protein quantification, as well as for rapid assessment of changes in the extent of phosphorylation within a given epitope in response to defined signals.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, POB 26, IL-76100 Rehovot, Israel.			Oren, Moshe/0000-0003-4311-7172	NCI NIH HHS [R01 CA-40099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Bond JA, 1999, ONCOGENE, V18, P3788, DOI 10.1038/sj.onc.1202733; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Craig AL, 1999, ONCOGENE, V18, P6305, DOI 10.1038/sj.onc.1203085; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; Juven-Gershon T, 1998, MOL CELL BIOL, V18, P3974, DOI 10.1128/MCB.18.7.3974; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Milne DM, 1996, ONCOGENE, V13, P205; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pitkanen K, 1998, ONCOGENE, V16, P459, DOI 10.1038/sj.onc.1201528; RAYNAL S, 1994, GROWTH FACTORS, V11, P197, DOI 10.3109/08977199409046917; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39	23	33	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3213	3215		10.1038/sj.onc.1203658	http://dx.doi.org/10.1038/sj.onc.1203658			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918576				2022-12-25	WOS:000088019200010
J	Deloulme, JC; Assard, N; Mbele, GO; Mangin, C; Kuwano, R; Baudier, J				Deloulme, JC; Assard, N; Mbele, GO; Mangin, C; Kuwano, R; Baudier, J			S100A6 and S100A11 are specific targets of the calcium- and zinc-binding S100B protein in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN CAPPING PROTEIN; C-TERMINAL DOMAIN; 2-HYBRID SYSTEM; S-100 PROTEIN; BOVINE BRAIN; RAT APO-S100B(BETA-BETA); ALZHEIMERS-DISEASE; IONS BINDING; IN-VITRO; CALMODULIN	In solution, S100B protein is a noncovalent homodimer composed of two subunits associated in an antiparallel manner. Upon calcium binding, the conformation of S100B changes dramatically, leading to the exposure of hydrophobic residues at the surface of S100B. The residues in the C-terminal domain of S100B encompassing Phe(87) and Phe(88) have been implicated in interaction with target proteins. In this study, we used two-hybrid technology to identify specific S100B target proteins. Using S100B as bait, we identify S100A6 and S100A11 as specific targets for S100B. S100A1, the closest homologue of S100B, is capable of interaction with S100B but does not interact with S100A6 or S100A11. S100B, S100A6, and S100A11 isoforms are co-regulated and,co-localized in astrocytoma U373 cells. Furthermore, co-immunoprecipitation experiments demonstrated that Ca2+/Zn2+ stabilizes S100B-S100A6 and S100B-S100A11 heterocomplexes. Deletion of the C-terminal domain or mutation of Phe(87) and Phe(88) residues has-no effect on S100B homodimerization and heterodimerization with S100A1 but drastically decreases interaction between S100B and S100A6 or S100A11. Our data, suggest that the interaction between S100B and S100A6 or S100A11 should not be viewed as a typical S100 heterodimerization but rather as a model of interaction between S100B and target proteins.	CEN G, BRCE, DBMS,CEA, INSERM Unite 244,Dept Biol Mol & Struct, F-38054 Grenoble 9, France; Niigata Univ, Res Lab Mol Genet, Niigata 951, Japan	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Niigata University	Deloulme, JC (corresponding author), CEN G, BRCE, DBMS,CEA, INSERM Unite 244,Dept Biol Mol & Struct, 17 Rue Martyrs, F-38054 Grenoble 9, France.		Deloulme, Jean Christophe/P-6858-2017; Baudier, Jacques/O-2183-2016	Deloulme, Jean Christophe/0000-0002-2234-5865; jacques, baudier/0000-0001-8427-4444				ALLORE R, 1988, SCIENCE, V239, P1311, DOI 10.1126/science.2964086; Barber KR, 1999, J BIOL CHEM, V274, P1502, DOI 10.1074/jbc.274.3.1502; BAUDIER J, 1986, J BIOL CHEM, V261, P8204; BAUDIER J, 1987, J BIOL CHEM, V262, P17577; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; BAUDIER J, 1995, BIOCHEMISTRY-US, V34, P7834, DOI 10.1021/bi00024a007; BERTOGLIO JH, 1987, LYMPHOKINE RES, V6, P83; BIANCHI R, 1993, J BIOL CHEM, V268, P12669; Boni R, 1997, J CUTAN PATHOL, V24, P76, DOI 10.1111/j.1600-0560.1997.tb01100.x; Brill S, 1996, MOL CELL BIOL, V16, P4869; Camby I, 1999, BRAIN PATHOL, V9, P1; Chao S, 1996, MOL BRAIN RES, V40, P195, DOI 10.1016/0169-328X(96)00049-6; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COCHRAN AJ, 1993, MELANOMA RES, V3, P325, DOI 10.1097/00008390-199310000-00004; DELLANGELICA EC, 1994, J BIOL CHEM, V269, P28929; DELOULME J, 2000, IN PRESS METHODS BIO; Delphin C, 1999, J BIOL CHEM, V274, P10539, DOI 10.1074/jbc.274.15.10539; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Drohat AC, 1996, BIOCHEMISTRY-US, V35, P11577, DOI 10.1021/bi9612226; Drohat AC, 1998, BIOCHEMISTRY-US, V37, P2729, DOI 10.1021/bi972635p; Drohat AC, 1999, PROTEIN SCI, V8, P800; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FILIPEK A, 1990, FEBS LETT, V264, P263, DOI 10.1016/0014-5793(90)80263-I; FUJII T, 1994, J BIOCHEM-TOKYO, V116, P121, DOI 10.1093/oxfordjournals.jbchem.a124484; Garbuglia M, 1996, FASEB J, V10, P317, DOI 10.1096/fasebj.10.2.8641565; Griffin WST, 1998, NEUROBIOL AGING, V19, P401, DOI 10.1016/S0197-4580(98)00074-8; ISOBE T, 1981, EUR J BIOCHEM, V116, P79, DOI 10.1111/j.1432-1033.1981.tb05303.x; IVANENKOV VV, 1995, J BIOL CHEM, V270, P14651, DOI 10.1074/jbc.270.24.14651; Kilby PM, 1996, STRUCTURE, V4, P1041, DOI 10.1016/S0969-2126(96)00111-6; Kilby PM, 1997, PROTEIN SCI, V6, P2494; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHAK DR, 1992, NEUROBIOL AGING, V13, P1, DOI 10.1016/0197-4580(92)90002-F; Matsumura H, 1998, STRUCTURE, V6, P233, DOI 10.1016/S0969-2126(98)00024-0; MILLER JH, 1992, SHORT COURSE BACTERI, P71; Miller JH., 1972, EXPT MOL GENETICS; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; Potts BCM, 1996, PROTEIN SCI, V5, P2162, DOI 10.1002/pro.5560051103; Prichard L, 1999, J BIOL CHEM, V274, P7689, DOI 10.1074/jbc.274.12.7689; Propper C, 1999, J BIOL CHEM, V274, P183, DOI 10.1074/jbc.274.1.183; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; Rustandi RR, 1999, PROTEIN SCI, V8, P1743, DOI 10.1110/ps.8.9.1743; Sakaguchi M, 2000, J CELL BIOL, V149, P1193, DOI 10.1083/jcb.149.6.1193; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scotto C, 1998, MOL CELL BIOL, V18, P4272, DOI 10.1128/MCB.18.7.4272; Scotto C, 1999, MOL CELL BIOL, V19, P7168; Seemann J, 1997, FEBS LETT, V413, P185, DOI 10.1016/S0014-5793(97)00911-3; SKRIPNIKOVA EV, 1989, FEBS LETT, V257, P380, DOI 10.1016/0014-5793(89)81577-7; Smith SP, 1997, J BIOMOL NMR, V10, P77, DOI 10.1023/A:1018397213369; Smith SP, 1996, BIOCHEMISTRY-US, V35, P8805, DOI 10.1021/bi952698c; Smith SP, 1998, STRUCTURE, V6, P211, DOI 10.1016/S0969-2126(98)00022-7; STANLEY LC, 1994, J NEUROPATH EXP NEUR, V53, P231, DOI 10.1097/00005072-199405000-00003; VOJTEK A, 1997, YEAST 2 HYBRID SYSTE; Wang GZ, 2000, J BIOL CHEM, V275, P11141, DOI 10.1074/jbc.275.15.11141; Yamashita N, 1997, BRAIN RES, V778, P388, DOI 10.1016/S0006-8993(97)01025-1; Yamashita N, 1999, J COMP NEUROL, V404, P235; Yang Q, 1999, EXP CELL RES, V246, P501, DOI 10.1006/excr.1998.4314	58	74	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35302	35310		10.1074/jbc.M003943200	http://dx.doi.org/10.1074/jbc.M003943200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10913138	hybrid			2022-12-25	WOS:000165422800064
J	Jia, HP; Wowk, SA; Schutte, BC; Lee, SK; Vivado, A; Tack, BF; Bevins, CL; McCray, PB				Jia, HP; Wowk, SA; Schutte, BC; Lee, SK; Vivado, A; Tack, BF; Bevins, CL; McCray, PB			A novel murine beta-defensin expressed in tongue, esophagus, and trachea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDE GENE; HUMAN BETA-DEFENSIN-1; EPITHELIAL-CELLS; AIRWAY EPITHELIA; MOUSE BETA-DEFENSIN-1; MOLECULAR-CLONING; CRYPTDIN LOCUS; PANETH CELLS; LIPOPOLYSACCHARIDE; LOCALIZATION	beta -Defensins are broad spectrum antimicrobial peptides expressed at epithelial surfaces. Two human p-defensins, HBD-1 and HBD-2, have been identified, In the lung, HBD-2 is an inducible product of airway epithelia and may play a role in innate mucosal defenses. We recently characterized rat homologs (RBD-1, RBD-2) of the human genes and used these sequences to identify novel mouse genes. Mouse beta -defensin-4 (MBD-4) was amplified from lung cDNA using polymerase chain reaction primers designed from conserved sequences of RBD-2 and HBD-2. A full-length cDNA was cloned which encodes a putative peptide with the sequence MRIHYLLFTFLLVLLSPLAAFTQIINNPITCMTNGAIC-WGPCPTAFRQIGNCGHFKVRCCKIR . The peptide shares similar to 40% identity with HBD-2. MBD-4 mRNA was expressed in the esophagus, tongue, and trachea but not in any of 20 other tissues surveyed. Cloning of the genomic sequence of MBD-4 revealed two nearly (>99%) identical sequences encoding MBD-4 and the presence of numerous additional highly similar genomic sequences. Radiation hybrid mapping localized this gene to a region of chromosome 8 near several other defensins, MBD-2, MBD-3, and alpha -defensins (cryptdins)-3 and -17, consistent with a gene cluster, Our genomic cloning and mapping data suggest that there is a large beta -defensin gene family in mice. Identification of murine beta -defensins provides an opportunity to understand further the role of these peptides in host defense through animal model studies and the generation of beta -defensin-deficient animals by gene targeting.	Univ Iowa, Coll Med, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Genet PhD Program, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Microbiol, Iowa City, IA 52242 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	University of Iowa; University of Iowa; University of Iowa; Cleveland Clinic Foundation	McCray, PB (corresponding author), Univ Iowa Hosp & Clin, Dept Pediat, 200 Hawkins Dr, Iowa City, IA 52242 USA.		jia, jhp@mm8899/AAH-6611-2020; Bevins, Charles L/P-4438-2015	Bevins, Charles L/0000-0003-2725-2622; McCray, Paul/0000-0002-4067-577X	NHLBI NIH HHS [HL-61234-01] Funding Source: Medline; NIAID NIH HHS [AI-32234, AI-32738] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL061234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI032234, R01AI032738, R01AI032234] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bals R, 1999, INFECT IMMUN, V67, P3542, DOI 10.1128/IAI.67.7.3542-3547.1999; Bals R, 1998, INFECT IMMUN, V66, P1225, DOI 10.1128/IAI.66.3.1225-1232.1998; Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; Bevins C L, 1997, Methods Mol Biol, V78, P151; Bevins CL, 1996, GENOMICS, V31, P95, DOI 10.1006/geno.1996.0014; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Diamond G, 1996, P NATL ACAD SCI USA, V93, P5156, DOI 10.1073/pnas.93.10.5156; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; DIAMOND G, 1993, P NATL ACAD SCI USA, V90, P4596, DOI 10.1073/pnas.90.10.4596; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDMAN MJ, 1997, CELL, V88, P1; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Harder J, 1997, GENOMICS, V46, P472, DOI 10.1006/geno.1997.5074; Hughes AL, 1997, J MOL EVOL, V44, P675, DOI 10.1007/PL00006191; Huttner KM, 1998, J NUTR, V128, p297S, DOI 10.1093/jn/128.2.297S; Huttner KM, 1997, FEBS LETT, V413, P45, DOI 10.1016/S0014-5793(97)00875-2; Huttner KM, 1999, PEDIATR RES, V45, P785, DOI 10.1203/00006450-199906000-00001; Jia HP, 1999, INFECT IMMUN, V67, P4827, DOI 10.1128/IAI.67.9.4827-4833.1999; JONES DE, 1992, J BIOL CHEM, V267, P23216; LEHRER RI, 1998, MUCOSAL IMMUNOLOGY, P89; LIN MY, 1992, GENOMICS, V14, P363, DOI 10.1016/S0888-7543(05)80227-7; Linzmeier R, 1999, GENE, V233, P205, DOI 10.1016/S0378-1119(99)00136-5; Liu L, 1998, GENE, V222, P237, DOI 10.1016/S0378-1119(98)00480-6; Liu LD, 1997, GENOMICS, V43, P316, DOI 10.1006/geno.1997.4801; Mathews M, 1999, INFECT IMMUN, V67, P2740, DOI 10.1128/IAI.67.6.2740-2745.1999; McCarthy LC, 1997, GENOME RES, V7, P1153, DOI 10.1101/gr.7.12.1153; McCray PB, 1999, AM J PHYSIOL-LUNG C, V277, pL183, DOI 10.1152/ajplung.1999.277.1.L183; McCray PB, 1997, AM J RESP CELL MOL, V16, P343, DOI 10.1165/ajrcmb.16.3.9070620; Morrison GM, 1998, MAMM GENOME, V9, P453, DOI 10.1007/s003359900795; Morrison GM, 1999, FEBS LETT, V442, P112, DOI 10.1016/S0014-5793(98)01630-5; OUELLETTE AJ, 1989, GENOMICS, V5, P233, DOI 10.1016/0888-7543(89)90051-7; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; Russell JP, 1996, INFECT IMMUN, V64, P1565, DOI 10.1128/IAI.64.5.1565-1568.1996; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Shi JS, 1999, INFECT IMMUN, V67, P3121, DOI 10.1128/IAI.67.6.3121-3127.1999; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Tarver AP, 1998, INFECT IMMUN, V66, P1045, DOI 10.1128/IAI.66.3.1045-1056.1998; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yount NY, 1999, J BIOL CHEM, V274, P26249, DOI 10.1074/jbc.274.37.26249; Zabner J, 1998, MOL CELL, V2, P397, DOI 10.1016/S1097-2765(00)80284-1; Zhang GL, 1999, J BIOL CHEM, V274, P24031, DOI 10.1074/jbc.274.34.24031; Zhao CQ, 1996, FEBS LETT, V396, P319, DOI 10.1016/0014-5793(96)01123-4	49	66	72	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33314	33320		10.1074/jbc.M006603200	http://dx.doi.org/10.1074/jbc.M006603200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10922379	hybrid			2022-12-25	WOS:000090104600022
J	Jorgensen, MM; Jensen, ON; Holst, HU; Hansen, JJ; Corydon, TJ; Bross, P; Bolund, L; Gregersen, N				Jorgensen, MM; Jensen, ON; Holst, HU; Hansen, JJ; Corydon, TJ; Bross, P; Bolund, L; Gregersen, N			Grp78 is involved in retention of mutant low density lipoprotein receptor protein in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE BIP; FAMILIAL HYPERCHOLESTEROLEMIA; LDL RECEPTOR; SELECTIVE PROTEINS; QUALITY-CONTROL; SECRETION; CELLS; STRESS; OVEREXPRESSION; DISEASE	The low density lipoprotein (LDL) receptor is responsible for removing the majority of the LDL cholesterol from the plasma. Mutations in the LDL receptor gene cause the disease familial hypercholesterolemia (FH), Approximately 50% of the mutations in the LDL receptor gene in patients with FH lead to receptor proteins that are retained in the endoplasmic reticulum (ER). Misfolding of mutant LDL receptors is a probable cause of this ER retention, resulting in no functional LDL receptors at the cell surface. However, the specific factors and mechanisms responsible for retention of mutant LDL receptors are unknown, In the present study we show that the molecular chaperone Grp78/BiP co-immunoprecipitates with both the wild type and two different mutant (W556S and C646Y) LDL receptors in lysates obtained from human liver cells overexpressing wild type or mutant LDL receptors, A pulse-chase study shows that the interaction between the wild type LDL receptor and Grp78 is no longer detectable after 2 1/2 h, whereas it persists for more than 4 h with the mutant receptors, Furthermore, about five times more Grp78 is co-immunoprecipitated with the mutant receptors than with the wild type receptor suggesting that Grp78 is involved in retention of mutant LDL receptors in the ER. Overexpression of Grp78 causes no major alterations on the steady state level of active LDL receptors at the cell surface. However, overexpression of Grp78 decreases the processing rate of newly synthesized wild type LDL receptors, This indicates that the Grp78 interaction is a rate-limiting step in the maturation of the wild type LDL receptor and that Grp78 may be an important factor in the quality control of newly synthesized LDL receptors.	Univ Aarhus, Skejby Sygehus, Res Unit Mol Med, DK-8200 Aarhus N, Denmark; Odense Univ, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark; Aarhus Univ, Inst Human Genet, DK-8000 Aarhus C, Denmark	Aarhus University; University of Southern Denmark; Aarhus University	Jorgensen, MM (corresponding author), Univ Aarhus, Skejby Sygehus, Res Unit Mol Med, Brendstrupgaardsvej, DK-8200 Aarhus N, Denmark.		Jensen, Ole N/J-1763-2012; Bross, Peter/B-7219-2013	Jensen, Ole N/0000-0003-1862-8528; Bross, Peter/0000-0001-9526-8525; Corydon, Thomas Juhl/0000-0003-3588-6350; Jorgensen, Malene Munk/0000-0002-0090-3563				Ailor E, 1998, BIOTECHNOL BIOENG, V58, P196, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<196::AID-BIT12>3.0.CO;2-B; BARAK LS, 1981, J CELL BIOL, V90, P595, DOI 10.1083/jcb.90.3.595; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; Beissinger M, 1998, BIOL CHEM, V379, P245; Belfi CA, 1999, BIOCHEM BIOPH RES CO, V257, P361, DOI 10.1006/bbrc.1999.0472; BERGER NA, 1982, CANCER RES, V42, P4382; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; Brooks DA, 1997, FEBS LETT, V409, P115, DOI 10.1016/S0014-5793(97)00423-7; Bross P, 1999, HUM MUTAT, V14, P186, DOI 10.1002/(SICI)1098-1004(1999)14:3<186::AID-HUMU2>3.0.CO;2-J; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; CARRELL RW, 1996, CHEST, V110, P243; CHATTERJEE S, 1994, CANCER RES, V54, P4405; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; Jensen HK, 1997, ATHEROSCLEROSIS, V131, P67, DOI 10.1016/S0021-9150(96)06059-5; Jensen O.N., 1997, PROTEIN STRUCTURE PR; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; Leborgne-Castel N, 1999, PLANT CELL, V11, P459, DOI 10.1105/tpc.11.3.459; LEITERSDORF E, 1990, J CLIN INVEST, V85, P1014, DOI 10.1172/JCI114531; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Muresan Z, 1998, MOL ENDOCRINOL, V12, P458, DOI 10.1210/me.12.3.458; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Soto C, 1999, J MOL MED-JMM, V77, P412, DOI 10.1007/s001090050371; Street JC, 1996, J BIOL CHEM, V271, P4113; SUDHOF TC, 1985, SCIENCE, V228, P893, DOI 10.1126/science.3873704; Tate CG, 1999, J BIOL CHEM, V274, P17551, DOI 10.1074/jbc.274.25.17551; Yang YN, 1998, J BIOL CHEM, V273, P25552, DOI 10.1074/jbc.273.40.25552	39	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33861	33868		10.1074/jbc.M004663200	http://dx.doi.org/10.1074/jbc.M004663200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10906332	hybrid			2022-12-25	WOS:000090104600094
J	Pryde, JG; Walker, A; Rossi, AG; Hannah, S; Haslett, C				Pryde, JG; Walker, A; Rossi, AG; Hannah, S; Haslett, C			Temperature-dependent arrest of neutrophil apoptosis - Failure of Bax insertion into mitochondria at 15 degrees C prevents the release of cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; PERMEABILITY TRANSITION PORE; DRUG-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; IN-VITRO; VITRONECTIN RECEPTOR; AGING NEUTROPHILS; PROTEASE ACTIVITY; NUCLEAR-CHANGES; BCL-2	Apoptosis is essential for the resolution of neutrophilic inflammation. To define the mechanisms triggering the execution phase of apoptosis we developed and utilized a model in which culture of human neutrophils at 15 degreesC for 20 h arrested apoptosis and subsequent warming to 37 degreesC triggered a synchronous burst of apoptosis. Treatment of 15 degreesC cultured neutrophils with the pan-caspase inhibitor zVAD-fmk just before warming to 37 degreesC inhibited the morphological changes associated with apoptosis, but did not prevent the insertion of the proapoptotic protein Bax into mitochondria nor the inhibition of secretion and the externalization of phosphatidylserine, indices of neutrophil apoptosis. In both intact neutrophils and a cell-free extract, cytochrome c released from mitochondria induced proteolytic cleavage of procaspase-3. At 15 degreesC the binding of Bax to mitochondria was uncoupled from Bax insertion into the mitochondrial membrane required for the release of cytochrome c. Apoptosis was also inhibited by low pH during warming to 37 degreesC, suggesting that changes to the conformation of Bax, necessary for membrane insertion, were being inhibited. Bax insertion was only sensitive to zVAD-fmk when added at the start of the 15 degreesC culture period, suggesting that a cytoplasmic substrate of the effector caspases may mediate in the mechanism of Bax insertion into mitochondria.	Univ Edinburgh, Sch Med, Dept Med RIE, Rayne Lab,Resp Med Unit, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh	Pryde, JG (corresponding author), Univ Edinburgh, Sch Med, Dept Med RIE, Rayne Lab,Resp Med Unit, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	j.pryde@ed.ac.uk						Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Benson RSP, 1999, J CELL SCI, V112, P1755; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Eldadah BA, 1996, NUCLEIC ACIDS RES, V24, P4092, DOI 10.1093/nar/24.20.4092; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Furlong IJ, 1997, J CELL SCI, V110, P653; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GREGORY CD, 1994, INT J CANCER, V57, P419, DOI 10.1002/ijc.2910570321; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; HANNAH S, 1995, FEBS LETT, V372, P233, DOI 10.1016/0014-5793(95)00986-J; HASLETT C, 1985, AM J PATHOL, V119, P101; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KUMAMOTO J, 1971, J THEOR BIOL, V31, P47, DOI 10.1016/0022-5193(71)90120-2; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; LEE A, 1993, J LEUKOCYTE BIOL, V54, P283, DOI 10.1002/jlb.54.4.283; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Liu GY, 1996, J BIOL CHEM, V271, P19717, DOI 10.1074/jbc.271.33.19717; MANARA FS, 1985, BIOCHEM BIOPH RES CO, V132, P696, DOI 10.1016/0006-291X(85)91188-X; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; MATSUMOTO K, 1995, BLOOD, V86, P1437, DOI 10.1182/blood.V86.4.1437.bloodjournal8641437; MEAGHER LC, 1992, J LEUKOCYTE BIOL, V52, P269, DOI 10.1002/jlb.52.3.269; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; Murphy KM, 1999, ONCOGENE, V18, P5991, DOI 10.1038/sj.onc.1203001; Musgrove E A, 1990, Methods Cell Biol, V33, P59; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NICHOLSON DW, 1984, CAN J BIOCHEM CELL B, V62, P1205, DOI 10.1139/o84-155; OHTA H, 1994, FEBS LETT, V355, P267, DOI 10.1016/0014-5793(94)01218-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PRYDE JG, 1994, J CELL SCI, V107, P3425; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Sanghavi DM, 1998, FEBS LETT, V422, P179, DOI 10.1016/S0014-5793(98)00004-0; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shimura M, 1997, FEBS LETT, V417, P379, DOI 10.1016/S0014-5793(97)01327-6; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; TARTAKOFF AM, 1986, EMBO J, V5, P1477, DOI 10.1002/j.1460-2075.1986.tb04385.x; Trevani AS, 1999, J IMMUNOL, V162, P4849; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Vander Heiden MG, 1999, MOL CELL, V3, P159; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; Weinmann P, 1999, BLOOD, V93, P3106; WHYTE MKB, 1993, J IMMUNOL, V150, P5124; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zhuang JG, 1998, J BIOL CHEM, V273, P15628, DOI 10.1074/jbc.273.25.15628; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	81	62	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33574	33584		10.1074/jbc.M001008200	http://dx.doi.org/10.1074/jbc.M001008200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10896657	hybrid			2022-12-25	WOS:000090104600057
J	Calvert, MJ; Ward, DG; Trayer, HR; Trayer, IP				Calvert, MJ; Ward, DG; Trayer, HR; Trayer, IP			The importance of the carboxyl-terminal domain of cardiac troponin C in Ca2+-sensitive muscle regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOFIBRILLAR ADENOSINE-TRIPHOSPHATASE; CALCIUM-SATURATED STATES; MAGNESIUM BINDING-SITES; NEUTRON-SCATTERING; N-DOMAIN; CALMODULIN; COMPLEX; RESOLUTION; MYOSIN; PHOSPHORYLATION	The interactions between troponin I and troponin C are central to the Ca2+-regulated control of striated muscle. Using isothermal titration microcalorimetry we have studied the binding of human cardiac troponin C (cTnC) and its isolated domains to human cardiac troponin I (cTnI). We provide the first binding data for these proteins while they are free in solution and unmodified by reporter groups. Our data reveal that the C-terminal domain of cTnC is responsible for most of the free energy change upon cTnC cTnI binding. Importantly, the interaction between cTnI and the C-terminal domain of cTnC is 8-fold stronger in the presence of Ca2+ than in the presence of Mg2+, suggesting that the C-terminal domain of cTnC may play a modulatory role in cardiac muscle regulation. Changes in the affinity of cTnI for cTnC and its isolated C-terminal domain in response to ionic strength support this finding, with both following similar trends. At physiological ionic strength the affinity of cTnC for cTnI changed very little in response to Ca2+, although the thermodynamic data show a clear distinction between binding in the presence of Ca2+ and in the presence of Mg2+.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Trayer, IP (corresponding author), Univ Birmingham, Sch Biosci, POB 363, Birmingham B15 2TT, W Midlands, England.		Calvert, Melanie/F-7055-2011	Calvert, Melanie/0000-0002-1856-837X; Ward, Douglas/0000-0002-2328-1445				ALHILLAWI E, 1995, EUR J BIOCHEM, V228, P962; ALHILLAWI E, 1994, EUR J BIOCHEM, V225, P1195, DOI 10.1111/j.1432-1033.1994.1195b.x; BINGHAM RP, 1998, THESIS U BIRMINGHAM; CHERVENKA CH, 1970, ANAL BIOCHEM, V34, P24, DOI 10.1016/0003-2697(70)90082-5; Christensen J.J., 1976, HDB PROTON IONIZATIO; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; Dong WJ, 1997, BIOCHEMISTRY-US, V36, P6754, DOI 10.1021/bi9622276; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Francois JM, 1997, J MUSCLE RES CELL M, V18, P323, DOI 10.1023/A:1018622109391; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; Gasmi-Seabrook GMC, 1999, BIOCHEMISTRY-US, V38, P8313, DOI 10.1021/bi9902642; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HOLROYDE MJ, 1980, J BIOL CHEM, V255, P1688; Houdusse A, 1997, STRUCTURE, V5, P1695, DOI 10.1016/S0969-2126(97)00315-8; IIO T, 1981, J BIOCHEM-TOKYO, V90, P163, DOI 10.1093/oxfordjournals.jbchem.a133446; KOMETANI K, 1983, BIOCHEM BIOPH RES CO, V114, P162, DOI 10.1016/0006-291X(83)91608-X; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; LI MX, 1994, BIOCHEMISTRY-US, V33, P917, DOI 10.1021/bi00170a010; LIAO RL, 1994, BIOCHEMISTRY-US, V33, P12729, DOI 10.1021/bi00208a026; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P8233, DOI 10.1021/bi00193a009; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P12800, DOI 10.1021/bi00209a011; PEARLSTONE JR, 1995, BIOCHEMISTRY-US, V34, P6932, DOI 10.1021/bi00021a004; Perry SV, 1999, MOL CELL BIOCHEM, V190, P9, DOI 10.1023/A:1006939307715; POTTER JD, 1975, J BIOL CHEM, V250, P4628; Reiffert SU, 1998, BIOCHEMISTRY-US, V37, P13516, DOI 10.1021/bi980280j; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Spyracopoulos L, 1998, BIOCHEMISTRY-US, V37, P18032, DOI 10.1021/bi9816960; Stone DB, 1998, J MOL BIOL, V281, P689, DOI 10.1006/jmbi.1998.1965; SWENSON CA, 1992, BIOCHEMISTRY-US, V31, P3420, DOI 10.1021/bi00128a017; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; Tsvetkov PO, 1999, J BIOL CHEM, V274, P18161, DOI 10.1074/jbc.274.26.18161; VANEERD JP, 1976, BIOCHEMISTRY-US, V15, P1171, DOI 10.1021/bi00650a033; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847; WEEDS AG, 1975, FEBS LETT, V49, P320, DOI 10.1016/0014-5793(75)80776-9; Wintrode PL, 1997, J MOL BIOL, V266, P1050, DOI 10.1006/jmbi.1996.0785; Yamada K, 1999, MOL CELL BIOCHEM, V190, P39, DOI 10.1023/A:1006943426370	40	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32508	32515		10.1074/jbc.M005764200	http://dx.doi.org/10.1074/jbc.M005764200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10921926	hybrid			2022-12-25	WOS:000090003800019
J	D'Amico, M; Hulit, J; Amanatullah, DF; Zafonte, BT; Albanese, C; Bouzahzah, B; Fu, MF; Augenlicht, LH; Donehower, LA; Takemaru, KI; Moon, RT; Davis, R; Lisanti, MP; Shtutman, M; Zhurinsky, J; Ben-Ze'ev, A; Troussard, AA; Dedhar, S; Pestell, RG				D'Amico, M; Hulit, J; Amanatullah, DF; Zafonte, BT; Albanese, C; Bouzahzah, B; Fu, MF; Augenlicht, LH; Donehower, LA; Takemaru, KI; Moon, RT; Davis, R; Lisanti, MP; Shtutman, M; Zhurinsky, J; Ben-Ze'ev, A; Troussard, AA; Dedhar, S; Pestell, RG			The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3 beta and cAMP-responsive element-binding protein-dependent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING TRANSCRIPTION FACTOR-2; SIGNAL-TRANSDUCTION PATHWAY; FOCAL ADHESION KINASE; BETA-CATENIN; TRANSGENIC MICE; PHOSPHATIDYLINOSITOL 3-KINASE; RETINOBLASTOMA PROTEIN; CELL-ADHESION; C-JUN; PHOSPHORYLATION	The cyclin D1 gene encodes the regulatory subunit of a holoenzyme that phosphorylates and inactivates the PRE tumor suppressor protein. Cyclin D1 is overexpressed in 20-30% of human breast tumors and is induced both by oncogenes including those for Ras, Neu, and Src, and by the beta -catenin/lymphoid enhancer factor (LEF)/T cell factor (TCF) pathway. The ankyrin repeat containing serine-threonine protein kinase, integrinlinked kinase (ILK), binds to the cytoplasmic domain of beta (1) and beta (3) integrin subunits and promotes anchorage-independent growth. We show here that ILK overexpression elevates cyclin D1 protein levels and directly induces the cyclin D1 gene in mammary epithelial cells. ILK activation of the cyclin D1 promoter was abolished by point mutation of a cAMP-responsive element-binding protein (CREB)/ATF-2 binding site at nucleotide -54 in the cyclin D1 promoter, and by overexpression of either glycogen synthase kinase-3 beta (GSK-3 beta) or dominant negative mutants of CREB or ATF-2. Inhibition of the PI 3-kinase and AKT/protein kinase B, but not of the p38, ERK, or JNK signaling pathways, reduced ILK induction of cyclin D1 expression. ILK induced CREB transactivation and CREB binding to the cyclin D1 promoter CRE, Wnt-1 overexpression in mammary epithelial cells induced cyclin D1 mRNA and targeted overexpression of Wnt-1 in the mammary gland of transgenic mice increased both ILK activity and cyclin D1 levels. We conclude that the cyclin D1 gene is regulated by the Wnt-1 and ILK signaling pathways and that ILK induction of cyclin D1 involves the CREB signaling pathway in mammary epithelial cells.	Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Dev & Mol Biol Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Pharmacol, Bronx, NY 10461 USA; Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA; Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Howard Hughes Med Inst, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Program Mol Biol, Worcester, MA 01605 USA; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; British Columbia Canc Agcy, Vancouver, BC V6H 3Z6, Canada; Vancouver Hosp, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Weizmann Institute of Science; British Columbia Cancer Agency; University of British Columbia	Pestell, RG (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Dev & Mol Biol Med, Chanin 302,1300 Morris Pk Ave, Bronx, NY 10461 USA.		Shtutman, Michael/AAB-8391-2020; Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013; Moon, Randall T/B-1743-2014; Roszak, Joanna/F-4003-2010	Shtutman, Michael/0000-0002-2458-3226; Lisanti, Michael/0000-0003-2034-1382; Moon, Randall T/0000-0002-9352-1408; Amanatullah, Derek/0000-0002-6203-5853; ben-ze'ev, avri/0000-0001-6113-3921; Dedhar, Shoukat/0000-0003-4355-1657	NATIONAL CANCER INSTITUTE [R01CA077552, R01CA075503, R01CA070897] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA77552, R01CA75503, R29CA70897] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; BOYLE W, 1990, CELL, V64, P573; Brown JD, 1998, CURR OPIN CELL BIOL, V10, P182, DOI 10.1016/S0955-0674(98)80140-3; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; IVASHKIV LB, 1992, NEW BIOL, V4, P360; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MAURER RA, 1989, J BIOL CHEM, V264, P6870; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sambrook T, 1989, MOL CLONING LAB MANU; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Vinals F, 1999, J BIOL CHEM, V274, P26776, DOI 10.1074/jbc.274.38.26776; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; WOODGETT JR, 1994, SEMIN CANCER BIOL, V5, P269; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Xu LF, 2000, GENE DEV, V14, P585; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	77	213	217	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32649	32657		10.1074/jbc.M000643200	http://dx.doi.org/10.1074/jbc.M000643200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10915780	hybrid			2022-12-25	WOS:000090003800039
J	Dormer, UH; Westwater, J; McLaren, NF; Kent, NA; Mellor, J; Jamieson, DJ				Dormer, UH; Westwater, J; McLaren, NF; Kent, NA; Mellor, J; Jamieson, DJ			Cadmium-inducible expression of the yeast GSH1 gene requires a functional sulfur-amino acid regulatory network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YAP-1 TRANSCRIPTIONAL REGULATION; OXIDATIVE STRESS RESPONSES; SACCHAROMYCES-CEREVISIAE; HYDROGEN-PEROXIDE; GLUTATHIONE-DEFICIENT; TARGET GENE; DNA-BINDING; ACTIVATION; METABOLISM; CENTROMERE	Glutathione (gamma -L-glutamyl-L-cysteinylglycine) is an important antioxidant molecule, helping to buffer the cell against free radicals and toxic electrophiles. Expression of the yeast GSH1 gene, encoding the first enzyme involved in glutathione biosynthesis, gamma -glutamylcysteine synthetase, is regulated by oxidants and the heavy metal cadmium at the level of transcription. We present evidence that the transcription factors involved in controlling the network of sulfur amino acid metabolism genes are also responsible for regulating GSH1 expression in response to cadmium. In particular the transcription factors Met-4, Met-31, and Met-32 are essential for cadmium-mediated regulation of gene expression, whereas the DNA-binding protein Cbf1 appears to play a negative role in controlling GSH1 expression.	Heriot Watt Univ, Dept Biol Sci, Edinburgh EH14 4AS, Midlothian, Scotland; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	Heriot Watt University; University of Oxford	Jamieson, DJ (corresponding author), Heriot Watt Univ, Dept Biol Sci, Edinburgh EH14 4AS, Midlothian, Scotland.	d.j.jamieson@hw.ac.uk	Kent, Nicholas/A-4503-2010	Kent, Nicholas/0000-0002-4114-1307				Blaiseau PL, 1998, EMBO J, V17, P6327, DOI 10.1093/emboj/17.21.6327; Blaiseau PL, 1997, MOL CELL BIOL, V17, P3640, DOI 10.1128/MCB.17.7.3640; Brennan RJ, 1996, MUTAT RES-FUND MOL M, V356, P171, DOI 10.1016/0027-5107(96)00051-6; COLLINSON LP, 1992, J GEN MICROBIOL, V138, P329, DOI 10.1099/00221287-138-2-329; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; ELSKENS MT, 1991, J GEN MICROBIOL, V137, P637, DOI 10.1099/00221287-137-3-637; Gietz R.D., 1994, MOL GENETICS YEAST P, P121; GLAESER H, 1991, CURR GENET, V19, P207, DOI 10.1007/BF00336488; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Grant CM, 1996, CURR GENET, V29, P511, DOI 10.1007/BF02426954; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; HIETER P, 1985, CELL, V42, P913, DOI 10.1016/0092-8674(85)90287-9; IZAWA S, 1995, FEBS LETT, V368, P73, DOI 10.1016/0014-5793(95)00603-7; Jamieson D. J., 1997, OXIDATIVE STRESS MOL, P91; Jamieson DJ, 1998, YEAST, V14, P1511, DOI 10.1002/(SICI)1097-0061(199812)14:16<1511::AID-YEA356>3.3.CO;2-J; JAMIESON DJ, 1995, REDOX REP, V1, P89, DOI 10.1080/13510002.1995.11746964; JAMIESON DJ, 1994, MICROBIOL-UK, V140, P3277, DOI 10.1099/13500872-140-12-3277; JAMIESON DJ, 1992, J BACTERIOL, V174, P6678, DOI 10.1128/JB.174.20.6678-6681.1992; KENT NA, 1994, MOL CELL BIOL, V14, P5229, DOI 10.1128/MCB.14.8.5229; KISTLER M, 1986, MUTAT RES, V173, P117, DOI 10.1016/0165-7992(86)90087-4; Kuras L, 1997, EMBO J, V16, P2441, DOI 10.1093/emboj/16.9.2441; Kuras L, 1996, EMBO J, V15, P2519, DOI 10.1002/j.1460-2075.1996.tb00609.x; LIU XF, 1994, MOL CELL BIOL, V14, P7037, DOI 10.1128/MCB.14.11.7037; Maris AF, 2000, CURR GENET, V37, P175, DOI 10.1007/s002940050516; Mehdi K, 1997, MICROBIOL-UK, V143, P1885, DOI 10.1099/00221287-143-6-1885; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MELLOR J, 1991, NUCLEIC ACIDS RES, V19, P2961, DOI 10.1093/nar/19.11.2961; Miyake T, 1999, YEAST, V15, P1449, DOI 10.1002/(SICI)1097-0061(199910)15:14<1449::AID-YEA469>3.0.CO;2-S; Rose M. D., 1990, METHODS YEAST GENETI, P155; SANTORO N, 1997, YEAST STRESS RESPONS, P171; Stephen DWS, 1997, MOL MICROBIOL, V23, P203, DOI 10.1046/j.1365-2958.1997.2081572.x; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; Stephen DWS, 1996, FEMS MICROBIOL LETT, V141, P207, DOI 10.1111/j.1574-6968.1996.tb08386.x; THOMAS D, 1992, MOL CELL BIOL, V12, P1719, DOI 10.1128/MCB.12.4.1719; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WEMMIE A, 1994, J BIOL CHEM, V269, P14690; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832	38	73	73	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32611	32616		10.1074/jbc.M004167200	http://dx.doi.org/10.1074/jbc.M004167200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10921921	hybrid			2022-12-25	WOS:000090003800034
J	Inoue, K; Mizuno, T; Wada, K; Hagiwara, M				Inoue, K; Mizuno, T; Wada, K; Hagiwara, M			Novel RING finger proteins, Air1p and Air2p, interact with Hmt1p and inhibit the arginine methylation of Npl3p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEINS; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; NUCLEOLAR ACCUMULATION; N-METHYLTRANSFERASE; NUCLEAR-PROTEIN; HNRNP PROTEINS; IN-VITRO; RGG BOX; YEAST	Heterogeneous nuclear ribonucleoproteins (hnRNPs) are involved in the mRNA processing and export and are post-translationally modified by methylation at arginine residues in their arginine-glycine-rich (RGG) domains. We screened the factors that can interact with the RGG domain of Np13p only in the presence of Hmt1p with the two-hybrid system in Saccharomyces cerevisiae, An isolated clone, YIL079, encodes a novel RING finger protein that was not directly bound to Np13p but associated with the N terminus of Hmt1p. Thus, we designated the gene product Air1p (arginine methyltransferase-interacting RING finger protein). Air1p inhibited the Hmt1p-mediated methylation of Np13p in vitro. Overexpression of Air1p repressed the Hmt1p-dependent growth of cells. Since homology searches indicate that the YDL175 gene product has significant identity (45%) with Air1p, we designated the gene AIR2. Air2p also has a RING finger domain and was bound to Hmt1p. Although single disruption of either gene gave no effect on the cell growth, cells lacking Air1p and Air2p grew at an extremely slow rate with accumulated poly(A)(+) RNA in the nucleus. Thus, Air1p and Air2p may affect mRNA transport by regulating the arginine methylation state of heterogeneous nuclear ribonucleoproteins.	Tokyo Med & Dent Univ, Med Res Inst, Dept Funct Genom, Bunkyo Ku, Tokyo 1138510, Japan; Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, SEEDS Lab, Tsukuba, Ibaraki 3058585, Japan	Tokyo Medical & Dental University (TMDU); Astellas Pharmaceuticals	Hagiwara, M (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Funct Genom, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.		Wada, Kazuhiro/A-6548-2012	Wada, Kazuhiro/0000-0001-8137-9144				Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Adams A, 1997, METHODS YEAST GENETI; Aleta JM, 1998, TRENDS BIOCHEM SCI, V23, P89, DOI 10.1016/S0968-0004(98)01185-2; AMERO SA, 1992, P NATL ACAD SCI USA, V89, P8409, DOI 10.1073/pnas.89.18.8409; ANDERSON JT, 1993, MOL CELL BIOL, V13, P2730, DOI 10.1128/MCB.13.5.2730; BARTA I, 1995, EMBO J, V14, P3800, DOI 10.1002/j.1460-2075.1995.tb00049.x; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bohm S, 1997, NUCLEIC ACIDS RES, V25, P2464, DOI 10.1093/nar/25.12.2464; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; BOSSIE MA, 1992, MOL BIOL CELL, V3, P875, DOI 10.1091/mbc.3.8.875; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; GIRARD JP, 1994, J BIOL CHEM, V269, P18499; Henry MF, 1996, MOL CELL BIOL, V16, P3668; HORVATH A, 1994, YEAST, V10, P1305, DOI 10.1002/yea.320101007; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; Kessler MM, 1997, GENE DEV, V11, P2545, DOI 10.1101/gad.11.19.2545; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KITADA K, 1995, GENE, V165, P203, DOI 10.1016/0378-1119(95)00552-H; KONKEL LMC, 1995, P NATL ACAD SCI USA, V92, P5558, DOI 10.1073/pnas.92.12.5558; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; LEE WC, 1992, MOL CELL BIOL, V12, P3865, DOI 10.1128/MCB.12.9.3865; LIN JJ, 1994, NUCLEIC ACIDS RES, V22, P4906, DOI 10.1093/nar/22.23.4906; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LIU Q, 1995, MOL CELL BIOL, V15, P2800; McBride AE, 2000, J BIOL CHEM, V275, P3128, DOI 10.1074/jbc.275.5.3128; Mears WE, 1996, J VIROL, V70, P7445, DOI 10.1128/JVI.70.11.7445-7453.1996; MICHAEL WM, 1995, CELL, V83, P415; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; PAIK WK, 1967, BIOCHEM BIOPH RES CO, V29, P14, DOI 10.1016/0006-291X(67)90533-5; Pan C, 1997, J BIOL CHEM, V272, P8165, DOI 10.1074/jbc.272.13.8165; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Shiratori A, 1999, YEAST, V15, P219, DOI 10.1002/(SICI)1097-0061(199902)15:3<219::AID-YEA349>3.3.CO;2-V; Siebel CW, 1996, P NATL ACAD SCI USA, V93, P13641, DOI 10.1073/pnas.93.24.13641; STANLEY JP, 1998, CELL, V92, P315; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; TANI T, 1995, MOL BIOL CELL, V6, P1515, DOI 10.1091/mbc.6.11.1515; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Williams BA, 1996, CURR GENET, V30, P305, DOI 10.1007/s002940050137; WILSON SM, 1994, J CELL BIOL, V127, P1173, DOI 10.1083/jcb.127.5.1173	47	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32793	32799		10.1074/jbc.M004560200	http://dx.doi.org/10.1074/jbc.M004560200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10896665	hybrid			2022-12-25	WOS:000090003800058
J	Keyhani, N; Rodgers, ME; Demeler, B; Hansen, JC; Roseman, S				Keyhani, N; Rodgers, ME; Demeler, B; Hansen, JC; Roseman, S			Analytical sedimentation of the IIA(Chb) and IIBChb proteins of the Escherichia coli N,N '-Diacetylchitobiose phosphotransferase system - Demonstration of a model phosphotransfer transition state complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; PHOSPHOENOL-PYRUVATE; BACTERIA; REVEALS	The phosphoenolpyruvate:glycose transferase system (PTS) is a prototypic signaling system responsible for the vectorial uptake and phosphorylation of carbohydrate substrates, The accompanying papers describe the proteins and product of the Escherichia coli N,N-diacetylchitobiose ((GlcNAc)(2)) PTS-mediated permease. Unlike most PTS transporters, the Chb system is composed of two soluble proteins, IIA(Chb) and IIBChb, and one transmembrane receptor (IICChb), The oligomeric states of PTS permease proteins and phosphoproteins have been difficult to determine. Using analytical ultracentrifugation, both dephospho and phosphorylated IIA(Chb) are shown to exist as stable dimers, whereas IIBChb, phos-pho-IIBChb and the mutant Cys10SerIIB(Chb) are monomers, The mutant protein Cys10SerIIB(Chb) is unable to accept phosphate from phospho-IIA(Chb) but forms a stable higher order complex with phospho-IIA(Chb) (but not with dephospho-IIA(Chb)). The stoichiometry of proteins in the purified complex was determined to be 1:1, indicating that two molecules of Cys10SerIIB(Chb) are associated with one phospho-IIA(Chb) dimer in the complex. The complex appears to be a transition state analogue in the phosphotransfer reaction between the proteins. A model is presented that describes the concerted assembly and disassembly of IIA(Chb)-IIBChb complexes contingent on phosphorylation-dependent conformational changes, especially of IIA(Chb).	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	Johns Hopkins University; Johns Hopkins University; University of Texas System; University of Texas Health San Antonio	Roseman, S (corresponding author), Johns Hopkins Univ, Dept Biol, Mudd Hall,Rm 214,3400 N Charles St, Baltimore, MD 21218 USA.		Keyhani, Nemat O/I-8150-2013	Demeler, Borries/0000-0002-2414-9518	NIGMS NIH HHS [GM38759] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038759, R01GM038759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AB E, 1994, PROTEIN SCI, V3, P282; Chauvin F, 1996, RES MICROBIOL, V147, P471, DOI 10.1016/0923-2508(96)84001-0; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; Demeler B, 1998, BIOPHYS J, V74, P444, DOI 10.1016/S0006-3495(98)77802-6; Demeler B, 1997, BIOPHYS J, V72, P397, DOI 10.1016/S0006-3495(97)78680-6; DEUTSCHER J, 1982, BIOCHEMISTRY-US, V21, P4867, DOI 10.1021/bi00263a006; HAYS JB, 1973, J BIOL CHEM, V248, P941; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Keyhani NO, 2000, J BIOL CHEM, V275, P33102, DOI 10.1074/jbc.M001045200; Keyhani NO, 2000, J BIOL CHEM, V275, P33091, DOI 10.1074/jbc.M001044200; Keyhani NO, 2000, J BIOL CHEM, V275, P33084, DOI 10.1074/jbc.M001043200; Keyhani NO, 2000, J BIOL CHEM, V275, P33068, DOI 10.1074/jbc.M001041200; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; Park JK, 2000, J BIOL CHEM, V275, P33077, DOI 10.1074/jbc.M001042200; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; RALSTON GB, 1993, INTRO ANAL ULTRACENT, P5; Sliz P, 1997, STRUCTURE, V5, P775, DOI 10.1016/S0969-2126(97)00232-3; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; vanMontfort RLM, 1997, STRUCTURE, V5, P217, DOI 10.1016/S0969-2126(97)00180-9	20	12	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33110	33115		10.1074/jbc.M001717200	http://dx.doi.org/10.1074/jbc.M001717200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913122	hybrid			2022-12-25	WOS:000090003800099
J	Oki, M; Nishimoto, T				Oki, M; Nishimoto, T			Yrb1p interaction with the Gsp1p C terminus blocks Mog1p stimulation of GTP release from Gsp1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEAR TRANSPORT; BINDING-PROTEIN; ACTIVATING PROTEIN; RAN-GTPASE; RCC1; RANGAP1; COMPLEX; RAN/TC4; IMPORT	Mog1p, a multicopy suppressor of gsp1, the temperature-sensitive mutant of the Saccharomyces cerevisiae Ran homologue, binds to GTP-Gsp1p but not to GDP-Gsp1p. The function of Mog1p in the Ran cycle is as yet unknown. This study found that Mog1p releases a nucleotide from GTP-Gsp1p but not from GDP-Gsp1p. Yrb1p, the S. cerevisiae homologue of RanBP1, which is a strong inhibitor of RCC1-stimulated nucleotide release, also inhibited the Mog1p-stimulated nucleotide release from GTP-Gsp1p. At a concentration corresponding to the molar concentration of GTP-Gsp1p, Yrb1p completely inhibited the Mog1p-stimulated nucleotide release. Consistently, the Yrb1p.GTP-Gsp1p complex was more stable than the Mog1p.GTP-Gsp1p complex. Yrb1p did not inhibit the Mog1p-stimulated nucleotide release from GTP-Gsp1 DeltaC. The Gsp1 DeltaC protein lacks the final eight amino acids of the C terminus, and for this reason, the interaction between GTP-Gsp1 DeltaC and Yrb1p was strongly reduced. On the other hand, Mog1p binds to GTP-Gsp1 DeltaC more efficiently than to GTP-Gsp1p.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan	Kyushu University	Nishimoto, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan.							BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; END P, 1993, J BIOL CHEM, V268, P10066; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; HAYASHI N, 1995, MOL GEN GENET, V247, P661, DOI 10.1007/BF00290397; Kahana JA, 1999, J CELL BIOL, V146, P1205, DOI 10.1083/jcb.146.6.1205; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Kuhlmann J, 1997, BIOCHEMISTRY-US, V36, P12027, DOI 10.1021/bi970524k; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Nishimoto T, 1999, BIOCHEM BIOPH RES CO, V262, P571, DOI 10.1006/bbrc.1999.1252; NISHIWAKI K, 1987, MOL GEN GENET, V208, P159, DOI 10.1007/BF00330437; Noguchi E, 1996, EMBO J, V15, P5595, DOI 10.1002/j.1460-2075.1996.tb00944.x; Noguchi E, 1999, J BIOCHEM-TOKYO, V125, P574, DOI 10.1093/oxfordjournals.jbchem.a022323; Noguchi E, 1997, MOL CELL BIOL, V17, P2235, DOI 10.1128/MCB.17.4.2235; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Oki M, 1998, P NATL ACAD SCI USA, V95, P15388, DOI 10.1073/pnas.95.26.15388; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; Steggerda SM, 2000, J BIOL CHEM, V275, P23175, DOI 10.1074/jbc.C000252200; Traglia HM, 1996, P NATL ACAD SCI USA, V93, P7667, DOI 10.1073/pnas.93.15.7667; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969	31	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32894	32900		10.1074/jbc.M910251199	http://dx.doi.org/10.1074/jbc.M910251199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10921930	Green Submitted, hybrid			2022-12-25	WOS:000090003800071
J	Windfuhr, M; Manegold, A; Muhlenhoff, M; Eckhardt, M; Gerardy-Schahn, R				Windfuhr, M; Manegold, A; Muhlenhoff, M; Eckhardt, M; Gerardy-Schahn, R			Molecular defects that cause loss of polysialic acid in the complementation group 2A10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; GOLGI VESICLE MEMBRANES; CENTRAL-NERVOUS-SYSTEM; N-CAM; MUTANT DEFICIENT; NCAM-H; EXPRESSION; POLYSIALYLTRANSFERASES; SIALYLTRANSFERASES; IDENTIFICATION	Polysialic acid (PSA) is a dynamically regulated posttranslational modification of the neural cell adhesion molecule (NCAM), which modulates NCAM binding functions. PSA biosynthesis is catalyzed by two polysialyltransferases, ST8SiaII and ST8SiaIV. The catalytic mechanisms of these enzymes are unknown. In. Chinese hamster ovary cells, ST8SiaIV is responsible for PSA expression. In the complementation group 2A10, the ST8SiaIV gene is disrupted. Investigating the molecular defects in this complementation group, seven clones with missense mutations in ST8SiaIV were found. Mutations cause replacement of amino acids that are highly conserved in alpha2,8-sialyltransferases. To verify the physiological relevance of identified mutations, identical amino acid substitutions were introduced into epitope-tagged variants of hamster ST8SiaIV and murine ST8SiaII and recombinant proteins were tested in vivo and in vitro. None of these constructs reconstituted PSA synthesis in 2A10 cells, although the proteins were expressed and with the exception of the cysteine variants ST8SiaIV-C356F and ST8SiaII-C371F correctly targeted to the Golgi apparatus. Interestingly, two mutations (ST8SiaIV-R277G and -M333V and the corresponding mutants ST8SiaII-R292G and -M348V) could be partially rescued if tested in vitro. Although these mutants were negative for autopolysialylation, partial reconstitution of both auto- and NCAM polysialylation was achieved in the presence of NCAM. The data presented in this study suggest a functional link between auto- and NCAM polysialylation.	Hannover Med Sch, Inst Med Mikrobiol, D-30625 Hannover, Germany; Univ Bonn, Inst Physiol Chem, D-53115 Bonn, Germany	Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Bonn	Gerardy-Schahn, R (corresponding author), Hannover Med Sch, Inst Med Mikrobiol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	gerardy@rgs.mikrobio.mh-hannover.de						Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Close BE, 2000, J BIOL CHEM, V275, P4484, DOI 10.1074/jbc.275.6.4484; Close BE, 1998, J BIOL CHEM, V273, P34586, DOI 10.1074/jbc.273.51.34586; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; FigarellaBranger D, 1996, J CLIN ONCOL, V14, P2066, DOI 10.1200/JCO.1996.14.7.2066; FREI T, 1992, J CELL BIOL, V118, P177, DOI 10.1083/jcb.118.1.177; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; GERARDYSCHAHN R, 1995, MOL MICROBIOL, V16, P441, DOI 10.1111/j.1365-2958.1995.tb02409.x; GERARDYSCHAHN R, 1994, INT J CANCER, P27; Geremia RA, 1997, GLYCOBIOLOGY, V7, pR5; Gluer S, 1998, BRIT J CANCER, V78, P106, DOI 10.1038/bjc.1998.450; Goridis C, 1992, Semin Cell Biol, V3, P189; Hildebrandt H, 1998, CANCER RES, V58, P779; Hildebrandt H, 1998, J NEUROCHEM, V71, P2339; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; KIBBELAAR RE, 1989, J PATHOL, V159, P23, DOI 10.1002/path.1711590108; Kiselyov VV, 1997, J BIOL CHEM, V272, P10125; Kiss JZ, 1997, CURR OPIN NEUROBIOL, V7, P640, DOI 10.1016/S0959-4388(97)80083-9; KISS JZ, 1994, EMBO J, V13, P5284, DOI 10.1002/j.1460-2075.1994.tb06862.x; Kojima N, 1997, J BIOCHEM-TOKYO, V122, P1265; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lantuejoul S, 1998, AM J SURG PATHOL, V22, P1267, DOI 10.1097/00000478-199810000-00012; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MOREMEN KW, 1986, J BIOL CHEM, V261, P945; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; Muhlenhoff M, 1998, CURR OPIN STRUC BIOL, V8, P558, DOI 10.1016/S0959-440X(98)80144-9; Muller D, 1996, NEURON, V17, P413, DOI 10.1016/S0896-6273(00)80174-9; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; Redies C, 1996, DEV BIOL, V180, P413, DOI 10.1006/dbio.1996.0315; Ronn LCB, 1998, EXP GERONTOL, V33, P853, DOI 10.1016/S0531-5565(98)00040-0; ROTH J, 1988, AM J PATHOL, V133, P227; Rutishauser U, 1996, CURR OPIN CELL BIOL, V8, P679, DOI 10.1016/S0955-0674(96)80109-8; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKI T, 1993, NEUROSCI RES, V17, P265, DOI 10.1016/0168-0102(93)90111-3; SEKI T, 1993, J NEUROSCI, V13, P2351, DOI 10.1523/JNEUROSCI.13-06-02351.1993; Sevigny MB, 1998, GLYCOBIOLOGY, V8, P857, DOI 10.1093/glycob/8.9.857; TEASDALE RD, 1994, GLYCOBIOLOGY, V4, P917, DOI 10.1093/glycob/4.6.917; Theodosis DT, 1999, J NEUROSCI, V19, P10228; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; Walsh FS, 1996, CURR OPIN CELL BIOL, V8, P707, DOI 10.1016/S0955-0674(96)80113-X; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628	54	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32861	32870		10.1074/jbc.M003507200	http://dx.doi.org/10.1074/jbc.M003507200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10921918	hybrid			2022-12-25	WOS:000090003800067
J	Moaddel, M; Falls, LA; Farrell, DH				Moaddel, M; Falls, LA; Farrell, DH			The role of gamma A/gamma ' fibrinogen in plasma factor XIII activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CHAIN; CROSS-LINKING; SUBUNIT STRUCTURES; HEPARIN-ANTITHROMBIN; THROMBIN; TRANSGLUTAMINASE; RESISTANCE; PLATELETS; SULFATION; FIBRINOLYSIS	Factor XIII zymogen activation is a complex series of events that involve fibrinogen acting in several different roles. This report focuses on the role of fibrinogen as a cofactor in factor MII activation by thrombin. We demonstrate that fibrinogen has two distinct activities that lead to an increased rate of factor XIII activation. First, the thrombin proteolytic activity is increased by fibrin. The cleavage rates of both a small chromogenic substrate and the factor XIII activation peptide are increased in the presence of either the major fibrin isoform, gamma A/gamma A fibrin, or a minor variant form, gamma A/gamma' fibrin. This enhancement of thrombin activity by fibrin is independent of fibrin polymerization and requires only cleavage of the fibrinopeptides. Subsequently, gamma A/gamma' fibrinogen accelerates plasma factor XIII activation by a non-proteolytic mechanism. This increased rate of activation results in a slightly more rapid cross-linking of fibrin gamma A and gamma' chains and a significantly more rapid cross-linking of fibrin alpha chain multimers. Together, these results show that although both forms of fibrin increase the rate of activation peptide cleavage by thrombin, gamma A/gamma' fibrinogen also increases the rate of factor XIII activation in a non-proteolytic manner. A revised model of factor XIII activation is presented below.	Oregon Hlth Sci Univ, Sch Dent, Dept Oral Mol Biol, Portland, OR 97201 USA; Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Oregon Health & Science University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Farrell, DH (corresponding author), Oregon Hlth Sci Univ, Sch Dent, Dept Oral Mol Biol, Portland, OR 97201 USA.				NHLBI NIH HHS [R29HL53997, K02HL04215] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL053997, K02HL004215] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOHN H, 1972, ANN NY ACAD SCI, V202, P256, DOI 10.1111/j.1749-6632.1972.tb16339.x; CARRELL NA, 1989, J BIOL CHEM, V264, P551; CHUNG DW, 1984, BIOCHEMISTRY-US, V23, P4232, DOI 10.1021/bi00313a033; CHUNG SI, 1972, ANN NY ACAD SCI, V202, P240, DOI 10.1111/j.1749-6632.1972.tb16338.x; CHUNG SI, 1974, J BIOL CHEM, V249, P940; CREDO RB, 1978, P NATL ACAD SCI USA, V75, P4234, DOI 10.1073/pnas.75.9.4234; Falls LA, 1997, J BIOL CHEM, V272, P14251, DOI 10.1074/jbc.272.22.14251; FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004; FARRELL DH, 1994, J BIOL CHEM, V269, P226; FINLAYSON JS, 1963, BIOCHEMISTRY-US, V2, P42, DOI 10.1021/bi00901a010; FORNACE AJ, 1984, J BIOL CHEM, V259, P2826; FRANCIS CW, 1980, J BIOL CHEM, V255, P5599; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HIROSE S, 1988, J BIOL CHEM, V263, P7426; HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619; HORNYAK TJ, 1992, BIOCHEMISTRY-US, V31, P423, DOI 10.1021/bi00117a017; HORTIN GL, 1989, BIOCHEM INT, V19, P1355; IKEMATSU S, 1981, J LAB CLIN MED, V97, P662; JANUS TJ, 1983, BIOCHEMISTRY-US, V22, P6269, DOI 10.1021/bi00295a035; KUNICKI TJ, 1985, BLOOD, V66, P808; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKI K, 1948, SCIENCE, V108, P280, DOI 10.1126/science.108.2802.280; Lewis KB, 1997, BIOCHEMISTRY-US, V36, P995, DOI 10.1021/bi961636z; LEWIS SD, 1985, BIOCHEMISTRY-US, V24, P6772, DOI 10.1021/bi00345a007; LOEWY AG, 1961, J BIOL CHEM, V236, P2634; LORAND L, 1993, METHOD ENZYMOL, V222, P22; Lorand L, 1998, P NATL ACAD SCI USA, V95, P537, DOI 10.1073/pnas.95.2.537; LORAND L, 1962, NATURE, V195, P911, DOI 10.1038/195911b0; Meh DA, 1996, J BIOL CHEM, V271, P23121, DOI 10.1074/jbc.271.38.23121; RADEK JT, 1993, BIOCHEMISTRY-US, V32, P3527, DOI 10.1021/bi00065a002; REED GL, 1992, THROMB HAEMOSTASIS, V68, P315; SCHWARTZ ML, 1971, J BIOL CHEM, V246, P5851; SCHWARTZ ML, 1971, J CLIN INVEST, V50, P1506, DOI 10.1172/JCI106636; SCHWARTZ ML, 1973, J BIOL CHEM, V248, P1395; SHAINOFF JR, 1962, J EXP MED, V116, P687, DOI 10.1084/jem.116.5.687; SIEBENLIST KR, 1994, J BIOL CHEM, V269, P28414; Siebenlist KR, 1996, BIOCHEMISTRY-US, V35, P10448, DOI 10.1021/bi9606206; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; WOLFENSTEINTODEL C, 1980, P NATL ACAD SCI-BIOL, V77, P5069, DOI 10.1073/pnas.77.9.5069; YEE VC, 1995, THROMB RES, V78, P389, DOI 10.1016/0049-3848(95)00072-Y	41	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32135	32140		10.1074/jbc.M000496200	http://dx.doi.org/10.1074/jbc.M000496200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913112	hybrid			2022-12-25	WOS:000089858900080
J	Taylor, WP; Sheflyan, GY; Woodard, RW				Taylor, WP; Sheflyan, GY; Woodard, RW			A single point mutation in 3-deoxy-D-manno-octulosonate-8-phosphate synthase is responsible for temperature sensitivity in a mutant strain of Salmonella typhimurium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID 8-PHOSPHATE SYNTHASE; PUTATIVE REACTION INTERMEDIATE; ESCHERICHIA-COLI; LIPID-A; 3-DEOXY-D-MANNO-2-OCTULOSONATE-8-PHOSPHATE SYNTHASE; BIOCHEMICAL-CHARACTERIZATION; CATALYTIC MECHANISM; KDO8P SYNTHASE; RNA-POLYMERASE; LETHAL MUTANT	Salmonella typhimurium mutants conditionally deficient in 3-deoxy-D-manno-octulosonate-8-phosphate (KDO8P) synthase activity play a central role in our understanding of lipopolysaccharide function in enteric bacteria. The detailed characterization of KDO8P synthase from such a mutant, however, has not been previously reported. To address this issue KDO8P synthase from S. typhimurium AG701 and from a related temperature-sensitive strain (S. typhimurium AG701i50) have been overexpressed in Escherichia coli and purified to homogeneity. The enzyme from the temperature-sensitive strain has a single proline to serine substitution at position 145, leading to an increase in K-m for both substrates, D-arabinose B-phosphate and phosphoenolpyruvate, Analytical gel filtration and native polyacrylamide gel electrophoresis indicate that this enzyme also has an altered oligomeric state. These observations are rationalized through an examination of the structure of E. coli KDO8P synthase, which has 93% sequence identity to the enzyme from S. typhimurium.	Univ Michigan, Coll Pharm, Interdept Program Med Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Woodard, RW (corresponding author), Univ Michigan, Coll Pharm, Interdept Program Med Chem, 428 Church St, Ann Arbor, MI 48109 USA.			Woodard, Ronald/0000-0002-7472-3653	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053069] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53069] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAASOV T, 1993, EUR J BIOCHEM, V217, P991, DOI 10.1111/j.1432-1033.1993.tb18330.x; Brabetz W, 1997, EUR J BIOCHEM, V244, P66, DOI 10.1111/j.1432-1033.1997.00066.x; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; DOONG RL, 1991, PLANT CELL ENVIRON, V14, P113, DOI 10.1111/j.1365-3040.1991.tb01377.x; DOTSON GD, 1995, J BIOL CHEM, V270, P13698, DOI 10.1074/jbc.270.23.13698; DOTSON GD, 1993, BIOCHEMISTRY-US, V32, P12392, DOI 10.1021/bi00097a017; DSouza FW, 1997, BIOORG MED CHEM LETT, V7, P2457, DOI 10.1016/S0960-894X(97)10019-1; Duewel HS, 1999, BIOCHEM BIOPH RES CO, V263, P346, DOI 10.1006/bbrc.1999.1361; DUGGLEBY RG, 1995, METHOD ENZYMOL, V249, P61; GHALAMBOR MA, 1966, J BIOL CHEM, V241, P3216; HANSENHAGGE T, 1985, EUR J BIOCHEM, V148, P21, DOI 10.1111/j.1432-1033.1985.tb08801.x; HEDSTROM L, 1988, BIOCHEM BIOPH RES CO, V157, P816, DOI 10.1016/S0006-291X(88)80322-X; KOHEN A, 1993, BIOORG MED CHEM LETT, V3, P1577, DOI 10.1016/S0960-894X(00)80021-9; LEVIN DH, 1959, J BIOL CHEM, V234, P2532; Radaev S, 2000, J BIOL CHEM, V275, P9476, DOI 10.1074/jbc.275.13.9476; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RICK PD, 1982, J BACTERIOL, V150, P447, DOI 10.1128/JB.150.2.447-455.1982; RICK PD, 1977, J BIOL CHEM, V252, P4895; RICK PD, 1972, P NATL ACAD SCI USA, V69, P3756, DOI 10.1073/pnas.69.12.3756; RIETSCHEL ET, 1987, SURFACE STRUCTURES M, P1; Sheflyan GY, 1999, BIOCHEMISTRY-US, V38, P14320, DOI 10.1021/bi9829884; Sheflyan GY, 1998, J AM CHEM SOC, V120, P11027, DOI 10.1021/ja9816281; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VOLK WA, 1960, BIOCHIM BIOPHYS ACTA, V37, P365, DOI 10.1016/0006-3002(60)90253-5; Walsh AG, 1999, FEMS MICROBIOL LETT, V173, P27, DOI 10.1111/j.1574-6968.1999.tb13480.x; WOISETSCHLAGER M, 1986, J BACTERIOL, V168, P437, DOI 10.1128/jb.168.1.437-439.1986	29	9	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32141	32146		10.1074/jbc.M001900200	http://dx.doi.org/10.1074/jbc.M001900200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913123	hybrid			2022-12-25	WOS:000089858900081
J	Wright, SK; Kish, MM; Viola, RE				Wright, SK; Kish, MM; Viola, RE			From malate dehydrogenase to phenyllactate dehydrogenase - Incorporation of unnatural amino acids to generate an improved enzyme-catalyzed activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTATE-DEHYDROGENASE; ESCHERICHIA-COLI; ASPARTATE-AMINOTRANSFERASE; SUBSTRATE-SPECIFICITY; QUANTITATION; SUBSTITUTION; RESOLUTION; FRAMEWORK; EVOLUTION; RESIDUES	Malate dehydrogenase (MDH) from Escherichia coli is highly specific for its keto acid substrate. The placement of the active site-binding groups in MDH effectively discriminates against both the shorter and the longer keto dicarboxylic acids that could potentially serve as alternative substrates. A notable exception to this specificity is the alternative substrate phenylpyruvate. This aromatic keto acid can be reduced by MDH, albeit at a somewhat slower rate and with greatly diminished affinity, despite the presence of several substrate-binding arginyl residues and the absence of a hydrophobic pocket in the active site, The specificity of MDH for phenylpyruvate has now been enhanced, and that for the physiological substrate oxaloacetate has been diminished, through the replacement of one of the binding arginyl residues with several unnatural alkyl and aryl amino acid analogs. This approach, called site-specific modulation, incorporates systematic structural variations at a site of interest. Molecular modeling studies have suggested a structural basis for the affinity of native MDH for phenylpyruvate and a rationale for the improved catalytic activity that is observed with these new, modified phenyllactate dehydrogenases.	Univ Akron, Dept Chem, Akron, OH 44325 USA	University System of Ohio; University of Akron	Viola, RE (corresponding author), Univ Toledo, Dept Chem, 2801 W Bancroft St, Toledo, OH 43606 USA.		Viola, Ronald/C-5904-2011					BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE AR, 1989, TRENDS BIOCHEM SCI, V14, P145, DOI 10.1016/0968-0004(89)90147-3; CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1; DHALLA AM, 1994, PROTEIN SCI, V3, P476; ElHawrani AS, 1996, J MOL BIOL, V264, P97, DOI 10.1006/jmbi.1996.0626; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GOWARD CR, 1994, PROTEIN SCI, V3, P1883, DOI 10.1002/pro.5560031027; GRAU UM, 1981, J MOL BIOL, V151, P289, DOI 10.1016/0022-2836(81)90516-7; HALL MD, 1991, J MOL BIOL, V220, P551, DOI 10.1016/0022-2836(91)90099-R; HALL MD, 1992, J MOL BIOL, V226, P867, DOI 10.1016/0022-2836(92)90637-Y; JONES DH, 1993, PCR PROTOCOLS CURREN, P269; NICHOLLS DJ, 1994, J PROTEIN CHEM, V13, P129, DOI 10.1007/BF01892000; NICHOLLS DJ, 1992, BIOCHEM BIOPH RES CO, V189, P1057, DOI 10.1016/0006-291X(92)92311-K; PLANAS A, 1991, BIOCHEMISTRY-US, V30, P8268, DOI 10.1021/bi00247a023; Schindler JF, 1996, J PROTEIN CHEM, V15, P737, DOI 10.1007/BF01887147; SMITH HB, 1988, J BIOL CHEM, V263, P4921; TARRAGONAFIOL A, 1993, PROTEIN ENG, V6, P901, DOI 10.1093/protein/6.8.901; WILKS HM, 1992, BIOCHEMISTRY-US, V31, P7802, DOI 10.1021/bi00149a009; Wright SK, 1998, ANAL BIOCHEM, V265, P8, DOI 10.1006/abio.1998.2858; WRIGHT SK, 1995, ARCH BIOCHEM BIOPHYS, V321, P289, DOI 10.1006/abbi.1995.1397; YOSHIMURA T, 1990, J BIOCHEM-TOKYO, V108, P699, DOI 10.1093/oxfordjournals.jbchem.a123266	21	9	9	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31689	31694		10.1074/jbc.M003652200	http://dx.doi.org/10.1074/jbc.M003652200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10915786	hybrid			2022-12-25	WOS:000089858900022
J	Arispe, N; De Maio, A				Arispe, N; De Maio, A			ATP and ADP modulate a cation channel formed by Hsc70 in acidic phospholipid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; SUBSTRATE-BINDING; CALCIUM CHANNELS; HSP70; POTASSIUM; DOMAIN; CELLS; BIP	Heat shock proteins are molecular chaperones that participate in different cellular processes, particularly the folding and translocation of polypeptides across membranes. In this regard, members of the Hsp70 family of heat shock proteins have been observed in close proximity to cellular membranes, In this study, the direct interaction between Hsc70, which is constitutively expressed in cells, and lipid membranes was investigated. Recombinant Hsc70 was incorporated into artificial lipid bilayers, and a transmembrane ion flow was detected, suggesting the incorporation of an ion pathway. This ion flow was very stable and occurred in well defined, multilevel discrete electrical current events, indicating the formation of a multiconductance ion channel, The Hsc70 channel activity is ATP-dependent and is reversibly blocked by ADP. This channel has cationic selectivity, Thus, Hsc70 can directly interact with lipid membranes to create functionally stable ATP-dependent cationic pathways.	Uniformed Serv Univ Hlth Sci, Dept Anat & Cell Biol, Bethesda, MD 20814 USA; Johns Hopkins Univ, Sch Med, Div Pediat Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Uniformed Services University of the Health Sciences - USA; Johns Hopkins University; Johns Hopkins University	Arispe, N (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat & Cell Biol, Bethesda, MD 20814 USA.	narispe@usuhs.mil			NIGMS NIH HHS [GM-50878] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDER GM, 1990, BIOSCIENCE REP, V10, P509, DOI 10.1007/BF01116611; Arispe N, 1996, BIOPHYS J, V71, P1764, DOI 10.1016/S0006-3495(96)79377-3; Arispe N, 2000, BIOPHYS J, V78, p36A; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; De Maio A, 1999, SHOCK, V11, P1, DOI 10.1097/00024382-199901000-00001; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; Gao BC, 1996, J BIOL CHEM, V271, P16792, DOI 10.1074/jbc.271.28.16792; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; Kurucz I, 1999, CELL STRESS CHAPERON, V4, P139; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Mirzabekov TA, 1996, J BIOL CHEM, V271, P1988, DOI 10.1074/jbc.271.4.1988; MORIMOTO RI, 1991, CANCER CELL-MON REV, V3, P295; Morshauser RC, 1999, J MOL BIOL, V289, P1387, DOI 10.1006/jmbi.1999.2776; MULTHOFF G, 1995, INT J CANCER, V61, P272, DOI 10.1002/ijc.2910610222; Negulyaev YA, 1996, BBA-BIOMEMBRANES, V1282, P156, DOI 10.1016/0005-2736(96)00055-7; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; POLLARD JR, 1994, BIOPHYS J, V67, P647, DOI 10.1016/S0006-3495(94)80525-9; ROJAS E, 1992, BONE MINER, V17, P214, DOI 10.1016/0169-6009(92)90739-Z; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; WELCH WJ, 1985, J CELL BIOL, V101, P1198, DOI 10.1083/jcb.101.4.1198; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	25	93	96	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30839	30843		10.1074/jbc.M005226200	http://dx.doi.org/10.1074/jbc.M005226200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10899168	hybrid			2022-12-25	WOS:000089762700017
J	Dey, R; Barrientos, A; Moraes, CT				Dey, R; Barrientos, A; Moraes, CT			Functional constraints of nuclear-mitochondrial DNA interactions in xenomitochondrial rodent cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS; RAPID EVOLUTION; SKELETAL-MUSCLE; MAMMALIAN-CELLS; SOMATIC-CELLS; HYBRID-CELLS; SEQUENCE; MUTATION; VERTEBRATES; EXPRESSION	The co-evolution of nuclear and mitochondrial genomes in vertebrates led to more than 100 specific interactions that are crucial for an optimized ATP generation. These interactions have been examined by introducing rat mtDNA into mouse cells devoid of mito chondrial DNA (mtDNA). When mtDNA-less cells derived from the common mouse (Mus musculus domesticus) were fused to cytoplasts prepared from Mus musculus, Mus spretus, or rat (Rattus norvegicus), a comparable number of respiring clones could be obtained. Mouse xenomitochondrial cybrids harboring rat mtDNA had a slower growth rate in medium containing galactose as the carbon source, suggesting a defect in oxidative phosphorylation. These clones respired approximately 50% less than the parental mouse cells or xenomitochondrial cybrids harboring Mus spretus mtDNA. The activities of respiratory complexes I and IV were approximately 50% lower, but mitochondrial protein synthesis was unaffected. The defects in complexes I and IV were associated with decreased steady-state levels of respective subunits suggesting problems in assembly. We also showed that the presence of 10% mouse mtDNA co-existing with rat mtDNA was sufficient to restore respiration to normal levels, Our results suggest that evolutionary distance alone is not a precise predictor of nuclear-mitochondrial interactions as previously suggested for primates.	Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA	University of Miami; University of Miami	Moraes, CT (corresponding author), Univ Miami, Sch Med, Dept Neurol, 1501 NW 9th Ave, Miami, FL 33136 USA.	cmoraes@med.miami.edu	Moraes, Carlos/AAT-3818-2021		NIGMS NIH HHS [GM55766] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI J, 1993, J MOL EVOL, V36, P270, DOI 10.1007/BF00160483; Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; ATTARDI B, 1972, P NATL ACAD SCI USA, V69, P129, DOI 10.1073/pnas.69.1.129; Barrientos A, 1998, J BIOL CHEM, V273, P14210, DOI 10.1074/jbc.273.23.14210; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BOULET L, 1992, AM J HUM GENET, V51, P1187; BROWN WM, 1980, P NATL ACAD SCI-BIOL, V77, P3605, DOI 10.1073/pnas.77.6.3605; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; Burton RS, 1999, AM ZOOL, V39, P451; CATZEFLIS FM, 1992, TRENDS ECOL EVOL, V7, P122, DOI 10.1016/0169-5347(92)90146-3; CHALINE J, 1994, TRANSPLANT INT, V7, P216; Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; CLARK MA, 1982, NATURE, V295, P605, DOI 10.1038/295605a0; CLAYTON DA, 1971, NATURE, V234, P560, DOI 10.1038/234560a0; DAWID IB, 1974, GENETICS, V78, P459; DEFRANCESCO L, 1980, P NATL ACAD SCI-BIOL, V77, P4079, DOI 10.1073/pnas.77.7.4079; Dey R, 2000, J BIOL CHEM, V275, P7087, DOI 10.1074/jbc.275.10.7087; DiMauro S, 1999, J CHILD NEUROL, V14, pS23, DOI 10.1177/0883073899014001051; DITTA G, 1976, SOMAT CELL GENET, V2, P331, DOI 10.1007/BF01538838; Flynn L. J., 1985, EVOLUTIONARY RELATIO, P589; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; GILES RE, 1980, SOMAT CELL GENET, V6, P543, DOI 10.1007/BF01539155; GRAVES JAM, 1984, CAN J GENET CYTOL, V26, P557; HAYASHI JI, 1982, EXP CELL RES, V138, P261, DOI 10.1016/0014-4827(82)90175-6; HAYASHI JI, 1986, CANCER RES, V46, P4001; HAYASHI JI, 1983, EXP CELL RES, V148, P258, DOI 10.1016/0014-4827(83)90206-9; HAYASHI JI, 1989, CANCER RES, V49, P4715; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1985, EXP CELL RES, V160, P387, DOI 10.1016/0014-4827(85)90185-5; HOLMES EC, 1991, J MOL EVOL, V33, P209, DOI 10.1007/BF02100671; Inoue K, 1997, BIOCHEM BIOPH RES CO, V239, P257, DOI 10.1006/bbrc.1997.7446; IWAKURA Y, 1985, CELL, V43, P777, DOI 10.1016/0092-8674(85)90251-X; JUKES TH, 1995, J MOL EVOL, V40, P537, DOI 10.1007/BF00166622; Kenyon L, 1997, P NATL ACAD SCI USA, V94, P9131, DOI 10.1073/pnas.94.17.9131; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Lanza RP, 1999, NAT MED, V5, P975, DOI 10.1038/12404; Manfred G, 1999, J BIOL CHEM, V274, P9386, DOI 10.1074/jbc.274.14.9386; MORAES CT, 1992, AM J HUM GENET, V50, P934; Moraes CT, 1999, MOL BIOL CELL, V10, P3345, DOI 10.1091/mbc.10.10.3345; MORAIS R, 1980, BIOCHEM BIOPH RES CO, V94, P71, DOI 10.1016/S0006-291X(80)80189-6; Robinson B H, 1996, Methods Enzymol, V264, P454, DOI 10.1016/S0076-6879(96)64041-5; ROSAMOND J, 1982, BIOCHEM J, V202, P1; SHAY JW, 1990, ANTICANCER RES, V10, P279; SHE JX, 1990, BIOL J LINN SOC, V41, P83, DOI 10.1111/j.1095-8312.1990.tb00823.x; SIBLEY CG, 1987, J MOL EVOL, V26, P99, DOI 10.1007/BF02111285; SOLUS JF, 1984, EXP CELL RES, V151, P299, DOI 10.1016/0014-4827(84)90380-X; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Thyagarajan B, 1996, J BIOL CHEM, V271, P27536, DOI 10.1074/jbc.271.44.27536; TONSGARD JH, 1990, BIOCHEM J, V270, P511, DOI 10.1042/bj2700511; Trounce I, 1996, SOMAT CELL MOLEC GEN, V22, P81, DOI 10.1007/BF02374379; Trounce I, 1999, AM J HUM GENET, V65, pA431; WEIDE LG, 1982, SOMAT CELL GENET, V8, P15, DOI 10.1007/BF01538647; ZIEGLER ML, 1981, SOMAT CELL GENET, V7, P73, DOI 10.1007/BF01544749; ZUCKERMAN SH, 1986, SOMAT CELL MOLEC GEN, V12, P449, DOI 10.1007/BF01539916	55	87	88	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31520	31527		10.1074/jbc.M004053200	http://dx.doi.org/10.1074/jbc.M004053200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10908562	hybrid			2022-12-25	WOS:000089762700107
J	Drori, S; Jansen, G; Mauritz, R; Peters, GJ; Assaraf, YG				Drori, S; Jansen, G; Mauritz, R; Peters, GJ; Assaraf, YG			Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; THYMIDYLATE SYNTHASE INHIBITORS; METHOTREXATE TRANSPORT; MAMMALIAN-CELLS; L1210 CELLS; FOLIC-ACID; MEMBRANE-TRANSPORT; TUMOR-CELLS; LOW PH; RESISTANCE	We have studied the molecular basis for the resistance of human CEM leukemia cells to GW1843, a thymidylate synthase inhibitor. GW1843-resistant cells displayed a similar to 100-fold resistance to GW1843 and methotrexate but were collaterally sensitive to the lipophilic antifolates trimetrexate and AG337, which enter cells by diffusion. These cells exhibited a 12-fold decreased methotrexate influx but surprisingly had a a-fold decreased folic acid growth requirement. This was associated with a I-fold increased influx of folic acid, a 3.5-fold increased steady-state level of folic acid, and a 2.3-fold expansion of the cellular folate pool. Characterization of the transport kinetic properties revealed that GW1843 resistant cells had the following alterations: (a) 11-fold decreased transport K-m for folic acid; (b) 6-fold increased transport K-m for GW1843; and (c) a slightly increased transport V-max for folic acid. Sequence analysis showed that GW1843-resistant cells contained the mutations Val-29 --> Leu, Glu-45 --> Lys, and Ser-46 --> Ile in the first transmembrane domain of the reduced folate carrier, Transfection of the mutant-reduced folate carrier cDNA into methotrexate transport null cells conferred resistance to GW1843, This is the first demonstration of multiple mutations in a confined region of the human reduced folate carrier in an antifolate-resistant mutant. We conclude that certain amino acid residues in the first transmembrane domain play a key role in (anti)folate binding and in the conferring of drug resistance.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Free Univ Amsterdam Hosp, Dept Oncol, NL-1081 HV Amsterdam, Netherlands	Technion Israel Institute of Technology; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Assaraf, YG (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	assaraf@tx.technion.ac.il	; Peters, Godefridus J/C-7562-2013	Jansen, Gerrit/0000-0001-8190-8368; Peters, Godefridus J/0000-0002-5447-2877				ANTONY AC, 1992, BLOOD, V79, P2807; ASSARAF YG, 1987, P NATL ACAD SCI USA, V84, P7154, DOI 10.1073/pnas.84.20.7154; Assaraf YG, 1998, J BIOL CHEM, V273, P8106, DOI 10.1074/jbc.273.14.8106; Assaraf YG, 1997, J BIOL CHEM, V272, P17460, DOI 10.1074/jbc.272.28.17460; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; Boritzki TJ, 1996, INVEST NEW DRUG, V14, P295, DOI 10.1007/BF00194533; BRIGLE KE, 1994, BIOCHEM PHARMACOL, V47, P337, DOI 10.1016/0006-2952(94)90025-6; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; Cocconi G, 1998, J CLIN ONCOL, V16, P2943, DOI 10.1200/JCO.1998.16.9.2943; DIXON KH, 1994, J BIOL CHEM, V269, P17; DRORI S, 2000, EUR J BIOCHEM, V267, P1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Ferguson PL, 1999, J BIOL CHEM, V274, P16269, DOI 10.1074/jbc.274.23.16269; FLINTOFF WF, 1983, ARCH BIOCHEM BIOPHYS, V223, P433, DOI 10.1016/0003-9861(83)90607-0; FREISHEIM JH, 1992, ADV ENZYME REGUL, V32, P17; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400; Gong MK, 1997, BLOOD, V89, P2494, DOI 10.1182/blood.V89.7.2494; Hanlon MH, 1996, CANCER RES, V56, P3301; HENDERSON GB, 1981, BIOCHEM BIOPH RES CO, V99, P163, DOI 10.1016/0006-291X(81)91727-7; HENDERSON GB, 1990, CANCER RES, V50, P1709; Jackman AL, 1995, ANN ONCOL, V6, P871, DOI 10.1093/oxfordjournals.annonc.a059353; JANSEN G, 1989, CANCER RES, V49, P1959; Jansen G, 1999, CANC DRUG DISC DEV, P293; Jansen G, 1998, J BIOL CHEM, V273, P30189, DOI 10.1074/jbc.273.46.30189; Jansen G, 1999, MOL PHARMACOL, V55, P761; Kumar CK, 1997, J BIOL CHEM, V272, P6226, DOI 10.1074/jbc.272.10.6226; LIN JT, 1991, CANCER INVEST, V9, P159, DOI 10.3109/07357909109044227; MATHERLY LH, 1992, J BIOL CHEM, V267, P23253; MAURITZ R, 1999, P AM ASSOC CANC RES, P1936; MINI E, 1985, CANCER RES, V45, P325; MOSCOW JA, 1995, CANCER RES, V55, P3790; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; RHEE MS, 1994, MOL PHARMACOL, V45, P783; ROSOWSKY A, 1980, BIOCHEM PHARMACOL, V29, P648, DOI 10.1016/0006-2952(80)90391-3; Rustum YM, 1997, J CLIN ONCOL, V15, P389, DOI 10.1200/JCO.1997.15.1.389; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; SCHUETZ JD, 1989, J BIOL CHEM, V264, P16261; Shih C, 1997, CANCER RES, V57, P1116; Sierra EE, 1997, BIOCHEM PHARMACOL, V53, P223, DOI 10.1016/S0006-2952(96)00730-7; SIROTNAK FM, 1981, CANCER RES, V41, P4447; SIROTNAK FM, 1985, CANCER RES, V45, P3992; SIROTNAK FM, 1987, NCI MONOGRAPHS, V5, P27; Stokstad ELR, 1990, FOLIC ACID METABOLIS, P1; Tse A, 1998, J BIOL CHEM, V273, P25953, DOI 10.1074/jbc.273.40.25953; Tse A, 1998, J BIOL CHEM, V273, P25944, DOI 10.1074/jbc.273.40.25944; WANG X, 1992, BIOCHEM PHARMACOL, V44, P1898; WESTERHOF GR, 1995, MOL PHARMACOL, V48, P459; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; Zhao R, 1998, J BIOL CHEM, V273, P19065, DOI 10.1074/jbc.273.30.19065; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873; Zhao RB, 1999, MOL PHARMACOL, V56, P68, DOI 10.1124/mol.56.1.68	55	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30855	30863		10.1074/jbc.M003988200	http://dx.doi.org/10.1074/jbc.M003988200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10899164	hybrid			2022-12-25	WOS:000089762700020
J	He, YC; Crouch, EC; Rust, K; Spaite, E; Brody, SL				He, YC; Crouch, EC; Rust, K; Spaite, E; Brody, SL			Proximal promoter of the surfactant protein D gene - Regulatory roles of AP-1, forkhead box, and GT box binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION-FACTOR-I; SP-A GENE; CELL-SPECIFIC EXPRESSION; COLLAGEN-LIKE DOMAIN; DNA-BINDING; B GENE; 5'-FLANKING REGION; MAMMALIAN LECTIN; LUNG; FAMILY	Surfactant protein D (SP-D) plays roles in pulmonary host defense and surfactant homeostasis and is increased following lung injury, Because AP-1 proteins regulate cellular responses to diverse environmental stimuli, we hypothesized that the conserved AP-1 motif (at -109) and flanking sequences in the human SP-D promoter contribute to the regulation of SP-D expression. The AP-1 sequence specifically bound to fra-1, junD, and junB in H441 lung adenocarcinoma nuclear extracts. Mutagenesis of the AP-1 motif in a chloramphenicol acetyltransferase reporter construct containing 285 base pairs of upstream sequence nearly abolished promoter activity, and co-transfection of junD significantly increased wild type but not mutant pro meter activity. The sequence immediately downstream of the AP-1 element contained a binding site for HNF-5 (FOXA), and simultaneous mutation of this site (fox-d) and an upstream FoxA binding site (-277, fox-u) caused a 4-fold reduction in chloramphenicol acetyltransferase activity. Immediately upstream of the AP-l-binding site, we identified a GT box-containing positive regulatory element, Despite finding regions of limited homology to the thyroid transcription factor 1-binding site, SP-D promoter activity did not require thyroid transcription factor 1, Thus, transcriptional regulation of SP-D gene expression involves complex interactions with ubiquitous and lineage dependent factors consistent with more generalized roles in innate immunity.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Crouch, EC (corresponding author), Barnes Jewish Hosp N, Dept Pathol & Immunol, Surg Pathol Mailstop 90-31-649,216 S Kingshighway, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044015, P01HL029594, R01HL056244, R29HL056244] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-56244, HL-44015, HL-29594] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BINGLE CD, 1995, BIOCHEM J, V308, P197, DOI 10.1042/bj3080197; BINGLE CD, 1993, BIOCHEM J, V295, P227, DOI 10.1042/bj2950227; BOHINSKI RJ, 1993, J BIOL CHEM, V268, P11160; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; Braun H, 1998, J BIOL CHEM, V273, P9821, DOI 10.1074/jbc.273.16.9821; Bravieri R, 1997, NUCLEIC ACIDS RES, V25, P2888, DOI 10.1093/nar/25.14.2888; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; Crowe AJ, 1999, J BIOL CHEM, V274, P25113, DOI 10.1074/jbc.274.35.25113; Dulkerian SJ, 1996, AM J RESP CELL MOL, V15, P781, DOI 10.1165/ajrcmb.15.6.8969273; Eggleton P, 1999, CURR OPIN IMMUNOL, V11, P28, DOI 10.1016/S0952-7915(99)80006-5; GAO E, 1993, J BIOL CHEM, V268, P19697; Gao EW, 1997, J BIOL CHEM, V272, P23398, DOI 10.1074/jbc.272.37.23398; Gotoh T, 1997, J BIOL CHEM, V272, P3694, DOI 10.1074/jbc.272.6.3694; Goytisolo FA, 1996, EMBO J, V15, P3421, DOI 10.1002/j.1460-2075.1996.tb00708.x; GREGORI C, 1994, NUCLEIC ACIDS RES, V22, P1242, DOI 10.1093/nar/22.7.1242; Hackett BP, 1996, ANNU REV PHYSIOL, V58, P51, DOI 10.1146/annurev.physiol.58.1.51; HROMAS R, 1995, CRIT REV ONCOL HEMAT, V20, P129, DOI 10.1016/1040-8428(94)00151-I; KAWASAKI N, 1994, BIOCHEM BIOPH RES CO, V198, P597, DOI 10.1006/bbrc.1994.1087; Kawasaki N, 1998, J BIOCHEM, V124, P1188, DOI 10.1093/oxfordjournals.jbchem.a022237; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; KLAMPFER L, 1994, MOL CELL BIOL, V14, P6561, DOI 10.1128/MCB.14.10.6561; Korfhagen TR, 1998, BBA-MOL BASIS DIS, V1408, P296, DOI 10.1016/S0925-4439(98)00075-1; Korfhagen TR, 1998, J BIOL CHEM, V273, P28438, DOI 10.1074/jbc.273.43.28438; Kumar AS, 1997, J BIOL CHEM, V272, P20764, DOI 10.1074/jbc.272.33.20764; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lawson PR, 1999, AM J RESP CELL MOL, V20, P953, DOI 10.1165/ajrcmb.20.5.3343; LIOU LS, 1994, J IMMUNOL, V153, P173; Madsen J, 2000, J IMMUNOL, V164, P5866, DOI 10.4049/jimmunol.164.11.5866; Magdaleno SM, 1997, AM J PHYSIOL-LUNG C, V272, pL1142, DOI 10.1152/ajplung.1997.272.6.L1142; Martin ML, 1996, MOL CELL BIOL, V16, P2110; McIntosh JC, 1996, AM J RESP CELL MOL, V15, P509, DOI 10.1165/ajrcmb.15.4.8879185; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; McWhinney CD, 1996, DNA CELL BIOL, V15, P519, DOI 10.1089/dna.1996.15.519; Miura N, 1998, GENOMICS, V50, P346, DOI 10.1006/geno.1998.5288; Noti JD, 1996, MOL CELL BIOL, V16, P2940; Perl AKT, 1999, CLIN GENET, V56, P14, DOI 10.1034/j.1399-0004.1999.560103.x; PERSSON A, 1996, AM J RESPIR CELL MOL, V153, P109; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; QIAN XB, 1995, MOL CELL BIOL, V15, P1364; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; Rust K, 1996, AM J RESP CELL MOL, V14, P121, DOI 10.1165/ajrcmb.14.2.8630261; RYSECK RP, 1991, ONCOGENE, V6, P533; SAWAYA PL, 1993, MOL CELL BIOL, V13, P3860, DOI 10.1128/MCB.13.7.3860; SAWAYA PL, 1994, J BIOL CHEM, V269, P22211; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sever-Chroneos Z, 1999, AM J PHYSIOL-LUNG C, V277, pL79, DOI 10.1152/ajplung.1999.277.1.L79; Shaw-White JR, 1999, J BIOL CHEM, V274, P2658, DOI 10.1074/jbc.274.5.2658; Toonen RFG, 1996, BIOCHEM J, V316, P467, DOI 10.1042/bj3160467; Wani MA, 1999, GENOMICS, V60, P78, DOI 10.1006/geno.1999.5888; Whitsett JA, 1998, BBA-MOL BASIS DIS, V1408, P303, DOI 10.1016/S0925-4439(98)00076-3; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Young PP, 1997, MOL ENDOCRINOL, V11, P1082, DOI 10.1210/me.11.8.1082; Zhang LQ, 1997, BBA-GENE STRUCT EXPR, V1350, P359, DOI 10.1016/S0167-4781(96)00180-7	57	48	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31051	31060		10.1074/jbc.M003499200	http://dx.doi.org/10.1074/jbc.M003499200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10915785	hybrid			2022-12-25	WOS:000089762700045
J	Hoggatt, AM; Kriegel, AM; Smith, AF; Herring, BP				Hoggatt, AM; Kriegel, AM; Smith, AF; Herring, BP			Hepatocyte nuclear factor-3 homologue 1 (HFH-1) represses transcription of smooth muscle-specific genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; ALPHA-ACTIN GENE; HEAVY-CHAIN GENE; TRANSGENIC MICE; CELL-DIFFERENTIATION; ESCHERICHIA-COLI; TINMAN HOMOLOG; FORK HEAD; IN-VIVO; EXPRESSION	Results show that smooth muscle-specific promoters represent novel downstream targets of the winged helix factor hepatocyte nuclear factor-3 homologue 1 (HFH-1). HFH-1 strongly represses telokin promoter activity when overexpressed in A10 vascular smooth muscle cells. HFH-1 was also found to repress transcription of several other smooth muscle-specific promoters, including the SM22 alpha: promoter. HFH-1 inhibits telokin promoter activity, by binding to a forkhead consensus site located within an AT-rich region of the telokin promoter. The DNA-binding domain alone was sufficient to mediate inhibition, suggesting that binding of HFH-1 blocks the binding of other positive-acting factors. HFH-1 does not disrupt serum response factor binding to an adjacent CArG box within the telokin promoter, implying that HFH-1 must compete with other unidentified trans-activators to mediate repression. The localization of HFH-1 mRNA to the epithelial cell layer of mouse bladder and stomach implicates HFH-1 in repressing telokin expression in epithelial cells. This suggests that cell-specific expression of telokin is likely mediated by both positive-acting factors in smooth muscle cells and negative-acting factors in nonmuscle cell types. We propose a model in which the smooth muscle specificity of the telokin promoter is regulated by interactions between positive- and negative-acting members of the hepatocyte nuclear factor-3/forkhead family of transcription factors.	Indiana Univ, Sch Med, Dept Physiol & Biophys, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Herring, BP (corresponding author), Indiana Univ, Sch Med, Dept Physiol & Biophys, 635 Barnhill Dr, Indianapolis, IN 46202 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058571] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-58571] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; Browning CL, 1998, DEV BIOL, V194, P18, DOI 10.1006/dbio.1997.8808; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; Chen CY, 1996, MOL CELL BIOL, V16, P6372; CLEVIDENCE DE, 1994, DEV BIOL, V166, P195, DOI 10.1006/dbio.1994.1307; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; Frank S, 1998, DNA CELL BIOL, V17, P679, DOI 10.1089/dna.1998.17.679; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; HALAYKO AJ, 1994, CAN J PHYSIOL PHARM, V72, P1448, DOI 10.1139/y94-209; Hautmann MB, 1998, J BIOL CHEM, V273, P8398, DOI 10.1074/jbc.273.14.8398; Hautmann MB, 1999, ARTERIOSCL THROM VAS, V19, P2049, DOI 10.1161/01.ATV.19.9.2049; Herring BP, 1997, AM J PHYSIOL-CELL PH, V272, pC1394, DOI 10.1152/ajpcell.1997.272.4.C1394; HERRING BP, 1996, AM J PHYSIOL, V270, pC1665; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Hong HK, 1999, HUM MOL GENET, V8, P625, DOI 10.1093/hmg/8.4.625; Johnson AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1420, DOI 10.1152/ajpcell.1999.276.6.C1420; KAISER P, 1993, BIOTECHNIQUES, V14, P552; KATAYAMA E, 1995, J BIOL CHEM, V270, P3919, DOI 10.1074/jbc.270.8.3919; Katoh Y, 1998, J BIOL CHEM, V273, P1511, DOI 10.1074/jbc.273.3.1511; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Kelm RJ, 1996, J BIOL CHEM, V271, P24278, DOI 10.1074/jbc.271.39.24278; Kelm RJ, 1997, J BIOL CHEM, V272, P26727, DOI 10.1074/jbc.272.42.26727; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; Kimura K, 1998, NUCLEIC ACIDS RES, V26, P2420, DOI 10.1093/nar/26.10.2420; Kopachik W, 1998, DEV DYNAM, V211, P131, DOI 10.1002/(SICI)1097-0177(199802)211:2<131::AID-AJA2>3.0.CO;2-I; Landerholm TE, 1999, DEVELOPMENT, V126, P2053; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; Mack CP, 1999, CIRC RES, V84, P852; Madsen CS, 1998, CIRC RES, V82, P908; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; MAJESKY MW, 1992, CIRC RES, V71, P759, DOI 10.1161/01.RES.71.4.759; Miano JM, 2000, J BIOL CHEM, V275, P9814, DOI 10.1074/jbc.275.13.9814; MIN BH, 1990, J BIOL CHEM, V265, P16667; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Owens GK, 1998, ACTA PHYSIOL SCAND, V164, P623, DOI 10.1111/j.1365-201X.1998.tb10706.x; OWENS GK, 1995, PHYSIOL REV, V75, P487; PATAPOUTIAN A, 1993, DEVELOPMENT, V118, P61; Peterson RS, 1997, MECH DEVELOP, V69, P53, DOI 10.1016/S0925-4773(97)00153-6; Qian J, 1996, DEV DYNAM, V207, P135; RUIZ I, 1993, MECH DEVELOP, V44, P91; SAWAYA PL, 1994, J BIOL CHEM, V269, P22211; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; Smith AF, 1998, AM J PHYSIOL-CELL PH, V274, pC1188, DOI 10.1152/ajpcell.1998.274.5.C1188; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; STEWART AG, 1993, TRENDS PHARMACOL SCI, V14, P275, DOI 10.1016/0165-6147(93)90130-C; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; Swartz EA, 1998, AM J PHYSIOL-CELL PH, V275, pC608, DOI 10.1152/ajpcell.1998.275.2.C608; Tichelaar JW, 1999, DEV BIOL, V213, P405, DOI 10.1006/dbio.1999.9380; Winnier GE, 1999, DEV BIOL, V213, P418, DOI 10.1006/dbio.1999.9382; Wu XQ, 1998, J BIOL CHEM, V273, P11362, DOI 10.1074/jbc.273.18.11362; XANTHOPOULOS KG, 1993, EUR J BIOCHEM, V216, P353, DOI 10.1111/j.1432-1033.1993.tb18152.x; Zilberman A, 1998, CIRC RES, V82, P566, DOI 10.1161/01.RES.82.5.566	58	37	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31162	31170		10.1074/jbc.M005595200	http://dx.doi.org/10.1074/jbc.M005595200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896677	hybrid			2022-12-25	WOS:000089762700059
J	Nosjean, O; Ferro, M; Coge, F; Beauverger, P; Henlin, JM; Lefoulon, F; Fauchere, JL; Delagrange, P; Canet, E; Boutin, JA				Nosjean, O; Ferro, M; Coge, F; Beauverger, P; Henlin, JM; Lefoulon, F; Fauchere, JL; Delagrange, P; Canet, E; Boutin, JA			Identification of the melatonin-binding site MT3 as the quinone reductase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAD(P)H-QUINONE REDUCTASE; DT-DIAPHORASE; MOUSE-LIVER; OXIDOREDUCTASE; SEQUENCE; RECEPTOR; GENE; LOCALIZATION; PURIFICATION; DERIVATIVES	The regulation of the circadian rhythm is relayed from the central nervous system to the periphery by melatonin, a hormone synthesized at night in the pineal gland. Besides two melatonin G-coupled receptors, mt, and MT2, the existence of a novel putative melatonin receptor, MT3, was hypothesized from the observation of a binding site in both central. and peripheral hamster tissues with an original binding profile and a very rapid kinetics of ligand exchange compared with mt(1) and MT2. In this report, we present the purification of MT3 from Syrian hamster kidney and its identification as the hamster homologue of the human quinone reductase 2 (QR(2), EC 1.6.99.2), Our purification strategy included the use of an affinity chromatography step which was crucial in purifying MT3 to homogeneity. The protein was sequenced by tandem mass spectrometry and shown to align with 95% identity with human QR(2). After transfection of CHO-K1 cells with the human QR(2) gene, not only did the QR(2) enzymatic activity appear, but also the melatonin-binding sites with MT3 characteristics, both being below the limit of detection in the native cells. We further confronted inhibition data from MT3 binding and QR(2) enzymatic activity obtained from samples of Syrian hamster kidney or QR(2)-overexpressing Chinese hamster ovary cells, and observed an overall good correlation of the data, In summary, our results provide the identification of the melatonin-binding site MT3 as the quinone reductase QR(2) and open perspectives as to the function of this enzyme, known so far mainly for its detoxifying properties.	Inst Rech Servier, F-78290 Croissy Sur Seine, France; CEA, Lab Chim Prot, F-38000 Grenoble, France; Technol Servier, F-45007 Orleans, France; Inst Rech Servier, F-92150 Suresnes, France; Inst Rech Int Servier, F-92415 Courbevoie, France	Servier; Institut de Recherches Internationales Servier; CEA; Servier; Servier; Institut de Recherches Internationales Servier; Servier; Institut de Recherches Internationales Servier	Boutin, JA (corresponding author), Inst Rech Servier, 125 Chemin de Ronde, F-78290 Croissy Sur Seine, France.	jaboutin@netgrs.com	FERRO, Myriam/O-6588-2014; Boutin, Jean Albert/W-9103-2019	FERRO, Myriam/0000-0002-4222-6847; Boutin, Jean Albert/0000-0003-0068-7204				CHEN SU, 1994, PROTEIN SCI, V3, P1296, DOI 10.1002/pro.5560030816; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DEPREUX P, 1994, J MED CHEM, V37, P3231, DOI 10.1021/jm00046a006; DUBOCOVICH ML, 1995, TRENDS PHARMACOL SCI, V16, P50, DOI 10.1016/S0165-6147(00)88978-6; DUBOCOVICH ML, 1998, IUPHAR COMPENDIUM RE, P187; DUNCAN MJ, 1988, ENDOCRINOLOGY, V122, P1825, DOI 10.1210/endo-122-5-1825; Ferry G, 2000, J BIOL CHEM, V275, P8794, DOI 10.1074/jbc.275.12.8794; Foster CE, 1999, BIOCHEMISTRY-US, V38, P9881, DOI 10.1021/bi990799v; FRIEDLOS F, 1992, BIOCHEM PHARMACOL, V44, P25, DOI 10.1016/0006-2952(92)90033-F; Helenius A, 1979, Methods Enzymol, V56, P734; JAISWAL AK, 1994, J BIOL CHEM, V269, P14502; JAISWAL AK, 1990, BIOCHEMISTRY-US, V29, P1899, DOI 10.1021/bi00459a034; JAISWAL AK, 1988, J BIOL CHEM, V263, P13572; Kodama T, 1997, NEPHROL DIAL TRANSPL, V12, P1453, DOI 10.1093/ndt/12.7.1453; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI RB, 1995, P NATL ACAD SCI USA, V92, P8846, DOI 10.1073/pnas.92.19.8846; LIAO S, 1962, J BIOL CHEM, V237, P2981; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Molinari EJ, 1996, EUR J PHARMACOL, V301, P159, DOI 10.1016/0014-2999(95)00870-5; Paul P, 1999, J PHARMACOL EXP THER, V290, P334; PICKERING DS, 1990, EUR J PHARMACOL, V175, P71, DOI 10.1016/0014-2999(90)90154-X; Poeggeler Burkhard, 1999, P421; POWELL MF, 1982, P NATL ACAD SCI-BIOL, V79, P4604, DOI 10.1073/pnas.79.15.4604; PROCHASKA HJ, 1986, J BIOL CHEM, V261, P1372; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; ROY D, 1988, J BIOL CHEM, V263, P3646; Zhao QJ, 1997, P NATL ACAD SCI USA, V94, P1669, DOI 10.1073/pnas.94.5.1669	28	425	451	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31311	31317		10.1074/jbc.M005141200	http://dx.doi.org/10.1074/jbc.M005141200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10913150	hybrid			2022-12-25	WOS:000089762700080
J	Yuasa, K; Kotera, J; Fujishige, K; Michibata, H; Sasaki, T; Omori, K				Yuasa, K; Kotera, J; Fujishige, K; Michibata, H; Sasaki, T; Omori, K			Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-SPECIFIC PHOSPHODIESTERASE; CGMP-SPECIFIC PHOSPHODIESTERASE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; DEPENDENT PROTEIN-KINASE; N-TERMINAL DOMAIN; MOLECULAR-CLONING; SPLICE VARIANTS; MESSENGER-RNA; MEMBRANE ASSOCIATION; GENE-EXPRESSION	cDNAs encoding a novel phosphodiesterase, phosphodiesterase 11A (PDE11A), were isolated by a combination of reverse transcriptase-polymerase chain reaction using degenerate oligonucleotide primers and rapid amplification of cDNA ends, Their catalytic domain was identical to that of PDE11A1 (490 amino acids) reported during the course of this study. However, the cDNAs we isolated had N termini distinct from PDE11A1, indicating two novel N-terminal variants of PDE11A, PDE11A3 cDNA encoded a 684-amino acid protein including one complete and one incomplete GAF domain in the N-terminal region. PDE11A4 was composed of 934 amino acids including two complete GAF domains and shared 630 C-terminal amino acids with PDE11A3 but had a distinct N terminus containing the putative phosphorylation sites for cAMP- and cGMP dependent protein kinases, PDE11A3 transcripts were specifically expressed in testis, whereas PDE11A4 transcripts were particularly abundant in prostate. Recombinant PDE11A4 expressed in COS-7 cells hydrolyzed cAMP and cGMP with K-m values of 3.0 and 1.4 mu M, respectively, and the V-max value with cAMP was almost twice that with cGMP. Although PDE11A3 showed the same Ii, values as PDE11A4, the relative V-max values of PDE11A3 were ap proximately one-sixth of those of PDE11A4. PDE11A4, but not PDE11A3, was phosphorylated by both cAMP- and cGMP-dependent protein kinases in vitro, Thus, the PDE11A gene undergoes tissue-specific alternative splicing that generates structurally and functionally distinct gene products.	Tanabe Seiyaku Co Ltd, Discovery Res Lab, Toda, Saitama 3358505, Japan	Mitsubishi Tanabe Pharma Corporation	Omori, K (corresponding author), Tanabe Seiyaku Co Ltd, Discovery Res Lab, 2-50 Kawagishi 2 Chome, Toda, Saitama 3358505, Japan.							Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; Bolger GB, 1996, J BIOL CHEM, V271, P1065, DOI 10.1074/jbc.271.2.1065; Burns F, 1996, Adv Pharmacol, V36, P29, DOI 10.1016/S1054-3589(08)60575-X; Cox ME, 1999, CANCER RES, V59, P3821; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; Fawcett L, 2000, P NATL ACAD SCI USA, V97, P3702, DOI 10.1073/pnas.050585197; Fisher DA, 1998, BIOCHEM BIOPH RES CO, V246, P570, DOI 10.1006/bbrc.1998.8684; Fisher DA, 1998, J BIOL CHEM, V273, P15559, DOI 10.1074/jbc.273.25.15559; FLORIO VA, 1994, BIOCHEMISTRY-US, V33, P8948, DOI 10.1021/bi00196a012; Fujishige K, 1999, EUR J BIOCHEM, V266, P1118, DOI 10.1046/j.1432-1327.1999.00963.x; Fujishige K, 1999, J BIOL CHEM, V274, P18438, DOI 10.1074/jbc.274.26.18438; Gautier-Courteille C, 1998, ENDOCRINOLOGY, V139, P2588, DOI 10.1210/en.139.5.2588; Goto T, 1999, INT J UROL, V6, P314, DOI 10.1046/j.1442-2042.1999.00069.x; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; Guh JH, 1998, MOL PHARMACOL, V53, P467, DOI 10.1124/mol.53.3.467; Han P, 1997, J BIOL CHEM, V272, P16152, DOI 10.1074/jbc.272.26.16152; Hayashi M, 1998, BIOCHEM BIOPH RES CO, V250, P751, DOI 10.1006/bbrc.1998.9379; Huston E, 1997, BIOCHEM J, V328, P549, DOI 10.1042/bj3280549; Huston E, 1996, J BIOL CHEM, V271, P31334, DOI 10.1074/jbc.271.49.31334; Korsa I, 1997, J BACTERIOL, V179, P41, DOI 10.1128/jb.179.1.41-45.1997; Kotera J, 1998, J BIOL CHEM, V273, P26982, DOI 10.1074/jbc.273.41.26982; Kotera J, 1999, BIOCHEM BIOPH RES CO, V261, P551, DOI 10.1006/bbrc.1999.1013; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lin CS, 2000, BIOCHEM BIOPH RES CO, V268, P628, DOI 10.1006/bbrc.2000.2187; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MACPHEE CH, 1988, J BIOL CHEM, V263, P10353; McAllisterLucas LM, 1995, J BIOL CHEM, V270, P30671, DOI 10.1074/jbc.270.51.30671; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MCPHEE I, 1995, BIOCHEM J, V310, P965, DOI 10.1042/bj3100965; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; OConnell JC, 1996, BIOCHEM J, V318, P255, DOI 10.1042/bj3180255; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REINHARDT RR, 1995, J CLIN INVEST, V95, P1528, DOI 10.1172/JCI117825; REPASKE DR, 1992, J BIOL CHEM, V267, P18683; Rosman GJ, 1997, GENE, V191, P89, DOI 10.1016/S0378-1119(97)00046-2; SAEKI T, 1994, J PHARMACOL EXP THER, V284, P25; Salanova M, 1999, ENDOCRINOLOGY, V140, P2297, DOI 10.1210/en.140.5.2297; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SCOTLAND G, 1995, BIOCHEM J, V308, P673, DOI 10.1042/bj3080673; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; SHAKUR Y, 1993, BIOCHEM J, V292, P677, DOI 10.1042/bj2920677; Snyder PB, 1999, CELL SIGNAL, V11, P535, DOI 10.1016/S0898-6568(99)00027-3; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Soderling SH, 1998, P NATL ACAD SCI USA, V95, P8991, DOI 10.1073/pnas.95.15.8991; Soderling SH, 1998, J BIOL CHEM, V273, P15553, DOI 10.1074/jbc.273.25.15553; TAKEDA M, 1995, UROLOGY, V45, P440, DOI 10.1016/S0090-4295(99)80013-2; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; Turko IV, 1996, J BIOL CHEM, V271, P22240, DOI 10.1074/jbc.271.36.22240; Turko IV, 1998, BIOCHEM J, V329, P505; Vemulapalli S, 1996, J CARDIOVASC PHARM, V28, P862, DOI 10.1097/00005344-199612000-00018; Vijayaraghavan S, 1997, J BIOL CHEM, V272, P4747, DOI 10.1074/jbc.272.8.4747; Wang X, 1997, J NEUROCHEM, V68, P443; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; Wiesner B, 1998, J CELL BIOL, V142, P473, DOI 10.1083/jcb.142.2.473; YAN C, 1994, J NEUROSCI, V14, P973; Yan C, 1996, J BIOL CHEM, V271, P25699, DOI 10.1074/jbc.271.41.25699; Yanaka N, 1998, EUR J BIOCHEM, V255, P391, DOI 10.1046/j.1432-1327.1998.2550391.x; YANG Q, 1994, BIOCHEM BIOPH RES CO, V205, P1850, DOI 10.1006/bbrc.1994.2886; Yuasa K, 1999, J BIOL CHEM, V274, P37429, DOI 10.1074/jbc.274.52.37429; Yuasa K, 2000, J BIOL CHEM, V275, P4897, DOI 10.1074/jbc.275.7.4897	65	112	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31469	31479		10.1074/jbc.M003041200	http://dx.doi.org/10.1074/jbc.M003041200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906126	hybrid			2022-12-25	WOS:000089762700101
J	Dranoff, JA; O'Neill, AF; Franco, AM; Cai, SY; Connolly, GC; Ballatori, N; Boyer, JL; Nathanson, MH				Dranoff, JA; O'Neill, AF; Franco, AM; Cai, SY; Connolly, GC; Ballatori, N; Boyer, JL; Nathanson, MH			A primitive ATP receptor from the little skate Raja erinacea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; NUCLEOTIDE RECEPTOR; ADENYLYL-CYCLASE; P2Y(2) RECEPTOR; EXPRESSION; RAT; CELLS; PURINOCEPTORS; MECHANISM; RELEASE	P2Y ATP receptors are widely expressed in mammalian tissues and regulate a broad range of activities. Multiple subtypes of P2Y receptors have been identified and are distinguished both on a molecular basis and by pharmacologic substrate preference. Functional evidence suggests that hepatocytes from the little skate Raja erinacea express a primitive P2Y ATP receptor lacking pharmacologic selectivity, so we cloned and characterized this receptor. Skate hepatocyte cDNA was amplified with degenerate oligonucleotide probes designed to identify known P2Y subtypes. A single polymerase chain reaction product was found and used to screen a skate liver cDNA library. A 2314-base pair cDNA clone was generated that contained a 1074-base pair open reading frame encoding a 357-amino acid gene product with 61-64% similarity to P2Y(1) receptors and 21-37% similarity to other P2Y receptor subtypes. Pharmacology of the putative P2Y receptor was examined using the Xenopus oocyte expression system and revealed activation by a range of nucleotides. The receptor was expressed widely in skate tissue and was expressed to a similar extent in other primitive organisms. Phylogenetic analysis suggested that this receptor is closely related to a common ancestor of the P2Y subtypes found in mammals, avians, and amphibians. Thus, the skate liver P2Y receptor functions as a primitive P2Y ATP receptor with broad pharmacologic selectivity and is related to the evolutionary forerunner of P2Y(1) receptors of higher organisms. This novel receptor should provide an effective comparative model for P2Y receptor pharmacology and may improve our understanding of nucleotide specificity among the family of P2Y ATP receptors.	Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Liver Study Unit, New Haven, CT 06520 USA; Mt Desert Isl Biol Lab, Salsbury Cove, ME 04672 USA; Univ Rochester, Sch Med, Dept Environm Med, Rochester, NY 14642 USA	Yale University; Yale University; Mount Desert Island Biological Laboratory; University of Rochester	Dranoff, JA (corresponding author), Yale Univ, Sch Med, Sect Digest Dis, LMP 1080,333 Cedar St, New Haven, CT 06510 USA.	jonathan.dranoff@yale.edu			NIDDK NIH HHS [DK25636, DK34989, DK45710] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK025636, R29DK045710, R01DK045710, R01DK025636, P30DK034989] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bogdanov YD, 1997, J BIOL CHEM, V272, P12583, DOI 10.1074/jbc.272.19.12583; Bogdanov YD, 1998, BRIT J PHARMACOL, V124, P428, DOI 10.1038/sj.bjp.0701880; BOYER JL, 1993, J PHARMACOL EXP THER, V267, P1140; Boyer JL, 1997, MOL PHARMACOL, V52, P928, DOI 10.1124/mol.52.6.928; BOYER JL, 1989, SCHIFFS DIS LIVER, P119; Burnstock G, 1997, NEUROPHARMACOLOGY, V36, P1127, DOI 10.1016/S0028-3908(97)00125-1; Chen ZP, 1996, ENDOCRINOLOGY, V137, P1833, DOI 10.1210/en.137.5.1833; Christoffersen BC, 1998, PFLUG ARCH EUR J PHY, V436, P33, DOI 10.1007/s004240050601; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; Cressman VL, 1999, J BIOL CHEM, V274, P26461, DOI 10.1074/jbc.274.37.26461; Fabre JE, 1999, NAT MED, V5, P1199, DOI 10.1038/13522; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Hwang TH, 1996, AM J PHYSIOL-CELL PH, V270, pC1611, DOI 10.1152/ajpcell.1996.270.6.C1611; King BF, 1996, NEUROSCIENCE, V74, P1187, DOI 10.1016/0306-4522(96)00209-6; Lazarowski ER, 1997, P NATL ACAD SCI USA, V94, P2599, DOI 10.1073/pnas.94.6.2599; Leon C, 1999, J CLIN INVEST, V104, P1731, DOI 10.1172/JCI8399; Luo X, 1999, AM J PHYSIOL-CELL PH, V277, pC205, DOI 10.1152/ajpcell.1999.277.2.C205; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; Nathanson MH, 1999, J EXP BIOL, V202, P3049; NATHANSON MH, 1992, J BIOL CHEM, V267, P23282; Nathanson MH, 1996, AM J PHYSIOL-REG I, V270, pR561, DOI 10.1152/ajpregu.1996.270.3.R561; Nicholas RA, 1996, J AUTON PHARMACOL, V16, P319, DOI 10.1111/j.1474-8673.1996.tb00044.x; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; Ralevic V, 1998, PHARMACOL REV, V50, P413; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SMITH DJ, 1987, J EXP ZOOL, V241, P291, DOI 10.1002/jez.1402410303; TOKUYAMA Y, 1995, BIOCHEM BIOPH RES CO, V211, P211, DOI 10.1006/bbrc.1995.1798; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Webb TE, 1996, MOL PHARMACOL, V50, P258; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; Webb TE, 1998, J NEUROCHEM, V71, P1348; Zheng HL, 2000, BIOTECHNIQUES, V28, P832, DOI 10.2144/00285bm01	34	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30701	30706		10.1074/jbc.M003366200	http://dx.doi.org/10.1074/jbc.M003366200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10900200	hybrid			2022-12-25	WOS:000089577900107
J	Gotoh, T; Cai, DP; Tian, XJ; Feig, LA; Lerner, A				Gotoh, T; Cai, DP; Tian, XJ; Feig, LA; Lerner, A			p130(Cas) regulates the activity of AND-34, a novel Ra1, Rap1, and R-Ras guanine nucleotide exchange factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAY; PUTATIVE EFFECTOR; PROTEIN-KINASE; DIRECT BINDING; BREAST-CANCER; FACTOR C3G; V-SRC; ACTIVATION; IDENTIFICATION; GTPASE	We previously identified a novel murine protein, AND-34, with a carboxyl-terminal domain homologous to Ras family guanine nucleotide exchange factors (GEFs), which bound to the focal adhesion docking protein p130(Cas). Work by others has implicated both the human homologue of AND-34, BCAR3, and human p130(Cas) BCAR1, in the resistance of breast cancer cells to the anti-estrogen tamoxifen. Here we report that AND-34 displays GEF activity on Ra1A, Rap1A, and R-Ras but not Ha-Ras GTPases in cells. In contrast to several other Ra1-GEFs, the Ra1 GEF activity of AND-34 is not augmented by constitutively active Ha-Ras(Val-12), consistent with the absence of a detectable Ras-binding domain. Efficient binding to AND-34 required both the Src-binding domain and a flanking carboxyl-terminal region of p130(Cas). The p130(Cas)-binding site mapped to a carboxyl-terminal sequence within the AND-34 GEF domain. Overexpression of p130(Cas), but not an AND-34-binding mutant of p130(Cas), inhibited the Ra1 GEF activity of co-transfected AND-34. This work identifies a new potential function for p130(Cas) and a new regulatory pathway involved in the control of Ra1, Rap, and R-Ras GTPases that may participate in the progression of breast cancer cells to tamoxifen resistance.	Boston Univ, Med Ctr, Dept Med, Evans Biomed Res Ctr,Sect Hematol & Oncol, Boston, MA 02118 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA	Boston University; Tufts University; Boston University	Lerner, A (corresponding author), Boston Univ, Med Ctr, Dept Med, Evans Biomed Res Ctr,Sect Hematol & Oncol, Rm 427,650 Albany St, Boston, MA 02118 USA.							Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Brinkman A, 2000, JNCI-J NATL CANCER I, V92, P112, DOI 10.1093/jnci/92.2.112; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Cai DP, 1999, J IMMUNOL, V163, P2104; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Dodelet VC, 1999, J BIOL CHEM, V274, P31941, DOI 10.1074/jbc.274.45.31941; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; Kirsch KH, 1998, J BIOL CHEM, V273, P25673, DOI 10.1074/jbc.273.40.25673; Lu YM, 1999, J BIOL CHEM, V274, P10047, DOI 10.1074/jbc.274.15.10047; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NICHOLSON S, 1989, LANCET, V1, P182; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Park SH, 1995, ONCOGENE, V11, P2349; Rebhun JF, 2000, J BIOL CHEM, V275, P13406, DOI 10.1074/jbc.C000085200; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sakakibara A, 2000, J BIOL CHEM, V275, P6404, DOI 10.1074/jbc.275.9.6404; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Suzuki J, 1997, ONCOGENE, V15, P1689, DOI 10.1038/sj.onc.1201333; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; van Agthoven T, 1998, EMBO J, V17, P2799, DOI 10.1093/emboj/17.10.2799; van der Flier S, 2000, JNCI-J NATL CANCER I, V92, P120, DOI 10.1093/jnci/92.2.120; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	32	79	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30118	30123		10.1074/jbc.M003074200	http://dx.doi.org/10.1074/jbc.M003074200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10896938	hybrid			2022-12-25	WOS:000089577900029
J	Liang, L; Lim, KL; Seow, KT; Ng, CH; Pallen, CJ				Liang, L; Lim, KL; Seow, KT; Ng, CH; Pallen, CJ			Calmodulin binds to and inhibits the activity of the membrane distal catalytic domain of receptor protein-tyrosine phosphatase alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC-FAMILY KINASES; 2 POINT MUTATIONS; PTP-ALPHA; CYTOPLASMIC DOMAIN; STRUCTURAL BASIS; KINETIC-ANALYSIS; DOWN-REGULATION; CD45; LAR; PURIFICATION	cDNA expression library screening revealed binding between the membrane distal catalytic domain (D2) of protein-tyrosine phosphatase alpha (PTP alpha) and calmodulin. Characterization using surface plasmon resonance showed that calmodulin bound to PTP alpha-D2 in a Ca2+-dependent manner but did not bind to the membrane proximal catalytic domain (D1) of PTP alpha, to the two tandem catalytic domains (D1D2) of PTP alpha, nor to the closely related D2 domain of PTP epsilon. Calmodulin bound to PTP alpha-D2 with high affinity, exhibiting a K-D similar to 3 nM. The calmodulin-binding site was localized to amino acids 520-538 in the N-terminal region of D2. Site-directed mutagenesis showed that Lys-521 and Asn-534 were required for optimum calmodulin binding and that restoration of these amino acids to the counterpart PTP epsilon sequence could confer calmodulin binding. The overlap of the binding site with the predicted lip of the catalytic cleft of PTP alpha-D2, in conjunction with the observation that calmodulin acts as a competitive inhibitor of D2-catalyzed dephosphorylation (K-i similar to 340 nM), suggests that binding of calmodulin physically blocks or distorts the catalytic cleft of PTP alpha-D2 to prevent interaction with substrate. When expressed in cells, full-length PTP alpha and PTP alpha lacking only D1, but not full-length PTP epsilon, bound to calmodulin beads in the presence of Ca2+. Also, PTP alpha was found in association with calmodulin immunoprecipitated from cell lysates. Thus calmodulin does associate with PTP alpha in vivo but not with PTP alpha-D1D2 in vitro, highlighting a potential conformational difference between these forms of the tandem catalytic domains. The above findings suggest that calmodulin is a possible specific modulator of PTP alpha-D2 and, via D2, of PTP alpha.	Inst Mol & Cell Biol, Cell Regulat Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Pallen, CJ (corresponding author), Inst Mol & Cell Biol, Cell Regulat Lab, 30 Med Dr, Singapore 117609, Singapore.		Lim, Kah-Leong/AAY-3308-2020; Lim, Kah/L-5426-2019	Lim, Kah-Leong/0000-0002-5440-2588; Pallen, Catherine/0000-0002-3576-5295; Ng, Chee Hoe/0000-0001-8545-0497				Bhandari V, 1998, J BIOL CHEM, V273, P8691, DOI 10.1074/jbc.273.15.8691; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Blanchetot C, 2000, J BIOL CHEM, V275, P12446, DOI 10.1074/jbc.275.17.12446; Buist P, 1999, BIOCHEMISTRY-US, V38, P914, DOI 10.1021/bi981936b; CHO HJ, 1992, BIOCHEMISTRY-US, V31, P133, DOI 10.1021/bi00116a019; COX JA, 1985, J BIOL CHEM, V260, P2527; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; GEBBINK MFBG, 1993, BIOCHEMISTRY-US, V32, P13516, DOI 10.1021/bi00212a017; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; Kashio N, 1998, J BIOL CHEM, V273, P33856, DOI 10.1074/jbc.273.50.33856; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; Lim KL, 1997, EUR J BIOCHEM, V245, P693, DOI 10.1111/j.1432-1033.1997.00693.x; Lim KL, 1998, J BIOL CHEM, V273, P28986, DOI 10.1074/jbc.273.44.28986; Lim KL, 1999, BBA-PROTEIN STRUCT M, V1434, P275, DOI 10.1016/S0167-4838(99)00189-2; MAULET Y, 1983, BIOCHEMISTRY-US, V22, P5680, DOI 10.1021/bi00293a035; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; POT DA, 1991, J BIOL CHEM, V266, P19688; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; SU J, 1994, J BIOL CHEM, V269, P18731; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6016; Tsai W, 1999, EMBO J, V18, P109, DOI 10.1093/emboj/18.1.109; Wallace MJ, 1998, MOL CELL BIOL, V18, P2608, DOI 10.1128/MCB.18.5.2608; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	39	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30075	30081		10.1074/jbc.M004843200	http://dx.doi.org/10.1074/jbc.M004843200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10893241	hybrid			2022-12-25	WOS:000089577900023
J	Miyazaki, M; Kim, YC; Gray-Keller, MP; Attie, AD; Ntambi, JM				Miyazaki, M; Kim, YC; Gray-Keller, MP; Attie, AD; Ntambi, JM			The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; 3T3-L1 PREADIPOCYTES; A DESATURASE; DIFFERENTIATION; EXPRESSION; LIVER; ACYLTRANSFERASE; METABOLISM; COENZYME; MOUSE	Stearoyl-CoA desaturase (SCD) is a microsomal enzyme required for the biosynthesis of oleate and palmitoleate, which are the major monounsaturated fatty acids of membrane phospholipids, triglycerides, and cholesterol esters. Two well characterized isoforms of SCD, SCD1 and SCD2, exist in the mouse. Most mouse tissues express SCD1 and 2 with the exception of the liver, which expresses mainly the SCD1 isoform. We found that asebia mice homozygous for a natural mutation of the gene for SCD1 (SCD-/-) are deficient in hepatic cholesterol esters and triglycerides despite the presence of normal activities of acyl-CoA:cholesterol acyltransferase and glycerol phosphate acyltransferase, the enzymes responsible for cholesterol ester and triglyceride synthesis, respectively, in the liver of these mice. Feeding diets supplemented with triolein or tripalmitolein to the SCD-/- mice resulted in an increase in the levels of 16:1 and 18:1 in the liver but failed to restore the 18:1 and 16:1 levels of the cholesterol ester and triglycerides to the levels found in normal mice, The SCD-/- mouse had very low levels of triglycerides in the VLDL and LDL lipoprotein fractions compared with the normal animal. Transient transfection of an SCD1 expression vector into Chinese hamster ovary cells resulted in increased SCD activity and esterification of cholesterol to cholesterol esters. Taken together, our observations demonstrate that the oleoyl-CoA and palmitoleyl-CoA produced by SCD1 are necessary to synthesize enough cholesterol esters and triglycerides in the liver and suggest that regulation of SCD1 activity plays an important role in mechanisms of cellular cholesterol homeostasis.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ntambi, JM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.							BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DAUMERIE CM, 1992, P NATL ACAD SCI USA, V89, P10797, DOI 10.1073/pnas.89.22.10797; ENOCH HG, 1978, BIOCHEMISTRY-US, V17, P4927, DOI 10.1021/bi00616a011; ERICKSON SK, 1980, J LIPID RES, V21, P930; GATES AH, 1965, SCIENCE, V148, P1471, DOI 10.1126/science.148.3676.1471; Heinemann FS, 1998, MOL BIOL CELL, V9, P3445, DOI 10.1091/mbc.9.12.3445; Janciauskiene S, 1999, HEPATOLOGY, V29, P434, DOI 10.1002/hep.510290217; JOSEFOWICZ WJ, 1978, GENET RES, V31, P145, DOI 10.1017/S0016672300017900; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; Kim YC, 1999, BIOCHEM BIOPH RES CO, V266, P1, DOI 10.1006/bbrc.1999.1704; Landau JM, 1997, BBA-LIPID LIPID MET, V1345, P349, DOI 10.1016/S0005-2760(97)00010-6; Lee KN, 1998, BIOCHEM BIOPH RES CO, V248, P817, DOI 10.1006/bbrc.1998.8994; Miyazaki M, 1998, LIPIDS, V33, P655, DOI 10.1007/s11745-998-0253-3; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; Ntambi JM, 1999, J LIPID RES, V40, P1549; NTAMBI JM, 1995, PROG LIPID RES, V34, P139, DOI 10.1016/0163-7827(94)00010-J; OSHINO N, 1966, BIOCHIM BIOPHYS ACTA, V128, P13, DOI 10.1016/0926-6593(66)90137-8; Sessler AM, 1996, J BIOL CHEM, V271, P29854, DOI 10.1074/jbc.271.47.29854; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; SUCKLING KE, 1985, J LIPID RES, V26, P647; SWEET H, 1978, MOUSE NEWS LETT, V59, P287; THOMAS PD, 1990, J BIOL CHEM, V265, P2684; WATERS KM, 1994, J BIOL CHEM, V269, P27773; Zheng Y, 1999, NAT GENET, V23, P268, DOI 10.1038/15446	25	355	378	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30132	30138		10.1074/jbc.M005488200	http://dx.doi.org/10.1074/jbc.M005488200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10899171	hybrid			2022-12-25	WOS:000089577900031
J	Pol, A; Lu, A; Pons, M; Peiro, S; Enrich, C				Pol, A; Lu, A; Pons, M; Peiro, S; Enrich, C			Epidermal growth factor-mediated caveolin recruitment to early endosomes and MAPK activation - Role of cholesterol and actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; CELL-SURFACE; ENDOCYTIC COMPARTMENT; INTRACELLULAR PATHWAY; RECYCLING ENDOSOMES; SIGNAL-TRANSDUCTION; KINASE CASCADE; ANNEXIN-II; PROTEIN; RECEPTOR	The endocytic compartment of eukaryotic cells is a complex intracellular structure involved in sorting, processing, and degradation of a great variety of internalized molecules. Recently, the uptake through caveolae has emerged as an alternative internalization pathway, which seems to be directly related with some signal transduction pathways. However, the mechanisms, molecules, and structures regulating the transport of caveolin from the cell surface into the endocytic compartment are largely unknown. In this study, normal quiescent fibroblasts (normal rat kidney (NRK)) were used to demonstrate that epidermal growth factor causes partial redistribution of caveolin from the cell surface into a cellubrevin early endocytic compartment. Treatment of NRK cells with cytochalasin D or latrunculin A inhibits this pathway and the concomitant activation of Mek and mitotic-activated protein (MAP) kinase; however, if cells were pre-treated with filipin, cytochalasin D does not inhibit the phosphorylation of MAP kinase induced by epidermal growth factor. From these results we conclude that in NRK cells the intact actin cytoskeleton is necessary for the EGF-mediated transport of caveolin from the cell surface into the early endocytic compartment and the activation of MAP kinase pathway.	Univ Barcelona, Fac Med, Inst Invest Biomed August Pi Sunyer, Dept Cellular Biol, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Enrich, C (corresponding author), Univ Barcelona, Fac Med, Inst Invest Biomed August Pi Sunyer, Dept Cellular Biol, Casanova 143, E-08036 Barcelona, Spain.	enrich@medicina.ub.es	LU, ALBERT/AAB-6134-2019; Pons, Monica/AAB-5309-2019; Pol, Albert/M-1865-2014	LU, ALBERT/0000-0002-7507-3330; Pol, Albert/0000-0002-1750-1085; Enrich, Carlos/0000-0003-0382-2993				ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Annaert WG, 1997, J CELL BIOL, V139, P1397, DOI 10.1083/jcb.139.6.1397; APODACA G, 1994, J BIOL CHEM, V269, P19005; Bottger G, 1996, J BIOL CHEM, V271, P29191, DOI 10.1074/jbc.271.46.29191; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BRUNS RR, 1968, J CELL BIOL, V37, P277, DOI 10.1083/jcb.37.2.277; Calvo M, 2000, J BIOL CHEM, V275, P7910, DOI 10.1074/jbc.275.11.7910; CARPENTIER JL, 1989, J CELL PHYSIOL, V138, P519, DOI 10.1002/jcp.1041380311; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gekle M, 1997, AM J PHYSIOL-RENAL, V272, pF668, DOI 10.1152/ajprenal.1997.272.5.F668; Gilbert A, 1999, J CELL SCI, V112, P1101; Gingras D, 1998, BIOCHEM BIOPH RES CO, V247, P888, DOI 10.1006/bbrc.1998.8885; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; Kiss AL, 1997, EUR J CELL BIOL, V73, P19; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Majo G, 1998, LIFE SCI, V62, P607, DOI 10.1016/S0024-3205(97)01156-9; MALABA L, 1995, J BIOL CHEM, V270, P15686, DOI 10.1074/jbc.270.26.15686; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; MILICI AJ, 1987, J CELL BIOL, V105, P2603, DOI 10.1083/jcb.105.6.2603; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; PALADE GR, 1953, J APPL PHYS, V24, P364; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; Pol A, 1998, FEBS LETT, V441, P34, DOI 10.1016/S0014-5793(98)01517-8; Pol A, 1999, HEPATOLOGY, V29, P1848, DOI 10.1002/hep.510290602; POL A, 2000, IN PRESS CELL SIGNAL; Pons M, 2000, EXP CELL RES, V257, P33, DOI 10.1006/excr.2000.4861; Predescu SA, 1997, AM J PHYSIOL-HEART C, V272, pH937, DOI 10.1152/ajpheart.1997.272.2.H937; Prekeris R, 1999, MOL BIOL CELL, V10, P3891, DOI 10.1091/mbc.10.11.3891; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SANDVIG K, 1990, J BIOL CHEM, V265, P6382; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Teter K, 1998, J BIOL CHEM, V273, P19625, DOI 10.1074/jbc.273.31.19625; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; Van Deurs Bo, 1993, Trends in Cell Biology, V3, P249; VANDEURS B, 1989, INT REV CYTOL, V117, P131; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4	70	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30566	30572		10.1074/jbc.M001131200	http://dx.doi.org/10.1074/jbc.M001131200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10889188	hybrid			2022-12-25	WOS:000089577900090
J	Xu, LH; Yang, XH; Bradham, CA; Brenner, DA; Baldwin, AS; Craven, RJ; Cance, WG				Xu, LH; Yang, XH; Bradham, CA; Brenner, DA; Baldwin, AS; Craven, RJ; Cance, WG			The focal adhesion kinase suppresses transformation-associated, anchorage-independent apoptosis in human breast cancer cells - Involvement of death receptor-related signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; TUMOR-CELLS; EXPRESSION; OVEREXPRESSION; PP125(FAK); INHIBITION; CASPASES; SURVIVAL; GROWTH; SRC	The focal adhesion kinase (FAK) is a mediator of cell-extracellular matrix signaling events and is overexpressed in tumor cells. In order to rapidly down-regulate FAK function in normal and transformed mammary cells, we have used adenoviral gene transduction of the carboxyl-terminal domain of FAK (FAK-CD). Transduction of adenovirus containing FAH-CD in breast cancer cells caused loss of adhesion, degradation of p125(FAK), and induced apoptosis. Furthermore, breast tumor cells that were viable without matrix attachment also underwent apoptosis upon interruption of FAK function, demonstrating that FAK is a survival signal in breast tumor cells even in the absence of matrix signaling. In addition, both anchorage-dependent and anchorage-independent apoptotic signaling required Fas-associated death domain and caspase-8, suggesting that a death receptor-mediated apoptotic pathway is involved. Finally, FAK-CD had no effect on adhesion or viability in normal mammary cells, despite the loss of tyrosine phosphorylation of p125(FAK). These results indicate that FAK-mediated signaling is required for both cell adhesion and anchorage-independent survival and the disruption of FAK function involves the Fas-associated death domain and caspase-8 apoptotic pathway.	Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Surg, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Cance, WG (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, CB 7210, Chapel Hill, NC 27599 USA.		Bradham, Cynthia/GXV-9373-2022	Brenner, David/0000-0003-2573-525X	NATIONAL CANCER INSTITUTE [R01CA065910] Funding Source: NIH RePORTER; NCI NIH HHS [CA65910] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; BROOKS SC, 1973, J BIOL CHEM, V248, P6251; Cary LA, 1996, J CELL SCI, V109, P1787; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FERNANDES RS, 1996, LEUKEMIA, V10, P17; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Han NM, 1997, ANN SURG ONCOL, V4, P264, DOI 10.1007/BF02306620; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HOFFMAN B, 1994, ONCOGENE, V9, P1807; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1998, J CELL BIOL, V143, P547; Kumar R, 1996, CLIN CANCER RES, V2, P1215; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; McGill G, 1997, J CELL BIOL, V138, P901, DOI 10.1083/jcb.138.4.901; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nolan K, 1999, MOL CELL BIOL, V19, P6120; OWENS LV, 1995, CANCER RES, V55, P2752; Owens LV, 1996, ANN SURG ONCOL, V3, P100, DOI 10.1007/BF02409059; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SOULE HD, 1990, CANCER RES, V50, P6075; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Withers BE, 1996, CANCER BIOCHEM BIOPH, V15, P127; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413	45	174	178	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30597	30604		10.1074/jbc.M910027199	http://dx.doi.org/10.1074/jbc.M910027199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10899173	hybrid			2022-12-25	WOS:000089577900093
J	Chernukhin, IV; Shamsuddin, S; Robinson, AF; Carne, AF; Paul, A; El-Kady, AI; Lobanenkov, VV; Klenova, EM				Chernukhin, IV; Shamsuddin, S; Robinson, AF; Carne, AF; Paul, A; El-Kady, AI; Lobanenkov, VV; Klenova, EM			Physical and functional interaction between two pluripotent proteins, the Y-box DNA/RNA-binding factor, YB-1, and the multivalent zinc finger factor, CTCF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC GENE; TRANSCRIPTION FACTOR YB-1; HUMAN POLYOMAVIRUS JC; NUCLEAR FACTOR; 5'-FLANKING SEQUENCE; PRECURSOR PROMOTER; MESSENGER-RNA; DNA-SEQUENCE; EXPRESSION; CELLS	CTCF is a unique, highly conserved, and ubiquitously expressed 11 zinc finger (ZF) transcriptional factor with multiple DNA site specificities. It is able to bind to varying target sequences to perform different regulatory roles, including promoter activation or repression, creating hormone-responsive gene silencing elements, and functional block of enhancer-promoter interactions. Because different sets of ZFs are utilized to recognize different CTCF target DNA sites, each of the diverse DNA.CTCF complexes might engage different essential protein partners to define distinct functional readouts. To identify such proteins, we developed an affinity chromatography method based on matrix-immobilized purified recombinant CTCF. This approach resulted in isolation of several CTCF protein partners. One of these was identified as the multifunctional Y-box DNA/RNA-binding factor, YB-1, known to be involved in transcription, replication, and RNA processing. We examined CTCF/YB-1 interaction by reciprocal immunoprecipitation experiments with anti-CTCF and anti-YB-l antibodies, and found that CTCF and YB-1 form complexes in vivo. We show that the bacterially expressed ZF domain of CTCF is fully sufficient to retain YB-1 in vitro. To assess possible functional significance of CTCF/YB-1 binding, we employed the very first identified by us, negatively regulated, target for CTCF (c-myc oncogene promoter) as a model in co-transfection assays with both CTCF and YB-1 expression vectors. Although expression of YB-1 alone had no effect, co-expression with CTCF resulted in a marked enhancement of CTCF-driven c-myc transcriptional repression. Thus our findings demonstrate, for the first time, the biological relevance of the CTCF/YB-1 interaction.	Univ Oxford, Dept Biochem, Genet Lab, Oxford OX1 3QU, England; Inst Canc Res, Haddow Labs, Surrey, England; NIAID, Sect Mol Pathol, Immunopathol Lab, NIH, Bethesda, MD 20892 USA	University of Oxford; University of London; Institute of Cancer Research - UK; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Klenova, EM (corresponding author), Univ Oxford, Dept Biochem, Genet Lab, S Parks Rd, Oxford OX1 3QU, England.	klenovae@bioch.ox.ac.uk	Shamsuddin, Shaharum/A-7907-2011; Lobanenkov, Victor V./AGQ-8903-2022; Lobanenkov, Victor/ABD-5710-2021; Elkady, Ayman/J-5738-2012	Shamsuddin, Shaharum/0000-0001-9997-7740; Lobanenkov, Victor/0000-0001-6665-3635				Ansari SA, 1999, J GEN VIROL, V80, P2629, DOI 10.1099/0022-1317-80-10-2629; ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; ASSELIN C, 1989, ONCOGENE, V4, P549; Awad TA, 1999, J BIOL CHEM, V274, P27092, DOI 10.1074/jbc.274.38.27092; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Bell AC, 1999, CURR OPIN GENET DEV, V9, P191, DOI 10.1016/S0959-437X(99)80029-X; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; Boulikas T, 1996, ANTICANCER RES, V16, P225; Burcin M, 1997, MOL CELL BIOL, V17, P1281, DOI 10.1128/MCB.17.3.1281; Chen CY, 2000, GENE DEV, V14, P1236; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Duh JL, 1995, J BIOL CHEM, V270, P30499, DOI 10.1074/jbc.270.51.30499; Englert C, 1998, TRENDS BIOCHEM SCI, V23, P389, DOI 10.1016/S0968-0004(98)01277-8; Fearon ER, 1999, CURR BIOL, V9, pR62, DOI 10.1016/S0960-9822(99)80012-8; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Filippova GN, 1998, GENE CHROMOSOME CANC, V22, P26, DOI 10.1002/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; Ise T, 1999, CANCER RES, V59, P342; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; Kanduri C, 2000, CURR BIOL, V10, P449, DOI 10.1016/S0960-9822(00)00442-5; KASHANCHI F, 1994, J VIROL, V68, P561, DOI 10.1128/JVI.68.1.561-565.1994; Klenova EM, 1997, NUCLEIC ACIDS RES, V25, P466, DOI 10.1093/nar/25.3.466; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Ladomery M, 1997, BIOESSAYS, V19, P903, DOI 10.1002/bies.950191010; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; LOBANENKOV VV, 1986, EUR J BIOCHEM, V159, P181, DOI 10.1111/j.1432-1033.1986.tb09850.x; LOBANENKOV VV, 1989, DOKL AKAD NAUK SSSR+, V309, P741; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; LOBANENKOV VV, 1989, GENE REGULATION AIDS, P45; MAREU KB, 1992, ANNU REV BIOCHEM, V61, P809; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Montani V, 1998, ENDOCRINOLOGY, V139, P280, DOI 10.1210/en.139.1.280; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Ohmori M, 1996, MOL ENDOCRINOL, V10, P76, DOI 10.1210/me.10.1.76; PATTERSON SD, 1995, ELECTROPHORESIS, V16, P1791, DOI 10.1002/elps.11501601299; PLUMB MA, 1986, NUCLEIC ACIDS RES, V14, P7675, DOI 10.1093/nar/14.19.7675; Potter M, 1997, CURR TOP MICROBIOL, V224, P1; QUITSCHKE WW, 1994, J BIOL CHEM, V269, P21229; Raj GV, 1996, J VIROL, V70, P5944, DOI 10.1128/JVI.70.9.5944-5953.1996; SABATH DE, 1990, J BIOL CHEM, V265, P12671; Safak M, 1999, J VIROL, V73, P10146, DOI 10.1128/JVI.73.12.10146-10157.1999; Saitoh N, 2000, EMBO J, V19, P2315, DOI 10.1093/emboj/19.10.2315; Sawaya BE, 1998, J GEN VIROL, V79, P239, DOI 10.1099/0022-1317-79-2-239; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shibao K, 1999, INT J CANCER, V83, P732; SHIU RP, 1993, CLIN CHEM, V39, P353; Sommerville J, 1996, CHROMOSOMA, V104, P469, DOI 10.1007/s004120050139; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Swamynathan SK, 2000, BIOCHEM J, V348, P297, DOI 10.1042/0264-6021:3480297; Swamynathan SK, 1998, FASEB J, V12, P515, DOI 10.1096/fasebj.12.7.515; Szabo PE, 2000, CURR BIOL, V10, P607, DOI 10.1016/S0960-9822(00)00489-9; TEVOSYAN S G, 1991, Molekulyarnaya Biologiya (Moscow), V25, P1013; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Vostrov AA, 1997, J BIOL CHEM, V272, P33353, DOI 10.1074/jbc.272.52.33353; Wolffe AP, 1996, INT J BIOCHEM CELL B, V28, P247, DOI 10.1016/1357-2725(95)00141-7; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; WOLFFE AP, 1994, DEV GENET, V15, P463, DOI 10.1002/dvg.1020150604; Yang YX, 1999, J NEUROCHEM, V73, P2286, DOI 10.1046/j.1471-4159.1999.0732286.x; Zou YM, 1997, DEVELOPMENT, V124, P793; ZOU YM, 1995, MOL CELL BIOL, V15, P2972	70	83	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29915	29921		10.1074/jbc.M001538200	http://dx.doi.org/10.1074/jbc.M001538200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10906122	hybrid			2022-12-25	WOS:000089439800100
J	Medina, I; Krapivinsky, G; Arnold, S; Kovoor, P; Krapivinsky, L; Clapham, DE				Medina, I; Krapivinsky, G; Arnold, S; Kovoor, P; Krapivinsky, L; Clapham, DE			A switch mechanism for G ss gamma activation of I-KACh	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER POTASSIUM CHANNELS; RECTIFYING K+ CHANNELS; G-BETA-GAMMA; INWARD RECTIFIER; FUNCTIONAL EXPRESSION; G-PROTEINS; SUBUNITS; ACETYLCHOLINE; LOCALIZATION; BINDING	G protein-gated inwardly rectifying potassium (GIRK) channels are a family of K+-selective ion channels that slow the firing rate of neurons and cardiac myocytes. GIRK channels are directly bound and activated by the G protein G beta gamma subunit. As heterotetramers, they comprise the GIRK1 and the GIRK2, -8, or -4 subunits. Here we show that GIRK1 but not the GIRK4 subunit is phosphorylated when heterologously expressed. We found also that phosphatase PP2A dephosphorylation of a protein in the excised patch abrogates channel activation by G beta gamma. Experiments with the truncated molecule demonstrated that the GIRK1 C-terminal is critical for both channel phosphorylation and channel regulation by protein phosphorylation, but the critical phosphorylation sites were not located on the C terminus. These data provide evidence for a novel switch mechanism in which protein phosphorylation enables G beta gamma gating of the channel complex.	Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Clapham, DE (corresponding author), Childrens Hosp, Howard Hughes Med Inst, 1309 Enders,320 Longwood Ave, Boston, MA 02115 USA.		Clapham, David/S-1123-2019; Clapham, David/R-5974-2019; Medina, Igor/O-5532-2016	Clapham, David/0000-0002-4459-9428; Medina, Igor/0000-0001-6839-5414; Arnold, Susanne/0000-0003-2667-5156				Corey S, 1998, J BIOL CHEM, V273, P5271, DOI 10.1074/jbc.273.9.5271; Dissmann E, 1996, BIOCHEM BIOPH RES CO, V223, P474, DOI 10.1006/bbrc.1996.0918; DUPRAT F, 1995, BIOCHEM BIOPH RES CO, V212, P657, DOI 10.1006/bbrc.1995.2019; HARTZELL HC, 1977, J PHYSIOL-LONDON, V271, P817, DOI 10.1113/jphysiol.1977.sp012027; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Jelacic TM, 1999, J MEMBRANE BIOL, V169, P123, DOI 10.1007/s002329900524; Kennedy ME, 1999, J BIOL CHEM, V274, P2571, DOI 10.1074/jbc.274.4.2571; Kim D, 1997, AM J PHYSIOL-HEART C, V272, pH195, DOI 10.1152/ajpheart.1997.272.1.H195; Kim D, 2000, J GEN PHYSIOL, V115, P287, DOI 10.1085/jgp.115.3.287; KIM D, 1991, J PHYSIOL-LONDON, V437, P133, DOI 10.1113/jphysiol.1991.sp018588; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LOEWI O., 1926, PFLUGER S ARCH GES PHYSIOL, V214, P678, DOI 10.1007/BF01741946; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Mullner C, 2000, J GEN PHYSIOL, V115, P547, DOI 10.1085/jgp.115.5.547; NELSON DA, 1992, J BIOL CHEM, V267, P14928; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; Wickman K, 1998, NEURON, V20, P103, DOI 10.1016/S0896-6273(00)80438-9; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	25	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29709	29716		10.1074/jbc.M004989200	http://dx.doi.org/10.1074/jbc.M004989200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10900209	hybrid			2022-12-25	WOS:000089439800071
J	Kubota, H; Yokota, S; Yanagi, H; Yura, T				Kubota, H; Yokota, S; Yanagi, H; Yura, T			Transcriptional regulation of the mouse cytosolic chaperonin subunit gene Ccta/t-complex polypeptide 1 by selenocysteine tRNA gene transcription activating factor family zinc finger proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; EUKARYOTIC CYTOSOL; ENDOPLASMIC-RETICULUM; STAF; EXPRESSION; TCP-1; IDENTIFICATION; REQUIRES; ACTIN; MOTIF	The chaperonin containing t-complex polypeptide 1 (CCT) is a molecular chaperone assisting in the folding of proteins in eukaryotic cytosol, and the Ccta (encoding the alpha subunit of CCT)lt-complex polypeptide 1 gene encodes the cw subunit of CCT. We show here that transcription of the mouse Ccta gene is regulated by selenocysteine tRNA gene transcription activating factor (Staf) family zinc-finger transcription factors ZNF143 and ZNF76. Reporter gene assay using HeLa cells indicated that the Ccta gene promoter contains two 18-base pair-long cis-acting elements with similar sequences at -70 and -20 base pairs (designated CCT or subunit gene transcription activating element 1 (CAE1) and CAE2, respectively). By yeast one-hybrid screening of CAE1-binding factors, we isolated human ZNF143, which is known to activate transcription of selenocysteine tRNA and small nuclear RNA genes. DNA binding domains of ZNF143 and ZNF76 produced in E. coli recognized CAE1 and CAE2 elements in electrophoretic mobility shift assay. HeLa cell nuclear extract contained a protein that specifically binds to CAE1 and CAE2 and recognized by anti-ZNF143 antibody. Transcription from a minimal Ccta promoter containing CAE2 element in HeLa cells was enhanced by overexpression of full-length ZNF143 and ZNF76 but inhibited by that of their DNA binding domains alone. These results demonstrate that the Staf family proteins control transcription of at least one of the chaperone-encoding genes besides that of tRNA and small nuclear RNA genes. These RNA and chaperone genes are suggested to be coregulated to facilitate synthesis of mature proteins during active cell growth.	HSP Res Inst, Shimogyo Ku, Kyoto 6008813, Japan		Kubota, H (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cellular Biol, Sakyo Ku, Kawahara Cho, Kyoto 6068397, Japan.		Yokota, Shin-ichi/K-8139-2019	Yokota, Shin-ichi/0000-0002-0831-3429				Adachi K, 1998, J BIOL CHEM, V273, P8598, DOI 10.1074/jbc.273.15.8598; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Farr GW, 1997, CELL, V89, P927, DOI 10.1016/S0092-8674(00)80278-0; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Kubota H, 1999, FEBS LETT, V461, P125, DOI 10.1016/S0014-5793(99)01437-4; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; Kubota H, 1999, EUR J BIOCHEM, V262, P492, DOI 10.1046/j.1432-1327.1999.00405.x; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; KUBOTA H, 1995, GENE, V154, P231, DOI 10.1016/0378-1119(94)00880-2; Lewis SA, 1996, J CELL BIOL, V132, P1, DOI 10.1083/jcb.132.1.1; Llorca O, 1999, NATURE, V402, P693, DOI 10.1038/45294; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; Myslinski E, 1998, J BIOL CHEM, V273, P21998, DOI 10.1074/jbc.273.34.21998; MYSLINSKI E, 1992, NUCLEIC ACIDS RES, V20, P203, DOI 10.1093/nar/20.2.203; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; RAGOUSSIS J, 1992, GENOMICS, V14, P673, DOI 10.1016/S0888-7543(05)80167-3; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Schaub M, 1997, EMBO J, V16, P173, DOI 10.1093/emboj/16.1.173; Schuster C, 1998, MOL CELL BIOL, V18, P2650, DOI 10.1128/MCB.18.5.2650; SCHUSTER C, 1995, EMBO J, V14, P3777, DOI 10.1002/j.1460-2075.1995.tb00047.x; Stoldt V, 1996, YEAST, V12, P523, DOI 10.1002/(SICI)1097-0061(199605)12:6<523::AID-YEA962>3.3.CO;2-3; Thulasiraman V, 1999, EMBO J, V18, P85, DOI 10.1093/emboj/18.1.85; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; TOMMERUP N, 1995, GENOMICS, V27, P259, DOI 10.1006/geno.1995.1040; Willison Keith R., 1996, P107, DOI 10.1016/B978-012237455-5/50006-3; WILLISON KR, 1990, GENET RES, V56, P193, DOI 10.1017/S0016672300035291; Won KA, 1998, MOL CELL BIOL, V18, P7584, DOI 10.1128/MCB.18.12.7584; Yokota S, 2000, EUR J BIOCHEM, V267, P1658, DOI 10.1046/j.1432-1327.2000.01157.x; Yokota S, 1999, J BIOL CHEM, V274, P37070, DOI 10.1074/jbc.274.52.37070; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	32	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28641	28648		10.1074/jbc.M005009200	http://dx.doi.org/10.1074/jbc.M005009200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893243	hybrid			2022-12-25	WOS:000089330700042
J	Nickoloff, BJ; Chaturvedi, V; Bacon, P; Qin, JZ; Denning, MF; Diaz, MO				Nickoloff, BJ; Chaturvedi, V; Bacon, P; Qin, JZ; Denning, MF; Diaz, MO			Id-1 delays senescence but does not immortalize keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; TELOMERASE ACTIVITY; REPLICATIVE SENESCENCE; RETINOBLASTOMA PROTEIN; CELL-GROWTH; INACTIVATION; GENE; HEAD; DIFFERENTIATION; P16(INK4A)	Defining the molecular basis responsible for regulating the proliferative potential of keratinocytes has important implications for normal homeostasis and neoplasia of the skin. Under current culture conditions, neonatal foreskin-derived human keratinocytes possess a relatively short replicative lifespan, Recently it was reported that forced overexpression of the helix-loop-helix protein Id-1 was capable of immortalizing keratinocytes, secondary to activation of telomerase activity and suppression of p16/Rb-mediated growth arrest pathways. To investigate the relationship between Id-1, telomerase activity, telomere length, pie, Rb cell cycle regulators, and senescence, whole populations of keratinocytes were infected with a retrovirus to induce overexpression of Id-1. In these unselected cultures, enhanced Id-1 levels clearly extended the lifespan of keratinocytes, but Id-1 did not prevent the onset of replicative senescence. Under these experimental conditions, Id-1 expression did not trigger induction of telomerase activity, and there was progressive shortening of the telomeres that was accompanied by elevated pie levels and prevalence of active Rb, The ability of Id-1 to postpone, but not prevent, senescence may be related to partial inhibition of pie expression, as the Id-1-overexpressing cultures displayed a decreased capacity for 12-O-tetradecanoylphorbol-13-acetate-mediated p16 induction, Thus, while no immortalization was observed, Id-1 could delay the onset of replicative senescence in unselected human keratinocyte populations.	Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Med, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago	Nickoloff, BJ (corresponding author), Cardinal Bernardin Canc Ctr, Skin Canc Res Program, Bldg 112,Rm 301,2160 S 1st Ave, Maywood, IL 60153 USA.	bnickol@lumc.edu						Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; Bickenbach JR, 1998, J INVEST DERMATOL, V111, P1045, DOI 10.1046/j.1523-1747.1998.00420.x; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Campisi C, 1998, LYMPHOLOGY, V31, P1; Campisi J, 1997, J AM GERIATR SOC, V45, P482, DOI 10.1111/j.1532-5415.1997.tb05175.x; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DEED RW, 1993, ONCOGENE, V8, P599; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; ElNaggar AK, 1997, AM J PATHOL, V151, P1767; Hara E, 1996, DEV GENET, V18, P161; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Loughran O, 1996, ONCOGENE, V13, P561; Munro J, 1999, CANCER RES, V59, P2516; Nickoloff BJ, 1999, J CLIN INVEST, V104, P1161, DOI 10.1172/JCI8633; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Pena JC, 1997, CELL GROWTH DIFFER, V8, P619; Qin JZ, 1999, J BIOL CHEM, V274, P37957, DOI 10.1074/jbc.274.53.37957; Reed AL, 1996, CANCER RES, V56, P3630; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687	28	109	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27501	27504						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10908559				2022-12-25	WOS:000089197100001
J	Kamohara, M; Takasaki, J; Matsumoto, M; Saito, T; Ohishi, T; Ishii, H; Furuichi, K				Kamohara, M; Takasaki, J; Matsumoto, M; Saito, T; Ohishi, T; Ishii, H; Furuichi, K			Molecular cloning and characterization of another leukotriene B-4 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE D4 RECEPTOR; IN-VITRO; CDNA CLONING; IDENTIFICATION; INFLAMMATION; ACTIVATION; EXPRESSION; POTENT; EOSINOPHILS; DISEASE	Leukotriene B-4 is a potent lipid mediator known to be implicated mainly in inflammatory actions. Previous pharmacological studies indicated the existence of only one class of G protein-coupled receptor for leukotriene B-4, for which a candidate gene, namely BLT, had been identified. Here we report the isolation of another gene encoding a functional G protein-coupled receptor for leukotriene B-4, named JULF2. JULF2 is a novel G protein-coupled receptor of 358 amino acids that shares 36.6% amino acid identity with human BLT, According to genomic information, the JULF2 gene is located on the chromosome 14, about 4 kilobases upstream of the BLT gene. During screening of endogenous ligands for JULF2, we found that leukotriene B-4 induced inhibition of forskolin-stimulated cAMP accumulation in Chinese hamster ovary cells, stably expressing JULF2, Additionally, Chinese hamster ovary cells expressing exogenous JULF2 showed chemotactic responses with leukotriene B-4 in a pertussis toxin-sensitive manner. A large amount of JULF2 mRNA was detected in the human spleen and the peripheral blood leukocytes. Furthermore, JULF2 mRNA was expressed in mononuclear lymphocytes, in which BLT mRNA was barely detected. The discovery of this second leukotriene B-4 receptor will eventually lead to a better understanding of the classification of leukotriene B-4 receptors and reconsideration of the pathophysiological role of leukotriene B-4.	Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Labs, Tsukuba, Ibaraki 3058585, Japan	Astellas Pharmaceuticals	Kamohara, M (corresponding author), Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Labs, 21 Miyukigaoka, Tsukuba, Ibaraki 3058585, Japan.	kamohara@yamanouchi.co.jp	Matsumoto, Mitsuyuki/G-3207-2012	Matsumoto, Mitsuyuki/0000-0002-1172-2354; Saito, Tetsu/0000-0002-9045-6743				Ali H, 1997, MED CLIN N AM, V81, P1, DOI 10.1016/S0025-7125(05)70503-4; Boie Y, 1999, EUR J PHARMACOL, V380, P203, DOI 10.1016/S0014-2999(99)00514-2; DEGIULIO R, 1993, ANN NY ACAD SCI, V685, P614, DOI 10.1111/j.1749-6632.1993.tb35925.x; EVANS JF, 1987, BIOCHIM BIOPHYS ACTA, V917, P406, DOI 10.1016/0005-2760(87)90119-6; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Gao JL, 1996, BIOCHEM BIOPH RES CO, V223, P679, DOI 10.1006/bbrc.1996.0955; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Gladue RP, 1996, J EXP MED, V183, P1893, DOI 10.1084/jem.183.4.1893; GOLDMAN DW, 1984, J ALLERGY CLIN IMMUN, V74, P373, DOI 10.1016/0091-6749(84)90133-7; GOLDMAN DW, 1984, J EXP MED, V159, P1027, DOI 10.1084/jem.159.4.1027; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; Huang WW, 1998, J EXP MED, V188, P1063, DOI 10.1084/jem.188.6.1063; Lynch KR, 1999, NATURE, V399, P789; Masuda K, 1999, BIOCHEM J, V342, P79, DOI 10.1042/0264-6021:3420079; Matsumoto M, 2000, GENE, V248, P183, DOI 10.1016/S0378-1119(00)00123-2; Matsumoto M, 1996, J NEUROCHEM, V66, P915; Matsumoto M, 1996, J BIOL CHEM, V271, P27217, DOI 10.1074/jbc.271.44.27217; MATSUMOTO M, 1995, MOL BRAIN RES, V29, P157, DOI 10.1016/0169-328X(94)00245-A; Medhurst AD, 2000, J NEUROSCI METH, V98, P9, DOI 10.1016/S0165-0270(00)00178-3; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nohgawa M, 1997, J LEUKOCYTE BIOL, V62, P203, DOI 10.1002/jlb.62.2.203; PAYAN DG, 1984, P NATL ACAD SCI-BIOL, V81, P3501, DOI 10.1073/pnas.81.11.3501; POST TW, 1995, J IMMUNOL, V155, P5299; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; SHARON P, 1984, GASTROENTEROLOGY, V86, P453; Showell HJ, 1996, BRIT J PHARMACOL, V117, P1127, DOI 10.1111/j.1476-5381.1996.tb16706.x; SHOWELL HJ, 1995, J PHARMACOL EXP THER, V273, P176; Toda A, 1999, BIOCHEM BIOPH RES CO, V262, P806, DOI 10.1006/bbrc.1999.1284; Turner CR, 1996, J CLIN INVEST, V97, P381, DOI 10.1172/JCI118426; YE RD, 1992, BIOCHEM BIOPH RES CO, V184, P582, DOI 10.1016/0006-291X(92)90629-Y; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	36	106	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27000	27004						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10889186				2022-12-25	WOS:000089144800045
J	Premont, RT; Claing, A; Vitale, N; Perry, SJ; Lefkowitz, RJ				Premont, RT; Claing, A; Vitale, N; Perry, SJ; Lefkowitz, RJ			The GIT family of ADP-ribosylation factor GTPase-activating proteins - Functional diversity of GIT2 through alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR KINASES; PHOSPHOLIPASE-D; ARF PROTEINS; IDENTIFICATION; LOCALIZATION; PURIFICATION; BINDS; MOTIF; SRC; PAK	We recently characterized a novel protein, GIT1, that interacts with G protein-coupled receptor kinases and possesses ADP-ribosylation factor (ARF) GTPase-activating protein activity. A second ubiquitously expressed member of the GIT protein family, GIT2, has been identified in data base searches. GIT2 undergoes extensive alternative splicing and exists in at least 10 and potentially as many as 33 distinct forms. The longest form of GIT2 is colinear with GIT1 and shares the same domain structure, whereas one major splice variant prominent in immune tissues completely lacks the carboxyl-terminal domain. The other 32 potential variants arise from the independent alternative splicing of five internal regions in the center of the molecule but share both the amino-terminal ARF GTPase-activating protein domain and carboxyl-terminal domain. Both the long and short carboxyl-terminal variants of GIT2 are active as GTPase-activating proteins for ARF1, and both also interact with G: protein-coupled receptor kinase 2 and with pal-activated kinase-interacting exchange factors complexed with pal-activated kinase but not with paxillin. Cellular overexpression of the longest variant of GIT2 leads to inhibition of beta(2)-adrenergic receptor sequestration, whereas the shortest splice variant appears inactive. Although GIT2 shares many properties with GIT1, it also exhibits both structural and functional diversity due to tissue-specific alternative splicing.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA; Ctr Neurochim, INSERM U 338, F-67084 Strasbourg, France	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Institut National de la Sante et de la Recherche Medicale (Inserm)	Premont, RT (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Box 3083, Durham, NC 27710 USA.	richard.premont@duke.edu	Lefkowitz, Robert/AAW-2649-2021; Vitale, Nicolas/G-5967-2014	Vitale, Nicolas/0000-0002-4752-4907; Premont, Richard/0000-0002-8053-5026	NHLBI NIH HHS [HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andreev J, 1999, MOL CELL BIOL, V19, P2338; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; King FJ, 1999, MOL CELL BIOL, V19, P2330; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; Mandiyan V, 1999, EMBO J, V18, P6890, DOI 10.1093/emboj/18.24.6890; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Nagase T, 1995, DNA Res, V2, P167, DOI 10.1093/dnares/2.4.167; Oh WK, 1997, BIOCHEM BIOPH RES CO, V235, P794, DOI 10.1006/bbrc.1997.6875; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; RANDAZZO PA, 1994, J BIOL CHEM, V269, P29490; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Vitale N, 2000, J BIOL CHEM, V275, P13901, DOI 10.1074/jbc.275.18.13901	26	114	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22373	22380		10.1074/jbc.275.29.22373	http://dx.doi.org/10.1074/jbc.275.29.22373			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10896954	hybrid			2022-12-25	WOS:000088363800084
J	Suzuki, A; Hayashida, M; Ito, T; Kawano, H; Nakano, T; Miura, M; Akahane, K; Shiraki, K				Suzuki, A; Hayashida, M; Ito, T; Kawano, H; Nakano, T; Miura, M; Akahane, K; Shiraki, K			Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/Cyclin E complex activation	ONCOGENE			English	Article						Survivin; Cdk; INK4a; p27; cell cycle progression	ANTI-APOPTOSIS GENE; DEPENDENT KINASE INHIBITOR; FAS-MEDIATED APOPTOSIS; TUMOR NECROSIS FACTOR; DEATH FACTOR; RETINOBLASTOMA PROTEIN; IAP GENE; CANCER; P21; EXPRESSION	Survivin is observed uniquely in tumor cells and developmental cells, which undergo either inappropriate or programmed cell growth, In the current study, we investigated the influence of Survivin on cell cycle, Overexpression of Survivin resulted in accelerated S phase shift, resistance to G1 arrest, and activated Cdk2/Cyclin E complex leading Rb phosphorylation, In addition, nuclear translocation of Survivin followed by an interaction with Cdk4 was detected. Interestingly, Survivin nuclear translocation coincided with S phase shift, and prevention of nuclear transport suppressed Survivin nuclear translocation and S phase shift. Further, we also observed that Survivin competitively interacted with the Cdk4/p16(INK4n) complex in a cell free system and in vivo. These results suggest that Survivin initiates the cell cycle entry as a result of nuclear translocation followed by an interaction with Cdk4.	Daiichi Pharmaceut Co Ltd, Basic Technol Res Lab, Project Cell Death Res, Tokyo R&D Ctr,Edogawa Ku, Tokyo 1348630, Japan; Mie Univ, Dept Internal Med 1, Sch Med, Tsu, Mie 5148507, Japan; Osaka Univ, Sch Med, Biomed Res Ctr, Dept Neuroanat, Suita, Osaka 565, Japan; Daiichi Pharmaceut Co Ltd, New Prod Res Labs 4, Tokyo R&D Ctr, Edogawa Ku, Tokyo 1348630, Japan	Daiichi Sankyo Company Limited; Mie University; Osaka University; Daiichi Sankyo Company Limited	Suzuki, A (corresponding author), Daiichi Pharmaceut Co Ltd, Basic Technol Res Lab, Project Cell Death Res, Tokyo R&D Ctr,Edogawa Ku, Kitakasai 1-16-13, Tokyo 1348630, Japan.							Adida C, 1998, LANCET, V351, P882, DOI 10.1016/S0140-6736(05)70294-4; Adida C, 1998, AM J PATHOL, V152, P43; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HARPER JW, 1993, CELL, V75, P805; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Ito T, 2000, HEPATOLOGY, V31, P1080, DOI 10.1053/he.2000.6496; Kawasaki H, 1998, CANCER RES, V58, P5071; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li FZ, 1999, CANCER RES, V59, P3143; LI Y, 1994, ONCOGENE, V9, P2261; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; Lu CD, 1998, CANCER RES, V58, P1808; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1994, PHILOS T ROY SOC B, V345, P281, DOI 10.1098/rstb.1994.0107; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Parry D, 1999, MOL CELL BIOL, V19, P1775; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Sugimoto M, 1999, GENE DEV, V13, P3027, DOI 10.1101/gad.13.22.3027; Suzuki A, 1996, EMBO J, V15, P211, DOI 10.1002/j.1460-2075.1996.tb00351.x; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Swana HS, 1999, NEW ENGL J MED, V341, P452, DOI 10.1056/NEJM199908053410614; Tamm I, 1998, CANCER RES, V58, P5315; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	48	163	231	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2000	19	29					3225	3234		10.1038/sj.onc.1203665	http://dx.doi.org/10.1038/sj.onc.1203665			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918579				2022-12-25	WOS:000088019300001
J	Roth, G; Kotzka, J; Kremer, L; Lehr, S; Lohaus, C; Meyer, HE; Krone, W; Muller-Wieland, D				Roth, G; Kotzka, J; Kremer, L; Lehr, S; Lohaus, C; Meyer, HE; Krone, W; Muller-Wieland, D			MAP kinases Erk1/2 phosphorylate sterol regulatory element-binding protein (SREBP)-1a at serine 117 in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; AMINO-ACID-SEQUENCES; SIGNAL-TRANSDUCTION; HEPG2 CELLS; TRANSCRIPTION; PATHWAY; ACTIVATION; PEPTIDES; INSULIN; SREBP	Sterol regulatory element-binding protein (SREBP)-1a is a transcription factor sensing cellular cholesterol levels and integrating gene regulatory signals mediated by MAP kinase cascades, Here we report the identification of serine 117 in SREBP-1a as the major phosphorylation site of the MAP kinases Erk1/2. This site was identified by nanoelectrospray mass spectrometry and peptide sequencing of recombinant fusion proteins phosphorylated by Erk1/2 in vitro. Serine 117 was verified as the major phosphorylation site by in vitro mutagenesis, Mutation of serine 117 to alanine abolished Erk2-mediated phosphorylation in vitro and the MAP kinase-related transcriptional activation of SREBP-1a by insulin and platelet-derived growth factor in vivo. Our data indicate that the MAP kinase-mediated effects on SREBP-1a-regulated target genes are linked to this phosphorylation site.	Univ Cologne, Klin & Poliklin Innere Med Klin 2, D-50924 Cologne, Germany; Ruhr Univ Bochum, Prot Strukturlab, D-50924 Cologne, Germany	University of Cologne; Ruhr University Bochum	Muller-Wieland, D (corresponding author), Univ Cologne, Klin & Poliklin Innere Med Klin 2, D-50924 Cologne, Germany.	dirk.mueller-wieland@medizin.uni-koeln.de		Kotzka, Jorg/0000-0003-1173-9372				Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Ericsson J, 1998, J BIOL CHEM, V273, P17865, DOI 10.1074/jbc.273.28.17865; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Kotzka J, 2000, J LIPID RES, V41, P99; Kotzka J, 1998, BIOCHEM BIOPH RES CO, V249, P375, DOI 10.1006/bbrc.1998.9161; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; LLOYD DB, 1995, J BIOL CHEM, V270, P25812, DOI 10.1074/jbc.270.43.25812; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Meier CA, 1997, EUR J ENDOCRINOL, V136, P271, DOI 10.1530/eje.0.1360271; MEYER HE, 1991, METHOD ENZYMOL, V201, P206; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SATO R, 1994, J BIOL CHEM, V269, P17267; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; STOPECK AT, 1993, J BIOL CHEM, V268, P17489; Streicher R, 1996, J BIOL CHEM, V271, P7128, DOI 10.1074/jbc.271.12.7128; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020	24	131	136	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33302	33307		10.1074/jbc.M005425200	http://dx.doi.org/10.1074/jbc.M005425200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10915800	hybrid			2022-12-25	WOS:000090104600020
J	Csordas, G; Santra, M; Reed, CC; Eichstetter, I; McQuillan, DJ; Gross, D; Nugent, MA; Hajnoczky, G; Iozzo, RV				Csordas, G; Santra, M; Reed, CC; Eichstetter, I; McQuillan, DJ; Gross, D; Nugent, MA; Hajnoczky, G; Iozzo, RV			Sustained down-regulation of the epidermal growth factor receptor by decorin - A mechanism for controlling tumor growth in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH PROTEOGLYCANS; DROSOPHILA EGF RECEPTOR; CELL-GROWTH; ACTIVATION; COLLAGEN; SIGNAL; LIGAND; FAMILY; SUPPRESSION; STIMULATION	The small leucine-rich proteoglycan decorin interacts with the epidermal growth factor receptor (EGFR) and triggers a signaling cascade that leads to elevation of endogenous p21 and growth suppression. We demonstrate that decorin causes a sustained down-regulation of the EGFR. Upon stable expression of decorin, the EGFR number is reduced by similar to 40%, without changes in EGFR expression. However, EGFR phosphorylation is nearly completely abolished. Concurrently, decorin attenuates the EGFR-mediated mobilization of intracellular calcium and blocks the growth of tumor xenografts by down-regulating the EGFR kinase in vivo. Thus, decorin acts as an autocrine and paracrine regulator of tumor growth and could be utilized as an effective anticancer agent.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, JAH, Philadelphia, PA 19107 USA; LifeCell Corp, Branchburg, NJ 08876 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Cell Biol & Signaling Program, Philadelphia, PA 19107 USA	Jefferson University; Boston University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, JAH, Rm 249,1020 Locust St, Philadelphia, PA 19107 USA.		Iozzo, Renato/AAS-1980-2020	Nugent, Matthew/0000-0002-8630-4712; Csordas, Gyorgy/0000-0003-3156-1460; Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [CA47282, CA39481] Funding Source: Medline; NEI NIH HHS [EY11004] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011004] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Berridge M, 1999, CURR BIOL, V9, pR157, DOI 10.1016/S0960-9822(99)80101-8; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Conrad H. E., 1998, HEPARIN BINDING PROT; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FILMUS J, 1987, MOL CELL BIOL, V7, P251, DOI 10.1128/MCB.7.1.251; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; Iozzo RV, 1999, P NATL ACAD SCI USA, V96, P3092, DOI 10.1073/pnas.96.6.3092; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Musacchio M, 1996, DEV BIOL, V178, P63, DOI 10.1006/dbio.1996.0198; Nash MA, 1999, CANCER RES, V59, P6192; NUGENT MA, 1989, CANCER RES, V49, P3884; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; Perrimon N, 1997, CELL, V89, P13, DOI 10.1016/S0092-8674(00)80177-4; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; QUI Y, 1998, NATURE, V393, P83; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SANTRA M, 2000, J BIOL CHEM     0814; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Weiss FU, 1997, CURR OPIN GENET DEV, V7, P80, DOI 10.1016/S0959-437X(97)80113-X; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369	44	191	206	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32879	32887		10.1074/jbc.M005609200	http://dx.doi.org/10.1074/jbc.M005609200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913155	hybrid			2022-12-25	WOS:000090003800069
J	Gibbons, HS; Lin, S; Cotter, RJ; Raetz, CRH				Gibbons, HS; Lin, S; Cotter, RJ; Raetz, CRH			Oxygen requirement for the biosynthesis of the S-2-hydroxymyristate moiety in Salmonella typhimurium lipid A - Function of LpxO, a new Fe2+/alpha-ketoglutarate-dependent dioxygenase homologue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINYL BETA-HYDROXYLASE; ESCHERICHIA-COLI; BACTERIAL VIRULENCE; PSEUDOMONAS-AERUGINOSA; POLYMYXIN RESISTANCE; GENE-EXPRESSION; REGULATED GENES; PHOP REGULON; IN-VIVO; LIPOPOLYSACCHARIDES	Lipid A molecules of certain Gram-negative bacteria, including Salmonella typhimurium and Pseudomonas aeruginosa, may contain secondary S-2-hydroxyacyl chains. S. typhimurium has recently been shown to synthesize its S-2-hydroxymyristate-modified lipid A in a PhoP/PhoQ-dependent manner, suggesting a possible role for the 2-OH group in pathogenesis, We postulated that 2-hydroxylation might be catalyzed by a novel dioxygenase. Lipid A was extracted from a PhoP-constitutive mutant of S. typhimurium grown in the presence or absence of O-2. Under anaerobic conditions, no 2-hydroxymyristate-containing lipid A was formed. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry of lipid A from cells grown in the presence of O-18(2) confirmed the direct incorporation of molecular oxygen into 2-hydroxyacyl-modified lipid A. Using several well characterized dioxygenase protein sequences as probes, tBLASTn searches revealed unassigned open reading frame(s) with similarity to mammalian aspartyl/asparaginyl beta -hydroxylases in bacteria known to make 2-hydroxyacylated lipid A molecules. The S. typhimurium aspartyl/asparaginyl beta -hydroxylase homologue (designated lpxO) was cloned into pBluescriptSK and expressed in Escherichia coli K-12, which does not contain lpxO. Analysis of the resulting construct revealed that lpxO expression is sufficient to induce O-2-dependent formation of 2-hydroxymyristate-modified lipid A in E. coli. LpxO very likely is a novel Fe2+/alpha -ketoglutarate-dependent dioxygenase that catalyzes the hydroxylation of lipid A (or of a key precursor). The S. typhimurium lpxO gene encodes a polypeptide of 302 amino acids with predicted membrane-anchoring sequences at both ends. We hypothesize that 2-hydroxymyristate chains released from lipopolysaccharide inside infected macrophages might be converted to 2-hydroxymyristoyl coenzyme A, a well characterized, potent inhibitor of protein N-myristoyl transferase.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Middle Atlantic Mass Spectrometry Lab, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu		Gibbons, Henry/0000-0002-5603-8679	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054882, R01GM051310] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07184-23, GM-54882, GM-51310] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BELDEN WJ, 1994, INFECT IMMUN, V62, P5095, DOI 10.1128/IAI.62.11.5095-5101.1994; Beutler B, 2000, CURR OPIN MICROBIOL, V3, P23, DOI 10.1016/S1369-5274(99)00046-6; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRYN K, 1978, EUR J BIOCHEM, V86, P311, DOI 10.1111/j.1432-1033.1978.tb12312.x; CHRIST WJ, 1994, J AM CHEM SOC, V116, P3637, DOI 10.1021/ja00087a075; Clementz T, 1997, J BIOL CHEM, V272, P10353; CLERESCI LS, 1989, STANDARD METHODS EXA; DINARELLO CA, 1991, BLOOD, V77, P1627; Eichhorn E, 1997, J BIOL CHEM, V272, P23031, DOI 10.1074/jbc.272.37.23031; Ernst RK, 1999, J INFECT DIS, V179, pS326, DOI 10.1086/513850; Ernst RK, 1999, SCIENCE, V286, P1561, DOI 10.1126/science.286.5444.1561; ERWIN AL, 1990, J BIOL CHEM, V265, P16444; ERWIN AL, 1992, BACTERIAL ENDOTOXIC, V1, P405; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garcia-del Portillo F, 1999, TRENDS MICROBIOL, V7, P467, DOI 10.1016/S0966-842X(99)01618-2; GOLDMAN RC, 1988, J BIOL CHEM, V263, P5217; Groisman EA, 1998, BIOESSAYS, V20, P96, DOI 10.1002/(SICI)1521-1878(199801)20:1<96::AID-BIES13>3.0.CO;2-3; GROISMAN EA, 1989, P NATL ACAD SCI USA, V86, P7077, DOI 10.1073/pnas.86.18.7077; Groisman EA, 1997, J BACTERIOL, V179, P7040, DOI 10.1128/jb.179.22.7040-7045.1997; GRONKE RS, 1989, P NATL ACAD SCI USA, V86, P3609, DOI 10.1073/pnas.86.10.3609; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; HANCOCK IC, 1970, BIOCHIM BIOPHYS ACTA, V202, P389, DOI 10.1016/0005-2760(70)90204-3; Hegg EL, 1999, BIOCHEMISTRY-US, V38, P16714, DOI 10.1021/bi991796l; Hegg EL, 1997, EUR J BIOCHEM, V250, P625, DOI 10.1111/j.1432-1033.1997.t01-1-00625.x; Heithoff DM, 1999, SCIENCE, V284, P967, DOI 10.1126/science.284.5416.967; Heithoff DM, 1997, P NATL ACAD SCI USA, V94, P934, DOI 10.1073/pnas.94.3.934; HOLME E, 1975, BIOCHEMISTRY-US, V14, P4999, DOI 10.1021/bi00693a033; HUMPHREYS GO, 1972, J GEN MICROBIOL, V71, P221, DOI 10.1099/00221287-71-2-221; JIA S, 1994, P NATL ACAD SCI USA, V91, P7227, DOI 10.1073/pnas.91.15.7227; JIA S, 1992, J BIOL CHEM, V267, P14322; Jones BD, 1996, ANNU REV IMMUNOL, V14, P533, DOI 10.1146/annurev.immunol.14.1.533; Katz SS, 1999, J BIOL CHEM, V274, P36579, DOI 10.1074/jbc.274.51.36579; KAWAHARA K, 1979, BIOCHIM BIOPHYS ACTA, V572, P1; KAWAI Y, 1982, J BACTERIOL, V151, P996, DOI 10.1128/JB.151.2.996-1005.1982; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Lindgren SW, 1996, P NATL ACAD SCI USA, V93, P4197, DOI 10.1073/pnas.93.9.4197; MAHAN MJ, 1995, P NATL ACAD SCI USA, V92, P669, DOI 10.1073/pnas.92.3.669; MAHAN MJ, 1993, SCIENCE, V259, P686, DOI 10.1126/science.8430319; MEADE HM, 1982, J BACTERIOL, V149, P114, DOI 10.1128/JB.149.1.114-122.1982; Miller J. H., 1972, EXPT MOL GENETICS, P439; MILLER SI, 1990, J BACTERIOL, V172, P2485, DOI 10.1128/jb.172.5.2485-2490.1990; Monack DM, 1996, P NATL ACAD SCI USA, V93, P9833, DOI 10.1073/pnas.93.18.9833; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; MUNFORD RS, 1986, SCIENCE, V234, P203, DOI 10.1126/science.3529396; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; PAIGE LA, 1990, BIOCHEMISTRY-US, V29, P10566, DOI 10.1021/bi00498a021; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1973, J BIOL CHEM, V248, P1098; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; Reissbrodt R, 1997, J BACTERIOL, V179, P4538, DOI 10.1128/jb.179.14.4538-4544.1997; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; RichterDahlfors A, 1997, J EXP MED, V186, P569, DOI 10.1084/jem.186.4.569; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanderson KE, 1996, ESCHERICHIA COLI SAL, V2, P1903; Schofield CJ, 1999, CURR OPIN STRUC BIOL, V9, P722, DOI 10.1016/S0959-440X(99)00036-6; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; STENFLO J, 1989, P NATL ACAD SCI USA, V86, P444, DOI 10.1073/pnas.86.2.444; THORNBURG LD, 1993, BIOCHEMISTRY-US, V32, P14034, DOI 10.1021/bi00213a037; Valegard K, 1998, NATURE, V394, P805, DOI 10.1038/29575; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; WELCH DF, 1991, CLIN MICROBIOL REV, V4, P422, DOI 10.1128/CMR.4.4.422-438.1991; Zahringer U, 1995, Prog Clin Biol Res, V392, P113; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	76	126	129	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32940	32949		10.1074/jbc.M005779200	http://dx.doi.org/10.1074/jbc.M005779200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10903325	hybrid			2022-12-25	WOS:000090003800078
J	Huang, CS; Zhang, Z; Ding, M; Li, JX; Ye, JP; Leonard, SS; Shen, HM; Butterworth, L; Lu, YJ; Costa, M; Rojanasakul, Y; Castranova, V; Vallyathan, V; Shin, XL				Huang, CS; Zhang, Z; Ding, M; Li, JX; Ye, JP; Leonard, SS; Shen, HM; Butterworth, L; Lu, YJ; Costa, M; Rojanasakul, Y; Castranova, V; Vallyathan, V; Shin, XL			Vanadate induces p53 transactivation through hydrogen peroxide and causes apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; MORPHOLOGICAL TRANSFORMATION; AMMONIUM METAVANADATE; ACTIVATOR PROTEIN-1; SIGNAL-TRANSDUCTION; RADICAL GENERATION; GENE-EXPRESSION; P38 KINASE; GROWTH	Vanadium is a metal widely distributed in the environment. Although vanadate-containing compounds exert potent toxic effects on a wide variety of biological systems, the mechanisms controlling vanadate-induced adverse effects remain to be elucidated. The present study investigated the vanadate-induced p53 activation and involvement of reactive oxygen species (ROS) in p53 activation as well as the role of p53 in apoptosis induction by vanadate. Exposure of mouse epidermal JB6 cells to vanadate led to transactivation of p53 activity in a time- and dose-dependent manner. It also caused mitochondrial damage, apoptosis, and generated ROS. Scavenging of vanadate-induced H2O2 by N-acetyl-L-cysteine (a general antioxidant) or catalase (a specific H2O2 inhibitor), or the chelation of vanadate by deferoxamine, resulted in inhibition of p53 activation and cell mitochondrial damage. In contract, an increase in H2O2 generation in response to superoxide dismutase or NADPH enhanced these effects caused by vanadate. Furthermore, vanadate-induced apoptosis occurred in cells expressing wild-type p53 (p53+/+) but was very weak in p53-deficient (p53-/-) cells. These results demonstrate that vanadate induces p53 activation mainly through H2O2 generation, and this activation is required for vanadate-induced apoptosis.	NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA; NYU, Sch Med, Nelson Inst Environm Med, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; W Virginia Univ, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); New York University; New York University; West Virginia University	Shin, XL (corresponding author), NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA.	xas0@cdc.gov	Ye, Jianping/N-1998-2017; SHEN, Han-Ming/B-5942-2011; Zhang, Zhuo/B-8601-2012; costa, max/H-1754-2012	Ye, Jianping/0000-0003-3875-365X; SHEN, Han-Ming/0000-0001-7369-5227; Huang, Chuanshu/0000-0003-4133-5096; Rojanasakul, Yon/0000-0002-8839-6462				Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; ALLEN PD, 1993, BLOOD REV, V7, P63, DOI 10.1016/0268-960X(93)90025-Y; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; Chen ZP, 1996, BIOCHEM MOL BIOL INT, V38, P607; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COHEN MD, 1992, MUTAT RES, V269, P141, DOI 10.1016/0027-5107(92)90169-3; Ding M, 1999, CARCINOGENESIS, V20, P663, DOI 10.1093/carcin/20.4.663; EDINGTON SM, 1993, BIOTECHNOLOGY, V11, P787; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; HARVEY M, 1993, ONCOGENE, V8, P2457; HENNET T, 1993, CANCER RES, V53, P1456; Huang CS, 1998, CANCER RES, V58, P4102; Huang CS, 1998, INT J ONCOL, V13, P711; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1997, P NATL ACAD SCI USA, V94, P11957, DOI 10.1073/pnas.94.22.11957; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; Meek DW, 1997, BIOCHEM SOC T, V25, P416, DOI 10.1042/bst0250416; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NORDEEN SK, 1976, J BIOL CHEM, V251, P7295; NRIAGU JO, 1988, NATURE, V333, P134, DOI 10.1038/333134a0; PARFETT CLJ, 1995, FOOD CHEM TOXICOL, V33, P301, DOI 10.1016/0278-6915(94)00141-A; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAFF MC, 1992, SCIENCE, V356, P397; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHEU CW, 1992, FOOD CHEM TOXICOL, V30, P307, DOI 10.1016/0278-6915(92)90008-9; SHI XL, 1992, FREE RADICAL RES COM, V17, P369, DOI 10.3109/10715769209083141; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Ye JP, 1999, MOL CELL BIOCHEM, V202, P9, DOI 10.1023/A:1007078915585; Ye JP, 1999, J BIOL CHEM, V274, P34974, DOI 10.1074/jbc.274.49.34974; YIN XF, 1992, MOL CELL BIOCHEM, V115, P85	48	147	151	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32516	32522		10.1074/jbc.M005366200	http://dx.doi.org/10.1074/jbc.M005366200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10922372	hybrid, Green Submitted			2022-12-25	WOS:000090003800020
J	Keyhani, NO; Li, XB; Roseman, S				Keyhani, NO; Li, XB; Roseman, S			Chitin catabolism in the marine bacterium Vibrio furnissii - Identification and molecular cloning of a chitoporin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAFFINOSE PLASMID PRSD2; GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; PHOSPHOTRANSFERASE SYSTEM; SUGAR-TRANSPORT; OUTER-MEMBRANE; DIFFUSION CHANNELS; RECEPTOR PROTEIN; ENTERIC BACTERIA; CASCADE	Chitin catabolism by the marine bacterium Vibrio furnissii involves many genes and proteins, including two unique periplasmic hydrolases, a chitodextrinase and a beta -N-acetylglucosaminidase (Keyhani, N. O., and Roseman, S, (1996) J. Biol; Chem. 271, 33414-33424 and 33425-33432). A specific chitoporin in the outer membrane may be required for these glycosidases to be accessible to extracellular chitooligosaccharides, (GlcN-Ac)(n), that are produced by chitinases. We report here the identification and molecular cloning of such a porin. An outer membrane protein, OMP (apparent molecular mass 40 kDa) was expressed when V, furnissii was induced by (GlcNAc)(n), n = 2-6, but not by GlcNAc or other sugars. Based on the N-terminal sequence of OMP, oligonucleotides were synthesized and used to clone the gene, chiP. The deduced amino acid sequence of ChiP is similar to several bacterial porins; OMP is a processed form of Chip. In Escherichia coli, two recombinant proteins were observed, corresponding to processed and unprocessed forms of ChiP, A null mutant of chiP was constructed in V. furnissii. In contrast to the parental strain, the mutant did not grow on (GlcNAc), and transported a nonmetabolizable analogue of (GlcNAc), at a reduced rate. These results imply that ChiP is a specific chitoporin.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Roseman, S (corresponding author), Johns Hopkins Univ, Dept Biol, Mudd Hall,Rm 214,3400 N Charles St, Baltimore, MD 21218 USA.		Keyhani, Nemat O/I-8150-2013		NIGMS NIH HHS [GM51215] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen C, 1998, EUR J BIOCHEM, V254, P679, DOI 10.1046/j.1432-1327.1998.2540679.x; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V1; BASSLER BL, 1991, J BIOL CHEM, V266, P24268; BASSLER BL, 1991, J BIOL CHEM, V266, P24276; BENZ R, 1988, ANNU REV MICROBIOL, V42, P359, DOI 10.1146/annurev.mi.42.100188.002043; Bouma CL, 1996, J BIOL CHEM, V271, P33457, DOI 10.1074/jbc.271.52.33457; Bouma CL, 1996, J BIOL CHEM, V271, P33468, DOI 10.1074/jbc.271.52.33468; Chitlaru E, 1996, J BIOL CHEM, V271, P33433, DOI 10.1074/jbc.271.52.33433; FILIP C, 1973, J BACTERIOL, V115, P717, DOI 10.1128/JB.115.3.717-722.1973; FORST S, 1988, J BACTERIOL, V170, P5080, DOI 10.1128/jb.170.11.5080-5085.1988; GEHRING K, 1991, J BACTERIOL, V173, P1873, DOI 10.1128/jb.173.6.1873-1878.1991; HOROWITZ ST, 1957, J AM CHEM SOC, V79, P5046, DOI 10.1021/ja01575a059; Keyhani N, 2000, J BIOL CHEM, V275, P33110, DOI 10.1074/jbc.M001717200; Keyhani NO, 2000, J BIOL CHEM, V275, P33102, DOI 10.1074/jbc.M001045200; Keyhani NO, 2000, J BIOL CHEM, V275, P33091, DOI 10.1074/jbc.M001044200; Keyhani NO, 2000, J BIOL CHEM, V275, P33084, DOI 10.1074/jbc.M001043200; Keyhani NO, 1996, J BIOL CHEM, V271, P33425, DOI 10.1074/jbc.271.52.33425; Keyhani NO, 1996, J BIOL CHEM, V271, P33414, DOI 10.1074/jbc.271.52.33414; Keyhani NO, 1996, J BIOL CHEM, V271, P33409, DOI 10.1074/jbc.271.52.33409; LUCKEY M, 1980, BIOCHEM BIOPH RES CO, V93, P166, DOI 10.1016/S0006-291X(80)80261-0; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; MCCARTER LL, 1987, J BACTERIOL, V169, P3441, DOI 10.1128/jb.169.8.3441-3449.1987; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; MILTON DL, 1992, J BACTERIOL, V174, P7235, DOI 10.1128/jb.174.22.7235-7244.1992; NIKAIDO H, 1994, J BIOL CHEM, V269, P3905; NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121; NIKAIDO H, 1992, MOL MICROBIOL, V6, P435, DOI 10.1111/j.1365-2958.1992.tb01487.x; Osborn M J, 1974, Methods Enzymol, V31, P642; Park JK, 2000, J BIOL CHEM, V275, P33077, DOI 10.1074/jbc.M001042200; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SCHMID K, 1991, MOL MICROBIOL, V5, P941, DOI 10.1111/j.1365-2958.1991.tb00769.x; Schulz GE, 1996, CURR OPIN STRUC BIOL, V6, P485, DOI 10.1016/S0959-440X(96)80113-8; SELVARAJ G, 1984, GENE, V32, P235, DOI 10.1016/0378-1119(84)90051-9; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; STOCK JB, 1982, J BIOL CHEM, V257, P4543; Ulmke C, 1997, J BACTERIOL, V179, P5783, DOI 10.1128/jb.179.18.5783-5788.1997; Wang LX, 1995, CARBOHYDR LETT, V1, P185; WANG YF, 1997, J MOL BIOL, V272, P57; WAYGOOD EB, 1979, ANAL BIOCHEM, V95, P293, DOI 10.1016/0003-2697(79)90219-7; YU C, 1993, J BIOL CHEM, V268, P9405; YU C, 1991, J BIOL CHEM, V266, P24260	43	60	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33068	33076		10.1074/jbc.M001041200	http://dx.doi.org/10.1074/jbc.M001041200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913115	hybrid			2022-12-25	WOS:000090003800094
J	Fan, XM; Brass, LF; Poncz, M; Spitz, F; Maire, P; Manning, DR				Fan, XM; Brass, LF; Poncz, M; Spitz, F; Maire, P; Manning, DR			The alpha subunits of G(z) and G(i) interact with the eyes absent transcription cofactor Eya2, preventing its interaction with the six class of homeodomain-containing proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; NUCLEOTIDE EXCHANGE FACTOR; GTPASE-ACTIVATING PROTEIN; HETEROTRIMERIC G-PROTEINS; CYCLIC-AMP ACCUMULATION; SERUM RESPONSE FACTOR; NF-KAPPA-B; BINDING PROTEIN; DROSOPHILA EYE; SF9 CELLS	Yeast two-hybrid techniques were used to identify possible effecters for the heterotrimeric G protein G, in human bone marrow cells. Eya2, a human homologue of the Drosophila Eya transcription co-activator, was identified. Eya2 interacts with activated G alpha(z), and at feast one other member of the G alpha(i) family, G alpha(i2),. Interactions were confirmed in mammalian two-hybrid and glutathione S-transferase fusion protein pull-down assays. Regions of Eya2-mediating interaction were mapped to the C-terminal Eya consensus domain. Eya2 is an intrinsically cytosolic protein that is translocated to the nucleus by members of the Six homeodomain-containing family of proteins. Activated G alpha(z) and G alpha(i2) prevent Eya2 translocation and inhibit Six/Eya2-mediated activation of a reporter gene controlled through the MEF3/TATA promoter. Although G proteins are known to regulate the activity of numerous transcription factors, this regulation is normally achieved indirectly via one or more intermediates. We show here a novel functional regulation of a co-activator directly by G protein subunits.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Paris 05, Inst Cochin Genet Mol, INSERM, U129, F-75014 Paris, France	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Manning, DR (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.		Maire, Pascal/E-6339-2016	Maire, Pascal/0000-0001-7795-0029	NHLBI NIH HHS [HL45181] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045181] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Barr AJ, 1997, J BIOL CHEM, V272, P2223; BERVEN LA, 1995, J BIOL CHEM, V270, P25893, DOI 10.1074/jbc.270.43.25893; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BONINI NM, 1995, CURR OPIN GENET DEV, V5, P507, DOI 10.1016/0959-437X(95)90056-M; Borsani G, 1999, HUM MOL GENET, V8, P11, DOI 10.1093/hmg/8.1.11; Boucher CA, 1996, GENOMICS, V33, P140, DOI 10.1006/geno.1996.0172; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; Chen LT, 1999, J BIOL CHEM, V274, P26931, DOI 10.1074/jbc.274.38.26931; Chen R, 1997, CELL, V91, P893, DOI 10.1016/S0092-8674(00)80481-X; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Crouch MF, 2000, CELL SIGNAL, V12, P153, DOI 10.1016/S0898-6568(99)00080-7; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Fishburn CS, 2000, P NATL ACAD SCI USA, V97, P1085, DOI 10.1073/pnas.97.3.1085; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Garcia DE, 1998, J NEUROSCI, V18, P9163; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; HALLAK H, 1994, J BIOL CHEM, V269, P4571; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Harhammer R, 1996, FEBS LETT, V399, P211, DOI 10.1016/S0014-5793(96)01327-0; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HIDE M, 1991, MOL PHARMACOL, V40, P473; HINTON DR, 1990, J NEUROSCI, V10, P2763; Jeong SW, 1998, NEURON, V21, P1201, DOI 10.1016/S0896-6273(00)80636-4; Johanson SO, 1996, NEUROCHEM RES, V21, P779, DOI 10.1007/BF02532300; JONES DT, 1987, J BIOL CHEM, V262, P14241; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Lin P, 2000, P NATL ACAD SCI USA, V97, P674, DOI 10.1073/pnas.97.2.674; Luo Y, 1999, J BIOL CHEM, V274, P10685, DOI 10.1074/jbc.274.16.10685; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Meng JW, 1999, J BIOL CHEM, V274, P36663, DOI 10.1074/jbc.274.51.36663; MOCHIZUKI N, 1995, FEBS LETT, V373, P155, DOI 10.1016/0014-5793(95)01031-9; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Ohto H, 1999, MOL CELL BIOL, V19, P6815; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Pryciak PM, 1996, MOL CELL BIOL, V16, P2614; PUMIGLIA KM, 1995, J BIOL CHEM, V270, P14251, DOI 10.1074/jbc.270.24.14251; Ram PT, 2000, SCIENCE, V287, P142, DOI 10.1126/science.287.5450.142; Shahrestanifar M, 1999, J BIOL CHEM, V274, P3828, DOI 10.1074/jbc.274.6.3828; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Spitz F, 1998, P NATL ACAD SCI USA, V95, P14220, DOI 10.1073/pnas.95.24.14220; Vorobiov D, 2000, J BIOL CHEM, V275, P4166, DOI 10.1074/jbc.275.6.4166; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; Xu PX, 1997, DEVELOPMENT, V124, P219; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZIGMAN JM, 1994, ENDOCRINOLOGY, V135, P31, DOI 10.1210/en.135.1.31; Zimmerman JE, 1997, GENOME RES, V7, P128, DOI 10.1101/gr.7.2.128	63	48	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32129	32134		10.1074/jbc.M004577200	http://dx.doi.org/10.1074/jbc.M004577200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10906137	hybrid			2022-12-25	WOS:000089858900079
J	Gadda, G; Banerjee, A; Dangott, LJ; Fitzpatrick, PF				Gadda, G; Banerjee, A; Dangott, LJ; Fitzpatrick, PF			Identification of a cysteine residue in the active site of nitroalkane oxidase by modification with N-ethylmaleimide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROOROTATE DEHYDROGENASE-A; FAD-CONTAINING FORM; FUSARIUM-OXYSPORUM; 2-NITROPROPANE DIOXYGENASE; FLAVIN; ENZYME; PRINCIPLE; MECHANISM	The flavoprotein nitroalkane oxidase catalyzes the oxidative denitrification of primary or secondary nitroalkanes to the corresponding aldehydes or ketones with production of hydrogen peroxide and nitrite. The enzyme is irreversibly inactivated by treatment with N-ethylmaleimide at pH 7. The inactivation is time-dependent and shows first-order kinetics for three half-lives. The second-order rate constant for inactivation is 3.4 +/- 0.06 M-1 min-l. The competitive inhibitor valerate protects the enzyme from inactivation, indicating an active site-directed modification. Comparison of tryptic maps of enzyme treated with N-[ethyl-1-C-14]maleimide in the absence and presence of valerate shows a single radioactive peptide differentially labeled in the unprotected enzyme. The sequence of this peptide was determined to be LLNEVMCYPLFDGGNIGLR using Edman degradation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The cysteine residue was identified as the site of alkylation by ion trap mass spectrometry.	2128 TAMU, Dept Biochem & Biophys, College Stn, TX 77843 USA; 2128 TAMU, Dept Chem, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University System; Texas A&M University College Station	Fitzpatrick, PF (corresponding author), 2128 TAMU, Dept Biochem & Biophys, College Stn, TX 77843 USA.		Gadda, Giovanni/M-2354-2016	Gadda, Giovanni/0000-0002-7508-4195	NIGMS NIH HHS [GM 58698] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNASCONI CF, 1992, ADV PHYS ORG CHEM, V27, P119; Bjornberg O, 1997, BIOCHEMISTRY-US, V36, P16197, DOI 10.1021/bi971628y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Davis Richard A., 1993, P599; Edmondson RD, 1996, J AM SOC MASS SPECTR, V7, P995, DOI 10.1016/1044-0305(96)00027-X; Edmondson RD, 1997, ANAL CHEM, V69, P2862, DOI 10.1021/ac9700989; Gadda G, 1997, J BIOL CHEM, V272, P5563, DOI 10.1074/jbc.272.9.5563; Gadda G, 2000, BIOCHEMISTRY-US, V39, P1400, DOI 10.1021/bi9922547; Gadda G, 1998, BIOCHEMISTRY-US, V37, P6154, DOI 10.1021/bi973085y; Gadda G, 1999, ARCH BIOCHEM BIOPHYS, V363, P309, DOI 10.1006/abbi.1998.1081; Gadda G, 2000, BIOCHEMISTRY-US, V39, P1406, DOI 10.1021/bi992255z; Gadda G, 2000, BIOCHEMISTRY-US, V39, P1162, DOI 10.1021/bi9921743; Gorlatova N, 1998, APPL ENVIRON MICROB, V64, P1029; Heasley CJ, 1996, BIOCHEM BIOPH RES CO, V225, P6, DOI 10.1006/bbrc.1996.1122; Jencks W. P., 1976, HDB BIOCH MOL BIOL, P305; KIDO T, 1984, AGR BIOL CHEM TOKYO, V48, P2549, DOI 10.1080/00021369.1984.10866530; KIDO T, 1978, J BACTERIOL, V133, P53, DOI 10.1128/JB.133.1.53-58.1978; PORTER DJT, 1972, Z NATURFORSCH PT B, VB 27, P1052; PORTER DJT, 1977, J BIOL CHEM, V252, P4361; QUINN DM, 1991, ENZYME MECH ISOTOPE, P73; Riordan J.F., 1967, METHOD ENZYMOL, V11, P541; Rowland P, 1998, PROTEIN SCI, V7, P1269, DOI 10.1002/pro.5560070601	22	12	12	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31891	31895		10.1074/jbc.M003679200	http://dx.doi.org/10.1074/jbc.M003679200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913134	hybrid			2022-12-25	WOS:000089858900049
J	Guagliardi, A; Cerchia, L; Moracci, M; Rossi, M				Guagliardi, A; Cerchia, L; Moracci, M; Rossi, M			The chromosomal protein Sso7d of the crenarchaeon Sulfolobus solfataricus rescues aggregated proteins in an ATP hydrolysis-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; IN-VITRO; MOLECULAR CHAPERONE; ARCHAEAL PROTEIN; IDENTIFICATION; REPLICATION; DOMAIN; HSP70; SAC7D	In this work, we show that the nonspecific DNA-binding protein Sso7d from the crenarchaeon Sulfolobus solfataricus displays a cation-dependent ATPase activity with a pH optimum around neutrality and a temperature optimum of 70 degrees C. Measurements of tryptophan fluorescence and experiments that used 1-anilinonaphthalene-8-sulfonic acid as probe demonstrated that ATP hydrolysis induces a conformational change in the molecule and that the binding of the nucleotide triggers the ATP hydrolysis-induced conformation of the protein to return to the native conformation. We found that Sso7d rescues previously aggregated proteins in an ATP hydrolysis-dependent manner; the native conformation of Sso7d forms a complex with the aggregates, while the ATP hydrolysis-induced conformation is incapable of this interaction. Sso7d is believed to be the first protein isolated from an archaeon capable of rescuing aggregates.	Univ Naples Federico II, Dipartimento Chim Organ & Biol, I-80134 Naples, Italy; CNR, Ist Biochim Prot & Enzimol, I-80125 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	Guagliardi, A (corresponding author), Univ Naples Federico II, Dipartimento Chim Organ & Biol, Via Mezzocannone 16, I-80134 Naples, Italy.	guaglia@unina.it	Moracci, Marco/B-8444-2015	Moracci, Marco/0000-0002-9846-2531; Cerchia, Laura/0000-0002-7633-7932				Agback P, 1998, NAT STRUCT BIOL, V5, P579, DOI 10.1038/836; Ball LJ, 1997, EMBO J, V16, P2473, DOI 10.1093/emboj/16.9.2473; BAUMANN H, 1994, NAT STRUCT BIOL, V1, P808, DOI 10.1038/nsb1194-808; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; Cerchia L, 2000, EXTREMOPHILES, V4, P1, DOI 10.1007/s007920050131; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; EDMONDSON SP, 1995, BIOCHEMISTRY-US, V34, P13289, DOI 10.1021/bi00041a004; Gao YG, 1998, NAT STRUCT BIOL, V5, P782, DOI 10.1038/1822; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; GUAGLIARDI A, 1994, BIOCATALYSIS, V11, P181, DOI 10.3109/10242429409034387; GUAGLIARDI A, 1995, J BIOL CHEM, V270, P28126; Guagliardi A, 1997, J MOL BIOL, V267, P841, DOI 10.1006/jmbi.1996.0873; GUAGLIARDI A, 1994, PROTEIN SCI, V3, P1436, DOI 10.1002/pro.5560030910; HWANG DS, 1990, J BIOL CHEM, V265, P19244; Jakob U, 1996, J BIOL CHEM, V271, P10035, DOI 10.1074/jbc.271.17.10035; Knapp S, 1998, PROTEINS, V31, P309, DOI 10.1002/(SICI)1097-0134(19980515)31:3<309::AID-PROT7>3.0.CO;2-D; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; Lopez-Garcia P, 1998, NUCLEIC ACIDS RES, V26, P2322, DOI 10.1093/nar/26.10.2322; Lundback T, 1998, J MOL BIOL, V276, P775, DOI 10.1006/jmbi.1997.1558; Moracci M, 1996, PROTEIN ENG, V9, P1191, DOI 10.1093/protein/9.12.1191; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Robinson H, 1998, NATURE, V392, P202, DOI 10.1038/32455; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Takahashi M, 1996, EUR J BIOCHEM, V242, P20, DOI 10.1111/j.1432-1033.1996.0020r.x; WHEELIS ML, 1992, P NATL ACAD SCI USA, V89, P2930, DOI 10.1073/pnas.89.7.2930	31	21	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31813	31818		10.1074/jbc.M002122200	http://dx.doi.org/10.1074/jbc.M002122200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10908560	hybrid			2022-12-25	WOS:000089858900039
J	Huang, XF; Van, LT				Huang, XF; Van, LT			Molecular characterization of a first human 3(alpha ->beta)-hydroxysteroid epimerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GALACTOSE 4'-EPIMERASE; RETINOL DEHYDROGENASE; DEFICIENCY GALACTOSEMIA; CLONING; CDNA; IDENTIFICATION; OXIDATION; GENE; RAT; 17-BETA-HYDROXYSTEROID-DEHYDROGENASE	In this report, we describe the isolation and characterization of a cDNA encoding an enzyme that exhibits catalytic characteristics of a 3(alpha-->beta)-hydroxysteroid epimerase (3(alpha-->beta)-HSE). The enzyme overexpressed in human 293 embryonic kidney cells transforms androsterone into epi-androsterone in two steps: the oxidation of androsterone to 5 alpha-androstane-3,17-dione, followed by the reduction of the latter to epi-androsterone. The reverse reaction, 3(beta-->alpha)-hydroxysteroid epimeration, is approximately 10-fold weaker. These results are confirmed by V-max/K-m determination, which shows that the enzyme catalyzes the oxidation of androsterone to 5 alpha-androstane-3,17-dione and the reduction of 5 alpha-androstane-3,17-dione to epi-androsterone more efficiently than the reverse reactions. The selective catalysis of the reaction following the 3(alpha-->beta) direction is also observed in intact transfected cells in culture, which better reflect physiological conditions. In vitro assays reveal that the recombinant enzyme prefers NAD(+) and NADH as cofactors and could recognize both C-19 and C-21 3 alpha-hydroxysteroids as substrates, DNA sequence analysis predicts a protein of 317 amino acids. Tissue distribution analysis using RT-PCR reveals that the mRNA of the enzyme is expressed in various tissues, including liver, brain, prostate, adrenal, and uterus, with the most abundant expression in the liver. Because active hydroxysteroids generally exert their effect in a stereospecific manner, 3(alpha-->beta)-HSE could thus potentially play an important role in regulating the biological activities of various steroids.	Univ Laval, Med Ctr, Oncol & Mol Endocrinol Res Ctr, Quebec City, PQ G1V 4G2, Canada	Laval University	Van, LT (corresponding author), Univ Laval, Med Ctr, Oncol & Mol Endocrinol Res Ctr, 2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada.							Alano A, 1998, J INHERIT METAB DIS, V21, P341, DOI 10.1023/A:1005342306080; Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; Calogero AE, 1998, J ENDOCRINOL, V158, P121, DOI 10.1677/joe.0.1580121; Carnell A J, 1999, Adv Biochem Eng Biotechnol, V63, P57; Chai XY, 1996, GENE, V169, P219, DOI 10.1016/0378-1119(95)00833-0; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; CHAI XY, 1995, J BIOL CHEM, V270, P28408, DOI 10.1074/jbc.270.47.28408; DAHM K, 1968, BIOCHIM BIOPHYS ACTA, V159, P377, DOI 10.1016/0005-2744(68)90086-7; DAUDE N, 1995, BIOCHEM MOL MED, V56, P1, DOI 10.1006/bmme.1995.1048; Dufort I, 1999, ENDOCRINOLOGY, V140, P568, DOI 10.1210/en.140.2.568; ECKSTEIN B, 1970, ENDOCRINOLOGY, V89, P347; ERTESVAG H, 1995, MOL MICROBIOL, V16, P719, DOI 10.1111/j.1365-2958.1995.tb02433.x; GENAZZANI AR, 1995, EUR J ENDOCRINOL, V133, P375, DOI 10.1530/eje.0.1330375; Gough WH, 1998, J BIOL CHEM, V273, P19778, DOI 10.1074/jbc.273.31.19778; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Jurukovski V, 1999, MOL GENET METAB, V67, P62, DOI 10.1006/mgme.1999.2840; Keppler OT, 1999, SCIENCE, V284, P1372, DOI 10.1126/science.284.5418.1372; KINGSTON RE, 1991, CURRENT PROTOCOLS MO; LuuThe V, 1995, J STEROID BIOCHEM, V55, P581, DOI 10.1016/0960-0760(95)00209-X; Maceratesi P, 1998, MOL GENET METAB, V63, P26, DOI 10.1006/mgme.1997.2645; Mahendroo MS, 1996, MOL ENDOCRINOL, V10, P380, DOI 10.1210/me.10.4.380; MAYER RT, 1979, STEROIDS, V34, P555, DOI 10.1016/S0039-128X(79)80016-1; MEIERDIETER U, 1990, J BIOL CHEM, V265, P13490; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; MONDER C, 1980, J BIOL CHEM, V255, P7192; Rheault P, 1999, BBA-GENE STRUCT EXPR, V1447, P17, DOI 10.1016/S0167-4781(99)00106-2; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Siu-Caldera ML, 1999, BONE, V24, P457, DOI 10.1016/S8756-3282(99)00019-8; SIUCALDERA ML, 1998, J BONE MINER RES S, V23, pS426; Smith SS, 1998, NATURE, V392, P926, DOI 10.1038/31948; Wohlers TM, 1999, AM J HUM GENET, V64, P462, DOI 10.1086/302263	31	61	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29452	29457		10.1074/jbc.M000562200	http://dx.doi.org/10.1074/jbc.M000562200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896656	hybrid			2022-12-25	WOS:000089439800038
J	Good, PJ; Chen, QD; Warner, SJ; Herring, DC				Good, PJ; Chen, QD; Warner, SJ; Herring, DC			A family of human RNA-binding proteins related to the Drosophila Bruno translational regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSKAR MESSENGER-RNA; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; AU-RICH ELEMENT; ELAV-LIKE GENES; MYOTONIC-DYSTROPHY; HNRNP A1; TRINUCLEOTIDE REPEAT; CAENORHABDITIS-ELEGANS; CONSERVED FAMILY; REPRESSOR BRUNO	The post-transcriptional regulation of gene expression by RNA-binding proteins is an. important element in controlling both normal cell functions and animal development. The diverse roles are demonstrated by the Elav family of RNA-binding proteins, where various members have been shown to regulate several processes involving mRNA We have identified another family of RNA-binding proteins distantly related to the Elav family but closely related to Bruno, a translational regulator in Drosophila melanogaster, In humans, six Bruno-like genes have been identified, whereas other species such as Drosophila, Xenopus laevis, and Caenorhabditis elegans have at least two members of this family, and related genes have also been detected in plants and ascidians. The human BRUNOL2 and BRUNOL3 are 92% identical in the RNA-binding domains, although the BRUNOL2 gene is expressed ubiquitously whereas BRUNOL3 is expressed predominantly in the heart, muscle, and nervous system. Both of these proteins bind the same target RNA the Bruno response element. The RNA-binding domain that recognizes the Bruno response element is composed of two consecutive RNA recognition motifs at the amino terminus of vertebrate Bruno protein. The possible involvement of the Bruno family of proteins in the CUG repeat expansion disease myotonic dystrophy is discussed.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Good, PJ (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Hwy, Shreveport, LA 71130 USA.	pgood@lsuhsc.edu						Abe R, 1996, NUCLEIC ACIDS RES, V24, P4895, DOI 10.1093/nar/24.24.4895; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Akamatsu W, 1999, P NATL ACAD SCI USA, V96, P9885, DOI 10.1073/pnas.96.17.9885; Amack JD, 1999, HUM MOL GENET, V8, P1975, DOI 10.1093/hmg/8.11.1975; Anderson P, 1995, Curr Top Microbiol Immunol, V198, P131; Antic D, 1999, GENE DEV, V13, P449, DOI 10.1101/gad.13.4.449; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Antic D, 1998, J CELL SCI, V111, P183; Atasoy U, 1998, J CELL SCI, V111, P3145; Audic Y, 1998, MOL CELL BIOL, V18, P6879, DOI 10.1128/MCB.18.12.6879; Bhagwati S, 1999, BBA-MOL BASIS DIS, V1453, P221, DOI 10.1016/S0925-4439(98)00104-5; BIAMONTI G, 1994, FEBS LETT, V340, P1, DOI 10.1016/0014-5793(94)80162-2; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; Caskey CT, 1996, COLD SPRING HARB SYM, V61, P607; Choi DK, 1999, GENE, V237, P135, DOI 10.1016/S0378-1119(99)00312-1; Choi DK, 1998, GENE, V223, P21, DOI 10.1016/S0378-1119(98)00364-3; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Draper DE, 1999, J MOL BIOL, V293, P255, DOI 10.1006/jmbi.1999.2991; Ebersole TA, 1996, NAT GENET, V12, P260, DOI 10.1038/ng0396-260; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Good PJ, 1997, SEMIN CELL DEV BIOL, V8, P577, DOI 10.1006/scdb.1997.0183; GOOD PJ, 1993, NUCLEIC ACIDS RES, V21, P999, DOI 10.1093/nar/21.4.999; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Hamshere MG, 1997, P NATL ACAD SCI USA, V94, P7394, DOI 10.1073/pnas.94.14.7394; Harlow E., 1988, ANTIBODIES LAB MANUA; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; Jeongsil KH, 1999, MOL CELL BIOL, V19, P2505; Kasashima K, 1999, GENES CELLS, V4, P667, DOI 10.1046/j.1365-2443.1999.00292.x; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIMHA J, 1995, CELL, V81, P403, DOI 10.1016/0092-8674(95)90393-3; KNECHT AK, 1995, DEVELOPMENT, V121, P1927; Koushika SP, 1996, CURR BIOL, V6, P1634, DOI 10.1016/S0960-9822(02)70787-2; KRAHE R, 1995, GENOMICS, V28, P1, DOI 10.1006/geno.1995.1099; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; Lie YS, 1999, DEVELOPMENT, V126, P4989; Lie YS, 1999, DEVELOPMENT, V126, P1129; Lu XH, 1999, HUM MOL GENET, V8, P53, DOI 10.1093/hmg/8.1.53; Lundquist EA, 1996, DEVELOPMENT, V122, P1601; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; Margolis RL, 1997, HUM GENET, V100, P114, DOI 10.1007/s004390050476; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; Milne CA, 1999, CURR BIOL, V9, P1243, DOI 10.1016/S0960-9822(99)80504-1; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Norvell A, 1999, GENE DEV, V13, P864, DOI 10.1101/gad.13.7.864; Paillard L, 1998, EMBO J, V17, P278, DOI 10.1093/emboj/17.1.278; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Perez I, 1997, BIOCHEMISTRY-US, V36, P11881, DOI 10.1021/bi9711745; Perron M, 1999, INT J DEV BIOL, V43, P295; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; PinolRoma S, 1997, SEMIN CELL DEV BIOL, V8, P57, DOI 10.1006/scdb.1996.0122; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; Reddy PS, 1997, CURR OPIN CELL BIOL, V9, P364, DOI 10.1016/S0955-0674(97)80009-9; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; Roberts R, 1997, P NATL ACAD SCI USA, V94, P13221, DOI 10.1073/pnas.94.24.13221; Rose MD., 1990, METHODS YEAST GENETI; Sakashita E, 1996, J BIOCHEM, V120, P1028; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Samuels M, 1998, NUCLEIC ACIDS RES, V26, P2625, DOI 10.1093/nar/26.11.2625; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; Serin G, 1997, J BIOL CHEM, V272, P13109, DOI 10.1074/jbc.272.20.13109; Siomi H, 1997, CURR OPIN GENET DEV, V7, P345, DOI 10.1016/S0959-437X(97)80148-7; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Sonoda J, 1999, GENE DEV, V13, P2704, DOI 10.1101/gad.13.20.2704; STEBBINSBOAZ B, 1994, MOL CELL BIOL, V14, P5870, DOI 10.1128/MCB.14.9.5870; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; Suzuki H, 2000, MECH DEVELOP, V93, P205, DOI 10.1016/S0925-4773(00)00270-7; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; Wakamatsu Y, 1997, DEVELOPMENT, V124, P3449; Wang JW, 1997, J BIOL CHEM, V272, P22227, DOI 10.1074/jbc.272.35.22227; Webster PJ, 1997, GENE DEV, V11, P2510, DOI 10.1101/gad.11.19.2510; White JA, 1997, GENOMICS, V45, P468, DOI 10.1006/geno.1997.4979; YAO KM, 1993, J NEUROBIOL, V24, P723, DOI 10.1002/neu.480240604; Zhang BL, 1999, METHOD ENZYMOL, V306, P93	83	109	126	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28583	28592		10.1074/jbc.M003083200	http://dx.doi.org/10.1074/jbc.M003083200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893231	hybrid			2022-12-25	WOS:000089330700035
J	Xiao, GT; Sun, SC				Xiao, GT; Sun, SC			Negative regulation of the nuclear factor kappa B-inducing kinase by a cis-acting domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; IKK-ALPHA; ACTIVATION; PROTEIN; COMPLEX; BETA; PHOSPHORYLATION; REQUIRES; SIGNALS; TARGET	Nuclear factor kappa B (NF-kappa B)-inducing kinase (NIK) participates in the activation of NF-kappa B, a family of eukaryotic transcription factors that mediate cell growth and transformation. NIK activates the I kappa B kinase both in vivo and in vitro, although how the activity of NIK is regulated has remained unclear. Here we show that the N-terminal region of NIK contains a negative-regulatory domain (NRD), which is composed of a basic motif and a proline-rich repeat motif. Deletion of these motifs leads to a marked enhancement of NIK function. We further demonstrate that the N-terminal NRD interacts with the C-terminal region of NIK, thereby inhibiting the binding of NIK to its substrate I kappa B kinase. Consistently, when expressed alone, the NRD potently inhibits NIK-mediated NF-kappa B signaling. These results provide a new insight into the mechanism of NIK regulation.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Microbiol & Immunol, POB 850, Hershey, PA 17033 USA.				NIAID NIH HHS [1 RO1 AI45045] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045045] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Foo SY, 1999, TRENDS GENET, V15, P229; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Hardy K, 1997, IMMUNOL CELL BIOL, V75, P528, DOI 10.1038/icb.1997.84; Harhaj EW, 1998, J BIOL CHEM, V273, P25185, DOI 10.1074/jbc.273.39.25185; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; Kaga S, 1998, J IMMUNOL, V160, P4182; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; LEE KAW, 1992, J CELL SCI, V103, P9; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1999, MOL CELL BIOL, V19, P4547	32	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21081	21085		10.1074/jbc.M002552200	http://dx.doi.org/10.1074/jbc.M002552200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10887201	hybrid			2022-12-25	WOS:000088230600018
J	Vigers, GPA; Dripps, DJ; Edwards, CK; Brandhuber, BJ				Vigers, GPA; Dripps, DJ; Edwards, CK; Brandhuber, BJ			X-ray crystal structure of a small antagonist peptide bound to interleukin-1 receptor type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-1 RECEPTOR; IDENTIFICATION; PROTEIN; REFINEMENT; MODELS; FAMILY; SITE	Interleukin (IL-1)alpha and IL-1 beta are important mediators of inflammation. The binding of IL-l to interleukin-l receptor (IL-1R) type 1 is the initial step in IL-1 signal transduction and therefore is a tempting target for antiinflammatory therapeutics. To advance our understanding of IL-1R1 binding interactions, we have determined the structure of the extracellular domains of IL-1R1 bound to a 21-amino acid IL-1 antagonist peptide at 3.0-Angstrom resolution. The antagonist peptide binds to the domain 1/2 junction of the receptor, which is a conserved binding site for IL-1 beta and IL-1 receptor antagonist (IL-1ra). This co-crystal structure also reveals that considerable flexibility is present in IL-1R1 because the carboxyl-terminal domain of the receptor is rotated almost 170 degrees relative to the first two domains of the receptor compared with the previously solved IL-1R1 ligand structures. The structure shows an unexpected binding mode for the peptide and may contribute to the design of smaller IL-1R antagonists.	Amgen Inc, Dept Inflammat Res, Boulder, CO 80301 USA	Amgen	Vigers, GPA (corresponding author), Array BioPharma Inc, 1885 33rd St, Boulder, CO 80301 USA.	gvigers@arraybiopharma.com		Vigers, Guy/0000-0003-4451-8453				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Born TL, 2000, J BIOL CHEM, V275, P29946, DOI 10.1074/jbc.M004077200; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; Cullinan EB, 1998, J IMMUNOL, V161, P5614; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; EISENBERG SP, 1991, P NATL ACAD SCI USA, V88, P5232, DOI 10.1073/pnas.88.12.5232; EVANS RJ, 1995, J BIOL CHEM, V270, P11477, DOI 10.1074/jbc.270.19.11477; Horai R, 2000, J EXP MED, V191, P313, DOI 10.1084/jem.191.2.313; Hoshino K, 1999, J IMMUNOL, V162, P5041; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1997, ACTA CRYSTALLOGR D, V53, P179, DOI 10.1107/S0907444996012279; LABRIOLATOMPKINS E, 1991, P NATL ACAD SCI USA, V88, P11182, DOI 10.1073/pnas.88.24.11182; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Nicklin MJH, 2000, J EXP MED, V191, P303, DOI 10.1084/jem.191.2.303; OTWINOWSKI Z, 1993, DATA COLLECTION PROC; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; Schreuder H, 1997, NATURE, V386, P194, DOI 10.1038/386194a0; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; Vigers GPA, 1997, NATURE, V386, P190, DOI 10.1038/386190a0; VIGERS GPK, 1994, J BIOL CHEM, V269, P12874; Yanofsky SD, 1996, P NATL ACAD SCI USA, V93, P7381, DOI 10.1073/pnas.93.14.7381	24	43	51	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36927	36933		10.1074/jbc.M006071200	http://dx.doi.org/10.1074/jbc.M006071200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10903327	hybrid			2022-12-25	WOS:000165577700068
J	Xiao, GT; Harhaj, EW; Sun, SC				Xiao, GT; Harhaj, EW; Sun, SC			Domain-specific interaction with the I kappa B kinase (IKK) regulatory subunit IKK gamma is an essential step in tax-mediated activation of IKK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; HTLV-I; TRANSACTIVATOR TAX; TRANSCRIPTIONAL ACTIVATOR; DNA-BINDING; TRANSFORMING PROTEIN; 21-BASE-PAIR REPEATS; BZIP PROTEINS; CREB BINDING	The human T-cell leukemia virus type 1 Tax oncoprotein deregulates the NF-kappaB signaling pathway by persistently stimulating a key signal transducer, the I kappaB kinase (IKK). Tax physically associates with the IKK regulatory subunit, IKK gamma, although the underlying biochemical mechanism and functional significance remain unclear. We show that the Tax-IKK gamma interaction requires two homologous leucine zipper domains located within IKK gamma. These leucine zipper domains are unique for the presence of a conserved upstream region that is essential for Tax binding. Site-directed mutagenesis analysis revealed that a leucine-repeat region of Tax is important for IKK gamma binding. Interestingly, all the Tax mutants defective in IKK gamma binding failed to engage the IKK complex or stimulate IKK activity, and these functional defects can be rescued by fusing the Tax mutants to IKK gamma These results provide mechanistic insights into how Tax specifically targets and functionally activates the cellular kinase IKK.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Microbiol & Immunol, 500 Univ Dr, Hershey, PA 17033 USA.	sxs70@psu.edu			NCI NIH HHS [1 R01 CA68471] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; Frishman D, 1996, PROTEIN ENG, V9, P133, DOI 10.1093/protein/9.2.133; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRILLI M, 1993, INT REV CYTOL, V143, P1; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Harhaj EW, 1998, J BIOL CHEM, V273, P25185, DOI 10.1074/jbc.273.39.25185; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 1998, CANCER J SCI AM, V4, pS92; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Moitra J, 1997, BIOCHEMISTRY-US, V36, P12567, DOI 10.1021/bi971424h; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Nicot C, 1998, J VIROL, V72, P6777, DOI 10.1128/JVI.72.8.6777-6784.1998; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Ressler S, 1996, FEMS MICROBIOL LETT, V140, P99, DOI 10.1016/0378-1097(96)00166-8; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Sun SC, 1996, MOL CELL BIOL, V16, P1058; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zandi E, 1999, MOL CELL BIOL, V19, P4547; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	67	87	88	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34060	34067		10.1074/jbc.M002970200	http://dx.doi.org/10.1074/jbc.M002970200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10906125	hybrid			2022-12-25	WOS:000165095300011
J	Burkhardt, M; Glazova, M; Gambaryan, S; Vollkommer, T; Butt, E; Bader, B; Heermeier, K; Lincoln, TM; Walter, U; Palmetshofer, A				Burkhardt, M; Glazova, M; Gambaryan, S; Vollkommer, T; Butt, E; Bader, B; Heermeier, K; Lincoln, TM; Walter, U; Palmetshofer, A			KT5823 inhibits cGMP-dependent protein kinase activity in vitro but not in intact human platelets and rat mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; SMOOTH-MUSCLE CELLS; TRANSMEMBRANE CONDUCTANCE REGULATOR; CYCLIC-GMP; NITRIC-OXIDE; IN-VITRO; NEUTROPHIL MIGRATION; K+ CHANNEL; PHOSPHORYLATION; CAMP	Many signal transduction pathways are mediated by the second messengers cGMP and cAMP, cGMP- and cAMP-dependent protein kinases (cGK and PHA), phosphodiesterases, and ion channels. To distinguish among the different cGMP effecters, inhibitors of cGK and PKA have been developed including the K-252 compound KT5823 and the isoquinolinesulfonamide H89, KT5823, an in vitro inhibitor of cGK, has also been used in numerous studies with intact cells to implicate or rule out the involvement of this protein kinase in a given cellular response, However, the efficacy and specificity of KT5823 as cGK inhibitor in intact cells or tissues have never been demonstrated. Here, we analyzed the effects of both KT5823 and H89 on cyclic-nucleotide-mediated phosphorylation of vasodilator-stimulated phosphoprotein (VASP) in intact human platelets and rat mesangial cells. These two cell types both express high levels of cGK. KT5823 inhibited purified cGK, However, with both intact human platelets and rat mesangial cells, KT5823 failed to inhibit cGK-mediated serine 157 and serine 239 phosphorylation of VASP induced by nitric oxide, atrial natriuretic peptide, or the membrane-permeant cGMP analog 8-pCPT-cGMP, KT5823 enhanced 8-pCPT-cGMP-stimulated VASP phosphorylation in platelets and did not inhibit forskolin-stimulated VASP phosphorylation in either platelets or mesangial cells, In contrast H89, an inhibitor of both PKA. and cGK, clearly inhibited 8-pCPT-cGMP and forskolin-stimulated VASP phosphorylation in the two cell types. The data indicate that KT5823 inhibits purified cGK but does not affect a cGK-mediated response in the two different cell types expressing cGK I. These observations indicate that data that interpret the effects of KT5823 in intact cells as the major or only criteria supporting the involvement of cGK clearly need to be reconsidered.	Med Univ Klin, Inst Klin Biochem & Pathobiochem, D-97080 Wurzburg, Germany; Med Univ Klin, Div Nephrol, D-97080 Wurzburg, Germany; Russian Acad Sci, Sechenov Evolutionary Physiol & Biochem Inst, St Petersburg 194223, Russia; Univ Alabama Birmingham, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Wurzburg; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Wurzburg; Russian Academy of Sciences; Sechenov Institute of Evolutionary Physiology & Biochemistry; University of Alabama System; University of Alabama Birmingham	Palmetshofer, A (corresponding author), Med Univ Klin, Inst Klin Biochem & Pathobiochem, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	palme@klin-biochem.uni-wuerzburg.de	Glazova, Margarita V/J-9938-2018; Glazova, Margarita/AAN-7567-2020; Glazova, Margarita/Q-8597-2016; Gambaryan, Stepan/I-3940-2016; Walter, ulrich/W-2478-2017	Glazova, Margarita V/0000-0001-6617-3404; Glazova, Margarita/0000-0001-6617-3404; Glazova, Margarita/0000-0001-6617-3404; Gambaryan, Stepan/0000-0002-1470-0791; Walter, ulrich/0000-0001-6784-2307; Bader, Benjamin/0000-0002-5299-396X				AbdAlla S, 1996, EUR J BIOCHEM, V241, P498, DOI 10.1111/j.1432-1033.1996.00498.x; Alioua A, 1998, J BIOL CHEM, V273, P32950, DOI 10.1074/jbc.273.49.32950; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Browning DD, 1999, J BIOL CHEM, V274, P537, DOI 10.1074/jbc.274.1.537; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; Butt E, 1995, BRIT J PHARMACOL, V116, P3110, DOI 10.1111/j.1476-5381.1995.tb15112.x; BUTT E, 1994, EUR J PHARM-MOLEC PH, V269, P265, DOI 10.1016/0922-4106(94)90095-7; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; BUTT E, 1994, J BIOL CHEM, V269, P14509; BUTTERWORTH PJ, 1972, BIOCHIM BIOPHYS ACTA, V289, P251, DOI 10.1016/0005-2744(72)90074-5; Chiche JD, 1998, J BIOL CHEM, V273, P34263, DOI 10.1074/jbc.273.51.34263; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cohen DM, 1997, COMP BIOCHEM PHYS A, V117, P291, DOI 10.1016/S0300-9629(96)00266-6; CORNWELL TL, 1994, AM J PHYSIOL, V267, P1; DARVISH N, 1995, AM J PHYSIOL-RENAL, V268, pF323, DOI 10.1152/ajprenal.1995.268.2.F323; DIXON M, 1972, BIOCHEM J, V129, P197, DOI 10.1042/bj1290197; DRAIJER R, 1995, CIRC RES, V77, P897, DOI 10.1161/01.RES.77.5.897; EIGENTHALER M, 1993, J BIOL CHEM, V268, P13526; EIGENTHALER M, 1992, EUR J BIOCHEM, V205, P471, DOI 10.1111/j.1432-1033.1992.tb16803.x; Elferink JGR, 1998, EUR J PHARMACOL, V350, P285, DOI 10.1016/S0014-2999(98)00265-9; Firestein BL, 1998, J NEUROCHEM, V71, P1846; Foster D C, 1999, Rev Physiol Biochem Pharmacol, V135, P1, DOI 10.1007/BFb0033668; Fukao M, 1999, J BIOL CHEM, V274, P10927, DOI 10.1074/jbc.274.16.10927; Fukumoto S, 1999, CIRC RES, V85, P985; FUKUSHIMA T, 1994, AM J RESP CELL MOL, V10, P65, DOI 10.1165/ajrcmb.10.1.8292382; GLASS DB, 1986, J BIOL CHEM, V261, P2166; Hauser W, 1999, P NATL ACAD SCI USA, V96, P8120, DOI 10.1073/pnas.96.14.8120; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; HIRSCH J, 1995, PFLUG ARCH EUR J PHY, V429, P338, DOI 10.1007/BF00374148; Hirsch JR, 1999, J PHYSIOL-LONDON, V519, P645, DOI 10.1111/j.1469-7793.1999.0645n.x; HOLTHOFER H, 1995, APMIS, V103, P354; Jiang LH, 2000, J BIOL CHEM, V275, P6135, DOI 10.1074/jbc.275.9.6135; JOYCE NC, 1986, J CYCLIC NUCL PROT, V11, P191; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KEMP BE, 1988, METHOD ENZYMOL, V159, P173; Koesling D, 1999, Rev Physiol Biochem Pharmacol, V135, P41, DOI 10.1007/BFb0033669; Komalavilas P, 1999, J BIOL CHEM, V274, P34301, DOI 10.1074/jbc.274.48.34301; Komalavilas P, 1996, J BIOL CHEM, V271, P21933, DOI 10.1074/jbc.271.36.21933; KramerGuth A, 1996, KIDNEY INT, V49, P1250, DOI 10.1038/ki.1996.179; KREISBERG JI, 1983, KIDNEY INT, V23, P439, DOI 10.1038/ki.1983.40; Lincoln T M, 1995, Adv Pharmacol, V34, P305; Lincoln TM, 1998, ACTA PHYSIOL SCAND, V164, P507, DOI 10.1111/j.1365-201X.1998.tb10700.x; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; Massberg S, 1999, J EXP MED, V189, P1255, DOI 10.1084/jem.189.8.1255; Pfeifer A, 1999, Rev Physiol Biochem Pharmacol, V135, P105, DOI 10.1007/BFb0033671; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Smolenski A, 1998, N-S ARCH PHARMACOL, V358, P134, DOI 10.1007/PL00005234; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; Syrovets T, 1997, BLOOD, V89, P4574, DOI 10.1182/blood.V89.12.4574; TIEN XY, 1994, J BIOL CHEM, V269, P51; VanUffelen BE, 1996, BIOCHEM BIOPH RES CO, V226, P21, DOI 10.1006/bbrc.1996.1305; WAHLER GM, 1995, AM J PHYSIOL-CELL PH, V268, pC45, DOI 10.1152/ajpcell.1995.268.1.C45; WALTER U, 1980, J BIOL CHEM, V255, P3757; Walter U, 1989, REV PHYSL BIOCH PHAR, V113, P41; WYATT TA, 1991, RES COMMUN CHEM PATH, V74, P3; WYATT TA, 1991, J BIOL CHEM, V266, P21274; Yu SM, 1997, CIRCULATION, V95, P1269	60	98	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33536	33541		10.1074/jbc.M005670200	http://dx.doi.org/10.1074/jbc.M005670200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10922374	hybrid			2022-12-25	WOS:000090104600051
J	Ong, LL; Lim, APC; Er, CPN; Kuznetsov, SA; Yu, H				Ong, LL; Lim, APC; Er, CPN; Kuznetsov, SA; Yu, H			Kinectin-kinesin binding domains and their effects on organelle motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNEIN SUPERFAMILY PROTEINS; CYTOPLASMIC DYNEIN; HEAVY-CHAIN; IN-VIVO; MEMBRANOUS ORGANELLES; ANTEROGRADE MOTOR; AXONAL-TRANSPORT; MONOMERIC MOTOR; GOLGI-COMPLEX; TAIL DOMAIN	Intracellular organelle motility involves motor proteins that move along microtubules or actin filaments. One of these motor proteins, kinesin, was proposed to bind to kinectin on membrane organelles during movement. Whether kinectin is the kinesin receptor on organelles with a role in organelle motility has been controversial. We have characterized the sites of interaction between human kinectin and conventional kinesin using in vivo and in vitro assays. The kinectin-binding domain on the kinesin tail partially overlaps its head-binding domain and the myosin-Va binding domain. The kinesin-binding domain on kinectin resides near the COOH terminus and enhances the microtubule-stimulated kinesin-ATPase activity, and the overexpression of the kinectin-kinesin binding domains inhibited kinesin-dependent organelle motility in vivo, These data, when combined with other studies, suggest a role for kinectin in organelle motility.	Natl Univ Singapore, Fac Med, NUMI, Singapore 117597, Singapore; Univ Rostock, Fachbereich Biowissensch, Inst Zellbiol & Biosystemtechnn, D-18055 Rostock, Germany	National University of Singapore; University of Rostock	Yu, H (corresponding author), Natl Univ Singapore, Fac Med, NUMI, Block MD11,03-02 Clin Res Ctr,10 Med Dr, Singapore 117597, Singapore.		Yu, Hanry/C-7375-2011; Yu, Hanry/C-1031-2013; Yu, Hanry/L-6050-2019	Yu, Hanry/0000-0002-0339-3685; Yu, Hanry/0000-0002-0339-3685				AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; Beck KA, 1998, BBA-MOL CELL RES, V1404, P153, DOI 10.1016/S0167-4889(98)00054-8; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Burkhardt JK, 1996, TRENDS CELL BIOL, V6, P127, DOI 10.1016/0962-8924(96)20002-9; Burkhardt JK, 1998, BBA-MOL CELL RES, V1404, P113, DOI 10.1016/S0167-4889(98)00052-4; Coy DL, 1999, NAT CELL BIOL, V1, P288, DOI 10.1038/13001; De Matteis MA, 1998, CURR OPIN CELL BIOL, V10, P542, DOI 10.1016/S0955-0674(98)80071-9; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Friedman DS, 1999, NAT CELL BIOL, V1, P293, DOI 10.1038/13008; FUTTERER A, 1995, MOL BIOL CELL, V6, P161; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kirchner J, 1999, BIOL CHEM, V380, P915, DOI 10.1515/BC.1999.113; Kirchner J, 1999, EMBO J, V18, P4404, DOI 10.1093/emboj/18.16.4404; KONDO S, 1994, J CELL BIOL, V125, P1095, DOI 10.1083/jcb.125.5.1095; Kraemer J, 1999, EUR J CELL BIOL, V78, P265, DOI 10.1016/S0171-9335(99)80060-0; Kumar J, 1998, J BIOL CHEM, V273, P31738, DOI 10.1074/jbc.273.48.31738; KUMAR J, 1995, SCIENCE, V267, P1834, DOI 10.1126/science.7892610; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; KUZNETSOV SA, 2000, IN PRESS METHODS MOL; LACEY ML, 1994, CELL MOTIL CYTOSKEL, V28, P205, DOI 10.1002/cm.970280304; LANGFORD GM, 1995, CURR OPIN CELL BIOL, V7, P82, DOI 10.1016/0955-0674(95)80048-4; LEE KD, 1995, J BIOL CHEM, V270, P5600, DOI 10.1074/jbc.270.10.5600; Leung E, 1996, IMMUNOL CELL BIOL, V74, P421, DOI 10.1038/icb.1996.72; Lindesmith L, 1997, J BIOL CHEM, V272, P22929, DOI 10.1074/jbc.272.36.22929; NAKATA T, 1995, J CELL BIOL, V131, P1039, DOI 10.1083/jcb.131.4.1039; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; NODA Y, 1995, J CELL BIOL, V129, P157, DOI 10.1083/jcb.129.1.157; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; PORTER ME, 1987, J BIOL CHEM, V262, P2794; Rogers SL, 1998, CURR BIOL, V8, P161, DOI 10.1016/S0960-9822(98)70063-6; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SEKINE Y, 1994, J CELL BIOL, V127, P187, DOI 10.1083/jcb.127.1.187; Sheetz MP, 1996, SEMIN CELL DEV BIOL, V7, P329, DOI 10.1006/scdb.1996.0042; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; Tabb JS, 1998, J CELL SCI, V111, P3221; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; VALLEE RB, 1988, NATURE, V332, P561, DOI 10.1038/332561a0; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899; Xia CH, 1998, GENOMICS, V52, P209, DOI 10.1006/geno.1998.5427; YU H, 1995, MOL BIOL CELL, V6, P171, DOI 10.1091/mbc.6.2.171; YU H, 1992, J BIOL CHEM, V267, P20457	53	46	48	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32854	32860		10.1074/jbc.M005650200	http://dx.doi.org/10.1074/jbc.M005650200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913441	hybrid			2022-12-25	WOS:000090003800066
J	Negroiu, G; Dwek, RA; Petrescu, SM				Negroiu, G; Dwek, RA; Petrescu, SM			Folding and maturation of tyrosinase-related protein-1 are regulated by the post-translational formation of disulfide bonds and by N-glycan processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; BROWN LOCUS; MELANOMA-CELLS; INFLUENZA HEMAGGLUTININ; SECRETORY PROTEINS; QUALITY-CONTROL; CALNEXIN; DITHIOTHREITOL; ISOMERASE; MOUSE	In this study we have explored the endoplasmic reticulum associated events accompanying the maturation of the tyrosinase-related protein-1 (TRP-1) nascent chain synthesized in mouse melanoma cells. We show that TRP-1 folding process occurs much more rapidly than for tyrosinase, a highly homologous protein, being completed post-translationally by the formation of critical disulfide bonds. In cells pretreated with dithiothreitol (DTT), unfolded TRP-1 is retained in the endoplasmic reticulum by a prolonged interaction with calnexin and BiP before being targeted for degradation. The TRP-1 chain was able to fold into DTT-resistant conformations both in the presence or absence of Lu-glucosidase inhibitors, but folding occurred through different pathways. During the normal folding pathway, TRP-1 interacts with calnexin. In the presence of a-glucosidase inhibitors, the interaction with calnexin is prevented, with TRP-1 folding being assisted by Dip. In this case, the process has similar kinetics to that of untreated TRP-1 and yields a compact form insensitive to DTT as well. However, this form has different thermal denaturation properties than the native conformation. We conclude that disulfide bridge burring is crucial for the TRP-1 export. This suggests that although various folding pathways may complete this process, the native form may be acquired only through the normal unperturbed pathway.	Romanian Acad, Inst Biochem, Bucharest 77700 17, Romania; Univ Oxford, Dept Biochem, Oxford Glycobiol Inst, Oxford OX1 3QU, England	Romanian Academy of Sciences; Institute of Biochemistry, Bucharest; University of Oxford	Petrescu, SM (corresponding author), Romanian Acad, Inst Biochem, Splaiul Independentei 296, Bucharest 77700 17, Romania.		Petrescu, Stefana/AAJ-9505-2021; Negroiu, Gabriela/G-4649-2016; Petrescu, Stefana M/I-9240-2012; Negroiu, Gabriela/AAO-3980-2020	Petrescu, Stefana/0000-0002-4047-0811; Petrescu, Stefana M/0000-0002-4047-0811; Negroiu, Gabriela/0000-0003-3712-7681				ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; AROCA P, 1993, J BIOL CHEM, V268, P25650; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Branza-Nichita N, 2000, J BIOL CHEM, V275, P8169, DOI 10.1074/jbc.275.11.8169; Branza-Nichita N, 1999, BIOCHEM BIOPH RES CO, V261, P720, DOI 10.1006/bbrc.1999.1030; DAVIS C G, 1990, New Biologist, V2, P410; DER JE, 1993, BRIT J CANCER, V67, P47, DOI 10.1038/bjc.1993.8; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; FENG W, 1995, J BIOL CHEM, V270, P11851, DOI 10.1074/jbc.270.20.11851; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Gelman MS, 1996, J BIOL CHEM, V271, P10709, DOI 10.1074/jbc.271.18.10709; GUNTHER R, 1993, J BIOL CHEM, V268, P7728; Halaban R, 2000, P NATL ACAD SCI USA, V97, P5889, DOI 10.1073/pnas.97.11.5889; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; HEARING VJ, 1993, PIGMENTATION PIGMENT, P3; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1997, J CELL BIOL, V139, P613, DOI 10.1083/jcb.139.3.613; HOUGHTON AN, 1994, J EXP MED, V180, P1, DOI 10.1084/jem.180.1.1; HOUGHTON AN, 1987, J EXP MED, V165, P812, DOI 10.1084/jem.165.3.812; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; King R., 1995, METABOLIC MOL BASES, P4353; Kobayashi T, 1998, J BIOL CHEM, V273, P31801, DOI 10.1074/jbc.273.48.31801; LEITZGEN K, 1998, CHEMTRACTS BIOCH MOL, V11, P423; LODISH HF, 1993, J BIOL CHEM, V268, P20598; LOSCH A, 1995, J BIOL CHEM, V270, P11543, DOI 10.1074/jbc.270.19.11543; McGinnes LW, 1996, VIROLOGY, V224, P465, DOI 10.1006/viro.1996.0553; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; Muresan Z, 1998, MOL ENDOCRINOL, V12, P458, DOI 10.1210/me.12.3.458; Negroiu G, 1999, BIOCHEM J, V344, P659, DOI 10.1042/0264-6021:3440659; Negroiu G, 1999, CELL MOL BIOL, V45, P1001; ORLOW SJ, 1994, J INVEST DERMATOL, V103, P196, DOI 10.1111/1523-1747.ep12392743; Petrescu SM, 1997, J BIOL CHEM, V272, P15796, DOI 10.1074/jbc.272.25.15796; Petrescu SM, 2000, BIOCHEMISTRY-US, V39, P5229, DOI 10.1021/bi000107z; Singh V, 2000, J BIOL CHEM, V275, P11765, DOI 10.1074/jbc.275.16.11765; SKOWRONEK NH, 1998, CELL, V92, P747; SPRITZ RA, 1991, AM J HUM GENET, V48, P318; Spritz Richard A., 1994, V22, P1; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; Toyofuku K, 1999, J BIOCHEM, V125, P82, DOI 10.1093/oxfordjournals.jbchem.a022272; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; VIJAYASARADHI S, 1991, EXP CELL RES, V196, P233, DOI 10.1016/0014-4827(91)90256-T; VIJAYASARADHI S, 1990, J EXP MED, V171, P1375, DOI 10.1084/jem.171.4.1375; WEY J, 1996, P NATL ACAD SCI USA, V93, P5269; ZDARSKY E, 1990, GENETICS, V126, P443; Zhang JX, 1997, MOL BIOL CELL, V8, P1943, DOI 10.1091/mbc.8.10.1943	48	44	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32200	32207		10.1074/jbc.M005186200	http://dx.doi.org/10.1074/jbc.M005186200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10915799	hybrid			2022-12-25	WOS:000089858900089
J	Saeki, K; Suzuki, H; Tsuneoka, M; Maeda, M; Iwamoto, R; Hasuwa, H; Shida, S; Takahashi, T; Sakaguchi, M; Endo, T; Miura, Y; Mekada, E; Mihara, K				Saeki, K; Suzuki, H; Tsuneoka, M; Maeda, M; Iwamoto, R; Hasuwa, H; Shida, S; Takahashi, T; Sakaguchi, M; Endo, T; Miura, Y; Mekada, E; Mihara, K			Identification of mammalian TOM22 as a subunit of the preprotein translocase of the mitochondrial outer membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; INTERMEMBRANE-SPACE DOMAIN; DIPHTHERIA-TOXIN RECEPTOR; PROTEIN IMPORT RECEPTOR; PRECURSOR PROTEINS; INNER MEMBRANE; TARGETING SEQUENCES; BINDING-SITE; COMPLEX; YEAST	A mitochondrial outer membrane protein of similar to 22 kDa (1C9-2) was purified from Vero cells assessing immunoreactivity with a monoclonal antibody, and the cDNA was cloned based on the partial amino acid sequence of the trypsin-digested fragments. 1C9-2 had 19-20% sequence identity to fungal Tom22, a component of the preprotein translocase of the outer membrane (the TOM complex) with receptor and organizer functions. Despite such a low sequence identity, both shared a remarkable structural similarity in the hydrophobicity profile, membrane topology in the Ncyt-Cin orientation through a transmembrane domain in the middle of the molecule, and the abundant acidic amino acid residues in the N-terminal domain. The antibodies against 1C9-2 inhibited the import of a matrix-targeted preprotein into isolated mitochondria. Blue native polyacrylamide gel electrophoresis of digitonin-solubilized outer membranes revealed that 1C9-2 is firmly associated with TOM40 in the similar to 400-kDa complex, with a size and composition similar to those of the fungal TOM core complex. Furthermore, 1C9-2 complemented the defects of growth and mitochondrial protein import in Delta tom22 yeast cells. Taken together, these results demonstrate that 1C9-2 is a functional homologue of fungal Tom22 and functions as a component of the TOM complex.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan; Nagoya Univ, Fac Sci, Dept Chem, Nagoya, Aichi 4648602, Japan	Kyushu University; Kurume University; Nagoya University	Mihara, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan.	mihara@cell.med.kyushu-u.ac.jp	Hasuwa, Hidetoshi/B-1083-2009; Miura, Yoshiki/U-8875-2019	Miura, Yoshiki/0000-0002-7596-0482; Mekada, Eisuke/0000-0001-8858-4781				Ahting U, 1999, J CELL BIOL, V147, P959, DOI 10.1083/jcb.147.5.959; Armstrong LC, 1997, J BIOL CHEM, V272, P6510, DOI 10.1074/jbc.272.10.6510; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; Court DA, 1996, MOL CELL BIOL, V16, P4035; Davis AJ, 1998, MOL BIOL CELL, V9, P2577, DOI 10.1091/mbc.9.9.2577; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; Dekker PJT, 1996, BIOL CHEM, V377, P535; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; GOPING IS, 1995, FEBS LETT, V373, P45; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; Hanson B, 1996, EUR J BIOCHEM, V235, P750, DOI 10.1111/j.1432-1033.1996.t01-1-00750.x; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; Ishihara N, 1998, J BIOCHEM-TOKYO, V123, P722; Iwahashi J, 1997, J BIOL CHEM, V272, P18467, DOI 10.1074/jbc.272.29.18467; IWAMOTO R, 1991, J BIOL CHEM, V266, P20463; Jansch L, 1998, J BIOL CHEM, V273, P17251, DOI 10.1074/jbc.273.27.17251; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; Kerscher O, 2000, MOL BIOL CELL, V11, P103, DOI 10.1091/mbc.11.1.103; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; Lill R, 1996, CURR OPIN CELL BIOL, V8, P505, DOI 10.1016/S0955-0674(96)80028-7; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; MATSUMOTO T, 1986, J BIOCHEM-TOKYO, V100, P1359, DOI 10.1093/oxfordjournals.jbchem.a121842; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; MEIJER M, 1996, ADV MOL CEL, V17, P127; MEKADA E, 1988, J CELL BIOL, V107, P511, DOI 10.1083/jcb.107.2.511; Mihara K, 1996, TRENDS CELL BIOL, V6, P104, DOI 10.1016/0962-8924(96)81000-2; Moczko M, 1997, MOL CELL BIOL, V17, P6574, DOI 10.1128/MCB.17.11.6574; Mori M, 1998, BBA-MOL CELL RES, V1403, P12, DOI 10.1016/S0167-4889(98)00021-4; Nakai M, 1995, J BIOL CHEM, V270, P30571, DOI 10.1074/jbc.270.51.30571; Nargang FE, 1998, MOL CELL BIOL, V18, P3173, DOI 10.1128/MCB.18.6.3173; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Nuttall SD, 1997, DNA CELL BIOL, V16, P1067, DOI 10.1089/dna.1997.16.1067; Omura T, 1998, J BIOCHEM-TOKYO, V123, P1010; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; Rapaport D, 1997, J BIOL CHEM, V272, P18725, DOI 10.1074/jbc.272.30.18725; Rassow J, 1999, J MOL BIOL, V286, P105, DOI 10.1006/jmbi.1998.2455; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schatz G, 1997, NATURE, V388, P121, DOI 10.1038/40510; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SEKI N, 1995, FEBS LETT, V375, P307, DOI 10.1016/0014-5793(95)01229-8; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; van Wilpe S, 1999, NATURE, V401, P485, DOI 10.1038/46802; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6	57	38	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31996	32002		10.1074/jbc.M004794200	http://dx.doi.org/10.1074/jbc.M004794200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10900208	hybrid			2022-12-25	WOS:000089858900062
J	Smith, JK; Poteet-Smith, CE; Lannigan, DA; Freed, TA; Zoltoski, AJ; Sturgill, TW				Smith, JK; Poteet-Smith, CE; Lannigan, DA; Freed, TA; Zoltoski, AJ; Sturgill, TW			Creation of a stress-activated p90 ribosomal S6 kinase - The carboxyl-terminal tail of the MAPK-activated protein kinases dictates the signal transduction pathway in which they function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MONOCLONAL-ANTIBODIES; IN-VIVO; SUBSTRATE-SPECIFICITY; DOCKING SITE; PHOSPHORYLATION; INHIBITOR; DOMAIN; IDENTIFICATION; TRANSCRIPTION; CASCADE	Mitogen-activated protein kinase-activated protein kinases (MAPKAPKs) lie immediately downstream of the mitogen-activated protein kinases (MAPKs), extracellular signal-regulated kinase (ERK), and p38 MAPK, Although the family of MAPKAPKs shares sequence similarity, it demonstrates selectivity for the upstream activator. Here we demonstrate that each of the ERK- and p38 MAPK-regulated MAPKAPKs contains a MAPK docking site positioned distally to the residue(s) phosphorylated by MAPKs. The isolated MAPK docking sites show specificity for the upstream activator similar to that reported for the full-length proteins. Moreover, replacement of the ERK docking site of p90 ribosomal S6 kinase with the p38 MAPK docking site of MAPKAPK2 converts p90 ribosomal S6 kinase into a stress-activated kinase in vivo, It is apparent that mechanisms controlling events downstream of the proline-directed MAPKs involve specific MAPK docking sites within the carboxyl termini of the MAPKAPKs that determine the cascade in which the MAPKAPK functions.	Univ Virginia, Hlth Sci Ctr, Markey Ctr Cell Signaling, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Howard Hughes Med Inst, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Med, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia; Howard Hughes Medical Institute; University of Virginia; University of Virginia; University of Virginia	Smith, JK (corresponding author), Univ Virginia, Hlth Sci Ctr, Markey Ctr Cell Signaling, Box 800577, Charlottesville, VA 22908 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041077] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41077] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams PD, 1999, MOL CELL BIOL, V19, P1068; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Poteet-Smith CE, 1999, J BIOL CHEM, V274, P22135, DOI 10.1074/jbc.274.32.22135; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; Traish AM, 1996, STEROIDS, V61, P549, DOI 10.1016/S0039-128X(96)00109-2; TRAISH AM, 1995, STEROIDS, V60, P467, DOI 10.1016/0039-128X(95)00061-T; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	22	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31588	31593		10.1074/jbc.M005892200	http://dx.doi.org/10.1074/jbc.M005892200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10922375	hybrid			2022-12-25	WOS:000089858900007
J	von Poser, C; Zhang, JZ; Mineo, C; Ding, W; Ying, YS; Sudhof, TC; Anderson, RGW				von Poser, C; Zhang, JZ; Mineo, C; Ding, W; Ying, YS; Sudhof, TC; Anderson, RGW			Synaptotagmin regulation of coated pit assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; LOW-DENSITY LIPOPROTEIN; PROTEIN-KINASE-C; C2B DOMAIN; TRANSMITTER RELEASE; ANTIBODY INJECTION; SYNAPTIC VESICLES; CLATHRIN LATTICES; MAMMALIAN-CELLS; CA2+ CHANNELS	Synaptotagmins bind clathrin AP-2 with high affinity via their second C-2 domain, which indicates they are involved in coated pit function. We now report that expression of synaptotagmins lacking either the second C-2 domain or the entire cytoplasmic region potently inhibit endocytosis. Inhibition was dependent on two intramembrane cysteine residues that were found to be essential for synaptotagmin oligomerization. Cells expressing the wild-type, but not the mutant, truncated synaptotagmin fragment had a reduced number of clathrin-coated pits. These results suggest that the formation of synaptotagmin multimers is an important step in the regulation of coated pit assembly.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Anderson, RGW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	anders06@utsw.swmed.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; Anderson R G, 1986, Methods Enzymol, V129, P201; ANDERSON RGW, 1977, NATURE, V270, P695, DOI 10.1038/270695a0; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Chapman ER, 1996, BIOCHEM BIOPH RES CO, V225, P326, DOI 10.1006/bbrc.1996.1174; Damer CK, 1996, J NEUROCHEM, V67, P1661; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DELALUNA S, 1988, GENE, V62, P121; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Kee Y, 1996, J NEUROSCI, V16, P1975; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; Kim K, 1997, P NATL ACAD SCI USA, V94, P14782, DOI 10.1073/pnas.94.26.14782; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MAHAFFEY DT, 1989, J CELL BIOL, V108, P1615, DOI 10.1083/jcb.108.5.1615; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; MILLER K, 1991, CELL, V65, P621, DOI 10.1016/0092-8674(91)90094-F; Mochida S, 1996, NEURON, V17, P781, DOI 10.1016/S0896-6273(00)80209-3; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; PEELER JS, 1993, J CELL BIOL, V120, P47, DOI 10.1083/jcb.120.1.47; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Reist NE, 1998, J NEUROSCI, V18, P7662; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rettig J, 1997, J NEUROSCI, V17, P6647; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; Schivell AE, 1996, J BIOL CHEM, V271, P27770, DOI 10.1074/jbc.271.44.27770; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; ULLRICH B, 1994, NEURON, V13, P1281, DOI 10.1016/0896-6273(94)90415-4; VALLEE RB, 1993, CIBA F SYMP, V176, P185; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	59	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30916	30924		10.1074/jbc.M005559200	http://dx.doi.org/10.1074/jbc.M005559200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906143	hybrid			2022-12-25	WOS:000089762700028
J	Stevens, K; Cirillo, L; Zaret, KS				Stevens, K; Cirillo, L; Zaret, KS			Creating temperature-sensitive winged helix transcription factors - Amino acids that stabilize the DNA binding domain of HNF3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; TURN-HELIX; FORK HEAD; SITE; PROTEINS; MOTIF; SPECTROSCOPY; NUCLEOSOME; REPRESSOR; COMPLEX	Winged helix transcription factors contain two polypeptide loops, or "wings," that make minor groove contacts with DNA from either side of a three-helix bundle that binds the DNA major groove. While wing 1 is stabilized by a beta-sheet, parameters that stabilize wing 2 are unknown. Herein we identify two bulky aromatic residues in wing 2 that stabilize the loop structure and, thereby, the entire protein's DNA binding and transcriptional stimulatory activity by interacting with other residues in the three-helix bundle. Mutations of these wing 2 residues create proteins that are temperature-sensitive for transcriptional activity. Aromatic and/or hydrophobic residues are highly conserved among the 150 known winged helix proteins, suggesting conserved function. We suggest that the winged helix structure evolved by the acquisition of aromatic and/or hydrophobic residues in distal polypeptide sequences that helped stabilize the association of a protein loop (wing 2) with the three helix bundle, thereby enhancing DNA binding.	Fox Chase Canc Ctr, Program Cell & Dev Biol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Zaret, KS (corresponding author), Fox Chase Canc Ctr, Program Cell & Dev Biol, Rm W410,7701 Burholme Ave, Philadelphia, PA 19111 USA.				NIGMS NIH HHS [GM47903] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047903] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENNAN RG, 1993, CELL, V74, P773, DOI 10.1016/0092-8674(93)90456-Z; CERF C, 1994, BIOCHEMISTRY-US, V33, P11079, DOI 10.1021/bi00203a004; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; DAMBERGER FF, 1994, PROTEIN SCI, V3, P1806, DOI 10.1002/pro.5560031020; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; FOGH RH, 1994, EMBO J, V13, P3936, DOI 10.1002/j.1460-2075.1994.tb06709.x; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; QIU XY, 1995, STRUCTURE, V3, P87, DOI 10.1016/S0969-2126(01)00137-X; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; Shim EY, 1998, GENE DEV, V12, P5, DOI 10.1101/gad.12.1.5; VUISTER GW, 1994, BIOCHEMISTRY-US, V33, P10, DOI 10.1021/bi00167a002; WILSON DB, 1992, NUCLEIC ACIDS RES, V20, P699; Zaret KS, 1995, PROTEIN EXPRES PURIF, V6, P821, DOI 10.1006/prep.1995.0014; ZARET KS, 1988, P NATL ACAD SCI USA, V85, P9076, DOI 10.1073/pnas.85.23.9076	26	10	10	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30471	30477		10.1074/jbc.M004891200	http://dx.doi.org/10.1074/jbc.M004891200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10896667	hybrid			2022-12-25	WOS:000089577900076
J	Berger, AL; Welsh, MJ				Berger, AL; Welsh, MJ			Differences between cystic fibrosis transmembrane conductance regulator and HisP in the interaction with the adenine ring of ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAINS; CFTR CHLORIDE CHANNEL; PROTEIN-KINASE-A; ABC TRANSPORTER; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; HISTIDINE PERMEASE; SYNTHETIC PEPTIDE; CRYSTAL-STRUCTURE; SUBUNIT	The cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel is a member of the ATP-binding cassette transporter family. The most conserved features of this family are the nucleotide-binding domains. As in other members of this family, these domains bind and hydrolyze ATP; in CFTR this opens and closes the channel pore. The recent crystal structures of related bacterial transporters show that an aromatic residue interacts with the adenine ring of ATP to stabilize nucleotide binding. CFTR contains six aromatic residues that are candidates to coordinate the nucleotide base, We mutated each to cysteine and examined the functional consequences. None of the mutations disrupted channel function or the ability to discriminate between ATP, GTP, and CTP. We also applied [2-(triethylammonium)ethyl] methanethiosulfonate to covalently modify the introduced cysteines, The mutant channels CFTR-F429C, F430C, F433C, and F1232C showed no difference from wild-type CFTR, indicating that either the residues were not accessible to modification, or cysteine modification did not affect function. Although modification inactivated CFTR-Y1219C more rapidly than wild-type CFTR, and inactivation of CFTR-F446C was nucleotide-dependent; failure of these mutations to alter gating suggested that Tyr(1219) and Phe(446) were not important for nucleotide binding. The results suggest that ATP binding may not involve the coordination of the adenine ring by an aromatic residue analogous to that in some bacterial transporters. Taken together with earlier work, this study points to a model in which most of the binding energy for ATP is contributed by the phosphate groups.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Biophys, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa	Welsh, MJ (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Internal Med, 500 EMRB, Iowa City, IA 52242 USA.			Welsh, Michael/0000-0002-1646-6206				ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; AMES GF, 1989, J BIOL CHEM, V264, P3998; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ARMSTRONG S, 1998, PEDIAT PULMONOL, V17, P91; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; Briozzo P, 1998, STRUCTURE, V6, P1517, DOI 10.1016/S0969-2126(98)00150-6; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; Cotten JF, 1998, J BIOL CHEM, V273, P31873, DOI 10.1074/jbc.273.48.31873; Croop JM, 1998, METHOD ENZYMOL, V292, P101; DAWSON DC, 1999, PHYSIOL REV, V79, P47; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; Foskett JK, 1998, ANNU REV PHYSIOL, V60, P689, DOI 10.1146/annurev.physiol.60.1.689; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Ikuma M, 2000, P NATL ACAD SCI USA, V97, P8675, DOI 10.1073/pnas.140220597; Jia YL, 1997, J BIOL CHEM, V272, P4978, DOI 10.1074/jbc.272.8.4978; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Linton KJ, 1998, MOL MICROBIOL, V28, P5, DOI 10.1046/j.1365-2958.1998.00764.x; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; MORBACH S, 1993, J BIOL CHEM, V268, P18617; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Ramjeesingh M, 1999, BIOCHEMISTRY-US, V38, P1463, DOI 10.1021/bi982243y; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; Schneider E, 1998, FEMS MICROBIOL REV, V22, P1; SCHULTZ BD, 1995, J GEN PHYSIOL, V105, P329, DOI 10.1085/jgp.105.3.329; Sheppard DN, 1999, PHYSIOL REV, V79, P23; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Szabo K, 1999, J BIOL CHEM, V274, P12209, DOI 10.1074/jbc.274.18.12209; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; TRAVIS SM, 1993, J BIOL CHEM, V268, P15336; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Weinreich F, 1999, J GEN PHYSIOL, V114, P55, DOI 10.1085/jgp.114.1.55; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0; Zhong XT, 1998, J BACTERIOL, V180, P1347, DOI 10.1128/JB.180.6.1347-1353.1998	43	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29407	29412		10.1074/jbc.M004790200	http://dx.doi.org/10.1074/jbc.M004790200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893239	hybrid			2022-12-25	WOS:000089439800032
J	Schweizer, A; Stahl, PD; Rohrer, J				Schweizer, A; Stahl, PD; Rohrer, J			A di-aromatic motif in the cytosolic tail of the mannose receptor mediates endosomal sorting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; TRANS-GOLGI NETWORK; 6-PHOSPHATE RECEPTOR; CYTOPLASMIC TAIL; ALVEOLAR MACROPHAGES; LYSOSOMAL MEMBRANE; DENDRITIC CELLS; CANDIDA-ALBICANS; PROTEIN; PHAGOCYTOSIS	The mannose receptor (MR), the prototype of a new family of multilectin receptor proteins important in innate immunity, undergoes rapid internalization and recycling from the endosomal system back to the cell surface. Sorting of the MR in endosomes prevents the receptor from entering lysosomes where it would be degraded. Here, we focused on a diaromatic sequence (Tyr(18)-Phe(19)) in the MR cytoplasmic tail as an endosomal sorting signal. The subcellular distribution of chimeric constructs between the MR and the cation-dependent mannose 6-phosphate receptor was assessed by Percoll density gradients and cell surface assays. Unlike the wild type constructs, mutant receptors with alanine substitutions of Tyr(18)-Phe(19) were highly missorted to lysosomes, indicating that the di-aromatic motif of the MR cytoplasmic tail mediates sorting in endosomes. Within this sequence Tyr(18) is the key residue with Phe(19) contributing to this function. Moreover, Tyr(18) was also found to be essential for internalization, consistent with the presence of overlapping signals for internalization and endosomal sorting in the cytosolic tail of the MR. A di-aromatic amino acid sequence in the cytosolic tail has now been shown to function in two receptors known to be internalized from the plasma membrane, the MR and the cation-dependent mannose 6-phosphate receptor. This feature therefore appears to be a general determinant for endosomal sorting.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Friedrich Miescher Institute for Biomedical Research; Washington University (WUSTL)	Rohrer, J (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.		Stahl, Philip/D-6315-2012	Rohrer, Jack/0000-0002-2058-490X	NIAID NIH HHS [2R01AI20015-16] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020015] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Behrendt N, 2000, J BIOL CHEM, V275, P1993, DOI 10.1074/jbc.275.3.1993; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; Brodsky FM, 1997, TRENDS CELL BIOL, V7, P175, DOI 10.1016/S0962-8924(97)01038-6; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Engering AJ, 1997, EUR J IMMUNOL, V27, P2417, DOI 10.1002/eji.1830270941; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; GARNER RE, 1994, J LEUKOCYTE BIOL, V55, P161, DOI 10.1002/jlb.55.2.161; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; HILLEREHFELD A, 1995, BBA-REV BIOMEMBRANES, V1241, P177, DOI 10.1016/0304-4157(95)00004-B; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRUSKAL BA, 1992, J EXP MED, V176, P1673, DOI 10.1084/jem.176.6.1673; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LARGENT BL, 1984, J BIOL CHEM, V259, P1764; LENNARTZ MR, 1989, J BIOL CHEM, V264, P2385; LUDWIG T, 1995, TRENDS CELL BIOL, V5, P202, DOI 10.1016/S0962-8924(00)89000-5; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MATOVCIK LM, 1990, EUR J CELL BIOL, V53, P203; MESSNER DJ, 1993, ARCH BIOCHEM BIOPHYS, V306, P391, DOI 10.1006/abbi.1993.1528; Orsel JG, 2000, P NATL ACAD SCI USA, V97, P9047, DOI 10.1073/pnas.160251397; PARISE ER, 1984, J LAB CLIN MED, V104, P908; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; PISKURICH JF, 1995, J IMMUNOL, V154, P1735; Pontow SE, 1996, J BIOL CHEM, V271, P30736, DOI 10.1074/jbc.271.48.30736; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Sambrook J, 1998, MOL CLONING LAB MANU, V2nd; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Schweizer A, 1997, P NATL ACAD SCI USA, V94, P14471, DOI 10.1073/pnas.94.26.14471; Shibata Y, 1997, J IMMUNOL, V159, P2462; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; SUNG SSJ, 1983, J CELL BIOL, V96, P160, DOI 10.1083/jcb.96.1.160; SWIGGARD WJ, 1995, CELL IMMUNOL, V165, P302, DOI 10.1006/cimm.1995.1218; Tan MCAA, 1997, EUR J IMMUNOL, V27, P2426, DOI 10.1002/eji.1830270942; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TIETZE C, 1982, J CELL BIOL, V92, P417, DOI 10.1083/jcb.92.2.417; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wu K, 1996, J BIOL CHEM, V271, P21323, DOI 10.1074/jbc.271.35.21323; Yamamoto Y, 1997, INFECT IMMUN, V65, P1077, DOI 10.1128/IAI.65.3.1077-1082.1997	50	49	51	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29694	29700		10.1074/jbc.M000571200	http://dx.doi.org/10.1074/jbc.M000571200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896932	hybrid			2022-12-25	WOS:000089439800069
J	Han, DC; Shen, TL; Guan, JL				Han, DC; Shen, TL; Guan, JL			Role of Grb7 targeting to focal contacts and its phosphorylation by focal adhesion kinase in regulation of cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-TYROSINE KINASE; SH2 DOMAIN PROTEINS; SRC FAMILY KINASES; SIGNAL-TRANSDUCTION; INSULIN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; ESOPHAGEAL-CARCINOMA; PLECKSTRIN HOMOLOGY; COMPLEX-FORMATION	We have previously described Grb7 association with focal adhesion kinase (FAR) and its possible roles in cell migration. In this paper, we investigated the mechanisms by which Grb7 and its association with FAK regulate cell migration. We found that deletion of the Grb7 SH2 domain eliminated partial Grb7 localization to focal contacts and its ability to stimulate cell. migration. Replacement of the SH2 domain with the focal adhesion targeting sequence from FAK resulted in the focal contacts localization of the chimeric molecule and restored its activity to stimulate cell migration. We also found that Grb7 could be phosphorylated by FAK, which was dependent on the FAK kinase activity but not the presence of the Src family kinases, Cell adhesion also enhanced Grb7 phosphorylation in FAK+/+ cells but not FAK-/- cells, suggesting that Grb7 is a physiological substrate of FAK, Furthermore, both Grb7 and the chimeric molecule did not increase migration of FAK-/- cells, although the chimeric molecule was targeted to the focal contacts. Last, we showed that other Grb7 family members could not stimulate cell migration under similar experimental conditions. Together, these results demonstrate a role for Grb7 targeting to focal contacts and its phosphorylation by FAK in the regulation of cell migration.	Cornell Univ, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA	Cornell University	Guan, JL (corresponding author), Cornell Univ, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA.		Shen, Tang-Long/C-7460-2011	Shen, Tang-Long/0000-0001-6264-3608	NIGMS NIH HHS [GM48050] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cary LA, 1996, J CELL SCI, V109, P1787; CHAN PY, 1994, J BIOL CHEM, V269, P20567; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Janes PW, 1997, J BIOL CHEM, V272, P8490, DOI 10.1074/jbc.272.13.8490; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Manser J, 1997, DEV BIOL, V184, P150, DOI 10.1006/dbio.1997.8516; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1621; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Tanaka S, 1997, CANCER RES, V57, P28; Tanaka S, 1998, J CLIN INVEST, V102, P821, DOI 10.1172/JCI2921; TURNER CE, 1994, J CELL SCI, V107, P1583; Vuori K, 1996, MOL CELL BIOL, V16, P2606; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	48	86	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28911	28917		10.1074/jbc.M001997200	http://dx.doi.org/10.1074/jbc.M001997200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893408	hybrid			2022-12-25	WOS:000089330700076
J	Wrenger, S; Faust, J; Mrestani-Klaus, C; Fengler, A; Stockel-Maschek, A; Lorey, S; Kahne, T; Brandt, W; Neubert, K; Ansorge, S; Reinhold, D				Wrenger, S; Faust, J; Mrestani-Klaus, C; Fengler, A; Stockel-Maschek, A; Lorey, S; Kahne, T; Brandt, W; Neubert, K; Ansorge, S; Reinhold, D			Down-regulation of T cell activation following inhibition of dipeptidyl peptidase IV/CD26 by the N-terminal part of the thromboxane A2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 TAT PROTEIN; IV DP-IV; CORRELATION SPECTROSCOPY; COHERENCE TRANSFER; HUMAN-LYMPHOCYTES; ROTATING FRAME; FORCE-FIELD; CD26; GROWTH; SUPPRESSION	Using synthetic inhibitors, it has been shown that the ectopeptidase dipeptidyl peptidase IV (DP IV) (CD26) plays an important role in the activation and proliferation of T lymphocytes, The human immunodeficiency virus-1 Tat protein, as well as the N-terminal nonapeptide Tat(1-9) and other peptides containing the N-terminal sequence XXP, also inhibit DP TV and therefore T cell activation. Studying the effect of amino acid exchanges in the N-terminal three positions of the Tat(1-9) sequence, we found that tryptophan in position 2 strongly improves DP IV inhibition. NMR spectroscopy and molecular modeling show that the effect of Trp(2)-Tat(1-9) could not be explained by significant alterations in the backbone structure and suggest that tryptophan enters favorable interactions with DP IV. Data base searches revealed the thromboxane A2 receptor (TXA2-R) as a membrane protein extracellularly exposing N-terminal MWP. TXA2-R is expressed within the immune system on antigen-presenting cells, namely monocytes, The N-terminal nonapeptide of TXA2-R, TXA2-R(1-9), inhibits DP IV and DNA synthesis and IL-2 production of tetanus toroid-stimulated peripheral blood mononuclear cells. Moreover, TXA2-R(1-9) induces the production of the immunosuppressive cytokine transforming growth factor-pi. These data suggest that the N-terminal part of TXA2-R is an endogenous inhibitory ligand of DP TV and may modulate T cell activation via DP IV/CD26 inhibition.	Otto Von Guericke Univ, Dept Internal Med, Inst Expt Internal Med, D-39120 Magdeburg, Germany; Univ Halle Wittenberg, Dept Biochem & Biotechnol, Inst Biochem, D-06120 Halle, Germany	Otto von Guericke University; Martin Luther University Halle Wittenberg	Wrenger, S (corresponding author), Otto Von Guericke Univ, Dept Internal Med, Inst Expt Internal Med, Leipziger Str 44, D-39120 Magdeburg, Germany.	sabine.wrenger@medizin.uni-magdeburg.de	Kaehne, Thilo/E-4858-2012	Wrenger, Sabine/0000-0002-9733-6162				ALLAN CJ, 1994, J PHARMACOL EXP THER, V270, P446; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRANDT W, 2000, IN PRESS ADV EXP MED, V477; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; DANIELPOUR D, 1993, J IMMUNOL METHODS, V158, P17, DOI 10.1016/0022-1759(93)90254-5; De Meester I, 1999, IMMUNOL TODAY, V20, P367, DOI 10.1016/S0167-5699(99)01486-3; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; Fengler A, 1998, J MOL MODEL, V4, P200, DOI 10.1007/s0089480040200; FLEISCHER B, 1994, IMMUNOL TODAY, V15, P180, DOI 10.1016/0167-5699(94)90316-6; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; GUTHEIL WG, 1994, P NATL ACAD SCI USA, V91, P6594, DOI 10.1073/pnas.91.14.6594; HEINS J, 1988, BIOCHIM BIOPHYS ACTA, V954, P161, DOI 10.1016/0167-4838(88)90067-2; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hirata T, 1996, J CLIN INVEST, V97, P949, DOI 10.1172/JCI118518; HOFFMANN T, 1995, J CHROMATOGR A, V716, P355, DOI 10.1016/0021-9673(95)00411-F; Kahne T, 1999, INT J MOL MED, V4, P3; KAMEOKA J, 1993, SCIENCE, V261, P466, DOI 10.1126/science.8101391; Korom S, 1997, TRANSPLANTATION, V63, P1495, DOI 10.1097/00007890-199705270-00021; KUBOTA T, 1992, CLIN EXP IMMUNOL, V89, P192; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Miggin SM, 1998, BBA-GEN SUBJECTS, V1425, P543, DOI 10.1016/S0304-4165(98)00109-3; Mrestani-Klaus C, 1998, J PEPT SCI, V4, P400, DOI 10.1002/(SICI)1099-1387(199809)4:6<400::AID-PSC162>3.0.CO;2-G; MULLER L, 1979, MOL PHYS, V38, P963, DOI 10.1080/00268977900102161; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Reinhold D, 1997, IMMUNOL LETT, V58, P29, DOI 10.1016/S0165-2478(97)02716-8; Reinhold D, 1997, IMMUNOLOGY, V91, P354, DOI 10.1046/j.1365-2567.1997.d01-2258.x; Reinhold D, 1997, J IMMUNOL METHODS, V209, P203, DOI 10.1016/S0022-1759(97)00160-9; REINHOLD D, 1993, IMMUNOBIOLOGY, V188, P403, DOI 10.1016/S0171-2985(11)80223-8; Reinhold D, 1996, IMMUNOBIOLOGY, V195, P119, DOI 10.1016/S0171-2985(96)80010-6; Rubartelli A, 1998, IMMUNOL TODAY, V19, P543, DOI 10.1016/S0167-5699(98)01351-6; SIMMONS TR, 1993, J LEUKOCYTE BIOL, V53, P173, DOI 10.1002/jlb.53.2.173; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STEINBRECHER A, 2000, IN PRESS ADV EXP MED, V477; SUBRAMANYAM M, 1993, J IMMUNOL, V150, P2544; Tanaka S, 1997, INT J IMMUNOPHARMACO, V19, P15, DOI 10.1016/S0192-0561(97)00004-0; Tanaka S, 1998, IMMUNOPHARMACOLOGY, V40, P21, DOI 10.1016/S0162-3109(98)00014-9; TORIMOTO Y, 1991, J IMMUNOL, V147, P2514; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; Wrenger S, 1996, FEBS LETT, V383, P145, DOI 10.1016/0014-5793(96)00221-9; Wrenger S, 2000, FEBS LETT, V466, P155, DOI 10.1016/S0014-5793(99)01779-2; Wrenger S, 1997, J BIOL CHEM, V272, P30283, DOI 10.1074/jbc.272.48.30283; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572	52	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22180	22186		10.1074/jbc.M002338200	http://dx.doi.org/10.1074/jbc.M002338200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10896952				2022-12-25	WOS:000088363800060
J	Su, ZZ; Shi, YJ; Fisher, PB				Su, ZZ; Shi, YJ; Fisher, PB			Cooperation between AP1 and PEA3 sites within the progression elevated gene-3 (PEG-3) promoter regulate basal and differential expression of PEG-3 during progression of the oncogenic phenotype in transformed rat embryo cells	ONCOGENE			English	Article						cancer progression; promoter analysis; transcriptional regulation	ANCHORAGE-INDEPENDENT GROWTH; TYPE-5 ADENOVIRUS; TUMOR PROMOTERS; BINDING-SITES; TRANSCRIPTION; AP-1; CANCER; INDUCTION; SUPPRESSION; PROTEIN	Cancer is a progressive disease in which a tumor cell temporally develops qualitatively new transformation related phenotypes or a further elaboration of existing transformation associated properties. Subtraction hybridization identified a novel gene associated with transformation progression in mutant adenovirus type 5, H5ts125, transformed rat embryo cells, progression elevated gene-3 (PEG-3). To define the mechanism by which expression of PEG-3 is enhanced as a function of cancer progression a 5'-flanking promoter region of similar to 2.0-kb, PEG-Prom, was Isolated, cloned and characterized. The full-length and various mutated regions of the PEG-From mere linked to a luciferase reporter construct and evaluated for promoter activity during cancer progression. These assays demonstrate a requirement for API and PEA3 sites adjacent to the TATA bos region of PEG-3 in mediating basal promoter activity and the enhanced expression of PEG-3 in progressed H5ts125-transformed rat embryo cells. An involvement of AP1 and PF Lambda 3 in PEG3 regulation was also confirmed by electrophoretic mobility shift assays (EMSA) and transfection studies with cJun and PEA3 expression vectors, Our findings document the importance of both AP1 and PEA3 transcription factors in mediating basal and elevated expression of PEG3 in H5ts125-transformed rat embryo cells displaying an aggressive and progressed cancer phenotype.	Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, BB-15-1501,630 W 168th St, New York, NY 10032 USA.				NATIONAL CANCER INSTITUTE [R01CA035675, R01CA074468] Funding Source: NIH RePORTER; NCI NIH HHS [CA74468, CA35675] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BABISS LE, 1985, SCIENCE, V228, P1099, DOI 10.1126/science.2581317; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; DeCesare D, 1996, ONCOGENE, V13, P2551; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUIGOU GJ, 1991, ONCOGENE, V6, P1813; DUIGOU GJ, 1990, MOL CELL BIOL, V10, P2027, DOI 10.1128/MCB.10.5.2027; DUIGOU GJ, 1989, ANN NY ACAD SCI, V567, P302, DOI 10.1111/j.1749-6632.1989.tb16487.x; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; FISHER PB, 1979, CELL, V18, P695, DOI 10.1016/0092-8674(79)90124-7; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FISHER PB, 1978, P NATL ACAD SCI USA, V75, P2311, DOI 10.1073/pnas.75.5.2311; FISHER PB, 1979, NATURE, V281, P591, DOI 10.1038/281591a0; FISHER PB, 1979, CANCER RES, V39, P3051; Fisher PB, 1984, TUMOR PROMOTION COCA, P57; Gopalkrishnan RV, 1999, NUCLEIC ACIDS RES, V27, P4775, DOI 10.1093/nar/27.24.4775; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Kang DC, 1998, P NATL ACAD SCI USA, V95, P13788, DOI 10.1073/pnas.95.23.13788; Kang DC, 1998, INT J ONCOL, V13, P1117; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOHN EC, 1995, CANCER RES, V55, P1856; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; Matrisian L M, 1990, Semin Cancer Biol, V1, P107; MATRISIAN LM, 1994, ANN NY ACAD SCI, V91, P10129; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; REDDY PG, 1993, METHODS MOL GENETICS, V1, P68; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; SU ZZ, 1994, ONCOGENE, V9, P1123; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; SU ZZ, 1995, INT J ONCOL, V7, P1279; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x	45	42	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2000	19	30					3411	3421		10.1038/sj.onc.1203666	http://dx.doi.org/10.1038/sj.onc.1203666			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918598				2022-12-25	WOS:000088198100009
J	Begley, GS; Furie, BC; Czerwiec, E; Taylor, KL; Furie, GL; Bronstein, L; Stenflo, J; Furie, B				Begley, GS; Furie, BC; Czerwiec, E; Taylor, KL; Furie, GL; Bronstein, L; Stenflo, J; Furie, B			A conserved motif within the vitamin K-dependent carboxylase gene is widely distributed across animal phyla	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC-ACID; GLUTAMYL CARBOXYLASE; RECOGNITION SITE; CONANTOKIN-G; CONUS TEXTILE; FACTOR-IX; SNAIL; IDENTIFICATION; PROTHROMBIN; PROPEPTIDE	The vitamin K-dependent gamma -glutamyl carboxylase catalyzes the posttranslational conversion of glutamic acid to gamma -carboxyglutamic acid, an amino acid critical to the function of the vitamin K-dependent blood coagulation proteins. Given the functional similarity of mammalian vitamin K-dependent carboxylases and the vitamin K-dependent carboxylase from Conus textile, a marine invertebrate, we hypothesized that structurally conserved regions would identify sequences critical to this common functionality. Furthermore, we examined the diversity of animal species that maintain vitamin K-dependent carboxylation to generate gamma -carboxyglutamic acid. We have cloned carboxylase homologs in full-length or partial form from the beluga whale (Delphinapterus leucas), toadfish (Opsanus tau), chicken (Gallus gallus), hagfish (Myxine glutinosa), horseshoe crab (Limulus polyphemus), and cone snail (Conus textile) to compare these structures to the known bovine, human, rat, and mouse cDNA sequences, Comparison of the predicted amino acid sequences identified a nearly perfectly conserved 38-amino acid residue region in all of these putative carboxylases. In addition, this amino acid motif is also present in the Drosophila genome and identified a Drosophila homolog of the gamma -carboxylase, Assay of hagfish liver demonstrated vitamin K-dependent carboxylase activity in this hemichordate. These results demonstrate the broad distribution of the vitamin K-dependent carboxylase gene, including a highly conserved motif that is likely critical for enzyme function. The vitamin K-dependent biosynthesis of gamma -carboxyglutamic acid appears to be a highly conserved function in the animal kingdom.	Marine Biol Lab, Woods Hole, MA 02543 USA; Harvard Univ, Sch Med, Ctr Hemostasis & Thrombosis Res, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Univ Lund, Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden	Marine Biological Laboratory - Woods Hole; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Lund University; Skane University Hospital	Furie, B (corresponding author), Marine Biol Lab, Woods Hole, MA 02543 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038216, R37HL038216, P01HL042443] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38216, HL42443] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bandyopadhyay PK, 1998, J BIOL CHEM, V273, P5447, DOI 10.1074/jbc.273.10.5447; Brenner B, 1998, BLOOD, V92, P4554, DOI 10.1182/blood.V92.12.4554.424k42_4554_4559; BUCHER D, 1976, FEBS LETT, V68, P293, DOI 10.1016/0014-5793(76)80456-5; Bush KA, 1999, BIOCHEMISTRY-US, V38, P14660, DOI 10.1021/bi991640l; ESMON CT, 1976, J BIOL CHEM, V251, P6238; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; Furie B, 1999, BLOOD, V93, P1798, DOI 10.1182/blood.V93.6.1798.406k22_1798_1808; HAUSCHKA PV, 1975, P NATL ACAD SCI USA, V72, P3925, DOI 10.1073/pnas.72.10.3925; HAUSCHKA PV, 1988, CURRENT ADV VITAMIN, P237; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; Li T, 2000, J BIOL CHEM, V275, P18291, DOI 10.1074/jbc.M001790200; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; NELSESTUEN GL, 1974, J BIOL CHEM, V249, P6347; PRICE PA, 1987, P NATL ACAD SCI USA, V84, P8335, DOI 10.1073/pnas.84.23.8335; PRICE PA, 1976, P NATL ACAD SCI USA, V73, P3374, DOI 10.1073/pnas.73.10.3374; Prorok M, 1996, BIOCHEMISTRY-US, V35, P16528, DOI 10.1021/bi9621122; REHEMTULLA A, 1993, P NATL ACAD SCI USA, V90, P4611, DOI 10.1073/pnas.90.10.4611; Rigby AC, 1997, BIOCHEMISTRY-US, V36, P15677, DOI 10.1021/bi9718550; Rigby AC, 1999, P NATL ACAD SCI USA, V96, P5758, DOI 10.1073/pnas.96.10.5758; Romero EE, 1998, BIOCHEM BIOPH RES CO, V248, P783, DOI 10.1006/bbrc.1998.8987; ROTH DA, 1995, J BIOL CHEM, V270, P5305, DOI 10.1074/jbc.270.10.5305; SHAH DV, 1979, P SOC EXP BIOL MED, V161, P498, DOI 10.3181/00379727-161-40582; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; Stanley TB, 1997, FEBS LETT, V407, P85, DOI 10.1016/S0014-5793(97)00299-8; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; Sugiura I, 1996, J BIOL CHEM, V271, P17837, DOI 10.1074/jbc.271.30.17837; TAI JY, 1977, J BIOL CHEM, V252, P2178; ULRICH MMW, 1988, J BIOL CHEM, V263, P9697; VANBUSKIRK JJ, 1978, BIOCHEM BIOPH RES CO, V80, P1329; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935	30	31	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36245	36249		10.1074/jbc.M003944200	http://dx.doi.org/10.1074/jbc.M003944200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10893417	hybrid, Green Published			2022-12-25	WOS:000165382000085
J	Otsuka, M; Kato, N; Lan, KH; Yoshida, H; Kato, J; Goto, T; Shiratori, Y; Omata, M				Otsuka, M; Kato, N; Lan, KH; Yoshida, H; Kato, J; Goto, T; Shiratori, Y; Omata, M			Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; POLYMERASE CHAIN-REACTION; PROGRAMMED CELL-DEATH; NON-B-HEPATITIS; HEPATOCELLULAR-CARCINOMA; TUMOR-SUPPRESSOR; NON-A; X PROTEIN; T-ANTIGEN; IN-VIVO	Hepatitis C virus (HCV) causes a persistent infection, chronic hepatitis, and hepatocellular carcinoma. Since there are several reports indicating that some viruses influence the tumor suppressor p53 function, we determined the effects of MCV proteins on p53 function and its mechanism determined by use of a reporter assay. Among seven HCV proteins investigated (core, NS2, NS3, NS4A, NS4B, NS5A, and NS5B), only core protein augmented the transcriptional activity of p53 and increased the expression of p21(waf1) protein, which is a major target of p53. Core protein increased both DNA-binding affinity of p53 in electrophoretic morbidity shift assay and transcriptional ability of p53 itself in a reporter assay. The direct interaction between core protein and C terminus of p53 was also shown by glutathione S-transferase fusion protein binding assay. In addition, core protein interacted with hTAF(II)28, a component of the transcriptional factor complex in vivo and in vitro. These results suggest that HCV core protein interacts with p53 and modulates p53-dependent promoter activities during HCV infection.	Univ Tokyo, Fac Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo	Kato, N (corresponding author), Univ Tokyo, Fac Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Otsuka, Motoyuki/H-9067-2019	Otsuka, Motoyuki/0000-0003-2869-2881				BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CHANG SC, 1994, BIOCHEM BIOPH RES CO, V205, P1284, DOI 10.1006/bbrc.1994.2804; Chen WP, 1996, J VIROL, V70, P4849, DOI 10.1128/JVI.70.7.4849-4853.1996; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Devireddy LR, 1999, J VIROL, V73, P3778, DOI 10.1128/JVI.73.5.3778-3788.1999; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Edamoto Y, 1996, CANCER, V77, P1787; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; Honda K, 1998, BRIT J CANCER, V77, P776, DOI 10.1038/bjc.1998.126; Hsieh TY, 1998, J BIOL CHEM, V273, P17651, DOI 10.1074/jbc.273.28.17651; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KATO N, 1993, BIOCHEM BIOPH RES CO, V192, P800, DOI 10.1006/bbrc.1993.1485; KATO N, 1990, J CLIN INVEST, V86, P1764, DOI 10.1172/JCI114903; Kato N, 1997, J VIROL, V71, P8856, DOI 10.1128/JVI.71.11.8856-8859.1997; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lu W, 1999, VIROLOGY, V264, P134, DOI 10.1006/viro.1999.9979; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; McCormack SJ, 1997, ONCOGENE, V15, P265, DOI 10.1038/sj.onc.1201186; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Megyeri K, 1999, VIROLOGY, V259, P74, DOI 10.1006/viro.1999.9757; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; MICHELLE EDM, 1998, J VIROL, V72, P3146; MILLER RH, 1990, P NATL ACAD SCI USA, V87, P2057, DOI 10.1073/pnas.87.6.2057; Muganda P, 1998, CELL MOL BIOL, V44, P321; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Murono S, 1999, HISTOPATHOLOGY, V34, P432; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOSE H, 1993, CANCER, V72, P355, DOI 10.1002/1097-0142(19930715)72:2<355::AID-CNCR2820720208>3.0.CO;2-W; ODA T, 1992, CANCER RES, V52, P3674; Ohashi M, 1999, GUT, V44, P366, DOI 10.1136/gut.44.3.366; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Prost S, 1998, J BIOL CHEM, V273, P33327, DOI 10.1074/jbc.273.50.33327; Qin LF, 1998, INT J CANCER, V79, P424, DOI 10.1002/(SICI)1097-0215(19980821)79:4<424::AID-IJC19>3.0.CO;2-4; RAVAGGI A, 1994, J HEPATOL, V20, P833, DOI 10.1016/S0168-8278(05)80157-6; RAY RB, 1995, VIRUS RES, V37, P209, DOI 10.1016/0168-1702(95)00034-N; Ray RB, 1997, J BIOL CHEM, V272, P10983; Ray RB, 1998, GENE, V208, P331, DOI 10.1016/S0378-1119(98)00030-4; ROGER JAG, 1996, VIROLOGY, V218, P23; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sheppard HM, 1999, MOL CELL BIOL, V19, P2746; SHIH CM, 1995, J VIROL, V69, P1160, DOI 10.1128/JVI.69.2.1160-1171.1995; SHIRATORI Y, 1995, HEPATOLOGY, V22, P1027, DOI 10.1002/hep.1840220403; TAKANO S, 1995, HEPATOLOGY, V21, P650; TANJI Y, 1995, J VIROL, V69, P1575, DOI 10.1128/JVI.69.3.1575-1581.1995; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Togo G, 1996, CANCER RES, V56, P5620; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; Uchida T, 1996, INT J CANCER, V67, P892; WANG XW, 1995, CANCER RES, V55, P6012; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998	73	134	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34122	34130		10.1074/jbc.M000578200	http://dx.doi.org/10.1074/jbc.M000578200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10924497	hybrid			2022-12-25	WOS:000165095300020
J	Fisher, CA; Narayanaswami, V; Ryan, RO				Fisher, CA; Narayanaswami, V; Ryan, RO			The lipid-associated conformation of the low density lipoprotein receptor binding domain of human apolipoprotein E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; LDL RECEPTOR; ALZHEIMERS-DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; AQUEOUS-SOLUTION; PROTEIN	Apolipoprotein E (apoE) is a 34-kDa exchangeable apolipoprotein that regulates metabolism of plasma lipoproteins by functioning as a ligand for members of the LDL receptor family, The receptor-binding region localizes to the vicinity of residues 130-150 within its independently folded 22-kDa N-terminal domain. In the absence of lipid, this domain exists as a receptor-inactive, globular four-helix bundle. Receptor recognition properties of this domain are manifest upon lipid association, which is accompanied by a conformational change in the protein. Fluorescence resonance energy transfer has been used to monitor helix repositioning, which accompanies lipid association of the apoE N-terminal domain. Site-directed mutagenesis was used to replace naturally occurring Trp residues with phenylalanine, creating a Trp-null apoE3 N-terminal domain (residues 1-183), Subsequently, tyrosine residues in helix 2, helix 3, or helix 4 were converted to Trp, generating single Trp mutant proteins. The lone cysteine at position 112 was covalently modified with N-iodoacetyl-N'-(5-Sulfo-1-naphthyl)ethylenediamine, which serves as an energy acceptor from excited tryptophan residues. Fluorescence resonance energy transfer analysis of apoE N-terminal domain variants in phospholipid disc complexes suggests that the helix bundle opens to adopt a partially extended conformation. A model is presented that depicts a tandem arrangement of the receptor-binding region of the protein in the disc complex, corresponding to its low density lipoprotein receptor-active conformation.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada	University of Alberta	Ryan, RO (corresponding author), Childrens Hosp Oakland, Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.			Narayanaswami, Vasanthy/0000-0001-7088-4057	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL064159, R01HL064159] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64159] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; DEPAUW M, 1995, BIOCHEMISTRY-US, V34, P10953, DOI 10.1021/bi00034a030; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; Fisher CA, 1999, J LIPID RES, V40, P93; Fisher CA, 1997, BIOCHEM CELL BIOL, V75, P45, DOI 10.1139/bcb-75-1-45; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P303; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; North CL, 1999, BIOCHEMISTRY-US, V38, P3926, DOI 10.1021/bi9821622; PITAS RE, 1980, J BIOL CHEM, V255, P5454; Poirier J, 1995, ANN MED, V27, P663, DOI 10.3109/07853899509019253; Raussens V, 1998, J BIOL CHEM, V273, P25825, DOI 10.1074/jbc.273.40.25825; Riddell DR, 1997, J BIOL CHEM, V272, P89; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; Swarnakar S, 1998, J BIOL CHEM, V273, P12140, DOI 10.1074/jbc.273.20.12140; THUREN T, 1991, J BIOL CHEM, V266, P4853; WEISGRABER KH, 1994, CURR OPIN STRUC BIOL, V4, P507, DOI 10.1016/S0959-440X(94)90212-7; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WEISGRABER KH, 1992, HIGH DENSITY LIPOPRO, V3, P175; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194	24	66	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33601	33606		10.1074/jbc.M002643200	http://dx.doi.org/10.1074/jbc.M002643200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10906325	hybrid			2022-12-25	WOS:000090104600060
J	Lehtonen, S; Ora, A; Olkkonen, VM; Geng, L; Zerial, M; Somlo, S; Lehtonen, E				Lehtonen, S; Ora, A; Olkkonen, VM; Geng, L; Zerial, M; Somlo, S; Lehtonen, E			In vivo interaction of the adapter protein CD2-associated protein with the type 2 polycystic kidney disease protein, polycystin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PKD1 GENE-PRODUCT; IDENTIFICATION; EXPRESSION; CHANNEL; ENCODES; DOMAINS; MICE	We identified a developmentally regulated gene from mouse kidney whose expression is up-regulated in metanephrogenic mesenchyme cells when they are induced to differentiate to epithelial cells during kidney organogenesis. The deduced 70.5-kDa protein, originally named METS-1 (mesenchyme-to-epithelium transition protein with SH3 domains), has since been cloned as a CD2-associated protein (CD2AP). CD2AP is strongly expressed in glomerular podocytes, and the absence of CD2AP in mice results in congenital nephrotic syndrome. We have found that METS-1/CD2AP thereafter referred to as CD2AP) is expressed at lower levels in renal tubular epithelial cells in the adult kidney, particularly in distal nephron segments. Independent yeast two-hybrid screens using the COOH-terminal region of either CD2AP or polycystin-2 as bait identified the COOH termini of polycystin-2 and CD2AP, respectively, as strong interacting partners. This interaction was confirmed in cultured cells by eo-immunoprecipitation of endogenous polycystin-2 with endogenous CD2AP and vice versa. CD2AP shows a diffuse reticular cytoplasmic and perinuclear pattern of distribution, similar to polycystin-2, in cultured cells, and the two proteins co-localize by indirect double immunofluorescence microscopy. CD2AP is an adapter molecule that associates with a variety of membrane proteins to organize the cytoskeleton around a polarized site. Such a function fits well with that hypothesized for the polycystin proteins in renal tubular epithelial cells, and the present findings suggest that CD2AP has a role in polycystin-2 function.	Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00290 Helsinki, Finland; Natl Publ Hlth Inst, Dept Biochem, FIN-00300 Helsinki, Finland; European Mol Biol Lab, D-6900 Heidelberg, Germany; Yale Univ, Sch Med, Nephrol Sect, New Haven, CT 06520 USA	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Finland National Institute for Health & Welfare; European Molecular Biology Laboratory (EMBL); Yale University	Somlo, S (corresponding author), Yale Univ, Sch Med, Nephrol Sect, 295 Congress Ave, New Haven, CT 06519 USA.		Lehtonen, Sanna/GRJ-3642-2022; ora, ari/P-5180-2015; Lehtonen, Sanna/AAE-4545-2020; Lehtonen, Eero/AGJ-4027-2022	Lehtonen, Sanna/0000-0003-4189-2415; Olkkonen, Vesa/0000-0001-5553-7997; Lehtonen, Eero/0000-0002-8218-635X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK057328] Funding Source: NIH RePORTER; NIDDK NIH HHS [P50 DK057328, P50DK57328] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnould T, 1999, MOL CELL BIOL, V19, P3423; Barasch J, 1999, CELL, V99, P377, DOI 10.1016/S0092-8674(00)81524-X; BURN TC, 1995, HUM MOL GENET, V4, P575, DOI 10.1093/hmg/4.4.575; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; CALVET JP, 1993, KIDNEY INT, V43, P101, DOI 10.1038/ki.1993.17; Charron AJ, 2000, J CELL BIOL, V149, P111, DOI 10.1083/jcb.149.1.111; Chen XZ, 1999, NATURE, V401, P383, DOI 10.1038/43907; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Emmons SW, 1999, NATURE, V401, P339, DOI 10.1038/43810; Foggensteiner L, 2000, J AM SOC NEPHROL, V11, P814, DOI 10.1681/ASN.V115814; Gallagher AR, 2000, P NATL ACAD SCI USA, V97, P4017, DOI 10.1073/pnas.97.8.4017; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Grantham JJ, 1997, CONTRIB NEPHROL, V122, P1; Guillaume R, 2000, MECH DEVELOP, V93, P179, DOI 10.1016/S0925-4773(00)00257-4; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Huan YH, 1999, J CLIN INVEST, V104, P1459, DOI 10.1172/JCI5111; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Jansson S, 1997, J CELL PHYSIOL, V173, P147, DOI 10.1002/(SICI)1097-4652(199711)173:2<147::AID-JCP13>3.0.CO;2-D; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; Lehtonen S, 1999, INT J DEV BIOL, V43, P425; Lehtonen S, 1998, INT J DEV BIOL, V42, P775; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Markowitz GS, 1999, AM J PHYSIOL-RENAL, V277, pF17, DOI 10.1152/ajprenal.1999.277.1.F17; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; MORTON CJ, 1994, CURR BIOL, V4, P615, DOI 10.1016/S0960-9822(00)00134-2; Nomura H, 1998, J BIOL CHEM, V273, P25967, DOI 10.1074/jbc.273.40.25967; Obermuller N, 1999, AM J PHYSIOL-RENAL, V277, pF914, DOI 10.1152/ajprenal.1999.277.6.F914; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PETERS DJM, 1992, CONTRIB NEPHROL, V97, P128; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Saxen L., 1987, ORGANOGENESIS KIDNEY; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Torres VE, 1998, CURR OPIN NEPHROL HY, V7, P159, DOI 10.1097/00041552-199803000-00004; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Veldhuisen B, 1999, EUR J HUM GENET, V7, P860, DOI 10.1038/sj.ejhg.5200383; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARD CJ, 1994, CELL, V77, P881; Wilson PD, 1999, EXP NEPHROL, V7, P114; Wilson PD, 1999, LAB INVEST, V79, P1311; Wu GQ, 2000, NAT GENET, V24, P75, DOI 10.1038/71724; Wu GQ, 1998, GENOMICS, V54, P564, DOI 10.1006/geno.1998.5618; Wu GQ, 1997, GENOMICS, V45, P220, DOI 10.1006/geno.1997.4920; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6	50	78	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32888	32893		10.1074/jbc.M006624200	http://dx.doi.org/10.1074/jbc.M006624200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913159	hybrid			2022-12-25	WOS:000090003800070
J	Litvak, V; Tian, D; Shaul, YD; Lev, S				Litvak, V; Tian, D; Shaul, YD; Lev, S			Targeting of PYK2 to focal adhesions as a cellular mechanism for convergence between integrins and G protein-coupled receptor signaling cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; TYROSINE KINASE; ACTIN CYTOSKELETON; CARDIAC MYOCYTES; ANGIOTENSIN-II; EGF RECEPTOR; PHOSPHORYLATION; ACTIVATION; IDENTIFICATION; ASSOCIATION	The non-receptor tyrosine kinase PYK2 appears to function at a point of convergence of integrins and certain G protein-coupled receptor (GPCR) signaling cascades. In this study, we provide evidence that translocation of PYK2 to focal adhesions is triggered both by cell adhesion to extracellular matrix proteins and by activation of the histamine GPCR. By using different mutants of PYK2 as green fluorescent fusion proteins, we show that the translocation of PYK2 to focal adhesions is not dependent on its catalytic activity but rather is mediated by its carboxyl-terminal domain. Translocation of PYK2 to focal adhesions was attributed to enhanced tyrosine phosphorylation of PYK2 and its association with the focal adhesion proteins paxillin and p130(Cas). Translocation of PYK2 to focal adhesions, as well as its tyrosine phosphorylation in response to histamine treatment, was abolished in the presence of protein kinase C inhibitors or cytochalasin D treatment, whereas activation of protein kinase C by phorbol ester resulted in focal adhesion targeting of PYR2 and its tyrosine phosphorylation in an integrin-clustering dependent manner. Overexpression of a wild-type PYK2 enhanced ERK activation in response to histamine, whereas a kinase-deficient mutant substantially inhibited this response. Furthermore, inhibition of PYK2 translocation to focal adhesions abolished ERK activation in response to histamine treatment. These results suggest that PYK2 apparently links between GPCRs and focal adhesion-dependent ERK activation and can provide the molecular basis underlying PYK2 function at a point of convergence between signaling pathways triggered by extracellular matrix proteins and certain GPCR agonists.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Lev, S (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.		Lev, Sima/AAP-7880-2020; Shaul, Yoav/AAY-7011-2020	Lev, Sima/0000-0002-2108-3330; 				Andreev J, 1999, MOL CELL BIOL, V19, P2338; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Bootman MD, 1996, BIOCHEM J, V314, P347, DOI 10.1042/bj3140347; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Giancotti FG, 2000, NAT CELL BIOL, V2, pE13, DOI 10.1038/71397; Gismondi A, 1997, J IMMUNOL, V159, P4729; GRINNELL F, 1986, EXP CELL RES, V162, P449, DOI 10.1016/0014-4827(86)90349-6; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Haimovich B, 1996, BLOOD, V87, P152, DOI 10.1182/blood.V87.1.152.bloodjournal871152; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Johnson JA, 1996, CIRC RES, V79, P1086, DOI 10.1161/01.RES.79.6.1086; Lakkakorpi PT, 1999, J BIOL CHEM, V274, P4900, DOI 10.1074/jbc.274.8.4900; Lev S, 1999, MOL CELL BIOL, V19, P2278; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI J, 1996, BLOOD, P417; Ma EA, 1997, EUR J IMMUNOL, V27, P329, DOI 10.1002/eji.1830270147; Ohba T, 1998, BIOCHEM J, V330, P1249, DOI 10.1042/bj3301249; Rodriguez-Fernandez JL, 1999, BIOESSAYS, V21, P1069, DOI 10.1002/(SICI)1521-1878(199912)22:1<1069::AID-BIES13>3.0.CO;2-C; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SanchezMateos P, 1996, SEMIN CANCER BIOL, V7, P99, DOI 10.1006/scbi.1996.0015; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHLAEPFER DD, 1994, NATURE, V372, P786; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VAN BT, 1995, NATURE, V376, P781; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WOODS A, 1992, J CELL SCI, V101, P277; Xiong WC, 1998, J CELL SCI, V111, P1981; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	50	69	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32736	32746		10.1074/jbc.M004200200	http://dx.doi.org/10.1074/jbc.M004200200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10915788	hybrid			2022-12-25	WOS:000090003800051
J	Sakamoto, I; Kishida, S; Fukui, A; Kishida, M; Yamamoto, H; Hino, S; Michiue, T; Takada, S; Asashima, M; Kikuchi, A				Sakamoto, I; Kishida, S; Fukui, A; Kishida, M; Yamamoto, H; Hino, S; Michiue, T; Takada, S; Asashima, M; Kikuchi, A			A novel beta-catenin-binding protein inhibits beta-catenin-dependent Tcf activation and axis formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT SIGNALING PATHWAY; GLYCOGEN-SYNTHASE KINASE-3-BETA; TRANSCRIPTION FACTOR TCF; MOUSE FUSED LOCUS; F-BOX PROTEIN; NEGATIVE REGULATOR; XENOPUS EMBRYOS; FUNCTIONAL INTERACTION; PHOSPHATASE 2A; COMPLEX	beta -Catenin is efficiently phosphorylated by glycogen synthase kinase-3 beta in the Axin complex in the cytoplasm, resulting in the down-regulation. In response to Wnt, beta -catenin is stabilized and translocated into the nucleus where it stimulates gene expression through Tcf/Lef, Here we report a novel protein, designated Duplin (for axis duplication inhibitor), which negatively regulates the function of beta -catenin in the nucleus. Duplin was located in the nucleus. Duplin bound directly to the Armadillo repeats of beta -catenin, thereby inhibiting the binding of Tcf to beta -catenin. It did not affect the stability of beta -catenin but inhibited Wnt- or beta -catenin-dependent Tcf activation. Furthermore, expression of Duplin in Xenopus embryos inhibited the axis formation and beta -catenin-dependent axis duplication, and prevented the beta -catenin's ability to rescue ventralizing phenotypes induced by ultraviolet light irradiation. Thus, Duplin is a nuclear protein that inhibits beta -catenin signaling.	Kyoto Univ, Fac Sci, Ctr Mol & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan; Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; PRESTO, Japan Sci & Technol Corp, Hiroshima 7348551, Japan; Univ Tokyo, Dept Life Sci Biol, Meguro Ku, Tokyo 1538902, Japan; Univ Tokyo, CREST Project, Meguro Ku, Tokyo 1538902, Japan; Japan Sci & Technol Corp, ERATO, Kondoh Differentiat Signaling Project, Kyoto 6068305, Japan	Kyoto University; Hiroshima University; Japan Science & Technology Agency (JST); University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo; Japan Science & Technology Agency (JST)	Kikuchi, A (corresponding author), Kyoto Univ, Fac Sci, Ctr Mol & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan.	akikuchi@mcai.med.hiroshima-u.ac.jp	Fukui, Akimasa/F-5284-2011	kishida, shosei/0000-0003-0405-851X; Takada, Shinji/0000-0003-4125-6056				Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brannon M, 1999, DEVELOPMENT, V126, P3159; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Dale TC, 1998, BIOCHEM J, V329, P209; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GLUECKSOHNSCHOENHEIMER S, 1949, J EXP ZOOL, V110, P47, DOI 10.1002/jez.1401100105; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; HURT EC, 1993, FEBS LETT, V325, P76, DOI 10.1016/0014-5793(93)81417-X; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; Kikuchi A, 1999, CELL SIGNAL, V11, P777, DOI 10.1016/S0898-6568(99)00054-6; Kikuchi A, 1999, CYTOKINE GROWTH F R, V10, P255, DOI 10.1016/S1359-6101(99)00017-9; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; Maniatis T., 1982, MOL CLONING LAB MANU; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1998, BIOESSAYS, V20, P536, DOI 10.1002/(SICI)1521-1878(199807)20:7<536::AID-BIES4>3.3.CO;2-U; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Okazaki M, 1996, CANCER RES, V56, P2387; PERRY WL, 1995, GENETICS, V141, P321; Pizzuti A, 1996, HUM MOL GENET, V5, P953, DOI 10.1093/hmg/5.7.953; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; SCHARF SR, 1980, DEV BIOL, V79, P181, DOI 10.1016/0012-1606(80)90082-2; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shibamoto S, 1998, GENES CELLS, V3, P659; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tian Q, 1999, DEVELOPMENT, V126, P3371; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	56	84	86	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32871	32878		10.1074/jbc.M004089200	http://dx.doi.org/10.1074/jbc.M004089200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10921920	hybrid			2022-12-25	WOS:000090003800068
J	Igarashi, J; Michel, T				Igarashi, J; Michel, T			Agonist-modulated targeting of the EDG-1 receptor to plasmalemmal caveolae - eNOS activation by sphingosine 1-phosphate and the role of caveolin-1 in sphingolipid signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; PROTEIN-COUPLED RECEPTOR; HUMAN ENDOTHELIAL-CELLS; LYSOPHOSPHATIDIC ACID; MOLECULAR-CLONING; CARDIAC MYOCYTES; DUAL ACYLATION; KINASE PATHWAY; SPHINGOSINE-1-PHOSPHATE; MEMBRANE	Plasmalemmal caveolae are membrane microdomains that are specifically enriched in sphingolipids and contain a wide array of signaling proteins, including the endothelial isoform of nitric-oxide synthase (eNOS). EDG-1 is a G protein-coupled receptor for sphingosine 1-phosphate (S1P) that is expressed in endothelial cells and has been implicated in diverse vascular signal transduction pathways. We analyzed the subcellular distribution of EDG-1 in COS-7 cells transiently transfected with cDNA constructs encoding epitope-tagged EDG-1. Subcellular fractionation of cell lysates resolved by ultracentrifugation in discontinuous sucrose gradients revealed that similar to 55% of the EDG-1 protein was recovered in fractions enriched in caveolin-1, a resident protein of caveolae, Co-immunoprecipitation experiments showed that EDG-1 could be specifically precipitated by antibodies directed against caveolin-1 and vice versa. The targeting of EDG-1 to caveolae-enriched fractions was markedly increased (from 51 +/- 11% to 93 +/- 14%) by treatment of transfected cells with S1P (5 mu M, 60 min). In co-transfection experiments expressing EDG-1 and eNOS cDNAs in COS-7 cells, we found that S1P treatment significantly and specifically increased nitric-oxide synthase activity, with an EC50 of 30 nM S1P. Overexpression of transfected caveolin-1 cDNA together with EDG-1 and eNOS markedly diminished S1P-mediated eNOS activation; caveolin overexpression also attenuated agonist-induced phosphorylation of EDG-1 receptor by >90%. These results suggest that the interaction of the EDG-1 receptor with caveolin may serve to inhibit signaling through the S1P pathway, even as the targeting of EDG-1 to caveolae facilitates the interactions of this receptor with ligands and effecters that are also targeted to caveolae. The agonist-modulated targeting of EDG-1 to caveolae and its dynamic inhibitory interactions with caveolin identify new points for regulation of sphingolipid-dependent signaling in the vascular wall.	Harvard Univ, Brigham & Womens Hosp, Div Cardiovasc, Sch Med, Boston, MA 02115 USA; Vet Affairs Boston Healthcare Syst, W Roxbury, MA 02132 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Michel, T (corresponding author), Harvard Univ, Brigham & Womens Hosp, Div Cardiovasc, Sch Med, 75 Francis St,Thorn Bldg,Rm 1210A, Boston, MA 02115 USA.	michel@calvin.bwh.harvard.edu						Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Feron O, 1998, BIOCHEMISTRY-US, V37, P193, DOI 10.1021/bi972307p; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; HLA T, 1990, J BIOL CHEM, V265, P9308; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; Igarashi J, 1999, P NATL ACAD SCI USA, V96, P12583, DOI 10.1073/pnas.96.22.12583; Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459; KU DD, 1993, AM J PHYSIOL, V265, pH586, DOI 10.1152/ajpheart.1993.265.2.H586; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Lee MJ, 1998, J BIOL CHEM, V273, P22105, DOI 10.1074/jbc.273.34.22105; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Liu CH, 1999, MOL BIOL CELL, V10, P1179, DOI 10.1091/mbc.10.4.1179; Liu J, 1999, J BIOL CHEM, V274, P15781, DOI 10.1074/jbc.274.22.15781; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Sekiguchi K, 1999, CIRC RES, V85, P1000; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stamler, 1996, METHODS NITRIC OXIDE, P249; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Yamazaki Y, 2000, BIOCHEM BIOPH RES CO, V268, P583, DOI 10.1006/bbrc.2000.2162; Yatomi Y, 1997, J BIOCHEM, V121, P969	44	136	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32363	32370		10.1074/jbc.M003075200	http://dx.doi.org/10.1074/jbc.M003075200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10921915	hybrid			2022-12-25	WOS:000089858900110
J	Taniguchi, N; Taniura, H; Niinobe, M; Takayama, C; Tominaga-Yoshino, K; Ogura, A; Yoshikawa, K				Taniguchi, N; Taniura, H; Niinobe, M; Takayama, C; Tominaga-Yoshino, K; Ogura, A; Yoshikawa, K			The postmitotic growth suppressor necdin interacts with a calcium-binding protein (NEFA) in neuronal cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRADER-WILLI-SYNDROME; NUCLEAR-PROTEIN; MOLECULAR-CLONING; CELL-GROWTH; GENE; NUCLEOBINDIN; MOUSE; DIFFERENTIATION; EXPRESSION; APOPTOSIS	Necdin, a growth suppressor expressed predominantly in postmitotic neurons, interacts with viral oncoproteins and cellular transcription factors E2F1 and p53. In search of other cellular targets of necdin, we screened cDNA libraries from neurally differentiated murine embryonal carcinoma P19 cells and adult rat brain by the yeast two-hybrid assay. We isolated cDNAs encoding partial sequences of mouse NEFA and rat nucleobindin (CALNUC), which are Ca2+-binding proteins possessing similar domain structures. Necdin interacted with NEFA via a domain encompassing two EF hand motifs, which had Ca2+ binding activity as determined by Ca-45(2+) overlay. NEFA was widely distributed in mouse organs, whereas necdin was expressed predominantly in the brain and skeletal muscle. In mouse brain in vivo, NEFA was localized in neuronal perikarya and dendrites. By immunoelectron microscopy, NEFA was localized to the cisternae of the endoplasmic reticulum and nuclear envelope in brain neurons. NEFA-green fluorescent protein (GFP) fusion protein expressed in neuroblastoma N1E-115 cells was retained in the cytoplasm and partly secreted into the culture medium. Necdin enhanced the cytoplasmic retention of NEFA-GFP and potentiated the effect of NEFA-GFP on caffeine-evoked elevation of cytosolic Ca2+ levels. Thus, necdin and NEFA might be involved in Ca2+ homeostasis in neuronal cytoplasm.	Osaka Univ, Inst Prot Res, Div Regulat Macromol Funct, Suita, Osaka 5650871, Japan; Hokkaido Univ, Sch Med, Dept Mol Neuroanat, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Osaka Univ, Grad Sch Sci, Dept Biol, Toyonaka, Osaka 5600043, Japan	Osaka University; Hokkaido University; Osaka University	Yoshikawa, K (corresponding author), Osaka Univ, Inst Prot Res, Div Regulat Macromol Funct, Yamadaoka 3-2, Suita, Osaka 5650871, Japan.		Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				AIZAWA T, 1992, DEV BRAIN RES, V68, P265, DOI 10.1016/0165-3806(92)90069-9; Azuma-Hara N, 1999, EXP CELL RES, V251, P442, DOI 10.1006/excr.1999.4593; Ballif BA, 1996, P NATL ACAD SCI USA, V93, P5544, DOI 10.1073/pnas.93.11.5544; BARNIKOLWATANABE S, 1994, BIOL CHEM H-S, V375, P497, DOI 10.1515/bchm3.1994.375.8.497; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; Gerard M, 1999, NAT GENET, V23, P199, DOI 10.1038/13828; Gill RM, 2000, J CELL BIOL, V148, P1187, DOI 10.1083/jcb.148.6.1187; HAYASHI Y, 1995, BIOCHEM BIOPH RES CO, V213, P317, DOI 10.1006/bbrc.1995.2132; Jay P, 1997, NAT GENET, V17, P357, DOI 10.1038/ng1197-357; KANAI Y, 1992, IMMUNOL LETT, V32, P43; Kawano J, 2000, EUR J CELL BIOL, V79, P208, DOI 10.1078/S0171-9335(04)70024-2; Koizumi S, 1999, J BIOL CHEM, V274, P33327, DOI 10.1074/jbc.274.47.33327; Kroll KA, 1999, BIOCHEM BIOPH RES CO, V260, P1, DOI 10.1006/bbrc.1999.0867; KUDO Y, 1986, BRIT J PHARMACOL, V89, P191, DOI 10.1111/j.1476-5381.1986.tb11135.x; Lin P, 1998, J CELL BIOL, V141, P1515, DOI 10.1083/jcb.141.7.1515; MacDonald HR, 1997, HUM MOL GENET, V6, P1873, DOI 10.1093/hmg/6.11.1873; Malviya AN, 1998, CELL, V92, P17, DOI 10.1016/S0092-8674(00)80895-8; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P291, DOI 10.1016/0006-291X(91)91812-Q; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; MIURA K, 1992, BIOCHEM BIOPH RES CO, V187, P375, DOI 10.1016/S0006-291X(05)81503-7; MIURA K, 1994, BIOCHEM BIOPH RES CO, V199, P1388, DOI 10.1006/bbrc.1994.1384; MOCHIZUKI N, 1995, FEBS LETT, V373, P155, DOI 10.1016/0014-5793(95)01031-9; Nakada Y, 1998, GENE, V213, P65, DOI 10.1016/S0378-1119(98)00206-6; Niinobe M, 2000, DEV NEUROSCI-BASEL, V22, P310, DOI 10.1159/000017455; Otte S, 1999, MECH DEVELOP, V86, P155, DOI 10.1016/S0925-4773(99)00103-3; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sutcliffe JS, 1997, LANCET, V350, P1520, DOI 10.1016/S0140-6736(05)63943-8; Taniura H, 1999, J BIOL CHEM, V274, P16242, DOI 10.1074/jbc.274.23.16242; Taniura H, 1998, J BIOL CHEM, V273, P720, DOI 10.1074/jbc.273.2.720; Uetsuki T, 1996, J BIOL CHEM, V271, P918, DOI 10.1074/jbc.271.2.918; Wendel M, 1998, J CELL BIOL, V141, P839, DOI 10.1083/jcb.141.3.839	33	77	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31674	31681		10.1074/jbc.M005103200	http://dx.doi.org/10.1074/jbc.M005103200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10915798	hybrid			2022-12-25	WOS:000089858900020
J	Van Uden, E; Sagara, Y; Van Uden, J; Orlando, R; Mallory, M; Rockenstein, E; Masliah, E				Van Uden, E; Sagara, Y; Van Uden, J; Orlando, R; Mallory, M; Rockenstein, E; Masliah, E			A protective role of the low density lipoprotein receptor-related protein against amyloid beta-protein toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; SPORADIC ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E RECEPTOR; KINASE-II; CELL-SURFACE; CALMODULIN ANTAGONIST; SCAVENGER RECEPTOR; ENDOCYTIC PATHWAY; PRECURSOR PROTEIN; TRANSGENIC MICE	In order to delineate the neuroprotective role of the low density lipoprotein receptor-related protein (LRP) against amyloid beta-protein toxicity, studies were performed in C6 cells challenged with amyloid beta-protein in the presence or absence of activated alpha(2)-macroglobulin. Toxicity was assessed via two cell viability assays. We found that this endocytic receptor conferred protection against amyloid beta-protein toxicity in the presence of activated alpha(2)-macroglobulin and its down-regulation via inhibition by receptor-associated protein or transfection of cells with presenilin 1, increased susceptibility to amyloid beta-protein toxicity. Increased surface LRP immunoreactivity in response to amyloid beta-protein challenge was associated with increased translocation of LRP from the endoplasmic reticulum to the surface. rather than from increased mRNA or protein expression. Furthermore, this translocation of LRP to the surface was mediated by a calcium/calmodulin protein kinase II-dependent signaling pathway. These studies provide evidence for a protective role of LRP against amyloid beta-protein toxicity and may explain the aggressive nature of presenilin-1 mutation in familial Alzheimer's disease.	Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Masliah, E (corresponding author), Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA.				NIA NIH HHS [AG5131, AG10869] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R29AG010869] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AOYAGI T, 1992, EXPERIENTIA, V48, P656, DOI 10.1007/BF02118312; APODACA G, 1994, J BIOL CHEM, V269, P19005; Arredondo L, 1998, GENETICS, V150, P265; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; Colombo MI, 1997, J BIOL CHEM, V272, P7707, DOI 10.1074/jbc.272.12.7707; CZEKAY RP, 1995, J CELL SCI, V108, P1433; Du YS, 1997, J NEUROCHEM, V69, P299; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; Feng TP, 1995, PROG BRAIN RES, V105, P55; FUKUNAGA K, 1995, J BIOL CHEM, V270, P6119, DOI 10.1074/jbc.270.11.6119; Haas C, 1997, BIOCHEM J, V325, P169, DOI 10.1042/bj3250169; Huang F, 1999, AM J PATHOL, V155, P1741, DOI 10.1016/S0002-9440(10)65489-2; Hughes SR, 1998, P NATL ACAD SCI USA, V95, P3275, DOI 10.1073/pnas.95.6.3275; HUNZIKER W, 1994, J BIOL CHEM, V269, P29003; Kang DE, 1997, NEUROLOGY, V49, P56, DOI 10.1212/WNL.49.1.56; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; LaDu MJ, 1997, J NEUROSCI RES, V49, P9, DOI 10.1002/(SICI)1097-4547(19970701)49:1<9::AID-JNR2>3.0.CO;2-H; Li WP, 1997, J MOL NEUROSCI, V8, P75, DOI 10.1007/BF02736774; LICASTRO F, 1995, J NEUROIMMUNOL, V57, P71, DOI 10.1016/0165-5728(94)00163-I; LIN JW, 1990, P NATL ACAD SCI USA, V87, P8257, DOI 10.1073/pnas.87.21.8257; LOPES MBS, 1994, FEBS LETT, V338, P301, DOI 10.1016/0014-5793(94)80288-2; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; Markesbery WR, 1999, BRAIN PATHOL, V9, P133; Masliah E, 1998, J NEUROPATH EXP NEUR, V57, P1041, DOI 10.1097/00005072-199811000-00007; McKee AC, 1998, AMYLOID, V5, P1, DOI 10.3109/13506129809007283; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; Miguel-Hidalgo JJ, 1998, ACTA NEUROPATHOL, V95, P455, DOI 10.1007/s004010050825; Narita M, 1997, J NEUROCHEM, V69, P1904; Nayak AS, 1996, P NATL ACAD SCI USA, V93, P15451, DOI 10.1073/pnas.93.26.15451; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; ORLANDO RA, 1993, P NATL ACAD SCI USA, V90, P4082, DOI 10.1073/pnas.90.9.4082; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; Pillot T, 1999, J NEUROCHEM, V72, P230, DOI 10.1046/j.1471-4159.1999.0720230.x; Qiu ZH, 1999, J NEUROCHEM, V73, P1393, DOI 10.1046/j.1471-4159.1999.0731393.x; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; REBECK GW, 1993, NEURON, V11, P575; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Taddei K, 1997, NEUROSCI LETT, V223, P29, DOI 10.1016/S0304-3940(97)13394-8; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Van Uden E, 1999, MOL CELL NEUROSCI, V14, P129, DOI 10.1006/mcne.1999.0772; Wang WS, 1997, BRAIN RES, V778, P6, DOI 10.1016/S0006-8993(97)00877-9; Wernyj RP, 1999, MOL BRAIN RES, V64, P69, DOI 10.1016/S0169-328X(98)00307-6; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0	47	36	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30525	30530		10.1074/jbc.M001151200	http://dx.doi.org/10.1074/jbc.M001151200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10899157	hybrid			2022-12-25	WOS:000089577900083
J	Yue, CP; Kus, CY; Liu, MY; Simon, MI; Sanborn, BM				Yue, CP; Kus, CY; Liu, MY; Simon, MI; Sanborn, BM			Molecular mechanism of the inhibition of phospholipase C beta(3) by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-BETA-3 PHOSPHORYLATION; CELLULAR-RESPONSES; ACTIVATION; CLONING; EXPRESSION; GAMMA; CELLS; DESENSITIZATION; PURIFICATION; STIMULATION	Activation of protein kinase C (PKC) can result from stimulation of the receptor-G protein-phospholipase C (PLC beta) pathway. In turn, phosphorylation of PLC beta by PKC may play a role in the regulation of receptor-mediated phosphatidylinositide (PI) turnover and intracellular Ca2+ release. Activation of endogenous PRC by phorbol 12-myristate 13 acetate inhibited both G alpha(q)-coupled (oxytocin and M1 muscarinic) and G alpha(i)-coupled (formyl-Met-Leu-Phe) receptor-stimulated PI turnover by 50-100% in PHM1, HeLa, COSM6, and RBL-2H3 cells expressing PLC beta(3). Activation of conventional PKCs with thymeleatoxin similarly inhibited oxytocin or formyl-Met-Leu-Phe receptor-stimulated PI turnover. The PKC inhibitory effect was also observed when PLC beta(3) was stimulated directly by G alpha(q) or G beta gamma in overexpression assays. PKC phosphorylated PLC beta(3) at the same predominant site in vivo and in vitro. Peptide sequencing of in vitro phosphorylated recombinant PLC beta(3) and site-directed mutagenesis identified Ser(1105) as the predominant phosphorylation site. Ser(1105) is also phosphorylated by protein kinase A (PKA; Yue, C., Dodge, K. L., Weber, G., and Sanborn, B. M. (1998) J. Biol. Chem. 273, 18023-18027). Similar to PKA, the inhibition by PKC of G alpha(q)-stimulated PLC beta(3) activity was completely abolished by mutation of Ser(1105) to Ala. In contrast, mutation of Ser(1105) or Ser(26), another putative phosphorylation target, to Ala had no effect on inhibition of G beta gamma-stimulated PLC beta(3) activity by PKC or PKA. These data indicate that PKC and PKA act similarly in that they inhibit G alpha(q)-stimulated PLC beta(3) as a result of phosphorylation of Ser(1105). Moreover, PKC and PKA both inhibit G beta gamma-stimulated activity by mechanisms that do not involve Ser(1105).	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA; Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Canc Biol & Nutr,Dept Med Biochem & Genet, Houston, TX 77030 USA; CALTECH, Dept Biol, Pasadena, CA 91125 USA	University of Texas System; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; California Institute of Technology	Sanborn, BM (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, POB 20708, Houston, TX 77225 USA.				NICHD NIH HHS [HD09618] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009618, R37HD009618] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; ALVAREZ RA, 1995, GENOMICS, V29, P53, DOI 10.1006/geno.1995.1214; ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BAHK YY, 1994, J BIOL CHEM, V269, P8240; BELL RM, 1991, J BIOL CHEM, V266, P4661; Cunningham ML, 1999, MOL PHARMACOL, V56, P265, DOI 10.1124/mol.56.2.265; Dodge KL, 1998, ENDOCRINOLOGY, V139, P2265, DOI 10.1210/en.139.5.2265; Dodge KL, 1999, MOL ENDOCRINOL, V13, P1977, DOI 10.1210/me.13.12.1977; Filtz TM, 1999, BIOCHEM J, V338, P257, DOI 10.1042/0264-6021:3380257; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; JHON DY, 1993, J BIOL CHEM, V268, P6654; Jiang HP, 1996, J BIOL CHEM, V271, P13430, DOI 10.1074/jbc.271.23.13430; KIM MJ, 1993, BIOCHEM BIOPH RES CO, V194, P706, DOI 10.1006/bbrc.1993.1879; KU CY, 1995, ENDOCRINOLOGY, V136, P1509, DOI 10.1210/en.136.4.1509; LEE CW, 1993, J BIOL CHEM, V268, P21318; Litosch I, 1996, RECEPT SIGNAL TRANS, V6, P87; Litosch I, 1997, BIOCHEM J, V326, P701, DOI 10.1042/bj3260701; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; Monga M, 1996, BIOL REPROD, V55, P427, DOI 10.1095/biolreprod55.2.427; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; PARK D, 1992, J BIOL CHEM, V267, P16048; Phillippe M, 1997, AM J PHYSIOL-ENDOC M, V273, pE665, DOI 10.1152/ajpendo.1997.273.4.E665; QATSHA KA, 1993, P NATL ACAD SCI USA, V90, P4674, DOI 10.1073/pnas.90.10.4674; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RICHARDON RM, 1995, J BIOL CHEM, V270, P27829, DOI 10.1074/jbc.270.46.27829; Richardson RM, 1998, J BIOL CHEM, V273, P10690, DOI 10.1074/jbc.273.17.10690; RYU SH, 1990, J BIOL CHEM, V265, P17941; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Stalberg P, 1999, FEBS LETT, V450, P210, DOI 10.1016/S0014-5793(99)00457-3; Strassheim D, 1998, MOL PHARMACOL, V53, P1047; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; Wang S, 1998, FEBS LETT, V441, P261, DOI 10.1016/S0014-5793(98)01518-X; WEBER G, 1994, HUM MOL GENET, V3, P1775, DOI 10.1093/hmg/3.10.1775; Woodruff ML, 1999, AM J PHYSIOL-LUNG C, V276, pL669, DOI 10.1152/ajplung.1999.276.4.L669; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; Xie W, 1999, P NATL ACAD SCI USA, V96, P10385, DOI 10.1073/pnas.96.18.10385; Yang H, 1998, ANTICANCER RES, V18, P1399; Yue CP, 1998, J BIOL CHEM, V273, P18023, DOI 10.1074/jbc.273.29.18023	40	79	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30220	30225		10.1074/jbc.M004276200	http://dx.doi.org/10.1074/jbc.M004276200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10893237	Green Accepted, hybrid			2022-12-25	WOS:000089577900043
J	Mordier, S; Deval, C; Bechet, D; Tassa, A; Ferrara, M				Mordier, S; Deval, C; Bechet, D; Tassa, A; Ferrara, M			Leucine limitation induces autophagy and activation of lysosome-dependent proteolysis in C2C12 myotubes through a mammalian target of rapamycin-independent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CONJUGATION SYSTEM; ISOLATED RAT HEPATOCYTES; AMINO-ACID-UPTAKE; P70 S6 KINASE; SKELETAL-MUSCLE; MESSENGER-RNAS; L6 MYOBLASTS; DEGRADATION; PROTEASOME; LIVER	Loss of muscle mass usually characterizes different pathologies (sepsis, cancer, trauma) and also occurs during normal aging. One reason for muscle wasting relates to a decrease in food intake. This study addressed the role of leucine as a regulator of protein breakdown in mouse C2C12 myotubes and aimed to determine which cellular responses regulate the process. Determination of the rate of protein breakdown indicated that leucine is one key regulator of this process in myotubes because starvation for this amino acid is responsible for 30-40% of the total increase generated by total amino acid starvation. Leucine restriction rapidly accelerates the rate of protein breakdown (+11 to 15% (p < 0.001) after 1 h of starvation) in a dose-dependent manner. By using various inhibitors, evidence is provided that acceleration of protein catabolism results mainly from an induction of autophagy, activation of lysosome-dependent proteolysis, without modification of mRNA levels encoding the lysosomal cathepsins B, L, or D. Those results suggest that autophagy is an essential cellular response for increasing protein breakdown in muscle following food deprivation, Induction of autophagy precedes a decrease in global protein synthesis (-20% to -30% (p < 0.001)) that occurs after 3 h of leucine starvation. Inhibition of the mammalian target of rapamycin (mTOR) activity does not abolish the effect of leucine starvation and the level of phosphorylated ribosomal S6 protein is not affected by leucine withdrawal. These latter data provide clear evidence that the mTOR signaling pathway is not involved in the mediation of leucine effects on both protein synthesis and degradation in C2C12 myotubes.	Inst Natl Rech Agron Theix, Unite Nutr Cellulaire & Mol, F-63122 St Genes Champanelle, France	INRAE	Mordier, S (corresponding author), Inst Natl Rech Agron Theix, Unite Nutr Cellulaire & Mol, F-63122 St Genes Champanelle, France.	mordier@clermont.inra.fr		Bechet, Daniel/0000-0002-3812-8099				ADIBI SA, 1973, AM J PHYSIOL, V225, P408, DOI 10.1152/ajplegacy.1973.225.2.408; Attaix D, 1998, ADV MOL CEL, V27, P235, DOI 10.1016/S1569-2558(08)60463-4; BARACOS VE, 1995, AM J PHYSIOL-ENDOC M, V268, pE996, DOI 10.1152/ajpendo.1995.268.5.E996; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BERGSTROM J, 1990, CLIN SCI, V79, P331, DOI 10.1042/cs0790331; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BUSE MG, 1975, J CLIN INVEST, V56, P1250, DOI 10.1172/JCI108201; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; DICE JF, 1992, ANN NY ACAD SCI, V674, P58, DOI 10.1111/j.1749-6632.1992.tb27477.x; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; GARCIAMARTINEZ C, 1995, MOL CELL BIOCHEM, V148, P17, DOI 10.1007/BF00929498; Grimble RF, 1996, CLIN SCI, V91, P121, DOI 10.1042/cs0910121; Grizard Jean, 1995, Nutrition Research Reviews, V8, P67, DOI 10.1079/NRR19950007; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HASSELGREN PO, 1988, ARCH SURG-CHICAGO, V123, P992; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HOLEN I, 1993, EUR J BIOCHEM, V215, P113, DOI 10.1111/j.1432-1033.1993.tb18013.x; HONG SOC, 1984, J NUTR, V114, P1204; Hulsewe KWE, 1997, P NUTR SOC, V56, P801, DOI 10.1079/PNS19970081; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Jousse C, 1999, Curr Opin Clin Nutr Metab Care, V2, P297, DOI 10.1097/00075197-199907000-00008; Kimball SR, 1998, J BIOL CHEM, V273, P30945, DOI 10.1074/jbc.273.47.30945; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; Kirschke H., 1987, CHEM LYSOSOMAL PROTE, P193; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mansoor O, 1996, P NATL ACAD SCI USA, V93, P2714, DOI 10.1073/pnas.93.7.2714; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889; MORTIMORE GE, 1989, DIABETES METAB REV, V5, P49, DOI 10.1002/dmr.5610050105; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Rehfeldt C, 1997, ANAL BIOCHEM, V251, P294, DOI 10.1006/abio.1997.2285; Rooyackers OE, 1997, ANNU REV NUTR, V17, P457, DOI 10.1146/annurev.nutr.17.1.457; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUGDEN PH, 1991, BIOCHEM J, V273, P21, DOI 10.1042/bj2730021; Tanaka K, 1998, BIOCHEM BIOPH RES CO, V247, P537, DOI 10.1006/bbrc.1998.8617; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; TEMPARIS S, 1994, CANCER RES, V54, P5568; Tiao G, 1997, J CLIN INVEST, V99, P163, DOI 10.1172/JCI119143; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Voisin L, 1996, J CLIN INVEST, V97, P1610, DOI 10.1172/JCI118586; WARNER BW, 1989, JPEN-PARENTER ENTER, V13, P344, DOI 10.1177/0148607189013004344; WING SS, 1991, BIOCHEM J, V275, P165, DOI 10.1042/bj2750165; WING SS, 1993, AM J PHYSIOL, V264, pE668, DOI 10.1152/ajpendo.1993.264.4.E668	48	159	177	3	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29900	29906		10.1074/jbc.M003633200	http://dx.doi.org/10.1074/jbc.M003633200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893413	hybrid, Green Published			2022-12-25	WOS:000089439800098
J	Nguyen, M; Lee, MC; Wang, JL; Tomlinson, JS; Shao, ZM; Alpaugh, ML; Barsky, SH				Nguyen, M; Lee, MC; Wang, JL; Tomlinson, JS; Shao, ZM; Alpaugh, ML; Barsky, SH			The human myoepithelial cell displays a multifaceted anti-angiogenic phenotype	ONCOGENE			English	Article						thrombospondin-l; hypoxia inducible factor-1; angiogenic inhibitors; angiogenic factors	BREAST-CARCINOMA; TUMOR-GROWTH; ENDOTHELIAL-CELLS; INHIBITOR; METASTASIS; CANCER; SERPIN; THROMBOSPONDIN-1; PROLIFERATION; COMPLEMENTARY	Human myoepithelial cells which surround ducts and acini of certain organs such as the breast form a natural border separating epithelial cells from stromal angiogenesis. Myoepithelial cell lines (HMS-1-6), derived from diverse benign myoepithelial tumors, all constitutively express high levels of active angiogenic inhibitors which include TIMP-1, thrombospondin-1 and soluble bFGF receptors but very low levels of angiogenic factors. These myoepithelial cell lines inhibit endothelial cell chemotaxis and proliferation. These myoepithelial cell lines sense hypoxia, respond to low O-2 tension by increased HIF-1 alpha but with only a minimal increase in VEGF and iNOS steady state mRNA levels. Their corresponding xenografts (HMS-X-6X) grow very slowly compared to their non-myoepithelial carcinomatous counterparts and accumulate an abundant extracellular matrix devoid of angiogenesis but containing bound angiogenic inhibitors. These myoepithelial xenografts exhibit only minimal hypoxia but extensive necrosis in comparison to their non-myoepithelial xenograft counterparts. These former xenografts inhibit local and systemic tumor-induced angiogenesis and metastasis presumably from their matrix-bound and released circulating angiogenic inhibitors. These observations collectively support the hypothesis that the human myoepithelial cell (even when transformed) is a natural suppressor of angiogenesis.	Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Div Surg Oncol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Revlon UCLA Breast Ctr, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Barsky, SH (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90095 USA.			DiNome, Maggie/0000-0002-1926-292X	NCI NIH HHS [CA71195, CA83111] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA071195, R21CA083111] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alpaugh ML, 1999, CANCER RES, V59, P5079; BAGAVANDOSS P, 1990, BIOCHEM BIOPH RES CO, V170, P867, DOI 10.1016/0006-291X(90)92171-U; CAVENEE WK, 1993, J CLIN INVEST, V91, P3, DOI 10.1172/JCI116185; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; CORNIL I, 1991, P NATL ACAD SCI USA, V88, P6028, DOI 10.1073/pnas.88.14.6028; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P1; Folkman J, 1995, MOL BASIS CANC, P206; FRIDMAN R, 1991, JNCI-J NATL CANCER I, V83, P769, DOI 10.1093/jnci/83.11.769; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; LANGONE JJ, 1982, ADV IMMUNOL, V32, P157; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; NGUYEN M, 1993, NATURE, V365, P267, DOI 10.1038/365267a0; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Safarians S, 1996, INT J CANCER, V66, P151, DOI 10.1002/(SICI)1097-0215(19960410)66:2<151::AID-IJC2>3.0.CO;2-1; Shao ZM, 1998, EXP CELL RES, V241, P394, DOI 10.1006/excr.1998.4066; Sternlicht MD, 1996, IN VITRO CELL DEV-AN, V32, P550; Sternlicht MD, 1996, LAB INVEST, V74, P781; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; Tobacman JK, 1997, CANCER RES, V57, P2823; Varia MA, 1998, GYNECOL ONCOL, V71, P270, DOI 10.1006/gyno.1998.5163; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Xiao GW, 1999, P NATL ACAD SCI USA, V96, P3700, DOI 10.1073/pnas.96.7.3700; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	31	73	75	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3449	3459		10.1038/sj.onc.1203677	http://dx.doi.org/10.1038/sj.onc.1203677			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918603				2022-12-25	WOS:000088346500001
J	Banky, P; Newlon, MG; Roy, M; Garrod, S; Taylor, SS; Jennings, PA				Banky, P; Newlon, MG; Roy, M; Garrod, S; Taylor, SS; Jennings, PA			Isoform-specific differences between the type I alpha and II alpha cyclic AMP-dependent protein kinase anchoring domains revealed by solution NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL-SHIFT INDEX; REGULATORY SUBUNIT; A-KINASE; SECONDARY STRUCTURE; SCAFFOLD PROTEINS; ESCHERICHIA-COLI; LARGER PROTEINS; SPECTROSCOPY; C-13; H-1	Cyclic AMP dependent protein kinase (PKA) is controlled, in part, by the subcellular localization of the enzyme (1). Discovery of dual Specificity anchoring proteins (D-AKAPs) indicates that not only is the type II, but also the type I, enzyme localized (2). It appears that the type I enzyme is localized in a novel, dynamic fashion as opposed to the apparent static localization of the type II enzyme. Recently, the structure of the dimerization/docking (D/D) domain from the type II enzyme was solved (3), This work revealed an X-type four-helix bundle motif with a hydrophobic patch that modulates AKAP interactions. To understand the dynamic versus static localization of PKA, multidimensional NMR techniques were used to investigate the structural features of the type I D/D domain. Our results indicate a conserved helix-turn-helix motif in the type I and type II D/D domains. However, important differences between the two-domains are evident in the extreme NH2 terminus: this region is extended in the type II domain, whereas it is helical in the type I protein. The NH2-terminal residues in RII alpha contain determinants for anchoring, and the orientation and packing of this helical element in the RI alpha structure may have profound consequences in:the recognition surface presented to the AKAPs.	Univ Calif San Diego, Dept Biochem & Chem, Sch Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, Sch Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Jennings, PA (corresponding author), Univ Calif San Diego, Dept Biochem & Chem, Sch Med, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034921] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK5444(P4)] Funding Source: Medline; NIGMS NIH HHS [GM34921] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; Angelo R, 1998, J BIOL CHEM, V273, P14633, DOI 10.1074/jbc.273.23.14633; Banky P, 1998, J BIOL CHEM, V273, P35048, DOI 10.1074/jbc.273.52.35048; BANKY P, 2000, THESIS U CALIFORNIA; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; BRUNGER AT, 1991, ACCOUNTS CHEM RES, V24, P54; BUBIS J, 1987, J BIOL CHEM, V262, P14961; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; GARCIA GM, 1986, CELL, V45, P453, DOI 10.1016/0092-8674(86)90331-4; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; HARPER JF, 1985, VITAM HORM, V42, P197; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; IKURA M, 1990, J MAGN RESON, V86, P204, DOI 10.1016/0022-2364(90)90227-Z; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Leon DA, 1997, J BIOL CHEM, V272, P28431, DOI 10.1074/jbc.272.45.28431; Lester LB, 1997, RECENT PROG HORM RES, V52, P409; Maniatis T., 1986, MOL CLONING LAB MANU; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P608; MCCOY MA, 1992, J MAGN RESON, V98, P674, DOI 10.1016/0022-2364(92)90023-Z; MCCOY MA, 1992, J AM CHEM SOC, V114, P2108, DOI 10.1021/ja00032a026; Miki E, 1998, J BIOL CHEM, V273, P34384, DOI 10.1074/jbc.273.51.34384; Miki K, 1999, J BIOL CHEM, V274, P29057, DOI 10.1074/jbc.274.41.29057; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; Newlon MG, 1997, J BIOL CHEM, V272, P23637, DOI 10.1074/jbc.272.38.23637; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; ODonoghue SI, 1996, J BIOMOL NMR, V8, P193, DOI 10.1007/BF00211165; PATT SL, 1992, J MAGN RESON, V96, P94, DOI 10.1016/0022-2364(92)90289-J; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Reinitz CA, 1997, ARCH BIOCHEM BIOPHYS, V348, P391, DOI 10.1006/abbi.1997.0401; Robinson ML, 1996, ARCH BIOCHEM BIOPHYS, V330, P181, DOI 10.1006/abbi.1996.0240; RUBIN CS, 1972, J BIOL CHEM, V247, P6135; RUBIN CS, 1994, BIOCHIM BIOPHYS ACTA, V1224, P407; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; Schillace RV, 1999, CURR BIOL, V9, P321, DOI 10.1016/S0960-9822(99)80141-9; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; VUISTER GW, 1993, J AM CHEM SOC, V115, P772; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yang WL, 1998, BIOCHEMISTRY-US, V37, P14175, DOI 10.1021/bi981402a	61	41	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35146	35152		10.1074/jbc.M003961200	http://dx.doi.org/10.1074/jbc.M003961200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10899163	hybrid			2022-12-25	WOS:000165422800044
J	Mikkelsen, MD; Hansen, CH; Wittstock, U; Halkier, BA				Mikkelsen, MD; Hansen, CH; Wittstock, U; Halkier, BA			Cytochrome P450CYP79B2 from Arabidopsis catalyzes the conversion of tryptophan to indole-3-acetaldoxime, a precursor of indole glucosinolates and indole-3-acetic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OILSEED RAPE LEAVES; ESCHERICHIA-COLI; CYANOGENIC GLUCOSIDES; CHINESE-CABBAGE; AMINO-ACID; BIOSYNTHESIS; ENZYME; EXPRESSION; PLANTS; METABOLISM	Glucosinolates are natural plant products known as flavor compounds, cancer-preventing agents, and biopesticides. We report cloning and characterization of the cytochrome P450 CYP79B2 from Arabidopsis, Heterologous expression of CYP79B2 in Escherichia coli shows that CYP79B2 catalyzes the conversion of tryptophan to indole-3-acetaldoxime. Recombinant CYP79B2 has a K-m of 21 muM and a V-max of 7.78 nmol/h/ml culture. Inhibitor studies show that CYP79B2 is different from a previously described enzyme activity that converts tryptophan to indole-3-acetaldoxime (Ludwig-Muller, J., and Hilgenberg, W, (1990) Phytochemistry, 29, 1397-1400). CYP79B2 is wound-inducible and expressed in leaves, stem, flowers, and roots, with the highest expression in roots. Arabidopsis overexpressing CYP79B2 has increased levels of indole glucosinolates, which strongly indicates that CYP79B2 is involved in indole glucosinolate biosynthesis, Our data show that oxime production by CYP79s is not restricted to those amino acids that are precursors for cyanogenic glucosides, Our data are consistent with the hypothesis that indole glucosinolates have evolved from cyanogenesis, Indole-3-acetaldoxime is a precursor of the plant hormone indole-3-acetic acid, which suggests that CYP79B2 might function in biosynthesis of indole-3-acetic acid. Identification of CYP79B2 provides an important tool for modification of the indole glucosinolate content to improve nutritional value and pest resistance.	Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, DK-1871 Frederiksberg C, Denmark; Royal Vet & Agr Univ, Ctr Mol Plant Physiol Pl, DK-1871 Frederiksberg C, Denmark	University of Copenhagen; University of Copenhagen	Halkier, BA (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, Thorvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.	halkier@biobase.dk	Halkier, Barbara A/H-3196-2014	Halkier, Barbara A/0000-0002-3742-702X; Wittstock, Ute/0000-0002-0914-8453				Andersen MD, 2000, J BIOL CHEM, V275, P1966, DOI 10.1074/jbc.275.3.1966; Bak S, 1999, PLANT J, V20, P663, DOI 10.1046/j.1365-313X.1999.00642.x; Bak S, 1998, PLANT MOL BIOL, V38, P725, DOI 10.1023/A:1006064202774; Barnes HJ, 1996, METHOD ENZYMOL, V272, P3, DOI 10.1016/S0076-6879(96)72003-7; Bartel Bonnie, 1997, Annu Rev Plant Physiol Plant Mol Biol, V48, P51, DOI 10.1146/annurev.arplant.48.1.51; BENNETT R, 1993, PLANT PHYSIOL, V102, P1307, DOI 10.1104/pp.102.4.1307; Bennett RN, 1996, PLANT CELL ENVIRON, V19, P801, DOI 10.1111/j.1365-3040.1996.tb00417.x; Bennett RN, 1997, PHYTOCHEMISTRY, V45, P59, DOI 10.1016/S0031-9422(96)00787-X; BENNETT RN, 1995, PLANT PHYSIOL, V109, P299, DOI 10.1104/pp.109.1.299; BODNARYK RP, 1994, PHYTOCHEMISTRY, V35, P301, DOI 10.1016/S0031-9422(00)94752-6; BODNARYK RP, 1992, PHYTOCHEMISTRY, V31, P2671, DOI 10.1016/0031-9422(92)83609-3; BUCHNER R, 1987, P50; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DOUGHTY KJ, 1995, PHYTOCHEMISTRY, V38, P347, DOI 10.1016/0031-9422(94)00653-B; Du LC, 1996, PLANT PHYSIOL, V111, P831, DOI 10.1104/pp.111.3.831; Du LC, 1995, P NATL ACAD SCI USA, V92, P12505, DOI 10.1073/pnas.92.26.12505; Ettlinger M.G., 1968, RECENT ADV PHYTOCHEM, V1, P59; GILLAM EMJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P123, DOI 10.1006/abbi.1993.1401; GROSSBERGER D, 1987, NUCLEIC ACIDS RES, V15, P6737, DOI 10.1093/nar/15.16.6737; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Halkier BA, 1999, NATURALLY OCCURRING GLYCOSIDES, P193; HALKIER BA, 1995, ARCH BIOCHEM BIOPHYS, V322, P369, DOI 10.1006/abbi.1995.1477; HAUGHN GW, 1991, PLANT PHYSIOL, V97, P217, DOI 10.1104/pp.97.1.217; HELMLINGER J, 1987, PHYTOCHEMISTRY, V26, P615, DOI 10.1016/S0031-9422(00)84751-2; HELMLINGER J, 1985, PHYTOCHEMISTRY, V24, P2497, DOI 10.1016/S0031-9422(00)80654-8; JEFFERSON RA, 1987, EMBO J, V6, P3901; JENKINS CM, 1994, J BIOL CHEM, V269, P27401; Joshi CP, 1997, PLANT MOL BIOL, V35, P993, DOI 10.1023/A:1005816823636; LUDWIGMULLER J, 1988, PHYSIOL PLANTARUM, V74, P240, DOI 10.1111/j.1399-3054.1988.tb00627.x; LUDWIGMULLER J, 1990, PHYSIOL PLANTARUM, V79, P311; Martin T., 1992, GUS protocols: using the GUS gene as a reporter of gene expression., P23; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Nelson DR, 1999, ARCH BIOCHEM BIOPHYS, V369, P1, DOI 10.1006/abbi.1999.1352; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; Nielsen JS, 1999, ARCH BIOCHEM BIOPHYS, V368, P121, DOI 10.1006/abbi.1999.1258; Normanly J, 1999, CURR OPIN PLANT BIOL, V2, P207, DOI 10.1016/S1369-5266(99)80037-5; RADWANSKI ER, 1995, PLANT CELL, V7, P921, DOI 10.1105/tpc.7.7.921; RAJAGOPAL R, 1972, PLANTA, V103, P45, DOI 10.1007/BF00394605; RAUSCH T, 1985, J CHROMATOGR, V318, P95, DOI 10.1016/S0021-9673(01)90667-3; Rodman J.E., 1981, PHYTOCHEMISTRY ANGIO, P43; Rodman JE, 1998, AM J BOT, V85, P997, DOI 10.2307/2446366; Saupe SG, 1981, PHYTOCHEMISTRY ANGIO, P80; SIBBESEN O, 1995, J BIOL CHEM, V270, P3506, DOI 10.1074/jbc.270.8.3506; Sorensen H., 1990, CANOLA RAPESEED PROD, P149; TATE WP, 1992, BIOCHEMISTRY-US, V31, P2443, DOI 10.1021/bi00124a001; TOPFER R, 1987, NUCLEIC ACIDS RES, V15, P5890, DOI 10.1093/nar/15.14.5890; WENJUN S, 1983, NUCLEIC ACIDS RES, V17, P8385; Wittstock U, 2000, J BIOL CHEM, V275, P14659, DOI 10.1074/jbc.275.19.14659; ZAMBRYSKI P, 1983, EMBO J, V2, P2143, DOI 10.1002/j.1460-2075.1983.tb01715.x	49	318	345	7	56	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33712	33717		10.1074/jbc.M001667200	http://dx.doi.org/10.1074/jbc.M001667200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10922360	hybrid			2022-12-25	WOS:000090104600074
J	Ding, VW; Chen, RH; McCormick, F				Ding, VW; Chen, RH; McCormick, F			Differential regulation of glycogen synthase kinase 3 beta by insulin and Wnt signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; INTEGRIN-LINKED KINASE; RABBIT SKELETAL-MUSCLE; BETA-CATENIN; PROTEIN-KINASE; INTACT-CELLS; FUNCTIONAL INTERACTION; PHOSPHORYLASE-KINASE; XENOPUS EMBRYOS; COLON-CARCINOMA	Glycogen synthase kinase 3 beta (GSK3 beta) is a key component in many biological processes including insulin and Wnt signaling. Since the activation of each signaling pathway results in a decrease in GSK3 beta activity, we examined the specificity of their downstream effects in the same cell type. Insulin induces an increased activity of glycogen synthase but has no influence on the protein level of beta -catenin. In contrast, Wnt increases the cytosolic pool of beta -catenin but not glycogen synthase activity. We found that, unlike insulin, neither the phosphorylation status of the serine9 residue of GSK3 beta nor the activity of protein kinase B is regulated by Wnt. Although the decrease in GSK3 beta activity is required, GSK3 beta may not be the limiting component for Wnt signaling in the cells that we examined. Our results suggest that the axin-conductin complexed GSK3 beta may be dedicated to Wnt rather than insulin signaling. Insulin and Wnt pathways regulate GSK3 beta through different mechanisms, and therefore lead to distinct downstream events.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	McCormick, F (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St,Box 0128, San Francisco, CA 94115 USA.							Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen RH, 2000, J BIOL CHEM, V275, P17894, DOI 10.1074/jbc.M905336199; CHENG K, 1983, MOL CELL BIOCHEM, V56, P183; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DICKENS M, 1992, BIOCHEM J, V287, P201, DOI 10.1042/bj2870201; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; GOODE N, 1992, J BIOL CHEM, V267, P16878; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HOOPER JE, 1994, NATURE, V372, P461, DOI 10.1038/372461a0; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Markuns JF, 1999, J BIOL CHEM, V274, P24896, DOI 10.1074/jbc.274.35.24896; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Proud CG, 1997, BIOCHEM J, V328, P329; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Ruel L, 1999, J BIOL CHEM, V274, P21790, DOI 10.1074/jbc.274.31.21790; RYLATT DB, 1980, EUR J BIOCHEM, V107, P529; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Semenov MV, 1997, GENOMICS, V42, P302, DOI 10.1006/geno.1997.4713; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Staal FJT, 1999, INT IMMUNOL, V11, P317, DOI 10.1093/intimm/11.3.317; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; Welsh GI, 1996, TRENDS CELL BIOL, V6, P274, DOI 10.1016/0962-8924(96)10023-4; Welsh GI, 1997, ANAL BIOCHEM, V244, P16, DOI 10.1006/abio.1996.9838; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; WOODGETT JR, 1993, BIOCHEM SOC T, V21, P905, DOI 10.1042/bst0210905; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419	53	358	366	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32475	32481		10.1074/jbc.M005342200	http://dx.doi.org/10.1074/jbc.M005342200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913153	hybrid			2022-12-25	WOS:000090003800015
J	Huxford, T; Malek, S; Ghosh, G				Huxford, T; Malek, S; Ghosh, G			Preparation and crystallization of dynamic NF-kappa B center dot I kappa B complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ANGSTROM-RESOLUTION; ENVELOPE GLYCOPROTEIN; P50/P65 HETERODIMER; RIBOSOMAL-SUBUNIT; DNA-BINDING; HOMODIMER; EXPRESSION; PROTEINS; BETA	The formation of single, well-diffracting crystals is a requirement for any molecular structure determination by x-ray crystallography. Crystallization of biological macromolecules can represent a significant obstacle when the subject exhibits internal flexibility or indiscriminate self-association. In such cases, the removal of inherently flexible regions and the addition of stabilizing ligands can improve the probability of crystal formation and ordered growth. We have applied these principles in order to form crystals of the Rel homology region of transcription factor NF-kappaB in complex with its inhibitors I kappaB alpha and I kappaB beta. None of these molecules crystallizes in the absence of a binding partner. Recombinant overexpression of truncated I kappaB alpha required selection of the correct start site. NF-kappaB .I kappaB alpha complex crystals formed under relatively stringent conditions. NF-kappaB .I kappaB beta complex crystals were formed by analogy to NF-kappaB .I kappaB alpha, although some modifications in purification and complex formation were necessary due to differences between the inhibitors.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92037 USA	University of California System; University of California San Diego	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Mail Code 0359,9500 Gilman Dr, La Jolla, CA 92037 USA.			Huxford, Tom/0000-0002-1939-7373; Malek, Shiva/0000-0002-9526-7968	NCI NIH HHS [5POCA23100-16, CA78749] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023100, R01CA078749] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Chen FE, 1999, PROTEIN ENG, V12, P423, DOI 10.1093/protein/12.5.423; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Clemons WM, 1999, NATURE, V400, P833, DOI 10.1038/23631; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; FURLONG J, 1992, NUCLEIC ACIDS RES, V20, P4668, DOI 10.1093/nar/20.17.4668; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Grimes JM, 1998, NATURE, V395, P470, DOI 10.1038/26694; Huang DB, 1997, STRUCTURE, V5, P1427, DOI 10.1016/S0969-2126(97)00293-1; Huxford T, 1999, COLD SPRING HARB SYM, V64, P533, DOI 10.1101/sqb.1999.64.533; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kwong PD, 1999, J BIOL CHEM, V274, P4115, DOI 10.1074/jbc.274.7.4115; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LOOMAN AC, 1987, EMBO J, V6, P2489, DOI 10.1002/j.1460-2075.1987.tb02530.x; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; McKinsey TA, 1997, J BIOL CHEM, V272, P22377, DOI 10.1074/jbc.272.36.22377; McPherson A., 1999, CRYSTALLIZATION BIOL; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Phelps CB, 2000, J BIOL CHEM, V275, P29840, DOI 10.1074/jbc.M004899200; Reinisch KM, 2000, NATURE, V404, P960, DOI 10.1038/35010041; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Thanaraj TA, 1996, PROTEIN SCI, V5, P1594, DOI 10.1002/pro.5560050814; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944	36	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32800	32806		10.1074/jbc.M006037200	http://dx.doi.org/10.1074/jbc.M006037200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10906335	hybrid			2022-12-25	WOS:000090003800059
J	Mochida, Y; Takeda, K; Saitoh, M; Nishitoh, H; Amagasa, T; Ninomiya-Tsuji, J; Matsumoto, K; Ichijo, H				Mochida, Y; Takeda, K; Saitoh, M; Nishitoh, H; Amagasa, T; Ninomiya-Tsuji, J; Matsumoto, K; Ichijo, H			ASK1 inhibits interleukin-1-induced NF-kappa B activity through disruption of TRAF6-TAK1 interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATING KINASE-1; TERMINAL KINASE; APOPTOSIS; PATHWAYS; MITOGEN; INDUCTION; BETA; TRANSDUCTION; CASCADES	Apoptosis signal-regulating kinase 1 (ASK1) is a mem ber of the MAPKKK family in the JNK and p38 mitogen-activated protein kinase cascades and critically involved in stress- and cytokine-induced apoptosis. The transcription factor nuclear factor-kappaB (NF-kappaB) is a pivotal regulator of immune and inflammatory responses and exerts anti-apoptotic roles in various cells. Here we show that ASK1 directly interacts with transforming growth factor-beta -activated kinase 1 (TAK1), another MAPKKK that has been identified as a signaling intermediate in the interleukin 1 (IL-1)-induced NF-kappaB pathway as well as the transforming growth factor-beta superfamily-induced JNK/p38 pathway. Overexpression of ASK1 inhibits IL-1-, TRAF6-, or TAK1-induced, but not NF-kappaB-inducing kinase-induced, NF-kappaB activation. ASK1 dissociates TAK1 but not NF-kappaB-inducing kinase from TRAF6. Moreover, IL-1-induced complex formation of endogenous TAK1 and TRAF6 was blocked by ASK1 overexpression. It thus appears that the inhibition of NF-kappaB by ASK1 may result at least in part from the disruption of the TRAF6 . TAK1 complex formation in the IL-1 signaling pathway. These results provide a new insight in the mode of action of MAPKKK family members; two distinct MAPRKKKs in the same MAP kinase cascades directly interact and exert opposite effects in another signaling pathway, NF-kappaB.	Tokyo Med & Dent Univ, Dept Hard Tissue Engn, Div Biomatrix, Grad Sch,Lab Cell Signalling,Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Dept Maxillofacial Reconstruct & Funct, Div Maxillofacial & Neck Reconstruct, Grad Sch,Bunkyo Ku, Tokyo 1138549, Japan; Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Chikusa Ku, Nagoya, Aichi 46401, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Nagoya University	Ichijo, H (corresponding author), Tokyo Med & Dent Univ, Dept Hard Tissue Engn, Div Biomatrix, Grad Sch,Lab Cell Signalling,Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.	ichijo.csi@tmd.ac.jp		Ichijo, Hidenori/0000-0002-5005-6438; Mochida, Yoshiyuki/0000-0002-2115-4303; Nishitoh, Hideki/0000-0002-8652-4109; Takeda, Kohsuke/0000-0002-8359-8399; Ninomiya-Tsuji, Jun/0000-0002-5584-0176				BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; Funato N, 1998, LAB INVEST, V78, P477; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Kashiwada M, 1998, J EXP MED, V187, P237, DOI 10.1084/jem.187.2.237; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nakahara S, 1999, J NEUROPATH EXP NEUR, V58, P442, DOI 10.1097/00005072-199905000-00003; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; NISHIDA E, 1992, INT REV CYTOL, V138, P211, DOI 10.1016/S0074-7696(08)61589-2; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takeda K, 2000, J BIOL CHEM, V275, P9805, DOI 10.1074/jbc.275.13.9805; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	39	45	47	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32747	32752		10.1074/jbc.M003042200	http://dx.doi.org/10.1074/jbc.M003042200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10921914	hybrid			2022-12-25	WOS:000090003800052
J	Achenbach, TV; Muller, R; Slater, EP				Achenbach, TV; Muller, R; Slater, EP			Bcl-2 independence of flavopiridol-induced apoptosis - Mitochondrial, depolarization in the absence of cytochrome c release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; CELL-CYCLE ARREST; CARCINOMA-CELLS; CANCER-CELLS; CASPASE ACTIVATION; LEUKEMIA-CELLS; DEATH; INDUCTION; MYC; EXPRESSION	The new chemotherapeutic agent, flavopiridol, presently in clinical trials, has been extensively studied yet little is known about its mechanism of action. In this study we show that the induction of apoptosis by flavopiridol is largely independent of Bcl-2. This is indicated by the observation that neither overexpression nor the antisense oligonucleotide-mediated down-regulation of Bcl-2 had any effect on flavopiridol-induced cell killing. Our results suggest that flavopiridol can induce apoptosis through different pathways of caspase activation with caspase 8 playing a pivotal role. In human lung carcinoma cells, which contain high levels of endogenous Bcl-2 and lack procaspase 8, flavopiridol treatment leads to mitochondrial depolarization in the absence of cytochrome c release, followed by the activation of caspase 3 and cell death. These results clearly differ from observations made with other anti-tumor drugs and might explain, at least in part, the unusual anti-tumor properties of flavopirido.	Univ Marburg, Inst Mol Biol & Tumor Res, D-35033 Marburg, Germany	Philipps University Marburg	Muller, R (corresponding author), Univ Marburg, Inst Mol Biol & Tumor Res, Emil Mannkopff Str 2, D-35033 Marburg, Germany.	mueller@imt.uni.marburg.de	Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ADAMS JM, 1992, CANCER SURV, V15, P119; Arguello F, 1998, BLOOD, V91, P2482; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bible KC, 1996, CANCER RES, V56, P4856; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Brusselbach S, 1998, INT J CANCER, V77, P146; Byrd JC, 1998, BLOOD, V92, P3804, DOI 10.1182/blood.V92.10.3804; Carlson BA, 1996, CANCER RES, V56, P2973; Chaloupka R, 1999, FEBS LETT, V462, P295, DOI 10.1016/S0014-5793(99)01538-0; Cory S, 1999, CANCER RES, V59, p1685S; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; CZECH J, 1995, INT J ONCOL, V6, P31; Deigner HP, 1999, CURR MED CHEM, V6, P399; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dobbelstein M, 1996, J VIROL, V70, P6479, DOI 10.1128/JVI.70.9.6479-6485.1996; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALDAR S, 1989, NATURE, V342, P195, DOI 10.1038/342195a0; Hooijberg JH, 1999, BRIT J CANCER, V81, P269, DOI 10.1038/sj.bjc.6690687; Houghton Janet A., 1999, Current Opinion in Oncology, V11, P475, DOI 10.1097/00001622-199911000-00008; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KAUR G, 1992, J NATL CANCER I, V84, P1736, DOI 10.1093/jnci/84.22.1736; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Konig A, 1997, BLOOD, V90, P4307; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Motwani M, 1999, CLIN CANCER RES, V5, P1876; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Parker BW, 1998, BLOOD, V91, P458, DOI 10.1182/blood.V91.2.458.458_458_465; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Reed J C, 1996, Behring Inst Mitt, P72; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; Sauter ER, 1999, CANCER RES, V59, P4876; Schrump DS, 1998, CLIN CANCER RES, V4, P2885; Senderowicz AM, 1998, J CLIN ONCOL, V16, P2986, DOI 10.1200/JCO.1998.16.9.2986; Shapiro GI, 1999, CLIN CANCER RES, V5, P2925; Shimizu S, 1996, ONCOGENE, V12, P2251; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wagenknecht B, 1998, CELL DEATH DIFFER, V5, P894, DOI 10.1038/sj.cdd.4400435; Wright J, 1998, Oncology (Williston Park), V12, P1023; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593; Ziegler A, 1997, JNCI-J NATL CANCER I, V89, P1027, DOI 10.1093/jnci/89.14.1027	58	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32089	32097		10.1074/jbc.M005267200	http://dx.doi.org/10.1074/jbc.M005267200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10896673	hybrid			2022-12-25	WOS:000089858900074
J	Baldwin, TA; Gogela-Spehar, M; Ostergaard, HL				Baldwin, TA; Gogela-Spehar, M; Ostergaard, HL			Specific isoforms of the resident endoplasmic reticulum protein glucosidase II associate with the CD45 protein-tyrosine phosphatase via a lectin-like interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; LINKED OLIGOSACCHARIDES; CALNEXIN; GLYCOPROTEIN; CALRETICULIN; SUBSTRATE; RECOGNITION; EXPRESSION; GALECTIN-1; APOPTOSIS	We have previously demonstrated that CD45 physically associates with the endoplasmic reticulum processing enzyme glucosidase II (GII). GII consists of the catalytic alpha-chain and an associated beta-chain. To gain insight into the basis of the association between CD45 and GII, we examined the biochemical requirements for the interaction. We show that the alpha-subunit is essential for the interaction. Interestingly, only a higher molecular weight form of GII alpha! is capable of associating with CD45 in a competitive situation where multiple GII alpha isoforms are expressed. Further, transfection studies demonstrate that only isoforms containing the alternatively spliced sequence Box Al are capable of binding CD45, although all isoforms are catalytically active, The interaction between CD45 and GII is dependent on the active site of GII, is mediated through the carbohydrate on CD45, and can be inhibited with mannose. Taken together, these results suggest that GII alpha acts as a lectin and binds to CD45 in an exon-dependent manner. This lectin activity of GIT may be a novel mechanism for the regulation of CD45 biology and play a role in immune function, possibly by regulating CD45 glycosylation.	Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2S2, Canada	University of Alberta	Ostergaard, HL (corresponding author), Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2S2, Canada.							Arendt CW, 1999, GLYCOBIOLOGY, V9, P277, DOI 10.1093/glycob/9.3.277; Arendt CW, 1997, J BIOL CHEM, V272, P13117, DOI 10.1074/jbc.272.20.13117; ARENDT CW, 1995, J BIOL CHEM, V270, P2313; Arendt CW, 2000, GLYCOBIOLOGY, V10, P487, DOI 10.1093/glycob/10.5.487; Ashwell JD, 1999, IMMUNOL TODAY, V20, P412, DOI 10.1016/S0167-5699(99)01505-4; BEGOVAC PC, 1994, J BIOL CHEM, V269, P31793; Flura T, 1997, GLYCOBIOLOGY, V7, P617, DOI 10.1093/glycob/7.5.617; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KAUSHAL GP, 1990, J BIOL CHEM, V265, P16271; LUCOCQ JM, 1986, J CELL BIOL, V102, P2137, DOI 10.1083/jcb.102.6.2137; Ma JY, 1996, J BIOL CHEM, V271, P7758, DOI 10.1074/jbc.271.13.7758; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; Pace KE, 1999, J IMMUNOL, V163, P3801; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; PULIDO R, 1992, EUR J IMMUNOL, V22, P463, DOI 10.1002/eji.1830220226; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; SGROI D, 1995, P NATL ACAD SCI USA, V92, P4026, DOI 10.1073/pnas.92.9.4026; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; THOMAS ML, 1988, IMMUNOL TODAY, V9, P320, DOI 10.1016/0167-5699(88)91326-6; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; TROPEA JE, 1989, BIOCHEMISTRY-US, V28, P2027, DOI 10.1021/bi00431a010; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Uemura K, 1996, J BIOL CHEM, V271, P4581; Wada I, 1997, EMBO J, V16, P5420, DOI 10.1093/emboj/16.17.5420; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3	33	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32071	32076		10.1074/jbc.M003088200	http://dx.doi.org/10.1074/jbc.M003088200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10921916	hybrid			2022-12-25	WOS:000089858900072
J	Ikeda, Y; Koizumi, N; Kusano, T; Sano, H				Ikeda, Y; Koizumi, N; Kusano, T; Sano, H			Specific binding of a 14-3-3 protein to autophosphorylated WPK4, an SNF1-related wheat protein kinase, and to WPK4-phosphorylated nitrate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITOR PROTEIN; PHOSPHORYLATION; 14-3-3-PROTEINS; TRANSCRIPTS; INTERACT; SUCROSE; HOMOLOG; LEAVES; PLANTS; LIGHT	WPK4 is a wheat protein kinase related to the yeast protein kinase SNF1, which plays a role in catabolite repression. To identify proteins involved in signal transduction through WPK4, we performed yeast two-hybrid screens and isolated two cDNA clones designated as TaWIN1 and TaWIN2. Both encode 14-3-3 proteins that, upon autophosphorylation, bind the C-terminal regulatory domain of WPK4. Mutational analysis through amino acid substitution revealed that TaWIN1 and TaWIN2 primarily bind WPK4 through phosphoserines at the positions 388 and 418, both located in the C-terminal region. Mutations in the conserved residues of the TaWIN1 amphipathic groove impaired the ability of TaWIN1 to bind to WPK4. A screen for in vitro phosphorylation of proteins involved in nutrient metabolism revealed a putative WPK4 substrate, nitrate reductase; its hinge 1 region was efficiently phosphorylated by WPK4. Subsequent far Western blots showed that it specifically bound TaWIN1. Since nitrate reductase has been shown to be inactivated by phosphorylation upon 14-3-3 binding, the present findings strongly suggest that WPK4 is the protein kinase responsible for controlling the nitrogen metabolic pathway, assembling the nitrate reductase and 14-3-3 complex through its phosphorylation specificity.	Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300101, Japan	Nara Institute of Science & Technology	Sano, H (corresponding author), Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300101, Japan.		Ikeda, Yoshihisa/B-4614-2013					BACHMANN M, 1995, PLANT PHYSIOL, V108, P1083, DOI 10.1104/pp.108.3.1083; Bachmann M, 1996, FEBS LETT, V387, P127, DOI 10.1016/0014-5793(96)00478-4; Bhalerao RP, 1999, P NATL ACAD SCI USA, V96, P5322, DOI 10.1073/pnas.96.9.5322; Bouly JP, 1999, PLANT J, V18, P541, DOI 10.1046/j.1365-313X.1999.00476.x; Camoni L, 1998, FEBS LETT, V430, P381, DOI 10.1016/S0014-5793(98)00696-6; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; CRAWFORD NM, 1995, PLANT CELL, V7, P859, DOI 10.1105/tpc.7.7.859; Douglas P, 1997, BIOCHEM J, V325, P101, DOI 10.1042/bj3250101; Douglas P, 1995, FEBS LETT, V377, P113, DOI 10.1016/0014-5793(95)01300-8; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Finnie C, 1999, PLANT MOL BIOL, V40, P545, DOI 10.1023/A:1006211014713; Halford NG, 1998, PLANT MOL BIOL, V37, P735, DOI 10.1023/A:1006024231305; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Ikeda Y, 1999, PLANT PHYSIOL, V121, P813, DOI 10.1104/pp.121.3.813; Kaiser WM, 1999, PHYSIOL PLANTARUM, V105, P385, DOI 10.1034/j.1399-3054.1999.105225.x; Kinoshita T, 1999, EMBO J, V18, P5548, DOI 10.1093/emboj/18.20.5548; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LU GH, 1994, PLANT CELL, V6, P501, DOI 10.1105/tpc.6.4.501; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Purcell PC, 1998, PLANT J, V14, P195, DOI 10.1046/j.1365-313X.1998.00108.x; SANO H, 1994, P NATL ACAD SCI USA, V91, P2582, DOI 10.1073/pnas.91.7.2582; Schultz TF, 1998, PLANT CELL, V10, P837, DOI 10.1105/tpc.10.5.837; Shi JR, 1999, PLANT CELL, V11, P2393, DOI 10.1105/tpc.11.12.2393; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	24	58	67	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31695	31700		10.1074/jbc.M004892200	http://dx.doi.org/10.1074/jbc.M004892200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10918058	hybrid			2022-12-25	WOS:000089858900023
J	Kumar, S; Lee, IH; Plamann, M				Kumar, S; Lee, IH; Plamann, M			Cytoplasmic dynein ATPase activity is regulated by dynactin-dependent phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-RELATED PROTEIN; MICROTUBULE-ASSOCIATED PROTEINS; LIGHT-CHAIN; NUCLEAR-DISTRIBUTION; HEAVY-CHAIN; ASPERGILLUS-NIDULANS; INTERMEDIATE-CHAIN; NEUROSPORA-CRASSA; MITOTIC SPINDLE; MOTOR PROTEINS	Cytoplasmic dynein is a microtubule-associated motor that utilizes ATP hydrolysis to conduct minus-end directed transport of various organelles. Dynactin is a multisubunit complex that has been proposed to both link dynein with cargo and activate dynein motor function. The mechanisms by which dynactin regulates dynein activity are not clear. In this study, we examine the role of dynactin in regulating dynein ATPase activity. We show that dynein-microtubule binding and ATP-dependent release of dynein from microtubules are reduced in dynactin null mutants, Delta ro-3 (p150(Glued)) and Delta ro-4 (Arp1), relative to wild-type. The dynein-microtubule binding activity, but not the ATP-dependent release of dynein from microtubules, is restored by in vitro mixing of extracts from dynein and dynactin mutants. Dynein produced in a Delta ro-3 mutant has similar to 8-fold reduced ATPase activity relative to dynein isolated from wildtype. However, dynein ATPase activity from wild-type is not reduced when dynactin is separated from dynein, suggesting that dynein produced in a dynactin mutant is inactivated. Treatment of dynein isolated from the Delta ro-3 mutant with lambda protein phosphatase restores the ATPase activity to near wild-type levels. The reduced dynein ATPase activity observed in dynactin null mutants is mainly due to altered affinity for ATP. Radiolabeling experiments revealed that low molecular mass proteins, particularly 20- and 8-kDa proteins, that immunoprecipitate with dynein heavy chain are hyperphosphorylated in the dynactin mutant and dephosphorylated upon A protein phosphatase treatment. The results suggest that cytoplasmic dynein ATPase activity is regulated by dynactin-dependent phosphorylation of dynein light chains.	Univ Missouri, Sch Biol Sci, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Plamann, M (corresponding author), Univ Missouri, Sch Biol Sci, 5100 Rockhill Rd, Kansas City, MO 64110 USA.	plamannm@umkc.edu			NIGMS NIH HHS [GM51217] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM051217, R01GM051217] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan V, 1996, CURR BIOL, V6, P630, DOI 10.1016/S0960-9822(09)00434-5; BARKALOW K, 1994, J CELL BIOL, V126, P727, DOI 10.1083/jcb.126.3.727; Beckwith SM, 1998, J CELL BIOL, V143, P1239, DOI 10.1083/jcb.143.5.1239; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Bowman AB, 1999, J CELL BIOL, V146, P165; Bruno KS, 1996, P NATL ACAD SCI USA, V93, P4775, DOI 10.1073/pnas.93.10.4775; CLARK SW, 1994, J CELL BIOL, V127, P129, DOI 10.1083/jcb.127.1.129; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; Dickman MB, 1999, FUNGAL GENET BIOL, V26, P99, DOI 10.1006/fgbi.1999.1118; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Eckley DM, 1999, J CELL BIOL, V147, P307, DOI 10.1083/jcb.147.2.307; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; Farshori P, 1997, BIOCHEM BIOPH RES CO, V232, P810, DOI 10.1006/bbrc.1997.6379; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; Habura A, 1999, J BIOL CHEM, V274, P15447, DOI 10.1074/jbc.274.22.15447; HAMASAKI T, 1991, P NATL ACAD SCI USA, V88, P7918, DOI 10.1073/pnas.88.18.7918; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; Holleran EA, 1998, INT REV CYTOL, V182, P69, DOI 10.1016/S0074-7696(08)62168-3; Holleran EA, 1998, TRENDS CELL BIOL, V8, P26, DOI 10.1016/S0962-8924(97)01195-1; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; Huang CYF, 1999, J BIOL CHEM, V274, P14262, DOI 10.1074/jbc.274.20.14262; Inaba K, 1999, BIOCHEM BIOPH RES CO, V256, P177, DOI 10.1006/bbrc.1999.0309; KARKI S, 1995, J BIOL CHEM, V131, P385; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; King SJ, 1999, MOL BIOL CELL, V10, p248A; King SM, 1996, J BIOL CHEM, V271, P19358, DOI 10.1074/jbc.271.32.19358; KING SM, 1995, J BIOL CHEM, V270, P11445, DOI 10.1074/jbc.270.19.11445; King SM, 1996, J BIOL CHEM, V271, P32281, DOI 10.1074/jbc.271.50.32281; King SM, 1998, BIOCHEMISTRY-US, V37, P15033, DOI 10.1021/bi9810813; Koonce MP, 1997, J BIOL CHEM, V272, P19714, DOI 10.1074/jbc.272.32.19714; Kumar S, 2000, BIOCHIMIE, V82, P229, DOI 10.1016/S0300-9084(00)00206-6; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009; LIN SXH, 1993, J CELL SCI, V105, P579; MCGRAIL M, 1995, J CELL BIOL, V131, P411, DOI 10.1083/jcb.131.2.411; Minke PF, 1999, MOL MICROBIOL, V32, P1065, DOI 10.1046/j.1365-2958.1999.01421.x; MUHUA L, 1994, CELL, V78, P669, DOI 10.1016/0092-8674(94)90531-2; PASCHAL BM, 1991, METHOD ENZYMOL, V196, P181; Pazour GJ, 1999, MOL BIOL CELL, V10, P3507, DOI 10.1091/mbc.10.10.3507; PLAMANN M, 1994, J CELL BIOL, V127, P139, DOI 10.1083/jcb.127.1.139; Reese EL, 1999, MOL BIOL CELL, V10, p250A; Runnegar MT, 1999, BIOCHEM J, V342, P1, DOI 10.1042/0264-6021:3420001; Schafer DA, 1999, ANNU REV CELL DEV BI, V15, P341, DOI 10.1146/annurev.cellbio.15.1.341; SCHAFER DA, 1994, J CELL BIOL, V126, P403, DOI 10.1083/jcb.126.2.403; Schroer TA, 1996, SEMIN CELL DEV BIOL, V7, P321, DOI 10.1006/scdb.1996.0041; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; Seiler S, 1999, CURR BIOL, V9, P779, DOI 10.1016/S0960-9822(99)80360-1; SLOBODA RD, 1976, BIOCHEMISTRY-US, V15, P4497, DOI 10.1021/bi00665a026; Sloboda RD, 1998, PROTEIN EXPRES PURIF, V13, P205, DOI 10.1006/prep.1998.0902; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tai AW, 1999, MOL BIOL CELL, V10, p368A; Tinsley JH, 1998, MOL GEN GENET, V259, P601, DOI 10.1007/s004380050853; Tinsley JH, 1996, MOL BIOL CELL, V7, P731, DOI 10.1091/mbc.7.5.731; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; WEBER A, 1994, J CELL BIOL, V127, P1627, DOI 10.1083/jcb.127.6.1627; Wu HW, 1999, MOL BIOL CELL, V10, p369A; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100	63	35	37	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31798	31804		10.1074/jbc.M000449200	http://dx.doi.org/10.1074/jbc.M000449200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10921911	hybrid			2022-12-25	WOS:000089858900037
J	Hebbes, TR; Allen, SCH				Hebbes, TR; Allen, SCH			Multiple histone acetyltransferases are associated with a chicken erythrocyte chromatin fraction enriched in active genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIC-STRENGTH; ACETYLATION; TRANSCRIPTION; SUBUNIT; DOMAIN; ALTERS; CELLS; YEAST	We have examined salt-soluble chromatin released by micrococcal nuclease from a 15-day-old chicken embryo erythrocyte nuclei for histone acetyltransferase (HAT) activities. This chromatin is enriched in transcriptionally active sequences from within the active beta-globin locus and contains elevated levels of acetylated core histones. HAT activities present in this fraction target histones H4, H3, and H2A when the chromatin itself is used as the substrate. In gel HAT activity assay demonstrates that the salt-soluble chromatin fraction contains four acetyltransferase molecules distinguished by their different molecular masses (47, 33, 32, and 28 kDa). Further separation of the chromatin by centrifugation through sucrose gradients shows that the acetyltransferases segregate into chromatin-bound and chromatin-free populations. The 32- and 28-kDa HATs are associated with chromatin, whereas the 47- and 33-kDa HAT molecules are not. The chromatin-bound HAT activities predominantly target H4 to give the diacetyl and tri-acetyl species; some acetylation of H2A can also be seen. Our results suggest that the chromatin-associated acetyltransferases have a role in gene regulation.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	University of Warwick	Hebbes, TR (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.							ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; BOHM J, 1980, EUR J BIOCHEM, V112, P353, DOI 10.1111/j.1432-1033.1980.tb07212.x; BONNER WM, 1980, EUR J BIOCHEM, V109, P17, DOI 10.1111/j.1432-1033.1980.tb04762.x; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; DORBIC T, 1987, EMBO J, V6, P2393, DOI 10.1002/j.1460-2075.1987.tb02517.x; Elefant F, 2000, J BIOL CHEM, V275, P13827, DOI 10.1074/jbc.275.18.13827; Grant PA, 1999, SEMIN CELL DEV BIOL, V10, P169, DOI 10.1006/scdb.1999.0298; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HEBBES TR, 1992, NUCLEIC ACIDS RES, V20, P1017, DOI 10.1093/nar/20.5.1017; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Herrera JE, 1999, MOL CELL BIOL, V19, P3466; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; O'Neill LP, 1999, EMBO J, V18, P2897, DOI 10.1093/emboj/18.10.2897; RIDSDALE JA, 1987, BIOCHEMISTRY-US, V26, P290, DOI 10.1021/bi00375a040; RIDSDALE JA, 1987, NUCLEIC ACIDS RES, V15, P1081, DOI 10.1093/nar/15.3.1081; RIDSDALE JA, 1990, J BIOL CHEM, V265, P5150; Schubeler D, 2000, GENE DEV, V14, P940; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; SUN YL, 1986, EMBO J, V5, P293, DOI 10.1002/j.1460-2075.1986.tb04212.x; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659	28	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31347	31352		10.1074/jbc.M004830200	http://dx.doi.org/10.1074/jbc.M004830200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896666	hybrid			2022-12-25	WOS:000089762700085
J	McAllister, KA; Peery, RB; Meier, TI; Fischl, AS; Zhao, G				McAllister, KA; Peery, RB; Meier, TI; Fischl, AS; Zhao, G			Biochemical and molecular analyses of the Streptococcus pneumoniae acyl carrier protein synthase, an enzyme essential for fatty acid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI K-12; COENZYME-A; POLYKETIDE SYNTHASE; BACILLUS-SUBTILIS; PDXJ OPERON; GENES; PURIFICATION; STREPTOMYCES; CLUSTER	Acyl carrier protein synthase (AcpS) is an essential enzyme in the biosynthesis of fatty acids in all bacteria. AcpS catalyzes the transfer of 4'-phosphopantetheine from coenzyme A (CoA) to apo-ACP, thus converting apo-ACP to holo-ACP that serves as an acyl carrier for the biosynthesis of fatty acids and lipids. To further understand the physiological role of AcpS, we identified, cloned, and expressed the acpS and acpP genes of Streptococcus pneumoniae and purified both products to homogeneity. Both acpS and acpP form operons with the genes whose functions are required for other cellular metabolism. The acpS gene complements an Escherichia coli mutant defective in the production of AcpS and appears to be essential for the growth of S. pneumoniae. Gel filtration and cross-linking analyses establish that purified AcpS exists as a homotrimer. AcpS activity was significantly stimulated by apo-ACP at concentrations over 10 mu M and slightly inhibited at concentrations of 5-10 mu M. Double reciprocal analysis of initial velocities of AcpS at various concentrations of CoA or apo-ACP indicated a random or compulsory ordered bi bi type of reaction mechanism. Further analysis of the inhibition kinetics of the product (3',5'-ADP) suggested that it is competitive with respect to CoA but mixed (competitive and noncompetitive) with respect to apo-ACP. Finally, apo-ACP bound tightly to AcpS in the absence of CoA, but CoA failed to do so in the absence of apo-ACP. Together, these results suggest that AcpS may be allosterically regulated by apo ACP and probably proceeds by an ordered reaction mechanism with the first formation of the AcpS-apo-ACP complex and the subsequent transfer of 4'-phosphopantetheine to the apo-ACP of the complex.	Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA	Eli Lilly	Zhao, G (corresponding author), Eli Lilly & Co, Lilly Res Labs, DC 0438, Indianapolis, IN 46285 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Baltz RH, 1998, MICROB DRUG RESIST, V4, P1, DOI 10.1089/mdr.1998.4.1; BALTZ RH, 1997, 37 ICAAC INT C ANT A, P391; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carreras CW, 1997, BIOCHEMISTRY-US, V36, P11757, DOI 10.1021/bi971350+; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; COOPER CL, 1987, BIOCHEMISTRY-US, V26, P2740, DOI 10.1021/bi00384a013; COPELAND RA, 1996, ENZYMES PRACTICAL IN; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; CROSBY J, 1995, BBA-PROTEIN STRUCT M, V1251, P32, DOI 10.1016/0167-4838(95)00053-W; ELOVSON J, 1968, J BIOL CHEM, V243, P3603; Flugel RS, 2000, J BIOL CHEM, V275, P959, DOI 10.1074/jbc.275.2.959; Gehring AM, 1997, CHEM BIOL, V4, P17, DOI 10.1016/S1074-5521(97)90233-7; Heath RJ, 1996, J BIOL CHEM, V271, P1833, DOI 10.1074/jbc.271.4.1833; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; JACKOWSKI S, 1984, J BACTERIOL, V158, P115, DOI 10.1128/JB.158.1.115-120.1984; JACKOWSKI S, 1986, J BACTERIOL, V166, P866, DOI 10.1128/jb.166.3.866-871.1986; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; JACKOWSKI S, 1983, J BIOL CHEM, V258, P5186; Kalman S, 1999, NAT GENET, V21, P385, DOI 10.1038/7716; KEATING DH, 1995, J BIOL CHEM, V270, P22229, DOI 10.1074/jbc.270.38.22229; KUBITSCHEK HE, 1986, J BACTERIOL, V168, P1466, DOI 10.1128/jb.168.3.1466-1467.1986; Kullik I, 1998, GENE, V219, P9, DOI 10.1016/S0378-1119(98)00404-1; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Kutchma AJ, 1999, J BACTERIOL, V181, P5498, DOI 10.1128/JB.181.17.5498-5504.1999; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM HM, 1992, J BACTERIOL, V174, P1554, DOI 10.1128/jb.174.5.1554-1567.1992; Lambalot RH, 1997, METHOD ENZYMOL, V279, P254; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; LAMBALOT RH, 1995, J BIOL CHEM, V270, P24658, DOI 10.1074/jbc.270.42.24658; LLOYD RG, 1996, ESCHERICHIA COLI SAL, P2336; MAJERUS PW, 1965, P NATL ACAD SCI USA, V53, P410, DOI 10.1073/pnas.53.2.410; Morbidoni HR, 1996, J BACTERIOL, V178, P4794, DOI 10.1128/jb.178.16.4794-4800.1996; Quadri LEN, 1998, BIOCHEMISTRY-US, V37, P1585, DOI 10.1021/bi9719861; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; ROCK CO, 1979, J BIOL CHEM, V254, P9778; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; Shen ZW, 1996, J BACTERIOL, V178, P571, DOI 10.1128/jb.178.2.571-573.1996; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; TAKIFF HE, 1992, J BACTERIOL, V174, P1544, DOI 10.1128/jb.174.5.1544-1553.1992; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Tropf S, 1998, CHEM BIOL, V5, P135, DOI 10.1016/S1074-5521(98)90058-8; VALLARI DS, 1988, J BACTERIOL, V170, P3961, DOI 10.1128/jb.170.9.3961-3966.1988; VALLARI DS, 1987, J BIOL CHEM, V262, P2468; Zhao GS, 1999, MICROBIOL-UK, V145, P791, DOI 10.1099/13500872-145-4-791; Zhou P, 1999, CHEM BIOL, V6, P577, DOI 10.1016/S1074-5521(99)80090-8	47	30	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30864	30872		10.1074/jbc.M004475200	http://dx.doi.org/10.1074/jbc.M004475200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10903317	hybrid			2022-12-25	WOS:000089762700021
J	Watanabe, T; Inoue, R; Kimura, N; Furukawa, K				Watanabe, T; Inoue, R; Kimura, N; Furukawa, K			Versatile transcription of biphenyl catabolic bph operon in Pseudomonas pseudoalcaligenes KF707	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN KKS102; GRAM-NEGATIVE BACTERIA; RHODOCOCCUS SP M5; NUCLEOTIDE-SEQUENCE; ENCODING BIPHENYL; CHLOROBIPHENYL DEGRADATION; TRANSPOSON MUTAGENESIS; FUNCTIONAL-ANALYSIS; SOIL BACTERIA; GENE-CLUSTER	Pseudomonas pseudoalcaligenes KF707 possesses a chromosomally encoded bph gene cluster responsible for the catabolism of biphenyl/polychlorinated biphenyls. The gene cluster consists of (orf0)bphA1A-2(orf3)bphA3A4BCX0X1X2X3D. We studied the role of orf0 and transcription in the KF707 bph operon, Primer extension analyses revealed that at least as many as six transcriptional initiation sites exist upstream of orf0, bphA1, bphX0, bphX1, and bphD, including two upstream of bphD. The orf0-disruptant failed to grow on biphenyl but accumulated large amounts of the biphenyl ring meta-cleavage yellow compound (2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate). Western blot analysis revealed that ORF0 protein is inducibly expressed in KF707 in the presence of biphenyl. Gel shift assay revealed that ORFO directly binds to the orf0 operator region, This binding was greatly enhanced by addition of the biphenyl ring meta-cleavage yellow compound. These results indicated that orf0, bphA1A2(orf3)bphA3A4BC and bphX0X1X2X3D are independently transcribed, and that ORFO protein belonging to the GntR family is involved in the regulation of the bph operon in KF707 and is absolutely required for the expression of orf0 and bphX0X1X2X3D.	Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Appl Microbiol Lab, Fukuoka 8128581, Japan	Kyushu University	Furukawa, K (corresponding author), Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Appl Microbiol Lab, Hakozaki 6-10-1, Fukuoka 8128581, Japan.	kfurukaw@agr.kyushu-u.ac.jp	KENSUKE, FURUKAWA/R-3105-2019; Kimura, Nobutada/D-5399-2017	Kimura, Nobutada/0000-0003-1483-0024				ALLISON SL, 1990, J BACTERIOL, V172, P5470, DOI 10.1128/jb.172.9.5470-5476.1990; Arai H, 1999, MOL MICROBIOL, V33, P1132, DOI 10.1046/j.1365-2958.1999.01554.x; Ausubel FM, 1994, CURRENT PROTOCOLS MO; ERICKSON BD, 1992, J BACTERIOL, V174, P2903, DOI 10.1128/JB.174.9.2903-2912.1992; FUJITA Y, 1987, P NATL ACAD SCI USA, V84, P4524, DOI 10.1073/pnas.84.13.4524; FUJITA Y, 1990, FEBS LETT, V267, P71, DOI 10.1016/0014-5793(90)80290-Y; FURUKAWA K, 1987, J BACTERIOL, V169, P427, DOI 10.1128/jb.169.1.427-429.1987; FURUKAWA K, 1991, GENE, V98, P21; FURUKAWA K, 1986, J BACTERIOL, V166, P392, DOI 10.1128/jb.166.2.392-398.1986; Habig W H, 1981, Methods Enzymol, V77, P398; HAYASE N, 1990, J BACTERIOL, V172, P1160, DOI 10.1128/jb.172.2.1160-1164.1990; HAYDON DJ, 1991, FEMS MICROBIOL LETT, V79, P291, DOI 10.1016/0378-1097(91)90101-F; HOFER B, 1994, GENE, V144, P9, DOI 10.1016/0378-1119(94)90196-1; HOFER B, 1993, GENE, V130, P47, DOI 10.1016/0378-1119(93)90345-4; IMAJOHOHMI S, 1994, KOUPEPUTIDOKOUTAI JI, P47; KIKUCHI Y, 1994, J BACTERIOL, V176, P1689, DOI 10.1128/jb.176.6.1689-1694.1994; KIKUCHI Y, 1994, J BACTERIOL, V176, P4269, DOI 10.1128/jb.176.14.4269-4276.1994; Kim E, 1996, APPL ENVIRON MICROB, V62, P262, DOI 10.1128/AEM.62.1.262-265.1996; KIM E, 1995, J BACTERIOL, V177, P3095, DOI 10.1128/jb.177.11.3095-3103.1995; KIMBARA K, 1989, J BACTERIOL, V171, P2740, DOI 10.1128/jb.171.5.2740-2747.1989; Kimura N, 1997, J BACTERIOL, V179, P3936, DOI 10.1128/jb.179.12.3936-3943.1997; Labbe D, 1997, J BACTERIOL, V179, P2772, DOI 10.1128/jb.179.8.2772-2776.1997; Lau PCK, 1996, GENE, V171, P53, DOI 10.1016/0378-1119(96)00025-X; Masai E, 1997, GENE, V187, P141, DOI 10.1016/S0378-1119(96)00748-2; MASAI E, 1995, APPL ENVIRON MICROB, V61, P2079, DOI 10.1128/AEM.61.6.2079-2085.1995; Merlin C, 1999, PLASMID, V41, P40, DOI 10.1006/plas.1998.1375; Merlin C, 1997, MOL GEN GENET, V253, P499; Mouz S, 1999, MOL GEN GENET, V262, P790, DOI 10.1007/s004380051142; Nishi A, 2000, J BACTERIOL, V182, P1949, DOI 10.1128/JB.182.7.1949-1955.2000; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHINGLER V, 1992, J BACTERIOL, V174, P711, DOI 10.1128/jb.174.3.711-724.1992; SIMON R, 1989, GENE, V80, P161, DOI 10.1016/0378-1119(89)90262-X; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SPRINGAEL D, 1993, J BACTERIOL, V175, P1674, DOI 10.1128/JB.175.6.1674-1681.1993; TAIRA K, 1992, J BIOL CHEM, V267, P4844; WANG Y, 1995, GENE, V164, P117, DOI 10.1016/0378-1119(95)00448-F; YOSHIDA K, 1995, MOL GEN GENET, V248, P583, DOI 10.1007/BF02423454	37	41	45	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31016	31023		10.1074/jbc.M003023200	http://dx.doi.org/10.1074/jbc.M003023200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10900199	hybrid			2022-12-25	WOS:000089762700041
J	Yorimitsu, T; Asai, Y; Sato, K; Homma, M				Yorimitsu, T; Asai, Y; Sato, K; Homma, M			Intermolecular cross-linking between the periplasmic Loop(3-4) regions of PomA, a component of the Na+-driven flagellar motor of Vibrio alginolyticus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE CHANNEL COMPONENTS; ESCHERICHIA-COLI; SCANNING MUTAGENESIS; AMILORIDE ANALOG; POLAR; PHENAMIL; MOTILITY; PROTEIN; FORCE; MUTATIONS	PomA and PomB form a complex that conducts sodium ions and generates the torque for the Na+-driven polar flagellar motor of Vibrio alginolyticus, PomA has four transmembrane segments. One periplasmic loop (loop,,) connects segments 1 and 2, and another (loop(3-4)), in which cysteine-scanning mutagenesis had been carried out, connects segments 3 and 4, When PomA with an introduced Cys residue (Cys-PomA) in the C-terminal periplasmic loop (loop(3-4)) was examined without exposure to a reducing reagent, a 43-kDa band was observed, whereas only a 25-kDa band, which corresponds to monomeric PomA, was observed under reducing conditions, The intensity of the 43-kDa band was enhanced in most mutants by the oxidizing reagent CuCl2. The 43-kDa band was strongest in the P172C mutant. The motility of the P172C mutant was severely reduced, and P172C showed a dominant-negative effect, whereas substitution of Pro with Ala, Ile, or Ser at this position did not affect motility, In the presence of DTT, the ability to swim was partially restored; and the amount of 43-kDa protein was reduced. These results suggest that the disulfide cross-link disturbs the Reaction of PomA, When the mutated Cys residue was modified with N-ethyhmaleimide, only the 25-kDa PomA band was labeled, demonstrating that the 43-kDa form is a cross-linked homodimer and suggesting that the loops,4 of adjacent subunits of PomA are close to each other in the assembled motor. We propose that this loop region is important for dimer formation and motor function.	Nagoya Univ, Div Biol Sci, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University	Homma, M (corresponding author), Nagoya Univ, Div Biol Sci, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.							Aizawa SI, 1996, MOL MICROBIOL, V19, P1, DOI 10.1046/j.1365-2958.1996.344874.x; Asai Y, 2000, J BACTERIOL, V182, P1001, DOI 10.1128/JB.182.4.1001-1007.2000; Asai Y, 1997, J BACTERIOL, V179, P5104, DOI 10.1128/jb.179.16.5104-5110.1997; Asai Y, 1999, J BACTERIOL, V181, P6332, DOI 10.1128/JB.181.20.6332-6338.1999; BLAIR DF, 1990, CELL, V60, P439, DOI 10.1016/0092-8674(90)90595-6; BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; BLAIR DF, 1988, SCIENCE, V242, P1678, DOI 10.1126/science.2849208; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Furuno M, 1999, MICROBIOL IMMUNOL, V43, P39, DOI 10.1111/j.1348-0421.1999.tb02370.x; Hase CC, 1999, P NATL ACAD SCI USA, V96, P3183, DOI 10.1073/pnas.96.6.3183; Homma M, 1996, MICROBIOL-UK, V142, P2777, DOI 10.1099/13500872-142-10-2777; IMAE Y, 1989, J BIOENERG BIOMEMBR, V21, P705, DOI 10.1007/BF00762688; Jaques S, 1999, P NATL ACAD SCI USA, V96, P5740, DOI 10.1073/pnas.96.10.5740; Kimura T, 1998, BIOCHEMISTRY-US, V37, P5475, DOI 10.1021/bi973188g; Kojima S, 1999, J BACTERIOL, V181, P1927, DOI 10.1128/JB.181.6.1927-1930.1999; Kojima S, 1999, MICROBIOL-UK, V145, P1759, DOI 10.1099/13500872-145-7-1759; Kojima S, 1997, J MOL BIOL, V265, P310, DOI 10.1006/jmbi.1996.0732; Kojima S, 2000, J BACTERIOL, V182, P3314, DOI 10.1128/JB.182.11.3314-3318.2000; Kojima S, 1999, J MOL BIOL, V285, P1537, DOI 10.1006/jmbi.1998.2377; Kubo Y, 1998, FEBS LETT, V435, P69, DOI 10.1016/S0014-5793(98)01038-2; MANSON MD, 1977, P NATL ACAD SCI USA, V74, P3060, DOI 10.1073/pnas.74.7.3060; MCCARTER LL, 1994, J BACTERIOL, V176, P5988, DOI 10.1128/jb.176.19.5988-5998.1994; MCCARTER LL, 1994, J BACTERIOL, V176, P4219, DOI 10.1128/jb.176.14.4219-4225.1994; MURAMOTO K, 1994, J BIOL CHEM, V269, P3374; Okunishi I, 1996, J BACTERIOL, V178, P2409, DOI 10.1128/jb.178.8.2409-2415.1996; PerezGarcia MT, 1996, P NATL ACAD SCI USA, V93, P300, DOI 10.1073/pnas.93.1.300; Sato K, 2000, J BIOL CHEM, V275, P5718, DOI 10.1074/jbc.275.8.5718; Sato K, 2000, J BIOL CHEM, V275, P20223, DOI 10.1074/jbc.M002236200; SHARP LL, 1995, BIOCHEMISTRY-US, V34, P9166, DOI 10.1021/bi00028a028; STOLZ B, 1991, J BACTERIOL, V173, P7033, DOI 10.1128/jb.173.21.7033-7037.1991; Tang H, 1996, J MOL BIOL, V261, P209, DOI 10.1006/jmbi.1996.0453; WILSON ML, 1990, J BACTERIOL, V172, P3932, DOI 10.1128/jb.172.7.3932-3939.1990; Yorimitsu T, 1999, J BACTERIOL, V181, P5103, DOI 10.1128/JB.181.16.5103-5106.1999	33	15	15	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31387	31391		10.1074/jbc.M000848200	http://dx.doi.org/10.1074/jbc.M000848200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10900193	hybrid			2022-12-25	WOS:000089762700090
J	Cheng, LY; Rossi, F; Fang, WZ; Mori, T; Cobrinik, D				Cheng, LY; Rossi, F; Fang, WZ; Mori, T; Cobrinik, D			Cdk2-dependent phosphorylation and functional inactivation of the pRB-related p130 protein in pRB(-), p16(INK4A)(+) tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							E2F TRANSCRIPTION FACTORS; RETINOBLASTOMA GENE-PRODUCT; CYCLIN-DEPENDENT KINASES; S-PHASE ENTRY; HISTONE DEACETYLASE; IN-VIVO; GROWTH SUPPRESSION; NUCLEAR-PROTEIN; MAMMALIAN-CELLS; FAMILY MEMBERS	The retinoblastoma family proteins pRB, p107, and p130 are phosphorylated and released from E2Fs in the late G(1) phase of the cell cycle. This phosphorylation is thought to contribute to the derepression of E2F-responsive genes and to be mediated, in part, by Cdk4 and Cdk6. Evidence that Cdk4/6 activity is inhibited by p16(INK4A) in most pRB(-) cells suggests that p107 and p130 may be underphosphorylated and remain associated with E2Fs during G(1)-S progression in cells that lack pRB. To examine this, we evaluated the cell cycle-dependent phosphorylation and E2F binding abilities of p107 and p130 in pRB(-), p16(+) Saos-2 osteosarcoma cells. p130, but not p107, was phosphorylated and released from E2F-4 in late G(1) and S phase cells, although p130 phosphorylation differed qualitatively in these and other pRB(-), p16(+) cells as compared with pRB(+), p16(-) cell types. p130 phosphorylation occurred in the absence of cyclin D-Cdk4/6 complexes, coincided with cyclin E- and Cdk2-associated kinase activity, and was prevented by expression of dominant negative Cdk2. Moreover, dominant negative Cdk2 prevented the dissociation of endogenous p130-E2F-4 complexes and inhibited E2F-4-dependent transcription. These findings show that p130 can be phosphorylated and functionally inactivated in a Cdk2-dependent process, and they highlight the involvement of distinct Cdks in the regulation of different pRB family proteins.	Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Inst Canc Genet, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Cobrinik, D (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.							Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chesnut JD, 1996, J IMMUNOL METHODS, V193, P17, DOI 10.1016/0022-1759(96)00032-4; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, ONCOGENE, V10, P2125; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magae J, 1996, J CELL SCI, V109, P1717; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MAYOL X, 1993, ONCOGENE, V8, P2561; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muller H, 1997, MOL CELL BIOL, V17, P5508; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Mulligan GJ, 1998, MOL CELL BIOL, V18, P206, DOI 10.1128/MCB.18.1.206; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Philips A, 1998, ONCOGENE, V16, P1373, DOI 10.1038/sj.onc.1201655; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Reed SI, 1997, CANCER SURV, V29, P7; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Starostik P, 1996, MOL CELL BIOL, V16, P3606; Stiegler P, 1998, CANCER RES, V58, P5049; Strober BE, 1996, MOL CELL BIOL, V16, P1576; TAM SW, 1994, ONCOGENE, V9, P2663; TAM SW, 1994, CANCER RES, V54, P5816; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; TSAI LH, 1993, ONCOGENE, V8, P1593; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; YEAGER T, 1995, CANCER RES, V55, P493; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; ZHANG YH, 1995, ONCOGENE, V10, P2085; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	109	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30317	30325		10.1074/jbc.M005707200	http://dx.doi.org/10.1074/jbc.M005707200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10906146	hybrid			2022-12-25	WOS:000089577900056
J	Jedlitschky, G; Burchell, B; Keppler, D				Jedlitschky, G; Burchell, B; Keppler, D			The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER CELL-LINES; NITRIC-OXIDE; SUBSTRATE-SPECIFICITY; CONJUGATE TRANSPORT; HUMAN ERYTHROCYTES; DRUG-RESISTANCE; SMOOTH-MUSCLE; GENE; EGRESSION; FAMILY	Cellular export of cyclic nucleotides has been observed in various tissues and may represent an elimination pathway for these signaling molecules, in addition to degradation by phosphodiesterases. In the present study we provide evidence that this export is mediated by the multidrug resistance protein isoform MRP5 (gene symbol ABCC5). The transport function of MRP5 was studied in V79 hamster lung fibroblasts transfected with a human MRP5 cDNA. An MRP5-specific antibody detected an overexpression of the glycoprotein of 185 +/- 15 kDa in membranes from MRP5-transfected cells and a low basal expression of hamster Mrp5 in control membranes. ATP-dependent transport of 3',5'-cyclic GMP at a substrate concentration of 1 mu M was 4-fold higher in membrane vesicles from MRP5-transfected cells than in control membranes. This transport was saturable with a K-m value of 2.1 mu M. MRP5-mediated transport was also detected for 3',5'-cyclic AMP at a lower affinity, with a K-m value of 379 mu M. A potent inhibition of MRP5-mediated transport was observed by several compounds, known as phosphodiesterase modulators, including trequinsin, with a K-i of 240 nM, and sildenafil, with a K-i value of 267 nM. Thus, cyclic nucleotides are physiological substrates for MRP5; moreover, MRP5 may represent a novel pharmacological target for the enhancement of tissue levels of cGMP.	Deutsch Krebsforschungszentrum, Div Tumor Biochem, D-69120 Heidelberg, Germany; Univ Dundee, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland	Helmholtz Association; German Cancer Research Center (DKFZ); University of Dundee	Jedlitschky, G (corresponding author), Deutsch Krebsforschungszentrum, Div Tumor Biochem, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	g.jedlitschky@dkfz-heidelberg.de	Keppler, Dietrich/A-5528-2013	Keppler, Dietrich/0000-0003-2964-2333				Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; ASHMAN DF, 1963, BIOCHEM BIOPH RES CO, V11, P330, DOI 10.1016/0006-291X(63)90566-7; Bellamy TC, 2000, P NATL ACAD SCI USA, V97, P2928, DOI 10.1073/pnas.97.6.2928; BILLIAR TR, 1992, AM J PHYSIOL, V262, pC1077, DOI 10.1152/ajpcell.1992.262.4.C1077; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; BRUNTON LL, 1988, METHOD ENZYMOL, V159, P83; BUEHLER M, 1996, J BIOL CHEM, V271, P15091; BUTCHER RW, 1962, J BIOL CHEM, V237, P1244; CARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683; Chen WY, 1997, P NATL ACAD SCI USA, V94, P5798, DOI 10.1073/pnas.94.11.5798; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Cui YH, 1999, MOL PHARMACOL, V55, P929; FEHR TF, 1990, J BIOL CHEM, V265, P10974; FRIEDLANDER G, 1995, KIDNEY INT, V47, P1500, DOI 10.1038/ki.1995.212; HAMET P, 1989, J BIOL CHEM, V264, P12364; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; JANSSENS PMW, 1987, MICROBIOL REV, V51, P396, DOI 10.1128/MMBR.51.4.396-418.1987; Jedlitschky G, 1999, BIOCHEM J, V340, P837, DOI 10.1042/0264-6021:3400837; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; Keppler D, 1998, METHOD ENZYMOL, V292, P607; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Kool M, 1997, CANCER RES, V57, P3537; Kruh GD, 1999, J NATL CANCER I, V91, P888; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; McAleer MA, 1999, J BIOL CHEM, V274, P23541, DOI 10.1074/jbc.274.33.23541; MILLUL V, 1996, AM J PHYSIOL, V39, pC1051; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; PATEL MJ, 1995, J PHARMACOL EXP THER, V273, P16; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; PODEVIN RA, 1980, BIOCHIM BIOPHYS ACTA, V629, P135, DOI 10.1016/0304-4165(80)90272-X; Sager G, 1996, SCAND J CLIN LAB INV, V56, P289, DOI 10.3109/00365519609090579; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; Schultz C, 1998, BIOCHEMISTRY-US, V37, P1161, DOI 10.1021/bi9713409; Sundkvist E, 2000, BBA-BIOMEMBRANES, V1463, P121, DOI 10.1016/S0005-2736(99)00184-4; Suzuki T, 2000, GENE, V242, P167, DOI 10.1016/S0378-1119(99)00529-6; Suzuki T, 1997, BIOCHEM BIOPH RES CO, V238, P790, DOI 10.1006/bbrc.1997.7346; Taniguchi K, 1996, CANCER RES, V56, P4124; Warrington JS, 2000, DRUG METAB DISPOS, V28, P392; Wijnholds J., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P315; Wijnholds J, 2000, P NATL ACAD SCI USA, V97, P7476, DOI 10.1073/pnas.120159197; WOODS M, 1991, BIOCHEM PHARMACOL, V41, P385, DOI 10.1016/0006-2952(91)90535-D	44	360	371	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30069	30074		10.1074/jbc.M005463200	http://dx.doi.org/10.1074/jbc.M005463200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10893247	hybrid			2022-12-25	WOS:000089577900022
J	Wu, GK; Lee, WH; Chen, PL				Wu, GK; Lee, WH; Chen, PL			NBS1 and TRF1 colocalize at promyelocytic leukemia bodies during late S/G(2) phases in immortalized telomerase-negative cells - Implication of NBS1 in alternative lengthening of telomeres	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIJMEGEN BREAKAGE SYNDROME; DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; SYNDROME PROTEIN; IN-VITRO; MRE11; REPAIR; COMPLEX; RAD50; RECOMBINATION	Nijmegen breakage syndrome, a chromosomal instability disorder, is characterized in part by cellular hypersensitivity to ionizing radiation. The NBS1 gene product, p95 (NBS1 or nibrin) forms a complex with Rad50 and Mre11. Cells deficient in the formation of this complex are defective in DNA double-strand break repair, cell cycle checkpoint control, and telomere length maintenance. How the NBS1 complex is involved in telomere length maintenance remains unclear. Here we show that the C-terminal region of NBS1 interacts directly with a telomere repeat binding factor, TRF1, by both yeast two-hybrid and in vivo DNA-coimmunoprecipitation assays. NBS1 and Mre11 colocalize with TRF1 at promyelocytic leukemia (PML) nuclear bodies in immortalized telomerase-negative cell lines, but rarely in telomerase-positive cell lines. The translocation of NBS1 to PML bodies occurs specifically during late S to G(2) phases of the cell cycle and coincides with active DNA synthesis in these NBS1-containing PML bodies. These results suggest that NBS1 may be involved in alternative lengthening of telomeres in telomerase-negative immortalized cells.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Chen, PL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.				NATIONAL CANCER INSTITUTE [P01CA081020, R01CA085605] Funding Source: NIH RePORTER; NCI NIH HHS [CA85605, CA81020] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; DETKE S, 1979, P NATL ACAD SCI USA, V76, P4995, DOI 10.1073/pnas.76.10.4995; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Featherstone C, 1998, CURR BIOL, V8, pR622, DOI 10.1016/S0960-9822(98)70392-6; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Le S, 1999, GENETICS, V152, P143; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Moreau S, 1999, MOL CELL BIOL, V19, P556; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Prescott J, 1997, GENE DEV, V11, P528, DOI 10.1101/gad.11.4.528; Prescott JC, 1999, CURR OPIN GENET DEV, V9, P368, DOI 10.1016/S0959-437X(99)80055-0; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; Reddel RR, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1254; Shore D, 1998, SCIENCE, V281, P1818, DOI 10.1126/science.281.5384.1818; TOBEY RA, 1990, P NATL ACAD SCI USA, V87, P5104, DOI 10.1073/pnas.87.13.5104; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yeager TR, 1999, CANCER RES, V59, P4175; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	34	176	182	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30618	30622		10.1074/jbc.C000390200	http://dx.doi.org/10.1074/jbc.C000390200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10913111	hybrid			2022-12-25	WOS:000089577900096
J	Matsuo, M; Tanabe, K; Kioka, N; Amachi, T; Ueda, K				Matsuo, M; Tanabe, K; Kioka, N; Amachi, T; Ueda, K			Different binding properties and affinities for ATP and ADP among sulfonylurea receptor subtypes, SUR1, SUR2A, and SUR2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE K+ CHANNELS; TRANSMEMBRANE CONDUCTANCE REGULATOR; PANCREATIC BETA-CELLS; HAMSTER OVARY CELLS; P-GLYCOPROTEIN; SUBUNIT STOICHIOMETRY; POTASSIUM CHANNELS; INSULIN-SECRETION; SKELETAL-MUSCLE; ACTIVATION	ATP-sensitive potassium (K-ATP) channels, composed of sulfonylurea receptor (SURx) and Kir6.x, play important roles by linking cellular metabolic state to membrane potential in various tissues. Pancreatic, cardiac, and vascular smooth muscle K-ATP channels, which consist of different subtypes of SURx, differ in their responses to cellular metabolic state, To explore the possibility that different interactions of SURx with nucleotides cause differential regulation of K-ATP, channels, we analyzed the properties of nucleotide-binding folds (NBFs) of SUR1, SUR2A, and SUR2B. SURx in crude membrane fractions was incubated with 8-azido[alpha-P-32]ATP Or 8-azido-[gamma-P-32]ATP under various conditions and was photoaffinity-labeled. Then, SURx was digested mildly with trypsin, and partial tryptic fragments were immunoprecipitated with antibodies against NBF1 and NBF2. Some nucleotide-binding properties were different among SUR subtypes as follows. 1) Mg2+ dependence of nucleotide binding of NBF2 of SUR1 was high, whereas those of SUR2A and SUR2B were low. 2) The affinities of NBF1 of SUR1 for ATP and ADP, especially for ATP, were significantly higher than those of SUR2A and SUR2B. 3) The affinities of NBF2 of SUR2B for ATP and ADP were significantly higher than those of SUR2A This is the first biochemical study to analyze and compare the nucleotide-binding properties of NBFs of three SUR subtypes, and our results suggest that their different properties may explain, in part, the differential regulation of KATP channel subtypes. The high nucleotide-binding affinities of SUR1 may explain the high ability of SUR1 to stimulate pancreatic K-ATP channels. It is also suggested that the C-terminal 42 amino acids affect the physiological roles of SUR2A and SUR2B by changing the nucleotide-binding properties of their NBFs.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Biochem Lab, Kyoto 6068502, Japan	Kyoto University	Ueda, K (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Biochem Lab, Kyoto 6068502, Japan.	uedak@kais.kyoto-u.ac.jp		Kioka, Noriyuki/0000-0002-2708-537X; Ueda, Kazumitsu/0000-0003-2980-6078				Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; ASHCROFT FM, 1989, J PHYSIOL-LONDON, V416, P349, DOI 10.1113/jphysiol.1989.sp017765; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; Babenko AP, 1999, J BIOL CHEM, V274, P11587, DOI 10.1074/jbc.274.17.11587; Babenko AP, 2000, J BIOL CHEM, V275, P717, DOI 10.1074/jbc.275.2.717; Bear CE, 1997, J BIOENERG BIOMEMBR, V29, P465, DOI 10.1023/A:1022435007193; Beguin P, 1999, EMBO J, V18, P4722, DOI 10.1093/emboj/18.17.4722; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; D'Hahan N, 1999, MOL PHARMACOL, V56, P308, DOI 10.1124/mol.56.2.308; D'hahan N, 1999, P NATL ACAD SCI USA, V96, P12162, DOI 10.1073/pnas.96.21.12162; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gribble FM, 2000, MOL PHARMACOL, V57, P1256; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; Gribble FM, 1998, P NATL ACAD SCI USA, V95, P7185, DOI 10.1073/pnas.95.12.7185; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1997, JPN J PHYSIOL, V47, P11, DOI 10.2170/jjphysiol.47.11; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Matsuo M, 1999, FEBS LETT, V458, P292, DOI 10.1016/S0014-5793(99)01170-9; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Nagata K, 2000, J BIOL CHEM, V275, P17626, DOI 10.1074/jbc.M000792200; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Proks P, 1999, J BIOL CHEM, V274, P25393, DOI 10.1074/jbc.274.36.25393; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; Schwanstecher M, 1998, EMBO J, V17, P5529, DOI 10.1093/emboj/17.19.5529; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; Shindo T, 1998, BRIT J PHARMACOL, V124, P985, DOI 10.1038/sj.bjp.0701927; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; Szabo K, 1999, J BIOL CHEM, V274, P12209, DOI 10.1074/jbc.274.18.12209; Taguchi Y, 1997, FEBS LETT, V401, P11, DOI 10.1016/S0014-5793(96)01421-4; Tanabe K, 2000, BIOCHEM BIOPH RES CO, V272, P316, DOI 10.1006/bbrc.2000.2780; Tanabe K, 1999, J BIOL CHEM, V274, P3931, DOI 10.1074/jbc.274.7.3931; Tanizawa Y, 2000, DIABETES, V49, P114, DOI 10.2337/diabetes.49.1.114; Trapp S, 1997, P NATL ACAD SCI USA, V94, P8872, DOI 10.1073/pnas.94.16.8872; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Ueda K, 1999, BBA-BIOMEMBRANES, V1461, P305, DOI 10.1016/S0005-2736(99)00157-1; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; Uhde I, 1999, J BIOL CHEM, V274, P28079, DOI 10.1074/jbc.274.40.28079; URBATSCH IL, 1995, ARCH BIOCHEM BIOPHYS, V316, P135, DOI 10.1006/abbi.1995.1020; Yamada M, 1997, J PHYSIOL-LONDON, V499, P715, DOI 10.1113/jphysiol.1997.sp021963; Yokoshiki H, 1998, AM J PHYSIOL-CELL PH, V274, pC25, DOI 10.1152/ajpcell.1998.274.1.C25; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	58	114	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28757	28763		10.1074/jbc.M004818200	http://dx.doi.org/10.1074/jbc.M004818200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893240	hybrid			2022-12-25	WOS:000089330700057
J	Quimby, BB; Lamitina, T; L'Hernault, SW; Corbett, AH				Quimby, BB; Lamitina, T; L'Hernault, SW; Corbett, AH			The mechanism of Ran import into the nucleus by nuclear transport factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; CAENORHABDITIS-ELEGANS; PORE COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT; SACCHAROMYCES-CEREVISIAE; GENE ENCODES; FACTOR P10; C-ELEGANS; IN-VIVO; NTF2	The small GTPase Ran is essential for virtually all nucleocytoplasmic transport events. It is hypothesized that Ran drives vectorial transport of macromolecules into and out of the nucleus via the establishment of a Ran gradient between the cytoplasm and nucleoplasm. Although Ran shuttles between the nucleus and cytoplasm, it is concentrated in the nucleus at steady state. We show that nuclear transport factor 2 (NTF2) is required to concentrate Ran in the nucleus in the budding yeast, Saccharomyces cerevisiae. To analyze the mechanism of Ran import into the nucleus by NTF2, we use mutants in a variety of nuclear transport factors along with biochemical analyses of NTF2 complexes. We find that Ran remains concentrated in the nucleus when importin-mediated protein import is disrupted and demonstrate that NTF2 does not form a stable complex with the transport receptor, importin-beta. Consistent with a critical role for NTF2 in establishing and maintaining the Ran gradient, we show that NTP2 is required for early embryogenesis in Caenorhabditis elegans. Our data distinguish between two possible mechanisms for Ran import by NTF2 and demonstrate that Ran import is independent from importin-beta-mediated protein import.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Dept Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Corbett, AH (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd NE, Atlanta, GA 30322 USA.	acorbe2@emory.edu	Corbett, Anita/AAH-6106-2021	Corbett, Anita/0000-0002-0461-6895	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040697, T32GM008367] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM08367, 5F32GMF19681, GMRO1GM40697] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; Ashcroft NR, 1999, DEV BIOL, V206, P15, DOI 10.1006/dbio.1998.9135; Bayliss R, 1999, J MOL BIOL, V293, P579, DOI 10.1006/jmbi.1999.3166; BECKER J, 1995, J BIOL CHEM, V270, P11860, DOI 10.1074/jbc.270.20.11860; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; Boxem M, 1999, DEVELOPMENT, V126, P2227; BRENNER S, 1974, GENETICS, V77, P71; Chaillan-Huntington C, 2000, J BIOL CHEM, V275, P5874, DOI 10.1074/jbc.275.8.5874; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Clarkson WD, 1996, J MOL BIOL, V263, P517, DOI 10.1006/jmbi.1996.0594; Cole CN, 1998, CURR BIOL, V8, pR368, DOI 10.1016/S0960-9822(98)70239-8; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; Corbett AH, 1996, J BIOL CHEM, V271, P18477, DOI 10.1074/jbc.271.31.18477; Feldherr C, 1998, J CELL SCI, V111, P1889; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Guo S, 1996, NATURE, V382, P455, DOI 10.1038/382455a0; Hieda M, 1999, J CELL BIOL, V144, P645, DOI 10.1083/jcb.144.4.645; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; Iborra FJ, 2000, J CELL SCI, V113, P291; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; KAHANA JA, 1995, P NATL ACAD SCI USA, V92, P9707, DOI 10.1073/pnas.92.21.9707; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P4318, DOI 10.1073/pnas.92.10.4318; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Okkema PG, 1997, DEVELOPMENT, V124, P3965; Paschal BM, 1997, J BIOL CHEM, V272, P21534, DOI 10.1074/jbc.272.34.21534; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Percipalle P, 1997, J MOL BIOL, V266, P722, DOI 10.1006/jmbi.1996.0801; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; ROSE MD, 1990, METHODS YEAST GENETI, P145; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Sambrook J., 1989, MOL CLONING, pA1; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Singson A, 1998, CELL, V93, P71, DOI 10.1016/S0092-8674(00)81147-2; Smith A, 1998, CURR BIOL, V8, P1403, DOI 10.1016/S0960-9822(98)00023-2; Steggerda SM, 2000, MOL BIOL CELL, V11, P703, DOI 10.1091/mbc.11.2.703; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wong DH, 1997, MOL CELL BIOL, V17, P3755, DOI 10.1128/MCB.17.7.3755; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416	56	32	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28575	28582		10.1074/jbc.M005055200	http://dx.doi.org/10.1074/jbc.M005055200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10889207	hybrid			2022-12-25	WOS:000089330700034
J	Rohwer, JM; Meadow, ND; Roseman, S; Westerhoff, HV; Postman, PW				Rohwer, JM; Meadow, ND; Roseman, S; Westerhoff, HV; Postman, PW			Understanding glucose transport by the bacterial phosphoenolpyruvate : glycose phosphotransferase system on the basis of kinetic measurements in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOCARRIER PROTEIN-IIIGLC; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; SUGAR-TRANSPORT; ENZYME-I; INDUCER EXCLUSION; FLUORESCENCE ANISOTROPY; CONTROL COEFFICIENTS; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING	The kinetic parameters in vitro of the components of the phosphoenolpyruvate:glycose phosphotransferase system (PTS) in enteric bacteria were collected. To address the issue of whether the behavior in vivo of the PTS can be understood in terms of these enzyme kinetics, a detailed kinetic model was constructed. Each overall phosphotransfer reaction was separated into two elementary reactions, the first entailing association of the phosphoryl donor and acceptor into a complex and the second entailing dissociation of the complex into dephosphorylated donor and phosphorylated acceptor. Literature data on the K-m values and association constants of PTS proteins for their substrates, as well as equilibrium and rate constants for the overall phosphotransfer reactions, were related to the rate constants of the elementary steps in a set of equations; the rate constants could be calculated by solving these equations simultaneously. No kinetic parameters were fitted. As calculated by the model, the kinetic parameter values in vitro could describe experimental results in vivo when varying each of the PTS protein concentrations individually while keeping the other protein concentrations constant. Using the same kinetic constants, but adjusting the protein concentrations in the model to those present in cell-free extracts, the model could reproduce experiments in vitro analyzing the dependence of the flux on the total PTS protein concentration. For modeling conditions in vivo it was crucial that the PTS protein concentrations be implemented at their high in vivo values. The model suggests a new interpretation of results hitherto not understood; in vivo, the major fraction of the PTS proteins may exist as complexes with other PTS proteins or boundary metabolites, whereas in vitro, the fraction of complexed proteins is much smaller.	Univ Stellenbosch, Dept Biochem, ZA-7602 Matieland, South Africa; Univ Amsterdam, BioCentrum, EC Slater Inst, NL-1018 TV Amsterdam, Netherlands; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Vrije Univ Amsterdam, BioCentrum, Inst Mol Biol Sci, NL-1081 HV Amsterdam, Netherlands	Stellenbosch University; University of Amsterdam; Johns Hopkins University; Vrije Universiteit Amsterdam	Rohwer, JM (corresponding author), Univ Stellenbosch, Dept Biochem, Private Bag X1, ZA-7602 Matieland, South Africa.	jr@maties.sun.ac.za	Westerhoff, Hans V/I-5762-2012; Rohwer, Johann/A-2027-2008	Westerhoff, Hans V/0000-0002-0443-6114; Rohwer, Johann/0000-0001-6288-8904				ANDERSON JW, 1991, BIOCHEMISTRY-US, V30, P9601, DOI 10.1021/bi00104a006; BENESKI DA, 1982, J BIOL CHEM, V257, P4492; BOUMA CL, 1987, P NATL ACAD SCI USA, V84, P930, DOI 10.1073/pnas.84.4.930; Briggs GE, 1925, BIOCHEM J, V19, P338, DOI 10.1042/bj0190338; CHAUVIN F, 1994, J BIOL CHEM, V269, P20263; CHAUVIN F, 1994, J BIOL CHEM, V269, P20270; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME; FEESE M, 1994, P NATL ACAD SCI USA, V91, P3544, DOI 10.1073/pnas.91.9.3544; GARNER MM, 1994, AM J PHYSIOL, V266, pC877, DOI 10.1152/ajpcell.1994.266.4.C877; GRENIER FC, 1986, J CELL BIOCHEM, V31, P97, DOI 10.1002/jcb.240310203; HAN MK, 1990, J BIOL CHEM, V265, P1996; HEINRICH R, 1974, EUR J BIOCHEM, V42, P89, DOI 10.1111/j.1432-1033.1974.tb03318.x; HELLINGWERF KJ, 1995, FEMS MICROBIOL REV, V16, P309; Hoch JA, 1995, 2 COMPONENT SIGNAL T; Hogema BM, 1998, MOL MICROBIOL, V30, P487, DOI 10.1046/j.1365-2958.1998.01053.x; HOVING H, 1982, BIOCHEMISTRY-US, V21, P3128, DOI 10.1021/bi00256a015; JABLONSKI EG, 1983, J BIOL CHEM, V258, P9690; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; KHOLODENKO BN, 1995, BIOPHYS CHEM, V56, P215, DOI 10.1016/0301-4622(95)00039-Z; KHOLODENKO BN, 1995, BBA-BIOENERGETICS, V1229, P256, DOI 10.1016/0005-2728(95)00014-A; KHOLODENKO BN, 1995, TRENDS BIOCHEM SCI, V20, P52, DOI 10.1016/S0968-0004(00)88955-0; KODAKI T, 1981, J BIOCHEM-TOKYO, V90, P1437, DOI 10.1093/oxfordjournals.jbchem.a133610; KUKURUZINSKA MA, 1984, J BIOL CHEM, V259, P1679; LENGELER JW, 1994, BBA-BIOENERGETICS, V1188, P1, DOI 10.1016/0005-2728(94)90017-5; LICALSI C, 1991, J BIOL CHEM, V266, P19519; LOLKEMA JS, 1995, BBA-PROTEIN STRUCT M, V1252, P284, DOI 10.1016/0167-4838(95)00112-8; LOWRY OH, 1971, J BIOL CHEM, V246, P6511; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MATTOO RL, 1983, CAN J BIOCHEM CELL B, V61, P29, DOI 10.1139/o83-005; MEADOW ND, 1982, J BIOL CHEM, V257, P4526; Meadow ND, 1996, J BIOL CHEM, V271, P33440, DOI 10.1074/jbc.271.52.33440; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MENDES P, 1996, BIOTHERMOKINETICS LI, P258; MINTON AP, 1983, MOL CELL BIOCHEM, V55, P119, DOI 10.1007/BF00673707; MISSET O, 1983, BIOCHEMISTRY-US, V22, P6163, DOI 10.1021/bi00295a019; MISSET O, 1980, BIOCHEMISTRY-US, V19, P883, DOI 10.1021/bi00546a009; MORIKAWA M, 1980, J BIOCHEM-TOKYO, V87, P441, DOI 10.1093/oxfordjournals.jbchem.a132764; NINFA AJ, 1996, CELLULAR MOL BIOL, V1, P1246; Plumbridge J, 1999, MOL MICROBIOL, V33, P260, DOI 10.1046/j.1365-2958.1999.01462.x; POSTMA PW, 1977, J BACTERIOL, V129, P630, DOI 10.1128/JB.129.2.630-639.1977; POSTMA PW, 1996, CELLULAR MOL BIOL, V1, P1149; REIZER J, 1992, J BIOL CHEM, V267, P9158; ROBILLARD GT, 1988, BIOCHIM BIOPHYS ACTA, V947, P493, DOI 10.1016/0304-4157(88)90005-6; ROHWER J, 1997, THESIS U AMSTERDAM; Rohwer JM, 1998, MOL MICROBIOL, V29, P641, DOI 10.1046/j.1365-2958.1998.00963.x; Rohwer JM, 1998, P NATL ACAD SCI USA, V95, P10547, DOI 10.1073/pnas.95.18.10547; ROHWER JM, 1998, BIOTHERMOKINETICS PO, P340; RUIJTER GJG, 1992, J BACTERIOL, V174, P2843, DOI 10.1128/JB.174.9.2843-2850.1992; RUIJTER GJG, 1991, J BACTERIOL, V173, P6184; SAFFEN DW, 1987, J BIOL CHEM, V262, P16241; SAIER MH, 1980, J BIOL CHEM, V255, P8579; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; SAURO HM, 1993, COMPUT APPL BIOSCI, V9, P441; SCHOLTE BJ, 1981, J BACTERIOL, V148, P257, DOI 10.1128/JB.148.1.257-264.1981; SCHUSTER S, 1992, BIOSYSTEMS, V27, P1, DOI 10.1016/0303-2647(92)90042-W; STOCK JB, 1982, J BIOL CHEM, V257, P4543; VANDAM K, 1993, EUR J BIOCHEM, V212, P791; VANDERVLAG J, 1995, MOL GEN GENET, V248, P236, DOI 10.1007/BF02190806; VANDERVLAG J, 1995, EUR J BIOCHEM, V230, P170; VOGLER AP, 1988, MOL MICROBIOL, V2, P719, DOI 10.1111/j.1365-2958.1988.tb00082.x; WAEBER U, 1993, FEBS LETT, V324, P109, DOI 10.1016/0014-5793(93)81542-8; WAYGOOD EB, 1987, J BACTERIOL, V169, P2810, DOI 10.1128/jb.169.6.2810-2818.1987; WAYGOOD EB, 1980, CAN J BIOCHEM CELL B, V58, P40, DOI 10.1139/o80-006; WEIGEL N, 1982, J BIOL CHEM, V257, P4461; WEIGEL N, 1982, J BIOL CHEM, V257, P4477; WINKLER HH, 1966, J BIOL CHEM, V241, P2200; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331; ZWAIG N, 1970, J BACTERIOL, V102, P753, DOI 10.1128/JB.102.3.753-759.1970	69	98	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34909	34921		10.1074/jbc.M002461200	http://dx.doi.org/10.1074/jbc.M002461200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10889194	Green Published, hybrid			2022-12-25	WOS:000165422800014
J	Friesen, RHE; Knol, J; Poolman, B				Friesen, RHE; Knol, J; Poolman, B			Quaternary structure of the lactose transport protein of Streptococcus thermophilus in the detergent-solubilized and membrane-reconstituted state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PERMEASE; LIPOSOMES; MOLECULES; MONOMER; BINDING; FAMILY; DOMAIN	The quaternary structure of LacS, the lactose transporter of Streptococcus thermophilus, has been determined for the detergent-solubilized and the membrane-reconstituted state of the protein. The quaternary structure of the n-dodecyl-beta -D-maltoside-solubilized state was studied using a combination of sedimentation velocity and equilibrium centrifugation analysis. From these measurements it followed that the detergent-solubilized LacS undergoes reversible self-association with a monomer to dimer mode of association. The association constants were 5.4 +/- 3.6 and 4.4 +/- 1.0 ml mg(-1) as determined from the velocity and equilibrium sedimentation measurements, respectively. The experiments did not indicate significant changes in the shape of the protein-detergent complex or the amount of detergent bound in going from the monomeric to dimeric state of LacS. Importantly, a single Cys mutant of LacS is labeled by 2-(4'-maleimidylanilino)naphthalene-6-sulfonic acid in a substrate-dependent manner, indicating that the detergent-solubilized protein exhibits ligand binding activity. The quaternary structure of membrane-reconstituted LacS was determined by freeze-fracture electron microscopy analysis. Recent developments in the analysis of freeze-fracture images (Eskandari, S, P,, Wright, E, Ri,, Freman, M., Starace, D, M,, and Zampighi, G. A. (1998) Proc. Natl. Acad, Sci, U, S, A. 95, 11235-11240) allowed us to directly correlate the cross-sectional area of the transmembrane segment to a dimeric state of the functionally membrane-reconstituted LacS protein. The cross-sectional area of the LacS protein was calibrated using the membrane-reconstituted transmembrane domain of the mannitol transporter enzyme II, an intramembrane particle for which the cross-sectional area was obtained from maps of two-dimensional crystals. The consequences of the determined quaternary structure for the transport function and regulation of LacS are discussed.	Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands	University of Groningen	Poolman, B (corresponding author), Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Knol, Jan/AAL-6487-2020; Poolman, Bert/D-1882-2012; Knol, Jan/A-2178-2010	Knol, Jan/0000-0002-2103-5961; Knol, Jan/0000-0002-2103-5961				AMBUDKAR SV, 1990, J BIOL CHEM, V265, P12287; AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; ARISAKA F, 1979, J MOL BIOL, V134, P41, DOI 10.1016/0022-2836(79)90413-3; Cann J. R., 1970, INTERACTING MACROMOL; CASASSA EF, 1964, ADV PROTEIN CHEM, V19, P287, DOI 10.1016/S0065-3233(08)60191-6; CHEN CC, 1986, P NATL ACAD SCI USA, V83, P2652, DOI 10.1073/pnas.83.8.2652; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; COSTELLO MJ, 1983, J MICROSC-OXFORD, V125, P125; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; GRASBERGER B, 1986, P NATL ACAD SCI USA, V83, P6258, DOI 10.1073/pnas.83.17.6258; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Knol J, 1998, BIOCHEMISTRY-US, V37, P16410, DOI 10.1021/bi981596u; Knol J, 1996, J BIOL CHEM, V271, P15358, DOI 10.1074/jbc.271.26.15358; Koning RI, 1999, J MOL BIOL, V287, P845, DOI 10.1006/jmbi.1999.2650; Lamm O., 1929, ARK MAT ASTR FYS, V21B, P1; LEACH SJ, 1960, J AM CHEM SOC, V82, P4790, DOI 10.1021/ja01503a008; LEMAIRE M, 1983, BIOCHIM BIOPHYS ACTA, V722, P150, DOI 10.1016/0005-2728(83)90168-8; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9583, DOI 10.1021/bi00104a004; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOLLER JV, 1993, J BIOL CHEM, V268, P18659; NICHOL LW, 1964, PROTEINS; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Poolman B, 1996, MOL MICROBIOL, V19, P911, DOI 10.1046/j.1365-2958.1996.397949.x; Pourcher T, 1996, BIOCHEMISTRY-US, V35, P4161, DOI 10.1021/bi9527496; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; ROARK DE, 1969, ANN NY ACAD SCI, V164, P245, DOI 10.1111/j.1749-6632.1969.tb14043.x; SAHINTOTH M, 1994, P NATL ACAD SCI USA, V91, P5421, DOI 10.1073/pnas.91.12.5421; SCHUBERT D, 1994, PROG COLL POL SCI S, V94, P14; Spooner PJR, 2000, BIOPHYS J, V79, P756, DOI 10.1016/S0006-3495(00)76333-8; Spooner PJR, 1999, BIOCHEMISTRY-US, V38, P9634, DOI 10.1021/bi990745l; TANFORD C, 1974, BIOCHEMISTRY-US, V13, P2369, DOI 10.1021/bi00708a021; Veenhoff LM, 1999, J BIOL CHEM, V274, P33244, DOI 10.1074/jbc.274.47.33244; VERKLEIJ AJ, 1978, BIOCHIM BIOPHYS ACTA, V515, P303, DOI 10.1016/0304-4157(78)90017-5; WAGNER R, 1989, EUR J BIOCHEM, V182, P165, DOI 10.1111/j.1432-1033.1989.tb14813.x; WRIGHT JK, 1983, FEBS LETT, V162, P11; WU JH, 1994, PROTEIN SCI, V3, P2294, DOI 10.1002/pro.5560031214	36	38	38	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33527	33535		10.1074/jbc.M004066200	http://dx.doi.org/10.1074/jbc.M004066200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10921919	Green Published, hybrid			2022-12-25	WOS:000090104600050
J	Hebert, SS; Daviau, A; Grondin, G; Latreille, M; Aubin, RA; Blouin, R				Hebert, SS; Daviau, A; Grondin, G; Latreille, M; Aubin, RA; Blouin, R			The mixed lineage kinase DLK is oligomerized by tissue transglutaminase during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN NH2-TERMINAL KINASE; PROTEIN-KINASE; CALPHOSTIN-C; SIGNAL-TRANSDUCTION; CELL-DEATH; ZPK GENE; MOLECULAR-CLONING; BINDING-PROTEINS; GOLGI-APPARATUS; EMERGING ROLES	Current evidence suggests that the mixed lineage kinase family member dual leucine zipper-bearing kinase (DLK) might play a significant role in the regulation of cell growth and differentiation, particularly during the process of tissue remodeling. To further explore this working model, we have investigated the regulation of host and recombinant DLK in NIH3T3 and COS-1 cells undergoing apoptosis, Using calphostin C, a potent and selective inhibitor of protein kinase C and a recognized apoptosis inducer for various cell types, we demonstrate, by immunoblot analysis, that DLK protein levels are rapidly and dramatically down-regulated during the early phases of apoptosis, Down-regulation in calphostin C-treated cells was also accompanied by the appearance of SDS- and mercaptoethanol-resistant high molecular weight DLK immunoreactive oligomers, Experiments aimed at elucidating the mechanism(s) underlying DLK oligomerization revealed that the tissue transglutaminase (tTG) inhibitor monodansylcadaverine antagonized the effects of calphostin C almost completely, thereby suggesting the involvement of a tTG-catalyzed reaction as the root cause of DLK downregulation and accumulation as high molecular weight species. In support of this notion, we also show that DLK can serve as a substrate for tTG-dependent cross-linking in vitro and that this covalent post-translational modification leads to the functional inactivation of DLK, Taken together, these observations suggest that transglutamination and oligomerization may constitute a relevant physiological mechanism for the regulation of DLK activity.	Univ Sherbrooke, Dept Biol, Fac Sci, Ctr Rech Mecanismes Express Genet, Sherbrooke, PQ J1K 2R1, Canada; Sante Canada, Program Prod Therapeut, Bur Prod Biol & Radiopharmaceut, Div Serv Rech Biotechnol, Ottawa, ON K1A 0L2, Canada	University of Sherbrooke	Blouin, R (corresponding author), Univ Sherbrooke, Dept Biol, Fac Sci, Ctr Rech Mecanismes Express Genet, 2500 Blvd Univ, Sherbrooke, PQ J1K 2R1, Canada.	rblouin@courrier.usherb.ca	Hébert, Sébastien S./Q-2729-2017	Latreille, Mathieu/0000-0001-8542-749X; Hebert, Sebastien/0000-0002-0391-9325				Alonso M, 1998, EUR J CELL BIOL, V76, P93, DOI 10.1016/S0171-9335(98)80021-6; Autuori F, 1998, Adv Biochem Eng Biotechnol, V62, P129, DOI 10.1007/BFb0102308; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bergeron P, 1997, BIOCHEM BIOPH RES CO, V231, P153, DOI 10.1006/bbrc.1997.6073; Blouin R, 1996, DNA CELL BIOL, V15, P631, DOI 10.1089/dna.1996.15.631; BROWN WJ, 1989, METHOD CELL BIOL, V31, P553; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Cockcroft S, 1999, CHEM PHYS LIPIDS, V98, P23, DOI 10.1016/S0009-3084(99)00015-8; CORDELLAMIELE E, 1990, J BIOL CHEM, V265, P17180; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Donaldson JG, 2000, CELL, V101, P693, DOI 10.1016/S0092-8674(00)80881-8; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; Douziech M, 1999, J HISTOCHEM CYTOCHEM, V47, P1287, DOI 10.1177/002215549904701008; Douziech M, 1998, BIOCHEM BIOPH RES CO, V249, P927, DOI 10.1006/bbrc.1998.9249; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; EZOE K, 1994, ONCOGENE, V9, P935; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GERMAIN L, 2000, IN PRESS J INVEST DE; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GORDGE PC, 1994, CELL SIGNAL, V6, P871, DOI 10.1016/0898-6568(94)90020-5; Hirai S, 1996, ONCOGENE, V12, P641; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; IKEMOTO H, 1995, J NEUROSURG, V83, P1008, DOI 10.3171/jns.1995.83.6.1008; ING YL, 1994, ONCOGENE, V9, P1745; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jarpe MB, 1998, ONCOGENE, V17, P1475, DOI 10.1038/sj.onc.1202183; KATOH M, 1995, ONCOGENE, V10, P1447; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Matsui N, 1996, BIOCHEM BIOPH RES CO, V229, P571, DOI 10.1006/bbrc.1996.1845; Mayne GC, 1998, J BIOL CHEM, V273, P24115, DOI 10.1074/jbc.273.37.24115; Melino G, 1998, FEBS LETT, V430, P59, DOI 10.1016/S0014-5793(98)00521-3; Melino G, 1997, EXP CELL RES, V235, P55, DOI 10.1006/excr.1997.3656; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; Nadeau A, 1997, J HISTOCHEM CYTOCHEM, V45, P107, DOI 10.1177/002215549704500114; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Oliverio S, 1999, J BIOL CHEM, V274, P34123, DOI 10.1074/jbc.274.48.34123; Ozaki I, 1999, J BIOL CHEM, V274, P5310, DOI 10.1074/jbc.274.9.5310; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Piredda L, 1999, FASEB J, V13, P355, DOI 10.1096/fasebj.13.2.355; Pollack IF, 1997, J NEURO-ONCOL, V31, P255, DOI 10.1023/A:1005729626354; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Rasmussen RK, 1998, BIOCHEM J, V335, P119, DOI 10.1042/bj3350119; Reddy UR, 1999, ONCOGENE, V18, P4474, DOI 10.1038/sj.onc.1202813; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Thomazy VA, 1999, CELL DEATH DIFFER, V6, P146, DOI 10.1038/sj.cdd.4400464; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Zhang HF, 1999, EXP CELL RES, V247, P133, DOI 10.1006/excr.1998.4329; Zhu DM, 1998, CLIN CANCER RES, V4, P2967	63	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32482	32490		10.1074/jbc.M006528200	http://dx.doi.org/10.1074/jbc.M006528200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10922377	hybrid			2022-12-25	WOS:000090003800016
J	Keyhani, NO; Wang, LX; Lee, YC; Roseman, S				Keyhani, NO; Wang, LX; Lee, YC; Roseman, S			The chitin disaccharide, N,N '-diacetylchitobiose, is catabolized by Escherichia coli and is transported/phosphorylated by the Phosphoenolpyruvate : Glycose phosphotransferase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIUM VIBRIO-FURNISSII; MARINE-BACTERIA; MOLECULAR-CLONING; SUGAR-TRANSPORT; PROTEIN FAMILY; HUMAN SERUM; CEL OPERON; SEQUENCE; OLIGOSACCHARIDES; CHITOTRIOSIDASE	We have previously reported that wild type strains of Escherichia coli grow on the chitin disaccharide N,N'-diacetylchitobiose, (GlcNAc)(2), as the sole source of carbon (Keyhani, N. O., and Roseman, S. (1997) Proc. Natl. Acad Sci., U.S. A. 94, 14367-14371). A nonhydrolyzable analogue of (GlcNAc)(2), methyl beta -N, N'-[H-3]diacetyl-thiochitobioside ([H-3]Me-TCB), was used to characterize the disaccharide transport process, which was found to be mediated by the phosphoenolpyruvate:glycose phosphotransferase system (PTS). Here and in the accompanying papers (Keyhani, N. O., Boudker, O., and Roseman, S. (2000) J. Biol. Chem. 275, 33091-33101; Keyhani, N. O., Bacia, K., and Roseman, S. (2000) J. Biol. Chem. 275, 33102-33109; Keyhani, N. O., Rodgers, M., Demeler, B., Hansen, J., and Roseman, S. (2000) J. Biol. Chem. 275, 33110-33115), we report that transport of [H-3]Me-TCB and (GlcNAc), involves a specific PTS Enzyme II complex, requires Enzyme I and HPr of the PTS, and results in the accumulation of the sugar derivative as a phosphate ester. The phosphoryl group is linked to the C-6 position of the GlcNAc residue at the nonreducing end of the disaccharide. The [H-3]Me-TCB uptake system was induced only by (GlcNAc)(n), n = 2 or 3. The apparent K-m of transport was 50-100 muM, and effective inhibitors of uptake included (GlcNAc),, n = 2 or 3, cellobiose, and other PTS sugars, ie. glucose and GlcNAc. Presumably the PTS sugars inhibit by competing for PTS components. Kinetic properties of the transport system are described.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Roseman, S (corresponding author), Johns Hopkins Univ, Dept Biol, Mudd Hall,Rm 214,3400 N Charles St, Baltimore, MD 21218 USA.		Keyhani, Nemat O/I-8150-2013; Wang, Lai-Xi/E-8790-2019; Wang, Lai-Xi/E-8755-2019; wang, xl/Y-8251-2019	Wang, Lai-Xi/0000-0003-4293-5819; 	NIDDK NIH HHS [DK 009970] Funding Source: Medline; NIGMS NIH HHS [GM38759] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK009970, R01DK009970] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038759, R01GM038759] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASSLER BL, 1991, J BIOL CHEM, V266, P24268; BASSLER BL, 1991, J BIOL CHEM, V266, P24276; BERLIN WK, 1995, TRENDS GLYCOSCI GLYC, V7, P101; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOOT RG, 1995, J BIOL CHEM, V270, P26252, DOI 10.1074/jbc.270.44.26252; Bouma CL, 1996, J BIOL CHEM, V271, P33457, DOI 10.1074/jbc.271.52.33457; Bouma CL, 1996, J BIOL CHEM, V271, P33468, DOI 10.1074/jbc.271.52.33468; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; ESCOTT GM, 1995, INFECT IMMUN, V63, P4770, DOI 10.1128/IAI.63.12.4770-4773.1995; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; HOROWITZ ST, 1957, J AM CHEM SOC, V79, P5046, DOI 10.1021/ja01575a059; Hu B, 1996, J BIOL CHEM, V271, P19415, DOI 10.1074/jbc.271.32.19415; JEUNIAUX C, 1961, NATURE, V192, P135, DOI 10.1038/192135a0; Keyhani N, 2000, J BIOL CHEM, V275, P33110, DOI 10.1074/jbc.M001717200; Keyhani NO, 2000, J BIOL CHEM, V275, P33102, DOI 10.1074/jbc.M001045200; Keyhani NO, 2000, J BIOL CHEM, V275, P33091, DOI 10.1074/jbc.M001044200; Keyhani NO, 2000, J BIOL CHEM, V275, P33068, DOI 10.1074/jbc.M001041200; Keyhani NO, 1996, J BIOL CHEM, V271, P33409, DOI 10.1074/jbc.271.52.33409; Keyhani NO, 1997, P NATL ACAD SCI USA, V94, P14367, DOI 10.1073/pnas.94.26.14367; KRANTZ MJ, 1976, ANAL BIOCHEM, V71, P318, DOI 10.1016/0003-2697(76)90044-0; KRICKER M, 1987, GENETICS, V115, P419; LAI XK, 1993, J BACTERIOL, V175, P6441, DOI 10.1128/jb.175.20.6441-6450.1993; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBLAD G, 1979, EUR J BIOCHEM, V100, P455, DOI 10.1111/j.1432-1033.1979.tb04188.x; OVERDIJK B, 1994, GLYCOBIOLOGY, V4, P797, DOI 10.1093/glycob/4.6.797; PALUH JL, 1986, NUCLEIC ACIDS RES, V14, P7851, DOI 10.1093/nar/14.20.7851; Park JK, 2000, J BIOL CHEM, V275, P33077, DOI 10.1074/jbc.M001042200; PARKER LL, 1990, GENETICS, V124, P455; RENKEMA GH, 1995, J BIOL CHEM, V270, P2198, DOI 10.1074/jbc.270.5.2198; Segel IH, 1976, BIOCH CALCULATIONS, P214; Thompson J, 1999, J BACTERIOL, V181, P7339, DOI 10.1128/JB.181.23.7339-7345.1999; WAYGOOD EB, 1979, ANAL BIOCHEM, V95, P293, DOI 10.1016/0003-2697(79)90219-7; YU C, 1993, J BIOL CHEM, V268, P9405; YU C, 1991, J BIOL CHEM, V266, P24260	34	44	48	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33084	33090		10.1074/jbc.M001043200	http://dx.doi.org/10.1074/jbc.M001043200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913117	hybrid			2022-12-25	WOS:000090003800096
J	Raddatz, R; Wilson, AE; Artymyshyn, R; Bonini, JA; Borowsky, B; Boteju, LW; Zhou, SQ; Kouranova, EV; Nagorny, R; Guevarra, MS; Dai, M; Lerman, GS; Vaysse, PJ; Branchek, TA; Gerald, C; Forray, C; Adham, N				Raddatz, R; Wilson, AE; Artymyshyn, R; Bonini, JA; Borowsky, B; Boteju, LW; Zhou, SQ; Kouranova, EV; Nagorny, R; Guevarra, MS; Dai, M; Lerman, GS; Vaysse, PJ; Branchek, TA; Gerald, C; Forray, C; Adham, N			Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SPINAL-CORD; XENOPUS OOCYTES; GASTROINTESTINAL-TRACT; SEROTONIN RECEPTORS; RAT; IMMUNOREACTIVITY; PRECURSOR; CLONING; GALANIN; BRAIN	Two structurally related, G-protein-coupled receptors were identified as receptors for the neuropeptide, neuromedin U, This peptide is found in highest levels in the gut and genitourinary system where it potently contracts smooth muscle but is also expressed in the spinal cord and discrete regions of the brain. Binding sites for neuromedin U have been characterized in rat uterus, however, little is known about the activity of this peptide in the regions of the central nervous system where it is expressed. The receptors characterized in this report are activated by neuromedin U at nanomolar potency in heterologous expression systems and bind radiolabeled neuromedin U with high affinity. Localization of the receptor RNA by quantitative reverse transcription-polymerase chain reaction in a variety of human tissues shows distinct expression patterns for the two receptors, NMU1 is expressed predominantly in peripheral tissues, whereas NMU2 is more highly expressed in the central nervous system. Identification of neuromedin U receptor subtypes will greatly aid in the determination of the physiological roles of this peptide.	Synapt Pharmaceut Corp, Paramus, NJ 07652 USA		Raddatz, R (corresponding author), Synapt Pharmaceut Corp, 215 Coll Rd, Paramus, NJ 07652 USA.		Adham, Nika/N-4376-2017	Adham, Nika/0000-0002-2773-2522				AUSTIN C, 1995, J MOL ENDOCRINOL, V14, P157, DOI 10.1677/jme.0.0140157; BALLESTA J, 1988, NEUROSCIENCE, V25, P797, DOI 10.1016/0306-4522(88)90037-1; BENITOORFILA MA, 1991, EUR J PHARMACOL, V193, P329, DOI 10.1016/0014-2999(91)90147-I; BROWN DR, 1988, EUR J PHARMACOL, V155, P159, DOI 10.1016/0014-2999(88)90415-3; CIMINI V, 1993, CELL TISSUE RES, V272, P137, DOI 10.1007/BF00323579; DOMIN J, 1989, J BIOL CHEM, V264, P20881; DOMIN J, 1990, CELL TISSUE RES, V260, P131, DOI 10.1007/BF00297498; DOMIN J, 1987, PEPTIDES, V8, P779, DOI 10.1016/0196-9781(87)90058-1; Fujii R, 2000, J BIOL CHEM, V275, P21068, DOI 10.1074/jbc.M001546200; GARDINER SM, 1990, AM J PHYSIOL, V258, pR32, DOI 10.1152/ajpregu.1990.258.1.R32; GUNDERSEN CB, 1983, PROC R SOC SER B-BIO, V219, P103, DOI 10.1098/rspb.1983.0062; HASHIMOTO T, 1991, CHEM PHARM BULL, V39, P2319; HONZAWA M, 1987, NEUROSCIENCE, V23, P1103, DOI 10.1016/0306-4522(87)90185-0; LO G, 1992, MOL ENDOCRINOL, V6, P1538, DOI 10.1210/me.6.10.1538; MAGGI CA, 1990, BRIT J PHARMACOL, V99, P186, DOI 10.1111/j.1476-5381.1990.tb14675.x; MALENDOWICZ LK, 1994, HISTOL HISTOPATHOL, V9, P591; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MINAMINO N, 1985, PEPTIDES, V6, P245, DOI 10.1016/0196-9781(85)90381-X; MINAMINO N, 1985, BIOCHEM BIOPH RES CO, V130, P1078, DOI 10.1016/0006-291X(85)91726-7; NANDHA KA, 1993, BIOMED RES-TOKYO, V14, P71; NANDHA KA, 1993, ENDOCRINOLOGY, V133, P482, DOI 10.1210/en.133.2.482; QUICK MW, 1994, METH NEUROSCI, V19, P261; SAKURA N, 1991, CHEM PHARM BULL, V39, P2016; Smith KE, 1997, J BIOL CHEM, V272, P24612, DOI 10.1074/jbc.272.39.24612; STEEL JH, 1988, ENDOCRINOLOGY, V122, P270, DOI 10.1210/endo-122-1-270; SUMI S, 1987, LIFE SCI, V41, P1585, DOI 10.1016/0024-3205(87)90725-9; Szekeres PG, 2000, J BIOL CHEM, V275, P20247, DOI 10.1074/jbc.C000244200; TAKAHASHI T, 1987, P NATL ACAD SCI USA, V84, P5063, DOI 10.1073/pnas.84.14.5063	28	164	182	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32452	32459		10.1074/jbc.M004613200	http://dx.doi.org/10.1074/jbc.M004613200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10899166	hybrid			2022-12-25	WOS:000090003800012
J	Park, OK; Schaefer, LK; Wang, WL; Schaefer, TS				Park, OK; Schaefer, LK; Wang, WL; Schaefer, TS			Dimer stability as a determinant of differential DNA binding activity of Stat3 isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVITY; CONSTITUTIVE ACTIVATION; SIGNAL TRANSDUCERS; CELLS; INTERFERON; RECEPTOR; PROTEIN; SRC; TRANSFORMATION; CYTOKINES	Stat3 alpha and Stat3 beta are two Stat3 isoforms with marked quantitative differences in their DNA binding activities. To examine the molecular basis of the differential DNA binding activities, we measured DNA binding strength and dimer stability, two possible mechanisms responsible for these differences. Stat3 alpha and Stat3 beta showed no difference in DNA binding strength, i.e. they had similar association and dissociation rates for DNA binding However, competition analyses performed with dissociating reagents including an anti-phosphotyrosine antibody, SH2 domain protein, and a phosphopeptide demonstrated that Stat3 beta dimers are more stable than Stat3 alpha dimers. We report here that dimer stability of activated forms plays a critical role in determining DNA binding activity of Stat3 isoforms. We found that C-terminal deletions of Stat3 alpha increased both DNA binding activity and dimer stability of Stat3 alpha. Our findings suggest that the acidic C-terminal region of Stat3 alpha does not interfere with the DNA binding of activated Stat3 alpha dimers, but destabilizes the dimeric forms of Stat3 alpha. We propose that dimer stability described in vitro may be the underlying mechanism of in vivo stability of activated Stat3 proteins, regulating dephosphorylation of tyrosine 705.	KLESL, Kumho Life & Environm Sci Lab, Puk Gu, Kwangju 500480, South Korea; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; AI duPont Hosp Children, Dept Clin & Med Sci, Wilmington, DE 19803 USA	University of Texas System; UTMD Anderson Cancer Center; Nemours Alfred I. duPont Hospital for Children	Park, OK (corresponding author), KLESL, Kumho Life & Environm Sci Lab, Puk Gu, 1 Oryong Dong, Kwangju 500480, South Korea.							ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ihle JN, 1998, ANN NY ACAD SCI, V865, P1, DOI 10.1111/j.1749-6632.1998.tb11157.x; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; IVASHKIV LB, 1995, IMMUNITY, V3, P1, DOI 10.1016/1074-7613(95)90152-3; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Ni Z, 2000, CANCER RES, V60, P1225; Niu GL, 1999, CANCER RES, V59, P5059; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; Schaefer LK, 1999, BIOCHEM BIOPH RES CO, V266, P481, DOI 10.1006/bbrc.1999.1853; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Shuai K, 1996, MOL CELL BIOL, V16, P4932; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Strehlow I, 1998, J BIOL CHEM, V273, P28049, DOI 10.1074/jbc.273.43.28049; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Xia Z, 1998, CANCER RES, V58, P3173; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang XK, 1999, MOL CELL BIOL, V19, P7138	36	44	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32244	32249		10.1074/jbc.M005082200	http://dx.doi.org/10.1074/jbc.M005082200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10915797	hybrid			2022-12-25	WOS:000089858900095
J	Sargueil, B; McKenna, J; Burke, JM				Sargueil, B; McKenna, J; Burke, JM			Analysis of the functional role of a G center dot A sheared base pair by in vitro genetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOZYME-SUBSTRATE COMPLEX; TERTIARY STRUCTURE FORMATION; RINGSPOT VIRUS SATELLITE; YELLOW MOTTLE VIRUS; HAIRPIN RIBOZYME; HAMMERHEAD RIBOZYME; IN-VITRO; JUNCTION CONFORMATION; SECONDARY STRUCTURE; EFFICIENT CLEAVAGE	A classical genetic strategy has been combined with an in vitro selection method to search for functional interactions between the two domains of the hairpin ribozyme, G(21) is located within internal loop B; it is proposed to form a sheared base pair with A(43) across loop B and to bind a Mg2+ ion, Both nucleotides are important for ribozyme function, and G.A sheared base pairs are a very widespread motif in structured RNA. We took advantage of its presence in the hairpin ribozyme to study its functional role. Pseudorevertants, in which the loss of G(21) was compensated by mutations at other positions, were isolated by in vitro selection. The vast majority of G(21) revertants contained substitutions within domain A, pointing to functional communication between specific sites within the two domains of the hairpin ribozyme. The possibility of a direct or redundant contacts is supported by electrophoretic mobility shift studies showing that a complex formed between domain B of the ribozyme and the substrate was disrupted and restored by base substitutions that have analogous effects on catalytic activity. The functional significance of this complex, the role of the nucleotides involved, and the basis for magnesium ion requirement is discussed.	CNRS, Ctr Genet Mol, F-91190 Gif Sur Yvette, France; Univ Vermont, Dept Microbiol & Mol Genet, Markey Ctr Mol Genet, Burlington, VT 05405 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Vermont	Sargueil, B (corresponding author), CNRS, Ctr Genet Mol, Ave Terrasse, F-91190 Gif Sur Yvette, France.	sargueil@smigiris.cgm.cnrs-gif.fr	, John/AAB-5945-2021	sargueil, bruno/0000-0003-4483-355X				ANDERSON P, 1994, NUCLEIC ACIDS RES, V22, P1096, DOI 10.1093/nar/22.6.1096; Been MD, 1997, EUR J BIOCHEM, V247, P741, DOI 10.1111/j.1432-1033.1997.00741.x; BERZALHERRANZ A, 1992, GENE DEV, V6, P129, DOI 10.1101/gad.6.1.129; BERZALHERRANZ A, 1993, EMBO J, V12, P2567, DOI 10.1002/j.1460-2075.1993.tb05912.x; BURKE JM, 1996, NUCL ACIDS MOL BIOL, V10, P129; BUTCHER SE, 1994, BIOCHEMISTRY-US, V33, P992, DOI 10.1021/bi00170a018; BUTCHER SE, 1994, J MOL BIOL, V244, P52, DOI 10.1006/jmbi.1994.1703; BUTCHER SE, 1995, J BIOL CHEM, V270, P29648; Butcher SE, 2000, BIOCHEMISTRY-US, V39, P2174, DOI 10.1021/bi9923454; Butcher SE, 1999, NAT STRUCT BIOL, V6, P212; Cai ZP, 1996, BIOCHEMISTRY-US, V35, P6026, DOI 10.1021/bi952985g; CHOWRIRA BM, 1992, NUCLEIC ACIDS RES, V20, P2835, DOI 10.1093/nar/20.11.2835; DEYOUNG MB, 1995, BIOCHEMISTRY-US, V34, P15785, DOI 10.1021/bi00048a024; Earnshaw DJ, 1997, J MOL BIOL, V274, P197, DOI 10.1006/jmbi.1997.1405; Esteban JA, 1998, P NATL ACAD SCI USA, V95, P6091, DOI 10.1073/pnas.95.11.6091; Esteban JA, 1997, J BIOL CHEM, V272, P13629, DOI 10.1074/jbc.272.21.13629; Fedor MJ, 2000, J MOL BIOL, V297, P269, DOI 10.1006/jmbi.2000.3560; FEDOR MJ, 1990, P NATL ACAD SCI USA, V87, P1668, DOI 10.1073/pnas.87.5.1668; Feig A. L., 1999, RNA WORLD, P287; FELDSTEIN PA, 1993, NUCLEIC ACIDS RES, V21, P1991, DOI 10.1093/nar/21.8.1991; FU DJ, 1993, BIOCHEMISTRY-US, V32, P10629, DOI 10.1021/bi00091a013; FU DJ, 1992, BIOCHEMISTRY-US, V31, P10941, DOI 10.1021/bi00160a001; GRASBY JA, 1995, BIOCHEMISTRY-US, V34, P4068, DOI 10.1021/bi00012a025; GREEN R, 1991, Methods (Orlando), V2, P75, DOI 10.1016/S1046-2023(05)80127-6; HAMPEL A, 1990, NUCLEIC ACIDS RES, V18, P299, DOI 10.1093/nar/18.2.299; Hampel A, 1997, CHEM BIOL, V4, P513, DOI 10.1016/S1074-5521(97)90323-9; Hampel KJ, 1998, BIOCHEMISTRY-US, V37, P14672, DOI 10.1021/bi981083n; JOSEPH S, 1993, J BIOL CHEM, V268, P24515; JOSEPH S, 1993, GENE DEV, V7, P130, DOI 10.1101/gad.7.1.130; KOMATSU Y, 1995, J MOL BIOL, V252, P296, DOI 10.1006/jmbi.1995.0497; Leontis NB, 1998, RNA, V4, P1134, DOI 10.1017/S1355838298980566; MCKAY DB, 1999, RNA WORLD, P265; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Murchie AIH, 1998, MOL CELL, V1, P873, DOI 10.1016/S1097-2765(00)80086-6; Murray JB, 2000, MOL CELL, V5, P279, DOI 10.1016/S1097-2765(00)80423-2; Murray JB, 1998, CHEM BIOL, V5, P587, DOI 10.1016/S1074-5521(98)90116-8; Nesbitt S, 1997, CHEM BIOL, V4, P619, DOI 10.1016/S1074-5521(97)90247-7; Nesbitt SM, 1999, J MOL BIOL, V286, P1009, DOI 10.1006/jmbi.1999.2543; Pinard R, 1999, J MOL BIOL, V287, P239, DOI 10.1006/jmbi.1999.2626; Pinard R, 1999, BIOCHEMISTRY-US, V38, P16035, DOI 10.1021/bi992024s; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; Rastogi T, 1998, J MOL BIOL, V277, P215, DOI 10.1006/jmbi.1997.1623; RUBINO L, 1990, J GEN VIROL, V71, P1897, DOI 10.1099/0022-1317-71-9-1897; Ryder SP, 1999, J MOL BIOL, V291, P295, DOI 10.1006/jmbi.1999.2959; SANTALUCIA J, 1993, BIOCHEMISTRY-US, V32, P12612, DOI 10.1021/bi00210a009; SANTALUCIA J, 1992, SCIENCE, V256, P217, DOI 10.1126/science.1373521; SARGUEIL B, 1995, BIOCHEMISTRY-US, V34, P7739, DOI 10.1021/bi00023a021; Sargueil B, 1997, Methods Mol Biol, V74, P289; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; Schmidt S, 1996, NUCLEIC ACIDS RES, V24, P573, DOI 10.1093/nar/24.4.573; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; Siwkowski A, 1998, BIOTECHNIQUES, V24, P278, DOI 10.2144/98242st05; Siwkowski A, 1997, BIOCHEMISTRY-US, V36, P3930, DOI 10.1021/bi9628735; SZEWCZAK AA, 1993, P NATL ACAD SCI USA, V90, P9581, DOI 10.1073/pnas.90.20.9581; Thomson JB, 1999, RNA, V5, P180, DOI 10.1017/S1355838299981670; WALTER AE, 1994, BIOCHEMISTRY-US, V33, P11349, DOI 10.1021/bi00203a033; Walter F, 1998, BIOCHEMISTRY-US, V37, P14195, DOI 10.1021/bi981513+; Walter F, 1998, BIOCHEMISTRY-US, V37, P17629, DOI 10.1021/bi9821115; Walter NG, 1998, CURR OPIN CHEM BIOL, V2, P24, DOI 10.1016/S1367-5931(98)80032-X; Walter NG, 1997, RNA, V3, P392; Walter NG, 1998, EMBO J, V17, P2378, DOI 10.1093/emboj/17.8.2378; Walter NG, 2000, J MOL BIOL, V298, P539, DOI 10.1006/jmbi.2000.3691; Wang SL, 1999, BIOCHEMISTRY-US, V38, P14363, DOI 10.1021/bi9913202; WIMBERLY B, 1994, NAT STRUCT BIOL, V1, P820, DOI 10.1038/nsb1194-820; WIMBERLY B, 1993, BIOCHEMISTRY-US, V32, P1078, DOI 10.1021/bi00055a013; Young KJ, 1999, J MOL BIOL, V288, P853, DOI 10.1006/jmbi.1999.2748; Young KJ, 1997, NUCLEIC ACIDS RES, V25, P3760, DOI 10.1093/nar/25.19.3760	68	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32157	32166		10.1074/jbc.M005591200	http://dx.doi.org/10.1074/jbc.M005591200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10906144	hybrid			2022-12-25	WOS:000089858900083
J	Guerini, D; Zecca-Mazza, A; Carafoli, E				Guerini, D; Zecca-Mazza, A; Carafoli, E			Single amino acid mutations in transmembrane domain 5 confer to the plasma membrane Ca2+ pump properties typical of the Ca2+ pump of endo(sarco)plasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SARCOPLASMIC-RETICULUM; FUNCTIONAL DOMAINS; CA-2+ PUMP; ENDOPLASMIC-RETICULUM; CALCIUM-PUMP; CA2+-ATPASE; EXPRESSION; MECHANISM; ATPASE	Conserved residues in some of the transmembrane domains are proposed to mediate ion translocation by P-type pumps. The plasma membrane Ca2+ pump (PMCA) lacks 2 of these residues in transmembrane domains (TM) 5 and 8, In particular, a glutamic acid (Glu-771) residue in TM5, which is proposed to be involved in the binding and transport of Ca2+ by the sarcoplasmic reticulum Ca2+ pump (SERCA), is replaced by an alanine (Ala-854) in the PMCA pump. Ala-854 has been mutated to Glu, Asp, or Gin; Glu-975 in TM8, which is an Ala in the SERCA pump, has been mutated to Gin, Asp, or Ala, The mutants have been expressed in three cell systems, with or without the help of viruses. When expressed in large amounts in Sf9 cells, the mutated pumps were isolated and analyzed in the purified state. Two of the three TM8 mutants were correctly delivered to the plasma membrane and were active. AU the TM5 mutants were retained in the endoplasmic reticulum; two of them (A854Q and A854E) retained activity. Their properties (La3+ sensitivity and decay of the phosphorylated intermediate, higher cooperativity of Ca2+ binding with a Hill's coefficient approaching 2) differed from those of the expressed wild type PMCA pump, and resembled those of the SERCA pump.	Univ Padua, Dept Biochem, I-35121 Padua, Italy; Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland	University of Padua; Swiss Federal Institutes of Technology Domain; ETH Zurich	Carafoli, E (corresponding author), Univ Padua, Dept Biochem, I-35121 Padua, Italy.	carafoli@civ.bio.unipd.it	Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094	Telethon [963] Funding Source: Medline	Telethon(Fondazione Telethon)		ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; ADAMO HP, 1992, J BIOL CHEM, V267, P14244; ADEBAYO AO, 1995, J BIOL CHEM, V270, P27812, DOI 10.1074/jbc.270.46.27812; ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; CARAFOLI E, 1994, J NEUROBIOL, V25, P312, DOI 10.1002/neu.480250311; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FOLETTI D, 1995, FASEB J, V9, P670, DOI 10.1096/fasebj.9.8.7768360; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GARRAHAN PJ, 1978, BIOCHIM BIOPHYS ACTA, V513, P59, DOI 10.1016/0005-2736(78)90111-6; Guerini D, 1998, ACTA PHYSIOL SCAND, V163, P265; Guerini D, 1996, BIOCHEMISTRY-US, V35, P3290, DOI 10.1021/bi952572f; Guerini D, 1999, CALCIUM AS A CELLULAR REGULATOR, P249; HAO LN, 1994, J BIOL CHEM, V269, P14268; HEIM R, 1992, J BIOL CHEM, V267, P24476; Herscher CJ, 1997, ANN NY ACAD SCI, V834, P407, DOI 10.1111/j.1749-6632.1997.tb52284.x; Herscher CJ, 1996, BIOCHEMISTRY-US, V35, P14917, DOI 10.1021/bi961879r; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1992, ANN NY ACAD SCI, V671, P32, DOI 10.1111/j.1749-6632.1992.tb43782.x; JAMES P, 1988, J BIOL CHEM, V263, P2905; JAMES P, 1987, BIOCHEM BIOPH RES CO, V149, P7, DOI 10.1016/0006-291X(87)91597-X; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; NIGGLI V, 1982, J BIOL CHEM, V257, P2350; NIGGLI V, 1981, J BIOL CHEM, V256, P395; NIGGLI V, 1979, J BIOL CHEM, V254, P9955; SCHATZMANN HJ, 1966, EXPERIENTIA, V22, P364, DOI 10.1007/BF01901136; SCOFANO HM, 1981, J BIOL CHEM, V256, P4282; Seiz Preiano Brigitta, 1996, Biochemistry, V35, P7946, DOI 10.1021/bi9527404; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; SUISSA M, 1983, ANAL BIOCHEM, V133, P511, DOI 10.1016/0003-2697(83)90117-3; SUMMERS MD, 1988, TEXAS AGR EXP STN B, V1555; VERMA AK, 1988, J BIOL CHEM, V263, P14152; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959; ZVARITCH E, 1995, J BIOL CHEM, V270, P2679, DOI 10.1074/jbc.270.6.2679	41	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31361	31368		10.1074/jbc.M003474200	http://dx.doi.org/10.1074/jbc.M003474200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10899160	hybrid			2022-12-25	WOS:000089762700087
J	Thuveson, M; Fries, E				Thuveson, M; Fries, E			The low pH in trans-Golgi triggers autocatalytic cleavage of pre-alpha-inhibitor heavy chain precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY CROSS-LINKS; AMINO-ACID-SEQUENCE; TRYPSIN-INHIBITOR; SECRETORY PROTEINS; RAT HEPATOCYTES; ACIDIFICATION; BIKUNIN; CELLS; BIOSYNTHESIS; PROPEPTIDE	Pre-alpha-inhibitor is a plasma protein whose physiological function is still unknown, but in vitro studies suggest that it might be involved in inflammatory reactions. Pre-alpha-inhibitor consists of a 25- and a 75-kDa polypeptide: bikunin and heavy chain 3 (H3), respectively. H3 is synthesized with a 30-kDa C-terminal extension, which is released in the Golgi complex through cleavage between an Asp and a Pro residue. We now provide evidence that this cleavage is triggered by the low pH in the late Golgi and occurs through an intramolecular process. First, incubation in vitro of the H3 precursor (proH3) at pH 6.0 or lower results in rapid cleavage of the protein. Second, the rate of the cleavage reaction does not depend on the concentration of proH3 and is not affected by the presence of various protease inhibitors. Third, raising the pH in organelles of cells producing proH3 abolishes cleavage during secretion. The amino acid residues near the cleavage site of proH3 differ from those of previously described self-cleaving proteins, indicating that the mechanisms of scission are different.	Agr Univ Sweden, Biomed Ctr, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	Swedish University of Agricultural Sciences	Thuveson, M (corresponding author), Agr Univ Sweden, Biomed Ctr, Dept Vet Med Chem, S-75123 Uppsala, Sweden.							Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; Blom AM, 1997, BIOCHEM J, V328, P185; BOURGUIGNON J, 1993, EUR J BIOCHEM, V212, P771, DOI 10.1111/j.1432-1033.1993.tb17717.x; CHAN P, 1995, BIOCHEM J, V306, P505, DOI 10.1042/bj3060505; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; FRIES E, 1984, EMBO J, V3, P147, DOI 10.1002/j.1460-2075.1984.tb01775.x; GEBHARD W, 1989, EUR J BIOCHEM, V181, P571, DOI 10.1111/j.1432-1033.1989.tb14762.x; HALBAN PA, 1994, BIOCHEM J, V299, P1; Hui N, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P46; Landon, 1977, Methods Enzymol, V47, P145; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Martin-Vandelet N, 1999, EUR J BIOCHEM, V259, P476, DOI 10.1046/j.1432-1327.1999.00067.x; MELLMAN I, 1992, J EXP BIOL, V172, P39; MORELLE W, 1994, EUR J BIOCHEM, V221, P881, DOI 10.1111/j.1432-1033.1994.tb18803.x; ODA K, 1986, BIOCHEM J, V240, P739, DOI 10.1042/bj2400739; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; PISZKIEW.D, 1970, BIOCHEM BIOPH RES CO, V40, P1173, DOI 10.1016/0006-291X(70)90918-6; Salier JP, 1996, BIOCHEM J, V315, P1, DOI 10.1042/bj3150001; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SJOBERG EM, 1992, ARCH BIOCHEM BIOPHYS, V295, P217, DOI 10.1016/0003-9861(92)90509-U; THOGERSEN IB, 1995, J BIOL CHEM, V270, P18700; Thuveson M, 1999, J BIOL CHEM, V274, P6741, DOI 10.1074/jbc.274.10.6741; VETR H, 1990, BIOL CHEM H-S, V371, P1185, DOI 10.1515/bchm3.1990.371.2.1185; WISNIEWSKI HG, 1994, BIOCHEMISTRY-US, V33, P7423, DOI 10.1021/bi00189a049; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657	28	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30996	31000		10.1074/jbc.M002399200	http://dx.doi.org/10.1074/jbc.M002399200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10893227	hybrid			2022-12-25	WOS:000089762700038
J	Leibiger, B; Wahlander, K; Berggren, PO; Leibiger, IB				Leibiger, B; Wahlander, K; Berggren, PO; Leibiger, IB			Glucose-stimulated insulin biosynthesis depends on insulin-stimulated insulin gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; RECEPTOR; TRANSLATION; EXPRESSION; PROTEINS	Glucose stimulation of pancreatic p-cells leads to insulin secretion as well as up-regulation of insulin biosynthesis. The acute elevation in pro-insulin levels is thought to be exclusively because of the activation of translation of pre existing prepro-insulin mRNA. Glucose-stimulated insulin gene transcription is believed to be a long term effect and should therefore not contribute to the acute elevation in pro-insulin levels. We have recently shown that glucose activates insulin gene transcription within minutes and that secreted insulin is one of the key factors triggering this process in an autocrine manner. We now provide evidence that 50% of the glucose-stimulated, acute pro-insulin biosynthesis within 30 min results from up-regulated insulin gene transcription. Our data led us to propose that glucose elevates pro-insulin levels by stimulating both transcriptional and post-transcriptional/post-translational events to an equal extent. Whereas the stimulatory effect on transcription is mediated by insulin secreted in response to glucose, glucose directly stimulates the post-transcriptional/post-translational processes.	Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res, Karolinska Hosp L102, S-17176 Stockholm, Sweden	Karolinska Institutet	Berggren, PO (corresponding author), Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res, Karolinska Hosp L102, S-17176 Stockholm, Sweden.			Berggren, Per-Olof/0000-0001-8991-413X				Aspinwall CA, 1999, J BIOL CHEM, V274, P6360, DOI 10.1074/jbc.274.10.6360; EFRAT S, 1991, J BIOL CHEM, V266, P11141; GUEST PC, 1991, BIOCHEM J, V274, P73, DOI 10.1042/bj2740073; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Leibiger B, 1998, P NATL ACAD SCI USA, V95, P9307, DOI 10.1073/pnas.95.16.9307; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; MALAISSE WJ, 1977, HORM RES, V8, P203; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; Proud CG, 1997, BIOCHEM J, V328, P329; Rhodes Christopher J., 1996, P27; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; Xu GG, 1998, DIABETES, V47, P1243, DOI 10.2337/diabetes.47.8.1243	17	62	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30153	30156		10.1074/jbc.M005216200	http://dx.doi.org/10.1074/jbc.M005216200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10913151	hybrid			2022-12-25	WOS:000089577900034
J	Yoo, SH; Lewis, MS				Yoo, SH; Lewis, MS			Interaction of chromogranin B and the near N-temninal region of chromogranin B with an intraluminal loop peptide of the inositol 1,4,5-trisphosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY VESICLE MEMBRANE; PH-DEPENDENT INTERACTION; DISULFIDE-BONDED LOOP; TRISPHOSPHATE RECEPTOR; BINDING REGION; CONFORMATIONAL CHANGE; INTRACELLULAR STORES; CA2+ MOBILIZATION; CALCIUM RELEASE; MATRIX PROTEINS	Given the interaction of the inositol 1,4,5-trisphosphate receptor (IP3R) with chromogranins A (CGA) and B (CGB), two major Ca2+ storage proteins of secretory granules that have been shown to be IP3-sensitive intracellular Ca2+ store of neuroendocrine cells, we have investigated the potential interaction of the intraluminal loop regions of the IP3R with both intact CGB and the conserved near N-terminal region of CGB. The interaction studies carried out with CGB and glutathione S-transferase fusion proteins of intraluminal loop regions of bovine type 1 IP3R showed that CGB interacts with intraluminal loop 3-2 (the second loop formed between transmembrane regions 5 and 6) of the IP3R at both pH 5.5 and 7.5. Analytical ultracentrifugation studies also indicated-that CGB interacts with the same intraluminal loop region of the IP3R and the interaction was much stronger than that between CGA and the loop. Moreover, the conserved near N-terminal region of CGB also interacted with the intraluminal loop region of the IP3R. The CGB interaction with the IP3R intraluminal loop peptide at pH 7.5 showed a Delta G(0) value of -8.1 kcal/ mol at 37 degrees C for a 1:1 stoichiometry, indicating a K-d of similar to 1.9 mu M. These results give insight into the molecular organization of the IP3-sensitive Ca2+ store.	Korea Adv Inst Sci & Technol, Biomed Res Ctr, Natl Creat Res Initiat Ctr Secretory Granule Res, Taejon 305701, South Korea; NIH, Div Bioengn & Phys Sci, Off Res Serv, Bethesda, MD 20892 USA	Korea Advanced Institute of Science & Technology (KAIST); National Institutes of Health (NIH) - USA	Yoo, SH (corresponding author), Korea Adv Inst Sci & Technol, Biomed Res Ctr, Natl Creat Res Initiat Ctr Secretory Granule Res, Taejon 305701, South Korea.				OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [Z01OD010184] Funding Source: NIH RePORTER	OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BAUER JW, 1991, BIOCHIM BIOPHYS ACTA, V1089, P124, DOI 10.1016/0167-4781(91)90094-3; BENEDUM UM, 1987, EMBO J, V6, P1203, DOI 10.1002/j.1460-2075.1987.tb02355.x; BLONDEL O, 1994, P NATL ACAD SCI USA, V91, P7777, DOI 10.1073/pnas.91.16.7777; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; BULENDA D, 1985, BIOCHEMISTRY-US, V24, P7760, DOI 10.1021/bi00347a039; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; HUTTON JC, 1989, DIABETOLOGIA, V32, P271, DOI 10.1007/BF00265542; IACANGELO AL, 1995, REGUL PEPTIDES, V58, P65, DOI 10.1016/0167-0115(95)00069-N; JOSEPH SK, 1995, J BIOL CHEM, V270, P23310, DOI 10.1074/jbc.270.40.23310; Kang YK, 1997, FEBS LETT, V404, P87, DOI 10.1016/S0014-5793(97)00099-9; Kromer A, 1998, J CELL BIOL, V140, P1331, DOI 10.1083/jcb.140.6.1331; LEWIS MS, 1994, MODERN ANAL ULTRACEN, P94; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; MUALLEM S, 1989, J BIOL CHEM, V264, P205; Nguyen T, 1998, NATURE, V395, P908, DOI 10.1038/27686; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; POHL TM, 1990, FEBS LETT, V262, P219, DOI 10.1016/0014-5793(90)80194-N; REIFFEN FU, 1986, FEBS LETT, V195, P327, DOI 10.1016/0014-5793(86)80187-9; Srivastava M, 1999, P NATL ACAD SCI USA, V96, P13783, DOI 10.1073/pnas.96.24.13783; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; Thiele C, 1998, J BIOL CHEM, V273, P1223, DOI 10.1074/jbc.273.2.1223; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; YAMADA N, 1994, BIOCHEM J, V302, P781, DOI 10.1042/bj3020781; YOO SH, 1995, BIOCHEMISTRY-US, V34, P8680, DOI 10.1021/bi00027a017; Yoo SH, 2000, J BIOL CHEM, V275, P12553, DOI 10.1074/jbc.275.17.12553; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1994, J BIOL CHEM, V269, P12001; Yoo SH, 1996, J BIOL CHEM, V271, P17041, DOI 10.1074/jbc.271.29.17041; Yoo SH, 1996, J BIOL CHEM, V271, P1558; YOO SH, 1995, J BIOL CHEM, V270, P12578, DOI 10.1074/jbc.270.21.12578; Yoo SH, 1997, FEBS LETT, V406, P259, DOI 10.1016/S0014-5793(97)00276-7; YOO SH, 1991, J BIOL CHEM, V266, P7740; YOO SH, 1990, J BIOL CHEM, V265, P13446; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8213, DOI 10.1021/bi00083a023; Yoo SH, 1998, FEBS LETT, V427, P55, DOI 10.1016/S0014-5793(98)00393-7; YOO SH, 1995, BIOCHEMISTRY-US, V34, P632, DOI 10.1021/bi00002a030; YOO SH, 1993, BIOCHIM BIOPHYS ACTA, V1179, P239, DOI 10.1016/0167-4889(93)90078-4	47	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30293	30300		10.1074/jbc.M001204200	http://dx.doi.org/10.1074/jbc.M001204200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10906121	hybrid			2022-12-25	WOS:000089577900053
J	Yang, T; Goldstein, JL; Brown, MS				Yang, T; Goldstein, JL; Brown, MS			Overexpression of membrane domain of SCAP prevents sterols from inhibiting SCAP center dot SREBP exit from endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE-ACTIVATING PROTEIN; CELL-MEMBRANES; IDENTIFICATION; DEGRADATION; REDUCTASE; PATHWAY	SCAP (SREBP cleavage-activating protein) forms a complex with sterol regulatory element-binding proteins (SREBPs) and escorts them from the endoplasmic reticulum (ER) to the Golgi complex where proteases release transcriptionally active segments of SREBPs, which enter the nucleus to activate lipid synthesis. The NH2-terminal segment of SCAP contains eight transmembrane helices, five of which (TM2-6) comprise the sterol-sensing domain. This domain responds to sterols by causing the SCAP SREBP complex to be retained in the ER, preventing proteolytic release and reducing transcription of lipogenic genes. Here, we use transfection techniques to overexpress a segment of SCAP containing transmembrane helices 1-6 in hamster and human cells. This segment does not interfere with SCAP SREBP movement to the Golgi in the absence of sterols, but it prevents sterols from suppressing this movement. This block is abolished when SCAP(TM1-6) contains a point mutation (Y298C) that is known to abolish the activity of the sterol-sensing domain. We interpret these findings to indicate that sterols cause the SCAP SREBP complex to bind to an ER retention protein through an interaction that involves the sterol-sensing domain. The SCAP(TM1-6) segment competes with the SCAP SREBP complex for binding to this putative retention protein, thereby liberating the SCAP SREBP complex so that it can move to the Golgi despite the presence of sterols, These studies provide a potential mechanistic explanation for the ability of sterols to block SCAP SREBP movement from the ER and thereby to control lipid synthesis in animal cells.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Goldstein, JL (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd,Rm L5-238, Dallas, TX 75390 USA.							Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Duncan EA, 1998, J BIOL CHEM, V273, P17801, DOI 10.1074/jbc.273.28.17801; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; KUMAGAI H, 1995, J BIOL CHEM, V270, P19107, DOI 10.1074/jbc.270.32.19107; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Nohturfft A, 1998, P NATL ACAD SCI USA, V95, P12848, DOI 10.1073/pnas.95.22.12848; Nohturfft A, 1999, P NATL ACAD SCI USA, V96, P11235, DOI 10.1073/pnas.96.20.11235; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213	19	72	75	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29881	29886		10.1074/jbc.M005439200	http://dx.doi.org/10.1074/jbc.M005439200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896675	hybrid			2022-12-25	WOS:000089439800095
J	Goretzki, L; Lombardo, CR; Stallcup, WB				Goretzki, L; Lombardo, CR; Stallcup, WB			Binding of the NG2 proteoglycan to kringle domains modulates the functional properties of angiostatin and plasmin(ogen)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CHONDROITIN SULFATE PROTEOGLYCAN; MEMBRANE-SPANNING PROTEOGLYCAN; FIBROBLAST-GROWTH-FACTOR; PDGF ALPHA-RECEPTOR; HUMAN-PLASMINOGEN; ENDOTHELIAL-CELLS; VI COLLAGEN; EXTRACELLULAR-MATRIX; BOUND PLASMIN	Interactions of the developmentally regulated chondroitin sulfate proteoglycan NG2 with human plasminogen and kringle domain-containing plasminogen fragments have been analyzed by solid-phase immunoassays and by surface plasmon resonance. In immunoassays, the core protein of NG2 binds specifically and saturably to plasminogen, which consists of five kringle domains and a serine protease domain, and to angiostatin, which contains plasminogen kringle domains 1-3. Apparent dissociation constants for these interactions range from 12 to 75 nM. Additional evidence for NG2 interaction with kringle domains comes from its binding to plasminogen kringle domain 4 and to miniplasminogen (kringle domain 5 plus the protease domain) with apparent dissociation constants in the 18-71 nM range. Inhibition of plasminogen and angiostatin binding to NG2 by g-aminohexanoic acid suggests that lysine binding sites are involved in kringle interaction with NG2, The interaction of NG2 with plasminogen and angiostatin has very interesting functional consequences. 1) Soluble NG2 significantly enhances the activation of plasminogen by urokinase type plasminogen activator. 2) The antagonistic effect of angiostatin on endothelial cell proliferation is inhibited by soluble NG2, Both of these effects of NG2 should make the proteoglycan a positive regulator of the cell migration and proliferation required for angiogenesis.	La Jolla Canc Res Ctr, Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Stallcup, WB (corresponding author), La Jolla Canc Res Ctr, Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	stallcup@burnham.org			NATIONAL CANCER INSTITUTE [T32CA009579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044400] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021990] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09579] Funding Source: Medline; NIAMS NIH HHS [R01 AR44400] Funding Source: Medline; NINDS NIH HHS [R01 NS21990] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barritt DS, 2000, J CELL BIOCHEM, V79, P213, DOI 10.1002/1097-4644(20001101)79:2<213::AID-JCB50>3.0.CO;2-G; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; Burg MA, 1996, J BIOL CHEM, V271, P26110, DOI 10.1074/jbc.271.42.26110; Burg MA, 1997, EXP CELL RES, V235, P254, DOI 10.1006/excr.1997.3674; Burg MA, 1998, J CELL PHYSIOL, V177, P299, DOI 10.1002/(SICI)1097-4652(199811)177:2<299::AID-JCP12>3.3.CO;2-0; Burg MA, 1999, CANCER RES, V59, P2869; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; ELLIS V, 1991, J BIOL CHEM, V266, P12752; Fang XX, 1999, MOL BIOL CELL, V10, P3373, DOI 10.1091/mbc.10.10.3373; Felez J, 1998, FIBRINOLYSIS PROTEOL, V12, P183, DOI 10.1016/S0268-9499(98)80012-X; Folkman J, 1996, SCI AM, V275, P150, DOI 10.1038/scientificamerican0996-150; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; Goretzki L, 1999, J BIOL CHEM, V274, P16831, DOI 10.1074/jbc.274.24.16831; Grako KA, 1999, J CELL SCI, V112, P905; GRAKO KA, 1995, EXP CELL RES, V221, P231, DOI 10.1006/excr.1995.1371; HIGHSMITH RF, 1981, J BIOL CHEM, V256, P6788; Hirschi K K, 1997, EXS, V79, P419; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Ji WDR, 1998, FASEB J, V12, P1731, DOI 10.1096/fasebj.12.15.1731; KOBAYASHI H, 1994, CANCER RES, V54, P844; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; LERCH PG, 1980, EUR J BIOCHEM, V107, P7, DOI 10.1111/j.1432-1033.1980.tb04617.x; Lin XH, 1996, J CELL BIOCHEM, V63, P463, DOI 10.1002/(SICI)1097-4644(19961215)63:4<463::AID-JCB8>3.0.CO;2-R; Lin XH, 1996, MOL BIOL CELL, V7, P1977, DOI 10.1091/mbc.7.12.1977; Lindahl P, 1998, CURR OPIN NEPHROL HY, V7, P21, DOI 10.1097/00041552-199801000-00004; Lucas R, 1998, BLOOD, V92, P4730; MacDonald NJ, 1999, BIOCHEM BIOPH RES CO, V264, P469, DOI 10.1006/bbrc.1999.1486; Markus G, 1996, FIBRINOLYSIS, V10, P75, DOI 10.1016/S0268-9499(96)80082-8; MARTI D, 1994, EUR J BIOCHEM, V219, P455, DOI 10.1111/j.1432-1033.1994.tb19959.x; MEISSAUER A, 1992, EXP CELL RES, V199, P179, DOI 10.1016/0014-4827(92)90423-6; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Miles L. A., 1993, Biologia and Clinica Hematologica, V15, P107; MILLER B, 1995, J COMP NEUROL, V355, P615, DOI 10.1002/cne.903550410; MOSER TL, 1993, J BIOL CHEM, V268, P18917; NEHLS V, 1992, CELL TISSUE RES, V270, P469, DOI 10.1007/BF00645048; NEWCOMB PM, 1993, J CELL PHYSIOL, V155, P385, DOI 10.1002/jcp.1041550220; NISHIYAMA A, 1993, MOL BIOL CELL, V4, P1097, DOI 10.1091/mbc.4.11.1097; NISHIYAMA A, 1995, MOL BIOL CELL, V6, P1819, DOI 10.1091/mbc.6.12.1819; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; REJANTE MR, 1991, BIOCHEMISTRY-US, V30, P11081, DOI 10.1021/bi00110a010; Rifkin DB, 1997, FIBRINOLYSIS PROTEOL, V11, P3, DOI 10.1016/S0268-9499(97)80003-3; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P163; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SALONEN EM, 1985, J BIOL CHEM, V260, P2302; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SCHLINGEMANN RO, 1990, AM J PATHOL, V136, P1393; Schlingemann RO, 1996, J PATHOL, V179, P436; SCHRAPPE M, 1991, CANCER RES, V51, P4986; SILVERSTEIN RL, 1985, J BIOL CHEM, V260, P346; SIMS DE, 1986, TISSUE CELL, V18, P153, DOI 10.1016/0040-8166(86)90026-1; SOTTRUPJENSEN L, 1978, ATLAS PROTEIN SEQ S3, V5, P91; STACK MS, 1992, BIOCHEM J, V284, P103, DOI 10.1042/bj2840103; STACK S, 1990, BIOCHEMISTRY-US, V29, P4966, DOI 10.1021/bi00472a029; STALLCUP WB, 1990, J CELL BIOL, V111, P3177, DOI 10.1083/jcb.111.6.3177; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; THEWES T, 1990, J BIOL CHEM, V265, P3906; THOMPSON RW, 1989, ANN NY ACAD SCI, V556, P255; Tillet E, 1997, J BIOL CHEM, V272, P10769; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; Walter JJ, 1999, ARTERIOSCL THROM VAS, V19, P2041, DOI 10.1161/01.ATV.19.9.2041; WESSELING P, 1995, J NEUROPATH EXP NEUR, V54, P304, DOI 10.1097/00005072-199505000-00003; WILHELM O, 1990, BLOOD, V75, P1673; WIMAN B, 1975, EUR J BIOCHEM, V50, P489, DOI 10.1111/j.1432-1033.1975.tb09887.x	74	54	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28625	28633		10.1074/jbc.M002290200	http://dx.doi.org/10.1074/jbc.M002290200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10889192	hybrid			2022-12-25	WOS:000089330700040
J	Gillet, R; Grimber, G; Bennoun, M; de Fromentel, CC; Briand, P; Joulin, V				Gillet, R; Grimber, G; Bennoun, M; de Fromentel, CC; Briand, P; Joulin, V			The consequence of p53 overexpression for liver tumor development and the response of transformed murine hepatocytes to genotoxic agents	ONCOGENE			English	Article						transgenic mice; p53; hepatocarcinoma; apoptosis; DNA damage	WILD-TYPE P53; LARGE T-ANTIGEN; BREAST-CANCER CELLS; TRANSGENIC MICE; IN-VIVO; GENE-THERAPY; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVITY; DECREASED SENSITIVITY; SPINDLE CHECKPOINT	To analyse the effect of p53 on liver tumor development, we generated transgenic mice overexpressing wild-type p53 in the liver and crossed them with transgenic mice in which the expression of the SV40 large T antigen (TAg) induces hepatic tumors. Remarkably, whereas preneoplastic TAg liver exhibited anisocaryosis and anisocytosis, TAg/p53 liver never presented any dysplastic cells. Moreover, whereas expression of p53 did not affect hepatic development, its constitutive expression in tumorigenic livers resulted in a significantly enhanced apoptosis once nodules had appeared. In contrast, p53 overexpression did not modify the elevated proliferation of TAg-transformed hepatocytes and had no effect on hepatocarcinoma progression. In vitro analysis of primary hepatocytes exposed to various genotoxic agents showed that p53 failed to sensitize normal or TAg-transformed hepatocytes to apoptosis, except when high doses of doxorubicin, UV-B and UV-C radiation were used. Our results confirmed that the hepatocyte cell type is very resistant to genotoxic agents and showed that constitutive expression of p53 failed to improve their responsiveness. In addition, our results showed that suppression of dysplastic cells, probably by restoring normal cytokinesis and karyokinesis, and enhancement of apoptosis by means of p53 overexpression were insufficient to counteract or delay the TAg-induced liver tumoral progression.	Inst Cochin Genet Mol, INSERM, U380, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Joulin, V (corresponding author), Inst Cochin Genet Mol, INSERM, U380, 22 Rue Mechain, F-75014 Paris, France.		de Fromentel, Claude Caron/Y-9715-2019	de Fromentel, Claude Caron/0000-0001-7566-3958; JOULIN, Virginie/0000-0003-1091-7819				Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Allemand I, 1995, ONCOGENE, V11, P2583; Allemand I, 1999, ONCOGENE, V18, P6521, DOI 10.1038/sj.onc.1203052; Bellamy COC, 1997, J PATHOL, V183, P177, DOI 10.1002/(SICI)1096-9896(199710)183:2<177::AID-PATH909>3.0.CO;2-E; Bellamy COC, 1997, FASEB J, V11, P591, DOI 10.1096/fasebj.11.7.9212083; Bennoun M, 1998, ONCOGENE, V17, P1253, DOI 10.1038/sj.onc.1202047; Blagosklonny MV, 1998, INT J CANCER, V75, P933, DOI 10.1002/(SICI)1097-0215(19980316)75:6<933::AID-IJC17>3.0.CO;2-3; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Conzen SD, 1997, J VIROL, V71, P4536, DOI 10.1128/JVI.71.6.4536-4543.1997; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUBOIS N, 1991, J HEPATOL, V13, P227, DOI 10.1016/0168-8278(91)90819-W; FAN SJ, 1994, CANCER RES, V54, P5824; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUJIWARA T, 1994, CANCER RES, V54, P2287; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; Ghebranious N, 1998, HEPATOLOGY, V27, P967, DOI 10.1002/hep.510270411; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Godley LA, 1996, GENE DEV, V10, P836, DOI 10.1101/gad.10.7.836; Goto A, 1998, JPN J CANCER RES, V89, P539, DOI 10.1111/j.1349-7006.1998.tb03295.x; Gudas JM, 1996, CARCINOGENESIS, V17, P1417, DOI 10.1093/carcin/17.7.1417; Gurnani M, 1999, CANCER CHEMOTH PHARM, V44, P143, DOI 10.1007/s002800050959; Hickman ES, 1997, J VIROL, V71, P3710, DOI 10.1128/JVI.71.5.3710-3718.1997; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; Ju JF, 1998, CLIN CANCER RES, V4, P1315; Jung YK, 1997, ONCOGENE, V14, P1207, DOI 10.1038/sj.onc.1200943; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Khan SH, 1998, CANCER RES, V58, P396; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; MacCallum DE, 1996, ONCOGENE, V13, P2575; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; Nielsen LL, 1998, CANCER GENE THER, V5, P52; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; Piovesan B, 1998, ONCOGENE, V17, P2339, DOI 10.1038/sj.onc.1202147; Procopio A, 1998, Monaldi Arch Chest Dis, V53, P241; ROUQUET N, 1995, ONCOGENE, V11, P1061; Seth P, 1997, CANCER GENE THER, V4, P383; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Song KM, 1997, ONCOL RES, V9, P603; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TREMP GL, 1995, GENE, V156, P199, DOI 10.1016/0378-1119(95)00010-4; Tsai SC, 2000, J BIOL CHEM, V275, P3239, DOI 10.1074/jbc.275.5.3239; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	60	24	27	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3498	3507		10.1038/sj.onc.1203671	http://dx.doi.org/10.1038/sj.onc.1203671			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918608				2022-12-25	WOS:000088346500006
J	Haniu, M; Denis, P; Young, Y; Mendiaz, EA; Fuller, J; Hui, JO; Bennett, BD; Kahn, S; Ross, S; Burgess, T; Katta, V; Rogers, G; Vassar, R; Citron, M				Haniu, M; Denis, P; Young, Y; Mendiaz, EA; Fuller, J; Hui, JO; Bennett, BD; Kahn, S; Ross, S; Burgess, T; Katta, V; Rogers, G; Vassar, R; Citron, M			Characterization of Alzheimer's beta-secretase protein BACE - A pepsin family member with unusual properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; DISEASE; PURIFICATION; PEPTIDE	The cerebral deposition of amyloid beta-peptide is an early and critical feature of Alzheimer's disease. Amyloid beta-peptide is released from the amyloid precursor protein by the sequential action of two proteases, beta-secretase and gamma-secretase, and these proteases are prime targets for therapeutic intervention. We have recently cloned a novel aspartic protease, BACE, with all the known properties of beta-secretase. Here we demonstrate that BACE is an N-glycosylated integral membrane protein that undergoes constitutive N-terminal processing in the Golgi apparatus. We have used a secreted Fc fusion-form of BACE (BACE-IgG) that contains the entire ectodomain for a detailed analysis of posttranslational modifications, This molecule starts at Glu(46) and contains four N-glycosylation sites (Asn(153) Asn(172), Asn(223), and Asn(354)). The six Cys residues in the ectodomain form three intramolecular disulfide linkages (Cys(216)-Cys(420), Cys(278)-Cys(443), and Cys(330)-Cys(380)). Despite the conservation of the active site residues and the 30-37% amino acid homology with known aspartic proteases, the disulfide motif is fundamentally different from that of other aspartic proteases, This difference may affect the substrate specificity of the enzyme. Taken together, both the presence of a transmembrane domain and the unusual disulfide bond structure lead us to conclude that BACE is an atypical pepsin family member.	Amgen Inc, Thousand Oaks, CA 91320 USA	Amgen	Haniu, M (corresponding author), Amgen Inc, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.							Alzheimer A., 1907, Z GESAMTE NEUROL PSY, V18, P177; Anumula KR, 1998, GLYCOBIOLOGY, V8, P685, DOI 10.1093/glycob/8.7.685; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kervinen J, 1999, EMBO J, V18, P3947, DOI 10.1093/emboj/18.14.3947; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1	14	201	219	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21099	21106		10.1074/jbc.M002095200	http://dx.doi.org/10.1074/jbc.M002095200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10887202	hybrid			2022-12-25	WOS:000088230600021
J	Meroni, G; Cairo, S; Merla, G; Messali, S; Brent, R; Ballabio, A; Reymond, A				Meroni, G; Cairo, S; Merla, G; Messali, S; Brent, R; Ballabio, A; Reymond, A			Mlx, a new Max-Like bHLHZip family member: the center stage of a novel transcription factors regulatory pathway?	ONCOGENE			English	Article						bHLHZip; Myc; Max; Rox; cell proliferation	HELIX-ZIPPER PROTEIN; C-MYC; DNA-BINDING; HISTONE DEACETYLASE; GROWTH-FACTOR; CELL-PROLIFERATION; E-BOX; RAS COTRANSFORMATION; OPPOSITE REGULATION; MAMMALIAN-CELLS	The Myc proto-oncogene family members have been identified as the cellular homologs of the transforming oncogene of avian retro viruses. They encode central regulators of mammalian cell proliferation and apoptosis, and they associate with the bHLHZip protein Max to hind specific DNA sequences and regulate the expression of genes important for cell cycle progression. The other family members, Mad1, Mxi1, Mad3, Mad4 and Rox (Mnt) antagonize their activities. The Mads and Ros compete with Myc in heterodimerizing with Max and in binding to the same specific target sequences, These Mads:Max and Rox:Max dimers repress transcription through binding to the mSIN3 corepressor protein and by tethering histone deacetylase-containing complexes to the DNA. In a screen for Rox interactors we isolated Mlx, a bHLHZip protein previously identified in a screen for Mad1 interactors. In the present work we extend the known dimerization partners of Mlx by demonstrating its ability to interact with Rox. Moreover, we show that contrary to previous reports Mlx is able to homodimerize and to bind E-box sequences at low concentration Levels. The possible role of Mlx in an emerging regulatory pathway and acting parallel to the Max driven network is discussed.	Telethon Inst Genet & Med, I-20132 Milan, Italy; Inst Mol Sci, Berkeley, CA 94704 USA; Univ Vita & Salute, Milan, Italy	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); The Molecular Sciences Institute; Vita-Salute San Raffaele University	Reymond, A (corresponding author), Telethon Inst Genet & Med, SAn Raffaele Biomed Sci Pk, I-20132 Milan, Italy.		Cairo, Stefano/O-2831-2016; BALLABIO, Andrea/AAL-2672-2020; merla, giuseppe/K-4627-2012	Cairo, Stefano/0000-0002-4725-5970; BALLABIO, Andrea/0000-0003-1381-4604; merla, giuseppe/0000-0001-5078-928X; Reymond, Alexandre/0000-0003-1030-8327	Telethon [TGM00S01, TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; Billin AN, 1999, J BIOL CHEM, V274, P36344, DOI 10.1074/jbc.274.51.36344; Bjerknes M, 1996, GENE, V181, P7, DOI 10.1016/S0378-1119(96)00376-9; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Dang CV, 1999, MOL CELL BIOL, V19, P1; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; Eilers M, 1999, MOL CELLS, V9, P1; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; FitzGerald MJ, 1999, ONCOGENE, V18, P2489, DOI 10.1038/sj.onc.1202611; FRIEDMAN LS, 1995, GENOMICS, V25, P256, DOI 10.1016/0888-7543(95)80133-7; FRIEDMAN LS, 1994, CANCER RES, V54, P6374; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HESKETH R, 1997, ONCOGENE TUMOUR SUPP, P1; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; Hurlin PJ, 1996, EMBO J, V15, P2030, DOI 10.1002/j.1460-2075.1996.tb00555.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Kasten MM, 1997, MOL CELL BIOL, V17, P4852, DOI 10.1128/MCB.17.8.4852; Kasten MM, 1996, MOL CELL BIOL, V16, P4215; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LARSSON LG, 1994, ONCOGENE, V9, P1247; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Li XJ, 1999, JPN J CANCER RES, V90, P740, DOI 10.1111/j.1349-7006.1999.tb00809.x; Lo Nigro C, 1998, GENOMICS, V49, P275; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Peters MA, 1998, CRIT REV EUKAR GENE, V8, P277, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.30; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; Reymond A, 1999, ONCOGENE, V18, P7244, DOI 10.1038/sj.onc.1203140; REYMOND A, 1995, ONCOGENE, V11, P1173; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Ryan KM, 1997, BIOCHEM J, V325, P79, DOI 10.1042/bj3250079; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SchreiberAgus N, 1997, P NATL ACAD SCI USA, V94, P1235, DOI 10.1073/pnas.94.4.1235; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; Tangir J, 1996, ONCOGENE, V12, P735; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; VASTRIK I, 1993, ONCOGENE, V8, P503; VOGELSTEIN B, 1994, CELL, V79, P1, DOI 10.1016/0092-8674(94)90393-X; WALKER CW, 1992, ONCOGENE, V7, P2007; Yin XY, 1998, ONCOGENE, V16, P2629, DOI 10.1038/sj.onc.1201777; Yuan J, 1998, ONCOGENE, V17, P1109, DOI 10.1038/sj.onc.1202036; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505; Zhao Z, 1996, MAMM GENOME, V7, P686, DOI 10.1007/s003359900206	86	59	63	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2000	19	29					3266	3277		10.1038/sj.onc.1203634	http://dx.doi.org/10.1038/sj.onc.1203634			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918583				2022-12-25	WOS:000088019300005
J	Branch, P; Masson, M; Aquilina, G; Bignami, M; Karran, P				Branch, P; Masson, M; Aquilina, G; Bignami, M; Karran, P			Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells	ONCOGENE			English	Article						A2780 ovarian carcinoma; hMLHI silencing; methylation tolerance	OVARIAN-CANCER; DNA-DAMAGE; COLORECTAL-CARCINOMA; ACQUIRED-RESISTANCE; METHYLATING AGENTS; MUTATOR PHENOTYPE; HMLH1 PROMOTER; SENSITIVITY; APOPTOSIS; LINES	The contributions of defective mismatch repair and mutated p53 to cisplatin resistance of human tumor cells were analysed. Mismatch repair defects were not associated with a predictable degree of resistance among several tumor cell Lines. Repair defective variants of the A2780 ovarian carcinoma cell Line which were isolated 62 selection for a methylation tolerant phenotype and did not express the hMLH1 mismatch repair protein, were highly resistant to cisplatin, Their cisplatin resistance was not a simple consequence of the mismatch repair defect. They were members of a drug-naive subpopulation of A2780 in which a silent hMLH1 gene accompanies a mutated p53. Two complementary approaches indicated that each defect contributes to cisplatin resistance independently and to a different extent, Firstly separate introduction of a p53 defect into A2780 cells significantly increased their cisplatin resistance; defective hMLH1 provided less extensive protection. Secondly, azadeoxycytidine reactivation of the silent hMLH1 gene or expression of a transfected hMLH1 cDNA sensitized the doubly hMLH1/p53 deficient cells only slightly to cisplatin, Both approaches indicate that defective p53 status is a major determinant of cisplatin resistance and defective mismatch repair is a minor, and independent, contributor. The data have implications for the development of intrinsic cisplatin resistance.	Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; Ist Super Sanita, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Karran, P (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.		Aquilina, Gabriele/AAI-7978-2021	Aquilina, Gabriele/0000-0002-3280-7883				Aebi S, 1996, CANCER RES, V56, P3087; Anthoney DA, 1996, CANCER RES, V56, P1374; AQUILINA G, 1995, CANCER RES, V55, P2569; Aquilina G, 1998, CANCER RES, V58, P135; Aquilina G, 2000, CLIN CANCER RES, V6, P671; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRANCH P, 1995, CANCER RES, V55, P2304; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; Buermeyer AB, 1999, CANCER RES, V59, P538; D'Atri S, 1998, MOL PHARMACOL, V54, P334, DOI 10.1124/mol.54.2.334; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Durant ST, 1999, CURR BIOL, V9, P51, DOI 10.1016/S0960-9822(99)80047-5; Einhorn LH, 1997, CLIN CANCER RES, V3, P2630; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; FAN SJ, 1995, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; Fink D, 1996, CANCER RES, V56, P4881; Fink D, 1998, CLIN CANCER RES, V4, P1; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; Hampson R, 1997, J BIOL CHEM, V272, P28596, DOI 10.1074/jbc.272.45.28596; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Humbert O, 1999, CARCINOGENESIS, V20, P205, DOI 10.1093/carcin/20.2.205; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; JOHNSON SW, 1994, CANCER RES, V54, P5911; KARRAN P, 1993, J BIOL CHEM, V268, P15878; Koberle B, 1999, CURR BIOL, V9, P273, DOI 10.1016/S0960-9822(99)80118-3; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MCLAUGHLIN K, 1991, CANCER RES, V51, P2242; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; O'Driscoll M., 1998, NUCL ACID M, V12, P173; Siddik ZH, 1998, CANCER RES, V58, P698; Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540; Vasey PA, 1996, MOL PHARMACOL, V50, P1536; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491; [No title captured]	39	103	106	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3138	3145		10.1038/sj.onc.1203668	http://dx.doi.org/10.1038/sj.onc.1203668			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918568				2022-12-25	WOS:000088019200002
J	Renshaw, MW; Lewis, JM; Schwartz, MA				Renshaw, MW; Lewis, JM; Schwartz, MA			The c-Abl tyrosine kinase contributes to the transient activation of MAP kinase in cells plated on fibronectin	ONCOGENE			English	Article						Erk2; Ras; signal transduction; extracellular matrix; cell adhesion	FOCAL ADHESION KINASE; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; GROWTH-FACTOR; V-ABL; SHC; RAS; MIGRATION; INTEGRINS; MOTILITY	Previous work showed that integrin stimulation triggers activation of the c-Abl tyrosine kinase and its transient localization to focal adhesions. We now report that plating cells on fibronectin triggers association of Grb2 with c-Abl, suggesting possible involvement of c-Abl with integrin activation of the MAP kinase pathway. Expression of a kinase-defective c-Abl specifically inhibited the transient induction of Erk2 activity following cell adhesion, Together with the known ability of activated, oncogenic forms of c-Abl to activate Ras and the MAP kinase pathway, these data suggest that c-myc contributes to the integrin induction of MAP kinase activity.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schwartz, MA (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Lewis, Jean/0000-0001-6978-5166; schwartz, martin/0000-0002-2071-1243	NCI NIH HHS [R29 CA74230] Funding Source: Medline; NHLBI NIH HHS [P01 HL57900] Funding Source: Medline; NIGMS NIH HHS [F32 GM18298] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074230] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018298] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agami R, 1999, NATURE, V399, P809; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; CHANG JH, 1995, METHOD ENZYMOL, V254, P430; CHEN QM, 1994, J BIOL CHEM, V269, P26602; GOGA A, 1995, CELL, V82, P891; Gong JG, 1999, NATURE, V399, P806; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; KAMASHITA I, 1989, ANAL BIOCHEM, V183, P139; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Lin TH, 1997, J BIOL CHEM, V272, P8849; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Raffel GD, 1996, J BIOL CHEM, V271, P4640; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; ZHAO X, 1999, J BIOL CHEM, V272, P18141	30	23	23	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 29	2000	19	28					3216	3219		10.1038/sj.onc.1203667	http://dx.doi.org/10.1038/sj.onc.1203667			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918577				2022-12-25	WOS:000088019200011
J	Chrysina, ED; Brew, K; Acharya, KR				Chrysina, ED; Brew, K; Acharya, KR			Crystal structures of apo- and holo-bovine alpha-lactalbumin at 2.2-A resolution reveal an effect of calcium on inter-lobe interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN GLOBULE STATE; AMINO-ACID-SEQUENCE; GUINEA-PIG; BINDING SITE; CA2+ BINDING; PROTEIN; LYSOZYME; ENVIRONMENTS; FLUORESCENCE; ASSOCIATION	High affinity binding of Ca2+ to a-lactalbumin (LA) stabilizes the native structure and is required for the efficient generation of native protein with correct disulfide bonds from the reduced denatured state. A progressive increase in affinity of LA conformers for Ca2+ as they develop increasingly native structures can account for the tendency of the apo form to assume a molten globule state and the large acceleration of folding by Ca2+. To investigate the effect of calcium on structure of bovine LA, x-ray structures have been determined for crystals of the apo and hole forms at 2.2-Angstrom resolution. In both crystal forms, which were grown at high ionic strength, the protein is in a similar global native conformation consisting of alpha -helical and beta -subdomains separated by a cleft. Even though alternative cations and Ca2+ liganding solvent molecules are absent, removal of Ca2+ has only minor effects on the structure of the metal-binding site and a structural change was observed in the cleft on the opposite face of the molecule adjoining Tyr(103) of the helical lobe and Gln(54) of the beta -lobe. Changes include increased separation of the lobes, loss of a buried solvent molecule near the Ca2+-binding site, and the replacement of inter- and intra-lobe II-bonds of Tyr(103) by interactions with new immobilized water molecules. The more open cleft structure in the apo protein appears to be an effect of calcium binding transmitted via a change in orientation of helix H3 relative to the beta -lobe to the inter-lobe interface. Calcium is well known to promote the folding of Lk The results from the comparison of apo and hole structures of LA provide high resolution structural evidence that the acceleration of folding by Ca2+ is mediated by an effect on interactions between the two subdomains.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Bath; University of Miami	Acharya, KR (corresponding author), Univ Bath, Dept Biol & Biochem, Claverton Down, Bath BA2 7AY, Avon, England.	K.R.Acharya@bath.ac.uk	Brew, Keith/A-6746-2009; Brew, Keith/W-1643-2019; Chrysina, Evangelia/E-6464-2016	Brew, Keith/0000-0003-1306-1032; Chrysina, Evangelia/0000-0001-8147-9030; Acharya, K. Ravi/0000-0002-3009-4058	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058773] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58773] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHARYA KR, 1989, J MOL BIOL, V208, P99, DOI 10.1016/0022-2836(89)90091-0; ACHARYA KR, 1991, J MOL BIOL, V221, P571; ALEXANDRESCU AT, 1992, EUR J BIOCHEM, V210, P699, DOI 10.1111/j.1432-1033.1992.tb17471.x; ALEXANDRESCU AT, 1993, BIOCHEMISTRY-US, V32, P1707, DOI 10.1021/bi00058a003; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arai M, 1996, FOLD DES, V1, P275, DOI 10.1016/S1359-0278(96)00041-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BERLINER LJ, 1983, BIOCHEMISTRY-US, V22, P5061, DOI 10.1021/bi00291a002; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; BREW K, 1967, J BIOL CHEM, V242, P3747; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brunger AT, 1992, XPLOR VERSION 3 1 MA; Calderone V, 1996, FEBS LETT, V394, P91, DOI 10.1016/0014-5793(96)00933-7; Chandra N, 1998, BIOCHEMISTRY-US, V37, P4767, DOI 10.1021/bi973000t; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3677, DOI 10.1021/bi00065a022; Forge V, 1999, J MOL BIOL, V288, P673, DOI 10.1006/jmbi.1999.2687; GERKEN TA, 1984, BIOCHEMISTRY-US, V23, P4688, DOI 10.1021/bi00315a026; GROBLER JA, 1994, ARCH BIOCHEM BIOPHYS, V313, P360, DOI 10.1006/abbi.1994.1399; GROBLER JA, 1992, ADV DAIRY CHEM, V1, P191; Guss JM, 1997, ACTA CRYSTALLOGR D, V53, P355, DOI 10.1107/S0907444996015831; GUSSAKOVSKY EE, 1995, PROTEIN SCI, V4, P2319, DOI 10.1002/pro.5560041109; HARATA K, 1992, J BIOL CHEM, V267, P1419; HILL RL, 1975, ADV ENZYMOL RAMB, V43, P411; HIRAOKA Y, 1985, INT J PEPT PROT RES, V26, P252; IKEGUCHI M, 1986, J BIOCHEM-TOKYO, V99, P1191, DOI 10.1093/oxfordjournals.jbchem.a135582; INAKA K, 1991, J BIOL CHEM, V266, P20666; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRONMAN MJ, 1981, J BIOL CHEM, V256, P8582; KRONMAN MJ, 1989, CRIT REV BIOCHEM MOL, V24, P565, DOI 10.3109/10409238909080054; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1989, J MOL BIOL, V206, P547, DOI 10.1016/0022-2836(89)90500-7; LALA AK, 1992, J BIOL CHEM, V267, P19914; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PENG ZY, 1994, BIOCHEMISTRY-US, V33, P2136, DOI 10.1021/bi00174a021; PEPYS MB, 1993, NATURE, V362, P553, DOI 10.1038/362553a0; PERMYAKOV EA, 1981, BIOCHEM BIOPH RES CO, V100, P191, DOI 10.1016/S0006-291X(81)80081-2; Pike ACW, 1996, STRUCTURE, V4, P691, DOI 10.1016/S0969-2126(96)00075-5; RAO KR, 1989, BIOCHEM BIOPH RES CO, V163, P1390, DOI 10.1016/0006-291X(89)91133-9; REN JS, 1993, J BIOL CHEM, V268, P19292; SCHAER JJ, 1985, FEBS LETT, V190, P77, DOI 10.1016/0014-5793(85)80431-2; SMITH SG, 1987, BIOCHEM J, V242, P353, DOI 10.1042/bj2420353; SONG HW, 1994, J MOL BIOL, V244, P522, DOI 10.1006/jmbi.1994.1750; Steinrauf LK, 1998, ACTA CRYSTALLOGR D, V54, P767, DOI 10.1107/S0907444997016922; STUART DI, 1986, NATURE, V324, P84, DOI 10.1038/324084a0; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; Svensson M, 1999, J BIOL CHEM, V274, P6388, DOI 10.1074/jbc.274.10.6388; THUNNISSEN AMWH, 1995, PROTEINS, V22, P245, DOI 10.1002/prot.340220305; TSUGE H, 1992, J BIOCHEM-TOKYO, V111, P141, DOI 10.1093/oxfordjournals.jbchem.a123727; VANDERHEEREN G, 1994, J BIOL CHEM, V269, P7090; Veillon C, 1978, Methods Enzymol, V54, P446; WANG M, 1989, J BIOL CHEM, V264, P21116; WU LC, 1995, NAT STRUCT BIOL, V2, P281, DOI 10.1038/nsb0495-281	59	208	216	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37021	37029		10.1074/jbc.M004752200	http://dx.doi.org/10.1074/jbc.M004752200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10896943	hybrid			2022-12-25	WOS:000165577700080
J	Jiang, Y; Qian, WJ; Hawes, JW; Walsh, JP				Jiang, Y; Qian, WJ; Hawes, JW; Walsh, JP			A domain with homology to neuronal calcium sensors is required for calcium-dependent activation of diacylglycerol kinase alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EF-HAND MOTIFS; PHOSPHATIDIC-ACID; 3-DIMENSIONAL STRUCTURE; BOVINE NEUROCALCIN; BINDING PROTEINS; ESCHERICHIA-COLI; HUMAN-PLATELETS; 2ND MESSENGERS; RAT-BRAIN; EXPRESSION	Diacylglycerol kinases (DGKs) phosphorylate diacylglycerol produced during stimulus-induced phosphoinositide turnover and attenuate protein kinase C activation. Diacylglycerol kinase alpha is an 82-kDa DGK isoform that is activated in vitro by Ca2+. The DGK alpha regulatory region includes tandem C1 protein kinase C homology domains and Ca2+-binding EF hand motifs, It also contains an N-terminal recoverin homology (RVH) domain that is related to the N termini of the recoverin family of neuronal calcium sensors. To probe the structural basis of Ca2+ regulation, we expressed a series of DGK alpha deletions spanning its regulatory domain in COS-l cells. Deletion of the RVH domain resulted in loss of Ca2+-dependent activation. Further deletion of the EF hands resulted in a constitutively active enzyme, suggesting that sequences in or near the EF hands are sufficient for autoinhibition, Binding of Ca2+ to the EF hands protected sites within both the RVH domain and EF hands from trypsin cleavage and increased the phenyl-Sepharose binding of a recombinant DGK alpha fragment that included both the RVH domain and EF hands. These observations suggested that Ca2+ elicits a concerted conformational change of these two domains. A cationic amphiphile, octadecyltrimethylammonium chloride, also activated DGK alpha. As with Ca2+, this activation required the RVH domain. However, this agent did not protect the EF hands and RVH domain from trypsin cleavage. These findings indicate that the EF hands and RVH domain act as a functional unit during Ca2+-induced DGK alpha activation.	Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Walsh, JP (corresponding author), Richard L Roudebush Vet Affairs Med Ctr, Sect Endocrinol & Metab 111E, 1481 W 10th St, Indianapolis, IN 46202 USA.	jpwalsh@iupui.edu						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMES BN, 1960, J BIOL CHEM, V235, P769; Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; BISHOP WR, 1986, J BIOL CHEM, V261, P6993; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braunewell KH, 1999, CELL TISSUE RES, V295, P1, DOI 10.1007/s004410051207; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLINT JH, 1975, J CHEM SOC FARAD T 1, V71, P1327, DOI 10.1039/f19757101327; DELAAGE M, 1967, BIOCHEM BIOPH RES CO, V28, P390, DOI 10.1016/0006-291X(67)90323-3; Erickson RW, 1999, J BIOL CHEM, V274, P22243, DOI 10.1074/jbc.274.32.22243; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; Hurley JH, 1997, PROTEIN SCI, V6, P477; Jiang Y, 2000, BIOCHEM PHARMACOL, V59, P763, DOI 10.1016/S0006-2952(99)00395-0; KANOH H, 1993, CELL SIGNAL, V5, P495, DOI 10.1016/0898-6568(93)90045-N; KATO M, 1990, J BIOL CHEM, V265, P794; Landar A, 1998, BIOCHEMISTRY-US, V37, P17429, DOI 10.1021/bi9817921; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; Matsuda S, 1998, J BIOL CHEM, V273, P20223, DOI 10.1074/jbc.273.32.20223; Montgomery RB, 1997, BIOCHEM BIOPH RES CO, V232, P111, DOI 10.1006/bbrc.1997.6237; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; SAKANE F, 1991, J BIOL CHEM, V266, P7096; Sakane F, 1997, INT J BIOCHEM CELL B, V29, P1139, DOI 10.1016/S1357-2725(97)00037-X; SAKANE F, 1991, BIOCHEM BIOPH RES CO, V181, P1015, DOI 10.1016/0006-291X(91)92038-L; Sakane F, 1996, BIOCHEM J, V318, P583, DOI 10.1042/bj3180583; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Sciorra VA, 1996, J BIOL CHEM, V271, P14226, DOI 10.1074/jbc.271.24.14226; SIPOS T, 1970, BIOCHEMISTRY-US, V9, P2766, DOI 10.1021/bi00816a003; Tachibanaki S, 2000, J BIOL CHEM, V275, P3313, DOI 10.1074/jbc.275.5.3313; TENG DHF, 1994, J BIOL CHEM, V269, P31900; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; WALSH JP, 1992, METHOD ENZYMOL, V209, P153; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WALSH JP, 1995, J BIOL CHEM, V270, P28647, DOI 10.1074/jbc.270.48.28647; YADA Y, 1990, J BIOL CHEM, V265, P19237; Yamada K, 1997, BIOCHEM J, V321, P59, DOI 10.1042/bj3210059; YAMADA K, 1988, BIOCHEM J, V255, P601; YAMADA K, 1993, BIOCHIM BIOPHYS ACTA, V1169, P211; ZOZULYA S, 1995, METHOD ENZYMOL, V250, P383	46	48	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34092	34099		10.1074/jbc.M004914200	http://dx.doi.org/10.1074/jbc.M004914200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10918059	hybrid			2022-12-25	WOS:000165095300016
J	Membrillo-Hernandez, J; Echave, P; Cabiscol, E; Tamarit, J; Ros, J; Lin, ECC				Membrillo-Hernandez, J; Echave, P; Cabiscol, E; Tamarit, J; Ros, J; Lin, ECC			Evolution of the adhE gene product of Escherichia coli from a functional reductase to a dehydrogenase - Genetic and biochemical studies of the mutant proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERMENTATIVE ALCOHOL-DEHYDROGENASE; ENCODING ETHANOL OXIDOREDUCTASE; PROPANEDIOL OXIDOREDUCTASE; ZYMOMONAS-MOBILIS; OXIDATIVE STRESS; ENZYMES; L-1,2-PROPANEDIOL; SEQUENCE; CLONING; FUCOSE	The multifunctional AdhE protein of Escherichia coli (encoded by the adhE gene) physiologically catalyzes the sequential reduction of acetyl-CoA to acetaldehyde and then to ethanol under fermentative conditions. The NH2-terminal region of the AdhE protein is highly homologous to aldehyde:NAD(+) oxidoreductases, whereas the COOH-terminal region is homologous to a family of Fe2+-dependent ethanol:NAD(+) oxidoreductases. This fusion protein also functions as a pyruvate formate lyase deactivase. E. coli cannot grow aerobically on ethanol as the sole carbon and energy source because of inadequate rate of adhE transcription and the vulnerability of the AdhE protein to metal-catalyzed oxidation. In this study, we characterized 16 independent two-step mutants with acquired and improved aerobic growth ability on ethanol, The AdhE proteins in these mutants catalyzed the sequential oxidation of ethanol to acetaldehyde and to acetyl-CoA All first stage mutants grew on ethanol with a doubling time of about 240 min. Sequence analysis of a randomly chosen mutant revealed an Ala-267 --> Thr substitution in the acetaldehyde:NAD(+) oxidoreductase domain of AdhE. All second stage mutants grew on ethanol with a doubling time of about 90 min, and all of them produced an AdhE(E568K)(A267T/), Purified AdhE(A267T) and AdhE(A267T/E568K) showed highly elevated acetaldehyde dehydrogenase activities. It therefore appears that when AdhE catalyzes the two sequential reactions in the counter-physiological direction, acetaldehyde dehydrogenation is the rate-limiting step. Both mutant proteins were more thermosensitive than the wild-type protein, but AdhE(A267T/E568K) was more thermal stable than AdhE(A267T). Since both mutant enzymes exhibited similar kinetic properties, the second mutation probably conferred an increased growth rate on ethanol by stabilizing AdhE(A267T).	Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Lleida 25198, Spain; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Universitat de Lleida; Harvard University; Harvard Medical School	Ros, J (corresponding author), Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Lleida 25198, Spain.		Membrillo-Hernández, Jorge/AAN-4996-2021; Ros, Joaquim/A-7507-2010; Tamarit, Jordi/C-6316-2008; Cabiscol, Elisa/A-4584-2009; ROS, Joaquim/ABG-7487-2020	Membrillo-Hernández, Jorge/0000-0001-7650-8116; Tamarit, Jordi/0000-0003-3227-6928; Cabiscol, Elisa/0000-0003-2795-7999; ROS, Joaquim/0000-0003-0901-8648	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040993] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40993] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLYN MKB, 1996, ESCHERICHIA COLI SAL, P1715; BORONAT A, 1981, BIOCHIM BIOPHYS ACTA, V672, P98, DOI 10.1016/0304-4165(81)90283-X; BORONAT A, 1979, J BACTERIOL, V140, P320, DOI 10.1128/JB.140.2.320-326.1979; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P134; CABISCOL E, 1994, J BIOL CHEM, V269, P6592; CHEN YM, 1991, J BACTERIOL, V173, P8009, DOI 10.1128/jb.173.24.8009-8013.1991; CHEN YM, 1989, J BACTERIOL, V171, P6097, DOI 10.1128/jb.171.11.6097-6105.1989; CLARK D, 1980, J BACTERIOL, V141, P177, DOI 10.1128/JB.141.1.177-183.1980; CLARK DP, 1980, J BACTERIOL, V144, P179, DOI 10.1128/JB.144.1.179-184.1980; CLARK DP, 1989, FEMS MICROBIOL LETT, V63, P223, DOI 10.1111/j.1574-6968.1989.tb03398.x; COCKS GT, 1974, J BACTERIOL, V118, P83, DOI 10.1128/JB.118.1.83-88.1974; CONWAY T, 1989, J BACTERIOL, V171, P3754, DOI 10.1128/jb.171.7.3754-3759.1989; CUNNINGHAM PR, 1986, MOL GEN GENET, V205, P487, DOI 10.1007/BF00338087; GOODLOVE PE, 1989, GENE, V85, P209, DOI 10.1016/0378-1119(89)90483-6; Gupta S, 2000, FEMS MICROBIOL LETT, V182, P51, DOI 10.1111/j.1574-6968.2000.tb08872.x; KESSLER D, 1992, J BIOL CHEM, V267, P18073; KESSLER D, 1991, FEBS LETT, V281, P59, DOI 10.1016/0014-5793(91)80358-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONARDO MR, 1993, J BACTERIOL, V175, P870, DOI 10.1128/JB.175.3.870-878.1993; Leonardo MR, 1996, J BACTERIOL, V178, P6013, DOI 10.1128/jb.178.20.6013-6018.1996; LEVINE RL, 1984, METHOD ENZYMOL, V107, P370; Lu Z, 1998, J BIOL CHEM, V273, P8308, DOI 10.1074/jbc.273.14.8308; LURZ R, 1979, ARCH MICROBIOL, V120, P255, DOI 10.1007/BF00423073; MCPHEDRAN P, 1961, J BACTERIOL, V81, P852, DOI 10.1128/JB.81.6.852-857.1961; Membrillo-Hernandez J, 1999, J BACTERIOL, V181, P7390; Membrillo-Hernandez J, 1999, J BACTERIOL, V181, P7571; MILLER JG, 1972, SHORT COURSE BACTERI; RACKER E, 1955, METHOD ENZYMOL, V1, P500, DOI 10.1016/0076-6879(55)01084-7; Rosenthal B, 1997, J BACTERIOL, V179, P3736, DOI 10.1128/jb.179.11.3736-3745.1997; Sambrook J., 2002, MOL CLONING LAB MANU; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SMITH LT, 1980, ARCH BIOCHEM BIOPHYS, V203, P663, DOI 10.1016/0003-9861(80)90224-6; SRIDHARA S, 1969, J BACTERIOL, V98, P87, DOI 10.1128/JB.98.1.87-95.1969; Tamarit J, 1998, J BIOL CHEM, V273, P3027, DOI 10.1074/jbc.273.5.3027; Wood W. A., 1961, BACTERIA	35	69	88	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33869	33875		10.1074/jbc.M005464200	http://dx.doi.org/10.1074/jbc.M005464200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10922373	Green Published, hybrid, Green Submitted			2022-12-25	WOS:000090104600095
J	Suzuki, M; Yoshida, S; Adman, ET; Blank, A; Loeb, LA				Suzuki, M; Yoshida, S; Adman, ET; Blank, A; Loeb, LA			Thermus aquaticus DNA polymerase I mutants with altered fidelity - Interacting mutations in the O-helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLENOW FRAGMENT; CRYSTAL-STRUCTURE; ACTIVE-SITE; REPLICATION; ERRORS; MUTAGENESIS; RESOLUTION; COMPLEX; PROGRAM	Phe(667) in the conserved O-helix of Thermus aquaticus (Taq) DNA polymerase I (pol I) is known to be important for discrimination against dideoxy-NTPs. We show here that Phe(667) is also important for base selection fidelity. In a forward mutation assay at high polymerase concentration, wild type pol I catalyzed frequent A --> T and G --> T transversions and -1 frameshifts at nonreiterated sites involving loss of a purine immediately downstream of a pyrimidine, The mutants F667L and A661E,I665T, F667L exhibited large decreases in A --> T and G --> T transversions, and the triple mutant displayed reduction in the aforementioned -1 frameshifts as well. Kinetic analysis showed that the F667L and A661E,I665T, F667L polymerases discriminated against synthesis of A:A mispairs more effectively and catalyzed less extension of A:A mispairs than the wild type enzyme. These data indicate that Phe(667) functions in maintaining the error frequency and spectrum, and the catalytic efficiency, of wild type pol I. We also found that the strong general mutator activity conferred by the single A661E substitution was entirely suppressed in the A661E, I665T,F667L polymerase, exemplifying how interactions among O-helix residues can contribute to fidelity. We discuss the mutator and anti-mutator mutations in light of recently obtained three-dimensional structures of T, aquaticus pol I.	Univ Washington, Dept Pathol, Joseph Gottstein Mem Canc Res Lab, Seattle, WA 98195 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Nagoya Univ, Sch Med, Dis Mechanism & Control Res Inst, Nagoya, Aichi 4668550, Japan	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Nagoya University	Loeb, LA (corresponding author), Univ Washington, Dept Pathol, Joseph Gottstein Mem Canc Res Lab, Box 357705, Seattle, WA 98195 USA.	laloeb@u.washington.edu	Suzuki, Motoshi/I-7246-2014	Suzuki, Motoshi/0000-0003-0682-5006	NATIONAL CANCER INSTITUTE [R01CA078885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG001751] Funding Source: NIH RePORTER; NCI NIH HHS [CA78885] Funding Source: Medline; NIA NIH HHS [AG01751] Funding Source: Medline; NIEHS NIH HHS [P30 ES07033] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; Astatke M, 1998, J MOL BIOL, V278, P147, DOI 10.1006/jmbi.1998.1672; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345; BERNSTEIN FC, 1977, EUR J BIOCHEM, V80, P319, DOI 10.1111/j.1432-1033.1977.tb11885.x; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; FEIG DI, 1994, P NATL ACAD SCI USA, V91, P6609, DOI 10.1073/pnas.91.14.6609; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; HUANG MM, 1992, NUCLEIC ACIDS RES, V20, P4567, DOI 10.1093/nar/20.17.4567; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOYCE CM, 1992, J BIOL CHEM, V267, P24485; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KORNBERG A, 1992, DNA REPLICATION, P498; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li Y, 1999, P NATL ACAD SCI USA, V96, P9491, DOI 10.1073/pnas.96.17.9491; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; LOEB LA, 1982, ANNU REV BIOCHEM, V51, P429, DOI 10.1146/annurev.bi.51.070182.002241; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; MIZRAHI V, 1986, P NATL ACAD SCI USA, V83, P231, DOI 10.1073/pnas.83.2.231; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Suzuki M, 1996, P NATL ACAD SCI USA, V93, P9670, DOI 10.1073/pnas.93.18.9670; Suzuki M, 1997, J BIOL CHEM, V272, P11228; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027	34	59	65	5	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32728	32735		10.1074/jbc.M000097200	http://dx.doi.org/10.1074/jbc.M000097200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10906120	hybrid			2022-12-25	WOS:000090003800050
J	Bell, SD; Jackson, SP				Bell, SD; Jackson, SP			Mechanism of autoregulation by an archaeal transcriptional repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE PROMOTER ELEMENT; RNA-POLYMERASE-II; DNA-BINDING; PREINITIATION COMPLEX; FACTOR REQUIREMENTS; TATA-BOX; PROTEIN; EUKARYOTES; SHIBATAE	The basal transcription machinery of archaea corresponds to the core components of the eucaryal RNA polymerase II apparatus. Thus, archaea possess a complex multi-subunit RNA polymerase, a TATA box-binding protein and a protein termed transcription factor B (TFB), which is a homologue of eucaryal transcription factor IIB (TFIIB). Intriguingly, archaeal genome sequencing projects have revealed the existence of homologues of bacterial transcriptional regulators. To investigate the mechanism of transcriptional regulation in archaea we have studied one such molecule, Lrs14, a Sulfolobus solfataricus P2 homologue of the bacterial leucine-responsive regulatory protein, Lrp. We find that purified Lrs14 specifically represses the transcription of its own gene in a reconstituted in vitro transcription system. Furthermore, we show that Lrs14 binding sites overlap the basal promoter elements of the Lrs14 promoter and reveal that binding of Lrs14 to these sites prevents promoter recognition by TATA box-binding protein and TFB.	Inst Canc & Dev Biol, Wellcome Trust, Cambridge CB2 1QR, England; Inst Canc & Dev Biol, CRC, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	Wellcome Trust Sanger Institute; University of Cambridge	Jackson, SP (corresponding author), Inst Canc & Dev Biol, Wellcome Trust, Tennis Court Rd, Cambridge CB2 1QR, England.		Dry, Kate/I-2328-2014; Jackson, Stephen Philip/R-4548-2019	Jackson, Stephen Philip/0000-0001-9317-7937; Bell, Stephen/0000-0002-8474-6592				Aravind L, 1999, NUCLEIC ACIDS RES, V27, P4658, DOI 10.1093/nar/27.23.4658; Bell SD, 2000, J BIOL CHEM, V275, P12934, DOI 10.1074/jbc.275.17.12934; Bell SD, 1999, MOL CELL, V4, P971, DOI 10.1016/S1097-2765(00)80226-9; Bell SD, 1998, P NATL ACAD SCI USA, V95, P15218, DOI 10.1073/pnas.95.26.15218; Bell SD, 1998, TRENDS MICROBIOL, V6, P222, DOI 10.1016/S0966-842X(98)01281-5; Bell SD, 1999, P NATL ACAD SCI USA, V96, P13662, DOI 10.1073/pnas.96.24.13662; Burke TW, 1998, COLD SPRING HARB SYM, V63, P75, DOI 10.1101/sqb.1998.63.75; Kosa PF, 1997, P NATL ACAD SCI USA, V94, P6042, DOI 10.1073/pnas.94.12.6042; Kyrpides NC, 1999, P NATL ACAD SCI USA, V96, P8545, DOI 10.1073/pnas.96.15.8545; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; Napoli A, 1999, J BACTERIOL, V181, P1474, DOI 10.1128/JB.181.5.1474-1480.1999; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Qureshi SA, 1997, EMBO J, V16, P2927, DOI 10.1093/emboj/16.10.2927; Qureshi SA, 1998, MOL CELL, V1, P389, DOI 10.1016/S1097-2765(00)80039-8; ROWLANDS T, 1994, SCIENCE, V264, P1326, DOI 10.1126/science.8191287; Sambrook J., 2002, MOL CLONING LAB MANU; Smale ST, 1998, COLD SPRING HARB SYM, V63, P21, DOI 10.1101/sqb.1998.63.21; Soppa J, 1999, MOL MICROBIOL, V31, P1295, DOI 10.1046/j.1365-2958.1999.01273.x; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088	20	79	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31624	31629		10.1074/jbc.M005422200	http://dx.doi.org/10.1074/jbc.M005422200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10900210	hybrid			2022-12-25	WOS:000089858900012
J	Blain, SW; Massague, J				Blain, SW; Massague, J			Different sensitivity of the transforming growth factor-ss cell cycle arrest pathway to c-Myc and IMDM-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA; TGF-BETA; TRANSCRIPTIONAL ACTIVITY; MAMMALIAN-CELLS; I RECEPTORS; MDM2; PROTEINS; REPRESSION; ACTIVATION; P15(INK4B)	Recently, the oncoprotein MDM-2 was implicated in the transforming growth factor-beta (TGF-beta) growth inhibitory pathway by the finding that prolonged, constitutive expression of MDM-2 in mink lung epithelial cells could overcome the antiproliferative effect of TGF-beta (Sun, P., Dong, P., Dal, K., Hannon, G. J., and Beach, D. (1998) Science 282, 2270-2272). However, using Mv1Lu cells conditionally expressing MDM-2, we found that MDM-2 does not overcome TGF-beta-mediated growth arrest. No detectable changes were observed in various TGF-beta responses, including cell cycle arrest, activation of transcriptional reporters, and TGF-beta-dependent Smad2/3 nuclear accumulation. This finding was in direct contrast to the effect of forcing c-Myc expression, a bona fide member of the TGF-beta growth inhibitory pathway, which renders cells refractory to TGF-beta-induced cell cycle arrest. Our results suggest that an MDM-2-dependent increase in cell cycle progression may allow the acquisition of additional mutations over time and that these alterations then allow cells to evade a TGF-beta-mediated growth arrest. Our conclusion is that, whereas c-Mye down-regulation by TGF-beta is a required event in the cell cycle arrest response of epithelial cells, MDM-2 is not a direct participant in the normal TGF-beta antiproliferative response.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, POB 116,1275 York Ave, New York, NY 10021 USA.			Massague, Joan/0000-0001-9324-8408				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; AMATI B, 1994, CURR OPIN GENET DEV, P4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Connell-Crowley L, 1998, CURR BIOL, V8, P65, DOI 10.1016/S0960-9822(98)70021-1; Dang CV, 1999, MOL CELL BIOL, V19, P1; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Iavarone A, 1997, NATURE, V387, P417; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MALLIRI A, 1996, CELL GROWTH DIFFER, V7, P12991; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yam CH, 1999, CANCER RES, V59, P5075; Yap DBS, 1999, ONCOGENE, V18, P7681, DOI 10.1038/sj.onc.1202954; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	32	20	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32066	32070		10.1074/jbc.M006496200	http://dx.doi.org/10.1074/jbc.M006496200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10906337	hybrid			2022-12-25	WOS:000089858900071
J	Maccarrone, M; Lorenzon, T; Bari, M; Melino, G; Finazzi-Agro, A				Maccarrone, M; Lorenzon, T; Bari, M; Melino, G; Finazzi-Agro, A			Anandamide induces apoptosis in human cells via vanilloid receptors - Evidence for a protective role of cannabinoid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; MESENTERIC VASODILATION; CB2 RECEPTORS; GLIOMA-CELLS; DELTA(9)-TETRAHYDROCANNABINOL; DEGRADATION; INDUCTION; CALCIUM; AGONIST; NEURONS	The endocannabinoid anandamide (AEA) is shown to induce apoptotic bodies formation and DNA fragmentation, hallmarks of programmed cell death, in human neuroblastoma CHP100 and lymphoma U937 cells. RNA and protein synthesis inhibitors like actinomycin D and cycloheximide reduced to one-fifth the number of apoptotic bodies induced by AEA, whereas the AEA transporter inhibitor AM404 or the AEA hydrolase inhibitor ATFMK significantly increased the number of dying cells. Furthermore, specific antagonists of cannabinoid or vanilloid receptors potentiated or inhibited cell death induced by AEA, respectively. Other endocannabinoids such as 2-arachidonoylglycerol, linoleoylethanolamide, oleoylethanolamide, and palmitoylethanolamide did not promote cell death under the same experimental conditions. The formation of apoptotic bodies induced by AEA was paralleled by increases in intracellular calcium (3-fold over the controls), mitochondrial uncoupling (6-fold), and cytochrome c release (3-fold). The intracellular calcium chelator EGTA-AM reduced the number of apoptotic bodies to 40% of the controls, and electrotransferred anti-cytochrome c monoclonal antibodies fully prevented apoptosis induced by AEA, Moreover, 5-lipoxygenase inhibitors 5,8,11,14-eicosatetraynoic acid and MK886, cyclooxygenase inhibitor indomethacin, caspase-3 and caspase-9 inhibitors Z-DEVD-FMK and Z-LEHD-FMK, but not nitric oxide synthase inhibitor Nw-nitro-L-arginine methyl ester, significantly reduced the cell death-inducing effect of AEA. The data presented indicate a protective role of cannabinoid receptors against apoptosis induced by AEA via vanilloid receptors.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy	University of Rome Tor Vergata	Finazzi-Agro, A (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Via Tor Vergata 135, I-00133 Rome, Italy.	Finazzi@uniroma2.it						Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Ara G, 1996, PROSTAG LEUKOTR ESS, V54, P3, DOI 10.1016/S0952-3278(96)90075-7; Basavarajappa BS, 1999, J NEUROCHEM, V72, P522, DOI 10.1046/j.1471-4159.1999.0720522.x; Biro T, 1998, MOL BRAIN RES, V56, P89, DOI 10.1016/S0169-328X(98)00033-3; Chan GCK, 1998, J NEUROSCI, V18, P5322, DOI 10.1523/JNEUROSCI.18-14-05322.1998; Datta K, 1998, J BIOL CHEM, V273, P28163, DOI 10.1074/jbc.273.43.28163; De Petrocellis L, 1998, P NATL ACAD SCI USA, V95, P8375, DOI 10.1073/pnas.95.14.8375; Derocq JM, 1998, FEBS LETT, V425, P419, DOI 10.1016/S0014-5793(98)00275-0; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; Deutsch DG, 1997, J CLIN INVEST, V100, P1538, DOI 10.1172/JCI119677; Di Marzo V, 1998, NATURE, V396, P636, DOI 10.1038/25267; Di Marzo V, 1999, EUR J BIOCHEM, V264, P258, DOI 10.1046/j.1432-1327.1999.00631.x; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Goparaju SK, 1998, FEBS LETT, V422, P69, DOI 10.1016/S0014-5793(97)01603-7; Jarai Z, 1999, P NATL ACAD SCI USA, V96, P14136, DOI 10.1073/pnas.96.24.14136; KOUTEK B, 1994, J BIOL CHEM, V269, P22937; Maccarrone M, 2000, J BIOL CHEM, V275, P13484, DOI 10.1074/jbc.275.18.13484; Maccarrone M, 2000, FEBS LETT, V468, P176, DOI 10.1016/S0014-5793(00)01223-0; Maccarrone M, 1996, EUR J BIOCHEM, V241, P297, DOI 10.1111/j.1432-1033.1996.0297t.x; MACCARRONE M, 1992, EUR J BIOCHEM, V205, P995, DOI 10.1111/j.1432-1033.1992.tb16866.x; Maccarrone M, 1997, CELL DEATH DIFFER, V4, P396, DOI 10.1038/sj.cdd.4400255; Maccarrone M, 2000, LANCET, V355, P1326, DOI 10.1016/S0140-6736(00)02115-2; Maccarrone M, 1998, J BIOL CHEM, V273, P32332, DOI 10.1074/jbc.273.48.32332; Macho A, 1999, CELL DEATH DIFFER, V6, P155, DOI 10.1038/sj.cdd.4400465; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; Neame SJ, 1998, J CELL BIOL, V142, P1583, DOI 10.1083/jcb.142.6.1583; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Piomelli D, 1999, P NATL ACAD SCI USA, V96, P5802, DOI 10.1073/pnas.96.10.5802; Pop E, 1999, CURR OPIN CHEM BIOL, V3, P418, DOI 10.1016/S1367-5931(99)80062-3; Ruiz L, 1999, FEBS LETT, V458, P400, DOI 10.1016/S0014-5793(99)01073-X; Saito M, 1999, NEUROCHEM RES, V24, P1107, DOI 10.1023/A:1020704218574; Sanchez C, 1998, FEBS LETT, V436, P6, DOI 10.1016/S0014-5793(98)01085-0; Sarker KP, 2000, FEBS LETT, V472, P39, DOI 10.1016/S0014-5793(00)01425-3; SCHWARZ H, 1994, J NEUROIMMUNOL, V55, P107, DOI 10.1016/0165-5728(94)90152-X; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Smart D, 2000, TRENDS PHARMACOL SCI, V21, P134, DOI 10.1016/S0165-6147(00)01459-0; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Sugimoto T, 1999, BRAIN RES, V818, P147, DOI 10.1016/S0006-8993(98)01227-X; Ushmorov A, 1999, BLOOD, V93, P2342, DOI 10.1182/blood.V93.7.2342.407k09_2342_2352; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; Vanags DM, 1997, CELL DEATH DIFFER, V4, P479, DOI 10.1038/sj.cdd.4400269; VANDENBERGHE PA, 1990, J IMMUNOL METHODS, V127, P197, DOI 10.1016/0022-1759(90)90069-8; Wagner JA, 1999, HYPERTENSION, V33, P429, DOI 10.1161/01.HYP.33.1.429; Walker JM, 1999, P NATL ACAD SCI USA, V96, P12198, DOI 10.1073/pnas.96.21.12198; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	50	283	293	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31938	31945		10.1074/jbc.M005722200	http://dx.doi.org/10.1074/jbc.M005722200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913156	hybrid			2022-12-25	WOS:000089858900055
J	Miyakawa, Y; Drachman, JG; Gallis, B; Kaushansky, A; Kaushansky, K				Miyakawa, Y; Drachman, JG; Gallis, B; Kaushansky, A; Kaushansky, K			A structure-function analysis of serine/threonine phosphorylation of the thrombopoietin receptor, c-Mpl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BLOOD-PLATELETS; PROTEIN-TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ACTIVATION; KINASE; CELLS; IDENTIFICATION; PROLIFERATION; PATHWAY; DOMAIN	Thrombopoietin (TPO), the critical regulator of platelet production, acts by binding to its cell surface receptor, c-Mpl. Numerous studies have shown that TPO binding leads to JAK2 kinase activation and Tyr phosphorylation of c-Mpl and several intracellular signaling intermediates, events vital for the biological activity of the hormone. In contrast, virtually nothing is known of the role of Ser or Thr phosphorylation of c-Mpl. By using phosphoamino acid analysis we found that Ser residues of c-Mpl were constitutively phosphorylated in receptor-bearing cells, levels that were increased following exposure of cells to TPO. To identify which residues were modified, and to determine the functional consequences of their phosphorylation, we generated a series of Ser to Ala mutations of a truncated c-Mpl receptor (T69) capable of supporting TPO-induced cell growth. Of the eight Ser within T69 we found that at least four are phosphorylated in TPO-stimulated cells. The mutation of each of these residues alone had minimal effects on TPO-induced proliferation, but substitution of all of the phosphoserine residues with Ala reduced the capacity of the receptor to support cell growth by over 50%. Additionally, the Ser at cytoplasmic position 18 is not detectably phosphorylated. However, the mutation of Ser-18 to Ala nearly abrogates TPO-induced proliferation and co-precipitation of JAK2 with Mpl. This study provides the first systematic analysis of the role of Ser residues in c-Mpl signaling.	Univ Washington, Sch Med, Div Hematol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Div Cardiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Kaushansky, K (corresponding author), Univ Washington, Sch Med, Div Hematol, 1959 NE Pacific St, Seattle, WA 98195 USA.	kkaushan@u.washington.edu	Kaushansky, Alexis/U-6695-2019		NATIONAL CANCER INSTITUTE [R01CA031615] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064228] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049855] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA31615] Funding Source: Medline; NHLBI NIH HHS [1RO1HL64228] Funding Source: Medline; NIDDK NIH HHS [R01 DK49855] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander WS, 1996, BLOOD, V87, P2162, DOI 10.1182/blood.V87.6.2162.bloodjournal8762162; BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; CHEN JC, 1995, BLOOD, V86, P4054, DOI 10.1182/blood.V86.11.4054.bloodjournal86114054; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Dorsch M, 1997, J EXP MED, V186, P1947, DOI 10.1084/jem.186.12.1947; Drachman JG, 1999, J BIOL CHEM, V274, P13480, DOI 10.1074/jbc.274.19.13480; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; LIU L, 1995, J BIOL CHEM, V270, P22422, DOI 10.1074/jbc.270.38.22422; Luoh SM, 2000, MOL CELL BIOL, V20, P507, DOI 10.1128/MCB.20.2.507-515.2000; MIYAKAWA Y, 1995, BLOOD, V86, P23, DOI 10.1182/blood.V86.1.23.bloodjournal86123; Miyakawa Y, 1996, BLOOD, V87, P439, DOI 10.1182/blood.V87.2.439.bloodjournal872439; MU SX, 1995, BLOOD, V86, P4532, DOI 10.1182/blood.V86.12.4532.bloodjournal86124532; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Oda A, 1996, BLOOD, V88, P1330, DOI 10.1182/blood.V88.4.1330.bloodjournal8841330; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; Rojnuckarin P, 1999, BLOOD, V94, P1273, DOI 10.1182/blood.V94.4.1273.416k04_1273_1282; Sawyer ST, 1996, J BIOL CHEM, V271, P32430, DOI 10.1074/jbc.271.50.32430; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; Solar GP, 1998, BLOOD, V92, P4, DOI 10.1182/blood.V92.1.4.413k38_4_10; Stomski FC, 1999, BLOOD, V94, P1933; Van Linden AA, 2000, J BIOL CHEM, V275, P6996, DOI 10.1074/jbc.275.10.6996; Zhang LR, 1997, J BIOL CHEM, V272, P14762, DOI 10.1074/jbc.272.23.14762	25	19	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32214	32219		10.1074/jbc.M005080200	http://dx.doi.org/10.1074/jbc.M005080200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10918061	hybrid			2022-12-25	WOS:000089858900091
J	Schwarz, DA; Barry, G; Eliasof, SD; Petroski, RE; Conlon, PJ; Maki, RA				Schwarz, DA; Barry, G; Eliasof, SD; Petroski, RE; Conlon, PJ; Maki, RA			Characterization of gamma-aminobutyric acid receptor GABA(B(1e)), a GABA(B(1)) splice variant encoding a truncated receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; LIGAND-BINDING; EXTRACELLULAR DOMAIN; TERMINAL DOMAIN; GABA-RECEPTORS; EXPRESSION; GABA(B)R1; AGONIST; IDENTIFICATION; SELECTIVITY	We have identified a splice variant encoding only the extracellular ligand-binding domain of the gamma-aminobutyric acid B (GABA(B)) receptor subunit GABA(B(1a)). This isoform, which we have named GABA(B(1e)), is detected in both rats and humans, While GABA(B(1e)) is a minor component of the total pool of GABA(B(1)) transcripts detected in the central nervous system, it is the primary isoform found in all peripheral tissues examined. When expressed in a heterologous system, the truncated receptor is both secreted and membrane associated. However, GABA(B(1e)) lacks the ability to bind the radiolabeled antagonist [H-3]CGP 54626A, activate G-protein coupled inwardly rectifying potassium channels, or inhibit forskolin-induced cAMP production when it is expressed alone or together with GABA(B(2)). Interestingly, when co-expressed with GABA(B(2)), not only does the truncated receptor heterodimerize with GABA(B(2)), he association is of sufficient avidity to disrupt the normal GABA(B(1a))/GABA(B(2)) association. Despite this strong interaction, GABA(B(1e)) fails to disrupt G-protein coupled inwardly rectifying potassium activation by the full-length heterodimer pair of GABA(B(1a))/GABA(B(2)).	Neurocrine Biosci Inc, San Diego, CA 92121 USA	Neurocrine Biosciences	Schwarz, DA (corresponding author), Neurocrine Biosci Inc, 10555 Sci Ctr Dr, San Diego, CA 92121 USA.		Barry, Guy/C-1188-2011	Barry, Guy/0000-0001-6404-086X				Benke D, 1999, J BIOL CHEM, V274, P27323, DOI 10.1074/jbc.274.38.27323; Bettler B, 1998, CURR OPIN NEUROBIOL, V8, P345, DOI 10.1016/S0959-4388(98)80059-7; BOWERY NG, 1981, EUR J PHARMACOL, V71, P53, DOI 10.1016/0014-2999(81)90386-1; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; Han GM, 1999, J BIOL CHEM, V274, P10008, DOI 10.1074/jbc.274.15.10008; Hawrot E, 1998, FEBS LETT, V432, P103, DOI 10.1016/S0014-5793(98)00794-7; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kaupmann K, 1998, P NATL ACAD SCI USA, V95, P14991, DOI 10.1073/pnas.95.25.14991; KERR DI, 1995, PHARMACOL THERAPEUT, V6, P187; KERR DIB, 1993, EUR J PHARMACOL, V236, P239, DOI 10.1016/0014-2999(93)90594-8; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Malitschek B, 1999, MOL PHARMACOL, V56, P448, DOI 10.1124/mol.56.2.448; Martin SC, 1999, MOL CELL NEUROSCI, V13, P180, DOI 10.1006/mcne.1999.0741; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; ONG J, 1990, LIFE SCI, V46, P1489, DOI 10.1016/0024-3205(90)90421-M; Peters HC, 1998, NEUROGENETICS, V2, P47, DOI 10.1007/s100480050051; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354	28	91	97	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32174	32181		10.1074/jbc.M005333200	http://dx.doi.org/10.1074/jbc.M005333200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10906333	hybrid			2022-12-25	WOS:000089858900085
J	Takeshita, A; Watanabe, A; Takada, Y; Hanazawa, S				Takeshita, A; Watanabe, A; Takada, Y; Hanazawa, S			Selective stimulation by ceramide of the expression of the a isoform of retinoic acid and retinoid X receptors in osteoblastic cells - A role of sphingosine 1-phosphate-mediated AP-1 in the ligand-dependent transcriptional activity of these receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT JE; PROTEIN-KINASE; CHLORAMPHENICOL ACETYLTRANSFERASE; NEUTRAL SPHINGOMYELINASE; INTERLEUKIN-6 SYNTHESIS; GENE-EXPRESSION; MC3T3-E1 CELLS; ACTIVATION; ALPHA; BETA	Recent studies have demonstrated that sphingosine l-phosphate (SPP) plays a functional role as a signaling molecule in gene expression in several kinds of cells. The present study demonstrates selective expression by ceramide of retinoic acid receptor-alpha (RAR-alpha) and retinoic X receptor-alpha (RXR-alpha) in osteoblastic MC3T3-E1 cells and a functional role of SPP-mediated AP-1 in the signaling mechanism of ligand-dependent transcriptional activity of heterodimers of these receptors in the cells. C-2- and C-6-ceramides selectively stimulated the expression of RAR-alpha and RXR-alpha genes, but not that of beta and gamma isoform genes of RAR and RXR, in the cells. The C-2-ceramide-induced stimulation was clearly inhibited by DL-threo-dihydrosphingosine, an inhibitor of sphingosine kinase. SPP also selectively stimulated the expression of both receptors and increased the specific binding of the nuclear proteins to direct repeat 5 (DR-S), a consensus sequence of RAR-RXR. In addition, SPP markedly stimulated transient chloramphenicol acetyltransferase (CAT) activity of retinoic acid-dependent transcriptional activity in the cells transfected with a DR-B-CAT reporter gene. The SPP stimulation was activation protein-1 (AP-l)-dependent, because the SPP stimulatory action toward these nuclear gene expressions and the transient CAT activity were inhibited by antisense c-fos and c-jun oligonucleotides. We observed that SPP actually stimulated AP-1 transcriptional activity in the cells. This study suggests an important role of SPP-mediated AP-1 in the selective expression of RAR-a! and RXR-alpha in osteoblastic cells via the sphingosine pathway.	Meikai Univ, Sch Dent, Dept Oral Microbiol, Sakado, Saitama 3500283, Japan; Snow Brand Milk Prod Co Ltd, Tech Res Inst, Kawagoe, Saitama 3501165, Japan	Meikai University; Snow Brand Milk Products Co., Ltd.	Hanazawa, S (corresponding author), Kyushu Univ, Fac Dent Sci, Div Oral Infect Dis & Immunol, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.	hanazawa@dent.kyushu-u.ac.jp						Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNETTE E, 1992, NUCLEIC ACIDS RES, V20, P1151, DOI 10.1093/nar/20.5.1151; Chen Y, 1996, J BIOL CHEM, V271, P31602, DOI 10.1074/jbc.271.49.31602; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANAZAWA S, 1994, J BIOL CHEM, V269, P21379; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Kanety H, 1996, J BIOL CHEM, V271, P9895, DOI 10.1074/jbc.271.17.9895; Kastner P, 1997, DEVELOPMENT, V124, P313; Kitajima I, 1996, BONE, V19, P263, DOI 10.1016/8756-3282(96)00181-0; Kozawa O, 1997, J BIOL CHEM, V272, P25099, DOI 10.1074/jbc.272.40.25099; Kozawa O, 1997, FEBS LETT, V418, P149, DOI 10.1016/S0014-5793(97)01366-5; LIU R, 1995, BIOCHEM BIOPH RES CO, P676; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; Luo JM, 1996, MECH DEVELOP, V55, P33, DOI 10.1016/0925-4773(95)00488-2; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Maniatis T., 1982, MOL CLONING LAB MANU; Manji SS, 1998, J CELL PHYSIOL, V176, P1; MURRAY IA, 1991, NUCLEIC ACIDS RES, V19, P6648; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; ROBERTS AB, 1984, RETINOIDS, V2, P28; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHUTZE S, 1995, IMMUNOBIOLOGY, V193, P193, DOI 10.1016/S0171-2985(11)80543-7; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; SU Y, 1994, J BIOL CHEM, V269, P16512; Takeda H, 1998, FEBS LETT, V422, P255, DOI 10.1016/S0014-5793(98)00005-2; TAKESHITA A, 1995, J IMMUNOL, V155, P419; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; Yasuda H, 1999, BONE, V25, P109, DOI 10.1016/S8756-3282(99)00121-0	38	18	19	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32220	32226		10.1074/jbc.M002569200	http://dx.doi.org/10.1074/jbc.M002569200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10915783	hybrid			2022-12-25	WOS:000089858900092
J	Chou, KM; Kukhanova, M; Cheng, YC				Chou, KM; Kukhanova, M; Cheng, YC			A novel action of human apurinic/apyrimidinic endonuclease - Excision of L-configuration deoxyribonucleoside analogs from the 3 ' termini of DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APURINIC ENDONUCLEASE; L-DIOXOLANE-CYTIDINE; IN-VITRO; CYTOSINE-ARABINOSIDE; NUCLEOSIDE ANALOGS; ANTITUMOR-ACTIVITY; PROTEIN APE/REF-1; BINDING ACTIVITY; AP-ENDONUCLEASE; NUCLEAR-PROTEIN	beta-L-Dioxolane-cytidine (L-OddC, BCH-4556, Troxacitabine) is a novel unnatural stereochemical nucleoside analog that is under phase II clinical study for cancer treatment. This nucleoside analog could be phosphorylated and subsequently incorporated into the 3' terminus of DNA. The cytotoxicity of L-OddC was correlated with the amount of L-OddCMP in DNA, which depends on the incorporation by DNA polymerases and the removal by exonucleases. Here we reported the purification and identification of the major enzyme that could preferentially remove L-OddCMP compared with dCMP from the 3' termini of DNA in human cells. Surprisingly, this enzyme was found to be apurinic/apyrimidinic endonuclease (APE1) (1), a well characterized DNA base excision repair protein, APE1 preferred to remove L- over D-configuration nucleosides from 3' termini of DNA. The efficiency of removal of these deoxycytidine analogs were as follows: L-OddC > beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine > beta-L-2',3'-dideoxycytidine > beta-L-2',3'-dideoxy-3'-thiocytidine > beta-D-2',3'-dideoxycytidine > beta-D-2',2'-difluorodeoxycytidine > beta-D-8'-deoxycytidine greater than or equal to beta-D-arabinofuranosylcytosine. This report is the first demonstration that an exonuclease can preferentially excise L-configuration nucleoside analogs. This discovery suggests that APE1 could be critical for the activity of L-OddC or other L-nucleoside analogs and may play additional important roles in cells that were not previously known.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Cheng, YC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, Sterling Hall Med,B315,333 Cedar St, New Haven, CT 06520 USA.				NCI NIH HHS [CA 63477] Funding Source: Medline; NIAID NIH HHS [AI 39204] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA063477, R01CA063477] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBRUZZESE JL, 1991, J CLIN ONCOL, V9, P491, DOI 10.1200/JCO.1991.9.3.491; BARZILAY G, 1995, BIOESSAYS, V17, P713, DOI 10.1002/bies.950170808; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Chaudhry MA, 1999, BIOCHEM PHARMACOL, V57, P531, DOI 10.1016/S0006-2952(98)00327-X; CHEN DS, 1993, RADIAT RES, V135, P405, DOI 10.2307/3578882; COHEN SS, 1977, CANCER-AM CANCER SOC, V40, P509, DOI 10.1002/1097-0142(197707)40:1+<509::AID-CNCR2820400717>3.0.CO;2-8; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DEVINENI D, 1995, CLIN PHARMACOKINET, V28, P351, DOI 10.2165/00003088-199528050-00002; Dutschman GE, 1998, ANTIMICROB AGENTS CH, V42, P1799, DOI 10.1128/AAC.42.7.1799; Fritz G, 1999, ONCOGENE, V18, P1033, DOI 10.1038/sj.onc.1202394; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; GOSSELIN G, 1994, ANTIMICROB AGENTS CH, V38, P1292, DOI 10.1128/AAC.38.6.1292; Grindey G B, 1990, Cancer Invest, V8, P313, DOI 10.3109/07357909009017602; Grove KL, 1996, CANCER RES, V56, P4187; GROVE KL, 1995, CANCER RES, V55, P3008; HERTEL LW, 1990, CANCER RES, V50, P4417; HIDDEMANN W, 1991, ANN HEMATOL, V62, P119, DOI 10.1007/BF01702925; Izumi T, 1998, CARCINOGENESIS, V19, P525, DOI 10.1093/carcin/19.3.525; Kadhim SA, 1997, CANCER RES, V57, P4803; Kukhanova M, 2000, NUCLEOS NUCLEOT NUCL, V19, P435, DOI 10.1080/15257770008033019; KUKHANOVA M, 1995, J BIOL CHEM, V270, P23055, DOI 10.1074/jbc.270.39.23055; Lamartine J, 1997, CYTOGENET CELL GENET, V78, P31, DOI 10.1159/000134621; Lin TS, 1996, J MED CHEM, V39, P1757, DOI 10.1021/jm950836q; LONGLEY MJ, 1993, METHOD ENZYMOL, V218, P587; Ludwig DL, 1998, MUTAT RES-DNA REPAIR, V409, P17, DOI 10.1016/S0921-8777(98)00039-1; LUND B, 1993, CANCER TREAT REV, V19, P45, DOI 10.1016/0305-7372(93)90026-N; Marty J., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P123; Mazur DJ, 1999, J BIOL CHEM, V274, P19655, DOI 10.1074/jbc.274.28.19655; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Moore LE, 1997, CANCER CHEMOTH PHARM, V39, P532, DOI 10.1007/s002800050609; Nakagawa Y, 1997, ACTA MED OKAYAMA, V51, P195; PATNAIK A, 2000, P AM ASSOC CANC RES, V41, P815; Pelicano H, 2000, MOL PHARMACOL, V57, P1051; Perrino Fred W., 1999, Cell Biochemistry and Biophysics, V30, P331, DOI 10.1007/BF02738118; PERRINO FW, 1994, J BIOL CHEM, V269, P16357; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P1087, DOI 10.1093/nar/19.5.1087; Rothwell DG, 1997, ONCOL RES, V9, P275; RUTH JL, 1981, MOL PHARMACOL, V20, P415; SHELTON MJ, 1993, ANN PHARMACOTHER, V27, P480; SKALSKI V, 1995, BIOCHEM PHARMACOL, V50, P815, DOI 10.1016/0006-2952(95)00205-E; SKALSKI V, 1993, J BIOL CHEM, V268, P23234; TABOR CW, 1976, ANNU REV BIOCHEM, V45, P285, DOI 10.1146/annurev.bi.45.070176.001441; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yacoub A, 1997, CANCER RES, V57, P5457; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997	48	100	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31009	31015		10.1074/jbc.M004082200	http://dx.doi.org/10.1074/jbc.M004082200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906132	hybrid			2022-12-25	WOS:000089762700040
J	Pei, L				Pei, L			Activation of mitogen-activated protein kinase cascade regulates pituitary tumor-transforming gene transactivation function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MAP KINASES; SUBSTRATE RECOGNITION; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; HUMAN HOMOLOG; S6 KINASE; C-MYC; IDENTIFICATION	Pituitary tumor-transforming gene (PTTG) is a recently characterized oncogene that can act as a transcriptional activator. In this study, we have characterized the transactivation domain of PTTG. Transient transfection of fusion constructs containing GAL4 DNA-binding domain and different parts of PTTG indicated the transactivation domain of PTTG is located between amino acids 119 and 164. Mitogen-activated protein (MAP) kinase cascade is important in the regulation of cell growth, apoptosis, and differentiation. Therefore, we have explored the possibility that this kinase cascade plays a role in regulating PTTG transactivation function. Activation of the MAP kinase cascade by epidermal growth factor or an expression vector for a constitutively active form of the MAP kinase kinase (MEK1) led to stimulation of PTTG transactivation activity. We showed that PTTG is phosphorylated in vitro on Ser(162) by MAP kinase and that this phosphorylation site plays an essential role in PTTG transactivation function. We demonstrated that PTTG interacts directly with MEK1 through a putative SH3 domain-binding site located between amino acids 51 and 54 and that this interaction is crucial for PTTG transactivation function. In addition, we showed that activation of MAP kinase phosphorylation cascade resulted in nuclear translocation of PTTG. Together, our data establish that a growth factor-stimulated MAP kinase plays an important role in modulating PTTG function.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Div Endocrinol & Metab, Sch Med, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pei, L (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Div Endocrinol & Metab, Sch Med, 8700 Beverly Blvd,D2019, Los Angeles, CA 90048 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK056608, K08DK002346] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-56608, DK-02346] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Chien WW, 2000, J BIOL CHEM, V275, P19422, DOI 10.1074/jbc.M910105199; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORENO S, 1990, NATURE, V374, P131; NAGAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207; Papin C, 1996, ONCOGENE, V12, P2213; Pei L, 1998, J BIOL CHEM, V273, P5219, DOI 10.1074/jbc.273.9.5219; Pei L, 1999, J BIOL CHEM, V274, P3151, DOI 10.1074/jbc.274.5.3151; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Ramos-Morales F, 2000, ONCOGENE, V19, P403, DOI 10.1038/sj.onc.1203320; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Saez C, 1999, ONCOGENE, V18, P5473, DOI 10.1038/sj.onc.1202914; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SETH A, 1991, J BIOL CHEM, V266, P23521; SETH A, 1992, J BIOL CHEM, V267, P24796; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVER PA, 1988, GENE DEV, V2, P707, DOI 10.1101/gad.2.6.707; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	52	62	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31191	31198		10.1074/jbc.M002451200	http://dx.doi.org/10.1074/jbc.M002451200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906323	hybrid			2022-12-25	WOS:000089762700063
J	Villemain, JL; Ma, YJ; Giedroc, DP; Morrical, SW				Villemain, JL; Ma, YJ; Giedroc, DP; Morrical, SW			Mutations in the N-terminal cooperativity domain of gene 32 protein alter properties of the T4 DNA replication and recombination systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; NUCLEIC-ACID COMPLEXES; BINDING-PROTEIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; POLYMERASE HOLOENZYME; BACTERIOPHAGE-T4; PURIFICATION; MECHANISM; DISSOCIATION	The gene 32 protein (gp32) of bacteriophage T4 is the essential single-stranded DNA (ssDNA)-binding protein required for phage DNA replication and recombination, gp32 binds ssDNA with high affinity and cooperativity, forming contiguous clusters that optimally configure the ssDNA for recognition by DNA polymerase or recombination enzymes. The precise roles of gp32 affinity and cooperativity in promoting replication and recombination have yet to be defined, however. Previous work established that the N-terminal "B-domain" of gp32 is essential for cooperativity and that point mutations at Arg(4) and Lys(3) positions have varying and dramatic effects on gp32-ssDNA interactions. Therefore, we examined the effects of six different gp32 B-domain mutants on T4 in vitro systems for DNA synthesis and homologous pairing, We find that the B-domain is essential for gp32's stimulation of these reactions. The stimulatory efficacy of gp32 B-domain mutants generally correlates with the hierarchy of relative ssDNA binding affinities, i.e, wild-type gp32 approximate to R4K > K3A approximate to R4Q > R4T > R4G much greater than gp32-B. However, the functional defect of a particular mutant is often greater than can be explained simply by its ability to saturate the ssDNA at equilibrium, suggesting additional defects in the proper assembly and activity of DNA polymerase and recombinase complexes on ssDNA, which may derive from a decreased lifetime of gp32-ssDNA clusters.	Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	University of Vermont; Texas A&M University System; Texas A&M University College Station	Morrical, SW (corresponding author), Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA.	smorrica@zoo.uvm.edu	Giedroc, David/A-8608-2018	Giedroc, David/0000-0002-2342-1620	NIGMS NIH HHS [GM48847, GM42569] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM042569, R01GM042569, R56GM048847, R01GM048847] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; BITTNER M, 1979, J BIOL CHEM, V254, P9565; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkarev A, 1999, EMBO J, V18, P4498, DOI 10.1093/emboj/18.16.4498; CHA TA, 1989, J BIOL CHEM, V264, P12220; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; DOTTO GP, 1981, P NATL ACAD SCI-BIOL, V78, P5421, DOI 10.1073/pnas.78.9.5421; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; GIEDROC DP, 1986, P NATL ACAD SCI USA, V83, P8452, DOI 10.1073/pnas.83.22.8452; GIEDROC DP, 1990, J BIOL CHEM, V265, P11444; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; JIANG H, 1993, J BIOL CHEM, V268, P7904; Karpel R.L., 1990, BIOL NONSPECIFIC DNA, P103; KODADEK T, 1988, J BIOL CHEM, V263, P9427; KODADEK T, 1990, J BIOL CHEM, V265, P20966; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; KOWALCZYKOWSKI SC, 1990, LANDOLTBORNSTEIN NUM, P244; Lefebvre SD, 1997, J MOL BIOL, V272, P312, DOI 10.1006/jmbi.1997.1264; LOHMAN TM, 1986, J MOL BIOL, V187, P603, DOI 10.1016/0022-2836(86)90338-4; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1984, BIOCHEMISTRY-US, V23, P4665, DOI 10.1021/bi00315a023; MILLER H, 1987, METHOD ENZYMOL, V152, P145; Morrical SW, 1996, J BIOL CHEM, V271, P20198, DOI 10.1074/jbc.271.33.20198; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; QIU HW, 1994, J BIOL CHEM, V269, P2773; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; Sweezy MA, 1997, J MOL BIOL, V266, P927, DOI 10.1006/jmbi.1996.0829; VILLEMAIN JL, 1993, BIOCHEMISTRY-US, V32, P11235, DOI 10.1021/bi00092a038; Villemain JL, 1996, BIOCHEMISTRY-US, V35, P14395, DOI 10.1021/bi961482n; Villemain JL, 1996, J BIOL CHEM, V271, P27623, DOI 10.1074/jbc.271.44.27623; Webster G, 1997, FEBS LETT, V411, P313, DOI 10.1016/S0014-5793(97)00747-3; WILLIAMS KR, 1994, MOL BIOL BACTERIOP T, V4, P301; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; Yang C, 1997, NAT STRUCT BIOL, V4, P153, DOI 10.1038/nsb0297-153	39	11	22	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31496	31504		10.1074/jbc.M002902200	http://dx.doi.org/10.1074/jbc.M002902200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906124	hybrid			2022-12-25	WOS:000089762700104
J	Fan, MY; Goodwin, M; Vu, T; Brantley-Finley, C; Gaarde, WA; Chambers, TC				Fan, MY; Goodwin, M; Vu, T; Brantley-Finley, C; Gaarde, WA; Chambers, TC			Vinblastine-induced phosphorylation of Bcl-2 and Bcl-X-L is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAY; RAF-1/BCL-2 PHOSPHORYLATION; CANCER CELLS; APOPTOSIS; DEATH; ACTIVATION; RAF-1	Microtubule-damaging agents arrest cells at G(2)/M and induce apoptosis in association with phosphorylation of the anti-apoptotic proteins Bcl-2 and Bcl-X-L. Because microtubule inhibitors activate JNK, we sought to determine whether JNK was responsible for Bcl-2/Bcl-X-L phosphorylation in KB-3 cells treated with vinblastine. Two major endogenous forms of JNK, p46(JNK1) and p54(JNK2), were present in KB-3 cells, and both isoforms were activated by vinblastine as determined by Mono Q chromatography. We used antisense oligonucleotides (AS) to specifically inhibit their expression. A combination of AS-JNK1 with AS-JNK2 inhibited by 80% vinblastine-induced phosphorylation of two known JNK substrates, c-Jun and ATF-2. In addition, AS-JNK1/2 inhibited vinblastine-induced phosphorylation of Bcl-2 by 85% and that of Bcl-X-L by 65%. Stable expression of the JNK scaffold protein JIP-1 blocked vinblastine-induced phosphorylation of c-Jun and ATF-2, but did not affect Bcl-2/Bcl-X-L phosphorylation, confirming a bifurcation in JNK signaling involving both nuclear and non-nuclear substrates. Vinblastine-induced phosphorylation of Raf-1 was unaffected by AS-JNK1/2 and was associated with loss of activity for MEK substrate in vitro and inactivation of ERK in vivo. These results provide evidence for a direct role of the JNK pathway in apoptotic regulation through Bcl-2/ Bcl-X-L phosphorylation.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; ISIS Pharmaceut Inc, Dept Mol Pharmacol, Carlsbad, CA 92008 USA	University of Arkansas System; University of Arkansas Medical Sciences; Isis Pharmaceuticals Inc	Chambers, TC (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Mail Slot 516,4301 W Markham St, Little Rock, AR 72205 USA.	chamberstimothyc@exchange.uams.edu			NCI NIH HHS [CA-75577] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075577] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attalla H, 1998, BIOCHEM BIOPH RES CO, V247, P616, DOI 10.1006/bbrc.1998.8870; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Blagosklonny MV, 1999, LEUKEMIA, V13, P1028, DOI 10.1038/sj.leu.2401449; Blagosklonny MV, 1997, CANCER RES, V57, P130; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Haskell CM., 1995, CANC TREATMENT, P78; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Rowinsky E. K., 1998, CHEMOTHERAPY SOURCE, P387; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; Torres K, 1998, CANCER RES, V58, P3620; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	29	264	276	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29980	29985		10.1074/jbc.M003776200	http://dx.doi.org/10.1074/jbc.M003776200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10913135	hybrid			2022-12-25	WOS:000089577900010
J	Inoue, S; Lin, SL; Inoue, Y				Inoue, S; Lin, SL; Inoue, Y			Chemical analysis of the developmental pattern of polysialylation in chicken brain - Expression of only an extended form of polysialyl chains during embryogenesis and the presence of disialyl residues in both embryonic and adult chicken brains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; PERFORMANCE LIQUID-CHROMATOGRAPHY; ANION-EXCHANGE CHROMATOGRAPHY; CENTRAL-NERVOUS-SYSTEM; 2-KETO-3-DEOXY-D-GLYCERO-D-GALACTONONONIC ACID; 2 POLYSIALYLTRANSFERASES; CARBOHYDRATE UNITS; RAT BRAIN; GLYCOPROTEINS; STX	Recent studies have demonstrated the involvement of two polysialyltransferases in neural cell adhesion molecule (N-CAM) polysialylation. The availability of cDNAs encoding these enzymes facilitated studies on polysialylation of N-CAM. However, there is a dearth of detailed structural information on the degree of polymerization (DP), DP ranges, and the influence of embryogenesis on the DP. It is also unclear how many polysialic acid (polySia) chains are attached to a single core N-glycan. In this paper we applied new, efficient, and sensitive high pressure liquid chromatography methods to qualitatively and quantitatively analyze the polySia structures expressed on embryonic and adult chicken brain N-CAM. Our studies resulted in the following new findings. 1) The DP of the polySia chains was invariably 40-50 throughout developmental stages from embryonic day 5 to 21 after fertilization. In contrast, glycopeptides containing polySia with shorter DPs, ranging from 15 to 35, were isolated from adult brain. 2) Chemical evidence showed glycan chains abundant in Neu5Ac alpha 2,8Neu5Ac were expressed during all developmental stages including adult. 3) Levels of both di- and polySia were found to show distinctive changes during embryonic development.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan	Academia Sinica - Taiwan	Inoue, Y (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.	syinoue@gate.sinica.edu.tw			NHLBI NIH HHS [NHRI-GT-EX89B805P] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; ASHWELL G, 1994, ANAL BIOCHEM, V222, P495, DOI 10.1006/abio.1994.1523; BITTERSUERMANN D, 1987, IMMUNOL RES, V6, P225, DOI 10.1007/BF02935517; BONFANTI L, 1992, NEUROSCIENCE, V49, P419, DOI 10.1016/0306-4522(92)90107-D; Chaplin M. F., 1994, CARBOHYDRATE ANAL PR, P27; Close BE, 2000, J BIOL CHEM, V275, P4484, DOI 10.1074/jbc.275.6.4484; Close BE, 1998, J BIOL CHEM, V273, P34586, DOI 10.1074/jbc.273.51.34586; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; FINNE J, 1982, J BIOL CHEM, V257, P1966; FINNE J, 1983, LANCET, V2, P355; FINNE J, 1983, BIOCHEM BIOPH RES CO, V112, P482, DOI 10.1016/0006-291X(83)91490-0; FINNE J, 1987, J IMMUNOL, V138, P4402; Funakoshi Y, 1997, GLYCOBIOLOGY, V7, P195, DOI 10.1093/glycob/7.2.195; HARA S, 1987, ANAL BIOCHEM, V164, P138, DOI 10.1016/0003-2697(87)90377-0; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HOFFMAN S, 1982, J BIOL CHEM, V257, P7720; INOUE S, 1986, J BIOL CHEM, V261, P5256; Inoue S, 1996, J BIOL CHEM, V271, P24341, DOI 10.1074/jbc.271.40.24341; Inoue Y, 1999, PURE APPL CHEM, V71, P789, DOI 10.1351/pac199971050789; KITAJIMA K, 1992, ANAL BIOCHEM, V205, P244, DOI 10.1016/0003-2697(92)90430-F; KITAZUME S, 1994, J BIOL CHEM, V269, P22712; Kojima N, 1996, J BIOL CHEM, V271, P22058, DOI 10.1074/jbc.271.36.22058; Kojima N, 1997, J BIOCHEM-TOKYO, V122, P1265; Kudo M, 1998, GLYCOBIOLOGY, V8, P771, DOI 10.1093/glycob/8.8.771; Kudo M, 1996, J BIOL CHEM, V271, P32667, DOI 10.1074/jbc.271.51.32667; Lin SL, 1999, GLYCOBIOLOGY, V9, P807, DOI 10.1093/glycob/9.8.807; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; MANZI AE, 1994, J BIOL CHEM, V269, P23617; MCCOY RD, 1985, J BIOL CHEM, V260, P2695; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; NOMOTO H, 1982, ARCH BIOCHEM BIOPHYS, V218, P335, DOI 10.1016/0003-9861(82)90352-6; OKA S, 1995, J BIOL CHEM, V270, P19357, DOI 10.1074/jbc.270.33.19357; Ong E, 1998, GLYCOBIOLOGY, V8, P415, DOI 10.1093/glycob/8.4.415; RUTISHAUSER U, 1992, DEVELOPMENT, P99; Rutishauser U, 1996, CURR OPIN CELL BIOL, V8, P679, DOI 10.1016/S0955-0674(96)80109-8; Sato C, 1999, ANAL BIOCHEM, V266, P102, DOI 10.1006/abio.1998.2921; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SEKI T, 1993, NEUROSCI RES, V17, P265, DOI 10.1016/0168-0102(93)90111-3; Sevigny MB, 1998, GLYCOBIOLOGY, V8, P857, DOI 10.1093/glycob/8.9.857; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; VIMR ER, 1984, P NATL ACAD SCI-BIOL, V81, P1971, DOI 10.1073/pnas.81.7.1971; Wood GK, 1997, MOL BRAIN RES, V51, P69, DOI 10.1016/S0169-328X(97)00209-X; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628; Zhang Y, 1999, J BIOL CHEM, V274, P6183, DOI 10.1074/jbc.274.10.6183; Zhang Y, 1997, ANAL BIOCHEM, V250, P245, DOI 10.1006/abio.1997.2225; ZUBER C, 1992, J BIOL CHEM, V267, P9965	47	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29968	29979		10.1074/jbc.M004150200	http://dx.doi.org/10.1074/jbc.M004150200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10908565	hybrid			2022-12-25	WOS:000089577900009
J	Horie, K; Insel, PA				Horie, K; Insel, PA			Retrovirally mediated transfer of a G protein-coupled receptor kinase (GRK) dominant-negative mutant enhances endogenous calcitonin receptor signaling in Chinese hamster ovary cells - GRK inhibition enhances expression of receptors and receptor mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(1B)-ADRENERGIC RECEPTOR; DOWN-REGULATION; DESENSITIZATION; PHOSPHORYLATION; IDENTIFICATION; ISOFORMS	G protein-coupled receptor kinases (GRKs) initiate pathways leading to agonist-dependent phosphorylation and desensitization of G protein-coupled receptors. However, the role of GRKs in modulation of signaling properties of native receptors has not been clearly defined. Here we addressed this question by generating Chinese hamster ovary (CHO) cells stably expressing a dominant-negative mutant of GRK2 (DN-GRK2), K220R, using retrovirally mediated gene transfer, and we assessed function of the endogenously expressed calcitonin (CT) receptors. We found that CT-mediated responses were prominently enhanced in CHO cells expressing DN-GRK2 compared with mock-infected control CHO cells with similar to 3-fold increases in CT-promoted cAMP production in whole cells and adenylyl cyclase activity in membrane fractions. CT-promoted phosphoinositide hydrolysis was also enhanced in DN-GRK2 cells. The number of CT receptors was increased similar to 3-fold in DN-GRK2 cells, as assessed by I-125-salmon CT-specific binding, and this was associated with increased CT receptor mRNA levels. These results indicate that DN-GRK2 has multiple consequences for CT receptor signaling, but a primary effect is an increase in CT receptor mRNA and receptor number and, in turn, enhanced CT receptor signaling. As such, our findings provide a mechanistic basis for previous observations regarding agonist-promoted down-regulation of CT receptors and for resistance and escape from response to CT in vitro and in vivo. Moreover, the data suggest that blunting of receptor desensitization by DN-GRK2 blocks a GRK-mediated tonic inhibition of CT receptor expression and response. We speculate that GRKs play a similar role for other G protein-coupled receptors as well.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Insel, PA (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.							Aragay AM, 1998, P NATL ACAD SCI USA, V95, P2985, DOI 10.1073/pnas.95.6.2985; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Chen ST, 1996, P NATL ACAD SCI USA, V93, P10057, DOI 10.1073/pnas.93.19.10057; Diviani D, 1996, J BIOL CHEM, V271, P5049; FORCE T, 1992, AM J PHYSIOL, V262, pF1110, DOI 10.1152/ajprenal.1992.262.6.F1110; George SE, 1997, J NEUROCHEM, V69, P1278; GOTTESMAN M, 1983, METHOD ENZYMOL, V99, P197; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; HORIE K, 1995, MOL PHARMACOL, V48, P392; HORIE K, 1993, INVEST OPHTH VIS SCI, V34, P2769; HOUSSAMI S, 1994, ENDOCRINOLOGY, V135, P183, DOI 10.1210/en.135.1.183; Hughes RJ, 1996, AM J PHYSIOL-CELL PH, V270, pC885, DOI 10.1152/ajpcell.1996.270.3.C885; Iacovelli L, 1999, MOL PHARMACOL, V56, P316, DOI 10.1124/mol.56.2.316; Inoue D, 1999, ENDOCRINOLOGY, V140, P1060, DOI 10.1210/en.140.3.1060; KLIJN K, 1991, MOL PHARMACOL, V39, P407; KONG GH, 1994, J BIOL CHEM, V269, P13084; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lazari MDM, 1999, MOL ENDOCRINOL, V13, P866, DOI 10.1210/me.13.6.866; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Mundell SJ, 1997, MOL PHARMACOL, V51, P991, DOI 10.1124/mol.51.6.991; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; SEXTON PM, 1993, MOL ENDOCRINOL, V7, P815, DOI 10.1210/me.7.6.815; Shetzline MA, 1998, J BIOL CHEM, V273, P6756, DOI 10.1074/jbc.273.12.6756; Tucker C, 1997, J BIOL CHEM, V272, P9481; WADA S, 1995, ENDOCRINOLOGY, V136, P2611, DOI 10.1210/en.136.6.2611; Wada S, 1996, ENDOCRINOLOGY, V137, P1042, DOI 10.1210/en.137.3.1042; Xing MZ, 1999, J BIOL CHEM, V274, P10035, DOI 10.1074/jbc.274.15.10035	27	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29433	29440		10.1074/jbc.M003413200	http://dx.doi.org/10.1074/jbc.M003413200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10889199	hybrid			2022-12-25	WOS:000089439800036
J	Nguyen, VT; Ndoye, A; Grando, SA				Nguyen, VT; Ndoye, A; Grando, SA			Pemphigus vulgaris antibody identifies pemphaxin - A novel keratinocyte annexin-like molecule binding acetylcholine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	60th Annual Meeting of the Society-for-Investigative-Dermatology	MAY 05-09, 1999	CHICAGO, IL	Soc Investigat Dermatol			DERMO-EPIDERMAL SEPARATION; BLISTER-CAUSING ANTIBODIES; CELL-SURFACE; HUMAN SKIN; SUBCELLULAR-LOCALIZATION; CHOLINERGIC RECEPTORS; MUSCARINIC RECEPTOR; NEONATAL MICE; TENASCIN-C; CADHERIN	Because pemphigus vulgaris (PV) IgGs adsorbed on the rDsg3-Ig-His baculoprotein induced blisters in neonatal mice, it was proposed that anti-desmoglein 3 (Dsg 3) autoantibody causes PV. However, we found that rDsg3-Ig-His absorbs autoantibodies to different antigens, including a non-Dsg 3 keratinocyte protein of 130 kDa. This prompted our search for novel targets of PV autoimmunity. The PV IgG eluted from a 75-kDa keratinocyte protein band both stained epidermis in a pemphigus-like pattern and induced acantholysis in keratinocyte monolayers. Screening of a keratinocyte lambda gt11 cDNA library with this antibody identified clones carrying cDNA inserts encoding a novel molecule exhibiting similar to 40% similarity with annexin-2, named pemphaxin (PX). Recombinant PX (rPX-His) was produced in Escherichia coli M15 cells, and, because annexins can act as cholinergic receptors, its conformation was tested in a cholinergic radioligand binding assay, rPX-His specifically bound [H-3]acetylcholine, suggesting that PX is one of the keratinocyte cholinergic receptors known to be targeted by disease-causing PV antibodies. Preabsorption of PV sera with rPX-His eliminated acantholytic activity, and eluted antibody immunoprecipitated native PX This antibody alone did not cause skin blisters in vivo, but its addition to the preabsorbed PV IgG fraction restored acantholytic activity, indicating that acantholysis in PV results from synergistic action of antibodies to different keratinocyte self-antigens, including both acetylcholine receptors and desmosomal cadherins.	Univ Calif Davis, Med Ctr, Dept Dermatol, Sacramento, CA 95817 USA	University of California System; University of California Davis	Grando, SA (corresponding author), Univ Calif Davis, Med Ctr, Dept Dermatol, 4860 Y St,Suite 3400, Sacramento, CA 95817 USA.	sagrando@ucdavis.edu		Nguyen, Vu/0000-0002-1142-6352				AHMED AR, 1982, J AM ACAD DERMATOL, V7, P221; AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; Amagai M, 2000, J CLIN INVEST, V105, P625, DOI 10.1172/JCI8748; AMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968; AMAGAI M, 1994, J CLIN INVEST, V94, P59, DOI 10.1172/JCI117349; Amagai M, 1998, J CLIN INVEST, V102, P775, DOI 10.1172/JCI3647; Amagai M, 1999, J DERMATOL SCI, V20, P92, DOI 10.1016/S0923-1811(99)00016-X; ANHALT GJ, 1982, NEW ENGL J MED, V306, P1189, DOI 10.1056/NEJM198205203062001; Barwise JL, 1996, J CELL SCI, V109, P247; BASTIAN BC, 1993, J INVEST DERMATOL, V101, P359, DOI 10.1111/1523-1747.ep12365541; BEUTNER EH, 1985, INT J DERMATOL, V24, P405, DOI 10.1111/j.1365-4362.1985.tb05507.x; Chung CY, 1996, MOL BIOL CELL, V7, P883, DOI 10.1091/mbc.7.6.883; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; Cohen Lisa M., 1997, P209; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; CULARD JF, 1992, J INVEST DERMATOL, V98, P436, DOI 10.1111/1523-1747.ep12499850; CURTIS CAM, 1989, J BIOL CHEM, V264, P489; DEMANGE P, 1994, TRENDS BIOCHEM SCI, V19, P272, DOI 10.1016/0968-0004(94)90002-7; Ding X, 1999, J INVEST DERMATOL, V112, P739, DOI 10.1046/j.1523-1747.1999.00585.x; Donnelly SR, 1997, CELL MOL LIFE SCI, V53, P533, DOI 10.1007/s000180050068; FALCONE DJ, 1995, FASEB J, V9, pA412; Fan JL, 1999, J IMMUNOL, V163, P6228; FAVA RA, 1993, J INVEST DERMATOL, V101, P732, DOI 10.1111/1523-1747.ep12371684; Feliciani C, 2000, J INVEST DERMATOL, V114, P71, DOI 10.1046/j.1523-1747.2000.00835.x; Fujimoto K, 1997, J CELL SCI, V110, P311; Grando S. A., 1993, J EUR ACAD DERMATOL, V2, P72; GRANDO SA, 1989, AUTOIMMUNITY, V3, P247, DOI 10.3109/08916938908997095; GRANDO SA, 1993, SKIN PHARMACOL, V6, P135; GRANDO SA, 1990, J CLIN LAB IMMUNOL, V32, P137; GRANDO SA, 1989, ARCH DERMATOL, V125, P925, DOI 10.1001/archderm.125.7.925; Grando SA, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P41, DOI 10.1038/jidsymp.1997.10; GRANDO SA, 1997, CURR OPIN DERMATOL, V4, P262; Hajjar KA, 1997, ANN NY ACAD SCI, V811, P337, DOI 10.1111/j.1749-6632.1997.tb52013.x; HASHIMOTO K, 1989, J INVEST DERMATOL, V92, P310, DOI 10.1111/1523-1747.ep12277087; Hu ZL, 2000, NAT GENET, V24, P61, DOI 10.1038/71701; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; IWATSUKI K, 1995, BRIT J DERMATOL, V133, P209, DOI 10.1111/j.1365-2133.1995.tb02617.x; JONES PG, 1992, J BIOL CHEM, V267, P13993; JOST M, 1992, EUR J BIOCHEM, V207, P923, DOI 10.1111/j.1432-1033.1992.tb17125.x; JOST M, 1994, BIOCHEM J, V298, P553, DOI 10.1042/bj2980553; KARPATI S, 1993, J CELL BIOL, V122, P409, DOI 10.1083/jcb.122.2.409; KAWANA S, 1989, J INVEST DERMATOL, V92, P588, DOI 10.1111/1523-1747.ep12709624; Keith D, 1999, HUM MOL GENET, V8, P143, DOI 10.1093/hmg/8.1.143; Kitajima Y, 1999, J INVEST DERM SYMP P, V4, P137, DOI 10.1038/sj.jidsp.5640197; KITAJIMA Y, 1987, J INVEST DERMATOL, V89, P167, DOI 10.1111/1523-1747.ep12470554; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lin MS, 1997, CLIN EXP IMMUNOL, V107, P9; Ma ASP, 1996, ARCH DERMATOL RES, V288, P596, DOI 10.1007/s004030050109; Mahoney MG, 1999, J CLIN INVEST, V103, P461, DOI 10.1172/JCI5252; MATUSLEIBOVITCH N, 1992, BIOCHEM J, V285, P753, DOI 10.1042/bj2850753; Memar OM, 1996, J INVEST DERMATOL, V106, P261, DOI 10.1111/1523-1747.ep12340663; MEMAR OM, 1995, CHARACTERIZATION PEM; Morgan RO, 1997, CELL MOL LIFE SCI, V53, P508, DOI 10.1007/s000180050064; Moss SE, 1997, TRENDS CELL BIOL, V7, P87, DOI 10.1016/S0962-8924(96)10049-0; NAKAO H, 1994, EUR J BIOCHEM, V223, P901, DOI 10.1111/j.1432-1033.1994.tb19067.x; Nguyen VT, 1998, ARCH DERMATOL, V134, P971, DOI 10.1001/archderm.134.8.971; NGUYEN VT, 2000, IN PRESS AM J PATHOL; NGUYEN VT, 1993, J INVEST DERMATOL, V100, P349; Ohata Y, 1995, CLIN EXP DERMATOL, V20, P454, DOI 10.1111/j.1365-2230.1995.tb01376.x; PATEL HP, 1984, J INVEST DERMATOL, V83, P409, DOI 10.1111/1523-1747.ep12273480; Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451; Reutelingsperger CPM, 1997, CELL MOL LIFE SCI, V53, P527, DOI 10.1007/s000180050067; Rickman L, 1999, HUM MOL GENET, V8, P971, DOI 10.1093/hmg/8.6.971; Robinson JC, 1997, ORAL SURG ORAL MED O, V84, P349, DOI 10.1016/S1079-2104(97)90030-5; ROSENBERG FR, 1976, ARCH DERMATOL, V112, P962, DOI 10.1001/archderm.112.7.962; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; SCHENK S, 1995, BRIT J DERMATOL, V133, P13; Shtrom SS, 1996, J BIOL CHEM, V271, P25506, DOI 10.1074/jbc.271.41.25506; Siever DA, 1997, INT J BIOCHEM CELL B, V29, P1219, DOI 10.1016/S1357-2725(97)00057-5; SMITH PD, 1994, TRENDS GENET, V10, P241, DOI 10.1016/0168-9525(94)90171-6; STANLEY JR, 1995, CIBA F SYMP, V189, P107; STANLEY JR, 1984, J CLIN INVEST, V74, P313, DOI 10.1172/JCI111426; STANLEY JR, 1982, J CLIN INVEST, V70, P281, DOI 10.1172/JCI110615; STERZ R, 1986, BRAIN RES, V385, P99, DOI 10.1016/0006-8993(86)91551-9; SWANSON DL, 1983, J INVEST DERMATOL, V81, P258, DOI 10.1111/1523-1747.ep12518278; TAYLOR IK, 1975, EUR J PHARMACOL, V31, P319, DOI 10.1016/0014-2999(75)90055-2; Toto P, 2000, J IMMUNOL, V164, P522, DOI 10.4049/jimmunol.164.1.522; TRESSLER RJ, 1993, J CELL BIOCHEM, V53, P265, DOI 10.1002/jcb.240530311; Udey MC, 1999, JAMA-J AM MED ASSOC, V282, P572, DOI 10.1001/jama.282.6.572; ULUS IH, 1988, BIOCHEM PHARMACOL, V37, P2747, DOI 10.1016/0006-2952(88)90037-8; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; vonderMark K, 1997, CELL MOL LIFE SCI, V53, P539, DOI 10.1007/s000180050069; Whittock NV, 1999, J INVEST DERMATOL, V113, P940, DOI 10.1046/j.1523-1747.1999.00783.x; Witcher LL, 1996, J BIOL CHEM, V271, P10904, DOI 10.1074/jbc.271.18.10904; ZIMMERMAN UJP, 1995, BIOCHEM MOL BIOL INT, V35, P307	87	99	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29466	29476		10.1074/jbc.M003174200	http://dx.doi.org/10.1074/jbc.M003174200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	356JH	10899159	hybrid			2022-12-25	WOS:000089439800040
J	Shenai, BR; Sijwali, PS; Singh, A; Rosenthal, PJ				Shenai, BR; Sijwali, PS; Singh, A; Rosenthal, PJ			Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LYTIC PROTEASE; HUMAN CATHEPSIN-K; ESCHERICHIA-COLI; MALARIA PARASITES; PLASMEPSIN-II; ACTIVE-SITE; PRO-REGION; INTRAMOLECULAR CHAPERONE; PROTEINASE-INHIBITORS; HUMAN-ERYTHROCYTES	Trophozoites of the malaria parasite Plasmodium falciparum hydrolyze erythrocyte hemoglobin in an acidic food vacuole to provide amino acids for parasite protein synthesis, Cysteine protease inhibitors block hemoglobin degradation, indicating that a cysteine protease plays a key role in this process. A principal trophozoite cysteine protease was purified by affinity chromatography, Sequence analysis indicated that the protease is encoded by a previously unidentified gene, falcipain-2. Falcipain-2 was predominantly expressed in trophozoites, was concentrated in food vacuoles, and was responsible for at least 93% of trophozoite soluble cysteine protease activity. A construct encoding mature falcipain-2 and a small portion of the prodomain was expressed in Escherichia coli and refolded to active enzyme. Specificity for the hydrolysis of peptide substrates by native and recombinant falcipain-2 was very similar, and optimal at acid pH in a reducing environment, Under physiological conditions (pH 5.5, 1 mM glutathione), falcipain-2 hydrolyzed both native hemoglobin and denatured globin, Our results suggest that falcipain-2 can initiate cleavage of native hemoglobin in the P. falciparum food vacuole, that, following initial cleavages, the protease plays a key role in rapidly hydrolyzing globin fragments, and that a drug discovery effort targeted at this protease is appropriate.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94143 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Rosenthal, PJ (corresponding author), Univ Calif San Francisco, Box 0811, San Francisco, CA 94143 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035800, R56AI035800, R29AI035800] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01081] Funding Source: Medline; NIAID NIH HHS [AI35800] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ascoli F, 1981, Methods Enzymol, V76, P72; ATAMNA H, 1994, MOL BIOCHEM PARASIT, V67, P79, DOI 10.1016/0166-6851(94)90098-1; Atamna H, 1997, EUR J BIOCHEM, V250, P670, DOI 10.1111/j.1432-1033.1997.00670.x; Ayi K, 1998, FEBS LETT, V424, P257, DOI 10.1016/S0014-5793(98)00185-9; BAILLY E, 1992, J PROTOZOOL, V39, P593, DOI 10.1111/j.1550-7408.1992.tb04856.x; BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083; Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMME D, 1994, J BIOL CHEM, V269, P30238; CHAKRABARTI D, 1994, MOL BIOCHEM PARASIT, V66, P97, DOI 10.1016/0166-6851(94)90039-6; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; deDominguez NDG, 1996, BLOOD, V87, P4448, DOI 10.1182/blood.V87.10.4448.bloodjournal87104448; DLUZEWSKI AR, 1986, EXP PARASITOL, V62, P416, DOI 10.1016/0014-4894(86)90050-0; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; Eggleson KK, 1999, J BIOL CHEM, V274, P32411, DOI 10.1074/jbc.274.45.32411; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Francis SE, 1996, MOL BIOCHEM PARASIT, V83, P189, DOI 10.1016/S0166-6851(96)02772-7; GABAY T, 1993, EXP PARASITOL, V77, P261, DOI 10.1006/expr.1993.1084; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; Haque TS, 1999, J MED CHEM, V42, P1428, DOI 10.1021/jm980641t; HILL J, 1994, FEBS LETT, V352, P155, DOI 10.1016/0014-5793(94)00940-6; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; Jerala R, 1998, J BIOL CHEM, V273, P11498, DOI 10.1074/jbc.273.19.11498; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P7134, DOI 10.1073/pnas.92.15.7134; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; LaLonde JM, 1999, BIOCHEMISTRY-US, V38, P862, DOI 10.1021/bi9822271; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LI YY, 1995, J BIOL CHEM, V270, P25127, DOI 10.1074/jbc.270.42.25127; Marie-Claire C, 1999, J MOL BIOL, V285, P1911, DOI 10.1006/jmbi.1998.2449; MASON RW, 1987, BIOCHEM J, V248, P449, DOI 10.1042/bj2480449; McQueney MS, 1997, J BIOL CHEM, V272, P13955, DOI 10.1074/jbc.272.21.13955; Mills BJ, 1996, BIOCHEM PHARMACOL, V52, P401, DOI 10.1016/0006-2952(96)00241-9; Moon RP, 1998, ADV EXP MED BIOL, V436, P397; Mukhopadhyay A, 1997, Adv Biochem Eng Biotechnol, V56, P61; Olliaro P, 1996, JAMA-J AM MED ASSOC, V275, P230, DOI 10.1001/jama.275.3.230; Olliaro PL, 1999, PHARMACOL THERAPEUT, V81, P91, DOI 10.1016/S0163-7258(98)00036-9; Olson JE, 1999, BIOORGAN MED CHEM, V7, P633, DOI 10.1016/S0968-0896(99)00004-8; Pasquier C, 1999, PROTEIN ENG, V12, P381, DOI 10.1093/protein/12.5.381; Peters RJ, 1998, BIOCHEMISTRY-US, V37, P12058, DOI 10.1021/bi980883v; Podobnik M, 1997, J MOL BIOL, V271, P774, DOI 10.1006/jmbi.1997.1218; RAMOS C, 1994, J BIOL CHEM, V269, P7006; RICH DH, 1986, BIOCHEM J, V235, P731, DOI 10.1042/bj2350731; ROSENTHAL PJ, 1993, BIOCHIM BIOPHYS ACTA, V1173, P91, DOI 10.1016/0167-4781(93)90250-H; ROSENTHAL PJ, 1989, MOL BIOCHEM PARASIT, V35, P177, DOI 10.1016/0166-6851(89)90120-5; ROSENTHAL PJ, 1994, J MOL BIOL, V241, P312, DOI 10.1006/jmbi.1994.1506; Rosenthal PJ, 1996, ANTIMICROB AGENTS CH, V40, P1600, DOI 10.1128/AAC.40.7.1600; ROSENTHAL PJ, 1991, J CLIN INVEST, V88, P1467, DOI 10.1172/JCI115456; ROSENTHAL PJ, 1992, MOL BIOCHEM PARASIT, V51, P143, DOI 10.1016/0166-6851(92)90209-3; Rosenthal PJ, 1996, MOL BIOCHEM PARASIT, V83, P131, DOI 10.1016/S0166-6851(96)02763-6; ROSENTHAL PJ, 1988, J CLIN INVEST, V82, P1560, DOI 10.1172/JCI113766; ROSENTHAL PJ, 1987, J EXP MED, V166, P816, DOI 10.1084/jem.166.3.816; ROSENTHAL PJ, 1993, J CLIN INVEST, V91, P1052, DOI 10.1172/JCI116262; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; Rudolph R, 1996, FASEB J, V10, P49, DOI 10.1096/fasebj.10.1.8566547; SALAS F, 1995, INFECT IMMUN, V63, P2120, DOI 10.1128/IAI.63.6.2120-2125.1995; SAUL A, 1990, MOL BIOCHEM PARASIT, V42, P55, DOI 10.1016/0166-6851(90)90112-Y; SAUL A, 1988, MOL BIOCHEM PARASIT, V27, P35, DOI 10.1016/0166-6851(88)90022-9; Semenov A, 1998, ANTIMICROB AGENTS CH, V42, P2254, DOI 10.1128/AAC.42.9.2254; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; Silva AM, 1996, P NATL ACAD SCI USA, V93, P10034, DOI 10.1073/pnas.93.19.10034; SMITH SM, 1989, J BIOL CHEM, V264, P20487; TAYLOR MAJ, 1992, PROTEIN ENG, V5, P455, DOI 10.1093/protein/5.5.455; Thompson SK, 1997, P NATL ACAD SCI USA, V94, P14249, DOI 10.1073/pnas.94.26.14249; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VITALE A, 1992, BIOESSAYS, V14, P151, DOI 10.1002/bies.950140303; White NJ, 1998, BRIT MED BULL, V54, P703, DOI 10.1093/oxfordjournals.bmb.a011721; YAYON A, 1984, EMBO J, V3, P2695, DOI 10.1002/j.1460-2075.1984.tb02195.x	78	301	309	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29000	29010		10.1074/jbc.M004459200	http://dx.doi.org/10.1074/jbc.M004459200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10887194	hybrid			2022-12-25	WOS:000089330700087
J	Antonin, W; Meyer, HA; Hartmann, E				Antonin, W; Meyer, HA; Hartmann, E			Interactions between Spc2p and other components of the endoplasmic reticulum translocation sites of the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL PEPTIDASE ACTIVITY; PROTEIN-TRANSPORT; ER MEMBRANE; COMPLEX; SEC11; GENE; SUBUNITS; DISTINCT; HOMOLOG; MUTANT	In yeast, the endoplasmic reticulum membrane proteins Sec11p and Spc3p are essential for the cleavage of signal peptides of nascent polypeptide chains during their passage through translocation sites. Genetic and biochemical experiments demonstrate that Sec11p and Spc3p are tightly associated with two other proteins, Spc1p and Spc2p, whose functions are largely unknown. Using anti-Spc2p antibodies, we show here that this heterotetrameric complex associates with Sbh1p and Sbh2p, the beta -subunits of the Sec61p complex and the Ssh1p complex respectively. Depletion of Spc2p decreased the enzymatic activity of the SPC in vitro, led to a loss of Spc1p, and led to a down-regulation of the amount of Sec11p and Spc3p in the endoplasmic reticulum. Moreover, the deletion of Spc2p also decreased the expression level of Sbh2p. These data implicate that Spc2p not only enhances the enzymatic activity of the SPC but also facilitates the interactions between different components of the translocation site.	Univ Gottingen, Biochem Abt 2, Zentrum Biochem & Mol Zellbiol, D-37073 Gottingen, Germany	University of Gottingen	Hartmann, E (corresponding author), Univ Gottingen, Biochem Abt 2, Zentrum Biochem & Mol Zellbiol, Heinrich Duker Weg 12, D-37073 Gottingen, Germany.		Antonin, Wolfram/P-3648-2019; Hartmann, Enno/C-5687-2013; Antonin, Wolfram/A-8656-2014	Antonin, Wolfram/0000-0003-4669-379X; Antonin, Wolfram/0000-0003-4669-379X				Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; Fang H, 1996, J BIOL CHEM, V271, P16460, DOI 10.1074/jbc.271.28.16460; Fang H, 1997, J BIOL CHEM, V272, P13152, DOI 10.1074/jbc.272.20.13152; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; Johnson CH, 1999, YEAST, V15, P799, DOI 10.1002/(SICI)1097-0061(19990630)15:9&lt;799::AID-YEA419&gt;3.0.CO;2-N; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; Kalies KU, 1996, J BIOL CHEM, V271, P3925; Kalies KU, 1998, J CELL BIOL, V141, P887, DOI 10.1083/jcb.141.4.887; LIVELY MO, 1983, J BIOL CHEM, V258, P9488; Meyer HA, 1997, J BIOL CHEM, V272, P13159, DOI 10.1074/jbc.272.20.13159; Mullins C, 1996, J BIOL CHEM, V271, P29094, DOI 10.1074/jbc.271.46.29094; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIKORSKI RS, 1989, GENETICS, V122, P19; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VanValkenburgh C, 1999, J BIOL CHEM, V274, P11519, DOI 10.1074/jbc.274.17.11519; WALTER P, 1983, METHOD ENZYMOL, V96, P84; YADEAU JT, 1991, P NATL ACAD SCI USA, V88, P517, DOI 10.1073/pnas.88.2.517; ZWIZINSKI C, 1980, J BIOL CHEM, V255, P7973	26	20	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34068	34072		10.1074/jbc.M006126200	http://dx.doi.org/10.1074/jbc.M006126200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10921929	Green Published, hybrid			2022-12-25	WOS:000165095300012
J	Vancompernolle, K; Boonefaes, T; Mann, M; Fiers, W; Grooten, J				Vancompernolle, K; Boonefaes, T; Mann, M; Fiers, W; Grooten, J			Tumor necrosis factor-induced microtubule stabilization mediated by hyperphosphorylated oncoprotein 18 promotes cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DESTABILIZING ACTIVITY; FACTOR RECEPTOR; INTACT-CELLS; PHOSPHORYLATION; STATHMIN; GENE; DYNAMICS; IDENTIFICATION; PHOSPHOPROTEIN	Tumor necrosis factor (TNF)-induced cell death in the fibrosarcoma cell line L929 occurs independently of caspase activation and cytochrome c release. However, it is dependent on mitochondria and is characterized by increased production of reactive oxygen intermediates that are essential to the death process. To identify signaling molecules involved in this TNF-induced, reactive oxygen intermediate-dependent cell death pathway, we performed a comparative study by two-dimensional gel electrophoresis of phosphoproteins from a mitochondria-enriched fraction derived from TNF-treated and control cells. TNF induced rapid and persistent phosphorylation of the phosphorylation-responsive regulator of the microtubule (MT) dynamics, oncoprotein 18 (Op18). By using induced overexpression of wild type Op18 and phosphorylation site-deficient mutants S25A/S38A and S16A/S63A in L929 cells, we show that TNF-induced phosphorylation on each of the four Ser residues of Op18 promotes cell death and that Ser(16) and Ser(63) are the primary sites, This hyperphosphorylation of Op18 is known to completely turn off its NPT-destabilizing activity. As a result, TNF treatment of L929 cells induced elongated and extremely tangled microtubules. These TNF-induced changes to the MT network were also observed in cells overexpressing wild type Op18 and, to a lesser extent, in cells overexpressing the S25A/S38A mutant. No changes in the MT network were observed upon TNF treatment of cells overexpressing the S16A/S63A mutant, and these cells were desensitized to TNF-induced cell death. These findings indicate that TNF-induced MT stabilization is mediated by hyperphosphorylation of Op18 and that this promotes cell death. The data suggest that Op18 and the MT network play a functional role in transduction of the cell death signal to the mitochondria.	State Univ Ghent, Dept Mol Biol, B-9000 Ghent, Belgium; Flanders Interuniv Inst Biotechnol, B-9000 Ghent, Belgium; European Mol Biol Lab, Prot & Peptide Grp, D-69117 Heidelberg, Germany	Ghent University; European Molecular Biology Laboratory (EMBL)	Vancompernolle, K (corresponding author), State Univ Ghent, Dept Mol Biol, KL Ledeganckstr 35, B-9000 Ghent, Belgium.		Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799				Ahn J, 1999, ONCOGENE, V18, P5954, DOI 10.1038/sj.onc.1202986; Ameyar M, 1999, ONCOGENE, V18, P5464, DOI 10.1038/sj.onc.1202919; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERETTA L, 1993, J BIOL CHEM, V268, P20076; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bieche I, 1998, BRIT J CANCER, V78, P701, DOI 10.1038/bjc.1998.565; BRATTSAND G, 1993, LEUKEMIA, V7, P569; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; DiPaolo G, 1997, FEBS LETT, V416, P149, DOI 10.1016/S0014-5793(97)01188-5; DOYE V, 1989, J BIOL CHEM, V264, P12134; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Goossens V, 1999, BIOFACTORS, V10, P145, DOI 10.1002/biof.5520100210; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Gradin HM, 1998, J CELL BIOL, V140, P131, DOI 10.1083/jcb.140.1.131; GROOTEN J, 1993, CYTOKINE, V5, P546, DOI 10.1016/S1043-4666(05)80003-1; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; GUY GR, 1991, J BIOL CHEM, V266, P14343; GUY GR, 1992, J BIOL CHEM, V267, P1846; Hanash SM, 1998, ELECTROPHORESIS, V19, P2004, DOI 10.1002/elps.1150191119; Hehner SP, 1998, J BIOL CHEM, V273, P18117, DOI 10.1074/jbc.273.29.18117; Horwitz SB, 1997, J BIOL CHEM, V272, P8129, DOI 10.1074/jbc.272.13.8129; Howell B, 1999, J CELL SCI, V112, P3713; HUG H, 1988, MOL CELL BIOL, V8, P3065, DOI 10.1128/MCB.8.8.3065; Jeha S, 1996, CANCER RES, V56, P1445; Larsson N, 1997, MOL CELL BIOL, V17, P5530, DOI 10.1128/MCB.17.9.5530; Lawler S, 1998, CURR BIOL, V8, pR212, DOI 10.1016/S0960-9822(98)70128-9; Li YB, 1998, MOL BRAIN RES, V55, P277, DOI 10.1016/S0169-328X(98)00008-4; LLEONART R, 1990, BIO-TECHNOL, V8, P1263, DOI 10.1038/nbt1290-1263; Lovric J, 1998, J BIOL CHEM, V273, P22848; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	37	28	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33876	33882		10.1074/jbc.M004785200	http://dx.doi.org/10.1074/jbc.M004785200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10913145	hybrid			2022-12-25	WOS:000090104600096
J	Schmidt, M; Frings, M; Mono, ML; Guo, YJ; Weernink, PAO; Evellin, S; Han, L; Jakobs, KH				Schmidt, M; Frings, M; Mono, ML; Guo, YJ; Weernink, PAO; Evellin, S; Han, L; Jakobs, KH			G protein-coupled receptor-induced sensitization of phospholipase C stimulation by receptor tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; GROWTH-FACTOR RECEPTOR; HETEROLOGOUS POTENTIATION; SPHINGOSINE KINASE; INSULIN-RECEPTOR; EGF RECEPTOR; INHIBITION; ISOZYMES; GAMMA	Activation of stably expressed M-2 and M-3 muscarinic acetylcholine receptors (mAChRs) as well as of endogenously expressed lysophosphatidic acid and purinergic receptors in HEK-293 cells can induce a long lasting potentiation of phospholipase C (PLC) stimulation by these and other G protein-coupled receptors (GPCRs), Here, we report that GPCRs can induce an up-regulation of PLC stimulation by receptor tyrosine kinases (RTKs) as well and provide essential mechanistic characteristics of this sensitization process. Pretreatment of HEK-293 cells for 2 min with carbachol, a mAChR agonist, lysophosphatidic acid, or ATP, followed by agonist washout, strongly increased (by 23-fold) maximal PLC stimulation (measured greater than or equal to 40 min later) by epidermal growth factor and platelet-derived growth factor, but not insulin, and largely enhanced PLC sensitivity to these RTK agonists, The up-regulation of RTK-induced PLC stimulation was cycloheximide-insensitive and was observed for up to similar to 90 min after removal of the GPCR agonist, Sensitization of receptor-induced PLC stimulation caused by prior M-2 mAChR activation was fully prevented by pertussis toxin and strongly reduced by expression of G beta gamma scavengers. Furthermore, inhibition of conventional protein kinase C (PKC) isoenzymes and chelation of intracellular Ca2+ suppressed the sensitization process, while overexpression of PKC-alpha, but not PKC-beta1, further enhanced the M-2 mAChR-induced sensitization of PLC stimulation. None of these treatments affected acute PLC stimulation by either GPCR or RTK agonists, Taken together, short term activation of GPCRs can induce a strong and long lasting sensitization of PLC stimulation by RTKs, a process apparently involving G(i)-derived G beta gammas as well as increases in intracellular Ca2+ and activation of a PKC isoenzyme, most likely PKC-alpha.	Univ Essen Gesamthsch Klinikum, Inst Pharmakol, D-45122 Essen, Germany	University of Duisburg Essen	Schmidt, M (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Pharmakol, Hufelandstr 55, D-45122 Essen, Germany.		Schmidt, Martina/C-5339-2018	Schmidt, Martina/0000-0003-3075-0630				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; CHILVERS ER, 1991, BIOCHEM J, V275, P373, DOI 10.1042/bj2750373; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Gautam N, 1998, CELL SIGNAL, V10, P447, DOI 10.1016/S0898-6568(98)00006-0; Heringdorf DM, 1999, FEBS LETT, V461, P217, DOI 10.1016/S0014-5793(99)01463-5; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Kayali AG, 1998, J BIOL CHEM, V273, P13808, DOI 10.1074/jbc.273.22.13808; KELLERER M, 1991, BIOCHEM BIOPH RES CO, V181, P566, DOI 10.1016/0006-291X(91)91227-4; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOVALENKO M, 1994, CANCER RES, V54, P6106; Krudewig R, 2000, J NEUROCHEM, V74, P1721, DOI 10.1046/j.1471-4159.2000.0741721.x; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SALTIEL AR, 1996, AM J PHYSIOL, V270, P375; Schmidt M, 1996, MOL PHARMACOL, V50, P1038; SCHMIDT M, 1995, N-S ARCH PHARMACOL, V352, P469, DOI 10.1007/BF00169379; SCHMIDT M, 1995, J BIOL CHEM, V270, P19949, DOI 10.1074/jbc.270.34.19949; Schmidt M, 1998, MOL PHARMACOL, V53, P1139; SCHMIDT M, 1994, EUR J BIOCHEM, V225, P667, DOI 10.1111/j.1432-1033.1994.00667.x; Schmidt M, 1999, J BIOL CHEM, V274, P14648, DOI 10.1074/jbc.274.21.14648; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; VanEppsFung M, 1997, ENDOCRINOLOGY, V138, P5170, DOI 10.1210/en.138.12.5170; Voss M, 1999, J BIOL CHEM, V274, P34691, DOI 10.1074/jbc.274.49.34691; Whitehead JP, 2000, CURR OPIN CELL BIOL, V12, P222, DOI 10.1016/S0955-0674(99)00079-4; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	32	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32603	32610		10.1074/jbc.M004784200	http://dx.doi.org/10.1074/jbc.M004784200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10908568	hybrid			2022-12-25	WOS:000090003800033
J	Kang, J; Kim, T; Ko, YG; Rho, SB; Park, SG; Kim, MJ; Kwon, HJ; Kim, S				Kang, J; Kim, T; Ko, YG; Rho, SB; Park, SG; Kim, MJ; Kwon, HJ; Kim, S			Heat shock protein 90 mediates protein-protein interactions between human aminoacyl-tRNA synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; MOLECULAR CHAPERONE; NUCLEOTIDE-SEQUENCE; COMPLEX; HSP90; FAMILY; CYTOKINE; GENE; ATP; IDENTIFICATION	Heat shock protein 90 (hsp90) is a molecular chaperone responsible for protein folding and maturation in vivo. Interaction of hsp90 with human glutamyl-prolyl-tRNA synthetase (EPRS) was found by genetic screening, co-immunoprecipitation, and in vitro binding experiments. This interaction was sensitive to the hsp90 inhibitor, geldanamycin, and also ATP, suggesting that the chaperone activity of hsp90 is required for interaction with EPRS. Interaction of EPRS with hsp90 was targeted to the region of three tandem repeats linking the two catalytic domains of EPRS that is also responsible for the interaction with isoleucyl-tRNA synthetase (IRS), Interaction of EPRS and IRS also depended on the activity of hsp90, implying that their association was mediated by hsp90. EPRS and IRS form a macromolecular protein complex with at least six other tRNA synthetases and three cofactors, hsp90 preferentially binds to most of the complex-forming enzymes rather than those that are not found in the complex. In addition, inactivation of hsp90 interfered with the in vivo incorporation of the nascent aminoacyl-tRNA synthetases into the multi-ARS complex. Thus, hsp90 appears to mediate protein-protein interactions of mammalian tRNA synthetases.	Sungkyunkwan Univ, Ctr ARS Network, Natl Creat Res Initiat Ctr, Jangan Gu, Suwon 440746, Kyunggido, South Korea; Sejong Univ, Dept Biosci & Biotechnol, Kwangjin Gu, Seoul 143747, South Korea	Sungkyunkwan University (SKKU); Sejong University	Kim, S (corresponding author), Sungkyunkwan Univ, Ctr ARS Network, Natl Creat Res Initiat Ctr, Jangan Gu, 300 Chunchundong, Suwon 440746, Kyunggido, South Korea.	shkim@yurim.skku.ac.kr	Kim, Sunghoon/AAE-8314-2020; 권, 호정/AAS-3642-2021					Bijlmakers MJJE, 2000, MOL BIOL CELL, V11, P1585, DOI 10.1091/mbc.11.5.1585; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Cerini C, 1997, EUR J BIOCHEM, V244, P176, DOI 10.1111/j.1432-1033.1997.00176.x; CIRAKOGLU B, 1985, FEBS LETT, V183, P185; Cruciat CM, 1999, EMBO J, V18, P5226, DOI 10.1093/emboj/18.19.5226; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; FARRELLY FW, 1984, J BIOL CHEM, V259, P5745; FETT R, 1991, J BIOL CHEM, V266, P1448; FROLOVA LY, 1991, GENE, V109, P291, DOI 10.1016/0378-1119(91)90624-K; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grimaud R, 1998, J BACTERIOL, V180, P1148, DOI 10.1128/JB.180.5.1148-1153.1998; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HSIEH SL, 1991, BIOCHEM J, V278, P809, DOI 10.1042/bj2780809; KELLERMAYER MSZ, 1995, BIOCHEM BIOPH RES CO, V211, P166, DOI 10.1006/bbrc.1995.1792; Kleeman TA, 1997, J BIOL CHEM, V272, P14420, DOI 10.1074/jbc.272.22.14420; KRONE PH, 1994, BIOCHEM BIOPH RES CO, V204, P746, DOI 10.1006/bbrc.1994.2522; Liu XD, 1999, J BIOL CHEM, V274, P26654, DOI 10.1074/jbc.274.38.26654; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; MIRANDE M, 1982, EMBO J, V1, P733, DOI 10.1002/j.1460-2075.1982.tb01238.x; MOORE SK, 1989, J BIOL CHEM, V264, P5343; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; NORCUM MT, 1989, J BIOL CHEM, V264, P15043; Norcum MT, 1998, PROTEIN SCI, V7, P79, DOI 10.1002/pro.5560070108; Park SG, 1999, J BIOL CHEM, V274, P16673, DOI 10.1074/jbc.274.24.16673; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Quevillon S, 1996, FEBS LETT, V395, P63, DOI 10.1016/0014-5793(96)01005-8; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Quevillon S, 1997, J BIOL CHEM, V272, P32573, DOI 10.1074/jbc.272.51.32573; REBBE NF, 1987, GENE, V53, P235, DOI 10.1016/0378-1119(87)90012-6; Rho SB, 1996, P NATL ACAD SCI USA, V93, P10128, DOI 10.1073/pnas.93.19.10128; Rho SB, 1999, P NATL ACAD SCI USA, V96, P4488, DOI 10.1073/pnas.96.8.4488; Rho SB, 1998, J BIOL CHEM, V273, P11267, DOI 10.1074/jbc.273.18.11267; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schulte TW, 1998, CELL STRESS CHAPERON, V3, P100, DOI 10.1379/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2; SHIBA K, 1994, J BIOL CHEM, V269, P30049; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; TSUI FWL, 1987, NUCLEIC ACIDS RES, V15, P3349, DOI 10.1093/nar/15.8.3349; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	42	29	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31682	31688		10.1074/jbc.M909965199	http://dx.doi.org/10.1074/jbc.M909965199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913161	hybrid			2022-12-25	WOS:000089858900021
J	Todorov, AG; Einicker-Lamas, M; de Castro, SL; Oliveira, MM; Guilherme, A				Todorov, AG; Einicker-Lamas, M; de Castro, SL; Oliveira, MM; Guilherme, A			Activation of host cell phosphatidylinositol 3-kinases by Trypanosoma cruzi infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; C2 DOMAIN; INVASION; KINASE; MACROPHAGES; CALCIUM; PRODUCTS; PATHWAYS	Trypanosoma cruzi, the causative agent of Chagas' disease in humans, is an intracellular protozoan parasite with the ability to invade a wide variety of mammalian cells by a unique and remarkable process in cell biology that is poorly understood. Here we present evidence suggesting a role for the host phosphatidylinositol (PI) S-kinases during T. cruzi invasion. The PI 3-kinase inhibitor wortmannin marked inhibited T. cruzi infection when macrophages were pretreated for 20 min at 37 degrees C before inoculation. Infection of macrophages with T. cruzi markedly stimulated the formation of the lipid products of the phosphatidylinositol (PI) 3-kinases, PI 3-phospate, PI 3,4-biphosphate, and PI 3,4,5-triphosphate, but not PI 4-phosphate or PI 4,5-biphosphate. This activation was inhibited by wortmannin. Infection with T. cruzi also stimulated a marked increase in the in vitro lipid kinase activities that are present in the immunoprecipitates of anti-p85 subunit of class I PI 3-kinase and anti-phosphotyrosine. In addition, T. cruzi invasion also activated lipid kinase activity found in immunoprecipitates of class II and class III PI 3-kinases. These data demonstrate that T. cruzi invasion into macrophages strongly activates separated PI 3-kinase isoforms. Furthermore, the inhibition of the class I and class III PI 3-kinase activities abolishes the parasite entry into macrophages. These findings suggest a prominent role for the host PI 3-kinase activities during the T. cruzi infection process.	Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941900 Rio De Janeiro, Brazil; Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Dept Ultraestrutura & Biol Celular, BR-21045900 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz	Guilherme, A (corresponding author), Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA.	Adilson.Guilherme@umassmed.edu	Castro, Solange L/K-9342-2015					ANDREWS NW, 1983, GENES ANTIGENS PARAS, P37; Arcaro A, 1998, J BIOL CHEM, V273, P33082, DOI 10.1074/jbc.273.49.33082; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown RA, 1999, J BIOL CHEM, V274, P14529, DOI 10.1074/jbc.274.21.14529; BURLEIGH BA, 1995, ANNU REV MICROBIOL, V49, P175, DOI 10.1146/annurev.mi.49.100195.001135; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Forney JR, 1999, INFECT IMMUN, V67, P844, DOI 10.1128/IAI.67.2.844-852.1999; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; GUILHERME A, 1991, BIOCHEMISTRY-US, V30, P5700, DOI 10.1021/bi00237a010; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Malaquias AT, 1999, ACTA TROP, V73, P93, DOI 10.1016/S0001-706X(99)00016-9; MING M, 1995, CELL, V82, P287, DOI 10.1016/0092-8674(95)90316-X; MORENO SNJ, 1994, J EXP MED, V180, P1535, DOI 10.1084/jem.180.4.1535; *NAT I ALL INF DIS, 1996, COUNCIL NEWS, V5, P1; Ono F, 1998, J BIOL CHEM, V273, P7731, DOI 10.1074/jbc.273.13.7731; Ruta S, 1996, PARASITOL RES, V82, P481, DOI 10.1007/s004360050149; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Turner SJ, 1998, J BIOL CHEM, V273, P25987, DOI 10.1074/jbc.273.40.25987; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; VIEIRA MCF, 1994, BIOCHEM BIOPH RES CO, V203, P967, DOI 10.1006/bbrc.1994.2276; Villalta F, 1998, BIOCHEM BIOPH RES CO, V249, P247, DOI 10.1006/bbrc.1998.9127; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; WHO, 2000, WEEKLY EPIDEMIOL REC, V894, DOI [10.1016/S0140-6736(57)91352-1, DOI 10.1016/S0140-6736(57)91352-1]; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Zhang J, 1998, J BIOL CHEM, V273, P14081, DOI 10.1074/jbc.273.23.14081	31	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32182	32186		10.1074/jbc.M909440199	http://dx.doi.org/10.1074/jbc.M909440199			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913160	hybrid			2022-12-25	WOS:000089858900086
J	Zhu, WG; Williams, RS; Kodadek, T				Zhu, WG; Williams, RS; Kodadek, T			A CDC6 protein-binding peptide selected using a bacterial two-hybrid-like system is a cell cycle inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC SELECTION; DNA-REPLICATION; IN-VIVO; REPRESSOR FUSIONS; EUKARYOTIC CELLS; SMALL MOLECULES; APTAMERS; LIBRARY; ASSAYS; SCREEN	Peptides or small molecules able to modulate protein-protein interactions hold promise as tools with which to probe and manipulate biological pathways. An important issue in this nascent field is to evaluate different methods with which to search libraries for molecules that modulate the function of specific target proteins. One strategy is to screen libraries for molecules that bind specifically to a protein known to be critical in the pathway of interest, with the expectation that the molecules isolated will recognize regions of the target protein important for its function and thereby exhibit biological activity. Here, a peptide library was screened using a two-hybrid-like system for molecules able to bind human CDC6 protein (CDC6p), required for the initiation of DNA replication in eukaryotic cells. From a collection of over a million peptides, a single species that exhibited good affinity and specificity for binding CDC6p was obtained. When expressed in human cells, the peptide inhibited cell cycle progression and exhibited other properties expected of a CDC6p inhibitor. This approach, which does not require detailed knowledge of the mechanism of action of a protein target, may be generally useful for isolating peptides capable of manipulating biological pathways.	Univ Texas, SW Med Ctr, Dept Internal Med, Ryburn Ctr Mol Cardiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Ctr Biomed Invent, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Williams, RS (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Ryburn Ctr Mol Cardiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Kodadek, Thomas/0000-0003-1930-4795	NHLBI NIH HHS [HL06296] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUNKER CA, 1995, NUCLEIC ACIDS RES, V23, P269, DOI 10.1093/nar/23.2.269; Cairns MT, 1997, GENE, V185, P5, DOI 10.1016/S0378-1119(96)00601-4; Cohen BA, 1998, P NATL ACAD SCI USA, V95, P14272, DOI 10.1073/pnas.95.24.14272; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; Dong DL, 1999, CHEM BIOL, V6, P133, DOI 10.1016/S1074-5521(99)89005-X; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FREIFELDER D, 1982, PHYSICAL BIOCH APPLI, P654; Geyer CR, 1999, P NATL ACAD SCI USA, V96, P8567, DOI 10.1073/pnas.96.15.8567; Gius DR, 1999, CANCER RES, V59, P2577; HU JC, 1995, STRUCTURE, V3, P431, DOI 10.1016/S0969-2126(01)00176-9; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; Hu JC, 2000, METHODS, V20, P80, DOI 10.1006/meth.1999.0908; Hyde-DeRuyscher R, 2000, CHEM BIOL, V7, P17, DOI 10.1016/S1074-5521(00)00062-4; Jappelli R, 1996, J MOL BIOL, V259, P575, DOI 10.1006/jmbi.1996.0340; Kolonin MG, 1998, P NATL ACAD SCI USA, V95, P14266, DOI 10.1073/pnas.95.24.14266; Lee D, 1999, J AM CHEM SOC, V121, P10648, DOI 10.1021/ja992658m; Lindsley CW, 2000, J AM CHEM SOC, V122, P422, DOI 10.1021/ja993674m; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; NEEDELS MC, 1993, P NATL ACAD SCI USA, V90, P10700, DOI 10.1073/pnas.90.22.10700; Norman TC, 1999, SCIENCE, V285, P591, DOI 10.1126/science.285.5427.591; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Scott CP, 1999, P NATL ACAD SCI USA, V96, P13638, DOI 10.1073/pnas.96.24.13638; Singh D, 1998, BIOCHEMISTRY-US, V37, P5798, DOI 10.1021/bi972762l; Stockwell BR, 1999, CHEM BIOL, V6, P71, DOI 10.1016/S1074-5521(99)80004-0; Tan DS, 1999, J AM CHEM SOC, V121, P9073, DOI 10.1021/ja992144n; Tan DS, 1998, J AM CHEM SOC, V120, P8565, DOI 10.1021/ja981746o; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; VAN DG, 1991, SCIENCE, V252, P839; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; YANG MJ, 1995, NUCLEIC ACIDS RES, V23, P1152, DOI 10.1093/nar/23.7.1152; Zhang LS, 1998, P NATL ACAD SCI USA, V95, P9184, DOI 10.1073/pnas.95.16.9184; Zhang ZW, 2000, NAT BIOTECHNOL, V18, P71, DOI 10.1038/71951; Zhang ZW, 1999, CURR BIOL, V9, P417, DOI 10.1016/S0960-9822(99)80188-2	39	14	15	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32098	32105		10.1074/jbc.M001560200	http://dx.doi.org/10.1074/jbc.M001560200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10896933	hybrid			2022-12-25	WOS:000089858900075
J	Santana, MA; Pedraza-Alva, G; Olivares-Zavaleta, N; Madrid-Marina, V; Horejsi, V; Burakoff, SJ; Rosenstein, Y				Santana, MA; Pedraza-Alva, G; Olivares-Zavaleta, N; Madrid-Marina, V; Horejsi, V; Burakoff, SJ; Rosenstein, Y			CD43-mediated signals induce DNA binding activity of AP-1, NF-AT, and NF kappa B transcription factors in human T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH SYNDROME; CELL ACTIVATION; PROTEIN-KINASE; NUCLEAR FACTOR; SURFACE SIALOGLYCOPROTEIN; CD43 LEUKOSIALIN; GENE-EXPRESSION; CYCLOSPORINE-A; CROSS-LINKING; IL-2 GENE	Although numerous reports document a role for CD43 in T cell signaling, the direct participation of this molecule in cell activation has been questioned. In this study we show that CD43 ligation on human normal peripheral T cells was sufficient to induce interleukin-2, CD69, and CD40-L gene expression, without requiring signals provided by additional receptor molecules. This response was partially inhibited by cyclosporin A and staurosporine, suggesting the participation of both the Ca2+ and the protein kinase C pathways in CD43 signaling. Consistent with the transient CD43-dependent intracellular Ca2+ peaks reported by others, signals generated through the CD43 molecule resulted in the induction of NF-AT DNA binding activity. CD43-dependent signals resulted also in AP-1 and NF kappa B activation, probably as a result of protein kinase C involvement. AP-1 complexes bound to the AP-1 sequence contained c-Jun, and those bound to the NF-AT-AP-1 composite site contained c-Jun and Fos. NF kappa B complexes containing p65 could be found as early as 1 h after CD43 crosslinking, suggesting that CD43 participates in early events of T cell activation. The induction of the interleukin-a, CD69, and CD-40L genes and the participation of AP-1, NF-AT, and NF kappa B in the CD43-mediated signaling cascade implicate an important role for this molecule in the regulation of gene expression and cell function.	Univ Nacl Autonoma Mexico, Inst Biotecnol, Cuernavaca 62250, Morelos, Mexico; Inst Nacl Salud Publ, Ctr Invest Enfermedades Infecciosas, Dept Inmunol Viral, Cuernavaca 62508, Morelos, Mexico; Acad Sci Czech Republ, Inst Mol Genet, CR-14220 Prague, Czech Republic; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Universidad Nacional Autonoma de Mexico; Instituto Nacional de Salud Publica; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Rosenstein, Y (corresponding author), Univ Nacl Autonoma Mexico, Inst Biotecnol, Apartado Postal 510-3, Cuernavaca 62250, Morelos, Mexico.		Santana, M. Angélica/F-3593-2019; Horejsi, Vaclav/G-3113-2014	Santana, M. Angélica/0000-0001-8373-7873; Horejsi, Vaclav/0000-0003-4925-0142				AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; ALVARADO M, 1995, EUR J IMMUNOL, V25, P1051, DOI 10.1002/eji.1830250429; AXELSSON B, 1988, J IMMUNOL, V141, P2912; Babina M, 1997, EUR J IMMUNOL, V27, P1147, DOI 10.1002/eji.1830270515; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown TJ, 1996, J BIOL CHEM, V271, P27686, DOI 10.1074/jbc.271.44.27686; Castellanos MD, 1997, J IMMUNOL, V159, P5463; Chen SQ, 1997, P NATL ACAD SCI USA, V94, P3172, DOI 10.1073/pnas.94.7.3172; Corinti S, 1999, J IMMUNOL, V162, P6331; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; CYSTER JG, 1992, EUR J IMMUNOL, V22, P2565, DOI 10.1002/eji.1830221015; delPozo MA, 1997, J CELL BIOL, V137, P493; DESMET W, 1993, IMMUNOLOGY, V79, P46; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Ellies LG, 1996, BLOOD, V88, P1725, DOI 10.1182/blood.V88.5.1725.bloodjournal8851725; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Ghosh P, 1996, J BIOL CHEM, V271, P7700, DOI 10.1074/jbc.271.13.7700; GIORDANENGO V, 1995, BLOOD, V86, P2302, DOI 10.1182/blood.V86.6.2302.bloodjournal8662302; Grassl C, 1999, J AM SOC NEPHROL, V10, P1466; Harrington LE, 2000, J EXP MED, V191, P1241, DOI 10.1084/jem.191.7.1241; Huang TT, 1999, MOL CELL ENDOCRINOL, V152, P21, DOI 10.1016/S0303-7207(99)00067-2; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Jones A.M., 1994, BRIT J MANAGE, V5, P153, DOI DOI 10.1111/J.1467-8551.1994.TB00075.X; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LOPEZCABRERA M, 1995, J BIOL CHEM, V270, P21545, DOI 10.1074/jbc.270.37.21545; MANJUNATH N, 1993, J IMMUNOL, V151, P1528; MANJUNATH N, 1995, NATURE, V377, P535, DOI 10.1038/377535a0; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; Mondino A, 1996, J IMMUNOL, V157, P2048; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OSTERBERG JR, 1998, IMMUNOL TODAY, V19, P546; PADILLANORIEGA L, 1993, J CLIN MICROBIOL, V31, P622, DOI 10.1128/JCM.31.3.622-628.1993; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PARK JK, 1991, NATURE, V350, P706, DOI 10.1038/350706a0; Pedraza-Alva G, 1998, J BIOL CHEM, V273, P14218, DOI 10.1074/jbc.273.23.14218; PEDRAZAALVA G, 1994, J BIOL CHEM, V269, P6978; PedrazaAlva G, 1996, J BIOL CHEM, V271, P27564, DOI 10.1074/jbc.271.44.27564; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; REMOLDODONNELL E, 1986, J BIOL CHEM, V261, P7526; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; Rosenstein Y, 1999, IMMUNOL RES, V20, P89, DOI 10.1007/BF02786465; SANCHEZMATEOS P, 1995, BLOOD, V86, P2228, DOI 10.1182/blood.V86.6.2228.bloodjournal8662228; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SPERLING AI, 1995, J EXP MED, V182, P139, DOI 10.1084/jem.182.1.139; Srivastava S, 1999, J CLIN INVEST, V104, P503, DOI 10.1172/JCI7094; STEFANOVA I, 1988, FOLIA BIOL-PRAGUE, V34, P255; Stockl J, 1996, J EXP MED, V184, P1769, DOI 10.1084/jem.184.5.1769; Stockton BM, 1998, IMMUNITY, V8, P373, DOI 10.1016/S1074-7613(00)80542-7; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Timmerman LA, 1997, J IMMUNOL, V159, P2735; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Tsytsykova AV, 1996, J BIOL CHEM, V271, P3763; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WONG RCK, 1990, J IMMUNOL, V144, P1455	69	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31460	31468		10.1074/jbc.M005231200	http://dx.doi.org/10.1074/jbc.M005231200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10908570	hybrid			2022-12-25	WOS:000089762700100
J	Gruber, G; Svergun, DI; Godovac-Zimmermann, J; Harvey, WR; Wieczorek, H; Koch, MHJ				Gruber, G; Svergun, DI; Godovac-Zimmermann, J; Harvey, WR; Wieczorek, H; Koch, MHJ			Evidence for major structural changes in the Manduca sexta midgut V(1) ATPase due to redox modulation - A small angle X-ray scattering study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO HORNWORM MIDGUT; VACUOLAR H+-ATPASE; TRANSPORTING PLASMA-MEMBRANES; DISULFIDE BOND FORMATION; VESICLE V-ATPASE; ELECTRON-MICROSCOPY; SYNCHROTRON RADIATION; MASS-SPECTROMETRY; PROTON PUMP; SUBUNIT-A	The shape and overall dimensions of the oxidized and reduced form of the V(1) ATPase from Manduca sexta were investigated by synchrotron radiation x-ray solution scattering. The radius of gyration of the oxidized and reduced complex differ noticeably, with dimensions of 6.20 +/- 0.06 and 5.84 +/- 0.06 nm, respectively, whereas the maximum dimensions remain constant at 22.0 +/- 0.1 nm. Comparison of the low resolution shapes of both forms, determined ab initio, indicates that the main structural alteration occurs in the head piece, where the major subunits A and B are located, and at the bottom of the stalk. In conjunction with the solution scattering data, decreased susceptibility to tryptic digestion and tryptophan fluorescence of the reduced V(1) molecule pro vide the first strong evidence for major structural changes in the V(1) ATPase because of redox modulation.	Univ Osnabruck, Fachbereich Biol Chem, D-49069 Osnabruck, Germany; Univ Florida, Whitney Lab, St Augustine, FL 32086 USA; DESY, European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany; Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia; UCL, Ctr Mol Med, London WC1E 6JJ, England	University Osnabruck; State University System of Florida; University of Florida; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS; University of London; University College London	Gruber, G (corresponding author), Univ Osnabruck, Fachbereich Biol Chem, D-49069 Osnabruck, Germany.	grueber@biologie.uni-osnabrueck.de	Zimmermann, Jasminka Godovac/E-6863-2010	Svergun, Dmitri/0000-0003-0830-5696	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022444] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 22444] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; Bakhtiari N, 1999, J BIOL CHEM, V274, P16363, DOI 10.1074/jbc.274.23.16363; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Boekema EJ, 1998, PHOTOSYNTH RES, V57, P267, DOI 10.1023/A:1006044931980; Bottcher B, 2000, J MOL BIOL, V296, P449, DOI 10.1006/jmbi.1999.3435; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; BOWMAN BJ, 1997, MYCOTA, V3, P57; Dietz KJ, 1998, BBA-BIOMEMBRANES, V1373, P87, DOI 10.1016/S0005-2736(98)00094-7; DSCHIDA WJA, 1995, J BIOL CHEM, V270, P1557, DOI 10.1074/jbc.270.4.1557; DUNKER AK, 1976, BIOCHEM J, V153, P191, DOI 10.1042/bj1530191; FENG Y, 1992, J BIOL CHEM, V267, P19769; FENG Y, 1994, J BIOL CHEM, V269, P13224; Forgac M, 1999, J BIOL CHEM, V274, P1301, DOI 10.1074/jbc.274.3.1301; Forgac M, 2000, J EXP BIOL, V203, P71; GABRIEL A, 1982, NUCL INSTRUM METHODS, V201, P223, DOI 10.1016/0167-5087(82)90031-X; GRAF R, 1994, J BIOL CHEM, V269, P3767; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; GRAF R, 1992, FEBS LETT, V300, P119, DOI 10.1016/0014-5793(92)80177-I; Gruber G, 2000, BIOCHEMISTRY-US, V39, P8609, DOI 10.1021/bi000103u; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Kane PM, 2000, FEBS LETT, V469, P137, DOI 10.1016/S0014-5793(00)01265-5; KANE PM, 1995, J BIOL CHEM, V270, P17025; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Kozin MB, 1997, J APPL CRYSTALLOGR, V30, P811, DOI 10.1107/S0021889897001830; Kuprin S, 1995, BIOCHEM BIOPH RES CO, V217, P1151, DOI 10.1006/bbrc.1995.2889; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; MASHIMO S, 1991, J CHEM PHYS, V95, P6257, DOI 10.1063/1.461546; Merzendorfer H, 1997, J EXP BIOL, V200, P225; Merzendorfer H, 2000, BBA-BIOMEMBRANES, V1467, P369, DOI 10.1016/S0005-2736(00)00233-9; MOORE PB, 1980, J APPL CRYSTALLOGR, V13, P168, DOI 10.1107/S002188988001179X; NOVAK FJS, 1992, BIOCHIM BIOPHYS ACTA, V1132, P67, DOI 10.1016/0167-4781(92)90053-3; Oluwatosin YE, 1997, J BIOL CHEM, V272, P28149, DOI 10.1074/jbc.272.44.28149; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; Radermacher M, 1999, FEBS LETT, V453, P383, DOI 10.1016/S0014-5793(99)00739-5; Roos M, 1998, J BIOL CHEM, V273, P924, DOI 10.1074/jbc.273.2.924; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SCHWEIKL H, 1989, J BIOL CHEM, V264, P11136; Shannon C., 1964, MATH THEORY COMMUNIC; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Svergun DI, 2000, J BIOL CHEM, V275, P4210, DOI 10.1074/jbc.275.6.4210; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; SVERGUN DI, 1993, J APPL CRYSTALLOGR, V26, P258, DOI 10.1107/S0021889892011828; Svergun DI, 1998, BIOCHEMISTRY-US, V37, P17659, DOI 10.1021/bi982367a; SVOBODA M, 1995, J MASS SPECTROM, V30, P1562, DOI 10.1002/jms.1190301107; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Vasilyeva E, 1998, J BIOL CHEM, V273, P23823, DOI 10.1074/jbc.273.37.23823; WIECZOREK H, 1989, J BIOL CHEM, V264, P11143; Wieczorek H, 1999, J BIOENERG BIOMEMBR, V31, P67, DOI 10.1023/A:1005448614450; Wieczorek H, 2000, J EXP BIOL, V203, P127; WIECZOREK H, 1990, METHOD ENZYMOL, V192, P608; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; ZHANG JM, 1995, J BIOL CHEM, V270, P15494, DOI 10.1074/jbc.270.26.15494	60	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30082	30087		10.1074/jbc.M002976200	http://dx.doi.org/10.1074/jbc.M002976200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10893230	hybrid			2022-12-25	WOS:000089577900024
J	Paulson, AF; Mooney, E; Fang, X; Ji, H; McCrea, PD				Paulson, AF; Mooney, E; Fang, X; Ji, H; McCrea, PD			Xarvcf, Xenopus member of the p120 catenin subfamily associating with cadherin juxtamembrane region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROXIMAL REGION; ARMADILLO FAMILY MEMBER; SEGMENT POLARITY GENE; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; DESMOSOMAL PLAQUE; CELL-ADHESION; BETA-CATENIN; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS	The catenin ARVCF is a member of the p120(ctn) subfamily of Armadillo proteins. A number of catenins directly bind cadherin cytoplasmic tails, contributing to the modulation of cell-cell adhesion and motility processes. Some catenins, such as beta-catenin (and likely p120(ctn)), have additional roles within signaling pathways regulating gene transcription. We have isolated the Xenopus homolog of human ARVCF. Utilizing the cadherin membrane proximal region known to bind p120(ctn) and delta-catenin, coimmunoprecipitation experiments demonstrate that Xarvcf, likewise, binds cadherin in this region and that corresponding point mutations within conserved residues abrogate the Xarvcf cadherin association. Western blot analysis of Xarvcf protein across a series of developmental stages reveals changes in protein mobility, likely due to changes in phosphorylation. Xarvcf is a maternally provided transcript and expressed in the embryo throughout all stages of development. Interestingly, Xarvcf mRNA is differentially spliced to produce several isoforms, one of which is developmentally regulated. In common with the putative post-translational modifications of the Xarvcf protein, the presence of alternative splice isoforms suggests that Xarvcf possesses the capacity to effect developmental functions in a regulatable manner.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol 117, Program Genes & Dev, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	McCrea, PD (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol 117, Program Genes & Dev, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA-16672] Funding Source: Medline; NIGMS NIH HHS [GM-5-T32-HD07325, R01-GM-52112] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052112] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGHIB DF, 1995, EXP CELL RES, V218, P359, DOI 10.1006/excr.1995.1167; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bonne S, 1999, J CELL SCI, V112, P2265; BUSS JE, 1988, MOL CELL BIOL, V8, P3960, DOI 10.1128/MCB.8.9.3960; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; DOWNING JR, 1991, ONCOGENE, V6, P607; Esser S, 1998, J CELL SCI, V111, P1853; EVANS JP, 1991, XENOPUS LAEVIS PRACT, P133; Faber J., 1994, NORMAL TABLE XENOPUS, P2; Finnemann S, 1997, J BIOL CHEM, V272, P11856, DOI 10.1074/jbc.272.18.11856; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Geis K, 1998, DEV GENES EVOL, V207, P471, DOI 10.1007/s004270050138; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; Hatzfeld M, 1996, J CELL SCI, V109, P2767; HEID HW, 1994, DIFFERENTIATION, V58, P113; Hudson C, 1997, CELL, V91, P397, DOI 10.1016/S0092-8674(00)80423-7; Ide N, 1999, BIOCHEM BIOPH RES CO, V256, P456, DOI 10.1006/bbrc.1999.0364; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; Katz BZ, 1998, EXP CELL RES, V243, P415, DOI 10.1006/excr.1998.4194; Keirsebilck A, 1998, GENOMICS, V50, P129, DOI 10.1006/geno.1998.5325; KINTNER CR, 1987, DEVELOPMENT, V99, P311; Lampugnani MG, 1997, J CELL SCI, V110, P2065; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; MACRAE AD, 1994, GENOMICS, V24, P176, DOI 10.1006/geno.1994.1596; Mariner DJ, 2000, J CELL SCI, V113, P1481; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Medina M, 2000, GENOMICS, V63, P157, DOI 10.1006/geno.1999.6090; Mertens C, 1996, J CELL BIOL, V135, P1009, DOI 10.1083/jcb.135.4.1009; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Navarro P, 1995, J BIOL CHEM, V270, P30965, DOI 10.1074/jbc.270.52.30965; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Ozawa M, 1998, J CELL BIOL, V142, P1605, DOI 10.1083/jcb.142.6.1605; Paffenholz R, 1997, DIFFERENTIATION, V61, P293, DOI 10.1046/j.1432-0436.1997.6150293.x; Paulson AF, 1999, DEV BIOL, V207, P350, DOI 10.1006/dbio.1998.9158; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; REYNOLDS AB, 1997, CYTOSKELETAL MEMBRAN, P1; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; Schmidt A, 1999, DIFFERENTIATION, V64, P291, DOI 10.1046/j.1432-0436.1999.6450291.x; Schmidt A, 1997, CELL TISSUE RES, V290, P481, DOI 10.1007/s004410050956; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; Sirotkin H, 1997, GENOMICS, V41, P75, DOI 10.1006/geno.1997.4627; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983; Yap AS, 1998, CANCER INVEST, V16, P252, DOI 10.3109/07357909809039774; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0; Zhou JH, 1997, NEUROREPORT, V8, P1489, DOI 10.1097/00001756-199704140-00033	62	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30124	30131		10.1074/jbc.M003048200	http://dx.doi.org/10.1074/jbc.M003048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10899158	hybrid			2022-12-25	WOS:000089577900030
J	Dhanvantari, S; Loh, YP				Dhanvantari, S; Loh, YP			Lipid raft association of carboxypeptidase E is necessary for its function as a regulated secretory pathway sorting receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; INFLUENZA-VIRUS HEMAGGLUTININ; DISULFIDE-BONDED LOOP; TRANS-GOLGI NETWORK; CHROMOGRANIN-B; TRANSMEMBRANE DOMAIN; MEMBRANE DOMAINS; CELL-SURFACE; CHOLESTEROL; IDENTIFICATION	Membrane carboxypeptidase E (CPE) is a sorting receptor for targeting prohormones, such as pro-opiomelanocortin, to the regulated secretory pathway in endocrine cells. Its membrane association is necessary for it to bind a prohormone sorting signal at the trans-Golgi network (TGN) to facilitate targeting. In this study, we examined the lipid interaction of CPE in bovine pituitary secretory granule membranes, which are derived from the TGN. We show that CPE is associated with detergent-resistant lipid domains, or rafts, within secretory granule membranes. Lipid analysis revealed that these rafts are enriched in glycosphingolipids and cholesterol. Pulse-chase and subcellular fractionation experiments in AtT-20 cells show that the association of CPE with membrane rafts occurred only after it reached the Golgi. Cholesterol depletion resulted in dissociation of CPE from secretory granule membranes and decreased the binding of prohormones to membranes, lit vivo cholesterol depletion using lovastatin resulted in the lack of sorting of CPE and its cargo to the regulated secretory pathway. We propose that the sorting receptor function of CPE necessitates its interaction with glycosphingolipid-cholesterol rafts at the TGN, thereby anchoring it in position to bind to its prohormone cargo.	NICHD, Cellular Neurobiol Sect, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Loh, YP (corresponding author), NICHD, Cellular Neurobiol Sect, Dev Neurobiol Lab, NIH, Bldg 49,Rm 5A38,MSC 4480,9000 Rockville Pike, Bethesda, MD 20892 USA.	ypl@codon.nih.gov	Dhanvantari, Savita/B-5362-2015		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000056] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000056] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARIGA T, 1988, BIOCHEMISTRY-US, V27, P52, DOI 10.1021/bi00401a010; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; BUCKLAND RM, 1978, BIOCHIM BIOPHYS ACTA, V513, P321, DOI 10.1016/0005-2736(78)90202-X; Chanat E, 1998, METH MOL B, V88, P285; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; COOL DR, 1994, BIOCHIMIE, V76, P265, DOI 10.1016/0300-9084(94)90156-2; Cool DR, 1998, MOL CELL ENDOCRINOL, V139, P7, DOI 10.1016/S0303-7207(98)00081-1; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; Fernandez CJ, 1997, MOL BIOL CELL, V8, P2171, DOI 10.1091/mbc.8.11.2171; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Glombik MM, 1999, EMBO J, V18, P1059, DOI 10.1093/emboj/18.4.1059; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Kromer A, 1998, J CELL BIOL, V140, P1331, DOI 10.1083/jcb.140.6.1331; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; Lipardi C, 2000, MOL BIOL CELL, V11, P531, DOI 10.1091/mbc.11.2.531; LOH YP, 1984, J BIOL CHEM, V259, P8238; MACALA LJ, 1983, J LIPID RES, V24, P1243; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Normant E, 1998, ENDOCRINOLOGY, V139, P2137, DOI 10.1210/en.139.4.2137; ORCI L, 1981, P NATL ACAD SCI-BIOL, V78, P293, DOI 10.1073/pnas.78.1.293; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; QUINN D, 1991, J CELL BIOL, V113, P987, DOI 10.1083/jcb.113.5.987; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; Thiele C, 1998, J BIOL CHEM, V273, P1223, DOI 10.1074/jbc.273.2.1223; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; VILHARDT H, 1972, ACTA ENDOCRINOL-COP, V71, P638, DOI 10.1530/acta.0.0710638; Watanabe R, 1996, J BIOL CHEM, V271, P26868, DOI 10.1074/jbc.271.43.26868; WESTHEAD EW, 1982, NEUROSCIENCE, V7, P1611, DOI 10.1016/0306-4522(82)90018-5; WESTHEAD EW, 1987, ANN NY ACAD SCI, V493, P92, DOI 10.1111/j.1749-6632.1987.tb27186.x; Yoo SH, 1996, J BIOL CHEM, V271, P17041, DOI 10.1074/jbc.271.29.17041; Zhang CF, 1999, MOL ENDOCRINOL, V13, P527, DOI 10.1210/me.13.4.527	47	100	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29887	29893		10.1074/jbc.M005364200	http://dx.doi.org/10.1074/jbc.M005364200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896946	hybrid			2022-12-25	WOS:000089439800096
J	Henneberry, AL; Wistow, G; McMaster, CR				Henneberry, AL; Wistow, G; McMaster, CR			Cloning, genomic organization, and characterization of a human cholinephosphotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDP-CHOLINE PATHWAY; PLATELET-ACTIVATING-FACTOR; SACCHAROMYCES-CEREVISIAE; TRANSFER PROTEIN; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; PHOSPHOLIPID BIOSYNTHESIS; SN-1,2-DIACYLGLYCEROL CHOLINEPHOSPHOTRANSFERASE; PHOSPHATIDYLETHANOLAMINE BIOSYNTHESIS; FINAL STEP; ETHANOLAMINEPHOSPHOTRANSFERASE	A cholinephosphotransferase activity catalyzes the final step in the de novo synthesis of phosphatidylcholine Dia the transfer of a phosphocholine moiety from CDP choline to diacylglycerol. Ethanolaminephosphotransferase activity catalyzes a similar reaction substituting CDP ethanolamine as the phosphobase donor. We report the identification and cloning of a human cDNA (human cholinephosphotransferase (hCPT1)) that codes for a cholinephosphotransferase-specific enzyme. This was demonstrated using in vitro enzyme assays and in vivo measurement of the reconstitution of the phosphatidylcholine and phosphatidylethanolamine biosynthetic pathways in yeast cells devoid of their own endogenous cholinephosphotransferase and ethanolaminephosphotransferase activities. This contrasted with our previously cloned human choline/ethanolaminephosphotransferase cDNA that was demonstrated to code for a dual specificity choline/ethanolaminephosphotransferase. The hCPT1 and human choline/ethanolaminephosphotransferase (hCEPT1) predicted amino acid sequences possessed 60% overall identity and had only one variation in the amino acid residues within the CDP-alcohol phosphotransferase catalytic motif, In vitro assessment of hCPT1 and hCEPT1 derived cholinephosphotransferase activities also revealed differences in diradylglycerol specificities including their capacity to synthesize platelet-activating factor and platelet-activating factor precursor. Expression of the hCPT1 mRNA varied greater than 100-fold between tissues and was most abundant in testis followed by colon, small intestine, heart, prostate, and spleen. This was in marked contrast to the hCEPT1 mRNA, which has been found in similar abundance in all tissues tested to date. Both the hCPT1 and hCEPT1 enzymes were able to reconstitute the synthesis of PC in yeast to levels provided by the endogenous yeast cholinephosphotransferase; however, only hCEPT1-derived activity was able to complement the yeast CPT1 gene in its interaction with SEC14 and affect cell growth.	Dalhousie Univ, IWK Grace Hlth Ctr, Dept Pediat, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, IWK Grace Hlth Ctr, Dept Biochem & Mol Biol, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada; NEI, Sect Mol Struct & Funct, NIH, Bethesda, MD 20892 USA	Dalhousie University; Dalhousie University; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	McMaster, CR (corresponding author), Dalhousie Univ, IWK Grace Hlth Ctr, Dept Pediat, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada.			McMaster, Christopher/0000-0003-0822-5776	NATIONAL EYE INSTITUTE [ZIAEY000320, Z01EY000320] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMES BN, 1960, J BIOL CHEM, V235, P769; BRU R, 1993, ARCH BIOCHEM BIOPHYS, V307, P295, DOI 10.1006/abbi.1993.1592; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CORNELL RB, 1992, METHOD ENZYMOL, V209, P267; CUI Z, 1994, J BIOL CHEM, V269, P24531; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; DEWEY RE, 1994, PLANT CELL, V6, P1495, DOI 10.1105/tpc.6.10.1495; FORD DA, 1992, J BIOL CHEM, V267, P11222; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; Henneberry AL, 1999, BIOCHEM J, V339, P291, DOI 10.1042/0264-6021:3390291; HJELMSTAD RH, 1994, J BIOL CHEM, V269, P20995; HJELMSTAD RH, 1992, METHOD ENZYMOL, V209, P273; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; JUSTIN AM, 1985, BIOCHIM BIOPHYS ACTA, V836, P1, DOI 10.1016/0005-2760(85)90212-7; Kaiser C., 1994, METHODS YEAST GENETI; Kearns BG, 1998, TRENDS CELL BIOL, V8, P276, DOI 10.1016/S0962-8924(98)01281-1; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; Kuge O, 1998, P NATL ACAD SCI USA, V95, P4199, DOI 10.1073/pnas.95.8.4199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mancini A, 1999, BBA-MOL CELL BIOL L, V1437, P80, DOI 10.1016/S1388-1981(98)00011-0; MCGEE TP, 1994, J BACTERIOL, V176, P6861, DOI 10.1128/JB.176.22.6861-6868.1994; MCMASTER CR, 1992, J BIOL CHEM, V267, P14586; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; McMaster CR, 1996, BIOCHEM J, V313, P729, DOI 10.1042/bj3130729; McMaster CR, 1997, BBA-LIPID LIPID MET, V1348, P100, DOI 10.1016/S0005-2760(97)00097-0; McMaster CR, 1997, BBA-LIPID LIPID MET, V1348, P117, DOI 10.1016/S0005-2760(97)00098-2; MUNBERG D, 1995, GENE, V156, P119; O KM, 1989, BIOCHEM CELL BIOL, V67, P680; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; POLOKOFF MA, 1981, J BIOL CHEM, V256, P7687; RAETZ CRH, 1986, ANNU REV GENET, V20, P253, DOI 10.1146/annurev.ge.20.120186.001345; RIDGWAY ND, 1989, J BIOL CHEM, V264, P1203; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schuler GD, 1997, J MOL MED, V75, P694, DOI 10.1007/s001090050155; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; SLEIGHT R, 1980, J BIOL CHEM, V255, P644; Snyder F, 1997, BBA-LIPID LIPID MET, V1348, P111, DOI 10.1016/S0005-2760(97)00109-4; Stein LD, 1999, TRENDS GENET, V15, P425, DOI 10.1016/S0168-9525(99)01805-3; STERN I, 1953, J CLIN PATHOL, V6, P158, DOI 10.1136/jcp.6.2.158; Stone SJ, 1998, J BIOL CHEM, V273, P7293, DOI 10.1074/jbc.273.13.7293; Tessitore L, 2000, INT J CANCER, V86, P362, DOI 10.1002/(SICI)1097-0215(20000501)86:3&lt;362::AID-IJC10&gt;3.0.CO;2-A; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; VANCE DE, 1996, BIOCH LIPIDS LIPOPRO, P153; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; WEISS SB, 1958, J BIOL CHEM, V231, P53; Williams JG, 1998, J BIOL CHEM, V273, P13482, DOI 10.1074/jbc.273.22.13482; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; WOODARD DS, 1987, J BIOL CHEM, V262, P2520; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346; YANG TT, 1995, BIOTECHNIQUES, V18, P498	54	79	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29808	29815		10.1074/jbc.M005786200	http://dx.doi.org/10.1074/jbc.M005786200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893425	hybrid			2022-12-25	WOS:000089439800086
J	Pages, S; Heijne, WHM; Kester, HCM; Visser, J; Benen, JAE				Pages, S; Heijne, WHM; Kester, HCM; Visser, J; Benen, JAE			Subsite mapping of Aspergillus niger endopolygalacturonase II by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-SEQUENCE SIMILARITIES; CRYSTAL-STRUCTURE; GENE; ENZYMES; POLYGALACTURONASE; IDENTIFICATION; CLASSIFICATION; FAMILY	To assess the subsites involved in substrate binding in Aspergillus niger endopolygalacturonase II, residues located in the potential substrate binding cleft stretching along the enzyme from the N to the C terminus were subjected to site-directed mutagenesis. Mutant enzymes were characterized with respect to their kinetic parameters using polygalacturonate as a substrate and with respect to their mode of action using oligogalacturonates of defined length (n = 3-6). In addition, the effect of the mutations on the hydrolysis of pectins with various degrees of esterification was studied. Based on the results obtained with enzymes N186E and D282K it was established that the substrate binds with the nonreducing end toward the N terminus of the enzyme. Asn(186) is located at subsite -4, and Asp(282) is located at subsite +2. The mutations D183N and M150Q, both located at subsite -2, affected catalysis, probably mediated via the sugar residue bound at subsite -1. Tyr(291), located at subsite +1 and strictly conserved among endopolygalacturonases appeared indispensable for effective catalysis. The mutations E252A and Q288E, both located at subsite +2, showed only slight effects on catalysis and mode of action. Tyr(326) is probably located at the imaginary subsite +3. The mutation Y326L affected the stability of the enzyme. For mutant E252A, an increased affinity for partially methylesterified substrates was recorded. Enzyme N186E displayed the opposite behavior; the specificity for completely demethylesterified regions of substrate, already high for the native enzyme, was increased. The origin of the effects of the mutations is discussed.	Univ Wageningen & Res Ctr, Sect Mol Genet Ind Microorganisms, NL-6703 HA Wageningen, Netherlands	Wageningen University & Research	Benen, JAE (corresponding author), Univ Wageningen & Res Ctr, Sect Mol Genet Ind Microorganisms, Dreyenlaan 2, NL-6703 HA Wageningen, Netherlands.	jac.benen@algemeen.mgim.wau.nl						ALLEN JD, 1976, BIOCHEM J, V159, P105, DOI 10.1042/bj1590105; Armand S, 2000, J BIOL CHEM, V275, P691, DOI 10.1074/jbc.275.1.691; Benen JAE, 1999, EUR J BIOCHEM, V259, P577, DOI 10.1046/j.1432-1327.1999.00080.x; BUSSINK HJD, 1991, CURR GENET, V20, P301, DOI 10.1007/BF00318519; BUSSINK HJD, 1990, FEBS LETT, V273, P127, DOI 10.1016/0014-5793(90)81066-W; BUSSINK HJD, 1992, EUR J BIOCHEM, V208, P83, DOI 10.1111/j.1432-1033.1992.tb17161.x; DEGRAAFF L, 1992, CURR GENET, V22, P21, DOI 10.1007/BF00351737; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Kester HCM, 2000, BIOCHEM J, V346, P469, DOI 10.1042/0264-6021:3460469; Korner R, 1999, ANAL CHEM, V71, P1421, DOI 10.1021/ac981240o; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Parenicova L, 2000, BIOCHEM J, V345, P637, DOI 10.1042/0264-6021:3450637; Parenicova L, 1998, EUR J BIOCHEM, V251, P72, DOI 10.1046/j.1432-1327.1998.2510072.x; Petersen TN, 1997, STRUCTURE, V5, P533, DOI 10.1016/S0969-2126(97)00209-8; Pickersgill R, 1998, J BIOL CHEM, V273, P24660, DOI 10.1074/jbc.273.38.24660; SOMEREN MAK, 1991, CURR GENET, V20, P293, DOI 10.1007/BF00318518; THOMA JA, 1970, BIOCHEMISTRY-US, V9, P1768, DOI 10.1021/bi00810a016; THOMA JA, 1971, J BIOL CHEM, V246, P5621; van Santen Y, 1999, J BIOL CHEM, V274, P30474, DOI 10.1074/jbc.274.43.30474	20	41	41	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29348	29353		10.1074/jbc.M910112199	http://dx.doi.org/10.1074/jbc.M910112199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893426	hybrid			2022-12-25	WOS:000089439800024
J	Takeuchi, S; Takayama, Y; Ogawa, A; Tamura, K; Okada, M				Takeuchi, S; Takayama, Y; Ogawa, A; Tamura, K; Okada, M			Transmembrane phosphoprotein Cbp positively regulates the activity of the carboxyl-terminal Src kinase, Csk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; T-CELL ACTIVATION; NEGATIVE REGULATION; FAMILY KINASES; C-SRC; SUPPRESSION; MEMBRANES; P50(CSK); RAFTS	Csk (carboxyl-terminal Src kinase) is a cytoplasmic tyrosine kinase that phosphorylates a critical tyrosine residue in each of the Src family kinases (SFKs) to inhibit their activities. Recently, we identified a transmembrane protein, Cbp (Csk-binding protein), that, when phosphorylated, can recruit Csk to the membrane where the SFKs are located. The Cbp-mediated relocation of Csk to the membrane may play a role in turning off the signaling events initiated by SFKs, To further characterize the Csk-Cbp interaction, we have generated a reconstituted system using soluble, highly purified proteins. Csk and phosphorylated Cbp were co-purified as a large protein complex consisting of at least four Csk-Cbp units. The addition of the phosphorylated, but not nonphosphorylated, Cbp to an in vitro assay stimulated Csk activity toward Src. Csk was also activated by a phosphopeptide containing the tyrosine in Cbp that binds to Csk (Tyr-314), Kinetic analysis revealed that Cbp or the phosphopeptide induced up to a g-fold reduction in the K-m for Src, indicating that the Csk Cbp complex has a greater affinity for Src than free Csk. These findings suggest that Cbp is involved in the regulation of SFKs not only by relocating Csk to the membrane but also by directly activating Csk.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	Osaka University	Okada, M (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Takayama, Yoshiharu/M-8826-2019; Takayama, Yoshiharu/E-3662-2010	Takayama, Yoshiharu/0000-0003-4532-7114; Takayama, Yoshiharu/0000-0003-4532-7114				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CLOUTIER JF, 1995, MOL CELL BIOL, V15, P5937; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sun GQ, 1999, ARCH BIOCHEM BIOPHYS, V367, P167, DOI 10.1006/abbi.1999.1253; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	19	128	135	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29183	29186		10.1074/jbc.C000326200	http://dx.doi.org/10.1074/jbc.C000326200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10918051	hybrid			2022-12-25	WOS:000089439800002
J	Chao, SH; Fujinaga, K; Marion, JE; Taube, R; Sausville, EA; Senderowicz, AM; Peterlin, BM; Price, DH				Chao, SH; Fujinaga, K; Marion, JE; Taube, R; Sausville, EA; Senderowicz, AM; Peterlin, BM; Price, DH			Flavopiridol inhibits P-TEFb and blocks HIV-1 replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; BREAST-CARCINOMA CELLS; IN-VITRO; ELONGATION COMPLEXES; TAT TRANSACTIVATION; KINASE-ACTIVITY; TRANSCRIPTION; PROTEIN; ACTIVATION; PHOSPHATASE	Flavopiridol (L86-8275, HMR1275) is a cyclin-dependent kinase (Cdk) inhibitor that is in clinical trials as a cancer treatment because of its antiproliferative properties. We found that the flavonoid potently inhibited transcription by RNA polymerase II in vitro by blocking the transition into productive elongation, a step controlled by P-TEFb, The ability of P-TEFb to phosphorylate the carboxyl-terminal domain of the large subunit of RNA polymerase II was inhibited by flavopiridol with a K-i of 3 nM. Interestingly, the drug was not competitive with ATP. P-TEFb composed of Cdk9 and cyclin T1 is a required cellular cofactor for the human immunodeficiency virus (HIV-1) transactivator, Tat, Consistent with its ability to inhibit P-TEFb, flavopiridol blocked Tat transactivation of the viral promoter in vitro. Furthermore, flavopiridol blocked HIV-1 replication in both single-round and viral spread assays with an IC50 of less than 10 nM.	Univ Iowa, Program Mol Biol, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; NCI, Dev Therapeut Program, Clin Trials Unit, Div Canc Treatment & Diag,NIH, Bethesda, MD 20892 USA	University of Iowa; University of Iowa; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Senderowicz, AM (corresponding author), Univ Iowa, Program Mol Biol, Iowa City, IA 52242 USA.		Price, David H/F-6173-2010; TAUBE, RAN/F-2029-2012	TAUBE, RAN/0000-0002-2062-4537; Price, David/0000-0002-5597-385X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043691] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43691] Funding Source: Medline; NIGMS NIH HHS [GM35500] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bieniasz PD, 1999, MOL CELL BIOL, V19, P4592, DOI 10.1128/mcb.19.7.4592; Carlson B, 1999, CANCER RES, V59, P4634; Carlson BA, 1996, CANCER RES, V56, P2973; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Cleland W W, 1979, Methods Enzymol, V63, P103; DE AWJ, 1996, P NATL ACAD SCI USA, V93, P2735; Fackler OT, 1997, EUR J BIOCHEM, V247, P843, DOI 10.1111/j.1432-1033.1997.00843.x; Flores OL, 1999, P NATL ACAD SCI USA, V96, P7208, DOI 10.1073/pnas.96.13.7208; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Garber ME, 1999, CURR OPIN IMMUNOL, V11, P460, DOI 10.1016/S0952-7915(99)80077-6; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Garriga J, 1998, ONCOGENE, V17, P3093, DOI 10.1038/sj.onc.1202548; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; Marshall NF, 1998, J BIOL CHEM, V273, P31726, DOI 10.1074/jbc.273.48.31726; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Peng J, 1998, COLD SPRING HARB SYM, V63, P365, DOI 10.1101/sqb.1998.63.365; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Senderowicz AM, 1998, J CLIN ONCOL, V16, P2986, DOI 10.1200/JCO.1998.16.9.2986; Taube R, 1999, VIROLOGY, V264, P245, DOI 10.1006/viro.1999.9944; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wu-Baer F, 1998, J MOL BIOL, V277, P179, DOI 10.1006/jmbi.1997.1601; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	30	404	438	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28345	28348		10.1074/jbc.C000446200	http://dx.doi.org/10.1074/jbc.C000446200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10906320	hybrid			2022-12-25	WOS:000089330700002
J	Zhou, XL; Espey, MG; Chen, JX; Hofseth, LJ; Miranda, KM; Hussain, SP; Wink, DA; Harris, CC				Zhou, XL; Espey, MG; Chen, JX; Hofseth, LJ; Miranda, KM; Hussain, SP; Wink, DA; Harris, CC			Inhibitory effects of nitric oxide and nitrosative stress on dopamine-beta-hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NG-MONOMETHYL ARGININE; ANOCOCCYGEUS MUSCLE; STRIATAL SLICES; H-3 DOPAMINE; RELEASE; RAT; RELAXATION; KINETICS; INSIGHTS; ASSAY	Dopamine-beta-hydroxylase (D beta H) is a copper-containing enzyme that uses molecular oxygen and ascorbate to catalyze the addition of a hydroxyl group on the beta-carbon of dopamine to form norepinephrine. While norepinephrine causes vasoconstriction following reflex sympathetic stimulation, nitric oxide (NO) formation results in vasodilatation via a guanylyl cyclase-dependent mechanism. In this report, we investigated the relationship between NO and D beta H enzymatic activity. In the initial in vitro experiments, the activity of purified D beta H was inhibited by the NO donor, diethylamine/NO (DEA/NO), with an IC50 of 1 mM. The inclusion of either azide or GSH partially restored D beta H activity, suggesting the involvement of the reactive nitrogen oxide species, N2O3. Treatment of human neuroblastoma cells (SK-N-MC) with diethylamine/NO decreased cellular D beta H activity without affecting their growth rate and was augmented by the depletion of intracellular GSH. Coculture of the SK-N-MC cells with interferon-gamma and lipopolysaccharide-activated macrophages, which release NO, also reduced the D beta H activity in the neuroblastoma cells. Our results are consistent with the hypothesis that nitrosative stress, mediated by N2O3, can result in the inhibition of norepinephrine biosynthesis and may contribute to the regulation of neurotransmission and vasodilatation.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; NCI, Radiat Biol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, Bldg 37,Rm 2C05,37 Convent Dr, Bethesda, MD 20892 USA.		Miranda, Katrina M/B-7823-2009	Wink, David/0000-0002-5652-7480; Azad, Mahan/0000-0002-8633-3513	NATIONAL CANCER INSTITUTE [Z01BC010033, ZIABC010033] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AXELROD J, 1972, PHARMACOL REV, V24, P233; BREWSTER MA, 1979, ANN CLIN LAB SCI, V9, P343; CEDERQVIST B, 1991, NEUROSCI LETT, V127, P67, DOI 10.1016/0304-3940(91)90896-2; Espey MG, 2000, J BIOL CHEM, V275, P11341, DOI 10.1074/jbc.275.15.11341; FITZPATRICK PF, 1987, ARCH BIOCHEM BIOPHYS, V257, P231, DOI 10.1016/0003-9861(87)90563-7; FORD PC, 1993, FEBS LETT, V326, P1, DOI 10.1016/0014-5793(93)81748-O; GIBSON A, 1990, BRIT J PHARMACOL, V99, P602, DOI 10.1111/j.1476-5381.1990.tb12976.x; Griscavage J M, 1995, Adv Pharmacol, V34, P215; HANBAUER I, 1992, NEUROREPORT, V3, P409, DOI 10.1097/00001756-199205000-00008; KATO T, 1978, BIOCHEM PHARMACOL, V27, P829, DOI 10.1016/0006-2952(78)90538-5; KATO T, 1974, BIOCHEM MED METAB B, V10, P320, DOI 10.1016/0006-2944(74)90035-0; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; KOBAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P1089, DOI 10.1093/nar/17.3.1089; LI CG, 1989, CLIN EXP PHARMACOL P, V16, P933, DOI 10.1111/j.1440-1681.1989.tb02404.x; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; LONART G, 1993, J NEUROSCI RES, V35, P192, DOI 10.1002/jnr.490350210; LORRAIN DS, 1993, NEUROREPORT, V5, P87, DOI 10.1097/00001756-199310000-00024; Miles AM, 1996, METHOD ENZYMOL, V268, P105; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; NAGATSU T, 1991, NEUROSCI RES, V12, P315, DOI 10.1016/0168-0102(91)90001-F; PALACIOS M, 1989, BIOCHEM BIOPH RES CO, V165, P802, DOI 10.1016/S0006-291X(89)80037-3; ROBERTSON D, 1991, HYPERTENSION, V18, P1, DOI 10.1161/01.HYP.18.1.1; RUSH RA, 1980, CRC CR REV CL LAB SC, V12, P241, DOI 10.3109/10408368009108731; SAMS CF, 1984, BIOCHIM BIOPHYS ACTA, V787, P61, DOI 10.1016/0167-4838(84)90108-0; SEILICOVICH A, 1995, P NATL ACAD SCI USA, V92, P11299, DOI 10.1073/pnas.92.24.11299; Simon DI, 1996, P NATL ACAD SCI USA, V93, P4736, DOI 10.1073/pnas.93.10.4736; SOKOLOFF RL, 1985, J NEUROCHEM, V44, P411, DOI 10.1111/j.1471-4159.1985.tb05431.x; TERRY LC, 1985, NEUROENDOCRINOLOGY, V41, P467, DOI 10.1159/000124221; THOENEN H, 1971, P NATL ACAD SCI USA, V68, P1598, DOI 10.1073/pnas.68.7.1598; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TODA N, 1990, JPN J PHARMACOL, V52, P170, DOI 10.1254/jjp.52.170; Williams DLH, 1997, NITRIC OXIDE-BIOL CH, V1, P522, DOI 10.1006/niox.1997.0159; Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6; Wink DA, 1996, METHOD ENZYMOL, V268, P120; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007	36	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21241	21246		10.1074/jbc.M904498199	http://dx.doi.org/10.1074/jbc.M904498199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10887204	hybrid			2022-12-25	WOS:000088230600039
J	Crook, T; Nicholls, JM; Brooks, L; O'Nions, J; Allday, MJ				Crook, T; Nicholls, JM; Brooks, L; O'Nions, J; Allday, MJ			High level expression of Delta N-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)?	ONCOGENE			English	Article						p53; p63; p14(ARF); undifferentiated nasopharyngeal carcinoma; NPC	BARR-VIRUS INFECTION; TUMOR-SUPPRESSOR GENE; P16 GENE; POINT MUTATION; MDM2; PROTEIN; P63; LYMPHOMAGENESIS; OVEREXPRESSION; DEGRADATION	Undifferentiated nasopharyngeal carcinoma (NPC) is an epithelial malignancy that is consistently associated with Epstein-Barr virus (EBV) but which very rarely has p53 gene mutations in primary tumours, Since the tumour suppressor p53 is mutated in most human canters or the wild type protein is inactivated in a significant number of the remainder, here we have investigated cellular factors that could compromise p53 function in primary NPC, Twenty-five primary tumours were judged to carry only wild type p53 by SSCP analysis of all exons and sequence determination of exons 4-9, Only one tumour was found to express significant levels of hMdm2 and in 24/25 there were no detectable mutations or deletions in exons 1 beta and 2 of the p14(ARF) gene. However, immunohistochemistry consistently revealed that all the tumour cells express substantial amounts of the p53-related protein p63, Semi-quantitative RT- PCR analysis of mRNA from tumour biopsies showed that the dominant species expressed was invariably the truncated Delta N-isotype. Since this can block p53-mediated transactivation, it is potentially a dominant-negative isoform, In normal nasopharyngeal epithelium the distribution of p63 was restricted to the proliferating basal and suprabasal layers. We suggest that Delta N-p63 is a good candidate as a suppressor of wild type p53 function in these tumours and also that it may prove to be a valuable diagnostic marker for undifferentiated NPC.	Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Sect Virol & Cell Biol, London W2 1PG, England; Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England	Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; University of Hong Kong; University of London; London School of Hygiene & Tropical Medicine	Allday, MJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, St Marys Campus,Norfolk Pl, London W2 1PG, England.		Nicholls, John Malcolm/C-4375-2009	Nicholls, John Malcolm/0000-0001-7217-7444				ALLDRED DC, 1993, J NATL CANCER I, V85, P200; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gazzeri S, 1998, ONCOGENE, V16, P497, DOI 10.1038/sj.onc.1201559; Gulley ML, 1998, AM J PATHOL, V152, P865; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KLEIN G, 1979, EPSTEIN BARR VIRUS; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lo KW, 1996, CANCER RES, V56, P2721; LO KW, 1992, ANTICANCER RES, V12, P1957; LO KW, 1995, CANCER RES, V55, P2039; McGregor JM, 1997, ONCOGENE, V15, P1737, DOI 10.1038/sj.onc.1201339; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Murono S, 1999, HISTOPATHOLOGY, V34, P432; Niedobitek G, 1996, SEMIN CANCER BIOL, V7, P165, DOI 10.1006/scbi.1996.0023; NIEDOBITEK G, 1993, J PATHOL, V170, P457, DOI 10.1002/path.1711700409; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARSA R, 1999, J INVEST DERMATOL, V113; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1997, P NATL ACAD SCI USA, V94, P3436; Rickinson A. B., 1996, FIELDS VIROLOGY; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SHEU LF, 1995, HUM PATHOL, V26, P380, DOI 10.1016/0046-8177(95)90137-X; SPRUCK CH, 1992, CANCER RES, V52, P4787; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; SUN Y, 1995, ONCOGENE, V10, P785; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	42	172	189	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 13	2000	19	30					3439	3444		10.1038/sj.onc.1203656	http://dx.doi.org/10.1038/sj.onc.1203656			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918601				2022-12-25	WOS:000088198100012
J	Silles, E; Mazon, MJ; Gevaert, K; Goethals, M; Vandekerckhove, J; Leber, R; Sandoval, IV				Silles, E; Mazon, MJ; Gevaert, K; Goethals, M; Vandekerckhove, J; Leber, R; Sandoval, IV			Targeting of aminopeptidase I to the yeast vacuole ts mediated by Ssa1p, a cytosolic member of the 70-kDa stress protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CYTOPLASM; PATHWAY; HSP70; IDENTIFICATION; TRANSLOCATION; PRESEQUENCE; AUTOPHAGY; TRANSPORT; MECHANISM	The two cytosolic members of the highly conserved 70-kDa stress protein family, Ssa1p and Ssa2p, were specifically retained by the prepro-NH2 extension of the vacuolar aminopeptidase I precursor (pAPI) conjugated to agarose (Sulfolink). A temperature-sensitive mutant strain a1(ts)a234 (ssa1(ts) ssa2 ssa3 ssa4), when incubated at the restrictive temperature, was able to assemble the API precursor into dodecamers, but failed to pack pAPI into vesicles and to convert it into mature API (mAPI), a process that occurs in the vacuole. Altogether these results indicate that Ssa1p mediates the targeting of pAPI to the vacuole.	Univ Autonoma Madrid, Fac Ciencias, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; Univ Autonoma Madrid, Fac Ciencias, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; State Univ Ghent VIB, Dept Biochem, B-9000 Ghent, Belgium	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Flanders Institute for Biotechnology (VIB); Ghent University	Sandoval, IV (corresponding author), Univ Autonoma Madrid, Fac Ciencias, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.	isandoval@cbm.uam.es	Gevaert, Kris/AAE-4212-2019; Calpena, María Jesús Mazón/E-9168-2016; Gevaert, Kris/H-3637-2013; Gevaert, Kris/D-6489-2017	Gevaert, Kris/0000-0002-4237-0283; Calpena, María Jesús Mazón/0000-0003-4151-4051; Gevaert, Kris/0000-0002-4237-0283; Gevaert, Kris/0000-0002-4237-0283; Leber, Regina/0000-0001-5306-5834				ARNOLD CE, 1994, J BIOL CHEM, V269, P30412; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Becker J, 1996, MOL CELL BIOL, V16, P4378; Endo T, 1996, J BIOL CHEM, V271, P4161; Gevaert K, 1998, ELECTROPHORESIS, V19, P909, DOI 10.1002/elps.1150190606; Griffin PR, 1995, RAPID COMMUN MASS SP, V9, P1546, DOI 10.1002/rcm.1290091515; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kim J, 1997, J CELL BIOL, V137, P609, DOI 10.1083/jcb.137.3.609; Kim S, 1998, P NATL ACAD SCI USA, V95, P12860, DOI 10.1073/pnas.95.22.12860; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Liu Y, 1996, EMBO J, V15, P6750, DOI 10.1002/j.1460-2075.1996.tb01064.x; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Martinez E, 1997, J MOL BIOL, V267, P1124, DOI 10.1006/jmbi.1997.0925; Martinez E, 1999, MOL MICROBIOL, V33, P52, DOI 10.1046/j.1365-2958.1999.01446.x; McClellan AJ, 1998, MOL BIOL CELL, V9, P3533, DOI 10.1091/mbc.9.12.3533; Oda MN, 1996, J CELL BIOL, V132, P999, DOI 10.1083/jcb.132.6.999; Sambrook J., 2002, MOL CLONING LAB MANU; Satyanarayana C, 2000, FEBS LETT, V470, P232, DOI 10.1016/S0014-5793(00)01324-7; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Scott SV, 1995, J CELL BIOL, V131, P1727, DOI 10.1083/jcb.131.6.1727; SEGUIREAL B, 1995, EMBO J, V14, P5476, DOI 10.1002/j.1460-2075.1995.tb00234.x; Sherman F, 1986, LAB COURSE MANUAL ME; SIKORSKI RS, 1989, GENETICS, V122, P19; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Unno K, 1997, BIOL PHARM BULL, V20, P1240; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310	29	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34054	34059		10.1074/jbc.M003514200	http://dx.doi.org/10.1074/jbc.M003514200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10903313	hybrid			2022-12-25	WOS:000165095300010
J	Miles, CA; Sionkowska, A; Hulin, SL; Sims, TJ; Avery, NC; Bailey, AJ				Miles, CA; Sionkowska, A; Hulin, SL; Sims, TJ; Avery, NC; Bailey, AJ			Identification of an intermediate state in the helix-coil degradation of collagen by ultraviolet light	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT TAIL TENDON; THERMAL-STABILITY; CROSS-LINKING; TRIPLE HELIX; DENATURATION; MECHANISM; PROTEINS	Differential scanning calorimetry has revealed the presence of a new denaturation endotherm at 32 degreesC following UV irradiation of collagen, compared with 39 degreesC for the native triple helix. Kinetic analyses showed that the new peak was a previously unknown intermediate state in the collagen helix-coil transition induced by UV light, and at least 80% of the total collagen was transformed to random chains via this state. Its rate of formation was increased by hydrogen peroxide and inhibited by free radical scavengers. SDS-polyacrylamide gels showed evidence of competing reactions of crosslinking and random primary chain scission. The crosslinking was evident from initial gelling of the collagen solution, but there was no evidence for a dityrosine cross-link. Primary chain scission was confirmed by end group analysis using fluorescamine. Electron microscopy showed that the segment long spacing crystallites formed from the intermediate state were identical to the native molecules. Clearly, collagen can undergo quite extensive damage by cleavage of peptide bonds without disorganizing the triple helical structure. This leads to the formation of a damaged intermediate state prior to degradation of the molecules to short random chains.	Univ Bristol, Collagen Res Grp, Sch Vet Sci, Bristol BS40 5DU, Avon, England; Nicholas Copernicus Univ, Dept Chem, PL-87100 Torun, Poland	University of Bristol; Nicolaus Copernicus University	Miles, CA (corresponding author), Univ Bristol, Collagen Res Grp, Sch Vet Sci, Bristol BS40 5DU, Avon, England.		Curtis, Sarah/AAM-5290-2020; Sionkowska, Alina/I-5599-2014	Curtis, Sarah/0000-0003-0889-964X				Atkins PW, 1978, PHYSICAL CHEM, P868; BAILEY AJ, 1967, RADIAT RES, V31, P206, DOI 10.2307/3572321; BERGMAN I, 1963, ANAL CHEM, V35, P1961, DOI 10.1021/ac60205a053; BURJANADZE TV, 1992, BIOPOLYMERS, V32, P951, DOI 10.1002/bip.360320806; DANIELSEN CC, 1990, BIOCHEM J, V272, P697, DOI 10.1042/bj2720697; FUJIMORI E, 1988, FEBS LETT, V235, P98, DOI 10.1016/0014-5793(88)81241-9; GRANT RA, 1964, J CLIN PATHOL, V17, P685, DOI 10.1136/jcp.17.6.685; HARRINGTON WF, 1969, ADV PROTEIN CHEM, V16, P1; HAYASHI T, 1979, BIOCHEMISTRY-US, V18, P4182, DOI 10.1021/bi00586a022; Kaminska A, 1996, POLYM DEGRAD STABIL, V51, P19, DOI 10.1016/0141-3910(95)00159-X; KATO Y, 1995, PHOTOCHEM PHOTOBIOL, V61, P367, DOI 10.1111/j.1751-1097.1995.tb08624.x; KATO Y, 1994, PHOTOCHEM PHOTOBIOL, V59, P343, DOI 10.1111/j.1751-1097.1994.tb05045.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILES CA, 1995, J MOL BIOL, V245, P437, DOI 10.1006/jmbi.1994.0035; Miles CA, 1999, BIOPHYS J, V76, P3243, DOI 10.1016/S0006-3495(99)77476-X; NOMURA K, 1990, BIOCHEMISTRY-US, V29, P4525, DOI 10.1021/bi00471a004; PRIVALOV PL, 1979, J MOL BIOL, V127, P203, DOI 10.1016/0022-2836(79)90240-7; ROSE C, 1988, BIOCHEM J, V249, P127, DOI 10.1042/bj2490127; Rossi A, 1997, J MOL BIOL, V269, P488, DOI 10.1006/jmbi.1997.1046; SIMS TJ, 1992, J CHROMATOGR-BIOMED, V582, P49, DOI 10.1016/0378-4347(92)80301-6; Sionkowska A, 1999, INT J BIOL MACROMOL, V24, P337, DOI 10.1016/S0141-8130(99)00047-1; SMOLENSKI KA, 1983, BIOCHEM J, V213, P525, DOI 10.1042/bj2130525; Tiktopulo EI, 1998, BIOCHEMISTRY-US, V37, P8147, DOI 10.1021/bi980360n; [No title captured]	24	90	96	3	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33014	33020		10.1074/jbc.M002346200	http://dx.doi.org/10.1074/jbc.M002346200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10893225	hybrid			2022-12-25	WOS:000090003800087
J	Brehelin, C; Mouaheb, N; Verdoucq, L; Lancelin, JM; Meyer, Y				Brehelin, C; Mouaheb, N; Verdoucq, L; Lancelin, JM; Meyer, Y			Characterization of determinants for the specificity of Arabidopsis thioredoxins h in yeast complementation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; IN-VIVO; PLANT THIOREDOXINS; GLUTAREDOXINS; REDUCTASE; PATHWAY; MUTANT; CELLS; NMR	The disruption of the two thioredoxin genes in Saccharomyces cerevisiae leads to a complex phenotype, including the inability to use methionine sulfoxide as sulfur source, modified cell cycle parameters, reduced H2O2 tolerance, and inability to use sulfate as sulfur source. Expression of one of the multiple Arabidopsis thaliana thioredoxins h in this mutant complements only some aspects of the phenotype, depending on the expressed thioredoxin: AtTRX2 or AtTRX3 induce methionine sulfoxide assimilation and restore a normal cell cycle. In addition AtTRX2 also confers growth on sulfate but no H2O2 tolerance, In contrast, AtTRX3 does not confer growth on sulfate but induces H2O2 tolerance. We have constructed hybrid proteins between these two thioredoxins and show that all information necessary for sulfate assimilation is present in the C-terminal part of AtTRX2, whereas some information needed for H2O2 tolerance is located in the N-terminal part of AtTRX3. In addition, mutation of the atypical redox active site WCPPC to the classical site WCGPC restores some growth on sulfate. All these data suggest that the multiple Arabidopsis thioredoxins h originate from a totipotent ancestor with all the determinants necessary for interaction with the different thioredoxin target proteins. After duplications each member evolved by losing or masking some of the determinants.	Univ Perpignan, UMR CNRS 5096, Lab Genome & Dev Plantes, F-66860 Perpignan, France; Univ Lyon 1, Lab Resonance Magnet Nucl Biomol, CNRS, F-69622 Villeurbanne, France; Ecole Super Chim Phys & Elect, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); Universite Perpignan Via Domitia; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Meyer, Y (corresponding author), Univ Perpignan, UMR CNRS 5096, Lab Genome & Dev Plantes, 52 Av Villeneuve, F-66860 Perpignan, France.	ymeyer@univ-perp.fr	Lancelin, Jean-marc/AAC-5686-2019	Brehelin, Claire/0000-0002-1889-9582; Verdoucq, Lionel/0000-0001-8238-3700				CHEREST H, 1992, GENETICS, V130, P51; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P15810, DOI 10.1021/bi971504l; COLE GM, 1990, MOL CELL BIOL, V10, P510, DOI 10.1128/MCB.10.2.510; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; FORMANKAY JD, 1992, J BIOMOL NMR, V2, P431, DOI 10.1007/BF02192807; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jacquot JP, 1997, NEW PHYTOL, V136, P543, DOI 10.1046/j.1469-8137.1997.00784.x; Jaramillo JL, 1998, PLANT J, V15, P155, DOI 10.1046/j.1365-313X.1998.00176.x; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee J, 1999, J BIOL CHEM, V274, P4537, DOI 10.1074/jbc.274.8.4537; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; Meyer Y, 1999, TRENDS PLANT SCI, V4, P388, DOI 10.1016/S1360-1385(99)01475-2; Mittard V, 1997, EUR J BIOCHEM, V243, P374, DOI 10.1111/j.1432-1033.1997.0374a.x; Mouaheb N, 1998, P NATL ACAD SCI USA, V95, P3312, DOI 10.1073/pnas.95.6.3312; MULLER EGD, 1992, YEAST, V8, P117, DOI 10.1002/yea.320080206; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; RIVERAMADRID R, 1995, P NATL ACAD SCI USA, V92, P5620, DOI 10.1073/pnas.92.12.5620; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sherman F, 1979, METHODS YEAST GENETI; Verdoucq L, 1999, J BIOL CHEM, V274, P19714, DOI 10.1074/jbc.274.28.19714	29	36	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31641	31647		10.1074/jbc.M002916200	http://dx.doi.org/10.1074/jbc.M002916200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10906327	hybrid, Green Published			2022-12-25	WOS:000089858900015
J	Kapus, A; Di Ciano, C; Sun, JG; Zhan, X; Kim, L; Wong, TW; Rotstein, OD				Kapus, A; Di Ciano, C; Sun, JG; Zhan, X; Kim, L; Wong, TW; Rotstein, OD			Cell volume-dependent phosphorylation of proteins of the cortical cytoskeleton and cell-cell contact sites - The role of Fyn and FER kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC FAMILY KINASES; CADHERIN CATENIN COMPLEX; HAMSTER OVARY CELLS; TYROSINE PHOSPHORYLATION; BETA-CATENIN; BINDING PROTEIN; GROWTH-FACTOR; ADHERENS JUNCTIONS; SIGNAL TRANSDUCER; OSMOTIC-STRESS	Cell volume affects diverse functions including cytoskeletal organization, but the underlying signaling pathways remained undefined. We have shown previously that shrinkage induces Fyn-dependent tyrosine phosphorylation of the cortical actin-binding protein, cortactin, Because FER kinase was implicated in the direct phosphorylation of cortactin, we investigated the osmotic responsiveness of FER and its relationship to Fyn and cortactin. Shrinkage increased FER activity and tyrosine phosphorylation, These effects were abolished by the Src family inhibitor PP2 and strongly mitigated in Fyn-deficient but not in Src-deficient cells. FER overexpression caused cortactin phosphorylation that was further enhanced by hypertonicity. Exchange of tyrosine residues 421, 466, and 482 for phenylalanine prevented cortactin phosphorylation by hypertonicity and strongly decreased it upon FER overexpression, suggesting that FER targets primarily the same osmo-sensitive tyrosines, Because constituents of the cell-cell contacts are substrates of Fyn and FER, we investigated the effect of shrinkage on the adherens junctions. Hypertonicity provoked Fyn-dependent tyrosine phosphorylation in beta-catenin, alpha-catenin, and p120(Cas) and caused the dissociation of beta-catenin from the contacts, This process was delayed in Fyn-deficient or PP2-treated cells. Thus, FER is a volume-sensitive kinase downstream from Fyn, and the Fyn/FER pathway may contribute to the cell size-dependent reorganization of the cytoskeleton and the cell-cell contacts.	Toronto Gen Hosp, Dept Surg, Toronto, ON M5G 1L7, Canada; Univ Toronto, Toronto, ON M5G 1L7, Canada; Amer Red Cross, Jerome H Holland Lab, Dept Expt Pathol, Rockville, MD 20855 USA; NIDDK, NIH, Bethesda, MD 20892 USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; American Red Cross; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Bristol-Myers Squibb	Kapus, A (corresponding author), Toronto Gen Hosp, Dept Surg, Rm CCRW 2-850,101 Coll St, Toronto, ON M5G 1L7, Canada.							Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Clerk A, 1997, FEBS LETT, V403, P23, DOI 10.1016/S0014-5793(97)00020-3; Craig AWB, 1999, J BIOL CHEM, V274, P19934, DOI 10.1074/jbc.274.28.19934; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; Garcia JGN, 1999, AM J PHYSIOL-LUNG C, V276, pL989, DOI 10.1152/ajplung.1999.276.6.L989; Gatsios P, 1998, J BIOL CHEM, V273, P22962, DOI 10.1074/jbc.273.36.22962; Gloushankova NA, 1997, P NATL ACAD SCI USA, V94, P879, DOI 10.1073/pnas.94.3.879; Gloushankova NA, 1998, P NATL ACAD SCI USA, V95, P4362, DOI 10.1073/pnas.95.8.4362; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hansen K, 1997, BIOCHEM BIOPH RES CO, V241, P355, DOI 10.1006/bbrc.1997.7743; Herring TL, 1999, J MEMBRANE BIOL, V171, P151, DOI 10.1007/s002329900567; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P19248, DOI 10.1074/jbc.272.31.19248; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; KAPUS A, 1994, J BIOL CHEM, V269, P23544; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; KIM L, 1995, MOL CELL BIOL, V15, P4553; Klein JD, 1995, AM J PHYSIOL-CELL PH, V269, pC1524, DOI 10.1152/ajpcell.1995.269.6.C1524; Krump E, 1997, J BIOL CHEM, V272, P17303, DOI 10.1074/jbc.272.28.17303; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Levenberg S, 1998, CELL ADHES COMMUN, V6, P161, DOI 10.3109/15419069809004473; Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Priel-Halachmi S, 2000, J BIOL CHEM, V275, P28902, DOI 10.1074/jbc.M003402200; Ragsdale GK, 1997, BIOPHYS J, V73, P2798, DOI 10.1016/S0006-3495(97)78309-7; Rivero F, 1996, J CELL SCI, V109, P2679; Rizoli SB, 2000, AM J PHYSIOL-CELL PH, V279, pC619, DOI 10.1152/ajpcell.2000.279.3.C619; Roig J, 2000, J BIOL CHEM, V275, P16933, DOI 10.1074/jbc.M001627200; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; SARTOR O, 1993, J BIOL CHEM, V268, P21014; Smithgall TE, 1998, CRIT REV ONCOGENESIS, V9, P43, DOI 10.1615/CritRevOncog.v9.i1.40; Szaszi K, 1997, J BIOL CHEM, V272, P16670, DOI 10.1074/jbc.272.26.16670; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; WANG YM, 2000, BIOCHEM J, V346, P209; Weed SA, 1998, J CELL SCI, V111, P2433; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yates KE, 1996, STEM CELLS, V14, P714, DOI 10.1002/stem.140714; Zischka H, 1999, EMBO J, V18, P4241, DOI 10.1093/emboj/18.15.4241	58	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32289	32298		10.1074/jbc.M003172200	http://dx.doi.org/10.1074/jbc.M003172200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10921917	hybrid			2022-12-25	WOS:000089858900101
J	Liu, KY; Li, LM; Cohen, SN				Liu, KY; Li, LM; Cohen, SN			Antisense RNA-mediated deficiency of the calpain protease, nCL-4, in NIH3T3 cells is associated with neoplastic transformation and tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC CALPAIN; TUMOR-SUPPRESSOR GENES; DRUG-INDUCED APOPTOSIS; DYSTROPHY TYPE 2A; PHYSIOLOGICAL-FUNCTION; PROTEOLYTIC-ENZYME; MOLECULAR-CLONING; SKELETAL-MUSCLE; DIGESTIVE-TRACT; FAMILY MEMBERS	We previously have described the use of an antisense RNA strategy termed random homozygous knock-out (RHKO) to identify negative regulators of cell proliferation, Here we report the discovery that RHKO-mediated deficiency of the nCL-4 calpain protease results in cellular transformation of and tumorigenesis by murine NIH3T3 fibroblasts. We isolated cell clones able to form colonies on 0.5% soft agar and found that these cells generated tumors when injected subcutaneously into nude mice. The gene inactivated by RHKO was identified as nCL-4 by genomic library screening, transcript analysis, and DNA sequencing. Anchorage-independent growth, as indicated by colony formation on soft agar, was reversed by reversal of antisense-mediated homozygous inactivation, but continued haplo-insufficiency of nCL-4 resulting from insertional mutagenesis of one nCL-4 allele was associated with persistent tumorigenesis. nCL-4 cDNA expressed in naive 3T3 cells in the antisense, but not sense, direction under control of the cytomegalovirus early promoter reproduced the anchorage-independent growth effects of RHKO. Our results implicate deficiency of the nCL-4 calpain protease in neoplastic transformation.	Stanford Univ, Sch Med, Med Ctr, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Cohen, SN (corresponding author), Stanford Univ, Sch Med, Med Ctr, Dept Genet, Rm M320, Stanford, CA 94305 USA.	sncohen@stanford.edu			NCI NIH HHS [CA09302] Funding Source: Medline; NHGRI NIH HHS [HG 00044-04] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Baghdiguian S, 1999, NAT MED, V5, P503, DOI 10.1038/8385; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; Busquets S, 2000, BBA-GEN SUBJECTS, V1475, P5, DOI 10.1016/S0304-4165(00)00050-7; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Debiasi RL, 1999, J VIROL, V73, P695, DOI 10.1128/JVI.73.1.695-701.1999; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Gonen H, 1997, FEBS LETT, V406, P17, DOI 10.1016/S0014-5793(97)00225-1; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Jang JS, 1999, ONCOGENE, V18, P1789, DOI 10.1038/sj.onc.1202497; Jang JS, 1999, INT J MOL MED, V4, P487; Kimura Y, 1998, NAT MED, V4, P915, DOI 10.1038/nm0898-915; Kinbara K, 1998, BIOCHEM PHARMACOL, V56, P415; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kulkarni S, 1999, J BIOL CHEM, V274, P21265, DOI 10.1074/jbc.274.30.21265; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Lee HJ, 1998, BIOL CHEM, V379, P175, DOI 10.1515/bchm.1998.379.2.175; Lee HJ, 1999, ARCH BIOCHEM BIOPHYS, V362, P22, DOI 10.1006/abbi.1998.1021; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Liu KY, 1999, MOL CELL BIOL, V19, P3696; LUPTON SD, 1991, MOL CELL BIOL, V11, P3374, DOI 10.1128/MCB.11.6.3374; NAKAMURA M, 1992, EXP CELL RES, V200, P513, DOI 10.1016/0014-4827(92)90203-K; Ono Y, 1998, BIOCHEM BIOPH RES CO, V245, P289, DOI 10.1006/bbrc.1998.8085; Ono Y, 1998, J BIOL CHEM, V273, P17073, DOI 10.1074/jbc.273.27.17073; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Patel YM, 1999, P NATL ACAD SCI USA, V96, P1279, DOI 10.1073/pnas.96.4.1279; Penna D, 1999, J IMMUNOL, V163, P50; Ray SK, 1999, BRAIN RES, V829, P18, DOI 10.1016/S0006-8993(99)01290-1; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; Shields DC, 1999, P NATL ACAD SCI USA, V96, P11486, DOI 10.1073/pnas.96.20.11486; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; Tagawa K, 2000, HUM MOL GENET, V9, P1393, DOI 10.1093/hmg/9.9.1393; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tidball JG, 2000, INT J BIOCHEM CELL B, V32, P1, DOI 10.1016/S1357-2725(99)00095-3; Ueki K, 1999, CANCER RES, V59, P5995; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; Yoshikawa Y, 2000, JPN J CANCER RES, V91, P459, DOI 10.1111/j.1349-7006.2000.tb00967.x; Zhang WL, 1997, ONCOGENE, V14, P255, DOI 10.1038/sj.onc.1200841	61	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31093	31098		10.1074/jbc.M005451200	http://dx.doi.org/10.1074/jbc.M005451200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906334	hybrid			2022-12-25	WOS:000089762700050
J	Ohnishi, K; Shimizu, T; Karasuyama, H; Melchers, F				Ohnishi, K; Shimizu, T; Karasuyama, H; Melchers, F			The identification of a nonclassical cadherin expressed during B cell development and its interaction with surrogate light chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE BONE-MARROW; MU HEAVY-CHAIN; LYMPHOCYTE-B; ALLELIC EXCLUSION; EPITHELIAL-CELLS; PRO-B; GENE; SURFACE; ADHESION; SUPERFAMILY	A 130-kDa glycoprotein (p130) has been found to be associated with surrogate light chain on pro- and pre-B I cells. Using peptide sequences obtained from purified p130 we have cloned its gene. The gene encodes a typical cadherin type 1 membrane protein with six extracellular cadherin domains tone pseudo domain) but lacking the catenin-binding site in its cytoplasmic part. Even without this catenin-binding site, p130 mediates Ca2+- dependent homotypic adhesion of cells. The interaction of p130 with surrogate light chain is confirmed by cotransfection and co-immunoprecipitation experiments. The expression of p130 is biphasic during the B cell development. Reverse transcriptase-polymerase chain reaction and flow cytometric analyses revealed that it is expressed on B220(+)c-Kit(+) pro-B and pre-B-I cells as well as on B220(+)CD25(-)IgM(+) immature and mature B cells but not on B220(+)CD25(+) pre-B-II cells. It is also expressed in fetal liver, at low levels in myeloid cells, and strongly in intestinal epithelial cells. In the spleen, p130-expressing cells are mainly localized in the marginal zone. We call this B lineage-, intestine-, liver- and leukocyte-expressed gene BILL-cadherin. The possible functions of BILL cadherin in B cell development are discussed.	Basel Inst Immunol, CH-4005 Basel, Switzerland; Tokyo Metropolitan Inst Med Sci, Dept Immunol, Tokyo 1138613, Japan	Tokyo Metropolitan Institute of Medical Science	Ohnishi, K (corresponding author), Natl Inst Infect Dis, Dept Immunol, Tokyo 1628640, Japan.		Karasuyama, Hajime/A-7966-2011	Karasuyama, Hajime/0000-0003-0689-0836				BAUER SR, 1986, J IMMUNOL, V136, P4695; BERNDORFF D, 1994, J CELL BIOL, V125, P1353, DOI 10.1083/jcb.125.6.1353; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; Chen XJ, 1997, INT IMMUNOL, V9, P27, DOI 10.1093/intimm/9.1.27; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cowin P, 1996, CURR OPIN CELL BIOL, V8, P56, DOI 10.1016/S0955-0674(96)80049-4; DANTZIG AH, 1994, SCIENCE, V264, P430, DOI 10.1126/science.8153632; DAVIDSON WF, 1988, J EXP MED, V168, P389, DOI 10.1084/jem.168.1.389; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; JACOBSEN K, 1990, EUR J IMMUNOL, V20, P2395, DOI 10.1002/eji.1830201106; KARASUYAMA H, 1993, J EXP MED, V178, P469, DOI 10.1084/jem.178.2.469; KARASUYAMA H, 1994, CELL, V77, P133, DOI 10.1016/0092-8674(94)90241-0; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; Karecla PI, 1996, J BIOL CHEM, V271, P30909, DOI 10.1074/jbc.271.48.30909; KARECLA PI, 1995, EUR J IMMUNOL, V25, P852, DOI 10.1002/eji.1830250333; Kincade P W, 1993, Curr Top Microbiol Immunol, V184, P215; Kincade P W, 1991, Semin Immunol, V3, P379; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; Kreft B, 1997, J CELL BIOL, V136, P1109, DOI 10.1083/jcb.136.5.1109; LEPTIN M, 1985, EUR J IMMUNOL, V15, P131, DOI 10.1002/eji.1830150206; Loffert D, 1996, IMMUNITY, V4, P133, DOI 10.1016/S1074-7613(00)80678-0; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Melchers F, 1999, SEMIN IMMUNOL, V11, P307, DOI 10.1006/smim.1999.0187; MELCHERS F, 1993, IMMUNOL TODAY, V14, P60, DOI 10.1016/0167-5699(93)90060-X; MELCHERS F, 1995, CURR OPIN IMMUNOL, V7, P214, DOI 10.1016/0952-7915(95)80006-9; Melchers F, 1999, P NATL ACAD SCI USA, V96, P2571, DOI 10.1073/pnas.96.6.2571; Minegishi Y, 1999, P NATL ACAD SCI USA, V96, P3041, DOI 10.1073/pnas.96.6.3041; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; NISHIKAWA SI, 1988, EUR J IMMUNOL, V18, P1767, DOI 10.1002/eji.1830181117; Ogawa M, 1998, EXP HEMATOL, V26, P478; OHNISHI K, 1994, J BIOL CHEM, V269, P28347; Oliver AM, 1997, EUR J IMMUNOL, V27, P2366, DOI 10.1002/eji.1830270935; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Osmond D G, 1990, Semin Immunol, V2, P173; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; RANSCHT B, 1994, CURR OPIN CELL BIOL, V6, P740, DOI 10.1016/0955-0674(94)90102-3; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROLINK A, 1993, EUR J IMMUNOL, V23, P1284, DOI 10.1002/eji.1830230614; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; Sambrook J., 2002, MOL CLONING LAB MANU; Sanz E, 1996, J EXP MED, V183, P2693, DOI 10.1084/jem.183.6.2693; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; SHAPIRO L, 1995, P NATL ACAD SCI USA, V92, P6793, DOI 10.1073/pnas.92.15.6793; SHINJO F, 1994, INT IMMUNOL, V6, P393, DOI 10.1093/intimm/6.3.393; SPRENT J, 1973, CELL IMMUNOL, V7, P10, DOI 10.1016/0008-8749(73)90180-9; SPRINGER TA, 1981, J BIOL CHEM, V256, P3833; STEVENS SK, 1982, J IMMUNOL, V128, P844; SUDO T, 1989, J EXP MED, V170, P333, DOI 10.1084/jem.170.1.333; Sugino H, 2000, GENOMICS, V63, P75, DOI 10.1006/geno.1999.6066; Suzuki ST, 1996, J CELL SCI, V109, P2609; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; TAKEMORI T, 1987, EMBO J, V6, P951, DOI 10.1002/j.1460-2075.1987.tb04844.x; THOMSON RB, 1995, J BIOL CHEM, V270, P17594, DOI 10.1074/jbc.270.29.17594; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Uemura T, 1998, CELL, V93, P1095, DOI 10.1016/S0092-8674(00)81452-X; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WAGNER G, 1995, SCIENCE, V267, P342, DOI 10.1126/science.7824932; WALLNY HJ, 1995, EUR J IMMUNOL, V25, P1262, DOI 10.1002/eji.1830250520; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WINKLER TH, 1995, EUR J IMMUNOL, V25, P446, DOI 10.1002/eji.1830250221; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8	65	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31134	31144		10.1074/jbc.M005901200	http://dx.doi.org/10.1074/jbc.M005901200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906147	hybrid			2022-12-25	WOS:000089762700056
J	Potter, LR; Hunter, T				Potter, LR; Hunter, T			Activation of protein kinase C stimulates the dephosphorylation of natriuretic peptide receptor-B at a single serine residue - A possible mechanism of heterologous desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED MOUSE ASTROCYTES; CYCLIC-GMP RESPONSES; GUANYLYL CYCLASE-A; SMOOTH-MUSCLE; ADENINE-NUCLEOTIDES; CGMP ACCUMULATION; PHOSPHORYLATION; SYSTEM; CELLS; PLASMA	The binding of atrial natriuretic peptide and C-type natriuretic peptide (CNP) to the guanylyl cyclase-linked natriuretic peptide receptors A and B (NPR-A and -B), respectively, stimulates increases in intracellular cGMP concentrations. The vasoactive peptides vasopressin, angiotensin II, and endothelin inhibit natriuretic peptide-dependent cGMP elevations by activating protein kinase C (PKC). Recently, we identified six in vivo phosphorylation sites for NPR-A and five sites for NPR-B and demonstrated that the phosphorylation of these sites is required for ligand-dependent receptor activation. Here, we show that phorbol 12-myristate 13-acetate, a direct activator of PKC, causes the dephosphorylation and desensitization of NPR-B. In contrast to the CNP-dependent desensitization process, which results in coordinate dephosphorylation of all five sites in the receptor, phorbol la-myristate 13-acetate treatment causes the dephosphorylation of only one site, which we have identified as Ser(523). The conversion of this residue to alanine or glutamate did not reduce the amount of mature receptor protein as indicated by detergent-dependent guanylyl cyclase activities or Western blot analysis but completely blocked the ability of PKC to induce the dephosphorylation and desensitization of NPR-B, Thus, in contrast to previous reports suggesting that PKC directly phosphorylates and inhibits guanylyl cyclase linked natriuretic peptide receptors, we show that PRC-dependent dephosphorylation of NPR-B at Ser523 provides a possible molecular explanation for how presser hormones inhibit CNP signaling.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA	Salk Institute	Potter, LR (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, Gortner Lab 356, 1479 Gortner Ave, St Paul, MN 55108 USA.	Potter@tc.umn.edu			NCI NIH HHS [CA39780, CA14195, F32 CA067452, CA-67452] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA067452, P30CA014195, R35CA039780] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; APPEL RG, 1992, AM J PHYSIOL, V262, pF911, DOI 10.1152/ajprenal.1992.262.6.F911; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CHANG CH, 1990, BIOCHIM BIOPHYS ACTA, V1052, P159, DOI 10.1016/0167-4889(90)90071-K; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; Chrisman TD, 1999, J BIOL CHEM, V274, P4293, DOI 10.1074/jbc.274.7.4293; CHRISMAN TD, 1993, J BIOL CHEM, V268, P3698; Crook RB, 1997, BIOCHEM J, V324, P49, DOI 10.1042/bj3240049; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; DUDA T, 1995, BIOCHEM BIOPH RES CO, V209, P286, DOI 10.1006/bbrc.1995.1501; DUDA T, 1990, MOL CELL BIOCHEM, V93, P179; Forssmann WG, 1998, HISTOCHEM CELL BIOL, V110, P335, DOI 10.1007/s004180050295; Foster DC, 1998, J BIOL CHEM, V273, P16311, DOI 10.1074/jbc.273.26.16311; Fowkes RC, 2000, J ENDOCRINOL, V166, P195, DOI 10.1677/joe.0.1660195; FURUYA M, 1995, ANN NY ACAD SCI, V748, P517; HAGIWARA H, 1994, J BIOL CHEM, V269, P10729; Hagiwara H, 1996, AM J PHYSIOL-CELL PH, V270, pC1311, DOI 10.1152/ajpcell.1996.270.5.C1311; HANEDA M, 1991, KIDNEY INT, V40, P188, DOI 10.1038/ki.1991.199; HOLLIDAY LS, 1995, J BIOL CHEM, V270, P18983, DOI 10.1074/jbc.270.32.18983; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; Itoh H, 1997, ANN NY ACAD SCI, V811, P533, DOI 10.1111/j.1749-6632.1997.tb52037.x; IWATA T, 1991, J BIOCHEM-TOKYO, V110, P35, DOI 10.1093/oxfordjournals.jbchem.a123539; JAISWAL RK, 1992, BIOCHEM BIOPH RES CO, V182, P395, DOI 10.1016/S0006-291X(05)80158-5; Kitano K, 1996, J IMMUNOL METHODS, V194, P147, DOI 10.1016/0022-1759(96)00075-0; KOLLER KJ, 1993, J BIOL CHEM, V268, P5997; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KUROSE H, 1987, FEBS LETT, V219, P375, DOI 10.1016/0014-5793(87)80256-9; LAROSE L, 1992, MOL CELL BIOCHEM, V115, P203, DOI 10.1007/BF00230332; LEFKOWITZ RJ, 1986, CURR TOP CELL REGUL, V28, P209; Levin ER, 1998, NEW ENGL J MED, V339, P321; LOWE DG, 1992, BIOCHEMISTRY-US, V31, P10421, DOI 10.1021/bi00158a001; Maack T, 1996, KIDNEY INT, V49, P1732, DOI 10.1038/ki.1996.257; Matsukawa N, 1999, P NATL ACAD SCI USA, V96, P7403, DOI 10.1073/pnas.96.13.7403; MCARDLE CA, 1993, ENDOCRINOLOGY, V132, P2065, DOI 10.1210/en.132.5.2065; NAMBI P, 1986, P NATL ACAD SCI USA, V83, P8492, DOI 10.1073/pnas.83.22.8492; Oliver PM, 1997, P NATL ACAD SCI USA, V94, P14730, DOI 10.1073/pnas.94.26.14730; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Potter LR, 1998, J BIOL CHEM, V273, P15533, DOI 10.1074/jbc.273.25.15533; POTTER LR, 1992, J BIOL CHEM, V267, P14531; Potter LR, 1998, BIOCHEMISTRY-US, V37, P2422, DOI 10.1021/bi972303k; POTTER LR, 1994, J BIOL CHEM, V269, P14636; Potter LR, 1999, MOL BIOL CELL, V10, P1811, DOI 10.1091/mbc.10.6.1811; Potter LR, 1999, METHODS, V19, P506, DOI 10.1006/meth.1999.0893; Potter LR, 1998, MOL CELL BIOL, V18, P2164, DOI 10.1128/MCB.18.4.2164; Richards AM, 1996, HEART, V76, P36, DOI 10.1136/hrt.76.3_Suppl_3.36; SHARMA R K, 1989, Steroids, V53, P437, DOI 10.1016/0039-128X(89)90024-X; SHINOMIYA M, 1994, BIOCHEM BIOPH RES CO, V205, P1051, DOI 10.1006/bbrc.1994.2772; STINGO AJ, 1992, AM J PHYSIOL, V263, pH1318, DOI 10.1152/ajpheart.1992.263.4.H1318; Suda M, 1998, P NATL ACAD SCI USA, V95, P2337, DOI 10.1073/pnas.95.5.2337; SUGA S, 1992, J CLIN INVEST, V90, P1145, DOI 10.1172/JCI115933; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; Tsang D, 1997, REGUL PEPTIDES, V70, P91, DOI 10.1016/S0167-0115(97)00013-X; Yasoda A, 1998, J BIOL CHEM, V273, P11695, DOI 10.1074/jbc.273.19.11695; YASUNARI K, 1992, HYPERTENSION, V19, P314, DOI 10.1161/01.HYP.19.4.314; Yeung VTF, 1996, J NEUROSCI RES, V46, P686, DOI 10.1002/(SICI)1097-4547(19961215)46:6<686::AID-JNR6>3.0.CO;2-B; YEUNG VTF, 1992, FEBS LETT, V308, P301, DOI 10.1016/0014-5793(92)81298-Z	61	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31099	31106		10.1074/jbc.M005506200	http://dx.doi.org/10.1074/jbc.M005506200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10915802	hybrid			2022-12-25	WOS:000089762700051
J	Bai, LC; Merchant, JL				Bai, LC; Merchant, JL			Transcription factor ZBP-89 cooperates with histone acetyltransferase p300 during butyrate activation of p21(waf1) transcription in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; ZINC-FINGER PROTEIN; GENE PROMOTER; GROWTH-INHIBITION; BINDING PROTEIN; DNA-BINDING; SP1; DIFFERENTIATION; ACETYLATION; EXPRESSION	Inducible p53-independent regulation of the cyclin-dependent kinase inhibitor p21(waf1) transcription is mediated through proximal GC-rich sites. Prior studies have shown that Sp1, Sp3, and the histone acetylase co-activator p300 are components of the complexes binding to these sites. Although Sp1 and Sp3 collaborate with p300, a direct interaction between Sp1 and p300 does not occur. This study sought to determine whether ZBP-89 rather than Sp1 is the direct target of p300 during butyrate induction of p21(waf1). ZBP-89 (BFCOL1, BERF-1, ZNF 148) is a Kruppel-type zinc finger transcription factor that binds to GC-rich elements and represses or activates known target genes. Adenoviral-mediated expression of ZBP-89 in HT-29 cells revealed that ZBP-89 potentiates butyrate induction of endogenous p21(waf1) gene expression. Further, cotransfection of a ZBP-89 expression vector with a 2.3-kilobase p21(waf1) reporter recapitulated the potentiation by butyrate. DNase I foot-printing analysis of the human p21(waf1) promoter with recombinant ZBP-89 identified a binding site at -245 to -215. Electrophoretic mobility shift assays confirmed that both recombinant and endogenous ZBP-89 and Sp1 bind to this element. The potentiation was abolished in the presence of adenoviral protein E1A. Deletion of the N-terminal domain of ZBP-89 abolished the potentiation mediated by butyrate treatment. This same deletion mutant abolished the ZBP-89 interaction with p300. Cotransfection of p300 with ZBP-89 stimulated the p21(waf1) promoter in the absence of butyrate, p300 co-precipitated with ZBP-89 but not with Sp1, whereas ZBP-89 co-precipitated with Sp1. Together, these findings demonstrate that ZBP-89 also plays a critical role in butyrate activation of the p21(waf)1 promoter and reveals preferential cooperation of this four-zinc finger transcription factor with p300.	Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Merchant, JL (corresponding author), 1150 W Med Dr,MSRB 1,3510, Ann Arbor, MI 48109 USA.		Merchant, Juanita/AAF-8277-2019	Merchant, Juanita/0000-0002-6559-8184	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034533, R01DK045729, R56DK055732, R37DK045729, R01DK055732] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-55732, DK-34533, DK-45729] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aoki K, 1999, MOL MED, V5, P224, DOI 10.1007/BF03402119; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Ausubel FM., 2006, ENZYMATIC MANIPULATI; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BARNARD JA, 1993, CELL GROWTH DIFFER, V4, P495; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Eckner R, 1996, BIOL CHEM, V377, P685; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; Hasegawa T, 1999, BIOCHEM BIOPH RES CO, V256, P249, DOI 10.1006/bbrc.1999.0275; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; Hollander MC, 1997, J BIOL CHEM, V272, P13731, DOI 10.1074/jbc.272.21.13731; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Kung AL, 2000, GENE DEV, V14, P272; Law DJ, 1998, MAMM GENOME, V9, P165, DOI 10.1007/s003359900711; Law GL, 1998, J BIOL CHEM, V273, P19955, DOI 10.1074/jbc.273.32.19955; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Muraoka M, 1996, ONCOGENE, V12, P1565; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Parks CL, 1997, J VIROL, V71, P9600, DOI 10.1128/JVI.71.12.9600-9607.1997; Passantino R, 1998, J BIOL CHEM, V273, P484, DOI 10.1074/jbc.273.1.484; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Reizis B, 1999, J EXP MED, V189, P1669, DOI 10.1084/jem.189.10.1669; Remington MC, 1997, BIOCHEM BIOPH RES CO, V237, P230, DOI 10.1006/bbrc.1997.7119; Siavoshian S, 2000, GUT, V46, P507, DOI 10.1136/gut.46.4.507; Sowa Y, 1999, CANCER RES, V59, P4266; Taniuchi T, 1997, BIOCHEM BIOPH RES CO, V233, P154, DOI 10.1006/bbrc.1997.6310; WANG YK, 1993, MOL CELL BIOL, V13, P5691, DOI 10.1128/MCB.13.9.5691; Wieczorek E, 2000, J BIOL CHEM, V275, P12879, DOI 10.1074/jbc.275.17.12879; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Xiao HY, 1997, BIOCHEM BIOPH RES CO, V237, P457, DOI 10.1006/bbrc.1997.7158; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Ye S, 1999, FEBS LETT, V450, P268, DOI 10.1016/S0014-5793(99)00509-8; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	51	97	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30725	30733		10.1074/jbc.M004249200	http://dx.doi.org/10.1074/jbc.M004249200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10899165	hybrid			2022-12-25	WOS:000089577900110
J	Boutaud, A; Borza, DB; Bondar, O; Gunwar, S; Netzer, KO; Singh, N; Ninomiya, Y; Sado, Y; Noelken, ME; Hudson, BG				Boutaud, A; Borza, DB; Bondar, O; Gunwar, S; Netzer, KO; Singh, N; Ninomiya, Y; Sado, Y; Noelken, ME; Hudson, BG			Type IV collagen of the glomerular basement membrane - Evidence that the chain specificity of network assembly is encoded by the noncollagenous NC1 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHMID METAPHYSEAL CHONDRODYSPLASIA; RECESSIVE ALPORT-SYNDROME; GOODPASTURE ANTIGEN; GLOBULAR DOMAIN; MONOCLONAL-ANTIBODIES; ALPHA-3(IV) CHAIN; X COLLAGEN; IDENTIFICATION; ORGANIZATION; MUTATIONS	The ultrafiltration function of the glomerular basement membrane (GBM) of the kidney is impaired in genetic and acquired diseases that affect type IV collagen. The GEM is composed of five (alpha 1 to alpha 5) of the six chains of type IV collagen, organized into an alpha 1.alpha 2(IV) and an alpha 3.alpha 4.alpha 5(IV) network. In Alport syndrome, mutations in any of the genes encoding the alpha 3(IV), alpha 4(IV), and alpha 5(IV) chains cause the absence of the alpha 3.alpha 4.alpha 5 network, which leads to progressive renal failure. In the present study, the molecular mechanism underlying the network defect was explored by further characterization of the chain organization and elucidation of the discriminatory interactions that govern network assembly. The existence of the two networks was further established by analysis of the hexameric complex of the noncollagenous (NC1) domains, and the alpha 5 chain was shown to be linked to the alpha 3 and alpha 4 chains by interaction through their respective NC1 domains. The potential recognition function of the NC1 domains in network assembly was investigated by comparing the composition of native NC1 hexamers with hexamers that were dissociated and reconstituted in vitro and with hexamers assembled in vitro from purified alpha 1-alpha 5(IV) NC1 monomers. The results showed that NC1 monomers associate to form nativelike hexamers characterized by two distinct populations, an alpha 1.alpha 2 and alpha 3.alpha 4.alpha 5 heterohexamer. These findings indicate that the NC1 monomers contain recognition sequences for selection of chains and protomers that are sufficient to encode the assembly of the alpha 1.alpha 2 and alpha 3.alpha 4.alpha 5 networks of GEM. Moreover, hexamer formation from the alpha 3, alpha 4, and alpha 5 NC1 monomers required co-assembly of all three monomers, suggesting that mutations in the NC1 domain in Alport syndrome may disrupt the assembly of the alpha 3.alpha 4.alpha 5 network by interfering with the assembly of the alpha 3.alpha 4.alpha 5 NC1 hexamer.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Okayama Univ, Sch Med, Dept Mol Biol & Biochem, Okayama 700, Japan; Shigei Med Res Inst, Div Immunol, Okayama 7010202, Japan	University of Kansas; University of Kansas Medical Center; Okayama University	Hudson, BG (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.		Borza, Dorin-Bogdan/AAF-2156-2020	Borza, Dorin-Bogdan/0000-0003-4568-279X; Hudson, Billy/0000-0002-5420-4100	NIDDK NIH HHS [DK18381, DK53763] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018381, R01DK018381, P01DK053763] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Borza DB, 2000, J BIOL CHEM, V275, P6030, DOI 10.1074/jbc.275.8.6030; BOUTAUD A, 1996, FASEB J, V10, P1259; Boye E, 1998, AM J HUM GENET, V63, P1329, DOI 10.1086/302106; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; CHAN D, 1995, J BIOL CHEM, V270, P4558, DOI 10.1074/jbc.270.9.4558; DOLZ R, 1988, EUR J BIOCHEM, V178, P357, DOI 10.1111/j.1432-1033.1988.tb14458.x; Dublet B, 1999, J BIOL CHEM, V274, P18909, DOI 10.1074/jbc.274.27.18909; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; GUNWAR S, 1991, J BIOL CHEM, V266, P14088; Gunwar S, 1998, J BIOL CHEM, V273, P8767, DOI 10.1074/jbc.273.15.8767; Harvey SJ, 1998, KIDNEY INT, V54, P1857, DOI 10.1046/j.1523-1755.1998.00188.x; HEIDET L, 2000, IN PRESS J AM SOC NE, V11; HUDSON BG, 1989, LAB INVEST, V61, P256; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; Jais JP, 2000, J AM SOC NEPHROL, V11, P649, DOI 10.1681/ASN.V114649; JOHANSSON C, 1991, CONNECT TISSUE RES, V25, P229, DOI 10.3109/03008209109029159; JOHANSSON C, 1992, J BIOL CHEM, V267, P24533; Kahsai TZ, 1997, J BIOL CHEM, V272, P17023, DOI 10.1074/jbc.272.27.17023; Kalluri R, 1997, J CLIN INVEST, V99, P2470, DOI 10.1172/JCI119431; KLEPPEL MM, 1992, J BIOL CHEM, V267, P4137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGEVELD JPM, 1988, J BIOL CHEM, V263, P10481; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; MOCHIZUKI T, 1994, NAT GENET, V8, P77, DOI 10.1038/ng0994-77; Netzer KO, 1999, J BIOL CHEM, V274, P11267, DOI 10.1074/jbc.274.16.11267; NINOMIYA Y, 1995, J CELL BIOL, V130, P1219, DOI 10.1083/jcb.130.5.1219; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; RIES A, 1995, J BIOL CHEM, V270, P23790, DOI 10.1074/jbc.270.40.23790; Sado Y, 1998, KIDNEY INT, V53, P664, DOI 10.1046/j.1523-1755.1998.00795.x; SAUS J, 1988, J BIOL CHEM, V263, P13374; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; SUSI H, 1986, METHOD ENZYMOL, V130, P290; TIMONEDA J, 1990, CONNECT TISSUE RES, V24, P169, DOI 10.3109/03008209009152147; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TSILIBARY EC, 1988, J BIOL CHEM, V263, P4302; WEBER S, 1984, EUR J BIOCHEM, V139, P401, DOI 10.1111/j.1432-1033.1984.tb08019.x; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564; WIESLANDER J, 1987, CLIN EXP IMMUNOL, V69, P332; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040; Zhang Y, 1999, J BIOL CHEM, V274, P22409, DOI 10.1074/jbc.274.32.22409	42	157	167	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30716	30724		10.1074/jbc.M004569200	http://dx.doi.org/10.1074/jbc.M004569200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10896941	hybrid			2022-12-25	WOS:000089577900109
J	Jackson, M; Crick, DC; Brennan, PJ				Jackson, M; Crick, DC; Brennan, PJ			Phosphatidylinositol is an essential phospholipid of mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBERCULOSIS; LIPOARABINOMANNAN; SYNTHASE; SMEGMATIS; GENE; BIOSYNTHESIS; BACTERIA; MUTANTS; ANCHOR	Phosphatidylinositol (PI) and metabolically derived products such as the phosphatidylinositol mannosides and linear and mature branched lipomannan and lipoarabinomannan are prominent phospholipids/lipoglycans of Mycobacterium sp. believed to play important roles in the structure and physiology of the bacterium as well as during host infection. To determine if PI is an essential phospholipid of mycobacteria, we identified the pgsA gene of Mycobacterium tuberculosis encoding the phosphatidylinositol synthase enzyme and constructed a pgsA conditional mutant of Mycobacterium smegmatis. The ability of this mutant to synthesize phosphatidylinositol synthase and subsequently PI was dependent on the presence of a functional copy of the pgsA gene carried on a thermosensitive plasmid. The mutant grew like the control strain under permissive conditions (30 degrees C), but ceased growing when placed at 42 degrees C, a temperature at which the rescue plasmid is lost. Loss of cell viability at 42 degrees C was observed when PI and phosphatidylinositol dimannoside contents dropped to similar to 30 and 50% of the wild-type levels, respectively. This work provides the first evidence of the essentiality of PI to the survival of mycobacteria. PI synthase is thus an essential enzyme of Mycobacterium that shows promise as a drug target for anti-tuberculosis therapy.	Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA	Colorado State University	Brennan, PJ (corresponding author), Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA.	pbrennan@cvmbs.colostate.edu	Crick, Dean/H-8251-2017; Jackson, Mary/D-5345-2017	Crick, Dean/0000-0001-9281-7058; Jackson, Mary/0000-0002-9212-0258	NIAID NIH HHS [AI18357, AI46393] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI018357, R37AI018357, R01AI018357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Antonsson B, 1997, BBA-LIPID LIPID MET, V1348, P179, DOI 10.1016/S0005-2760(97)00105-7; BELISLE JT, 1994, J BACTERIOL, V176, P2151, DOI 10.1128/JB.176.8.2151-2157.1994; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; Blanchard JS, 1996, ANNU REV BIOCHEM, V65, P215, DOI 10.1146/annurev.bi.65.070196.001243; BRENNAN P, 1968, BIOCHEM BIOPH RES CO, V30, P69, DOI 10.1016/0006-291X(68)90714-6; BRENNAN P, 1967, J BIOL CHEM, V242, P3046; BRENNAN PJ, 1971, LIPIDS, V6, P401, DOI 10.1007/BF02531377; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; Chopra I, 1998, TUBERCLE LUNG DIS, V78, P89, DOI 10.1016/S0962-8479(98)80001-4; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; CURCIC R, 1994, MOL MICROBIOL, V13, P1057, DOI 10.1111/j.1365-2958.1994.tb00496.x; DITTMER JC, 1964, J LIPID RES, V5, P126; ELSBACH P, 1988, BIOCHIM BIOPHYS ACTA, V947, P29, DOI 10.1016/0304-4157(88)90018-4; Goren M. B., 1984, MYCOBACTERIA SOURC A, P379; GUILHOT C, 1992, FEMS MICROBIOL LETT, V98, P181; HUNTER SW, 1986, J BACTERIOL, V168, P917, DOI 10.1128/jb.168.2.917-922.1986; HUNTER SW, 1986, J BIOL CHEM, V261, P2345; Jackson M, 1997, INFECT IMMUN, V65, P2883, DOI 10.1128/IAI.65.7.2883-2889.1997; KATAOKA T, 1967, BIOCHIM BIOPHYS ACTA, V144, P681, DOI 10.1016/0005-2760(67)90058-6; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; LABIDI A, 1984, CURR MICROBIOL, V11, P235, DOI 10.1007/BF01567167; MATHUR AK, 1976, CAN J MICROBIOL, V22, P354, DOI 10.1139/m76-054; Matsumoto K, 1997, BBA-LIPID LIPID MET, V1348, P214, DOI 10.1016/S0005-2760(97)00110-0; Nigou J, 1997, J BIOL CHEM, V272, P23094, DOI 10.1074/jbc.272.37.23094; Nikawa J, 1997, BBA-LIPID LIPID MET, V1348, P173, DOI 10.1016/S0005-2760(97)00103-3; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; NIKAWA JI, 1982, EUR J BIOCHEM, V125, P445, DOI 10.1111/j.1432-1033.1982.tb06703.x; Parish T, 1997, J BACTERIOL, V179, P7827, DOI 10.1128/jb.179.24.7827-7833.1997; Pelicic V, 1996, MOL MICROBIOL, V20, P919, DOI 10.1111/j.1365-2958.1996.tb02533.x; Pelicic V, 1997, P NATL ACAD SCI USA, V94, P10955, DOI 10.1073/pnas.94.20.10955; Salman M, 1999, BBA-MOL CELL BIOL L, V1436, P437, DOI 10.1016/S0005-2760(98)00151-9; Schlame M, 1997, BBA-LIPID LIPID MET, V1348, P201, DOI 10.1016/S0005-2760(97)00117-3; SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; TABAUD H, 1971, BIOCHIMIE, V53, P55, DOI 10.1016/S0300-9084(71)80083-4; Tropp BE, 1997, BBA-LIPID LIPID MET, V1348, P192, DOI 10.1016/S0005-2760(97)00100-8; YANO I, 1969, J BACTERIOL, V98, P124, DOI 10.1128/JB.98.1.124-130.1969	40	178	187	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30092	30099		10.1074/jbc.M004658200	http://dx.doi.org/10.1074/jbc.M004658200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10889206	hybrid			2022-12-25	WOS:000089577900026
J	Budiman, T; Bamberg, E; Koepsell, H; Nagel, G				Budiman, T; Bamberg, E; Koepsell, H; Nagel, G			Mechanism of electrogenic cation transport by the cloned organic cation transporter 2 from rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; PUMP CURRENTS; SUBSTRATE-SPECIFICITY; VOLTAGE-DEPENDENCE; ATP CONCENTRATION; MEMBRANE PATCHES; KINETICS; CLONING; KIDNEY; ROCT1	The organic cation transporter 2 (OCT2) is expressed in plasma membranes of kidney and brain. Its transport mechanism and substrates are debated. We studied substrate-induced changes of electrical current with the patch clamp technique after expression of rat OCT2 in oocytes. Activation of current, corresponding to efflux, was observed for small organic cations, e.g. choline. In contrast, the bigger cations quinine and tetrabutylammonium elicited no change in current. However, transport of choline could be inhibited by applying quinine or tetrabutylammonium to the cytoplasmic side. Inhibition of organic cation efflux by quinine was competitive with substrates. Quinine at the inside also inhibited substrate influx from the outside. Current-voltage analysis showed that both maximal turnover and apparent affinity to substrates are voltage-dependent. Substrate-induced currents with organic cations on both membrane sides reversed as predicted from the Nernst potential. Our results clearly identify the electrochemical potential as driving force for transport at neutral pH and exclude an electroneutral H+/organic cation(+) exchange. We suggest the existence of an electroneutral organic cation(+) exchange and propose a model for a carrier-type transport mechanism.	Max Planck Inst Biophys, D-60596 Frankfurt, Germany; Univ Wurzburg, Inst Anat, D-97070 Wurzburg, Germany	Max Planck Society; University of Wurzburg	Nagel, G (corresponding author), Max Planck Inst Biophys, Kennedyallee 70, D-60596 Frankfurt, Germany.	nagel@mpibp-frankfurt.mpg.de		Nagel, Georg/0000-0001-8174-8712				Busch AE, 1996, J BIOL CHEM, V271, P32599, DOI 10.1074/jbc.271.51.32599; DAVID C, 1995, PFLUG ARCH EUR J PHY, V430, P477, DOI 10.1007/BF00373884; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Endou H, 1998, TOXICOL LETT, V103, P29, DOI 10.1016/S0378-4274(98)00275-6; FENDLER K, 1987, FEBS LETT, V224, P83, DOI 10.1016/0014-5793(87)80427-1; Fendler K, 1999, BIOCHEMISTRY-US, V38, P1850, DOI 10.1021/bi982238u; Friedrich T, 1997, BIOPHYS J, V73, P186, DOI 10.1016/S0006-3495(97)78059-7; Friedrich T, 1996, BIOPHYS J, V71, P2486, DOI 10.1016/S0006-3495(96)79442-0; Gorboulev V, 1999, MOL PHARMACOL, V56, P1254, DOI 10.1124/mol.56.6.1254; Gorboulev V, 1997, DNA CELL BIOL, V16, P871, DOI 10.1089/dna.1997.16.871; Grundemann D, 1997, J BIOL CHEM, V272, P10408; Grundemann D, 1999, MOL PHARMACOL, V56, P1, DOI 10.1124/mol.56.1.1; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; HANSEN UP, 1981, J MEMBRANE BIOL, V63, P165, DOI 10.1007/BF01870979; Hilgemann DW, 1998, METHOD ENZYMOL, V293, P267; HILGEMANN DW, 1989, PFLUG ARCH EUR J PHY, V415, P247, DOI 10.1007/BF00370601; Hille B., 1992, IONIC CHANNELS EXCIT; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; Koepsell H, 1998, ANNU REV PHYSIOL, V60, P243, DOI 10.1146/annurev.physiol.60.1.243; Koepsell H, 1999, J MEMBRANE BIOL, V167, P103, DOI 10.1007/s002329900475; Lauger P., 1991, ELECTROGENIC ION PUM; Nagel G, 1995, FEBS LETT, V377, P263, DOI 10.1016/0014-5793(95)01356-3; Nagel G, 1997, J BIOL CHEM, V272, P31953, DOI 10.1074/jbc.272.51.31953; NAKAO M, 1986, NATURE, V323, P628, DOI 10.1038/323628a0; Okuda M, 1999, BBA-BIOMEMBRANES, V1417, P224, DOI 10.1016/S0005-2736(99)00005-X; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; Sweet DH, 1999, AM J PHYSIOL-RENAL, V277, pF890, DOI 10.1152/ajprenal.1999.277.6.F890; Ullrich K, 1999, MEMBRANE TRANSPORTER, P159; Ullrich KJ, 1997, J MEMBRANE BIOL, V158, P95, DOI 10.1007/s002329900247; Urakami Y, 1998, J PHARMACOL EXP THER, V287, P800; Weinreich F, 1999, J GEN PHYSIOL, V114, P55, DOI 10.1085/jgp.114.1.55; Weinreich F, 1997, PFLUG ARCH EUR J PHY, V434, P484, DOI 10.1007/s004240050424	32	71	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29413	29420		10.1074/jbc.M004645200	http://dx.doi.org/10.1074/jbc.M004645200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10889205	hybrid			2022-12-25	WOS:000089439800033
J	He, YW; Armanious, MK; Thomas, MJ; Cress, WD				He, YW; Armanious, MK; Thomas, MJ; Cress, WD			Identification of E2F-3B, an alternative form of E2F-3 lacking a conserved N-terminal region	ONCOGENE			English	Article						E2F; E2F-3; retinoblastoma; cell cycle	C-MYC PROTEINS; TRANSCRIPTION FACTORS E2F-1; FIBROBLAST GROWTH-FACTOR; DNA-BINDING SITE; S-PHASE ENTRY; CELL-CYCLE; IN-VIVO; NUCLEAR-LOCALIZATION; FAMILY MEMBERS; REGULATING TRANSCRIPTION	We have identified a novel form of the full-length E2F-3 protein that we term E2F-3B, In contrast to full-length E2F-3, which is expressed only at the G1/S boundary, E2F-3B is detected throughout the cell cycle with peak levels in GO where it is associated with Rb, Transfection and in vitro translation experiments demonstrate that a protein identical to E2F-3B in size and iso-electric point is produced from the E2F-3 mRNA via the use of an alternative translational start site, This alternative initiation codon was mapped hy mutagenesis to codon 102, an ACG codon, Mutation of the ACC codon at position 102 abolished E2F-3B expression, whereas the conversion of ACG 102 to a consensus ATG led to the expression of a protein indistinguishable from E2F-3B, Given these results, E2F-3B is missing 101 N-terminal amino acids relative to full-length E2F-3. This region includes a moderately conserved sequence of unknown function that is present only in the growth-promoting E2F family members, including E2F-1, 2 and full-length E2F-3. These observations make E2F-3B the first example of an E2F gene giving rise to two different protein species and also suggest that E2F-3 and E2F-3B may have opposing roles in cell cycle control.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Biochem & Mol Biol,Program Mol Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Med Microbiol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Cress, WD (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Biochem & Mol Biol,Program Mol Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NCI NIH HHS [CA78214] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078214] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen KE, 1997, J CELL SCI, V110, P2819; Arnaud E, 1999, MOL CELL BIOL, V19, P505; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BOYD L, 1993, P NATL ACAD SCI USA, V90, P9164, DOI 10.1073/pnas.90.19.9164; BUCK V, 1995, ONCOGENE, V11, P31; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; COLIGAN J, CURRENT PROTOCOLS PR; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; Cress WD, 1996, MOL CELL BIOL, V16, P2119; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FALVEY E, 1995, EMBO J, V14, P4307, DOI 10.1002/j.1460-2075.1995.tb00105.x; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Flores AM, 1998, ONCOGENE, V16, P1289, DOI 10.1038/sj.onc.1201633; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; HANN SR, 1995, ADV EXP MED BIOL, V375, P107; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANN SR, 1994, BIOCHIMIE, V76, P880, DOI 10.1016/0300-9084(94)90190-2; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Humbert PO, 2000, GENE DEV, V14, P690; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Imataka H, 1997, EMBO J, V16, P817, DOI 10.1093/emboj/16.4.817; ITOH A, 1995, CELL MOL BIOL RES, V41, P147; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON AF, 1993, ECOSYSTEMS WORLD, V2, P365; Johnson BE, 1998, MATH MECH SOLIDS, V3, P447, DOI 10.1177/108128659800300405; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KITAGAWA M, 1995, ONCOGENE, V10, P229; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Madigan SJ, 1996, MOL CELL BIOL, V16, P4222; Magae J, 1996, J CELL SCI, V109, P1717; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Muller H, 1997, MOL CELL BIOL, V17, P5508; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; Pierce AM, 1998, MOL CARCINOGEN, V22, P190, DOI 10.1002/(SICI)1098-2744(199807)22:3<190::AID-MC7>3.0.CO;2-P; Riechmann JL, 1999, MOL CELL BIOL, V19, P8505; Rogers KT, 1996, P NATL ACAD SCI USA, V93, P7594, DOI 10.1073/pnas.93.15.7594; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Shin EK, 1996, J BIOL CHEM, V271, P12261, DOI 10.1074/jbc.271.21.12261; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WU CL, 1995, MOL CELL BIOL, V15, P2536; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHANG YH, 1995, ONCOGENE, V10, P2085	79	67	69	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2000	19	30					3422	3433		10.1038/sj.onc.1203682	http://dx.doi.org/10.1038/sj.onc.1203682			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918599				2022-12-25	WOS:000088198100010
J	Liu, SL; Rand, A; Kelm, RJ; Getz, MJ				Liu, SL; Rand, A; Kelm, RJ; Getz, MJ			The retinoblastoma gene family members pRB and p107 coactivate the AP-1-dependent mouse tissue factor promoter in fibroblasts	ONCOGENE			English	Article						tissue factor; adenovirus EIA; retinoblastoma tumor suppressor; pRB; p107; AP-1	GROWTH-FACTOR-BETA; SERUM-STIMULATED FIBROBLASTS; TUMOR-SUPPRESSOR PROTEIN; CREB BINDING-PROTEIN; C-FOS; TRANSCRIPTION FACTOR; CELL-GROWTH; BLOOD-COAGULATION; ENDOTHELIAL-CELLS; EXPRESSION	Serum-stimulation of quiescent mouse fibroblasts results in transcriptional activation of tissue factor (TF), the cellular initiator of blood coagulation. This requires the rapid entry of c-Fos into specific AP-1 DNA-binding complexes and can be strongly inhibited by the adenovirus E1A 12S gene product. In this study, we utilized a panel of E1A mutants deficient in cellular protein binding to analyse the molecular basis for E1A inhibition of a minimal, c-Fos-dependent TF promoter/reporter construct in mouse AKR-2B fibroblasts, Mutations which impaired binding of the retinoblastoma tumor suppressor protein family members pRB, p107, and p130 relieved E1A-mediated inhibition of transcription in response to serum-stimulation or c-Fos overexpression. Inhibition was restricted to the G(0) to G(1) transition, consistent with the specificity of E1A for hypophosphorylated forms of RE proteins. Although E1A mutants deficient in CBP/p300 binding retained the ability to inhibit TF transcription, deletion of the aminoterminal portion of the CBP/p300 interaction domain was required to permit rescue of TF promoter activity by coexpression of pRB, Moreover, ectopic p107 could effectively substitute for pRB in relieving E1A-mediated repression. In primary mouse embryo fibroblasts, activity of the minimal AP(-/-) dependent TF promoter was suppressed in Rb-/- cells compared to parallel Rb+/- and Rh+/+ transfectants, Ectopic expression of either PRB or p107 markedly enhanced TF promoter activity in Rh-/- fibroblasts. Collectively, these data imply that pRB and p107 can cooperate with c-Fos to activate TF gene transcription in fibroblasts and suggest a requirement for another, as yet unidentified, E1A-binding protein.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Program Tumor Biol, Rochester, MN 55905 USA	Mayo Clinic	Kelm, RJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Program Tumor Biol, Rochester, MN 55905 USA.				NCI NIH HHS [T32 CA09441, CA76083] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076083, T32CA009441] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BARBEAU D, 1994, ONCOGENE, V9, P359; BISPHOPRIC NH, 1997, J BIOL CHEM, V272, P20584; BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P6258, DOI 10.1073/pnas.93.13.6258; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; Erlich J, 1999, P NATL ACAD SCI USA, V96, P8138, DOI 10.1073/pnas.96.14.8138; Felts SJ, 1997, ONCOGENE, V14, P1679, DOI 10.1038/sj.onc.1201006; FELTS SJ, 1995, BIOCHEMISTRY-US, V34, P12355, DOI 10.1021/bi00038a032; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Giannini G, 1997, J BIOL CHEM, V272, P5313, DOI 10.1074/jbc.272.8.5313; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; Kingston RE, 1999, NATURE, V399, P199, DOI 10.1038/20302; KRAUS VB, 1994, P NATL ACAD SCI USA, V91, P6279, DOI 10.1073/pnas.91.14.6279; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; NEVINS JR, 1992, SCIENCE, V258, P424; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; REDDY JC, 1995, J BIOL CHEM, V270, P29976; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; SONG CZ, 1995, P NATL ACAD SCI USA, V92, P10330, DOI 10.1073/pnas.92.22.10330; STOFLET ES, 1992, MOL BIOL CELL, V3, P1073, DOI 10.1091/mbc.3.10.1073; TAYLOR DA, 1993, MOL CELL BIOL, V13, P4714, DOI 10.1128/MCB.13.8.4714; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Vrana JA, 1996, CANCER RES, V56, P5063; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9	57	18	18	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 13	2000	19	30					3352	3362		10.1038/sj.onc.1203675	http://dx.doi.org/10.1038/sj.onc.1203675			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918592				2022-12-25	WOS:000088198100003
J	Sanceau, J; Hiscott, J; Delattre, O; Wietzerbin, J				Sanceau, J; Hiscott, J; Delattre, O; Wietzerbin, J			IFN-beta induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7	ONCOGENE			English	Article						Ewing's sarcoma; interferon-beta; IRF-1; apoptosis; caspase-7	I INTERFERON RECEPTOR; NECROSIS-FACTOR-ALPHA; KINASE INHIBITOR P21; REGULATORY FACTOR-I; SIGNALING PATHWAY; TRANSCRIPTIONAL ACTIVATION; MOLECULAR-CLONING; GROWTH-INHIBITION; P53 MUTATIONS; HUMAN TUMORS	Four human cell lines derived from Ewing's sarcoma, EW-7, EW-1, COH and ORS, were investigated to establish the effects of human recombinant interferon-alpha 2a and human recombinant interferon-beta on cell proliferation and apoptosis, All four cell lines were much more sensitive to the antiproliferative effects of IFN-beta than of IFN-alpha. Analysis of the early signals triggered by IFN-alpha and IFN-beta demonstrated that the two IFNs were similarly effective in inducing tyrosine phosphorylation of the Jak-1 and Tyk-2 kinases and the transcription factors Stat-1 and Stat-2, Interestingly, an additional rapid phosphorylation of Stat-1 on serine was observed after IFN-beta treatment, with concomitant activation of p38 mitogen-activated protein kinase, In these cells, Stat-1 Ser727 phosphorylation in response to IFN-beta was found to be impaired by p38 MAPkinase inhibitor (SB203580). IFN-beta induced the formation of the Interferon Stimulated Gene Factor 3 complex more efficiently than IFN-alpha, as well as sustained induction of IRF-1, which may account for its greater induction of 2'5'oligo(A)synthetase and greater inhibition of cell proliferation. IFN-beta, but not IFN-alpha, induced apoptosis in wild-type p53 EW-7 and COH cell lines, but not in the mutated p53 EW-1 or ORS cell lines. The apoptosis induced by IFN-beta in EW-7 and COH cell lines appeared to be mediated by IRF-1 and involved the activation of caspase-7, Ectopic expression of IRF-1 induced apoptosis in all four cell lines which correlated with the activation of caspase-7 and,vith the downregulation of the Bcl-2 oncoprotein, as observed for IFN-beta-induced apoptosis in parental EW-7 and COH cell lines.	Inst Curie, INSERM, U365, Sect Rech, F-75248 Paris 05, France; McGill Univ, Lady Davis Inst Res, Montreal, PQ H3T 1E2, Canada; Inst Curie, INSERM, U509, Sect Rech, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Lady Davis Institute; McGill University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Sanceau, J (corresponding author), Inst Curie, INSERM, U365, Sect Rech, 26 Rue Ulm, F-75248 Paris 05, France.			delattre, olivier/0000-0002-8730-2276				AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; Arriola EL, 1999, ONCOGENE, V18, P1457, DOI 10.1038/sj.onc.1202420; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; AURIAS A, 1983, NEW ENGL J MED, V309, P496; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; Borden, 1998, Oncologist, V3, P198; BRAILLY RA, 1993, MOL CELL BIOL, V14, P3230; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COLAMONICI OR, 1995, J BIOL CHEM, V270, P8188, DOI 10.1074/jbc.270.14.8188; Croze E, 1996, J BIOL CHEM, V271, P33165, DOI 10.1074/jbc.271.52.33165; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEMARCO F, 1995, J GEN VIROL, V76, P445, DOI 10.1099/0022-1317-76-2-445; Domanski P, 1998, J BIOL CHEM, V273, P3144, DOI 10.1074/jbc.273.6.3144; Domanski Paul, 1996, Cytokine and Growth Factor Reviews, V7, P143, DOI 10.1016/1359-6101(96)00017-2; DORR RT, 1993, DRUGS, V45, P177, DOI 10.2165/00003495-199345020-00003; EILERS A, 1995, MOL CELL BIOL, V15, P3579; Fizazi K, 1998, J CLIN ONCOL, V16, P3736, DOI 10.1200/JCO.1998.16.12.3736; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Giandomenico V, 1998, EUR CYTOKINE NETW, V9, P619; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Grander D, 1997, EUR J HAEMATOL, V59, P129; Grumbach IM, 1999, J INTERF CYTOK RES, V19, P797, DOI 10.1089/107999099313659; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Hadida F, 1999, HUM GENE THER, V10, P1803, DOI 10.1089/10430349950017482; HAMELIN R, 1994, INT J CANCER, V57, P336, DOI 10.1002/ijc.2910570308; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; Horowitz Marc E., 1997, P831; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; Hotchkiss RS, 1999, J IMMUNOL, V162, P4148; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; Kimura T, 1996, GENES CELLS, V1, P115, DOI 10.1046/j.1365-2443.1996.08008.x; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Marcelli M, 1998, CANCER RES, V58, P76; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MICHALEVICZ R, 1988, LEUKEMIA RES, V12, P845, DOI 10.1016/0145-2126(88)90038-0; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; ROKLIN OW, 1996, CANCER RES, V58, P5870; Rosolen A, 1997, MODERN PATHOL, V10, P55; Runkel L, 1998, J BIOL CHEM, V273, P8003, DOI 10.1074/jbc.273.14.8003; Sacchi S, 1998, J CLIN ONCOL, V16, P882, DOI 10.1200/JCO.1998.16.3.882; Salmeron J, 1999, LIVER, V19, P275, DOI 10.1111/j.1478-3231.1999.tb00049.x; SALVESEN G, 1997, CELL, V91, P433; SANCEAU J, 1995, J BIOL CHEM, V270, P27920, DOI 10.1074/jbc.270.46.27920; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; Tanneberger S, 1996, J INTERF CYTOK RES, V16, P339, DOI 10.1089/jir.1996.16.339; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VANVALEN F, 1993, J CANCER RES CLIN, V119, P615, DOI 10.1007/BF01372725; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	70	98	101	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 13	2000	19	30					3372	3383		10.1038/sj.onc.1203670	http://dx.doi.org/10.1038/sj.onc.1203670			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918594				2022-12-25	WOS:000088198100005
J	Bruni, P; Boccia, A; Baldassarre, G; Trapasso, F; Santoro, M; Chiappetta, G; Fusco, A; Viglietto, G				Bruni, P; Boccia, A; Baldassarre, G; Trapasso, F; Santoro, M; Chiappetta, G; Fusco, A; Viglietto, G			PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells is mediated by p27(kip1)	ONCOGENE			English	Article						PTEN; thyroid cancer; growth suppression; AKT; p27(kip1)	TUMOR-SUPPRESSOR; COWDEN-DISEASE; GLIOBLASTOMA CELLS; PROSTATE-CANCER; GENE; MUTATION; PTEN/MMAC1; SURVIVAL; PROTEIN; PKB/AKT	The dual-specificity phosphatase PTEN/MMAC1/TEP1 has recently been identified as the tumor suppressor gene most frequently mutated and/or deleted in human tumors. Germline mutations of PTEN give rise to Cowden Disease (CD), an autosomal dotninantly-inherited cancer syndrome which predisposes to increased risk of developing breast and thyroid tumors. However, PTEN mutations have rarely been detected in sporadic thyroid carcinomas. In this study, we confirm that PTEN mutations in sporadic thyroid cancer are infrequent as we found one point mutation and one heterozygous deletion of PTEN gene in 26 tumors and eight cell lines screened. However, we report that PTEN expression is reduced both at the mRNA and at the protein level - in five out of eight tumor-derived cell Lines and in 24 out of 61 primary tumors. In most cases, decreased PTEN expression is correlated with increased phosphorylation of the P-TEN-regulated protein kinase Akt/PKB. Moreover, we demonstrate that PTEN may act as a suppressor of thyroid cancerogenesis as the constitutive re-expression of PTEN into two different thyroid tumor cell lines markedly inhibits cell growth. PTEN-dependent inhibition of BrdU incorporation is accompanied by enhanced expression of the cyclin-dependent kinase inhibitor p27(kip1) and can be overcome by simultaneous co-transfection of an excess p27(kip1) antisense plasmid Accordingly, in a subset of thyroid primary carcinomas and tumor-derived cell Lines, a striking correlation between PTEN expression and the level of p27(kip1) protein was observed, In conclusion, our findings demonstrate that inactivation of PTEN may play a role in the development of sporadic thyroid carcinomas and that one key target of PTEN suppressor activity is represented by the cyclin-dependent kinase inhibitor p27(kip1).	Univ Naples Federico II, Fac Med & Chirurg, Dip BIol & Patol Cellulare & Mol, CNR,Ctr Endocrinol & Oncol Superimentale, I-80131 Naples, Italy; Ist Nazl Tumori, Serv Oncol Sperimentale E, I-80131 Naples, Italy; Univ Magna Groecia, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro	Fusco, A (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dip BIol & Patol Cellulare & Mol, CNR,Ctr Endocrinol & Oncol Superimentale, Via S Pansini 5, I-80131 Naples, Italy.		Viglietto, Giuseppe/AAC-2852-2019; Baldassarre, Gustavo/K-1350-2016	Viglietto, Giuseppe/0000-0003-2327-7515; Baldassarre, Gustavo/0000-0002-9750-8825; Fusco, Alfredo/0000-0003-3332-5197				Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cheney IW, 1998, CANCER RES, V58, P2331; Cheyney IW, 1999, CANCER RES, V59, P2318; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Dahia PLM, 1997, CANCER RES, V57, P4710; DAMING L, 1998, P NATL ACAD SCI USA, V95, P15406; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Eng C, 1998, INT J ONCOL, V12, P701; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Halachmi N, 1998, GENE CHROMOSOME CANC, V23, P239, DOI 10.1002/(SICI)1098-2264(199811)23:3<239::AID-GCC5>3.0.CO;2-2; HANSSEN AMN, 1995, J MED GENET, V32, P117, DOI 10.1136/jmg.32.2.117; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Longy M, 1996, ANN GENET-PARIS, V39, P35; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rasheed BKA, 1997, CANCER RES, V57, P4187; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; Scala S, 1998, INT J ONCOL, V13, P665; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246	35	128	143	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3146	3155		10.1038/sj.onc.1203633	http://dx.doi.org/10.1038/sj.onc.1203633			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918569				2022-12-25	WOS:000088019200003
J	Weimar, T; Bukowski, R; Young, NM				Weimar, T; Bukowski, R; Young, NM			The conformation of the T-antigen disaccharide found to Maclura pomifera agglutinin in aqueous solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; CARBOHYDRATE SPECIFICITY; LECTIN; NMR; SPECTROSCOPY; COMPLEX	The complex of Maclura pomifera agglutinin with the T-antigen disaccharide (beta -D-Gal-(1-->3)-alpha -D-GalNAc-(1-->O)- Me) was investigated by NMR spectroscopy in aqueous solution Intramolecular transferred nuclear Overhauser enhancement (NOE) effects between the monosaccharide moieties were used to derive the Ligand conformation in the lectin-bound state. Ligand protons in contact with the protein were identified by saturation transfer difference experiments and intermolecular transferred NOE effects. It is demonstrated that structural differences exist for the ligand-lectin complex in aqueous solution as compared with the previously published crystal structure (Lee,X, Thompson, A, Zhiming, Z., Ton-that, H., Biesterfeldt, J., Ogata, C., Xu, L., Johnston, R. A Z., and Young, N. M. (1998) J. Biol: Chem 273, 6312-6318). Tn order to accommodate the O-methyl group of the disaccharide, the amino acid side chain of Tyr-122 has to rotate from its position in the crystal The NMR data are in accord with two conformational families at the beta-(1-->3)glycosidic linkage in the solution complex with interglycosidic angles phi/psi = 45/-65 degrees and -65/ -18 degrees. These differ from the bound conformation of the ligand in the crystal (phi/psi = 39/-8 degrees) and are not highly populated by the ligand in the free state. The reason for the structural, differences at the beta-(1-->)glycosidic linkage are hydrogen bonds that stabilize the relative orientation of the monosaccharide units in the crystal. Our results demonstrate that the crystallization of a protein-carbohydrate complex car interfere with the delicate process of carbohydrate recognition in solution.	Med Univ Lubeck, Inst Chem, D-23538 Lubeck, Germany; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of Lubeck; National Research Council Canada	Weimar, T (corresponding author), Med Univ Lubeck, Inst Chem, Ratzeburger Allee 160, D-23538 Lubeck, Germany.							Feeney R E, 1978, Adv Protein Chem, V32, P191, DOI 10.1016/S0065-3233(08)60576-8; Friedenreich V., 1930, THOMSEN HEMAGGLUTINA; GEEN H, 1991, J MAGN RESON, V93, P93, DOI 10.1016/0022-2364(91)90034-Q; Haselhorst T, 1999, BIOCHEMISTRY-US, V38, P6449, DOI 10.1021/bi982984z; Lee X, 1998, J BIOL CHEM, V273, P6312, DOI 10.1074/jbc.273.11.6312; Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q; NI F, 1994, PROG NUCL MAG RES SP, V26, P517, DOI 10.1016/0079-6565(94)90000-0; PERLMAN ME, 1994, BIOCHEMISTRY-US, V33, P7547, DOI 10.1021/bi00190a007; PETERS T, 1993, CARBOHYD RES, V238, P49, DOI 10.1016/0008-6215(93)87005-D; Peters T, 1996, CURR OPIN STRUC BIOL, V6, P710, DOI 10.1016/S0959-440X(96)80039-X; Poveda A, 1997, J MOL GRAPH MODEL, V15, P9, DOI 10.1016/S1093-3263(97)00012-0; Ravishankar R, 1997, CURR SCI INDIA, V72, P855; Sankaranarayanan R, 1996, NAT STRUCT BIOL, V3, P596, DOI 10.1038/nsb0796-596; SARKAR M, 1981, ARCH BIOCHEM BIOPHYS, V209, P204, DOI 10.1016/0003-9861(81)90273-3; SCHERF T, 1993, BIOPHYS J, V64, P754, DOI 10.1016/S0006-3495(93)81436-X; SPRINGER GF, 1995, CRIT REV ONCOGENESIS, V6, P57, DOI 10.1615/CritRevOncog.v6.i1.50; STUIKEPRILL R, 1990, EUR J BIOCHEM, V194, P903, DOI 10.1111/j.1432-1033.1990.tb19485.x; THOMSEN OLUF, 1927, ZEITSCHR IMMUNITATSFORSCH U EXP THERAP, V52, P85; Transue TR, 1997, NAT STRUCT BIOL, V4, P779, DOI 10.1038/nsb1097-779; VERMA M, 1994, GLYCOCONJUGATE J, V11, P172, DOI 10.1007/BF00731215; Vincent SJF, 1997, P NATL ACAD SCI USA, V94, P4383, DOI 10.1073/pnas.94.9.4383; YOUNG NM, 1989, ARCH BIOCHEM BIOPHYS, V270, P596, DOI 10.1016/0003-9861(89)90542-0	22	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37006	37010		10.1074/jbc.M005092200	http://dx.doi.org/10.1074/jbc.M005092200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10913148	hybrid			2022-12-25	WOS:000165577700078
J	Bolesch, DG; Keasling, JD				Bolesch, DG; Keasling, JD			Polyphosphate binding and chain length recognition of Escherichia coli exopolyphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPIONIBACTERIUM-SHERMANII; KINASE; GLUCOKINASE; MECHANISM; PROTEINS; ACTIN; GENE	Exopolyphosphatase of Escherichia coli (PPX) is a highly processive enzyme demonstrating the ability to recognize polyphosphates of specific lengths. The mechanisms responsible for the processivity and polymer length recognition of the enzyme were investigated in relation to the manner in which polyphosphate is bound to the enzyme. Multiple polyphosphate binding sites were identified on distant portions of the enzyme and were determined to be responsible for the polymer length recognition of the enzyme. In addition, two independently folded domains were identified. The N-terminal domain contained a quasi-processive polyphosphatase active site belonging to the sugar kinase/actin/hsp70 superfamily. The C-terminal domain contained a single polyphosphate binding site and was responsible for nearly all of the PPX affinity for polyphosphate. This domain was also found to confer a highly processive mode of action to PPX. Collectively; these results cc-ere used to describe the interaction of polyphosphate with PPX.	Univ Calif Berkeley, Dept Chem Engn, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Bolesch, DG (corresponding author), Chiron Corp, 4560 Horton St,M-200, Emeryville, CA 94608 USA.		Keasling, Jay D/J-9162-2012	Keasling, Jay D/0000-0003-4170-6088	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008352] Funding Source: NIH RePORTER; NIGMS NIH HHS [2T32GM08352] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN KH, 1990, J BIOL CHEM, V265, P11734; AKIYAMA M, 1993, J BIOL CHEM, V268, P633; AKIYAMA M, 1992, J BIOL CHEM, V267, P22556; BOLESCH DG, 1997, THESIS U CALIFORNIA; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; Brandrup J., 1989, POLYM HDB, V3rd ed.; Cashel M, 1987, ESCHERICHIA COLI SAL, P1410; CLARK JE, 1987, ANAL BIOCHEM, V161, P280, DOI 10.1016/0003-2697(87)90452-0; CROOKE E, 1994, J BIOL CHEM, V269, P6290; KEASLING JD, 1993, P NATL ACAD SCI USA, V90, P7029, DOI 10.1073/pnas.90.15.7029; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; Kulaev IS, 1979, BIOCH INORGANIC POLY; PEPIN CA, 1987, J BIOL CHEM, V262, P5223; PEPIN CA, 1986, J BIOL CHEM, V261, P4476; Rao NN, 1996, J BACTERIOL, V178, P1394, DOI 10.1128/jb.178.5.1394-1400.1996; REIZER J, 1993, TRENDS BIOCHEM SCI, V18, P247, DOI 10.1016/0968-0004(93)90172-J; REUSCH RN, 1988, P NATL ACAD SCI USA, V85, P4176, DOI 10.1073/pnas.85.12.4176; ROBINSON NA, 1984, BIOCHEM INT, V8, P757; SPRIA B, 1995, J BACTERIOL, V177, P4053; STRAUSS UP, 1953, J AM CHEM SOC, V75, P3935, DOI 10.1021/ja01112a017; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60	21	28	29	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33814	33819		10.1074/jbc.M002039200	http://dx.doi.org/10.1074/jbc.M002039200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10922361	hybrid			2022-12-25	WOS:000090104600088
J	Mast, AE; Stadanlick, JE; Lockett, JM; Dietzen, DJ; Hasty, KA; Hall, CL				Mast, AE; Stadanlick, JE; Lockett, JM; Dietzen, DJ; Hasty, KA; Hall, CL			Tissue factor pathway inhibitor binds to platelet thrombospondin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; ANTITHROMBIN-III; FACTOR-XA; COAGULATION INHIBITOR; FACTOR-VIIA; IN-VITRO; SECRETE THROMBOSPONDIN; CARBOXY-TERMINUS; HEPARIN; RECEPTOR	Tissue factor pathway inhibitor (TFPI) is a Kunitz-type serine proteinase inhibitor that down-regulates tissue factor-initiated blood coagulation. The most biologically active pool of TFPI is associated with the vascular endothelium, however, the biochemical mechanisms responsible for its cellular binding are not entirely defined. Proposed cellular binding sites for TFPI include nonspecific association with cell surface glycosaminoglycans and binding to glycosyl phosphatidylinositol-anchored proteins. Here, we report that TFPI binds specifically and saturably to thrombospondin-l (TSP-1) purified from platelet alpha-granules with an apparent K-D of similar to 7.5 nM. Binding is inhibited by polyclonal antibodies against TFPI and partially inhibited by the B-7 monoclonal anti-TSP-l antibody. TFPI bound to immobilized TSP-1 remains an active proteinase inhibitor. Additionally, in solution phase assays measuring TFPI inhibition of factor VIIa/tissue factor catalytic activity, the rate of factor Xa generation was decreased 55% in the presence of TSP-1 compared with TFPI alone. Binding experiments done in the presence of heparin and with altered forms of TFPI suggest that the basic C-terminal region of TFPI is required for TSP-1 binding. The data provide a mechanism for the recruitment and localization of TFPI to extravascular surfaces within a bleeding wound, where it can efficiently down-regulate the procoagulant activity of tissue factor and allow subsequent aspects of platelet-mediated healing to proceed.	Univ Tennessee, Res Serv, Dept Vet Affairs, Memphis, TN 38104 USA; Univ Tennessee, Pathol Serv, Dept Vet Affairs, Memphis, TN 38104 USA; Univ Tennessee, Dept Pathol, Memphis, TN 38104 USA; Univ Tennessee, Dept Anat, Memphis, TN 38104 USA; Univ Memphis, Dept Biomed Engn, Memphis, TN 38152 USA	University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Memphis	Mast, AE (corresponding author), VA Hosp, Res Serv 151, 1030 Jefferson Ave, Memphis, TN 38104 USA.	alan@pathology.utmem.edu						AMERI A, 1992, BLOOD, V79, P3219; BAENZIGER NL, 1972, J BIOL CHEM, V247, P2723; Baugh RJ, 1998, J BIOL CHEM, V273, P4378, DOI 10.1074/jbc.273.8.4378; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; BROZE GJ, 1994, BLOOD COAGUL FIBRIN, V5, P551; BROZE GJ, 1993, BLOOD, V82, P1679; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529; de Jonge E, 2000, BLOOD, V95, P1124, DOI 10.1182/blood.V95.4.1124.002k20_1124_1129; DiPietro LA, 1996, AM J PATHOL, V148, P1851; DIXIT VM, 1984, J BIOL CHEM, V259, P100; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; Hansen JB, 1996, THROMB HAEMOSTASIS, V76, P703; Hansen JB, 1997, THROMB RES, V85, P413, DOI 10.1016/S0049-3848(97)00029-7; Huang ZF, 1997, BLOOD, V90, P944, DOI 10.1182/blood.V90.3.944.944_944_951; JAFFE EA, 1985, BLOOD, V65, P79; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; Jesty J, 1996, BLOOD, V87, P2301, DOI 10.1182/blood.V87.6.2301.bloodjournal8762301; KONDO S, 1987, THROMB RES, V46, P325, DOI 10.1016/0049-3848(87)90294-5; LAHAV J, 1984, EUR J BIOCHEM, V145, P151, DOI 10.1111/j.1432-1033.1984.tb08534.x; LAWLER J, 1989, BLOOD, V74, P2022; LAWLER J, 1982, J BIOL CHEM, V257, P2257; LAWLER J, 1983, J BIOL CHEM, V258, P2098; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER JW, 1981, THROMB RES, V22, P267, DOI 10.1016/0049-3848(81)90119-5; LAWSON JH, 1993, J BIOL CHEM, V268, P767; LINDHOUT T, 1994, BIOCHEM J, V297, P131, DOI 10.1042/bj2970131; Lupu C, 1997, ARTERIOSCL THROM VAS, V17, P2964, DOI 10.1161/01.ATV.17.11.2964; Mast AE, 1997, BIOCHEM J, V327, P577; MOSHER DF, 1982, J CELL BIOL, V93, P343, DOI 10.1083/jcb.93.2.343; NOVOTNY WF, 1988, BLOOD, V72, P2020; NOVOTNY WF, 1991, BLOOD, V78, P387; Ott I, 2000, ARTERIOSCL THROM VAS, V20, P874, DOI 10.1161/01.ATV.20.3.874; Pendurthi UR, 1999, BLOOD, V94, P579, DOI 10.1182/blood.V94.2.579.414k23_579_586; POLVERINI PJ, 1995, FASEB J, V9, pA272; RAUGI GJ, 1987, J INVEST DERMATOL, V89, P551, DOI 10.1111/1523-1747.ep12461198; SANDSET PM, 1988, THROMB RES, V50, P803, DOI 10.1016/0049-3848(88)90340-4; SANTORO SA, 1987, METHOD ENZYMOL, V144, P438; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; Sevinsky JR, 1996, J CELL BIOL, V133, P293, DOI 10.1083/jcb.133.2.293; SILVERSTEIN RL, 1984, J CLIN INVEST, V74, P1625, DOI 10.1172/JCI111578; SUGIHARA K, 1992, BLOOD, V80, P2634; VALENTIN S, 1993, BLOOD COAGUL FIBRIN, V4, P713, DOI 10.1097/00001721-199304050-00007; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WARSHAWSKY I, 1995, J CLIN INVEST, V95, P1773, DOI 10.1172/JCI117855; WESSELSCHMIDT R, 1992, BLOOD, V79, P2004; WESSELSCHMIDT R, 1993, BLOOD COAGUL FIBRIN, V4, P661, DOI 10.1097/00001721-199304050-00001; Wojtukiewicz MZ, 1999, THROMB HAEMOSTASIS, V82, P1659	50	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31715	31721		10.1074/jbc.M006595200	http://dx.doi.org/10.1074/jbc.M006595200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10922378	hybrid			2022-12-25	WOS:000089858900026
J	Yamazaki, N; Shinohara, Y; Kajimoto, K; Shindo, M; Terada, H				Yamazaki, N; Shinohara, Y; Kajimoto, K; Shindo, M; Terada, H			Novel expression of equivocal messages containing both regions of choline/ethanolamine kinase and muscle type carnitine palmitoyltransferase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; MESSENGER-RNAS; DNA-SEQUENCE; GENE; IDENTIFICATION; COMPLEMENTARY; ACETYLCHOLINE; TRANSPORTER; TISSUE; CPT1B	For characterization of the detailed gene structure of human muscle type carnitine palmitoyltransferase I (M-CPTI), we analyzed the 5'-upstream region of the M-CPTI transcripts. As a result, we found a cDNA clone containing a nucleotide sequence unexpected from the reported M-CPTI gene structure in the upstream region of its 5' end. Comparison of this nucleotide sequence with that of genomic DNA showed that this sequence was derived from the 3'-untranslated region of the gene encoding choline/ethanolamine kinase-beta (CK/EK-beta) located upstream of the M-CPTI gene. Southern blot analysis showed that there was no other region homologous to the CK/EK-beta gene in the whole human genome. Thus, the overlapping transcript was concluded to be produced from the functional genes of CK/EK-beta and M-CPTI. Furthermore, cDNAs containing both exons of these genes were detected by the polymerase chain reaction using the cDNA of human heart M-CPTI obtained by specific reverse transcription from its S'-untranslated region as a template. From these results, the production and organization of these overlapping transcripts are discussed.	Univ Tokushima, Fac Pharmaceut Sci, Tokushima 7708505, Japan	Tokushima University	Terada, H (corresponding author), Univ Tokushima, Fac Pharmaceut Sci, Shomachi 1, Tokushima 7708505, Japan.	hterada@ph.tokushima-u.ac.jp	Shindo, Mitsuru/ABN-5203-2022; Kajimoto, Kazuaki/A-3799-2012; Kajimoto, Kazuaki/L-6418-2018; Yamazaki, N/K-7420-2019	Kajimoto, Kazuaki/0000-0002-1636-4154; Shindo, Mitsuru/0000-0002-0588-8075				Aoyama C, 1998, BBA-LIPID LIPID MET, V1393, P179, DOI 10.1016/S0005-2760(98)00062-9; Aoyama C, 1998, BBA-LIPID LIPID MET, V1390, P1, DOI 10.1016/S0005-2760(97)00177-X; Aoyama C, 2000, J LIPID RES, V41, P452; BEJANIN S, 1994, J BIOL CHEM, V269, P21944; Britton CH, 1997, GENOMICS, V40, P209, DOI 10.1006/geno.1996.4539; Chen Z, 1996, TRENDS GENET, V12, P87, DOI 10.1016/0168-9525(96)81412-0; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; HOSHIMARU M, 1987, J BIOL CHEM, V262, P14625; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; NORMARK S, 1983, ANNU REV GENET, V17, P499, DOI 10.1146/annurev.ge.17.120183.002435; Sambrook J., 1989, MOL CLONING, pA1; vanderLeij FR, 1997, BBA-GENE STRUCT EXPR, V1352, P123, DOI 10.1016/S0167-4781(97)00037-7; WANG B, 1988, J BIOL CHEM, V263, P15841; Wang DC, 1998, GENOMICS, V48, P314, DOI 10.1006/geno.1997.5184; WILLIAMS T, 1986, NATURE, V322, P275, DOI 10.1038/322275a0; Yamazaki N, 1997, FEBS LETT, V409, P401, DOI 10.1016/S0014-5793(97)00561-9; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G; Yamazaki N, 1996, BBA-GENE STRUCT EXPR, V1307, P157, DOI 10.1016/0167-4781(96)00069-3; Yu GS, 1998, J BIOL CHEM, V273, P32901, DOI 10.1074/jbc.273.49.32901	22	17	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31739	31746		10.1074/jbc.M006322200	http://dx.doi.org/10.1074/jbc.M006322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10918069	hybrid			2022-12-25	WOS:000089858900029
J	Chen, WG; Silver, DL; Smith, JD; Tall, AR				Chen, WG; Silver, DL; Smith, JD; Tall, AR			Scavenger receptor-BI inhibits ATP-binding cassette transporter 1-mediated cholesterol efflux in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; SELECTIVE LIPID UPTAKE; SR-BI; TANGIER-DISEASE; CELLULAR CHOLESTEROL; HDL RECEPTOR; CELLS; PROMOTES; SURFACE; GENE	Scavenger receptor BI (SR-BI) facilitates the efflux of cellular cholesterol to plasma high density lipoprotein (HDL). Recently, the ATP-binding cassette transporter 1 (ABC1) was identified as a key mediator of cholesterol efflux to apolipoproteins and HDL. The goal of the present study was to determine a possible interaction between the SR-BI and ABC1 cholesterol efflux pathways in macrophages. Free cholesterol efflux to HDL was increased (similar to 2,2-fold) in SR-BI transfected RAW macrophages in association with increased SR-BI protein levels. Treatment of macrophages with 8-bromo-cAMP (cAMP) resulted in a 4.1-fold increase in ABC1 mRNA level and also increased cholesterol efflux to HDL (2.2-fold) and apoA-I (5.5-fold). However, in SR-BI transfected RAW cells, cAMP treatment produced a much smaller increment in cholesterol efflux to HDL (1.1-fold) or apoA-I (3.3-fold) compared with control cells. In macrophages loaded with cholesterol by acetyl-LDL treatment, SR-BI overexpression did not increase cholesterol efflux to HDL but did inhibit cAMP-mediated cholesterol efflux to apoA-I or HDL. SR-BI neutralizing antibody led to a dose- and time dependent increase of cAMP-mediated cholesterol efflux in both SR-BI transfected and control cells, indicating that SR-BI inhibits ABC1-mediated cholesterol efflux even at low SR-BI expression level. Transfection of a murine ABC1 cDNA into 293 cells led to a 2.3-fold increase of cholesterol efflux to apoA-I, whereas co-transfection of SR-BI with ABC1 blocked this increase in cholesterol efflux, SR-BI and ABC1 appear to have distinct and competing roles in mediating cholesterol flux between HDL and macrophages. In nonpolarized cells, SR-BI promotes the reuptake of cholesterol actively effluxed by ABC1, creating a futile cycle.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA; Rockefeller Univ, Biochem Genet & Metab Lab, New York, NY 10021 USA	Columbia University; Rockefeller University	Tall, AR (corresponding author), Columbia Univ, Dept Med, Div Mol Med, 603 W 168th St, New York, NY 10032 USA.	art1@columbia.edu	Tall, Alan/AAT-8528-2021	Silver, David/0000-0002-7289-9890	NHLBI NIH HHS [HL 22682, HL 56984] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056984, R37HL022682, R01HL022682] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Buton X, 1999, J BIOL CHEM, V274, P32112, DOI 10.1074/jbc.274.45.32112; Costet P, 2000, J BIOL CHEM, V275, P28240; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; HARA H, 1991, J BIOL CHEM, V266, P3080; Huszar D, 2000, ARTERIOSCL THROM VAS, V20, P1068, DOI 10.1161/01.ATV.20.4.1068; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; KARLIN JB, 1987, J BIOL CHEM, V262, P12557; Kellner-Weibel G, 2000, BIOCHEMISTRY-US, V39, P221, DOI 10.1021/bi991666c; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Marcil M, 1999, ARTERIOSCL THROM VAS, V19, P159, DOI 10.1161/01.ATV.19.1.159; Oram JF, 1996, J LIPID RES, V37, P2473; Panousis CG, 2000, J LIPID RES, V41, P75; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; ROESSNER A, 1987, PATHOL RES PRACT, V182, P694; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sehayek E, 1998, P NATL ACAD SCI USA, V95, P10194, DOI 10.1073/pnas.95.17.10194; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; Tall AR, 1998, EUR HEART J, V19, pA31; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; Xu SZ, 1997, J LIPID RES, V38, P1289	46	90	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30794	30800		10.1074/jbc.M004552200	http://dx.doi.org/10.1074/jbc.M004552200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896940	hybrid			2022-12-25	WOS:000089762700010
J	Evans, BN; Rosenblatt, MI; Mnayer, LO; Oliver, KR; Dickerson, IM				Evans, BN; Rosenblatt, MI; Mnayer, LO; Oliver, KR; Dickerson, IM			CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; CENTRAL-NERVOUS-SYSTEM; ANTISENSE RNA; RAT; BRAIN; IDENTIFICATION; ACTIVATION; DOMAIN	It is becoming clear that receptors that initiate signal transduction by interacting with G-proteins do not function as monomers, but often require accessory proteins for function. Some of these accessory proteins are chaperones, required for correct transport of the receptor to the cell surface, but the function of many accessory proteins remains unknown, We determined the role of an accessory protein for the receptor for calcitonin gene-related peptide (CGRP), a potent vasodilator neuropeptide. me have previously shown that this accessory protein, the CGRP-receptor component protein (RCP), is expressed in CGRP responsive tissues and that RCP protein expression correlates with the biological efficacy of CGRP in vivo, However, the function of RCP has remained elusive. In this study stable cell lines were made that express antisense RCP RNA, and CGRP- and adrenomedullin-mediated signal transduction were greatly reduced, However, the loss of RCP did not effect CGRP binding or receptor density, indicating that RCP did not behave as a chaperone but was instead coupling the CGRP receptor to downstream effecters. A candidate CGRP receptor named calcitonin receptor-like receptor (CRLR) has been identified, and in this study RCP co-immunoprecipitated with CRLR indicating that these two proteins interact directly. Since CGRP and adrenomedullin can both signal through CRLR, which has been previously shown to require a chaperone protein for function, we now propose that a functional CGRP or adrenomedullin receptor consists of at least three proteins: the receptor (CRLR), the chaperone protein (RAMP), and RCP that couples the receptor to the cellular signal transduction pathway.	Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Univ Miami, Sch Med, Neurosci Program, Miami, FL 33101 USA; Merck Sharp & Dohme Res Labs, Ctr Res Neurosci, Harlow CM20 2QR, Essex, England	University of Miami; University of Miami; University of Miami; Merck & Company	Dickerson, IM (corresponding author), Univ Miami, Sch Med, Dept Physiol & Biophys, POB 016430, Miami, FL 33101 USA.			Dickerson, Ian/0000-0002-2480-0606	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052328] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52328, R01 DK052328] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; Battastini AMO, 1998, INT J BIOCHEM CELL B, V30, P669, DOI 10.1016/S1357-2725(98)00022-3; Buhlmann N, 1999, ENDOCRINOLOGY, V140, P2883, DOI 10.1210/en.140.6.2883; CHANG CP, 1993, NEURON, V11, P1187, DOI 10.1016/0896-6273(93)90230-O; CHATTERJEE TK, 1991, MOL PHARMACOL, V39, P798; EDVINSSON L, 1987, J CEREBR BLOOD F MET, V7, P720, DOI 10.1038/jcbfm.1987.126; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; FLUHMANN B, 1995, BIOCHEM BIOPH RES CO, V206, P341, DOI 10.1006/bbrc.1995.1047; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; Han ZQ, 1997, J MOL ENDOCRINOL, V18, P267, DOI 10.1677/jme.0.0180267; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; JOHNSON RA, 1994, METHOD ENZYMOL, V238, P56; Kato A, 1998, J BIOL CHEM, V273, P23969, DOI 10.1074/jbc.273.37.23969; Knight YE, 1999, NEUROPEPTIDES, V33, P41, DOI 10.1054/npep.1999.0009; Luebke AE, 1996, P NATL ACAD SCI USA, V93, P3455, DOI 10.1073/pnas.93.8.3455; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Menard DP, 1996, J NEUROSCI, V16, P2342; Naghashpour M, 2000, AM J PHYSIOL-CELL PH, V278, pC561, DOI 10.1152/ajpcell.2000.278.3.C561; Naghashpour M, 1997, ENDOCRINOLOGY, V138, P4207, DOI 10.1210/en.138.10.4207; NELSON MT, 1990, NATURE, V344, P770, DOI 10.1038/344770a0; Oliver KR, 1999, MOL BRAIN RES, V66, P205, DOI 10.1016/S0169-328X(99)00036-4; Oliver KR, 1998, MOL BRAIN RES, V57, P149, DOI 10.1016/S0169-328X(98)00052-7; POYNER DR, 1992, BRIT J PHARMACOL, V105, P441, DOI 10.1111/j.1476-5381.1992.tb14272.x; Roche KW, 1999, J BIOL CHEM, V274, P25953, DOI 10.1074/jbc.274.36.25953; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Rosenblatt MI, 1997, PEPTIDES, V18, P567, DOI 10.1016/S0196-9781(97)00055-7; Rosenblatt MI, 2000, INVEST OPHTH VIS SCI, V41, P1159; Sarkar A, 1997, J NEUROCHEM, V69, P455; VANVALEN F, 1990, NEUROSCI LETT, V119, P195, DOI 10.1016/0304-3940(90)90832-T; YUN HY, 1993, ARCH BIOCHEM BIOPHYS, V301, P77, DOI 10.1006/abbi.1993.1117	30	258	283	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31438	31443		10.1074/jbc.M005604200	http://dx.doi.org/10.1074/jbc.M005604200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10903324	hybrid			2022-12-25	WOS:000089762700097
J	Hall, RK; Yamasaki, T; Kucera, T; Waltner-Law, M; O'Brien, R; Granner, DK				Hall, RK; Yamasaki, T; Kucera, T; Waltner-Law, M; O'Brien, R; Granner, DK			Regulation of phosphoenolpyruvate carboxykinase and insulin-like growth factor-binding protein-1 gene expression by insulin - The role of winged helix/forkhead proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; AGE-1 PI3 KINASE; CAENORHABDITIS-ELEGANS; RESPONSE SEQUENCE; AMINOTRANSFERASE GENE; SIGNALING PATHWAY; NUCLEAR FACTOR-3; FAMILY MEMBER; FACTOR FKHR; PROMOTER	Winged helix/forkhead (Fox) transcription factors have been implicated in the regulation of a number of insulin-responsive genes. The insulin response elements (IREs) of the phosphoenolpyruvate carboxykinase (PEPCK) and insulin-like growth factor-binding protein-1 (IGFBP-1) genes bind members of the FKHR and HNF3 subclasses of Fox proteins. Previous mutational analyses of the PEPCK and IGFBP-1 IREs revealed mutations which do not affect the binding of HNF3 proteins to these elements but do eliminate the ability of the IREs to mediate an insulin response. This dissociation of binding and function provided compelling evidence that HNF3 proteins, per se, are not insulin response proteins. The same approach was used here to determine if FKHRL1, a member of the FKHR subclass of Fox proteins, binds to the PEPCK and IGFBP-1 IREs in a manner that correlates with the ability of these elements to mediate an insulin response. Overexpression of FKHRL1 stimulates transcription from transfected reporter constructs that contain a multimerized PEPCK IRE or an IGFBP-1 IRE and this stimulation is repressed by insulin. There is a direct correlation between the ability of mutant versions of the PEPCK and IGFBP-1 IREs to bind FKHRL1 and their ability to mediate FRHRL1-induced transcription when FKHRL1 is overexpressed. However, under conditions where FKHRL1 is not overexpressed, there is a lack of correlation between FKHRL1 binding to mutant versions of the PEPCK and IGFBP-1 IREs and the ability of these elements to mediate an insulin response. Therefore, the PEPCK and IGFBP-1 IREs mediate FKHRL1-induced transcription and its inhibition by insulin when this protein is overexpressed, but at the normal cellular concentration of FKHRL1 the insulin response mediated by these elements must involve another protein.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Vanderbilt University	Granner, DK (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 707 Light Hall, Nashville, TN 37232 USA.							Beurton F, 1999, BIOCHEM J, V343, P687, DOI 10.1042/0264-6021:3430687; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CHEN M, 1994, J LIPID RES, V35, P1918; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; GANSS R, 1994, MOL ENDOCRINOL, V8, P895, DOI 10.1210/me.8.7.895; GOSWAMI R, 1994, ENDOCRINOLOGY, V134, P736, DOI 10.1210/en.134.2.736; GOTTLIEB S, 1994, GENETICS, V137, P107; GRANNER D, 1991, RECENT PROG HORM RES, V47, P319; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Powell David R., 1995, Progress in Growth Factor Research, V6, P93, DOI 10.1016/0955-2235(95)00034-8; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tissenbaum HA, 1998, GENETICS, V148, P703; Tomizawa M, 2000, J BIOL CHEM, V275, P7289, DOI 10.1074/jbc.275.10.7289; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794	38	232	240	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30169	30175		10.1074/jbc.M004898200	http://dx.doi.org/10.1074/jbc.M004898200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10913147	hybrid			2022-12-25	WOS:000089577900037
J	Nakabayashi, K; Kudo, M; Kobilka, B; Hsueh, AWJ				Nakabayashi, K; Kudo, M; Kobilka, B; Hsueh, AWJ			Activation of the luteinizing hormone receptor following substitution of Ser-277 with selective hydrophobic residues in the ectodomain hinge region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; LEUCINE-RICH REPEATS; HUMAN LUTROPIN/CHORIOGONADOTROPIN RECEPTOR; FOLLICLE-STIMULATING-HORMONE; 3RD INTRACELLULAR LOOP; CHORIONIC-GONADOTROPIN; THYROTROPIN RECEPTOR; CONSTITUTIVE ACTIVATION; MOLECULAR-CLONING; LH RECEPTOR	Glycoprotein hormone receptors are G protein-coupled receptors with ligand-binding ectodomains consisting of leucine-rich repeats. The ectodomain is connected by a conserved cysteine-rich hinge region to the seven transmembrane (TM) region. Gain-of-function mutants of luteinizing hormone (LH) and thyroid-stimulating hormone receptors found in patients allowed identification of residues important for receptor activation. Based on constitutively active mutations at Ser-281 in the hinge region of the thyroid-stimulating hormone receptor, we mutated the conserved serine in the LH (S277I) and follicle-stimulating hormone receptors (S273I) and observed increased basal cAMP production and ligand affinity by mutant receptors, For the LH receptor, conversion of Ser-277 to all natural amino acids led to varying degrees of receptor activation. Hydropathy index analysis indicated that substitution of neutral serine with selective nonpolar hydrophobic residues (Leu>Val>Met>Ile) confers constitutive receptor activation whereas serine deletion or substitution with charged Arg, Lys, or Asp led to defective receptor expression. Furthermore, mutation of the angular proline near Ser-273 to flexible Gly also led to receptor activation. The findings suggest the ectodomain of glycoprotein hormone receptors constrain the TM region. Point mutations in the hinge region of these proteins, or ligand binding to these receptors, could cause conformational changes in the TM region that result in G(S) activation.	Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Hsueh, AWJ (corresponding author), Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA.			Kobilka, Brian/0000-0001-5958-3990	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023273, R37HD023273] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-23273] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Cetani F, 1996, FEBS LETT, V378, P27, DOI 10.1016/0014-5793(95)01384-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVOREN JB, 1985, BIOL REPROD, V33, P37, DOI 10.1095/biolreprod33.1.37; DUFAU ML, 1989, J STEROID BIOCHEM, V33, P715, DOI 10.1016/0022-4731(89)90482-2; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; Duprez L, 1997, FEBS LETT, V409, P469, DOI 10.1016/S0014-5793(97)00532-2; FRASER CM, 1994, PROG NUCLEIC ACID RE, V49, P113; GARNIER J, 1990, BIOCHIMIE, V72, P513, DOI 10.1016/0300-9084(90)90115-W; Gilchrist RL, 1996, J BIOL CHEM, V271, P19283, DOI 10.1074/jbc.271.32.19283; Grewal N, 1997, BIOPHYS J, V73, P1190, DOI 10.1016/S0006-3495(97)78151-7; Gruters A, 1998, J CLIN ENDOCR METAB, V83, P1431, DOI 10.1210/jc.83.5.1431; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; Hauser F, 1997, J BIOL CHEM, V272, P1002, DOI 10.1074/jbc.272.2.1002; HELLBERG S, 1987, J MED CHEM, V30, P1126, DOI 10.1021/jm00390a003; Hermey G, 1999, BIOCHEM BIOPH RES CO, V254, P273, DOI 10.1006/bbrc.1998.9882; Hirsch B, 1996, MOL ENDOCRINOL, V10, P1127, DOI 10.1210/me.10.9.1127; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1830, DOI 10.1210/me.12.12.1830; JI I, 1993, J BIOL CHEM, V268, P20851; JI I, 1991, J BIOL CHEM, V266, P13076; JI IH, 1993, J BIOL CHEM, V268, P22971; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JIA XC, 1991, MOL ENDOCRINOL, V5, P759, DOI 10.1210/mend-5-6-759; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; Kopp P, 1997, J CLIN INVEST, V100, P1634, DOI 10.1172/JCI119687; Kosugi S, 1998, MOL PHARMACOL, V53, P894; Kosugi S, 1996, J BIOL CHEM, V271, P31813, DOI 10.1074/jbc.271.50.31813; Kudo M, 2000, MOL ENDOCRINOL, V14, P272, DOI 10.1210/me.14.2.272; Kudo M, 1996, J BIOL CHEM, V271, P22470, DOI 10.1074/jbc.271.37.22470; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAUE L, 1995, P NATL ACAD SCI USA, V92, P1906, DOI 10.1073/pnas.92.6.1906; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; Mancilla EE, 1998, MOL GENET METAB, V64, P198, DOI 10.1006/mgme.1998.2716; McDonald T, 1998, BIOCHEM BIOPH RES CO, V247, P266, DOI 10.1006/bbrc.1998.8774; MIYACHI Y, 1972, J CLIN ENDOCR METAB, V34, P23, DOI 10.1210/jcem-34-1-23; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; NOTHACKER HP, 1993, BIOCHEM BIOPH RES CO, V197, P1062, DOI 10.1006/bbrc.1993.2586; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Parma J, 1997, J CLIN ENDOCR METAB, V82, P2695, DOI 10.1210/jc.82.8.2695; Perez DM, 1996, MOL PHARMACOL, V49, P112; PODESTA EJ, 1983, P NATL ACAD SCI-BIOL, V80, P3986, DOI 10.1073/pnas.80.13.3986; Rapoport B, 1998, ENDOCR REV, V19, P673, DOI 10.1210/er.19.6.673; REN Q, 1993, J BIOL CHEM, V268, P16483; Ryu K, 1998, J BIOL CHEM, V273, P28953, DOI 10.1074/jbc.273.44.28953; Ryu KS, 1998, J BIOL CHEM, V273, P6285, DOI 10.1074/jbc.273.11.6285; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Schulz A, 1999, MOL ENDOCRINOL, V13, P181, DOI 10.1210/me.13.2.181; SHENKER A, 1995, BAILLIERE CLIN ENDOC, V9, P427, DOI 10.1016/S0950-351X(95)80519-2; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SU JGJ, 1992, BIOCHEM BIOPH RES CO, V186, P293, DOI 10.1016/S0006-291X(05)80806-X; Vassart G, 1997, HORM RES, V48, P47, DOI 10.1159/000191313	56	81	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30264	30271		10.1074/jbc.M005568200	http://dx.doi.org/10.1074/jbc.M005568200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10889210	hybrid			2022-12-25	WOS:000089577900049
J	Ota, K; Sakaguchi, M; Hamasaki, N; Mihara, K				Ota, K; Sakaguchi, M; Hamasaki, N; Mihara, K			Membrane integration of the second transmembrane segment of band 3 requires a closely apposed preceding signal-anchor sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; PROTEIN TRANSLOCATION; CLEAVAGE SITES; IDENTIFICATION; TOPOGENESIS; ORIENTATION; PREDICTION; TRANSPORT; MECHANISM; PEPTIDES	We have investigated the topogenic rules of multispanning membrane proteins using erythrocyte band 3. Here, the fine structural requirements for the correct disposition of its second transmembrane segment (TM2) were assessed. We made fusion proteins where TM1 and the loop sequence preceding TM2 were changed and fused to prolactin, They were expressed in a cell-free system supplemented with rough microsomal membrane, and their topologies on the membrane were assessed by protease sensitivity and N-glycosylation, TM1 was demonstrated to be a signal-anchor sequence that mediates translocation of the downstream portion, and thus TM2 should be responsible to halt the translocation to acquire TM topology. When the loop between TM1 and TM2 was elongated, however, TM2 was readily translocated through the membrane and not integrated. For the membrane integration of TM2, TM2 must be in close proximity to TM1. The TM1 can be replaced with another signal-anchor sequence with a long hydrophobic segment but not with a signal sequence with shorter hydrophobic stretch. The length of the hydrophobic segment affected final topology of TM2. We concluded that the two TM segments work synergistically within the translocon to acquire the correct topology and that the length of the preceding signal sequence is critical for stable transmembrane assembly of TM2. We propose that direct interaction among the TRI segments is one of the critical factors for the transmembrane topogenesis of multispanning membrane proteins.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Fac Med, Dept Clin Chem & Lab Med, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Sakaguchi, M (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; DENZER AJ, 1995, EMBO J, V14, P5311; Hamasaki N, 1998, BIOCHEM CELL BIOL, V76, P729, DOI 10.1139/bcb-76-5-729; Hamasaki N, 1996, CELL MOL BIOL, V42, P1025; Hamasaki N, 1997, J BIOCHEM-TOKYO, V122, P577; Hegde RS, 1997, CELL, V91, P575, DOI 10.1016/S0092-8674(00)80445-6; HIGH S, 1992, Current Opinion in Cell Biology, V4, P581, DOI 10.1016/0955-0674(92)90075-N; Kuma H, 1998, J BIOCHEM-TOKYO, V124, P509, DOI 10.1093/oxfordjournals.jbchem.a022142; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; Kuroiwa T, 1996, J BIOL CHEM, V271, P6423, DOI 10.1074/jbc.271.11.6423; KUROIWA T, 1990, J BIOCHEM, V108, P829, DOI 10.1093/oxfordjournals.jbchem.a123288; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LODISH HF, 1988, TRENDS BIOCHEM SCI, V13, P332, DOI 10.1016/0968-0004(88)90101-6; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; OGATA S, 1989, J BIOL CHEM, V264, P3596; Ota K, 1998, J BIOL CHEM, V273, P28286, DOI 10.1074/jbc.273.43.28286; Ota K, 1998, MOL CELL, V2, P495, DOI 10.1016/S1097-2765(00)80149-5; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SAKAGUCHI M, 1992, J BIOCHEM, V112, P243, DOI 10.1093/oxfordjournals.jbchem.a123884; SAKAGUCHI M, 1997, MOL B INT U, P135; Sakaki K, 1999, FEBS LETT, V454, P345, DOI 10.1016/S0014-5793(99)00842-X; TAM LY, 1994, J BIOL CHEM, V269, P32542; Tector M, 1999, EMBO J, V18, P6290, DOI 10.1093/emboj/18.22.6290; Travaglini-Allocatelli C, 1999, J MOL BIOL, V289, P1459, DOI 10.1006/jmbi.1999.2852; Uozumi N, 1998, P NATL ACAD SCI USA, V95, P9773, DOI 10.1073/pnas.95.17.9773; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; WOOD PG, 1992, PROGR CELL RES, V2, P325	35	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29743	29748		10.1074/jbc.M002468200	http://dx.doi.org/10.1074/jbc.M002468200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893228	hybrid			2022-12-25	WOS:000089439800076
J	Strack, P; Caligiuri, M; Pelletier, M; Boisclair, M; Theodoras, A; Beer-Romero, P; Glass, S; Parsons, T; Copeland, RA; Auger, KR; Benfield, P; Brizuela, L; Rolfe, M				Strack, P; Caligiuri, M; Pelletier, M; Boisclair, M; Theodoras, A; Beer-Romero, P; Glass, S; Parsons, T; Copeland, RA; Auger, KR; Benfield, P; Brizuela, L; Rolfe, M			SCF beta-TRCP and phosphorylation dependent ubiquitination of I kappa B alpha catalyzed by Ubc3 and Ubc4	ONCOGENE			English	Article						I kappa B alpha; NF kappa B; SCF beta-TRCP; cullin; ubiquitin	F-BOX PROTEIN; LIGASE COMPLEX; ENZYME CDC34; HUMAN CUL-1; CELL-CYCLE; DEGRADATION; CATENIN; FAMILY; PATHWAY; SKP1	NF kappa B is an important transcriptional regulator of multiple pro-inflammatory genes. In non-stimulated cells NF kappa B is anchored in the cytoplasm via the inhibitory protein I kappa B alpha. Following exposure to diverse proinflammatory signals (e.g. TNF alpha, IL1, LPS) various signal transduction cascades are initiated converging on the I kappa B kinase (IKK). IKK phosphorylates I kappa B alpha on serines 32 and 36 signaling the inhibitory protein for ubiquitin-mediated degradation. The SCFbeta-TRCP complex is the ubiquitin ligase responsible for mediating phosphorylation dependent ubiquitination of I kappa-B alpha. Here we reconstitute phosphorylation dependent ubiquitination of I kappa B alpha using recombinant components. Our results suggest that the cullin specificity of the SCF complex may reflect its ability to associate with Rbx1, We demonstrate specific ubiquitination of I kappa B alpha by Ubc3 and Ubc4 in a phosphorylation and SCFbeta-TRCP dependent manner and that both are capable of associating with the SCFbeta-TRCP complex isolated from human cells. Finally, we show that Ubc4 is in excess to Ubc3 in THP.1 cells and 19 times more efficient in catalyzing the reaction, suggesting that Ubc4 is the preferentially used Ubc in this reaction in vivo. Our results also suggest that ubiquitin is transferred directly from the Ubc to phospho-I kappa B alpha in a SCFbeta-TRCP dependent reaction.	Mitotix Inc, Cambridge, MA 02139 USA; DuPont Pharmaceut Co, Wilmington, DE 19880 USA	DuPont	Caligiuri, M (corresponding author), Mitotix Inc, 1 Kendall Sq,Bldg 600,Suite 622, Cambridge, MA 02139 USA.			Strack, Peter/0000-0003-4042-0416				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; COPELAND RA, 1996, ENZYMES PRACTICAL IN, P93; Elledge SJ, 1998, BBA-REV CANCER, V1377, pM61, DOI 10.1016/S0304-419X(98)00005-5; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Gonen H, 1999, J BIOL CHEM, V274, P14823, DOI 10.1074/jbc.274.21.14823; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Vuillard L, 1999, FEBS LETT, V455, P311, DOI 10.1016/S0014-5793(99)00895-9; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	37	36	39	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3529	3536		10.1038/sj.onc.1203647	http://dx.doi.org/10.1038/sj.onc.1203647			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918611				2022-12-25	WOS:000088346500009
J	Skalski, V; Lin, ZY; Choi, BY; Brown, KR				Skalski, V; Lin, ZY; Choi, BY; Brown, KR			Substrate specificity of the p53-associated 3 '-5 ' exonuclease	ONCOGENE			English	Article						p53; 3 '-5 ' exonuclease; mismatches; DNA double-strand breaks	DNA-REPLICATION FIDELITY; C-TERMINAL DOMAIN; P53 CORE DOMAIN; WILD-TYPE; 3'-TO-5' EXONUCLEASE; POLYMERASE-ALPHA; N-TERMINUS; PROTEIN; REPAIR; DAMAGE	p53 exhibits 3'-5' exonuclease activity and the significance of this biochemical function is currently not defined. In order to gain information about the potential role(s) of this exonuclease activity, recombinant and wild-type human p53 was examined for excision of nucleotides from defined synthetic DNA substrates. p53 removes nucleotides threefold faster from single-strand DNA than from DNA duplexes, exhibits a 1.5-fold preference for 3'-terminals of DNA that contain a single nucleotide mispair (mismatch) as compared to correctly paired DNA and efficiently excises nucleotides from 3'-ends of blunt and cohesive (staggered) DNA double-strand breaks, The p53 exonuclease is predominantly non-processive on DIVA which is 17 nucleotides long (or shorter) and processive on the longer 30-mers, The processivity of nucleotide excision is decreased in the presence of 50 mM potassium phosphate and eliminated when full-length p53 is replaced with the core domain, comprised of amino acids 82-292, Photoaffinity labeling indicates that (1) p53 monomers, rather than dimers, bind to single-strand forms of these oligomers; (2) complexes between p53 and 30-mers are more stable than those formed with 17-mers, The stability of these complexes determines processivity during nucleotide removal and modulates the 3'-5' exonuclease activity of p53. The relevance of substrate specificity of the p53 exonuclease to DNA repair is discussed.	Univ Toronto, Div Expt Therapeut, Ontario Canc Inst, Princess Margaret Hosp, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Skalski, V (corresponding author), Univ Toronto, Div Expt Therapeut, Ontario Canc Inst, Princess Margaret Hosp, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Brown, Kevin/0000-0002-5514-2538				Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Arrowsmith CH, 1996, ONCOGENE, V12, P1379; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BELYAKOVA NV, 1993, EUR J BIOCHEM, V217, P493, DOI 10.1111/j.1432-1033.1993.tb18269.x; BRYANT PE, 1994, INT J RADIAT BIOL, V66, P597, DOI 10.1080/09553009414551681; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; BUTCHER S, 1994, BIOCHEM J, V298, P513, DOI 10.1042/bj2980513; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Chuang YYE, 1999, CANCER RES, V59, P3073; Davison TS, 1998, ONCOGENE, V17, P651, DOI 10.1038/sj.onc.1202062; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; HARPER JW, 1993, CELL, V75, P805; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; INSDORF NF, 1989, J BIOL CHEM, V264, P21498; Janus F, 1999, MOL CELL BIOL, V19, P2155; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Kamiya K, 1996, J BIOL CHEM, V271, P19428, DOI 10.1074/jbc.271.32.19428; KASTAN MB, 1991, CANCER RES, V51, P6304; KOLESNIKOV VA, 1981, FEBS LETT, V132, P101, DOI 10.1016/0014-5793(81)80437-1; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; KUKHANOVA M, 1995, J BIOL CHEM, V270, P23055, DOI 10.1074/jbc.270.39.23055; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; LALUMIERE M, 1995, BACULOVIRUS EXPRESSI, P161; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LOEB LA, 1990, MUTAT RES, V238, P297, DOI 10.1016/0165-1110(90)90021-3; Mazur DJ, 1999, J BIOL CHEM, V274, P19655, DOI 10.1074/jbc.274.28.19655; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NICHOLAS AL, 1994, MOL CELL BIOL, V14, P170; NISHINO H, 1995, ONCOGENE, V11, P263; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; Pelicano H., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P28; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; Rogers S G, 1980, Methods Enzymol, V65, P201; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; Shevelev IV, 1996, MUTAT RES-FUND MOL M, V352, P51, DOI 10.1016/0027-5107(95)00230-8; SKALSKI V, 1995, BIOCHEM PHARMACOL, V50, P815, DOI 10.1016/0006-2952(95)00205-E; SKALSKI V, 1993, J BIOL CHEM, V268, P23234; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; TARUNINA M, 1993, ONCOGENE, V8, P3165; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; ZU L, 1999, BIOCHEM BIOPH RES CO, V259, P262	47	28	29	1	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2000	19	29					3321	3329		10.1038/sj.onc.1203649	http://dx.doi.org/10.1038/sj.onc.1203649			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918588				2022-12-25	WOS:000088019300010
J	Xu, XZ; Kelleher, KF; Liao, J; Creek, KE; Pirisi, L				Xu, XZ; Kelleher, KF; Liao, J; Creek, KE; Pirisi, L			Unique carboxyl-terminal sequences of wild type and alternatively spliced variant forms of transforming growth factor-alpha precursors mediate specific interactions with ErbB4 and ErbB2	ONCOGENE			English	Article						TGF-alpha variants; ErbBs; protein interaction; CHO cells	SIGNAL-TRANSDUCTION; FACTOR RECEPTOR; PROTGF-ALPHA; NEU PROTOONCOGENE; VALINE RESIDUES; PDZ DOMAINS; PROTEIN; BETACELLULIN; MEMBRANE; COEXPRESSION	We have previously reported that the human transforming growth factor-alpha (TGF-alpha) gene encodes three forms of TGF-alpha precursors, designated wild type (WT), variant I (VaI), and variant II (VaII), derived from alternative splicing, The two carboxyl-terminal valine residues of WT are replaced by 5 (GCRLY) or 4 (ATLG) amino acids in VaI or VaII, respectively. When overexpressed in Chinese hamster ovary (CHO) cells, VaI and VaII, but not WT, support autonomous growth, We detected tyrosine phosphorylation of ErbB2 in the absence of serum, in CHO cells expressing WT, VaI, or VaII, but not in mock transfectants. These observations prompted us to investigate possible interactions between the ErbBs and the TGF-alpha precursors in CHO cells. All TGF-alpha precursors mere found to co-immunoprecipitate with the ErbBs. but with different specificity, WT co-immunoprecipitated with ErbB4, but not with ErbB1, ErbB2, or ErbB3, VaI and VaII co-immunoprecipitated with ErbB2, but not with ErbB1, ErbB3, or ErbB4. Confocal fluorescent microscopy analysis demonstrated that WT, VaI. and VaII all distribute equally to the cell surface while, as expected, a WT mutant lacking the tno C-terminal value residues does not. Point and deletion mutants involving the unique carboxyl-terminal residues of WT, Val and VaII, indicated that the interactions between the three TGF-alpha precursors and the ErbBs were mediated by their carboxyl-terminal regions, which constitute distinct protein-binding motifs, A chimera of the intracellular domain of WT TGF-alpha linked to exogenous transmembrane and extracellular domains retained both the cell surface distribution and the specific interaction with ErbB4 of full-length WT, confirming that this interaction is mediated by the C-terminus of the TGF-a precursor. While interactions of WT and variant TGF-alpha with the ErbBs all result in ErbB2 activation, they produce different biological consequences, suggesting that the various TGF-alpha precursors differentially modulate ErbB signaling.	Univ S Carolina, Sch Med, Dept Pathol, Columbia, SC 29208 USA; Univ S Carolina, Sch Med, Childrens Canc Res Lab, Dept Pediat, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Pirisi, L (corresponding author), Univ S Carolina, Sch Med, Dept Pathol, Columbia, SC 29208 USA.		xu, xingzhi/E-8158-2012	xu, xingzhi/0000-0002-4459-2082	NATIONAL CANCER INSTITUTE [R01CA062094] Funding Source: NIH RePORTER; NCI NIH HHS [CA62094] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamson ED, 1997, CURR TOP DEV BIOL, V35, P71, DOI 10.1016/S0070-2153(08)60257-4; Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Cohen BD, 1998, BIOCHEM SOC SYMP, P199; DOUGALL WC, 1994, ONCOGENE, V9, P2109; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Gilbertson RJ, 1997, CANCER RES, V57, P3272; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; LEE DC, 1995, PHARMACOL REV, V47, P51; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; NAKAMURA T, 1994, GENE, V140, P251, DOI 10.1016/0378-1119(94)90553-3; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pinkas-Kramarski R, 1998, ONCOGENE, V16, P1249, DOI 10.1038/sj.onc.1201642; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Shackney SE, 1998, CLIN CANCER RES, V4, P913; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Urena JM, 1999, J CELL SCI, V112, P773; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; Xie W, 1999, ONCOGENE, V18, P3593, DOI 10.1038/sj.onc.1202673; Xu XZ, 1999, ONCOGENE, V18, P5554, DOI 10.1038/sj.onc.1203091; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	31	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3172	3181		10.1038/sj.onc.1203645	http://dx.doi.org/10.1038/sj.onc.1203645			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918572				2022-12-25	WOS:000088019200006
J	Boopathi, E; Anandatheerthavarada, HK; Bhagwat, SV; Biswas, G; Fang, JK; Avadhani, NG				Boopathi, E; Anandatheerthavarada, HK; Bhagwat, SV; Biswas, G; Fang, JK; Avadhani, NG			Accumulation of mitochondrial P450MT2, NH2-terminal truncated cytochrome P4501A1 in rat brain during chronic treatment with beta-naphthoflavone - A role in the metabolism of neuroactive drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C6 CELL-LINE; MULTIPLE FORMS; INDUCTION; SYSTEM; IDENTIFICATION; ADRENODOXIN; EXPRESSION; PROTEINS; BINDING; LIVER	The biochemical and molecular characteristics of cytochrome P4501A1 targeted to rat brain mitochondria was studied to determine the generality of the targeting mechanism previously described for mitochondrial cytochrome P450MT2 (P450MT2) from rat liver. In rat brain and C6 glioma cells chronically exposed to beta -naphoflavone (BNF), P450MT2 content reached 50 and 95% of the total cellular pool, respectively. P450MT2 from 10 days of BNF-treated rat brain was purified to over 85% purity using hydrophobic chromatography followed by adrenodoxin affinity binding. Purified brain P450MT2 consisted of two distinct molecular species with NH2 termini identical to liver mitochondrial forms. These results confirm the specificity of endoprotease-processing sites. The purified P450MT2 showed a preference for adrenodoxin + adrenodoxin reductase electron donor system and exhibited high erythromycin N-demethylation activity. Brain mitoplasts from 10-day BNF-treated rats and also purified P450MT2 exhibited high N-demethylation activities for a number of neuroactive drugs, including trycyclic anti-depressants, anti-convulsants, and opiates. At 10 days of BNF treatment, the mitochondrial metabolism of these neuroactive drugs represented about 85% of the total tissue activity. These results provide new insights on the role of P450MT2 in modulating the pharmacological potencies of different neuroactive drugs in chronically exposed individuals.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu		Ettickan, Boopathi/0000-0001-9431-7719	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034883] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34883, R01 GM034883] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDYA S, 1994, ARCH BIOCHEM BIOPHYS, V310, P82, DOI 10.1006/abbi.1994.1143; ADDYA S, 1991, BIOCHEMISTRY-US, V30, P8323, DOI 10.1021/bi00098a007; Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; Anandatheerthavarada HK, 1999, J BIOL CHEM, V274, P6617, DOI 10.1074/jbc.274.10.6617; ANANDATHEERTHAVARADA HK, 1990, BRAIN RES, V536, P339, DOI 10.1016/0006-8993(90)90047-F; Anandatheerthavarada HK, 1998, BIOCHEMISTRY-US, V37, P1150, DOI 10.1021/bi972046j; ANANDATHEERTHAVARADA HK, 1993, BIOCHEM BIOPH RES CO, V194, P312, DOI 10.1006/bbrc.1993.1821; Anandatheerthavarada HK, 1997, ARCH BIOCHEM BIOPHYS, V339, P136, DOI 10.1006/abbi.1996.9855; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; Bergh AF, 1996, MOL CELL BIOCHEM, V162, P31; Bhagwat SV, 1999, J BIOL CHEM, V274, P24014, DOI 10.1074/jbc.274.34.24014; Bhagwat SV, 1999, TOXICOL APPL PHARM, V156, P231, DOI 10.1006/taap.1999.8646; BHAGWAT SV, 1995, ARCH BIOCHEM BIOPHYS, V320, P73, DOI 10.1006/abbi.1995.1344; BHAMRE S, 1993, ARCH BIOCHEM BIOPHYS, V339, P136; BHAT NK, 1982, BIOCHEMISTRY-US, V21, P2452, DOI 10.1021/bi00539a026; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIAN WR, 1990, BIOCHEMISTRY-US, V29, P11280, DOI 10.1021/bi00503a018; BURKE MD, 1985, BIOCHEM PHARMACOL, V34, P3337, DOI 10.1016/0006-2952(85)90355-7; CLARK BJ, 1991, J BIOL CHEM, V266, P5898; COGHLAN VM, 1991, J BIOL CHEM, V266, P18606; Egashira T, 1999, JPN J PHARMACOL, V81, P115, DOI 10.1254/jjp.81.115; GENG J, 1993, BIOCHEM BIOPH RES CO, V197, P1179, DOI 10.1006/bbrc.1993.2601; Geng J, 1997, BRAIN RES, V774, P11, DOI 10.1016/S0006-8993(97)81681-2; GENG J, 1995, J NEUROCHEM, V65, P554; Geng J, 1998, BRAIN RES, V784, P276, DOI 10.1016/S0006-8993(97)01346-2; GONZALEZ FJ, 1990, PHARMACOL THERAPEUT, V45, P1, DOI 10.1016/0163-7258(90)90006-N; HANUKOGLU I, 1981, J BIOL CHEM, V256, P4321, DOI 10.1016/S0021-9258(19)69436-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEPER J, 1993, GASTROENTEROLOGY, V104, P203, DOI 10.1016/0016-5085(93)90853-5; MATSUBARA T, 1976, ANAL BIOCHEM, V75, P596, DOI 10.1016/0003-2697(76)90114-7; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NEBERT DW, 1991, MOL ENDOCRINOL, V5, P1203, DOI 10.1210/mend-5-9-1203; NIRANJAN BG, 1984, J BIOL CHEM, V259, P2495; OKEY AB, 1986, CLIN BIOCHEM, V19, P132, DOI 10.1016/S0009-9120(86)80060-1; Parkinson A, 1996, TOXICOL PATHOL, V24, P45, DOI 10.1177/019262339602400107; RAZA H, 1988, J BIOL CHEM, V263, P9533; RIZZOLO LJ, 1985, J CELL BIOL, V101, P1351, DOI 10.1083/jcb.101.4.1351; Robin Marie-Anne, 1997, Journal of Hepatology, V26, P23, DOI 10.1016/S0168-8278(97)82329-X; SHAYIQ RM, 1991, METHOD ENZYMOL, V206, P587; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; SOURKES TL, 1981, BASIC NEUROCHEMISTRY, P737; Strobel HW, 1997, DRUG METAB REV, V29, P1079, DOI 10.3109/03602539709002244; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WADA A, 1992, J BIOL CHEM, V267, P22877	44	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34415	34423		10.1074/jbc.M004431200	http://dx.doi.org/10.1074/jbc.M004431200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10915793	Green Accepted, hybrid			2022-12-25	WOS:000165095300057
J	Enyeart, JA; Xu, L; Enyeart, JJ				Enyeart, JA; Xu, L; Enyeart, JJ			A bovine adrenocortical Kv1.4 K+ channel whose expression is potently inhibited by ACTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL-CORTICAL CELLS; GATED TRANSIENT CURRENTS; ZONA-FASCICULATA CELLS; POTASSIUM CHANNEL; CALCIUM-CHANNEL; ANGIOTENSIN-II; CYCLIC-AMP; TRANSCRIPTION; HORMONE; STEROIDOGENESIS	We have cloned a bovine adrenal cortical (bKv1.4) KC channel cDNA whose expression is rapidly inhibited by adrenocorticotropic hormone (ACTH). The 4386-nucleotide cDNA is homologous to other voltage-gated, rapidly inactivating Kv1.4 channels, and includes a 1986-nucleotide coding region and large 5'- and 3'-untranslated regions. Bovine Kv1.4-specific mRNA from adrenal zona fasciculata (AZF) cells was rapidly and potently reduced by ACTH, with a t(1/2) of approximately 1 h and an IC50 of 1.2 pM. The membrane-permeable cAMP analog 8-pcpt-cAMP also reduced bKv1.4 mRNA expression with kinetics similar to that observed with ACTH. Reduction of bKv1.4 mRNA expression by ACTH and 8-pcpt-cAMP was only partially inhibited by the selective protein kinase A antagonist H-89. Consistent with their effect on bKv1.4 mRNA, ACTH and 8-pcpt-cAMP both dramatically reduced the expression of bKv1.4-associated A-type current measured over 72 h. These results demonstrate that bovine AZF cells synthesize a Kv1.4-type channel whose expression is inhibited at the pretranslational level by ACTH and 8-pcpt-cAMP by a mechanism that is partially dependent on the activation of protein kinase A. The rapid, potent reduction of bKv1.4 mRNA produced by ACTH and 8-pcpt-cAMP indicates that the expression of this K+ channel is under tonic inhibitory control of the hypothalamic-pituitary-adrenal axis. The basic electrical properties of AZF cells might be tightly regulated at the transcriptional level by the normal diurnal pattern of ACTH secretion, and altered during bouts of stress by the enhanced release of this pituitary peptide. Under conditions of prolonged stress or adrenal insufficiency, persistent ACTH-induced changes in the electrical properties of AZF cells could be coupled to parallel changes in cortisol secretion.	Ohio State Univ, Coll Med, Dept Neurosci, Columbus, OH 43210 USA	Ohio State University	Enyeart, JJ (corresponding author), Ohio State Univ, Coll Med, Dept Neurosci, 5190 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.	enyeart.1@osu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047875] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK47875] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen ML, 1998, P NATL ACAD SCI USA, V95, P7693, DOI 10.1073/pnas.95.13.7693; BARBARA JG, 1995, J PHYSIOL-LONDON, V488, P609, DOI 10.1113/jphysiol.1995.sp020994; BONDY P K, 1985, P816; CATALANO RD, 1986, J CLIN ENDOCR METAB, V62, P300, DOI 10.1210/jcem-62-2-300; CHANDY KG, 1994, LIGAND VOLTAGE GATED, P1; DAVIS IJ, 1994, MOL CELL BIOL, V14, P3469, DOI 10.1128/MCB.14.5.3469; Enyeart JJ, 1996, MOL CELL ENDOCRINOL, V124, P97, DOI 10.1016/S0303-7207(96)03938-X; Enyeart JJ, 1997, J GEN PHYSIOL, V110, P679, DOI 10.1085/jgp.110.6.679; Enyeart JJ, 1998, J MEMBRANE BIOL, V164, P139; ENYEART JJ, 1993, MOL ENDOCRINOL, V7, P1031, DOI 10.1210/me.7.8.1031; Enyeart JJ, 1996, J GEN PHYSIOL, V108, P251, DOI 10.1085/jgp.108.4.251; GARCIAGUZMAN M, 1994, FEBS LETT, V354, P173, DOI 10.1016/0014-5793(94)01117-6; GARCIAGUZMAN M, 1992, FEBS LETT, V308, P283, DOI 10.1016/0014-5793(92)81294-V; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIDAKA H, 1991, METHOD ENZYMOL, V201, P328; Hille B., 1992, IONIC CHANNELS EXCIT; KOJIMA I, 1986, J BIOL CHEM, V261, P9832; KOJIMA I, 1985, J BIOL CHEM, V260, P9171; LYMANGROVER JR, 1982, ENDOCRINOLOGY, V110, P462, DOI 10.1210/endo-110-2-462; MARTY A, 1985, J PHYSIOL-LONDON, V367, P117, DOI 10.1113/jphysiol.1985.sp015817; MLINAR B, 1993, J BIOL CHEM, V268, P8640; MLINAR B, 1993, J GEN PHYSIOL, V102, P239, DOI 10.1085/jgp.102.2.239; MLINAR B, 1993, J GEN PHYSIOL, V102, P217, DOI 10.1085/jgp.102.2.217; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MORI Y, 1993, J BIOL CHEM, V268, P26482; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MOYLE WR, 1973, J BIOL CHEM, V248, P2409; Parker KL, 1995, VITAM HORM, V51, P339, DOI 10.1016/S0083-6729(08)61044-4; QUINN SJ, 1988, ANNU REV PHYSIOL, V50, P409, DOI 10.1146/annurev.ph.50.030188.002205; RAIKHINSTEIN M, 1994, BBA-MOL CELL RES, V1220, P329, DOI 10.1016/0167-4889(94)90157-0; SALA GB, 1979, J BIOL CHEM, V254, P3861; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; VELAN B, 1995, CURRENT PROTOCOLS BI, V1; VELDHUIS JD, 1990, J CLIN ENDOCR METAB, V71, P452, DOI 10.1210/jcem-71-2-452; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; Wymore RS, 1996, J BIOL CHEM, V271, P15629, DOI 10.1074/jbc.271.26.15629; Yamazaki T, 1998, ENDOCRINOLOGY, V139, P4765, DOI 10.1210/en.139.12.4765; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899; ZUBER MX, 1986, J BIOL CHEM, V261, P2475	43	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34640	34649		10.1074/jbc.M004214200	http://dx.doi.org/10.1074/jbc.M004214200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10913143	hybrid			2022-12-25	WOS:000165095300087
J	Hayashi, M; Yamada, H; Mitamura, T; Horii, T; Yamamoto, A; Moriyama, Y				Hayashi, M; Yamada, H; Mitamura, T; Horii, T; Yamamoto, A; Moriyama, Y			Vacuolar H+-ATPase localized in plasma membranes of malaria parasite cells, Plasmodium falciparum, is involved in regional acidification of parasitized erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASES; INFECTED ERYTHROCYTES; SYNCHRONIZED CULTURES; LACTATE PRODUCTION; CHLOROQUINE; SUBUNIT; BAFILOMYCINS; COMPARTMENT; EXPRESSION; MOLECULES	Recent biochemical studies involving 2',7'-bis-(2-carboxyethyl)-5,6 -carboxylfluorescein (BCECF)-labeled saponin-permeabilized and parasitized erythrocytes indicated that malaria parasite cells maintain the resting cytoplasmic pH at about 7.3, and treatment with vacuolar proton-pump inhibitors reduces the resting pH to 6.7, suggesting proton extrusion from the parasite cells via vacuolar H+-ATPase (Saliba, K. J., and Kirk, K. (1999) J, Biol. Chem, 274, 33213-33219), In the present study, we investigated the localization of vacuolar H+-ATPase in Plasmodium falciparum cells infecting erythrocytes, Antibodies against vacuolar H+-ATPase subunit A and B specifically immunostained the infecting parasite cells and recognized a single 67- and 55-kDa polypeptide, respectively. Immunoelectron microscopy indicated that the immunological counterpart of V-ATPase subunits A and B is localized at the plasma membrane, small clear vesicles, and food vacuoles, a lower extent being detected at the parasitophorus vacuolar membrane of the parasite cells. We measured the cytoplasmic pH of both infected erythrocytes and invading malaria parasite cells by microfluorimetry using BCECF fluorescence. It was found that a restricted area of the erythrocyte cytoplasm near a parasite cell is slightly acidic, being about pH 6.9. The pH increased to pH 7.3 upon the addition of either concanamycin B or bafilomycin A(1), specific inhibitors of vacuolar H+-ATPase. Simultaneously, the cytoplasmic pH of the infecting parasite cell decreased from pH 7.3 to 7.1. Neither vanadate at 0.5 mM, an inhibitor of P-type H+-ATPase, nor ethylisopropylamiloride at 0.2 mM, an inhibitor of Na+/H+-exchanger, affected the cytoplasmic pH of erythrocytes or infecting parasite cells. These results constitute direct evidence that plasma membrane vacuolar H+-ATPase is responsible for active exclusion of protons from the parasite cells.	Okayama Univ, Fac Pharmaceut Sci, Dept Biochem, Okayama 7008530, Japan; Osaka Univ, Inst Microbial Dis, Suita, Osaka 5650871, Japan; Kansai Med Univ, Dept Physiol, Osaka 5708506, Japan	Okayama University; Osaka University; Kansai Medical University	Moriyama, Y (corresponding author), Okayama Univ, Fac Pharmaceut Sci, Dept Biochem, 3-1-1 Tsushima Naka, Okayama 7008530, Japan.	moriyama@pheasant.pharm.okayama-u.ac.jp	Yamada, Hiroshi/AGZ-4497-2022; YAMADA, Hiroshi/B-2251-2011	Yamada, Hiroshi/0000-0002-9328-3446; YAMADA, Hiroshi/0000-0002-9328-3446; Horii, Toshihiro/0000-0002-3000-2045				ATKINSON CT, 1990, BLOOD CELLS, V16, P351; Blackman MJ, 1998, J BIOL CHEM, V273, P23398, DOI 10.1074/jbc.273.36.23398; BOSIA A, 1993, J CELL PHYSIOL, V154, P527, DOI 10.1002/jcp.1041540311; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRAY PG, 1992, BIOCHEM PHARMACOL, V43, P1219, DOI 10.1016/0006-2952(92)90495-5; CHOI I, 1988, MOL BIOCHEM PARASIT, V31, P71, DOI 10.1016/0166-6851(88)90146-6; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; FUKUI Y, 1992, J HISTOCHEM CYTOCHEM, V40, P73, DOI 10.1177/40.1.1729355; Haldar K, 1996, TRENDS CELL BIOL, V6, P398, DOI 10.1016/0962-8924(96)10032-5; ITO K, 1995, J ANTIBIOT, V48, P488, DOI 10.7164/antibiotics.48.488; JENSEN JB, 1979, EXP PARASITOL, V48, P36, DOI 10.1016/0014-4894(79)90052-3; KARCZ SR, 1994, MOL BIOCHEM PARASIT, V65, P123, DOI 10.1016/0166-6851(94)90121-X; KARCZ SR, 1993, MOL BIOCHEM PARASIT, V58, P333, DOI 10.1016/0166-6851(93)90056-4; KELLENBERGER E, 1987, J HISTOCHEM CYTOCHEM, V35, P959, DOI 10.1177/35.9.3302020; KRISHNA S, 1993, J CELL BIOL, V120, P385, DOI 10.1083/jcb.120.2.385; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; Lingelbach K, 1998, J CELL SCI, V111, P1467; MIKKELSEN RB, 1982, J CELL BIOL, V93, P685, DOI 10.1083/jcb.93.3.685; MIKKELSEN RB, 1986, MOL BIOCHEM PARASIT, V21, P83, DOI 10.1016/0166-6851(86)90082-4; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; MORIYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V980, P241, DOI 10.1016/0005-2736(89)90405-7; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; PFALLER MA, 1982, EXP PARASITOL, V54, P391, DOI 10.1016/0014-4894(82)90048-0; Saliba KJ, 1999, J BIOL CHEM, V274, P33213, DOI 10.1074/jbc.274.47.33213; SASAKI T, 1994, CELL TISSUE RES, V278, P265, DOI 10.1007/s004410050216; SHERMAN IW, 1979, MICROBIOL REV, V43, P453, DOI 10.1128/MMBR.43.4.453-495.1979; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; TAKADA T, 1992, HISTOCHEMISTRY, V98, P183, DOI 10.1007/BF00315877; Tomochika K, 1997, FEBS LETT, V404, P61, DOI 10.1016/S0014-5793(97)00090-2; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; UYAMA T, 1994, J EXP ZOOL, V270, P148, DOI 10.1002/jez.1402700204; VANDERJAGT DL, 1990, MOL BIOCHEM PARASIT, V42, P277, DOI 10.1016/0166-6851(90)90171-H; Ward GE, 1997, PARASITOL TODAY, V13, P57, DOI 10.1016/S0169-4758(96)10080-6; WHITE NJ, 1998, MALARIA PARASITE BIO, P371; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; Woodrow CJ, 1999, J BIOL CHEM, V274, P7272, DOI 10.1074/jbc.274.11.7272; Wunsch S, 1998, J CELL BIOL, V140, P335, DOI 10.1083/jcb.140.2.335; YAMAMOTO A, 1994, J HISTOCHEM CYTOCHEM, V42, P1463, DOI 10.1177/42.11.7930528; YAYON A, 1984, EMBO J, V3, P2695, DOI 10.1002/j.1460-2075.1984.tb02195.x; ZOLG JW, 1984, IN VITRO CELL DEV B, V20, P205, DOI 10.1007/BF02618189	41	92	93	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34353	34358		10.1074/jbc.M003323200	http://dx.doi.org/10.1074/jbc.M003323200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10915784	hybrid			2022-12-25	WOS:000165095300049
J	Gouveia, AMM; Reguenga, C; Oliveira, MEM; Sa-Miranda, C; Azevedo, JE				Gouveia, AMM; Reguenga, C; Oliveira, MEM; Sa-Miranda, C; Azevedo, JE			Characterization of peroxisomal Pex5p from rat liver - Pex5p in the Pex5p-Pex14p membrane complex is a transmembrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETING SIGNAL; PTS1 RECEPTOR; SACCHAROMYCES-CEREVISIAE; PICHIA-PASTORIS; IMPORT; PEX14P; IDENTIFICATION; BIOGENESIS; DOCKING; MATRIX	Pex5p is the receptor for the vast majority of peroxisomal matrix proteins. Here, we show that about 15% of rat liver Pex5p is found in the peroxisomal fraction representing 0.06% of total peroxisomal protein. This population of Pex5p displays all the characteristics of an intrinsic membrane protein. Protease protection assays indicate that this pool of Pex5p has domains exposed on both sides of the peroxisomal membrane. The strong interaction of Pex5p with the membrane of the organelle is not affected by mild protease treatment of intact organelles, conditions that result in the partial degradation of Pex13p. Cytosolic Pex5p is a monomeric protein. In contrast, virtually all peroxisomal Pex5p was found to be part of a stable 250-kDa protein assembly. This complex was isolated and shown to comprise just two subunits, Pex5p and Pex14p.	UP, IBMC, P-4150180 Oporto, Portugal; UP, Inst Ciencias Biomed Abel Salazar, P-4150180 Oporto, Portugal; Inst Genet Med Jacinto Magalhaes, P-4050466 Oporto, Portugal	Universidade do Porto; Universidade do Porto	Azevedo, JE (corresponding author), UP, IBMC, Rua do Campo Alegre 823, P-4150180 Oporto, Portugal.	jazevedo@ibmc.up.pt	Gouveia, Alexandra/P-3525-2016; sá Miranda, Maria Clara/K-3920-2013; Azevedo, Jorge E/A-4113-2008	Gouveia, Alexandra/0000-0001-8784-4246; sá Miranda, Maria Clara/0000-0003-0123-5525; Azevedo, Jorge E/0000-0001-7714-5302; Oliveira, Marcia/0000-0003-2437-2004; Reguenga, Carlos/0000-0003-1219-9961				Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Baes M, 1997, NAT GENET, V17, P49, DOI 10.1038/ng0997-49; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; Chang CC, 1999, J CELL BIOL, V147, P761, DOI 10.1083/jcb.147.4.761; Chang CC, 1997, NAT GENET, V15, P385, DOI 10.1038/ng0497-385; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; Elgersma Y, 1998, J CELL BIOL, V140, P807, DOI 10.1083/jcb.140.4.807; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FURUTA S, 1986, P NATL ACAD SCI USA, V83, P313, DOI 10.1073/pnas.83.2.313; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Gouveia AMM, 1999, ANAL BIOCHEM, V274, P270, DOI 10.1006/abio.1999.4281; Harlow E, 1998, ANTIBODIES LAB MANUA; HARTL FU, 1985, ARCH BIOCHEM BIOPHYS, V237, P124, DOI 10.1016/0003-9861(85)90261-9; Hettema EH, 1999, BBA-MOL CELL RES, V1451, P17, DOI 10.1016/S0167-4889(99)00087-7; Komori M, 1997, EMBO J, V16, P44, DOI 10.1093/emboj/16.1.44; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; MERRIL CR, 1990, METHOD ENZYMOL, V182, P477; Motley AM, 1997, NAT GENET, V15, P377, DOI 10.1038/ng0497-377; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; Rehling P, 2000, J BIOL CHEM, V275, P3593, DOI 10.1074/jbc.275.5.3593; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; TERLECKY SR, 1995, EMBO J, V14, P3627, DOI 10.1002/j.1460-2075.1995.tb00032.x; Urquhart AJ, 2000, J BIOL CHEM, V275, P4127, DOI 10.1074/jbc.275.6.4127; VANDERKLEI IJ, 1995, J BIOL CHEM, V270, P17229, DOI 10.1074/jbc.270.29.17229; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; Will GK, 1999, MOL CELL BIOL, V19, P2265	40	95	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32444	32451		10.1074/jbc.M004366200	http://dx.doi.org/10.1074/jbc.M004366200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10889202	hybrid			2022-12-25	WOS:000090003800011
J	Tynan, SH; Purohit, A; Doxsey, SJ; Vallee, RB				Tynan, SH; Purohit, A; Doxsey, SJ; Vallee, RB			Light intermediate chain 1 defines a functional subfraction of cytoplasmic dynein which binds to pericentrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE ORGANIZATION; GAMMA-TUBULIN; COMPLEX; CENTROSOME; DYNACTIN; MITOSIS; PROTEINS; MICROTUBULES; KINETOCHORES; ALIGNMENT	The light intermediate chains (LICs) of cytoplasmic dynein consist of multiple isoforms, which undergo post-translational modification to produce a large number of species separable by two-dimensional electrophoresis and which we have proposed to represent at least two gene products. Recently, we demonstrated the first known function for the LICs: binding to the centrosomal protein, pericentrin, which represents a novel, non-dynactin-based cargo-binding mechanism. Here we report the cloning of rat LIC1, which is approximately 75% homologous to rat LICE and also contains a P-loop consensus sequence, We compared LIC1 and LICE for the ability to interact with pericentrin, and found that only LIC1 will bind. A functional P-loop sequence is not required for this interaction. We have mapped the interaction to the central region of both LIC1 and pericentrin. Using recombinant LICs, we found that they form homooligomers, but not heterooligomers, and exhibit mutually exclusive binding to the heavy chain. Additionally, overexpressed pericentrin is seen to interact with endogenous LIC1 exclusively. Together these results demonstrate the existence of two subclasses of cytoplasmic dynein: LIC1-containing dynein, and LIC2-containing dynein, only the former of which is involved in pericentrin association with dynein.	Univ Massachusetts, Med Ctr, Dept Cell Biol, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Vallee, RB (corresponding author), Univ Massachusetts, Med Ctr, Dept Cell Biol, 377 Plantat St, Worcester, MA 01605 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM047434, R01GM051994, R01GM047434, R56GM051994] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47434, GM51994] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bowman AB, 1999, J CELL BIOL, V146, P165; Busson S, 1998, CURR BIOL, V8, P541, DOI 10.1016/S0960-9822(98)70208-8; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; GILL SR, 1994, MOL BIOL CELL, V5, P645, DOI 10.1091/mbc.5.6.645; Gonczy P, 1999, J CELL BIOL, V147, P135, DOI 10.1083/jcb.147.1.135; Harrison A, 1998, J CELL BIOL, V140, P1137, DOI 10.1083/jcb.140.5.1137; HUGHES SM, 1995, J CELL SCI, V108, P17; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; Khodjakov A, 1999, J CELL BIOL, V146, P585, DOI 10.1083/jcb.146.3.585; King SM, 1996, J BIOL CHEM, V271, P32281, DOI 10.1074/jbc.271.50.32281; Maeda S, 1998, CELL STRUCT FUNCT, V23, P169, DOI 10.1247/csf.23.169; MORRIS NR, 1976, EXP CELL RES, V98, P204, DOI 10.1016/0014-4827(76)90480-8; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; PLAMANN M, 1994, J CELL BIOL, V127, P139, DOI 10.1083/jcb.127.1.139; Purohit A, 1999, J CELL BIOL, V147, P481, DOI 10.1083/jcb.147.3.481; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tynan SH, 2000, J BIOL CHEM, V275, P32769, DOI 10.1074/jbc.M001537200; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100; Young A, 2000, MOL BIOL CELL, V11, P2047, DOI 10.1091/mbc.11.6.2047	28	112	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32763	32768		10.1074/jbc.M001536200	http://dx.doi.org/10.1074/jbc.M001536200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10893222	hybrid			2022-12-25	WOS:000090003800054
J	Cha, SS; Sung, BJ; Kim, YA; Song, YL; Kim, HJ; Kim, S; Lee, MS; Oh, BH				Cha, SS; Sung, BJ; Kim, YA; Song, YL; Kim, HJ; Kim, S; Lee, MS; Oh, BH			Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING LIGAND; TNF RECEPTOR SUPERFAMILY; NECROSIS-FACTOR-RECEPTOR; DEATH DOMAIN; ANTITUMOR-ACTIVITY; FAMILY; MEMBER; APO2L/TRAIL; ACTIVATION; RESOLUTION	TRAIL is a cytokine that induces apoptosis in a wide variety of tumor cells but rarely in normal cells. It contains an extraordinarily elongated loop because of an unique insertion of 12-16 amino acids compared with the other members of tumor necrosis factor family. Biological implication of the frame insertion has not been clarified. We have determined the crystal structure of TRAIL in a complex with the extracellular domain of death receptor DR5 at 2.2 Angstrom resolution. The structure reveals extensive contacts between the elongated loop and DR5 in an interaction mode that would not be allowed without the frame insertion. These interactions are missing in the structures of the complex determined by others recently. This observation, along with structure-inspired deletion analysis, identifies the critical role of the frame insertion as a molecular strategy conferring specificity upon the recognition of cognate receptors. The structure also suggests that a built-in flexibility of the tumor necrosis factor receptor family members is likely to play a general and important role in the binding and recognition of tumor necrosis factor family members.	Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, Kyungbuk, South Korea; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul 135710, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Sungkyunkwan University (SKKU); Samsung Medical Center	Oh, BH (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea.	bhoh@postech.ac.kr	Lee, Myung Shik/C-9606-2011; Oh, Byung-Ha/C-2061-2011	Cha, Sun-Shin/0000-0002-0913-8706				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BAZAN JF, 1993, CURR BIOL, V3, P603, DOI 10.1016/0960-9822(93)90009-D; BRUNGER AT, 1992, XPLOR VERSION 3 843; Cha SS, 1999, IMMUNITY, V11, P253, DOI 10.1016/S1074-7613(00)80100-4; COSMAN D, 1994, STEM CELLS, V12, P440, DOI 10.1002/stem.5530120501; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; DU ZJ, 1995, BIOTECHNIQUES, V18, P376; ECK MJ, 1992, J BIOL CHEM, V267, P2119; Hymowitz SG, 2000, BIOCHEMISTRY-US, V39, P633, DOI 10.1021/bi992242l; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; JONES TA, 1993, O VERSION 5 9; Lotz M, 1996, J LEUKOCYTE BIOL, V60, P1; Mariani SM, 1998, EUR J IMMUNOL, V28, P1492, DOI 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Mongkolsapaya J, 1999, NAT STRUCT BIOL, V6, P1048; Mongkolsapaya J, 1998, J IMMUNOL, V160, P3; Naismith JH, 1996, STRUCTURE, V4, P1251, DOI 10.1016/S0969-2126(96)00134-7; Naismith JH, 1998, TRENDS BIOCHEM SCI, V23, P74, DOI 10.1016/S0968-0004(97)01164-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199; VANOSTADE X, 1994, PROTEIN ENG, V7, P5, DOI 10.1093/protein/7.1.5; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wong BR, 1999, J LEUKOCYTE BIOL, V65, P715, DOI 10.1002/jlb.65.6.715	37	104	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31171	31177		10.1074/jbc.M004414200	http://dx.doi.org/10.1074/jbc.M004414200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10893238	hybrid			2022-12-25	WOS:000089762700060
J	Bisgrove, DA; Monckton, EA; Packer, M; Godbout, R				Bisgrove, DA; Monckton, EA; Packer, M; Godbout, R			Regulation of brain fatty acid-binding protein expression by differential phosphorylation of nuclear factor I in malignant glioma cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ASTROCYTOMA-CELLS; TUMOR-SUPPRESSOR GENE; DNA-REPLICATION; COMPLEMENTARY-DNA; JC-VIRUS; TRANSCRIPTION; PROMOTER; FAMILY; GROWTH; LOCALIZATION	Brain fatty acid-binding protein (B-FABP) is expressed in the radial glial cells of the developing central nervous system as well as in a subset of human malignant glioma cell lines. Most of the malignant glioma lines that express B-FABP also express GFAP, an intermediate filament protein found in mature astrocytes. We are studying the regulation of the B-FABP gene to determine the basis for its differential expression in malignant glioma lines. By DNase I footprinting, we have identified five DNA-binding sites located within 400 base pairs (bp) of the B-FABP transcription start site, including two nuclear factor I (NFL)-binding sites at -35 to -58 bp (footprint 1, fp1) and -237 to -260 bp (fp3), respectively. Competition experiments, supershift experiments with anti-NFI antibody, and methylation interference experiments all indicate that the factor binding to fp1 and fp3 is NFI. By site-directed mutagenesis of both NFI-binding sites, we show that the most proximal NFI site is essential for B-FABP promoter activity in transiently transfected malignant glioma cells. Different band shift patterns are observed with nuclear extracts from B-FABP(+) and B-FABP(-) malignant glioma lines, with the latter generating complexes that migrate more slowly than those obtained with B-FABP(+) extracts. All bands are converted to a faster migrating form with potato acid phosphatase treatment, indicating that NFI is differentially phosphorylated in B-FABP(+) and B-FABP(-) lines. Our results suggest that B-FABP expression in malignant glioma lines is determined by the extent of NFI phosphorylation which, in turn, is controlled by a phosphatase activity specific to B-FABP(+) lines.	Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Edmonton, AB T6G 1Z2, Canada	University of Alberta; University of Alberta	Godbout, R (corresponding author), Cross Canc Inst, Dept Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.		Godbout, Roseline/I-4639-2016	Godbout, Roseline/0000-0002-4779-9265				AMEMIYA K, 1992, J BIOL CHEM, V267, P14204; APT D, 1994, NUCLEIC ACIDS RES, V22, P3825, DOI 10.1093/nar/22.19.3825; BELIKOV S, 1995, NUCLEIC ACIDS RES, V23, P310, DOI 10.1093/nar/23.2.310; Chaudhry AZ, 1998, J BIOL CHEM, V273, P18538, DOI 10.1074/jbc.273.29.18538; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; Cooke DW, 1999, J BIOL CHEM, V274, P12917, DOI 10.1074/jbc.274.18.12917; das Neves L, 1999, P NATL ACAD SCI USA, V96, P11946, DOI 10.1073/pnas.96.21.11946; DEVRIES E, 1987, EMBO J, V6, P161, DOI 10.1002/j.1460-2075.1987.tb04734.x; ENG LF, 1978, J HISTOCHEM CYTOCHEM, V26, P513, DOI 10.1177/26.7.357640; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; FENG L, 1995, DEVELOPMENT, V121, P1719; GARABEDIAN MJ, 1993, GENE TRANSCRIPTION P, P243; Godbout R, 1998, ONCOGENE, V16, P1955, DOI 10.1038/sj.onc.1201740; Gray IC, 1998, BRIT J CANCER, V78, P1296, DOI 10.1038/bjc.1998.674; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P964, DOI 10.1128/MCB.5.5.964; Hatten ME, 1999, ANNU REV NEUROSCI, V22, P511, DOI 10.1146/annurev.neuro.22.1.511; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; INOUE T, 1990, J BIOL CHEM, V265, P19065; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; Josephson R, 1998, DEVELOPMENT, V125, P3087; KAWAMURA H, 1993, BIOCHEM BIOPH RES CO, V192, P1424, DOI 10.1006/bbrc.1993.1575; Krebs CJ, 1996, J NEUROCHEM, V66, P1354; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; KUMAR KU, 1993, J VIROL, V67, P572, DOI 10.1128/JVI.67.1.572-576.1993; KURTZ A, 1994, DEVELOPMENT, V120, P2637; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu YC, 1997, J BIOL CHEM, V272, P10739; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; Murphy KG, 1998, J NEUROSURG, V89, P997, DOI 10.3171/jns.1998.89.6.0997; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Ortiz L, 1999, J BIOL CHEM, V274, P15213, DOI 10.1074/jbc.274.21.15213; QIAN F, 1995, GENOMICS, V28, P66, DOI 10.1006/geno.1995.1107; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; Roulet E, 2000, J MOL BIOL, V297, P833, DOI 10.1006/jmbi.2000.3614; ROY RJ, 1991, BIOTECHNIQUES, V11, P770; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; Russell D, 1989, PATHOLOGY TUMOURS NE; RUTKA JT, 1993, CANCER RES, V53, P3624; RUTKA JT, 1994, CANCER RES, V54, P3267; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHMECHEL DE, 1979, ANAT EMBRYOL, V156, P115, DOI 10.1007/BF00300010; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sumner C, 1996, J NEUROVIROL, V2, P87, DOI 10.3109/13550289609146542; Toda M, 1999, NEUROCHEM RES, V24, P339, DOI 10.1023/A:1022538810581; VANDERMEULEN JDM, 1978, NEUROPATH APPL NEURO, V4, P177; VELASCO ME, 1980, CANCER, V45, P484, DOI 10.1002/1097-0142(19800201)45:3<484::AID-CNCR2820450312>3.0.CO;2-9; VERITY AN, 1988, J NEUROSCI RES, V21, P238, DOI 10.1002/jnr.490210216; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093	54	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30668	30676		10.1074/jbc.M003828200	http://dx.doi.org/10.1074/jbc.M003828200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10896661	hybrid			2022-12-25	WOS:000089577900103
J	Hu, YK; Eisses, JF; Kaplan, JH				Hu, YK; Eisses, JF; Kaplan, JH			Expression of an active Na,K-ATPase with an alpha-subunit lacking all twenty-three native cysteine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ADENOSINE-TRIPHOSPHATASE; SULFHYDRYL-GROUPS; H+-ATPASE; TRANSPORT; ISOZYMES; ISOFORM; PROTEIN	We have constructed a mutant Na,K-ATPase alpha 1-subunit with all native cysteine residues replaced. Using the baculovirus system, this cysteine-less alpha 1-subunit and wild-type beta 1-subunit were expressed in High Five cells. After 3 days of infection, cells were fractionated, and endoplasmic reticulum. Golgis apparatus, and plasma membranes were isolated. The molecular activity of the cysteine-less mutant in the plasma membranes was close to the wild-type protein (8223 min(-1) versus 6655 min(-1)). Cation and ATP activation of Na,K-ATPase activities revealed that replacing all 23 cysteines resulted in only a 50% reduction of K-m for Na+, a 2-fold increase in K-m for K+, and no changes inK(m) for ATP. The distribution of alpha-subunits among the membranes showed a high percentage of cysteine-less protein in the endoplasmic reticulum and Golgi apparatus compared with the wild-type protein. Furthermore, the cellular stability of the alpha beta assembly appeared reduced in the cysteine-less mutant. Cells harvested after more than 3 days of infection showed extensive degradation of the cysteine-less alpha-subunit, which is not observed with the wild-type enzyme. Thus the Na,K-ATPase contains no cysteine residues that are critical for function, but the folding and/or assembly pathway of this enzyme is affected by total cysteine substitution.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Kaplan, JH (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, L224,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.			Kaplan, Jack/0000-0002-7048-6574	NIGMS NIH HHS [GM39500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039500] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANNER BM, 1990, BIOCHEM BIOPH RES CO, V167, P1115, DOI 10.1016/0006-291X(90)90638-4; Beggah A, 1996, J BIOL CHEM, V271, P20895, DOI 10.1074/jbc.271.34.20895; BLANCO G, 1995, BIOCHEMISTRY-US, V34, P9897, DOI 10.1021/bi00031a011; Blanco G, 1999, BIOCHEMISTRY-US, V38, P13661, DOI 10.1021/bi991207b; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; CASEY JR, 1995, J BIOL CHEM, V270, P8521, DOI 10.1074/jbc.270.15.8521; DETOMASO AW, 1993, J BIOL CHEM, V268, P1470; ESMANN M, 1982, BIOCHIM BIOPHYS ACTA, V688, P251, DOI 10.1016/0005-2736(82)90601-0; FAHN S, 1966, J BIOL CHEM, V241, P1890; Gatto C, 1999, J BIOL CHEM, V274, P24995, DOI 10.1074/jbc.274.35.24995; GEERING K, 1987, J CELL BIOL, V105, P2613, DOI 10.1083/jcb.105.6.2613; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hu YK, 2000, J BIOL CHEM, V275, P19185, DOI 10.1074/jbc.M000641200; KAPLAN JH, 1985, ARCH BIOCHEM BIOPHYS, V237, P386, DOI 10.1016/0003-9861(85)90290-5; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Mahanty SK, 1996, J BIOL CHEM, V271, P367, DOI 10.1074/jbc.271.1.367; PATZELTWENCZLER R, 1981, EUR J BIOCHEM, V114, P79; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; PETROV VV, 1995, J BIOL CHEM, V270, P28535, DOI 10.1074/jbc.270.48.28535; POST RL, 1975, J BIOL CHEM, V250, P691; SCHULTHEIS PJ, 1993, BIOCHEMISTRY-US, V32, P544, DOI 10.1021/bi00053a020; Shi HLG, 2000, BBA-BIOMEMBRANES, V1464, P177, DOI 10.1016/S0005-2736(99)00245-X; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; VANIWAARDEN PR, 1991, BIOCHEMISTRY-US, V30, P9595, DOI 10.1021/bi00104a005; Wang SG, 1998, J BIOL CHEM, V273, P29400, DOI 10.1074/jbc.273.45.29400; Woo AL, 1999, J MEMBRANE BIOL, V169, P39, DOI 10.1007/PL00005899	30	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30734	30739		10.1074/jbc.M003737200	http://dx.doi.org/10.1074/jbc.M003737200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10906129	hybrid			2022-12-25	WOS:000089577900111
J	Hua, SM; Inesi, G				Hua, SM; Inesi, G			Distinct topologies of mono- and decavanadate binding and photo-oxidative cleavage in the sarcoplasmic reticulum ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; CHEMICAL MECHANISM; TRANSITION-STATE; VANADATE; PHOSPHATE; CA-2+-ATPASE; PHOTOCLEAVAGE; CA2+-ATPASE; PROTEINS; VESICLES	UV irradiation of the sarcoplasmic reticulum (SR) ATPase in the presence of vanadate cleaves the enzyme at either of two different sites. Under conditions favoring the presence of monovanadate, and in the presence of Ca2+, ADP, and Mg2+ cleavage results in two fragments of 71- and 38-kDa electrophoretic mobility. On the other hand, under conditions permitting formation of decavanadate, and in the absence of Ca2+ and ADP, cleavage results in two fragments of 88- and 21-kDa electrophoretic mobility. The amino terminus resulting from cleavage is blocked and resistant to Edman degradation. However, the initial photo-oxidation product can be reduced with (NaBH4)-H-3, resulting in incorporation of radioactive H-3 label. Extensive digestion of the labeled protein with trypsin then yields labeled peptides that are specific for the each of the photo-oxidation conditions, and can be sequenced after purification. Collection of the Edman reaction fractional products reveals the radioactive label and demonstrates that Thr(353) is the residue oxidized by monovanadate at the phosphorylation site (i.e. Asp(351)). Correct positioning of monovanadate at the phosphorylation site requires binding of Mg2+ and ADP to the Ca2+-dependent conformation of the enzyme. Subsequent hydrolytic cleavage is likely assisted by the neighboring Asp(601), and yields the 71- and 38-kDa fragments. On the other hand, Ser(186) (and possibly the following three residues: Val(187), Ile(188) and Lys(189)) is the residue that is photo-oxidized by de cavanadate in the absence of ADP. Hydrolytic cleavage of the oxidized product at this site is likely assisted by neighboring acidic residues, and yields the 88- and 21-kDa fragments. The bound decavanadate, which we find to produce steric interference with TNP-AMP binding, must therefore extend to the A domain (i.e. small cytosolic loop) in order to oxidize Ser(186). This protein conformation is only obtained in the absence of Ca2+.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 113, Japan	University System of Maryland; University of Maryland Baltimore; University of Tokyo	Inesi, G (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.	ginesi@umaryland.edu		Toyoshima, Chikashi/0000-0001-9640-0778	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL27867] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AURELIANO M, 1994, BBA-MOL CELL RES, V1221, P259, DOI 10.1016/0167-4889(94)90249-6; BASTIDE F, 1973, J BIOL CHEM, V248, P8485; CREMO CR, 1989, J BIOL CHEM, V264, P6608; DEGANI C, 1973, J BIOL CHEM, V248, P8222; DUPONT Y, 1982, FEBS LETT, V139, P237, DOI 10.1016/0014-5793(82)80860-0; DUX L, 1983, J BIOL CHEM, V258, P2599; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; Goldshleger R, 1999, J BIOL CHEM, V274, P16213, DOI 10.1074/jbc.274.23.16213; Grammer JC, 1996, BIOCHEMISTRY-US, V35, P15582, DOI 10.1021/bi961901g; GRAMMER JC, 1988, BIOCHEMISTRY-US, V27, P8408, DOI 10.1021/bi00422a017; Hua SM, 1999, BIOPHYS J, V77, P2217, DOI 10.1016/S0006-3495(99)77062-1; INESI G, 1980, J BIOL CHEM, V255, P6040; Ko YH, 1999, J BIOL CHEM, V274, P28853, DOI 10.1074/jbc.274.41.28853; Ko YH, 1997, J BIOL CHEM, V272, P18875, DOI 10.1074/jbc.272.30.18875; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; MOLNAR E, 1991, BIOCHIM BIOPHYS ACTA, V1068, P17, DOI 10.1016/0005-2736(91)90056-E; MUHLRAD A, 1995, MET IONS BIOL SYST, V31, P211; NAKAMOTO RK, 1984, J BIOL CHEM, V259, P2961; PICK U, 1982, J BIOL CHEM, V257, P6111; TAYLOR KA, 1986, J MOL BIOL, V187, P417, DOI 10.1016/0022-2836(86)90442-0; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; VEGH M, 1990, BIOCHIM BIOPHYS ACTA, V1023, P168, DOI 10.1016/0005-2736(90)90411-G; WATANABE T, 1982, J BIOL CHEM, V257, P1510; WEBER K, 1969, J BIOL CHEM, V244, P4406; Young HS, 1997, BIOPHYS J, V72, P2545, DOI 10.1016/S0006-3495(97)78898-2	27	42	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30546	30550		10.1074/jbc.M003218200	http://dx.doi.org/10.1074/jbc.M003218200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10906127	hybrid			2022-12-25	WOS:000089577900086
J	Wei, Y; Guffanti, AA; Ito, M; Krulwich, TA				Wei, Y; Guffanti, AA; Ito, M; Krulwich, TA			Bacillus subtilis YqkI is a novel malic/Na(+)-lactate antiporter that enhances growth on malate at low protonmotive force	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTIC-ACID BACTERIA; MALOLACTIC FERMENTATION; ESCHERICHIA-COLI; NA+/H+ ANTIPORTER; PH HOMEOSTASIS; SACCHAROMYCES-CEREVISIAE; LACTOBACILLUS-PLANTARUM; ENERGY TRANSDUCTION; MOTIVE FORCE; FIRMUS OF4	Bacillus subtilis yheL encodes a Na(+)/H(+) antiporter, whereas its paralogue, yqkI, encodes a novel antiporter that achieves a simultaneous Na(+)/R(+) and malolactate antiport. B. subtilis yufR, a control in some experiments, encodes a Na(+)/malate symporter. YqkI complemented a malate transport mutant of Escherichia coli if Na(+) and lactate were present. YheL conferred Na(+) uptake capacity on everted membrane vesicles from an antiporter-deficient E. coli mutant that was consistent with a secondary Na(+)/H(+) antiport, but YqkI-dependent Na(+) uptake depended on intravesicular malate and extravesicular lactate. YqkI-dependent lactate uptake depended on intravesicular malate and extravesicular Na(+). YqkI mediated an electroneutral exchange, which is proposed to be a malic(-2)-2H(+) (or fully protonated malate)/Na(+)-lactate(-1) antiport, Because the composite YqkI-mediated exchanges could be driven by gradients of the malate-lactate pair, this transporter could play a role in growth of B. subtilis on malate at low protonmotive force. A mutant with a disruption of yqkI exhibited an abrupt arrest in the mid-logarithmic phase of growth on malate when low concentrations of protonophore were present. Thus growth of B. subtilis to high density on a putatively nonfermentative dicarboxylic acid substrate depends on a malolactate exchange at suboptimal protonmotive force.	Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Krulwich, TA (corresponding author), Mt Sinai Sch Med, Dept Biochem & Mol Biol, Box 1020,1 Gustave L Levy Pl, New York, NY 10029 USA.	terry.krulwich@mssm.edu	ITO, MASAHIRO/H-1960-2013	ITO, MASAHIRO/0000-0002-4976-762X	NIGMS NIH HHS [GM52837, GM28454] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028454] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe K, 1996, J BIOL CHEM, V271, P3079, DOI 10.1074/jbc.271.6.3079; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMBUDKAR SV, 1984, J BIOL CHEM, V259, P6142; ANANTHARAM V, 1989, J BIOL CHEM, V264, P7244; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bandell M, 1997, J BIOL CHEM, V272, P18140, DOI 10.1074/jbc.272.29.18140; Bony M, 1997, FEBS LETT, V410, P452, DOI 10.1016/S0014-5793(97)00637-6; CASPRITZ G, 1983, J BIOL CHEM, V258, P4907; DAVIS CR, 1988, AM J ENOL VITICULT, V39, P137; DENAYROLLES M, 1994, FEMS MICROBIOL LETT, V116, P79, DOI 10.1016/0378-1097(94)90111-2; Dimroth P, 1997, BBA-BIOENERGETICS, V1318, P11, DOI 10.1016/S0005-2728(96)00127-2; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; Guffanti AA, 1998, J BIOL CHEM, V273, P26447, DOI 10.1074/jbc.273.41.26447; GUFFANTI AA, 1987, J BACTERIOL, V169, P4469, DOI 10.1128/jb.169.10.4469-4478.1987; HAROLD FM, 1986, VITAL FORCE STUDY BI, P57; HENICKKLING T, 1995, J APPL BACTERIOL, V79, pS29; Higuchi T, 1997, J BACTERIOL, V179, P3362, DOI 10.1128/JB.179.10.3362-3364.1997; Ito M, 1999, J BACTERIOL, V181, P2394, DOI 10.1128/JB.181.8.2394-2402.1999; Ito M, 1997, J BACTERIOL, V179, P3851, DOI 10.1128/jb.179.12.3851-3857.1997; IVEY DM, 1991, J BIOL CHEM, V266, P23483; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; Kakinuma Y, 1998, MICROBIOL MOL BIOL R, V62, P1021, DOI 10.1128/MMBR.62.4.1021-1045.1998; Kawai S, 1997, J BACTERIOL, V179, P4056, DOI 10.1128/jb.179.12.4056-4060.1997; Konings WN, 1997, ANTON LEEUW INT J G, V71, P117, DOI 10.1023/A:1000143525601; KRULWICH TA, 1994, J EXP BIOL, V196, P457; Krulwich TA, 1999, NOVART FDN SYMP, V221, P167; KUNKEE RE, 1991, FEMS MICROBIOL LETT, V88, P55, DOI 10.1016/0168-6445(91)90006-4; Labarre C, 1996, APPL ENVIRON MICROB, V62, P1274, DOI 10.1128/AEM.62.4.1274-1282.1996; LLOKEMA JS, 1995, J BIOENERG BIOMEMBR, V27, P467; LO TCY, 1972, J BIOL CHEM, V247, P6323; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACNAB RM, 1987, BIOPHYS J, V52, P637, DOI 10.1016/S0006-3495(87)83255-1; MOLENAAR D, 1993, J BACTERIOL, V175, P2864, DOI 10.1128/JB.175.10.2864-2870.1993; OLSEN EB, 1991, J BACTERIOL, V173, P6199, DOI 10.1128/jb.173.19.6199-6206.1991; Padan E, 2000, BACTERIAL STRESS RESPONSES, P117; PADAN E, 1994, BBA-BIOENERGETICS, V1185, P129, DOI 10.1016/0005-2728(94)90204-6; Padan E., 1996, HDB BIOL PHYS, V2, P501; PINNER E, 1993, J BIOL CHEM, V268, P1729; POOLMAN B, 1991, J BACTERIOL, V173, P6030, DOI 10.1128/jb.173.19.6030-6037.1991; REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5; Takami H, 2000, EXTREMOPHILES, V4, P19, DOI 10.1007/s007920050133; Volschenk H, 1997, NAT BIOTECHNOL, V15, P253, DOI 10.1038/nbt0397-253; Wang W, 2000, J BACTERIOL, V182, P2088, DOI 10.1128/JB.182.8.2088-2095.2000; WEST IC, 1974, BIOCHEM J, V144, P87, DOI 10.1042/bj1440087	44	62	67	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30287	30292		10.1074/jbc.M001112200	http://dx.doi.org/10.1074/jbc.M001112200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10903309	hybrid			2022-12-25	WOS:000089577900052
J	Liu, JH; Itagaki, Y; Ben-Shabat, S; Nakanishi, K; Sparrow, JR				Liu, JH; Itagaki, Y; Ben-Shabat, S; Nakanishi, K; Sparrow, JR			The biosynthesis of A2E, a fluorophore of aging retina, involves the formation of the precursor, A2-PE, in the photoreceptor outer segment membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT EPITHELIUM; MACULAR DEGENERATION; FUNDUS FLAVIMACULATUS; STARGARDTS-DISEASE; LIPOFUSCIN; ABCR; AUTOFLUORESCENCE; PROTEIN	The autofluorescent lipofuscin that accumulates in retinal pigment epithelial cells with age may contribute to an age-related decline in cell function. The major lipofuscin fluorophore, A2E, is a pyridinium bisretinoid. We previously proposed that the biogenesis of A2E involves the following: (i) formation of the Schiff base, N-retinylidene phosphatidylethanolamine from all-trans-retinal and phosphatidylethanolamine in the photoreceptor outer segment membrane; (ii) further reaction of N-retinylidene phosphatidylethanolamine with retinal to yield phosphatidylethanolamine-bisretinoid, A2-PE; (iii) hydrolysis of A2-PE to generate A2E. To provide evidence for this biogenic scheme, all-trans-retinal was reacted with dipalmitoyl-L-alpha-phosphatidylethanolamine to yield DP-A2-PE (A2-PE), as confirmed by UV, with mass spectrometry revealing the molecular ion at m/z 1222.9 (C77H124O8PN) accompanied by product ion at m/z 672.8, representing the phosphoryl-A2E fragment of A2-PE. In reaction mixtures of retinal and outer segments and in samples of Royal College of Surgeons rat retina containing outer segment membranous debris, A2-PE was detected as a series of high performance liquid chromatography peaks, each with UV similar to reference A2-PE. By mass spectrometry, A2-PE consisted of multiple peaks, representing fatty acids with different chain lengths, and the phosphoryl-A2E moiety, m/z 673. Incubation of the retinal/outer segment reaction mixture with phospholipase D generated A2E, as detected by high performance liquid chromatography, thus confirming A2-PE as the A2E precursor.	Columbia Univ, Dept Chem, New York, NY 10027 USA; Columbia Univ Coll Phys & Surg, Dept Ophthalmol, New York, NY 10028 USA	Columbia University; Columbia University	Nakanishi, K (corresponding author), Columbia Univ, Dept Chem, New York, NY 10027 USA.				NATIONAL EYE INSTITUTE [R01EY012951] Funding Source: NIH RePORTER; NEI NIH HHS [EY12951] Funding Source: Medline; PHS HHS [34509] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; ANDERSON RE, 1970, BIOCHEMISTRY-US, V9, P3624, DOI 10.1021/bi00820a019; BIRNBACH CD, 1994, OPHTHALMOLOGY, V101, P1211; BRESSLER SB, 1999, RETINA VITREOUS MACU, P79; BUNTMILAM AH, 1983, INVEST OPHTH VIS SCI, V24, P458; DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327; DOWLING JE, 1962, J CELL BIOL, V14, P73, DOI 10.1083/jcb.14.1.73; Eldred GE, 1995, GERONTOLOGY, V41, P15; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; ELDRED GE, 1998, RETINAL PIGMENT EPIT, P651; Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209; KATZ ML, 1978, INVEST OPHTH VIS SCI, V17, P1049; KATZ ML, 1986, EXP EYE RES, V43, P561, DOI 10.1016/S0014-4835(86)80023-9; Katz ML, 1996, MECH AGEING DEV, V92, P159, DOI 10.1016/S0047-6374(96)01817-9; KATZ ML, 1987, MECH AGEING DEV, V39, P81, DOI 10.1016/0047-6374(87)90088-1; Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.3.CO;2-E; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609; POINCELOT RP, 1969, NATURE, V221, P256, DOI 10.1038/221256a0; Ren RXF, 1997, J AM CHEM SOC, V119, P3619, DOI 10.1021/ja9700414; Ryeom SW, 1996, J CELL SCI, V109, P387; SAIKAI N, 1996, J AM CHEM SOC, V118, P1559; Salvador GA, 1998, LIPIDS, V33, P853, DOI 10.1007/s11745-998-0281-z; SHICHI H, 1983, BIOCH VISION, P122; Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988; Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; SZAMIER RB, 1977, INVEST OPHTH VIS SCI, V16, P947; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9	30	197	201	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29354	29360		10.1074/jbc.M910191199	http://dx.doi.org/10.1074/jbc.M910191199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10887199	hybrid			2022-12-25	WOS:000089439800025
J	Milstone, AM; Harrison, LM; Bungiro, RD; Kuzmic, P; Cappello, M				Milstone, AM; Harrison, LM; Bungiro, RD; Kuzmic, P; Cappello, M			A broad spectrum Kunitz type serine protease inhibitor secreted by the hookworm Ancylostoma ceylanicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINUM ANTICOAGULANT PEPTIDE; ASCARIS-LUMBRICOIDES; ANISAKIS SIMPLEX; SPLICED LEADER; CLEAVAGE SITES; FACTOR XA; INFECTION; EXPRESSION; NEMATODES; CLONING	Although blood-feeding hookworms infect over a billion people worldwide, little is known about the molecular mechanisms through which these parasitic nematodes cause gastrointestinal hemorrhage and iron deficiency anemia. A cDNA corresponding to a secreted Kunitz type serine protease inhibitor has been cloned from adult Ancylostoma ceylanicum hookworm RNA. The translated sequence of the A. ceylanicum Kunitz type inhibitor 1 (AceKI-1) cDNA predicts a 16-amino acid secretory signal sequence, followed by a 68-amino acid mature protein with a molecular mass of 7889 daltons. Recombinant protein (rAceKI-1) was purified from induced lysates of Escherichia coli transformed with the rAceKI-1/pET 28a plasmid, and in vitro studies demonstrate that rAceKI-1 is a tight binding inhibitor of the serine proteases chymotrypsin, pancreatic elastase, neutrophil elastase, and trypsin, AceKI-1 inhibitory activity is present in soluble protein extracts and excretory/secretory products of adult hookworms but not the infective third stage larvae. The native AceKI-1 inhibitor has been purified to homogeneity from soluble extracts of adult A. ceylanicum using size exclusion and reverse-phase high pressure liquid chromatography. As a potent inhibitor of mammalian intestinal proteases, AceKI-1 may play a role in parasite survival and the pathogenesis of hookworm anemia.	Yale Univ, Sch Med, Dept Pediat, Yale Child Hlth Res Ctr,Infect Dis Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Yale Child Hlth Res Ctr,Infect Dis Sect, New Haven, CT 06520 USA; BioKin Ltd, Madison, WI 53708 USA	Yale University; Yale University	Cappello, M (corresponding author), Yale Univ, Sch Med, Dept Pediat, Yale Child Hlth Res Ctr,Infect Dis Sect, POB 208081, New Haven, CT 06520 USA.	michael.cappello@yale.edu	Bungiro, Rick/AAJ-1736-2021; Bungiro, Richard/AAH-9406-2021; Bungiro, Rick/AAJ-1758-2021	Kuzmic, Petr/0000-0001-5250-8381; Milstone, Aaron/0000-0001-8498-8682; Cappello, Michael/0000-0003-2255-8833	NIAID NIH HHS [K11 AI01299, T32 AI07404] Funding Source: Medline; NICHD NIH HHS [P30 HD2775] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI001299, T32AI007404] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albonico M, 1999, ADV PARASIT, V42, P277, DOI 10.1016/S0065-308X(08)60151-7; ALBONICO M, 1995, T ROY SOC TROP MED H, V89, P538, DOI 10.1016/0035-9203(95)90101-9; Albonico M, 1999, INT J EPIDEMIOL, V28, P591, DOI 10.1093/ije/28.3.591; BABIN DR, 1984, ARCH BIOCHEM BIOPHYS, V232, P143, DOI 10.1016/0003-9861(84)90530-7; BEKTESH S, 1988, GENE DEV, V2, P1277, DOI 10.1101/gad.2.10.1277; BERNARD VD, 1993, ARCH BIOCHEM BIOPHYS, V303, P367, DOI 10.1006/abbi.1993.1297; Blaxter M, 1996, INT J PARASITOL, V26, P1025, DOI 10.1016/S0020-7519(96)00060-4; Cappello M, 1998, P NATL ACAD SCI USA, V95, P14290, DOI 10.1073/pnas.95.24.14290; CAPPELLO M, 1995, P NATL ACAD SCI USA, V92, P6152, DOI 10.1073/pnas.92.13.6152; Cappello M, 1996, MOL BIOCHEM PARASIT, V80, P113, DOI 10.1016/0166-6851(96)02658-8; CAPPELLO M, 1993, J INFECT DIS, V167, P1474, DOI 10.1093/infdis/167.6.1474; CARROLL SM, 1986, TROP GEOGR MED, V38, P38; CARROLL SM, 1984, J HELMINTHOL, V58, P313, DOI 10.1017/S0022149X00025189; CARROLL SM, 1984, J INFECT DIS, V150, P284, DOI 10.1093/infdis/150.2.284; Chadderdon RC, 1999, J INFECT DIS, V179, P1235, DOI 10.1086/314724; CHOWDHURY AB, 1972, AM J TROP MED HYG, V21, P300, DOI 10.4269/ajtmh.1972.21.300; CREIGHTON TE, 1975, NATURE, V255, P743, DOI 10.1038/255743a0; DeClercq D, 1997, AM J TROP MED HYG, V57, P25, DOI 10.4269/ajtmh.1997.57.25; Delaria KA, 1997, J BIOL CHEM, V272, P12209, DOI 10.1074/jbc.272.18.12209; ENJYOJI K, 1992, J BIOCHEM-TOKYO, V111, P681, DOI 10.1093/oxfordjournals.jbchem.a123818; GARSIDE P, 1989, PARASITOLOGY, V98, P283, DOI 10.1017/S003118200006220X; GILLES HM, 1985, REV INFECT DIS, V7, P111; HARROP SA, 1995, TROP MED PARASITOL, V46, P119; HAWDON JM, 1993, PARASITOLOGY, V106, P163, DOI 10.1017/S0031182000074953; HAWDON JM, 1992, J PARASITOL, V78, P1036, DOI 10.2307/3283226; HOTEZ P, 1990, INFECT IMMUN, V58, P3883, DOI 10.1128/IAI.58.12.3883-3892.1990; HOTEZ P, 1994, J INFECT DIS, V170, P918, DOI 10.1093/infdis/170.4.918; HOTEZ PJ, 1985, J BIOL CHEM, V260, P7343; HOTEZ PJ, 1995, SCI AM, V272, P68, DOI 10.1038/scientificamerican0695-68; Hotez PJ, 1997, PEDIATR INFECT DIS J, V16, P935, DOI 10.1097/00006454-199710000-00006; HOTEZ PJ, 1995, INFECT AGENT DIS, V4, P71; HOTEZ PJ, 1995, MOL APPROACHES PARAS; JESPERS LS, 1995, BIO-TECHNOL, V13, P378, DOI 10.1038/nbt0495-378; KALKOFEN UP, 1970, Z PARASITENK, V33, P339, DOI 10.1007/BF00331470; KEYMER A, 1989, NATURE, V337, P114, DOI 10.1038/337114a0; Kraunsoe JAE, 1996, BIOCHEMISTRY-US, V35, P9090, DOI 10.1021/bi953013b; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Kuzmic P, 2000, ANAL BIOCHEM, V281, P62, DOI 10.1006/abio.2000.4501; Lawson CL, 1974, SOLVING LEAST SQUARE; LAYRISSE M, 1964, AM J HYG, V79, P279, DOI 10.1093/oxfordjournals.aje.a120383; Lu CC, 1998, EXP PARASITOL, V89, P257, DOI 10.1006/expr.1998.4284; Lu WY, 1997, J MOL BIOL, V266, P441, DOI 10.1006/jmbi.1996.0781; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MOYLE M, 1994, J BIOL CHEM, V269, P10008; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PRESS WH, 1992, NUMERICAL RECIPES, P696; Pritchard L, 1999, J MOL BIOL, V285, P1589, DOI 10.1006/jmbi.1998.2437; QUINNELL RJ, 1993, PARASITOLOGY, V106, P379, DOI 10.1017/S0031182000067123; Reynoldson JA, 1997, ACTA TROP, V68, P301, DOI 10.1016/S0001-706X(97)00106-X; Rhoads ML, 2000, EXP PARASITOL, V94, P1, DOI 10.1006/expr.1999.4466; RicoHesse R, 1997, VIROLOGY, V230, P244, DOI 10.1006/viro.1997.8504; ROCHE MARCEL, 1966, AMER J TROP MED HYG, V15, P1031; SASAKI T, 1984, J BIOCHEM-TOKYO, V95, P1009, DOI 10.1093/oxfordjournals.jbchem.a134688; SCHAD GA, 1979, EXP PARASITOL, V47, P246, DOI 10.1016/0014-4894(79)90077-8; SCHAEFER BC, 1995, ANAL BIOCHEM, V227, P255, DOI 10.1006/abio.1995.1279; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Smillie WG, 1926, AM J DIS CHILD, V31, P151, DOI 10.1001/archpedi.1926.04130020003001; Stanssens P, 1996, P NATL ACAD SCI USA, V93, P2149, DOI 10.1073/pnas.93.5.2149; STEPHENSON LS, 1990, T ROY SOC TROP MED H, V84, P277, DOI 10.1016/0035-9203(90)90286-N; Stoltzfus RJ, 1997, AM J CLIN NUTR, V65, P153, DOI 10.1093/ajcn/65.1.153; Stone KL, 1998, ELECTROPHORESIS, V19, P1046, DOI 10.1002/elps.1150190620; STONE KL, 1992, TECHNIQUES PROTEIN C, V3; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Williams J W, 1979, Methods Enzymol, V63, P437; WILLIAMS KR, 1996, PROTEIN PROTOCOLS HD; ZIMMERMAN HM, 1946, AM J PATHOL, V22, P1081	66	65	71	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29391	29399		10.1074/jbc.M002715200	http://dx.doi.org/10.1074/jbc.M002715200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893410	hybrid			2022-12-25	WOS:000089439800030
J	Xie, YM; Tisi, MA; Yeo, TT; Longo, FM				Xie, YM; Tisi, MA; Yeo, TT; Longo, FM			Nerve growth factor (NGF) loop 4 dimeric mimetics activate ERK and AKT and promote NGF-like neurotrophic effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 CELLS; NEURITE OUTGROWTH; RECEPTOR-BINDING; PROTEIN-KINASE; NEURONAL DIFFERENTIATION; SIGNAL-TRANSDUCTION; CARBOXYL-TERMINUS; CRYSTAL-STRUCTURE; CROSS-LINKING; TRKA RECEPTOR	Previous work indicating that nerve growth factor (NGF) protein loops 2 and 4 interact with TrkA receptors raise the possibility that small molecule mimetics corresponding to TrkA-interacting domains that have NGF agonist activity can be developed. We applied our previously developed strategy of dimeric peptidomimetics to address the hypothesis that loop 4 small molecule dimeric mimetics would activate TrkA-related signal transduction and mimic NGF neurotrophic effects in a structure-specific manner. A loop 4 cyclized peptide dimer demonstrated NGF-like neurotrophic activity, whereas peptides with scrambled sequence, added or substituted residues, or cyclized in monomeric form were inactive. Activity was blocked by the TrkA inhibitors K252a and AG879 but not by NGF p75 receptor blocking antibody. Dimeric, but not monomeric, peptides partially blocked NGF activity. This profile was consistent with that of a NGF partial agonist. ERK and AKT phosphorylation was stimulated only by biologically active peptides and was blocked by K252a. The ERK inhibitor U0126 blocked the neurite- but not the survival-promoting activity of both NGF and active peptide. These studies support the proof of concept that small molecule NGF loop 4 mimetics can activate NGF signaling pathways and can mimic death-preventing and neurite-promoting effects of NGF. This finding will guide the rational design of NGF single-domain mimetics and contribute to elucidating NGF signal transduction mechanisms.	Vet Affairs Med Ctr, Dept Neurol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Longo, FM (corresponding author), Vet Affairs Med Ctr, Dept Neurol, 4150 Clement St, San Francisco, CA 94121 USA.				NINDS NIH HHS [NS37309] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R55NS037309] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashcroft M, 1999, ONCOGENE, V18, P4586, DOI 10.1038/sj.onc.1202814; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BERG MM, 1992, J BIOL CHEM, V267, P13; BOURNE HR, 1998, BASIC CLIN PHARM, P9; BRADSHAW RA, 1994, PROTEIN SCI, V3, P1901, DOI 10.1002/pro.5560031102; Bredesen DE, 1998, CELL DEATH DIFFER, V5, P365, DOI 10.1038/sj.cdd.4400378; Chao M, 1998, BRAIN RES REV, V26, P295, DOI 10.1016/S0165-0173(97)00036-2; CLARY DO, 1994, MOL BIOL CELL, V5, P549, DOI 10.1091/mbc.5.5.549; Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Cunningham BC, 1997, CURR OPIN STRUC BIOL, V7, P457, DOI 10.1016/S0959-440X(97)80107-8; DRINKWATER CC, 1993, J BIOL CHEM, V268, P23202; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Frade JM, 1998, BIOESSAYS, V20, P137, DOI 10.1002/(SICI)1521-1878(199802)20:2<137::AID-BIES6>3.0.CO;2-Q; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; HOLLAND DR, 1994, J MOL BIOL, V239, P385, DOI 10.1006/jmbi.1994.1380; HRUBY VJ, 1990, BIOCHEM J, V268, P249, DOI 10.1042/bj2680249; HUBER LJ, 1995, J NEUROSCI RES, V40, P557, DOI 10.1002/jnr.490400415; Hughes RA, 1999, DRUG DEVELOP RES, V46, P268, DOI 10.1002/(SICI)1098-2299(199903/04)46:3/4<268::AID-DDR12>3.0.CO;2-G; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; Johnson DL, 1998, BIOCHEMISTRY-US, V37, P3699, DOI 10.1021/bi971956y; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Kenakin T, 1999, TRENDS PHARMACOL SCI, V20, P400, DOI 10.1016/S0165-6147(99)01361-9; KieberEmmons T, 1997, CURR OPIN BIOTECH, V8, P435, DOI 10.1016/S0958-1669(97)80065-1; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; KOIZUMI S, 1988, J NEUROSCI, V8, P715; Kruttgen A, 1997, J BIOL CHEM, V272, P29222, DOI 10.1074/jbc.272.46.29222; Kullander K, 1997, J BIOL CHEM, V272, P9300; LESAUTEUR L, 1995, J BIOL CHEM, V270, P6564, DOI 10.1074/jbc.270.12.6564; Lipworth BJ, 1997, BRIT J CLIN PHARMACO, V43, P9, DOI 10.1111/j.1365-2125.1997.tb00025.x; LONGO FM, 1990, CELL REGUL, V1, P189, DOI 10.1091/mbc.1.2.189; Longo FM, 1997, J NEUROSCI RES, V48, P1, DOI 10.1002/(SICI)1097-4547(19970401)48:1<1::AID-JNR1>3.0.CO;2-K; Maliartchouk S, 2000, J BIOL CHEM, V275, P9946, DOI 10.1074/jbc.275.14.9946; Maliartchouk S, 1997, J NEUROSCI, V17, P6031; MCCARTHY KD, 1976, BRAIN RES, V114, P391, DOI 10.1016/0006-8993(76)90962-8; MCDONALD NQ, 1995, J BIOL CHEM, V270, P19669, DOI 10.1074/jbc.270.34.19669; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; McInnes C, 1997, BIOPOLYMERS, V43, P339, DOI 10.1002/(SICI)1097-0282(1997)43:5<339::AID-BIP2>3.0.CO;2-W; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; O'Leary PD, 1998, J NEUROCHEM, V70, P1712; OHMICHI M, 1993, BIOCHEMISTRY-US, V32, P4650, DOI 10.1021/bi00068a024; PELTON JT, 1985, P NATL ACAD SCI USA, V82, P236, DOI 10.1073/pnas.82.1.236; Perron JC, 1999, MOL CELL NEUROSCI, V13, P362, DOI 10.1006/mcne.1999.0753; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; Pliska V, 1999, J RECEPT SIGNAL TR R, V19, P597, DOI 10.3109/10799899909036675; Poduslo JF, 1996, MOL BRAIN RES, V36, P280, DOI 10.1016/0169-328X(95)00250-V; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Ross GM, 1998, EUR J NEUROSCI, V10, P890, DOI 10.1046/j.1460-9568.1998.00094.x; Saltzman WM, 1999, PHARMACEUT RES, V16, P232, DOI 10.1023/A:1018824324275; Shamovsky IL, 1999, PROTEIN SCI, V8, P2223; Shu XQ, 1999, P NATL ACAD SCI USA, V96, P7693, DOI 10.1073/pnas.96.14.7693; SNOW DM, 1992, J NEUROBIOL, V23, P322, DOI 10.1002/neu.480230311; Taglialatela G, 1996, J NEUROCHEM, V66, P1826; VOLONTE C, 1993, J BIOL CHEM, V268, P21410; Wiesmann C, 1999, NATURE, V401, P184, DOI 10.1038/43705; WOO SB, 1995, J BIOL CHEM, V270, P6278, DOI 10.1074/jbc.270.11.6278; Woo SB, 1998, PROTEIN SCI, V7, P1006; Wrighton NC, 1997, NAT BIOTECHNOL, V15, P1261, DOI 10.1038/nbt1197-1261; Xie Y. M., 1997, Society for Neuroscience Abstracts, V23, P1701; Yuen EC, 1996, BRAIN DEV-JPN, V18, P362, DOI 10.1016/0387-7604(96)00051-4; ZHOU J, 1995, J NEUROCHEM, V65, P1146	62	74	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29868	29874		10.1074/jbc.M005071200	http://dx.doi.org/10.1074/jbc.M005071200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896671	hybrid			2022-12-25	WOS:000089439800093
J	Regier, DS; Greene, DG; Sergeant, S; Jesaitis, AJ; McPhail, LC				Regier, DS; Greene, DG; Sergeant, S; Jesaitis, AJ; McPhail, LC			Phosphorylation of p22phox is mediated by phospholipase D-dependent and -independent mechanisms - Correlation of NADPH oxidase activity and p22phox phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; CHRONIC GRANULOMATOUS-DISEASE; CHOLINE-CONTAINING PHOSPHOGLYCERIDES; PERMEABILIZED HUMAN NEUTROPHILS; PHOSPHATIDIC-ACID PRODUCTION; STIMULATED HUMAN-NEUTROPHILS; DIFFERENTIATED HL60 CELLS; RESPIRATORY BURST; CYTOCHROME-B	Human neutrophils participate in the host innate immune response, partly mediated by the multicomponent superoxide-generating enzyme NADPH oxidase. A correlation between phosphorylation of cytosolic NADPH oxidase components and enzyme activation has been identified but is not well understood. We previously showed that p22(phox), the small subunit of the membrane-bound oxidase component flavocytochrome b(558), is an in vitro substrate for both a phosphatidic acid-activated kinase and conventional protein kinase C isoforms (Regier, D. S., Waite, K. A, Wallin, R., and McPhail, L. C. (1999) J. Biol. Chem. 274, 36601-36608). Here we show that several neutrophil agonists (phorbol myristate acetate, opsonized zymosan, and N-formyl-methionyl-leucyl-phenylalanine) induce p22(phox) phosphorylation in intact neutrophils. To determine if phospholipase D (PLD) is needed for p22(phox) phosphorylation, cells were pretreated with ethanol, which reduces phosphatidic acid production by PLD in stimulated cells. Phorbol myristate acetate-induced phosphorylation of p22(phox) and NADPH oxidase activity were not reduced by ethanol, In contrast, ethanol reduced both activities when cells were stimulated by N-formyl-methionyl-leucyl-phenylalanine or opsonized zymosan. Varying the time of stimulation with opsonized zymosan showed that the phosphorylation of p22(phox) coincides with NADPH oxidase activation. GF109203X, an inhibitor of protein kinase C and the phosphatidic acid-activated protein kinase, decreased both p22(phox) phosphorylation and NADPH oxidase activity in parallel in opsonized zymosan-stimulated cells. Stimulus-induced phosphorylation of p22(phox) was on Thr residue(s), in agreement with in vitro results. Overall, these data show that NADPH oxidase activity and p22(phox) phosphorylation are correlated and suggest two mechanisms (PLD-dependent and -independent) by which p22(phox) phosphorylation occurs.	Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Div Infect Dis, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Med, Div Infect Dis, Winston Salem, NC 27157 USA; Montana State Univ, Dept Microbiol, Bozeman, MT 59717 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Montana State University System; Montana State University Bozeman	McPhail, LC (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Div Infect Dis, Med Ctr Blvd, Winston Salem, NC 27157 USA.	lmcphail@wfubmc.edu	McPhail, Linda C/D-9505-2013	McPhail, Linda C/0000-0002-8670-306X; Jesaitis, Algirdas/0000-0001-9001-5617	NCI NIH HHS [CA-09422] Funding Source: Medline; NIAID NIH HHS [R01-AI22564, R01 AI022564, R01-AI26711] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026711, R01AI022564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; AGWU DE, 1991, J IMMUNOL, V146, P3895; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AGWU DE, 1989, J BIOL CHEM, V264, P1405; Ahmed S, 1998, J BIOL CHEM, V273, P15693, DOI 10.1074/jbc.273.25.15693; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bauldry SA, 1997, BIOCHEM J, V322, P353, DOI 10.1042/bj3220353; BAULDRY SA, 1992, J BIOL CHEM, V267, P25141; BAULDRY SA, 1992, J BIOL CHEM, V267, P323; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURNHAM DN, 1989, ARCH BIOCHEM BIOPHYS, V269, P345, DOI 10.1016/0003-9861(89)90116-1; BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974; CALDWELL SE, 1988, J CLIN INVEST, V81, P1485, DOI 10.1172/JCI113480; CHABOT MC, 1992, BIOCHEM J, V286, P693, DOI 10.1042/bj2860693; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; CROSS AR, 1995, J BIOL CHEM, V270, P17075, DOI 10.1074/jbc.270.29.17075; DANA R, 1994, BIOCHEM J, V297, P217, DOI 10.1042/bj2970217; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; DAWSON RMC, 1967, BIOCHEM J, V102, P205, DOI 10.1042/bj1020205; DeLeo FR, 2000, J BIOL CHEM, V275, P13986, DOI 10.1074/jbc.275.18.13986; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DELLABIANCA V, 1991, BIOCHEM BIOPH RES CO, V177, P948, DOI 10.1016/0006-291X(91)90630-P; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ElBenna J, 1997, J BIOL CHEM, V272, P17204, DOI 10.1074/jbc.272.27.17204; Escriou V, 1996, BIOCHEM BIOPH RES CO, V219, P930, DOI 10.1006/bbrc.1996.0335; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fuchs A, 1997, EUR J BIOCHEM, V249, P531, DOI 10.1111/j.1432-1033.1997.00531.x; GARCIA RC, 1986, BIOCHEM J, V239, P647, DOI 10.1042/bj2390647; GARCIA RC, 1988, BIOCHEM J, V252, P901, DOI 10.1042/bj2520901; GODFREY RW, 1987, J CELL BIOL, V104, P925, DOI 10.1083/jcb.104.4.925; Hantgan RR, 1998, BLOOD, V92, P2064, DOI 10.1182/blood.V92.6.2064.418k07_2064_2074; HEYWORTH PG, 1989, J BIOL CHEM, V264, P14935; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; Hsu MF, 1997, BRIT J PHARMACOL, V120, P917, DOI 10.1038/sj.bjp.0700974; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; IMAJOHOHMI S, 1992, J BIOL CHEM, V267, P180; Karlsson A, 2000, J LEUKOCYTE BIOL, V67, P396, DOI 10.1002/jlb.67.3.396; Kent JD, 1996, J IMMUNOL, V157, P4641; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; Korchak HM, 1998, J BIOL CHEM, V273, P27292, DOI 10.1074/jbc.273.42.27292; Koshkin V, 1995, BBA-BIOENERGETICS, V1232, P225, DOI 10.1016/0005-2728(95)00123-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; Li Q, 1999, J BIOL CHEM, V274, P3764, DOI 10.1074/jbc.274.6.3764; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; McPhail LC, 1999, BBA-MOL CELL BIOL L, V1439, P277, DOI 10.1016/S1388-1981(99)00100-6; MCPHAIL LC, 1994, J EXP MED, V180, P2011, DOI 10.1084/jem.180.6.2011; MCPHAIL LC, 1983, J CLIN INVEST, V72, P192, DOI 10.1172/JCI110957; MCPHAIL LC, 1995, P NATL ACAD SCI USA, V92, P7931, DOI 10.1073/pnas.92.17.7931; MCPHAIL LC, 1993, NATURAL IMMUNE SYSTE, P63; MESHULAM T, 1988, BIOCHEM BIOPH RES CO, V150, P532, DOI 10.1016/0006-291X(88)90426-3; MESHULAM T, 1995, J LEUKOCYTE BIOL, V57, P842, DOI 10.1002/jlb.57.6.842; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; Nixon JB, 1999, J IMMUNOL, V163, P4574; OKAMURA N, 1988, BLOOD, V72, P811; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PAI JK, 1988, J BIOL CHEM, V263, P12472; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; QUINN MT, 1995, METHOD ENZYMOL, V255, P476; QUINN MT, 1992, J BIOL CHEM, V267, P7303; Regier DS, 1999, J BIOL CHEM, V274, P36601, DOI 10.1074/jbc.274.51.36601; ROOS D, 1981, J IMMUNOL, V126, P433; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; Sergeant S, 1997, J IMMUNOL, V159, P2877; SOZZANI S, 1994, BLOOD, V84, P3895, DOI 10.1182/blood.V84.11.3895.bloodjournal84113895; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; TAYLOR WR, 1993, PROTEIN SCI, V2, P1675, DOI 10.1002/pro.5560021013; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERHOEVEN AJ, 1989, BLOOD, V73, P1686; Waite KA, 1997, J BIOL CHEM, V272, P15569, DOI 10.1074/jbc.272.24.15569; Wayne DW., 1999, BIOSTATISTICS FDN AN, V7 ed	80	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28406	28412		10.1074/jbc.M004703200	http://dx.doi.org/10.1074/jbc.M004703200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893420	hybrid			2022-12-25	WOS:000089330700011
J	Szaszi, K; Kurashima, K; Kapus, A; Paulsen, A; Kaibuchi, K; Grinstein, S; Orlowski, J				Szaszi, K; Kurashima, K; Kapus, A; Paulsen, A; Kaibuchi, K; Grinstein, S; Orlowski, J			RhoA and Rho kinase regulate the epithelial Na+/H+ exchanger NHE3 - Role of myosin light chain phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; RENAL BRUSH-BORDER; PROTEIN-KINASE; FOCAL ADHESIONS; H+ EXCHANGE; MEDIATED INHIBITION; MAMMALIAN-CELLS; ERM PROTEINS; CYTOSKELETON; ISOFORM	The activity of the Na+/H+ exchanger NHE3 isoform, which is found primarily in epithelial cells, is sensitive to the state of actin polymerization. Actin assembly, in turn, is controlled by members of the small GTPase Rho family, namely Rad, Cdc42, and RhoA We therefore investigated the possible role of these GTPases in modulating NHE3 activity. Cells stably expressing NHE3 were transiently transfected with inhibitory forms of Rad, Cdc42, or RhoA and transport activity was assessed using microfluorimetry. NHE3 activity was not adversely affected by either dominant-negative Rad or Cdc42. By contrast, the inhibitory form of RhoA greatly depressed NHE3 activity, without noticeably altering its subcellular distribution. NHE3 activity was equally reduced by inhibiting p160 Rho-associated kinase I (ROK), a downstream effector of RhoA, with the selective antagonist Y-27632 and a dominant-negative form of ROK. Furthermore, inhibition of ROK reduced the phosphorylation of myosin light chain. A comparable net dephosphorylation was achieved by the myosin light chain kinase inhibitor ML9, which similarly inhibited NHE3. These data suggest that optimal NHE3 activity requires a functional RhoA-ROK signaling pathway which acts, at least partly, by controlling the phosphorylation of myosin light chain and, ultimately, the organization of the actin cytoskeleton.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada; Hosp Sick Children, Cell Biol Programme, Toronto, ON M5G 1X8, Canada; Toronto Hosp, Dept Surg, Toronto, ON M5G 1L7, Canada; Univ Toronto, Toronto, ON M5G 1L7, Canada; Nara Inst Sci & Technol, Div Signal Transduct, Nara 6300101, Japan	McGill University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Nara Institute of Science & Technology	Orlowski, J (corresponding author), McGill Univ, Dept Physiol, 3655 Promenade Sir William Osler,McIntyre Med Sci, Montreal, PQ H3G 1Y6, Canada.		Szaszi, Katalin/J-7522-2012	Orlowski, John/0000-0001-7371-175X; Szaszi, Katalin/0000-0002-2490-8422				Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; BOIVIN D, 1995, AM J PHYSIOL-RENAL, V269, pF180, DOI 10.1152/ajprenal.1995.269.2.F180; BOOKSTEIN C, 1994, J CLIN INVEST, V93, P106, DOI 10.1172/JCI116933; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chow CW, 1999, J BIOL CHEM, V274, P37551, DOI 10.1074/jbc.274.53.37551; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; Gan BS, 1998, AM J PHYSIOL-CELL PH, V275, pC1158, DOI 10.1152/ajpcell.1998.275.4.C1158; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Janecki AJ, 1998, J BIOL CHEM, V273, P8790, DOI 10.1074/jbc.273.15.8790; KAPUS A, 1994, J BIOL CHEM, V269, P23544; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kotani H, 1997, ONCOGENE, V14, P1705, DOI 10.1038/sj.onc.1200998; Kreisberg JI, 1997, AM J PHYSIOL-RENAL, V273, pF283, DOI 10.1152/ajprenal.1997.273.2.F283; Kurashima K, 1999, J BIOL CHEM, V274, P29843, DOI 10.1074/jbc.274.42.29843; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; Leung T, 1996, MOL CELL BIOL, V16, P5313; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Orlowski J, 1996, J BIOL CHEM, V271, P19922, DOI 10.1074/jbc.271.33.19922; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; Ramakers GJA, 1998, EXP CELL RES, V245, P252, DOI 10.1006/excr.1998.4224; RESHKIN SJ, 1992, AM J PHYSIOL, V262, pF572, DOI 10.1152/ajprenal.1992.262.4.F572; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; SOLEIMANI M, 1994, J BIOL CHEM, V269, P15613; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Vexler ZS, 1996, J BIOL CHEM, V271, P22281, DOI 10.1074/jbc.271.37.22281; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	45	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28599	28606		10.1074/jbc.M001193200	http://dx.doi.org/10.1074/jbc.M001193200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893221	hybrid			2022-12-25	WOS:000089330700037
J	de Koning, JP; Soede-Bobok, AA; Ward, AC; Schelen, AM; Antonissen, C; van Leeuwen, D; Lowenberg, B; Touw, IP				de Koning, JP; Soede-Bobok, AA; Ward, AC; Schelen, AM; Antonissen, C; van Leeuwen, D; Lowenberg, B; Touw, IP			STAT3-mediated differentiation and survival of myeloid cells in response to granulocyte colony-stimulating factor: role for the cyclin-degendent kinase inhibitor p27(Kip1)	ONCOGENE			English	Article						G-CSF; STAT3; p27(Kip1); neutrophilic differentiation; survival	DISTINCT CYTOPLASMIC REGIONS; G-CSF RECEPTOR; TRANSCRIPTION FACTOR; ACTIVATION; STAT3; PROLIFERATION; GENE; GROWTH; SIGNALS; INVOLVEMENT	The signal transducer and activator of transcription (STAT) proteins have been implicated in cytokine-regulated proliferation, differentiation and cell survival. Granulocyte colony-stimulating factor (G-CSF), a regulator of granulocytic differentiation, induces a robust and sustained activation of STAT3. Here, we show that introduction of dominant negative (DN) forms of STAT3 interferes with G-CSF-induced differentiation and survival in murine 32D cells, G-CSF induces expression of the cyclin-dependent kinase (cdk) inhibitor p27(Kip1) (but not p21(Cip1)), which is completely blocked by DN-STAT3. The ability of tyrosine-to-phenylalanine substitution mutants of the G-CSF receptor to activate STAT3 strongly correlated with their capacity to induce p27 expression and their ability to mediate differentiation and survival, suggesting a causal relationship between STAT3 activation, p27 expression and the observed cellular responses. We identified a putative STAT binding site in the promoter region of p27 that showed both STAT3 binding in electrophoretic mobility shift assays and functional activity in luciferase reporter assays, Finally, we studied G-CSF-induced responses in primary bone marrow and spleen cells of p27-deficient mice. Compared with wildtype, myeloid progenitors from p27-deficient mice showed significantly increased proliferation and reduced differentiation in response to G-CSF. These findings indicate that STAT3 controls myeloid differentiation, at least partly, via upregulation of p27(Kip1).	Erasmus Univ, Inst Hematol, NL-3000 DR Rotterdam, Netherlands; Dr Daniel Den Hoed Canc Ctr, Dept Hematol, NL-3008 AE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	Touw, IP (corresponding author), Erasmus Univ, Inst Hematol, Room H Ee 13-14,POB 1738, NL-3000 DR Rotterdam, Netherlands.			Ward, Alister/0000-0001-7945-7975				Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Chakraborty A, 1999, BLOOD, V93, P15, DOI 10.1182/blood.V93.1.15.401a46_15_24; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; de Koning JP, 1998, BLOOD, V91, P1924, DOI 10.1182/blood.V91.6.1924.1924_1924_1933; deKoning JP, 1996, BLOOD, V87, P132; deKoning JP, 1996, BLOOD, V87, P1335, DOI 10.1182/blood.V87.4.1335.bloodjournal8741335; DEMETRI GD, 1991, BLOOD, V78, P2791; Dong F, 1998, J IMMUNOL, V161, P6503; DONG F, 1995, BLOOD, V85, P902, DOI 10.1182/blood.V85.4.902.bloodjournal854902; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NICOLA NA, 1987, INT J CELL CLONING, V5, P1, DOI 10.1002/stem.5530050102; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; OKUDA K, 1994, J BIOL CHEM, V269, P24602; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Tian SS, 1996, BLOOD, V88, P4435, DOI 10.1182/blood.V88.12.4435.bloodjournal88124435; TIAN SS, 1994, BLOOD, V84, P1760; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Ward AC, 1999, J BIOL CHEM, V274, P14956, DOI 10.1074/jbc.274.21.14956; Ward AC, 1996, BIOCHEM BIOPH RES CO, V224, P10, DOI 10.1006/bbrc.1996.0976; Ward AC, 1999, BLOOD, V93, P113, DOI 10.1182/blood.V93.1.113.401k33_113_124; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	46	110	111	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2000	19	29					3290	3298		10.1038/sj.onc.1203627	http://dx.doi.org/10.1038/sj.onc.1203627			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918585				2022-12-25	WOS:000088019300007
J	Robertson, H; Hime, GR; Lada, H; Bowtell, DDL				Robertson, H; Hime, GR; Lada, H; Bowtell, DDL			A Drosophila analogue of v-Cbl is a dominant-negative oncoprotein in vivo	ONCOGENE			English	Article						cbl; oncogene; Drosophila; ubiquitin; endocytosis; EGFR	GROWTH-FACTOR RECEPTOR; C-CBL; EGF RECEPTOR; TYROSINE KINASE; SH3 DOMAIN; MEDIATED ENDOCYTOSIS; HORMONE RECEPTOR; CELL-DEATH; T-CELLS; PROTEIN	Cells rely on the ability to receive and interpret external signals to regulate growth, differentiation, and death. Positive transduction of these signals to the cytoplasm and nucleus has been extensively characterized, and genetic studies in Drosophila have made major contributions to the understanding of these pathways, Less well understood, but equally important, are the mechanisms underlying signal down-regulation. Here me report biochemical and genetic characterization of the Drosophila homologue of c-Cbl, a negative regulator of signal transduction with ubiquitin-protein ligase activity. A new isoform of D-Cbl, D-CblL, has been identified that contains SH3-binding and UBA domains previously reported to he absent. Genetic analysis demonstrates that Dv-cbl, analogous to the mammalian v-cbl oncogene, is a dominant negative mutation able to enhance signalling from the Drosophila Egfr and cooperate with activating mutations in the sevenless pathway to produce melanotic tumours, In addition, our data show genetic and biochemical links between D-Cbl and proteins involved in endocytosis and ubiquitination, suggesting that v-Cbl may exert its oncogenic effect by enhancing receptor signalling as a consequence of suppressing receptor endocytosis.	Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 8006, Australia	Peter Maccallum Cancer Center	Bowtell, DDL (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, Locked Bag 1,A Beckett St, Melbourne, Vic 8006, Australia.		Bowtell, David/H-1007-2016; Hime, Gary/B-7162-2015	Bowtell, David/0000-0001-9089-7525; Hime, Gary/0000-0003-4732-3184				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BEMENT WM, 1994, J MOL BIOL, V243, P356, DOI 10.1006/jmbi.1994.1662; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; BRAND AH, 1993, DEVELOPMENT, V118, P401; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; DIAZBENJUMEA FJ, 1990, P ROY SOC B-BIOL SCI, V242, P36, DOI 10.1098/rspb.1990.0100; Feldmann P, 1999, MOL CELL BIOL, V19, P1928; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; HAY BA, 1994, DEVELOPMENT, V120, P2121; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JONGEWARD GD, 1995, GENETICS, V139, P1553; Karim FD, 1998, DEVELOPMENT, V125, P1; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; LAI KMV, 1995, MOL CELL BIOL, V15, P4810; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; MASUI H, 1991, CANCER RES, V51, P6170; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Potter CJ, 2000, TRENDS GENET, V16, P33, DOI 10.1016/S0168-9525(99)01878-8; Robertson H, 1997, BIOCHEM BIOPH RES CO, V240, P46, DOI 10.1006/bbrc.1997.7608; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; Rorth P, 1998, DEVELOPMENT, V125, P1049; Roth AF, 1998, J CELL BIOL, V142, P949, DOI 10.1083/jcb.142.4.949; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Rubin GM, 1997, COLD SPRING HARB SYM, V62, P347; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Wieschaus E., 1986, P199; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	58	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2000	19	29					3299	3308		10.1038/sj.onc.1203624	http://dx.doi.org/10.1038/sj.onc.1203624			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918586				2022-12-25	WOS:000088019300008
J	Mwanjewe, J; Martinez, R; Agrawal, P; Samson, SE; Coughlin, MD; Brassard, P; Grover, AK				Mwanjewe, J; Martinez, R; Agrawal, P; Samson, SE; Coughlin, MD; Brassard, P; Grover, AK			On the Ca2+ dependence of non-transferrin-bound iron uptake in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; SUBCELLULAR-LOCALIZATION; MEMBRANE-VESICLES; HELA-CELLS; RAT-LIVER; TRANSPORT; EXPRESSION; SYSTEM	Non-transferrin-bound iron (NTBI) uptake has been reported to follow two pathways, Ca2+-dependent and Ca2+-independent (Wright, T. L., Brissot, P,, Ma, W, L,, and Weisiger, R. A. (1986) J. Biol. Chern, 261, 10909-10914; Sturrock, k, Alexander, J,, Lamb, J,, Craven, C, M., and Kaplan, J, (1990) J, Biol. Chem. 265, 3139-3145). Studies reporting the two pathways have ignored the weak interactions of Ca2+ with the chelator nitrilotriacetate (NTA) and the reducing agent ascorbate. These studies used a constant ratio of total Fe2+ to NTA with and without Ca2+, We observed Ca2+ activation of NTBI uptake in PC12 cells with the characteristics reported for other cells upon using 1 mM ascorbate and a constant ratio of total Fe2+ to NTA with or without Ca2+. However, Ca2+ did not affect NTBI uptake in solutions without NTA. We then determined conditional stability constants for NTA binding to Ca2+ and Fe2+ by potentiometry under conditions of NTBI uptake experiments (pH, ionic strength, temperature, ascorbate, total Fe2+, and total Ca2+ concentrations). In solutions based on these constants and taking Ca2+ chelation into account, Ca2+ did not affect NTBI uptake over a range of free Fe2+ concentrations. Thus, the Ca2+ activation of NTBI uptake observed using the constant total Fe2+ to NTA ratio was because of Ca2+-NTA chelation rather than an activation of the NTBI transporter itself, It is suggested that the previously reported Ca2+ dependence of NTBI uptake be re-evaluated.	McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Chem, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University; McMaster University	Grover, AK (corresponding author), McMaster Univ, Dept Med, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.							AHNERTHILGER G, 1987, J NEUROCHEM, V49, P764, DOI 10.1111/j.1471-4159.1987.tb00959.x; Baker E, 1998, BBA-GEN SUBJECTS, V1380, P21, DOI 10.1016/S0304-4165(97)00120-7; BARISANI D, 1995, AM J PHYSIOL-GASTR L, V269, pG570, DOI 10.1152/ajpgi.1995.269.4.G570; Bouron A, 1999, N-S ARCH PHARMACOL, V359, P370, DOI 10.1007/PL00005363; Canonne-Hergaux F, 1999, BLOOD, V93, P4406, DOI 10.1182/blood.V93.12.4406.412k21_4406_4417; DIAMOND J, 1992, J NEUROSCI, V12, P1467; Garrick MD, 1999, BBA-MOL CELL RES, V1449, P125, DOI 10.1016/S0167-4889(99)00006-3; GUSTAFSON RL, 1963, J PHYS CHEM-US, V67, P576, DOI 10.1021/j100797a008; INMAN RS, 1993, J BIOL CHEM, V268, P8521; Keller D, 2000, NEUROREPORT, V11, P65, DOI 10.1097/00001756-200001170-00013; Kim S, 1999, J BIOL CHEM, V274, P33035, DOI 10.1074/jbc.274.46.33035; LAMB JE, 1983, J BIOL CHEM, V258, P8751; Liu HL, 1997, J BIOL CHEM, V272, P6038, DOI 10.1074/jbc.272.9.6038; MARTELL AE, 1999, CRITICAL STABILITY C, V5, P62; NAKAGAWA G, 1980, B CHEM SOC JPN, V53, P1303, DOI 10.1246/bcsj.53.1303; Parkes JG, 1997, TOXICOLOGY, V117, P141, DOI 10.1016/S0300-483X(96)03566-4; RANDELL EW, 1994, J BIOL CHEM, V269, P16046; Richert R, 1997, RRD MACROMOL RES, V2, P1; STREMMEL W, 1987, EUR J CLIN INVEST, V17, P136, DOI 10.1111/j.1365-2362.1987.tb02393.x; STURROCK A, 1990, J BIOL CHEM, V265, P3139; Wessling-Resnick M, 1999, CRIT REV BIOCHEM MOL, V34, P285, DOI 10.1080/10409239991209318; WRIGHT TL, 1990, HEPATOLOGY, V12, P498, DOI 10.1002/hep.1840120309; WRIGHT TL, 1986, J BIOL CHEM, V261, P909; YUCHI A, 1983, ANAL CHIM ACTA, V149, P209, DOI 10.1016/S0003-2670(00)83177-3	24	11	11	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33512	33515		10.1074/jbc.M005435200	http://dx.doi.org/10.1074/jbc.M005435200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10906140	hybrid			2022-12-25	WOS:000090104600047
J	Kokame, K; Agarwala, KL; Kato, H; Miyata, T				Kokame, K; Agarwala, KL; Kato, H; Miyata, T			Herp, a new ubiquitin-like membrane protein induced by endoplasmic reticulum stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; TRANSCRIPTION FACTOR; TRANSMEMBRANE PROTEIN; RESPONSE ELEMENT; MESSENGER-RNA; QUALITY-CONTROL; ER; HOMOCYSTEINE; RETENTION; PATHWAY	Hyperhomocysteinemia, a risk factor for vascular disease, injures endothelial cells through undefined mechanisms. We previously identified several homocysteine-responsive genes in cultured human vascular endothelial cells, including the endoplasmic reticulum (ER)-resident molecular chaperone GRP78/BiP. Here, we demonstrate that homocysteine induces the ER stress response and leads to the expression of a novel protein, Herp, containing a ubiquitin-like domain at the N terminus. mRNA expression of Herp was strongly upregulated by inducers of ER stress, including mercaptoethanol, tunicamycin, A23187, and thapsigargin. The ER stress-dependent induction of Herp was also observed at the protein level. Immunochemical analyses using Herp-specific antibodies indicated that Herp is a 54-kDa, membrane-associated ER protein. Herp is the first integral membrane protein regulated by the ER stress response pathway. Both the N and C termini face the cytoplasmic side of the ER; this membrane topology makes it unlikely that Herp acts as a molecular chaperone for proteins in the ER, in contrast to GRP78 and other ER stress-responsive proteins. Herp may, therefore, play an unknown role in the cellular survival response to stress.	Natl Cardiovasc Ctr, Res Inst, Suita, Osaka 5658565, Japan	National Cerebral & Cardiovascular Center - Japan	Kokame, K (corresponding author), Natl Cardiovasc Ctr, Res Inst, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan.			Kokame, Koichi/0000-0002-9654-6299				AGARWALA KL, 1994, BIOCHEMISTRY-US, V33, P5167, DOI 10.1021/bi00183a021; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; Brower CS, 1999, J BIOL CHEM, V274, P13629, DOI 10.1074/jbc.274.19.13629; BUCHMAN TG, 1990, SURGERY, V108, P559; Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; Cosson P, 1998, EMBO J, V17, P6863, DOI 10.1093/emboj/17.23.6863; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; DELAHUNTY MD, 1993, J BIOL CHEM, V268, P12017; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; Duell PB, 1997, CURR OPIN LIPIDOL, V8, P28, DOI 10.1097/00041433-199702000-00007; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Hodges M, 1998, CURR BIOL, V8, pR749, DOI 10.1016/S0960-9822(07)00477-0; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lentz S R, 1998, Curr Opin Hematol, V5, P343, DOI 10.1097/00062752-199809000-00007; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Mori K, 2000, P NATL ACAD SCI USA, V97, P4660, DOI 10.1073/pnas.050010197; Mori K, 1998, J BIOL CHEM, V273, P9912, DOI 10.1074/jbc.273.16.9912; MORI K, 1993, CELL, V74, P743; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; Outinen PA, 1998, BIOCHEM J, V332, P213, DOI 10.1042/bj3320213; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Sato M, 1996, J CELL BIOL, V134, P279, DOI 10.1083/jcb.134.2.279; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Tanaka K, 1998, MOL CELLS, V8, P503; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; van Laar T, 2000, FEBS LETT, V469, P123, DOI 10.1016/S0014-5793(00)01253-9; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	50	249	256	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32846	32853		10.1074/jbc.M002063200	http://dx.doi.org/10.1074/jbc.M002063200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10922362	hybrid			2022-12-25	WOS:000090003800065
J	Soutourina, J; Plateau, P; Blanquet, S				Soutourina, J; Plateau, P; Blanquet, S			Metabolism of D-aminoacyl-tRNAs in Escherichia coli and Saccharomyces cerevisiae cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; RIBONUCLEIC-ACID SYNTHETASE; D-ASPARTATE; TRYPTOPHAN SYNTHASE; SERINE RACEMASE; GENE; PURIFICATION; PERMEASE; REPRESSION; SEQUENCE	In Escherichia coli, tyrosyl-tRNA synthetase is known to esterify tRNA(Tyr) with tyrosine. Resulting D-Tyr-tRNA(Tyr) can be hydrolyzed by a D-Tyr-tRNA(Tyr) deacylase, By monitoring E. coli growth in liquid medium, we systematically searched for other D-amino acids, the toxicity of which might be exacerbated by the inactivation of the gene encoding D-Tyr-tRNA(Tyr) deacylase, In addition to the already documented case of D-tyrosine, positive responses were obtained with D-tryptophan, D-aspartate, D-serine, and D-glutamine. In agreement with this observation, production of D-Asp-tRNA(Asp) and D-Trp-tRNA(Typ) by aspartyl-tRNA synthetase and tryptophanyl-tRNA synthetase, respectively, was established in vitro. Furthermore, the two D-aminoacylated tRNAs behaved as substrates of purified E. coli D-Tyr-tRNA(Tyr) deacylase. These results indicate that an unexpected high number of D-amino acids can impair the bacterium growth through the accumulation of D-aminoacyl-tRNA(Tyr) molecules and that D-Tyr-tRNA(Tyr) deacylase has a specificity broad enough to recycle any of these molecules. The same strategy of screening was applied using Saccharomyces cerevisiae, the tyrosyl-tRNA synthetase of which also produces D-Tyr-tRNA(Tyr), and which, like E. coli, possesses a D-Tyr-tRNATyr deacylase activity. In this case, inhibition of growth by the various 19 D-amino acids was followed on solid medium. Two isogenic strains containing or not the deacylase were compared. Toxic effects of D-tyrosine and D-leucine were reinforced upon deprivation of the deacylase, This observation suggests that, in yeast, at least two D-amino acids succeed in being transferred onto tRNAs and that, like in E. coli, the resulting two D-aminoacyl-tRNAs are substrates of a same D-aminoacyl-tRNA deacylase.	Ecole Polytech, CNRS, UMR 7654, Biochim Lab, F-91128 Palaiseau, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut Polytechnique de Paris	Plateau, P (corresponding author), Ecole Polytech, CNRS, UMR 7654, Biochim Lab, F-91128 Palaiseau, France.	plateau@coli.polytechnique.fr	Soutourina, Julie/F-8305-2014	Soutourina, Julie/0000-0001-5218-2350				ADAMS AEM, 1989, GENETICS, V121, P675; AHMED SA, 1986, BIOCHEMISTRY-US, V25, P4233, DOI 10.1021/bi00363a010; BATURINA ID, 1972, FEBS LETT, V22, P235, DOI 10.1016/0014-5793(72)80053-X; BERGMANN F, 1961, J BIOL CHEM, V236, P1735; BLANQUET S, 1974, EUR J BIOCHEM, V44, P343, DOI 10.1111/j.1432-1033.1974.tb03491.x; BLOOM FR, 1975, J BACTERIOL, V121, P1078, DOI 10.1128/JB.121.3.1078-1084.1975; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1690, DOI 10.1021/bi00869a034; CALENDAR R, 1967, J MOL BIOL, V26, P39, DOI 10.1016/0022-2836(67)90259-8; CAPARROS M, 1991, RES MICROBIOL, V142, P345, DOI 10.1016/0923-2508(91)90050-K; Capparos M, 1992, J BACTERIOL, V174, P5549; CHAMPNEY WS, 1970, J BACTERIOL, V104, P107, DOI 10.1128/JB.104.1.107-116.1970; COSLOY SD, 1973, J BACTERIOL, V114, P685, DOI 10.1128/JB.114.2.685-694.1973; ERIANI G, 1990, NUCLEIC ACIDS RES, V18, P7109, DOI 10.1093/nar/18.23.7109; FISHER GH, 1992, NEUROSCI LETT, V143, P215, DOI 10.1016/0304-3940(92)90268-C; FLOSSDORF J, 1973, EUR J BIOCHEM, V36, P534, DOI 10.1111/j.1432-1033.1973.tb02940.x; FLOSSDORF J, 1976, EUR J BIOCHEM, V66, P147, DOI 10.1111/j.1432-1033.1976.tb10435.x; FRANKLIN FCH, 1976, MOL GEN GENET, V149, P229, DOI 10.1007/BF00332894; Friedman M, 1999, J AGR FOOD CHEM, V47, P3457, DOI 10.1021/jf990080u; FRIEDMAN M, 1991, ADV EXP MED BIOL, V289, P447; GARTLAND WJ, 1966, P NATL ACAD SCI USA, V55, P948, DOI 10.1073/pnas.55.4.948; GRENSON M, 1983, EUR J BIOCHEM, V133, P141, DOI 10.1111/j.1432-1033.1983.tb07439.x; GRENSON M, 1983, EUR J BIOCHEM, V133, P135, DOI 10.1111/j.1432-1033.1983.tb07438.x; HALL CV, 1981, J BACTERIOL, V148, P941, DOI 10.1128/JB.148.3.941-949.1981; HARRIS CL, 1981, J BACTERIOL, V145, P1031, DOI 10.1128/JB.145.2.1031-1035.1981; HELENE C, 1971, J MOL BIOL, V58, P349, DOI 10.1016/0022-2836(71)90251-8; HIREL PH, 1988, BIOCHIMIE, V70, P773, DOI 10.1016/0300-9084(88)90107-1; Jack RW, 1998, CHIMIA, V52, P48; JAUNIAUX JC, 1990, EUR J BIOCHEM, V190, P39, DOI 10.1111/j.1432-1033.1990.tb15542.x; JENSEN RA, 1972, ARCH MIKROBIOL, V87, P173, DOI 10.1007/BF00424998; KANZAKI H, 1987, EUR J BIOCHEM, V163, P105, DOI 10.1111/j.1432-1033.1987.tb10742.x; KUHN J, 1974, BIOCHIM BIOPHYS ACTA, V332, P298, DOI 10.1016/0005-2736(74)90382-4; KUMAGAI H, 1970, BIOCHEM BIOPH RES CO, V39, P796, DOI 10.1016/0006-291X(70)90393-1; LEPORE GC, 1975, EUR J BIOCHEM, V56, P369, DOI 10.1111/j.1432-1033.1975.tb02242.x; LINDAHL T, 1966, P NATL ACAD SCI USA, V55, P941, DOI 10.1073/pnas.55.4.941; MAN EH, 1987, J NEUROCHEM, V48, P510, DOI 10.1111/j.1471-4159.1987.tb04122.x; MARTIN F, 1993, J MOL BIOL, V234, P965, DOI 10.1006/jmbi.1993.1651; MCFALL E, 1987, ESCHERICHIA COLI SAL, P1520; MEINNEL T, 1988, NUCLEIC ACIDS RES, V16, P8095, DOI 10.1093/nar/16.16.8095; METZLER DE, 1954, J AM CHEM SOC, V76, P648, DOI 10.1021/ja01632a004; MILES EW, 1986, BIOCHEMISTRY-US, V25, P4240, DOI 10.1021/bi00363a011; MILLER HI, 1980, CELL, V20, P711, DOI 10.1016/0092-8674(80)90317-7; Miller J.H., 1992, SHORT COURSE BACTERI, P150; OHNISHI E, 1962, J BIOL CHEM, V237, P138; OLSIEWSKI PJ, 1980, J BIOL CHEM, V255, P4487; OWENS SL, 1968, J MOL BIOL, V38, P145, DOI 10.1016/0022-2836(68)90137-X; OWENS SL, 1970, J BIOL CHEM, V245, P5515; Park J. T., 1987, ESCHERICHIA COLI SAL, P663; PEYPOUX F, 1985, EUR J BIOCHEM, V153, P335, DOI 10.1111/j.1432-1033.1985.tb09307.x; RYTKA J, 1975, J BACTERIOL, V121, P562, DOI 10.1128/JB.121.2.562-570.1975; Schell MJ, 1997, P NATL ACAD SCI USA, V94, P2013, DOI 10.1073/pnas.94.5.2013; SCHMITT JH, 1968, ANAL BIOCHEM, V23, P433, DOI 10.1016/0003-2697(68)90235-2; SHOJI J, 1976, J ANTIBIOT, V29, P1275, DOI 10.7164/antibiotics.29.1275; SIVONEN K, 1992, CHEM RES TOXICOL, V5, P464, DOI 10.1021/tx00028a003; Soutourina J, 1999, J BIOL CHEM, V274, P19109, DOI 10.1074/jbc.274.27.19109; Soutourina J, 2000, J BIOL CHEM, V275, P11626, DOI 10.1074/jbc.275.16.11626; TSURUOKA T, 1984, J BACTERIOL, V160, P889, DOI 10.1128/JB.160.3.889-894.1984; WILD J, 1981, MOL GEN GENET, V181, P373, DOI 10.1007/BF00425614; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P13409, DOI 10.1073/pnas.96.23.13409; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P721, DOI 10.1073/pnas.96.2.721; WOODWARD JR, 1980, BIOCHEM J, V192, P659, DOI 10.1042/bj1920659; ZENK MH, 1965, BIOCHEM Z, V342, P54	61	106	116	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32535	32542		10.1074/jbc.M005166200	http://dx.doi.org/10.1074/jbc.M005166200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10918062	hybrid			2022-12-25	WOS:000090003800023
J	Bing, ZY; Huang, JYH; Liao, WSL				Bing, ZY; Huang, JYH; Liao, WSL			NF kappa B interacts with serum amyloid A3 enhancer factor to synergistically activate mouse serum amyloid A3 gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACUTE-PHASE RESPONSE; CELL-ADHESION MOLECULE-1; DNA-BINDING ACTIVITY; IFN-BETA GENE; GLUCOCORTICOID RECEPTOR; HEPATOMA-CELLS; FAMILY MEMBERS; NUCLEAR FACTOR; FACTOR LSF	We had previously identified a distal regulatory element (DRE) in the mouse serum amyloid A3 (SAA3) promoter that functions as a cytokine-inducible transcription enhancer. Within this DRE, three functional elements interact with CCAAT/enhancer-binding protein (C/EBP) and SAA3 enhancer factor (SEF) transcription factors. In this study, we show that cotransfection of the SEF expression plasmid with an SAA3/luciferase reporter resulted in 3-5-fold activation of the SAA3 promoter. When SEF-transfected cells were further stimulated with conditioned medium or interleukin-l, SAA3 promoter activity was dramatically increased, suggesting that SEF may cooperate functionally with other interleukin-l-inducible transcription factors to synergistically up-regulate SAA3 gene transcription. Indeed, cotransfection of SEF and NF kappa Bp65 expression DNAs resulted in synergistic activation of the SAA3 promoter. Intriguingly, no consensus NF kappa B-binding site was found in the SAA3 promoter region; rather a putative NF kappa B-binding sequence with 3-base pair mismatches was identified in the DRE, When this sequence was used in an electrophoretic mobility shift assay, it interacted with NF kappa Bp50, albeit with binding affinities that were several hundredfold lower than that with the consensus NF kappa B probe. Functional cooperation between SEF and NF kappa B was further strengthened by the finding that SEF and NF kappa B formed stable cytokine-inducible protein-protein complexes. Finally, despite its weak binding, mutation of this NF kappa B-binding site nevertheless dramatically reduced both NF kappa Bp65- and cytokine-mediated induction of SAA3 promoter. Therefore, the molecular basis for the functional synergy between SEF and NF kappa B may, in part, be the ability of SEF to recruit NF kappa B through physical interactions that lead to enhancement or stabilization of NF kappa B binding to the SAA3 promoter element.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Program Genes & Dev, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Liao, WSL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Program Genes & Dev, Box 117,1515 Holcombe Blvd, Houston, TX 77030 USA.				NIAMS NIH HHS [AR38858] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR038858, R01AR038858] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; AOUDJIT F, 1994, INT J CANCER, V58, P543, DOI 10.1002/ijc.2910580416; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Bing ZY, 1999, J BIOL CHEM, V274, P24649, DOI 10.1074/jbc.274.35.24649; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DARLINGTON GJ, 1986, J CELL BIOL, V103, P787, DOI 10.1083/jcb.103.3.787; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Franzoso G, 1996, EMBO J, V15, P3403, DOI 10.1002/j.1460-2075.1996.tb00706.x; GRILLI M, 1993, INT REV CYTOL, V143, P1; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; HOFFMAN JS, 1982, J BIOL CHEM, V257, P510; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; HUANG JH, 1990, MOL CELL BIOL, V10, P3619, DOI 10.1128/MCB.10.7.3619; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; Huang JYH, 1999, J INTERF CYTOK RES, V19, P1403, DOI 10.1089/107999099312867; JOSHIBARVE SS, 1993, J BIOL CHEM, V268, P18018; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Li L, 1999, BIOCHEM BIOPH RES CO, V264, P395, DOI 10.1006/bbrc.1999.1527; LI X, 1992, NUCLEIC ACIDS RES, V20, P4765, DOI 10.1093/nar/20.18.4765; LI XX, 1990, MOL CELL BIOL, V10, P6624, DOI 10.1128/MCB.10.12.6624; LI XX, 1991, J BIOL CHEM, V266, P15192; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; LOWELL CA, 1986, J BIOL CHEM, V261, P8442; LOWELL CA, 1986, J BIOL CHEM, V261, P8453; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; MAIZEL AL, 1981, J IMMUNOL, V127, P1058; MALIM MH, 1989, J VIROL, V63, P3213, DOI 10.1128/JVI.63.8.3213-3219.1989; MESSER G, 1990, Cytokine, V2, P389, DOI 10.1016/1043-4666(90)90046-V; MORROW JF, 1981, P NATL ACAD SCI-BIOL, V78, P4718, DOI 10.1073/pnas.78.8.4718; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Ren YS, 1999, J BIOL CHEM, V274, P37154, DOI 10.1074/jbc.274.52.37154; Romerio F, 1997, J VIROL, V71, P9375, DOI 10.1128/JVI.71.12.9375-9382.1997; Ruocco MR, 1996, J BIOL CHEM, V271, P22479, DOI 10.1074/jbc.271.37.22479; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; STEARMAN RS, 1986, NUCLEIC ACIDS RES, V14, P797, DOI 10.1093/nar/14.2.797; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; SUNDSETH R, 1992, J BIOL CHEM, V267, P7845; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VANDIJK MA, 1995, MECH DEVELOP, V52, P99, DOI 10.1016/0925-4773(95)00394-G; Volker JL, 1997, GENE DEV, V11, P1435, DOI 10.1101/gad.11.11.1435; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649; Yu Y, 1997, NATURE, V385, P552, DOI 10.1038/385552a0; Zambrano N, 1998, J BIOL CHEM, V273, P20128, DOI 10.1074/jbc.273.32.20128	61	26	29	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31616	31623		10.1074/jbc.M005378200	http://dx.doi.org/10.1074/jbc.M005378200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10899169	hybrid			2022-12-25	WOS:000089858900011
J	Chikazu, D; Hakeda, Y; Ogata, N; Nemoto, K; Itabashi, A; Takato, T; Kumegawa, M; Nakamura, K; Kawaguchi, H				Chikazu, D; Hakeda, Y; Ogata, N; Nemoto, K; Itabashi, A; Takato, T; Kumegawa, M; Nakamura, K; Kawaguchi, H			Fibroblast growth factor (FGF)-2 directly stimulates mature osteoclast function through activation of FGF receptor 1 and p42/p44 MAP kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLASTIC MC3T3-E1 CELLS; MESSENGER-RNA LEVELS; BONE-RESORPTION; PROTEIN-KINASE; CATHEPSIN-K; MATRIX METALLOPROTEINASE-9; MOLECULAR-CLONING; TYROSINE KINASE; IN-VITRO; C-SRC	We previously reported that fibroblast growth factor-2 (FGF-S) acts not only on osteoblasts 60 stimulate osteoclastic bone resorption indirectly but also on mature osteoclasts directly. In this study, we investigated the mechanism of this direct action of FGF-S on mature osteoclasts using mouse and rabbit osteoclast culture systems. FGF-S stimulated pit formation resorbed by isolated rabbit osteoclasts moderately from low concentrations (greater than or equal to 10(-12) M)) whereas at high concentrations (greater than or equal to 10(-9) d it showed stimulation on pit formation resorbed by unfractionated bone cells very potently. FGF-S (greater than or equal to 10(-12) M) also increased cathepsin K and MMP-9 mRNA levels in mouse and rabbit osteoclasts. Among FGF receptors (FGFR1 to 4) only FGFR1 was detected on isolated mouse osteoclasts, whereas all FGFRs were identified on mouse osteoblasts. FGF-P (greater than or equal to 10(-12) M) upregulated the phosphorylation of cellular proteins, including p42/p44 mitogen-activated protein (MAP) kinase, and increased the kinase activity of immunoprecipitated FGFR1 in mouse osteoclasts. The stimulation of FGF-2 on mouse and rabbit osteoclast functions was abrogated by PD-98059, a specific inhibitor of p42/p44 MAP kinase. These results strongly suggest that FGF-2 acts directly on mature osteoclasts through activation of FGFR1 and p42/p44 MAP kinase, causing the stimulation of bone resorption at physiological or pathological concentrations.	Univ Tokyo, Grad Sch Med, Dept Orthopaed Surg, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Oral & Maxillofacial Surg, Tokyo 1138655, Japan; Saitama Med Sch, Clin Lab, Iruma, Saitama 3500495, Japan; Meikai Univ, Sch Dent, Dept Oral Anat, Sakado, Saitama 3500248, Japan	University of Tokyo; University of Tokyo; Saitama Medical University; Meikai University	Kawaguchi, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Orthopaed Surg, Hongo 7-3-1, Tokyo 1138655, Japan.	kawaguchi-ort@h.u-tokyo.ac.jp						AKATSU T, 1992, J BONE MINER RES, V7, P1297; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ASPENBERG P, 1989, ACTA ORTHOP SCAND, V60, P473, DOI 10.3109/17453678909149323; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; Baron R, 1996, REV RHUM, V63, P633; CANALIS E, 1988, J CLIN INVEST, V81, P1572, DOI 10.1172/JCI113490; Chikazu D, 1999, J BONE MINER RES, V14, pS360; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GLOBUS RK, 1989, ENDOCRINOLOGY, V124, P1539, DOI 10.1210/endo-124-3-1539; Hurley MM, 1998, BONE, V22, P309, DOI 10.1016/S8756-3282(97)00292-5; HURLEY MM, 1993, J BIOL CHEM, V268, P5588; HURLEY MM, 1994, J BIOL CHEM, V269, P9392; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790; Inui T, 1997, J BIOL CHEM, V272, P8109, DOI 10.1074/jbc.272.13.8109; JIMI E, 1995, ENDOCRINOLOGY, V136, P808, DOI 10.1210/en.136.2.808; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kameda T, 1996, BIOCHEM BIOPH RES CO, V220, P515, DOI 10.1006/bbrc.1996.0436; Kato T, 1998, J ORTHOP RES, V16, P654, DOI 10.1002/jor.1100160605; KAWAGUCHI H, 1994, ENDOCRINOLOGY, V135, P774, DOI 10.1210/en.135.2.774; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P923, DOI 10.1172/JCI118140; Kawaguchi H, 2000, J BONE MINER RES, V15, P466, DOI 10.1359/jbmr.2000.15.3.466; Klint P, 1999, ONCOGENE, V18, P3354, DOI 10.1038/sj.onc.1202680; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kozawa O, 1999, J CELL BIOCHEM, V74, P479, DOI 10.1002/(SICI)1097-4644(19990901)74:3<479::AID-JCB15>3.3.CO;2-0; LANDGREN E, 1995, ONCOGENE, V10, P2027; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Manabe N, 1999, RHEUMATOLOGY, V38, P714, DOI 10.1093/rheumatology/38.8.714; Nakagawa N, 1999, BIOCHEM BIOPH RES CO, V265, P158, DOI 10.1006/bbrc.1999.1601; Nakamura K, 1997, J ORTHOPAED RES, V15, P307, DOI 10.1002/jor.1100150222; NAKAMURA T, 1995, ENDOCRINOLOGY, V136, P1276, DOI 10.1210/en.136.3.1276; Nakamura T, 1998, J BONE MINER RES, V13, P942, DOI 10.1359/jbmr.1998.13.6.942; Nakamura YS, 1998, STEM CELLS, V16, P229, DOI 10.1002/stem.160229; OKADA Y, 1995, LAB INVEST, V72, P311; Okazaki H, 1999, CALCIFIED TISSUE INT, V64, P542, DOI 10.1007/s002239900646; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RODAN SB, 1989, J BIOL CHEM, V264, P19934; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; Sato T, 1998, J BONE MINER RES, V13, P59, DOI 10.1359/jbmr.1998.13.1.59; Sato T, 1997, J CELL SCI, V110, P589; Schwartz M A, 1992, Prog Med Chem, V29, P271, DOI 10.1016/S0079-6468(08)70011-0; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; SIMMONS HA, 1991, J BONE MINER RES, V6, P1301; Suzuki A, 1996, J CELL BIOCHEM, V63, P491, DOI 10.1002/(SICI)1097-4644(19961215)63:4<491::AID-JCB10>3.0.CO;2-H; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; TEZUKA K, 1994, J BIOL CHEM, V269, P15006; TEZUKA K, 1992, BONE MINER, V17, P347; Votta BJ, 1997, J BONE MINER RES, V12, P1396, DOI 10.1359/jbmr.1997.12.9.1396; Webster MK, 1996, MOL CELL BIOL, V16, P4081; ZHAN X, 1994, J BIOL CHEM, V269, P20221	55	87	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31444	31450		10.1074/jbc.M910132199	http://dx.doi.org/10.1074/jbc.M910132199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896947	hybrid			2022-12-25	WOS:000089762700098
J	Kim, JE; Kim, SJ; Lee, BH; Park, RW; Kim, KS; Kim, IS				Kim, JE; Kim, SJ; Lee, BH; Park, RW; Kim, KS; Kim, IS			Identification of motifs for cell adhesion within the repeated domains of transforming growth factor-beta-induced gene, beta ig-h3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE COLLAGEN ALPHA-1(IV)531-543; ALPHA(3)BETA(1) INTEGRIN; FASCICLIN-I; PEPTIDE; PROTEIN; MOLECULE; BINDING; ALPHA-3A-BETA-1; CHONDROCYTES; RECOGNITION	beta ig-h3 is a transforming growth factor-beta-inducible cell adhesion molecule that has four characteristic homologous repeated domains. We made recombinant beta ig-h3 proteins, which were highly active in mediating human corneal epithelial (HCE) cell adhesion and spreading. The 2nd and the 4th repeated domains were sufficient to mediate HCE cell adhesion, A sequence analysis showed that aspartic acid (Asp) and isoleucine (Ile) of the 2nd and the 4th domains are highly conserved in many fasciclin 1 homologous (fas-l) domains, Substitution mutational study identified these two amino acids are essential for cell adhesion. Synthetic peptides containing Asp and Re, NKDIL and EPDIM derived from the 2nd and the 4th domains, respectively, almost completely blocked cell adhesion mediated by not only wild type beta ig-h3 but also each of the 2nd and the 4th domains. These peptides alone were fully active in mediating cell adhesion. In addition, we demonstrated the functional receptor for beta ig-h3 is alpha(3)beta(1) integrin. These results, therefore, establish the essential motifs within the 2nd and the 4th domains of beta ig-h3, which interact with alpha(3)beta(1) integrin to mediate HCE cell adhesion to beta ig-h3 and suggest that other proteins containing Asp-ne in their fas-l domains could possibly function as cell adhesion molecules.	Kyungpook Natl Univ, Sch Med, Dept Biochem, Jung Gu, Taegu 700422, South Korea; Kyungpook Natl Univ, Sch Med, Biomol Engn Ctr, Taegu 700422, South Korea; Dongguk Univ, Sch Med, Dept Biochem, Kyungju 780714, South Korea; Keimyung Univ, Sch Med, Dept Ophthalmol, Taegu 700310, South Korea	Kyungpook National University; Kyungpook National University; Dongguk University; Keimyung University	Kim, IS (corresponding author), Kyungpook Natl Univ, Sch Med, Dept Biochem, Jung Gu, 101 Dongindong, Taegu 700422, South Korea.	iskim@kyungpook.ac.kr	김, 인산/I-8988-2014					DEDHAR S, 1992, J BIOL CHEM, V267, P18908; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; Dieudonne SC, 2000, J CELL BIOCHEM, V76, P231, DOI 10.1002/(SICI)1097-4644(20000201)76:2<231::AID-JCB7>3.0.CO;2-X; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; EBEL JA, 1997, MOL BIOL INTELLIGENC, P1; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239; HUBER O, 1994, EMBO J, V13, P4212, DOI 10.1002/j.1460-2075.1994.tb06741.x; Kawamoto T, 1998, BBA-GENE STRUCT EXPR, V1395, P288, DOI 10.1016/S0167-4781(97)00172-3; Kim IS, 1996, MOL CELL BIOL, V16, P4003; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Krutzsch HC, 1999, J BIOL CHEM, V274, P24080, DOI 10.1074/jbc.274.34.24080; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LEBARON RG, 1995, J INVEST DERMATOL, V104, P844, DOI 10.1111/1523-1747.ep12607024; Lee EH, 2000, INVEST OPHTH VIS SCI, V41, P1840; MILES AJ, 1994, J BIOL CHEM, V269, P30939; MILES AJ, 1995, J BIOL CHEM, V270, P29047, DOI 10.1074/jbc.270.49.29047; Munier FL, 1997, NAT GENET, V15, P247, DOI 10.1038/ng0397-247; OBrien ER, 1996, ARTERIOSCL THROM VAS, V16, P576, DOI 10.1161/01.ATV.16.4.576; Ohno S, 1999, BBA-MOL CELL RES, V1451, P196, DOI 10.1016/S0167-4889(99)00093-2; Rawe IM, 1997, INVEST OPHTH VIS SCI, V38, P893; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; WANG WC, 1993, J BIOL CHEM, V268, P1448; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651	26	235	249	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30907	30915		10.1074/jbc.M002752200	http://dx.doi.org/10.1074/jbc.M002752200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906123	hybrid			2022-12-25	WOS:000089762700027
J	Nelson, SW; Choe, JY; Honzatko, RB; Fromm, HJ				Nelson, SW; Choe, JY; Honzatko, RB; Fromm, HJ			Mutations in the hinge of a dynamic loop broadly influence functional properties of fructose-1,6-bisphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG-KIDNEY FRUCTOSE-1,6-BISPHOSPHATASE; FRUCTOSE 2,6-BISPHOSPHATE; CRYSTAL-STRUCTURE; LIVER FRUCTOSE-1,6-BISPHOSPHATASE; AMP INHIBITION; MECHANISM; BISPHOSPHATASE; 6-PHOSPHATE; RESOLUTION; TRANSITION	Loop 52-72 of porcine fructose-1,6-bisphosphatase may play a central role in the mechanism of catalysis and allosteric inhibition by AMP. The loop pivots between different conformational states about a hinge located at residues 50 and 51. The insertion of proline separately at positions 50 and 51 reduces k(cat) by up to 3-fold, with no effect on the K-m for fructose 1,6-bisphosphate. The K-a for Mg2+ in the Lys(50) --> Pro mutant increases similar to 15-fold, whereas that for the Ala(51) --> Pro mutant is unchanged. Although these mutants retain wildtype binding affinity for AMP and the fluorescent AMP analog 2'(3')-O-(trinitrophenyl) adenosine 5'-monophosphate, the K-i for AMP increases 8000- and 280-fold in the position 50 and 51 mutants, respectively. In fact, the mutation Lys(50) --> Pro changes the mechanism of AMP inhibition with respect to Mg2+ from competitive to noncompetitive and abolishes K+ activation. The K-i for fructose 2,6-bisphosphate increases similar to 20- and 30-fold in the Lys(50) --> Pro and Ala(51) --> Pro mutants, respectively. Fluorescence from a tryptophan introduced by the mutation of Tyr(57) suggests an altered conformational state for Loop 52-72 due to the proline at position 50. Evidently, the Pro(50) mutant binds AMP with high affinity at the allosteric site, but the mechanism of allosteric regulation of catalysis has been disabled.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Fromm, HJ (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1992, XPLOR VERSION 3 1; Carcamo JG, 2000, EUR J BIOCHEM, V267, P2242, DOI 10.1046/j.1432-1327.2000.01227.x; Choe JY, 2000, BIOCHEMISTRY-US, V39, P8565, DOI 10.1021/bi000574g; Choe JY, 1998, BIOCHEMISTRY-US, V37, P11441, DOI 10.1021/bi981112u; HORECKER BL, 1975, ADV ENZYMOL RAMB, V42, P193; Iversen LF, 1997, PROTEIN SCI, V6, P971, DOI 10.1002/pro.5560060503; KE HM, 1991, P NATL ACAD SCI USA, V88, P2989, DOI 10.1073/pnas.88.8.2989; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurbanov FT, 1998, J BIOL CHEM, V273, P17511, DOI 10.1074/jbc.273.28.17511; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J. R., 1999, PRINCIPLES FLUORESCE, P52; LEATHERBARROW RJ, 1987, ENZFITTER, P13; LUI F, 1990, J BIOL CHEM, V265, P7401; LUI F, 1988, J BIOL CHEM, V263, P9122; MARCUS F, 1982, P NATL ACAD SCI-BIOL, V79, P7161, DOI 10.1073/pnas.79.23.7161; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NELSON SW, 2000, IN PRESS BIOCHEMISTR; NIMMO HG, 1975, EUR J BIOCHEM, V58, P567, DOI 10.1111/j.1432-1033.1975.tb02407.x; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PILKIS SJ, 1981, J BIOL CHEM, V256, P1489; Schaftingen EV, 1981, P NATL ACAD SCI USA, V78, P2861; SCHEFFLER JE, 1986, BIOCHEMISTRY-US, V25, P6659, DOI 10.1021/bi00369a050; Shyur LF, 1996, J BIOL CHEM, V271, P33301, DOI 10.1074/jbc.271.52.33301; Shyur LF, 1997, J BIOL CHEM, V272, P26295, DOI 10.1074/jbc.272.42.26295; SHYUR LF, 1995, J BIOL CHEM, V270, P123; STONE SR, 1980, BIOCHEMISTRY-US, V19, P620, DOI 10.1021/bi00545a003; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; Van Schaftingen E., 1987, ADV ENZYMOL RELAT AR, V59, P45; XUE YF, 1994, P NATL ACAD SCI USA, V91, P12482, DOI 10.1073/pnas.91.26.12482; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	33	24	24	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29986	29992		10.1074/jbc.M000473200	http://dx.doi.org/10.1074/jbc.M000473200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10896931	hybrid, Green Published			2022-12-25	WOS:000089577900011
J	Fujino, H; Pierce, KL; Srinivasan, D; Protzman, CE; Krauss, AH; Woodward, DF; Regan, JW				Fujino, H; Pierce, KL; Srinivasan, D; Protzman, CE; Krauss, AH; Woodward, DF; Regan, JW			Delayed reversal of shape change in cells expressing FPB prostanoid receptors - Possible role of receptor resensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; KINASE-C; ISOFORMS; CLONING; DESENSITIZATION; PHOSPHORYLATION; INVOLVEMENT; TAIL	Prostaglandin F-2 alpha (PGF(2 alpha)) receptors are G-protein-coupled receptors consisting of two alternative mRNA splice variants, named FPA and FPB. As compared with the FPA isoform, the FPB isoform lacks the last 46 amino acids of the carboxyl terminus and, therefore, represents a truncated version of the FPA. We recently found (Pierce, K. L,, Fujino, H., Srinivasan, D., and Began, J. W. (1999) J, Biol; Chem. 274, 35944-35949) that stimulation of both isoforms with PGF(2 alpha) leads to activation of a Rho signaling pathway, resulting in tyrosine phosphorylation of p125 focal adhesion kinase, formation of actin stress fibers, and cell rounding, Although the activation of Rho and subsequent cell rounding occur at a similar rate for both isoforms, we now report that following the removal of PGF(2 alpha) the reversal of cell rounding is much slower for cells expressing the FPB isoform as compared with the FPA isoform, Thus, in HEK-293 cells that stably express the FPA isoform, the reversal of cell rounding appears to be complete after 1 h, whereas for FPB-expressing cells there is essentially no reversal even after 2 h, Similarly, the disappearance of stress fibers and dephosphorylation of p125 focal adhesion kinase following removal of agonist are much slower in FPB-expressing cells than in FPA-expressing cells. The mechanism of this differential reversal appears to involve a difference in receptor resensitization following the removal of agonist, Based upon whole cell radioligand binding, agonist-induced stimulation of inositol phosphate formation, and mobilization. of intracellular Ca2+, the FPB isoform resensitizes more slowly than the FPA isoform, These findings suggest that the carboxyl terminus of the FPA is critical for resensitization and that the slower resensitization of the FPA isoform leads to prolonged signaling. This differential signaling distinguishes the FPA and FPB receptor isoforms and could be important toward understanding the physiological actions of PGF(2 alpha).	Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Allergan Inc, Dept Biol Sci, Irvine, CA 92713 USA	University of Arizona; Duke University; Howard Hughes Medical Institute; AbbVie; Allergan	Regan, JW (corresponding author), Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.				NEI NIH HHS [EY11291] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011291] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bastepe M, 1999, BRIT J PHARMACOL, V126, P365, DOI 10.1038/sj.bjp.0702291; Chan BS, 1998, J BIOL CHEM, V273, P6689, DOI 10.1074/jbc.273.12.6689; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Fujino H, 2000, MOL PHARMACOL, V57, P353; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Habib A, 1997, J BIOL CHEM, V272, P7191, DOI 10.1074/jbc.272.11.7191; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Pierce KL, 1997, J BIOL CHEM, V272, P883, DOI 10.1074/jbc.272.2.883; Pierce KL, 1999, J BIOL CHEM, V274, P35944, DOI 10.1074/jbc.274.50.35944; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; REGAN JW, 1994, BRIT J PHARMACOL, V112, P377, DOI 10.1111/j.1476-5381.1994.tb13082.x; Smyth EM, 1998, J BIOL CHEM, V273, P23258, DOI 10.1074/jbc.273.36.23258	16	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29907	29914		10.1074/jbc.M003467200	http://dx.doi.org/10.1074/jbc.M003467200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893233	Green Submitted, hybrid			2022-12-25	WOS:000089439800099
J	Giovannucci, DR; Groblewski, GE; Sneyd, J; Yule, DI				Giovannucci, DR; Groblewski, GE; Sneyd, J; Yule, DI			Targeted phosphorylation of inositol 1,4,5-trisphosphate receptors selectively inhibits localized Ca2+ release and shapes oscillatory Ca2+ signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; EXOCRINE PANCREAS; GENE-EXPRESSION; FLUID SECRETION; DOWN-REGULATION; GLAND CELLS; CALCIUM; CAMP	Current study provides biochemical and functional evidence that the targeting of protein kinase A (PBA) to sites of localized Ca2+ release confers rapid, specific phosphoregulation of Ca2+ signaling in pancreatic acinar cells, Regulatory control of Ca2+ release by PKA-dependent phosphorylation of inositol 1,4,5-trisphosphate (InsP(3)) receptors was investigated by monitoring Ca2+ dynamics in pancreatic acinar cells evoked by the flash photolysis of caged InsP(3) prior to and following PRA activation, Ca2+ dynamics were imaged with high temporal resolution by digital imaging and electrophysiological methods. The whole cell patch clamp technique was used to introduce caged compounds and to record the activity of a Ca2+-activated Cl- current, Photolysis of low concentrations of caged InsP(3) evoked Cl- currents that were inhibited by treatment with dibutryl-cAMP or forskolin. In contrast, PKA activators had no significant inhibitory effect on the activation of Cl- current evoked by uncaging Ca2+ or by the photolytic release of higher concentrations of InsP(3). Treatment with Rp-adenosine-3',5'-cyclic monophoshorothioate, a selective inhibitor of PKA, or with Ht31, a peptide known to disrupt the targeting of PKA, largely abolished forskolin-induced inhibition of Ca2+ release. Further evidence for the targeting of PKA to the sites of Ca2+ mobilization was revealed using immunocytochemical methods demonstrating that the R-II beta subunit of PKA. was localized to the apical regions of acinar cells and co-immunoprecipitated with the type III but not the type I or type II InsP(3) receptors, Finally, we demonstrate that the pattern of signaling evoked by acetylcholine can be converted to one that is more "CCK-like" by raising cAMP levels. Our data provide a simple mechanism by which distinct oscillatory Ca2+ patterns can he shaped.	Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA; Massey Univ, Inst Informat & Mat Sci, Auckland, New Zealand	University of Rochester; University of Wisconsin System; University of Wisconsin Madison; Massey University	Giovannucci, DR (corresponding author), Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA.	david_giovannucci@urmc.rochester.edu	Sneyd, James/C-8995-2009; Giovannucci, David R/A-5657-2018	Sneyd, James/0000-0001-7305-2862; 	NIDDK NIH HHS [DK 54568] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK054568, R01DK054568] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER PF, 1981, PHILOS T R SOC B, V296, P83, DOI 10.1098/rstb.1981.0174; Begenisich T, 1998, J MEMBRANE BIOL, V163, P77, DOI 10.1007/s002329900372; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bugrim AE, 1999, CELL CALCIUM, V25, P219, DOI 10.1054/ceca.1999.0027; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; Camello PJ, 1996, PFLUG ARCH EUR J PHY, V432, P775, DOI 10.1007/s004240050198; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Cancela JM, 1998, PFLUG ARCH EUR J PHY, V435, P746, DOI 10.1007/s004240050578; CARR DW, 1992, J BIOL CHEM, V267, P16816; CHEN Y, 1993, FEBS LETT, V336, P191, DOI 10.1016/0014-5793(93)80800-A; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Feliciello A, 1997, CURR BIOL, V7, P1011, DOI 10.1016/S0960-9822(06)00424-6; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Hirono C, 1998, J MEMBRANE BIOL, V164, P197, DOI 10.1007/s002329900405; Ito K, 1997, EMBO J, V16, P242, DOI 10.1093/emboj/16.2.242; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KASE H, 1991, PFLUG ARCH EUR J PHY, V419, P668, DOI 10.1007/BF00370314; LeBeau AP, 1999, J GEN PHYSIOL, V113, P851, DOI 10.1085/jgp.113.6.851; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; Luo X, 1999, J BIOL CHEM, V274, P17684, DOI 10.1074/jbc.274.25.17684; LYNCH M, 1992, CELL CALCIUM, V13, P227, DOI 10.1016/0143-4160(92)90011-G; Mak DOD, 2000, J GEN PHYSIOL, V115, P241, DOI 10.1085/jgp.115.3.241; Muallem S, 1999, CELL CALCIUM, V26, P173, DOI 10.1054/ceca.1999.0077; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PENNER R, 1988, J EXP BIOL, V139, P329; PETERSEN OH, 1991, CELL CALCIUM, V12, P135, DOI 10.1016/0143-4160(91)90015-7; Petersen OH, 1999, TRENDS NEUROSCI, V22, P488, DOI 10.1016/S0166-2236(99)01456-3; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; RUBIN RP, 1994, J PHARMACOL EXP THER, V268, P600; SCHNEFEL S, 1990, BIOCHEM J, V269, P483, DOI 10.1042/bj2690483; Sjodin L, 1997, PFLUG ARCH EUR J PHY, V433, P397, DOI 10.1007/s004240050294; SNYDER SH, 1989, CELL CALCIUM, V10, P337, DOI 10.1016/0143-4160(89)90059-6; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; Tertyshnikova S, 1998, P NATL ACAD SCI USA, V95, P1613, DOI 10.1073/pnas.95.4.1613; THORN P, 1992, J GEN PHYSIOL, V100, P11, DOI 10.1085/jgp.100.1.11; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; Tibbs VC, 1998, J BIOL CHEM, V273, P25783, DOI 10.1074/jbc.273.40.25783; TORTORICI G, 1994, J BIOL CHEM, V269, P29621; WAKUI M, 1991, J MEMBRANE BIOL, V124, P179, DOI 10.1007/BF01870462; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; Wojcikiewicz RJH, 1999, GASTROENTEROLOGY, V116, P1194, DOI 10.1016/S0016-5085(99)70023-5; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Wojcikiewicz RJH, 1998, J BIOL CHEM, V273, P5670, DOI 10.1074/jbc.273.10.5670; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yule DI, 1999, AM J PHYSIOL-GASTR L, V276, pG271, DOI 10.1152/ajpgi.1999.276.1.G271; Yule DI, 1997, J BIOL CHEM, V272, P9093; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8; Zeng WZ, 1996, J BIOL CHEM, V271, P18520, DOI 10.1074/jbc.271.31.18520	59	73	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33704	33711		10.1074/jbc.M004278200	http://dx.doi.org/10.1074/jbc.M004278200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10887192	hybrid			2022-12-25	WOS:000090104600073
J	Komoto, J; Huang, YF; Gomi, T; Ogawa, H; Takata, Y; Fujioka, M; Takusagawa, F				Komoto, J; Huang, YF; Gomi, T; Ogawa, H; Takata, Y; Fujioka, M; Takusagawa, F			Effects of site-directed mutagenesis on structure and function of recombinant rat liver S-adenosylhomocysteine hydrolase - Crystal structure of D244E mutant enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME BINDING; MECHANISM; 2'-DEOXYADENOSINE; INACTIVATION; ACID; CDNA	A site-directed mutagenesis, D244E, of S-adenosylhomocysteine hydrolase (AdoHcyase) changes drastically the nature of the protein, especially the NAD(+) binding affinity. The mutant enzyme contained NADH rather than NAD(+) (Gomi, T., Takata, Y., Date, T., Fujioka, M., Aksamit, R. R., Backlund, P. S., and Cantoni, G. L. (1990) J. Biol. Chem. 265, 16102-16107). In contrast to the site-directed mutagenesis study, the crystal structures of human and rat AdoHcyase recently determined have shown that the carboxyl group of Asp-244 points in a direction opposite to the bound NAD molecule and does not participate in any hydrogen bonds with the NAD molecule. To explain the discrepancy between the mutagenesis study and the x-ray studies, we have determined the crystal structure of the recombinant rat-liver D244E mutant enzyme to 2.8-Angstrom resolution. The D244E mutation changes the enzyme structure from the open to the closed conformation by means of a similar to 17 degrees rotation of the individual catalytic domains around the molecular hinge sections, The D244E mutation shifts the catalytic reaction from a reversible to an irreversible fashion. The large affinity difference between NAD(+) and NADH is mainly due to the enzyme conformation, but not to the binding-site geometry; an NAD(+) in the open conformation is readily released from the enzyme, whereas an NADH in the closed conformation is trapped and cannot leave the enzyme. A catalytic mechanism of AdoHcyase has been proposed on the basis of the crystal structures of the wild-type and D244E enzymes.	Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA; Toyama Med & Pharmaceut Univ, Fac Med, Dept Biochem, Sugitani, Toyama 9300194, Japan	University of Kansas; University of Toyama	Takusagawa, F (corresponding author), Univ Kansas, Dept Mol Biosci, 3042 Haworth Hall, Lawrence, KS 66045 USA.				NIGMS NIH HHS [GM37233] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELES RH, 1982, BIOCHEMISTRY-US, V21, P5557, DOI 10.1021/bi00265a027; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1993, XPLOR 3 1 SYSTEM XRA; CHIANG PK, 1979, TRANSMETHYLATION, P165; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; FUJIOKA M, 1981, J BIOL CHEM, V256, P1631; GOMI T, 1989, BIOCHIM BIOPHYS ACTA, V994, P172, DOI 10.1016/0167-4838(89)90157-X; GOMI T, 1989, J BIOL CHEM, V264, P16138; GOMI T, 1984, BIOCHIM BIOPHYS ACTA, V785, P177, DOI 10.1016/0167-4838(84)90141-9; GOMI T, 1990, J BIOL CHEM, V265, P16102; HERSHFIELD MS, 1979, J BIOL CHEM, V254, P22; Hu YB, 1999, BIOCHEMISTRY-US, V38, P8323, DOI 10.1021/bi990332k; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; OGAWA H, 1987, P NATL ACAD SCI USA, V84, P719, DOI 10.1073/pnas.84.3.719; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALMER JL, 1979, J BIOL CHEM, V254, P1217; PALMER JL, 1976, J BIOL CHEM, V251, P5817; RICHARDS HH, 1978, J BIOL CHEM, V253, P4476; Turner MA, 1998, NAT STRUCT BIOL, V5, P369, DOI 10.1038/nsb0598-369	20	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32147	32156		10.1074/jbc.M003725200	http://dx.doi.org/10.1074/jbc.M003725200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913437	hybrid			2022-12-25	WOS:000089858900082
J	Norman, RA; Poh, CL; Pearl, LH; O'Hara, BP; Drew, RE				Norman, RA; Poh, CL; Pearl, LH; O'Hara, BP; Drew, RE			Steric hindrance regulation of the Pseudomonas aeruginosa amidase operon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING ATTENUATION PROTEIN; NIFL-NIFA COMPLEX; TRANSCRIPTION ANTITERMINATION; ALIPHATIC AMIDASE; NUCLEOTIDE-SEQUENCE; NITROGEN-FIXATION; CRYSTAL-STRUCTURE; GENE AMIR; RNA; EXPRESSION	Expression of the amidase operon of Pseudomonas aeruginosa is controlled by AmiC, the ligand sensor and negative regulator, and AmiR the transcription antitermination factor activator. We have titrated out AmiC repression activity in vivo by increased AmiR production in trans and shown AmiC regulation of the antitermination activity of AmiR by a steric hindrance mechanism. In the presence of the co-repressor butyramide we have isolated a stable AmiC.AmiR complex, Addition of the inducing ligand acetamide to the complex trips the molecular switch, causing complex dissociation and release of AmiR. The AmiC.AmiR butyramide complex exhibits acetamide-dependent, sequence-specific RNA binding activity and a K(d) of 1.0 nM has been calculated for the Ami.R RNA interaction. The results show that amidase operon expression is controlled by a novel type of signal transduction system in which activity of a site-specific RNA binding activator is regulated via a sequestration mechanism.	UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Natl Univ Singapore, Dept Microbiol, Singapore 119260, Singapore	University of London; University College London; National University of Singapore	Norman, RA (corresponding author), Imperial Canc Res Fund, Struct Biol Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	R.Norman@icrf.icnet.uk	LAA, POH CHIT LAA CL POH CHIT/B-9498-2010	Pearl, Laurence/0000-0002-6910-1809; Poh, Chit-Laa/0000-0001-8475-6291				Antson AA, 1999, NATURE, V401, P235, DOI 10.1038/45730; AUSTIN S, 1994, J BACTERIOL, V176, P3460, DOI 10.1128/JB.176.12.3460-3465.1994; Baumann C, 1996, J BIOL CHEM, V271, P12269, DOI 10.1074/jbc.271.21.12269; BRAMMAR WJ, 1987, FEBS LETT, V215, P291, DOI 10.1016/0014-5793(87)80164-3; BRAMMAR WJ, 1964, J GEN MICROBIOL, V37, P307, DOI 10.1099/00221287-37-3-307; CHEN L, 1995, P NATL ACAD SCI USA, V92, P5077, DOI 10.1073/pnas.92.11.5077; CHEN L, 1994, BIOCHEMISTRY-US, V33, P2708, DOI 10.1021/bi00175a046; COUSENS DJ, 1987, J GEN MICROBIOL, V133, P2041; Dixon R, 1998, ARCH MICROBIOL, V169, P371, DOI 10.1007/s002030050585; DRAPER DE, 1996, ESCHERICHIA COLI SAL, P902; DREW R, 1989, J GEN MICROBIOL, V135, P817; DREW R, 1984, J GEN MICROBIOL, V130, P3101; Govantes F, 1998, EMBO J, V17, P2368, DOI 10.1093/emboj/17.8.2368; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JAEGER JA, 1990, METHODS ENZYMOL, V183, P281; KELLY M, 1962, J GEN MICROBIOL, V27, P305, DOI 10.1099/00221287-27-2-305; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HS, 1993, J BACTERIOL, V175, P7683, DOI 10.1128/JB.175.23.7683-7688.1993; Lei S, 1999, J BACTERIOL, V181, P6535, DOI 10.1128/JB.181.20.6535-6539.1999; LOWE N, 1989, FEBS LETT, V246, P39, DOI 10.1016/0014-5793(89)80249-2; Money T, 1999, J BACTERIOL, V181, P4461, DOI 10.1128/JB.181.15.4461-4468.1999; MORRET E, 1993, J BACTERIOL, V175, P6067; NARBERHAUS F, 1995, J BACTERIOL, V177, P5078, DOI 10.1128/jb.177.17.5078-5087.1995; O'Hara BP, 1999, EMBO J, V18, P5175, DOI 10.1093/emboj/18.19.5175; PEARL L, 1994, EMBO J, V13, P5810, DOI 10.1002/j.1460-2075.1994.tb06924.x; Torgov MY, 1998, J BACTERIOL, V180, P4339, DOI 10.1128/JB.180.17.4339-4343.1998; WILSON S, 1991, J BACTERIOL, V173, P4914, DOI 10.1128/jb.173.16.4914-4921.1991; WILSON SA, 1995, J BIOL CHEM, V270, P18818, DOI 10.1074/jbc.270.32.18818; WILSON SA, 1995, J BACTERIOL, V177, P3052, DOI 10.1128/jb.177.11.3052-3057.1995; WILSON SA, 1993, EMBO J, V12, P3637, DOI 10.1002/j.1460-2075.1993.tb06037.x; Wilson SA, 1996, EMBO J, V15, P5907, DOI 10.1002/j.1460-2075.1996.tb00977.x; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	32	15	15	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30660	30667		10.1074/jbc.M000813200	http://dx.doi.org/10.1074/jbc.M000813200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10893220	hybrid			2022-12-25	WOS:000089577900102
J	Kawano, Y; Okamoto, I; Murakami, D; Itoh, H; Yoshida, M; Ueda, S; Saya, H				Kawano, Y; Okamoto, I; Murakami, D; Itoh, H; Yoshida, M; Ueda, S; Saya, H			Ras oncoprotein induces CD44 cleavage through phosphoinositide 3-OH kinase and the rho family of small G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-CELL MIGRATION; ACTIN STRESS FIBERS; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL-CELLS; H-RAS; METASTATIC PHENOTYPE; ACTIVATED RAS; MAP KINASE; B-RAF	CD44 is a cell surface adhesion molecule for several extracellular matrix components. We previously showed that CD44 expressed in cancer cells is proteolytically cleaved at the ectodomain through membrane-anchored metalloproteases and that CD44 cleavage plays a critical role in cancer cell migration. Therefore, cellular signals that promote the migration and metastatic activity of cancer cells may regulate the CD44 ectodomain cleavage. Here, we demonstrate that the expression of the dominant active mutant of Ha-has (Ha-Ras(Val-12)) induces redistribution of CD44 to the newly generated membrane ruffling area and CD44 ectodomain cleavage. The migration assay revealed that the CD44 cleavage contributes to the Ha-Ras(Val-12)-induced migration of NIH3T3 cells on hyaluronate substrate. Treatment with LY294002, an inhibitor for phosphoinositide 3-OH kinase (PI3K), significantly inhibits Ha-Ras(Val-12)-induced CD44 cleavage, whereas that with PD98059, an inhibitor for MER, does not. The active mutant p110 subunit of PI3K has also been shown to enhance the CD44 cleavage, suggesting that PI3K mediates the has-induced CD44 cleavage. Moreover, the expression of dominant negative mutants of Cdc42 and Rad inhibits the HaRas(Val-12)-induced CD44 cleavage. These results suggest that Ras > PI3K > Cdc42/Rac1 pathway plays an important role in CD44 cleavage and may provide a novel molecular basis to explain how the activated has facilitates cancer cell migration.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Urol, Kumamoto 8600811, Japan; Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Kumamoto University; Kumamoto University; Tokyo Institute of Technology	Itoh, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Saya, Hideyuki/J-4325-2013					ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BONDY GP, 1985, CANCER RES, V45, P6005; BOS JL, 1989, CANCER RES, V49, P4682; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Edamatsu H, 1998, FEBS LETT, V440, P231, DOI 10.1016/S0014-5793(98)01457-4; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FOX PL, 1994, ONCOGENE, V9, P3519; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Heino J, 1996, INT J CANCER, V65, P717, DOI 10.1002/(SICI)1097-0215(19960315)65:6<717::AID-IJC1>3.3.CO;2-P; HOFMANN M, 1993, CANCER RES, V53, P1516; JAMAL HH, 1994, ONCOGENE, V9, P417; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LIOTTA LA, 1988, J NATL CANCER I, V80, P468, DOI 10.1093/jnci/80.7.468; Manna SK, 1998, J BIOL CHEM, V273, P33333, DOI 10.1074/jbc.273.50.33333; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Okamoto I, 1999, J BIOL CHEM, V274, P25525, DOI 10.1074/jbc.274.36.25525; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODEIGUEZVICIAN.P, 1997, CELL, V89, P457; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sarner S, 2000, MOL CELL BIOL, V20, P158, DOI 10.1128/MCB.20.1.158-172.2000; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Svee K, 1996, J CLIN INVEST, V98, P1713, DOI 10.1172/JCI118970; Takahashi K, 1999, INT J CANCER, V80, P387, DOI 10.1002/(SICI)1097-0215(19990129)80:3<387::AID-IJC9>3.0.CO;2-T; Tang Y, 1999, MOL CELL BIOL, V19, P1881; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VAN AL, 1997, GENE DEV, V11, P2295; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wells A, 2000, ADV CANCER RES, V78, P31; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	59	58	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29628	29635		10.1074/jbc.M002440200	http://dx.doi.org/10.1074/jbc.M002440200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896935	hybrid			2022-12-25	WOS:000089439800061
J	Traut, TW; Temple, BRS				Traut, TW; Temple, BRS			The chemistry of the reaction determines the invariant amino acids during the evolution and divergence of orotidine 5 '-monophosphate decarboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URIDINE 5'-PHOSPHATE SYNTHASE; 3-HEXULOSE-6-PHOSPHATE SYNTHASE; OROTIDINE-5'-PHOSPHATE DECARBOXYLASE; CONFORMATION STATES; PROTEIN; GENE; AGGREGATION; DEPENDENCE; KINGDOMS; ENZYMES	Orotidine 5'-phosphate (OMP) decarboxylase has the largest rate enhancement for any known enzyme. For an average protein. of 270 amino acids from more than 80 species, only 8 amino acids are invariant, and 7 of these correspond to ligand-binding residues in the crystal structures of the enzyme from four species. It appears that the chemistry required for catalysis determines the invariant residues for this enzyme structure. A motif of three invariant amino acids at the catalytic site (DXKXXD) is also found in the enzyme hexulose-phosphate synthase. Although the core of OMP decarboxylase is conserved, it has undergone a variety of changes in subunit size or fusion to other protein domains, such as orotate phosphoribosyltransferase, during evolution in different kingdoms. The phylogeny of OMP decarboxylase shows a unique subgroup distinct from the three kingdoms of life. The enzyme subunit size almost doubles from Archaea (average mass of 24.5 kDa) to certain fungi (average mass of 41.7 kDa), These observed changes in subunit size are produced by insertions at 12 sites, largely in loops and on the exterior of the core protein. The consensus for all sequences has a minimal size of <20 kDa.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Traut, TW (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.				NATIONAL CANCER INSTITUTE [P30CA016086] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appleby TC, 2000, P NATL ACAD SCI USA, V97, P2005, DOI 10.1073/pnas.259441296; CHRISTOPHER J, 1998, PROGRAM MANUAL; Cui WD, 1999, BIOCHEM BIOPH RES CO, V259, P133, DOI 10.1006/bbrc.1999.0737; Doolittle RF, 1996, SCIENCE, V271, P470, DOI 10.1126/science.271.5248.470; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FERENCI T, 1974, BIOCHEM J, V144, P477, DOI 10.1042/bj1440477; Gao GH, 1999, J MOL BIOL, V285, P149, DOI 10.1006/jmbi.1998.2293; Harris P, 2000, BIOCHEMISTRY-US, V39, P4217, DOI 10.1021/bi992952r; KATO N, 1990, METHOD ENZYMOL, V188, P397; KIMSEY HH, 1992, J BIOL CHEM, V267, P819; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Miller BG, 1999, J BIOL CHEM, V274, P23841, DOI 10.1074/jbc.274.34.23841; Miller BG, 2000, P NATL ACAD SCI USA, V97, P2011, DOI 10.1073/pnas.030409797; MULLER RH, 1990, METHOD ENZYMOL, V188, P401; RADFORD A, 1993, J MOL EVOL, V36, P389; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; Rivera MC, 1998, P NATL ACAD SCI USA, V95, P6239, DOI 10.1073/pnas.95.11.6239; SCAPIN G, 1994, BIOCHEMISTRY-US, V33, P1287, DOI 10.1021/bi00172a001; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRAUT TW, 1980, BIOCHEMISTRY-US, V19, P6068, DOI 10.1021/bi00567a019; Traut TW, 1996, PROG NUCLEIC ACID RE, V53, P1, DOI 10.1016/S0079-6603(08)60142-7; TRAUT TW, 1980, BIOCHEMISTRY-US, V19, P6062, DOI 10.1021/bi00567a018; TRAUT TW, 1989, ARCH BIOCHEM BIOPHYS, V268, P108, DOI 10.1016/0003-9861(89)90570-5; WOESE CR, 1983, MICROBIOL REV, V47, P621, DOI 10.1128/MMBR.47.4.621-669.1983; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088; Wu N, 2000, P NATL ACAD SCI USA, V97, P2017, DOI 10.1073/pnas.050417797; Yablonski MJ, 1996, J BIOL CHEM, V271, P10704, DOI 10.1074/jbc.271.18.10704; Yanase H, 1996, FEMS MICROBIOL LETT, V135, P201, DOI 10.1016/0378-1097(95)00450-5	29	31	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28675	28681		10.1074/jbc.M003468200	http://dx.doi.org/10.1074/jbc.M003468200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893234	hybrid, Green Published			2022-12-25	WOS:000089330700046
J	Giannini, AL; Vivanco, MDM; Kypta, RM				Giannini, AL; Vivanco, MDM; Kypta, RM			alpha-Catenin inhibits beta-catenin signaling by preventing formation of a beta-catenin T-cell factor DNA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-CADHERIN; TRANSCRIPTIONAL ACTIVATION; JUNCTIONAL COMPLEX; ADHESION COMPLEX; COLON-CARCINOMA; CYCLIN D1; IN-VITRO; PROTEIN; ACTIN; EXPRESSION	alpha-Catenin and beta-catenin link cadherins to the cytoskeleton at adherens junctions. beta-Catenin also associates with members of the T-cell factor (Tcf) family of transcription factors, and mutations in beta-catenin lead to activation of Tcf-dependent transcription and increased cell growth. Although the loss of alpha-catenin expression can also promote cell growth, the role of endogenous alpha-catenin in beta-catenin signaling is unclear. Here we show that loss of alpha-catenin expression in a colon cancer cell line correlates with increased Tcf-dependent transcription. The presence of alpha-catenin in colon cancer cell nuclei suggests that it inhibits transcription directly, and, in agreement with this, ectopic expression of alpha-catenin in the nucleus represses Tcf-dependent transcription. Furthermore, recombinant alpha-catenin disrupts the interaction between the beta-catenin Tcf complex and DNA. We conclude that alpha-catenin inhibits beta-catenin signaling in the nucleus by interfering with the formation of a beta-cateni.Tcf.DNA complex.	UCL, LMCB, MRC, London WC1E 6BT, England; Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, London SW3 6JB, England	University of London; University College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Kypta, RM (corresponding author), UCL, LMCB, MRC, Gower St, London WC1E 6BT, England.	r.kypta@ucl.ac.uk	Vivanco, Maria/G-2393-2011; Kypta, Robert/F-7699-2011	Vivanco, Maria/0000-0002-9540-247X; Kypta, Robert/0000-0002-2389-310X				ABERLE H, 1994, J CELL SCI, V107, P3655; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Bullions LC, 1997, MOL CELL BIOL, V17, P4501, DOI 10.1128/MCB.17.8.4501; CLAVERIE JM, 1993, GENOMICS, V15, P13, DOI 10.1006/geno.1993.1004; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; FISCHERFANTUZZI L, 1988, MOL CELL BIOL, V8, P5495, DOI 10.1128/MCB.8.12.5495; Gallet A, 1999, EMBO J, V18, P2208, DOI 10.1093/emboj/18.8.2208; Giannini AL, 2000, EXP CELL RES, V255, P207, DOI 10.1006/excr.1999.4785; Gofuku J, 1999, AM J CLIN PATHOL, V111, P29; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Huber O, 1997, J CELL SCI, V110, P1759; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Koslov ER, 1997, J BIOL CHEM, V272, P27301, DOI 10.1074/jbc.272.43.27301; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nieset JE, 1997, J CELL SCI, V110, P1013; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; Obama H, 1997, J BIOL CHEM, V272, P11017; Ozawa M, 1998, J BIOL CHEM, V273, P29524, DOI 10.1074/jbc.273.45.29524; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sehgal RNM, 1997, J CELL BIOL, V139, P1033, DOI 10.1083/jcb.139.4.1033; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Torres M, 1997, P NATL ACAD SCI USA, V94, P901, DOI 10.1073/pnas.94.3.901; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; VIVANCO MD, 1995, EMBO J, V14, P2217, DOI 10.1002/j.1460-2075.1995.tb07216.x; Wada A, 1998, EMBO J, V17, P1635, DOI 10.1093/emboj/17.6.1635; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119	44	72	74	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21883	21888		10.1074/jbc.M001929200	http://dx.doi.org/10.1074/jbc.M001929200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10896949	hybrid			2022-12-25	WOS:000088363800020
J	Fuh, G; Pisabarro, MT; Li, Y; Quan, C; Lasky, LA; Sidhu, SS				Fuh, G; Pisabarro, MT; Li, Y; Quan, C; Lasky, LA; Sidhu, SS			Analysis of PDZ domain-ligand interactions using carboxyl-terminal phage display	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE RECOGNITION; PROTEIN; RECEPTOR; MEMBRANE; LIBRARIES; COMPLEXES; PTB	PDZ domains mediate protein-protein interactions at specialized subcellular sites, such as epithelial cell tight junctions and neuronal post-synaptic densities. Because most PDZ domains bind extreme carboxyl-terminal sequences, the phage display method has not been amenable to the study of PDZ domain binding specificities. For the first time, we demonstrate the functional display of a peptide library fused to the carboxyl terminus of the M13 major coat protein. We used this library to analyze carboxyl-terminal peptide recognition by two PDZ domains. For each PDZ domain, the library provided specific ligands with sub-micromolar binding affinities. Synthetic peptides and homology modeling were used to dissect and rationalize the binding interactions. Our results establish carboxyl-terminal phage display as a powerful new method for mapping PDZ domain binding specificity.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioorgan Chem, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Sidhu, SS (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, San Francisco, CA 94080 USA.	sidhu@gene.com	Pisabarro, M. Teresa/D-4270-2012					Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Cowburn D, 1997, CURR OPIN STRUC BIOL, V7, P835, DOI 10.1016/S0959-440X(97)80155-8; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; CULL MG, 1992, P NATL ACAD SCI USA, V89, P1865, DOI 10.1073/pnas.89.5.1865; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Gee SH, 1998, J BIOL CHEM, V273, P21980, DOI 10.1074/jbc.273.34.21980; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kortemme T, 1998, SCIENCE, V281, P253, DOI 10.1126/science.281.5374.253; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lowman HB, 1998, BIOCHEMISTRY-US, V37, P8870, DOI 10.1021/bi980426e; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Marvin DA, 1998, CURR OPIN STRUC BIOL, V8, P150, DOI 10.1016/S0959-440X(98)80032-8; *MOL SIM INC, 1999, INS 2; Oschkinat H, 1999, NAT STRUCT BIOL, V6, P408, DOI 10.1038/8203; Palzkill T, 1998, GENE, V221, P79, DOI 10.1016/S0378-1119(98)00425-9; Pearce KH, 1997, J BIOL CHEM, V272, P20595, DOI 10.1074/jbc.272.33.20595; SIDHU SS, 2000, IN PRESS METHODS ENZ; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Tochio H, 1999, NAT STRUCT BIOL, V6, P417; Tsunoda S, 1998, CURR OPIN GENET DEV, V8, P419, DOI 10.1016/S0959-437X(98)80112-3; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Wilson DR, 1998, CAN J MICROBIOL, V44, P313, DOI 10.1139/cjm-44-4-313; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	30	110	125	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21486	21491		10.1074/jbc.275.28.21486	http://dx.doi.org/10.1074/jbc.275.28.21486			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10887205	hybrid			2022-12-25	WOS:000088230600071
J	Holloway, AF; Occhiodoro, F; Mittler, G; Meisterernst, M; Shannon, MF				Holloway, AF; Occhiodoro, F; Mittler, G; Meisterernst, M; Shannon, MF			Functional interaction between the HIV transactivator Tat and the transcriptional coactivator PC4 in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RNA-POLYMERASE-II; LONG TERMINAL REPEAT; ACTIVATION-RESPONSIVE REGION; TYPE-1 TAT; TRANS-ACTIVATION; HIGH-AFFINITY; PROTEIN; DOMAIN; BINDING	The human immunodeficiency virus (HIV) transactivator Tat is a potent activator of transcription from the HIV long terminal repeat and is essential for efficient viral gene expression and replication. Tat has been shown to interact with components of the basal transcription machinery and transcriptional activators. Here we identify the cellular coactivator PC4 as a Tat-interacting protein using the yeast two-hybrid system and confirmed this interaction both in vitro and in vivo by coimmunoprecipitation. We found that this interaction has a functional outcome in that PC4 overexpression enhanced activation of the HIV long terminal repeat in transient transfection studies in a Tat-dependent manner. The domains of PC4 and Tat required for the interaction were mapped. In vitro binding studies showed that the basic transactivation-responsive binding domain of Tat is required for the interaction with PC4. The minimum region of PC4 required for Tat binding was amino acids 22-91, whereas mutation of the lysine-rich domain between amino acids 22 and 43 prevented interaction with Tat. Tat-PC4 interactions may be controlled by phosphorylation, because phosphorylation of PC4 by casein kinase II inhibited interactions with Tat both in vivo and in vitro. We propose that PC4 may be involved in linking Tat to the basal transcription machinery.	Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 2601, Australia; CSIRO, Div Human Nutr, Cooperat Res Ctr Tissue Growth & Repair, Adelaide, SA 5000, Australia; GSF Munich, Dept Prot Biochem, Inst Mol Immunol, D-81377 Munich, Germany	Australian National University; John Curtin School of Medical Research; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Shannon, MF (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 2601, Australia.	frances.shannon@anu.edu.au		Holloway, Adele/0000-0003-2213-1717				ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; Blau J, 1996, MOL CELL BIOL, V16, P2044; Brandsen J, 1997, NAT STRUCT BIOL, V4, P900, DOI 10.1038/nsb1197-900; CHANG YN, 1992, NUCLEIC ACIDS RES, V20, P5465, DOI 10.1093/nar/20.20.5465; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; Cujec TP, 1997, MOL CELL BIOL, V17, P1817, DOI 10.1128/MCB.17.4.1817; Currie RA, 1998, J BIOL CHEM, V273, P18220, DOI 10.1074/jbc.273.29.18220; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; FAVIER D, 1994, ONCOGENE, V9, P305; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAUBER J, 1988, J VIROL, V62, P673, DOI 10.1128/JVI.62.3.673-679.1988; Himes SR, 1996, J VIROL, V70, P4001, DOI 10.1128/JVI.70.6.4001-4008.1996; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; Kannan F, 1999, MOL CELL BIOL, V19, P899; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LIU JS, 1992, J VIROL, V66, P3883, DOI 10.1128/JVI.66.6.3883-3887.1992; Macian F, 1999, MOL CELL BIOL, V19, P3645, DOI 10.1128/mcb.19.5.3645; Malik S, 1998, P NATL ACAD SCI USA, V95, P2192, DOI 10.1073/pnas.95.5.2192; Mavankal G, 1996, P NATL ACAD SCI USA, V93, P2089, DOI 10.1073/pnas.93.5.2089; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481; Ott M, 1998, J IMMUNOL, V160, P2872; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROSEN CA, 1986, NATURE, V319, P555, DOI 10.1038/319555a0; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; Ulich C, 1999, J VIROL, V73, P2499, DOI 10.1128/JVI.73.3.2499-2508.1999; VESCHAMBRE P, 1995, J MOL BIOL, V250, P169, DOI 10.1006/jmbi.1995.0368; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Werten S, 1998, EMBO J, V17, P5103, DOI 10.1093/emboj/17.17.5103; Werten S, 1998, J MOL BIOL, V276, P367, DOI 10.1006/jmbi.1997.1534; Yankulov K, 1998, CURR BIOL, V8, pR447, DOI 10.1016/S0960-9822(98)70289-1; YU L, 1995, J VIROL, V69, P3007, DOI 10.1128/JVI.69.5.3007-3016.1995; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681	56	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21668	21677		10.1074/jbc.M909058199	http://dx.doi.org/10.1074/jbc.M909058199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10887206	hybrid			2022-12-25	WOS:000088230600094
J	Yao, TT; Cohen, RE				Yao, TT; Cohen, RE			Cyclization of polyubiquitin by the E2-25K ubiquitin conjugating enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL HYDROLASES; DEUBIQUITINATING ENZYMES; MULTIUBIQUITIN CHAINS; DEPENDENT PROTEOLYSIS; PROTEIN-DEGRADATION; IN-VIVO; SPECIFICITY; PROTEASOME; ISOPEPTIDASE; MECHANISM	For most substrates of ubiquitin (Ub)-dependent degradation, recognition by the proteasome is mediated by a covalently attached signal assembled hom multiple ubiquitins linked to each other via the C terminus of one Ub and the E-amine of Lys(48) Of another Uh. Among Ub-conjugating enzymes, E2-25K is unique in its ability to synthesize in vitro unanchored Lys(48)-linked poly-Uh chains from mono- or poly-Uh, E1, and ATP; thus, E2-25K has distinct binding sites for donor and acceptor (poly)Ub. During studies of chain assembly by E2-25K we observed that Lys(48)-linked tri-Ub was efficiently converted to a new species that upon SDS-polyacrylamide gel electrophoresis migrated between linear di-Ub and tri-Ub. Analysis of this product by mass spectrometry and tryptic digestion showed that it was a cyclic form of tri-Ub. Cyclization of tri-Ub requires E1, E2-25K ATP, and that the Linear substrate has a free Gly(76) C terminus on the proximal end Ub and a Lys48 Side chain available on the distal end Ub. E2-25K similarly can catalyze the cyclization of longer poly-Uh chains, including tetra- and penta-Ub. Although cyclic tri-Ub resists hydrolysis by the PA700 or isopeptidase T deubiquitinating enzymes, it can be disassembled to Ub monomers by isopeptidase(s) in a red blood cell extract. Thus, if cyclic poly-Uh forms in vivo, it will not accumulate as a deadend product.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Cohen, RE (corresponding author), Univ Iowa, Dept Biochem, 51 Newton Rd, Iowa City, IA 52242 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037666] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37666] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 1997, EMBO J, V16, P4826; Ausubel FM., 2006, ENZYMATIC MANIPULATI; Beal RE, 1998, BIOCHEMISTRY-US, V37, P2925, DOI 10.1021/bi972514p; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1991, J BIOL CHEM, V266, P15698; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; COOK WJ, 1992, J BIOL CHEM, V267, P16467; COX MJ, 1986, ARCH BIOCHEM BIOPHYS, V250, P400, DOI 10.1016/0003-9861(86)90742-3; Dang LC, 1998, BIOCHEMISTRY-US, V37, P1868, DOI 10.1021/bi9723360; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Dubiel W, 1999, CURR BIOL, V9, pR554, DOI 10.1016/S0960-9822(99)80353-4; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1985, J BIOL CHEM, V260, P2464; Haas AL, 1997, FASEB J, V11, P1257; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; Lam YA, 1997, J BIOL CHEM, V272, P28438, DOI 10.1074/jbc.272.45.28438; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; Mastrandrea LD, 1998, BIOCHEMISTRY-US, V37, P9784, DOI 10.1021/bi9800911; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; PICKART CM, 1986, J BIOL CHEM, V261, P210; PICKART CM, 1992, J BIOL CHEM, V267, P14418; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Piotrowski J, 1997, J BIOL CHEM, V272, P23712, DOI 10.1074/jbc.272.38.23712; Shaeffer JR, 1997, BLOOD, V90, P1300, DOI 10.1182/blood.V90.3.1300.1300_1300_1308; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; VANNOCKER S, 1993, J BIOL CHEM, V268, P24766; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; WILKINSON KD, 1981, J BIOL CHEM, V256, P9235; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; XU W, 1999, THESIS U IOWA	40	19	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36862	36868		10.1074/jbc.M006050200	http://dx.doi.org/10.1074/jbc.M006050200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10906148	hybrid			2022-12-25	WOS:000165577700060
J	Stevanin, TM; Ioannidis, N; Mills, CE; Kim, SO; Hughes, MN; Poole, RK				Stevanin, TM; Ioannidis, N; Mills, CE; Kim, SO; Hughes, MN; Poole, RK			Flavohemoglobin hmp affords inducible protection for Escherichia coli respiration, catalyzed by cytochromes bo ' or bd, from nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVOHAEMOGLOBIN HMP; OXIDATIVE-STRESS; C-OXIDASE; OXYGEN-AFFINITY; NITROSATIVE STRESS; IN-VIVO; BINDING; NO; INHIBITION; MECHANISM	Respiration of Escherichia coli catalyzed either by cytochrome bo' or bd is sensitive to micromolar extracellular NO; extensive, transient inhibition of respiration increases as dissolved oxygen tension in the medium decreases. At low oxygen concentrations (25-33 muM), the duration of inhibition of respiration by 9 muM NO is increased by mutation of either oxidase. Respiration of an hmp mutant defective in flavohemoglobin (Hmp) synthesis is extremely NO-sensitive (I(50) about 0.8 muM); conversely, cells pre-grown with sodium nitroprusside or overexpressing plasmid-borne hmp(+) are insensitive to 60 muM NO and have elevated levels of immunologically detectable Hmp. Purified Hmp consumes O(2), at a rate that,is instantaneously and extensively (>10-fold) stimulated by MO due to NO oxygenase activity but, in the absence of NO, limp does not contribute measurably to cell oxygen consumption. Cyanide binds to Hmp (K(d) 3 muM). Concentrations of KCN (100 muM) that do not significantly inhibit cell respiration markedly suppress the protection of respiration from NO afforded by Hmp and abolish NO oxygenase activity of purified Hmp, The results demonstrate the role of limp in protecting respiration from NO stress and are discussed in relation to the energy metabolism off. coli in natural O(2)-depleted environments.	Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Natl Ctr Sci Res Demokritos, Aghia Paraskevi 15310, Greece; Kings Coll London, Dept Chem, London WC2R 2LS, England	University of Sheffield; National Centre of Scientific Research "Demokritos"; University of London; King's College London	Poole, RK (corresponding author), Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Firth Court,Western Bank, Sheffield S10 2TN, S Yorkshire, England.	r.poole@sheffield.ac.uk	Ioannidis, Nikolaos/AFS-4799-2022	Ioannidis, Nikolaos/0000-0002-2528-5271				Bolognesi M, 1999, J MOL BIOL, V291, P637, DOI 10.1006/jmbi.1999.2975; Bonner F. T., 1988, COMMENTS INORG CHEM, V7, P215, DOI DOI 10.1080/02603598808072309; Bonner F.T., 2010, CHEMINFORM, V28, DOI [10.1002/chin.199715245, DOI 10.1002/CHIN.199715245]; BRUDVIG GW, 1980, BIOCHEMISTRY-US, V19, P5275, DOI 10.1021/bi00564a020; Butler CS, 1997, BIOCHEMISTRY-US, V36, P16259, DOI 10.1021/bi971481a; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Cooper CE, 1999, BBA-BIOENERGETICS, V1411, P290, DOI 10.1016/S0005-2728(99)00021-3; Crawford MJ, 1998, J BIOL CHEM, V273, P12543, DOI 10.1074/jbc.273.20.12543; DEGROOTE MA, 1995, CLIN INFECT DIS, V21, pS162, DOI 10.1093/clinids/21.Supplement_2.S162; Dmello R, 1996, MICROBIOL-UK, V142, P755, DOI 10.1099/00221287-142-4-755; DMELLO R, 1995, J BACTERIOL, V177, P867, DOI 10.1128/jb.177.3.867-870.1995; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Gardner PR, 1998, J BIOL CHEM, V273, P26528, DOI 10.1074/jbc.273.41.26528; Gaston B, 1999, BBA-BIOENERGETICS, V1411, P323, DOI 10.1016/S0005-2728(99)00023-7; Gennis R. B., 1996, ESCHERICHIA COLI SAL, P217; Giuffre A, 1999, P NATL ACAD SCI USA, V96, P14718, DOI 10.1073/pnas.96.26.14718; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Guest John R., 1996, P317; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Hori H, 1996, J BIOL CHEM, V271, P9254, DOI 10.1074/jbc.271.16.9254; Hu YM, 1999, J BACTERIOL, V181, P3486, DOI 10.1128/JB.181.11.3486-3493.1999; HUBBARD JAM, 1983, FEBS LETT, V164, P241, DOI 10.1016/0014-5793(83)80293-2; HUBBARD JAM, 1985, MICROBIAL GAS METABO, P231; Hughes MN, 1999, BBA-BIOENERGETICS, V1411, P263, DOI 10.1016/S0005-2728(99)00019-5; IOANNIDIS N, 1992, BIOCHEM J, V288, P649, DOI 10.1042/bj2880649; JI XB, 1988, APPL ENVIRON MICROB, V54, P1791, DOI 10.1128/AEM.54.7.1791-1794.1988; Kalnenieks U, 1998, FEMS MICROBIOL LETT, V168, P91; Kim SO, 1999, FEBS LETT, V445, P389, DOI 10.1016/S0014-5793(99)00157-X; Maloy SR., 1996, GENETIC ANAL PATHOGE; Membrillo-Hernandez J, 1998, MOL MICROBIOL, V29, P1101, DOI 10.1046/j.1365-2958.1998.01000.x; Membrillo-Hernandez J, 1999, J BIOL CHEM, V274, P748, DOI 10.1074/jbc.274.2.748; MembrilloHernandez J, 1996, FEBS LETT, V382, P141, DOI 10.1016/0014-5793(96)00154-8; Millar AH, 1996, FEBS LETT, V398, P155, DOI 10.1016/S0014-5793(96)01230-6; Murad F, 1999, BIOSCIENCE REP, V19, P133, DOI 10.1023/A:1020265417394; Nagata K, 1998, J BIOL CHEM, V273, P14071, DOI 10.1074/jbc.273.23.14071; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; Poole R.K., 2000, SPECTROPHOTOMETRY SP, P1; Poole RK, 1996, J BACTERIOL, V178, P5487, DOI 10.1128/jb.178.18.5487-5492.1996; Poole RK, 2000, MOL MICROBIOL, V36, P775, DOI 10.1046/j.1365-2958.2000.01889.x; Poole RK, 1997, MICROBIOL-SGM, V143, P1557, DOI 10.1099/00221287-143-5-1557; POOLE RK, 1989, J GEN MICROBIOL, V135, P1865; POOLE RK, 1994, P ROY SOC B-BIOL SCI, V255, P251, DOI 10.1098/rspb.1994.0036; Poole RK, 2000, ADV MICROB PHYSIOL, V43, P165, DOI 10.1016/S0065-2911(00)43005-5; Poole RK, 1996, MICROBIOL-SGM, V142, P1141, DOI 10.1099/13500872-142-5-1141; POOLE RK, 1987, ESCHERICHIA COLI SAL, P170; RENART J, 1984, METHOD ENZYMOL, V104, P455; Rudolph J, 1996, J ATMOS CHEM, V23, P275, DOI 10.1007/BF00055157; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOEDON G, 1995, CLIN INFECT DIS, V21, pS152, DOI 10.1093/clinids/21.Supplement_2.S152; Soballe B, 1998, MICROBIOL-UK, V144, P361, DOI 10.1099/00221287-144-2-361; Stubauer G, 1998, BIOCHEM BIOPH RES CO, V245, P459, DOI 10.1006/bbrc.1998.8457; Torres J, 1998, J BIOENERG BIOMEMBR, V30, P63, DOI 10.1023/A:1020559528124; Torres J, 1999, BBA-BIOENERGETICS, V1411, P310, DOI 10.1016/S0005-2728(99)00022-5; VASUDEVAN SG, 1991, MOL GEN GENET, V226, P49, DOI 10.1007/BF00273586; Watmough NJ, 1999, BBA-BIOENERGETICS, V1411, P456, DOI 10.1016/S0005-2728(99)00032-8; Wu GH, 2000, J BIOL CHEM, V275, P4679, DOI 10.1074/jbc.275.7.4679; Yoshimura T, 1995, MCBU, P217; Yu H, 1997, FEBS LETT, V409, P161, DOI 10.1016/S0014-5793(97)00494-8	59	130	135	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35868	35875		10.1074/jbc.M002471200	http://dx.doi.org/10.1074/jbc.M002471200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10915782	hybrid			2022-12-25	WOS:000165382000034
J	Lin, RT; Mamane, Y; Hiscott, J				Lin, RT; Mamane, Y; Hiscott, J			Multiple regulatory domains control IRF-7 activity in response to virus infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-ALPHA GENES; JAK-STAT PATHWAY; TRANSCRIPTION FACTOR; POSITIVE FEEDBACK; IFN; INDUCTION; EXPRESSION; ACTIVATION; ELEMENTS; BINDS	Recent studies implicate the interferon regulatory factors (IRF), IRF-3 and IRF-7, as key activators of Type 1 interferon genes, as well as the RANTES (regulated on activation normal T cell expressed) chemokine gene. Both IRF-3 and IRF-7 are regulated in part by virus-induced C-terminal phosphorylation, leading to nuclear translocation, stimulation of DNA binding, and transcriptional activities, Structure-function studies with IRF-7 suggested a complex organization of the C-terminal region, with a constitutive activation domain located between amino acids 150-246, an accessory inducibility region at the very end of IRF-7 between amino acids 467 and 503, and an inhibitory region (amino acids 341-467) adjacent to the C-terminal end that interferes with transactivation, Furthermore, an element that increases basal and virus-inducible activity is located between amino acids 278 and 305, A transcriptionally active form of IRF-7 was also generated by substitution of Ser-477 and Ser-479 residues with the phosphomimetic Asp, IRF-7, particularly IRF-7(S477D/S479D), was a strong transactivator of type I interferon and RANTES chemokine gene expression. Unlike wild type IRF-3, IRF-7 overexpression was able to stimulate inteferon gene expression in the absence of virus infection. Using tagged versions of IRF-7 and IRF-8, the formation of homo- and heterodimers was detected by eo-immunoprecipitation. These results demonstrate that IRF-5 and IRF-7 transcription factors possess distinct structural characteristics that impart complementary rather than redundant functional roles in cytokine gene activation.	Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Lin, RT (corresponding author), Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	mdli@musica.mcgill.ca	Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; Genin P, 2000, J IMMUNOL, V164, P5352, DOI 10.4049/jimmunol.164.10.5352; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hiscott J, 1999, J INTERF CYTOK RES, V19, P1, DOI 10.1089/107999099314360; HISCOTT J, 1995, SEMIN VIROL, V6, P161, DOI 10.1006/smvy.1995.0021; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; LEVY DE, 1995, SEMIN VIROL, V6, P181, DOI 10.1006/smvy.1995.0023; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Nonkwelo C, 1997, J VIROL, V71, P6887, DOI 10.1128/JVI.71.9.6887-6897.1997; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; PITHA PM, 1995, SEMIN VIROL, V6, P151, DOI 10.1006/smvy.1995.0020; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; VILCEK J, 1996, VIROLOGY, P375; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; YEOW W, 1998, J BIOL CHEM, V275, P6313; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748	38	194	202	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34320	34327		10.1074/jbc.M002814200	http://dx.doi.org/10.1074/jbc.M002814200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10893229	hybrid			2022-12-25	WOS:000165095300045
J	Gross, C; Kelleher, M; Iyer, VR; Brown, PO; Winge, DR				Gross, C; Kelleher, M; Iyer, VR; Brown, PO; Winge, DR			Identification of the copper regulon in Saccharomyces cerevisiae by DNA microarrays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR MAC1; GENE-EXPRESSION; MOLECULAR CHARACTERIZATION; SUPEROXIDE-DISMUTASE; METALLOTHIONEIN GENE; PHYSIOLOGICAL-ROLE; TRANSPORT PROTEIN; BINDING PROTEIN; YEAST COPPER; IRON UPTAKE	In Saccharomyces cerevisiae, copper ions regulate gene expression through the two transcriptional activators, Ace1 and Mad. Ace1 mediates copper-induced gene expression in cells exposed to stressful levels of copper salts, whereas Mad activates a subset of genes under copper-deficient conditions. DNA microarray hybridization experiments revealed a limited set of yeast genes differentially expressed under growth conditions of excess copper or copper deficiency. Mad activates the expression of six S. cerevisiae genes, including CTR1, CTR3, FRE1, FRE7, YFR055w, and YJL217w, Two of the last three newly identified Mad target genes have no known function; the third, YFR055w, is homologous to cystathionine gamma-lyase encoded by CYS3. Several genes that are differentially expressed in cells containing a constitutively active Mad, designated Mac1(up1), are not direct targets of Mad. Induction or repression of these genes is likely a secondary effect of cells because of constitutive Mad activity. Elevated copper levels induced the expression of the metallothioneins CUP1 and CRS5 and two genes, FET3 and FTR1, in the iron uptake system. Copper-induced FET3 and FTR1 expression arises from an indirect copper effect on cellular iron pools.	Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA; Stanford Univ, Sch Med, Dept Biochem, Howard Hughes Med Inst, Stanford, CA 94305 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Stanford University	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA.	dennis.winge@hsc.utah.edu	Winge, Dennis/G-3611-2010		NCI NIH HHS [5P30-CA 42014, CA61286] Funding Source: Medline; NHGRI NIH HHS [HG00983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061286, P30CA042014] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000983] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BAKERBRACHMANN C, 1998, YEAST, V14, P115; BUCHMAN C, 1989, MOL CELL BIOL, V9, P4091, DOI 10.1128/MCB.9.9.4091; BUCHMAN C, 1990, MOL CELL BIOL, V10, P4778, DOI 10.1128/MCB.10.9.4778; CULOTTA VC, 1994, J BIOL CHEM, V269, P25295; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dix D, 1997, J BIOL CHEM, V272, P11770, DOI 10.1074/jbc.272.18.11770; FOGEL S, 1982, P NATL ACAD SCI-BIOL, V79, P5342, DOI 10.1073/pnas.79.17.5342; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; GRALLA EB, 1991, P NATL ACAD SCI USA, V88, P8558, DOI 10.1073/pnas.88.19.8558; HAMER DH, 1985, SCIENCE, V228, P685, DOI 10.1126/science.3887570; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Jensen LT, 1996, J BIOL CHEM, V271, P18514, DOI 10.1074/jbc.271.31.18514; Jensen LT, 1998, J BIOL CHEM, V273, P23805, DOI 10.1074/jbc.273.37.23805; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; KAMPFENKEL K, 1995, J BIOL CHEM, V270, P28479, DOI 10.1074/jbc.270.47.28479; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; Lesuisse E, 1996, J BIOL CHEM, V271, P13578, DOI 10.1074/jbc.271.23.13578; Liu XF, 1997, J BIOL CHEM, V272, P11763, DOI 10.1074/jbc.272.18.11763; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; McDaniels CPJ, 1999, J BIOL CHEM, V274, P26962, DOI 10.1074/jbc.274.38.26962; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Ono B, 1999, YEAST, V15, P1365, DOI 10.1002/(SICI)1097-0061(19990930)15:13<1365::AID-YEA468>3.0.CO;2-U; Serpe M, 1999, J BIOL CHEM, V274, P29211, DOI 10.1074/jbc.274.41.29211; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; Winge DR, 1998, CURR OPIN CHEM BIOL, V2, P216, DOI 10.1016/S1367-5931(98)80063-X; Winge DR, 1998, PROG NUCLEIC ACID RE, V58, P165; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zhao H, 1998, J BIOL CHEM, V273, P28713, DOI 10.1074/jbc.273.44.28713; Zhu ZW, 1998, J BIOL CHEM, V273, P1277, DOI 10.1074/jbc.273.3.1277	41	141	151	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32310	32316		10.1074/jbc.M005946200	http://dx.doi.org/10.1074/jbc.M005946200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10922376	hybrid			2022-12-25	WOS:000089858900103
J	Holliday, LS; Lu, M; Lee, BS; Nelson, RD; Solivan, S; Zhang, L; Gluck, SL				Holliday, LS; Lu, M; Lee, BS; Nelson, RD; Solivan, S; Zhang, L; Gluck, SL			The amino-terminal domain of the B subunit of vacuolar H+-ATPase contains a filamentous actin binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCLASTS; EXPRESSION; KIDNEY; ACIDIFICATION; ASSOCIATION; RESORPTION; ISOFORM; MYOSIN; MOUSE; MICE	Vacuolar H+-ATPase (V-ATPase) binds actin filaments with high affinity (K-d = 55 nM; Lee, B. S., Gluck, S. L., and Holliday, L. S. (1999) J. Biol. Chem. 274, 29164-29171). We have proposed that this interaction is an important mechanism controlling transport of V-ATPase from the cytoplasm to the plasma membrane of osteoclasts. Here we show that both the B1 (kidney) and B2 (brain) isoforms of the B subunit of V-ATPase contain a microfilament binding site in their amino-terminal domain. In pelleting assays containing actin filaments and partially disrupted V-ATPase, B subunits were found in greater abundance in actin pellets than were other V-ATPase subunits, suggesting that the B subunit contained an F-actin binding site. In overlay assays, biotinylated actin filaments also bound to the B subunit. A fusion protein containing the amino-terminal half of B1 subunit bound actin filaments tightly, but fusion proteins containing the carboxyl-terminal half of B1 subunit, or the full-length E subunit, did not bind F-actin. Fusion proteins containing the amino-terminal 106 amino acids of the B1 isoform or the amino-terminal 112 amino acids of the 112 isoform bound filamentous actin with K-d values of 130 and 190 nM, respectively, and approached saturation at 1 mel of fusion protein/mol of filamentous actin. The B1 and B2 amino-terminal fusion proteins competed with V-ATPase for binding to filamentous actin. In summary, binding sites for F-actin are present in the aminoterminal domains of both isoforms of the B subunit, and likely are responsible for the interaction between V-ATPase and actin filaments in vivo.	Univ Florida, Coll Med, Dept Med, Div Nephrol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Univ Utah, Dept Pediat, Salt Lake City, UT 84132 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Washington University (WUSTL); Utah System of Higher Education; University of Utah	Holliday, LS (corresponding author), Univ Florida, Coll Med, Dept Med, Div Nephrol, 1600 Archer Rd,Campus Box 100224, Gainesville, FL 32610 USA.		Lee, Beth S/E-9578-2010; Holliday, Lexie/GYQ-4972-2022	Lee, Beth S/0000-0002-1468-6387; Holliday, Lexie/0000-0002-0844-1965	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038848, R01DK052131] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK52131, R01 DK38848] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AbuAmer Y, 1997, J CELL BIOL, V137, P247, DOI 10.1083/jcb.137.1.247; BASTANI B, 1991, J CLIN INVEST, V88, P126, DOI 10.1172/JCI115268; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; Boekema EJ, 1999, NATURE, V401, P37, DOI 10.1038/43369; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; Breton S, 1996, NAT MED, V2, P470, DOI 10.1038/nm0496-470; BROWN D, 1987, J CELL BIOL, V105, P1636; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Forgac M, 2000, J EXP BIOL, V203, P71; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; GLUCK S, 1987, J BIOL CHEM, V262, P15780; Gluck S L, 1993, Int Rev Cytol, V137C, P105; Gluck SL, 1996, ANNU REV PHYSIOL, V58, P427, DOI 10.1146/annurev.physiol.58.1.427; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; HOLLIDAY LS, 1995, J BIOL CHEM, V270, P18983, DOI 10.1074/jbc.270.32.18983; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; Lee BS, 1999, J BIOL CHEM, V274, P29164, DOI 10.1074/jbc.274.41.29164; Lee BS, 1999, J BONE MINER RES, V14, P2127, DOI 10.1359/jbmr.1999.14.12.2127; LEE BS, 1996, AM J PHYSIOL, V39, pC382; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Luna EJ, 1998, METHOD ENZYMOL, V298, P32, DOI 10.1016/S0076-6879(98)98006-5; MARKS SC, 1985, J HERED, V76, P171, DOI 10.1093/oxfordjournals.jhered.a110059; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Nakamura I, 1997, FEBS LETT, V401, P207, DOI 10.1016/S0014-5793(96)01454-8; Nelson N, 2000, J EXP BIOL, V203, P89; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; Sambrook J., 1989, MOL CLONING LAB MANU, V3, P18; SATO M, 1990, CELL MOTIL CYTOSKEL, V17, P250, DOI 10.1002/cm.970170311; Scimeca JC, 2000, BONE, V26, P207, DOI 10.1016/S8756-3282(99)00278-1; Skinner MA, 1999, J HISTOCHEM CYTOCHEM, V47, P1247, DOI 10.1177/002215549904701004; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TISHER CC, 1991, CONTRIB NEPHROL, V95, P168; VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305; Wax MB, 1997, P NATL ACAD SCI USA, V94, P6752, DOI 10.1073/pnas.94.13.6752; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Zhang N, 1999, ONCOGENE, V18, P2273, DOI 10.1038/sj.onc.1202545	39	151	156	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32331	32337		10.1074/jbc.M004795200	http://dx.doi.org/10.1074/jbc.M004795200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10915794	hybrid			2022-12-25	WOS:000089858900106
J	Inbar, O; Liefshitz, B; Bitan, G; Kupiec, M				Inbar, O; Liefshitz, B; Bitan, G; Kupiec, M			The relationship between homology length and crossing over during the repair of a broken chromosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAK; SACCHAROMYCES-CEREVISIAE MSH2; GENE CONVERSION TRACTS; YEAST MATING TYPE; MISMATCH-REPAIR; MITOTIC RECOMBINATION; DNA; PROTEINS; RESOLUTION; BINDS	Homologous recombination can result in the transfer of genetic information from one DNA molecule to another (gene conversion). These events are often accompanied by a reciprocal exchange between the interacting molecules (termed "crossing over"). This association suggests that the two types of events could be mechanistically related. We have analyzed the repair, by homologous recombination, of a broken chromosome in yeast. We show that gene conversion can be uncoupled from crossing over when the length of homology of the interacting substrates is below a certain threshold. In addition, a minimal length of homology on each broken chromosomal arm is needed for crossing over. We also show that the coupling between gene conversion and crossing over is affected by the mismatch repair system; mutations in the MSH2 or MSH6 genes cause an increase in the crossing over observed for short alleles. Our results provide a mechanism to explain how chromosomal recombinational repair can take place without altering the stability of the genome.	Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, IL-69978 Ramat Aviv, Israel	Tel Aviv University	Kupiec, M (corresponding author), Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, IL-69978 Ramat Aviv, Israel.		Bitan, Gal/U-2204-2019	Bitan, Gal/0000-0001-7046-3754				AGUILERA A, 1989, GENETICS, V123, P683; ALANI E, 1994, GENETICS, V137, P19; Alani E, 1996, MOL CELL BIOL, V16, P5604; BELMAAZA A, 1994, MUTAT RES, V314, P199, DOI 10.1016/0921-8777(94)90065-5; BENNETT CB, 1993, P NATL ACAD SCI USA, V90, P5613, DOI 10.1073/pnas.90.12.5613; Chen WL, 1998, MOL CELL BIOL, V18, P6525, DOI 10.1128/MCB.18.11.6525; Datta A, 1996, MOL CELL BIOL, V16, P1085; Datta A, 1997, P NATL ACAD SCI USA, V94, P9757, DOI 10.1073/pnas.94.18.9757; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; FUJITANI Y, 1995, GENETICS, V140, P797; HABER JE, 1993, P NATL ACAD SCI USA, V90, P3363, DOI 10.1073/pnas.90.8.3363; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; Inbar O, 1999, MOL CELL BIOL, V19, P4134; JINKSROBERTSON S, 1993, MOL CELL BIOL, V13, P3937, DOI 10.1128/MCB.13.7.3937; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; KLAR AJS, 1984, NATURE, V310, P744, DOI 10.1038/310744a0; LICHTEN M, 1989, GENETICS, V123, P261; Marsischky GT, 1999, J BIOL CHEM, V274, P7200, DOI 10.1074/jbc.274.11.7200; MCGILL CB, 1993, CURR GENET, V23, P305, DOI 10.1007/BF00310891; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; NASMYTH KA, 1982, ANNU REV GENET, V16, P439, DOI 10.1146/annurev.ge.16.120182.002255; NASSIF N, 1994, MOL CELL BIOL, V14, P1613, DOI 10.1128/MCB.14.3.1613; NICKOLOFF JA, 1990, MOL CELL BIOL, V10, P1174, DOI 10.1128/MCB.10.3.1174; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; Paques F, 1997, MOL CELL BIOL, V17, P6765, DOI 10.1128/MCB.17.11.6765; Paques F, 1998, MOL CELL BIOL, V18, P2045, DOI 10.1128/MCB.18.4.2045; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; Porter G, 1996, GENETICS, V143, P755; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; SWEETSER DB, 1994, MOL CELL BIOL, V14, P3863, DOI 10.1128/MCB.14.6.3863; SZOSTAK JW, 1983, CELL, V3, P725; Weng YS, 1998, GENETICS, V148, P59; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; ZENVIRTH D, 1992, EMBO J, V11, P3441, DOI 10.1002/j.1460-2075.1992.tb05423.x	39	56	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30833	30838		10.1074/jbc.C000133200	http://dx.doi.org/10.1074/jbc.C000133200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10924495	hybrid			2022-12-25	WOS:000089762700016
J	Overgaard, MT; Haaning, J; Boldt, HB; Olsen, IM; Laursen, LS; Christiansen, M; Gleich, GJ; Sottrup-Jensen, L; Conover, CA; Oxvig, C				Overgaard, MT; Haaning, J; Boldt, HB; Olsen, IM; Laursen, LS; Christiansen, M; Gleich, GJ; Sottrup-Jensen, L; Conover, CA; Oxvig, C			Expression of recombinant human pregnancy-associated plasma protein-A and identification of the proform of eosinophil major basic protein as its physiological inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR BINDING PROTEIN-4; MESSENGER-RIBONUCLEIC-ACID; MATRIX METALLOPROTEINASES; HUMAN FIBROBLASTS; CYSTEINE SWITCH; DOWN-SYNDROME; PAPP-A; SERUM; PRECURSOR; PURIFICATION	Pregnancy-associated plasma protein-A (PAPP-A), originally known from human pregnancy serum, has recently been demonstrated to be a metzincin superfamily metalloproteinase involved in normal and pathological insulin-like growth factor (IGF) physiology. PAPP-A specifically cleaves IGF-binding protein (LGFBP)-4, one of six antagonists of IGF action, which results in release of IGF bound to IGFBP-4. IGFBP-4 is the only known PAPP-A substrate. Its cleavage by PAPP-A uniquely depends on the presence of IGF. We here report mammalian expression and purification of recombinant 1547-residue PAPP-A (rPAPP-A). The recombinant protein is secreted as a homodimer of about 400 kDa composed of two 200-kDa disulfide-bound subunits. Antigenically and functionally, rPAPP-A behaves like the native protein. In human pregnancy, PAPP-A is known to circulate as a 500-kDa disulfide-bound 2:2 complex with the proform of eosinophil major basic protein (proMBP), PAPP-A/proMBP. A comparison between rPAPP-A and pregnancy serum PAPP-A/proMBP complex surprisingly reveals a difference greater than 100-fold in proteolytic activity, showing that proMBP functions as a proteinase inhibitor in vivo. We find that polyclonal antibodies against PAPP-A abrogate all detectable IGFBP-4 proteolytic activity in pregnancy serum, pointing at PAPP-A as the dominating, if not the only, IGFBP-4 proteinase present in the circulation. We further show that pregnancy serum and plasma contain traces (<1%) of uncomplexed PAPP-A with a much higher specific activity than the PAPP-A/proMBP complex. The measurable activity of the PAPP-A/proMBP complex probably results from the presence of a minor subpopulation of partly inhibited PAPP-A that exists in a 2:1 complex with proMBP. Inhibition of PAPP-A by proMBP represents a novel inhibitory mechanism with the enzyme irreversibly bound to its inhibitor by disulfide bonds.	Aarhus Univ, Dept Mol & Struct Biol, DK-8000 Aarhus C, Denmark; Statens Serum Inst, Dept Clin Biochem, DK-2300 Copenhagen S, Denmark; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Endocrine Res Unit, Rochester, MN 55905 USA	Aarhus University; Statens Serum Institut; Mayo Clinic; Mayo Clinic	Oxvig, C (corresponding author), Aarhus Univ, Dept Mol & Struct Biol, Sci Pk,Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.	co@mbio.aau.dk	Christiansen, Michael/B-4588-2009; Overgaard, Michael Toft/E-1354-2011	Christiansen, Michael/0000-0003-4713-755X; Overgaard, Michael Toft/0000-0002-1423-2481; Laursen, Lisbeth Schmidt/0000-0002-8676-5869; Oxvig, Claus/0000-0002-4715-9719				Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BARKER RL, 1991, J CLIN INVEST, V88, P798, DOI 10.1172/JCI115379; BARKER RL, 1988, J EXP MED, V168, P1493, DOI 10.1084/jem.168.4.1493; BISCHOF P, 1979, ARCH GYNECOL, V227, P315, DOI 10.1007/BF02109920; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; BONNO M, 1994, LAB INVEST, V71, P560; Byun D, 2000, J CLIN ENDOCR METAB, V85, P373, DOI 10.1210/jc.85.1.373; Christiansen M, 1999, PRENATAL DIAG, V19, P905, DOI 10.1002/(SICI)1097-0223(199910)19:10<905::AID-PD658>3.0.CO;2-Q; Conover CA, 1999, J CLIN ENDOCR METAB, V84, P4742, DOI 10.1210/jc.84.12.4742; CONOVER CA, 1993, J CLIN INVEST, V91, P1129, DOI 10.1172/JCI116272; DAVEY MW, 1983, ANAL BIOCHEM, V131, P18, DOI 10.1016/0003-2697(83)90130-6; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; FOLKERSEN J, 1981, AM J OBSTET GYNECOL, V139, P910, DOI 10.1016/0002-9378(81)90957-1; Fowlkes JL, 1997, TRENDS ENDOCRIN MET, V8, P299, DOI 10.1016/S1043-2760(97)00112-4; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Haaning J, 1996, EUR J BIOCHEM, V237, P159, DOI 10.1111/j.1432-1033.1996.0159n.x; KRISTENSEN T, 1994, BIOCHEMISTRY-US, V33, P1592, DOI 10.1021/bi00172a040; Kubler B, 1998, ENDOCRINOLOGY, V139, P1556, DOI 10.1210/en.139.4.1556; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence JB, 1999, GROWTH HORM IGF RES, V9, P25, DOI 10.1054/ghir.1998.0083; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; LIN TM, 1974, AM J OBSTET GYNECOL, V118, P223, DOI 10.1016/0002-9378(74)90553-5; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; MCGROGAN M, 1988, J EXP MED, V168, P2295, DOI 10.1084/jem.168.6.2295; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Overgaard MT, 1999, BIOL REPROD, V61, P1083, DOI 10.1095/biolreprod61.4.1083; OXVIG C, 1994, FEBS LETT, V341, P213, DOI 10.1016/0014-5793(94)80459-1; OXVIG C, 1994, BIOCHEM MOL BIOL INT, V33, P329; OXVIG C, 1995, J BIOL CHEM, V270, P13645, DOI 10.1074/jbc.270.23.13645; OXVIG C, 1993, J BIOL CHEM, V268, P12243; OXVIG C, 1994, BBA-GEN SUBJECTS, V1201, P415, DOI 10.1016/0304-4165(94)90071-X; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Popken-Harris P, 1998, BLOOD, V92, P623, DOI 10.1182/blood.V92.2.623.414k32_623_631; Qin QP, 1997, CLIN CHEM, V43, P2323; Qin XZ, 1998, J BIOL CHEM, V273, P23509, DOI 10.1074/jbc.273.36.23509; Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801; SINOSICH MJ, 1990, ELECTROPHORESIS, V11, P70, DOI 10.1002/elps.1150110115; SOTTRUPJENSEN L, 1993, BIOCHEM MOL BIOL INT, V30, P789; SOTTRUPJENSEN L, 1995, ANAL BIOCHEM, V225, P187, DOI 10.1006/abio.1995.1137; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; Tsukuba T, 1998, J BIOL CHEM, V273, P35260, DOI 10.1074/jbc.273.52.35260; WESTERGAARD JG, 1983, PLACENTA, V4, P13, DOI 10.1016/S0143-4004(83)80013-7	43	154	169	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31128	31133		10.1074/jbc.M001384200	http://dx.doi.org/10.1074/jbc.M001384200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10913121	hybrid			2022-12-25	WOS:000089762700055
J	Jeon, H; Shipley, GG				Jeon, H; Shipley, GG			Localization of the N-terminal domain of the low density lipoprotein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; CYSTEINE-RICH REPEAT; LIGAND-BINDING DOMAIN; LDL RECEPTOR; FAMILIAL HYPERCHOLESTEROLEMIA; 3-DIMENSIONAL STRUCTURE; NUCLEOTIDE-SEQUENCE; FACTOR PRECURSOR; CALCIUM-BINDING; PROTEINS	The low density lipoprotein (LDL) receptor is a transmembrane glycoprotein performing "receptor-mediated endocytosis" of cholesterol-rich lipoproteins. At the N terminus, the LDL receptor has modular cysteine-rich repeats in both the ligand binding domain and the epidermal growth factor (EGF) precursor homology domain. Each repeat contains six disulfide-bonded cysteine residues, and this structural motif has also been found in many other proteins. The bovine LDL receptor has been purified and reconstituted into egg yolk phosphatidylcholine vesicle bilayers, Using gel electrophoresis and cryoelectron microscopy (cryoEM), the ability of the reconstituted LDL receptor to bind its ligand LDL has been demonstrated. After reduction of the disulfide-bonds in the N-terminal domain of the receptor, the reduced LDL receptor was visualized using cryoEM; reduced LDL receptors showed images with a diffuse density region at the distal end of the extracellular domain. Gold labeling of the reduced cysteine residues was achieved with monomaleimido-Nanogold, and the bound Nanogold was visualized in cryoEM images of the reduced, gold-labeled receptor. Multiple gold particles were observed in the diffuse density region at the distal end of the receptor. Thus, the location of the ligand binding domain of the LDL receptor has been determined, and a model is suggested for the arrangement of the seven cysteine-rich repeats of the ligand binding domain and two EGF-like cysteine-rich repeats of the EGF precursor homology domain.	Boston Univ, Sch Med, Ctr Adv Biomed Res, Dept Biophys, Boston, MA 02118 USA; Boston Univ, Sch Med, Ctr Adv Biomed Res, Dept Biochem, Boston, MA 02118 USA	Boston University; Boston University	Shipley, GG (corresponding author), Boston Univ, Sch Med, Ctr Adv Biomed Res, Dept Biophys, 715 Albany St, Boston, MA 02118 USA.	shipley@med-biophd.bu.edu		Shipley, G./0000-0001-9603-5555	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057405, P01HL026335] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 57405, HL 26335] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bieri S, 1998, BIOCHEMISTRY-US, V37, P10994, DOI 10.1021/bi980452c; BISHOP RW, 1992, J LIPID RES, V33, P549; Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; DAHLBACK B, 1986, P NATL ACAD SCI USA, V83, P4199, DOI 10.1073/pnas.83.12.4199; DALY NL, 1995, BIOCHEMISTRY-US, V34, P14474, DOI 10.1021/bi00044a025; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; DAVIS CG, 1987, NATURE, V326, P760, DOI 10.1038/326760a0; Dirlam KA, 1996, PROTEIN EXPRES PURIF, V8, P489, DOI 10.1016/S1046-5928(96)90129-1; DOOLITTLE RF, 1985, TRENDS BIOCHEM SCI, V10, P233, DOI 10.1016/0968-0004(85)90140-9; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOFFER MJV, 1993, BIOCHEM BIOPH RES CO, V191, P880, DOI 10.1006/bbrc.1993.1299; HOMMEL U, 1992, J MOL BIOL, V227, P271, DOI 10.1016/0022-2836(92)90697-I; JACKMAN RW, 1986, P NATL ACAD SCI USA, V83, P8834, DOI 10.1073/pnas.83.23.8834; Jeon H, 2000, J BIOL CHEM, V275, P30458, DOI 10.1074/jbc.M002583200; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE LY, 1989, NUCLEIC ACIDS RES, V17, P1259, DOI 10.1093/nar/17.3.1259; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1984, J LIPID RES, V25, P1277; MEHTA KD, 1991, J BIOL CHEM, V266, P10406; MONTELIONE GT, 1992, BIOCHEMISTRY-US, V31, P236, DOI 10.1021/bi00116a033; North CL, 1999, BIOCHEMISTRY-US, V38, P3926, DOI 10.1021/bi9821622; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SCHNEIDER WJ, 1985, METHOD ENZYMOL, V109, P405; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; Simmons T, 1997, J BIOL CHEM, V272, P25531, DOI 10.1074/jbc.272.41.25531; Spin JM, 1997, THESIS BOSTON U; SUDHOF TC, 1985, SCIENCE, V228, P893, DOI 10.1126/science.3873704; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	41	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30465	30470		10.1074/jbc.M002582200	http://dx.doi.org/10.1074/jbc.M002582200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10889195	hybrid			2022-12-25	WOS:000089577900075
J	Ryu, J; Pyo, H; Jou, I; Joe, EH				Ryu, J; Pyo, H; Jou, I; Joe, EH			Thrombin induces NO release from cultured rat microglia via protein kinase C, mitogen-activated protein kinase, and NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ENDOTHELIAL-CELLS; TYROSINE KINASE; GLIOMA-CELLS; RECEPTOR; BRAIN; LIPOPOLYSACCHARIDE; ASTROCYTES; PATHWAY; INDUCTION	Microglia, brain resident macrophages, become activated in brains injured due to trauma, ischemia, or neurodegenerative diseases. In this study, we found that thrombin treatment of microglia induced NO release/ inducible nitric-oxide synthase expression, a prominent marker of activation. The effect of thrombin on NO release increased dose-dependently within the range of 5-20 units/ml. In immunoblot analyses, inducible nitric-oxide synthase expression was detected within 9 h after thrombin treatment. This effect of thrombin was significantly reduced by protein kinase C inhibitors, such as Go6976, bisindolylmaleimide, and Ro31-8220. Within 15 min, thrombin activated three subtypes of mitogen-activated protein kinases: extracellular signal-regulated kinase, p38, and c-Jun N-terminal kinase/stress-activated protein kinase. Inhibition of the extracellular signal-regulated kinase pathway and p38 reduced the NO release of thrombin-treated microglia. Thrombin also activated nuclear factor kappa B (NF-kappa KB) within 5 min, and N-acetyl cysteine, an inhibitor of NF-kappa B, reduced NO release. However, thrombin receptor agonist peptide (an agonist of protease activated receptor-1 (PAR-1)), could not mimic the effect of thrombin, and cathepsin G, a PAR 1 inhibitor, did not reduce the effect of thrombin. These results suggest that thrombin can activate microglia via protein kinase C, mitogen-activated protein kinases, and NF-kappa B but that this occurs independently of PAR-1.	Ajou Univ, Sch Med, Dept Pharmacol, Suwon 442721, South Korea	Ajou University	Joe, EH (corresponding author), San-5 Woncheon-dong, Suwon 442721, Kyunggido, South Korea.							BHAT NR, 1995, J CELL PHYSIOL, V165, P417, DOI 10.1002/jcp.1041650223; Bonaiuto C, 1997, J NEUROIMMUNOL, V77, P51, DOI 10.1016/S0165-5728(97)00054-4; Brass LF, 1997, THROMB HAEMOSTASIS, V78, P234; BREITNER JCS, 1994, NEUROLOGY, V44, P227, DOI 10.1212/WNL.44.2.227; CARTER AN, 1994, BIOCHEM J, V301, P415, DOI 10.1042/bj3010415; Chinni C, 1999, J BIOL CHEM, V274, P9169, DOI 10.1074/jbc.274.14.9169; Debeir T, 1997, EUR J PHARMACOL, V323, P111, DOI 10.1016/S0014-2999(97)00018-6; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; DING AH, 1988, J IMMUNOL, V141, P2407; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; FENTON JW, 1991, HAEMOSTASIS, V21, P27; Fiebich BL, 1998, J NEUROIMMUNOL, V92, P170, DOI 10.1016/S0165-5728(98)00201-X; GIULIAN D, 1986, J NEUROSCI, V6, P2163; GLENN KC, 1980, J BIOL CHEM, V255, P6609; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; Hellendall RP, 1997, J NEUROIMMUNOL, V74, P19, DOI 10.1016/S0165-5728(96)00202-0; Holland JA, 1998, ENDOTHELIUM-NEW YORK, V6, P113, DOI 10.3109/10623329809072198; JONES A, 1990, IMMUNOLOGY, V71, P236; Kaufmann R, 1996, J NEUROSCI RES, V46, P641, DOI 10.1002/(SICI)1097-4547(19961215)46:6<641::AID-JNR1>3.0.CO;2-F; Krymskaya VP, 1999, AM J PHYSIOL-LUNG C, V277, pL65; Kurkowska-Jastrzebska I, 1999, EXP NEUROL, V156, P50, DOI 10.1006/exnr.1998.6993; LEE SC, 1993, J IMMUNOL, V150, P2659; LIU Y, 1994, P NATL ACAD SCI USA, V91, P10300, DOI 10.1073/pnas.91.22.10300; McMillian MK, 1997, J NEUROPATH EXP NEUR, V56, P301, DOI 10.1097/00005072-199703000-00009; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MINGHETTI L, 1995, J NEUROCHEM, V65, P2690; Nakai M, 1999, J NEUROCHEM, V72, P1179, DOI 10.1046/j.1471-4159.1999.0721179.x; Naldini A, 1998, J CELL PHYSIOL, V177, P76, DOI 10.1002/(SICI)1097-4652(199810)177:1<76::AID-JCP8>3.0.CO;2-B; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; Ofosu FA, 1998, BIOCHEM J, V336, P283, DOI 10.1042/bj3360283; OLIVIER D, 1998, AM J PHYSIOL, V274, pC1429; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; Pyo H, 1998, NEUROREPORT, V9, P871, DOI 10.1097/00001756-199803300-00020; Pyo H, 1999, J BIOL CHEM, V274, P34584, DOI 10.1074/jbc.274.49.34584; Roebuck KA, 1999, INT J MOL MED, V4, P223; Rupalla K, 1998, ACTA NEUROPATHOL, V96, P172, DOI 10.1007/s004010050878; Sower LE, 1999, EXP CELL RES, V247, P422, DOI 10.1006/excr.1998.4372; Suidan HS, 1997, GLIA, V21, P244, DOI 10.1002/(SICI)1098-1136(199710)21:2<244::AID-GLIA7>3.0.CO;2-6; Turgeon VL, 1998, J NEUROSCI, V18, P6882; Ubl JJ, 1997, PFLUG ARCH EUR J PHY, V433, P312; Ubl JJ, 1998, NEUROSCIENCE, V86, P597, DOI 10.1016/S0306-4522(97)00686-6; Vlahopoulos S, 1999, BLOOD, V94, P1878, DOI 10.1182/blood.V94.6.1878; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhang ZG, 1997, BRAIN RES, V744, P189, DOI 10.1016/S0006-8993(96)01085-2; ZIELASEK J, 1992, CELL IMMUNOL, V141, P111, DOI 10.1016/0008-8749(92)90131-8	46	139	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29955	29959		10.1074/jbc.M001220200	http://dx.doi.org/10.1074/jbc.M001220200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10893407	hybrid			2022-12-25	WOS:000089577900007
J	Santos, MA; Jimenez, A; Revuelta, JL				Santos, MA; Jimenez, A; Revuelta, JL			Molecular characterization of FMN1, the structural gene for the monofunctional flavokinase of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-DINUCLEOTIDE SYNTHETASE; RAT-LIVER; RIBOFLAVIN BIOSYNTHESIS; ESCHERICHIA-COLI; FAD SYNTHETASE; PROTEIN; YEAST; MITOCHONDRIA; PURIFICATION; EXPRESSION	Flavokinase catalyzes the transfer of the gamma-phosphoryl group of ATP to riboflavin to form the flavocoenzyme FMN. Consistent patterns of sequence similarities have identified the open reading frame of unknown function YDR236c as a candidate to encode flavokinase in Saccharomyces cerevisiae, In order to determine whether the product of this gene corresponds to yeast flavokinase, its coding region was amplified from S, cerevisiae genomic DNA by polymerase chain reaction and expressed in Escherichia coli, The purified form of the expressed recombinant protein efficiently catalyzed the formation of FMN from riboflavin and ATP, In contrast to bifunctional prokaryotic flavokinase/FAD synthetase enzymes, the yeast enzyme did not show accompanying FAD synthetase activity. Deletion of YDR236c produced yeast mutants unable to grow on rich medium; however, the growth of the ydr236c Delta mutants could be rescued by the addition of FMN to the medium. Overexpression of YDR236e caused a 50-fold increase in flavokinase specific activity in yeast cells. These findings demonstrate that YDR236e corresponds to the gene encoding a monofunctional flavokinase in yeast, which we propose to be designated as FMN1. The FMN1 gene codes for a 25-kDa protein with characteristics of signals for import into mitochondria. By immunoblotting analysis of Saccharomyces subcellular fractions, we provide evidence that the Fmn1 protein is localized in microsomes and in mitochondria, Analysis of submitochondrial fractions revealed that the mitochondrial form of Fmn1p is an integral protein of the inner membrane exposing its COOH-terminal domain to the matrix space. A similarity search in the data base banks revealed the presence of sequences homologous to yeast flavokinase in the genome of several eukaryotic organisms such as Schizosaccharomyces pombe, Arabidopsis thaliana, Drosophila melanogaster, Caenorhabditis elegans, and humans.	Univ Salamanca, CSIC, Dept Genet & Microbiol, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca	Revuelta, JL (corresponding author), Univ Salamanca, CSIC, Dept Genet & Microbiol, Campus Miguel de Unamuno, Salamanca 37007, Spain.		Santos, Maria Angeles/H-2239-2015; Jiménez, Alberto/A-6234-2009; Revuelta, Jose Luis/ABG-1502-2020; Revuelta, Jose L/C-2324-2012	Santos, Maria Angeles/0000-0002-1257-7611; Jiménez, Alberto/0000-0003-3685-6479; Revuelta, Jose Luis/0000-0001-7838-5308; Revuelta, Jose L/0000-0001-7838-5308				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BARILE M, 1993, ARCH BIOCHEM BIOPHYS, V305, P442, DOI 10.1006/abbi.1993.1444; Brachmann CB, 1998, YEAST, V14, P115; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cooperman J.M., 1984, HDB VITAMINS NUTR BI, P299; Dawson R. M. C., 1991, DATA BIOCH RES, V3rd, P363; Forster C, 1999, J BIOL CHEM, V274, P9442, DOI 10.1074/jbc.274.14.9442; GARCIARAMIREZ JJ, 1995, J BIOL CHEM, V270, P23801, DOI 10.1074/jbc.270.40.23801; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOMES B, 1983, P SOC EXP BIOL MED, V172, P250; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Jacq C, 1997, NATURE, V387, P75, DOI 10.1038/387s075; KEARNEY EB, 1979, J BIOL CHEM, V254, P9551; Koonin EV, 1998, CURR OPIN STRUC BIOL, V8, P355, DOI 10.1016/S0959-440X(98)80070-5; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mack M, 1998, J BACTERIOL, V180, P950, DOI 10.1128/JB.180.4.950-955.1998; MANSTEIN DJ, 1986, J BIOL CHEM, V261, P6169; MCCORMICK DB, 1989, PHYSIOL REV, V69, P1170, DOI 10.1152/physrev.1989.69.4.1170; MCCORMICK DB, 1987, FLAVINS FLAVOPROTEIN, P459; MERRILL AH, 1980, J BIOL CHEM, V255, P1335; MITSUDA H, 1966, P JPN ACAD, V42, P940, DOI 10.2183/pjab1945.42.940; NAKANO H, 1991, FLAVINS AND FLAVOPROTEINS 1990, P89; NAKANO H, 1991, J BIOL CHEM, V266, P22125; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OKA M, 1987, J BIOL CHEM, V262, P7418; Pallotta ML, 1998, FEBS LETT, V428, P245, DOI 10.1016/S0014-5793(98)00544-4; REDDY ARV, 1980, J BIOSCIENCE, V2, P211; REID GA, 1982, J BIOL CHEM, V257, P3068; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; SANTOS MA, 1995, J BIOL CHEM, V270, P437, DOI 10.1074/jbc.270.1.437; SCHRECKER AW, 1950, J BIOL CHEM, V182, P795; Sherman F., 1986, METHODS YEAST GENETI, P163; SOBHANADITYA J, 1981, BIOCHEM J, V197, P227, DOI 10.1042/bj1970227; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Tzagoloff A, 1996, J BIOL CHEM, V271, P7392, DOI 10.1074/jbc.271.13.7392; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WU M, 1995, MOL CELL BIOL, V15, P264, DOI 10.1128/MCB.15.1.264; YAMADA Y, 1990, ARCH BIOCHEM BIOPHYS, V278, P125, DOI 10.1016/0003-9861(90)90240-Y; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	45	59	63	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28618	28624		10.1074/jbc.M004621200	http://dx.doi.org/10.1074/jbc.M004621200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10887197	hybrid			2022-12-25	WOS:000089330700039
J	Hannan, KM; Kennedy, BK; Cavanaugh, AH; Hannan, RD; Hirschler-Laszkiewicz, I; Jefferson, LS; Rothblum, LI				Hannan, KM; Kennedy, BK; Cavanaugh, AH; Hannan, RD; Hirschler-Laszkiewicz, I; Jefferson, LS; Rothblum, LI			RNA polymerase I transcription in confluent cells: Rb downregulates rDNA transcription during confluence-induced cell cycle arrest	ONCOGENE			English	Article						retinoblastoma protein; ribosomal RNA; transcription; confluence; cell cycle	RIBOSOMAL DNA-TRANSCRIPTION; RETINOBLASTOMA GENE-PRODUCT; UPSTREAM BINDING-FACTOR; FACTOR-TIF-IA; FACTOR UBF; INITIATION-FACTOR; CARDIOMYOCYTE HYPERTROPHY; NEONATAL CARDIOMYOCYTES; C-FOS; PROMOTER	When 3T6 cells are confluent, they withdraw from the cell cycle. Concomitant with cell cycle arrest significant reduction in RNA polymerase I transcription (80% decrease at 100% confluence) is observed. In the present study, we examined mechanism(s) through which transcription of the ribosomal genes is coupled to cell cycle arrest induced by cell density. Interestingly with an increase in cell density (from 3-43% confluence), a significant accumulation in the cellular content of hyperphosphorylated Rb was observed. As cell density increased further, the hypophosphorylated form of Rb became predominant and accumulated in the nucleoli, Co-immunoprecipitation experiments demonstrated there was also a significant rise in the amount of hypophosphorylated Rb associated with the rDNA transcription factor UBF, This increased interaction between Rb and UBF correlated with the reduced rate of rDNA transcription. Furthermore, overexpression of recombinant Rb inhibited UBF-dependent activation of transcription from a cotransfected rDNA reporter in either confluent or exponential cells. The amounts or activities of the rDNA transcription components we examined did not significantly change with cell cycle arrest. Although the content of PAF53, a polymerase associated factor was altered marginally (decreased 38%), the time course and magnitude of the decrease did not correlate with the reduced rate of rDNA transcription. The results presented support a model wherein regulation of the binding of UBF to Rb and, perhaps the cellular content of PAF53, are components of the mechanism through which cell cycle and rDNA transcription are linked.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Massachusetts Gen Hosp, Ctr Canc, Dept Mol Oncol, Charlestown, MA 02129 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Harvard University; Massachusetts General Hospital	Rothblum, LI (corresponding author), Penn State Univ, Coll Med, Sigfried & Janet Weis Ctr Res, Henry Hood Res Program, Danville, PA 17822 USA.			Hannan, Katherine/0000-0003-4186-8167; Hannan, Ross/0000-0002-2166-4493; Kennedy, Brian/0000-0002-5754-1874	NIDDK NIH HHS [DK13499, DK15658] Funding Source: Medline; NIGMS NIH HHS [GM48991] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015658, R01DK013499, R37DK013499] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberts B., 1994, MOL BIOL CELL; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BECKMANN H, 1995, SCIENCE, V270, P1506, DOI 10.1126/science.270.5241.1506; BRUN RP, 1994, MOL CELL BIOL, V14, P5010, DOI 10.1128/MCB.14.7.5010; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CAVANAUGH AH, 1984, P NATL ACAD SCI-BIOL, V81, P718, DOI 10.1073/pnas.81.3.718; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; GLIBETIC M, 1995, J BIOL CHEM, V270, P4209, DOI 10.1074/jbc.270.9.4209; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAGLUND RE, 1987, MOL CELL BIOCHEM, V73, P11; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; Hanada K, 1996, EMBO J, V15, P2217, DOI 10.1002/j.1460-2075.1996.tb00575.x; HANNAN KM, 1999, UNPUB ONCOGENE; Hannan KM, 1998, FRONT BIOSCI, V3, P376, DOI [10.2741/A282, DOI 10.2741/A282]; Hannan R, 1999, NUCLEIC ACIDS RES, V27, P1205, DOI 10.1093/nar/27.4.1205; HANNAN RD, 1995, J BIOL CHEM, V270, P8290, DOI 10.1074/jbc.270.14.8290; Hannan RD, 1996, J BIOL CHEM, V271, P3213, DOI 10.1074/jbc.271.6.3213; HANNAN RD, 1995, CARDIOVASC RES, V30, P501, DOI 10.1016/S0008-6363(95)00095-X; Hannan RD, 1996, P NATL ACAD SCI USA, V93, P8750, DOI 10.1073/pnas.93.16.8750; Hannan RD, 1998, J BIOL CHEM, V273, P1257, DOI 10.1074/jbc.273.2.1257; HANNAN RD, 1993, J MOL CELL CARDIOL, V25, P1137, DOI 10.1006/jmcc.1993.1127; Heix J, 1998, EMBO J, V17, P7373, DOI 10.1093/emboj/17.24.7373; Hempel WM, 1996, MOL CELL BIOL, V16, P557; Kihm AJ, 1998, P NATL ACAD SCI USA, V95, P14816, DOI 10.1073/pnas.95.25.14816; KUHN A, 1994, EMBO J, V13, P416, DOI 10.1002/j.1460-2075.1994.tb06276.x; LARSON DE, 1993, P NATL ACAD SCI USA, V90, P7933, DOI 10.1073/pnas.90.17.7933; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; Luyken J, 1996, CIRC RES, V78, P354, DOI 10.1161/01.RES.78.3.354; MAHAJAN PB, 1990, J BIOL CHEM, V265, P16225; MAUCK JC, 1973, P NATL ACAD SCI USA, V70, P2819, DOI 10.1073/pnas.70.10.2819; MIESFELD R, 1984, MOL CELL BIOL, V4, P221, DOI 10.1128/MCB.4.2.221; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MISHIMA Y, 1982, NUCLEIC ACIDS RES, V10, P6659, DOI 10.1093/nar/10.21.6659; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; NEVINS JR, 1992, SCIENCE, V258, P424; OMAHONY DJ, 1991, P NATL ACAD SCI USA, V88, P3180, DOI 10.1073/pnas.88.8.3180; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; PALMER TD, 1993, NUCLEIC ACIDS RES, V21, P3451, DOI 10.1093/nar/21.15.3451; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PAULE MR, 1994, TRANSCRIPTION MECH R; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; SCHNAPP A, 1993, MOL CELL BIOL, V13, P6723, DOI 10.1128/MCB.13.11.6723; SCHNAPP G, 1994, EMBO J, V13, P190, DOI 10.1002/j.1460-2075.1994.tb06248.x; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Smith S. David, 1993, Gene Expression, V3, P229; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; Voit R, 1999, EMBO J, V18, P1891, DOI 10.1093/emboj/18.7.1891; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x	52	68	68	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3487	3497		10.1038/sj.onc.1203690	http://dx.doi.org/10.1038/sj.onc.1203690			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918607				2022-12-25	WOS:000088346500005
J	Bemark, M; Neuberger, MS				Bemark, M; Neuberger, MS			The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line	ONCOGENE			English	Article						somatic hypermutation; immunoglobulin genes; c-MYC	HEAVY-CHAIN LOCUS; RNA-POLYMERASE-II; SOMATIC HYPERMUTATION; IMMUNOGLOBULIN GENES; CHROMOSOME-TRANSLOCATION; B-CELLS; TRANSCRIPTION; MUTATION; REGION; ACTIVATION	Burkitt's lymphomas harbour chromosomal translocations bringing c-MYC into the vicinity of one of the immunoglobulin gene loci. Point mutations have been described within c-MYC in several Burkitt's lymphomas and it has been proposed that translocation into the Ig loci might have transformed c-MYC into a substrate for the antibody hypermutation mechanism. Here we test this hypothesis by exploiting a Burkitt's lymphoma line (Ramos) that,ve have previously shown to hypermutate its immunoglobulin genes constitutively, We find that, during in vitro culture, Ramos mutates the c-MYC allele that is translocated into the IgH locus whilst leaving the untranslocated c-MYC and other control genes essentially unaffected. The mutations are introduced downstream of the c-MYC transcription start with the pattern of substitutions being characteristic of the antibody hypermutation mechanism; the mutation frequency is 2-3-fold lower than for the endogenous functional IgH allele, Thus chromosomal translocations involving the Ig loci may not only contribute to transformation by deregulating oncogene expression but could also act by potentiating subsequent oncogene hypermutation.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Bemark, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.		Bemark, Mats/B-2578-2019	Bemark, Mats/0000-0001-7416-9819				Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; BETZ AG, 1993, P NATL ACAD SCI USA, V90, P2385, DOI 10.1073/pnas.90.6.2385; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Frey S, 1998, IMMUNITY, V9, P127, DOI 10.1016/S1074-7613(00)80594-4; Fukita Y, 1998, IMMUNITY, V9, P105, DOI 10.1016/S1074-7613(00)80592-0; Goossens T, 1998, P NATL ACAD SCI USA, V95, P2463, DOI 10.1073/pnas.95.5.2463; Goyenechea B, 1997, EMBO J, V16, P3987, DOI 10.1093/emboj/16.13.3987; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; HAMLYN PH, 1983, NATURE, V304, P135, DOI 10.1038/304135a0; JOHNSTON JM, 1992, LEUKEMIA LYMPHOMA, V8, P431, DOI 10.3109/10428199209051025; JOHNSTON JM, 1991, BLOOD, V78, P2419; Keene RG, 1999, NUCLEIC ACIDS RES, V27, P3173, DOI 10.1093/nar/27.15.3173; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; LEBECQUE SG, 1990, J EXP MED, V172, P1717, DOI 10.1084/jem.172.6.1717; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MORSE B, 1989, MOL CELL BIOL, V9, P74, DOI 10.1128/MCB.9.1.74; MULLER JR, 1995, P NATL ACAD SCI USA, V92, P6577, DOI 10.1073/pnas.92.14.6577; NEUBERGER MS, 1983, NATURE, V305, P240, DOI 10.1038/305240a0; PARHAM P, 1998, IMMUNOL REV; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Peters A, 1996, IMMUNITY, V4, P57, DOI 10.1016/S1074-7613(00)80298-8; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; RABBITTS TH, 1983, NATURE, V306, P806, DOI 10.1038/306806a0; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Rada C, 1997, EUR J IMMUNOL, V27, P3115, DOI 10.1002/eji.1830271206; Rada C, 1998, IMMUNITY, V9, P135, DOI 10.1016/S1074-7613(00)80595-6; Sale JE, 1998, IMMUNITY, V9, P859, DOI 10.1016/S1074-7613(00)80651-2; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; TACHIBANA K, 1993, GENE, V124, P231, DOI 10.1016/0378-1119(93)90398-M; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; Tumas-Brundage K, 1996, Semin Immunol, V8, P141, DOI 10.1006/smim.1996.0018; TumasBrundage K, 1997, J EXP MED, V185, P239, DOI 10.1084/jem.185.2.239; Wagner SD, 1996, INT IMMUNOL, V8, P701, DOI 10.1093/intimm/8.5.701; Wagner SD, 1996, ANNU REV IMMUNOL, V14, P441, DOI 10.1146/annurev.immunol.14.1.441; Wilson PC, 1998, J EXP MED, V187, P59, DOI 10.1084/jem.187.1.59; WIMAN KG, 1984, P NATL ACAD SCI-BIOL, V81, P6798, DOI 10.1073/pnas.81.21.6798; YELAMOS J, 1995, NATURE, V376, P225; ZAJECKAYE M, 1988, SCIENCE, V240, P1776	48	42	44	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 13	2000	19	30					3404	3410		10.1038/sj.onc.1203686	http://dx.doi.org/10.1038/sj.onc.1203686			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918597				2022-12-25	WOS:000088198100008
J	Timme, TL; Goltsov, A; Tahir, S; Li, LK; Wang, JX; Ren, CZ; Johnston, RN; Thompson, TC				Timme, TL; Goltsov, A; Tahir, S; Li, LK; Wang, JX; Ren, CZ; Johnston, RN; Thompson, TC			Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis	ONCOGENE			English	Article						caveolin; c-myc; apoptosis; prostate cancer	IN-SITU HYBRIDIZATION; ONCOGENICALLY TRANSFORMED-CELLS; PROSTATE-CANCER; UP-REGULATION; CHROMOSOMAL-ANOMALIES; BREAST-CANCER; TARGET GENES; EXPRESSION; GROWTH; TRANSCRIPTION	accent data indicating that overexpression of caveolin-1 as well as c-myc are relatively. common features of advanced prostate cancer prompted us to test for potential cooperative interactions between caveolin-1 and c-myc that would be consistent with malignant progression. We used the well-characterized Rat1AmycER(TM) cells to show that the caleolin-1 gene is down-regulated at the level of transcription by c-myc. BS maintaining relatively high levels of caveolin-1 with an adenoviral vector or in stably transfected clones we show; that caveolin-1 can suppress c-myc-induced apoptosis, Further we established human prostate cancer cell lines with the mycER(TM) construct and show that clones with increased caveolin-1 are more resistant to myc-induced apoptosis and have increased capacity for growth in soft agar when c-myc is activated.	Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Calgary	Thompson, TC (corresponding author), Baylor Coll Med, Scott Dept Urol, 6560 Fannin St,Suite 2100, Houston, TX 77030 USA.		Johnston, Randal/B-9247-2009		NCI NIH HHS [P50-CA58204, CA50588, R0-1 CA68814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058204, R01CA050588, R01CA068814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; Bubendorf L, 1999, CANCER RES, V59, P803; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Dang CV, 1999, MOL CELL BIOL, V19, P1; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Helbing CC, 1998, ONCOGENE, V17, P1491, DOI 10.1038/sj.onc.1202241; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; Jenkins RB, 1997, CANCER RES, V57, P524; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Lavie Y, 1998, J BIOL CHEM, V273, P32380, DOI 10.1074/jbc.273.49.32380; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Nasu Y, 1998, NAT MED, V4, P1062, DOI 10.1038/2048; Nupponen NN, 1998, AM J PATHOL, V153, P141, DOI 10.1016/S0002-9440(10)65554-X; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Qian JQ, 1997, MODERN PATHOL, V10, P1113; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Sato K, 1999, JNCI-J NATL CANCER I, V91, P1574, DOI 10.1093/jnci/91.18.1574; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Shinoura N, 1999, CANCER RES, V59, P4119; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Thompson TC, 1999, APOPTOSIS, V4, P233, DOI 10.1023/A:1009612708099; THOMPSON TC, 1999, EMERGING THERAPEUTIC, V3, P337; Ulrich E, 1998, ONCOGENE, V16, P825, DOI 10.1038/sj.onc.1201842; Vairo G, 1996, ONCOGENE, V13, P1511; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Yang CPH, 1998, FEBS LETT, V439, P368, DOI 10.1016/S0014-5793(98)01354-4; Yang G, 1999, CANCER RES, V59, P5719; Yang G, 1998, CLIN CANCER RES, V4, P1873; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	50	121	124	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2000	19	29					3256	3265		10.1038/sj.onc.1203654	http://dx.doi.org/10.1038/sj.onc.1203654			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918582				2022-12-25	WOS:000088019300004
J	Morrison, DL; Yee, A; Paddon, HB; Vilimek, D; Aebersold, R; Pelech, SL				Morrison, DL; Yee, A; Paddon, HB; Vilimek, D; Aebersold, R; Pelech, SL			Regulation of the meiosis-inhibited protein kinase, a p38(MAPK) isoform, during meiosis and following fertilization of seastar oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA STAR OOCYTES; TYROSINE PHOSPHORYLATION; SUBSTRATE-SPECIFICITY; MAP KINASE; RIBOSOMAL-S6 KINASES; M-PHASE; ACTIVATION; MATURATION; PURIFICATION; CLONING	A p38(MAPK) homolog Mipk (meiosis-inhibited protein kinase) was cloned from seastar oocytes. This 40-kDa protein shares approximately 65% amino acid identity with mammalian p38-alpha isoforms. Mipk was one of the major tyrosine-phosphorylated proteins in immature oocytes arrested at the G(2)/M transition of meiosis I. The tyrosine phosphorylation of Mipk was increased in response to anisomycin, heat, and osmotic shock of oocytes. During 1-methyladenine-induced oocyte maturation, Mipk underwent tyrosine dephosphorylation and remained dephosphorylated in mature oocytes and during the early mitotic cell divisions until approximately 12 h after fertilization. At the time of differentiation and acquisition of G phases in the developing embryos, Mipk was rephosphorylated on tyrosine. In oocytes that were microinjected with Mipk antisense oligonucleotides and subsequently were allowed to mature and become fertilized, differentiation was blocked. Because MipK antisense oligonucleotides and a dominant-negative (K62R)Mipk when microinjected into immature oocytes failed to induce germinal vesicle breakdown, inhibition of Mipk function was not sufficient by itself to cause oocyte maturation. These findings point to a putative role for Mipk in cell cycle control as a G-phase-promoting factor.	Univ British Columbia, Dept Med, Vancouver, BC V6T 1Z3, Canada; Kinetek Pharmaceut Inc, Vancouver, BC V6P 6P2, Canada; Univ Washington, Dept Biotechnol, Seattle, WA 98105 USA	University of British Columbia; University of Washington; University of Washington Seattle	Pelech, SL (corresponding author), Univ British Columbia, Dept Med, 2nd Floor,2211 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.							Abrieu A, 1997, MOL BIOL CELL, V8, P249, DOI 10.1091/mbc.8.2.249; ALI SA, 1995, BIOTECHNIQUES, V18, P746; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Charlton LA, 1999, J CELL BIOCHEM, V75, P310; Chenchik A, 1996, BIOTECHNIQUES, V21, P526; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; FRASER A, 1981, CAN J ZOOL, V59, P1700, DOI 10.1139/z81-234; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; GUERRIER P, 1977, MOL CELL ENDOCRINOL, V7, P137, DOI 10.1016/0303-7207(77)90063-6; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN JH, 1993, J BIOL CHEM, V268, P25009; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; KALVAKOLANU DVR, 1991, BIOTECHNIQUES, V10, P176; Kishimoto T, 1996, TRENDS BIOCHEM SCI, V21, P35, DOI 10.1016/0968-0004(96)80885-1; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; KURODA S, 1995, J BIOL CHEM, V270, P2460, DOI 10.1074/jbc.270.6.2460; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lefebvre DL, 1999, J CELL BIOCHEM, V75, P272; Masui Y, 1979, Int Rev Cytol, V57, P185, DOI 10.1016/S0074-7696(08)61464-3; MEIJER L, 1987, BIOCHEMISTRY-US, V26, P7968, DOI 10.1021/bi00398a063; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; Murray A, 1993, CELL CYCLE INTRO; PELECH SL, 1987, BIOCHEMISTRY-US, V26, P7960, DOI 10.1021/bi00398a062; PELECH SL, 1988, DEV BIOL, V130, P28, DOI 10.1016/0012-1606(88)90410-1; PELECH SL, 1995, MAP KINASE DEPENDENT, V1, P33; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; Sadler KC, 1998, DEV BIOL, V197, P25, DOI 10.1006/dbio.1998.8869; Sagata N, 1996, TRENDS CELL BIOL, V6, P22, DOI 10.1016/0962-8924(96)81034-8; Sambrook J., 1989, MOL CLONING, pA1; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SANGHERA JS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P153, DOI 10.1016/0167-4889(91)90078-C; SANGHERA JS, 1992, BIOCHEM J, V283, P829, DOI 10.1042/bj2830829; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; Stapleton G, 1998, DEV BIOL, V193, P36, DOI 10.1006/dbio.1997.8791; Suzanne M, 1999, GENE DEV, V13, P1464, DOI 10.1101/gad.13.11.1464; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; WATTS JD, 1994, J BIOL CHEM, V269, P29520; XU Z, 1993, DEV GENET, V14, P424, DOI 10.1002/dvg.1020140604; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723	45	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34236	34244		10.1074/jbc.M004656200	http://dx.doi.org/10.1074/jbc.M004656200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10906138	hybrid			2022-12-25	WOS:000165095300034
J	Birch, OM; Hewitson, KS; Fuhrmann, M; Burgdorf, K; Baldwin, JE; Roach, PL; Shaw, NM				Birch, OM; Hewitson, KS; Fuhrmann, M; Burgdorf, K; Baldwin, JE; Roach, PL; Shaw, NM			MioC is an FMN-binding protein that is essential for Escherichia coli biotin synthase activity in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE; GENE-CLUSTER; REPLICATION; FLAVODOXIN; TRANSCRIPTION; DETHIOBIOTIN; MECHANISM; SEQUENCE; SULFUR; INITIATION	Biotin synthase is required for the conversion of dethiobiotin to biotin and requires a number of accessory proteins and small molecule cofactors for activity in vitro. We have previously identified two of these proteins as flavodoxin and ferredoxin (flavodoxin) NADP(+) reductase. We now report the identification of MioC as a third essential protein, together with its cloning, purification, and characterization. Purified MioC has a UV-visible spectrum characteristic of a flavoprotein and contains flavin mononucleotide. The presence of flavin mononucleotide and the primary sequence similarity to flavodoxin suggest that. MioC may function as an electron transport protein. The role of MioC in the biotin synthase reaction is discussed, and the structure and function of MioC is compared with that of flavodoxin.	Lonza AG, Biotechnol Res, CH-3930 Visp, Switzerland; Univ Oxford, Dyson Perrins Lab, Oxford OX1 3QY, England; Univ Southampton, Dept Chem, Southampton SO17 1BJ, Hants, England	Lonza Group; University of Oxford; University of Southampton	Shaw, NM (corresponding author), Lonza AG, Biotechnol Res, CH-3930 Visp, Switzerland.		Roach, Peter/C-6248-2013; Roach, Peter/AAW-7071-2021					ASAI T, 1991, JPN J GENET, V66, P85, DOI 10.1266/jjg.66.85; Bates DB, 1997, P NATL ACAD SCI USA, V94, P12497, DOI 10.1073/pnas.94.23.12497; Becker A, 1999, NAT STRUCT BIOL, V6, P969; BIRCH OM, 1995, J BIOL CHEM, V270, P19158, DOI 10.1074/jbc.270.32.19158; BIRCH OM, 1994, Patent No. 08023; Bui BTS, 1998, FEBS LETT, V440, P226, DOI 10.1016/S0014-5793(98)01464-1; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; Escalettes F, 1999, J AM CHEM SOC, V121, P3571, DOI 10.1021/ja9811748; FLINT DH, 1997, METHOD ENZYMOL, V279, P356; Gibson KJ, 1999, BIOCHEM BIOPH RES CO, V254, P632, DOI 10.1006/bbrc.1998.9991; GRANDORI R, 1994, PROTEIN SCI, V3, P2185, DOI 10.1002/pro.5560031204; Guianvarc'h D, 1997, BIOCHEM BIOPH RES CO, V236, P402, DOI 10.1006/bbrc.1997.6952; HUGHES GJ, 1990, BIOCHEM J, V271, P641, DOI 10.1042/bj2710641; IFUKU O, 1994, EUR J BIOCHEM, V224, P173, DOI 10.1111/j.1432-1033.1994.tb20009.x; LOBNEROLESEN A, 1992, NUCLEIC ACIDS RES, V20, P3029, DOI 10.1093/nar/20.12.3029; LOBNEROLESEN A, 1987, J BACTERIOL, V169, P2835, DOI 10.1128/jb.169.6.2835-2842.1987; McIver L, 1998, EUR J BIOCHEM, V257, P577, DOI 10.1046/j.1432-1327.1998.2570577.x; Mejean A, 1995, BIOCHEM BIOPH RES CO, V217, P1231, DOI 10.1006/bbrc.1995.2900; MULLIEZ E, 1999, IRON METABOLISM; Nakamura M, 1999, J BIOCHEM, V126, P10, DOI 10.1093/oxfordjournals.jbchem.a022409; OGAWA T, 1994, J BACTERIOL, V176, P1609, DOI 10.1128/jb.176.6.1609-1615.1994; OHSHIRO T, 1994, BIOSCI BIOTECH BIOCH, V58, P1738, DOI 10.1271/bbb.58.1738; OSBORNE C, 1991, J BACTERIOL, V173, P1729, DOI 10.1128/jb.173.5.1729-1737.1991; Sambrook J., 2002, MOL CLONING LAB MANU; Sanyal I, 1996, ARCH BIOCHEM BIOPHYS, V326, P48, DOI 10.1006/abbi.1996.0045; Shaw NM, 1998, BIOCHEM J, V330, P1079; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	28	25	27	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32277	32280		10.1074/jbc.M004497200	http://dx.doi.org/10.1074/jbc.M004497200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913144	hybrid			2022-12-25	WOS:000089858900099
J	Moltedo, O; Verde, C; Capasso, A; Parisi, E; Remondelli, P; Bonatti, S; Alvarez-Hernandez, X; Glass, J; Alvino, CG; Leone, A				Moltedo, O; Verde, C; Capasso, A; Parisi, E; Remondelli, P; Bonatti, S; Alvarez-Hernandez, X; Glass, J; Alvino, CG; Leone, A			Zinc transport and metallothionein secretion in the intestinal human cell line Caco-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFERS RESISTANCE; GENE-EXPRESSION; PLASMA-MEMBRANE; SINDBIS VIRUS; PROTEIN; ABSORPTION; COPPER; MOUSE; DIFFERENTIATION; BIOSYNTHESIS	Caco-2, a human cell line, displays several biochemical and morphological characteristics of differentiated enterocytes. Among these is the ability to transport zinc from the apical to the basal compartment. This process was enhanced following exposure by the apical compartment to increasing concentrations of the metal. High pressure liquid chromatography fractionation of the media obtained from cells labeled with radioactive zinc showed that metallothioneins (MTs), small metal-binding, cysteine-rich proteins), were present in the apical and basal media of controls as well as in cells grown in the presence of high concentrations of zinc. Following exposure to the metal, the levels of Zn-MTs in the apical medium increased, while in the basal compartment the greatest part of zinc appeared in a free form with minor changes in the levels of basal MTs. Metabolic labeling experiments with radioactive cysteine confirmed the apical secretion of MTs. A stable transfectant clone of Caco-8 cells (CL11) was selected for its ability to express constitutively high levels of the mouse metallothionein I protein. This cell line showed an enhanced transport of the metal following exposure to high concentrations of zinc and a constitutive secretion of the mouse metallothionein I protein in the apical compartment. Together, these findings strongly support the hypothesis of a functional role between the biosynthesis and secretion of MTs and the transport of zinc in intestinal cells.	Univ Salerno, Dipartimento Sci Farmaceut, I-84084 Salerno, Italy; Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; CNR, Ist Biochim Prot & Enzimol, I-80125 Naples, Italy; Louisiana State Univ, Hlth Sci Ctr, Dept Med, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA; CNR, Ctr Endocrinol & Oncol Sperimentale G Salvatore, I-80131 Naples, Italy	University of Salerno; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Consiglio Nazionale delle Ricerche (CNR)	Leone, A (corresponding author), Univ Salerno, Dipartimento Sci Farmaceut, Via Ponte Don Melillo, I-84084 Salerno, Italy.		Remondelli, Paolo/X-7805-2019	REMONDELLI, Paolo/0000-0002-3698-3497; VERDE, Cinzia/0000-0001-6185-282X	Telethon [E.0373] Funding Source: Medline	Telethon(Fondazione Telethon)		Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463; BONATTI S, 1983, METHOD ENZYMOL, V96, P512; BREMNER I, 1990, ANNU REV NUTR, V10, P63, DOI 10.1146/annurev.nu.10.070190.000431; BREMNER I, 1987, METALLOTHIONEIN, V2, P52; Chesters J. K., 1997, Handbook of nutritionally essential mineral elements., P185; Cigliano S, 1996, EXP CELL RES, V228, P173, DOI 10.1006/excr.1996.0314; COUSINS RJ, 1985, PHYSIOL REV, V65, P238, DOI 10.1152/physrev.1985.65.2.238; Davis SR, 1998, J NUTR, V128, P825, DOI 10.1093/jn/128.5.825; DURNAM DM, 1980, P NATL ACAD SCI-BIOL, V77, P6511, DOI 10.1073/pnas.77.11.6511; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; FALCK FY, 1983, BRIT J IND MED, V40, P305; FLANAGAN PR, 1983, J NUTR, V113, P962, DOI 10.1093/jn/113.5.962; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HEMPE JM, 1991, P NATL ACAD SCI USA, V88, P9671, DOI 10.1073/pnas.88.21.9671; HEMPE JM, 1992, J NUTR, V122, P89, DOI 10.1093/jn/122.1.89; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; JACKSON MJ, 1981, BRIT J NUTR, V46, P15, DOI 10.1079/BJN19810005; JACKSON MJ, 1984, BRIT J NUTR, V51, P199, DOI 10.1079/BJN19840024; LONNERDAL B, 1988, ZINC HUMAN BIOL, P33; MENARD MP, 1981, J NUTR, V111, P1353, DOI 10.1093/jn/111.8.1353; MIGLIACCIO G, 1990, EUR J CELL BIOL, V52, P291; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; NETTESHEIM DG, 1985, BIOCHEMISTRY-US, V24, P6744, DOI 10.1021/bi00345a003; Otvos J D, 1987, Experientia Suppl, V52, P171; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Payne AS, 1998, P NATL ACAD SCI USA, V95, P10854, DOI 10.1073/pnas.95.18.10854; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; PINTO M, 1983, BIOL CELL, V47, P323; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; RICHARDS MP, 1975, BIOCHEM BIOPH RES CO, V64, P1215, DOI 10.1016/0006-291X(75)90822-0; Rubartelli A., 1997, UNUSUAL SECRETORY PA, P87, DOI [10.1007/978-3-662-22581-3_3, DOI 10.1007/978-3-662-22581-3_3]; SANTERRE RF, 1984, GENE, V30, P147, DOI 10.1016/0378-1119(84)90115-X; SATO M, 1984, J NUTR, V114, P1683, DOI 10.1093/jn/114.9.1683; SCHMIDT CJ, 1986, P NATL ACAD SCI USA, V83, P3346, DOI 10.1073/pnas.83.10.3346; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WELCH WJ, 1979, J VIROL, V29, P1186, DOI 10.1128/JVI.29.3.1186-1195.1979	41	48	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31819	31825		10.1074/jbc.M002907200	http://dx.doi.org/10.1074/jbc.M002907200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10896936	hybrid			2022-12-25	WOS:000089858900040
J	Wang, XJ; Ching, YP; Lam, WH; Qi, Z; Zhang, MJ; Wang, JH				Wang, XJ; Ching, YP; Lam, WH; Qi, Z; Zhang, MJ; Wang, JH			Identification of a common protein association region in the neuronal Cdk5 activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; BOVINE BRAIN; CDC2-LIKE KINASE; P35(-/-) MICE; TAU-PROTEIN; P35; DIFFERENTIATION; DISRUPTION; DEFECTS; SUBUNIT	Cyclin-dependent protein kinase 5 (CdkB) depends on the association with neuronal CdkB activator (Nck5a) for kinase activity. A variety of cellular proteins have been shown to undergo high affinity association with Nck5a, including three novel proteins, C42, C48, and C53 found by a yeast two-hybrid screen (Ching, Y. P., Qi, Z., and Wang, J. H. (2000) Gene 242, 285-294). The three proteins show competitive binding to Nck5a suggesting that they bind at a common site. The binding site has been mapped to a region of 26 amino acid residues (residues 145 to 170) at the N-terminal boundary of the kinase activation domain of Nck5a. This region of Nck5a contains an amphipathic a-helix whose hydrophobic face is involved in Cdk5 activation (Chin, K. T., Ohki, S, Tang, D., Cheng, H. C., Wang, J. H., and Zhang, M. (1999) J. Biol. Chem. 274, 7120-7127). Several lines of evidence suggest that Nck5a interacts with the binding proteins at the hydrophilic face of the amphipathic cu-helix. First, the Nck5a-(145-170) peptide can bind CdkB and Nck5a-binding proteins simultaneously. Second, the association of Nck5a-(145-170) to C48 can be markedly reduced by high ionic strength whereas the interaction between Nck5a and CdkB is not affected. Third, substitution of Glu(157) by glutamine in Nck5a-(145-170) abolishes the peptide's ability to bind to the three Nck5a-binding proteins without diminishing its Cdk5 binding activity.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore	Hong Kong University of Science & Technology; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Wang, JH (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China.	jerwang@ust.hk	Ching, Yick Pang/C-4244-2009	Zhang, Mingjie/0000-0001-9404-0190; CHING, Yick Pang/0000-0002-6461-8358				Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Chin KT, 1999, J BIOL CHEM, V274, P7120, DOI 10.1074/jbc.274.11.7120; Ching YP, 2000, GENE, V242, P285, DOI 10.1016/S0378-1119(99)00499-0; Chou KC, 1999, BIOCHEM BIOPH RES CO, V259, P420, DOI 10.1006/bbrc.1999.0792; Gilmore EC, 1998, J NEUROSCI, V18, P6370; HAYES TE, 1991, NEW BIOL, V3, P259; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; Kwon YT, 2000, CURR BIOL, V10, P363, DOI 10.1016/S0960-9822(00)00411-5; Kwon YT, 1998, J COMP NEUROL, V395, P510, DOI 10.1002/(SICI)1096-9861(19980615)395:4<510::AID-CNE7>3.0.CO;2-4; Kwon YT, 1999, J COMP NEUROL, V415, P218, DOI 10.1002/(SICI)1096-9861(19991213)415:2<218::AID-CNE6>3.0.CO;2-F; Lee KY, 1996, J BIOL CHEM, V271, P1538, DOI 10.1074/jbc.271.3.1538; Lee KY, 1997, J BIOL CHEM, V272, P5622, DOI 10.1074/jbc.272.9.5622; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MIYAJIMA M, 1995, NEUROREPORT, V6, P1130, DOI 10.1097/00001756-199505300-00014; Moorthamer M, 1999, FEBS LETT, V446, P343, DOI 10.1016/S0014-5793(99)00248-3; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; NUGENT JHA, 1991, J CELL SCI, V99, P669; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Paglini G, 1998, J NEUROSCI, V18, P9858; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Qi Z, 1998, J BIOL CHEM, V273, P2329, DOI 10.1074/jbc.273.4.2329; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tang DM, 1997, J BIOL CHEM, V272, P12318, DOI 10.1074/jbc.272.19.12318; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	32	36	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31763	31769		10.1074/jbc.M004358200	http://dx.doi.org/10.1074/jbc.M004358200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10915792	hybrid			2022-12-25	WOS:000089858900032
J	Lazarowski, ER; Boucher, RC; Harden, TK				Lazarowski, ER; Boucher, RC; Harden, TK			Constitutive release of ATP and evidence for major contribution of ecto-nucleotide pyrophosphatase and nucleoside diphosphokinase to extracellular nucleotide concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-VOLUME REGULATION; MOLECULAR-CLONING; EPITHELIAL-CELLS; AIRWAY EPITHELIA; CYSTIC-FIBROSIS; RECEPTOR; RAT; MECHANISM; UTP; STIMULATION	Nucleotides are important extracellular signaling molecules, At least five mammalian P2Y receptors exist that are specifically activated by ATP, UTP, ADP, or UDP, Although the existence of ectoenzymes that metabolize extracellular nucleotides is well established, the relative flux of ATP and UTP through their extracellular metabolic products remains undefined. Therefore, we have studied the kinetics of accumulation and metabolism of endogenous ATP in the extracellular medium of four different cell lines. ATP concentrations reached a maximum immediately after change of medium and decreased thereafter with a single exponential decay (t1/2 similar to 30-40 min). ATP levels did not fall to zero but attained a base-line concentration that was independent of the medium volume and of the initial ATP concentration, Although the base line concentration of ATP remained stable for up to 12 h, [gamma-P-32]ATP added to resting cells as a radiotracer was completely degraded within 120 min, indicating that steady state reflected a basal rate of ATP release balanced by ATP hydrolysis (20-200 fmol x min(-1) x cell(-6)). High performance liquid chromatography analysis revealed that the gamma-phosphate of ATP was rapidly, although transiently, transferred during steady state to species subsequently identified as UTP and GTP, indicating the existence of both ecto-nucleoside diphosphokinase activity and the accumulation of endogenous UDP and GDP, Conversely, addition of [gamma-P-32]UTP, resting cells resulted in transient formation of [gamma-P-32]ATP, indicating phosphorylation of endogenous ADP by nucleoside diphosphokinase, The final P-32-products of [gamma-P-32]ATP metabolism were [P-32]orthophosphoric acid and a P-32-labeled species that was further purified and identified as [P-32]inorganic pyrophosphate, In C6 cells, the formation of [P-32]pyrophosphate from [gamma-P-32]ATP at steady state exceeded by 3-fold that of [P-32]orthophosphate. These results illustrate for the first time a constitutive release of ATP and other nucleotides and reveal the existence of a complex extracellular metabolic pathway for released nucleotides, In addition to the existence of an ecto-ATPase activity, our results suggest a major scavenger role of ecto-ATP pyrophosphatase and a transphosphorylating activity of nucleoside diphosphokinase.	Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Lazarowski, ER (corresponding author), Univ N Carolina, Sch Med, Dept Med, CB 7248,7017 Thurston Bowles Bldg, Chapel Hill, NC 27599 USA.				NHLBI NIH HHS [HL34322] Funding Source: Medline; NIGMS NIH HHS [GM38213] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038213] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Bogdanov YD, 1998, BRIT J PHARMACOL, V124, P428, DOI 10.1038/sj.bjp.0701880; Boucher RC, 1999, J PHYSIOL-LONDON, V516, P631, DOI 10.1111/j.1469-7793.1999.0631u.x; Brown J, 2000, LAB INVEST, V80, P37, DOI 10.1038/labinvest.3780006; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; BURNSTOCK G, 1998, P2 NUCLEOTIDE RECEPT, P3; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; DAVIS CW, 1992, AM J PHYSIOL, V262, pC1313, DOI 10.1152/ajpcell.1992.262.5.C1313; Evans RJ, 1998, P2 NUCLEOTIDE RECEPT, P43; Feranchak AP, 1998, J BIOL CHEM, V273, P14906, DOI 10.1074/jbc.273.24.14906; Ferguson DR, 1997, J PHYSIOL-LONDON, V505, P503, DOI 10.1111/j.1469-7793.1997.503bb.x; Fredholm BB, 1997, TRENDS PHARMACOL SCI, V18, P79, DOI 10.1016/S0165-6147(96)01038-3; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Grobben B, 1999, J NEUROCHEM, V72, P826, DOI 10.1046/j.1471-4159.1999.0720826.x; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; Hamada K, 1998, J BIOL CHEM, V273, P6334, DOI 10.1074/jbc.273.11.6334; HARDEN TK, 1998, P2 NUCLEOTIDE RECEPT, P109; HASSESSIAN H, 1993, BRIT J PHARMACOL, V109, P466, DOI 10.1111/j.1476-5381.1993.tb13592.x; Hazama A, 1999, J GEN PHYSIOL, V114, P525, DOI 10.1085/jgp.114.4.525; King BF, 1998, TRENDS PHARMACOL SCI, V19, P506, DOI 10.1016/S0165-6147(98)01271-1; Korngreen A, 1996, J PHYSIOL-LONDON, V497, P53, DOI 10.1113/jphysiol.1996.sp021749; Lazarowski ER, 1996, BRIT J PHARMACOL, V117, P203, DOI 10.1111/j.1476-5381.1996.tb15175.x; Lazarowski ER, 1997, J BIOL CHEM, V272, P20402, DOI 10.1074/jbc.272.33.20402; Lazarowski ER, 1999, BRIT J PHARMACOL, V127, P1272, DOI 10.1038/sj.bjp.0702654; LAZAROWSKI ER, 1995, BRIT J PHARMACOL, V116, P1619, DOI 10.1111/j.1476-5381.1995.tb16382.x; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; LAZAROWSKI ER, 2000, ECTO ATPASES RELATED, P283; LETHEM MI, 1993, AM J RESP CELL MOL, V9, P315, DOI 10.1165/ajrcmb/9.3.315; Mitchell CH, 1998, P NATL ACAD SCI USA, V95, P7174, DOI 10.1073/pnas.95.12.7174; Roman RM, 1997, J BIOL CHEM, V272, P21970, DOI 10.1074/jbc.272.35.21970; Saiag B, 1995, ENDOTHELIUM, V2, P279, DOI 10.3109/10623329509024644; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Todorov LD, 1996, J PHYSIOL-LONDON, V496, P731, DOI 10.1113/jphysiol.1996.sp021723; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; VILLALON M, 1989, BIOPHYS J, V56, P1255, DOI 10.1016/S0006-3495(89)82772-9; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Watt WC, 1998, J BIOL CHEM, V273, P14053, DOI 10.1074/jbc.273.22.14053; Webb TE, 1998, J NEUROCHEM, V71, P1348; Zimmermann H, 1996, DRUG DEVELOP RES, V39, P337, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<337::AID-DDR15>3.0.CO;2-Z; [No title captured]	41	262	266	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31061	31068		10.1074/jbc.M003255200	http://dx.doi.org/10.1074/jbc.M003255200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10913128	hybrid, Green Published			2022-12-25	WOS:000089762700046
J	Shaikh, AC; Sadowski, PD				Shaikh, AC; Sadowski, PD			Trans complementation of variant Cre proteins for defects in cleavage and synapsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; FLP RECOMBINASE; SACCHAROMYCES-CEREVISIAE; INTEGRASE FAMILY; 2-MU-M PLASMID; DNA; MECHANISM; TYROSINE; RESIDUE; CIRCLE	The Cre recombinase is a member of the integrase family of conservative site-specific recombinases. These proteins share five conserved catalytic residues, one of which is a tyrosine that acts as the nucleophile to attack the scissile phosphodiester bond in the DNA target. Recombination by the Cre recombinase takes place in a supramolecular structure called a synapse that consists of four molecules of Cre bound to two DNA target sequences called lox sites. The synapse is held together by an intricate network of protein-protein interactions. They bend the two sites into square planar structure that resembles a Holliday intermediate. We have studied three mutant Cre proteins that appear to have defects in synapsis (Cre A36V, Cre T41F, and Cre G314R). We found that they were unable to carry out strand cleavage but that cleavage occurred if they were mixed with a cleavage-defective Cre protein that lacks the catalytic nucleophilic tyrosine residue. The three variant proteins could also be complemented for the formation of a novel structure ("complexV"), which may be a cleaved synaptic intermediate. We suggest that these three mutant proteins have a defect in DNA bending and discuss the relationship between bending, synapsis, and cleavage.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto	Sadowski, PD (corresponding author), Univ Toronto, Dept Mol & Med Genet, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.							ABREMSKI K, 1983, CELL, V32, P1301, DOI 10.1016/0092-8674(83)90311-2; ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; ANDREWS BJ, 1987, J MOL BIOL, V193, P345, DOI 10.1016/0022-2836(87)90223-3; AUSTIN S, 1981, CELL, V25, P729, DOI 10.1016/0092-8674(81)90180-X; Cao YH, 1999, J MOL BIOL, V289, P517, DOI 10.1006/jmbi.1999.2793; CHEN JW, 1992, GENE, V119, P37; CHEN JW, 1991, J MOL BIOL, V218, P107, DOI 10.1016/0022-2836(91)90877-9; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DIXON JE, 1995, MOL MICROBIOL, V18, P449, DOI 10.1111/j.1365-2958.1995.mmi_18030449.x; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; EVANS BR, 1990, J BIOL CHEM, V265, P18504; Gopaul Deshmukh N., 1999, Current Opinion in Structural Biology, V9, P14, DOI 10.1016/S0959-440X(99)80003-7; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P3274, DOI 10.1128/MCB.5.11.3274; Guo F, 1999, P NATL ACAD SCI USA, V96, P7143, DOI 10.1073/pnas.96.13.7143; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; HOESS R, 1987, P NATL ACAD SCI USA, V84, P6840, DOI 10.1073/pnas.84.19.6840; HOESS R, 1990, J MOL BIOL, V216, P873, DOI 10.1016/S0022-2836(99)80007-2; HOESS RH, 1990, NUCLEIC ACIDS MOL BI, V4, P99; HOESS RH, 1990, STRUCTURE METHODS, V1, P203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; SADOWSKI PD, 1995, PROG NUCLEIC ACID RE, V51, P53, DOI 10.1016/S0079-6603(08)60876-4; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWARTZ CJE, 1989, J MOL BIOL, V205, P647, DOI 10.1016/0022-2836(89)90310-0; Shaikh AC, 2000, J MOL BIOL, V302, P27, DOI 10.1006/jmbi.2000.3967; Shaikh AC, 1997, J BIOL CHEM, V272, P5695, DOI 10.1074/jbc.272.9.5695; SHAIKH AC, 2000, THESIS U TORONTO; SHAIKH AC, 1997, THESIS U TORONTO; WIERZBICKI A, 1987, J MOL BIOL, V195, P785, DOI 10.1016/0022-2836(87)90484-0	33	8	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30186	30195		10.1074/jbc.M005256200	http://dx.doi.org/10.1074/jbc.M005256200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10903322	hybrid			2022-12-25	WOS:000089577900039
J	Wynn, RM; Chuang, JL; Cote, CD; Chuang, DT				Wynn, RM; Chuang, JL; Cote, CD; Chuang, DT			Tetrameric assembly and conservation in the ATP-binding domain of rat branched-chain alpha-ketoacid dehydrogenase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYRUP-URINE-DISEASE; PROTEIN-KINASES; DIHYDROLIPOYL ACETYLTRANSFERASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; LIPOYL DOMAIN; COMPLEX; EXPRESSION; LIVER; DECARBOXYLASE	We showed previously that the rat branched-chain alpha-ketoacid dehydrogenase (BCKD) kinase is capable of autophosphorylation. However, despite its sequence similarity to bacterial histidine protein kinases, BCKD kinase does not function as a histidine protein kinase. In the present study, we report that the rat BCKD kinase exists as a homotetramer of M-r = 185,000, based on results of gel filtration and dynamic light scattering. This is in contrast to the related mammalian pyruvate dehydrogenase kinase isozymes that occur as homodimers. The tetrameric assembly of BCKD kinase was confirmed by the presence of four 5' -adenylyl-imidodiphosphate-binding sites (K-D = 4.1 x 10(-6) M) per molecule of the kinase. Incubation of the BCKD kinase with increasing concentrations of urea resulted in dissociation of the tetramer to dimers and eventually to monomers as separated on a sucrose density gradient. Both tetramers and dimers, but not the monomer, maintained the conformation capable of binding ATP and undergoing autophosphorylation. BCKD kinase depends on a fully lipoylated transacylase for maximal activity, but the interaction between the kinase and the transacylase is impeded in the presence of high salt concentrations. Alterations of conserved residues in the ATP-binding domain led to a marked reduction or complete loss in the catalytic efficiency of the BCKD kinase. The results indicate that BCKD kinase, similar to pyruvate dehydrogenase kinase isozymes, belongs to the superfamily of ATPase/kinase.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wynn, RM (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Wynn, Richard/0000-0002-1879-2136	NIDDK NIH HHS [DK-26758] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026758] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AFTRING RP, 1988, AM J PHYSIOL, V254, pE292, DOI 10.1152/ajpendo.1988.254.3.E292; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; BLOCK KP, 1985, BIOCHEM J, V232, P593, DOI 10.1042/bj2320593; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; Bowker-Kinley M, 1999, BIOCHEM J, V344, P47, DOI 10.1042/0264-6021:3440047; CHUANG JL, 1995, J CLIN INVEST, V95, P954, DOI 10.1172/JCI117804; Chuang JL, 2000, METHOD ENZYMOL, V324, P413; DAMUNI Z, 1984, P NATL ACAD SCI-BIOL, V81, P4335, DOI 10.1073/pnas.81.14.4335; DAVIE JR, 1995, J BIOL CHEM, V270, P19861, DOI 10.1074/jbc.270.34.19861; GRIFFIN TA, 1990, J BIOL CHEM, V265, P12104; HARRIS RA, 1995, ADV ENZYME REGUL, V35, P147, DOI 10.1016/0065-2571(94)00020-4; HARRIS RA, 1986, ADV ENZYME REGUL, V25, P219, DOI 10.1016/0065-2571(86)90016-6; Lee, 1991, CHEM BIOCH FLAVOENZY, V2, P109; LIU SJ, 1995, J BIOL CHEM, V270, P793, DOI 10.1074/jbc.270.2.793; MacColl R, 1998, BIOCHEMISTRY-US, V37, P417, DOI 10.1021/bi971453s; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MILLER RH, 1988, J BIOL CHEM, V263, P3454; PAUL HS, 1982, J BIOL CHEM, V257, P4875; POPOV KM, 1992, J BIOL CHEM, V267, P13127; POPOV KM, 1993, J BIOL CHEM, V268, P26602; RADKE GA, 1993, BIOCHEM BIOPH RES CO, V190, P982, DOI 10.1006/bbrc.1993.1146; Ravindran S, 1996, J BIOL CHEM, V271, P653, DOI 10.1074/jbc.271.2.653; ROCHE TE, 1996, ALPHA KETO ACID DEHY, P33; SHIMOMURA Y, 1990, ARCH BIOCHEM BIOPHYS, V283, P293, DOI 10.1016/0003-9861(90)90645-F; SILVERMAN RB, 1995, METHOD ENZYMOL, V249, P240; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WYNN RM, 1992, J BIOL CHEM, V267, P12400; Wynn RM, 1998, J BIOL CHEM, V273, P13110, DOI 10.1074/jbc.273.21.13110; YEAMAN SJ, 1989, BIOCHEM J, V257, P625, DOI 10.1042/bj2570625	29	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30512	30519		10.1074/jbc.M005075200	http://dx.doi.org/10.1074/jbc.M005075200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10903321	hybrid			2022-12-25	WOS:000089577900081
J	Furukawa, T; Tanese, N				Furukawa, T; Tanese, N			Assembly of partial TFIID complexes in mammalian cells reveals distinct activities associated with individual TATA box-binding protein-associated factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CORE PROMOTER SELECTIVITY; HISTONE-LIKE TAFS; LARGE T-ANTIGEN; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; CYCLE PROGRESSION; MOLECULAR-CLONING; TERMINAL DOMAIN; 230-KDA SUBUNIT	The TATA box-binding protein (TBP) and TBP-associated factors (TAF(II)s) compose the general transcription factor TFIID. The TAF(II) subunits mediate activated transcription by RNA polymerase II by interacting directly with site-specific transcriptional regulators. TAF(II)s also participate in promoter recognition by contacting core promoter elements in the context of TFIID. To further dissect the contribution of individual TAF(II) subunits to mammalian TFIID function, we employed a vaccinia virus-based protein expression system to study protein-protein interactions and complex assembly. We identified the domains of human (h) TAF(II)130 required for TAF(II)-TAF(II) interactions and formation of a complex with hTBP, hTAF(II)100, and hTAF(II)250. Functional analysis of partial TFIID complexes formed in vivo indicated that hTAF(II)130 was required for transcriptional activation by Sp1 in vitro. DNase I footprinting experiments demonstrated that purified hTBP/hTAF(II)250 complex reconstituted with or without additional TAF(II)s was significantly reduced for TATA box binding las much as 9-fold) compared with free hTBP. By contrast, hTAF(II)130 stabilized binding of hTBP to the TATA box, whereas hTAF(II)100 had little effect. Thus, our biochemical analysis supports the notion that TAF(II)s possess distinct functions to regulate the activity of TFIID.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University	Tanese, N (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.			Tanese, Naoko/0000-0002-1946-3211	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051314] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51314] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; AUSUBEL FM, 1988, CURRENT PROTOCOLS MO, V2; Bjorklund S, 1999, CELL, V96, P759, DOI 10.1016/S0092-8674(00)80586-3; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Burley SK, 1998, CELL, V94, P551, DOI 10.1016/S0092-8674(00)81596-2; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CLEARY MA, 1995, MOL CELL BIOL, V15, P2090; Coleman RA, 1999, MOL CELL, V4, P451, DOI 10.1016/S1097-2765(00)80453-0; Damania B, 1998, MOL CELL BIOL, V18, P3926, DOI 10.1128/MCB.18.7.3926; Damania B, 1996, GENE DEV, V10, P1369, DOI 10.1101/gad.10.11.1369; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; Gangloff YG, 2000, MOL CELL BIOL, V20, P340, DOI 10.1128/MCB.20.1.340-351.2000; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; Kaufmann J, 1996, GENE DEV, V10, P873, DOI 10.1101/gad.10.7.873; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; KOKUBO T, 1993, P NATL ACAD SCI USA, V90, P5896, DOI 10.1073/pnas.90.13.5896; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; Marshak DR, 1996, STRATEGIES PROTEIN P; Martin J, 1999, MOL CELL BIOL, V19, P5548; Martinez E, 1998, MOL CELL BIOL, V18, P6571, DOI 10.1128/MCB.18.11.6571; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; MOSS B, 1990, NATURE, V348, P919; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; Natarajan K, 1998, MOL CELL, V2, P683, DOI 10.1016/S1097-2765(00)80166-5; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Ozer J, 1998, J BIOL CHEM, V273, P14293, DOI 10.1074/jbc.273.23.14293; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; Ruppert SML, 1996, HYBRIDOMA, V15, P55, DOI 10.1089/hyb.1996.15.55; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; Sauer F, 1997, CURR OPIN GENET DEV, V7, P176, DOI 10.1016/S0959-437X(97)80126-8; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; Tao Y, 1997, J BIOL CHEM, V272, P6714, DOI 10.1074/jbc.272.10.6714; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; Zhou JM, 1998, P NATL ACAD SCI USA, V95, P13483, DOI 10.1073/pnas.95.23.13483	72	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29847	29856		10.1074/jbc.M002989200	http://dx.doi.org/10.1074/jbc.M002989200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896937	hybrid			2022-12-25	WOS:000089439800091
J	Hosoya, M; Moriya, T; Kawamata, Y; Ohkubo, S; Fujii, R; Matsui, H; Shintani, Y; Fukusumi, S; Habata, Y; Hinuma, S; Onda, H; Nishimura, O; Fujino, M				Hosoya, M; Moriya, T; Kawamata, Y; Ohkubo, S; Fujii, R; Matsui, H; Shintani, Y; Fukusumi, S; Habata, Y; Hinuma, S; Onda, H; Nishimura, O; Fujino, M			Identification and functional characterization of a novel subtype of neuromedin U receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SPINAL-CORD; PROLACTIN-RELEASING PEPTIDE; SMALL-INTESTINE; GUINEA-PIG; GASTROINTESTINAL-TRACT; SUBSTANCE-P; RAT; IMMUNOREACTIVITY; EXPRESSION; CLONING	Neuromedin U is a bioactive peptide isolated originally from the porcine spinal cord. We recently identified neuromedin U as the cognate ligand for the orphan Gr protein-coupled receptor FM-3. In this study, we isolated cDNA coding for a novel G protein-coupled receptor, TGR-1, which was highly homologous with FM-3, We found that neuromedin U specifically and clearly elevated the extracellular acidification rates, arachidonic acid metabolite release, and intracellular Ca2+ mobilization in Chinese hamster ovary cells expressing TGR-1. Radiolabeled neuromedin U specifically bound with high affinity to membrane fractions prepared from these cells. These results show that TGR-1, like FM-3, is a specific and functional receptor for neuromedin U, We analyzed TGR-1 mRNA tissue distribution in rats using quantitative reverse transcription-polymerase chain reaction and found it to considerably differ from that of FM-3 mRNA. TGR-1 mRNA was primarily expressed in the uterus, suggesting that TGR-1 mediates the contractile activity of neuromedin U in this tissue. The identification of specific and functional receptor subtypes for neuromedin U will facilitate the study of their physiological roles and the search for their specific agonists and antagonists.	Takeda Chem Ind Ltd, Pharmaceut Discovery Res Div, Tsukuba, Ibaraki 3004293, Japan	Takeda Chemical Industries	Hinuma, S (corresponding author), Takeda Chem Ind Ltd, Pharmaceut Discovery Res Div, Wadai 10, Tsukuba, Ibaraki 3004293, Japan.			Kawamata, Yuji/0000-0001-5652-4899				AUGOOD SJ, 1988, REGUL PEPTIDES, V20, P281, DOI 10.1016/0167-0115(88)90063-8; AUSTIN C, 1995, J MOL ENDOCRINOL, V14, P157, DOI 10.1677/jme.0.0140157; BALLESTA J, 1988, NEUROSCIENCE, V25, P797, DOI 10.1016/0306-4522(88)90037-1; BENITOORFILA MA, 1991, EUR J PHARMACOL, V193, P329, DOI 10.1016/0014-2999(91)90147-I; BROWN DR, 1988, EUR J PHARMACOL, V155, P159, DOI 10.1016/0014-2999(88)90415-3; DOMIN J, 1986, BIOCHEM BIOPH RES CO, V140, P1127, DOI 10.1016/0006-291X(86)90752-7; DOMIN J, 1987, PEPTIDES, V8, P779, DOI 10.1016/0196-9781(87)90058-1; Fujii R, 2000, J BIOL CHEM, V275, P21068, DOI 10.1074/jbc.M001546200; Fujii R, 1999, REGUL PEPTIDES, V83, P1, DOI 10.1016/S0167-0115(99)00028-2; FURNESS JB, 1989, CELL TISSUE RES, V257, P415, DOI 10.1007/BF00261844; Hinuma S, 1999, J MOL MED, V77, P495, DOI 10.1007/s001090050403; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; HINUMA S, 1994, BBA-GENE STRUCT EXPR, V1219, P251, DOI 10.1016/0167-4781(94)90046-9; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MAGGI CA, 1990, BRIT J PHARMACOL, V99, P186, DOI 10.1111/j.1476-5381.1990.tb14675.x; MALENDOWICZ LK, 1994, NEUROPEPTIDES, V26, P47, DOI 10.1016/0143-4179(94)90092-2; MINAMINO N, 1985, PEPTIDES, V6, P245, DOI 10.1016/0196-9781(85)90381-X; MINAMINO N, 1985, BIOCHEM BIOPH RES CO, V130, P1078, DOI 10.1016/0006-291X(85)91726-7; Nandha KA, 1999, PEPTIDES, V20, P1203, DOI 10.1016/S0196-9781(99)00124-2; NANDHA KA, 1993, ENDOCRINOLOGY, V133, P482, DOI 10.1210/en.133.2.482; STEEL JH, 1988, ENDOCRINOLOGY, V122, P270, DOI 10.1210/endo-122-1-270; SUMI S, 1987, LIFE SCI, V41, P1585, DOI 10.1016/0024-3205(87)90725-9; Tan CP, 1998, GENOMICS, V52, P223, DOI 10.1006/geno.1998.5441; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; TIMMERMANS JP, 1990, CELL TISSUE RES, V260, P367, DOI 10.1007/BF00318639; TIMMERMANS JP, 1989, CELL TISSUE RES, V258, P331, DOI 10.1007/BF00239453	26	102	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29528	29532		10.1074/jbc.M004261200	http://dx.doi.org/10.1074/jbc.M004261200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10887190	hybrid			2022-12-25	WOS:000089439800047
J	Webster, CRL; Blanch, CJ; Phillips, J; Anwer, MS				Webster, CRL; Blanch, CJ; Phillips, J; Anwer, MS			Cell swelling-induced translocation of rat liver Na+/taurocholate cotransport polypeptide is mediated via the phosphoinositide 3-kinase signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADENOSINE-MONOPHOSPHATE; PROTEIN-KINASE-B; BILE-ACID UPTAKE; PHOSPHATIDYLINOSITOL 3-KINASE; TAUROCHOLATE EXCRETION; GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; LIPID PRODUCTS; HEPATOCYTES; EXPRESSION	Cell swelling stimulates phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) in hepatocytes, and the PI3K signaling pathway is involved in cAMP-mediated translocation of sinusoidal Na+/taurocholate (TC) cotransporter (Ntcp) to the plasma membrane. We determined whether cell swelling also stimulates TC uptake and Ntcp translocation via the PI3K and/or MAPK signaling pathway. All studies were conducted in isolated rat hepatocytes, Hepatocyte swelling induced by hypotonic media resulted in: 1) time- and medium osmolarity-dependent increases in TC uptake, 2) an increase in the V-max of Na+/TC cotransport, and 3) wortmannin-sensitive increases in TC uptake and plasma membrane Ntcp mass. Hepatocyte swelling also induced wortmannin-sensitive activation of PI3K, protein kinase B, and p70(S6K). Rapamycin, an inhibitor of p70(S6K), inhibited cell swelling-induced activation of p70(S6K) but failed to inhibit cell swelling-induced stimulation of TC uptake. Because PD98095, an inhibitor of MAPK, did not inhibit cell swelling-induced increases in TC uptake, it is unlikely that the effect of cell swelling on TC uptake is mediated via the MAPK signaling pathway. Taken together, these results indicate that 1) cell swelling stimulates TC uptake by translocating Ntcp to the plasma membrane, 2) this effect is mediated via the PI3K, but not MAPK, signaling pathway, and 3) protein kinase B, but not p70(S6K), is a likely downstream effector of PI3K.	Tufts Univ, Sch Vet Med, Dept Biomed Sci, North Grafton, MA 01536 USA	Tufts University	Anwer, MS (corresponding author), Tufts Univ, Sch Vet Med, Dept Biomed Sci, 200 Westboro Rd, North Grafton, MA 01536 USA.	SANWER@INFONET.TUFTS.EDU			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033436] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33436] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANTHANARAYANAN M, 1994, AM J PHYSIOL-GASTR L, V267, pG637, DOI 10.1152/ajpgi.1994.267.4.G637; ANWER MS, 1978, H-S Z PHYSIOL CHEM, V359, P181; ANWER MS, 1976, H-S Z PHYSIOL CHEM, V357, P1477, DOI 10.1515/bchm2.1976.357.2.1477; ANWER MS, 1993, ADV VET SCI COMP MED, V37, P1; BRUCK R, 1992, AM J PHYSIOL, V262, pG806, DOI 10.1152/ajpgi.1992.262.5.G806; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CORASANTI JG, 1990, AM J PHYSIOL, V258, pG290, DOI 10.1152/ajpgi.1990.258.2.G290; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Dranoff JA, 1999, HEPATOLOGY, V30, P223, DOI 10.1002/hep.510300136; Feranchak AP, 1999, J BIOL CHEM, V274, P30979, DOI 10.1074/jbc.274.43.30979; Feranchak AP, 1998, J BIOL CHEM, V273, P14906, DOI 10.1074/jbc.273.24.14906; Folli F, 1997, GASTROENTEROLOGY, V113, P954, DOI 10.1016/S0016-5085(97)70192-6; Gartung C, 1996, GASTROENTEROLOGY, V110, P199, DOI 10.1053/gast.1996.v110.pm8536857; Gatmaitan ZC, 1997, AM J PHYSIOL-GASTR L, V272, pG1041, DOI 10.1152/ajpgi.1997.272.5.G1041; Glavy JS, 2000, J BIOL CHEM, V275, P1479, DOI 10.1074/jbc.275.2.1479; GRUNE S, 1993, J BIOL CHEM, V268, P17734; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HALLBRUCKER C, 1992, BIOCHEM J, V281, P593, DOI 10.1042/bj2810593; Haussinger D, 1996, BIOCHEM J, V313, P697; HAUSSINGER D, 1993, BIOCHEM J, V291, P355; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Koopen NR, 1999, J HEPATOL, V30, P14, DOI 10.1016/S0168-8278(99)80003-8; Krause U, 1996, J BIOL CHEM, V271, P16668, DOI 10.1074/jbc.271.28.16668; KUTIZ R, 1991, GASTROENTEROLOGY, V113, P1438; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG D, 1993, HEPATOLOGY, V18, P1162; Liu Y, 1997, AM J PHYSIOL-GASTR L, V272, pG46, DOI 10.1152/ajpgi.1997.272.1.G46; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Misra S, 1999, HEPATOLOGY, V30, p306A; Moseley RH, 1996, AM J PHYSIOL-GASTR L, V271, pG137, DOI 10.1152/ajpgi.1996.271.1.G137; Mukhopadhayay S, 1997, AM J PHYSIOL-GASTR L, V273, pG842, DOI 10.1152/ajpgi.1997.273.4.G842; Mukhopadhyay S, 1998, J BIOL CHEM, V273, P30039, DOI 10.1074/jbc.273.45.30039; Mukhopadhyay S, 1998, HEPATOLOGY, V28, P1629, DOI 10.1002/hep.510280624; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; Noe B, 1996, GASTROENTEROLOGY, V110, P858, DOI 10.1053/gast.1996.v110.pm8608896; PFALLER W, 1993, J CELL PHYSIOL, V154, P248, DOI 10.1002/jcp.1041540206; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Reichel C, 1999, GASTROENTEROLOGY, V117, P688, DOI 10.1016/S0016-5085(99)70463-4; Simon FR, 1996, AM J PHYSIOL-GASTR L, V271, pG1043, DOI 10.1152/ajpgi.1996.271.6.G1043; STIEGER B, 1994, GASTROENTEROLOGY, V107, P1781, DOI 10.1016/0016-5085(94)90821-4; Su TZ, 1998, J BIOL CHEM, V273, P3173, DOI 10.1074/jbc.273.6.3173; SUSA M, 1992, J BIOL CHEM, V267, P22951; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Webster CRL, 1999, AM J PHYSIOL-GASTR L, V277, pG1165, DOI 10.1152/ajpgi.1999.277.6.G1165; Webster CRL, 1998, HEPATOLOGY, V27, P1324, DOI 10.1002/hep.510270519; WETTSTEIN M, 1995, HEPATOLOGY, V22, P235, DOI 10.1002/hep.1840220134; Wijkander J, 1997, J BIOL CHEM, V272, P21520, DOI 10.1074/jbc.272.34.21520; YANO H, 1993, J BIOL CHEM, V268, P25846	50	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29754	29760		10.1074/jbc.M002831200	http://dx.doi.org/10.1074/jbc.M002831200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10889198	hybrid			2022-12-25	WOS:000089439800078
J	Sumner, R; Crawford, A; Mucenski, M; Frampton, J				Sumner, R; Crawford, A; Mucenski, M; Frampton, J			Initiation of adult myelopoiesis can occur in the absence of c-Myb whereas subsequent development is strictly dependent on the transcription factor	ONCOGENE			English	Article						c-Myb; knockout; definitive haemopoiesis; megakaryocytes; foetal liver	HEMATOPOIETIC-CELLS; STEM-CELLS; FACTOR GATA-2; YOLK-SAC; V-MYB; DIFFERENTIATION; KIT; EXPRESSION; APOPTOSIS; MOUSE	The c-Myb transcriptional regulator is crucial to the development and functioning of haemopoietic cells, so much so that mouse embryos homozygous for an inactivated c-myb allele die from anaemia at about day 15 of gestation. BS analysing c-myb(-/-) chimaeras we show that no mature cells of any lymphoid or myeloid lineage can be detected in adult haemopoietic tissues. This demonstrates that the effects of c-myb ablation on haemopoiesis are cell autonomous and correlates with an absence in the c-myb(-/-) foetal liver of uni- and multilineage CFUs. Indeed, CFU assays performed on E8.5 yolk sac cells revealed that haemopoietic progenitors are already defective at this st-age. However, although cells expressing high levels of c-Kit were absent, we could detect a high proportion of CD34(+) CD45(+) cells in the c-myb(-/-) foetal liver. Examination of chimaeric embryos revealed that c-myb(-/-) donor-derived CD34(+)/Kit(+) cells, representing committed definitive progenitors, initially populated the foetal liver, but are unable to expand like wild type progenitors. Our results showing no megakaryocytic CFUs and a reduction in the absolute numbers of megakargocytes in the c-myb(-/-) foetal liver also refute early suggestions that megakaryopoiesis is unaffected by the absence of c-Myb.	John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England; John Radcliffe Hosp, Biomed Serv, Oxford OX3 9DS, England; Childrens Hosp, Div Pulm Biol, Cincinnati, OH 45229 USA	University of Oxford; University of Oxford; Cincinnati Children's Hospital Medical Center	Frampton, J (corresponding author), John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England.							Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; Bernex F, 1996, DEVELOPMENT, V122, P3023; Bonifer C, 1998, IMMUNOL TODAY, V19, P236, DOI 10.1016/S0167-5699(98)01259-6; Dzierzak E, 1998, IMMUNOL TODAY, V19, P228, DOI 10.1016/S0167-5699(98)01258-4; Frampton J, 1997, MOL B INT U, P287; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Hogan B, 1994, MANIPULATING MOUSE E; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; Krause DS, 1998, EXP HEMATOL, V26, P1086; LEDBETTER JA, 1979, IMMUNOGENETICS, V8, P347, DOI 10.1007/BF01561445; Lin HH, 1997, GENOMICS, V41, P301, DOI 10.1006/geno.1997.4674; Lin HH, 1996, CURR TOP MICROBIOL, V211, P79; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; MATSUMURA G, 1989, J ANAT, V167, P181; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Mukouyama YS, 1999, CURR BIOL, V9, P833, DOI 10.1016/S0960-9822(99)80368-6; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; OGAWA M, 1993, DEVELOPMENT, V117, P1089; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; Yoder MC, 1997, IMMUNITY, V7, P335, DOI 10.1016/S1074-7613(00)80355-6	28	81	87	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2000	19	30					3335	3342		10.1038/sj.onc.1203660	http://dx.doi.org/10.1038/sj.onc.1203660			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918590				2022-12-25	WOS:000088198100001
J	Brenner, KA; Corbett, SA; Schwarzbauer, JE				Brenner, KA; Corbett, SA; Schwarzbauer, JE			Regulation of fibronectin matrix assembly by activated Ras in transformed cells	ONCOGENE			English	Article						Ras; fibronectin; matrix assembly	CHICK-EMBRYO FIBROBLASTS; FOCAL ADHESION KINASE; FIBRO-SARCOMA CELLS; PROTEIN-KINASE; EXTRACELLULAR-MATRIX; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; INTEGRIN ACTIVATION; CYCLE PROGRESSION; GROWTH-FACTOR	Fibronectin extracellular matrix plays a critical role in the microenvironment of cells. Loss of this matrix frequently accompanies oncogenic transformation, allowing changes in cell growth, morphology, and tissue organization. The HT1080 human fibrosarcoma cell lint is deficient in formation of fibronectin match fibrils but assembly can be induced by the glucocorticoid dex-amethasone, Here we show that fibronectin assembly can also be restored by stimulation of alpha(5)beta(1) integrin with activating antibody or with Mn2+ suggesting that integrin activity is reduced in these cells. While dexamethasone promoted actin stress fiber formation, actin filaments remained cortical following Mn2+ treatment shelving that the dexamethasone effect is not due solely to cytoskeletal changes. HT1080 cells have one activated allele of N-ras and PD98059 inhibition of signaling from Ras through ERK increased fibronectin matrix accumulation. Conversely, the p38 MAP kinase inhibitor SB203580 blocked induction of matrix and increased ERK phosphorylation, Thus, two MAP kinase pathways contribute to the control of integrin-mediated fibronectin assembly, ERK activity and fibronectin assembly were linked in three different ras-transformed cell Lines but not in SV40- or RSV-transformed cells indicating that oncogenic Ras uses a distinct mechanism to down-regulate cell-fibronectin interactions.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ 08903 USA	Princeton University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Schwarzbauer, JE (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.			Schwarzbauer, Jean/0000-0003-1012-7593				AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; DAMSKY CH, 1992, J CLIN INVEST, V89, P210, DOI 10.1172/JCI115565; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766; FURCHT LT, 1979, CANCER RES, V39, P2077; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GRENZ H, 1993, J CELL SCI, V105, P739; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Hulley PA, 1998, ENDOCRINOLOGY, V139, P2423, DOI 10.1210/en.139.5.2423; HYNES RO, 1975, VIROLOGY, V64, P492, DOI 10.1016/0042-6822(75)90126-9; HYNES RO, 1977, J SUPRAMOL STR CELL, V7, P397, DOI 10.1002/jss.400070311; Hynes RO, 1990, FIBRONECTINS; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; KOHNO M, 1985, J BIOL CHEM, V260, P1771; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1987, J CELL BIOL, V104, P601, DOI 10.1083/jcb.104.3.601; MEYER M, 1991, J BIOL CHEM, V266, P8230; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; MOSHER DF, 1993, CURR OPIN STRUC BIOL, V3, P214, DOI 10.1016/S0959-440X(05)80155-1; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Moustakas A, 1999, J CELL SCI, V112, P1169; OLDEN K, 1977, CELL, V11, P957, DOI 10.1016/0092-8674(77)90307-5; OLIVER N, 1983, CELL, V33, P287, DOI 10.1016/0092-8674(83)90357-4; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHWARZBAUER JE, 1989, J CELL BIOL, V109, P3445, DOI 10.1083/jcb.109.6.3445; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; Sechler JL, 1998, J BIOL CHEM, V273, P25533, DOI 10.1074/jbc.273.40.25533; Sechler JL, 1997, MOL BIOL CELL, V8, P2563, DOI 10.1091/mbc.8.12.2563; Sechler JL, 1996, CELL ADHES COMMUN, V4, P413, DOI 10.3109/15419069709004458; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; Sottile J, 1998, J CELL SCI, V111, P2933; Stice Ligaya L., 1999, Frontiers in Bioscience, V4, pD72, DOI 10.2741/Stice; STONE KR, 1974, VIROLOGY, V58, P86, DOI 10.1016/0042-6822(74)90143-3; Uht RM, 1997, ENDOCRINOLOGY, V138, P2900, DOI 10.1210/en.138.7.2900; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; WAHRMAN MZ, 1985, TUMOUR BIOL, V6, P41; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; Wu C, 1997, HISTOL HISTOPATHOL, V12, P233; YAMADA KM, 1976, P NATL ACAD SCI USA, V73, P1217, DOI 10.1073/pnas.73.4.1217; YAMADA KM, 1990, CANCER RES, V50, P4485; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415; ZHANG QH, 1994, J CELL BIOL, V127, P1447, DOI 10.1083/jcb.127.5.1447; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	63	63	65	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3156	3163		10.1038/sj.onc.1203626	http://dx.doi.org/10.1038/sj.onc.1203626			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918570				2022-12-25	WOS:000088019200004
J	Seiffert, D; Bradley, JD; Rominger, CM; Rominger, DH; Yang, FD; Meredith, JE; Tang, Q; Roach, AH; Thompson, LA; Spitz, SM; Higaki, JN; Prakash, SR; Combs, AP; Copeland, RA; Arneric, SP; Hartig, PR; Robertson, DW; Cordell, B; Stern, AM; Olson, RE; Zaczek, R				Seiffert, D; Bradley, JD; Rominger, CM; Rominger, DH; Yang, FD; Meredith, JE; Tang, Q; Roach, AH; Thompson, LA; Spitz, SM; Higaki, JN; Prakash, SR; Combs, AP; Copeland, RA; Arneric, SP; Hartig, PR; Robertson, DW; Cordell, B; Stern, AM; Olson, RE; Zaczek, R			Presenilin-1 and-2 are molecular targets for gamma-secretase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; BETA-SECRETASE; CLEAVAGE; DEFICIENCY; COMPLEX	Presenilins are integral membrane protein involved in the production of amyloid beta -protein, Mutations of the presenilin-1 and -2 gene are associated with familial Alzheimer's disease and are thought to alter gamma -secretase cleavage of the beta -amyloid precursor protein, leading to increased production of longer and more amyloidogenic forms of A beta, the 4-kDa beta -peptide, Here, we show that radiolabeled gamma -secretase inhibitors bind to mammalian cell membranes, and a benzophenone analog specifically photocross-links three major membrane polypeptides. A positive correlation is observed among these compounds for inhibition of cellular A beta formation, inhibition of membrane binding and cross-linking. Immunological techniques establish N- and C-terminal fragments of presenilin-1 as specifically cross-linked polypeptides, Furthermore, binding of gamma -secretase inhibitors to embryonic membranes derived fi om presenilin-1 knockout embryos is reduced in a gene dose-dependent manner. In addition, C-terminal fragments of presenilin-2 are specifically cross-linked. Taken together, these results indicate that potent and selective gamma -secretase inhibitors block A beta formation by binding to presenilin-1 and -2.	DuPont Pharmaceut Co, Expt Stn, Wilmington, DE 19880 USA; Scios Inc, Sunnyvale, CA 94086 USA	DuPont; Scios	Seiffert, D (corresponding author), DuPont Pharmaceut Co, Expt Stn, POB 80400, Wilmington, DE 19880 USA.			Stern, Andrew/0000-0002-8437-2957				BECKETT RP, 1993, SYNLETT, P137; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Czech C, 2000, PROG NEUROBIOL, V60, P363, DOI 10.1016/S0301-0082(99)00033-7; De Strooper B, 1999, NATURE, V402, P471, DOI 10.1038/44973; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Harlow E., 1999, USING ANTIBODIES LAB; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Higaki JN, 1999, J MED CHEM, V42, P3889, DOI 10.1021/jm990009f; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HUSSAIN I, 1999, MOL CELL NEUROSCI; KEEN M, 1999, RECEPTOR BINDING TEC, P106; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Moore CL, 1999, EXPERT OPIN THER PAT, V9, P135, DOI 10.1517/13543776.9.2.135; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	24	287	345	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34086	34091		10.1074/jbc.M005430200	http://dx.doi.org/10.1074/jbc.M005430200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10915801	hybrid			2022-12-25	WOS:000165095300015
J	Kotamraju, S; Konorev, EA; Joseph, J; Kalyanaraman, B				Kotamraju, S; Konorev, EA; Joseph, J; Kalyanaraman, B			Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen - Role of reactive oxygen and nitrogen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-RADICAL FORMATION; DAUNORUBICIN-INDUCED APOPTOSIS; OXIDATIVE STRESS MEASUREMENTS; INDUCED CARDIOTOXICITY; SUPEROXIDE-DISMUTASE; HORSERADISH-PEROXIDASE; INDUCED CARDIOMYOPATHY; GLUTATHIONE SYNTHESIS; REDUCED GLUTATHIONE; ELECTRON-TRANSPORT	Doxorubicin (DOX) is a broad spectrum anthracycline antibiotic used to treat a variety of cancers. Redox activation of DOX to form reactive oxygen species has been implicated in DOX-induced cardiotoxicity, In this work we investigated DOX-induced apoptosis in cultured bovine aortic endothelial cells and cardiomyocytes isolated from adult rat heart. Exposure of bovine aortic endothelial cells or myocytes to submicromolar levels of DOX induced significant apoptosis as measured by DNA fragmentation and terminal deoxynucleotidyltransferase-mediated nick-end labeling assays, Pretreatment of cells with 100 muM nitrone spin traps, N-tert-butyl-alpha -phenylnitrone (PBN) or alpha-(4-pyridyl-1-oxide)-N-tert-butylnitrone (POBN) dramatically inhibited DOX-induced apoptosis, Ebselen (20-50 muM), a glutathione peroxidase mimetic, also significantly inhibited apoptosis, DOX (0.5-1 muM) inactivated mitochondrial complex I by a superoxide-dependent mechanism. PEN (100 muM), POBN (100 muM), and ebselen (50 muM) restored complex I activity. These compounds also inhibited DOX-induced caspase-3 activation and cytochrome c release. PEN and ebselen also restored glutathione levels in DOX-treated cells. We conclude that nitrone spin traps and ebselen inhibit the DOX-induced apoptotic signaling mechanism and that this antiapoptotic mechanism may be linked in part to the inhibition in formation or scavenging of hydrogen peroxide. Therapeutic strategies to mitigate DOX cardiotoxicity should be reexamined in light of these emerging antiapoptotic mechanisms of antioxidants.	Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Biophys Res Inst, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	balarama@mcw.edu			NATIONAL CANCER INSTITUTE [R01CA077822] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; Asakura T, 1999, BRIT J CANCER, V80, P711, DOI 10.1038/sj.bjc.6690414; Atamna H, 2000, J BIOL CHEM, V275, P6741, DOI 10.1074/jbc.275.10.6741; BACHUR NR, 1977, MOL PHARMACOL, V13, P901; BALLA G, 1991, ARTERIOSCLER THROMB, V11, P1700, DOI 10.1161/01.ATV.11.6.1700; Bergmeyer HU, 1974, METHODS ENZYMATIC AN; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUZDAR AU, 1985, CANCER, V55, P2761, DOI 10.1002/1097-0142(19850615)55:12<2761::AID-CNCR2820551206>3.0.CO;2-P; Chen QM, 2000, ARCH BIOCHEM BIOPHYS, V373, P242, DOI 10.1006/abbi.1999.1558; COVA D, 1992, FREE RADICAL RES COM, V15, P353, DOI 10.3109/10715769209049151; DAVIES KJA, 1986, J BIOL CHEM, V261, P3060; Day BJ, 1995, J PHARMACOL EXP THER, V275, P1227; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; GOODMAN J, 1977, BIOCHEM BIOPH RES CO, V77, P797, DOI 10.1016/S0006-291X(77)80048-X; GOTOH N, 1993, BIOCHEM J, V296, P151, DOI 10.1042/bj2960151; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; HANDA K, 1976, GANN, V67, P523; Hensley K, 1998, J NEUROCHEM, V71, P2549; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; Ito A, 1999, BBA-MOL CELL RES, V1452, P263, DOI 10.1016/S0167-4889(99)00131-7; JANZEN EG, 1979, TETRAHEDRON LETT, P3229; KALYANARAMAN B, 1980, BIOCHIM BIOPHYS ACTA, V630, P119, DOI 10.1016/0304-4165(80)90142-7; Karoui H, 1996, J BIOL CHEM, V271, P6000, DOI 10.1074/jbc.271.11.6000; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KONOPA J, 1988, BIOCHEM PHARMACOL, V37, P2303, DOI 10.1016/0006-2952(88)90355-3; Konorev EA, 1999, ARCH BIOCHEM BIOPHYS, V368, P421, DOI 10.1006/abbi.1999.1337; Konorev EA, 1996, BRIT J PHARMACOL, V119, P511, DOI 10.1111/j.1476-5381.1996.tb15701.x; Kotake Y, 1999, ANTIOXID REDOX SIGN, V1, P481, DOI 10.1089/ars.1999.1.4-481; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Messner UK, 1999, KIDNEY INT, V55, P2322, DOI 10.1046/j.1523-1755.1999.00473.x; Minotti G, 1999, FASEB J, V13, P199, DOI 10.1096/fasebj.13.2.199; MONTI E, 1991, FREE RADICAL RES COM, V14, P41, DOI 10.3109/10715769109088940; MYERS C, 1986, FASEB J, V45, P2792; Myers C, 1998, SEMIN ONCOL, V25, P10; MYERS CE, 1977, SCIENCE, V197, P165, DOI 10.1126/science.877547; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Piper H, 1990, CELL CULTURE TECHNIQ, P36; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; Robinson KA, 1999, J NEUROSCI RES, V55, P724, DOI 10.1002/(SICI)1097-4547(19990315)55:6<724::AID-JNR7>3.3.CO;2-0; Rota C, 1999, J BIOL CHEM, V274, P28161, DOI 10.1074/jbc.274.40.28161; Rota C, 1999, FREE RADICAL BIO MED, V27, P873, DOI 10.1016/S0891-5849(99)00137-9; Sarvazyan N, 1996, AM J PHYSIOL-HEART C, V271, pH2079, DOI 10.1152/ajpheart.1996.271.5.H2079; Sawyer DB, 1999, CIRC RES, V84, P257, DOI 10.1161/01.RES.84.3.257; Singal PK, 1998, NEW ENGL J MED, V339, P900, DOI 10.1056/NEJM199809243391307; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; SLATER AFG, 1995, BIOCHEM J, V306, P771, DOI 10.1042/bj3060771; Sussman MA, 1997, CIRC RES, V80, P52, DOI 10.1161/01.RES.80.1.52; SVINGEN BA, 1981, ARCH BIOCHEM BIOPHYS, V209, P119, DOI 10.1016/0003-9861(81)90263-0; SWIFT ML, 2000, AM J PHYSIOL, V278, pH982; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Vasquez-Vivar J, 2000, J BIOL CHEM, V275, P14064, DOI 10.1074/jbc.275.19.14064; VasquezVivar J, 1997, BIOCHEMISTRY-US, V36, P11293, DOI 10.1021/bi971475e; Yang CF, 2000, ARCH BIOCHEM BIOPHYS, V374, P142, DOI 10.1006/abbi.1999.1574; Yen HC, 1999, ARCH BIOCHEM BIOPHYS, V362, P59, DOI 10.1006/abbi.1998.1011; Zhu WD, 1999, CIRCULATION, V100, P2100, DOI 10.1161/01.CIR.100.20.2100	65	316	327	2	28	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33585	33592		10.1074/jbc.M003890200	http://dx.doi.org/10.1074/jbc.M003890200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10899161	hybrid			2022-12-25	WOS:000090104600058
J	Kueltzo, LA; Normand, N; O'Hare, P; Middaugh, CR				Kueltzo, LA; Normand, N; O'Hare, P; Middaugh, CR			Conformational lability of herpesvirus protein VP22	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; HIV-1 TAT PROTEIN; MOLTEN GLOBULE STATE; CIRCULAR-DICHROISM; INTERCELLULAR TRAFFICKING; SECONDARY STRUCTURE; MEMBRANE-INSERTION; FUSION PROTEINS; I TAT; DELIVERY	The herpesvirus protein VP22 traffics between cells, being exported from expressing cells in a non-Golgi-dependent manner and localizing in the nuclei of surrounding cells. This transport is retained in certain VP22 fusion proteins, making VP22 a candidate for use in macromolecular drug delivery. In an effort to understand the physical basis for this activity, we have initiated structural studies of VP22.C1, the C-terminal half of VP22, which possesses the full transport activity of the native protein. CD and Fourier transform infrared analyses indicate a secondary structure consisting of approximately 30% alpha -helix, 17% beta -sheet, and 51% disordered and turn structure. Unfolding studies conducted by CD, differential scanning calorimetry, and fluorescence reveal a series of discrete structural transitions in the range of 20-60 degreesC, CD and fluorescence studies of interactions between VP22.C1 and divalent cations and model polyanions indicate that Mg2+, Zn2+, oligonucleotides, and heparin interact with the protein, causing changes in secondary structure and thermal stability. Additionally, the interaction of VP22.C1 with model lipids was examined. Fluorescence titrations of the protein with trans-parinaric acid at various temperatures suggest the binding of one to two molecules of parinaric acid to VP22.C1 at temperatures >40 degreesC, suggesting the possibility of conformation dependent membrane interaction under physiological conditions.	Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA; Marie Curie Res Inst, Oxford RH8 0TL, Surrey, England	University of Kansas	Middaugh, CR (corresponding author), Univ Kansas, Dept Pharmaceut Chem, 2095 Constant Ave, Lawrence, KS 66047 USA.	middaugh@ukans.edu		O'Hare, Peter/0000-0003-4508-5602; Kueltzo, Lisa/0000-0001-7157-320X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008359] Funding Source: NIH RePORTER; NIGMS NIH HHS [2 T32 GM08359-11] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BARRICK D, 1993, PROTEIN SCI, V2, P869, DOI 10.1002/pro.5560020601; BAYER P, 1995, J MOL BIOL, V247, P529, DOI 10.1016/S0022-2836(05)80133-0; BYCHKOVA VE, 1992, BIOCHEMISTRY-US, V31, P7566, DOI 10.1021/bi00148a018; BYCHKOVA VE, 1988, FEBS LETT, V238, P231, DOI 10.1016/0014-5793(88)80485-X; COLLINS D, 1994, BIOCHEMISTRY-US, V33, P4521, DOI 10.1021/bi00181a012; Conrad H. E., 1998, HEPARIN BINDING PROT; COPELAND RA, 1991, ARCH BIOCHEM BIOPHYS, V289, P53, DOI 10.1016/0003-9861(91)90441-K; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Dilber MS, 1999, GENE THER, V6, P12, DOI 10.1038/sj.gt.3300838; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Elliott G, 1998, J VIROL, V72, P6448, DOI 10.1128/JVI.72.8.6448-6455.1998; Elliott G, 1999, GENE THER, V6, P149, DOI 10.1038/sj.gt.3300850; Elliott G, 1996, VIROLOGY, V226, P140, DOI 10.1006/viro.1996.0638; ELLIOTT GD, 1992, J GEN VIROL, V73, P723, DOI 10.1099/0022-1317-73-3-723; Fischer PM, 2000, J PEPT RES, V55, P163, DOI 10.1034/j.1399-3011.2000.00163.x; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HAUGLAND RP, 1996, HDB FLUORESCENT PROB, P297; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; Kuchler K, 1990, CURR OPIN CELL BIOL, V2, P617, DOI 10.1016/0955-0674(90)90102-K; Linemeyer DL, 1990, GROWTH FACTORS, V3, P287, DOI 10.3109/08977199009003671; MACH H, 1995, BIOCHEMISTRY-US, V34, P9913, DOI 10.1021/bi00031a013; MACH H, 1993, BIOCHEMISTRY-US, V32, P7703, DOI 10.1021/bi00081a015; MACH H, 1994, ANAL BIOCHEM, V222, P323, DOI 10.1006/abio.1994.1499; Mach H, 1995, Methods Mol Biol, V40, P91; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MIDDAUGH CR, 1995, PROTEIN STABILITY FO, V40, P137; MIDDAUGH CR, 1993, CURR OPIN INVEST DR, V2, P991; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; ORTEGA S, 1991, J BIOL CHEM, V266, P5842; Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Rubartelli A, 1998, IMMUNOL TODAY, V19, P543, DOI 10.1016/S0167-5699(98)01351-6; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; Rubartelli A., 1997, UNUSUAL SECRETORY PA, P87, DOI [10.1007/978-3-662-22581-3_3, DOI 10.1007/978-3-662-22581-3_3]; Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SKLAR LA, 1976, J SUPRAMOL STR CELL, V4, P449, DOI 10.1002/jss.400040404; SKLAR LA, 1977, BIOCHEMISTRY-US, V16, P813, DOI 10.1021/bi00624a001; Soulages JL, 1998, BIOCHEMISTRY-US, V37, P10203, DOI 10.1021/bi980622l; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Stolowich NJ, 1997, BIOCHEMISTRY-US, V36, P1719, DOI 10.1021/bi962317a; SUSI H, 1986, METHOD ENZYMOL, V130, P290; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; Vecsey-Semjen B, 1999, BIOCHEMISTRY-US, V38, P4296, DOI 10.1021/bi982472k; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; WIEDLOCHA A, 1992, EMBO J, V11, P4835, DOI 10.1002/j.1460-2075.1992.tb05589.x	50	31	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33213	33221		10.1074/jbc.M002476200	http://dx.doi.org/10.1074/jbc.M002476200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10913125	hybrid			2022-12-25	WOS:000090104600008
J	Zhang, L; Spratt, SK; Liu, Q; Johnstone, B; Qi, H; Raschke, EE; Jamieson, AC; Rebar, EJ; Wolffe, AP; Case, CC				Zhang, L; Spratt, SK; Liu, Q; Johnstone, B; Qi, H; Raschke, EE; Jamieson, AC; Rebar, EJ; Wolffe, AP; Case, CC			Synthetic zinc finger transcription factor action at an endogenous chromosomal site - Activation of the human erythropoietin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; RIBOSOMAL-RNA GENES; FACTOR ACCESS; FACTOR-IIIA; IN-VIVO; 5S RNA; XENOPUS OOCYTE; POSITIVE ROLE; HISTONE H1; CHROMATIN	We have targeted the activation of an endogenous chromosomal locus including the human erythropoietin gene using synthetic transcription factors. These transcription factors are targeted to particular DNA sequences in the 5'-flanking region of the erythropoietin gene through engineering of a zinc finger DNA binding domain. The DNA binding domain is linked to a VP16 transcriptional activation domain. We find that these synthetic transcription factors invariably activate transiently transfected templates in which sequences within the 5' flank of the erythropoietin gene are fused to a luciferase reporter. The efficiency of activation under these circumstances at a defined site is dependent on DNA binding affinity. In contrast, only a subset of these same zinc finger proteins is able to activate the endogenous chromosomal locus. The activity of these proteins is influenced by their capacity to gain access to their recognition elements within the chromatin infrastructure, Zinc finger transcription factors will provide a powerful tool to probe the determinants of chromatin accessibility and remodeling within endogenous chromosomal loci.	Sangamo Biosci Inc, Point Richmond Tech Ctr, Richmond, CA 94804 USA	Sangamo Therapeutics, Inc.	Wolffe, AP (corresponding author), Sangamo Biosci Inc, Point Richmond Tech Ctr, 501 Canal Blvd,Suite A100, Richmond, CA 94804 USA.							ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628; Beerli RR, 2000, P NATL ACAD SCI USA, V97, P1495, DOI 10.1073/pnas.040552697; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; Chan WK, 1999, J BIOL CHEM, V274, P12115, DOI 10.1074/jbc.274.17.12115; CHIPEV CC, 1992, MOL CELL BIOL, V12, P45, DOI 10.1128/MCB.12.1.45; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; Crane-Robinson C, 1998, TRENDS GENET, V14, P477, DOI 10.1016/S0168-9525(98)01621-7; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; ENGLANDER EW, 1993, J BIOL CHEM, V268, P19565; ENGLANDER EW, 1995, J BIOL CHEM, V270, P10091, DOI 10.1074/jbc.270.17.10091; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GOTTESFELD J, 1982, CELL, V28, P781, DOI 10.1016/0092-8674(82)90057-5; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; Gupta M, 1996, NUCLEIC ACIDS RES, V24, P4768, DOI 10.1093/nar/24.23.4768; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; Hu B, 1997, MOL CELL BIOL, V17, P851, DOI 10.1128/MCB.17.2.851; Jamieson AC, 1996, P NATL ACAD SCI USA, V93, P12834, DOI 10.1073/pnas.93.23.12834; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; Kim JS, 1997, J BIOL CHEM, V272, P29795, DOI 10.1074/jbc.272.47.29795; Kim JS, 1997, P NATL ACAD SCI USA, V94, P3616, DOI 10.1073/pnas.94.8.3616; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Lee HJ, 1996, J BIOL CHEM, V271, P10405, DOI 10.1074/jbc.271.17.10405; Panetta G, 1998, J MOL BIOL, V282, P683, DOI 10.1006/jmbi.1998.2087; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; RHODES D, 1985, EMBO J, V4, P3473, DOI 10.1002/j.1460-2075.1985.tb04106.x; Sera T, 1998, MOL CELL BIOL, V18, P3668, DOI 10.1128/MCB.18.7.3668; TREMETHICK D, 1990, J BIOL CHEM, V265, P5014; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; Tse C, 1998, P NATL ACAD SCI USA, V95, P12169, DOI 10.1073/pnas.95.21.12169; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; Vitolo JM, 2000, MOL CELL BIOL, V20, P2167, DOI 10.1128/MCB.20.6.2167-2175.2000; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344	39	150	198	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33850	33860		10.1074/jbc.M005341200	http://dx.doi.org/10.1074/jbc.M005341200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10913152	hybrid			2022-12-25	WOS:000090104600093
J	Keyhani, NO; Bacia, K; Roseman, S				Keyhani, NO; Bacia, K; Roseman, S			The transport/phosphorylation of N-N '-Diacetylchitobiose in Escherichia coli - Characterization of phospho-IIBChb and of a potential transition state analogue in the phosphotransfer reaction between the proteins IIA(Chb) and IIBChb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; GLUCOSE-TRANSPORTER; CEL OPERON; INTERMEDIATE; SYSTEM; PHOSPHOCYSTEINE; PHOSPHOENOLPYRUVATE; CYSTEINE; VISUALIZATION; CATALYSIS	Enzyme II permeases of the phosphoenolpyruvate:glycose phosphotransferase system comprise one to five separately encoded polypeptides, but most contain similar domains (IIA RB, and IIC). The phosphoryl group is transferred from one domain to another, with histidine as the phosphoryl acceptor in IIA and cysteine as the acceptor in certain IIB domains. IIBChb is a phosphocarrier in the uptake/phosphorylation of the chitin disaccharide, (Glc-NAc)(2) by Escherichia coli and is unusual because it is separately encoded and soluble. Both the crystal and solution structures of a IIBChb mutant (C10S) have been reported. In the present studies, homogeneous phospho-IIBChb was isolated, and the phosphoryl-Cys linkage was established by Slp NMR spectroscopy. Rate constants for the hydrolysis of phospho-IIBChb plotted versus pH gave the same shape peak reported for the model compound, butyl thiophosphate, but was shifted about 4 pH units. Evidence is presented for a stable complex between homogeneous Cys10SerIIB(Chb) (which cannot be phosphorylated) and phospho-IIA(Chb) but not with IIA(Chb). The complex (a tetramer (3)) contains equimolar quantities of the two proteins and has been chemically cross-linked. It appears to be an analogue of the transition state complex in the reaction: phospho-IIA(Chb) + IIBChb <-> IIA(Chb) + phospho-IIBChb. This is apparently the first report of the isolation of a transition state analogue in a protein-protein phosphotransfer reaction.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Roseman, S (corresponding author), Johns Hopkins Univ, Dept Biol, Mudd Hall,Rm 214,3400 N Charles St, Baltimore, MD 21218 USA.		Keyhani, Nemat O/I-8150-2013		PHS HHS [38759] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AB E, 1994, PROTEIN SCI, V3, P282; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; ERNI B, 1989, FEMS MICROBIOL LETT, V63, P13, DOI 10.1016/0168-6445(89)90004-1; Gemmecker G, 1997, BIOCHEMISTRY-US, V36, P7408, DOI 10.1021/bi963053v; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HERR EB, 1957, BIOCHIM BIOPHYS ACTA, V25, P219, DOI 10.1016/0006-3002(57)90456-0; Keyhani N, 2000, J BIOL CHEM, V275, P33110, DOI 10.1074/jbc.M001717200; Keyhani NO, 2000, J BIOL CHEM, V275, P33091, DOI 10.1074/jbc.M001044200; Keyhani NO, 2000, J BIOL CHEM, V275, P33084, DOI 10.1074/jbc.M001043200; Keyhani NO, 2000, J BIOL CHEM, V275, P33068, DOI 10.1074/jbc.M001041200; Keyhani NO, 1997, P NATL ACAD SCI USA, V94, P14367, DOI 10.1073/pnas.94.26.14367; MATHEIS G, 1984, INT J BIOCHEM, V16, P867, DOI 10.1016/0020-711X(84)90145-9; MEINS M, 1993, J BIOL CHEM, V268, P11604; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Park JK, 2000, J BIOL CHEM, V275, P33077, DOI 10.1074/jbc.M001042200; PARKER LL, 1990, GENETICS, V124, P455; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5515, DOI 10.1021/bi00415a019; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5835, DOI 10.1021/bi00416a002; PAS HH, 1991, J BIOL CHEM, V266, P6690; POGGEVONSTRANDM.P, 1995, EUR J BIOCHEM, V233, P1166; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; vanMontfort RLM, 1997, STRUCTURE, V5, P217, DOI 10.1016/S0969-2126(97)00180-9; VANMONTFORT RLM, 1994, J MOL BIOL, V239, P588, DOI 10.1006/jmbi.1994.1399; VOGEL HJ, 1989, METHOD ENZYMOL, V177, P263; WEIGEL N, 1982, J BIOL CHEM, V257, P4477	27	17	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33102	33109		10.1074/jbc.M001045200	http://dx.doi.org/10.1074/jbc.M001045200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913119	hybrid			2022-12-25	WOS:000090003800098
J	Ko, YH; Hullihen, J; Hong, S; Pedersen, PL				Ko, YH; Hullihen, J; Hong, S; Pedersen, PL			Mitochondrial F(0)F1 ATP synthase - Subunit regions on the F-1 motor shielded by F-0, functional significance, and evidence for an involvement of the unique F-0 subunit F-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; ESCHERICHIA-COLI F1-ATPASE; RAT-LIVER MITOCHONDRIA; GAMMA-SUBUNIT; SUBMITOCHONDRIAL PARTICLES; OXIDATIVE-PHOSPHORYLATION; MEMBRANE TOPOGRAPHY; EPSILON-SUBUNIT; CROSS-LINKING; DELTA-SUBUNIT	Studies reported here were undertaken to gain greater molecular insight into the complex structure of mitochondrial ATP synthase (F0F1) and its relationship to the enzyme's function and motor-related properties. Significantly, these studies, which employed N-terminal sequence, mass spectral, proteolytic, immunological, and functional analyses, led to the following novel findings. First, at the top of F-1 within F0F1, all six N-terminal regions derived from alpha + beta subunits are shielded, indicating that one or more F-0 subunits forms a "cap." Second, at the bottom of F-1 within F0F1, the N-terminal region of the single delta subunit and the C-terminal regions of all three alpha subunits are shielded also by F-0. Third, and in contrast, part of the gamma subunit located at the bottom of F-1 is already shielded in F-1, indicating that there is a preferential propensity for interaction with other F-1 subunits, most likely delta and epsilon. Fourth, and consistent with the first two conclusions above that specific regions at the top and bottom of F-1 are shielded by F-0, further proteolytic shaving of alpha and beta subunits at these locations eliminates the capacity of F-1 to couple a proton gradient to ATP synthesis. Finally, evidence was obtained that the F-0 subunit called "F-6," unique to animal ATP syntheses, is involved in shielding F-1. The significance of the studies reported here, in relation to current views about ATP synthase structure and function in animal mitochondria, is discussed.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Pedersen, PL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL CANCER INSTITUTE [R01CA010951, R37CA010951] Funding Source: NIH RePORTER; NCI NIH HHS [CA 10951] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Altendorf K, 2000, J EXP BIOL, V203, P19; Bakhtiari N, 1999, J BIOL CHEM, V274, P16363, DOI 10.1074/jbc.274.23.16363; Belogrudov GI, 1996, J BIOL CHEM, V271, P20340, DOI 10.1074/jbc.271.34.20340; BELOGRUDOV GI, 1995, J BIOL CHEM, V270, P2053, DOI 10.1074/jbc.270.5.2053; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; BOYER PD, 1997, ANNU REV BIOCHEM, V66, P714; CATTERALL WA, 1971, J BIOL CHEM, V246, P4987; Collinson IR, 1996, BIOCHEMISTRY-US, V35, P12640, DOI 10.1021/bi960969t; COLLINSON IR, 1994, J MOL BIOL, V242, P408; COLLINSON IR, 1994, BIOCHEM J, V303, P639, DOI 10.1042/bj3030639; CROSS RL, 1981, ANNU REV BIOCHEM, V50, P681, DOI 10.1146/annurev.bi.50.070181.003341; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; DOOLITTLE RF, 1968, BIOCHEMISTRY-US, V7, P516, DOI 10.1021/bi00842a005; EDMAN P, 1950, ACTA CHEM SCAND, V4, P283, DOI 10.3891/acta.chem.scand.04-0283; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; FESSENDENRADEN JM, 1972, J BIOL CHEM, V247, P2351; GOGEL EP, 1987, FEBS LETT, V219, P274; Hausrath AC, 1999, P NATL ACAD SCI USA, V96, P13697, DOI 10.1073/pnas.96.24.13697; HEKMAN C, 1991, J BIOL CHEM, V266, P13564; HUNKAPILLER MW, 1983, SCIENCE, V219, P650, DOI 10.1126/science.6687410; JACOBS EE, 1956, J BIOL CHEM, V223, P147; JOUNOUCHI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P376, DOI 10.1016/0003-9861(92)90005-H; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; KAGAWA Y, 1972, BIOCHIM BIOPHYS ACTA, V265, P297, DOI 10.1016/0304-4157(72)90012-3; Karrasch S, 1999, J MOL BIOL, V290, P379, DOI 10.1006/jmbi.1999.2897; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Kinosita K, 1998, CELL, V93, P21, DOI 10.1016/S0092-8674(00)81142-3; Ko YH, 1997, J BIOL CHEM, V272, P18875, DOI 10.1074/jbc.272.30.18875; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCENERY MW, 1984, J BIOL CHEM, V259, P4642; NAGLEY P, 1988, TRENDS GENET, V4, P46, DOI 10.1016/0168-9525(88)90066-2; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Oster G, 1999, STRUCTURE, V7, pR67, DOI 10.1016/S0969-2126(99)80046-X; Pan WY, 1998, BIOCHEMISTRY-US, V37, P6911, DOI 10.1021/bi9800698; PEDERSEN PL, 1978, J BIOL CHEM, V253, P2176; PEDERSEN PL, 1995, J BIOL CHEM, V270, P1775, DOI 10.1074/jbc.270.4.1775; PENIN F, 1990, BIOCHEMISTRY-US, V29, P9358, DOI 10.1021/bi00492a008; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SCHIGGER H, 1987, ANAL BIOCHEM, V166, P368; SEBALD W, 1981, CURR TOP BIOENERG, V12, P1; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; SOPER JW, 1979, J BIOL CHEM, V254, P1170; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; WALKER JE, 1994, FEBS LETT, V346, P39, DOI 10.1016/0014-5793(94)00368-8; WALKER JE, 1991, BIOCHEMISTRY-US, V30, P5369, DOI 10.1021/bi00236a007; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Wilkens S, 2000, J MOL BIOL, V295, P387, DOI 10.1006/jmbi.1999.3381; WILKENS S, 1994, FEBS LETT, V354, P37, DOI 10.1016/0014-5793(94)01059-5; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609	56	23	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32931	32939		10.1074/jbc.M004453200	http://dx.doi.org/10.1074/jbc.M004453200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10887193	hybrid			2022-12-25	WOS:000090003800077
J	Chen, L; Smith, L; Johnson, MR; Wang, KS; Diasio, RB; Smith, JB				Chen, L; Smith, L; Johnson, MR; Wang, KS; Diasio, RB; Smith, JB			Activation of protein kinase C induces nuclear translocation of RFX1 and down-regulates c-myc via an intron 1 X box in undifferentiated leukemia HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B VIRUS ENHANCER; DNA-BINDING PROTEIN; REPRESSION DOMAINS; HL60 CELLS; DIFFERENTIATION; TRANSCRIPTION; PROMOTER; EXPRESSION; BLOCK; GENE	Treatment of human promyelocytic leukemia cells (HL-60) with phorbol la-myristate 13-acetate (PMA) is known to decrease c-myc mRNA by blocking transcription elongation at sites near the first exon/intron border. Treatment of HL-60 cells with either PMA or bryostatin 1, which acutely activates protein kinase C (PKC), decreased the levels of myc mRNA and Myc protein. The inhibition of Myc synthesis accounted for the drop in Myc protein, because PMA treatment had no effect on Myc turnover. Treatment with PMA or bryostatin 1 increased nuclear protein binding to MIE1, a c-myc intron 1 element that defines an RFX1-binding X box. RFX1 antiserum supershifted MIE1-protein complexes. Increased MIE1 binding was independent of protein synthesis and abolished by a selective PKC inhibitor, which also prevented the effect of PMA on myc mRNA and protein levels and Myc synthesis. PMA treatment increased RFX1 in the nuclear fraction and decreased it in the cytosol without affecting total RFX1. Transfection of HL-60 cells with myc reporter gene constructs showed that the RFX1-binding X box was required for the downregulation of reporter gene expression by PMA. These findings suggest that nuclear translocation and binding of RFX1 to the X box cause the down-regulation of myc expression, which follows acute PKC activation in undifferentiated HL-60 cells.	Univ Alabama, Sch Med, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; Univ Alabama, Sch Med, Ctr Comprehens Canc, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Ctr Comprehens Canc, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Smith, JB (corresponding author), Univ Alabama, Sch Med, Dept Pharmacol & Toxicol, Volker Hall G133E,1670 Univ Blvd, Birmingham, AL 35294 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060383] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60383] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BENLEVY R, 1989, MOL CELL BIOL, V9, P1804, DOI 10.1128/MCB.9.4.1804; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; Blake M, 1996, J VIROL, V70, P6060, DOI 10.1128/JVI.70.9.6060-6066.1996; Chen L, 2000, ARCH BIOCHEM BIOPHYS, V374, P306, DOI 10.1006/abbi.1999.1603; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Dang CV, 1999, MOL CELL BIOL, V19, P1; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; Emery P, 1996, MOL CELL BIOL, V16, P4486; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Iwama A, 1999, MOL CELL BIOL, V19, P3940; Katan Y, 1997, NUCLEIC ACIDS RES, V25, P3621, DOI 10.1093/nar/25.18.3621; Katan-Khaykovich Y, 1998, J BIOL CHEM, V273, P24504, DOI 10.1074/jbc.273.38.24504; KRAFT AS, 1986, P NATL ACAD SCI USA, V83, P1334, DOI 10.1073/pnas.83.5.1334; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee HW, 1996, AM J PHYSIOL-CELL PH, V271, pC304, DOI 10.1152/ajpcell.1996.271.1.C304; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Lee HW, 1997, MOL PHARMACOL, V51, P439; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; OSTAPCHUK P, 1989, MOL CELL BIOL, V9, P2787, DOI 10.1128/MCB.9.7.2787; Pan QT, 1999, J BIOL CHEM, V274, P8437, DOI 10.1074/jbc.274.13.8437; REINHOLD W, 1995, MOL CELL BIOL, V15, P3041; REITH W, 1989, P NATL ACAD SCI USA, V86, P4200, DOI 10.1073/pnas.86.11.4200; SALEHI Z, 1988, J BIOL CHEM, V263, P1898; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; Simpson RU, 1998, J BIOL CHEM, V273, P19587, DOI 10.1074/jbc.273.31.19587; SIMPSON RU, 1989, J BIOL CHEM, V264, P19710; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; TONETTI DA, 1994, J BIOL CHEM, V269, P23230; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Westerheide SD, 1999, NUCLEIC ACIDS RES, V27, P1635, DOI 10.1093/nar/27.7.1635; YU BW, 1993, J BIOL CHEM, V268, P19586; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZHANG XY, 1990, CANCER RES, V50, P6865; ZHANG XY, 1993, MOL CELL BIOL, V13, P6810, DOI 10.1128/MCB.13.11.6810	45	34	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32227	32233		10.1074/jbc.M002645200	http://dx.doi.org/10.1074/jbc.M002645200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10918054	hybrid			2022-12-25	WOS:000089858900093
J	Harborth, J; Weber, K; Osborn, M				Harborth, J; Weber, K; Osborn, M			GAS41, a highly conserved protein in eukaryotic nuclei, binds to NuMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC SPINDLE; SECONDARY-STRUCTURE; ACUTE-LEUKEMIA; COILED-COIL; PHOSPHORYLATION; APPARATUS; SEQUENCE; SITES; PREDICTION; INTERACTS	The yeast two-hybrid system was used to identify binding partners of NuMA, a component of the nuclear matrix in interphase cells. By using the C-terminal half of NuMA as bait, a human cDNA sequence coding for a 223-amino acid protein with a non-helical N-terminal domain and a C-terminal a-helical portion was identified and fully sequenced. It was identical to GAS41, a sequence amplified in human gliomas, The sequence of the homologous Drosophila protein was established, and the alignment for GAS41 from nine different species showed that GAS41 is a general eukaryotic protein found in species as diverse as Arabidopsis, Drosophila, Caenorhabditis elegans, yeast, and man. Northern blot analysis showed a single transcript in eight human tissues. A polyclonal antibody to GAS41 showed a dotted staining pattern in interphase nuclei and a uniform distribution in mitotic cells. A GFP-GAS41 fusion protein displayed equivalent patterns. In vitro GAS41 bound to the C-terminal part of the rod region of NuMA, as shown by dot overlay and by surface plasmon resonance measurements. The K-d of the complex was 2 x 10(-7) M. GAS41 is related to the AF-9 and ENL proteins, which are putative transcription factors found as fusion proteins in some acute leukemias. The NuMA/GAS41 interaction may provide a link between nuclear structure and gene expression.	Max Planck Inst Biophys Chem, Dept Biochem, D-37077 Gottingen, Germany	Max Planck Society	Harborth, J (corresponding author), Max Planck Inst Biophys Chem, Dept Biochem, Fassberg 11, D-37077 Gottingen, Germany.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COMPTON DA, 1995, J CELL SCI, V108, P621; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; Fischer U, 1997, HUM MOL GENET, V6, P1817, DOI 10.1093/hmg/6.11.1817; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Gueth-Hallonet C, 1998, EXP CELL RES, V243, P434, DOI 10.1006/excr.1998.4178; Harborth J, 1999, EMBO J, V18, P1689, DOI 10.1093/emboj/18.6.1689; HARBORTH J, 1995, EMBO J, V14, P2447, DOI 10.1002/j.1460-2075.1995.tb07242.x; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; KALLAJOKI M, 1991, EMBO J, V10, P3351, DOI 10.1002/j.1460-2075.1991.tb04899.x; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUDERUS MEE, 1994, MOL CELL BIOL, V14, P6297, DOI 10.1128/MCB.14.9.6297; LYDERSEN BK, 1980, CELL, V22, P489, DOI 10.1016/0092-8674(80)90359-1; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NISHIKAWA K, 1983, BIOCHIM BIOPHYS ACTA, V748, P285, DOI 10.1016/0167-4838(83)90306-0; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SPARKS CA, 1995, J CELL SCI, V108, P3389; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; YANG CH, 1992, J CELL BIOL, V116, P1303, DOI 10.1083/jcb.116.6.1303; YANG CH, 1992, MOL BIOL CELL, V3, P1259, DOI 10.1091/mbc.3.11.1259	31	38	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31979	31985		10.1074/jbc.M000994200	http://dx.doi.org/10.1074/jbc.M000994200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913114	hybrid			2022-12-25	WOS:000089858900060
J	Liang, JS; Wu, XY; Fisher, EA; Ginsberg, HN				Liang, JS; Wu, XY; Fisher, EA; Ginsberg, HN			The amino-terminal domain of apolipoprotein B does not undergo retrograde translocation from the endoplasmic reticulum to the cytosol - Proteasomal degradation of nascent apolipoprotein B begins at the carboxyl terminus of the protein, while apolipoprotein B is still in its original, translocon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; HEP G2 CELLS; INTRACELLULAR DEGRADATION; CONTAINING LIPOPROTEINS; SECRETORY PROTEIN; ER DEGRADATION; PAUSE TRANSFER; MEMBRANE; UBIQUITIN; PATHWAY	We studied the sequential topology of the NH, and COOH termini of apoB during translocation by expressing, in Chinese hamster ovary (CHO) and HepG2 cells, an apoB42 construct with c-Myc and hemagglutinin (HA) tags at 2 and 41% (relative to apoB100) of its amino acid sequence. We conducted similar studies using monoclonal antibodies against the NH, and COOH termini of apoB100 in HepG2 cells. After radiolabeling, microsomes were immunoisolated from transfected CHO cells using anti-c-Mye or anti-HA antibodies. Throughout a 60-min chase in the presence of N-acetyl-leucylnorleucinal, more than 90% of microsomes were isolated by anti-HA antibodies, whereas less than 10% were isolated by anti-c-Mye antibodies. Proteinase K digestion of total microsomes consistently generated two fragments (similar to 70 and similar to 120 kDa) of apoB42 containing the NH, terminus throughout the chase; no fragments containing the COOH terminus were detected. Immunofluorescent studies of transfected CHO cells were consistent with results from the labeling studies. Essentially identical results were obtained from pulse-chase studies in both native and apoB42-transfected HepG2 cells. The present studies support a model in which, in the absence of adequate core lipid synthesis, there is partial translocation of apoB leading to cytosolic exposure, ubiquitination, and proteasomal degradation directly from the original translocation channel.	Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Mt Sinai Sch Med, Cardiovasc Inst, Lab Lipoprot Res, New York, NY 10029 USA	Columbia University; Icahn School of Medicine at Mount Sinai	Liang, JS (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.	jl698@columbia.edu		Fisher, Edward/0000-0001-9802-143X	NHLBI NIH HHS [T32 HL07343, HL58541, HL55638] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007343, R01HL058541, R01HL055638] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; Corsi AK, 1996, J BIOL CHEM, V271, P30299, DOI 10.1074/jbc.271.48.30299; Cresswell P, 1997, CURR BIOL, V7, pR552, DOI 10.1016/S0960-9822(06)00279-X; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DU EZ, 1994, J BIOL CHEM, V269, P24169; Du XB, 1998, J CELL BIOL, V141, P585, DOI 10.1083/jcb.141.3.585; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Huang XF, 1999, J LIPID RES, V40, P2212; Ingram MF, 1997, J BIOL CHEM, V272, P10279; Kivlen MH, 1997, J LIPID RES, V38, P1149; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LIANG J, 1988, J BIOL CHEM, V273, P35216; Liao W, 1998, J BIOL CHEM, V273, P27225, DOI 10.1074/jbc.273.42.27225; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Pease RJ, 1996, CURR OPIN LIPIDOL, V7, P132, DOI 10.1097/00041433-199606000-00004; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Rusinol AE, 1998, J LIPID RES, V39, P1287; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; Shelness GS, 1999, J NUTR, V129, p456S, DOI 10.1093/jn/129.2.456S; SPARKS JD, 1992, J CLIN INVEST, V89, P1418, DOI 10.1172/JCI115731; STEINBERG D, 1989, CIRCULATION, V80, P719, DOI 10.1161/01.CIR.80.3.719; Suzuki T, 1998, J BIOL CHEM, V273, P10083, DOI 10.1074/jbc.273.17.10083; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Yao ZM, 1997, J LIPID RES, V38, P1937; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	42	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32003	32010		10.1074/jbc.M004646200	http://dx.doi.org/10.1074/jbc.M004646200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10922368	hybrid			2022-12-25	WOS:000089858900063
J	Liu, PS; Wang, PY; Michaely, P; Zhu, MF; Anderson, RGW				Liu, PS; Wang, PY; Michaely, P; Zhu, MF; Anderson, RGW			Presence of oxidized cholesterol in caveolae uncouples active platelet-derived growth factor receptors from tyrosine kinase substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; MEDIATED ENDOCYTOSIS; SIGNAL-TRANSDUCTION; BILAYER MEMBRANES; LIPID-MEMBRANES; CULTURED-CELLS; OXIDATION; ORGANIZATION; LOCALIZATION; MODULATION	Platelet-derived growth factor receptor beta (PDGFR beta) in fibroblasts is concentrated in caveolae where it controls the tyrosine phosphorylation of multiple proteins. Caveolae are enriched in cholesterol and sphingolipids, but the role of these lipids in PDGFR signal transduction is unknown. We report that introduction of cholest-4-en-3-one into caveolae membranes uncouples PDGFR autophosphorylation from tyrosine phosphorylation of neighboring proteins. Cholest-4-en-3-one appears to interfere with the normal interaction between PDGFR and its partners. The results suggest that tightly packed caveolae lipids form a membrane platform that functions as a lipid scaffold for organizing the molecular interactions of multiple signaling pathways.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Anderson, RGW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Liu, Pingsheng/B-7124-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052016] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline; NIGMS NIH HHS [GM 52016] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; Claesson-Welsh Lena, 1994, Progress in Growth Factor Research, V5, P37, DOI 10.1016/0955-2235(94)90016-7; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; GAMBLE W, 1978, J LIPID RES, V19, P1068; Gil T, 1998, BBA-REV BIOMEMBRANES, V1376, P245, DOI 10.1016/S0304-4157(98)00022-7; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; LAU WF, 1995, EXPERIENTIA, V51, P731, DOI 10.1007/BF01941271; Liu PS, 1999, BIOCHEM BIOPH RES CO, V261, P695, DOI 10.1006/bbrc.1999.1082; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; LUU B, 1991, BIOCHIMIE, V73, P1317, DOI 10.1016/0300-9084(91)90095-I; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OWICKI JC, 1978, P NATL ACAD SCI USA, V75, P1616, DOI 10.1073/pnas.75.4.1616; OWICKI JC, 1979, P NATL ACAD SCI USA, V76, P4750, DOI 10.1073/pnas.76.10.4750; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; SMITH RM, 1990, ENDOCRINOLOGY, V126, P1551, DOI 10.1210/endo-126-3-1551; TOMASKA L, 1993, J BIOL CHEM, V268, P5317; Verhagen JCD, 1996, J LIPID RES, V37, P1488; WOOD WG, 1995, BRAIN RES, V683, P36; YATES AJ, 1995, J NEURO-ONCOL, V24, P65, DOI 10.1007/BF01052661	36	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31648	31654		10.1074/jbc.M004599200	http://dx.doi.org/10.1074/jbc.M004599200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10918056	hybrid			2022-12-25	WOS:000089858900016
J	Qu, ZQ; Yang, ZJ; Cui, NR; Zhu, GY; Liu, CX; Xu, HX; Chanchevalap, S; Shen, WZ; Wu, JP; Li, YJ; Jiang, C				Qu, ZQ; Yang, ZJ; Cui, NR; Zhu, GY; Liu, CX; Xu, HX; Chanchevalap, S; Shen, WZ; Wu, JP; Li, YJ; Jiang, C			Gating of inward rectifier K+ channels by proton-mediated interactions of N- and C-terminal domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-GATED CHANNELS; POTASSIUM CHANNEL; MOLECULAR-BASIS; OPEN-STATE; PH; ACTIVATION; IDENTIFICATION; INACTIVATION; RESIDUE; INHIBITION	Ion channels play an important role in cellular functions, and specific cellular activity can be produced by gating them. One important gating mechanism is produced by intra- or extracellular ligands, Although the ligand-mediated channel gating is an important cellular process, the relationship between ligand binding and channel gating is not well understood, It is possible that ligands are involved in the interactions of different protein domains of the channel leading to opening or closing. To test this hypothesis, we studied the gating of Kir2.3 (HIR) by intracellular protons. Our results showed that hypercapnia or intracellular acidification strongly inhibited these channels. This effect relied on both the N and C termini, The CO2/pH sensitivities were abolished or compromised when one of the intracellular termini was replaced. Using purified N- and C-terminal peptides, we found that the N and C termini bound to each other in vitro. Although their binding was weak at pH 7.4, stronger binding was seen at pH 6.6, Two short sequences in the N and C termini were found to be critical for the N/C-terminal interaction. Interestingly, there was no titratable residue in these motifs, To identify the potential protonation sites, we systematically mutated most histidine residues in the intracellular N and C termini, We found that mutations of several histidine residues in the C but not the N terminus had a major effect on channel sensitivities to CO2 and pH(i). These results suggest that at acidic pH, protons appear to interact with the C-terminal histidine residues and present the C terminus to the N terminus. Consequentially, these two intracellular termini bound to each other through two short motifs and closed the channel. Thus, a novel mechanism for K+ channel gating is demonstrated, which involves the N- and C-terminal interaction with protons as the mediator.	Georgia State Univ, Dept Biol, Atlanta, GA 30302 USA	University System of Georgia; Georgia State University	Jiang, C (corresponding author), Georgia State Univ, Dept Biol, 24 Peachtree Cent Ave, Atlanta, GA 30303 USA.			Wu, Jianping/0000-0002-2684-6122; Yang, Zhenjiang/0000-0002-9315-154X	NHLBI NIH HHS [R01 HL058410, R01 HL58410] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058410] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams CM, 1998, J BIOL CHEM, V273, P30204, DOI 10.1074/jbc.273.46.30204; Buckley JT, 1995, BIOCHEMISTRY-US, V34, P16450, DOI 10.1021/bi00050a028; Cao YW, 1998, J NEUROSCI, V18, P7739; Chanchevalap S, 2000, J BIOL CHEM, V275, P7811, DOI 10.1074/jbc.275.11.7811; Choe H, 1997, AM J PHYSIOL-RENAL, V273, pF516, DOI 10.1152/ajprenal.1997.273.4.F516; COULTER KL, 1995, NEURON, V15, P1157, DOI 10.1016/0896-6273(95)90103-5; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; EK JF, 1994, CIRC RES, V74, P1058, DOI 10.1161/01.RES.74.6.1058; EkVitorin JF, 1996, BIOPHYS J, V71, P1273, DOI 10.1016/S0006-3495(96)79328-1; England PM, 1999, CELL, V96, P89, DOI 10.1016/S0092-8674(00)80962-9; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; HILLE B, 1992, IONIC CHANNELS EXCIT, P472; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Hoth S, 1997, P NATL ACAD SCI USA, V94, P4806, DOI 10.1073/pnas.94.9.4806; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; Klockner U, 1996, J BIOL CHEM, V271, P22293; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; Meera P, 1997, P NATL ACAD SCI USA, V94, P14066, DOI 10.1073/pnas.94.25.14066; Morrill JA, 1999, J GEN PHYSIOL, V114, P71, DOI 10.1085/jgp.114.1.71; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Paoletti P, 1999, J GEN PHYSIOL, V113, P17, DOI 10.1085/jgp.113.1.17; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Qu Z., 1999, Society for Neuroscience Abstracts, V25, P935; Qu ZQ, 1999, J BIOL CHEM, V274, P13783, DOI 10.1074/jbc.274.20.13783; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Schreiber M, 1999, NAT NEUROSCI, V2, P416, DOI 10.1038/8077; Schulte U, 1999, P NATL ACAD SCI USA, V96, P15298, DOI 10.1073/pnas.96.26.15298; Schulte U, 1998, J BIOL CHEM, V273, P34575, DOI 10.1074/jbc.273.51.34575; Shuck ME, 1997, J BIOL CHEM, V272, P586; Steidl JV, 1999, MOL PHARMACOL, V55, P812; Stergiopoulos K, 1999, CIRC RES, V84, P1144, DOI 10.1161/01.RES.84.10.1144; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TSAI TD, 1995, AM J PHYSIOL-CELL PH, V268, pC1173, DOI 10.1152/ajpcell.1995.268.5.C1173; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1999, J BIOL CHEM, V274, P33393, DOI 10.1074/jbc.274.47.33393; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Varnum MD, 1997, SCIENCE, V278, P110, DOI 10.1126/science.278.5335.110; WANG TL, 1995, J NEUROSCI, V15, P7684; XU H, 2000, IN PRESS AM J PHYSL; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8; Yang ZJ, 1999, J PHYSIOL-LONDON, V520, P921, DOI 10.1111/j.1469-7793.1999.00921.x; Zhu GY, 1999, J PHYSIOL-LONDON, V516, P699, DOI 10.1111/j.1469-7793.1999.0699u.x; Zhu GY, 2000, J CELL PHYSIOL, V183, P53, DOI 10.1002/(SICI)1097-4652(200004)183:1<53::AID-JCP7>3.3.CO;2-I	44	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31573	31580		10.1074/jbc.M003473200	http://dx.doi.org/10.1074/jbc.M003473200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10896660	hybrid			2022-12-25	WOS:000089858900005
J	Solban, N; Jia, HP; Richard, S; Tremblay, S; Devlin, AM; Peng, JZ; Gossard, F; Guo, DF; Morel, G; Hamet, P; Lewanczuk, R; Tremblay, J				Solban, N; Jia, HP; Richard, S; Tremblay, S; Devlin, AM; Peng, JZ; Gossard, F; Guo, DF; Morel, G; Hamet, P; Lewanczuk, R; Tremblay, J			HCaRG, a novel calcium-regulated gene coding for a nuclear protein, is potentially involved in the regulation of cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR CALCIUM; CA2+-SENSING RECEPTOR; FUNCTIONAL EXPRESSION; TRANSCRIPTION FACTOR; HYPERTENSIVE RATS; MOLECULAR-CLONING; PARATHYROID CELLS; SENSING RECEPTOR; BLOOD-PRESSURE; RENIN-ACTIVITY	Since a negative calcium balance is present in spontaneously hypertensive rats, we searched for the gene(s) involved in this dysregulation. A cDNA library was constructed from the spontaneously hypertensive rat parathyroid gland, which is a key regulator of serum-ionized calcium. From seven overlapping DNA fragments, a 1100-base pair novel cDNA containing an open reading frame of 224 codons was reconstituted. This novel gene, named HCaRG (hypertension-related, calcium-regulated gene), was negatively regulated by extracellular calcium con centration, and its basal mRNA levels were higher in hypertensive animals. The deduced protein showed no transmembrane domain, 67% alpha-helix content, a mutated calcium-binding site (EF-hand motif), four putative "leucine zipper" moths, and a nuclear receptor-binding domain. At the subcellular level, HCaRG had a nuclear localization. We cloned the human homolog of this gene. Sequence comparison revealed 80% homology between rats and humans at the nucleotide and amino acid sequences. Tissue distribution showed a preponderance in the heart, stomach, jejunum, kidney (tubular fraction), liver, and adrenal gland (mainly in the medulla). HCaRG mRNA was significantly more expressed in adult than in fetal organs, and its levels were decreased in tumors and cancerous cell lines. We observed that after 60-min ischemia followed by reperfusion, HCaRG mRNA declined rapidly in contrast with an increase in c-myc mRNA. Its levels then rose steadily to exceed base Line at 48 h of reperfusion. HEK293 cells stably transfected with HCaRG exhibited much lower proliferation, as shown by cell count and [H-3]thymidine incorporation. Taken together, our results suggest that HCaRG is a nuclear protein potentially involved in the control of cell proliferation.	CHU Montreal, Hotel Dieu, Lab Cellular Biol Hypertens, Ctr Rech, Montreal, PQ H2W 1T8, Canada; Univ Alberta, Dept Endocrinol, Edmonton, AB T6G 2S2, Canada; Univ Lyon 1, F-69365 Lyon, France	Laval University; Universite de Montreal; University of Alberta; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Tremblay, J (corresponding author), CHU Montreal, Hotel Dieu, Lab Cellular Biol Hypertens, Ctr Rech, 3850 St Urbain St, Montreal, PQ H2W 1T8, Canada.		jia, jhp@mm8899/AAH-6611-2020; Cossette, Suzanne/I-8008-2016					Arthur JM, 1997, AM J PHYSIOL-RENAL, V273, pF129, DOI 10.1152/ajprenal.1997.273.1.F129; BACALLAO R, 1989, AM J PHYSIOL, V257, pF913, DOI 10.1152/ajprenal.1989.257.6.F913; BENISHIN CG, 1991, P NATL ACAD SCI USA, V88, P6372, DOI 10.1073/pnas.88.14.6372; Benishin CG, 1999, AM J HYPERTENS, V12, P1260, DOI 10.1016/S0895-7061(99)00173-9; BONVENTRE JV, 1995, EXP NEPHROL, V3, P159; Brown Edward M., 1996, American Journal of the Medical Sciences, V312, P99; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIRILLO M, 1989, AM J HYPERTENS, V2, P741, DOI 10.1093/ajh/2.10.741; Cohn David V., 1994, P107; DRUEKE T, 1994, AM J MED SCI S, V307, P96; ERNE P, 1989, HYPERTENSION, V14, P145, DOI 10.1161/01.HYP.14.2.145; FEINLEIB M, 1984, SCIENCE, V226, P384, DOI 10.1126/science.6494890; Franz C, 1998, J BIOL CHEM, V273, P18826, DOI 10.1074/jbc.273.30.18826; FRIED TA, 1984, AM J PHYSIOL, V247, pF568, DOI 10.1152/ajprenal.1984.247.4.F568; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Gomez E, 1997, BIOL REPROD, V56, P1513, DOI 10.1095/biolreprod56.6.1513; HATTON DC, 1994, HYPERTENSION, V23, P513, DOI 10.1161/01.HYP.23.4.513; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Huang ZQ, 1999, J BIOL CHEM, V274, P7640, DOI 10.1074/jbc.274.12.7640; Kato A, 1997, NEPHRON, V75, P72, DOI 10.1159/000189502; KATO A, 1995, KIDNEY INT, V48, P1577, DOI 10.1038/ki.1995.450; KAY LE, 1991, BIOCHEMISTRY-US, V30, P4323, DOI 10.1021/bi00231a031; KIFOR O, 1992, J BONE MINER RES, V7, P1327; Kifor O, 1997, J BONE MINER RES, V12, P715, DOI 10.1359/jbmr.1997.12.5.715; Knuutila S, 1998, AM J PATHOL, V152, P1107; Kohn WD, 1997, J BIOL CHEM, V272, P2583, DOI 10.1074/jbc.272.5.2583; KUNES J, 1986, CLIN SCI, V70, P185, DOI 10.1042/cs0700185; LINSE S, 1993, PROTEIN SCI, V2, P985, DOI 10.1002/pro.5560020612; Lobie PE, 1999, EXP CELL RES, V246, P47, DOI 10.1006/excr.1998.4288; MCHAFFIE GS, 1995, BONE, V17, P11, DOI 10.1016/8756-3282(95)00131-V; Mckusick V.A., 1994, MENDELIAN INHERITANC; MOLITORIS BA, 1988, J MEMBRANE BIOL, V106, P233, DOI 10.1007/BF01872161; Mueller A, 1999, HISTOCHEM CELL BIOL, V111, P453, DOI 10.1007/s004180050381; Nakajima T, 1996, AM J PHYSIOL-RENAL, V271, pF846, DOI 10.1152/ajprenal.1996.271.4.F846; NYGREN P, 1988, BIOCHIM BIOPHYS ACTA, V968, P253, DOI 10.1016/0167-4889(88)90014-6; OKAZAKI T, 1992, J CLIN INVEST, V89, P1268, DOI 10.1172/JCI115711; Onyango I, 1999, EXP CELL RES, V247, P9, DOI 10.1006/excr.1998.4324; ORLOV SN, 1995, SEMIN NEPHROL, V15, P569; REID RE, 1981, J BIOL CHEM, V256, P2742; Resnick Lawrence M., 1995, P1169; RESNICK LM, 1987, AM J MED, V82, P16, DOI 10.1016/0002-9343(87)90267-1; RESNICK LM, 1983, NEW ENGL J MED, V309, P888, DOI 10.1056/NEJM198310133091504; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; SHAW GS, 1992, BIOCHEMISTRY-US, V31, P9572, DOI 10.1021/bi00155a009; SHAW GS, 1994, PROTEIN SCI, V3, P1010, DOI 10.1002/pro.5560030703; SOWERS JR, 1989, J LAB CLIN MED, V114, P338; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; WALLIN A, 1992, LAB INVEST, V66, P474; Wicki R, 1997, CELL CALCIUM, V22, P243, DOI 10.1016/S0143-4160(97)90063-4; WITZGALL R, 1993, MOL CELL BIOL, V13, P1933, DOI 10.1128/MCB.13.3.1933; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514	55	37	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32234	32243		10.1074/jbc.M001352200	http://dx.doi.org/10.1074/jbc.M001352200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10918053	hybrid			2022-12-25	WOS:000089858900094
J	Thomson, AM; Rogers, JT; Leedman, PJ				Thomson, AM; Rogers, JT; Leedman, PJ			Thyrotropin-releasing hormone and epidermal growth factor regulate iron-regulatory protein binding in pituitary cells via protein kinase C-dependent and -independent signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRITIN MESSENGER-RNA; TRANSFERRIN RECEPTOR EXPRESSION; TUMOR-NECROSIS-FACTOR; RESPONSIVE ELEMENT; OXIDATIVE STRESS; GH3 CELLS; DIFFERENTIAL REGULATION; THYROID-HORMONE; NITRIC-OXIDE; HEAVY-CHAIN	Intracellular iron homeostasis is regulated, in part, by interactions between iron-regulatory proteins (IRP1 and IRP2) and iron-responsive elements (IREs) in ferritin and transferrin receptor mRNAs. In addition to iron, cellular oxidative stress induced by H2O2, nitric oxide, and hypoxia, and hormonal activation by thyroid hormone and erythropoeitin have each been shown to regulate IRP binding to IREs. Hormonal signals, in particular mediated through protein kinase C (PKC), play a central role in the modulation of IRP/IRE interactions since phorbol esters were shown to activate IRP binding (Eisenstein, R. S., Tuazon, P. T., Schalinske, K. L., Anderson, S. A., and Traugh, J. A. (1993) J. Biol. Chem. 268, 27363-27370). In pituitary thyrotrophs (TtT97), we found that thyrotropin releasing hormone (TRH) and epidermal growth factor (EGF) increased IRP binding to a ferritin IRE, dependent on PKC and mitogen-activated protein kinase (MAPK) activity. In contrast, TRH and EGF decreased IRP binding in pituitary lactotrophs (GH3), despite activation of PKC and MAPK. IRP1 and IRP2 levels remained constant and IRP2 binding was predominant throughout. TRH and EGF markedly decreased IRP binding in MAPK kinase inhibitor-treated GH3 cells, whereas, they increased IRP binding in phosphatase inhibitor-treated GH3 cells. IRE-dependent CAT reporter translational expression closely reflected IRP binding to the ferritin IRE in both GH3 and TtT97 cells. Interestingly, ferritin protein levels were regulated similarly by TRH in both cell lines. These data link two different cell receptor systems to common signaling pathways that regulate IRP binding and ferritin expression. Remarkably, for TRH and EGF, these effects may be PKC-dependent or -independent determined by the cell type.	Univ Western Australia, Royal Perth Hosp, Western Australian Inst Med Res, Dept Med, Perth, WA 6000, Australia; Univ Western Australia, Royal Perth Hosp, Western Australian Inst Med Res, Lab Canc Med, Perth, WA 6000, Australia; Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Genet & Aging Unit, Charlestown, MA 02129 USA	Royal Perth Hospital; University of Western Australia; Royal Perth Hospital; University of Western Australia; Harvard University	Leedman, PJ (corresponding author), Univ Perth, Royal Perth Hosp, Dept Med, Box X2213 GPO, Perth, WA 6001, Australia.	peterl@cyllene.uwa.edu.au	Leedman, Peter J/O-4044-2014	Rogers, Jack/0000-0003-1262-8578				BRUNET N, 1981, J CELL PHYSIOL, V109, P363, DOI 10.1002/jcp.1041090220; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CHAIDARUN SS, 1994, ENDOCRINOLOGY, V135, P2012, DOI 10.1210/en.135.5.2012; CHAZENBALK GD, 1990, MOL ENDOCRINOL, V4, P1117, DOI 10.1210/mend-4-8-1117; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P666; CHOU CC, 1986, MOL CELL BIOL, V6, P566, DOI 10.1128/MCB.6.2.566; COLUCCIDAMATO LG, 1989, BIOCHEM BIOPH RES CO, V165, P506, DOI 10.1016/0006-291X(89)91098-X; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DAVIS RC, 1987, DEV BIOL, V119, P164, DOI 10.1016/0012-1606(87)90218-1; Dawson John F., 1999, Frontiers in Bioscience, V4, pd646, DOI 10.2741/Dawson; DESILVA DM, 1993, CAN J PHYSIOL PHARM, V71, P715, DOI 10.1139/y93-107; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; EISENSTEIN RS, 1993, J BIOL CHEM, V268, P27363; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; Faccenda E, 1996, CLIN ENDOCRINOL, V44, P341, DOI 10.1046/j.1365-2265.1996.684506.x; Fleming RE, 2000, P NATL ACAD SCI USA, V97, P2214, DOI 10.1073/pnas.040548097; GAMA R, 1995, POSTGRAD MED J, V71, P297, DOI 10.1136/pgmj.71.835.297; GATTI RA, 1987, AM J HUM GENET, V41, P654; GOOSSEN B, 1990, EMBO J, V9, P4127, DOI 10.1002/j.1460-2075.1990.tb07635.x; Gray NK, 1996, P NATL ACAD SCI USA, V93, P4925, DOI 10.1073/pnas.93.10.4925; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; GUO B, 1994, J BIOL CHEM, V269, P24252; Hanson ES, 1998, J BIOL CHEM, V273, P7588, DOI 10.1074/jbc.273.13.7588; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HINKLE PM, 1991, ENDOCRINOLOGY, V129, P1283, DOI 10.1210/endo-129-3-1283; Iwasaki H, 1999, ENDOCRINOLOGY, V140, P4659, DOI 10.1210/en.140.10.4659; JinsiParimoo A, 1997, ENDOCRINOLOGY, V138, P1471, DOI 10.1210/en.138.4.1471; Kanasaki H, 1999, BIOL REPROD, V61, P319, DOI 10.1095/biolreprod61.1.319; Ke YH, 1998, J BIOL CHEM, V273, P23637, DOI 10.1074/jbc.273.37.23637; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KIM HY, 1995, J BIOL CHEM, V270, P4983, DOI 10.1074/jbc.270.10.4983; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KLAUSNER RD, 1996, P NATL ACAD SCI USA, V93, P8175; Konijn AM, 1999, BLOOD, V94, P2128, DOI 10.1182/blood.V94.6.2128.418k20_2128_2134; Leedman PJ, 1996, J BIOL CHEM, V271, P12017, DOI 10.1074/jbc.271.20.12017; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946; MONDEN T, 1995, J MOL ENDOCRINOL, V15, P73, DOI 10.1677/jme.0.0150073; NARAYANAN CS, 1992, J BIOL CHEM, V267, P17296; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; Palomero T, 1998, MOL PHARMACOL, V53, P613, DOI 10.1124/mol.53.4.613; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; Pantopoulos K, 1997, J BIOL CHEM, V272, P9802; Phillips JD, 1996, BLOOD, V87, P2983, DOI 10.1182/blood.V87.7.2983.bloodjournal8772983; ROGERS JT, 1990, J BIOL CHEM, V265, P14572; ROGERS JT, 1994, NUCLEIC ACIDS RES, V22, P2678, DOI 10.1093/nar/22.13.2678; Rogers JT, 1996, BLOOD, V87, P2525, DOI 10.1182/blood.V87.6.2525.bloodjournal8762525; ROGERS JT, 1992, IRON HUMAN DIS, P78; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; Schalinske KL, 1997, P NATL ACAD SCI USA, V94, P10681, DOI 10.1073/pnas.94.20.10681; Schalinske KL, 1997, BIOCHEMISTRY-US, V36, P3950, DOI 10.1021/bi9624447; Schalinske KL, 1996, J BIOL CHEM, V271, P7168, DOI 10.1074/jbc.271.12.7168; SCHONBRUNN A, 1980, J CELL BIOL, V85, P786, DOI 10.1083/jcb.85.3.786; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; Staton JM, 1998, ENDOCRINOLOGY, V139, P1093, DOI 10.1210/en.139.3.1093; Thomson AM, 1999, INT J BIOCHEM CELL B, V31, P1139, DOI 10.1016/S1357-2725(99)00080-1; Thomson AM, 1999, BIOTECHNIQUES, V27, P1032, DOI 10.2144/99275rr03; Thorner MO, 1998, WILLIAMS TXB ENDOCRI, P249; Toth I, 1999, J BIOL CHEM, V274, P4467, DOI 10.1074/jbc.274.7.4467; TSUJI Y, 1991, J BIOL CHEM, V266, P7257; URSINI MV, 1988, BIOCHEM BIOPH RES CO, V150, P287, DOI 10.1016/0006-291X(88)90518-9; Wang W, 1999, ENDOCRINOLOGY, V140, P4916, DOI 10.1210/en.140.10.4916; Weiss G, 1997, BLOOD, V89, P680, DOI 10.1182/blood.V89.2.680; YAJIMA Y, 1982, IN VITRO CELL DEV B, V18, P1009, DOI 10.1007/BF02796376; YAJIMA Y, 1984, J CELL PHYSIOL, V120, P249, DOI 10.1002/jcp.1041200220	70	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31609	31615		10.1074/jbc.M002354200	http://dx.doi.org/10.1074/jbc.M002354200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10889193	hybrid			2022-12-25	WOS:000089858900010
J	Amemiya-Kudo, M; Shimano, H; Yoshikawa, T; Yahagi, N; Hasty, AH; Okazaki, H; Tamura, Y; Shionoiri, F; Iizuka, Y; Ohashi, K; Osuga, J; Harada, K; Gotoda, T; Sato, R; Kimura, S; Ishibashi, S; Yamada, N				Amemiya-Kudo, M; Shimano, H; Yoshikawa, T; Yahagi, N; Hasty, AH; Okazaki, H; Tamura, Y; Shionoiri, F; Iizuka, Y; Ohashi, K; Osuga, J; Harada, K; Gotoda, T; Sato, R; Kimura, S; Ishibashi, S; Yamada, N			Promoter analysis of the mouse sterol regulatory element-binding protein-1c gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; SREBP-1C MESSENGER-RNA; TRANSGENIC MICE; CHOLESTEROL-SYNTHESIS; TRANSCRIPTION FACTOR; SYNTHASE PROMOTER; ADIPOSE-TISSUE; CULTURED-CELLS; NF-Y; EXPRESSION	Recent data suggest that sterol regulatory-binding protein (SREBP)-1c plays a key role in the transcriptional regulation of different lipogenic genes mediating lipid synthesis as a key regulator of fuel metabolism. SREBP-1c regulates its downstream genes by changing its own mRNA level, which led us to sequence and analyze the promoter region of the mouse SREBP-1c gene. A cluster of putative binding sites of several transcription factors composed of an NF-Y site, an E-box, a sterol-regulatory element 3, and an Spl site were located at -90 base pairs of the SREBP-1c promoter. Luciferase reporter gene assays indicated that this SRE complex is essential to the basal promoter activity and confers responsiveness to activation by nuclear SREBPs, Deletion and mutation analyses suggest that the NF-Y site and SRE3 in the SRE complex are responsible for SREBP activation, although the other sites were also involved in the basal activity. Gel mobility shift assays demonstrate that SREBP-1 binds to the SRE3, Taken together, these findings implicate a positive loop production of SREBP-1c through the SRE complex, possibly leading to the overshoot in induction of SREBP-1c and its downstream genes seen in the livers of refed mice. Furthermore, reporter assays using larger upstream fragments indicated another region that was inducible by addition of sterols. The presence of the SRE complex and a sterol-inducible region in the same promoter suggests a novel regulatory Link between cholesterol and fatty acid synthesis.	Univ Tsukuba, Inst Clin Med, Dept Internal Med, Tsukuba, Ibaraki 3058575, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Metab Dis, Fac Med, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138655, Japan	University of Tsukuba; University of Tokyo; University of Tokyo	Shimano, H (corresponding author), Univ Tsukuba, Inst Clin Med, Dept Internal Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	shimano-tky@umin.ac.jp	Shimano, Hitoshi/AAI-5648-2020; Hasty, Alyssa/AAA-2757-2020; Yahagi, Naoya/D-2360-2014; Shimano, Hitoshi/V-1761-2019	Hasty, Alyssa/0000-0001-7302-8045; Yahagi, Naoya/0000-0002-1823-1865; Shimano, Hitoshi/0000-0002-5562-5572				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; Hasty AH, 2000, J BIOL CHEM, V275, P31069, DOI 10.1074/jbc.M003335200; HEINEMEYER T, 1999, NUCLEIC ACIDS RES, V26, P364; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; Kim HJ, 1999, J BIOL CHEM, V274, P25892, DOI 10.1074/jbc.274.36.25892; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Koo SH, 2000, J BIOL CHEM, V275, P5200, DOI 10.1074/jbc.275.7.5200; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Soukas A, 2000, GENE DEV, V14, P963; Thewke DP, 1998, J BIOL CHEM, V273, P21402, DOI 10.1074/jbc.273.33.21402; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; WANG XD, 1993, J BIOL CHEM, V268, P14497; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Xiong SB, 2000, P NATL ACAD SCI USA, V97, P3948, DOI 10.1073/pnas.040574197; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840	38	203	205	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31078	31085		10.1074/jbc.M005353200	http://dx.doi.org/10.1074/jbc.M005353200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10918064	hybrid			2022-12-25	WOS:000089762700048
J	Boulanger, A; Liu, SY; Henningsgaard, AA; Yu, S; Redmond, TM				Boulanger, A; Liu, SY; Henningsgaard, AA; Yu, S; Redmond, TM			The upstream region of the Rpe65 gene confers retinal pigment epithelium-specific expression in vivo and in vitro and contains critical octamer and E-box binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR OTF-1; HELIX-LOOP-HELIX; MESSENGER-RNA; VISUAL CYCLE; CONGENITAL AMAUROSIS; MICROSOMAL PROTEIN; SEQUENCE ELEMENTS; TRANSGENIC MICE; FACTOR OCT-1; CELL LINE	RPE65 is essential for all-trans- to Il-cis-retinoid isomerization, the hallmark reaction of the retinal pigment epithelium (RPE). Here, we identify regulatory elements in the Rpe65 gene and demonstrate their functional relevance to Rpe65 gene expression. We show that the 5' flanking region of the mouse Rpe65 gene, like the human gene, lacks a canonical TATA box and consensus GC and CAAT boxes. The mouse and human genes do share several cis acting elements, including an octamer, a nuclear factor one (NFI) site, and two E-box sites, suggesting a conserved mode of regulation. A mouse Rpe65 promoter/beta-galactosidase transgene containing bases -655 to +52 (TR4) of the mouse 5' flanking region was sufficient to direct high RPE-specific expression in transgenic mice, whereas shorter fragments (-297 to +52 or -188 to +52) generated only background activity. Furthermore, transient transfection of analogous TR4/luciferase constructs also directed high reporter activity in the human RPE cell line D407 but weak activity in the non-RPE cell Lines HeLa, HepG2, and HS27. Functional binding of potential transcription factors to the octamer sequence, AP-4, and NFI sites was demonstrated by directed mutagenesis, electrophoretic mobility shift assay, and cross linking. Mutations of these sites abolished binding and corresponding transcriptional activity and indicated that octamer and E-box transcription factors synergistically regulate the RPE65 promoter function. Thus, we have identified the regulatory region in the Rpe65 gene that accounts for tissue-specific expression in the RPE and found that octamer and E-box transcription factors play a critical role in the transcriptional regulation of the Rpe65 gene.	NEI, LRCMB, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Boulanger, A (corresponding author), NEI, LRCMB, Bldg 6,Rm 339,6 Ctr Dr,MSC 2740, Bethesda, MD 20892 USA.			Redmond, T. Michael/0000-0002-1813-5291	NATIONAL EYE INSTITUTE [Z01EY000260, ZIAEY000260] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aguirre G D, 1998, Mol Vis, V4, P23; BERNSTEIN PS, 1986, BIOCHEMISTRY-US, V25, P6473, DOI 10.1021/bi00369a020; BOBOLA N, 1995, J BIOL CHEM, V270, P1289, DOI 10.1074/jbc.270.3.1289; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; CLARK ME, 1995, MOL CELL BIOL, V15, P6169; DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; DENT CL, 1991, NUCLEIC ACIDS RES, V19, P4531, DOI 10.1093/nar/19.16.4531; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020; Fadel BM, 1999, J BIOL CHEM, V274, P20376, DOI 10.1074/jbc.274.29.20376; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GORING DR, 1987, SCIENCE, V235, P456, DOI 10.1126/science.3099390; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; HAMEL CP, 1993, J BIOL CHEM, V268, P15751; HAMEL CP, 1994, GENOMICS, V20, P509, DOI 10.1006/geno.1994.1212; HAMEL CP, 1993, J NEUROSCI RES, V34, P414, DOI 10.1002/jnr.490340406; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KEMLER I, 1990, FASEB J, V4, P1444, DOI 10.1096/fasebj.4.5.2407588; Kennedy BN, 1998, J BIOL CHEM, V273, P5591, DOI 10.1074/jbc.273.10.5591; Lakich MM, 1998, J BIOL CHEM, V273, P15217, DOI 10.1074/jbc.273.24.15217; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Li SM, 1998, J BIOL CHEM, V273, P31191, DOI 10.1074/jbc.273.47.31191; Liu SY, 1998, ARCH BIOCHEM BIOPHYS, V357, P37, DOI 10.1006/abbi.1998.0817; Ma JX, 1998, BBA-GENE STRUCT EXPR, V1443, P255, DOI 10.1016/S0167-4781(98)00221-8; Manes G, 1998, FEBS LETT, V423, P133, DOI 10.1016/S0014-5793(98)00081-7; Marlhens F, 1998, EUR J HUM GENET, V6, P527, DOI 10.1038/sj.ejhg.5200205; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088; NICOLETTI A, 1995, HUM MOL GENET, V4, P641, DOI 10.1093/hmg/4.4.641; Nicoletti A, 1998, INVEST OPHTH VIS SCI, V39, P637; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337; SAARI JC, 1988, J BIOL CHEM, V263, P8084; SAARI JC, 1994, BIOCHEMISTRY-US, V33, P3106, DOI 10.1021/bi00176a045; SAARI JC, 1988, EXP EYE RES, V46, P569, DOI 10.1016/S0014-4835(88)80013-7; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; TVERBERG LA, 1993, J BIOL CHEM, V268, P15965; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; Winston A, 1998, BIOCHEMISTRY-US, V37, P2044, DOI 10.1021/bi971908d; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8; ZHOU DX, 1991, MOL CELL BIOL, V11, P1353, DOI 10.1128/MCB.11.3.1353	51	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31274	31282		10.1074/jbc.M003441200	http://dx.doi.org/10.1074/jbc.M003441200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896939	hybrid			2022-12-25	WOS:000089762700075
J	Wallis, R; Dodd, RB				Wallis, R; Dodd, RB			Interaction of mannose-binding protein with associated serine proteases - Effects of naturally occurring mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RA-REACTIVE FACTOR; LECTIN ACTIVATION PATHWAY; HUMAN-COMPLEMENT; MANNAN-BINDING; BACTERICIDAL FACTOR; IMMUNE-SYSTEM; VERTEBRATES; COMPONENTS; SEQUENCE; DOMAIN	Mannose binding protein (MBP; mannose-binding lectin) forms part of the innate immune system. By binding directly to carbohydrates on the surfaces of potential microbial pathogens, MBP and MBP-associated serine proteases (MASPs) can replace antibodies and complement components C1q, C1r, and C1s of the classical complement pathway. In order to investigate the mechanisms of MASP activation by MBP, the cDNAs of rat MASP-1 and -2 have been isolated, and portions encompassing the N-terminal CUB and epidermal growth factor-like domains have been expressed and purified. Biophysical characterization of the purified proteins indicates that each truncated MASP is a Ca2+-independent homodimer in solution, in which the interacting modules include the N-terminal two domains. Binding studies reveal that both MASPs associate independently with rat MBP in a Ca2+-dependent manner through interactions involving the N-terminal three domains. The biophysical properties of the truncated MASPs indicate that the interactions with MBP leading to complement activation differ significantly from those between components C1q, C1r, and C1s of the classical pathway. Analysis of MASP binding by rat MBP containing naturally occurring mutations equivalent to those associated with human immunodeficiency indicates that binding to both truncated MASP-1 and MASP-2 proteins is defective in such mutants.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	University of Oxford	Wallis, R (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.		Dodd, Roger/B-4917-2008	Wallis, Russell/0000-0002-8705-5295; Dodd, Roger/0000-0003-4268-1863				BUSBY TF, 1990, BIOCHEMISTRY-US, V29, P4613, DOI 10.1021/bi00471a016; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; Eftink MR, 1997, METHOD ENZYMOL, V278, P258; Endo Y, 1998, J IMMUNOL, V161, P4924; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; IOBST ST, 1994, J BIOL CHEM, V269, P15505; Ji X, 1997, P NATL ACAD SCI USA, V94, P6340, DOI 10.1073/pnas.94.12.6340; JI YH, 1993, J IMMUNOL, V150, P571; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P537, DOI 10.1016/0076-6879(90)85044-O; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; Lacroix M, 1997, BIOCHEMISTRY-US, V36, P6270, DOI 10.1021/bi962719i; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING LAB MANU; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; Matsushita M, 1998, CURR OPIN IMMUNOL, V10, P29, DOI 10.1016/S0952-7915(98)80027-7; REID KBM, 1983, BIOCHEM SOC T, V11, P1; Stover CM, 1999, J IMMUNOL, V163, P6848; Stover CM, 1999, J IMMUNOL, V162, P3481; TAKADA F, 1993, BIOCHEM BIOPH RES CO, V196, P1003, DOI 10.1006/bbrc.1993.2349; Takahashi M, 1999, INT IMMUNOL, V11, P859, DOI 10.1093/intimm/11.5.859; TAKAYAMA Y, 1994, J IMMUNOL, V152, P2308; Terai I, 1997, CLIN EXP IMMUNOL, V110, P317; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; THIELENS NM, 1990, J BIOL CHEM, V265, P14469; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; VALERA PF, 1997, J MOL BIOL, V274, P635; Wallis R, 1999, J BIOL CHEM, V274, P3580, DOI 10.1074/jbc.274.6.3580; Wallis R, 1999, J IMMUNOL, V163, P4953; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x	31	74	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30962	30969		10.1074/jbc.M004030200	http://dx.doi.org/10.1074/jbc.M004030200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10913141	hybrid			2022-12-25	WOS:000089762700034
J	Nakajima, A; Sugimoto, Y; Yoneyama, H; Nakae, T				Nakajima, A; Sugimoto, Y; Yoneyama, H; Nakae, T			Localization of the outer membrane subunit OprM of resistance-nodulation-cell division family multicomponent efflux pump in Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; MULTIDRUG EFFLUX; EXTRUSION; OVEREXPRESSION; RESOLUTION; PROTEINS; CHANNELS; SYSTEMS; OPERON	The outer membrane subunit OprM of the multicomponent efflux pump of Pseudomonas aeruginosa has been assumed to form a transmembrane xenobiotic exit channel across the outer membrane. We challenged this hypothesis to clarify the underlying ambiguity by manipulating the amino-terminal signal sequence of the OprM protein of the MexAB-OprM efflux pump in P. aeruginosa, [H-3]Palmitate uptake experiments revealed that OprM is a lipoprotein. The following lines of evidence unequivocally established that the OprM protein functioned at the periplasmic space. (i) The OprM protein, in which a signal sequence including Cys-18 was replaced with that of periplasmic azurin, appeared in the periplasmic space but not in the outer membrane fraction, and the protein fully functioned as the pump subunit. (ii) The hybrid OprM containing the N-terminal transmembrane segment of the inner membrane protein, MexF, appeared exclusively in the inner membrane fraction. The hybrid protein containing 186 or 331 amino acid residues of MexF was fully active for the antibiotic extrusion, but a 42-residue protein was totally inactive. (iii) The mutant OprM, in which the N-terminal cysteine residue was replaced with another amino acid, appeared unmodified with fatty acid and was fractionated in both the periplasmic space and the inner membrane fraction but not in the outer membrane fraction. The Cys-18-modified OprM functioned for the antibiotic extrusion indistinguishably from that in the wild-type strain. We concluded, based on these results, that the OprM protein was anchored in the outer membrane via fatty acid(s) attached to the N-terminal cysteine residue and that the entire polypeptide moiety was exposed to the periplasmic space.	Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Kanagawa 2591193, Japan	Tokai University	Nakae, T (corresponding author), Tokai Univ, Sch Med, Dept Mol Life Sci, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.	nakae@is.icc.u-tokai.ac.jp						COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Forst D, 1998, NAT STRUCT BIOL, V5, P37, DOI 10.1038/nsb0198-37; Guan L, 1999, J BIOL CHEM, V274, P10517, DOI 10.1074/jbc.274.15.10517; Horton R M, 1993, Methods Mol Biol, V15, P251, DOI 10.1385/0-89603-244-2:251; Kohler T, 1996, ANTIMICROB AGENTS CH, V40, P2288, DOI 10.1128/AAC.40.10.2288; Kohler T, 1997, ANTIMICROB AGENTS CH, V41, P2540, DOI 10.1128/AAC.41.11.2540; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEI Y, 1991, FEMS MICROBIOL LETT, V80, P337; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma Dzwokai, 1994, Trends in Microbiology, V2, P489, DOI 10.1016/0966-842X(94)90654-8; Mine T, 1999, ANTIMICROB AGENTS CH, V43, P415, DOI 10.1128/AAC.43.2.415; MIZUNO T, 1978, J BIOCHEM, V84, P179, DOI 10.1093/oxfordjournals.jbchem.a132106; MORSHED SRM, 1995, BIOCHEM BIOPH RES CO, V210, P356, DOI 10.1006/bbrc.1995.1669; NAKAE T, 1979, J BIOL CHEM, V254, P1457; Nakae Taiji, 1997, J Infect Chemother, V3, P173, DOI 10.1007/BF02490031; NAKAMURA K, 1976, J BIOCHEM, V80, P1411, DOI 10.1093/oxfordjournals.jbchem.a131414; Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Pautsch A, 1998, NAT STRUCT BIOL, V5, P1013, DOI 10.1038/2983; POOLE K, 1993, J BACTERIOL, V175, P7363, DOI 10.1128/JB.175.22.7363-7372.1993; Poole K, 1996, MOL MICROBIOL, V21, P713, DOI 10.1046/j.1365-2958.1996.281397.x; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RELLA M, 1982, ANTIMICROB AGENTS CH, V22, P242, DOI 10.1128/AAC.22.2.242; ROSENBUSCH JP, 1974, J BIOL CHEM, V249, P8019; Saito K, 1999, FEMS MICROBIOL LETT, V179, P67, DOI 10.1016/S0378-1097(99)00394-8; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Srikumar R, 2000, J BACTERIOL, V182, P1410, DOI 10.1128/JB.182.5.1410-1414.2000; Tseng Tsai-Tien, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P107; WEISS MS, 1992, J MOL BIOL, V227, P493, DOI 10.1016/0022-2836(92)90903-W; Wong KKY, 2000, J BACTERIOL, V182, P2402, DOI 10.1128/JB.182.9.2402-2410.2000; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; Yoneyama H, 1997, BIOCHEM BIOPH RES CO, V233, P611, DOI 10.1006/bbrc.1997.6506; Yoneyama H, 2000, J BIOL CHEM, V275, P4628, DOI 10.1074/jbc.275.7.4628; Yoneyama H, 1998, BIOCHEM BIOPH RES CO, V244, P898, DOI 10.1006/bbrc.1998.8351; Zgurskaya HI, 1999, P NATL ACAD SCI USA, V96, P7190, DOI 10.1073/pnas.96.13.7190	40	37	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30064	30068		10.1074/jbc.M005742200	http://dx.doi.org/10.1074/jbc.M005742200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10889211	hybrid			2022-12-25	WOS:000089577900021
J	Cabezon, E; Arechaga, I; Butler, PJG; Walker, JE				Cabezon, E; Arechaga, I; Butler, PJG; Walker, JE			Dimerization of bovine F-1-ATPase by binding the inhibitor protein, IF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUNDARY ANALYSIS; ATP SYNTHASE; SUBUNIT	In mitochondria, the hydrolytic activity of ATP synthase is regulated by a natural inhibitor protein, IF1. The binding of IF1 to ATP synthase depends on pH values, and below neutrality, IF1 forms a stable complex with the enzyme. Bovine IF1 has two oligomeric states, dimer and tetramer, depending on pH values. At pH 6.5, where it is active, IF1 dimerizes by formation of an antiparallel alpha-helical coiled-coil in its C-terminal region. This arrangement places the inhibitory N-terminal regions in opposition, implying that active dimeric IF1 can bind two F-1 domains simultaneously. Evidence of dimerization of F-1-ATPase by binding to IF1 is provided by gel filtration chromatography, analytical ultracentrifugation, and electron microscopy. At present, it is not known whether IF1 can bring about the dimerization of the F1F0-ATPase complex.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; MRC Laboratory Molecular Biology	Walker, JE (corresponding author), MRC, Dunn Human Nutr Unit, Hills Rd, Cambridge CB2 2XY, England.		Cabezon, Elena/K-5874-2014; Arechaga, Ignacio/K-2198-2014	Arechaga, Ignacio/0000-0002-1342-9370; Cabezon, Elena/0000-0002-6177-5016; Walker, John/0000-0001-7929-2162				Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Cabezon E, 2000, J BIOL CHEM, V275, P25460, DOI 10.1074/jbc.M003859200; FABERGE AC, 1974, J MICROSC-PARIS, V20, P241; JACKSON PJ, 1988, FEBS LETT, V229, P224, DOI 10.1016/0014-5793(88)80832-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Orriss GL, 1998, STRUCT FOLD DES, V6, P831, DOI 10.1016/S0969-2126(98)00085-9; PANCHENKO MV, 1985, FEBS LETT, V184, P226, DOI 10.1016/0014-5793(85)80611-6; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Stafford WF, 1997, CURR OPIN BIOTECH, V8, P14, DOI 10.1016/S0958-1669(97)80152-8; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; WALKER JE, 1994, CURR OPIN STRUC BIOL, V4, P912, DOI 10.1016/0959-440X(94)90274-7; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4	15	92	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28353	28355		10.1074/jbc.C000427200	http://dx.doi.org/10.1074/jbc.C000427200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10918052	hybrid			2022-12-25	WOS:000089330700004
J	Yen, L; You, XL; Al Moustafa, AE; Batist, G; Hynes, NE; Mader, S; Meloche, S; Alaoui-Jamali, MA				Yen, L; You, XL; Al Moustafa, AE; Batist, G; Hynes, NE; Mader, S; Meloche, S; Alaoui-Jamali, MA			Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis	ONCOGENE			English	Article						ErbB receptors; heregulin beta 1; VEGF; cell proliferation; HUVEC	NEU DIFFERENTIATION FACTOR; RECEPTOR TYROSINE KINASES; NIH 3T3 CELLS; PERMEABILITY FACTOR; TUMOR-GROWTH; SIGNAL-TRANSDUCTION; BREAST-CANCER; MESSENGER-RNA; FACTOR VEGF; MAP KINASE	The interaction between the erbB tyrosine kinase receptors and their ligands plays an important role in tumor growth via the regulation of autocrine and paracrine loops. We report the effect of heregulin beta 1, the ligand for erbB-3 and erbB-4 receptors, on the regulation of vascular endothelial growth factor (VEGF) expression, using a panel of breast and lung cancer cell lines with constitutive erbB-2 overexpression or engineered to stably overexpress the erbB-2 receptor. We demonstrate that heregulin beta 1 induces VEGF secretion in most cancer cell lines, while no significant effect was observed in normal human mammary and bronchial primary cells. Overexpression of erbB-2 receptor results in induction of the basal level of VEGF and exposure to heregulin further enhances VEGF secretion. This is associated with increased VEGF mRNA expression. In contrast, VEGF induction is significantly decreased in a T47D cell line where erbB-2 is functionally inactivated. Conditioned media from heregulin-treated cancer cells, but not from normal cells, stimulates endothelial cell proliferation; this paracrine stimulation is inhibited by co-exposure to a specific VEGF neutralizing antibody, Furthermore, heregulin-mediated angiogenesis is observed in the in vivo CAM assay. This study reports the first evidence of VEGF regulation by heregulin in cancer cells.	McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Pharmacol Therapeut, Montreal, PQ H3T 1E2, Canada; McGill Univ, McGill Ctr Translat Res Canc, Montreal, PQ H3T 1E2, Canada; Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Univ Montreal, Dept Biochem, Montreal, PQ H3T 1P1, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H2W 1T8, Canada; Hotel Dieu Montreal, Ctr Rech, Montreal, PQ H2W 1T8, Canada	Lady Davis Institute; McGill University; McGill University; McGill University; Friedrich Miescher Institute for Biomedical Research; Universite de Montreal; Universite de Montreal; Universite de Montreal	Alaoui-Jamali, MA (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, Room 523,3755 Cote St Catherine, Montreal, PQ H3T 1E2, Canada.							ALMOUSTAFA AE, 1988, CELL DIFFER DEV, V25, P119, DOI 10.1016/0922-3371(88)90005-6; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Balbay MD, 1999, CLIN CANCER RES, V5, P783; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROWN LF, 1997, EXS, V79, P233; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; Claffey KP, 1996, CANCER METAST REV, V15, P165, DOI 10.1007/BF00437469; Claffey KP, 1996, CANCER RES, V56, P172; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Feldkamp MM, 1999, INT J CANCER, V81, P118, DOI 10.1002/(SICI)1097-0215(19990331)81:1<118::AID-IJC20>3.3.CO;2-X; Feleszko W, 1999, INT J CANCER, V81, P560, DOI 10.1002/(SICI)1097-0215(19990517)81:4<560::AID-IJC10>3.0.CO;2-7; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Im SA, 1999, CANCER RES, V59, P895; Jannot CB, 1996, ONCOGENE, V13, P275; Joukov V, 1996, EMBO J, V15, P290; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KUMAR R, 1991, Current Opinion in Oncology, V3, P70, DOI 10.1097/00001622-199102000-00011; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Lin PN, 1998, CELL GROWTH DIFFER, V9, P49; Liu JJ, 1999, INVEST OPHTH VIS SCI, V40, P752; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MARTE BM, 1995, ONCOGENE, V10, P167; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; Melnyk O, 1999, J UROLOGY, V161, P960, DOI 10.1016/S0022-5347(01)61829-9; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; NOGUCHI M, 1993, CANCER RES, V53, P2035; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Perrotte P, 1999, CLIN CANCER RES, V5, P257; Petit AMV, 1997, AM J PATHOL, V151, P1523; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Pluda JM, 1997, SEMIN ONCOL, V24, P203; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; RAK J, 1995, CANCER RES, V55, P4575; Rak J, 2000, CANCER RES, V60, P490; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rofstad EK, 1999, BRIT J CANCER, V80, P1697, DOI 10.1038/sj.bjc.6690586; Rossler J, 1999, INT J CANCER, V81, P113; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Tan M, 1997, CANCER RES, V57, P1199; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TSAI JC, 1995, J NEUROSURG, V82, P864, DOI 10.3171/jns.1995.82.5.0864; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Watanabe Y, 1997, ONCOGENE, V14, P2025, DOI 10.1038/sj.onc.1201033; Whittle C, 1999, CLIN SCI, V97, P303, DOI 10.1042/CS19990016; Yamada Y, 1997, GENOMICS, V42, P483, DOI 10.1006/geno.1997.4774; Yen L, 1997, ONCOGENE, V14, P1827, DOI 10.1038/sj.onc.1201019; You XL, 1998, ONCOGENE, V17, P3177, DOI 10.1038/sj.onc.1202246; YU DH, 1994, CANCER RES, V54, P3260; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562; Zhang K, 1996, J BIOL CHEM, V271, P3884	78	192	210	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2000	19	31					3460	3469		10.1038/sj.onc.1203685	http://dx.doi.org/10.1038/sj.onc.1203685			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918604				2022-12-25	WOS:000088346500002
J	Almog, N; Goldfinger, N; Rotter, V				Almog, N; Goldfinger, N; Rotter, V			p53-dependent apoptosis is regulated by a C-terminally alternatively spliced form of murine p53	ONCOGENE			English	Article						p53; alternative splicing; C-terminus	WILD-TYPE P53; NUCLEOTIDE EXCISION-REPAIR; TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; DNA-BINDING; IONIZING-RADIATION; SINGLE STRANDS; MYELOID CELLS; MOUSE P53; DOMAIN	It is now well accepted that the p53 C-terminus plays a central role in controlling the activity of the wild-type molecule. In our previous studies, we observed that a C-terminally altered p53 protein (p53AS), generated by an alternative spliced p53 mRNA, induces an attenuated p53-dependent apoptosis, compared to that induced by the regularly spliced form (p53RS). In the present study we analysed the interrelationships between these two physiological variants of wild-type p53, and found that in cells co-expressing both forms, in contrast to the expected additive effect on the induction of apoptosis, p53AS inhibits apoptosis induced by p53RS, This inhibitory effect is specific for p53-dependent apoptosis and was not evident in a p53-independent apoptotic pathway induced by growth factor deprivation. Furthermore, the expression of p53AS in transiently transfected cells caused both inhibition of apoptosis and inhibition of the p53RS-dependent transactivation of a number of p53 target genes. These results suggest that expression of an alternatively spliced p53 form may serve as an additional level in controlling the complexity of p53 function by the C-terminal domain.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.							Almog N, 1997, MOL CELL BIOL, V17, P713, DOI 10.1128/MCB.17.2.713; Almog Nava, 1998, Biochimica et Biophysica Acta, V1378, pR43; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Flaman JM, 1996, ONCOGENE, V12, P813; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALL PA, 1997, CURR BIOL, V7, P144; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko JL, 1996, GENE DEV, V10, P1054; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; McMasters KM, 1996, ONCOGENE, V13, P1731; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Miner Z, 1997, NUCLEIC ACIDS RES, V25, P1319, DOI 10.1093/nar/25.7.1319; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Peled A, 1996, CANCER RES, V56, P2148; Peled A, 1996, EXP HEMATOL, V24, P728; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Rehberger PA, 1997, CELL GROWTH DIFFER, V8, P851; ROTTGER J, 1994, COSPAR COLL, V5, P29; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SHAULIAN E, 1995, ONCOGENE, V10, P671; Shaw P, 1996, ONCOGENE, V12, P921; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; WILL K, 1995, NUCLEIC ACIDS RES, V23, P4023, DOI 10.1093/nar/23.20.4023; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; WOLKOWICZ R, 1995, P NATL ACAD SCI USA, V92, P6842, DOI 10.1073/pnas.92.15.6842; Wolkowicz R, 1997, PATHOL BIOL, V45, P785; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; Wu Y, 1997, P NATL ACAD SCI USA, V94, P8982, DOI 10.1073/pnas.94.17.8982; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; Zhou XL, 1999, CANCER RES, V59, P843	74	25	28	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 13	2000	19	30					3395	3403		10.1038/sj.onc.1203673	http://dx.doi.org/10.1038/sj.onc.1203673			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918596				2022-12-25	WOS:000088198100007
J	Park, US; Park, SK; Lee, YI; Park, JG; Lee, YI				Park, US; Park, SK; Lee, YI; Park, JG; Lee, YI			Hepatitis B virus-X protein upregulates the expression of p21(waf1/cip1) and prolongs G1 -> S transition via a p53-independent pathway in human hepatoma cells	ONCOGENE			English	Article						hepatitis B virus-X; p21(waf1/cip1); cyclin-dependent kinase inhibitor; hepatocellular carcinoma; p53	ETS GENE FAMILY; P53-MEDIATED G(1) ARREST; WILD-TYPE P53; TRANSGENIC MICE; FUNCTIONAL-ANALYSIS; ONCOGENIC ACTIVITY; TRANSACTIVATOR-X; MAMMALIAN-CELLS; WAF1/CIP1 GENE; LEUKEMIC-CELLS	Progression through the cell cycle is controlled by the induction of cyclins and activation of cognate cyclin-dependent kinases, The human hepatitis B virus-X (HBV-X) protein functions in gene expression alterations, in the sensitization of cells to apoptotic killing and deregulates cell growth arrest in certain cancer cell types, We have pursued the mechanism of growth arrest in Hep3B cells, a p53-mutant human hepatocellular carcinoma (HCC) cell line, In stable or transient HBV-X transformed Hep3B cells, HBV-X increased protein and mRNA levels of the cyclin-dependent kinase inhibitor (CDKI) p21(wafl/cipl), increased binding of p21(wafl/cipl) with cyclin-dependent kinase 2 (CDK2), markedly inhibited cyclin E and CDK2 associated phosphorylation of histone HI and induced the activation of a p21 promoter reporter construct, By using p21 promoter deletion constructs, the HBV-X responsive element was mapped to a region between -1185 and -1482, relative to the transcription start site, Promoter mutation analysis indicated that the HBV-X responsive site coincides with the ets factor binding sites. These data indicate that in human hepatocellular carcinoma cells, HBV-X can circumvent the loss of p53 functions and induces critical downstream regulatory events leading to transcriptional activation of p21(wafl/cipl). AS a consequence, there is an increased chance of acquisition of mutations which can enhance the genesis of hepatomas, Our results also emphasize the chemotherapeutic potential of p21(wafl/cipl) inhibitors, particularly in the HBV-X infected hepatoma which lacks functional p53.	Korea Res Inst Biosci & Biotechnol, Biosci Res Div, Liver Cell Signal Transduct Res Unit, Taejon 305600, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Lee, YI (corresponding author), Korea Res Inst Biosci & Biotechnol, Biosci Res Div, Liver Cell Signal Transduct Res Unit, POB 115, Taejon 305600, South Korea.							BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chisari FV, 1996, CURR TOP MICROBIOL, V206, P149; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gorospe M, 1996, CANCER RES, V56, P475; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANA X, 1995, ONCOGENE, V11, P211; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KIM YH, 1993, BIOCHEM BIOPH RES CO, V197, P894, DOI 10.1006/bbrc.1993.2563; KIM YS, 1984, KOREAN BIOCH J, V17, P7076; Ko JH, 1999, J BIOL CHEM, V274, P22941, DOI 10.1074/jbc.274.33.22941; Kobayashi T, 1995, ONCOGENE, V11, P2311; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; Lee Y, 1998, GENE, V207, P111, DOI 10.1016/S0378-1119(97)00603-3; Lee YI, 1998, ONCOGENE, V16, P2367, DOI 10.1038/sj.onc.1201760; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Takada S, 1997, ONCOGENE, V15, P1895, DOI 10.1038/sj.onc.1201369; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang BS, 1996, MOL CELL BIOL, V16, P538; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zeng YX, 1996, ONCOGENE, V12, P1557; Zhang W, 1995, CLIN CANCER RES, V1, P1051; ZHANG W, 1995, CANCER RES, V55, P668	52	67	75	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2000	19	30					3384	3394		10.1038/sj.onc.1203674	http://dx.doi.org/10.1038/sj.onc.1203674			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918595				2022-12-25	WOS:000088198100006
J	Ali, BRS; Tjernberg, A; Chait, BT; Field, MC				Ali, BRS; Tjernberg, A; Chait, BT; Field, MC			A microsomal GTPase is required for glycopeptide export from the mammalian endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMANNOSE-TYPE OLIGOSACCHARIDES; QUALITY-CONTROL; SACCHAROMYCES-CEREVISIAE; GUANYLATE KINASE; SECRETORY PATHWAY; HEPG2 CELLS; PROTEIN; TRANSPORT; CYTOSOL; PROTEASOME	Bidirectional transport of proteins via the Sec61p translocon across the endoplasmic reticulum (ER) membrane is a recognized component of the ER quality control machinery. Following translocation and engagement by the luminal quality control system, misfolded and unassembled proteins are exported from the ER lumen back to the cytosol for degradation by the proteasome. Additionally, other ER contents, including oligosaccharides, oligopeptides, and glycopeptides, are efficiently exported from mammalian and yeast systems, indicating that bidirectional transport across ER membranes is a general eukaryotic phenomenon Glycopeptide and protein export from the ER in in vitro systems is both ATP- and cytosol-dependent. Using a well established system to study glycopeptide export and conventional liquid chromatography, we isolated a single polypeptide species of 23 kDa from rat Liver cytosol that was capable of fully supporting glycopeptide export from rat microsomes in the presence of an ATP-regenerating system. The protein was identified by mass spectrometric sequence analysis as guanylate kinase (GK), a housekeeping enzyme critical in the regulation of cellular GTP levels. We confirmed the ability of GK to substitute for complete cytosol by reconstitution of glycopeptide export from rat Liver microsomes using highly purified recombinant GK from Saccharomyces cerevisiae. Most significantly, we found that the GK (and hence the cytosolic component) requirement was fully bypassed by low micromolar concentrations of GDP or GTP. Similarly, export was inhibited by non-hydrolyzable analogues of GDP and GTP, indicating a requirement for GTP hydrolysis. Membrane integrity was fully maintained under assay conditions, as no ER luminal. proteins mere released. Competence for glycopeptide export was abolished by very mild protease treatment of microsomes, indicating the presence of an essential protein on the cytosolic face of the ER membrane. These data demonstrate that export of glycopeptide export is controlled by a microsomal GTPase and is independent of cytosolic protein factors.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Wellcome Trust Labs Mol Parasitol, London SW7 2AY, England; Rockefeller Univ, Lab Biol Mass Spectrometry & Gaseous Ion Chem, New York, NY 10021 USA	Imperial College London; Rockefeller University	Field, MC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Wellcome Trust Labs Mol Parasitol, Exhibit Rd, London SW7 2AY, England.		Field, Mark/AAD-6455-2021; Ali, Bassam/J-7014-2012	Field, Mark/0000-0002-4866-2885; Ali, Bassam R/0000-0003-1306-6618	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00862] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ali BRS, 2000, GLYCOBIOLOGY, V10, P383, DOI 10.1093/glycob/10.4.383; Bacik I, 1997, J EXP MED, V186, P479, DOI 10.1084/jem.186.4.479; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; Banhegyi G, 1999, J BIOL CHEM, V274, P12213, DOI 10.1074/jbc.274.18.12213; BERNINSONE P, 1994, J BIOL CHEM, V269, P207; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Brady WA, 1996, J BIOL CHEM, V271, P16734, DOI 10.1074/jbc.271.28.16734; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Cacan R, 2000, GLYCOBIOLOGY, V10, P645, DOI 10.1093/glycob/10.7.645; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fenyo D, 1998, ELECTROPHORESIS, V19, P998, DOI 10.1002/elps.1150190615; Gaut JR, 1993, CURR OPIN CELL BIOL, V5, P589, DOI 10.1016/0955-0674(93)90127-C; Gillece P, 2000, P NATL ACAD SCI USA, V97, P4609, DOI 10.1073/pnas.090083497; HALL SW, 1986, EUR J BIOCHEM, V161, P551, DOI 10.1111/j.1432-1033.1986.tb10477.x; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Imamura T, 1998, J BIOL CHEM, V273, P11183, DOI 10.1074/jbc.273.18.11183; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Lavoie C, 1996, J CELL SCI, V109, P1415; Li Y, 1996, J BIOL CHEM, V271, P28038, DOI 10.1074/jbc.271.45.28038; Moore SEH, 1999, TRENDS CELL BIOL, V9, P441, DOI 10.1016/S0962-8924(99)01648-7; Moore SEH, 1998, GLYCOBIOLOGY, V8, P373, DOI 10.1093/glycob/8.4.373; MOORE SEH, 1995, EMBO J, V14, P6034, DOI 10.1002/j.1460-2075.1995.tb00292.x; PAIEMENT J, 1983, J CELL BIOL, V96, P1791, DOI 10.1083/jcb.96.6.1791; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Qin J, 1998, RAPID COMMUN MASS SP, V12, P209, DOI 10.1002/(SICI)1097-0231(19980314)12:5<209::AID-RCM141>3.0.CO;2-S; ROELSE J, 1994, J EXP MED, V180, P1591, DOI 10.1084/jem.180.5.1591; ROMISCH K, 1992, P NATL ACAD SCI USA, V89, P7227, DOI 10.1073/pnas.89.15.7227; Romisch K, 1997, P NATL ACAD SCI USA, V94, P6730, DOI 10.1073/pnas.94.13.6730; SaintPol A, 1997, J CELL BIOL, V136, P45, DOI 10.1083/jcb.136.1.45; SCHUMACHER TNM, 1994, J EXP MED, V179, P533, DOI 10.1084/jem.179.2.533; Suzuki T, 1998, J BIOL CHEM, V273, P10083, DOI 10.1074/jbc.273.17.10083; WALTER P, 1979, P NATL ACAD SCI USA, V76, P1795, DOI 10.1073/pnas.76.4.1795; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wilbourn B, 1998, BIOCHEM J, V332, P111, DOI 10.1042/bj3320111; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	38	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33222	33230		10.1074/jbc.M003845200	http://dx.doi.org/10.1074/jbc.M003845200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10913137	Green Published, hybrid			2022-12-25	WOS:000090104600009
J	Reinard, T; Janke, V; Willard, J; Buck, F; Jacobsen, HJ; Vockley, J				Reinard, T; Janke, V; Willard, J; Buck, F; Jacobsen, HJ; Vockley, J			Cloning of a gene for an acyl-CoA dehydrogenase from Pisum sativum L. and purification and characterization of its product as an isovaleryl-CoA dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; RAT-LIVER MITOCHONDRIA; MEDIUM-CHAIN; IDENTIFICATION; PROTEIN; PLANTS; CELLS	Isovaleryl-CoA dehydrogenase (IVD, EC 1.3.99.10) catalyzes the third step in the catabolism of leucine in mammals. Deficiency of this enzyme leads to the clinical disorder isovaleric acidemia. IVD has been purified and characterized from human and rat liver, and the x-ray crystallographic structure of purified recombinant human IVD has been reported. Nothing is known about IVD activity in plants, although cDNA clones from Arabidopsis thaliana and partial sequences from Gossypium hirsutum and Oryza sativa have been identified as putative IVDs based on sequence homology and immune cross-reactivity, In this report we describe the identification and characterization of an IVD from pea, purification of the enzyme using a novel and rapid auxin affinity chromatography matrix, and cloning of the corresponding gene. At the amino acid level, pea IVD is 60% similar to human and rat IVD, The specific activity and abundance of plant IVD was found to be significantly lower than for its human counterpart and exhibits developmental regulation. Substrate specificity of the plant enzyme is similar to the human TVD, and it crossreacts to anti-human IVD antibodies. Molecular modeling of the pea enzyme based on the structure of human IVD indicates a high degree of structural similarity among these enzymes. Glu-244, shown to function as the catalytic base in human IVD along with most of the amino acids that make up the acyl CoA binding pocket, is conserved in pea IVD, The genomic structure of the plant IVD gene consists of 13 exons and 12 introns, spanning approximately 4 kilobases, and the predicted RNA splicing sites exhibit the extended consensus sequence described for other plant genes.	Univ Hannover, LG Mol Genet, D-30419 Hannover, Germany; Mayo Clin & Mayo Fdn, Dept Med Genet, Rochester, MN 55905 USA; Univ Hamburg, Krankenhaus Eppendorf, Inst Zellbiochem & Klin Neurobiol, D-20246 Hamburg, Germany	Leibniz University Hannover; Mayo Clinic; University of Hamburg	Reinard, T (corresponding author), Univ Hannover, LG Mol Genet, Herrenhauser Str, D-30419 Hannover, Germany.		Vockley, Jerry/AAF-8523-2020; Vockley, Jerry/B-5210-2016	Vockley, Jerry/0000-0002-8180-6457; Vockley, Jerry/0000-0002-8180-6457	NIDDK NIH HHS [1RO1-DK45482] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045482] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson MD, 1998, PLANT PHYSIOL, V118, P1127, DOI 10.1104/pp.118.4.1127; Aubert S, 1996, FEBS LETT, V383, P175, DOI 10.1016/0014-5793(96)00244-X; Battaile KP, 1998, BBA-LIPID LIPID MET, V1390, P333, DOI 10.1016/S0005-2760(97)00185-9; Daschner K, 1999, PLANT MOL BIOL, V39, P1275; DOYLE JJ, 1990, FOCUS IDAHO, V122, P13; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; Finocchiaro G, 1988, Adv Neurol, V48, P221; Fujiki Yuki, 1997, Plant Physiology (Rockville), V114, P95; FULLMER CS, 1984, ANAL BIOCHEM, V142, P336, DOI 10.1016/0003-2697(84)90473-1; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; Hooks MA, 1996, BIOCHEM J, V320, P607, DOI 10.1042/bj3200607; IKEDA Y, 1983, J BIOL CHEM, V258, P1066; IKEDA Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P662, DOI 10.1016/0003-9861(87)90072-5; IKEDA Y, 1983, J BIOL CHEM, V258, P1077; Mohsen AA, 1998, BIOCHEMISTRY-US, V37, P10325, DOI 10.1021/bi973096r; MOHSEN AWA, 1995, GENE, V160, P263, DOI 10.1016/0378-1119(95)00256-6; PARIMOO B, 1993, GENOMICS, V15, P582, DOI 10.1006/geno.1993.1111; REINARD T, 1995, J PLANT PHYSIOL, V147, P132, DOI 10.1016/S0176-1617(11)81425-2; Reinard T, 1998, PLANT CELL PHYSIOL, V39, P874, DOI 10.1093/oxfordjournals.pcp.a029447; Telford EAR, 1999, BBA-GENE STRUCT EXPR, V1446, P371, DOI 10.1016/S0167-4781(99)00102-5; Tiffany KA, 1997, BIOCHEMISTRY-US, V36, P8455, DOI 10.1021/bi970422u; VOCKLEY J, 2000, IN PRESS METHODS ENZ, V324	22	20	20	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33738	33743		10.1074/jbc.M004178200	http://dx.doi.org/10.1074/jbc.M004178200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10913142	hybrid			2022-12-25	WOS:000090104600077
J	Hoover, DM; Rajashankar, KR; Blumenthal, R; Puri, A; Oppenheim, JJ; Chertov, O; Lubkowski, J				Hoover, DM; Rajashankar, KR; Blumenthal, R; Puri, A; Oppenheim, JJ; Chertov, O; Lubkowski, J			The structure of human beta-defensin-2 shows evidence of higher order oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PERMEABILIZATION; ANTIMICROBIAL PEPTIDES; DIFFRACTION DATA; HUMAN DEFENSINS; LIPID BILAYERS; OUTER-MEMBRANE; BETA-DEFENSINS; PROTEIN; CRYSTALLOGRAPHY; REFINEMENT	Defensins are small cationic peptides that are crucial components of innate immunity, serving as both antimicrobial agents and chemoattractant molecules. The specific mechanism of antimicrobial activity involves permeabilization of bacterial membranes. It has been postulated that individual monomers oligomerize to form a pore through anionic membranes, although the evidence is only indirect. Here, we report two high resolution x-ray structures of human beta -defensin-2 (hBD2). The phases were experimentally determined by the multiwavelength anomalous diffraction method, utilizing a novel, rapid method of derivatization with halide ions. Although the shape and charge distribution of the monomer are similar to those of other defensins, an additional alpha -helical region makes this protein topologically distinct from the mammalian alpha- and beta -defensin structures reported previously. hBD2 forms dimers topologically distinct from that of human neutrophil peptide-3. The quaternary octameric arrangement of hBD2 is conserved in two crystal forms. These structures provide the first detailed description of dimerization of beta -defensins, and we postulate that the mode of dimerization of hBD2 is representative of other beta -defensins. The structural and electrostatic properties of the hBD2 octamer support an electrostatic charge-based mechanism of membrane permeabilization by beta -defensins, rather than a mechanism based on formation of bilayer-spanning pores.	NCI, Macromol Crystallog Lab, Program Struct Biol, Frederick Canc Res & Dev Ctr,NIH, Frederick, MD 21702 USA; NCI, SAIC Frederick, Frederick Canc Res & Dev Ctr, NIH, Frederick, MD 21702 USA; Brookhaven Natl Lab, Upton, NY 11973 USA; NCI, Lab Expt & Computat Biol, Frederick Canc Res & Dev Ctr, NIH, Frederick, MD 21702 USA; NCI, Mol Immunoregulat Lab, Frederick Canc Res & Dev Ctr, NIH, Frederick, MD 21702 USA; NCI, Intramural Res Support Program, SAIC Frederick, Frederick Canc Res & Dev Ctr,NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; United States Department of Energy (DOE); Brookhaven National Laboratory; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Lubkowski, J (corresponding author), NCI, Macromol Crystallog Lab, Program Struct Biol, Frederick Canc Res & Dev Ctr,NIH, Frederick, MD 21702 USA.			Chertov, Oleg/0000-0002-0426-2521	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC009369, Z01BC008303] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bechinger B, 1997, J MEMBRANE BIOL, V156, P197, DOI 10.1007/s002329900201; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Dauter Z, 2000, ACTA CRYSTALLOGR D, V56, P232, DOI 10.1107/S0907444999016352; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FOGH RH, 1990, J BIOL CHEM, V265, P13016; FUJII G, 1993, PROTEIN SCI, V2, P1301, DOI 10.1002/pro.5560020813; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GALVEZ A, 1991, J BACTERIOL, V173, P886, DOI 10.1128/jb.173.2.886-892.1991; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hristova K, 1997, J BIOL CHEM, V272, P24224, DOI 10.1074/jbc.272.39.24224; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; Lehrer RI, 1996, ANN NY ACAD SCI, V797, P228, DOI 10.1111/j.1749-6632.1996.tb52963.x; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; Ludtke SJ, 1996, BIOCHEMISTRY-US, V35, P13723, DOI 10.1021/bi9620621; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OTWINOWSKI Z, 1991, P CCP4 STUD WEEK DAR; PALLAGHY PK, 1995, BIOCHEMISTRY-US, V34, P3782, DOI 10.1021/bi00011a036; Rana F, 1989, Prog Clin Biol Res, V292, P77; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Torres AM, 1999, BIOCHEM J, V341, P785, DOI 10.1042/0264-6021:3410785; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; VILJANEN P, 1988, INFECT IMMUN, V56, P2324, DOI 10.1128/IAI.56.9.2324-2329.1988; WALKER JM, 1996, PROTEIN PROTOCOLS HD; WHITE SH, 1995, CURR OPIN STRUC BIOL, V5, P521, DOI 10.1016/0959-440X(95)80038-7; WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525	40	261	281	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32911	32918		10.1074/jbc.M006098200	http://dx.doi.org/10.1074/jbc.M006098200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10906336	hybrid			2022-12-25	WOS:000090003800074
J	Keyhani, NO; Boudker, O; Roseman, S				Keyhani, NO; Boudker, O; Roseman, S			Isolation and characterization of IIA(Chb), a soluble protein of the enzyme II complex required for the transport/phosphorylation of N,N '-Diacetylchitobiose in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCING PROTEIN; SUGAR PHOSPHOTRANSFERASE SYSTEM; BACTERIAL PHOSPHOENOLPYRUVATE; PHOSPHOCARRIER PROTEIN; STAPHYLOCOCCUS-AUREUS; PHOSPHORYL TRANSFER; NMR TECHNIQUES; IIIGLC; TRANSPORT; SEQUENCE	N,N'-Diacetylchitobiose is transported/phosphorylated in Escherichia coli by the (GlcNAc)(2)-specific Enzyme II permease of the phosphoenolpyruvate:glycose phosphotransferase system. IIA(Chb), one protein of the Enzyme II complex, was cloned and purified to homogeneity. IIA(Chb) and phospho-IIA(Chb) form stable homodimers (3). Phospho-IIA(Chb) behaves as a typical epsilon2-N (i.e. N-3) phospho-His protein. However, the rate constants for hydrolysis of phospho-IIA(Chb) at pH 8.0 unexpectedly increased 7-fold between 25 and 37 degreesC and increased similar to 4-fold with decreasing protein concentration at 37 degreesC (but not 25 degreesC), The data were explained by thermal denaturation studies using CD spectroscopy. IIA(Chb) and phospho-IIA(Chb) exhibit virtually identical spectra at 25 degreesC (similar to 80% alpha -helix), but phospho-IIA(Chb) loses about 30% of its helicity at 37 degreesC, whereas IIA(Chb) shows only a slight change. Furthermore, the T-m for thermal denaturation of IIA(Chb) Wag 54 degreesC, only slightly affected by concentration, whereas the T-m for phospho-IIA(Chb) was much lower, ranging from 40 to 46 degreesC, depending on concentration. In addition, divalent cations (Mg2+, Cu2+, and Ni2+) have a dramatic and differential effect on the structure, depending on the state of phosphorylation of the protein. Thus, phosphorylation destabilizes IIA(Chb) at 37 degreesC, potentially affecting the monomer/dimer transition, which correlates with its chemical instability at this temperature. The physiological consequences of this phenomenon are briefly considered.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Roseman, S (corresponding author), Johns Hopkins Univ, Dept Biol, Mudd Hall,Rm 214,3400 N Charles St, Baltimore, MD 21218 USA.		Keyhani, Nemat O/I-8150-2013		NIGMS NIH HHS [GM38759] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038759, R37GM038759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AB E, 1994, PROTEIN SCI, V3, P282; ANDERSON JW, 1992, BIOCHEM CELL BIOL, V70, P242, DOI 10.1139/o92-036; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V1; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BUHR A, 1993, J BIOL CHEM, V268, P11599; DEUTSCHER J, 1982, BIOCHEMISTRY-US, V21, P4867, DOI 10.1021/bi00263a006; Feese MD, 1997, BIOCHEMISTRY-US, V36, P16087, DOI 10.1021/bi971999e; HALL BG, 1992, MOL BIOL EVOL, V9, P688; HAYS JB, 1973, J BIOL CHEM, V248, P941; JAENICKE L, 1974, ANAL BIOCHEM, V61, P623, DOI 10.1016/0003-2697(74)90429-1; Keyhani N, 2000, J BIOL CHEM, V275, P33110, DOI 10.1074/jbc.M001717200; Keyhani NO, 2000, J BIOL CHEM, V275, P33102, DOI 10.1074/jbc.M001045200; Keyhani NO, 2000, J BIOL CHEM, V275, P33084, DOI 10.1074/jbc.M001043200; Keyhani NO, 2000, J BIOL CHEM, V275, P33068, DOI 10.1074/jbc.M001041200; Keyhani NO, 1997, P NATL ACAD SCI USA, V94, P14367, DOI 10.1073/pnas.94.26.14367; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; KUNDIG W, 1966, METHOD ENZYMOL, V9, P396; Park JK, 2000, J BIOL CHEM, V275, P33077, DOI 10.1074/jbc.M001042200; Pelton JG, 1996, J BIOL CHEM, V271, P33446, DOI 10.1074/jbc.271.52.33446; PELTON JG, 1992, BIOCHEMISTRY-US, V31, P5215, DOI 10.1021/bi00137a017; PELTON JG, 1991, BIOCHEMISTRY-US, V30, P10043, DOI 10.1021/bi00105a032; PELTON JG, 1993, PROTEIN SCI, V2, P543; PETTIGREW DW, 1994, PHOSPHATE IN MICROORGANISMS, P335; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; Sambrook J., 2002, MOL CLONING LAB MANU; Sliz P, 1997, STRUCTURE, V5, P775, DOI 10.1016/S0969-2126(97)00232-3; WAYGOOD EB, 1985, BIOCHEMISTRY-US, V24, P6938, DOI 10.1021/bi00345a028; WEIGEL N, 1982, J BIOL CHEM, V257, P4477; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382	30	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33091	33101		10.1074/jbc.M001044200	http://dx.doi.org/10.1074/jbc.M001044200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913118	hybrid			2022-12-25	WOS:000090003800097
J	Johnson, TR; Biggs, JR; Winbourn, SE; Kraft, AS				Johnson, TR; Biggs, JR; Winbourn, SE; Kraft, AS			Regulation of dual-specificity phosphatases M3/6 and hVH5 by phorbol esters - Analysis of a delta-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MAP KINASE; C-JUN; TYROSINE-PHOSPHATASE; SELECTIVELY DEPHOSPHORYLATES; CATALYTIC ACTIVATION; MOLECULAR-CLONING; INTERACTION MOTIF; PTP-SL; STRESS	Treatment of leukemic cells with phorbol 12-myristate 13-acetate (PMA) induces a short-lived phosphorylation and activation of stress-activated protein kinase (SAPK) and cellular differentiation. To investigate whether the rapid deactivation of SAPK results from dephosphorylation by dual-specificity phosphatases (DSPs), we studied regulation of the DSP hVH5 and its murine orthologue M3/6 in K562 human leukemia cells. PMA treatment rapidly induced hVH5 transcripts in these cells, and induced expression of M3/6 completely inhibited PMA-stimulated phosphorylation of SAPK, suggesting a feedback loop to control SAPK activity. Using both stable cell lines and transient transfection we demonstrate that activation of SAPK rapidly stimulated phosphorylation of M3/6. This phosphorylation did not regulate the half-life of total cellular M3/6. hVH5 and M3/6 shares with all sequenced mammalian DSPs an amino acid motif, XILPXLXL, located approximately 80 amino acids from the active site. The hVH5-M3/6 sequence, RILPHLYL, shares significant homology with the SAPK binding site of the c-Jun protein, called the delta domain. This motif was found to be important for DSP function, because deletion of RILPHLYL inhibits SAPK-mediated phosphorylation of M3/6, and deletion of this sequence or mutation of the Ln portion blocks the ability of this phosphatase to dephosphorylate SAPK.	Univ Colorado, Hlth Sci Ctr, Dept Med Oncol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kraft, AS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med Oncol, 4200 E 9th Ave, Denver, CO 80262 USA.				NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER; NCI NIH HHS [CA42533] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1994, J BIOL CHEM, V269, P11186; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; BAICHWAL UR, 1990, CELL, V16, P815; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; DAI TN, 1995, ONCOGENE, V10, P849; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dowd S, 1998, J CELL SCI, V111, P3389; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Grumont RJ, 1996, MOL CELL BIOL, V16, P2913; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; Haneda M, 1999, EUR J PHARMACOL, V365, P1, DOI 10.1016/S0014-2999(98)00857-7; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LOZZIO CB, 1975, BLOOD, V45, P332; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Rininsland F, 1997, P NATL ACAD SCI USA, V94, P5854, DOI 10.1073/pnas.94.11.5854; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	46	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31755	31762		10.1074/jbc.M004182200	http://dx.doi.org/10.1074/jbc.M004182200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10915787	hybrid			2022-12-25	WOS:000089858900031
J	Macdonald, JM; Haas, AL; London, RE				Macdonald, JM; Haas, AL; London, RE			Novel mechanism of surface catalysis of protein adduct formation - NMR studies of the acetylation of ubiquitin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLIMIDAZOLE; NONENZYMATIC GLYCOSYLATION; AMADORI REARRANGEMENT; GROWTH-HORMONE; AMINO-GROUPS; GLYCATION; SITES; IDENTIFICATION; HEMOGLOBIN; SPECIFICITY	Reactivity of surface lysyl residues of proteins with a broad range of chemical agents has been proposed to be dependent on the catalytic microenvironment of the residue. We have investigated the acetylation of wild type ubiquitin and of the UbH68N mutant to evaluate the potential contribution of His-68 to the reactivity of Lys-6, which is about 4 Angstrom distant. These studies were performed using [1-C-13]acetyl salicylate or [1,1'-C-13(2)]acetic anhydride, and the acetylated products were detected by two-dimensional heteronuclear multiple quantum coherence spectroscopy. The results demonstrate that His-68 makes a positive contribution to the rate of acetylation of Lys-6 by labeled aspirin. Additionally, a pair of transient resonances is observed after treatment of wild type ubiquitin with the labeled acetic anhydride but not upon treatment of the H68N mutant. These resonances are assigned to the acetylated His-68 residue. The loss of intensity of the acetylhistidine resonances is accompanied by an increase in intensity of the acetyl-lys-g peak, supporting the existence of a transacetylation process between the acetylhistidine 68 and lysine 6 residues located on the protein surface. Hence, this may be the first direct demonstration of a catalytic intermediate forming on the protein surface.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Medical College of Wisconsin	London, RE (corresponding author), NIEHS, Struct Biol Lab, NIH, MR-01,Box 12233, Res Triangle Pk, NC 27709 USA.		London, Robert E/F-7990-2019	London, Robert E/0000-0001-9108-8463	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050111, ZIAES050111] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ACHARYA AS, 1983, J BIOL CHEM, V258, P2296; ARGUELLO JM, 1990, BIOCHEMISTRY-US, V29, P5775, DOI 10.1021/bi00476a019; Bailey AJ, 1998, MECH AGEING DEV, V106, P1, DOI 10.1016/S0047-6374(98)00119-5; BALDWIN JS, 1995, BBA-PROTEIN STRUCT M, V1247, P60, DOI 10.1016/0167-4838(94)00202-R; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; DESATZ VB, 1981, INT J PEPT PROT RES, V18, P492; GERIG JT, 1981, ORG MAGN RESONANCE, V15, P158, DOI 10.1002/mrc.1270150210; HAYDEN PJ, 1991, BIOCHEMISTRY-US, V30, P5935, DOI 10.1021/bi00238a018; HIPKISS AR, 1995, FEBS LETT, V371, P81, DOI 10.1016/0014-5793(95)00849-5; IBERG N, 1986, J BIOL CHEM, V261, P3542; KALIMAN P, 1991, INT J PEPT PROT RES, V38, P38; KHALIFAH RG, 1979, BIOCHEMISTRY-US, V18, P391, DOI 10.1021/bi00569a025; KINNUNEN PM, 1988, BIOCHEMISTRY-US, V27, P7344, DOI 10.1021/bi00419a025; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Macdonald JM, 1999, BIOCHEM PHARMACOL, V57, P1233, DOI 10.1016/S0006-2952(99)00039-8; MIYATA T, 1994, BIOCHEMISTRY-US, V33, P12215, DOI 10.1021/bi00206a026; MOORE GJ, 1985, INT J PEPT PROT RES, V26, P469; NACHARAJU P, 1992, BIOCHEMISTRY-US, V31, P12673, DOI 10.1021/bi00165a018; NIGEN AM, 1973, J BIOL CHEM, V248, P3724; RIORDAN JF, 1965, BIOCHEMISTRY-US, V4, P1758, DOI 10.1021/bi00885a012; SHILTON BH, 1991, J BIOL CHEM, V266, P5587; SHILTON BH, 1993, EUR J BIOCHEM, V215, P567, DOI 10.1111/j.1432-1033.1993.tb18067.x; SVENSSON L A, 1986, Proteins Structure Function and Genetics, V1, P370, DOI 10.1002/prot.340010410; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; WALKER JE, 1976, FEBS LETT, V66, P173, DOI 10.1016/0014-5793(76)80496-6; WATKINS NG, 1985, J BIOL CHEM, V260, P629; WELSCH DJ, 1988, BIOCHEMISTRY-US, V27, P7513, DOI 10.1021/bi00419a050; WLODAWER A, 1983, BIOCHEMISTRY-US, V22, P2720, DOI 10.1021/bi00280a021; WUNDERLIN M, 1994, THESIS U KONSTANZ GE; Xu ASL, 1999, BBA-PROTEIN STRUCT M, V1432, P333, DOI 10.1016/S0167-4838(99)00094-1	31	16	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31908	31913		10.1074/jbc.M000684200	http://dx.doi.org/10.1074/jbc.M000684200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10906321	hybrid			2022-12-25	WOS:000089858900051
J	Bazzoni, G; Martinez-Estrada, OM; Mueller, F; Nelboeck, P; Schmid, G; Bartfai, T; Dejana, E; Brockhaus, M				Bazzoni, G; Martinez-Estrada, OM; Mueller, F; Nelboeck, P; Schmid, G; Bartfai, T; Dejana, E; Brockhaus, M			Hemophilic interaction of junctional adhesion molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; CRYSTAL-STRUCTURE; IMMUNOGLOBULIN SUPERFAMILY; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; SOLUBLE FORM; CD58 LFA-3; DIMERIZATION; CD2; RESOLUTION	Junctional adhesion molecule (JAM) is an integral membrane protein that belongs to the immunoglobulin superfamily, localizes at tight junctions, and regulates both paracellular permeability and leukocyte transmigration. To investigate molecular determinants of JAM function, the extracellular domain of murine JAM was produced as a recombinant soluble protein (rsJAM) in insect cells, rsJAM consisted in large part of noncovalent homodimers, as assessed by analytical ultracentrifugation, JAM dimers were also detected at the surface of Chinese hamster ovary cells transfected with murine JAM, as evaluated by cross-linking and immunoprecipitation. Furthermore, fluid-phase rsJAM bound dose-dependently solid-phase rsJAM, and such hemophilic binding was inhibited by anti-JAM Fab BV11, but not by Fab BV12, Interestingly, Fab BV11 exclusively bound rsJAM dimers (but not monomers) in solution, whereas Fab BV12 bound both dimers and monomers, Finally, we mapped the BV11 and BV12 epitopes to a largely overlapping sequence in proximity of the extracellular amino terminus of JAM, me hypothesize that rsJAM dimerization induces a BV11-positive conformation which in turn is critical for rsJAM hemophilic interactions. Dimerization and hemophilic binding may contribute to both adhesive function and junctional organization of JAM.	Ist Ric Farmacol Mario Negri, Lab Vasc Biol, I-20157 Milan, Italy; F Hoffmann La Roche & Co Ltd, Pharmaceut Res, CH-4070 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Chem Technol, CH-4070 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Cent Nervous Syst Dis, CH-4070 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Fermentat Technol, CH-4070 Basel, Switzerland; Univ Insubria, Dipartimento Sci Clin & Biol, I-21100 Varese, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Roche Holding; Roche Holding; Roche Holding; Roche Holding; University of Insubria	Bazzoni, G (corresponding author), Ist Ric Farmacol Mario Negri, Lab Vasc Biol, Via Eritrea 62, I-20157 Milan, Italy.		Martinez-Estrada, Ofelia M/V-4733-2017	Martinez-Estrada, Ofelia M/0000-0002-1814-1974; DEJANA, ELISABETTA/0000-0002-0007-0426				Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; BEDNARCZYK JL, 1994, J BIOL CHEM, V269, P8348; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Casasnovas JM, 1998, P NATL ACAD SCI USA, V95, P4134, DOI 10.1073/pnas.95.8.4134; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; Del Maschio A, 1999, J EXP MED, V190, P1351, DOI 10.1084/jem.190.9.1351; Dustin ML, 1996, J CELL BIOL, V132, P465, DOI 10.1083/jcb.132.3.465; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hunter I, 1996, BIOCHEM J, V320, P847, DOI 10.1042/bj3200847; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KORNECKI E, 1990, J BIOL CHEM, V265, P10042; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; Leahy DJ, 1997, ANNU REV CELL DEV BI, V13, P363, DOI 10.1146/annurev.cellbio.13.1.363; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; Malergue F, 1998, MOL IMMUNOL, V35, P1111, DOI 10.1016/S0161-5890(98)00102-3; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; Ozaki H, 1999, J IMMUNOL, V163, P553; REILLY PL, 1995, J IMMUNOL, V155, P529; SCHUCK P, 1994, PROG COLL POL SCI S, V94, P1; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STUEBER D, 1990, IMMUNOL METHODS, V4, P122; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; WANG JM, 1994, J IMMUNOL METHODS, V171, P55, DOI 10.1016/0022-1759(94)90228-3; Williams LA, 1999, MOL IMMUNOL, V36, P1175, DOI 10.1016/S0161-5890(99)00122-4; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yauch RL, 1997, J EXP MED, V186, P1347, DOI 10.1084/jem.186.8.1347	31	124	133	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30970	30976		10.1074/jbc.M003946200	http://dx.doi.org/10.1074/jbc.M003946200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10913139	hybrid			2022-12-25	WOS:000089762700035
J	Huang, Y; Hamada, M; Maraia, RJ				Huang, Y; Hamada, M; Maraia, RJ			Isolation and cloning of four subunits of a fission yeast TFIIIC complex that includes an ortholog of the human regulatory protein TFIIIC beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TATA-BINDING PROTEIN; TRANSCRIPTION FACTOR; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; DNA-BINDING; ACETYLTRANSFERASE ACTIVITY; S-POMBE; GENE; EXPRESSION	Eukaryotic tRNA genes are controlled by proximal and downstream elements that direct transcription by RNA polymerase (pol) III. Transcription factors (TFs) that reside near the initiation site are related in Saccharomyces cerevisiae and humans, while those that reside at or downstream of the B box share no recognizable sequence relatedness. Human TFIIIC beta is a transcriptional regulator that exhibits no homology to S. cerevisiae sequences on its own. We cloned an essential Schizosaccharomyces pombe gene that encodes a protein, Sfc6p, with homology to the S. cerevisiae TFIIIC subunit, TFC6p, that extends to human TFIIIC beta. We also isolated and cloned S. pombe homologs of three other TFIIIC subunits, Sfc3p, Sfc4p, and Sfc1p, the latter two of which are conserved from S. cerevisiae to humans, while the former shares homology with the S. cerevisiae B box-binding homolog only. Sfc6p is a component of a sequence-specific DNA-binding complex that also contains the B box-binding homolog, Sfc3p. Immunoprecipitation of Sfc3p further revealed that Sfc1p, Sfc3p, Sfc4p, and Sfc6p are associated in vivo and that the isolated Sfc3p complex is active for pol III-mediated transcription of a S. pombe tRNA gene in vitro. These results establish a link between the downstream pol III TFs in yeast and humans.	NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Maraia, RJ (corresponding author), 6 Ctr Dr,Rm 416, Bethesda, MD 20892 USA.	maraiar@mail.nih.gov	Maraia, Richard/ABC-1442-2020	Maraia, Richard/0000-0002-5209-0066	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000412] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000412] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arrebola R, 1998, MOL CELL BIOL, V18, P1; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; Baserga S., 1993, RNA WORLD, P359; Chedin S, 1998, COLD SPRING HARB SYM, V63, P381, DOI 10.1101/sqb.1998.63.381; Chen L, 1997, NUCLEIC ACIDS RES, V25, P1633, DOI 10.1093/nar/25.8.1633; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; Dang VD, 1999, MOL CELL BIOL, V19, P2351; Deprez E, 1999, MOL CELL BIOL, V19, P8042; Dumay H, 1999, J BIOL CHEM, V274, P33462, DOI 10.1074/jbc.274.47.33462; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; Flores A, 1999, P NATL ACAD SCI USA, V96, P7815, DOI 10.1073/pnas.96.14.7815; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; Geiduschek E.P., 1992, TRANSCRIPTIONAL REGU, P247; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; Hamada M, 2000, J BIOL CHEM, V275, P29076, DOI 10.1074/jbc.M003980200; Hsieh YJ, 1999, MOL CELL BIOL, V19, P4944; Hsieh YJ, 1999, MOL CELL BIOL, V19, P7697; Huet J, 1996, METHOD ENZYMOL, V273, P249; KANTERSMOLER G, 1994, BIOTECHNIQUES, V16, P798; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; Kassavetis GA, 1999, EMBO J, V18, P5042, DOI 10.1093/emboj/18.18.5042; KASSAVETIS GA, 1994, TRANSCRIPTION MECHAN, P107; KOVELMAN R, 1992, J BIOL CHEM, V267, P24446; Kundu TK, 1999, MOL CELL BIOL, V19, P1605; LAGNA G, 1994, MOL CELL BIOL, V14, P3053, DOI 10.1128/MCB.14.5.3053; LETOILE ND, 1994, P NATL ACAD SCI USA, V91, P1652, DOI 10.1073/pnas.91.5.1652; LOBO SM, 1994, TRANSCRIPTION MECH R, P127; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; Manaud N, 1998, MOL CELL BIOL, V18, P3191, DOI 10.1128/MCB.18.6.3191; MAO JI, 1980, CELL, V21, P509, DOI 10.1016/0092-8674(80)90488-2; MARCK C, 1993, P NATL ACAD SCI USA, V90, P4027, DOI 10.1073/pnas.90.9.4027; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; Moir RD, 1997, MOL CELL BIOL, V17, P7119, DOI 10.1128/MCB.17.12.7119; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NICHOLS M, 1990, METHOD ENZYMOL, V181, P377; Ohi R, 1996, GENE, V174, P315, DOI 10.1016/0378-1119(96)00085-6; PARSONS MC, 1992, J BIOL CHEM, V267, P2894; RAMEAU G, 1994, MOL CELL BIOL, V14, P822, DOI 10.1128/MCB.14.1.822; Rodicker F, 1999, GENE EXPRESSION, V8, P165; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; Shen YH, 1996, MOL CELL BIOL, V16, P4163; SINN E, 1995, GENE DEV, V9, P675, DOI 10.1101/gad.9.6.675; SWANSON RN, 1991, P NATL ACAD SCI USA, V88, P4887, DOI 10.1073/pnas.88.11.4887; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; Wang ZX, 1997, GENE DEV, V11, P1315, DOI 10.1101/gad.11.10.1315; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WILLIS I, 1986, J BIOL CHEM, V261, P5878; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x	54	20	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31480	31487		10.1074/jbc.M004635200	http://dx.doi.org/10.1074/jbc.M004635200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906331	hybrid			2022-12-25	WOS:000089762700102
J	Uchida, T; Ishimori, K; Morishima, I				Uchida, T; Ishimori, K; Morishima, I			Unusual pressure effects on ligand rebinding to the human myoglobin leucine 29 mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLUME PROFILE ANALYSIS; SPERM WHALE MYOGLOBIN; CARBON-MONOXIDE; HYDROSTATIC-PRESSURE; FLASH-PHOTOLYSIS; LASER PHOTOLYSIS; BINDING-DYNAMICS; HEME POCKET; PROTEINS; SPECTRA	Using high pressure flash photolysis, we revealed that the side chain of Leu(29) controls the reaction volume of the ligand migration process in myoglobin, which is the primary factor for the unusual activation volume of ligand binding in some Leu(29) mutants. As we previously reported (Adachi, S., Sunohara, N., Ishimori, K., and Morishima, I. (1992) J. Biol. Chem. 267, 12614-12621), CO bimolecular rebinding in the L29A mutant was unexpectedly decelerated by pressurization, suggesting that the rate-determining step is switched to ligand migration. However, very slow CO bimolecular rebinding of the mutants implies that bond formation is still the rate-determining step. To gain further insights into effects of the side chain on ligand binding, we prepared some new Leu(29) mutants to measure the CO and O-2 rebinding reaction rates under high hydrostatic pressure. CO bimolecular rebinding in the mutants bearing Gly or Ser at position 29 was also decelerated upon pressurization, resulting in apparent positive activation volumes (Delta V-double dagger), as observed for O-2 binding. Based on the three-state model, we concluded that the increased space available to ligands in these mutants enhances the volume difference between the geminate and deoxy states (Delta V-32), which shifts the apparent activation volume to the positive side, and that the apparent positive activation volume is not due to contribution of the ligand migration process to the rate-determining step.	Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan	Kyoto University	Morishima, I (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan.		Ishimori, Koichiro/AAQ-4434-2021; Uchida, Takeshi/A-6455-2017; Ishimori, Koichiro/S-1247-2016	Ishimori, Koichiro/0000-0002-5868-0462; Uchida, Takeshi/0000-0001-9270-8329; Ishimori, Koichiro/0000-0002-5868-0462				ADACHI S, 1992, J BIOL CHEM, V267, P12614; ADACHI S, 1989, J BIOL CHEM, V264, P18896; ALDEN RG, 1989, J BIOL CHEM, V264, P1933; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN, P193; BALNY C, 1989, BIOPHYS CHEM, V33, P237, DOI 10.1016/0301-4622(89)80025-0; CARVER TE, 1990, J BIOL CHEM, V265, P20007; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; FRAUENFELDER H, 1990, J PHYS CHEM-US, V94, P1024, DOI 10.1021/j100366a002; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; GIBSON QH, 1977, J BIOL CHEM, V252, P4098; GROSS M, 1994, EUR J BIOCHEM, V221, P617, DOI 10.1111/j.1432-1033.1994.tb18774.x; HARA K, 1988, REV SCI INSTRUM, V59, P2397, DOI 10.1063/1.1139917; HASINOFF BB, 1974, BIOCHEMISTRY-US, V13, P3111, DOI 10.1021/bi00712a017; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; HEREMANS K, 1982, ANNU REV BIOPHYS BIO, V11, P1, DOI 10.1146/annurev.bb.11.060182.000245; HOA GHB, 1982, EUR J BIOCHEM, V124, P311; HOA GHB, 1989, BIOCHEMISTRY-US, V28, P651; JUNG C, 1995, EUR J BIOCHEM, V233, P600, DOI 10.1111/j.1432-1033.1995.600_2.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LAIRD BB, 1989, J CHEM PHYS, V90, P3274, DOI 10.1063/1.455881; LANGE R, 1994, BIOPHYS J, V66, P89, DOI 10.1016/S0006-3495(94)80772-6; Le Noble W.J., 1967, PROGR PHYS ORGANIC C, V5, P207; NEWMANN RC, 1973, J PHYS CHEM-US, V77, P2687; OGUNMOLA GB, 1977, P NATL ACAD SCI USA, V74, P1, DOI 10.1073/pnas.74.1.1; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; PROJAHN HD, 1991, INORG CHEM, V30, P3288, DOI 10.1021/ic00017a014; PROJAHN HD, 1990, J AM CHEM SOC, V112, P17, DOI 10.1021/ja00157a005; Scott EE, 1997, BIOCHEMISTRY-US, V36, P11909, DOI 10.1021/bi970719s; SLICHTER CP, 1980, PHYS REV B, V22, P4097, DOI 10.1103/PhysRevB.22.4097; TAKANO T, 1977, J MOL BIOL, V110, P537, DOI 10.1016/S0022-2836(77)80111-3; TAUBE DJ, 1990, J AM CHEM SOC, V112, P6880, DOI 10.1021/ja00175a023; Uchida T, 1997, J BIOL CHEM, V272, P30108, DOI 10.1074/jbc.272.48.30108; UNNO M, 1991, BIOCHEMISTRY-US, V30, P10679, DOI 10.1021/bi00108a011; UNNO M, 1990, BIOCHEMISTRY-US, V29, P10199, DOI 10.1021/bi00496a007; UNNO M, 1994, BIOCHEMISTRY-US, V33, P9762, DOI 10.1021/bi00198a047; VANELDIK R, 1989, CHEM REV, V89, P549, DOI 10.1021/cr00093a005; VANELLDIK R, 1986, INORGANIC HIGH PRESS; VARADARAJAN R, 1989, BIOCHEMISTRY-US, V28, P3771, DOI 10.1021/bi00435a022; VARADARAJAN R, 1985, P NATL ACAD SCI USA, V82, P5681, DOI 10.1073/pnas.82.17.5681	42	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30309	30316		10.1074/jbc.M910287199	http://dx.doi.org/10.1074/jbc.M910287199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10906339	hybrid			2022-12-25	WOS:000089577900055
J	Cao, J; Hymowitz, M; Conner, C; Bahou, WF; Zucker, S				Cao, J; Hymowitz, M; Conner, C; Bahou, WF; Zucker, S			The propeptide domain of membrane type 1-matrix metalloproteinase acts as an intramolecular chaperone when expressed in trans with the mature sequence in COS-l cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTASE-PHLORHIZIN HYDROLASE; PRO-GELATINASE-A; MATRIX-METALLOPROTEINASE; PROGELATINASE-A; TISSUE INHIBITOR; TRANSMEMBRANE DOMAIN; CATALYTIC DOMAIN; ACTIVATION; SURFACE; ENZYME	It has been assumed that cleavage of the N-terminal propeptide domain of membrane type-1 matrix metalloproteinase (MT1-MMP) is required for enzyme function, We recently demonstrated that the propeptide domain of MT1-MMP is not cleaved and actually is required for function of the membrane-bound enzyme in transfected COS-1 cells (Cao, J., Drews, M., Lee, H. M., Conner, C., Bahou, W. F., and Zucker, S. (1998) J. Biol. Chem. 273, 34745-34752). In this report, we have inserted the cDNA encoding the signal and propeptide sequences of MT1-MMP (MT(1-109)) and the cDNA encoding propeptide-deleted mature MT1-MMP (MT Delta pro) in expression vectors that were then transfected into matrix metalloproteinase-deficient COS-1 cells. Co-expression of both the mature sequence and the prosequence of MT1-MMP as independent polypeptides (in trans) in COS-1 cells resulted in reconstitution of MT1-MMP function in terms of facilitating (125)I-labeled tissue inhibitor of metalloproteinase 2 binding to transfected cells and subsequent activation of progelatinase A. Transfection of cells with either cDNA alone resulted in non-functional cells, These results are consistent with the propeptide sequence of MT1-MMP functioning as an intramolecular chaperone involved in protein folding and trafficking to the cell surface.	SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; Dept Vet Affairs Med Ctr, Northport, NY 11768 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Zucker, S (corresponding author), Vet Adm Med Ctr, Mail Code 151, Northport, NY 11768 USA.	s_zucker@yahoo.com			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002431] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-49149, HL-02431] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BISWAS C, 1995, CANCER RES, V55, P434; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Cao J, 1998, J BIOL CHEM, V273, P34745, DOI 10.1074/jbc.273.52.34745; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; Imai K, 1996, CANCER RES, V56, P2707; Kinoshita T, 1996, CANCER RES, V56, P2535; Kolkenbrock H, 1997, BIOL CHEM, V378, P71, DOI 10.1515/bchm.1997.378.2.71; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; MACH L, 1994, J BIOL CHEM, V269, P13036; Marie-Claire C, 1999, J MOL BIOL, V285, P1911, DOI 10.1006/jmbi.1998.2449; Nagamune K, 1997, J BIOL CHEM, V272, P1338, DOI 10.1074/jbc.272.2.1338; OBERHOLZER T, 1993, FEBS LETT, V333, P127, DOI 10.1016/0014-5793(93)80389-C; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shinde U, 1996, ADV EXP MED BIOL, V379, P147; Sohl JL, 1998, NATURE, V395, P817, DOI 10.1038/27470; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, GENE, V155, P293, DOI 10.1016/0378-1119(94)00637-8; Tsukuba T, 1998, J BIOL CHEM, V273, P35260, DOI 10.1074/jbc.273.52.35260; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Wuthrich M, 1997, FEBS LETT, V405, P321, DOI 10.1016/S0014-5793(97)00206-8; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	30	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29648	29653		10.1074/jbc.M001920200	http://dx.doi.org/10.1074/jbc.M001920200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10889191	hybrid			2022-12-25	WOS:000089439800064
J	Kawano, K; Qin, SC; Lin, M; Tall, AR; Jiang, XC				Kawano, K; Qin, SC; Lin, M; Tall, AR; Jiang, XC			Cholesteryl ester transfer protein and phospholipid transfer protein have nonoverlapping functions in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; BINDING CASSETTE TRANSPORTER-1; TRANSGENIC MICE; TANGIER-DISEASE; PLASMA-LIPOPROTEINS; EXCHANGE PROTEIN; APOLIPOPROTEIN-E; KNOCKOUT MICE; GENE; MUTATIONS	Plasma phospholipid transfer protein (PLTP) and cholesteryl ester transfer protein (CETP) are homologous molecules that mediate neutral lipid and phospholipid exchange between plasma lipoproteins, Biochemical experiments suggest that only CETP can transfer neutral lipids but that there could be overlap in the ability of PLTP and CETP to transfer or exchange phospholipids. Recently developed PLTP gene knock-out (PLTP0) mice have complete deficiency of plasma phospholipid transfer activity and markedly reduced high density lipoprotein (HDL) levels. To see whether CETP can compensate for PLTP deficiency in vivo, we bred the CETP transgene (CETPTg) into the PLTP0 background. Using an in vivo assay to measure the transfer of [H-3]PC from VLDL into HDL or an in vitro assay that determined [H-3]PC transfer from vesicles into HDL, we could detect no phospholipid transfer activity in either PLTP0 or CETPTg/PLTP0 mice. On a chow diet, HDL-PL, HDL-CE, and HDL-apolipoprotein Al in CETPTg/PLTP0 mice were significantly lower than in PLTP0 mice (45 +/- 7 versus 79 +/- 9 mg/dl; 9 +/- 2 versus 16 +/- 5 mg/dl; and 51 +/- 6 versus 100 +/- 9, arbitrary units, respectively). Similar results were obtained on a high fat, high cholesterol diet. These results indicate 1) that there is no redundancy in function of PLTP and CETP in vivo and 2) that the combination of the CETP transgene with PLTP deficiency results in an additive lowering of HDL levels, suggesting that the phenotype of a human PLTP deficiency state would include reduced HDL levels.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA	Columbia University	Jiang, XC (corresponding author), Columbia Univ, Dept Med, Div Mol Med, 630 W 168th St, New York, NY 10032 USA.		Tall, Alan/AAT-8528-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGELLON LB, 1991, J BIOL CHEM, V266, P10796; Beamer LJ, 1997, SCIENCE, V276, P1861, DOI 10.1126/science.276.5320.1861; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BRESLOW JL, 1989, METABOLIC BASIS INHE, P1251; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BROWN ML, 1989, NATURE, V342, P448, DOI 10.1038/342448a0; Brown ML, 1990, CURR OPIN LIPIDOL, V1, P122; Bruce C, 1998, CURR OPIN STRUC BIOL, V8, P426, DOI 10.1016/S0959-440X(98)80118-8; DAY JR, 1994, J BIOL CHEM, V269, P9388; FRANCONE OL, 1995, J CLIN INVEST, V96, P1440, DOI 10.1172/JCI118180; HAYEK T, 1993, J CLIN INVEST, V92, P1143, DOI 10.1172/JCI116683; HAYEK T, 1992, J CLIN INVEST, V90, P505, DOI 10.1172/JCI115887; HESLER CB, 1987, J BIOL CHEM, V262, P2275; Huuskonen J, 1999, J LIPID RES, V40, P1123; INAZU A, 1994, J CLIN INVEST, V94, P1872, DOI 10.1172/JCI117537; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; Jeong TS, 1998, J CLIN INVEST, V101, P905, DOI 10.1172/JCI870; JIANG XC, 1993, J BIOL CHEM, V268, P27406; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 1996, J CLIN INVEST, V98, P2373, DOI 10.1172/JCI119050; LAGROST L, 1994, J LIPID RES, V35, P825; Lusa S, 1996, BIOCHEM J, V313, P275, DOI 10.1042/bj3130275; MasucciMagoulas L, 1996, J CLIN INVEST, V97, P154, DOI 10.1172/JCI118384; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; MORTON RE, 1983, J BIOL CHEM, V258, P1751; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; Qin SC, 2000, J LIPID RES, V41, P269; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SWENSON TL, 1987, J BIOL CHEM, V262, P16271; TALL AR, 1983, J BIOL CHEM, V258, P2174; TALL AR, 1985, J LIPID RES, V26, P842; WANG S, 1992, J BIOL CHEM, V267, P17487; Wittrup HH, 1999, CIRCULATION, V99, P2901, DOI 10.1161/01.CIR.99.22.2901; Yu B, 1997, J CLIN INVEST, V99, P315, DOI 10.1172/JCI119160	35	49	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29477	29481		10.1074/jbc.M003523200	http://dx.doi.org/10.1074/jbc.M003523200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893412	hybrid			2022-12-25	WOS:000089439800041
J	Jewell-Motz, EA; Small, KM; Theiss, CT; Liggett, SB				Jewell-Motz, EA; Small, KM; Theiss, CT; Liggett, SB			alpha(2A)/alpha(2C)-adrenergic receptor third loop chimera show that agonist interaction with receptor subtype backbone establishes G protein-coupled receptor kinase phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3RD INTRACELLULAR LOOP; PROMOTED DESENSITIZATION; ALPHA-2-ADRENERGIC RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; SITES; ALPHA-2C10; MECHANISMS; CELLS; G(S)	alpha(2A)-adrenergic receptor (AR) undergoes rapid agonist-promoted desensitization due to phosphorylation by G protein-coupled receptor kinases (GRKs) 2 and 3 at serines in the third intracellular loop of the receptor. In contrast, the alpha(2C)AR fails to display such desensitization or phosphorylation, which has been. presumed to be due to this receptor lacking GRK phosphorylation sites. However, the alpha(2C)AR has multiple serines and threonines in putative favorable motifs within its third intracellular loop. We considered that the conformation of the third intracellular loop imposed by agonists binding to the transmembrane-spanning domains could be the basis of this subtype-specific property, rather than the presence or absence of phosphoacceptors per se. To address this, alpha(2A)/alpha(2C) third loop chimeric receptors were constructed. In whole cell phosphorylation studies, the alpha(2A) with the alpha(2C) third loop receptor underwent agonist-promoted phosphorylation while the alpha(2C) with the alpha(2A) third loop receptor did not, indicating that the agonist interaction with the parent receptor backbone establishes the phosphorylation phenotype. We postulated then that agonists with diverse structures that distinctly interact with alpha(2)AR should display different degrees of phosphorylation independent of receptor activation. Indeed, several full and partial agonists were identified, which evoked phosphorylation that was not related to intrinsic activity as established by [S-35]guanosine 5'-3-O-(thio)triphosphate binding. Taken together, it appears that phosphorylation of the alpha(2)AR evoked by agonist is highly sensitive to the conformation of the third intracellular loop induced/stabilized by agonist to such an extent that these properties dictate the extent of phosphorylation of the loop when phosphoacceptors are present, and are the basis for subtype-specific phosphorylation.	Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Liggett, SB (corresponding author), Univ Cincinnati, Coll Med, Dept Med, 231 Bethesda Ave,Rm 7507, Cincinnati, OH 45267 USA.	stephen.liggett@uc.edu	liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	NHLBI NIH HHS [HL41496] Funding Source: Medline; NIEHS NIH HHS [ES06096] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BENOVIC JL, 1988, J BIOL CHEM, V263, P3893; Bristow MR, 1998, LANCET, V352, P8; EASON MG, 1992, J BIOL CHEM, V267, P15795; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; EASON MG, 1994, MOL PHARMACOL, V45, P696; EASON MG, 1992, J BIOL CHEM, V267, P25473; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; JewellMotz EA, 1996, J BIOL CHEM, V271, P18082, DOI 10.1074/jbc.271.30.18082; Kukkonen JP, 1998, J PHARMACOL EXP THER, V287, P667; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUROSE H, 1994, J BIOL CHEM, V269, P10093; Liggett S B, 1998, Adv Pharmacol, V42, P438; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; Liggett SB, 1993, REGULATION CELLULAR, P71; Lohse MJ, 1996, BASIC RES CARDIOL, V91, P29, DOI 10.1007/BF00795359; McGraw DW, 1998, CELL SIGNAL, V10, P197, DOI 10.1016/S0898-6568(97)00112-5; METZGER H, 1991, CLIN EXP ALLERGY, V21, P269, DOI 10.1111/j.1365-2222.1991.tb01658.x; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Small KM, 2000, J BIOL CHEM, V275, P23059, DOI 10.1074/jbc.M000796200; VON ZM, 1993, J BIOL CHEM, V268, P763	23	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28989	28993		10.1074/jbc.M005381200	http://dx.doi.org/10.1074/jbc.M005381200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893245	hybrid			2022-12-25	WOS:000089330700085
J	Komori, K; Miyata, T; Daiyasu, H; Toh, H; Shinagawa, H; Ishino, Y				Komori, K; Miyata, T; Daiyasu, H; Toh, H; Shinagawa, H; Ishino, Y			Domain analysis of an archaeal RadA protein for the strand exchange activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECA PROTEIN; HOMOLOGOUS RECOMBINATION; HYPERTHERMOPHILIC ARCHAEON; SYNAPTONEMAL COMPLEXES; PYROCOCCUS-FURIOSUS; ESCHERICHIA-COLI; TERMINAL DOMAIN; DNA-BINDING; REPAIR; BRCA2	Archaeal RadA, like eukaryotic Rad51 and bacterial Reck promotes strand exchange between DNA strands with homologous sequences in vitro and is believed to participate in the homologous recombination in cells. The amino acid sequences of the archaeal RadA proteins are more similar to the eukaryotic Rad51s rather than the bacterial Reck, and the N-terminal region containing domain I is conserved among the RadA and Rad51 proteins but is absent from Reck To understand the structure-function relationship of RadA, we divided the RadA protein from Pyrococcus furiosus into two parts, the N-terminal one-third (RadA-n) and the residual C-terminal two-thirds (RadA-c), the latter of which contains the central core domain (domain II) of the RecA/Rad51 family proteins, RadA-c had the DNA-dependent ATPase activity and the strand exchange activity by itself, although much weaker (10%) than that of the intact RadA. These activities of RadA-c were restored to 60% of those of RadA by addition of RadA-n, indicating that the proper active structure of RadA was reconstituted in vitro. These results suggest that the basic activities of the RecA/Rad51 family proteins for homologous recombination are derived from domain II, and the N-terminal region may help to enhance the catalytic efficiencies.	Biomol Engn Res Inst, Dept Mol Biol, Suita, Osaka 5650874, Japan; Biomol Engn Res Inst, Dept Biol Struct, Suita, Osaka 5650874, Japan; Biomol Engn Res Inst, Dept Bioinformat, Suita, Osaka 5650874, Japan; Osaka Univ, Res Inst Microbial Dis, Dept Mol Microbiol, Suita, Osaka 5650871, Japan	Osaka University	Ishino, Y (corresponding author), Biomol Engn Res Inst, Dept Mol Biol, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.	ishino@beri.co.jp		Ishino, Yoshizumi/0000-0001-9419-0826				ADACHI J, 1996, MOLPHY VERSION 2 3B3; Aihara H, 1999, J MOL BIOL, V290, P495, DOI 10.1006/jmbi.1999.2904; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; DiRuggiero J, 1999, J MOL EVOL, V49, P474, DOI 10.1007/PL00006570; DiRuggiero J, 1997, J BACTERIOL, V179, P4643, DOI 10.1128/jb.179.14.4643-4645.1997; DONOVAN JW, 1994, GENE DEV, V8, P2552, DOI 10.1101/gad.8.21.2552; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FELSENSTEIN J, 1993, PHYLIP VERSION 3 5C; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; Katagiri T, 1998, GENE CHROMOSOME CANC, V21, P217, DOI 10.1002/(SICI)1098-2264(199803)21:3<217::AID-GCC5>3.0.CO;2-2; Kil YV, 2000, J BACTERIOL, V182, P130, DOI 10.1128/JB.182.1.130-134.2000; Komori K, 2000, J BIOL CHEM, V275, P33791, DOI 10.1074/jbc.M004556200; Kovalenko OV, 1997, NUCLEIC ACIDS RES, V25, P4946, DOI 10.1093/nar/25.24.4946; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kurumizaka H, 1996, J BIOL CHEM, V271, P33515, DOI 10.1074/jbc.271.52.33515; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; MORIMATSU K, 1995, EUR J BIOCHEM, V228, P779, DOI 10.1111/j.1432-1033.1995.0779m.x; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sandler SJ, 1999, J BACTERIOL, V181, P907, DOI 10.1128/JB.181.3.907-915.1999; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Seitz EM, 1998, GENE DEV, V12, P1248, DOI 10.1101/gad.12.9.1248; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SPIES M, EUR J BIOCH, V267, P1125; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Tarsounas M, 1999, J CELL BIOL, V147, P207, DOI 10.1083/jcb.147.2.207; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uemori T, 1997, GENES CELLS, V2, P499, DOI 10.1046/j.1365-2443.1997.1380336.x; Voloshin ON, 1996, SCIENCE, V272, P868, DOI 10.1126/science.272.5263.868; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Woods WG, 1997, MOL MICROBIOL, V23, P791, DOI 10.1046/j.1365-2958.1997.2651626.x	45	85	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33791	33797		10.1074/jbc.M004556200	http://dx.doi.org/10.1074/jbc.M004556200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10887195	hybrid			2022-12-25	WOS:000090104600085
J	Muehlenweg, B; Assfalg-Machleidt, I; Parrado, SG; Burgle, M; Creutzburg, S; Schmitt, M; Auerswald, EA; Machleidt, W; Magdolen, V				Muehlenweg, B; Assfalg-Machleidt, I; Parrado, SG; Burgle, M; Creutzburg, S; Schmitt, M; Auerswald, EA; Machleidt, W; Magdolen, V			A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction - Cystatin with a urokinase receptor binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-CELL INVASION; EGG-WHITE CYSTATIN; CATHEPSIN-B; CHICKEN CYSTATIN; PROTEASE INHIBITORS; TERMINAL FRAGMENT; ESCHERICHIA-COLI; METASTASIS; EXPRESSION; PROGRESSION	Cancer invasion and metastasis is a process requiring a coordinated series of (anti-)adhesive, migratory, and pericellular proteolytic events involving various proteases such as urokinase-type plasminogen activator (uPA)/plasmin, cathepsins B and L, and matrix metalloproteases. Novel types of double-headed inhibitors directed to different tumor-associated proteolytic systems were generated by substitution of a loop in chicken cystatin, which is nonessential for cysteine protease inhibition, with uPA-derived peptides covering the human uPA receptor binding sequence uPA-(19-31), The inhibition constants of these hybrids toward cysteine proteases are similar to those of wild-type cystatin (K-i, papain (pm), 1.9-2.4; K-i, cathepsin B (nM), 1.0-1.7; K-i, cathepsin L (par), 0.12-0.61). FAGS analyses revealed that the hybrids compete for binding of uPA to the cell surface-associated uPA receptor (uPAR) expressed on human U937 cells. The simultaneous interaction of the hybrid molecules with papain and uPAR was analyzed by surface plasmon resonance. The measured K-D value of a papain-bound cystatin variant harboring the uPAR binding sequence of uPA (chCys-uPA-(19-31)) and soluble uPAR was 17 nM (K-D value for uPA/uPAR interaction, 5 nM). These results indicate that cystatins with a uPAR binding site are efficient inhibitors of cysteine proteases and uPA/uPAR interaction at the same time. Therefore, these compact and small bifunctional inhibitors may represent promising agents for the therapy of solid tumors.	Tech Univ Munich, Frauenklin, Klin Forschergrp, D-81675 Munich, Germany; Wilex Biotechnol, D-81675 Munich, Germany; Univ Munich, Chirurg Klin Innenstadt, Abt Klin Chem & Klin Biochem, D-80336 Munich, Germany; Univ Munich, Chirurg Klin Innenstadt, Adolf Butenandt Inst Physiol Chem Phys Biochem &, D-80336 Munich, Germany	Technical University of Munich; University of Munich; University of Munich	Muehlenweg, B (corresponding author), Tech Univ Munich, Frauenklin, Klin Forschergrp, Ismaninger Str 22, D-81675 Munich, Germany.							Alvarez-Fernandez M, 1999, J BIOL CHEM, V274, P19195, DOI 10.1074/jbc.274.27.19195; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; AUERSWALD EA, 1994, EUR J BIOCHEM, V224, P407, DOI 10.1111/j.1432-1033.1994.00407.x; Auerswald EA, 1996, EUR J BIOCHEM, V235, P534, DOI 10.1111/j.1432-1033.1996.00534.x; AUERSWALD EA, 1992, EUR J BIOCHEM, V209, P837, DOI 10.1111/j.1432-1033.1992.tb17355.x; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BOKMAN AM, 1993, J BIOL CHEM, V268, P13858; Burgle M, 1997, BIOL CHEM, V378, P231, DOI 10.1515/bchm.1997.378.3-4.231; Coulibaly S, 1999, INT J CANCER, V83, P526, DOI 10.1002/(SICI)1097-0215(19991112)83:4<526::AID-IJC15>3.3.CO;2-D; Cox JL, 1999, MELANOMA RES, V9, P369, DOI 10.1097/00008390-199908000-00005; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DeClerck YA, 1997, ADV EXP MED BIOL, V425, P89; ENGH RA, 1993, J MOL BIOL, V234, P1060, DOI 10.1006/jmbi.1993.1659; Foekens JA, 2000, CANCER RES, V60, P636; Frosch BA, 1999, APMIS, V107, P28, DOI 10.1111/j.1699-0463.1999.tb01523.x; Grasberger H, 1999, J BIOL CHEM, V274, P15046, DOI 10.1074/jbc.274.21.15046; Harbeck N, 2000, INT J BIOL MARKER, V15, P79, DOI 10.1177/172460080001500115; Kobayashi H, 1998, EUR J BIOCHEM, V253, P817, DOI 10.1046/j.1432-1327.1998.2530817.x; Kolkhorst V, 1998, J CANCER RES CLIN, V124, P598, DOI 10.1007/s004320050221; Kruger A, 2000, CANCER GENE THER, V7, P292, DOI 10.1038/sj.cgt.7700144; LU H, 1994, FEBS LETT, V356, P56, DOI 10.1016/0014-5793(94)01237-7; MACHLEIDT W, 1995, FEBS LETT, V361, P185, DOI 10.1016/0014-5793(95)00174-8; MACHLEIDT W, 1993, MONOGRAPHS INNOVATIO, P179; MAGDOLEN V, 1995, ELECTROPHORESIS, V16, P813, DOI 10.1002/elps.11501601134; McCarthy BJ, 1997, J MOL BIOL, V267, P561, DOI 10.1006/jmbi.1996.0909; Min HY, 1996, CANCER RES, V56, P2428; Monahan PE, 2000, GENE THER, V7, P24, DOI 10.1038/sj.gt.3301109; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PADMANABHAN J, 1995, THROMB HAEMOSTASIS, V73, P829; Reuning U, 1998, INT J ONCOL, V13, P893; Schmitt M, 2000, FIBRINOLYSIS PROTEOL, V14, P114, DOI 10.1054/fipr.2000.0079; STRAUSS M, 1988, BIOL CHEM H-S, V369, P209; Thomssen C, 1995, CLIN CANCER RES, V1, P741; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Yan SQ, 1998, BIOL CHEM, V379, P113	36	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33562	33566		10.1074/jbc.C000383200	http://dx.doi.org/10.1074/jbc.C000383200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10913110	hybrid			2022-12-25	WOS:000090104600055
J	Spitaler, M; Villunger, A; Grunicke, H; Uberall, F				Spitaler, M; Villunger, A; Grunicke, H; Uberall, F			Unique structural and functional properties of the ATP-binding domain of atypical protein kinase C-iota	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROLYZING PHOSPHOLIPASE-C; DRUG-INDUCED APOPTOSIS; TYROSINE KINASE; CRYSTAL-STRUCTURE; INSULIN-RECEPTOR; IN-VIVO; CAENORHABDITIS-ELEGANS; EPITHELIAL-CELLS; DOWN-REGULATION; PKC-EPSILON	Atypical protein kinase C-iota (aPKC iota) plays an important role in mitogenic signaling, actin cytoskeleton organization, and cell survival. Apart from the differences in the regulatory domain, the catalytic domain of aPKC iota differs considerably from other known kinases, because it contains a modification within the glycine-rich loop motif (GXGXXG) that is found in the nucleotide-binding fold of virtually all nucleotide-binding proteins including PI(Cs, Ras, adenylate kinase, and the mitochondrial F1-ATPase, We have used site-directed mutagenesis and kinetic analysis to investigate whether these sequence differences affect the nucleotide binding properties and catalytic activity of aPKC iota. When lysine 274, a residue essential for ATP binding and activity conserved in most protein kinases, was replaced by arginine (K274R mutant), aPKC iota retained its normal kinase activity. This is in sharp contrast to results published for any other PKC or even distantly related kinases like phosphoinositide S-kinase gamma, where the same mutation completely abrogated the kinase activity. Furthermore, the sensitivity of aPKC iota for inhibition by GF109203X, a substance acting on the ATP-binding site, was not altered in the K274R mutant. In contrast, replacement of Lys-274 by tryptophan (K274W) completely abolished the kinase activity of PKC iota, In accordance with results obtained with other kinase-defective PKC mutants, in cultured cells aPKC iota -R274W acted in a dominant negative fashion on signal transduction pathways involving endogenous aPKC iota, whereas the effect of the catalytically active K274R mutant was identical to the wild type enzyme. In summary, aPKC iota differs from classical and novel PKCs also in the catalytic domain. This information could be of significant value for the development of specific inhibitors of aPKC iota as a key factor in central signaling pathways.	Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria	University of Innsbruck	Spitaler, M (corresponding author), Univ Innsbruck, Inst Med Chem & Biochem, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	martin.spitaler@uibk.ac.at		Spitaler, Martin/0000-0002-8833-638X				AHMAD S, 1993, MOL PHARMACOL, V43, P858; Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Bandyopadhyay G, 1999, BIOCHEM J, V337, P461, DOI 10.1042/0264-6021:3370461; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Bjorkoy G, 1997, J BIOL CHEM, V272, P11557; BJORKOY G, 1995, J BIOL CHEM, V270, P21299; Chan CL, 1996, J BIOL CHEM, V271, P22619, DOI 10.1074/jbc.271.37.22619; CHIN JE, 1993, J BIOL CHEM, V268, P6338; CHOU CK, 1987, J BIOL CHEM, V262, P1842; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Enke DA, 1999, J BIOL CHEM, V274, P1949, DOI 10.1074/jbc.274.4.1949; Gatti A, 1996, J BIOL CHEM, V271, P31718, DOI 10.1074/jbc.271.49.31718; Ghaffari-Tabrizi N, 1999, EUR J IMMUNOL, V29, P132; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GRAVITT KR, 1994, BIOCHEM PHARMACOL, V48, P375, DOI 10.1016/0006-2952(94)90110-4; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Kampfer S, 1998, EMBO J, V17, P4046, DOI 10.1093/emboj/17.14.4046; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Masso-Welch PA, 1998, EUR J CELL BIOL, V77, P48, DOI 10.1016/S0171-9335(98)80101-5; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; ORR JW, 1994, J BIOL CHEM, V269, P27715; Perletti GP, 1996, ONCOGENE, V12, P847; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; SchmitzPeiffer C, 1997, DIABETES, V46, P169, DOI 10.2337/diabetes.46.2.169; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Stoyanova S, 1997, BIOCHEM J, V324, P489, DOI 10.1042/bj3240489; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TONG L, 1989, NATURE, V337, P90, DOI 10.1038/337090a0; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; Uberall F, 1997, J BIOL CHEM, V272, P4072, DOI 10.1074/jbc.272.7.4072; WEINMASTER G, 1986, EMBO J, V5, P69, DOI 10.1002/j.1460-2075.1986.tb04179.x; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; ZHAO L, 1994, ENDOCRINOLOGY, V135, P2504, DOI 10.1210/en.135.6.2504; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	53	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33289	33296		10.1074/jbc.M002742200	http://dx.doi.org/10.1074/jbc.M002742200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10906326	hybrid			2022-12-25	WOS:000090104600018
J	Gardner, PR; Gardner, AM; Martin, LA; Dou, Y; Li, TS; Olson, JS; Zhu, H; Riggs, AF				Gardner, PR; Gardner, AM; Martin, LA; Dou, Y; Li, TS; Olson, JS; Zhu, H; Riggs, AF			Nitric-oxide dioxygenase activity and function of flavohemoglobins - Sensitivity to nitric oxide and carbon monoxide inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-BINDING HEMOGLOBIN; COLI FLAVOHAEMOGLOBIN HMP; ESCHERICHIA-COLI; ALCALIGENES-EUTROPHUS; OXIDATIVE STRESS; GENE-EXPRESSION; MYCOBACTERIUM-TUBERCULOSIS; SUPEROXIDE-DISMUTASE; YEAST HEMOGLOBIN; IN-VITRO	Widely distributed flavohemoglobins (flavoHbs) function as NO dioxygenases and confer upon cells a resistance to NO toxicity. FlavoHbs from Saccharomyces cerevisiae, Alcaligenes eutrophus, and Escherichia coli share similar spectra, O-2, NO, and CO binding kinetics, and steady-state NO dioxygenation kinetics. Turnover numbers (V-max) for S. cerevisiae, A. eutrophus, and E. coli flavoHbs are 112, 290, and 365 NO heme(-1) s(-1), respectively, at 37 degrees C with 200 mu M O-2. The K-M values for NO are low and range from 0.1 to 0.25 mu M. V-max/K-M(NO) ratios of 900-2900 mu M-1 s(-1) indicate an extremely efficient dioxygenation mechanism. Approximate K-M values for O-2 range from 60 to 90 mu M. NO inhibits the dioxygenases at NO:O-2 ratios of greater than or equal to 1:100 and makes true K-M(O-2) values difficult to determine, High and roughly equal second order rate constants for O-2 and NO association with the reduced flavoHbs (17-50 mu M-1 s(-1)) and small NO dissociation rate constants suggest that NO inhibits the dioxygenase reaction by forming inactive flavoHbNO complexes. Carbon monoxide also binds reduced flavoHbs with high affinity and competitively inhibits NO dioxygenases with respect to O-2 (K-I(CO) = similar to 1 mu M). These results suggest that flavoHbs and related hemoglobins evolved as NO detoxifying components of nitrogen metabolism capable of discriminating O-2 from inhibitory NO and CO.	Childrens Hosp, Med Ctr, Div Crit Care Med, Cincinnati, OH 45229 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, WM Keck Ctr Computat Biol, Houston, TX 77005 USA; Univ Texas, Sch Biol Sci, Neurobiol Sect, Austin, TX 78712 USA	Cincinnati Children's Hospital Medical Center; Rice University; Rice University; University of Texas System; University of Texas Austin	Gardner, PR (corresponding author), Childrens Hosp, Med Ctr, Div Crit Care Med, Cincinnati, OH 45229 USA.			Gardner, Anne/0000-0001-7095-772X; Gardner, Paul/0000-0001-8189-0903; Olson, John/0000-0002-0760-5403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035847, R01GM035649] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47020] Funding Source: Medline; NIGMS NIH HHS [GM35847, GM35649] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Appleby C A, 1978, Methods Enzymol, V52, P157; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPPELL JB, 1964, BIOCHEM J, V90, P225, DOI 10.1042/bj0900225; Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223; Cramm R, 1997, J BACTERIOL, V179, P6769, DOI 10.1128/jb.179.21.6769-6777.1997; CRAMM R, 1994, J BIOL CHEM, V269, P7349; Crawford MJ, 1998, J BIOL CHEM, V273, P12543, DOI 10.1074/jbc.273.20.12543; Crawford MJ, 1998, J BIOL CHEM, V273, P34028, DOI 10.1074/jbc.273.51.34028; CRAWFORD MJ, 1995, J BIOL CHEM, V270, P6991, DOI 10.1074/jbc.270.12.6991; CZAPSKI G, 1995, FREE RADICAL BIO MED, V19, P785, DOI 10.1016/0891-5849(95)00081-8; DICKERSON RE, 1969, STRUCTURE ACTION PRO, P44; DIKSHIT RP, 1992, ARCH BIOCHEM BIOPHYS, V293, P241, DOI 10.1016/0003-9861(92)90391-9; Doyle M P, 1985, J Free Radic Biol Med, V1, P145, DOI 10.1016/0748-5514(85)90019-4; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; Ermler U, 1995, EMBO J, V14, P6067, DOI 10.1002/j.1460-2075.1995.tb00297.x; ESCHENBRENNER M, 1994, BIOCHEM BIOPH RES CO, V198, P127, DOI 10.1006/bbrc.1994.1018; FAVEY S, 1995, MICROBIOL-UK, V141, P863, DOI 10.1099/13500872-141-4-863; Gardner AM, 2000, J BIOL CHEM, V275, P12581, DOI 10.1074/jbc.275.17.12581; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; GARDNER PR, 1993, J BIOL CHEM, V268, P12958; Gardner PR, 1997, J BIOL CHEM, V272, P25071, DOI 10.1074/jbc.272.40.25071; Gardner PR, 1998, J BIOL CHEM, V273, P26528, DOI 10.1074/jbc.273.41.26528; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hardison R, 1999, AM SCI, V87, P126, DOI 10.1511/1999.20.809; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Horvath I, 1998, THORAX, V53, P668, DOI 10.1136/thx.53.8.668; Hu YM, 1999, J BACTERIOL, V181, P3486, DOI 10.1128/JB.181.11.3486-3493.1999; Iijima M, 2000, CELL STRUCT FUNCT, V25, P47, DOI 10.1247/csf.25.47; IOANNIDIS N, 1992, BIOCHEM J, V288, P649, DOI 10.1042/bj2880649; IWAASA H, 1992, J MOL BIOL, V227, P948, DOI 10.1016/0022-2836(92)90236-D; KEELE BB, 1970, J BIOL CHEM, V245, P6176; KEILIN D, 1955, BIOCHEM J, V60, P310, DOI 10.1042/bj0600310; KEILIN D, 1953, NATURE, V172, P390, DOI 10.1038/172390a0; Kim SO, 1999, FEBS LETT, V445, P389, DOI 10.1016/S0014-5793(99)00157-X; Kurata S, 1996, J BIOCHEM-TOKYO, V120, P49; Labesse G, 1998, EUR J BIOCHEM, V253, P751, DOI 10.1046/j.1432-1327.1998.2530751.x; LaCelle M, 1996, J BACTERIOL, V178, P3803, DOI 10.1128/jb.178.13.3803-3808.1996; Lebioda L, 1999, NATURE, V401, P445, DOI 10.1038/46728; Liu LM, 2000, P NATL ACAD SCI USA, V97, P4672, DOI 10.1073/pnas.090083597; MCCARTER LL, 1994, J BACTERIOL, V176, P5988, DOI 10.1128/jb.176.19.5988-5998.1994; Membrillo-Hernandez J, 1997, FEMS MICROBIOL LETT, V155, P179, DOI 10.1111/j.1574-6968.1997.tb13875.x; Membrillo-Hernandez J, 1999, J BIOL CHEM, V274, P748, DOI 10.1074/jbc.274.2.748; MembrilloHernandez J, 1996, FEBS LETT, V382, P141, DOI 10.1016/0014-5793(96)00154-8; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; ORII Y, 1992, BIOCHEM BIOPH RES CO, V187, P94, DOI 10.1016/S0006-291X(05)81463-9; OSHINO R, 1973, EUR J BIOCHEM, V39, P581, DOI 10.1111/j.1432-1033.1973.tb03157.x; PERUTZ MF, 1979, ANNU REV BIOCHEM, V48, P327, DOI 10.1146/annurev.bi.48.070179.001551; Poole RK, 1996, J BACTERIOL, V178, P5487, DOI 10.1128/jb.178.18.5487-5492.1996; POOLE RK, 1994, P ROY SOC B-BIOL SCI, V255, P251, DOI 10.1098/rspb.1994.0036; POOLE RK, 1994, ANTON LEEUW INT J G, V65, P289, DOI 10.1007/BF00872215; PROBST I, 1979, BIOCHIM BIOPHYS ACTA, V576, P471, DOI 10.1016/0005-2795(79)90422-7; PRYOR WA, 1995, AM J PHYSIOL, V268, P699; RIGGS AF, 1991, AM ZOOL, V31, P535; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; Ross J., 1982, PYRIDINE NUCLEOTIDE, P19; Takaya N, 1997, FEBS LETT, V414, P545, DOI 10.1016/S0014-5793(97)01069-7; Wan LL, 1998, P NATL ACAD SCI USA, V95, P12825, DOI 10.1073/pnas.95.22.12825; WITTENBERG JB, 1990, ANNU REV BIOPHYS BIO, V19, P217; WU H, 1923, J BIOCHEM-TOKYO, V2, P189; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015	62	125	129	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31581	31587		10.1074/jbc.M004141200	http://dx.doi.org/10.1074/jbc.M004141200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10922365	hybrid			2022-12-25	WOS:000089858900006
J	Okano, J; Gaslightwala, I; Birnbaum, MJ; Rustgi, AK; Nakagawa, H				Okano, J; Gaslightwala, I; Birnbaum, MJ; Rustgi, AK; Nakagawa, H			Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; SERINE-THREONINE KINASE; HUMAN PANCREATIC-CANCER; NF-KAPPA-B; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; FACTOR RECEPTOR; ESOPHAGEAL-CARCINOMA; TRANSCRIPTION FACTOR; MOLECULAR-CLONING	Overexpression of epidermal growth factor receptor (EGFR) in certain cancers is well established. There is growing evidence that epidermal growth factor (EGF) activates Akt/protein kinase B (PKB) in a phosphoinositide 3-OH kinase (PI3K)-dependent manner, but it is not yet clear which Akt isoforms are involved in this signal transduction pathway. We investigated the functional regulation of three Akt isoforms, Akt1/PKB alpha, Akt2/PKB beta, and Akt3/PKB gamma, in esophageal cancer cells where EGFR is frequently overexpressed. Upon EGF simulation, phosphorylation of Akt1 at the Ser-473 residue was remarkably induced. This result was corroborated by in vitro Akt kinase assays using glycogen synthase kinase 3 beta as the substrate. PI3K inhibitors, wortmannin or LY294002, significantly blocked the Akt kinase activity induced by EGF. Akt2 activity was evaluated by electrophoretic mobility shift assays. Robust activation of Akt2 by EGF was observed in some cell lines in a PI3K-dependent manner. EGF-induced Akt3 activation was demonstrated by Ser-472 phosphorylation of Akt3 but in a restrictive fashion. In aggregate, EGF-mediated activation of Akt isoforms is overlapping and distinctive. The mechanism by which EGFR recruits the PI3K/Akt pathway was in part differentially regulated at the level of Ras but independent of heterodimerization of EGFR with either ErbB2 or ErbB3 based upon functional dissection of pathways in esophageal cancer cell lines.	Univ Penn, Div Gastroenterol, Philadelphia, PA 19104 USA; Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Rustgi, AK (corresponding author), Univ Penn, Div Gastroenterol, 600A CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.			Birnbaum, Morris/0000-0001-9972-8680	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053377] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53377] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Filippa N, 1999, MOL CELL BIOL, V19, P4989; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Friess H, 1999, WORLD J SURG, V23, P1010, DOI 10.1007/s002689900616; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Hardwick RH, 1997, EUR J SURG ONCOL, V23, P30, DOI 10.1016/S0748-7983(97)80139-4; Hayashi K, 1999, J CELL BIOL, V145, P727, DOI 10.1083/jcb.145.4.727; Huang GC, 1998, BIOCHEM J, V331, P113, DOI 10.1042/bj3310113; IIHARA K, 1993, CANCER, V71, P2902, DOI 10.1002/1097-0142(19930515)71:10<2902::AID-CNCR2820711004>3.0.CO;2-J; Islam M, 2000, EXP EYE RES, V70, P261, DOI 10.1006/exer.1999.0783; ITAKURA Y, 1994, CANCER, V74, P795, DOI 10.1002/1097-0142(19940801)74:3<795::AID-CNCR2820740303>3.0.CO;2-I; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; KIM HH, 1994, J BIOL CHEM, V269, P24747; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Konishi H, 1999, J BIOCHEM-TOKYO, V126, P1136, DOI 10.1093/oxfordjournals.jbchem.a022559; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lam KY, 1998, EUR J SURG ONCOL, V24, P431, DOI 10.1016/S0748-7983(98)92403-9; Lin JQ, 1999, CANCER RES, V59, P2891; Liu AX, 1998, CANCER RES, V58, P2973; Masure S, 1999, EUR J BIOCHEM, V265, P353, DOI 10.1046/j.1432-1327.1999.00774.x; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; Morimoto AM, 2000, ONCOGENE, V19, P200, DOI 10.1038/sj.onc.1203288; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; NAKAGAWA H, 1995, CANCER-AM CANCER SOC, V76, P541, DOI 10.1002/1097-0142(19950815)76:4<541::AID-CNCR2820760402>3.0.CO;2-I; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Ozes ON, 1999, NATURE, V401, P82; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sabbatini P, 1999, J BIOL CHEM, V274, P24263, DOI 10.1074/jbc.274.34.24263; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Summers SA, 1999, J BIOL CHEM, V274, P23858, DOI 10.1074/jbc.274.34.23858; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Tanaka S, 1997, CANCER RES, V57, P28; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	69	177	180	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30934	30942		10.1074/jbc.M004112200	http://dx.doi.org/10.1074/jbc.M004112200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10908564	hybrid			2022-12-25	WOS:000089762700030
J	Bernier, SG; Haldar, S; Michel, T				Bernier, SG; Haldar, S; Michel, T			Bradykinin-regulated interactions of the mitogen-activated protein kinase pathway with the endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; PHOSPHORYLATION; CELLS; TRANSLOCATION; CAVEOLAE; AKT; RECEPTORS; INHIBITOR; CASCADE	Activation of the bradykinin B2 receptor in endothelial cells initiates a complex array of cellular responses mediated by diverse signaling pathways, including stimulation of the mitogen-activated protein (MAP) kinase cascade and activation of the endothelial isoform of nitric-oxide synthase (eNOS). Several protein kinases have been implicated in eNOS regulation, but the role of MAP kinases remains less well understood. We explored the interactions between eNOS and components of the MAP kinase pathway in bovine aortic endothelial cells (BAEC), Using co-immunoprecipitation experiments, we isolated eNOS in a complex with the MAP kinases extracellular signal-regulated kinases 1 and 2 (ERK1/2) as well as the protein kinases Raf-1 and Akt. Within minutes of adding bradykinin to BAEC, the eNOS-Raf-1-ERK-Akt heteromeric complex dissociated, and it subsequently reassociated following more prolonged agonist stimulation. Bradykinin treatment of BAEC led to the activation of ERK, associated with an increase in phosphorylation of eNOS; phosphorylation of eNOS by ERK in vitro significantly reduced eNOS enzyme activity. Evidence for the direct phosphorylation of eNOS by MAP kinase in BAEC came from "back-phosphorylation" experiments using [gamma-P-32]ATP and ERK in vitro to phosphorylate eNOS isolated from cells previously treated with bradykinin or the MAP kinase inhibitor PD98059. The ERK-catalyzed in vitro P-32 phosphorylation of eNOS isolated from BAEC treated with bradykinin was significantly attenuated compared with untreated cells, indicating that bradykinin treatment led to the phosphorylation of ERK-sensitive sites in cells. Conversely, eNOS isolated from endothelial cells pretreated with the MAP kinase inhibitor PD98059 showed increased ERK-promoted phosphorylation in vitro. Taken together, our results suggest that bradykinin-induced activation of ERK leads to eNOS phosphorylation and enzyme inhibition, a process influenced by the reversible associations of members of the MAP kinase pathway with eNOS.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Vet Affairs Boston Healthcare Syst, W Roxbury, MA 02132 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Michel, T (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc, Thorn Bldg,Rm 1210A,75 Francis St, Boston, MA 02115 USA.							Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FLEMING I, 1995, CIRC RES, V76, P522, DOI 10.1161/01.RES.76.4.522; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Graness A, 1998, J BIOL CHEM, V273, P32016, DOI 10.1074/jbc.273.48.32016; HIRATA K, 1995, HYPERTENSION, V25, P180, DOI 10.1161/01.HYP.25.2.180; Jaffa AA, 1997, AM J PHYSIOL-RENAL, V273, pF916, DOI 10.1152/ajprenal.1997.273.6.F916; Kaplan AP, 1998, CLIN REV ALLERG IMMU, V16, P403, DOI 10.1007/BF02737659; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEE CM, 1995, J BIOL CHEM, V270, P27403, DOI 10.1074/jbc.270.46.27403; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Mombouli JV, 1999, J MOL CELL CARDIOL, V31, P61, DOI 10.1006/jmcc.1998.0844; MORGANBOYD R, 1987, AM J PHYSIOL, V253, pC588, DOI 10.1152/ajpcell.1987.253.4.C588; Naraba H, 1998, FEBS LETT, V435, P96, DOI 10.1016/S0014-5793(98)01045-X; Prabhakar P, 1998, J BIOL CHEM, V273, P27383, DOI 10.1074/jbc.273.42.27383; Robinson LJ, 1996, METHOD ENZYMOL, V268, P436; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; Sakamoto N, 1998, BRIT J PHARMACOL, V125, P283, DOI 10.1038/sj.bjp.0702060; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843	31	157	172	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30707	30715		10.1074/jbc.M005116200	http://dx.doi.org/10.1074/jbc.M005116200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10899167	hybrid			2022-12-25	WOS:000089577900108
J	Richardson, RT; Batova, IN; Widgren, EE; Zheng, LX; Whitfield, M; Marzluff, WF; O'Rand, MG				Richardson, RT; Batova, IN; Widgren, EE; Zheng, LX; Whitfield, M; Marzluff, WF; O'Rand, MG			Characterization of the histone H1-binding protein, NASP, as a cell cycle-regulated somatic protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR AUTOANTIGENIC PROTEIN; NUCLEOSOME ASSEMBLY INVITRO; DNA-REPLICATION INVITRO; XENOPUS-LAEVIS OOCYTES; BINDING-PROTEIN; ACROSOME REACTION; MESSENGER-RNA; EXPRESSION; LOCALIZATION; CHROMATIN	Nuclear autoantigenic sperm protein (NASP), initially described as a highly autoimmunogenic testis and sperm-specific protein, is a histone-binding protein that is a homologue of the N1/N2 gene expressed in oocytes of Xenopus laevis. Here, we report a somatic form of NASP (sNASP) present in all mitotic cells examined, including mouse embryonic cells and several mouse and human tissue culture cell lines. Affinity chromatography and histone isolation demonstrate that NASP from myeloma cells is complexed only with H1, linker histones. Somatic NASP is a shorter version of testicular NASP (tNASP) with two deletions in the coding region arising from alternative splicing and differs from tNASP in its 5' untranslated regions. We examined the relationship between NASP mRNA expression and the cell cycle and report that in cultures of synchronized mouse 3T3 cells and HeLa cells sNASP mRNA levels increase during S-phase and decline in G(2), concomitant with histone mRNA levels. NASP protein levels remain stable in these cells but become undetectable in confluent cultures of nondividing CV-1 cells and in nonmitotic cells in various body tissues. Expression of sNASP mRNA is regulated during the cell cycle and, consistent with a role as a histone transport protein, NASP mRNA expression parallels histone mRNA expression.	Univ N Carolina, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	O'Rand, MG (corresponding author), Univ N Carolina, Dept Cell Biol & Anat, CB 7090, Chapel Hill, NC 27599 USA.	morand@unc.edu	Whitfield, Michael/AAC-5010-2020; , UNC Flow Cytometry Core/AGU-9839-2022					ALMOUZNI G, 1990, NUCLEIC ACIDS RES, V18, P5767, DOI 10.1093/nar/18.19.5767; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Batova I, 1996, BIOL REPROD, V54, P1238, DOI 10.1095/biolreprod54.6.1238; BORUN TW, 1975, CELL, V4, P59, DOI 10.1016/0092-8674(75)90134-8; BROWN DT, 1993, J BIOL CHEM, V268, P713; CHIU IM, 1982, BIOCHIM BIOPHYS ACTA, V699, P173, DOI 10.1016/0167-4781(82)90105-1; DABAUVALLE MC, 1982, P NATL ACAD SCI-BIOL, V79, P5302, DOI 10.1073/pnas.79.17.5302; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; HARRIS ME, 1991, MOL CELL BIOL, V11, P2416, DOI 10.1128/MCB.11.5.2416; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; Ito T, 1996, MOL CELL BIOL, V16, P3112; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KIM YJ, 1987, DEV BIOL, V124, P23, DOI 10.1016/0012-1606(87)90455-6; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; KLEINSCHMIDT JA, 1988, EMBO J, V7, P1605, DOI 10.1002/j.1460-2075.1988.tb02986.x; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KROHNE G, 1985, EXP CELL RES, V158, P205, DOI 10.1016/0014-4827(85)90444-6; LASKOV R, 1970, Journal of Experimental Medicine, V131, P515, DOI 10.1084/jem.131.3.515; Lorain S, 1998, MOL CELL BIOL, V18, P5546, DOI 10.1128/MCB.18.9.5546; MEISTRICH ML, 1985, DEV BIOL, V112, P230, DOI 10.1016/0012-1606(85)90137-X; O'Rand MG, 2000, SERONO SYMP, P143; ORAND MG, 1992, DEV BIOL, V154, P37, DOI 10.1016/0012-1606(92)90045-I; RICHARDSON RT, 1991, BIOL REPROD, V45, P20, DOI 10.1095/biolreprod45.1.20; RICHARDSON RT, 1994, DEV BIOL, V165, P688, DOI 10.1006/dbio.1994.1285; RICHARDSON RT, 1993, SERONO SYM, V97, P41; Rodriguez P, 1997, GENOMICS, V44, P253, DOI 10.1006/geno.1997.4868; SALIK J, 1981, J CELL BIOL, V90, P385, DOI 10.1083/jcb.90.2.385; SAPP M, 1990, J BIOL CHEM, V265, P9357; SITTMAN DB, 1983, P NATL ACAD SCI-BIOL, V80, P1849, DOI 10.1073/pnas.80.7.1849; Sivashanmugam P, 1999, J ANDROL, V20, P384; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; WAITHE WI, 1983, BIOCHEMISTRY-US, V22, P1778, DOI 10.1021/bi00277a006; Wang ZF, 1997, J MOL BIOL, V271, P124, DOI 10.1006/jmbi.1997.1166; WASSARMAN PM, 1981, DEV BIOL, V84, P364, DOI 10.1016/0012-1606(81)90405-X; Watanabe TK, 1996, CYTOGENET CELL GENET, V74, P281, DOI 10.1159/000134435; WELCH JE, 1990, BIOL REPROD, V43, P559, DOI 10.1095/biolreprod43.4.559; WELCH JE, 1990, BIOL REPROD, V43, P569, DOI 10.1095/biolreprod43.4.569; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545	42	111	113	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30378	30386		10.1074/jbc.M003781200	http://dx.doi.org/10.1074/jbc.M003781200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10893414	hybrid, Green Published			2022-12-25	WOS:000089577900063
J	Krappmann, D; Hatada, EN; Tegethoff, S; Li, J; Klippel, A; Giese, K; Baeuerle, PA; Scheidereit, C				Krappmann, D; Hatada, EN; Tegethoff, S; Li, J; Klippel, A; Giese, K; Baeuerle, PA; Scheidereit, C			The I kappa B kinase (IKK) complex is tripartite and contains IKK gamma but not IKAP as a regular component	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; BETA SUBUNIT; ACTIVATION; ALPHA; PHOSPHORYLATION; PROTEIN; MICE; IDENTIFICATION; MECHANISMS; HOLOENZYME	A critical step in the activation of NF-kappa B is the phosphorylation of I kappa Bs by the I kappa B kinase (IKK) complex. IKK alpha and IKK beta are the two catalytic subunits of the IRK complex and two additional molecules, IKK gamma/NEMO and IKAP, have been described as further integral members. We have analyzed the function of both proteins for IKK complex composition and NF-kappa B signaling. IKAP and IKK gamma belong to distinct cellular complexes. Quantitative association of IKK gamma was observed with IKK alpha and IKK beta. In contrast IKAP was complexed with several distinct polypeptides. Overexpression of either IKK gamma or IKAP blocked tumor necrosis factor alpha induction of an NF-kappa B-dependent reporter construct, but IKAP in addition affected several NF-kappa B-independent promoters. Whereas specific down-regulation of IKK gamma protein levels by antisense oligonucleotides significantly reduced cytokine-mediated activation of the IKK complex and subsequent NF-kappa B activation, a similar reduction of IKAP protein levels had no effect on NF-kappa B signaling. Using solely IKK alpha, IKK beta, and IKK gamma, we could reconstitute a complex whose apparent molecular weight is comparable to that of the endogenous IKK complex. We conclude that while IKK gamma is a stoichiometric component of the IKK complex, obligatory for NF-kappa B signaling, IKAP is not associated with IKKs and plays no specific role in cytokine-induced NF-kappa B activation.	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Boehringer Ingelheim Pharmaceut Inc, Dept Biol, Ridgefield, CT 06877 USA; Atugen AG, D-13125 Berlin, Germany; Micromet GmbH, D-82152 Martinsried, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Boehringer Ingelheim; Amgen; Amgen Research Munich GmbH	Scheidereit, C (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.		Krappmann, Daniel/AAT-4354-2021; Krappmann, Daniel/ABF-4038-2021	Krappmann, Daniel/0000-0001-7640-3234; Krappmann, Daniel/0000-0001-7640-3234				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li YG, 1998, MOL CELL BIOL, V18, P1601, DOI 10.1128/MCB.18.3.1601; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; May MJ, 1999, SCIENCE, V284, P271, DOI 10.1126/science.284.5412.271; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROONEY JW, 1990, IMMUNOGENETICS, V31, P73, DOI 10.1007/BF00661216; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Scheidereit C, 1998, NATURE, V395, P225, DOI 10.1038/26121; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zandi E, 1999, MOL CELL BIOL, V19, P4547	41	102	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29779	29787		10.1074/jbc.M003902200	http://dx.doi.org/10.1074/jbc.M003902200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893415	hybrid			2022-12-25	WOS:000089439800082
J	Eastmond, PJ; Hooks, MA; Williams, D; Lange, P; Bechtold, N; Sarrobert, C; Nussaume, L; Graham, IA				Eastmond, PJ; Hooks, MA; Williams, D; Lange, P; Bechtold, N; Sarrobert, C; Nussaume, L; Graham, IA			Promoter trapping of a novel medium-chain acyl-CoA oxidase, which is induced transcriptionally during Arabidopsis seed germination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER PROTEIN THIOESTERASE; PEROXISOMAL BETA-OXIDATION; MALATE SYNTHASE GENE; FATTY-ACIDS; DEVELOPMENTAL REGULATION; EXPRESSION; PLANTS; RECEPTOR; BIOSYNTHESIS; PURIFICATION	The first step of peroxisomal fatty acid beta -oxidation is catalyzed by a family of acyl-CoA oxidase isozymes with distinct fatty acyl-CoA chain-length specificities. Here we identify a new acyl-CoA oxidase gene from Arabidopsis (AtACX3) following the isolation of a promoter-trapped mutant in which beta -glucuronidase expression was initially detected in the root meristem. In acx3 mutant seedlings medium-chain acyl-CoA oxidase activity was reduced by 95%, whereas long- and short-chain activities were unchanged. Despite this reduction in activity lipid catabolism and seedling development were not perturbed. AtACX3 was cloned and expressed in Escherichia coli. The recombinant enzyme displayed medium-chain acyl-CoA substrate specificity. Analysis of beta -glucuronidase activity in acx3 revealed that, in addition to constitutive expression in the root axis, AtACX3 is also up-regulated strongly in the hypocotyl and cotyledons of germinating seedlings. This suggests that beta -oxidation is regulated predominantly at the level of transcription in germinating oilseeds. After the discovery of AtACX3, the Arabidopsis acyl-CoA oxidase gene family now comprises four isozymes with substrate specificities that encompass the full range of acyl-CoA chain lengths that exist in vivo.	Univ York, Dept Biol, Ctr Novel Agr Prod, York YO10 5YW, N Yorkshire, England; Univ Wales, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales; Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Inst Rech Agron, Genet & Ameliorat Plantes Stn, F-78026 Versailles, France; CEA Saclay, Dept Ecophysiol Vegetale & Microbiol, F-13108 St Paul Les Durance, France	University of York - UK; Bangor University; University of Glasgow; INRAE; CEA	Graham, IA (corresponding author), CNAP, Cent Sci Lab, York YO41 1LZ, N Yorkshire, England.	iag1@cnap.york.ac.uk	NUSSAUME, Laurent/AAA-5980-2022; NUSSAUME, Laurent/AAB-8312-2020	NUSSAUME, Laurent/0000-0002-9445-2563; Eastmond, Peter/0000-0003-4526-5136				Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BLACK PN, 1994, BBA-LIPID LIPID MET, V1210, P123, DOI 10.1016/0005-2760(94)90113-9; BOUCHEZ D, 1993, CR ACAD SCI III-VIE, V316, P1188; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broun P, 1998, PLANT J, V13, P201, DOI 10.1046/j.1365-313X.1998.00023.x; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; CHU CH, 1994, BIOCHEM J, V302, P23, DOI 10.1042/bj3020023; DENYER K, 1988, PLANTA, V173, P172, DOI 10.1007/BF00403008; Do YY, 1997, ARCH BIOCHEM BIOPHYS, V344, P295, DOI 10.1006/abbi.1997.0212; Eastmond PJ, 2000, P NATL ACAD SCI USA, V97, P5669, DOI 10.1073/pnas.97.10.5669; Eastmond PJ, 2000, BIOCHEM SOC T, V28, P95, DOI 10.1042/bst0280095; Eccleston VS, 1998, PLANT CELL, V10, P613, DOI 10.1105/tpc.10.4.613; Eccleston VS, 1996, PLANTA, V198, P46, DOI 10.1007/BF00197585; FARMER EE, 1994, PLANT MOL BIOL, V26, P1423, DOI 10.1007/BF00016483; GERHARDT B, 1985, PHYTOCHEMISTRY, V24, P351, DOI 10.1016/S0031-9422(00)83551-7; GRAHAM IA, 1990, PLANT MOL BIOL, V15, P539, DOI 10.1007/BF00017829; GROSSI M, 1995, PLANT SCI, V105, P71, DOI 10.1016/0168-9452(94)04043-G; Hayashi H, 1998, J BIOL CHEM, V273, P8301, DOI 10.1074/jbc.273.14.8301; Hayashi H, 1999, J BIOL CHEM, V274, P12715, DOI 10.1074/jbc.274.18.12715; Hayashi M, 1998, PLANT CELL, V10, P183, DOI 10.1105/tpc.10.2.183; HOLTMAN WL, 1994, PLANT SCI, V99, P43, DOI 10.1016/0168-9452(94)90119-8; Hooks MA, 1999, PLANT J, V20, P1, DOI 10.1046/j.1365-313X.1999.00559.x; Hooks MA, 1996, BIOCHEM J, V320, P607, DOI 10.1042/bj3200607; Hooks MA, 1999, PLANTA, V207, P385, DOI 10.1007/s004250050496; HOOKS MA, 1995, PHYTOCHEMISTRY, V40, P657, DOI 10.1016/0031-9422(95)98169-H; HRYB DJ, 1979, BIOCHEM BIOPH RES CO, V87, P1200, DOI 10.1016/S0006-291X(79)80034-0; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; Karpichev IV, 1998, MOL CELL BIOL, V18, P6560, DOI 10.1128/MCB.18.11.6560; KAY R, 1987, SCIENCE, V236, P1299, DOI 10.1126/science.236.4806.1299; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KIM DJ, 1994, PLANT MOL BIOL, V26, P423, DOI 10.1007/BF00039551; KINDL H, 1987, BIOCH PLANTS, V9, P31; KIRSCH T, 1986, J BIOL CHEM, V261, P8570; Kleiter AE, 1998, PLANTA, V206, P125, DOI 10.1007/s004250050382; LANGE PR, 1998, ADV PLANT LIPID RES, P343; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Richmond TA, 1999, PLANT CELL, V11, P1911, DOI 10.1105/tpc.11.10.1911; SAMBROOK J, 1989, MOL CLONING LAB MANU, P320; Sarah CJ, 1996, MOL GEN GENET, V250, P153, DOI 10.1007/BF02174174; Takahashi H, 1997, PLANT J, V11, P993, DOI 10.1046/j.1365-313X.1997.11050993.x; Wasternack C, 1997, TRENDS PLANT SCI, V2, P302, DOI 10.1016/S1360-1385(97)89952-9; Wimmer C, 1998, PLANT J, V16, P453, DOI 10.1046/j.1365-313x.1998.00320.x; Wolf G, 1998, NUTR REV, V56, P61, DOI 10.1111/j.1753-4887.1998.tb01693.x; Zhang JZ, 1996, PLANT PHYSIOL, V110, P1069, DOI 10.1104/pp.110.4.1069	46	61	64	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34375	34381		10.1074/jbc.M004945200	http://dx.doi.org/10.1074/jbc.M004945200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10918060	Green Published, hybrid			2022-12-25	WOS:000165095300052
J	Baudoux, L; Defechereux, P; Rentier, B; Piette, J				Baudoux, L; Defechereux, P; Rentier, B; Piette, J			Gene activation by varicella-zoster virus IE4 protein requires its dimerization and involves both the arginine-rich sequence, the central part, and the carboxyl-terminal cysteine-rich region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; IMMEDIATE-EARLY PROTEIN; READING FRAME-4 ENCODES; ALPHA PROTEIN-ICP27; FUNCTIONALLY DISTINCT; TRANS-REPRESSOR; NUCLEAR IMPORT; LEUCINE-ZIPPER; ICP27 MAP; K-PROTEIN	Varicella-zoster virus (VZV) open reading frame 4-encoded protein (IE4) possesses transactivating properties for VZV genes as well as for those of heterologous viruses. Since most transcription factors act as dimers, IE4 dimerization was studied using the mammalian two-hybrid system. Introduction of mutations in the IE4 open reading frame demonstrated that both the central region and the carboxyl-terminal cysteine-rich domain were important for efficient dimerization. Within the carboxyl-terminal domain, substitution of amino acids encompassing residues 443-447 totally abolished dimerization. Gene activation by IE4 was studied by transient transfection with an IE4 expression plasmid and a reporter gene under the control of either the human immunodeficiency virus, type 1, long terminal repeat or the VZV thymidine kinase promoter. Regions of IE4 important for dimerization were also shown to be crucial for transactivation. In addition, the arginine-rich domains Rb and Re of the amino-terminal region were also demonstrated to be important for transactivation, whereas the Ra domain as well as an acidic and bZIP-containing regions were shown to be dispensable for gene transactivation. A nucleocytoplasmic shuttling of IE4 has also been characterized, involving a nuclear localization signal identified within the Rb domain and a nuclear export mechanism partially depending on Crm-1.	Univ Liege, Inst Pathol, Lab Fundamental Virol & Immunol B23, B-4000 Liege, Belgium	University of Liege	Piette, J (corresponding author), Univ Liege, Inst Pathol, Lab Fundamental Virol & Immunol B23, B-4000 Liege, Belgium.	jpiette@ulg.ac.be						Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; BAUDOUX L, 1995, NUCLEIC ACIDS RES, V23, P1341, DOI 10.1093/nar/23.8.1341; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DEBRUS S, 1995, J VIROL, V69, P3240, DOI 10.1128/JVI.69.5.3240-3245.1995; Defechereux P, 1996, J GEN VIROL, V77, P1505, DOI 10.1099/0022-1317-77-7-1505; Defechereux P, 1997, J VIROL, V71, P7073, DOI 10.1128/JVI.71.9.7073-7079.1997; DEFECHEREUX P, 1993, J VIROL, V67, P4379, DOI 10.1128/JVI.67.7.4379-4385.1993; Defechereux P, 1998, J BIOL CHEM, V273, P13636, DOI 10.1074/jbc.273.22.13636; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ELLENBERGER T, 1994, CURR OPIN STRUC BIOL, V4, P12, DOI 10.1016/S0959-440X(94)90054-X; EVERETT RD, 1986, J GEN VIROL, V67, P2507, DOI 10.1099/0022-1317-67-11-2507; FORGHANI B, 1990, VIRUS RES, V16, P195, DOI 10.1016/0168-1702(90)90023-5; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; HARDWICKE MA, 1989, J VIROL, V63, P4590, DOI 10.1128/JVI.63.11.4590-4602.1989; HAY J, 1994, SEMIN VIROL, V5, P241, DOI 10.1006/smvy.1994.1026; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; HIBBARD MK, 1995, J VIROL, V69, P4656, DOI 10.1128/JVI.69.8.4656-4667.1995; HONESS RW, 1974, J VIROL, V14, P8, DOI 10.1128/JVI.14.1.8-19.1974; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; INCHAUSPE G, 1989, VIROLOGY, V173, P700, DOI 10.1016/0042-6822(89)90583-7; Kruyt FAE, 1999, J BIOL CHEM, V274, P34212, DOI 10.1074/jbc.274.48.34212; MCMAHAN L, 1990, J VIROL, V64, P3471, DOI 10.1128/JVI.64.7.3471-3485.1990; Mears WE, 1996, J VIROL, V70, P7445, DOI 10.1128/JVI.70.11.7445-7453.1996; MEARS WE, 1995, J VIROL, V69, P935, DOI 10.1128/JVI.69.2.935-947.1995; Michael WM, 2000, TRENDS CELL BIOL, V10, P46, DOI 10.1016/S0962-8924(99)01695-5; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MORIUCHI H, 1994, J VIROL, V68, P1987, DOI 10.1128/JVI.68.3.1987-1992.1994; MORIUCHI H, 1993, J VIROL, V67, P4290, DOI 10.1128/JVI.67.7.4290-4295.1993; MORIUCHI H, 1993, J VIROL, V67, P2739, DOI 10.1128/JVI.67.5.2739-2746.1993; MORIUCHI M, 1995, VIROLOGY, V208, P376, DOI 10.1006/viro.1995.1164; NAGPAL S, 1991, J VIROL, V65, P5289, DOI 10.1128/JVI.65.10.5289-5296.1991; NICHOLAS J, 1988, J VIROL, V62, P3250, DOI 10.1128/JVI.62.9.3250-3257.1988; Panagiotidis CA, 1997, J VIROL, V71, P1547, DOI 10.1128/JVI.71.2.1547-1557.1997; PERERA LP, 1994, J VIROL, V68, P2468, DOI 10.1128/JVI.68.4.2468-2477.1994; PERERA LP, 1992, J VIROL, V66, P5298, DOI 10.1128/JVI.66.9.5298-5304.1992; Phelan A, 1998, SEMIN VIROL, V8, P309, DOI 10.1006/smvy.1997.0133; RICE SA, 1988, J VIROL, V62, P3814, DOI 10.1128/JVI.62.10.3814-3823.1988; RICE SA, 1990, J VIROL, V64, P1704, DOI 10.1128/JVI.64.4.1704-1715.1990; RICE SA, 1993, J VIROL, V67, P1778, DOI 10.1128/JVI.67.4.1778-1787.1993; Sandri-Goldin RM, 1998, GENE DEV, V12, P868, DOI 10.1101/gad.12.6.868; SandriGoldin RM, 1996, J VIROL, V70, P108, DOI 10.1128/JVI.70.1.108-118.1996; SEKULOVICH RE, 1988, J VIROL, V62, P4510, DOI 10.1128/JVI.62.12.4510-4522.1988; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SMITH IL, 1991, J VIROL, V65, P3656, DOI 10.1128/JVI.65.7.3656-3666.1991; SMITH RH, 1993, J VIROL, V67, P1105, DOI 10.1128/JVI.67.2.1105-1109.1993; Soliman TM, 2000, J VIROL, V74, P2814, DOI 10.1128/JVI.74.6.2814-2825.2000; Soliman TM, 1997, J VIROL, V71, P9188, DOI 10.1128/JVI.71.12.9188-9197.1997; SU LS, 1989, VIROLOGY, V170, P496, DOI 10.1016/0042-6822(89)90441-8; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Wadd S, 1999, J BIOL CHEM, V274, P28991, DOI 10.1074/jbc.274.41.28991; Zhi Y, 1999, VIROLOGY, V257, P341, DOI 10.1006/viro.1999.9698	55	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32822	32831		10.1074/jbc.M001444200	http://dx.doi.org/10.1074/jbc.M001444200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10889190	Green Submitted, hybrid			2022-12-25	WOS:000090003800062
J	Munoz-Alonso, MJ; Guillemain, G; Kassis, N; Girard, J; Burnol, AF; Leturque, A				Munoz-Alonso, MJ; Guillemain, G; Kassis, N; Girard, J; Burnol, AF; Leturque, A			A novel cytosolic dual specificity phosphatase, interacting with glucokinase, increases glucose phosphorylation rate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; IN-VIVO PHOSPHORYLATION; REGULATORY PROTEIN; SACCHAROMYCES-CEREVISIAE; KINASE PHOSPHATASE; CATALYTIC ROLE; LIVER; GENE; HEXOKINASE-2; SITE	A novel protein was cloned from a rat liver cDNA library by interaction with the liver glucokinase. This protein contained 339 residues and possessed a canonical consensus sequence for a dual specificity phosphatase. The recombinant protein was able to dephosphorylate phosphotyrosyl and phosphosery/threonyl substrates. We called this protein the glucokinase-associated phosphatase (GKAP). The GKAP partially dephosphorylated the recombinant glucokinase previously phosphorylated, in vitro, by protein kinase A. The GKAP fused with green fluorescent protein was located in the cytosol, where glucokinase phosphorylates glucose, and not in the nucleus where the glucokinase is retained inactive by the glucokinase regulatory protein. More importantly, the GKAP accelerated the glucokinase activity in a dose-dependent manner and with a stoichiometry compatible with a physiological mechanism. This strongly suggested that the interaction between GKAP and glucokinase had a functional significance. The cloning of this novel protein with a dual specificity phosphatase activity allows the description of a possible new regulatory step in controlling the glycolysis flux.	INSERM U505, Inst Biomed Cordeliers, F-75006 Paris, France; CNRS, UPR 1524, F-92190 Meudon, France; CNRS, UPRESA 7059, Lab Physiopathol Nutr, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Leturque, A (corresponding author), INSERM U505, Inst Biomed Cordeliers, 15 Rue Ecole Med, F-75006 Paris, France.	leturque@infobiogen.fr	Leturque, Armelle/Q-9437-2017; Guillemain, Ghislaine/P-7740-2017; Burnol, Anne-Francoise/P-2181-2017	Leturque, Armelle/0000-0001-6570-6387; Guillemain, Ghislaine/0000-0002-8256-9545				ADAMS V, 1991, BIOCHEM MED METAB B, V45, P271, DOI 10.1016/0885-4505(91)90032-G; AGIUS L, 1995, BIOCHEM J, V309, P711, DOI 10.1042/bj3090711; ANTOINE B, 1992, EXP CELL RES, V200, P175, DOI 10.1016/S0014-4827(05)80086-2; AORA KK, 1990, J BIOL CHEM, V265, P6481; Behlke J, 1998, BIOCHEMISTRY-US, V37, P11989, DOI 10.1021/bi980914m; Brown KS, 1997, DIABETES, V46, P179, DOI 10.2337/diabetes.46.2.179; CHARLES RS, 1994, DIABETES, V43, P784, DOI 10.2337/diab.43.6.784; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; EKMAN P, 1988, ARCH BIOCHEM BIOPHYS, V261, P275, DOI 10.1016/0003-9861(88)90342-6; Fang TY, 1998, J BIOL CHEM, V273, P19548, DOI 10.1074/jbc.273.31.19548; Farrelly D, 1999, P NATL ACAD SCI USA, V96, P14511, DOI 10.1073/pnas.96.25.14511; Fernandez-Novell JM, 1999, FEBS LETT, V459, P211, DOI 10.1016/S0014-5793(99)01249-1; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; Heidrich K, 1997, BIOCHEMISTRY-US, V36, P1960, DOI 10.1021/bi9623643; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRIEGEL TM, 1994, BIOCHEMISTRY-US, V33, P148, DOI 10.1021/bi00167a019; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; LIANG Y, 1991, J BIOL CHEM, V266, P6999; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; Martell KJ, 1998, MOL CELLS, V8, P2; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P4319; Randez-Gil F, 1998, MOL CELL BIOL, V18, P2940, DOI 10.1128/MCB.18.5.2940; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P179; VANSCHAFTINGEN E, 1994, FASEB J, V8, P414, DOI 10.1096/fasebj.8.6.8168691; XU LZ, 1995, J BIOL CHEM, V270, P9939, DOI 10.1074/jbc.270.17.9939; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	37	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32406	32412		10.1074/jbc.M000841200	http://dx.doi.org/10.1074/jbc.M000841200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913113	hybrid			2022-12-25	WOS:000090003800006
J	Boll, M; Fuchs, G; Meier, C; Trautwein, A; Lowe, DJ				Boll, M; Fuchs, G; Meier, C; Trautwein, A; Lowe, DJ			EPR and Mossbauer studies of Benzoyl-CoA reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAEROBIC AROMATIC METABOLISM; IRON-SULFUR PROTEIN; ELECTRON-PARAMAGNETIC-RES; ACIDAMINOCOCCUS-FERMENTANS; CLOSTRIDIUM-PASTEURIANUM; THAUERA-AROMATICA; KEY ENZYME; 2-HYDROXYGLUTARYL-COA DEHYDRATASE; 2<4FE-4SE>+ FERREDOXIN; CLUSTER	Benzoyl-CoA reductase catalyzes the two-electron transfer from a reduced ferredoxin to the aromatic ring of benzoyl-CoA; this reaction is coupled to stoichiometrical ATP hydrolysis, A very low reduction potential (less than -1V) is required for the first electron transfer to the aromatic ring, In this work the nature of the redox centers of purified benzoyl-CoA reductase from Thauera aromatica was studied by EPR and Mossbauer spectroscopy. The results obtained indicated the presence of three [4Fe-4S] clusters. Redox titration studies revealed that the reduction potentials of all three clusters were below -500 mV. The previously reported S = 7/2 state of the enzyme during benzoyl-CoA-independent ATPase activity (Boll, M., Albracht, S. J, P., and Fuchs, G, (1997) fur. J. Biochem. 244, 840-851) was confirmed by Mossbauer spectroscopy. Inactivation by oxygen was associated with the irreversible conversion of part of the [4Fe-4S] clusters to [3Fe-4S] clusters. Acetylene stimulated the benzoyl-CoA-independent ATPase activity and induced novel EPR signals with g(av) > 2. The presence of simple cubane clusters in benzoyl-CoA reductase as the sole redox-active metal centers demonstrates novel aspects of [4Fe-4S] clusters since they adopt the role of elemental sodium or lithium which are used as electron donors in the analogous chemical Birch reduction of aromatic rings.	Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany; John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England; Med Univ Lubeck, Inst Phys, D-2358 Lubeck, Germany	University of Freiburg; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Lubeck	Boll, M (corresponding author), Univ Freiburg, Inst Biol 2, Schanzlestr 1, D-79104 Freiburg, Germany.	boll@uni-freiburg.de						ABRAGAM A, 1951, PROC R SOC LON SER-A, V205, P135, DOI 10.1098/rspa.1951.0022; ANDERS HJ, 1995, INT J SYST BACTERIOL, V45, P327, DOI 10.1099/00207713-45-2-327; AURIC P, 1987, BIOCHEM J, V242, P525, DOI 10.1042/bj2420525; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BENDRAT K, 1993, FEBS LETT, V329, P329, DOI 10.1016/0014-5793(93)80247-R; Boll M, 1995, EUR J BIOCHEM, V234, P921, DOI 10.1111/j.1432-1033.1995.921_a.x; Boll M, 2000, BIOCHEMISTRY-US, V39, P4929, DOI 10.1021/bi9927890; Boll M, 1997, EUR J BIOCHEM, V244, P840, DOI 10.1111/j.1432-1033.1997.00840.x; Boll M, 1998, EUR J BIOCHEM, V251, P946, DOI 10.1046/j.1432-1327.1998.2510946.x; BRACKMANN R, 1993, EUR J BIOCHEM, V213, P563, DOI 10.1111/j.1432-1033.1993.tb17795.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breese K, 1998, EUR J BIOCHEM, V256, P148, DOI 10.1046/j.1432-1327.1998.2560148.x; Buckel W, 1996, FEBS LETT, V389, P20, DOI 10.1016/0014-5793(96)00530-3; Buckel W., 1995, ANGEW CHEM, V107, P1595; DUNHAM WR, 1991, BIOCHIM BIOPHYS ACTA, V1079, P253, DOI 10.1016/0167-4838(91)90066-9; DUTSCHO R, 1989, EUR J BIOCHEM, V181, P741, DOI 10.1111/j.1432-1033.1989.tb14786.x; Egland PG, 1997, P NATL ACAD SCI USA, V94, P6484, DOI 10.1073/pnas.94.12.6484; FRAISSE L, 1988, ARCH MICROBIOL, V150, P381, DOI 10.1007/BF00408311; HAGEN WR, 1987, EUR J BIOCHEM, V169, P457, DOI 10.1111/j.1432-1033.1987.tb13633.x; Hans M, 1999, EUR J BIOCHEM, V265, P404, DOI 10.1046/j.1432-1327.1999.00748.x; Harwood CS, 1998, FEMS MICROBIOL REV, V22, P439, DOI 10.1016/S0168-6445(98)00026-6; HEERING HA, 1995, EUR J BIOCHEM, V232, P811, DOI 10.1111/j.1432-1033.1995.811zz.x; Heider J, 1997, EUR J BIOCHEM, V243, P577, DOI 10.1111/j.1432-1033.1997.00577.x; Jung YS, 1997, J BIOL INORG CHEM, V2, P209, DOI 10.1007/s007750050126; KIM J, 1994, BIOCHEMISTRY-US, V33, P389, DOI 10.1021/bi00168a001; KOCH J, 1993, EUR J BIOCHEM, V211, P649, DOI 10.1111/j.1432-1033.1993.tb17593.x; KRAPCHO AP, 1959, J AM CHEM SOC, V81, P3658, DOI 10.1021/ja01523a042; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE DJ, 1978, BIOCHEM J, V173, P277, DOI 10.1042/bj1730277; MIDDLETON P, 1978, EUR J BIOCHEM, V88, P135, DOI 10.1111/j.1432-1033.1978.tb12430.x; MITTELBERGER T, 1996, THESIS U FREIBURG GE; MOULIS JM, 1984, J BIOL CHEM, V259, P1396; MULLER U, 1995, EUR J BIOCHEM, V230, P698, DOI 10.1111/j.1432-1033.1995.tb20611.x; NOODLEMAN L, 1991, INORG CHEM, V30, P246, DOI 10.1021/ic00002a019; ONATE YA, 1989, J BIOL CHEM, V264, P18386; SCHACHTER D, 1953, J BIOL CHEM, V203, P925; SCHWEIGER G, 1987, EUR J BIOCHEM, V169, P441, DOI 10.1111/j.1432-1033.1987.tb13631.x; THOMPSON CL, 1974, BIOCHEM J, V139, P97, DOI 10.1042/bj1390097; ZEHR BD, 1989, ANAL BIOCHEM, V182, P157, DOI 10.1016/0003-2697(89)90734-3	39	33	34	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31857	31868		10.1074/jbc.M001508200	http://dx.doi.org/10.1074/jbc.M001508200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10903310	hybrid			2022-12-25	WOS:000089858900045
J	Ito, M; Achermann, JC; Jameson, JL				Ito, M; Achermann, JC; Jameson, JL			A naturally occurring steroidogenic factor-1 mutation exhibits differential binding and activation of target genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; ORPHAN NUCLEAR RECEPTOR; AMINO-ACID-SEQUENCE; DNA-BINDING; FACTOR-I; GLUCOCORTICOID RECEPTOR; RESPONSE ELEMENTS; ESTROGEN-RECEPTOR; GRANULOSA-CELLS; HIGH-AFFINITY	Steroidogenic factor-1 (SF-l) is an orphan nuclear receptor that binds DNA as a monomer and regulates the transcription of multiple target genes. A mutation in the proximal (P)-box of the first zinc finger of SF-l (G35E) has been reported to cause complete XY sex reversal and adrenal insufficiency. Because this P-box region dictates DNA binding specificity, we investigated the effect of this mutation on DNA binding and regulation of target genes. Binding of the P-box mutant was markedly impaired for most native SF-1 response elements. However, mutant SF-l bound to a subset of response elements containing a CCA AGGTCA motif. Mutagenesis studies of response elements revealed that the first nucleotide position in the 5'-flanking sequence triplet and the central part of the half-site dictate DNA binding specificity by the mutant SF-1. Further, introduction of a mutation into the SF-l A-box, which has been proposed to bind to the 5'-flanking sequence triplet, eliminated binding by mutant SF-1 to all response elements tested. These data support the idea that the A-box stabilizes monomeric binding by nuclear receptors. This action may be particularly important when P-box binding affinity is compromised either by mutations in SF-l or by sequence alterations in its binding site.	Northwestern Univ, Div Endocrinol Metab & Mol Med, Sch Med, Chicago, IL 60611 USA	Northwestern University	Jameson, JL (corresponding author), Northwestern Univ, Div Endocrinol Metab & Mol Med, Sch Med, Tarry Bldg 15-709,303 E Chicago Ave, Chicago, IL 60611 USA.	ljameson@northwestern.edu	Achermann, John/C-5476-2008; Achermann, John/N-2906-2019	Achermann, John/0000-0001-8787-6272; Achermann, John/0000-0001-8787-6272; Jameson, James/0000-0001-9538-4059	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021921] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD029164] Funding Source: NIH RePORTER; NICHD NIH HHS [U54-HD-29164, P01-HD-21921] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Achermann JC, 1999, NAT GENET, V22, P125, DOI 10.1038/9629; CLEMENS JW, 1994, ENDOCRINOLOGY, V134, P1499, DOI 10.1210/en.134.3.1499; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FITZPATRICK SL, 1993, MOL ENDOCRINOL, V7, P341, DOI 10.1210/me.7.3.341; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Halvorson LM, 1998, J BIOL CHEM, V273, P14712, DOI 10.1074/jbc.273.24.14712; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HONDA S, 1993, J BIOL CHEM, V268, P7494; Ito M, 2000, MOL ENDOCRINOL, V14, P66, DOI 10.1210/me.14.1.66; Ito M, 1998, MOL ENDOCRINOL, V12, P290, DOI 10.1210/me.12.2.290; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; KATZ RW, 1993, J BIOL CHEM, V268, P19392; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; LYNCH JP, 1993, MOL ENDOCRINOL, V7, P776, DOI 10.1210/me.7.6.776; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Monte D, 1998, J BIOL CHEM, V273, P4585, DOI 10.1074/jbc.273.8.4585; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; NELSON CC, 1995, J BIOL CHEM, V270, P16981, DOI 10.1074/jbc.270.28.16981; NELSON CC, 1995, J BIOL CHEM, V270, P16988, DOI 10.1074/jbc.270.28.16988; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; Sugawara T, 1996, BIOCHEMISTRY-US, V35, P9052, DOI 10.1021/bi960057r; TSUKIYAMA T, 1992, NUCLEIC ACIDS RES, V20, P1477, DOI 10.1093/nar/20.7.1477; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; Yu RN, 1998, MOL ENDOCRINOL, V12, P1010, DOI 10.1210/me.12.7.1010; ZILLIACUS J, 1992, J BIOL CHEM, V267, P24941; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	38	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31708	31714		10.1074/jbc.M002892200	http://dx.doi.org/10.1074/jbc.M002892200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913126	hybrid			2022-12-25	WOS:000089858900025
J	Gilstring, CF; Ljungdahl, PO				Gilstring, CF; Ljungdahl, PO			A method for determining the in vivo topology of yeast polytopic membrane proteins demonstrates that Gap1p fully integrates into the membrane independently of Shr3p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID PERMEASES; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; TRANSPORT VESICLES; P-GLYCOPROTEIN; GENE FUSION; GLYCOSYLATION; INSERTION; GOLGI	The general amino acid permease (Gap1p) of Saccharomyces cerevisiae is an integral membrane protein that contains 12 hydrophobic regions predicted to be membrane-spanning segments. A topological reporter construct, encoding an internal 53-amino acid peptide of invertase (Suc2p) containing three Asp-X-Ser/Thr glycosylation sites, was inserted in-frame into the hydrophilic NH2- and COOH-terminal domains and each of the 11 hydrophilic loops that separate the 12 hydrophobic segments of Gap1p. The resulting 13 gene sandwich fusion proteins were expressed in a gap1 Delta null mutant strain; 9 of these retain amino acid transport activity and are folded and correctly targeted to the plasma membrane. The glycosylation state of each of the fusion proteins was monitored; the results indicate that all 12 hydrophobic segments of Gap1p span the membrane, and the MI, and COOH termini are cytoplasmically oriented. These results were independently tested by isolating sealed right-side out microsomes from sec12-1 strains expressing six different Gap1p constructs containing functional factor Xa protease cleavage sites. The pattern of factor Xa protease cleavage was found to be consistent with the presence of 12 membrane-spanning domains. Gap1p exhibited the same membrane topology in strains lacking Shr3p; therefore, Gap1p fully integrates into the ER membrane independently of this permease-specific packaging chaperone.	Ludwig Inst Canc Res, S-17177 Stockholm, Sweden	Ludwig Institute for Cancer Research	Ljungdahl, PO (corresponding author), Ludwig Inst Canc Res, Box 240, S-17177 Stockholm, Sweden.	plju@licr.ki.se	Ljungdahl, Per O/M-5258-2013	Ljungdahl, Per O/0000-0002-6625-3540				AHMAD M, 1988, MOL MICROBIOL, V2, P627, DOI 10.1111/j.1365-2958.1988.tb00071.x; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Barlowe C, 1998, BBA-MOL CELL RES, V1404, P67, DOI 10.1016/S0167-4889(98)00047-0; CHANG XB, 1994, J BIOL CHEM, V269, P18572; Cosgriff AJ, 1997, J BACTERIOL, V179, P3317, DOI 10.1128/jb.179.10.3317-3323.1997; DENFERT C, 1991, MOL CELL BIOL, V11, P5727, DOI 10.1128/MCB.11.11.5727; Didion T, 1998, MOL MICROBIOL, V27, P643, DOI 10.1046/j.1365-2958.1998.00714.x; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; ELLIS J, 1995, MICROBIOL-UK, V141, P1927, DOI 10.1099/13500872-141-8-1927; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; Gilstring CF, 1999, MOL BIOL CELL, V10, P3549, DOI 10.1091/mbc.10.11.3549; GREEN GN, 1989, J CELL SCI, P109; Guthrie C, 1991, METHODS ENZYMOL, V194; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; HOFFMANN W, 1987, MOL GEN GENET, V210, P277, DOI 10.1007/BF00325694; Holst B, 1996, EMBO J, V15, P3538, DOI 10.1002/j.1460-2075.1996.tb00723.x; HORAK J, 1993, BIOCHEM MOL BIOL INT, V29, P907; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; Iraqui I, 1999, MOL CELL BIOL, V19, P989; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAUNIAUX JC, 1990, EUR J BIOCHEM, V190, P39, DOI 10.1111/j.1432-1033.1990.tb15542.x; Jorgensen MU, 1998, YEAST, V14, P103, DOI 10.1002/(SICI)1097-0061(19980130)14:2<103::AID-YEA203>3.0.CO;2-C; Kaiser C, 1998, CURR OPIN CELL BIOL, V10, P477, DOI 10.1016/S0955-0674(98)80062-8; Klasson H, 1999, MOL CELL BIOL, V19, P5405; Kuehn MJ, 1996, J CELL BIOL, V135, P585, DOI 10.1083/jcb.135.3.585; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lau WTW, 2000, P NATL ACAD SCI USA, V97, P1107, DOI 10.1073/pnas.97.3.1107; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NILSSON I, 1993, J BIOL CHEM, V268, P5798; ORLEAN P, 1991, METHOD ENZYMOL, V194, P682; Paulsen IT, 1998, FEBS LETT, V430, P116, DOI 10.1016/S0014-5793(98)00629-2; Pi J, 1996, J BACTERIOL, V178, P2650, DOI 10.1128/jb.178.9.2650-2655.1996; REDDY VA, 1988, J BIOL CHEM, V263, P6978; Regenberg B, 1999, CURR GENET, V36, P317, DOI 10.1007/s002940050506; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; RYTKA J, 1975, J BACTERIOL, V121, P562, DOI 10.1128/JB.121.2.562-570.1975; SAHINTOTH M, 1995, BIOCHEMISTRY-US, V34, P1107, DOI 10.1021/bi00004a001; SENGSTAG C, 1990, MOL CELL BIOL, V10, P672, DOI 10.1128/MCB.10.2.672; Sherwood PW, 1999, P NATL ACAD SCI USA, V96, P7415, DOI 10.1073/pnas.96.13.7415; SILVE S, 1991, MOL CELL BIOL, V11, P1114, DOI 10.1128/MCB.11.2.1114; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; TRAXLER B, 1993, J MEMBRANE BIOL, V132, P1; Trilla JA, 1999, J CELL BIOL, V145, P1153, DOI 10.1083/jcb.145.6.1153; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; Zhang JT, 1996, MOL BIOL CELL, V7, P1709, DOI 10.1091/mbc.7.11.1709; ZHANG JT, 1995, J BIOL CHEM, V270, P1742, DOI 10.1074/jbc.270.4.1742	53	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31488	31495		10.1074/jbc.M005047200	http://dx.doi.org/10.1074/jbc.M005047200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10903320	hybrid			2022-12-25	WOS:000089762700103
J	Machide, M; Kamitori, K; Kohsaka, S				Machide, M; Kamitori, K; Kohsaka, S			Hepatocyte growth factor-induced differential activation of phospholipase C gamma 1 and phosphatidylinositol 3-kinase is regulated by tyrosine phosphatase SHP-1 in astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SCATTER FACTOR; C-MET/HGF RECEPTOR; NEUROTROPHIC FACTOR; EPITHELIAL-CELLS; KINASE RECEPTOR; PROTEIN; MET; PHOSPHORYLATION; IDENTIFICATION; SITE	Hepatocyte growth factor (HGF) elicits pleiotropic effects on various types of cells through the c-Met receptor tyrosine kinase. However, the mechanisms underlying the diverse responses of cells remain unknown. We show here that HGF promoted chemokinesis of rat primary astrocytes through the activation of phosphatidylinositol 3 (PI3)-kinase without any influence on mitogenesis of the cells. Under the same condition, phospholipase C gamma 1 (PLC gamma 1), which is another signal mediator of c-Met, was not tyrosine-phosphorylated during HGF stimulation. However, treatment of the cells with orthovanadate, a tyrosine phosphatase inhibitor, restored the HGF-induced tyrosine phosphorylation of PLC gamma 1. A tyrosine phosphatase, SHP-1, was associated with both PIS-kinase and PLC gamma 1 before HGF stimulation, but it was dissociated only from PB-kinase after the stimulation. Furthermore, transfectants of catalytically inactive mutant of SHP-1 showed tyrosine phosphorylation of PLC gamma 1 and mitogenic responses to HGF, and the mitogenic response was blocked with U73122, an inhibitor of phosphatidylinositol-specific PLC, and calphostin C, an inhibitor of protein kinase C downstream of the PLC gamma 1. These results indicate that PLC gamma 1 is selectively prevented from being a signal mediator by constitutive association of SHP-1, and that this selective inhibition of PLC gamma 1 may determine the cellular response of astrocytes to HGF.	Natl Inst Neurosci, Dept Neurochem, Kodaira, Tokyo 1878502, Japan	National Center for Neurology & Psychiatry - Japan	Kohsaka, S (corresponding author), Natl Inst Neurosci, Dept Neurochem, 4-1-1 Ogawa Higashi, Kodaira, Tokyo 1878502, Japan.							BARDELLI A, 1992, ONCOGENE, V7, P1973; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; BURRIDGE K, 1995, ANAL BIOCHEM, V232, P56, DOI 10.1006/abio.1995.9961; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; DERMAN MP, 1995, AM J PHYSIOL-RENAL, V268, pF1211, DOI 10.1152/ajprenal.1995.268.6.F1211; Derman MP, 1996, J BIOL CHEM, V271, P4251; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; FIXMAN ED, 1995, ONCOGENE, V10, P237; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Gesbert F, 1998, J BIOL CHEM, V273, P18273, DOI 10.1074/jbc.273.29.18273; GUAN KL, 1991, J BIOL CHEM, V266, P17026; Hamanoue M, 1996, J NEUROSCI RES, V43, P554, DOI 10.1002/(SICI)1097-4547(19960301)43:5<554::AID-JNR5>3.0.CO;2-H; HONDA S, 1995, MOL BRAIN RES, V32, P197, DOI 10.1016/0169-328X(95)00075-4; Imani F, 1997, J BIOL CHEM, V272, P7927, DOI 10.1074/jbc.272.12.7927; LEE CC, 1995, J BIOL CHEM, V270, P507, DOI 10.1074/jbc.270.2.507; LEE CC, 1994, J BIOL CHEM, V269, P19457; Machide M, 1998, J NEUROCHEM, V71, P592; Maina F, 1999, NAT NEUROSCI, V2, P213, DOI 10.1038/6310; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NALDINI L, 1991, ONCOGENE, V6, P501; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; OKANO Y, 1993, BIOCHEM BIOPH RES CO, V190, P842, DOI 10.1006/bbrc.1993.1125; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; TAKAISHI K, 1994, ONCOGENE, V9, P273; Wang ZX, 1998, MOL CELL BIOL, V18, P590, DOI 10.1128/MCB.18.1.590; Yamada M, 1999, J NEUROCHEM, V73, P41, DOI 10.1046/j.1471-4159.1999.0730041.x; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; YOSHIDA K, 1986, NEUROSCI LETT, V70, P34, DOI 10.1016/0304-3940(86)90433-7; Yu ZB, 1998, J BIOL CHEM, V273, P3687, DOI 10.1074/jbc.273.6.3687; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	36	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31392	31398		10.1074/jbc.M002817200	http://dx.doi.org/10.1074/jbc.M002817200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896658	hybrid			2022-12-25	WOS:000089762700091
J	Olosz, F; Malek, TR				Olosz, F; Malek, TR			Three loops of the common gamma chain ectodomain required for the binding of interleukin-2 and interleukin-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-RECEPTOR; IL-2 RECEPTOR; ERYTHROPOIETIN RECEPTOR; EPO RECEPTOR; COMPLEX; IDENTIFICATION; AFFINITY; EXPRESSION; GROWTH; MUTAGENESIS	The common gamma chain (gamma c), a subunit of the interleukin (IL)-2, IL-4, IL-7, IL-9, and IL-15 receptors, contributes to both cytokine binding and subsequent signal transduction. Using a model-based site-directed mutagenesis strategy, we have identified residues of the mouse gamma c extracellular domain that are required for normal gamma c-dependent enhancement of IL-2 and IL-7 binding. One of these sites, Tyr-103, is homologous to key ligand-interacting residues in the growth hormone and erythropoietin receptors, whereas Cys-161, Cys-210, and Gly-211 may function indirectly by maintaining the functional conformation of gamma c via formation of an intramolecular disulfide bond. These two cysteines are also required for the integrity of a putative epitope recognized by TUGm2, an antagonistic monoclonal antibody that blocks gamma c-dependent cytokine binding and bioactivity. These results are consistent with the involvement of three predicted loops in gamma c that contribute to the binding of both IL-2 and IL-7. Mutations in these loops have also been noted in the gamma c gene of patients with X-linked severe combined immunodeficiency.	Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33101 USA	University of Miami	Malek, TR (corresponding author), Univ Miami, Sch Med, Dept Microbiol & Immunol, POB 016960 R-138, Miami, FL 33101 USA.				NIAID NIH HHS [AI40114] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI040114, R01AI040114] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALASUBRAMANIAN S, 1995, INT IMMUNOL, V7, P1839, DOI 10.1093/intimm/7.11.1839; BAMBOROUGH P, 1994, STRUCTURE, V2, P839, DOI 10.1016/S0969-2126(94)00085-9; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Chastagner P, 1996, EUR J IMMUNOL, V26, P201, DOI 10.1002/eji.1830260131; Clackson T, 1998, J MOL BIOL, V277, P1111, DOI 10.1006/jmbi.1998.1669; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; GUSTCHINA A, 1995, PROTEINS, V21, P140, DOI 10.1002/prot.340210208; He YW, 1998, CRIT REV IMMUNOL, V18, P503, DOI 10.1615/CritRevImmunol.v18.i6.20; HE YW, 1995, J IMMUNOL, V154, P1596; Horsten U, 1997, J BIOL CHEM, V272, P23748, DOI 10.1074/jbc.272.38.23748; IMLER JL, 1992, EMBO J, V11, P2047, DOI 10.1002/j.1460-2075.1992.tb05262.x; KIMURA Y, 1995, INT IMMUNOL, V7, P115, DOI 10.1093/intimm/7.1.115; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; Kroemer RT, 1996, PROTEIN ENG, V9, P1135, DOI 10.1093/protein/9.12.1135; Layton JE, 1997, J BIOL CHEM, V272, P29735, DOI 10.1074/jbc.272.47.29735; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; MALEK TR, 1995, J INTERF CYTOK RES, V15, P447, DOI 10.1089/jir.1995.15.447; MALEK TR, 1983, P NATL ACAD SCI-BIOL, V80, P5694, DOI 10.1073/pnas.80.18.5694; Middleton SA, 1999, J BIOL CHEM, V274, P14163, DOI 10.1074/jbc.274.20.14163; Middleton SA, 1996, J BIOL CHEM, V271, P14045, DOI 10.1074/jbc.271.24.14045; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; Puck JM, 1996, IMMUNOL TODAY, V17, P507, DOI 10.1016/0167-5699(96)30062-5; Rajotte D, 1997, J EXP MED, V185, P1939, DOI 10.1084/jem.185.11.1939; Raskin N, 1998, J IMMUNOL, V161, P3474; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SARAGOVI H, 1987, J IMMUNOL, V139, P1918; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; Sugamura K, 1996, ANNU REV IMMUNOL, V14, P179, DOI 10.1146/annurev.immunol.14.1.179; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559	32	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30100	30105		10.1074/jbc.M004976200	http://dx.doi.org/10.1074/jbc.M004976200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10887198	hybrid			2022-12-25	WOS:000089577900027
J	Savage, JR; McLaughlin, JN; Skiba, NP; Hamm, HE; Willardson, BM				Savage, JR; McLaughlin, JN; Skiba, NP; Hamm, HE; Willardson, BM			Functional roles of the two domains of phosducin and phosducin-like protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSDUCIN BETA-GAMMA; ROD OUTER SEGMENTS; GTPASE-ACTIVATING PROTEINS; SURFACE-PLASMON RESONANCE; HETEROTRIMERIC G-PROTEINS; CRYSTAL-STRUCTURE; RETINAL RODS; BINDING PROTEIN; ALPHA-SUBUNITS; RGS PROTEIN	Phosducin and phosducin-like protein regulate G protein signaling pathways by binding the beta gamma subunit complex (G beta gamma) and blocking G beta gamma association with G alpha subunits, effector enzymes, or membranes. Both proteins are composed of two structurally independent domains, each constituting approximately half of the molecule. We investigated the functional roles of the two domains of phosducin and phosducin-like protein in binding retinal G(t)beta gamma. Kinetic measurements using surface plasmon resonance showed that: 1) phosducin bound G(t)beta gamma with a 2.5-fold greater affinity than phosducin-like protein; 2) phosphorylation of phosducin decreased its affinity by 3-fold, principally as a result of a decrease in k(1); and 3) most of the free energy of binding comes from the N-terminal domain with a lesser contribution from the C-terminal domain. In assays measuring the association of G(t)beta gamma with G(t)alpha and light-activated rhodopsin, both N-terminal domains inhibited binding while neither of the C-terminal domains had any effect. In assays measuring membrane binding of G(t)beta gamma, both the N- and C-terminal domains inhibited membrane association, but much less effectively than the fall-length proteins. This inhibition could only be described by models that included a change in G(t)beta gamma to a conformation that did not bind the membrane. These models yielded a free energy change of +1.5 +/- 0.25 kcal/moI for the transition from the G(t)alpha-binding to the Pd-binding conformation of G(t)beta gamma.	Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA; Northwestern Univ, Sch Med, Inst Neurosci, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA	Brigham Young University; Northwestern University	Willardson, BM (corresponding author), Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA.			Willardson, Barry/0000-0002-8503-2268	NEI NIH HHS [EY06062, EY12287] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012287, R01EY006062] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Bluml K, 1997, EMBO J, V16, P4908, DOI 10.1093/emboj/16.16.4908; BORNANCIN F, 1989, EUR J BIOCHEM, V184, P687, DOI 10.1111/j.1432-1033.1989.tb15068.x; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; Chen FY, 1997, BIOCHEM BIOPH RES CO, V233, P370, DOI 10.1006/bbrc.1997.6460; CRAFT CM, 1991, GENOMICS, V10, P400, DOI 10.1016/0888-7543(91)90325-9; Craft CM, 1998, BIOCHEMISTRY-US, V37, P15758, DOI 10.1021/bi980921a; Danner S, 1996, P NATL ACAD SCI USA, V93, P10145, DOI 10.1073/pnas.93.19.10145; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; FUNG BKK, 1983, J BIOL CHEM, V258, P495; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gaudet R, 1999, MOL CELL, V3, P649, DOI 10.1016/S1097-2765(00)80358-5; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HAWES BE, 1994, J BIOL CHEM, V269, P29825; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1984, BIOCHEMISTRY-US, V23, P1972, DOI 10.1021/bi00304a014; LIEBMAN PA, 1984, ADV CYCLIC NUCL PROT, V17, P215; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; Morton TA, 1998, METHOD ENZYMOL, V295, P268; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; REIG JA, 1990, J BIOL CHEM, V265, P5816; Schroder S, 1996, P NATL ACAD SCI USA, V93, P2100, DOI 10.1073/pnas.93.5.2100; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Tanaka H, 1997, NEUROCHEM INT, V31, P625, DOI 10.1016/S0197-0186(96)00053-8; Tanaka H, 1996, BIOCHEM BIOPH RES CO, V223, P587, DOI 10.1006/bbrc.1996.0939; Thibault C, 1997, J BIOL CHEM, V272, P12253, DOI 10.1074/jbc.272.19.12253; THULIN CD, 1999, MOL VIS, V5, P40; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wilkins JF, 1996, J BIOL CHEM, V271, P19232, DOI 10.1074/jbc.271.32.19232; Willardson BM, 1996, P NATL ACAD SCI USA, V93, P1475, DOI 10.1073/pnas.93.4.1475; WILLARDSON BM, 1993, J BIOL CHEM, V268, P6371; XU J, 1995, P NATL ACAD SCI USA, V92, P2986; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050	43	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30399	30407		10.1074/jbc.M005120200	http://dx.doi.org/10.1074/jbc.M005120200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10896945	hybrid			2022-12-25	WOS:000089577900066
J	Seo, T; Al-Haideri, M; Treskova, E; Worgall, TS; Kako, Y; Goldberg, IJ; Deckelbaum, RJ				Seo, T; Al-Haideri, M; Treskova, E; Worgall, TS; Kako, Y; Goldberg, IJ; Deckelbaum, RJ			Lipoprotein lipase-mediated selective uptake from low density lipoprotein requires cell surface proteoglycans and is independent of scavenger receptor class B type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; MOUSE ADRENOCORTICAL-CELLS; CHOLESTERYL ESTERS; PLASMA-LIPOPROTEINS; HEPATIC LIPASE; SR-BI; ATHEROSCLEROTIC LESIONS; HUMAN FIBROBLASTS; TRANSGENIC MICE; CULTURED-CELLS	Lipoprotein lipase (LpL) hydrolyzes chylomicron and very low density lipoprotein triglycerides to provide fatty acids to tissues. Aside from its lipolytic activity, LpL promotes lipoprotein uptake by increasing the association of these particles with cell surfaces allowing for the internalization by receptors and proteoglycans. Recent studies also indicate that LpL stimulates selective uptake of lipids from high density lipoprotein (HDL) and very low density Lipoprotein. To study whether LpL can mediate selective uptake of lipids from low density lipoprotein (LDL), LpL was incubated with LDL receptor negative fibroblasts, and the uptake of LDL protein, labeled with I-125 and cholesteryl esters traced with [H-3]cholesteryl oleoyl ether, was compared. LpL mediated greater uptake of [H-3]cholesteryl oleoyl ether than I-125-LDL protein, a result that indicated selective lipid uptake. Lipid enrichment of cells was confirmed by measuring cellular cholesterol mass, LpL-mediated LDL selective uptake was not affected by the LpL inhibitor tetrahydrolipstatin but was nearly abolished by heparin, monoclonal anti-LpL antibodies, or chlorate treatment of cells and was not found using proteoglycan-deficient Chinese hamster ovary cells. Selective uptake from HDL, but not LDL, was 2-3-fold greater in scavenger receptor class B type I overexpressing cells (SR-BI cells) than compared control cells. LpL, however, induced similar increases in selective uptake from LDL and HDL in either control or SR-BI cells, indicative of the SR-BI-independent pathway. This was further supported by ability of LpL to promote selective uptake from LDL in human embryonal kidney 293 cells, cells that do not express SR-BI. In Chinese hamster ovary cell lines that overexpress LpL, we also found that selective uptake from LDL was induced by both endogenous and exogenous LpL. Transgenic mice that overexpress hu man LpL via a muscle creatine kinase promoter had more LDL selective uptake in muscle than did wild type mice. In summary LpL stimulates selective uptake of cholesteryl esters from LDL via pathways that are distinct from SR-BI, Moreover this process also occurs in vivo in tissues where abundant LpL is present.	Columbia Univ, Inst Human Nutr, Dept Pediat, New York, NY 10032 USA; Columbia Univ, Inst Human Nutr, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University	Deckelbaum, RJ (corresponding author), Columbia Univ, Inst Human Nutr, Dept Pediat, 630W 168th St,PH 1512, New York, NY 10032 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040404, R01HL045095, R37HL045095, P50HL056984] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56984, HL40404, HL45095] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Auerbach BJ, 1996, J BIOL CHEM, V271, P1329, DOI 10.1074/jbc.271.3.1329; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; BERRYMAN DE, 1995, J BIOL CHEM, V270, P24525, DOI 10.1074/jbc.270.41.24525; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1976, CELL, V9, P663, DOI 10.1016/0092-8674(76)90130-6; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; Charest MC, 1999, EUR J BIOCHEM, V263, P402, DOI 10.1046/j.1432-1327.1999.00527.x; CORESH J, 1993, J LIPID RES, V34, P1687; DECKELBAUM RJ, 1992, BIOCHEMISTRY-US, V31, P8544, DOI 10.1021/bi00151a023; DOLE VP, 1956, J CLIN INVEST, V35, P150, DOI 10.1172/JCI103259; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; ESKO JD, 1987, J BIOL CHEM, V262, P12189; FernandezBorja M, 1996, J LIPID RES, V37, P464; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Galeano NF, 1998, J LIPID RES, V39, P1263; GLASS C, 1985, J BIOL CHEM, V260, P744; GOLDBERG IJ, 1986, BIOCHIM BIOPHYS ACTA, V878, P168, DOI 10.1016/0005-2760(86)90143-8; Goldberg IJ, 1996, J LIPID RES, V37, P693; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GREEN SR, 1991, J LIPID RES, V32, P667; ISHIKAWA TT, 1974, J LIPID RES, V15, P286; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Ji ZS, 1997, J BIOL CHEM, V272, P31285, DOI 10.1074/jbc.272.50.31285; Lambert G, 1999, J LIPID RES, V40, P1294; LevakFrank S, 1997, J BIOL CHEM, V272, P17182, DOI 10.1074/jbc.272.27.17182; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; LOOKENE A, 1994, EUR J BIOCHEM, V222, P395, DOI 10.1111/j.1432-1033.1994.tb18878.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUOMA J, 1994, J CLIN INVEST, V93, P2014, DOI 10.1172/JCI117195; Merkel M, 1998, P NATL ACAD SCI USA, V95, P13841, DOI 10.1073/pnas.95.23.13841; MISRA KB, 1994, J BIOL CHEM, V269, P23838; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; MULDER M, 1993, J BIOL CHEM, V268, P9369; Obunike JC, 1996, J LIPID RES, V37, P2439; Panzenboeck U, 1997, J LIPID RES, V38, P239; PITTMAN RC, 1983, BIOCHEM J, V212, P791, DOI 10.1042/bj2120791; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rinninger F, 1998, J LIPID RES, V39, P1335; RUMSEY SC, 1992, J LIPID RES, V33, P1551; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; RUMSEY SC, 1995, J BIOL CHEM, V270, P10008, DOI 10.1074/jbc.270.17.10008; Santamarina-Fojo Silvia, 1994, Current Opinion in Lipidology, V5, P117; SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P895, DOI 10.1161/01.ATV.9.6.895; Sendak RA, 1998, J LIPID RES, V39, P1310; Seo T, 1997, J LIPID RES, V38, P765; SOCORRO L, 1985, J BIOL CHEM, V260, P6324; Swarnakar S, 1998, J BIOL CHEM, V273, P12140, DOI 10.1074/jbc.273.20.12140; Swarnakar S, 1999, J BIOL CHEM, V274, P29733, DOI 10.1074/jbc.274.42.29733; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; THOMAS MS, 1983, ANAL BIOCHEM, V130, P215, DOI 10.1016/0003-2697(83)90672-3; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; Zechner R, 1997, CURR OPIN LIPIDOL, V8, P77, DOI 10.1097/00041433-199704000-00005	53	72	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30355	30362		10.1074/jbc.M910327199	http://dx.doi.org/10.1074/jbc.M910327199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10896681	hybrid			2022-12-25	WOS:000089577900060
J	de Bruyn, KMT; de Rooij, J; Wolthuis, RMF; Rehmann, H; Wesenbeek, J; Cool, RH; Wittinghofer, AH; Bos, JL				de Bruyn, KMT; de Rooij, J; Wolthuis, RMF; Rehmann, H; Wesenbeek, J; Cool, RH; Wittinghofer, AH; Bos, JL			RalGEF2, a pleckstrin homology domain containing guanine nucleotide exchange factor for Ral	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; GDP DISSOCIATION STIMULATOR; C-FOS PROMOTER; PHOSPHOLIPASE-D; PUTATIVE EFFECTOR; SIGNAL-TRANSDUCTION; BINDING PROTEIN-1; GENE-EXPRESSION; IDENTIFICATION; FAMILY	Ral is a ubiquitously expressed Ras-like small GTPase. Several guanine nucleotide exchange factors for Ral have been identified, including members of the RalGDS family, which exhibit a Pas binding domain and are regulated by binding to RasGTP. Here we describe a novel type of RalGEF, RalGEF2. This guanine nucleotide exchange factor has a characteristic Cdc25-like catalytic domain at the N terminus and a pleckstrin homology (PH) domain at the C terminus. RalGEF2 is able to activate Ral both in vivo and in vitro. Deletion of the PH domain results in an increased cytoplasmic localization of the protein and a corresponding reduction in activity in vivo, suggesting that the PH domain functions as a membrane anchor necessary for optimal activity in vivo.	Univ Med Ctr Utrecht, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Med Ctr Utrecht, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44227 Dortmund, Germany	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Max Planck Society	Bos, JL (corresponding author), Univ Med Ctr Utrecht, Dept Physiol Chem, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.		de rooij, johan/C-1325-2019	Cool, Robbert/0000-0002-9845-2202; Wolthuis, Rob/0000-0002-3109-1588				Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; Bauer B, 1999, J BIOL CHEM, V274, P17763, DOI 10.1074/jbc.274.25.17763; Bhullar RP, 1996, BBA-MOL CELL RES, V1311, P181, DOI 10.1016/0167-4889(96)00002-X; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; DAdamo DR, 1997, ONCOGENE, V14, P1295, DOI 10.1038/sj.onc.1200950; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; EMKEY R, 1991, J BIOL CHEM, V266, P9703; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Fruman DA, 1999, CELL, V97, P817, DOI 10.1016/S0092-8674(00)80792-8; Fuller SJ, 1998, BIOCHEM J, V335, P241, DOI 10.1042/bj3350241; Goi T, 1999, MOL CELL BIOL, V19, P1731; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; Hoshinoso M, 1999, J BIOL CHEM, V274, P17837, DOI 10.1074/jbc.274.25.17837; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Liscovitch M, 1999, BBA-MOL CELL BIOL L, V1439, P245, DOI 10.1016/S1388-1981(99)00098-0; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Luo JQ, 1997, BIOCHEM BIOPH RES CO, V235, P854, DOI 10.1006/bbrc.1997.6793; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; M'Rabet L, 1999, J BIOL CHEM, V274, P21847, DOI 10.1074/jbc.274.31.21847; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Murai H, 1997, J BIOL CHEM, V272, P10483; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; Park SH, 1995, ONCOGENE, V11, P2349; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Ramocki MB, 1998, J BIOL CHEM, V273, P17696, DOI 10.1074/jbc.273.28.17696; Sone M, 1997, SCIENCE, V275, P543, DOI 10.1126/science.275.5299.543; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Verheijen MHG, 1999, ONCOGENE, V18, P4435, DOI 10.1038/sj.onc.1202834; VOB M, 1999, J BIOL CHEM, V274, P34691; Wang KL, 1999, J BIOL CHEM, V274, P14525, DOI 10.1074/jbc.274.21.14525; Wang KL, 1997, J BIOL CHEM, V272, P16002, DOI 10.1074/jbc.272.25.16002; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230	56	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29761	29766		10.1074/jbc.M001160200	http://dx.doi.org/10.1074/jbc.M001160200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10889189	hybrid			2022-12-25	WOS:000089439800079
J	Kussel-Andermann, P; El-Amraoui, A; Safieddine, S; Hardelin, JP; Nouaille, S; Camonis, J; Petit, C				Kussel-Andermann, P; El-Amraoui, A; Safieddine, S; Hardelin, JP; Nouaille, S; Camonis, J; Petit, C			Unconventional myosin VIIA is a novel A-kinase-anchoring protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG COCHLEA; OUTER HAIR-CELLS; USHER 1B SYNDROME; RI-ALPHA; PHOTORECEPTOR CELLS; REGULATORY SUBUNITS; SHAKER-1 MUTATIONS; SENSORY EPITHELIA; GENE; DOMAIN	To gain an insight into the cellular function of the unconventional myosin VIIA, we sought proteins interacting with its tail region, using the yeast two-hybrid system. Here we report on one of the five candidate interactors we identified, namely the type I alpha regulatory subunit (RI alpha) of protein kinase A. The interaction of RI alpha with myosin VIIA tail was demonstrated by coimmunoprecipitation from transfected HEK293 cells. Analysis of deleted constructs in the yeast two-hybrid system showed that the interaction of myosin VIIA with RI alpha involves the dimerization domain of RI alpha. In vitro binding assays identified the C-terminal "4.1, ezrin, radixin, moesin" (FERM)-like domain of myosin VIIA as the interacting domain. In humans and mice, mutations in the myosin VIIA gene underlie hereditary hearing loss, which may or may not be associated with visual deficiency, Immunohistofluorescence revealed that myosin VILA and RI alpha are coexpressed in the outer hair cells of the cochlea and rod photoreceptor cells of the retina. Our results strongly suggest that myosin VILA is a novel protein kinase A-anchoring protein that targets protein kinase A to definite subcellular sites of these sensory cells.	CNRS, URA 1968, Unite Genet Deficits Sensoriels, F-75724 Paris 15, France; Inst Curie, INSERM, U248, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Petit, C (corresponding author), CNRS, URA 1968, Unite Genet Deficits Sensoriels, 25 Rue Dr Roux, F-75724 Paris 15, France.	cpetit@pasteur.fr		Safieddine, Saaid/0000-0002-6159-0572; Petit, Christine/0000-0002-9069-002X; EL-AMRAOUI, Aziz/0000-0003-2692-4984				ALGRAIN M, 1993, CURR BIOL, V3, P451, DOI 10.1016/0960-9822(93)90354-Q; Angelo R, 1998, J BIOL CHEM, V273, P14633, DOI 10.1074/jbc.273.23.14633; CARR DW, 1991, J BIOL CHEM, V266, P14188; Chen ZY, 1996, GENOMICS, V36, P440, DOI 10.1006/geno.1996.0489; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; COGHLAN VM, 1993, MOL CELL BIOCHEM, V128, P309, DOI 10.1007/BF01076780; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Dunah AW, 1998, MOL PHARMACOL, V53, P429, DOI 10.1124/mol.53.3.429; ElAmraoui A, 1996, HUM MOL GENET, V5, P1171, DOI 10.1093/hmg/5.8.1171; ELAMRAOUI A, 1997, J AUDIOL MED, V6, P170; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Hasson T, 1997, CELL MOTIL CYTOSKEL, V37, P127, DOI 10.1002/(SICI)1097-0169(1997)37:2<127::AID-CM5>3.0.CO;2-5; HASSON T, 1995, P NATL ACAD SCI USA, V92, P9815, DOI 10.1073/pnas.92.21.9815; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; Jagger DJ, 1999, PFLUG ARCH EUR J PHY, V437, P409, DOI 10.1007/s004240050795; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RH, 1984, BIOCHEMISTRY-US, V23, P1972, DOI 10.1021/bi00304a014; Leon DA, 1997, J BIOL CHEM, V272, P28431, DOI 10.1074/jbc.272.45.28431; Levy G, 1997, HUM MOL GENET, V6, P111, DOI 10.1093/hmg/6.1.111; Liu XR, 1999, J NEUROSCI, V19, P6267; Liu XR, 1997, CELL MOTIL CYTOSKEL, V37, P240, DOI 10.1002/(SICI)1097-0169(1997)37:3<240::AID-CM6>3.3.CO;2-2; Liu XR, 1998, NAT GENET, V19, P117, DOI 10.1038/470; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Liu XZ, 1997, NAT GENET, V17, P268, DOI 10.1038/ng1197-268; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Mburu Philomena, 1997, Genes and Function, V1, P191; Miki K, 1999, J BIOL CHEM, V274, P29057, DOI 10.1074/jbc.274.41.29057; Oliver TN, 1999, CELL MOL LIFE SCI, V56, P243, DOI 10.1007/s000180050426; Reddy ASN, 1996, J BIOL CHEM, V271, P7052, DOI 10.1074/jbc.271.12.7052; Ricci AJ, 1997, J PHYSIOL-LONDON, V501, P111, DOI 10.1111/j.1469-7793.1997.111bo.x; Richardson GP, 1997, J NEUROSCI, V17, P9506; Sahly I, 1997, ANAT EMBRYOL, V196, P159, DOI 10.1007/s004290050088; Self T, 1998, DEVELOPMENT, V125, P557; Solberg R, 1997, ENDOCRINOLOGY, V138, P169, DOI 10.1210/en.138.1.169; TASKEN K, 1993, J BIOL CHEM, V268, P21276; Titus MA, 1999, CURR BIOL, V9, P1297, DOI 10.1016/S0960-9822(00)80051-2; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Van den Abbeele T, 1999, AM J PHYSIOL-CELL PH, V277, pC913, DOI 10.1152/ajpcell.1999.277.5.C913; VanDenAbbeele T, 1996, J PHYSIOL-LONDON, V494, P77, DOI 10.1113/jphysiol.1996.sp021477; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALTER U, 1984, ADV CYCLIC NUCL PROT, V17, P249; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; Weil D, 1996, P NATL ACAD SCI USA, V93, P3232, DOI 10.1073/pnas.93.8.3232; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; Wolbring G, 1996, BIOCHEMISTRY-US, V35, P11013, DOI 10.1021/bi960699e; Wolfrum U, 1998, CELL MOTIL CYTOSKEL, V40, P261, DOI 10.1002/(SICI)1097-0169(1998)40:3<261::AID-CM5>3.3.CO;2-#	53	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29654	29659		10.1074/jbc.M004393200	http://dx.doi.org/10.1074/jbc.M004393200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10889203	hybrid			2022-12-25	WOS:000089439800065
J	Manganas, LN; Trimmer, JS				Manganas, LN; Trimmer, JS			Subunit composition determines Kv1 potassium channel surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED K+ CHANNELS; RAT HIPPOCAMPAL-NEURONS; BETA-SUBUNITS; ENDOPLASMIC-RETICULUM; MAMMALIAN BRAIN; ALPHA-SUBUNIT; XENOPUS-OOCYTES; PROTEIN; CELLS; ASSOCIATION	Shaker-related or Kv1 voltage-gated K+ channels play critical roles in regulating the excitability of mammalian neurons. Native Kv1 channel complexes are octamers of four integral membrane alpha subunits and four cytoplasmic beta subunits, such that a tremendous diversity of channel complexes can be assembled from the array of alpha and beta subunits expressed in the brain. However, biochemical and immunohistochemical studies have demonstrated that only certain complexes predominate in the mammalian brain, suggesting that regulatory mechanisms exist that ensure plasma membrane targeting of only physiologically appropriate channel complexes. Here we show that Kv1 channels assembled as homo- or heterotetrameric complexes had distinct surface expression characteristics in both transfected mammalian cells and hippocampal neurons. Homotetrameric Kv1.1 channels were localized to endoplasmic reticulum, Kv1.4 channels to the cell surface, and Kv1.2 channels to both endoplasmic reticulum and the cell surface. Heteromeric assembly with Kv1.4 resulted in dose-dependent increases in cell surface expression of coassembled Kv1.1 and Kv1.2, while coassembly with Kv1.1 had a dominant-negative effect on Kv1.2 and Kv1.4 surface expression. Coassembly with Kv beta subunits promoted cell surface expression of each Kv1 heteromeric complex. These data suggest that subunit composition and stoichiometry determine surface expression characteristics of Kv1 channels in excitable cells.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Trimmer, JS (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS034383, R01NS034383] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM008444] Funding Source: Medline; NINDS NIH HHS [NS34383] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BekeleArcuri Z, 1996, NEUROPHARMACOLOGY, V35, P851, DOI 10.1016/0028-3908(96)00128-1; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; CHANDY KG, 1995, LIGAND VOLTAGE GATED, P1; Coleman SK, 1999, J NEUROCHEM, V73, P849, DOI 10.1046/j.1471-4159.1999.0730849.x; Felix JP, 1999, BIOCHEMISTRY-US, V38, P4922, DOI 10.1021/bi982954w; GELMAN MS, 1995, J BIOL CHEM, V270, P15085, DOI 10.1074/jbc.270.25.15085; Green WN, 1999, J GEN PHYSIOL, V113, P163, DOI 10.1085/jgp.113.2.163; Hille B., 1992, IONIC CHANNELS EXCIT; HOPKINS WF, 1994, PFLUG ARCH EUR J PHY, V428, P382, DOI 10.1007/BF00724522; HSU VW, 1992, CELL, V69, P625, DOI 10.1016/0092-8674(92)90226-3; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P625; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Koch RO, 1997, J BIOL CHEM, V272, P27577, DOI 10.1074/jbc.272.44.27577; Li DQ, 2000, J BIOL CHEM, V275, P11597, DOI 10.1074/jbc.275.16.11597; Lim ST, 2000, NEURON, V25, P385, DOI 10.1016/S0896-6273(00)80902-2; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Murakoshi H, 1999, J NEUROSCI, V19, P1728; Nagaya N, 1999, RECEPTOR CHANNEL, V6, P229; Nakahira K, 1996, J BIOL CHEM, V271, P7084, DOI 10.1074/jbc.271.12.7084; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PONGS O, 1995, SEMIN NEUROSCI, V7, P137, DOI 10.1006/smns.1995.0015; Pongs O, 1999, FEBS LETT, V452, P31, DOI 10.1016/S0014-5793(99)00535-9; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Rhodes KJ, 1997, J NEUROSCI, V17, P8246; Rhodes KJ, 1996, J NEUROSCI, V16, P4846; RHODES KJ, 1995, J NEUROSCI, V15, P5360; Ribera AB, 1996, NEUROPHARMACOLOGY, V35, P1007, DOI 10.1016/0028-3908(96)00098-6; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Schulteis CT, 1998, J BIOL CHEM, V273, P26210, DOI 10.1074/jbc.273.40.26210; Shamotienko OG, 1997, BIOCHEMISTRY-US, V36, P8195, DOI 10.1021/bi970237g; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Shi G, 1999, J MEMBRANE BIOL, V168, P265, DOI 10.1007/s002329900515; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; SHI GY, 1994, J BIOL CHEM, V269, P23204; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; Tiffany AM, 2000, J CELL BIOL, V148, P147, DOI 10.1083/jcb.148.1.147; Trimmer JS, 1998, CURR OPIN NEUROBIOL, V8, P370, DOI 10.1016/S0959-4388(98)80063-9; Trouet D, 1997, PFLUG ARCH EUR J PHY, V434, P632, DOI 10.1007/s004240050445; Wang FC, 1999, EUR J BIOCHEM, V263, P230, DOI 10.1046/j.1432-1327.1999.00493.x; Warren G, 1999, CELL, V98, P125, DOI 10.1016/S0092-8674(00)81006-5; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	51	144	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29685	29693		10.1074/jbc.M005010200	http://dx.doi.org/10.1074/jbc.M005010200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896669	hybrid			2022-12-25	WOS:000089439800068
J	Wang, D; Chiara, DC; Xie, Y; Cohen, JB				Wang, D; Chiara, DC; Xie, Y; Cohen, JB			Probing the structure of the nicotinic acetylcholine receptor with 4-benzoylbenzoylcholine, a novel photoaffinity competitive antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SITES; NONCOMPETITIVE ANTAGONIST; ALPHA-SUBUNIT; AMINO-ACIDS; GAMMA-SUBUNIT; DELTA-SUBUNIT; IDENTIFICATION; RESIDUES; SELECTIVITY; CHANNEL	[H-3]4-Benzoylbenzoylcholine (Bz(2)choline) was synthesized as a photoaffinity probe for the Torpedo nicotinic acetylcholine receptor (nAChR). [H-3]Bz(2)choline acts as an nAChR competitive antagonist and binds at equilibrium with the same affinity (K-D = 1.4 mu M) to both agonist sites. Irradiation at 320 nm of nAChR-rich membranes equilibrated with [H-3]Bz(2)choline results in the covalent incorporation of [H-3]Bz(2)choline into the nAChR gamma- and delta-subunits that is inhibitable by agonist, with little specific incorporation in the alpha-subunits. To identify the sites of photoincorporation, gamma- and delta-subunits, isolated from nAChR-rich membranes photolabeled with [H-3]Bz(2)choline, were digested enzymatically, and the labeled fragments were isolated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and/or reversed-phase high performance liquid chromatography, For the gamma-subunit, Staphylococcus aureus V8 protease produced a specifically labeled peptide beginning at gamma VaI-102, whereas for the delta-subunit, endoproteinase Asp-N produced a labeled peptide beginning at delta Asp-99. Amino-terminal sequence analysis identified the homologous residues gamma Leu-109 and delta Leu-111 as the primary sites of [H-3]Bz(2)choline photoincorporation. This is the first identification by affinity labeling of non-reactive amino acids within the acetylcholine-binding sites, and these results establish that when choline esters of benzoic acid are bound to the nAChR agonist sites, the para substituent is selectively oriented toward and in proximity to amino acids gamma Leu-109/delta Leu-111.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Cohen, JB (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.	jonathan_cohen@hms.harvard.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019522] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 19522] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; Arias HR, 2000, NEUROCHEM INT, V36, P595, DOI 10.1016/S0197-0186(99)00154-0; Blanton MP, 1998, J BIOL CHEM, V273, P8659, DOI 10.1074/jbc.273.15.8659; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BOYD ND, 1984, BIOCHEMISTRY-US, V23, P4023, DOI 10.1021/bi00313a003; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; Bren N, 1997, J BIOL CHEM, V272, P30793, DOI 10.1074/jbc.272.49.30793; BROWNING ET, 1972, ANAL BIOCHEM, V46, P624, DOI 10.1016/0003-2697(72)90334-X; Chiara DC, 1999, BIOCHEMISTRY-US, V38, P6689, DOI 10.1021/bi9901735; Chiara DC, 1998, FEBS LETT, V423, P223, DOI 10.1016/S0014-5793(98)00093-3; Chiara DC, 1997, J BIOL CHEM, V272, P32940, DOI 10.1074/jbc.272.52.32940; COHEN JB, 1991, J BIOL CHEM, V266, P23354; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; CZAJKOWSKI C, 1995, J BIOL CHEM, V270, P3160, DOI 10.1074/jbc.270.7.3160; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; FU DX, 1994, J BIOL CHEM, V269, P26152; Gallagher MJ, 1999, MOL PHARMACOL, V56, P300, DOI 10.1124/mol.56.2.300; GALZI JL, 1991, P NATL ACAD SCI USA, V88, P5051, DOI 10.1073/pnas.88.11.5051; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GAO ZH, 1995, J BIOL CHEM, V270, P10125, DOI 10.1074/jbc.270.17.10125; KAO PN, 1984, J BIOL CHEM, V259, P1662; KOTZYBAHIBERT F, 1995, ANGEW CHEM INT EDIT, V34, P1296, DOI 10.1002/anie.199512961; LORING RH, 1993, METHODS NEUROSCI, V12, P324; MAHMOOD R, 1987, J BIOL CHEM, V262, P14479; Middleton RE, 1999, MOL PHARMACOL, V56, P290, DOI 10.1124/mol.56.2.290; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; Osaka H, 1999, J BIOL CHEM, V274, P9581, DOI 10.1074/jbc.274.14.9581; PEDERSEN SE, 1992, J BIOL CHEM, V267, P10489; PEDERSEN SE, 1986, J BIOL CHEM, V261, P3735; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; Prestwich GD, 1997, PHOTOCHEM PHOTOBIOL, V65, P222, DOI 10.1111/j.1751-1097.1997.tb08548.x; PRINCE RJ, 1998, NICOTINIC ACETYLCHOL, P31; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; TETAZ T, 1990, BIOCHEM INT, V22, P561; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; WEILAND G, 1979, MOL PHARMACOL, V15, P197; WHITE BH, 1988, BIOCHEMISTRY-US, V27, P8741, DOI 10.1021/bi00424a009; WHITE BH, 1991, J BIOL CHEM, V266, P21595; WHITE BH, 1992, J BIOL CHEM, V267, P15770	46	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28666	28674		10.1074/jbc.M005441200	http://dx.doi.org/10.1074/jbc.M005441200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893246	hybrid			2022-12-25	WOS:000089330700045
J	Garcia-Gras, EA; Chi, P; Thompson, EA				Garcia-Gras, EA; Chi, P; Thompson, EA			Glucocorticoid-mediated destabilization of cyclin D3 mRNA involves RNA-protein interactions in the 3 '-untranslated region of the mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; GAP-43 MESSENGER-RNA; C-PROTEINS; POLYPYRIMIDINE TRACT; GENE-EXPRESSION; BINDING-PROTEIN; RICH SEQUENCES; LYMPHOID-CELLS; ELEMENT; PURIFICATION	Glucocorticoids regulate the expression of the G(1) progression factor, cyclin D3, Cyclin D3 messenger RNA (CcnDS mRNA) stability decreases rapidly when murine T lymphoma cells are treated with the synthetic glucocorticoid dexamethasone. Basal stability of CcnDS mRNA is regulated by sequences within the 3'-untranslated region (3'-UTR), RNA-protein interactions occurring within the CcnD3 3'-UTR have been analyzed by RNA electrophoretic mobility shift assay, Three sites of RNA-protein interaction have been mapped using this approach, These elements include three pyrimidine-rich domains of 25, 26, and 37 nucleotides. When the cyclin D3 3'-UTR was stably overexpressed, the endogenous CcnD3 mRNA was no longer regulated by dexamethasone, Likewise, overexpression of a 215-nucleotide transgene that contains the 26- and 37-nucleotide elements blocks glucocorticoid inhibition of CcnD3 mRNA expression. These observations suggest that the 215-nucleotide 3'-UTR element may act as a molecular decoy, competing for proteins that bind to the endogenous transcript and thereby attenuating glucocorticoid responsiveness. W-cross-linking experiments showed that two proteins of approximate molecular weight 37,000 and 52,000 bind to this 3'-UTR element.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Thompson, EA (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.							AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BOTHWELL ALM, 1991, J BIOL CHEM, V266, P24657; CHANG KH, 1993, J VIROL, V67, P6716, DOI 10.1128/JVI.67.11.6716-6725.1993; CHANGNOVICH D, 1996, J BIOL CHEM, V271, P33580; CHANGNOVICH D, 1996, J BIOL CELL, V271, P33587; Cohen J J, 1992, Semin Immunol, V4, P363; CzyzykKrzeska MF, 1996, J BIOL CHEM, V271, P3293, DOI 10.1074/jbc.271.6.3293; DOMPENCIEL RE, 1995, J BIOL CHEM, V270, P6108, DOI 10.1074/jbc.270.11.6108; FORSTHOEFEL AM, 1987, MOL ENDOCRINOL, V1, P899, DOI 10.1210/mend-1-12-899; GADSON P, 1993, BIOCHIM BIOPHYS ACTA, V1173, P22, DOI 10.1016/0167-4781(93)90238-9; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HOLCOMB ER, 1984, J BIOL CHEM, V259, P31; HONORE B, 1995, J BIOL CHEM, V270, P28780; Irwin N, 1997, NUCLEIC ACIDS RES, V25, P1281, DOI 10.1093/nar/25.6.1281; Joseph B, 1998, J BIOL CHEM, V273, P20511, DOI 10.1074/jbc.273.32.20511; Kohn DT, 1996, MOL BRAIN RES, V36, P240, DOI 10.1016/0169-328X(95)00239-O; LEFFERS H, 1995, EUR J BIOCHEM, V230, P447, DOI 10.1111/j.1432-1033.1995.tb20581.x; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; PETERSEN DD, 1989, P NATL ACAD SCI USA, V86, P7800, DOI 10.1073/pnas.86.20.7800; REISMAN D, 1995, MOL ENDOCRINOL, V9, P1500, DOI 10.1210/me.9.11.1500; RHEE K, 1995, CANCER RES, V55, P4188; Sakai K, 1999, FEBS LETT, V446, P157, DOI 10.1016/S0014-5793(99)00206-9; SCHWARTZMAN RA, 1994, INT ARCH ALLERGY IMM, V105, P347, DOI 10.1159/000236781; Sun XL, 1996, J BIOL CHEM, V271, P25539; Wang XM, 1996, EMBO J, V15, P5040, DOI 10.1002/j.1460-2075.1996.tb00884.x; Wang ZF, 1996, GENE DEV, V10, P3028, DOI 10.1101/gad.10.23.3028; WINSTALL E, 1995, MOL CELL BIOL, V15, P3796; ZAIDI SHE, 1995, J BIOL CHEM, V270, P17292, DOI 10.1074/jbc.270.29.17292	35	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22001	22008		10.1074/jbc.M001048200	http://dx.doi.org/10.1074/jbc.M001048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10896950	hybrid			2022-12-25	WOS:000088363800036
J	Clarke, D; Vegiopoulos, A; Crawford, A; Mucenski, M; Bonifer, C; Frampton, J				Clarke, D; Vegiopoulos, A; Crawford, A; Mucenski, M; Bonifer, C; Frampton, J			In vitro differentiation of c-myb(-/-) ES cells reveals that the colony forming capacity of unilineage macrophage precursors and myeloid progenitor commitment are c-Myb independent	ONCOGENE			English	Article						c-Myb; knockout; ES cell differentiation; haemopoietic progenitors	MULTIPLE HEMATOPOIETIC LINEAGES; EMBRYONIC STEM-CELLS; TRANSCRIPTION FACTOR GATA-1; MICE LACKING; ERYTHROID DEVELOPMENT; YOLK-SAC; GENE; LEUKEMIA; MOUSE; MEGAKARYOCYTE	Mice homozygous for an inactivated c-myb allele exhibit embryonic (primitive) blood formation but die at about day 15 of gestation because of a failure to generate adult (definitive) haemopoiesis. Recently, it has been shown that commitment to definitive haemopoiesis does occur in vivo, but that some point in the subsequent development towards the differentiated lineages is compromised. Here we have asked whether it is possible to demonstrate this same distinction between the development of primitive and definitive haemopoiesis during the in vivo differentiation of c-myb null ES cells, and whether this can be used to define more precisely at which developmental stage the absence of c-Myb blocks the adult haemopoietic lineages. We investigated the kinetics of progenitor formation and commitment to differentiation using a combination of colony forming assays and analysis of RNA and surface antigen expression. Primitive unilineage macrophage and erythroid precursor commitment could develop in the absence of c-Myb. No precursors characteristic of definitive haemopoiesis were detected; nevertheless, we could show the expression of programme of transcription and surface antigens which is consistent with the appearance of definitive progenitors blocked at an early multipotential stage.	John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England; Univ Leeds, St James Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England; Childrens Hosp, Div Pulm Biol, Cincinnati, OH 45229 USA	University of Oxford; Saint James's University Hospital; University of Leeds; Cincinnati Children's Hospital Medical Center	Frampton, J (corresponding author), John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England.		Bonifer, Constanze/B-3000-2009	Bonifer, Constanze/0000-0002-4267-0825				Alexander WS, 1996, BLOOD, V87, P2162, DOI 10.1182/blood.V87.6.2162.bloodjournal8762162; Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dzierzak E, 1998, IMMUNOL TODAY, V19, P228, DOI 10.1016/S0167-5699(98)01258-4; Elefanty AG, 1997, BLOOD, V90, P1435, DOI 10.1182/blood.V90.4.1435.1435_1435_1447; Elwood NJ, 1998, BLOOD, V91, P3756; Faust N, 1997, EXP HEMATOL, V25, P432; FAUST N, 1994, DNA CELL BIOL, V13, P901, DOI 10.1089/dna.1994.13.901; Frampton J, 1997, MOL B INT U, P287; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; LONG MW, 1981, BLOOD, V58, P1032; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Mukouyama YS, 1999, CURR BIOL, V9, P833, DOI 10.1016/S0960-9822(99)80368-6; Naito M, 1996, J LEUKOCYTE BIOL, V59, P133, DOI 10.1002/jlb.59.2.133; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; NESS SA, 1996, BIOCHIM BIOPHYS ACTA, V12, P123; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Palis J, 1999, DEVELOPMENT, V126, P5073; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; RAVID K, 1991, P NATL ACAD SCI USA, V88, P1521, DOI 10.1073/pnas.88.4.1521; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Shavit JA, 1998, GENE DEV, V12, P2164, DOI 10.1101/gad.12.14.2164; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Sumner R, 2000, ONCOGENE, V19, P3335, DOI 10.1038/sj.onc.1203660; Suwabe N, 1998, BLOOD, V92, P4108, DOI 10.1182/blood.V92.11.4108.423k29_4108_4118; TAKAHASHI K, 1989, J LEUKOCYTE BIOL, V45, P87, DOI 10.1002/jlb.45.2.87; Trimborn T, 1999, GENE DEV, V13, P112, DOI 10.1101/gad.13.1.112; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Visvader JE, 1998, GENE DEV, V12, P473, DOI 10.1101/gad.12.4.473; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WILES MV, 1991, DEVELOPMENT, V111, P259; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890	43	28	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2000	19	30					3343	3351		10.1038/sj.onc.1203661	http://dx.doi.org/10.1038/sj.onc.1203661			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918591				2022-12-25	WOS:000088198100002
J	Kumar, S; Kalsi, J; Ravirajan, CT; Rahman, A; Athwal, D; Latchman, DS; Isenberg, DA; Pearl, LH				Kumar, S; Kalsi, J; Ravirajan, CT; Rahman, A; Athwal, D; Latchman, DS; Isenberg, DA; Pearl, LH			Molecular cloning and expression of the fabs of human autoantibodies in Escherichia coli - Determination of the heavy or light chain contribution to the anti-DNA/-cardiolipin activity of the Fab	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; V-LAMBDA REPERTOIRE; MONOCLONAL-ANTIBODY; BINDING; SPECIFICITY; NEPHRITIS; CDR3; REACTIVITY; DIVERSITY; PROFILES	The Fabs of three human autoantibodies (B3/33H11, anti-DNA; UK4, anti-phospholipid) and six related hybrids have been cloned, expressed in Escherichia coli, and purified to homogeneity, SDS-polyacrylamide gel electrophoresis and Western blot analysis of the recombinant Feb demonstrated the purified Fab to be of correct size and in assembled form. Protein expression levels of up to 5-9 mg per liter of culture were achievable. A sensitive and reliable comparative anti-DNA enzyme-linked immunosorbent assay, involving a defined biotinylated 35-mer oligonucleotide in its single- or double-stranded form, is also described. Crithidia assay and anti-DNA or anti-cardiolipin antibody enzyme-linked immunosorbent assay analyses demonstrated convincing binding of the recombinant Fab proteins to DNA/cardiolipin, confirming the expression of functional molecule. The comparative DNA/cardiolipin binding analyses of the nine Fabs revealed that the anti-DNA (light, B3/33H11) or anti-cardiolipin (heavy, UK4) activity lies predominantly on one of the two chains. However, a compatible partner chain is necessary for optimum antigen binding activity of the antibody.	UCL, Ctr Rheumatol, Bloomsbury Rheumatol Unit, London W1P 9PG, England; UCL, Dept Med, London W1P 9PG, England; UCL, Dept Biochem & Mol Biol, London W1P 9PG, England; Celltech Ltd, Therapeut, Slough SL1 4EN, Berks, England; Inst Child Hlth, London WC1N 1EH, England	University of London; University College London; University of London; University College London; University of London; University College London; Celltech Group Ltd; University of London; University College London	Kumar, S (corresponding author), Inst Canc Res, Chester Beatty Labs, 237 Fulham Rd, London SW3 6JB, England.	sanjeev@icr.ac.uk		Isenberg, David/0000-0001-9514-2455; Pearl, Laurence/0000-0002-6910-1809				BENCHETRIT E, 1988, IMMUNOLOGY, V65, P479; BOLLAG DM, 1991, PROTEIN METHODS, P46; BRINKMAN K, 1990, IMMUNOL TODAY, V11, P232, DOI 10.1016/0167-5699(90)90095-Q; de Wildt RMT, 1999, J MOL BIOL, V285, P895, DOI 10.1006/jmbi.1998.2396; EHRENSTEIN M, 1993, CLIN EXP IMMUNOL, V92, P39; EHRENSTEIN MR, 1995, KIDNEY INT, V48, P705, DOI 10.1038/ki.1995.341; EHRENSTEIN MR, 1994, J CLIN INVEST, V93, P1787, DOI 10.1172/JCI117164; Greagg MA, 1999, P NATL ACAD SCI USA, V96, P9045, DOI 10.1073/pnas.96.16.9045; HIETER PA, 1981, NATURE, V294, P536, DOI 10.1038/294536a0; IBRAHIM SM, 1995, J IMMUNOL, V155, P3223; Ignatovich O, 1997, J MOL BIOL, V268, P69, DOI 10.1006/jmbi.1997.0956; Isenberg D. A., 1998, OXFORD TXB RHEUMATOL, P1145; ISENBERG DA, 1987, ANN RHEUM DIS, V46, P448, DOI 10.1136/ard.46.6.448; Isenberg DA, 1997, BRIT J RHEUMATOL, V36, P229; Kalsi JK, 1996, MOL IMMUNOL, V33, P471, DOI 10.1016/0161-5890(95)00138-7; Kalsi JK, 1997, LUPUS, V6, P317, DOI 10.1177/096120339700600321; Katsube Y, 1998, INT J MOL MED, V1, P863; KIEBEREMMONS T, 1994, IMMUNOL RES, V13, P172, DOI 10.1007/BF02918278; KUMAR S, 1992, INT J PARASITOL, V22, P563, DOI 10.1016/0020-7519(92)90003-4; LACOUR M, 1991, EUR J IMMUNOL, V21, P839, DOI 10.1002/eji.1830210347; LEPAGE SH, 1989, CLIN EXP IMMUNOL, V77, P314; Marion TN, 1997, METHODS, V11, P3, DOI 10.1006/meth.1996.0381; Menon S, 1997, J AUTOIMMUN, V10, P43, DOI 10.1006/jaut.1996.0106; Mockridge CI, 1996, J IMMUNOL, V157, P2449; MORROW J, 1999, AUTOIMMUNE RHEUMATIC, P216; NISSONOFF A, 1975, ANTIBODY MOL, P299; OKAMURA M, 1993, ANN RHEUM DIS, V52, P14, DOI 10.1136/ard.52.1.14; Panayotou G, 1998, J BIOL CHEM, V273, P45, DOI 10.1074/jbc.273.1.45; PewznerJung Y, 1996, J IMMUNOL, V156, P3065; POLYMENIS M, 1994, J IMMUNOL, V152, P5318; PRODROMOU C, 1992, PROTEIN ENG, V5, P827, DOI 10.1093/protein/5.8.827; RADIC MZ, 1991, J IMMUNOL, V146, P176; RADIC MZ, 1993, J IMMUNOL, V150, P4966; Ravirajan CT, 1998, EUR J IMMUNOL, V28, P339, DOI 10.1002/(SICI)1521-4141(199801)28:01<339::AID-IMMU339>3.0.CO;2-C; RAVIRAJAN CT, 1992, LUPUS, V1, P157, DOI 10.1177/096120339200100307; RETTER MW, 1995, J IMMUNOL, V155, P2248; Roben P, 1996, J CLIN INVEST, V98, P2827, DOI 10.1172/JCI119111; SCHONER BE, 1984, P NATL ACAD SCI-BIOL, V81, P5403, DOI 10.1073/pnas.81.17.5403; SINGH AK, 1994, AUTOIMMUNITY, V18, P65, DOI 10.3109/08916939409014681; Stellar BD, 1997, METHODS, V11, P12, DOI 10.1006/meth.1996.0382; SWAAK AJG, 1979, ARTHRITIS RHEUM, V22, P226, DOI 10.1002/art.1780220304; Tomlinson IM, 1996, V BASE SEQUENCE DIRE; Williams SC, 1996, J MOL BIOL, V264, P220, DOI 10.1006/jmbi.1996.0636; WINKLER TH, 1991, CLIN EXP IMMUNOL, V85, P379; Wloch MK, 1997, J IMMUNOL, V159, P6083; YARRANTON GT, 1992, PROTEIN ENG PRACTICA, P302; ZOUALI M, 1986, J IMMUNOL METHODS, V90, P105, DOI 10.1016/0022-1759(86)90390-X	47	18	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35129	35136		10.1074/jbc.M001976200	http://dx.doi.org/10.1074/jbc.M001976200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10893224	hybrid			2022-12-25	WOS:000165422800042
J	Tomlinson, EJ; Ferguson, SJ				Tomlinson, EJ; Ferguson, SJ			Loss of either of the two heme-binding cysteines from a class I c-type cytochrome has a surprisingly small effect on physicochemical properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SEQUENCE; CLONING; C(552)	Almost without exception, c-type cytochromes have heme covalently attached via two thioether linkages to the cysteine residues of a CXXCH motif, The reasons for the covalent attachment are not understood. Reported here is cytoplasmic expression in Escherichia coli of AXXCH and CXXAH variants of cytochrome c(552) from Hydrogenobacter thermophilus; remarkably, the single thioether bond proteins have, apart from an altered visible absorption spectrum, almost identical properties, including thermal stability and reduction potential, to the wild type CXXCH protein. In combination with previous work showing that an AXXAH variant of cytochrome c(552) is much less stable than the CXXCH form, it can be concluded that covalent attachment of heme via either of thioether bonds is sufficient to confer considerable stability and that these bonds contribute little to the setting of the reduction potential. The absence of AXXCH or CXXAH heme-binding motifs from bacterial cytochromes c may relate to the coexistence of the assembly pathway with that for formation of disulfide bonds in the bacterial periplasm.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Ferguson, SJ (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.							Arnesano F, 2000, BIOCHEMISTRY-US, V39, P1499, DOI 10.1021/bi991831o; Barker PD, 1999, STRUCTURE, V7, pR281, DOI 10.1016/S0969-2126(00)88334-3; Bartsch R. G., 1971, METHODS ENZYMOL, V23, P344, DOI [10.1016/S0076-6879(71)23110-4, DOI 10.1016/S0076-6879(71)23110-4]; Dutton P L, 1978, Methods Enzymol, V54, P411; Keightley JA, 1998, J BIOL CHEM, V273, P12006, DOI 10.1074/jbc.273.20.12006; MOORE GR, 1985, BIOCHIM BIOPHYS ACTA, V829, P83, DOI 10.1016/0167-4838(85)90071-8; MUKAI K, 1989, EUR J BIOCHEM, V178, P649, DOI 10.1111/j.1432-1033.1989.tb14494.x; MUKAI K, 1989, J BIOCHEM-TOKYO, V106, P479, DOI 10.1093/oxfordjournals.jbchem.a122877; NALL BT, 1981, BIOCHEMISTRY-US, V20, P5403, DOI 10.1021/bi00522a008; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; PETTIGRE.GW, 1972, FEBS LETT, V22, P64, DOI 10.1016/0014-5793(72)80220-5; Pettigrew G.W., 1990, CYTOCHROMES C EVOLUT; PETTIGREW GW, 1973, NATURE, V241, P531, DOI 10.1038/241531a0; PETTIGREW GW, 1975, BIOCHEM J, V149, P155, DOI 10.1042/bj1490155; PRIEST JW, 1992, J BIOL CHEM, V267, P20188; SAMBONGI Y, 1994, FEBS LETT, V340, P65, DOI 10.1016/0014-5793(94)80174-6; SCHEJTER A, 1988, BIOCHEM J, V255, P353; Sinha N, 1998, FEMS MICROBIOL LETT, V161, P1; TANAKA Y, 1990, J BIOCHEM-TOKYO, V108, P7, DOI 10.1093/oxfordjournals.jbchem.a123165; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; Tomlinson EJ, 2000, P NATL ACAD SCI USA, V97, P5156, DOI 10.1073/pnas.090089397; Wittung-Stafshede P, 1998, BBA-PROTEIN STRUCT M, V1382, P324, DOI 10.1016/S0167-4838(97)00176-3; WOOD PM, 1983, FEBS LETT, V164, P223, DOI 10.1016/0014-5793(83)80289-0	23	41	43	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32530	32534		10.1074/jbc.M004022200	http://dx.doi.org/10.1074/jbc.M004022200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10922364	hybrid			2022-12-25	WOS:000090003800022
J	Bein, K; Simons, M				Bein, K; Simons, M			Thrombospondin type 1 repeats interact with matrix metalloproteinase 2 - Regulation of metalloproteinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE INHIBITOR; IV COLLAGENASE; CIRCUMSPOROZOITE PROTEIN; COMPLEMENT COMPONENTS; MOLECULAR-CLONING; CELL INVASION; ANGIOGENESIS; GENE; EXPRESSION; SEQUENCE	Thrombospondins are thought to function as inhibitors of angiogenesis, However, the mechanism(s) of this activity is not well understood. In this study, we have used the yeast two-hybrid system to identify proteins that interact with the thrombospondins 1 (TSP1) and 2 (TSP2) properdin-like type 1 repeats (TSR), One of the proteins identified that interacted with both TSR was matrix metalloproteinase 2 (MMP2). The isolated MMP2 cDNA clone encoded amino acid residues 237-633, which include the fibronectin-like gelatin binding region flanking the catalytic center and the carboxyl hemopexin-like region. Further testing of this clone demonstrated that the TSR interacted with the WH,terminal region of the MMP2 that contains the catalytic domain. The protein interaction observed in yeast was further demonstrated by immunoprecipitation and Western blotting using purified intact TSP1, TSP2, MMP2, and MMP9. Although MMP2 interacted with TSP1 and TSP2 via its gelatin-binding domain or a closely mapping site, neither TSP1 nor TSP2 was degraded by MMP2 in vitro. Tissue culture and in vitro assays demonstrated that the presence of purified TSR and intact TSP1 resulted in inhibition of MMP activity. The ability of TSP1 to inhibit MMP3-dependent activation of pro-MMP3 and thrombin-induced activation of pro-MMP2 suggests that the TSPs may inhibit MMP activity by preventing activation of the MMP2 and MMP9 zymogens.	Beth Israel Deaconess Med Ctr, Div Cardiovasc, Dept Med, Angiogenesis Res Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Simons, M (corresponding author), Beth Israel Deaconess Med Ctr, Div Cardiovasc, Dept Med, Angiogenesis Res Ctr, RW 453,330 Brookline Ave, Boston, MA 02215 USA.	msimons@bidmc.harvard.edu	Simons, Michael/G-8553-2014	Simons, Michael/0000-0003-0348-7734; Bein, Kiflai/0000-0002-5206-0801				AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; BENELLI R, 1994, ONCOL RES, V6, P251; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GOUNDIS D, 1988, NATURE, V335, P82, DOI 10.1038/335082a0; Guo NH, 1998, CANCER RES, V58, P3154; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; Kyriakides TR, 1999, P NATL ACAD SCI USA, V96, P4449, DOI 10.1073/pnas.96.8.4449; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAWLER J, 1993, J MOL EVOL, V36, P509, DOI 10.1007/BF00556355; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1992, BIOCHEMISTRY-US, V31, P1173, DOI 10.1021/bi00119a029; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; Lurlaro M, 1999, EUR J CLIN INVEST, V29, P793; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; Nguyen M, 2000, INT J BIOCHEM CELL B, V32, P621, DOI 10.1016/S1357-2725(00)00013-3; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OZAKI LS, 1983, CELL, V34, P815, DOI 10.1016/0092-8674(83)90538-X; Panetti TS, 1999, J BIOL CHEM, V274, P430, DOI 10.1074/jbc.274.1.430; PATTHY L, 1988, J MOL BIOL, V202, P689, DOI 10.1016/0022-2836(88)90550-5; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; REPONEN P, 1992, J BIOL CHEM, V267, P7856; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; Spano F, 1998, MOL BIOCHEM PARASIT, V92, P147, DOI 10.1016/S0166-6851(97)00243-0; Stearns ME, 1999, CLIN CANCER RES, V5, P189; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Streit M, 1999, P NATL ACAD SCI USA, V96, P14888, DOI 10.1073/pnas.96.26.14888; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TOMLEY FM, 1991, MOL BIOCHEM PARASIT, V49, P277, DOI 10.1016/0166-6851(91)90071-D; VOLPERT OV, 1995, BIOCHEM BIOPH RES CO, V217, P326, DOI 10.1006/bbrc.1995.2780; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201	48	201	207	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32167	32173		10.1074/jbc.M003834200	http://dx.doi.org/10.1074/jbc.M003834200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10900205	hybrid			2022-12-25	WOS:000089858900084
J	Kupke, T; Uebele, M; Schmid, D; Jung, G; Blaesse, M; Steinbacher, S				Kupke, T; Uebele, M; Schmid, D; Jung, G; Blaesse, M; Steinbacher, S			Molecular characterization of lantibiotic-synthesizing enzyme EpiD reveals a function for bacterial Dfp proteins in coenzyme A biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY BOUND PYRUVATE; OXIDATIVE DECARBOXYLATION; SACCHAROMYCES-CEREVISIAE; STREPTOCOCCUS-MUTANS; FLAVOPROTEIN; PURIFICATION; EPIDERMIN; SUBSTRATE; PEPTIDES; ACID	The lantibiotic-synthesizing flavoprotein EpiD catalyzes the oxidative decarboxylation of peptidylcysteines to peptidyl-aminoenethiols. The sequence motif responsible for flavin coenzyme binding and enzyme activity is conserved in different proteins from all kingdoms of life. Dfp proteins of eubacteria and archaebacteria and salt tolerance proteins of yeasts and plants belong to this new family of flavoproteins. The enzymatic function of all these proteins was not known, but our experiments suggested that they catalyze a similar reaction like EpiD and/or may have similar substrates and are homododecameric flavoproteins. We demonstrate that the N-terminal domain of the Escherichia coli Dfp protein catalyzes the decarboxylation of (R)-4'-phospho-N-pantothenoylcysteine to 4'-phosphopantetheine. This reaction is essential for coenzyme A biosynthesis.	Univ Tubingen, Lehrstuhl Mikrobielle Genet, D-72076 Tubingen, Germany; Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Planegg Martinsried, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Max Planck Society	Kupke, T (corresponding author), Univ Tubingen, Lehrstuhl Mikrobielle Genet, Morgenstelle 15, D-72076 Tubingen, Germany.		Zhang, Ning/F-1387-2014	Kupke, Thomas/0000-0003-2341-1710				ABIKO Y, 1967, J BIOCHEM-TOKYO, V61, P300, DOI 10.1093/oxfordjournals.jbchem.a128548; Abiko Y., 1975, Metabolism of sulphur compounds., P1; ALLGAIER H, 1985, ANGEW CHEM INT EDIT, V24, P1051, DOI 10.1002/anie.198510511; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breukink E, 1999, SCIENCE, V286, P2361, DOI 10.1126/science.286.5448.2361; BROWN GM, 1959, J BIOL CHEM, V234, P370; CLAUSEN M, 1994, GENE, V142, P107, DOI 10.1016/0378-1119(94)90363-8; Cormack B., 1991, CURRENT PROTOCOLS MO, V1, P851; de Nadal E, 1998, P NATL ACAD SCI USA, V95, P7357, DOI 10.1073/pnas.95.13.7357; DICOMO CJ, 1995, GENETICS, V139, P95; Duus F., 1978, COMPREHENSIVE ORGANI, V3, P373; Espinosa-Ruiz A, 1999, PLANT J, V20, P529, DOI 10.1046/j.1365-313X.1999.00626.x; FERRANDO A, 1995, MOL CELL BIOL, V15, P5470; GOLDWHITE H, 1957, J CHEM SOC, P2409, DOI 10.1039/jr9570002409; Gutierrez JA, 1996, J BACTERIOL, V178, P4166, DOI 10.1128/jb.178.14.4166-4175.1996; JACKOWSKI S, 1996, ESCHERICHIA COLI SAL, V1, P687; Kempter C, 1996, ANGEW CHEM INT EDIT, V35, P2104, DOI 10.1002/anie.199621041; Kupke T, 1997, J BIOL CHEM, V272, P4759, DOI 10.1074/jbc.272.8.4759; KUPKE T, 1993, FEMS MICROBIOL LETT, V112, P43, DOI 10.1016/0378-1097(93)90535-A; KUPKE T, 1992, J BACTERIOL, V174, P5354, DOI 10.1128/JB.174.16.5354-5361.1992; KUPKE T, 1994, J BIOL CHEM, V269, P5653; KUPKE T, 1995, J BIOL CHEM, V270, P11282, DOI 10.1074/jbc.270.19.11282; NAGASE O, 1967, CHEM PHARM BULL, V15, P648; Qi FX, 1999, APPL ENVIRON MICROB, V65, P3880; Sahl HG, 1998, ANNU REV MICROBIOL, V52, P41, DOI 10.1146/annurev.micro.52.1.41; SCANDURRA R, 1987, FEBS LETT, V212, P79, DOI 10.1016/0014-5793(87)81560-0; SCANDURRA R, 1974, EUR J BIOCHEM, V49, P1, DOI 10.1111/j.1432-1033.1974.tb03805.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; SCHNELL N, 1988, NATURE, V333, P276, DOI 10.1038/333276a0; SPITZER ED, 1988, J BACTERIOL, V170, P872, DOI 10.1128/jb.170.2.872-876.1988; SPITZER ED, 1985, J BACTERIOL, V164, P994, DOI 10.1128/JB.164.3.994-1003.1985; THORPE C, 1995, FASEB J, V9, P718, DOI 10.1096/fasebj.9.9.7601336; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; YANG HC, 1987, BIOCHEMISTRY-US, V26, P4076, DOI 10.1021/bi00387a050	37	79	119	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31838	31846		10.1074/jbc.M004273200	http://dx.doi.org/10.1074/jbc.M004273200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10922366	hybrid			2022-12-25	WOS:000089858900043
J	Schultz, SJ; Zhang, MH; Kelleher, CD; Champoux, JJ				Schultz, SJ; Zhang, MH; Kelleher, CD; Champoux, JJ			Analysis of plus-strand primer selection, removal, and reutilization by retroviral reverse transcriptases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; RNASE-H-DOMAIN; SEQUENCE FEATURES IMPORTANT; LONG TERMINAL REPEAT; DNA-SYNTHESIS; HIV-1 REVERSE; RIBONUCLEASE-H; DISPLACEMENT SYNTHESIS; POLYPURINE TRACT	The ability of reverse transcriptase to generate, extend, and remove the primer derived from the polypurine tract (PPT) is vital for reverse transcription, since this process determines one of the ends required for integration of the viral DNA. Based on the ability of the RNase H activity of Moloney murine leukemia virus reverse transcriptase to cleave a long RNA/DNA hybrid containing the PPT, it appears that cleavages that could generate the plus-strand primer can occur by an internal cleavage mechanism without any positioning by an RNA 5'-end, and such cleavages may serve to minimize cleavage events within the PPT itself. If the PPT were to be cleaved inappropriately just upstream of the normal plus-strand origin site, the resulting 3'-ends would not be extended by reverse transcriptase. Extension of the PPT primer by at least 2 nucleotides is sufficient for recognition and correct cleavage by RNase H at the RNA-DNA junction to remove the primer. Specific removal of the PPT primer after polymerase extension deviates from the general observation that primer removal occurs by cleavage one nucleotide away from the RNA-DNA junction and suggests that the same PPT specificity determinants responsible for generation of the PPT primer also direct PPT primer removal. Once the PPT primer has been extended and removed from the nascent plus-strand DNA, reinitiation at the resulting plus-strand primer terminus does not occur, providing a mechanism to prevent the repeated initiation of plus strands.	Univ Washington, Dept Microbiol, Sch Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Champoux, JJ (corresponding author), Univ Washington, Dept Microbiol, Sch Med, Box 357242, Seattle, WA 98195 USA.				NATIONAL CANCER INSTITUTE [R37CA051605] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA51605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arts EJ, 1998, PROG NUCLEIC ACID RE, V58, P339; BENARTZI H, 1993, J BIOL CHEM, V268, P16465; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; CHAMPOUX JJ, 1984, J VIROL, V49, P686, DOI 10.1128/JVI.49.3.686-691.1984; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; COLICELLI J, 1988, J MOL BIOL, V199, P47, DOI 10.1016/0022-2836(88)90378-6; COLLETT MS, 1978, J VIROL, V26, P498, DOI 10.1128/JVI.26.2.498-509.1978; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; DESTEFANO JJ, 1995, NUCLEIC ACIDS RES, V23, P3901, DOI 10.1093/nar/23.19.3901; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; Fedoroff OY, 1997, J MOL BIOL, V269, P225, DOI 10.1006/jmbi.1997.1024; FEDOROFF OY, 1993, J MOL BIOL, V233, P509, DOI 10.1006/jmbi.1993.1528; FINSTON WI, 1984, J VIROL, V51, P26, DOI 10.1128/JVI.51.1.26-33.1984; FU TB, 1992, J VIROL, V66, P4271, DOI 10.1128/JVI.66.7.4271-4278.1992; FUENTES GM, 1995, J BIOL CHEM, V270, P28169, DOI 10.1074/jbc.270.47.28169; Fuentes GM, 1996, NUCLEIC ACIDS RES, V24, P1719, DOI 10.1093/nar/24.9.1719; Fuentes GM, 1996, J BIOL CHEM, V271, P1966, DOI 10.1074/jbc.271.4.2063; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; FURFINE ES, 1991, BIOCHEMISTRY-US, V30, P7041, DOI 10.1021/bi00243a001; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; GOTTE M, 1995, EMBO J, V14, P833, DOI 10.1002/j.1460-2075.1995.tb07061.x; Gotte M, 1999, J BIOL CHEM, V274, P11159, DOI 10.1074/jbc.274.16.11159; HOTTIGER M, 1994, J BIOL CHEM, V269, P986; HUBER HE, 1990, J BIOL CHEM, V265, P10565; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kelleher CD, 1998, J BIOL CHEM, V273, P9976, DOI 10.1074/jbc.273.16.9976; Kelleher CD, 2000, J BIOL CHEM, V275, P13061, DOI 10.1074/jbc.275.17.13061; Klarmann GJ, 1997, J VIROL, V71, P9259, DOI 10.1128/JVI.71.12.9259-9269.1997; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOTEWICZ ML, 1988, NUCLEIC ACIDS RES, V16, P265, DOI 10.1093/nar/16.1.265; KRUG MS, 1989, P NATL ACAD SCI USA, V86, P3539, DOI 10.1073/pnas.86.10.3539; KULKOSKY J, 1990, J ACQ IMMUN DEF SYND, V3, P852; LEVIN JG, 1988, J VIROL, V62, P4376, DOI 10.1128/JVI.62.11.4376-4380.1988; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; OMER CA, 1982, CELL, V30, P797, DOI 10.1016/0092-8674(82)90284-7; OYAMA F, 1989, J BIOL CHEM, V264, P18808; Palaniappan C, 1998, J BIOL CHEM, V273, P3808, DOI 10.1074/jbc.273.7.3808; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; POST K, 1993, BIOCHEMISTRY-US, V32, P5508, DOI 10.1021/bi00072a004; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; PULLEN KA, 1992, J VIROL, V66, P367, DOI 10.1128/JVI.66.1.367-373.1992; PULLEN KA, 1993, J BIOL CHEM, V268, P6221; RANDOLPH CA, 1994, J BIOL CHEM, V269, P19207; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; RATTRAY AJ, 1987, J VIROL, V61, P2843, DOI 10.1128/JVI.61.9.2843-2851.1987; RESNICK R, 1984, J VIROL, V51, P813, DOI 10.1128/JVI.51.3.813-821.1984; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; RYCHLIK W, 1990, NUCLEIC ACIDS RES, V18, P6409, DOI 10.1093/nar/18.21.6409; SALAZAR M, 1993, BIOCHEMISTRY-US, V32, P4207, DOI 10.1021/bi00067a007; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SCHULTZ SJ, 1995, J BIOL CHEM, V270, P24135, DOI 10.1074/jbc.270.41.24135; Schultz SJ, 1999, J BIOL CHEM, V274, P34547, DOI 10.1074/jbc.274.49.34547; Schultz SJ, 1996, J VIROL, V70, P8630, DOI 10.1128/JVI.70.12.8630-8638.1996; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SHOEMAKER C, 1980, P NATL ACAD SCI-BIOL, V77, P3932, DOI 10.1073/pnas.77.7.3932; SKALKA A, 1993, REVERSE TRANSCRIPTAS; Smith CM, 1998, J VIROL, V72, P6805, DOI 10.1128/JVI.72.8.6805-6812.1998; Smith CM, 1997, VIROLOGY, V229, P437, DOI 10.1006/viro.1997.8454; SMITH JK, 1984, J VIROL, V52, P314, DOI 10.1128/JVI.52.2.314-319.1984; SMITH JS, 1992, J BIOL CHEM, V267, P15071; SMITH JS, 1993, J VIROL, V67, P4037, DOI 10.1128/JVI.67.7.4037-4049.1993; SMITH JS, 1990, J VIROL, V64, P6286, DOI 10.1128/JVI.64.12.6286-6290.1990; Sugimoto N, 1996, NUCLEIC ACIDS RES, V24, P4501, DOI 10.1093/nar/24.22.4501; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12468, DOI 10.1021/bi971218+; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; TANESE N, 1991, J VIROL, V65, P4387, DOI 10.1128/JVI.65.8.4387-4397.1991; TELESNITSKY A, 1993, P NATL ACAD SCI USA, V90, P1276, DOI 10.1073/pnas.90.4.1276; WHITCOMB JM, 1990, J VIROL, V64, P4903, DOI 10.1128/JVI.64.10.4903-4906.1990; Whiting SH, 1998, J MOL BIOL, V278, P559, DOI 10.1006/jmbi.1998.1720; WHITING SH, 1994, J VIROL, V68, P4747, DOI 10.1128/JVI.68.8.4747-4758.1994; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; WOHRL BM, 1995, SCIENCE, V267, P96, DOI 10.1126/science.7528942; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; Zhan XY, 1997, J BIOL CHEM, V272, P22023, DOI 10.1074/jbc.272.35.22023	80	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32299	32309		10.1074/jbc.M000021200	http://dx.doi.org/10.1074/jbc.M000021200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913435	hybrid			2022-12-25	WOS:000089858900102
J	Taira, Y; Kubo, T; Natori, S				Taira, Y; Kubo, T; Natori, S			Participation of transcription elongation factor XSII-K1 in mesoderm-derived tissue development in Xenopus laevis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; FACTOR-S-II; ASCITES TUMOR-CELLS; FACTOR-SII; EUKARYOTIC TRANSCRIPTION; MOLECULAR-CLONING; DEPENDENT TRANSCRIPTION; STIMULATORY FACTOR; MESSENGER-RNA; FACTOR TFIIS	We isolated a cDNA clone for a novel member of the S-II family of transcription elongation factors from;Xenopus laevis. This S-II, named XSII-K1, is assumed to be the Xenopus homologue of mouse SII-K1 that we reported previously (Taira, Y., Kubo, T., and Natori, S. (1998) Genes Cells 3, 289-296). Expression of the XSII-K1 gene was found to be restricted to mesoderm-derived tissues such as liver, kidney, and skeletal muscle. Contrary to the general S-II gene, expression of the XSII-K1 gene was not detected in embryos at stages earlier than 11. The animal cap assay revealed that activin A, but not basic fibroblast growth factor, induced expression of the XSII-K1 gene and that it participated in the expression of mesoderm-specific genes such as Xbra and X alpha-actin. This is the first demonstration that the regulation at the level of transcription elongation is included in the development of mesoderm-derived tissues.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Inst Phys & Chem Res, Natori Special Lab, Wako, Saitama 3510198, Japan	University of Tokyo; RIKEN	Natori, S (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan.			Kubo, Takeo/0000-0002-5914-5269				ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; BURATOWSKI S, 1995, SCIENCE, V270, P1773, DOI 10.1126/science.270.5243.1773; CHEN HC, 1992, GENE, V116, P253, DOI 10.1016/0378-1119(92)90522-Q; CORNELL RA, 1995, DEVELOPMENT, V121, P2429; DJE MK, 1990, NUCLEIC ACIDS RES, V18, P3489, DOI 10.1093/nar/18.12.3489; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; GURDON JB, 1985, J EMBRYOL EXP MORPH, V89, P125; Hatada S, 1997, GENE, V203, P183, DOI 10.1016/S0378-1119(97)00512-X; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; HORIKOSHI M, 1984, J BIOL CHEM, V259, P608; Ito T, 1996, FEBS LETT, V385, P21, DOI 10.1016/0014-5793(96)00340-7; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; KANAI A, 1991, J BIOCHEM-TOKYO, V109, P674, DOI 10.1093/oxfordjournals.jbchem.a123439; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KEPHART DD, 1994, J BIOL CHEM, V269, P13536; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kugawa F, 1996, BIOCHEM BIOPH RES CO, V222, P541, DOI 10.1006/bbrc.1996.0780; Labhart P, 1998, GENOMICS, V52, P278, DOI 10.1006/geno.1998.5449; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; MARSHALL TK, 1990, NUCLEIC ACIDS RES, V18, P6293, DOI 10.1093/nar/18.21.6293; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; NATORI S, 1982, MOL CELL BIOCHEM, V46, P173; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Plant KE, 1996, NUCLEIC ACIDS RES, V24, P3514, DOI 10.1093/nar/24.18.3514; PRINCE DH, 1989, MOL CELL BIOLL, V9, P1465; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; SEKIMIZU K, 1979, BIOCHEMISTRY-US, V18, P1582, DOI 10.1021/bi00575a031; SEKIMIZU K, 1982, J BIOL CHEM, V257, P2719; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SLACK JMW, 1990, PHILOS T R SOC B, V327, P75, DOI 10.1098/rstb.1990.0044; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; Taira Y, 1998, GENES CELLS, V3, P289, DOI 10.1046/j.1365-2443.1998.00188.x; Takebayashi K, 1997, EMBO J, V16, P384, DOI 10.1093/emboj/16.2.384; UENO K, 1979, NATURE, V277, P145, DOI 10.1038/277145a0; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; XU QH, 1994, J BIOL CHEM, V269, P3100; Yokota C, 1998, J BIOCHEM, V123, P339	51	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32011	32015		10.1074/jbc.M003920200	http://dx.doi.org/10.1074/jbc.M003920200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10900206	hybrid			2022-12-25	WOS:000089858900064
J	Wu, K; Chen, A; Pan, ZQ				Wu, K; Chen, A; Pan, ZQ			Conjugation of Nedd8 to CUL1 enhances the ability of the ROC1-CUL1 complex to promote ubiquitin polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULLIN PARTNERS; LIGASE ACTIVITY; PROTEIN LIGASE; PATHWAY; YEAST; SCF; SYSTEM; RBX1; E3; IDENTIFICATION	The SCF-ROC1 ubiquitin-protein isopeptide ligase (E3) ubiquitin ligase complex targets the ubiquitination and subsequent degradation of protein substrates required for the regulation of cell cycle progression and signal transduction pathways. We have previously shown that ROC1-CUL1 is a core subassembly within the SCF-ROC1 complex, capable of supporting the polymerization of ubiquitin. This report describes that the CUL1 subunit of the bacterially expressed, unmodified ROC1-CUL1 complex is conjugated with Nedd8 at Lys-720 by HeLa cell extracts or by a purified Nedd8 conjugation system (consisting of APP-BP1/Uba3, Ubc12, and Nedd8). This covalent linkage of Nedd8 to CUL1 is both necessary and sufficient to markedly enhance the ability of the ROC1-CUL1 complex to promote ubiquitin polymerization. A mutation of Lys-720 to arginine in CUL1 eliminates the Nedd8 modification, abolishes the activation of the ROC1-CUL1 ubiquitin ligase complex, and significantly reduces the ability of SCFHOS/beta-TRCP-ROC1 to support the ubiquitination of phosphorylated I kappa B alpha. Thus, although regulation of the SCF-ROC1 action has been previously shown to preside at the level of recognition of a phosphorylated substrate, we demonstrate that Nedd8 is a novel regulator of the efficiency of polyubiquitin chain synthesis and, hence, promotes rapid turnover of protein substrates.	Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Pan, ZQ (corresponding author), Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, 1 Gustave L Levy Pl, New York, NY 10029 USA.	zq_pan@smtplink.mssm.edu			NIGMS NIH HHS [GM55059] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen A, 2000, J BIOL CHEM, V275, P15432, DOI 10.1074/jbc.M907300199; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; Chow NW, 1996, J BIOL CHEM, V271, P11339, DOI 10.1074/jbc.271.19.11339; del Pozo JC, 1998, SCIENCE, V280, P1760, DOI 10.1126/science.280.5370.1760; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Jallepalli PV, 1998, P NATL ACAD SCI USA, V95, P8159, DOI 10.1073/pnas.95.14.8159; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; MuziFalconi M, 1996, P NATL ACAD SCI USA, V93, P1566, DOI 10.1073/pnas.93.4.1566; Ohta T, 1999, ONCOGENE, V18, P6758, DOI 10.1038/sj.onc.1203115; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Osaka F, 2000, EMBO J, V19, P3475, DOI 10.1093/emboj/19.13.3475; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Pause A, 1999, P NATL ACAD SCI USA, V96, P9533, DOI 10.1073/pnas.96.17.9533; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Wada H, 1999, BIOCHEM BIOPH RES CO, V257, P100, DOI 10.1006/bbrc.1999.0339; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832	37	161	163	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32317	32324		10.1074/jbc.M004847200	http://dx.doi.org/10.1074/jbc.M004847200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10921923	hybrid			2022-12-25	WOS:000089858900104
J	Farrar, MA; Tian, J; Perlmutter, RM				Farrar, MA; Tian, J; Perlmutter, RM			Membrane localization of Raf assists engagement of downstream effecters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MURINE SARCOMA-VIRUS; MAP KINASE; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; MAMMALIAN-CELLS; T-CELLS; CASCADE; PHOSPHORYLATION; DOMAIN	We have previously described a small molecule-directed protein dimerization strategy, using coumermycin to juxtapose Raf fusion proteins containing the coumermycin-binding domain GyrB. Oligomerization of cytoplasmically localized Raf-GyrB fusion proteins leads to an increase in the kinase activity of both Raf and its substrate Mek. Surprisingly, more distal targets, such as Erk1 and Erk2, are not activated using this approach. Here we report that coumermycin-induced oligomerization of a membrane-localized Raf-GyrB fusion protein potently activated Erk1 and Erk2, up-regulated Fos protein levels, and induced expression of many immediate-early response genes. Thus, both membrane localization and oligomerization of Raf-GyrB are required to target Raf signals to downstream effecters. The ability to activate the entire Raf signal transduction cascade conditionally, using coumermycin-induced oligomerization, should prove useful for dissecting Raf-mediated effects on gene expression and cellular differentiation.	Univ Minnesota, Ctr Immunol, Minneapolis, MN 55455 USA; Merck & Co Inc, Merck Sharp & Dohme Res Labs, Rahway, NJ 07065 USA	University of Minnesota System; University of Minnesota Twin Cities; Merck & Company	Farrar, MA (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, 312 Church St SE,BSBE,Rm 6-116, Minneapolis, MN 55455 USA.		Farrar, Michael A/M-7802-2013	Farrar, Michael/0000-0002-5569-0366				AHN NG, 1991, J BIOL CHEM, V266, P4220; BOS JL, 1989, CANCER RES, V49, P4682; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CANTRELL D, 1997, ANNU REV IMMUNOL, V15, P259; CASTLE JD, 1999, CURRENT PROTOCOLS PR, V1; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOI KY, 1994, CELL, V78, P499; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; EISENMANN DM, 1994, CURR OPIN GENET DEV, V4, P508, DOI 10.1016/0959-437X(94)90065-B; Farrar MA, 1998, BBA-REV CANCER, V1377, pF35, DOI 10.1016/S0304-419X(97)00038-3; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; Inouye K, 2000, J BIOL CHEM, V275, P3737, DOI 10.1074/jbc.275.6.3737; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mineo C, 1997, J BIOL CHEM, V272, P10345; Nelson BH, 1996, MOL CELL BIOL, V16, P309; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PRINTEN JA, 1994, GENETICS, V138, P609; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; SEGER R, 1994, J BIOL CHEM, V269, P25699; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; Sim ATR, 1999, CELL CALCIUM, V26, P209, DOI 10.1054/ceca.1999.0072; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; THORNTON M, 1994, MICROBIOL-UK, V140, P2371, DOI 10.1099/13500872-140-9-2371; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; Yablonski D, 1996, P NATL ACAD SCI USA, V93, P13864, DOI 10.1073/pnas.93.24.13864; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	50	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31318	31324		10.1074/jbc.M003399200	http://dx.doi.org/10.1074/jbc.M003399200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10913130	hybrid			2022-12-25	WOS:000089762700081
J	Kirk, RI; Sanderson, MR; Lerea, KM				Kirk, RI; Sanderson, MR; Lerea, KM			Threonine phosphorylation of the beta(3) integrin cytoplasmic tail, at a site recognized by PDK1 and Akt/PKB in vitro, regulates Shc binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; HUMAN PLATELETS; PHOSPHATIDYLINOSITOL 3,4-BISPHOSPHATE; PROTEIN-KINASE; OKADAIC ACID; RAS PATHWAY; DOMAIN; ACTIVATION	The mechanism of outside-in signaling by integrins parallels that for growth factor receptors, In both pathways, phosphorylation of a cytoplasmic segment on tyrosine generates a docking site for proteins containing Src homology 2 (SH2) and phosphotyrosine binding domains. We recently observed that phosphorylation of a threonine (Thr-753), six amino acids proximal to tyrosine 759 in beta(3) of the platelet specific integrin alpha(IIb)beta(3) inhibits outside-in signaling through this receptor. We hypothesized that the presence of phosphothreonine 753 either renders beta(3) a poor substrate for tyrosine kinases or inhibits the docking capabilities of the tyrosylphosphorylated form of beta(3). The first alternative was tested by comparing the phosphorylation of beta(3) model peptides by the tyrosine kinase pp60(c-src) and we found that the presence of a phosphate group on a residue corresponding to Thr-753 did not detectably alter the kinetics of tyrosine phosphorylation. However, the presence of phosphate on this threonine inhibited the binding of Shc to tyrosyl-phosphorylated beta(3) peptide. The inhibitory effect of the phosphate group could be mimicked by substituting an aspartic acid for Thr-753, suggesting that a negative charge at this position modulates the binding of Shc and possibly other phosphotyrosine binding domain- and SH2-containing proteins. A survey of several protein kinases revealed that Thr-753 was avidly phosphorylated by PDK1 and Akt/PKB in vitro. These observations suggest that activation of PDK1 and/or Akt/PHB in platelets may modulate the binding activity and/or specificity of beta(3) for signaling molecules.	New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA	New York Medical College	Lerea, KM (corresponding author), New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA.	ken_lerea@nymc.edu	Lerea, Ken/GWU-8597-2022					Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Banfic H, 1998, J BIOL CHEM, V273, P13, DOI 10.1074/jbc.273.1.13; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; Blystone SD, 1996, J BIOL CHEM, V271, P31458, DOI 10.1074/jbc.271.49.31458; Blystone SD, 1997, J BIOL CHEM, V272, P28757, DOI 10.1074/jbc.272.45.28757; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HILLERY CA, 1991, J BIOL CHEM, V266, P14663; HOYT CH, 1994, BLOOD, V83, P3517; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; KARAKI H, 1989, BRIT J PHARMACOL, V98, P590, DOI 10.1111/j.1476-5381.1989.tb12633.x; Kroll MH, 1996, BLOOD, V88, P1525; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LEREA KM, 1992, BIOCHEMISTRY-US, V31, P6553, DOI 10.1021/bi00143a027; LEREA KM, 1991, BIOCHEMISTRY-US, V30, P6819, DOI 10.1021/bi00242a003; Lerea KM, 1999, J BIOL CHEM, V274, P1914, DOI 10.1074/jbc.274.4.1914; Liu XY, 1996, P NATL ACAD SCI USA, V93, P11819, DOI 10.1073/pnas.93.21.11819; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Schaffner-Reckinger E, 1998, J BIOL CHEM, V273, P12623, DOI 10.1074/jbc.273.20.12623; SCHLAEPFER DD, 1994, NATURE, V372, P786; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Tahiliani PD, 1997, J BIOL CHEM, V272, P7892, DOI 10.1074/jbc.272.12.7892; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; vanWilligen G, 1996, BIOCHEM J, V314, P769, DOI 10.1042/bj3140769; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128	38	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30901	30906		10.1074/jbc.M001908200	http://dx.doi.org/10.1074/jbc.M001908200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896934	hybrid			2022-12-25	WOS:000089762700026
J	Naryshkina, T; Rogulja, D; Golub, L; Severinov, K				Naryshkina, T; Rogulja, D; Golub, L; Severinov, K			Inter- and intrasubunit interactions during the formation of RNA polymerase assembly intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BETA-SUBUNIT; 3-DIMENSIONAL STRUCTURE; ACTIVE-CENTER; YEAST; BINDING; MUTATIONS; GENE; PROTEIN; ENZYME	We used yeast two-hybrid and in vitro co-immobilization assays to study the interaction between the Escherichia coli RNA polymerase (RNAP) alpha and beta subunits during the formation of alpha(2)beta, a physiological RNAP assembly intermediate. We show that a 430-amino acid-long fragment containing beta conserved segments F, Gr, H, and a short part of segment I forms a minimal domain capable of specific interaction with alpha, The alpha-interacting domain is held together by protein-protein interactions between beta segments F and I. Residues in catalytically important beta segments H and I directly participate in ct binding; substitutions of strictly conserved segment H Asp(1084) and segment I Gly(1215) abolish alpha(2)beta formation in vitro and are lethal in vivo. The importance of these beta amino acids in cw binding is fully supported by the structural model of the Thermus aquaticus RNAP core enzyme. We also demonstrate that determinants of RNAP assembly are conserved, and that a homologue of beta Asp(1084) in A135, the beta-Like subunit of yeast RNAP I, is responsible for interaction with AC40, the largest alpha-like subunit, However, the A135-AC40 interaction is weak compared with the E. coli alpha-beta interaction, and A135 mutation that abolishes the interaction is phenotypically silent. The results suggest that in eukaryotes additional RNAP subunits orchestrate the enzyme assembly by stabilizing weak, but specific interactions of core subunits.	Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick	Severinov, K (corresponding author), Rutgers State Univ, Waksman Inst, 190 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	severik@waksman.rutgers.edu	Severinov, Konstantin/C-8545-2016		PHS HHS [R01 59295] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; AZUMA Y, 1993, NUCLEIC ACIDS RES, V21, P3749, DOI 10.1093/nar/21.16.3749; Bai C, 1996, METHOD ENZYMOL, V273, P331; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; Flores A, 1999, P NATL ACAD SCI USA, V96, P7815, DOI 10.1073/pnas.96.14.7815; IGARASHI K, 1990, NUCLEIC ACIDS RES, V18, P5945, DOI 10.1093/nar/18.20.5945; Ishihama A, 1981, Adv Biophys, V14, P1; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; Keener J, 1998, J BIOL CHEM, V273, P33795, DOI 10.1074/jbc.273.50.33795; Kimura M, 1997, J BIOL CHEM, V272, P25851, DOI 10.1074/jbc.272.41.25851; KOLODZIEJ PA, 1991, MOL CELL BIOL, V11, P4669, DOI 10.1128/MCB.11.9.4669; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6018, DOI 10.1073/pnas.88.14.6018; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; Nedea EC, 1999, J BACTERIOL, V181, P2663, DOI 10.1128/JB.181.8.2663-2665.1999; NOGI Y, 1991, P NATL ACAD SCI USA, V88, P3962, DOI 10.1073/pnas.88.9.3962; Nomura T, 1999, BIOCHEMISTRY-US, V38, P1346, DOI 10.1021/bi982381n; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; SAGITOV V, 1993, J BIOL CHEM, V268, P2195; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; SEVERINOV K, 1995, P NATL ACAD SCI USA, V92, P4591, DOI 10.1073/pnas.92.10.4591; Severinov K, 1996, J BIOL CHEM, V271, P27969, DOI 10.1074/jbc.271.44.27969; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; Wang DG, 1997, P NATL ACAD SCI USA, V94, P8433, DOI 10.1073/pnas.94.16.8433; Wang Y, 1997, J MOL BIOL, V270, P648, DOI 10.1006/jmbi.1997.1139; XIE WQ, 1989, J BACTERIOL, V171, P1967, DOI 10.1128/jb.171.4.1967-1973.1989; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9; ZILLIG W, 1976, RNA POLYMERASE, P101	36	8	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31183	31190		10.1074/jbc.M003884200	http://dx.doi.org/10.1074/jbc.M003884200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906130	hybrid			2022-12-25	WOS:000089762700062
J	Sanchez-Gongora, E; Lisbona, C; de Gregorio, R; Ballester, A; Calvo, V; Perez-Jurado, L; Alemany, S				Sanchez-Gongora, E; Lisbona, C; de Gregorio, R; Ballester, A; Calvo, V; Perez-Jurado, L; Alemany, S			COT kinase proto-oncogene expression in T cells - Implication of the JNK/SAPK signal transduction pathway in COT promoter activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TPL-2; PROTOONCOGENE; GENE; INTERLEUKIN-2; TRANSLATION; ONCOPROTEIN; INITIATION; EUKARYOTES; LYMPHOMAS; ELEMENTS	COT/Tpl-2 proto oncogene encodes a serine/threonine kinase implicated in cellular activation. In this study we have identified the human COT gene promoter region and three different human COT transcripts. These transcripts, with the same initiation site, display heterogeneity in their 5' untranslated regions and in their subcellular localization. Activation of Jurkat T cells with either calcium ionophore A23187 or alpha CD3 and a phorbol ester increases the levels of the different COT transcripts. Analysis of the 5' flanking region of the human COT gene reveals a unique transcription initiation site and a TATA element 20 nucleotides upstream. Transient expression of COT promoter constructs containing a reporter gene indicates that the transcriptional activity of the 5' flanking region of the COT gene is regulated by T cell-activating signals. Cotransfection of a dominant negative version of SEK-2 abolishes the inducible transcriptional activity of COT promoter, indicating that the inducible expression of the COT gene by T cell activating signals is mediated by the JNK/SAPK signal transduction pathway. All these data indicate stringent regulation of COT kinase proto-oncogene expression.	Univ Autonoma Madrid, Inst Invest Biomed, Consejo Super Invest Cient, Fac Med, E-28029 Madrid, Spain; Univ Madrid, Hosp La Paz, Serv Genet, Madrid 28046, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Hospital Universitario La Paz	Alemany, S (corresponding author), Univ Autonoma Madrid, Inst Invest Biomed, Consejo Super Invest Cient, Fac Med, Arturo Duperier 4, E-28029 Madrid, Spain.	salemany@biomed.iib.uam.es	Pérez Jurado, Luis Alberto/M-7706-2015; Alemany, Susana/J-6307-2014; Calvo, Victor/L-5024-2014	Alemany, Susana/0000-0002-4089-7620; Calvo, Victor/0000-0002-5913-7058; Ballester Jareno, Alicia/0000-0002-6474-7248				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AOKI M, 1991, ONCOGENE, V6, P1515; AOKI M, 1993, J BIOL CHEM, V268, P22723; Ballester A, 1998, J BIOL CHEM, V273, P14099, DOI 10.1074/jbc.273.23.14099; Ballester A, 1997, J IMMUNOL, V159, P1613; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; CHAN AML, 1993, ONCOGENE, V8, P1329; Erny KM, 1996, ONCOGENE, V13, P2015; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Jackson RJ, 1997, CURR OPIN GENET DEV, V7, P233, DOI 10.1016/S0959-437X(97)80133-5; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; OHARA R, 1993, JPN J CANCER RES, V84, P518, DOI 10.1111/j.1349-7006.1993.tb00170.x; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sourvinos G, 1999, ONCOGENE, V18, P4968, DOI 10.1038/sj.onc.1202891; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Tsatsanis C, 1998, ONCOGENE, V17, P2609, DOI 10.1038/sj.onc.1202460; Tsatsanis C, 1998, P NATL ACAD SCI USA, V95, P3827, DOI 10.1073/pnas.95.7.3827; WEIL D, 1990, MOL CELL BIOL, V10, P5865, DOI 10.1128/MCB.10.11.5865	37	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31379	31386		10.1074/jbc.M000382200	http://dx.doi.org/10.1074/jbc.M000382200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896655	hybrid			2022-12-25	WOS:000089762700089
J	Eckenhoff, RG; Petersen, CE; Ha, CE; Bhagavan, NV				Eckenhoff, RG; Petersen, CE; Ha, CE; Bhagavan, NV			Inhaled anesthetic binding sites in human serum albumin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOTHANE BINDING; HYDROGEN-EXCHANGE; THYROXINE-BINDING; CRYSTAL-STRUCTURE; SOLUBLE-PROTEINS; RESOLUTION; STABILITY; RECEPTORS; INCREASES; AFFINITY	Previous evidence suggests multiple anesthetic binding sites on human serum albumin, but to date, we have only identified Trp-214 in an interdomain cleft as contributing to a binding site. We used a combination of site-directed mutagenesis, photoaffinity labeling, amide hydrogen exchange, and tryptophan fluorescence spectroscopy to evaluate the importance to binding of a large domain III cavity and compare it to binding character of the 214 interdomain cleft. The data show anesthetic binding in this domain III cavity of similar character to the interdomain cleft, but selectivity for different classes of anesthetics exists. Occupancy of these sites stabilizes the native conformation of human serum albumin. The features necessary for binding in the cleft appear to be fairly degenerate, but in addition to hydrophobicity, there is evidence for the importance of polarity. Finally, myristate isosterically competes with anesthetic binding in the domain III cavity and allosterically enhances anesthetic binding in the interdomain cleft.	Univ Penn, Med Ctr, Dept Anesthesia, Philadelphia, PA 19104 USA; Univ Hawaii, John A Burns Sch Med, Dept Biochem & Biophys, Honolulu, HI 96822 USA	University of Pennsylvania; University of Hawaii System	Eckenhoff, RG (corresponding author), Univ Penn, Med Ctr, Dept Anesthesia, Philadelphia, PA 19104 USA.			Eckenhoff, Roderic/0000-0002-5581-746X	NIGMS NIH HHS [GM 55876, GM 51595] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAI YW, 1994, PROTEINS, V20, P4, DOI 10.1002/prot.340200103; Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; DUBOIS BW, 1992, BIOCHEMISTRY-US, V31, P7069, DOI 10.1021/bi00146a007; Eckenhoff MF, 1998, J PHARMACOL EXP THER, V285, P371; ECKENHOFF RG, 1993, ANESTHESIOLOGY, V79, P96, DOI 10.1097/00000542-199307000-00015; Eckenhoff RG, 1998, MOL PHARMACOL, V54, P610; Eckenhoff RG, 1996, J BIOL CHEM, V271, P15521, DOI 10.1074/jbc.271.26.15521; Eckenhoff RG, 1997, PHARMACOL REV, V49, P343; Eckenhoff RG, 1999, MOL PHARMACOL, V56, P414, DOI 10.1124/mol.56.2.414; ENGLANDER SW, 1994, METHOD ENZYMOL, V232, P26; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; GLATZ JFC, 1983, J BIOCHEM BIOPH METH, V8, P57, DOI 10.1016/0165-022X(83)90021-0; HARRIS BD, 1994, EUR J PHARM-MOLEC PH, V267, P269, DOI 10.1016/0922-4106(94)90150-3; JOHANSSON JS, 1995, ANESTHESIOLOGY, V83, P316, DOI 10.1097/00000542-199508000-00012; KOBLIN DD, 1994, ANESTH ANALG, V79, P1043; MOSS GWJ, 1991, P NATL ACAD SCI USA, V88, P134, DOI 10.1073/pnas.88.1.134; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; PETERSEN CE, 1995, BIOCHEM BIOPH RES CO, V214, P1121, DOI 10.1006/bbrc.1995.2402; Petersen CE, 1996, J BIOL CHEM, V271, P19110, DOI 10.1074/jbc.271.32.19110; Petersen CE, 1997, BIOCHEMISTRY-US, V36, P7012, DOI 10.1021/bi970225v; Raines DE, 1999, ANESTHESIOLOGY, V90, P135, DOI 10.1097/00000542-199901000-00019; Scharf D, 1996, CHEM PHYS LETT, V258, P276, DOI 10.1016/0009-2614(96)00652-5; Sugio S, 1999, PROTEIN ENG, V12, P439, DOI 10.1093/protein/12.6.439; Tanner JW, 1999, BBA-PROTEIN STRUCT M, V1430, P46, DOI 10.1016/S0167-4838(98)00258-1; Ueda I, 1997, BIOPHYS J, V72, P1812, DOI 10.1016/S0006-3495(97)78827-1	26	47	50	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30439	30444		10.1074/jbc.M005052200	http://dx.doi.org/10.1074/jbc.M005052200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10896670	hybrid			2022-12-25	WOS:000089577900071
J	Faenza, I; Matteucci, A; Manzoli, L; Billi, AM; Aluigi, M; Peruzzi, D; Vitale, M; Castorina, S; Suh, PG; Cocco, L				Faenza, I; Matteucci, A; Manzoli, L; Billi, AM; Aluigi, M; Peruzzi, D; Vitale, M; Castorina, S; Suh, PG; Cocco, L			A role for nuclear phospholipase C beta(1) in cell cycle control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL KINASE; SIGNAL-TRANSDUCTION; C BETA(1); 2 FORMS; DIFFERENTIATION; LOCALIZATION; PROGRESSION; PROTEIN; PHASE; G(1)	Phosphoinositide signaling resides in the nucleus, and among the enzymes of the cycle, phospholipase C (PLC) appears as the key element both in Saccharomyces cerevisiae and in mammalian cells. The yeast PLC pathway produces multiple inositol polyphosphates that modulate distinct nuclear processes. The mammalian PLC beta(1), which localizes in the nucleus, is activated in insulin-like growth factor 1-mediated mitogenesis and undergoes down-regulation during murine erythroleukemia differentiation. PLC beta(1) exists as two polypeptides of 150 and 140 kDa generated from a single gene by alternative RNA splicing, both of them containing in the COOH-terminal tail a cluster of lysine residues responsible for nuclear localization. These clues prompted us to try to establish the critical nuclear target(s) of PLC beta(1) subtypes in the control of cell cycle progression. The results reveal that the two subtypes of PLC beta(1) that localize in the nucleus induce cell cycle progression in Friend erythroleukemia cells. In fact when they are overexpressed in the nucleus, cyclin D3, along with its kinase (cdk4) but not cyclin E is overexpressed even though cells are serum-starved. As a consequence of this enforced expression, retinoblastoma protein is phosphorylated and E2F-1 transcription factor is activated as well. On the whole the results reveal a direct effect of nuclear PLC beta(1) signaling in G(1) progression by means of a specific target, i.e. cyclin D3/cdk4.	Univ Bologna, Dept Anat Sci, Cellular Signalling Lab, I-40126 Bologna, Italy; Rizzoli Inst, CNR, Inst Cytomorphol, I-40136 Bologna, Italy; Univ Brescia, Dept Biomed Sci & Biotechnol, I-25123 Brescia, Italy; Univ Catania, Dept Anat, I-95124 Catania, Italy; Pohang Univ Sci & Technol, Dept Life Sci, Div Mol Life Sci, Pohang 633165, South Korea	University of Bologna; Consiglio Nazionale delle Ricerche (CNR); University of Brescia; University of Catania; Pohang University of Science & Technology (POSTECH)	Cocco, L (corresponding author), Univ Bologna, Dept Anat Sci, Cellular Signalling Lab, Via Irnerio 48, I-40126 Bologna, Italy.		Vitale, Marco/O-8751-2015; Suh, Pann-Ghill/F-3610-2010	Vitale, Marco/0000-0002-3261-6868; Castorina, Sergio/0000-0002-0745-4107				Bahk YY, 1998, BBA-LIPID LIPID MET, V1389, P76, DOI 10.1016/S0005-2760(97)00128-8; BAHK YY, 1994, J BIOL CHEM, V269, P8240; Chi TH, 2000, SCIENCE, V287, P1937, DOI 10.1126/science.287.5460.1937; Cocco L, 1998, ADV ENZYME REGUL, V38, P351, DOI 10.1016/S0065-2571(97)00014-9; COCCO L, 1995, ADV ENZYME REGUL, V35, P23, DOI 10.1016/0065-2571(94)00004-M; Divecha N, 1998, NATURE, V394, P619, DOI 10.1038/29174; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; KATO J, 1993, P NATL ACAD SCI USA, V9, P11513; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Manzoli L, 1997, CANCER RES, V57, P2137; Maraldi NM, 1999, J CELL PHYSIOL, V181, P203, DOI 10.1002/(SICI)1097-4652(199911)181:2<203::AID-JCP3>3.0.CO;2-O; MARKS PA, 1994, P NATL ACAD SCI USA, V91, P10251, DOI 10.1073/pnas.91.22.10251; MARMIROLI S, 1994, J BIOL CHEM, V269, P13; Martelli AM, 2000, CANCER RES, V60, P815; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; Matteucci A, 1998, CANCER RES, V58, P5057; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; YORK JD, 1994, J BIOL CHEM, V269, P7847	28	132	146	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30520	30524		10.1074/jbc.M004630200	http://dx.doi.org/10.1074/jbc.M004630200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10913438	hybrid			2022-12-25	WOS:000089577900082
J	Guedin, S; Willery, E; Tommassen, J; Fort, E; Drobecq, H; Locht, C; Jacob-Dubuisson, F				Guedin, S; Willery, E; Tommassen, J; Fort, E; Drobecq, H; Locht, C; Jacob-Dubuisson, F			Novel topological features of FhaC, the outer membrane transporter involved in the secretion of the Bordetella pertussis filamentous hemagglutinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; FERRIC ENTEROBACTIN RECEPTOR; GRAM-NEGATIVE BACTERIA; 3-DIMENSIONAL STRUCTURE; SERRATIA-MARCESCENS; CRYSTAL-STRUCTURES; PROTEIN SECRETION; REPORTER EPITOPE; IRON RECEPTOR; HEMOLYSIN	Many pathogenic Gram-negative bacteria secrete virulence factors across the cell envelope into the extracellular milieu. The secretion of filamentous hemagglutinin (FHA) by Bordetella pertussis depends on the pore-forming outer membrane protein FhaC, which belongs to a growing family of protein transporters. Protein alignment and secondary structure predictions indicated that FhaC is likely to be a beta-barrel protein with an odd number of transmembrane beta-strands connected by large surface loops and short periplasmic turns. The membrane topology of FhaC was investigated by random insertion of the c-Myc epitope and the tobacco etch virus protease-specific cleavage sequence. FhaC was fairly permissive to short linker insertions. Furthermore, FhaC appeared to undergo conformational changes upon FHA secretion. Surface detection of the inserted sequences indicated that several predicted loops in the C-terminal moiety as well as the N terminus of the protein are exposed. However, a large surface-predicted region in the N-terminal moiety of FhaC was inaccessible from the surface. In addition, the activity and the stability of the protein were affected by insertions in that region, indicating that it may have important structural and/or functional roles. The surface exposure of the N terminus and the presence of an odd number of beta-strands are novel features for beta-barrel outer membrane proteins.	Inst Pasteur, IBL, INSERM, U447, F-59019 Lille, France; Univ Utrecht, Dept Mol Cell Biol, NL-3584 CH Utrecht, Netherlands; Inst Pasteur, IBL, CNRS, UMR 8525, F-59019 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Utrecht University; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Jacob-Dubuisson, F (corresponding author), Inst Pasteur, IBL, INSERM, U447, 1 Rue Calmette, F-59019 Lille, France.		Jacob-Dubuisson, Françoise/F-1610-2018; Locht, Camille/L-3516-2018; Tommassen, Jan/I-1690-2016	Jacob-Dubuisson, Françoise/0000-0002-5102-1704; Tommassen, Jan/0000-0001-7633-4945; Drobecq, Herve/0000-0002-4081-1575				ARMSTRONG SK, 1995, J BIOL CHEM, V270, P2483, DOI 10.1074/jbc.270.6.2483; BARANY F, 1988, DNA PROTEIN ENG TECH, V1, P29; BARENKAMP SJ, 1994, INFECT IMMUN, V62, P3320, DOI 10.1128/IAI.62.8.3320-3328.1994; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; CHARBIT A, 1991, J BACTERIOL, V173, P262, DOI 10.1128/jb.173.1.262-275.1991; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DELISSEGATHOYE AM, 1990, INFECT IMMUN, V58, P2895, DOI 10.1128/IAI.58.9.2895-2905.1990; DOMENIGHINI M, 1990, MOL MICROBIOL, V4, P787, DOI 10.1111/j.1365-2958.1990.tb00649.x; Ehrmann M, 1997, P NATL ACAD SCI USA, V94, P13111, DOI 10.1073/pnas.94.24.13111; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; Guedin S, 1998, MOL MICROBIOL, V29, P763, DOI 10.1046/j.1365-2958.1998.00970.x; Hirono I, 1997, MOL MICROBIOL, V24, P851, DOI 10.1046/j.1365-2958.1997.3971760.x; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Jacob-Dubuisson F, 1999, J BIOL CHEM, V274, P37731, DOI 10.1074/jbc.274.53.37731; JacobDubuisson F, 1996, MOL MICROBIOL, V19, P65, DOI 10.1046/j.1365-2958.1996.349883.x; JacobDubuisson F, 1997, J BACTERIOL, V179, P775, DOI 10.1128/jb.179.3.775-783.1997; KOEBNIK R, 1993, J BACTERIOL, V175, P826, DOI 10.1128/JB.175.3.826-839.1993; Konninger UW, 1999, MOL MICROBIOL, V32, P1212, DOI 10.1046/j.1365-2958.1999.01433.x; Lambert-Buisine C, 1998, MOL MICROBIOL, V28, P1283, DOI 10.1046/j.1365-2958.1998.00892.x; Lee CA, 1997, TRENDS MICROBIOL, V5, P148, DOI 10.1016/S0966-842X(97)01029-9; Letoffe S, 1996, EMBO J, V15, P5804, DOI 10.1002/j.1460-2075.1996.tb00967.x; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Locht C, 1999, Int Microbiol, V2, P137; LOCHT C, 1993, MOL MICROBIOL, V9, P653, DOI 10.1111/j.1365-2958.1993.tb01725.x; Merck KB, 1997, J BACTERIOL, V179, P3443, DOI 10.1128/jb.179.11.3443-3450.1997; MOECK GS, 1995, J BACTERIOL, V177, P6118, DOI 10.1128/jb.177.21.6118-6125.1995; MOECK GS, 1994, J BACTERIOL, V176, P4250, DOI 10.1128/jb.176.14.4250-4259.1994; MURPHY CK, 1990, J BACTERIOL, V172, P2736, DOI 10.1128/jb.172.5.2736-2746.1990; Newton SMC, 1996, J BACTERIOL, V178, P3447, DOI 10.1128/jb.178.12.3447-3456.1996; Palmer KL, 1995, MOL MICROBIOL, V18, P821, DOI 10.1111/j.1365-2958.1995.18050821.x; PAUL C, 1985, EMBO J, V4, P1593, DOI 10.1002/j.1460-2075.1985.tb03822.x; Pautsch A, 1998, NAT STRUCT BIOL, V5, P1013, DOI 10.1038/2983; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RenauldMongenie G, 1996, J BACTERIOL, V178, P1053, DOI 10.1128/jb.178.4.1053-1060.1996; ROSQVIST R, 1995, EMBO J, V14, P4187, DOI 10.1002/j.1460-2075.1995.tb00092.x; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SCHONHERR R, 1993, MOL MICROBIOL, V9, P1229, DOI 10.1111/j.1365-2958.1993.tb01252.x; STRUYVE M, 1993, MOL MICROBIOL, V7, P131, DOI 10.1111/j.1365-2958.1993.tb01104.x; STRUYVE M, 1991, J MOL BIOL, V218, P141, DOI 10.1016/0022-2836(91)90880-F; SUKHAN A, 1995, J BACTERIOL, V177, P4914, DOI 10.1128/jb.177.17.4914-4920.1995; Thanabalu T, 1998, EMBO J, V17, P6487, DOI 10.1093/emboj/17.22.6487; TOMMASSEN J, 1988, NATO ASI SERIES H, V16, P352; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WILLEMS RJL, 1994, MOL MICROBIOL, V11, P337, DOI 10.1111/j.1365-2958.1994.tb00314.x	45	79	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30202	30210		10.1074/jbc.M005515200	http://dx.doi.org/10.1074/jbc.M005515200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10906141	hybrid			2022-12-25	WOS:000089577900041
J	Onofri, F; Giovedi, S; Kao, HT; Valtorta, F; Borbone, LB; De Camilli, P; Greengard, P; Benfenati, F				Onofri, F; Giovedi, S; Kao, HT; Valtorta, F; Borbone, LB; De Camilli, P; Greengard, P; Benfenati, F			Specificity of the binding of synapsin I to Src homology 3 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; SH3 DOMAINS; F-ACTIN; NEUROTRANSMITTER RELEASE; SH3-LIGAND INTERACTIONS; PROTEIN MODULES; SKELETAL-MUSCLE; DISTINCT SITES; GENERAL-MODEL; C-SRC	Synapsins are synaptic vesicle-associated phosphoproteins involved in synapse formation and regulation of neurotransmitter release. Recently, synapsin I has been found to bind the Src homology 3 (SH3) domains of Grb2 and c-Src. In this work we have analyzed the interactions between synapsins and an array of SH3 domains belonging to proteins involved in signal transduction, cytoskeleton assembly, or endocytosis. The binding of synapsin I was specific for a subset of SH3 domains. The highest binding was observed with SH3 domains of c-Src, phospholipase C-gamma, p85 subunit of phosphatidylinositol 3-kinase, full-length and NH2-terminal Grb2, whereas binding was moderate with the SH3 domains of amphiphysins I/II, Crk, alpha-spectrin, and NADPH oxidase factor p47(phox) and negligible with the SH3 domains of p21(ras) GTPase-activating protein and COOH-terminal Grb2. Distinct sites in the proline-rich COOH-terminal region of synapsin I were found to be involved in binding to the various SH3 domains. Synapsin II also interacted with SH3 domains with a partly distinct binding pattern. Phosphorylation of synapsin I in the COOH-terminal region by Ca2+/calmodulin-dependent protein kinase II or mitogen-activated protein kinase modulated the binding to the SH3 domains of amphiphysins I/II, Crk, and alpha-spectrin without affecting the high affinity interactions. The SH3-mediated interaction of synapsin I with amphiphysins affected the ability of synapsin I to interact with actin and synaptic vesicles, and pools of synapsin I and amphiphysin I were shown to associate in isolated nerve terminals. The ability to bind multiple SH3 domains further implicates the synapsins in signal transduction and protein-protein interactions at the nerve terminal level.	Univ Modena, Physiol Sect, Dept Biomed Sci, I-41100 Modena, Italy; Univ Genoa, Physiol Sect, Dept Expt Med, I-16132 Genoa, Italy; Univ Roma Tor Vergata, Dept Neurosci, I-00133 Rome, Italy; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; NYU Med Ctr, Dept Psychiat, New York, NY 10016 USA; Ist Sci San Raffaele, Dept Neurosci, I-20132 Milan, Italy; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06536 USA	Universita di Modena e Reggio Emilia; University of Genoa; University of Rome Tor Vergata; Rockefeller University; New York University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Yale University	Benfenati, F (corresponding author), Univ Modena, Physiol Sect, Dept Biomed Sci, Via Campi 287, I-41100 Modena, Italy.	benfenat@mail.unimo.it	Giovedì, Silvia/AAB-7614-2019; Flavia, Valtorta/F-3450-2012	Flavia, Valtorta/0000-0001-9556-4746; GIOVEDI', SILVIA/0000-0001-7949-4274	NIA NIH HHS [AG15072] Funding Source: Medline; NIMH NIH HHS [MH39327] Funding Source: Medline; Telethon [1131] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039327, R01MH039327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG015072] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BAHLER M, 1989, J CELL BIOL, V108, P1841, DOI 10.1083/jcb.108.5.1841; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BENFENATI F, 1990, J BIOL CHEM, V265, P12584; BENFENATI F, 1989, J CELL BIOL, V108, P1863, DOI 10.1083/jcb.108.5.1863; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BENFENATI F, 1992, NEURON, V8, P377, DOI 10.1016/0896-6273(92)90303-U; Benfenati F, 1999, PHILOS T R SOC B, V354, P243, DOI 10.1098/rstb.1999.0376; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; Cestra G, 1999, J BIOL CHEM, V274, P32001, DOI 10.1074/jbc.274.45.32001; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; Esser L, 1998, EMBO J, V17, P977, DOI 10.1093/emboj/17.4.977; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Foster-Barber A, 1998, P NATL ACAD SCI USA, V95, P4673, DOI 10.1073/pnas.95.8.4673; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Hosaka M, 1999, J BIOL CHEM, V274, P16747, DOI 10.1074/jbc.274.24.16747; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Mundigl O, 1998, J NEUROSCI, V18, P93; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Nielander HB, 1997, EUR J NEUROSCI, V9, P2712, DOI 10.1111/j.1460-9568.1997.tb01700.x; Onofri F, 1997, P NATL ACAD SCI USA, V94, P12168, DOI 10.1073/pnas.94.22.12168; PANG DT, 1988, P NATL ACAD SCI USA, V85, P762, DOI 10.1073/pnas.85.3.762; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PIERIBONE VA, 1995, NATURE, V375, P493, DOI 10.1038/375493a0; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SIMON JA, 1995, CHEM BIOL, V2, P53, DOI 10.1016/1074-5521(95)90080-2; SIOW YL, 1992, BIOCHEMISTRY-US, V31, P4268, DOI 10.1021/bi00132a017; SIVADON P, 1995, MOL GEN GENET, V246, P485, DOI 10.1007/BF00290452; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEDA T, 1973, J BIOL CHEM, V248, P8295; Urquhart AJ, 2000, J BIOL CHEM, V275, P4127, DOI 10.1074/jbc.275.6.4127; Vaccaro P, 1997, MOL BRAIN RES, V52, P1, DOI 10.1016/S0169-328X(97)00219-2; VALTORTA F, 1992, J BIOL CHEM, V267, P11281; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8	58	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29857	29867		10.1074/jbc.M006018200	http://dx.doi.org/10.1074/jbc.M006018200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10899172	hybrid			2022-12-25	WOS:000089439800092
J	Finzer, P; Soto, U; Delius, H; Patzelt, A; Coy, JF; Poustka, A; zur Hausen, H; Rosl, F				Finzer, P; Soto, U; Delius, H; Patzelt, A; Coy, JF; Poustka, A; zur Hausen, H; Rosl, F			Differential transcriptional regulation of the monocyte-chemoattractant protein-1 (MCP-1) gene in tumorigenic and non-tumorigenic HPV 18 positive cells: The role of the chromatin structure and AP-1 composition	ONCOGENE			English	Article						chemokines; human papillomaviruses; cervical cancer; somatic cell hybrids; tumorigenicity	NF-KAPPA-B; CERVICAL INTRAEPITHELIAL NEOPLASIA; HUMAN PAPILLOMAVIRUS INFECTION; JE GENE; HELA-CELLS; HYBRIDS; ALPHA; EXPRESSION; GROWTH; DNA	The expression of the monocyte-chemoattractant-protein-1 (MCP-1) is closely linked with a non-tumorigenic phenotype in somatic cell hybrids made between the human papillomavirus type 18 (HPV 18) positive cervical carcinoma cell line HeLa and normal human fibroblasts, In contrast, MCP-1 transcription is absent in tumorigenic segregants derived from the same hybrids or in parental HeLa cells. Selectivity of MCP-1 transcription, which is regulated at the le, el of initiation of transcription, is mainly based on differences in the location and extension of DNAse I-hypersensitive regions (DHSR) at both ends of the gene, While TNF-alpha only moderately increases the sensitivity of pre-existing 5'-DHSRs, a 3'-end DHSR became strongly induced exclusively in non-malignant hybrids, DNA sequencing showed that the 3'-DHSR coincides with an additional AP-1 site located approximately 600 bp downstream of the polyadenylation site. Analyses of AP-1 composition revealed that MCP-1 is only expressed in those cells where jun-family members were mainly heterodimerized with the fos-related protein fra-1. In contrast, in tumorigenic cells the 1:1 ratio between jun and fra-1 is disturbed and the MCP-1 gene is no longer expressed. Hence, alterations in the heterodimerization pattern of AP-1 and its selective accessibility to opened chromatin may represent a novel regulatory pathway in the regulation of chemokines in malignant and non-malignant HPV-positive cells.	Deutsch Krebsforschungszentrum, Forschungsschwerpunkt Angew Tumorvirol, D-69120 Heidelberg, Germany; Forschungsschwerpunkt Genomforsch & Bioinformat, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Rosl, F (corresponding author), Deutsch Krebsforschungszentrum, Forschungsschwerpunkt Angew Tumorvirol, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.							ALTMANN A, 1994, INTERVIROLOGY, V37, P180, DOI 10.1159/000150376; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BIRAGYN A, 1995, J IMMUNOL, V155, P674; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; KENNY MK, 1988, J BIOL CHEM, V263, P9809; KLEINE K, 1995, MOL CARCINOGEN, V14, P179, DOI 10.1002/mc.2940140307; Kleine-Lowinski K, 1999, INT J CANCER, V82, P6, DOI 10.1002/(SICI)1097-0215(19990702)82:1<6::AID-IJC2>3.0.CO;2-3; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Maehama T, 1998, INT J CANCER, V76, P639, DOI 10.1002/(SICI)1097-0215(19980529)76:5<639::AID-IJC5>3.0.CO;2-R; Majewski S., 1996, PAPILLOMAVIRUS REPOR, V7, P143; MEHRABIAN M, 1991, GENOMICS, V9, P200, DOI 10.1016/0888-7543(91)90239-B; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; Ozbun MA, 1996, J VIROL, V70, P5437, DOI 10.1128/JVI.70.8.5437-5446.1996; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; Rosl F, 1999, CONT CANC RES, P207; ROSL F, 1994, J VIROL, V68, P2142; ROSL F, 1989, MOL CARCINOGEN, V2, P72, DOI 10.1002/mc.2940020205; Soto U, 1999, ONCOGENE, V18, P3187, DOI 10.1038/sj.onc.1202765; SOTO U, 2000, IN PRESS INT J CANC; SPINILLO A, 1993, GYNECOL ONCOL, V48, P210, DOI 10.1006/gyno.1993.1035; STANBRIDGE EJ, 1984, CANCER SURV, V3, P335; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TAY SK, 1987, BRIT J OBSTET GYNAEC, V94, P1094, DOI 10.1111/j.1471-0528.1987.tb02296.x; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; UEDA A, 1994, J IMMUNOL, V153, P2052; Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092; Wingender E, 1997, NUCLEIC ACIDS RES, V25, P265, DOI 10.1093/nar/25.1.265; ZURHAUSEN H, 1994, COLD SPRING HARB SYM, V59, P623, DOI 10.1101/SQB.1994.059.01.071	38	38	41	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2000	19	29					3235	3244		10.1038/sj.onc.1203643	http://dx.doi.org/10.1038/sj.onc.1203643			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918580				2022-12-25	WOS:000088019300002
J	Nesbit, CE; Tersak, JM; Grove, LE; Drzal, A; Choi, H; Prochownik, EV				Nesbit, CE; Tersak, JM; Grove, LE; Drzal, A; Choi, H; Prochownik, EV			Genetic dissection of c-myc apoptotic pathways	ONCOGENE			English	Article						IL-3; cDNA microarrays; interferon-gamma; max	IN-VIVO; TRANSCRIPTIONAL ACTIVATION; ORNITHINE DECARBOXYLASE; TRANSACTIVATION DOMAIN; LUNG-CARCINOMA; DNA-BINDING; CELL-GROWTH; PROTEIN; MAX; EXPRESSION	All biological functions mediated by the c-myc oncoprotein require an intact transactivation domain (TAD). We compared TAD mutants for their ability to promote apoptosis of 32D myeloid cells in response to interleukin-3 (IL-3) deprivation and exposure to chemotherapeutic drugs, and to activate ornithine decarboxylase, an endogenous c-myc target. Different sub-regions of the TAD were required to mediate each function. cDNA microarrays were then used to identify multiple c-myc-regulated transcripts, some of which were also modulated by IL-3 or cytotoxic drugs, as well as by specific sub-regions of the TAD. Several of the c-myc-regulated transcripts had also been previously identified as targets for IFN-gamma. The functional consequences of their deregulation were manifested by a marked sensitivity of c-myc-overexpressing cells to IFN-gamma-mediated apoptosis, Our results establish that several well-characterized functions of c-myc are separable and correlate with the expression of a novel group of target genes, some of which also mediate the apoptotic action of IFN-gamma.	Childrens Hosp Pittsburgh, Hematol Oncol Sect, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Program Mol Oncol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Hematol Oncol Sect, 3705 5th ave, Pittsburgh, PA 15213 USA.				NATIONAL CANCER INSTITUTE [R01CA078259] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NCI NIH HHS [CA78259] Funding Source: Medline; NHLBI NIH HHS [HL33741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; Aoyama K, 1999, BLOOD, V93, P2586, DOI 10.1182/blood.V93.8.2586.408k23_2586_2594; ASKEW DS, 1991, ONCOGENE, V6, P1915; Barr LF, 1998, CANCER RES, V58, P5537; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bonfil RD, 1998, ONCOL RES, V10, P15; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Cook GA, 1999, EXP CELL RES, V251, P356, DOI 10.1006/excr.1999.4596; Dang CV, 1999, MOL CELL BIOL, V19, P1; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KIJIMOTOOCHIAI S, 1995, GLYCOBIOLOGY, V5, P443, DOI 10.1093/glycob/5.4.443; Kraemer M, 1999, CELL GROWTH DIFFER, V10, P193; Krause T, 1999, CLIN EXP METASTAS, V17, P183, DOI 10.1023/A:1006626500852; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; MacGregor D, 1996, J CELL PHYSIOL, V167, P95, DOI 10.1002/(SICI)1097-4652(199604)167:1<95::AID-JCP11>3.3.CO;2-Q; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Nesbit CE, 1998, CELL GROWTH DIFFER, V9, P731; Nesbit CE, 1998, BLOOD, V92, P1003; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; O'Reilly MS, 1999, J BIOL CHEM, V274, P29568, DOI 10.1074/jbc.274.41.29568; Okochi H, 1997, BRIT J DERMATOL, V137, P856, DOI 10.1046/j.1365-2133.1997.19782088.x; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; Prochownik EV, 1998, GENE CHROMOSOME CANC, V22, P295, DOI 10.1002/(SICI)1098-2264(199808)22:4<295::AID-GCC5>3.0.CO;2-Q; PULVERER BJ, 1994, ONCOGENE, V9, P59; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Rosenfeld ME, 1998, SEMIN REPROD ENDOCR, V16, P249, DOI 10.1055/s-2007-1016285; Sakamuro D, 1995, ONCOGENE, V11, P2411; SHUMAKER DK, 1994, EXP CELL RES, V214, P440, DOI 10.1006/excr.1994.1280; Smits P, 1999, GENE, V226, P253, DOI 10.1016/S0378-1119(98)00558-7; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Thompson A, 1996, J BIOL CHEM, V271, P22976, DOI 10.1074/jbc.271.38.22976; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P7227, DOI 10.1073/pnas.94.14.7227; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416; ZHAO Q, 1998, GENE DEV, V12, P3803	63	53	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3200	3212		10.1038/sj.onc.1203636	http://dx.doi.org/10.1038/sj.onc.1203636			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918575				2022-12-25	WOS:000088019200009
J	Ayukawa, K; Taniguchi, S; Masumoto, J; Hashimoto, S; Sarvotham, H; Hara, A; Aoyama, T; Sagara, J				Ayukawa, K; Taniguchi, S; Masumoto, J; Hashimoto, S; Sarvotham, H; Hara, A; Aoyama, T; Sagara, J			La autoantigen is cleaved in the COOH terminus and loses the nuclear localization signal during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TERMINATION FACTOR LA; SS-B AUTOANTIGEN; TRANSCRIPTION TERMINATION; POLY(ADP-RIBOSE) POLYMERASE; LUPUS-ERYTHEMATOSUS; MATRIX PROTEINS; POLIOVIRUS RNA; CASPASE FAMILY; DEATH	La autoantigen is a 47-kDa nuclear protein that binds to nascent polymerase III transcripts and a number of viral RNAs. We show that La protein was cleaved to generate a 43-kDa fragment during apoptosis of human leukemic HL-60 cells treated with camptothecin or etoposide. Immunofluorescence microscopy showed that the La protein level was increased in the cytoplasm during apoptosis of HL-60 cells. In addition, UV irradiation of HeLa cells led to the cleavage and redistribution of La protein upon apoptosis. Several lines of evidence show that La protein is cleaved by caspase-3 or closely related proteases at Asp-374 in the COOH terminus. When the full-length (La) and COOH-terminally truncated (La Delta C374) forms of La protein were expressed as fusion proteins with green fluorescence protein (GFP), GFP-La Delta C374 was predominantly cytoplasmic, whereas GFP-La was localized in the nucleus. These results suggest that La protein loses the nuclear localization signal residing in the COOH terminus upon cleavage and is thus redistributed to the cytoplasm during apoptosis.	Shinshu Univ, Sch Med, Res Ctr Aging & Adaptat, Dept Mol Oncol & Angiol, Nagano 3908621, Japan; Shinshu Univ, Sch Med, Res Ctr Aging & Adaptat, Dept Aging Biochem, Nagano 3908621, Japan	Shinshu University; Shinshu University	Sagara, J (corresponding author), Shinshu Univ, Sch Med, Res Ctr Aging & Adaptat, Dept Mol Oncol & Angiol, Asahi 3-1-1, Nagano 3908621, Japan.		Hara, Atsushi/B-1127-2008					Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; CHAMBERS JC, 1985, P NATL ACAD SCI USA, V82, P2115, DOI 10.1073/pnas.82.7.2115; CHAMBERS JC, 1988, J BIOL CHEM, V263, P18043; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FEY EG, 1988, P NATL ACAD SCI USA, V85, P121, DOI 10.1073/pnas.85.1.121; Galfre G, 1981, Methods Enzymol, V73, P3; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; JEMMERSON R, 1985, P NATL ACAD SCI USA, V82, P1508, DOI 10.1073/pnas.82.5.1508; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; LERNER MR, 1981, SCIENCE, V211, P400, DOI 10.1126/science.6164096; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; Maraia RJ, 1996, P NATL ACAD SCI USA, V93, P3383, DOI 10.1073/pnas.93.8.3383; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; Miranda ME, 1998, J IMMUNOL, V161, P5061; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PIENTA KJ, 1994, MED HYPOTHESES, V42, P45, DOI 10.1016/0306-9877(94)90035-3; Pommier Y, 1993, CANCER CHEMOTHERAPY, P214; Rosen A, 1999, CELL DEATH DIFFER, V6, P6, DOI 10.1038/sj.cdd.4400460; Rutjes SA, 1999, CELL DEATH DIFFER, V6, P976, DOI 10.1038/sj.cdd.4400571; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Simons FHM, 1996, EXP CELL RES, V224, P224, DOI 10.1006/excr.1996.0132; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SVITKIN YV, 1994, J VIROL, V68, P1544, DOI 10.1128/JVI.68.3.1544-1550.1994; SVITKIN YV, 1994, J VIROL, V68, P7001, DOI 10.1128/JVI.68.11.7001-7007.1994; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; vanVenrooij WJ, 1995, CURR OPIN IMMUNOL, V7, P819, DOI 10.1016/0952-7915(95)80054-9; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZWEYER M, 1995, EXP CELL RES, V221, P27, DOI 10.1006/excr.1995.1349	40	74	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34465	34470		10.1074/jbc.M003673200	http://dx.doi.org/10.1074/jbc.M003673200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10913436	hybrid			2022-12-25	WOS:000165095300063
J	Chen, ZJ; Fitzgerald, RL; Averna, MR; Schonfeld, G				Chen, ZJ; Fitzgerald, RL; Averna, MR; Schonfeld, G			A targeted apolipoprotein B-38.9-producing mutation causes fatty livers in mice due to the reduced ability of apolipoprotein B-38.9 to transport triglycerides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B MESSENGER-RNA; FAMILIAL HYPOBETALIPOPROTEINEMIA; NONSENSE MUTATION; APO-B; TRUNCATED APOLIPOPROTEIN; HETEROZYGOUS HYPOBETALIPOPROTEINEMIA; EMBRYONIC LETHALITY; PLASMA-LIPOPROTEINS; MOUSE MODEL; GENE	Nonphysiological truncations of apolipoprotein (apo) B-100 cause familial hypobetalipoproteinemia (FHBL) in humans and mice. An elucidation of the mechanisms underlying the FHBL phenotypes may provide valuable information on the metabolism of apo B-containing lipoproteins and the structure-function relationship of apo B. To generate a faithful mouse model of human FHBL, a subtle mutation was introduced into the mouse apo B gene by targeting embryonic stem cells using homologous recombination followed by removal of the selection marker gene by Cre-loxP-mediated site-specific recombination. The engineered mice bear a premature stop codon at residue 1767 and a 42-base pair loxP inserted into intron 24 of the apo B gene, thus closely resembling the apo B-38.9-producing mutation in humans. Apo B-38.9 was the sole apo B protein in homozygote (apob(38.9/38.9)) plasma. In heterozygotes (apob(+/38.9)), apo B-100 and apo B-48 were reduced by 75 and 40%, respectively, and apo B-38.9 represented 20% of total circulating apo B. Hepatic apo B-38.9 mRNA levels were reduced by 40%. In cultured apob(+/38.9) hepatocytes, apo B-100 was produced in trace quantities, and the synthesis rate of apo B-38.9 relative to apo B-48 was reduced by 40%. However, almost equimolar amounts of apo B-38.9 and apo B-48 were secreted into the media, Pulse-chase studies revealed that apo B-38.9 was secreted at a faster rate and more efficiently than apoB-48. Nevertheless, both apob(+/38.9) and apob(38.9/38.9) mice had reduced hepatic triglyceride secretion rates and fatty livers. Thus, low mRNA levels or defective secretion of apo B-38.9 may not be responsible for the FHBL phenotypes caused by the apo B-38.9 mutation. Rather, a reduced capacity of apo B-38.9 for triglyceride transport may account for the fatty livers in these mice.	Washington Univ, Sch Med, Dept Med, Div Atherosclerosis Nutr & Lipid Res, St Louis, MO 63110 USA	Washington University (WUSTL)	Chen, ZJ (corresponding author), Washington Univ, Sch Med, Dept Med, Div Atherosclerosis Nutr & Lipid Res, Box 8046,660 S Euclid Ave, St Louis, MO 63110 USA.	zchen@im.wustl.edu	Averna, Maurizio/U-9527-2017	Averna, Maurizio/0000-0003-3558-9209	NHLBI NIH HHS [R37 HL-424460, R01 HL-59515] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059515] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmed A, 1998, AM J GASTROENTEROL, V93, P2598, DOI 10.1016/S0002-9270(98)00613-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; Castellano G, 1997, J CLIN GASTROENTEROL, V25, P379, DOI 10.1097/00004836-199707000-00021; Cavallo D, 1998, J BIOL CHEM, V273, P33397, DOI 10.1074/jbc.273.50.33397; CHAN L, 1992, J BIOL CHEM, V267, P25621; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Chen ZJ, 1999, J CLIN INVEST, V103, P1419, DOI 10.1172/JCI4921; Chen ZJ, 1999, CIRCULATION, V100, P329; Elias N, 1999, ARTERIOSCL THROM VAS, V19, P2714, DOI 10.1161/01.ATV.19.11.2714; Farese RV, 1996, P NATL ACAD SCI USA, V93, P6393, DOI 10.1073/pnas.93.13.6393; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; FRANGI D, 1991, J CLIN INVEST, V88, P755, DOI 10.1172/JCI115373; GREEVE J, 1993, J LIPID RES, V34, P1367; GROENEWEGEN WA, 1994, J LIPID RES, V35, P1012; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HAMOSH A, 1991, J CLIN INVEST, V88, P1880, DOI 10.1172/JCI115510; HIGUCHI K, 1992, J LIPID RES, V33, P1753; HOMANICS GE, 1993, P NATL ACAD SCI USA, V90, P2389, DOI 10.1073/pnas.90.6.2389; HUANG LS, 1995, J CLIN INVEST, V96, P2152, DOI 10.1172/JCI118269; Hug BA, 1996, MOL CELL BIOL, V16, P2906; JIAO S, 1990, J LIPID RES, V31, P467; Kim E, 1998, J BIOL CHEM, V273, P33977, DOI 10.1074/jbc.273.51.33977; Kim E, 1998, J CLIN INVEST, V101, P1468; KRUL ES, 1992, J LIPID RES, V33, P1037; LEHRMAN MA, 1987, J BIOL CHEM, V262, P401; Li XH, 1996, J LIPID RES, V37, P210; LIEBHABER SA, 1987, J CLIN INVEST, V80, P154, DOI 10.1172/JCI113041; LINTON MF, 1993, J LIPID RES, V34, P521; LONGO N, 1992, AM J HUM GENET, V50, P998; MARWELL MAK, 1978, ANAL BIOCHEM, V87, P206; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; Ogata H, 1997, AM J GASTROENTEROL, V92, P339; PARHOFER KG, 1992, J CLIN INVEST, V89, P1931, DOI 10.1172/JCI115799; Parhofer KG, 1996, J LIPID RES, V37, P844; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; SCHONFELD G, 1995, ANNU REV NUTR, V15, P23, DOI 10.1146/annurev.nu.15.070195.000323; Srivastava N, 1996, METABOLISM, V45, P1296, DOI 10.1016/S0026-0495(96)90251-6; Tarugi P, 1996, GASTROENTEROLOGY, V111, P1125, DOI 10.1016/S0016-5085(96)70082-3; Toth LR, 1996, GENE, V178, P161, DOI 10.1016/0378-1119(96)00360-5; Twisk J, 2000, J CLIN INVEST, V105, P521, DOI 10.1172/JCI8623; WINSLOW RM, 1976, J CLIN INVEST, V57, P772, DOI 10.1172/JCI108336; Wu JS, 1999, J LIPID RES, V40, P955; YAO ZM, 1991, J BIOL CHEM, V266, P3300; Zhu XF, 1997, ARTERIOSCL THROM VAS, V17, P1032, DOI 10.1161/01.ATV.17.6.1032	47	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32807	32815		10.1074/jbc.M004913200	http://dx.doi.org/10.1074/jbc.M004913200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10893242	hybrid			2022-12-25	WOS:000090003800060
J	Palmieri, D; Camardella, L; Ulivi, V; Guasco, G; Manduca, P				Palmieri, D; Camardella, L; Ulivi, V; Guasco, G; Manduca, P			Trimer carboxyl propeptide of collagen I produced by mature osteoblasts is chemotactic for endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN ALPHA-1-BETA-1; EXTRACELLULAR-MATRIX; TERMINAL PROPEPTIDE; GENE-EXPRESSION; GROWTH-FACTOR; C-PROPEPTIDE; ANGIOGENESIS; PROCOLLAGEN; MIGRATION; BINDING	During the second phase of osteogenesis in vitro, rat osteoblasts secrete inducer(s) of chemotaxis and chemoinvasion of endothelial and tumor cells. We report here the characterization and purification from mature osteoblast conditioned medium of the agent chemotactic for endothelial cells. The chemoactive conditioned medium specifically induces directional migration of endothelial cells, not affecting the expression and activation of gelatinases, cell proliferation, and scattering. Directional migration induced in endothelial cells by conditioned medium from osteoblasts is inhibited by pertussis toxin, by blocking antibodies to integrins alpha (1), beta (1), and beta (3), and by antibodies to metalloproteinase 2 and 9. The biologically active purified protein has two sequences, coincident with the amino-terminal amino acids, respectively, of the alpha (2) and of the alpha (2) carboxyl propeptides of type I collagen, as physiologically produced by procollagen C proteinase. Antibodies to type I collagen and to the carboxyl terminus of alpha (1) or alpha (2) chains inhibit chemotaxis. The chemoattractant is the propeptide trimer carboxyl-terminal to type I collagen, and its activity is lost upon reduction. These data illustrate a previously unknown function for the carboxyl-terminal trimer, possibly relevant in promoting endothelial cell migration and vascularization of tissues producing collagen type I.	Univ Genoa, Dipartimento Oncol Biol & Genet, I-16132 Genoa, Italy; CNR, IBPE, I-80100 Naples, Italy	University of Genoa; Consiglio Nazionale delle Ricerche (CNR)	Manduca, P (corresponding author), Univ Genoa, Dipartimento Oncol Biol & Genet, C Europa 26, I-16132 Genoa, Italy.							ALINI M, 1992, CALCIFIED TISSUE INT, V50, P327, DOI 10.1007/BF00301630; AYCOCK RS, 1986, J BIOL CHEM, V261, P14355; Broberg A, 1996, EXP CELL RES, V228, P29, DOI 10.1006/excr.1996.0295; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CHOGLAY AA, 1993, J BIOL CHEM, V268, P6107; Davies D, 1997, EUR J BIOCHEM, V246, P274, DOI 10.1111/j.1432-1033.1997.t01-1-00274.x; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DEJANA E, 1985, J CLIN INVEST, V75, P11, DOI 10.1172/JCI111661; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; Festuccia C, 1999, ONCOL RES, V11, P17; Festuccia C, 1999, INT J CANCER, V81, P395, DOI 10.1002/(SICI)1097-0215(19990505)81:3<395::AID-IJC13>3.0.CO;2-V; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Gardner H, 1999, J CELL SCI, V112, P263; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; GIUNCIUGLIO D, 1995, CANCER LETT, V97, P69, DOI 10.1016/0304-3835(95)03955-V; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Kamphaus GD, 2000, J BIOL CHEM, V275, P1209, DOI 10.1074/jbc.275.2.1209; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; Manduca P, 1997, BONE, V21, P31, DOI 10.1016/S8756-3282(97)00037-9; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Pozzi M, 1998, J CELL BIOL, V142, P587; Ramchandran R, 1999, BIOCHEM BIOPH RES CO, V255, P735, DOI 10.1006/bbrc.1999.0248; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; STRINGA E, 1995, BONE, V16, P663, DOI 10.1016/8756-3282(95)00100-R; VANDERREST M, 1986, BIOCHEM J, V237, P923, DOI 10.1042/bj2370923; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; WESTON SA, 1994, J BIOL CHEM, V269, P20982; WU CH, 1991, J BIOL CHEM, V266, P2983; YOSHITAKE H, 1999, J BONE MINER RES  S1, V14, P1004	35	32	34	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32658	32663		10.1074/jbc.M002698200	http://dx.doi.org/10.1074/jbc.M002698200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10924500	hybrid			2022-12-25	WOS:000090003800040
J	Dallabrida, SM; De Sousa, MA; Farrell, DH				Dallabrida, SM; De Sousa, MA; Farrell, DH			Expression of antisense to integrin subunit beta(3) inhibits microvascular endothelial cell capillary tube formation in fibrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; FIBROBLAST GROWTH-FACTOR; ALPHA-V INTEGRINS; ALPHA(V)BETA(3) INTEGRIN; GLANZMANN THROMBASTHENIA; ADHESION MOLECULES; BLOOD-VESSELS; GENE-THERAPY; ANGIOGENESIS; RECEPTOR	alpha(v)beta(3) antagonists are potent angiogenesis inhibitors, and several different classes of inhibitors have been developed, including monoclonal antibodies, synthetic peptides, and small organic molecules. However, each class of inhibitor works by the same principal, by blocking the binding of ligands to alpha(v)beta(3). In an effort to develop an alpha(v)beta(3) inhibitor that down-regulates the actual level of alpha(v)beta(3), we developed an antisense strategy to inhibit alpha(v)beta(3) expression in vitro. beta(3) antisense expressed in endothelial cells specifically down-regulated alpha(v)beta(3) and inhibited capillary tube formation, with the extent of down-regulation correlating with the extent of tube formation inhibition. This inhibition was matrix-specific, since tube formation was not inhibited in Matrigel. These findings support the notion that alpha(v)beta(3) is required for an essential step of angiogenesis in fibrin, namely capillary tube formation. These results suggest that pseudogenetic inhibition of beta(3) integrins using antisense techniques may ultimately provide a therapeutic means to inhibit angiogenesis in vivo.	Oregon Hlth & Sci Univ, Sch Dent, Dept Oral Mol Biol, Portland, OR 97201 USA; Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Oregon Health & Science University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Farrell, DH (corresponding author), Oregon Hlth & Sci Univ, Sch Dent, Dept Oral Mol Biol, Portland, OR 97201 USA.	farrelld@ohsu.edu			NHLBI NIH HHS [R29HL53997, K02HL04215] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL053997, K02HL004215] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Bach TL, 1998, J BIOL CHEM, V273, P30719, DOI 10.1074/jbc.273.46.30719; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; BOLEN JB, 1987, J VIROL, V61, P1079, DOI 10.1128/JVI.61.4.1079-1085.1987; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CHANG MC, 1995, THROMB HAEMOSTASIS, V74, P764; Cheresh DA, 1998, NAT MED, V4, P395, DOI 10.1038/nm0498-395; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; COLLER BS, 1991, BLOOD, V77, P75; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; Davis GE, 1996, EXP CELL RES, V224, P39, DOI 10.1006/excr.1996.0109; DEJANA E, 1988, BLOOD, V71, P566; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; DRAKE CJ, 1995, J CELL SCI, V108, P2655; Falls LA, 1997, J BIOL CHEM, V272, P14251, DOI 10.1074/jbc.272.22.14251; FINLAYSON JS, 1960, J CLIN INVEST, V39, P1837, DOI 10.1172/JCI104207; Folkman J, 1998, ENDOCRINOLOGY, V139, P441, DOI 10.1210/en.139.2.441; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 1998, P NATL ACAD SCI USA, V95, P9064, DOI 10.1073/pnas.95.16.9064; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; GAMBLE JR, 1993, J CELL BIOL, V121, P931, DOI 10.1083/jcb.121.4.931; GOTO F, 1993, LAB INVEST, V69, P508; Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; HOSHIGA M, 1995, CIRC RES, V77, P1129, DOI 10.1161/01.RES.77.6.1129; KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; Keenan RM, 1997, J MED CHEM, V40, P2289, DOI 10.1021/jm970205r; Koch AE, 1998, ARTHRITIS RHEUM-US, V41, P951, DOI 10.1002/1529-0131(199806)41:6<951::AID-ART2>3.0.CO;2-D; KOIVISTO L, 1994, BIOCHEM J, V300, P771, DOI 10.1042/bj3000771; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XW, 1998, INVAS METAST, V18, P1, DOI 10.1159/000024494; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; NEHLS V, 1995, MICROVASC RES, V50, P311, DOI 10.1006/mvre.1995.1061; Nicolaou KC, 1998, BIOORGAN MED CHEM, V6, P1185, DOI 10.1016/S0968-0896(98)00090-X; NICOSIA RF, 1991, AM J PATHOL, V138, P829; OBRIEN ER, 1994, AM J PATHOL, V145, P883; Okada Y, 1996, AM J PATHOL, V149, P37; Panda D, 1997, P NATL ACAD SCI USA, V94, P9308, DOI 10.1073/pnas.94.17.9308; PYTELA R, 1994, METHOD ENZYMOL, V245, P420; Roush W, 1997, SCIENCE, V276, P1192, DOI 10.1126/science.276.5316.1192; SAELMAN EUM, 1995, J CELL SCI, V108, P3531; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; SEPP NT, 1994, J INVEST DERMATOL, V103, P295, DOI 10.1111/1523-1747.ep12394617; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; STUPACK DG, 1991, SCAND J IMMUNOL, V34, P761, DOI 10.1111/j.1365-3083.1991.tb01601.x; Tam SH, 1998, CIRCULATION, V98, P1085, DOI 10.1161/01.CIR.98.11.1085; Thiagarajan P, 1996, BIOCHEMISTRY-US, V35, P4169, DOI 10.1021/bi952532b; Topol EJ, 1997, JAMA-J AM MED ASSOC, V278, P479, DOI 10.1001/jama.278.6.479; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WILLIAMS S, 1993, LAB INVEST, V69, P491; Wu HR, 1998, P NATL ACAD SCI USA, V95, P6037, DOI 10.1073/pnas.95.11.6037; XU YL, 1994, J INVEST DERMATOL, V102, P833, DOI 10.1111/1523-1747.ep12382086	59	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32281	32288		10.1074/jbc.M001446200	http://dx.doi.org/10.1074/jbc.M001446200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10922359	hybrid			2022-12-25	WOS:000089858900100
J	Kahnert, A; Kertesz, MA				Kahnert, A; Kertesz, MA			Characterization of a sulfur-regulated oxygenative alkylsulfatase from Pseudomonas putida S-313	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; ESCHERICHIA-COLI; FOREST SOIL; DIOXYGENASE; BIODEGRADATION; PURIFICATION; ACTIVATION; ENZYME; RESISTANCE; CLONING	The atsK gene of Pseudomonas putida S-313 was required for growth with alkyl sulfate esters as sulfur source. The AtsK protein was overexpressed in Escherichia coli and purified to homogeneity. Sequence analysis revealed that AtsK was closely related to E. coli taurine dioxygenase (38% amino acid identity). The AtsK protein catalyzed the alpha-ketoglutarate-dependent cleavage of a range of alkyl sulfate esters, with chain lengths ranging from C-4 to C-12, required oxygen and Fe2+ for activity and released succinate, sulfate, and the corresponding aldehyde as products. Enzyme activity was optimal at pH 7 and was strongly stimulated by ascorbate. Unlike most other characterized alpha-ketoglutarate-dependent dioxygenases, AtsK accepted a range of alpha-keto acids as co-substrates, including alpha-ketoglutarate (K-m 140 mu M), alpha-ketoadipate, alpha-ketovalerate, and alpha-ketooctanoate. The measured K-m values for hexyl sulfate and SDS were 40 and 34 mu M, respectively. The apparent M-r of the purified enzyme of 121,000 was consistent with a homotetrameric structure, which is unusual for this enzyme superfamily, members of which are usually monomeric or dimeric, The properties and amino acid sequence of the AtsK enzyme thus define it as an unusual oxygenolytic alkylsulfatase and a novel member of the alpha-ketoglutarate-dependent dioxygenase family.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; ETH Zentrum, Swiss Fed Inst Technol, Inst Microbiol, CH-8092 Zurich, Switzerland	University of Manchester; Swiss Federal Institutes of Technology Domain; ETH Zurich	Kertesz, MA (corresponding author), Univ Manchester, Sch Biol Sci, 1-800 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	michael.kertesz@man.ac.uk	Kertesz, Michael/A-6720-2011; KERTESZ, Michael/Q-7642-2019	Kertesz, Michael/0000-0003-2112-4451; KERTESZ, Michael/0000-0003-2112-4451				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; AUTRY AR, 1990, BIOL FERT SOILS, V10, P50; BARRETT CH, 1980, BIOCHEM J, V191, P467, DOI 10.1042/bj1910467; BARTHOLOMEW B, 1977, BIOCHEM J, V165, P575, DOI 10.1042/bj1650575; BATEMAN TJ, 1986, BIOCHEM J, V236, P401, DOI 10.1042/bj2360401; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLOVES JM, 1980, BIOCHEM J, V185, P23, DOI 10.1042/bj1850023; Davies I, 1990, BIODEGRADATION, V1, P229, DOI 10.1007/BF00119760; DAVISON J, 1992, GENE, V114, P19, DOI 10.1016/0378-1119(92)90702-Q; DECAROLIS E, 1994, PHYTOCHEMISTRY, V36, P1093, DOI 10.1016/S0031-9422(00)89621-1; Dodgson K.S., 1982, SULFATASES MICROBIAL; Eichhorn E, 1997, J BIOL CHEM, V272, P23031, DOI 10.1074/jbc.272.37.23031; FITZGERALD JW, 1975, CAN J MICROBIOL, V21, P59, DOI 10.1139/m75-008; FUKUMORI F, 1993, J BIOL CHEM, V268, P24311; HAINES TH, 1973, ANNU REV MICROBIOL, V27, P403, DOI 10.1146/annurev.mi.27.100173.002155; Hegg EL, 1999, BIOCHEMISTRY-US, V38, P16714, DOI 10.1021/bi991796l; Hegg EL, 1999, J AM CHEM SOC, V121, P1972, DOI 10.1021/ja983867u; HIGGINS TP, 1993, J GEN MICROBIOL, V139, P2915, DOI 10.1099/00221287-139-12-2915; Higgins TP, 1996, MICROBIOL-SGM, V142, P251, DOI 10.1099/13500872-142-2-251; Hummerjohann J, 2000, J BACTERIOL, V182, P2055, DOI 10.1128/JB.182.7.2055-2058.2000; Kahnert A, 2000, J BACTERIOL, V182, P2869, DOI 10.1128/JB.182.10.2869-2878.2000; KERTESZ MA, 1993, J BACTERIOL, V175, P1187, DOI 10.1128/JB.175.4.1187-1190.1993; Kertesz MA, 2000, FEMS MICROBIOL REV, V24, P135, DOI 10.1016/S0168-6445(99)00033-9; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; LIEM PQ, 1976, BIOCHIMIE, V58, P1381; LILLIS V, 1983, APPL ENVIRON MICROB, V46, P988, DOI 10.1128/AEM.46.5.988-994.1983; MATCHAM GWJ, 1977, BIOCHEM J, V167, P723, DOI 10.1042/bj1670723; MATTS PJ, 1994, BIOCHEM J, V304, P937, DOI 10.1042/bj3040937; MYLLYLA R, 1984, J BIOL CHEM, V259, P5403; PRESCOTT AG, 1993, J EXP BOT, V44, P849, DOI 10.1093/jxb/44.5.849; Quadroni M, 1999, EUR J BIOCHEM, V266, P986, DOI 10.1046/j.1432-1327.1999.00941.x; Que L, 1996, CHEM REV, V96, P2607, DOI 10.1021/cr960039f; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Serre L, 1999, STRUCTURE, V7, P977, DOI 10.1016/S0969-2126(99)80124-5; THOMAS ORT, 1989, BIOTECHNOL APPL BIOC, V11, P318; THOMAS ORT, 1988, J GEN MICROBIOL, V134, P1229; Valegard K, 1998, NATURE, V394, P805, DOI 10.1038/29575; vanderPloeg JR, 1996, J BACTERIOL, V178, P5438, DOI 10.1128/jb.178.18.5438-5446.1996; WATWOOD ME, 1986, CAN J FOREST RES, V16, P689, DOI 10.1139/x86-124; WEST SEH, 1994, GENE, V148, P81, DOI 10.1016/0378-1119(94)90237-2; WHITE GF, 1985, ENVIRON POLLUT A, V37, P1, DOI 10.1016/0143-1471(85)90020-0; YAGI T, 1966, J BIOCHEM-TOKYO, V59, P495, DOI 10.1093/oxfordjournals.jbchem.a128333	42	80	82	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31661	31667		10.1074/jbc.M005820200	http://dx.doi.org/10.1074/jbc.M005820200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913158	hybrid			2022-12-25	WOS:000089858900018
J	Tremblay, LO; Herscovics, A				Tremblay, LO; Herscovics, A			Characterization of a cDNA encoding a novel human Golgi alpha 1,2-mannosidase (IC) involved in N-glycan biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; SACCHAROMYCES-CEREVISIAE; GLYCOPROTEIN-BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; ALPHA-MANNOSIDASE; MOLECULAR-CLONING; PIG-LIVER; EXPRESSION; GLYCOSIDASES; ENZYME	A human cDNA encoding a 70.9-kDa type II membrane protein with sequence similarity to class I alpha 1,2-mannosidases was isolated. The enzymatic properties of the novel alpha 1,2-mannosidase IC were studied by expressing its catalytic domain in Pichia pastoris as a secreted glycoprotein. alpha 1,2-Mannosidase IC sequentially hydrolyzes the alpha 1,2-linked mannose residues of [H-3]mannose-labeled Man(9)GlcNAc to form [H-3]Man(6)GlcNAc and a small amount of [H-3]Man(5)GlcNAc. The enzyme requires calcium for activity and is inhibited by both 1-deoxymannojirimycin and kifunensine. The order of mannose removal was determined by separating oligosaccharide isomers formed from pyridylaminated Man(9)GlcNAc(2) by high performance liquid chromatography. The terminal alpha 1,2-linked mannose residue from the middle branch is the last mannose removed by the enzyme. This residue is the mannose cleaved from Man(9)GlcNAc(2) by the endoplasmic reticulum alpha 1,2-mannosidase I to form Man(8)GlcNAc(2) isomer B. The order of mannose hydrolysis from either pyridylaminated Man(9)GlcNAc(2) or Man(8)GlcNAc(2) isomer B differs from that previously reported for mammalian Golgi alpha 1,2-mannosidases LA and IB. The full-length alpha 1,2-mannosidase IC was localized to the Golgi of MDBK and MDCK cells by indirect immunofluorescence. Northern blot analysis showed tissue-specific expression of a major transcript of 3.8 kilobase pairs. The expression pattern is different from that of human Golgi alpha 1,2-mannosidases IA and IB. Therefore, the human genome contains at least three differentially regulated Golgi alpha 1,2-mannosidase genes encoding enzymes with similar, but not identical specificities.	McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada	McGill University	Herscovics, A (corresponding author), McGill Univ, Ctr Canc, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.							BAUSE E, 1993, EUR J BIOCHEM, V217, P535, DOI 10.1111/j.1432-1033.1993.tb18274.x; BAUSE E, 1992, EUR J BIOCHEM, V208, P451, DOI 10.1111/j.1432-1033.1992.tb17207.x; Bieberich E, 1997, EUR J BIOCHEM, V246, P681, DOI 10.1111/j.1432-1033.1997.t01-1-00681.x; CAMIRAND A, 1991, J BIOL CHEM, V266, P15120; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Gonzalez DS, 2000, MOL BIOL EVOL, V17, P292, DOI 10.1093/oxfordjournals.molbev.a026309; Gonzalez DS, 1999, J BIOL CHEM, V274, P21375, DOI 10.1074/jbc.274.30.21375; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HERSCOVICS A, 1987, ANAL BIOCHEM, V166, P85, DOI 10.1016/0003-2697(87)90550-1; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; HERSCOVICS A, 1994, J BIOL CHEM, V269, P9864; Igdoura SA, 1999, EUR J CELL BIOL, V78, P441, DOI 10.1016/S0171-9335(99)80071-5; JELINEKKELLY S, 1985, J BIOL CHEM, V260, P2253; Kawar Z, 2000, GLYCOBIOLOGY, V10, P347, DOI 10.1093/glycob/10.4.347; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAL A, 1994, J BIOL CHEM, V269, P9872; Lal A, 1998, GLYCOBIOLOGY, V8, P981, DOI 10.1093/glycob/8.10.981; Lipari F, 1999, BIOCHEMISTRY-US, V38, P1111, DOI 10.1021/bi981643i; Lipari F, 1996, J BIOL CHEM, V271, P27615, DOI 10.1074/jbc.271.44.27615; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; ROMERO PA, 1985, BIOCHEM J, V226, P733, DOI 10.1042/bj2260733; ROMERO PA, 1994, GLYCOBIOLOGY, V4, P135, DOI 10.1093/glycob/4.2.135; Romero PA, 2000, J BIOL CHEM, V275, P11071, DOI 10.1074/jbc.275.15.11071; SHAPER NL, 1985, J CELL BIOCHEM, V28, P229, DOI 10.1002/jcb.240280305; TABAS I, 1979, J BIOL CHEM, V254, P1655; Tremblay LO, 1998, GLYCOBIOLOGY, V8, P585, DOI 10.1093/glycob/8.6.585; Tremblay LO, 1999, GLYCOBIOLOGY, V9, P1073, DOI 10.1093/glycob/9.10.1073; Vallee F, 2000, EMBO J, V19, P581, DOI 10.1093/emboj/19.4.581; Yoshida T, 1998, BIOSCI BIOTECH BIOCH, V62, P309, DOI 10.1271/bbb.62.309	31	64	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31655	31660		10.1074/jbc.M004935200	http://dx.doi.org/10.1074/jbc.M004935200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10915796	hybrid			2022-12-25	WOS:000089858900017
J	Gunnarsson, A; Hellmark, T; Wieslander, J				Gunnarsson, A; Hellmark, T; Wieslander, J			Molecular properties of the Goodpasture epitope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR BASEMENT-MEMBRANE; IV COLLAGEN; ALPHA-3(IV) CHAIN; GBM ANTIBODIES; AUTOANTIGEN; ANTIGEN; DOMAIN; AUTOANTIBODIES; DISEASE; REGION	Goodpasture disease fulfils all criteria for a classical autoimmune disease, where autoantibodies targeted against the non-collagenous domain of the alpha 3-chain of collagen TV initiates an inflammatory destruction of the basement membrane in kidney glomeruli and lung alveoli. This leads to a rapidly progressive glomerulonephritis and severe pulmonary hemorrhage. Previous studies have indicated a limited epitope for the toxic antibodies in the N-terminal part of the non-collagenous domain. The epitope has been partially characterized by recreating the epitope in the non-reactive alpha 1-chain by exchanging nine residues to the corresponding ones of alpha 3. In this study we have investigated to what extent each of these amino acids contribute to the antibody binding in different patient sera. The results show that seven of the nine substitutions are enough to get an epitope that is recognized equally well as the native alpha 3-chain by all sera from 20 clinically verified Goodpasture patients. Furthermore, the patient sera reactivity against the different recombinant chains used in the study are very similar, with some minor exceptions, strongly supporting a highly defined and restricted epitope. We are convinced that the restriction of the epitope is of significant importance for the understanding of the etiology of the disease. Thereby also making every step on the way to characterization of the epitope a crucial step on the way to specific therapy for the disease.	Wieslab AB, S-22370 Lund, Sweden; Univ Lund Hosp, Dept Nephrol, S-22185 Lund, Sweden	Lund University; Skane University Hospital	Wieslander, J (corresponding author), Wieslab AB, S-22370 Lund, Sweden.		Hellmark, Thomas/U-6289-2017	Hellmark, Thomas/0000-0002-2952-1155				Borza DB, 2000, J BIOL CHEM, V275, P6030, DOI 10.1074/jbc.275.8.6030; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; HELLMARK T, 1994, KIDNEY INT, V46, P823, DOI 10.1038/ki.1994.338; Hellmark T, 1996, CLIN EXP IMMUNOL, V105, P504, DOI 10.1046/j.1365-2249.1996.119808.x; Hellmark T, 1999, J BIOL CHEM, V274, P25862, DOI 10.1074/jbc.274.36.25862; Hellmark T, 1999, KIDNEY INT, V55, P936, DOI 10.1046/j.1523-1755.1999.055003936.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KALLURI R, 1991, J BIOL CHEM, V266, P24018; Kalluri R, 1996, J BIOL CHEM, V271, P9062, DOI 10.1074/jbc.271.15.9062; LERNER RA, 1967, J EXP MED, V126, P989, DOI 10.1084/jem.126.6.989; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; Netzer KO, 1999, J BIOL CHEM, V274, P11267, DOI 10.1074/jbc.274.16.11267; Phelps RG, 1999, KIDNEY INT, V56, P1638, DOI 10.1046/j.1523-1755.1999.00720.x; Phelps RG, 1998, J BIOL CHEM, V273, P11440, DOI 10.1074/jbc.273.19.11440; PUSEY CD, 1987, LAB INVEST, V56, P23; QUINONES S, 1992, J BIOL CHEM, V267, P19780; Ryan JJ, 1998, CLIN EXP IMMUNOL, V113, P17, DOI 10.1046/j.1365-2249.1998.00623.x; Schulte S, 1998, J BIOL CHEM, V273, P1551, DOI 10.1074/jbc.273.3.1551; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; TURNER N, 1993, DISEASES KIDNEY, P1865; WIESLANDER J, 1984, P NATL ACAD SCI-BIOL, V81, P1544, DOI 10.1073/pnas.81.5.1544; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564	22	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30844	30848		10.1074/jbc.M004717200	http://dx.doi.org/10.1074/jbc.M004717200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896942	hybrid			2022-12-25	WOS:000089762700018
J	Hasty, AH; Shimano, H; Yahagi, N; Amemiya-Kudo, M; Perrey, S; Yoshikawa, T; Osuga, J; Okazaki, H; Tamura, Y; Iizuka, Y; Shionoiri, F; Ohashi, K; Harada, K; Gotoda, T; Nagai, R; Ishibashi, S; Yamada, N				Hasty, AH; Shimano, H; Yahagi, N; Amemiya-Kudo, M; Perrey, S; Yoshikawa, T; Osuga, J; Okazaki, H; Tamura, Y; Iizuka, Y; Shionoiri, F; Ohashi, K; Harada, K; Gotoda, T; Nagai, R; Ishibashi, S; Yamada, N			Sterol regulatory element-binding protein-1 is regulated by glucose at the transcriptional level	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; LIPOPROTEIN RECEPTOR PROMOTER; LIPOGENIC GENE-EXPRESSION; SREBP-1C MESSENGER-RNA; DIFFERENTIATION FACTOR-1; SYNTHASE PROMOTER; CULTURED-CELLS; INSULIN; LIVERS; ACTIVATION	In vivo studies suggest that sterol regulatory element-binding protein (SREBP)-1 plays a key role in the upregulation of lipogenic genes in the livers of animals that have consumed excess amounts of carbohydrates. In light of this, we sought to use an established mouse hepatocyte cell line, H2-35, to further define the mechanism by which glucose regulates nuclear SREBP-1 levels, First, we show that these cells transcribe high levels of SREBP-1c that are increased 4-fold upon differentiation from a prehepatocyte to a hepatocyte phenotype, making them an ideal cell culture model for the study of SREBP-1c induction. Second, we demonstrate that the presence of precursor and mature forms of SREBP-1 protein are positively regulated by medium glucose concentrations ranging from 5.5 to 25 mM, and are also regulated by insulin, with the amount of insulin in the fetal bovine serum being sufficient for maximal stimulation of SREBP-1 expression. Third, we show that the increase in SREBP-1 protein is due to an increase in SREBP-1 mRNA, Reporter gene analysis of the SREBP-1c promoter demonstrated a glucose-dependent induction of transcription. In contrast, expression of a fixed amount of the precursor form of SREBP-1c protein showed that glucose does not influence its cleavage. Fourth, we demonstrate that the glucose induction of SREBP could not be reproduced by fructose, xylose, or galactose nor by glucose analogs a-deoxy glucose and 3-O-methyl glucopyranose. These data provide strong evidence for the induction of SREBP-1c mRNA by glucose leading to increased mature protein in the nucleus, thus providing a potential mechanism for the up-regulation of lipogenic genes by glucose in vivo.	Univ Tsukuba, Inst Clin Med, Dept Internal Med, Tsukuba, Ibaraki 3058575, Japan; Univ Tokyo, Dept Metab Dis, Tokyo 1138655, Japan	University of Tsukuba; University of Tokyo	Shimano, H (corresponding author), Univ Tsukuba, Inst Clin Med, Dept Internal Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.		Yahagi, Naoya/D-2360-2014; Shimano, Hitoshi/AAI-5648-2020; perrey, stephane/B-7483-2008; Hasty, Alyssa/AAA-2757-2020; Shimano, Hitoshi/V-1761-2019	Yahagi, Naoya/0000-0002-1823-1865; perrey, stephane/0000-0002-8741-629X; Hasty, Alyssa/0000-0001-7302-8045; Shimano, Hitoshi/0000-0002-5562-5572				Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; DIPERSIO CM, 1991, MOL CELL BIOL, V11, P4405, DOI 10.1128/MCB.11.9.4405; DOIRON B, 1994, J BIOL CHEM, V269, P10213; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; Guan GM, 1997, J BIOL CHEM, V272, P10295; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P183, DOI 10.1007/BF02254759; HERBERT LF, 1996, J CLIN INVEST, V98, P930; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Kim HJ, 1999, J BIOL CHEM, V274, P25892, DOI 10.1074/jbc.274.36.25892; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875; Koo SH, 2000, J BIOL CHEM, V275, P5200, DOI 10.1074/jbc.275.7.5200; Kotzka J, 2000, J LIPID RES, V41, P99; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; Mourrieras F, 1997, BIOCHEM J, V326, P345, DOI 10.1042/bj3260345; Ntambi JM, 1996, BIOCHEM BIOPH RES CO, V220, P990, DOI 10.1006/bbrc.1996.0520; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sato R, 2000, J BIOL CHEM, V275, P12497, DOI 10.1074/jbc.275.17.12497; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Streicher R, 1996, J BIOL CHEM, V271, P7128, DOI 10.1074/jbc.271.12.7128; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; Takemoto M, 1999, BIOCHEM BIOPH RES CO, V258, P722, DOI 10.1006/bbrc.1999.0701; Thewke DP, 1998, J BIOL CHEM, V273, P21402, DOI 10.1074/jbc.273.33.21402; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1993, J BIOL CHEM, V268, P14497; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; ZARET KS, 1988, P NATL ACAD SCI USA, V85, P9076, DOI 10.1073/pnas.85.23.9076; ZARET KS, 1990, MOL CELL BIOL, V10, P4582, DOI 10.1128/MCB.10.9.4582	52	121	130	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31069	31077		10.1074/jbc.M003335200	http://dx.doi.org/10.1074/jbc.M003335200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10913129	hybrid			2022-12-25	WOS:000089762700047
J	Johnson, BW; Cepero, E; Boise, LH				Johnson, BW; Cepero, E; Boise, LH			Bcl-x(L) inhibits cytochrome c release but not mitochondrial depolarization during the activation of multiple death pathways by tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; INDUCED CELL-DEATH; MEDIATED APOPTOSIS; SIGNALING COMPLEX; CYCLOSPORINE-A; INNER MEMBRANE; BCL-2; CASPASES; FAS; PROTEASE	Cells can respond differently to anti-CD95 antibody treatment. Type I cells show strong activation of caspase-8 and directly activate caspase-3, Type II cells weakly activate caspase-8 and must amplify their death signal through the mitochondria, These cells can be rescued by Bcl-x(L). Here we show that tumor necrosis factor-alpha induces both Type I and II pathways, which can be inhibited by benzyloxycarbonyl-val-Ala-Asp-fluoromethyl ketone (Z-VAD-fmk) and Bcl-x(L) in a cooperative fashion. Death induced in the presence of Z-VAD-fmk was associated with a partial inhibition of caspase-8, whereas no effects on cytochrome c release, DEVDase activity, and intranucleosomal DNA cleavage were ob served. Thus, Z-VAD-fmk is likely weakening the death-inducing signaling complex-mediated activation of caspase-8 and diverting cells to a Type TI pathway, Bcl-x(L) cooperates with Z-VAD-fmk by blocking the Type II pathway at the level of cytochrome c release. Surprisingly, although Bcl-xL was able to block cytochrome c release, it was unable to block mitochondrial depolarization, suggesting that these are separate events, This suggests that mitochondria occupy two places in apoptotic signaling, as initiators of apoptosis through the release of cytochrome c as well as a target for effector caspases.	Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33101 USA; Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33101 USA	University of Miami; University of Miami	Boise, LH (corresponding author), Univ Miami, Sch Med, Dept Microbiol & Immunol, POB 016960 R-138, Miami, FL 33101 USA.		Boise, Lawrence/AAD-2314-2019	Boise, Lawrence/0000-0001-9436-8815	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM020435] Funding Source: NIH RePORTER; NIGMS NIH HHS [F31 GM20435] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Johnson BW, 1999, J BIOL CHEM, V274, P18552, DOI 10.1074/jbc.274.26.18552; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Mesner PW, 1999, J BIOL CHEM, V274, P22635, DOI 10.1074/jbc.274.32.22635; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XH, 1998, J BIOL CHEM, V273, P34278, DOI 10.1074/jbc.273.51.34278; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	50	51	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31546	31553		10.1074/jbc.M001363200	http://dx.doi.org/10.1074/jbc.M001363200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10913120	hybrid			2022-12-25	WOS:000089762700110
J	Li, XG; Multon, MC; Henin, Y; Schweighoffer, F; Venot, C; Josef, J; Zhou, CH; LaVecchio, J; Stuckert, P; Raab, M; Mhashilkar, A; Tocque, B; Marasco, WA				Li, XG; Multon, MC; Henin, Y; Schweighoffer, F; Venot, C; Josef, J; Zhou, CH; LaVecchio, J; Stuckert, P; Raab, M; Mhashilkar, A; Tocque, B; Marasco, WA			Grb3-3 is up-regulated in HIV-1-infected T-cells and can potentiate cell activation through NFATc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TRANSCRIPTION FACTOR NFAT1; NF-KAPPA-B; SIGNAL-TRANSDUCTION; TAT PROTEIN; HIV-1 INFECTION; CYCLOSPORINE-A; CD28 RECEPTOR; KINASE; PATHWAY	The MAPK pathway is required for T-cell activation; however, its role in modulating T-cell function following human immunodeficiency virus type 1 (HIV-1) infection is poorly understood. In this report, we investigated whether Grb3-3, an isoform of the Grb2 (growth factor receptor-bound protein-2) adaptor molecule that is associated with the MAPK pathway, could be involved. We found that Grb3-3, but not its isoform Grb2, is markedly up-regulated in CD4(+) peripheral blood mononuclear cells derived from either in vitro HIV-1-infected cultures or HIV-1-infected human subjects. Analysis of HIV-1 gene products indicated that Tat and Nef, both of which have been implicated in modulating T-cell function, can independently induce expression of Grb3-3. By using NFAT/AP-1, AP-1, or NFAT reporter assays, we found that Grb3-3 can potentiate NFAT (but not AP-1) promoter activity in Jurkat T-cells upon engagement of the T-cell receptor and CD28 co-receptor. In addition, potentiation of NFAT by Grb3-3 is substantially suppressed by MEKK1, a kinase that may play an important role in retaining NFAT in the cytoplasm, and by cyclosporin A. Finally, we also found that Grb3-3 potentiates HIV-1 long terminal (LTR) repeat promoter activity following T-cell receptor stimulation, an effect that can be largely suppressed by cyclosporin A. Taken together, this study indicates that Grb3-3 is a cellular factor that can be up-regulated by HIV-1. In addition, Grb3-3 can also function as a positive factor for T-cell activation and, in doing so, may aid in establishing an intracellular environment that can optimally support HIV-1 replication.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; Aventis Pharma Inc, F-94403 Vitry Sur Seine, France; Exonhit Therapeut, F-75013 Paris, France	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Sanofi-Aventis; Sanofi France	Marasco, WA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St,JFB 824, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [P30CA006516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041954, R01AI028785] Funding Source: NIH RePORTER; NCI NIH HHS [CA06516] Funding Source: Medline; NIAID NIH HHS [AI28785, AI41954] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Biggs TE, 1999, J MOL BIOL, V290, P21, DOI 10.1006/jmbi.1999.2849; Briant L, 1998, J IMMUNOL, V160, P1875; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Folgueira L, 1996, J VIROL, V70, P2332, DOI 10.1128/JVI.70.4.2332-2338.1996; FOLKS T, 1986, J IMMUNOL, V136, P4049; FRASER JD, 1993, IMMUNOL TODAY, V14, P357, DOI 10.1016/0167-5699(93)90236-E; Ganju RK, 1998, J VIROL, V72, P6131, DOI 10.1128/JVI.72.7.6131-6137.1998; Greenway A, 1996, J VIROL, V70, P6701, DOI 10.1128/JVI.70.10.6701-6708.1996; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; Iafrate A.J., 1997, EMBO J, V16, P673; Jacque JM, 1998, EMBO J, V17, P2607, DOI 10.1093/emboj/17.9.2607; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Kinoshita S, 1998, CELL, V95, P595, DOI 10.1016/S0092-8674(00)81630-X; Kumar A, 1998, J IMMUNOL, V161, P776; Li CJ, 1997, P NATL ACAD SCI USA, V94, P8116, DOI 10.1073/pnas.94.15.8116; Li XG, 1997, J VIROL, V71, P6003, DOI 10.1128/JVI.71.8.6003-6010.1997; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Luo W, 1997, J VIROL, V71, P9531, DOI 10.1128/JVI.71.12.9531-9537.1997; Macian F, 1999, MOL CELL BIOL, V19, P3645, DOI 10.1128/mcb.19.5.3645; Manninen A, 2000, J BIOL CHEM, V275, P16513, DOI 10.1074/jbc.M910032199; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481; PANTALEO G, 1995, ANNU REV IMMUNOL, V13, P487, DOI 10.1146/annurev.immunol.13.1.487; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; Pomerance M, 1998, J BIOL CHEM, V273, P24301, DOI 10.1074/jbc.273.38.24301; Popik W, 1998, J VIROL, V72, P6406, DOI 10.1128/JVI.72.8.6406-6413.1998; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RAO A, 1995, J LEUKOCYTE BIOL, V57, P536, DOI 10.1002/jlb.57.4.536; RAO A, 1991, CRIT REV IMMUNOL, V10, P495; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Schrager JA, 1999, P NATL ACAD SCI USA, V96, P8167, DOI 10.1073/pnas.96.14.8167; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SPINA CA, 1995, J VIROL, V69, P2997; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VACCA A, 1994, BIOCHEM BIOPH RES CO, V205, P467, DOI 10.1006/bbrc.1994.2689; Wang JK, 2000, P NATL ACAD SCI USA, V97, P394, DOI 10.1073/pnas.97.1.394; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Yang XY, 1999, J BIOL CHEM, V274, P27981, DOI 10.1074/jbc.274.39.27981; ZACK JA, 1988, SCIENCE, V240, P1026, DOI 10.1126/science.2835813; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502; Zauli G, 1996, J IMMUNOL, V157, P2216; ZHANG W, 1998, IMMUNITY, V9, P1; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	57	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30925	30933		10.1074/jbc.M005535200	http://dx.doi.org/10.1074/jbc.M005535200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906142	hybrid			2022-12-25	WOS:000089762700029
J	Hill, WG; Zeidel, ML				Hill, WG; Zeidel, ML			Reconstituting the barrier properties of a water-tight epithelial membrane by design of leaflet-specific liposomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN URINARY-BLADDER; CANINE KIDNEY-CELLS; APICAL MEMBRANE; NONELECTROLYTE PERMEABILITIES; BIOLOGICAL-MEMBRANES; PROTON; ASYMMETRY; VESICLES; CHOLESTEROL; CONDUCTANCE	To define aspects of lipid composition and bilayer asymmetry critical to barrier function, we examined the permeabilities of liposomes that model individual leaflets of the apical membrane of a barrier epithelium, Madin-Darby canine kidney type 1 cells. Using published Lipid compositions we prepared exofacial liposomes containing phosphatidylcholine, sphingomyelin, glycosphingolipids, and cholesterol; and cytoplasmic liposomes containing phosphatidylethanolamine, phosphatidylserine, and cholesterol. The osmotic permeability of cytoplasmic liposomes to water (P-f), solutes, and NH3 was 18-90-fold higher than for the exofacial liposomes (P-f(ex) = 2.4 +/- 0.4 x 10(-4) cm/s, P-f(cy) = 4.4 +/- 0.3 x 10(-3) cm/s; P-glycerol(ex) = 2.5 +/- 0.3 x 10(-8) cm/s, P-glycerol(cy) = 2.2 +/- 0.02 x 10(-6) cm/s; P-NH3(ex) = 0.13 +/- 0.4 x 10(-4) cm/s, P-NH3(cy) = 7.9 +/- 1.0 x 10(-3) cm/s). By contrast, the apparent proton permeability of exofacial liposomes was 4-fold higher than cytoplasmic liposomes (PH+(ex) = 1.1 +/- 0.1 x 10(-2) cm/s, PH+(cy) = 2.7 +/- 0.6 x 10(-3) cm/s). By adding single leaflet permeabilities, we calculated a theoretical P-f for a Madin-Darby canine kidney apical membrane of 4.6 x 10(-4) cm/s, which compares favorably with experimentally determined values. In exofacial liposomes lacking glycosphingolipids or sphingomyelin, permeabilities were 2-7-fold higher, indicating that both species play a role in barrier function. Removal of cholesterol resulted in 40-280-fold increases in permeability. Fire conclude: 1) that we have reconstituted the biophysical properties of a barrier membrane, 2) that the barrier resides in the exofacial leaflet, 3) that both sphingomyelin and glycosphingolipids play a role in reducing membrane permeability but that there is an ab solute requirement for cholesterol to mediate this effect, 4) that these results further validate the hypothesis that each leaflet offers an independent resistance to permeation, and 5) that proton permeation was enhanced by sphingolipid/cholesterol interactions.	Univ Pittsburgh, Renal Electrolyte Div, Lab Epithelial Cell Biol, Dept Med, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zeidel, ML (corresponding author), Univ Pittsburgh, Renal Electrolyte Div, Lab Epithelial Cell Biol, Dept Med, 1218 Scaifie Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	zeidel@msx.dept-med.pitt.edu	Hill, Warren/AAM-1917-2020	Hill, Warren/0000-0002-2772-7264	NIDDK NIH HHS [DK43955] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043955] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARSUKOV LI, 1986, BIOCHIM BIOPHYS ACTA, V862, P87, DOI 10.1016/0005-2736(86)90472-4; BITTMAN R, 1994, BIOCHEMISTRY-US, V33, P11776, DOI 10.1021/bi00205a013; Brookes PS, 1997, BBA-BIOMEMBRANES, V1330, P157, DOI 10.1016/S0005-2736(97)00160-0; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown RE, 1998, J CELL SCI, V111, P1; CHANG A, 1994, AM J PHYSIOL-CELL PH, V267, pC1483, DOI 10.1152/ajpcell.1994.267.5.C1483; DEAMER DW, 1983, P NATL ACAD SCI-BIOL, V80, P165, DOI 10.1073/pnas.80.1.165; DEAMER DW, 1995, PERMEABILITY STABILI, P161; Farinas J, 1996, BIOPHYS J, V71, P3511, DOI 10.1016/S0006-3495(96)79546-2; GROSSMAN EB, 1992, AM J PHYSIOL, V262, pC1109, DOI 10.1152/ajpcell.1992.262.5.C1109; GUTKNECHT J, 1987, J BIOENERG BIOMEMBR, V19, P427; GUTKNECHT J, 1987, P NATL ACAD SCI USA, V84, P6443, DOI 10.1073/pnas.84.18.6443; HANSSON GC, 1986, EMBO J, V5, P483, DOI 10.1002/j.1460-2075.1986.tb04237.x; Hill WG, 1999, J GEN PHYSIOL, V114, P405, DOI 10.1085/jgp.114.3.405; LANDE MB, 1994, AM J PHYSIOL, V267, pC367, DOI 10.1152/ajpcell.1994.267.2.C367; LANDE MB, 1995, J GEN PHYSIOL, V106, P67, DOI 10.1085/jgp.106.1.67; Lavelle JP, 1997, AM J PHYSIOL-RENAL, V273, pF67, DOI 10.1152/ajprenal.1997.273.1.F67; Lavelle JP, 1998, AM J PHYSIOL-RENAL, V274, pF205, DOI 10.1152/ajprenal.1998.274.1.F205; Lavelle JP, 2000, AM J PHYSIOL-RENAL, V278, pF540, DOI 10.1152/ajprenal.2000.278.4.F540; LEWIS SA, 1977, AM J PHYSIOL, V232, pF187, DOI 10.1152/ajprenal.1977.232.3.F187; LEWIS SA, 1984, J MEMBRANE BIOL, V82, P123, DOI 10.1007/BF01868937; LEWIS SA, 1990, METHOD ENZYMOL, V192, P632; LEWIS SA, 1977, J GEN PHYSIOL, V70, P427, DOI 10.1085/jgp.70.4.427; LICHTENBERGER LM, 1987, CLIN INVEST MED, V10, P181; NAGLE JF, 1978, P NATL ACAD SCI USA, V75, P298, DOI 10.1073/pnas.75.1.298; Negrete HO, 1996, J BIOL CHEM, V271, P11627, DOI 10.1074/jbc.271.20.11627; Negrete HO, 1996, AM J PHYSIOL-RENAL, V271, pF886, DOI 10.1152/ajprenal.1996.271.4.F886; NICHOLS JW, 1980, P NATL ACAD SCI-BIOL, V77, P2038, DOI 10.1073/pnas.77.4.2038; NOZAKI Y, 1981, P NATL ACAD SCI-BIOL, V78, P4324, DOI 10.1073/pnas.78.7.4324; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; Prasad GVR, 1998, J BIOL CHEM, V273, P33123, DOI 10.1074/jbc.273.50.33123; PRIVER NA, 1993, BIOCHEMISTRY-US, V32, P2459, DOI 10.1021/bi00061a002; Rivers R, 1998, AM J PHYSIOL-RENAL, V274, pF453, DOI 10.1152/ajprenal.1998.274.3.F453; Rivers RL, 1996, AM J PHYSIOL-CELL PH, V271, pC226, DOI 10.1152/ajpcell.1996.271.1.C226; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; Smaby JM, 1996, BIOCHEMISTRY-US, V35, P5696, DOI 10.1021/bi953057k; Timbs MM, 1996, J MEMBRANE BIOL, V153, P1, DOI 10.1007/s002329900104; VAN GENDEREN I, 1995, J CELL BIOL, V131, P645, DOI 10.1083/jcb.131.3.645; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VAN MEER G, 1986, NATURE, V322, P639, DOI 10.1038/322639a0; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; VENIEN C, 1988, BIOCHIM BIOPHYS ACTA, V942, P159, DOI 10.1016/0005-2736(88)90285-4; Zeidel ML, 1996, AM J PHYSIOL-RENAL, V271, pF243, DOI 10.1152/ajprenal.1996.271.2.F243	45	75	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30176	30185		10.1074/jbc.M003494200	http://dx.doi.org/10.1074/jbc.M003494200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10903312	hybrid			2022-12-25	WOS:000089577900038
J	Shangary, S; Brown, KD; Adamson, AW; Edmonson, S; Ng, B; Pandita, TK; Yalowich, J; Taccioli, GE; Baskaran, R				Shangary, S; Brown, KD; Adamson, AW; Edmonson, S; Ng, B; Pandita, TK; Yalowich, J; Taccioli, GE; Baskaran, R			Regulation of DNA-dependent protein kinase activity by ionizing radiation-activated Abl kinase is an ATM-dependent process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ABL; TYROSINE KINASE; CELL-CYCLE; CATALYTIC SUBUNIT; NUCLEAR-PROTEIN; GENE-PRODUCT; DAMAGE; BINDING; MUTANT; STRESS	Ionizing radiation (IR) treatment results in activation of the nonreceptor tyrosine kinase c-Abl because of phosphorylation by ATM. In vitro evidence indicates that DNA-dependent protein kinase (DNA-PK) can also phosphorylate and thus potentially activate Abl kinase activity in response to IR exposure. To unravel the role of ATM and DNA-PK in the activation of Abl, we assayed Abl, ATM, and DNA-PK activity in ATM- and DNA-PKcs-deficient cells after irradiation. Our results show that despite the presence of higher than normal levels of DNA-PK kinase activity, c-Abl fails to become activated after IR exposure in ATM-deficient cells. Conversely, normal activation of both ATM and c-Abl occurs in DNA-PKcs- deficient cells, indicating that ATM but not DNA-PK is required for activation of Abl in response to IR treatment. Moreover, activation of Abl kinase activity by IR correlates well with activation of ATM activity in all phases of the cell cycle. These results indicate that ATM is primarily responsible for activation of Abl in response to IR exposure in a cell cycle-independent fashion. Examination of DNA-PK activity in response to IR treatment in Abl-deficient cells expressing mutant forms of Abl or in normal cells exposed to an inhibitor of Abl suggests an in vivo role for Abl in the down-regulation of DNA-PK activity. Collectively, these results suggest a convergence of the ATM and DNA-PK pathways in the cellular response to IR through c-Abl kinase.	Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Med Ctr, Dept Pharmacol, Pittsburgh, PA 15261 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA; Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Columbia Univ, Ctr Radiol Res, New York, NY 10032 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Boston University; Columbia University	Baskaran, R (corresponding author), Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, E1205 Biomed Sci Tower, Pittsburgh, PA 15261 USA.		Pandita, Tej K/AAM-9188-2020	Yalowich, Jack/0000-0001-5414-573X	NATIONAL CANCER INSTITUTE [R01CA076409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER; NCI NIH HHS [CA76409] Funding Source: Medline; NINDS NIH HHS [NS 34746] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baskaran R, 1996, MOL CELL BIOL, V16, P3361; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Kumar S, 1998, J BIOL CHEM, V273, P25654, DOI 10.1074/jbc.273.40.25654; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Muller C, 1999, BIOCHIMIE, V81, P117, DOI 10.1016/S0300-9084(99)80044-3; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; Pandita TK, 2000, ONCOGENE, V19, P1386, DOI 10.1038/sj.onc.1203444; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; WANG JYJ, 1994, TRENDS BIOCHEM SCI, V19, P373, DOI 10.1016/0968-0004(94)90114-7; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; Watters D, 1999, IMMUNOL CELL BIOL, V77, P263, DOI 10.1046/j.1440-1711.1999.00824.x; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456	29	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30163	30168		10.1074/jbc.M004302200	http://dx.doi.org/10.1074/jbc.M004302200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10906134	hybrid			2022-12-25	WOS:000089577900036
J	Mayer, M; Kies, U; Kammermeier, R; Buchner, J				Mayer, M; Kies, U; Kammermeier, R; Buchner, J			BiP and PDI cooperate in the oxidative folding of antibodies in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; IMMUNOGLOBULIN HEAVY-CHAIN; CHAPERONE-LIKE ACTIVITY; ENDOPLASMIC-RETICULUM; BINDING-PROTEIN; LIGHT-CHAIN; RESIDENT PROTEIN; ATPASE ACTIVITY; SEQUENCES; HOMOLOG	Immunoglobulin heavy chain binding protein (BiP), a member of the Hsp70 chaperone family, and the oxidoreductase protein-disulfide isomerase (PDI) play an important role in the folding and oxidation of proteins in the endoplasmic reticulum. However, it was not clear whether both cooperate in this process. We show here that BiP and PDI act synergistically in the in vitro folding of the denatured and reduced Fab fragment. Several ATP-dependent cycles of binding, release, and rebinding of the unfolded antibody chains by Rip are required for efficient reactivation. Our data suggest that in the absence of BiP unfolded antibody chains collapse rapidly upon refolding, rendering cysteine side chains inaccessible for PDI. BiP binds the unfolded polypeptide chains and keeps them in a conformation in which the cysteine residues are accessible for PDI. These findings support the idea of a network of folding helper proteins in the endoplasmic reticulum, which makes this organelle a dedicated protein-processing compartment.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Buchner, J (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.		Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				BERGERON JJ, 1997, TRENDS BIOCHEM SCI, V19, P124; BERGMAN LW, 1979, J BIOL CHEM, V254, P5690; Bies C, 1999, BIOL CHEM, V380, P1175, DOI 10.1515/BC.1999.149; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGHTMAN SE, 1995, GENE, V153, P249, DOI 10.1016/0378-1119(94)00741-A; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; BUCKEL P, 1987, GENE, V51, P13, DOI 10.1016/0378-1119(87)90469-0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CAI H, 1994, J BIOL CHEM, V269, P24550; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FREEDMAN RB, 1991, CONFORMATIONS FORCES, P204; GAUT JR, 1993, J BIOL CHEM, V268, P7248; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; GETHING MJ, 1997, MOL CHAPERONES PROTE, P59; GOTO Y, 1981, J MOL BIOL, V146, P321, DOI 10.1016/0022-2836(81)90391-0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAAS IG, 1994, EXPERIENTIA, V50, P1012, DOI 10.1007/BF01923455; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; Knarr G, 1999, J BIOL CHEM, V274, P29850, DOI 10.1074/jbc.274.42.29850; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; LILIE H, 1994, J BIOL CHEM, V269, P14290; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; Nishikawa S, 1997, J BIOL CHEM, V272, P12889, DOI 10.1074/jbc.272.20.12889; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; RUDOLPH R, 1990, MODERN METHOD IN PROTEIN- AND NUCLEIC ACID RESEARCH, P149; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SEGAL MS, 1992, J CELL BIOL, V118, P227, DOI 10.1083/jcb.118.2.227; Skowronek MH, 1999, BIOL CHEM, V380, P1133, DOI 10.1515/BC.1999.142; SONG JL, 1995, EUR J BIOCHEM, V231, P312, DOI 10.1111/j.1432-1033.1995.tb20702.x; Stevens FJ, 1999, SEMIN CELL DEV BIOL, V10, P443, DOI 10.1006/scdb.1999.0315; Wang CC, 1998, ANN NY ACAD SCI, V864, P9, DOI 10.1111/j.1749-6632.1998.tb10283.x; WANG CC, 1993, FASEB J, V7, P1515, DOI 10.1096/fasebj.7.15.7903263; WEI JY, 1995, J BIOL CHEM, V270, P26670, DOI 10.1074/jbc.270.44.26670; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651	43	88	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29421	29425		10.1074/jbc.M002655200	http://dx.doi.org/10.1074/jbc.M002655200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893409	hybrid			2022-12-25	WOS:000089439800034
J	Davis, MS; Solbiati, J; Cronan, JE				Davis, MS; Solbiati, J; Cronan, JE			Overproduction of acetyl-CoA carboxylase activity increases the rate of fatty acid biosynthesis in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; ACYL CARRIER PROTEIN; BACTERIOPHAGE-T7 RNA-POLYMERASE; PHOSPHOLIPID-SYNTHESIS; BIOTIN CARBOXYLASE; EXPRESSION; CARBOXYLTRANSFERASE; OVEREXPRESSION; PURIFICATION; INHIBITION	Acetyl-CoA carboxylase (ACC) catalyzes the first committed step of the fatty acid synthetic pathway. Although ACC has often been proposed to be a major rate-controlling enzyme of this pathway, no direct tests of this proposal in vivo have been reported. We have tested this proposal in Escherichia coli. The genes encoding the four subunits off. coli ACC were cloned in a single plasmid under the control of a bacteriophage T7 promoter. Upon induction of gene expression, the four ACC subunits were overproduced in equimolar amounts. Overproduction of the proteins resulted in greatly increased ACC activity with a concomitant increase in the intracellular level of malonyl-CoA The effects of ACC overexpression on the rate of fatty acid synthesis were examined in the presence of a thioesterase, which provided a metabolic sink for fatty acid overproduction. Under these conditions ACC overproduction resulted in a 6-fold increase in the rate of fatty acid synthesis.	Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Cronan, JE (corresponding author), Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, 601 S Goodwin Ave, Urbana, IL 61801 USA.	j-cronan@life.uiuc.edu	Cronan, John/V-6626-2019					Abu-Elheiga L, 2000, P NATL ACAD SCI USA, V97, P1444, DOI 10.1073/pnas.97.4.1444; ALBERTS AW, 1972, ENZYMES, V6, P37; Blanchard CZ, 1998, J BIOL CHEM, V273, P19140, DOI 10.1074/jbc.273.30.19140; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P881, DOI 10.1042/bj3020881; CHO HS, 1995, J BIOL CHEM, V270, P4216, DOI 10.1074/jbc.270.9.4216; Emmerling M, 2000, BIOTECHNOL BIOENG, V67, P623, DOI [10.1002/(SICI)1097-0290(20000305)67:5<623::AID-BIT13>3.0.CO;2-W, 10.1002/(SICI)1097-0290(20000305)67:5&lt;623::AID-BIT13&gt;3.0.CO;2-W]; FALL RR, 1976, BIOCHIM BIOPHYS ACTA, V450, P475, DOI 10.1016/0005-2760(76)90022-9; FELL D, 1996, UNDERSTANDING CONTRO; GELMANN EP, 1972, J BACTERIOL, V112, P381, DOI 10.1128/JB.112.1.381-387.1972; GUCHHAIT RB, 1974, J BIOL CHEM, V249, P6633; HARDER ME, 1972, P NATL ACAD SCI USA, V69, P3105, DOI 10.1073/pnas.69.11.3105; HARWOOD JL, 1990, METHODS PLANT BIOCH, P96; HEATH RJ, 1994, J BIOL CHEM, V269, P26584; Heath RJ, 1996, J BIOL CHEM, V271, P1833, DOI 10.1074/jbc.271.4.1833; HEATH RJ, 1995, J BIOL CHEM, V270, P15531, DOI 10.1074/jbc.270.26.15531; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; Heinrich R., 1996, REGULATION CELLULAR; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; JENG ST, 1992, J BIOL CHEM, V267, P19306; JIANG P, 1994, J BACTERIOL, V176, P2814, DOI 10.1128/JB.176.10.2814-2821.1994; JOSHI VC, 1971, ARCH BIOCHEM BIOPHYS, V143, P493, DOI 10.1016/0003-9861(71)90234-7; Kim KH, 1997, ANNU REV NUTR, V17, P77, DOI 10.1146/annurev.nutr.17.1.77; LI SJ, 1992, J BACTERIOL, V174, P5755, DOI 10.1128/JB.174.17.5755-5757.1992; LI SJ, 1992, J BIOL CHEM, V267, P855; LI SJ, 1992, J BIOL CHEM, V267, P16841; LI SJ, 1993, J BACTERIOL, V175, P332, DOI 10.1128/JB.175.2.332-340.1993; Liao JC, 1996, BIOTECHNOL BIOENG, V52, P129, DOI 10.1002/(SICI)1097-0290(19961005)52:1<129::AID-BIT13>3.0.CO;2-J; Lyakhov DL, 1998, J MOL BIOL, V280, P201, DOI 10.1006/jmbi.1998.1854; METZGER S, 1988, J BIOL CHEM, V263, P15699; Millard CS, 1996, APPL ENVIRON MICROB, V62, P1808, DOI 10.1128/AEM.62.5.1808-1810.1996; Munday MR, 1999, ADV ENZYME REGUL, V39, P205, DOI 10.1016/S0065-2571(98)00016-8; PAGE RA, 1994, BBA-LIPID LIPID MET, V1210, P369, DOI 10.1016/0005-2760(94)90242-9; POLAKIS SE, 1973, J BIOL CHEM, V248, P7957; POLAKIS SE, 1974, J BIOL CHEM, V249, P6657; SANKAR P, 1993, J BACTERIOL, V175, P5145, DOI 10.1128/JB.175.16.5145-5152.1993; SILBERT DF, 1974, FED PROC, V33, P1725; SILBERT DF, 1976, J BACTERIOL, V126, P1351, DOI 10.1128/JB.126.3.1351-1354.1976; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WALSH K, 1985, P NATL ACAD SCI USA, V82, P3577, DOI 10.1073/pnas.82.11.3577	40	335	415	1	80	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28593	28598		10.1074/jbc.M004756200	http://dx.doi.org/10.1074/jbc.M004756200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893421	hybrid			2022-12-25	WOS:000089330700036
J	Smith, AJ; van Helvoort, A; van Meer, G; Szabo, K; Welker, E; Szakacs, G; Varadi, A; Sarkadi, B; Borst, P				Smith, AJ; van Helvoort, A; van Meer, G; Szabo, K; Welker, E; Szakacs, G; Varadi, A; Sarkadi, B; Borst, P			MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL INTRAHEPATIC CHOLESTASIS; RESISTANCE-ASSOCIATED PROTEIN; HUMAN MULTIDRUG TRANSPORTER; CANINE KIDNEY-CELLS; PLASMA-MEMBRANE; MONOCLONAL-ANTIBODIES; HOMOZYGOUS DISRUPTION; CYCLOSPORINE-A; INSECT CELLS; GENE FAMILY	The human MDR3 gene is a member of the multidrug resistance (MDR) gene family. The MDR3 P-glycoprotein is a transmembrane protein that translocates phosphatidylcholine. The MDR1 P-glycoprotein related transports cytotoxic drugs. Its overexpression can make cells resistant to a variety of drugs. Attempts to show that MDR3 P-glycoprotein can cause MDR have been unsuccessful thus far. Here, we report an increased directional transport of several MDR1 P-glycoprotein substrates, such as digoxin, paclitaxel, and vinblastine, through polarized monolayers of MDR3-transfected cells. Transport of other good MDR1 P-glycoprotein substrates, including cyclosporin A and dexamethasone, was not detectably increased. MDR3 P-glycoprotein-dependent transport of a short-chain phosphatidylcholine analog and drugs was inhibited by several MDR reversal agents and other drugs, indicating an interaction between these compounds and MDR3 P-gp, Insect cell membranes from Sf9 cells overexpressing MDR3 showed specific MgATP binding and a vanadate-dependent, N-ethylmaleimide-sensitive nucleotide trapping activity, visualized by covalent binding with [alpha-P-32]8 azido-ATP. Nucleotide trapping was (nearly) abolished by paclitaxel, vinblastine, and the MDR reversal agents verapamil, cyclosporin A, and PSC 833. We conclude that MDR3 P-glycoprotein can bind and transport a subset of MDR1 P-glycoprotein substrates. The rate of MDR3 P-wglycoprotein-mediated transport is low for most drugs, explaining why this protein is not detectably involved in multidrug resistance. It remains possible, however, that drug binding to MDR3 P-glycoprotein could adversely affect phospholipid or toxin secretion under conditions of stress (e.g. in pregnant heterozygotes with one MDR3 null allele).	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Cell Biol & Histol Lab, NL-1105 AZ Amsterdam, Netherlands; Hungarian Acad Sci, Membrane Res Grp, Natl Inst Haematol & Immunol, H-1113 Budapest, Hungary; Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1113 Budapest, Hungary; Univ Utrecht, Fac Med, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3584 CX Utrecht, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; Hungarian Academy of Sciences; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Utrecht University; Utrecht University	Borst, P (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Welker, Ervin/AAC-6493-2022; van Meer, Gerrit/AAH-1560-2021; Smith, Alexander/A-5142-2009; Szakacs, Gergely/A-2580-2009; van Helvoort, Ardy/U-7549-2019; Sarkadi, Balazs/I-5024-2013; Varadi, Andras/A-2055-2012	Szakacs, Gergely/0000-0002-9311-7827; van Helvoort, Ardy/0000-0002-3585-0676; van Meer, Gerrit/0000-0002-5976-6436				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUSCHMAN E, 1994, CANCER RES, V54, P4892; BUSCHMAN E, 1991, MOL CELL BIOL, V11, P595, DOI 10.1128/MCB.11.2.595; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIN KV, 1992, J CELL PHYSIOL, V152, P87, DOI 10.1002/jcp.1041520112; Crawford AR, 1997, J CLIN INVEST, V100, P2562, DOI 10.1172/JCI119799; De Vree JML, 1998, P NATL ACAD SCI USA, V95, P282, DOI 10.1073/pnas.95.1.282; Evers R, 1996, J CLIN INVEST, V97, P1211, DOI 10.1172/JCI118535; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; Germann UA, 1996, EUR J CANCER, V32A, P927, DOI 10.1016/0959-8049(96)00057-3; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; Groen AK, 1996, J THEOR BIOL, V182, P427, DOI 10.1006/jtbi.1996.0183; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HERWEIJER H, 1990, JNCI-J NATL CANCER I, V82, P1133, DOI 10.1093/jnci/82.13.1133; Jacquemin E, 1999, LANCET, V353, P210, DOI 10.1016/S0140-6736(05)77221-4; Kino K, 1996, FEBS LETT, V399, P29, DOI 10.1016/S0014-5793(96)01265-3; LINCKE CR, 1991, J BIOL CHEM, V266, P5303; MAUAD TH, 1994, AM J PATHOL, V145, P1237; Mayer U, 1997, J CLIN INVEST, V100, P2430, DOI 10.1172/JCI119784; NOOTER K, 1990, INT J CANCER, V45, P626, DOI 10.1002/ijc.2910450409; Raggers RJ, 1999, J CELL SCI, V112, P415; RAYMOND M, 1990, MOL CELL BIOL, V10, P1642, DOI 10.1128/MCB.10.4.1642; RUETZ S, 1994, TRENDS PHARMACOL SCI, V15, P260, DOI 10.1016/0165-6147(94)90322-0; RUETZ S, 1995, J BIOL CHEM, V270, P25388, DOI 10.1074/jbc.270.43.25388; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Scheffer G. L., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P667; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028; SCHINKEL AH, 1991, CANCER RES, V51, P2628; SCHINKEL AH, 1995, J CLIN INVEST, V96, P1698, DOI 10.1172/JCI118214; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Smith AJ, 1998, J NATL CANCER I, V90, P1161, DOI 10.1093/jnci/90.15.1161; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; Smith AJ, 1998, HEPATOLOGY, V28, P530, DOI 10.1002/hep.510280234; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; TANAKA S, 1990, BIOCHEM BIOPH RES CO, V166, P180, DOI 10.1016/0006-291X(90)91928-L; TANIGAWARA Y, 1992, J PHARMACOL EXP THER, V263, P840; UEDA K, 1992, J BIOL CHEM, V267, P24248; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; van der Bijl P, 1996, J CELL BIOL, V132, P813, DOI 10.1083/jcb.132.5.813; VAN GENDEREN I, 1995, J CELL BIOL, V131, P645, DOI 10.1083/jcb.131.3.645; VAN HELVOORT A, 1994, J BIOL CHEM, V269, P1763; VANDERBLIEK AM, 1987, EMBO J, V6, P3325, DOI 10.1002/j.1460-2075.1987.tb02653.x; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; VANDERBLIEK AM, 1988, CANCER RES, V48, P5927; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; ZAMAN GJR, 1996, MULTIDRUG RESISTANCE, P95	51	209	221	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23530	23539		10.1074/jbc.M909002199	http://dx.doi.org/10.1074/jbc.M909002199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10918072	hybrid, Green Published			2022-12-25	WOS:000088564200019
J	Cristofanelli, B; Valentinis, B; Soddu, S; Rizzo, MG; Marchetti, A; Bossi, G; Morena, AR; Dews, M; Baserga, R; Sacchi, A				Cristofanelli, B; Valentinis, B; Soddu, S; Rizzo, MG; Marchetti, A; Bossi, G; Morena, AR; Dews, M; Baserga, R; Sacchi, A			Cooperative transformation of 32D cells by the combined expression of IRS-1 and V-Ha-Ras	ONCOGENE			English	Article						myelodysplastic syndrome; Shc; PI3-K; MAPK; transformation	GROWTH-FACTOR-I; INSULIN-RECEPTOR SUBSTRATE-1; MULTIPLE SIGNALING PATHWAYS; HEMATOPOIETIC-CELLS; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; PHOSPHATIDYLINOSITOL 3'-KINASE; MATRIX ADHESION; IGF-I; P53; DIFFERENTIATION	32D cells expressing,v-Ha-Ras fail to show a transformed phenotype. Since Ras requires an active IGF-1R for transformation of fibroblasts, we asked whether expression of IRS-1 or Shc (two of the major substrates of the IGF-1R) could co-operate with oncogenic Ras in transforming 32D cells. We find that IRS-1, but not Shc, in combination with v-Ha-Ras generates a fully transformed phenotype in 32D cells, 32D cells expressing both IRS-1 and v-Ha-Ras (32D/IRS1/Ras) survive and proliferate in the absence of IL-3, do not undergo granulocytic differentiation in the presence of G-CSF and form tumors in nu/nu and syngeneic mice, In contrast, 32D cells expressing singly IRS-1 or v-Ha-Ras exhibit only a block in differentiation capacity. Over-expression of Shc proteins, by itself, promotes differentiation of 32D cells. Concomitant expression of IRS-1 and v-Ha-Ras synergistically phosphorylates ERK-1 and ERK-2 whereas a MEK inhibitor rapidly induces death of 32D/IRS1/Ras transformed cells. Furthermore, transformed 32D/IRS1/Ras cells display high levels of PI3-K activation and undergo rapid apoptosis when exposed to PI3-K inhibitors. The data indicate that: (1) a fully transformed phenotype in 32D cells is generated when a block in differentiation (v-Ha-Ras) is coupled with another differentiation block (IRS-1); (2) PI3-K and MAPK activity are required for the survival of transformed cells; (3) the signals generated by IRS-1 and oncogenic Ras converge on ERK and PI3-K resulting in high levels of activation.	Regina Elena Inst Canc Res, CRS, Mol Oncogenesis Lab, I-00158 Rome, Italy; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Jefferson University	Sacchi, A (corresponding author), Regina Elena Inst Canc Res, CRS, Mol Oncogenesis Lab, Via Messi Doro 156, I-00158 Rome, Italy.		Marchetti, Alessandra/AAD-5498-2019; Bossi, Gianluca/G-8375-2016; Bossi, Gianluca/B-9394-2017; Soddu, Silvia/ABH-6774-2020; Bossi, Gianluca/ABH-6846-2020; Rizzo, Maria/HGD-6576-2022; Soddu, Silvia/K-2467-2018	Bossi, Gianluca/0000-0002-2947-1063; Bossi, Gianluca/0000-0002-2947-1063; Soddu, Silvia/0000-0001-8526-0044; Bossi, Gianluca/0000-0002-2947-1063; Soddu, Silvia/0000-0001-8526-0044; MARCHETTI, ALESSANDRA/0000-0001-9706-848X	NCI NIH HHS [P01 CA 56309, CA 53424] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA056309] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; ASKEW DS, 1991, ONCOGENE, V6, P1915; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BOS JL, 1989, CANCER RES, V49, P4682; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; Dews M, 1997, RECEPT SIGNAL TRANS, V7, P231; DEWS M, 2000, IN PRESS ENDOCRINOLO, V141; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Fei ZL, 1997, ONCOGENE, V15, P961, DOI 10.1038/sj.onc.1201265; GREENBERGER JS, 1983, FED PROC, V42, P2762; GROOPMAN JE, 1989, NEW ENGL J MED, V321, P1449, DOI 10.1056/NEJM198911233212106; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; KASTAN MB, 1991, CANCER RES, V51, P4279; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LANFRANCONE L, 1995, ONCOGENE, V10, P907; MAVILIO F, 1989, ONCOGENE, V4, P301; METCALF D, 1985, BLOOD, V65, P357; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; Soddu S, 1996, MOL CELL BIOL, V16, P487; Soon L, 1999, MOL CELL BIOL, V19, P3816; Tanaka S, 1996, J BIOL CHEM, V271, P14610, DOI 10.1074/jbc.271.24.14610; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Valentinis B, 1999, ONCOGENE, V18, P1827, DOI 10.1038/sj.onc.1202471; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Yenush L, 1996, MOL CELL BIOL, V16, P2509	38	35	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2000	19	29					3245	3255		10.1038/sj.onc.1203664	http://dx.doi.org/10.1038/sj.onc.1203664			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918581				2022-12-25	WOS:000088019300003
J	Hart, KC; Robertson, SC; Kanemitsu, MY; Meyer, AN; Tynan, JA; Donoghue, DJ				Hart, KC; Robertson, SC; Kanemitsu, MY; Meyer, AN; Tynan, JA; Donoghue, DJ			Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4	ONCOGENE			English	Article						FGFR; transformation; Stats; signal transduction	FIBROBLAST-GROWTH-FACTOR; ELIMINATES PHOSPHATIDYLINOSITOL HYDROLYSIS; MYELOPROLIFERATIVE DISORDER FUSES; LIGAND-INDEPENDENT ACTIVATION; LETHAL SKELETAL DYSPLASIA; FACTOR RECEPTOR-3 GENE; THANATOPHORIC DYSPLASIA; TYROSINE KINASE; CONSTITUTIVE ACTIVATION; SIGNAL-TRANSDUCTION	The fibroblast growth factor receptor (FC;FR) family members mediate a number of important cellular processes, and are mutated or overexpressed in several forms of human cancer. Mutation of Lys650 --> Glu in the activation loop of the FGFR3 kinase domain causes the lethal human skeletal disorder thanatophoric dysplasia type II (TDII) and is also found in patients with multiple myeloma, bladder and cervical carcinomas. This mutation leads to constitutive activation of FGFR3, To compare the signaling activity of FGFR family members, this activating mutation aas generated in FGFR1, FGFR3, and FGFR I. We show that the kinase domains of FGFR1, FGFR3, and FGFR3 containing the activation loop mutation, when targeted to the plasma membrane by a myristylation signal, can transform NIH3T3 cells and induce neurite outgrowth in PC12 cells. Phosphorylation of Shp2, PLC-gamma, and MAPK was also stimulated by all three 'TDII-like' FGFR derivatives. Additionally, activation of Stat1 and Stat3 mas observed in cells expressing the activated FGFR deriVatives. Finally, we demonstrate that FGFR1, FGFR3, and FGFR4 derivatives can stimulate PI-3 kinase activity. Our comparison of these activated receptor derivatives reveals a significant overlap in the panel of effector proteins used to mediate downstream signals. This also represents the first demonstration that activation of FGFR3, in addition to FGFR1 and FGFR3, can induce cellular transformation. Moreover, our results suggest that Stat activation by FGFRs is important in their ability to act as oncogenes.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Donoghue, DJ (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.				NIDCR NIH HHS [R01 DE12581] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012581] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Besser D, 1999, MOL CELL BIOL, V19, P1401; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burke D, 1998, TRENDS BIOCHEM SCI, V23, P59, DOI 10.1016/S0968-0004(97)01170-5; BUSS JE, 1988, MOL CELL BIOL, V8, P3960, DOI 10.1128/MCB.8.9.3960; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; d'Avis PY, 1998, CELL GROWTH DIFFER, V9, P71; Galvin BD, 1996, P NATL ACAD SCI USA, V93, P7894, DOI 10.1073/pnas.93.15.7894; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hart KC, 1997, ONCOGENE, V14, P945, DOI 10.1038/sj.onc.1200908; HATTORI Y, 1992, CANCER RES, V52, P3367; Hughes SE, 1997, J HISTOCHEM CYTOCHEM, V45, P1005, DOI 10.1177/002215549704500710; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; Kirito K, 1998, BLOOD, V92, P462, DOI 10.1182/blood.V92.2.462.414k15_462_471; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KOUHARA H, 1995, ONCOGENE, V10, P2315; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Landgren E, 1998, ONCOGENE, V17, P283, DOI 10.1038/sj.onc.1201936; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Legeai-Mallet L, 1998, J BIOL CHEM, V273, P13007, DOI 10.1074/jbc.273.21.13007; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; Lin HY, 1996, J NEUROSCI, V16, P4579; Lin HY, 1998, MOL CELL BIOL, V18, P3762, DOI 10.1128/MCB.18.7.3762; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; NEILSON KM, 1995, J BIOL CHEM, V270, P26037, DOI 10.1074/jbc.270.44.26037; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; Olson DC, 1998, CELL GROWTH DIFFER, V9, P557; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; Perkins LA, 1996, DEV BIOL, V180, P63, DOI 10.1006/dbio.1996.0285; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; Popovici C, 1998, P NATL ACAD SCI USA, V95, P5712, DOI 10.1073/pnas.95.10.5712; Raffioni S, 1999, P NATL ACAD SCI USA, V96, P7178, DOI 10.1073/pnas.96.13.7178; Reiter A, 1998, BLOOD, V92, P1735, DOI 10.1182/blood.V92.5.1735.417k11_1735_1742; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Robertson SC, 1998, P NATL ACAD SCI USA, V95, P4567, DOI 10.1073/pnas.95.8.4567; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Smedley D, 1998, HUM MOL GENET, V7, P637, DOI 10.1093/hmg/7.4.637; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; STARK KL, 1991, DEVELOPMENT, V113, P641; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Szebenyi G, 1999, INT REV CYTOL, V185, P45; Tavormina PL, 1999, AM J HUM GENET, V64, P722, DOI 10.1086/302275; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; Vainikka S, 1996, J BIOL CHEM, V271, P1270, DOI 10.1074/jbc.271.3.1270; VANLEEUWEN F, 1995, SEMIN CANCER BIOL, V6, P127, DOI 10.1006/scbi.1995.0018; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Webster MK, 1997, MOL CELL BIOL, V17, P5739, DOI 10.1128/MCB.17.10.5739; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Webster MK, 1996, MOL CELL BIOL, V16, P4081; WEBSTER MK, 1998, GENE THER MOL BIOL, V1, P365; WILKIE AOM, 1995, CURR BIOL, V5, P500; Wright JA, 1996, HISTOL HISTOPATHOL, V11, P521; WRIGHT JA, 1993, CRIT REV ONCOGENESIS, V4, P473; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Yoshimura N, 1998, CLIN IMMUNOL IMMUNOP, V89, P28, DOI 10.1006/clin.1998.4551; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHAN X, 1994, J BIOL CHEM, V269, P20221; Zong C, 1996, EMBO J, V15, P4515, DOI 10.1002/j.1460-2075.1996.tb00829.x; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	78	207	214	0	15	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2000	19	29					3309	3320		10.1038/sj.onc.1203650	http://dx.doi.org/10.1038/sj.onc.1203650			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918587				2022-12-25	WOS:000088019300009
J	Schroeder, JA; Troyer, KL; Lee, DC				Schroeder, JA; Troyer, KL; Lee, DC			Cooperative induction of mammary tumorigenesis by TGF alpha and Wnts	ONCOGENE			English	Article						TGF alpha; MMTV; Wnt; mammary tumorigenesis; transgenics	GROWTH-FACTOR-ALPHA; MOUSE MAMMARY; TUMOR VIRUS; TRANSGENIC MICE; BETA-CATENIN; C-MYC; E-CADHERIN; EXPRESSION; GENE; TRANSFORMATION	We previously reported that multiparous WAP-TGF alpha transgenic mice develop mammary gland carcinomas with complete incidence, TGF alpha-induced tumors appear stochastically and with relatively long latency, indicating an additional requirement for other genetic alterations, To identify genes that cooperate with TGF alpha in mammary tumorigenesis, we used a retroviral insertion approach featuring a cloned and infectious hybrid MMTV (C3H/Mtv-1; (Shackleford and Varmus, 1988)), Tumor latency,vas decreased approximately 30% in MMTV-infected WAP-TGF alpha transgenic animals compared to noninfected transgenic controls, and >30% of the corresponding tumors displayed evidence of integrated C3H/Mtv-1 DNA, PCR-based analyses of DNAs from two virus-infected, transgenic tumors revealed integration of hybrid MMTV in 3' untranslated exons of the Wnt-1 or Wnt-3 oncogenes, Moreover, Northern blots confirmed dramatic induction of Wnt-1 or Wnt-3 transcripts in the respective turners, indicating that MMTV integration resulted in activated expression of these genes, Semi-quantitative RT-PCR analyses showed that overexpression of Wnt-1 or Wnt-3 was a common occurrence in MMTV-infected WAP-TGF alpha tumors, and some noninfected WAP-TGF alpha tumors also shelved evidence of elevated Wnt-3 transcripts, Collectively, these results reveal cooperative induction of mammary gland tumorigenesis by simultaneous deregulation of EGF-like (TGF alpha) and Wnt growth factors.	Univ N Carolina, Dept Microbiol & Immunol, Sch Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Sch Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Lee, DC (corresponding author), Univ N Carolina, Dept Microbiol & Immunol, Sch Med, Chapel Hill, NC 27599 USA.			schroeder, joyce/0000-0003-1277-5172	NCI NIH HHS [CA71341, CA61896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA071341, R01CA061896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; BRANDTCARLSON C, 1993, VIROLOGY, V193, P171, DOI 10.1006/viro.1993.1113; BUI TD, 1996, ONCOGENE, P1249; Callahan R, 1996, BREAST CANCER RES TR, V39, P33, DOI 10.1007/BF01806076; CHOOI KF, 1994, CANCER RES, V54, P6434; Dierick H, 1999, CURR TOP DEV BIOL, V43, P153, DOI 10.1016/S0070-2153(08)60381-6; GOLOVKINA TV, 1994, J VIROL, V68, P5019, DOI 10.1128/JVI.68.8.5019-5026.1994; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; HELD W, 1994, IMMUNOL TODAY, V15, P184, DOI 10.1016/0167-5699(94)90317-4; HUGUET EL, 1994, CANCER RES, V54, P2615; Ilyas M, 1997, J PATHOL, V182, P128; Julius MA, 1999, ONCOGENE, V18, P149, DOI 10.1038/sj.onc.1202268; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; LEE DC, 1995, PHARMACOL REV, V47, P51; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; MAJORS JE, 1983, J VIROL, V47, P495, DOI 10.1128/JVI.47.3.495-504.1983; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PETERSON DO, 1985, J VIROL, V54, P525, DOI 10.1128/JVI.54.2.525-531.1985; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; Schroeder JA, 1997, J MAMMARY GLAND BIOL, V2, P119, DOI 10.1023/A:1026347629876; SHACKLEFORD GM, 1988, P NATL ACAD SCI USA, V85, P9655, DOI 10.1073/pnas.85.24.9655; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; Shibata T, 1996, ONCOGENE, V13, P883; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; Wang YK, 1997, HUM MOL GENET, V6, P465, DOI 10.1093/hmg/6.3.465; Wang YS, 1996, J BIOL CHEM, V271, P4468; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Xu L, 1996, VIROLOGY, V215, P113, DOI 10.1006/viro.1996.0014	34	26	29	1	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 29	2000	19	28					3193	3199		10.1038/sj.onc.1203652	http://dx.doi.org/10.1038/sj.onc.1203652			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918574				2022-12-25	WOS:000088019200008
J	Horlitz, M; Klaff, P				Horlitz, M; Klaff, P			Gene-specific trans-regulatory functions of magnesium for chloroplast mRNA stability in higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' UNTRANSLATED REGION; IN-VIVO ANALYSIS; TRANSCRIPT LEVELS; BINDING-PROTEIN; ANTICODON LOOP; PSAA-PSAB; PSBA; EXPRESSION; TRANSLATION; LIGHT	In higher plant chloroplasts the accumulation of plastid-encoded mRNAs during leaf maturation is regulated via gene-specific mRNA stabilization. The half-lives of chloroplast RNAs are specifically affected by magnesium ions. psbA mRNA (D1 protein of photosystem II), rbcL mRNA (large subunit of ribulose-1,5-bisphosphate carboxylase), 16 S rRNA, and tRNA(His) gain stability at specific magnesium concentrations in an in vitro degradation system from spinach chloroplasts. Each RNA exhibits a typical magnesium concentration-dependent stabilization profile. It shows a cooperative response of the stability-regulated psbA mRNA and a saturation curve for the other RNAs. The concentration of free Mg2+ rises during chloroplast development within a range sufficient to mediate gene-specific mRNA stabilization in vivo as observed in vitro. We suggest that magnesium ions are a trans-acting factor mediating differential mRNA stability.	Univ Dusseldorf, Inst Phys Biol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Klaff, P (corresponding author), Univ Dusseldorf, Inst Phys Biol, Univ Str 1, D-40225 Dusseldorf, Germany.	klaff@biophys.uni-duesseldorf.de						ADAMS CC, 1990, NUCLEIC ACIDS RES, V18, P6003, DOI 10.1093/nar/18.20.6003; Alexander C, 1998, NUCLEIC ACIDS RES, V26, P2265, DOI 10.1093/nar/26.10.2265; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; ATWATER JA, 1990, ANNU REV GENET, V24, P519; Barber J., 1976, Topics in photosynthesis - Volume 1. The intact chloroplast., P89; BARKAN A, 1993, PLANT CELL, V5, P389, DOI 10.1105/tpc.5.4.389; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P6372, DOI 10.1021/bi00369a005; Cantor C.R., 1980, BIOPHYS CHEM; CHEN HC, 1991, MOL CELL BIOL, V11, P4380, DOI 10.1128/MCB.11.9.4380; CHEN QY, 1995, MOL CELL BIOL, V15, P2010; Drager RG, 1996, RNA, V2, P652; Eibl C, 1999, PLANT J, V19, P333, DOI 10.1046/j.1365-313X.1999.00543.x; Fargo DC, 1999, MOL CELL BIOL, V19, P6980; GRUISSEM W, 1986, METHOD ENZYMOL, V118, P253; GRUISSEM W, 1993, CRIT REV PLANT SCI, V12, P19, DOI 10.1080/07352689309382355; Gruissem W., 1993, CONTROL MRNA STABILI, P329; Grunberg-Manago M, 1999, ANNU REV GENET, V33, P193, DOI 10.1146/annurev.genet.33.1.193; Hayes R, 1999, TRENDS BIOCHEM SCI, V24, P199, DOI 10.1016/S0968-0004(99)01388-2; Hayes R, 1996, EMBO J, V15, P1132, DOI 10.1002/j.1460-2075.1996.tb00451.x; HELDT HW, 1973, BIOCHIM BIOPHYS ACTA, V314, P224, DOI 10.1016/0005-2728(73)90137-0; Higgs DC, 1999, MOL CELL BIOL, V19, P8479; JOHNSON CH, 1995, SCIENCE, V269, P1863, DOI 10.1126/science.7569925; KIM J, 1994, J BIOL CHEM, V269, P17918; Klaff P, 1997, RNA, V3, P1468; KLAFF P, 1991, PLANT CELL, V3, P517, DOI 10.1105/tpc.3.5.517; Klaff P, 1995, NUCLEIC ACIDS RES, V23, P4885, DOI 10.1093/nar/23.23.4885; Klaff P, 1995, PHOTOSYNTH RES, V46, P235, DOI 10.1007/BF00020436; KLEIN RR, 1987, J BIOL CHEM, V262, P4341; KLEIN RR, 1988, J CELL BIOL, V106, P289, DOI 10.1083/jcb.106.2.289; KUCHKA MR, 1989, CELL, V58, P869, DOI 10.1016/0092-8674(89)90939-2; LABUDA D, 1982, BIOCHEMISTRY-US, V21, P49, DOI 10.1021/bi00530a009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lilley DMJ, 1999, CURR OPIN STRUC BIOL, V9, P330, DOI 10.1016/S0959-440X(99)80044-X; Lisitsky I, 1997, PLANT J, V12, P1173, DOI 10.1046/j.1365-313X.1997.12051173.x; Lisitsky I, 1996, P NATL ACAD SCI USA, V93, P13398, DOI 10.1073/pnas.93.23.13398; MAYFIELD SP, 1994, J CELL BIOL, V127, P1537, DOI 10.1083/jcb.127.6.1537; Menger M, 1996, BIOCHEMISTRY-US, V35, P14710, DOI 10.1021/bi960440w; Misra VK, 1998, BIOPOLYMERS, V48, P113, DOI 10.1002/(SICI)1097-0282(1998)48:2<113::AID-BIP3>3.0.CO;2-Y; NICKELSEN J, 1994, EMBO J, V13, P3182, DOI 10.1002/j.1460-2075.1994.tb06617.x; Nickelsen J, 1999, PLANT CELL, V11, P957, DOI 10.1105/tpc.11.5.957; Noah JW, 1998, BIOCHEMISTRY-US, V37, P15442, DOI 10.1021/bi981148m; ROCHAIX JD, 1992, ANNU REV CELL BIOL, V8, P1, DOI 10.1146/annurev.cb.08.110192.000245; SAKAMOTO W, 1993, P NATL ACAD SCI USA, V90, P497, DOI 10.1073/pnas.90.2.497; SALVADOR ML, 1993, P NATL ACAD SCI USA, V90, P1556, DOI 10.1073/pnas.90.4.1556; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schuster G, 1999, PLANT PHYSIOL, V120, P937, DOI 10.1104/pp.120.4.937; SCHUSTER G, 1991, EMBO J, V10, P1493, DOI 10.1002/j.1460-2075.1991.tb07669.x; Scott WG, 1996, TRENDS BIOCHEM SCI, V21, P220; Shiina T, 1998, PLANT CELL, V10, P1713, DOI 10.1105/tpc.10.10.1713; STAUB JM, 1994, PLANT J, V6, P547, DOI 10.1046/j.1365-313X.1994.6040547.x; STERN DB, 1989, PLANT MOL BIOL, V13, P615, DOI 10.1007/BF00016017; STERN DB, 1991, PLANT CELL, V3, P285; Yang JJ, 1996, PLANT CELL, V8, P1409, DOI 10.1105/tpc.8.8.1409; ZHANG W, 1997, MAGNES B, V17, P125; ZURAWSKI G, 1982, P NATL ACAD SCI-BIOL, V79, P7699, DOI 10.1073/pnas.79.24.7699; ZURAWSKI G, 1981, NUCLEIC ACIDS RES, V9, P3251, DOI 10.1093/nar/9.14.3251	57	25	36	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35638	35645		10.1074/jbc.M005622200	http://dx.doi.org/10.1074/jbc.M005622200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10918066	hybrid			2022-12-25	WOS:000165422800107
J	Kim, HY; Akbar, M; Lau, A; Edsall, L				Kim, HY; Akbar, M; Lau, A; Edsall, L			Inhibition of neuronal apoptosis by docosahexaenoic acid (22 : 6n-3) - Role of phosphatidylserine in antiapoptotic effect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; ARACHIDONIC-ACID; CELL-DEATH; RETINAL PHOTORECEPTORS; RAF-1; SURVIVAL; PHOSPHORYLATION; SERINE; ACTIVATION; BINDING	Enrichment of Neuro 2A cells with docosahexaenoic acid (22:6n-3) decreased apoptotic cell death induced by serum starvation as evidenced by the reduced DNA fragmentation and caspase-3 activity. The protective effect of 22:6n-3 became evident only after at least 24 h of enrichment before serum starvation and was potentiated as a function of the enrichment period, During enrichment 22:6n-3 incorporated into phosphatidylserine (PS) steadily, resulting in a significant increase in the total PS content. Similar treatment with oleic acid (18:1n-9) neither altered PS content nor resulted in protective effect. Hindering PS accumulation by enriching cells in a serine-free medium diminished the protective effect of 22:6n-3. Membrane translocation of Raf-l was significantly enhanced by 22:6n-3 enrichment in Neuro 2A cells. Consistently, in vitro biomolecular interaction between PS/phosphatidylethanolamine /phosphatidylcholine liposomes, and Raf-l increased in a PS concentration-dependent manner. Collectively, enrichment of neuronal cells with 22:6n-3 increases the PS content and Raf-l translocation, down-regulates caspase-3 activity, and prevents apoptotic cell death. Both the antiapoptotic effect of 22:6n-3 and Raf-l translocation are sensitive to 22:6n-3 enrichment-induced PS accumulation, strongly suggesting that the protective effect of 22:6n-3 may be mediated at least in part through the promoted accumulation of PS in neuronal membranes.	NIAAA, LMBB, Sect Mass Spectrometry, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Kim, HY (corresponding author), NIAAA, LMBB, Sect Mass Spectrometry, NIH, 12420 Parklawn Dr, Rockville, MD 20852 USA.	hykim@nih.gov						Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; Birch EE, 1998, PEDIATR RES, V44, P201, DOI 10.1203/00006450-199808000-00011; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRIGHAMBURKE M, 1992, ANAL BIOCHEM, V205, P125, DOI 10.1016/0003-2697(92)90588-X; Carrie I, 1999, NEUROSCI LETT, V266, P69, DOI 10.1016/S0304-3940(99)00265-7; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUKE RC, 1992, CURRENT PROTOCOLS S, V3; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; Gamoh S, 1999, NEUROSCIENCE, V93, P237, DOI 10.1016/S0306-4522(99)00107-4; Garcia MC, 1998, J NEUROCHEM, V70, P24; Garcia MC, 1997, BRAIN RES, V768, P43, DOI 10.1016/S0006-8993(97)00583-0; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Goswami R, 2000, J NEUROSCI RES, V60, P141, DOI 10.1002/(SICI)1097-4547(20000415)60:2<141::AID-JNR2>3.0.CO;2-5; GRABER R, 1994, J LIPID MEDIAT CELL, V9, P91; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hamilton J, 2000, LIPIDS, V35, P863, DOI 10.1007/S11745-000-0595-x; HITZEMANN R, 1981, NEUROCHEM RES, V6, P935, DOI 10.1007/BF00965025; Hoffman DR, 1998, WORLD REV NUTR DIET, V83, P52; HOMMA S, 1994, J COMP NEUROL, V345, P377, DOI 10.1002/cne.903450305; Hoyle PE, 2000, LEUKEMIA, V14, P642, DOI 10.1038/sj.leu.2401720; KANFER JN, 1980, CAN J BIOCHEM CELL B, V58, P1370, DOI 10.1139/o80-186; Kaplan DR, 1998, PROG BRAIN RES, V117, P35; KIM HY, 1994, ANAL CHEM, V66, P3977, DOI 10.1021/ac00094a020; Kim HY, 1999, LIPIDS, V34, pS249, DOI 10.1007/BF02562308; Kim HY, 1999, ADV EXP MED BIOL, V447, P75; Kim HY, 2000, LIPIDS, V35, P187, DOI 10.1007/BF02664769; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kishida E, 1998, BBA-LIPID LIPID MET, V1391, P401, DOI 10.1016/S0005-2760(98)00015-0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Majewski M, 1999, CANCER RES, V59, P2815; MARTINEZ M, 1992, BRAIN RES, V583, P171, DOI 10.1016/S0006-8993(10)80021-6; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; Mitoma J, 1998, J BIOL CHEM, V273, P19363, DOI 10.1074/jbc.273.31.19363; MOORE SA, 1991, J NEUROCHEM, V56, P518, DOI 10.1111/j.1471-4159.1991.tb08180.x; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Mosior M, 1998, BIOCHEMISTRY-US, V37, P17271, DOI 10.1021/bi981344t; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Neuringer M, 2000, AM J CLIN NUTR, V71, p256S, DOI 10.1093/ajcn/71.1.256S; OPPENHEIM RW, 1992, J NEUROBIOL, V23, P1111, DOI 10.1002/neu.480230903; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rotstein NP, 1997, J NEUROCHEM, V69, P504; Rotstein NP, 1996, J NEUROCHEM, V66, P1851; SALEM N, 1989, OMEGA 3 FATTY ACIDS, P109; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; Sastry PS, 2000, J NEUROCHEM, V74, P1, DOI 10.1046/j.1471-4159.2000.0740001.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; White DA, 1973, FORM FUNCTION PHOSPH, P441; Winkler DG, 1998, J BIOL CHEM, V273, P21578, DOI 10.1074/jbc.273.34.21578; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; Yoshida S, 1997, J NEUROCHEM, V68, P1261; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	57	224	241	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35215	35223		10.1074/jbc.M004446200	http://dx.doi.org/10.1074/jbc.M004446200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10903316	hybrid			2022-12-25	WOS:000165422800053
J	Lund-Katz, S; Zaiou, M; Wehrli, S; Dhanasekaran, P; Baldwin, F; Weisgraber, KH; Phillips, MC				Lund-Katz, S; Zaiou, M; Wehrli, S; Dhanasekaran, P; Baldwin, F; Weisgraber, KH; Phillips, MC			Effects of lipid interaction on the lysine microenvironments in apolipoprotein E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-BINDING DOMAIN; N-TERMINAL DOMAIN; III HYPERLIPOPROTEINEMIA; CHOLESTEROL MOLECULES; ALZHEIMERS-DISEASE; E DEFICIENCY; NMR; CONFORMATION; ATHEROSCLEROSIS	Lysines in apolipoprotein (apo) E are key factors in the binding of apoE to the low density lipoprotein receptor, and high affinity binding requires that apoE be associated with lipid. To gain insight into this effect, we examined the microenvironments of the eight lysines in the 22-kDa fragment of apoE3 (residues 1-191) in the lipid-free and lipid-associated states. As shown by H-1,C-13 heteronuclear single quantum coherence nuclear magnetic resonance, lysine resonances in the lipid-free fragment were poorly resolved over a wide pH range, whereas in apoE3 dimyristoyl phosphatidylcholine (DMPC) discs, the lysine microenvironments and protein conformation were significantly altered. Sequence-specific assignments of the lysine resonances in the spectrum of the lipidated 22-kDa fragment were made. In the lipid-free protein, six lysines could be resolved, and all had pK(a) values above 10, In apoE3 DMPC complexes, however, all eight lysines were resolved, and the pK(a) values were 9.2-11.1, Lys-143 and Lys-146, both in the receptor binding region in helix 4, had unusually low pK(a) values of 9.5 and 9.2, respectively, likely as a result of local increases in positive electrostatic potential with lipid association, Shift reagent experiments with potassium ferricyanide showed that Lys-143 and Lys-146 were much more accessible to the ferricyanide anion in the apoE3 DMPC complex than in the lipid-free state. The angle of the nonpolar face of helix 4 is smaller than the angles of helices 1, 2, and 3, suggesting that helix 4 cannot penetrate as deeply into the DMPC acyl chains at the edge of the complex and that its polar face protrudes from the edge of the disc, This increased exposure and the greater positive electrostatic potential created by interaction with DMPC may explain why lipid association is required for high affinity binding of apoE to the low density lipoprotein receptor.	Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Philadelphia, PA 19104 USA; Med Coll Penn & Hahnemann Univ, Dept Biochem, Philadelphia, PA 19129 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Cardiovasc Res Inst, San Francisco, CA 94141 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Drexel University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes	Lund-Katz, S (corresponding author), Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Abramson Res Bldg,Suite 302,3516 Civic Ctr Blvd, Philadelphia, PA 19104 USA.		Zaiou, Mohamed/AAG-8923-2019	ZAIOU, Mohamed/0000-0002-4113-4350; Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056083, P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56083, HL41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANANTHARAMAIAH GM, 1993, AMPHIPATHIC HELIX, P109; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; DEPAUW M, 1995, BIOCHEMISTRY-US, V34, P10953, DOI 10.1021/bi00034a030; Dong LM, 1996, NAT STRUCT BIOL, V3, P718, DOI 10.1038/nsb0896-718; Fisher CA, 1999, J LIPID RES, V40, P93; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; HAMILTON JA, 1986, METHOD ENZYMOL, V128, P472; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu B, 2000, J BIOL CHEM, V275, P20775, DOI 10.1074/jbc.M003508200; LUNDKATZ S, 1991, J BIOL CHEM, V266, P2701; LUNDKATZ S, 1984, BIOCHEMISTRY-US, V23, P1130, DOI 10.1021/bi00301a015; LUNDKATZ S, 1995, BIOCHEMISTRY-US, V34, P9219, DOI 10.1021/bi00028a035; LUNDKATZ S, 1986, BIOCHEMISTRY-US, V25, P1562, DOI 10.1021/bi00355a016; LUNDKATZ S, 1988, J BIOL CHEM, V263, P13831; LUNDKATZ S, 1993, J BIOL CHEM, V268, P23008; MABUCHI H, 1989, METABOLISM, V38, P115, DOI 10.1016/0026-0495(89)90249-7; Mahley RW, 1996, ISRAEL J MED SCI, V32, P414; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1995, METABOLIC MOL BASES, P1953; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MAVRI J, 1994, PROTEINS, V18, P381, DOI 10.1002/prot.340180408; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; North CL, 2000, BIOCHEMISTRY-US, V39, P2564, DOI 10.1021/bi992087a; Raussens V, 1998, J BIOL CHEM, V273, P25825, DOI 10.1074/jbc.273.40.25825; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; Segelke BW, 2000, PROTEIN SCI, V9, P886, DOI 10.1110/ps.9.5.886; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; Vallejo Abbe N., 1995, P603; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WEISGRABER KH, 1992, HIGH DENSITY LIPOPRO, V3, P175; Zaiou M, 2000, J LIPID RES, V41, P1087; ZHANG MJ, 1994, J BIOL CHEM, V269, P5099; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	42	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34459	34464		10.1074/jbc.M005265200	http://dx.doi.org/10.1074/jbc.M005265200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10921925	hybrid			2022-12-25	WOS:000165095300062
J	Tynan, SH; Gee, MA; Vallee, RB				Tynan, SH; Gee, MA; Vallee, RB			Distinct but overlapping sites within the cytoplasmic dynein heavy chain for dimerization and for intermediate chain and light intermediate chain binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR DOMAIN; LOCALIZATION; TRANSPORT	Cytoplasmic dynein is a molecular motor complex consisting of four major classes of polypeptide: the catalytic heavy chains (HC), intermediate chains (IC), light intermediate chains (LIC), and light chains (LC). Previous studies have reported that the ICs bind near the N terminus of the HCs, which is thought to correspond to the base of the dynein complex. In this study, we co-overexpressed cytoplasmic dynein subunits in COS-7 cells to map HC binding sites for the ICs and LICs, as well as HC dimerization. We have found that the LICs bind directly to the N terminus of the HC, adjacent to and overlapping with the IC binding site, consistent with a role for the LICs in cargo binding. Mutation of the LIC P-loop had no detectable effect on RC binding, We detected no direct interaction between the ICs and LICs. Using triple overexpression of HC, IC and LIC, we found that both IC and LIC are present in the same complexes, a result verified by anti-IC immunoprecipitation of endogenous complexes and immunoblotting, Our results indicate that the LICs and ICs must be located on independent surfaces of cytoplasmic dynein to allow each to interact with other proteins without steric interference.	Univ Massachusetts, Med Ctr, Dept Cell Biol, Worcester, MA 01605 USA; Tropix PE Biosyst, Bedford, MA 01730 USA	University of Massachusetts System; University of Massachusetts Worcester	Vallee, RB (corresponding author), Univ Massachusetts, Med Ctr, Dept Cell Biol, 377 Plantat St, Worcester, MA 01605 USA.							DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; Dillman JF, 1996, J NEUROSCI, V16, P6742; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; GILL SR, 1994, MOL BIOL CELL, V5, P645, DOI 10.1091/mbc.5.6.645; Habura A, 1999, J BIOL CHEM, V274, P15447, DOI 10.1074/jbc.274.22.15447; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; KING SM, 1990, J BIOL CHEM, V265, P19807; Mazumdar M, 1996, P NATL ACAD SCI USA, V93, P6552, DOI 10.1073/pnas.93.13.6552; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; Purohit A, 1999, J CELL BIOL, V147, P481, DOI 10.1083/jcb.147.3.481; Samso M, 1998, J MOL BIOL, V276, P927, DOI 10.1006/jmbi.1997.1584; Steffen W, 1996, J STRUCT BIOL, V117, P227, DOI 10.1006/jsbi.1996.0087; Tynan SH, 2000, J BIOL CHEM, V275, P32763, DOI 10.1074/jbc.M001536200; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; VAUGHAN KT, 1995, BIOCHEM SOC T, V23, P50, DOI 10.1042/bst0230050; Young A, 2000, MOL BIOL CELL, V11, P2047, DOI 10.1091/mbc.11.6.2047	16	93	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32769	32774		10.1074/jbc.M001537200	http://dx.doi.org/10.1074/jbc.M001537200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10893223	hybrid			2022-12-25	WOS:000090003800055
J	Boyd, MT; Vlatkovic, N; Haines, DS				Boyd, MT; Vlatkovic, N; Haines, DS			A novel cellular protein (MTBP) binds to MDM2 and induces a G(1) arrest that is suppressed by MDM2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53 TUMOR SUPPRESSION; HUMAN CANCER-CELLS; WILD-TYPE P53; P53-INDEPENDENT ROLE; ONCOPROTEIN MDM2; HUMAN SARCOMAS; GENE; AMPLIFICATION; EXPRESSION; MUTATIONS	The MDM2 protein, through its interaction with p53, plays an important role in the regulation of the G(1) checkpoint of the cell cycle. In addition to binding to and inhibiting the transcriptional activation function of the p53 protein, MDM2 binds, inter alia, to RE and the E2F-1.DP-1 complex and in so doing may promote progression of cells into S phase, Mice transgenic for Mdm2 possess cells that have cell cycle regulation defects and develop an altered tumor profile independent of their p53 status. MDM2 also blocks the growth inhibitory effects of transforming growth factor-pr in a p53-independent manner. We show here that a novel growth regulatory molecule is also the target of MDM2-mediated inhibition, Using a yeast two-hybrid screen, we have identified a gene that encodes a novel cellular protein (MTBP) that binds to MDM2. MTBP can induce G(1) arrest, which in turn can be blocked by MDM2. Our results suggest the existence of another growth control pathway that may be regulated, at least in part, by MDM2.	Med Coll Penn & Hahnemann Univ, Ctr Canc, Div Hematol Oncol, Philadelphia, PA 19102 USA	Drexel University	Boyd, MT (corresponding author), Univ Liverpool, Dept Surg, Daulby St, Liverpool L69 3GA, Merseyside, England.		Boyd, Mark/AAB-8564-2021; Boyd, Mark T/I-6792-2012; Vlatkovic, Nikolina/I-3481-2013; Vlatkovic, Nikolina/AAH-6654-2020	Boyd, Mark/0000-0002-2336-2106; Boyd, Mark T/0000-0002-2336-2106; Vlatkovic, Nikolina/0000-0003-3003-794X; Vlatkovic, Nikolina/0000-0003-3003-794X	NATIONAL CANCER INSTITUTE [R29CA070165] Funding Source: NIH RePORTER; NCI NIH HHS [CA70165] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bender L, 1996, J CELL BIOL, V133, P879, DOI 10.1083/jcb.133.4.879; Cabib E, 1998, ANNU REV BIOCHEM, V67, P307, DOI 10.1146/annurev.biochem.67.1.307; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DASMAHAPATRA B, 1987, NUCLEIC ACIDS RES, V15, P3933, DOI 10.1093/nar/15.9.3933; DEOCALUNA R, 1995, NATURE, V0378; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; JUVEN T, 1993, ONCOGENE, V8, P3411; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LADANYI M, 1993, CANCER RES, V53, P16; LEACH FS, 1993, CANCER RES, V53, P2231; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Matsui Y, 1996, J CELL BIOL, V133, P865, DOI 10.1083/jcb.133.4.865; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; REIFENBERGER G, 1993, CANCER RES, V53, P2736; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Sambrook J., 2002, MOL CLONING LAB MANU; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vlatkovic N, 2000, NUCLEIC ACIDS RES, V28, P3581, DOI 10.1093/nar/28.18.3581; WALDMAN T, 1995, CANCER RES, V55, P5187; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	52	80	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31883	31890		10.1074/jbc.M004252200	http://dx.doi.org/10.1074/jbc.M004252200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10906133	hybrid			2022-12-25	WOS:000089858900048
J	Shih, SJ; Allan, C; Grehan, S; Tse, E; Moran, C; Taylor, JM				Shih, SJ; Allan, C; Grehan, S; Tse, E; Moran, C; Taylor, JM			Duplicated downstream enhancers control expression of the human apolipoprotein E gene in macrophages and adipose tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC CONTROL REGION; BONE-MARROW TRANSPLANTATION; E-DEFICIENT MICE; E MESSENGER-RNA; TRANSGENIC MICE; APOPROTEIN-E; C/EBP-ALPHA; IN-VIVO; C-I; ALZHEIMERS-DISEASE	Two distal enhancers that specify apolipoprotein (apo) E gene expression in isolated macrophages and adipose tissue were identified in transgenic mice that were generated with constructs of the human apoE/C-I/C-I'/C-IV/C-II gene cluster. One of these enhancers, multienhancer 1, consists of a 620-nucleotide sequence located 3.3 kilobases (kb) downstream of the apoE gene. The second enhancer, multienhancer 2, is a 619-nucleotide sequence located 15.9 kb downstream of the apoE gene and 5.9 kb downstream of the apoC-I gene. The two enhancers are 95% identical in sequence, and they are likely to have arisen as a consequence of the gene duplication event that yielded the apoC-I gene and the apoC-I' pseudogene. Both enhancer sequences appear to have equivalent activity in directing apoE gene expression in peritoneal macrophages and in adipocytes, suggesting that their activity in specific cell types may be determined by common regulatory elements.	J David Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Taylor, JM (corresponding author), J David Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037063] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37063] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN CM, 1995, J BIOL CHEM, V270, P26278, DOI 10.1074/jbc.270.44.26278; ALLAN CM, 1995, GENOMICS, V28, P291, DOI 10.1006/geno.1995.1144; Allan CM, 1997, J BIOL CHEM, V272, P29113, DOI 10.1074/jbc.272.46.29113; BASHEERUDDIN K, 1994, BBA-GENE STRUCT EXPR, V1218, P235, DOI 10.1016/0167-4781(94)90021-3; BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; BOISVERT WA, 1995, J CLIN INVEST, V96, P1118, DOI 10.1172/JCI118098; DANG Q, 1995, J BIOL CHEM, V270, P22577, DOI 10.1074/jbc.270.38.22577; Dang Q, 1996, J BIOL CHEM, V271, P28667, DOI 10.1074/jbc.271.45.28667; DAWSON PA, 1989, J LIPID RES, V30, P403; DESCAMPS O, 1993, J BIOL CHEM, V268, P974; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; GILMAN M, 1993, CURRENT PROTOCOLS MO, V1; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; Iwama A, 1998, NUCLEIC ACIDS RES, V26, P3034, DOI 10.1093/nar/26.12.3034; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kapitonov V, 1996, J MOL EVOL, V42, P59, DOI 10.1007/BF00163212; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1995, METABOLIC MOL BASES, P1953; Masliah E, 1996, PROG NEUROBIOL, V50, P493, DOI 10.1016/S0301-0082(96)00038-X; MAZZONE T, 1989, J LIPID RES, V30, P1055; Nakai M, 1996, NEUROSCI LETT, V211, P41, DOI 10.1016/0304-3940(96)12716-6; Okada N, 1991, CURR OPIN GENET DEV, V1, P498, DOI 10.1016/S0959-437X(05)80198-4; PAIK YK, 1985, P NATL ACAD SCI USA, V82, P3445, DOI 10.1073/pnas.82.10.3445; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; RAISONNIER A, 1991, J MOL EVOL, V32, P211; RALL SC, 1982, J BIOL CHEM, V257, P4171; REARDON CA, 1986, J BIOL CHEM, V261, P9858; ROSENFELD ME, 1993, ARTERIOSCLER THROMB, V13, P1382, DOI 10.1161/01.ATV.13.9.1382; ROSES AD, 1994, CURR NEUROL, V14, P111; SALOMON RN, 1992, P NATL ACAD SCI USA, V89, P2814, DOI 10.1073/pnas.89.7.2814; SHACHTER NS, 1993, J LIPID RES, V34, P1699; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SIMONET WS, 1991, J BIOL CHEM, V266, P8651; SING CF, 1985, AM J HUM GENET, V37, P268; Stone DJ, 1997, EXP NEUROL, V143, P313, DOI 10.1006/exnr.1996.6360; TAYLOR JM, 1993, CURR OPIN LIPIDOL, V4, P84, DOI 10.1097/00041433-199304000-00002; TAYLOR JM, 1991, CURR OPIN LIPIDOL, V2, P73; Valledor AF, 1998, J LEUKOCYTE BIOL, V63, P405, DOI 10.1002/jlb.63.4.405; van Dijk TB, 1999, J IMMUNOL, V163, P2674; WEISGRABER KH, 1985, ANAL BIOCHEM, V151, P455, DOI 10.1016/0003-2697(85)90204-0; WEISGRABER KH, 1994, CURR OPIN STRUC BIOL, V4, P507, DOI 10.1016/S0959-440X(94)90212-7; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WERB Z, 1983, J EXP MED, V158, P1272, DOI 10.1084/jem.158.4.1272; WERB Z, 1983, J CELL BIOL, V97, P1113, DOI 10.1083/jcb.97.4.1113; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; ZANNIS VI, 1981, BIOCHEMISTRY-US, V20, P1033, DOI 10.1021/bi00507a059; ZECHNER R, 1991, J BIOL CHEM, V266, P10583; ZUCKERMAN SH, 1993, ATHEROSCLEROSIS, V103, P43, DOI 10.1016/0021-9150(93)90038-V	54	85	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31567	31572		10.1074/jbc.M005468200	http://dx.doi.org/10.1074/jbc.M005468200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10893248	hybrid			2022-12-25	WOS:000089858900004
J	Deng, SJ; Bickett, DM; Mitchell, JL; Lambert, MH; Blackburn, RK; Carter, HL; Neugebauer, J; Pahel, G; Weiner, MP; Moss, ML				Deng, SJ; Bickett, DM; Mitchell, JL; Lambert, MH; Blackburn, RK; Carter, HL; Neugebauer, J; Pahel, G; Weiner, MP; Moss, ML			Substrate specificity of human collagenase 3 assessed using a phage-displayed peptide library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST CARCINOMAS; MATRIX; DEGRADATION; CARTILAGE; MMP-13; OPTIMIZATION; STROMELYSIN; EXPRESSION; ACTIVATION; INHIBITORS	The substrate specificity of human collagenase 3 (MMP-13), a member of the matrix metalloproteinase family, is investigated using a phage-displayed random hexapeptide Library containing 2 x 10(8) independent recombinants, A total of 35 phage clones that express a peptide sequence that can be hydrolyzed by the recombinant catalytic domain of human collagenase 3 are identified. The translated DNA sequence of these clones reveals highly conserved putative P1, P2, P3 and P1', P2', and P3' subsites of the peptide substrates, Kinetic analysis of synthetic peptide substrates made from human collagenase 3 selected phage clones reveals that some of the substrates are highly active and selective. The most active substrate, 2,4-dinitrophenyl-GPLGMRGL-NH2 (CP), has a k(cat)/K-m value of 4.22 x 10(6) M-1 s(-1) for hydrolysis by collagenase 3, CP was synthesized as a consensus sequence deduced from the preferred sub sites of the aligned 35 phage clones. Peptide substrate CP is 1300-, 11-, and 820-fold selective for human collagenase 3 over the MMPs stromelysin-l, gelatinase B, and collagenase 1, respectively. In addition, cleavage of CP is 37-fold faster than peptide NF derived from the major MMP-processing site in aggrecan, Phage display screening also selected five substrate sequences that share sequence homology with a major MMP cleavage sequence in aggrecan and seven substrate sequences that share sequence homology with the primary collagenase cleavage site of human type II collagen. In addition, putative cleavage sites similar to the consensus sequence are found in human type N collagen. These findings support previous observations that human collagenase 3 can degrade aggrecan, type Il and type IV collagens.	Glaxo Wellcome Inc, Dept Mol Sci, Res & Dev, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Dept Mol Biochem, Res & Dev, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Dept Struct Chem, Res & Dev, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Dept Genomic Sci, Res & Dev, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Deng, SJ (corresponding author), Glaxo Wellcome Inc, Dept Mol Sci, Res & Dev, POB 13398,5 Moore Dr, Res Triangle Pk, NC 27709 USA.	sjd20506@glaxowellcome.com						Beekman B, 1997, FEBS LETT, V418, P305, DOI 10.1016/S0014-5793(97)01371-9; BERMAN J, 1992, J BIOL CHEM, V267, P1434; Billinghurst RC, 1997, J CLIN INVEST, V99, P1534, DOI 10.1172/JCI119316; COX DA, 1995, CELL BIOL INT, V19, P357, DOI 10.1006/cbir.1995.1082; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; FIELDS GB, 1991, J THEOR BIOL, V153, P585, DOI 10.1016/S0022-5193(05)80157-2; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Flaumenhaft R, 1993, Adv Pharmacol, V24, P51, DOI 10.1016/S1054-3589(08)60933-3; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HASSELL AM, 1994, J MOL BIOL, V236, P1410, DOI 10.1016/0022-2836(94)90068-X; KASSEL DB, 1995, ANAL BIOCHEM, V228, P259, DOI 10.1006/abio.1995.1348; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Lauer-Fields JL, 2000, J BIOL CHEM, V275, P13282, DOI 10.1074/jbc.275.18.13282; Lovejoy B, 1999, NAT STRUCT BIOL, V6, P217; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MCGEEHAN GM, 1994, J BIOL CHEM, V269, P32814; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; MIYAZONO K, 1991, CIBA F SYMP, V157, P81; NAGASE H, 1994, J BIOL CHEM, V269, P20952; Nagase H, 1996, BIOPOLYMERS, V40, P399, DOI 10.1002/(SICI)1097-0282(1996)40:4<399::AID-BIP5>3.0.CO;2-R; Parish CR, 1998, IMMUNOL CELL BIOL, V76, P104, DOI 10.1046/j.1440-1711.1998.00722.x; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; SINGH J, 1995, J MED CHEM, V38, P217, DOI 10.1021/jm00002a001; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; STACK MS, 1989, J BIOL CHEM, V264, P4277; Tozser J, 1996, J BIOL CHEM, V271, P6781, DOI 10.1074/jbc.271.12.6781; Willmroth F, 1998, IMMUNOBIOLOGY, V198, P375, DOI 10.1016/S0171-2985(98)80046-6; Yu Q, 2000, GENE DEV, V14, P163	34	109	118	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31422	31427		10.1074/jbc.M004538200	http://dx.doi.org/10.1074/jbc.M004538200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906330	hybrid			2022-12-25	WOS:000089762700095
J	Diamond, SE; Gutierrez-Hartmann, A				Diamond, SE; Gutierrez-Hartmann, A			The Pit-1 beta domain dictates active repression and alteration of histone acetylation of the proximal prolactin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; GENE-EXPRESSION; TRANSCRIPTIONAL REPRESSION; FUNCTIONAL INTERACTION; PROTEIN; RAS; DEACETYLASE; ACTIVATION; ISOFORMS; PHOSPHORYLATION	A critical problem in current molecular biology is to gain a detailed understanding of the molecular mechanisms by which related transcription factor isoforms with identical DNA sequence specificity mediate distinct transcription responses. Pit-1 and Plt-1 beta constitute such a pair of transcription factor isoforms. Pit-1 enhances the Ras signaling pathway to the prolactin promoter, and Pit-1 beta represses basal prolactin promoter activity as well as Ras signaling to the prolactin promoter in pituitary cells. We have previously demonstrated that the beta-domain amino acid sequence dictates the transcriptional properties of Pit-1 beta. Here, we show that five hydrophobic beta-domain residues are required for Pit-1 isoform-specific repression of Res signaling, and we demonstrate that sodium butyrate and trichostatin A, pharmacological inhibitors of histone deacetylation, as well as viral Ski protein, a dominant-negative inhibitor of recruitment of N-CoR/mSin(3) histone deacetylase complexes, specifically reverse beta isoform-specific repression of Ras signaling. Moreover, we directly demonstrate, with a chromatin immunoprecipitation assay, that the Pit-1 beta isoform alters the histone acetylation state of the proximal prolactin promoter. This differential analysis of Pit-1/Pit-1 beta isoform function provides significant insights into the structural determinants that govern how different transcription factors with identical DNA sequence specificity can display opposite effects on target gene activity.	Univ Colorado, Hlth Sci Ctr, Colorado Canc Ctr, Program Mol Biol,Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Colorado Canc Ctr, Program Mol Biol,Dept Biochem & Mol Genet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gutierrez-Hartmann, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Colorado Canc Ctr, Program Mol Biol,Dept Med, 4200 E 9th Ave,Box B-151, Denver, CO 80262 USA.		Gutierrez-Hartmann, Arthur/F-1295-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037667, K01DK002752] Funding Source: NIH RePORTER; NIDDK NIH HHS [K01 DK02752-01, R01 DK37667] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agata Y, 1999, J BIOL CHEM, V274, P16412, DOI 10.1074/jbc.274.23.16412; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; Bradford AP, 2000, J BIOL CHEM, V275, P3100, DOI 10.1074/jbc.275.5.3100; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7; Choi CY, 1997, J BIOL CHEM, V272, P16934, DOI 10.1074/jbc.272.27.16934; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; CONRAD KE, 1992, ONCOGENE, V7, P1279; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Diamond SE, 1999, MOL ENDOCRINOL, V13, P228, DOI 10.1210/me.13.2.228; Diamond SE, 1996, J BIOL CHEM, V271, P28925, DOI 10.1074/jbc.271.46.28925; DIAMOND SE, 1994, J VIROL, V68, P863, DOI 10.1128/JVI.68.2.863-876.1994; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HOCH M, 1992, SCIENCE, V256, P94, DOI 10.1126/science.1348871; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; Hollenberg AN, 1996, J BIOL CHEM, V271, P28516, DOI 10.1074/jbc.271.45.28516; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KEECH CA, 1989, MOL ENDOCRINOL, V3, P832, DOI 10.1210/mend-3-5-832; Koenig RJ, 1998, THYROID, V8, P703, DOI 10.1089/thy.1998.8.703; KOIZUMI S, 1990, ONCOGENE, V5, P675; KONZAK KE, 1992, MOL ENDOCRINOL, V6, P241, DOI 10.1210/me.6.2.241; LAMBERT JR, 2000, METHODS STEROID RECE; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; LIM PS, 1990, J INFECT DIS, V162, P1263, DOI 10.1093/infdis/162.6.1263; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; PICKETT CA, 1997, CONT ENDOCRINOL, V3, P1; Sanchez-Pacheco A, 1998, FEBS LETT, V422, P103, DOI 10.1016/S0014-5793(97)01609-8; Saunders N, 1999, CANCER RES, V59, P399; Sladek FM, 1999, MOL CELL BIOL, V19, P6509; THEILL LE, 1992, EMBO J, V11, P2261, DOI 10.1002/j.1460-2075.1992.tb05285.x; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Tolon RM, 1998, J BIOL CHEM, V273, P26652, DOI 10.1074/jbc.273.41.26652; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; WERTMAN KF, 1992, GENETICS, V132, P337; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yang BS, 1996, MOL CELL BIOL, V16, P538; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	49	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30977	30986		10.1074/jbc.M006048200	http://dx.doi.org/10.1074/jbc.M006048200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10921928	hybrid			2022-12-25	WOS:000089762700036
J	Kim, SS; Tam, JK; Wang, AF; Hegde, RS				Kim, SS; Tam, JK; Wang, AF; Hegde, RS			The structural basis of DNA target discrimination by papillomavirus E2 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA CELL-LINES; BINDING DOMAIN; BACTERIOPHAGE-434 REPRESSOR; SEPARATE REGULATION; CRYSTAL-STRUCTURE; AFFINITY; SITE; RECOGNITION; SEQUENCE; PROMOTER	The papillomavirus E2 proteins regulate the transcription of all papillomavirus genes and are necessary for viral DNA replication. Disruption of the E2 gene is commonly associated with malignancy in cervical carcinoma, indicating that E2 has a role in regulating tumor progression. Although the E2 proteins from all characterized papillomaviruses bind specifically to the same la-base pair DNA sequence, the cancer-associated human papillomavirus E2 proteins display a unique ability to detect DNA flexibility and intrinsic curvature. To understand the structural basis for this phenomenon, we have determined the crystal structures of the human papillomavirus-ls E2 DNA-binding domain and its complexes with high and low affinity binding sites. The E2 protein is a dimeric P-barrel and the EB-DNA interaction is accompanied by a large deformation of the DNA as it conforms to the E2 surface. DNA conformation and E2-DNA contacts are similar in both high and low affinity complexes. The differences in affinity correlate with the flexibility of the DNA sequence. Preferences of E2 proteins from different papillomavirus strains for flexible or prebent DNA targets correlate with the distribution of positive charge on their DNA interaction surfaces, suggesting a role for electrostatic forces in the recognition of DNA deformability.	NYU, Med Ctr, Skirball Inst Biomol Med, Dept Biochem, New York, NY 10016 USA; NYU, Med Ctr, Skirball Inst Biomol Med, Program Struct Biol, New York, NY 10016 USA	New York University; New York University	Hegde, RS (corresponding author), NYU, Med Ctr, Skirball Inst Biomol Med, Dept Biochem, 540 1st Ave, New York, NY 10016 USA.				NATIONAL CANCER INSTITUTE [R01CA066964] Funding Source: NIH RePORTER; NCI NIH HHS [CA66964] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; Alexander KA, 1996, BIOCHEMISTRY-US, V35, P9864, DOI 10.1021/bi960447d; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BEDROSIAN CL, 1990, VIROLOGY, V174, P557, DOI 10.1016/0042-6822(90)90109-5; Berg M, 1997, J VIROL, V71, P3853, DOI 10.1128/JVI.71.5.3853-3863.1997; Bostock-Smith CE, 1999, BIOCHEM J, V342, P125, DOI 10.1042/0264-6021:3420125; BRUNGER A, 1992, CNS VERSION 0 9; Bussiere DE, 1998, ACTA CRYSTALLOGR D, V54, P1367, DOI 10.1107/S0907444998005587; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Chen G, 2000, J VIROL, V74, P1506, DOI 10.1128/JVI.74.3.1506-1512.2000; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; Dickerson RE, 1998, NUCLEIC ACIDS RES, V26, P1906, DOI 10.1093/nar/26.8.1906; DILORENZO TP, 1995, J VIROL, V69, P6865, DOI 10.1128/JVI.69.11.6865-6872.1995; DiLorenzo TP, 1998, VIROLOGY, V243, P130, DOI 10.1006/viro.1998.9042; Duong TH, 1998, J MOL BIOL, V280, P31, DOI 10.1006/jmbi.1998.1846; Grassmann K, 1996, J VIROL, V70, P2339, DOI 10.1128/JVI.70.4.2339-2349.1996; HEDGE RS, 1998, J MOL BIOL, V276, P797; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hegde RS, 1998, J MOL BIOL, V284, P1479, DOI 10.1006/jmbi.1998.2260; Hines CS, 1998, J MOL BIOL, V276, P809, DOI 10.1006/jmbi.1997.1578; KOUDELKA GB, 1992, NATURE, V355, P89, DOI 10.1038/355089a0; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; Liang H, 1996, BIOCHEMISTRY-US, V35, P2095, DOI 10.1021/bi951932w; Merkel JS, 1999, STRUCT FOLD DES, V7, P1333, DOI 10.1016/S0969-2126(00)80023-4; Merkel JS, 1998, FOLD DES, V3, P449, DOI 10.1016/S1359-0278(98)00062-5; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Olson WK, 1998, P NATL ACAD SCI USA, V95, P11163, DOI 10.1073/pnas.95.19.11163; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Rapp B, 1997, J VIROL, V71, P6956, DOI 10.1128/JVI.71.9.6956-6966.1997; Rozenberg H, 1998, P NATL ACAD SCI USA, V95, P15194, DOI 10.1073/pnas.95.26.15194; Schneider-Gadicke A, 1987, Haematol Blood Transfus, V31, P380; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SENEAR DF, 1993, ELECTROPHORESIS, V14, P704, DOI 10.1002/elps.11501401112; SENEAR DF, 1991, J BIOL CHEM, V266, P13661; Steger G, 1997, J VIROL, V71, P50, DOI 10.1128/JVI.71.1.50-58.1997; STUBENRAUCH F, 1994, J VIROL, V68, P6959, DOI 10.1128/JVI.68.11.6959-6966.1994; Stubenrauch F, 1998, J VIROL, V72, P8115, DOI 10.1128/JVI.72.10.8115-8123.1998; Thain A, 1997, J BIOL CHEM, V272, P8236, DOI 10.1074/jbc.272.13.8236; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	44	80	83	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31245	31254		10.1074/jbc.M004541200	http://dx.doi.org/10.1074/jbc.M004541200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906136	hybrid			2022-12-25	WOS:000089762700071
J	McKenzie, M; Trounce, I				McKenzie, M; Trounce, I			Expression of Rattus norvegicus mtDNA in Mus musculus cells results in multiple respiratory chain defects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY OPTIC NEUROPATHY; MITOCHONDRIAL-DNA; XENOMITOCHONDRIAL CYBRIDS; TRANSMITOCHONDRIAL MICE; MOUSE; CHLORAMPHENICOL; SEQUENCE; HETEROPLASMY; DISEASES	The production of in vitro and in vivo models of mitochondrial DNA (mtDNA) defects is currently limited by a lack of characterized mouse cell mtDNA mutants that may be expected to model human mitochondrial diseases. Here we describe the creation of transmitochondrial mouse (Mus musculus) cells repopulated with mtDNA from different murid species (xenomitochondrial cybrids). The closely related Mus spretus mtDNA is readily maintained when introduced into IM. musculus mtDNA-less (rho(0)) cells, and the resulting cybrids have normal oxidative phosphorylation (OXPHOS). When the more distantly related Rattus norvegicus mtDNA is transferred to the mouse nuclear background the mtDNA is replicated, transcribed, and translated efficiently. However, function of several OXPHOS complexes that depend on the coordinated assembly of nuclear and mtDNA-encoded proteins is impaired. Complex I activity in the Rattus xenocybrid was 46% of the control mean; complex III was 37%, and complex IV was 78%. These defects combined to restrict maximal respiration to 12-31% of the control and M. spretus xenocybrids, as measured polarographically using isolated cybrid mitochondria. These defects are distinct to those previously reported for human/primate xenocybrids. It should be possible to produce other mouse xenocybrid constructs with less severe OXPHOS phenotypes, to model human mtDNA diseases.	St Vincents Hosp, Mutat Res Ctr, Fitzroy, Vic 3065, Australia; Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia	St Vincent's Hospital Melbourne; St Vincent's Hospital Melbourne; University of Melbourne	Trounce, I (corresponding author), St Vincents Hosp, Mutat Res Ctr, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.	trouncia@svhm.org.au	Trounce, Ian A/F-8338-2010; McKenzie, Matthew/H-4926-2019	Trounce, Ian A/0000-0002-1070-8892; McKenzie, Matthew/0000-0001-7508-1800				Barrientos A, 1998, J BIOL CHEM, V273, P14210, DOI 10.1074/jbc.273.23.14210; Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BLANC H, 1981, P NATL ACAD SCI-BIOL, V78, P3789, DOI 10.1073/pnas.78.6.3789; Bonhomme F., 1996, GENETIC VARIANTS STR, P1577; BROWN MD, 1992, AM J HUM GENET, V51, P378; CATZEFLIS FM, 1993, MAMMAL PHYLOGENY : PLACENTALS, P159; Clayton DA, 2000, EXP CELL RES, V255, P4, DOI 10.1006/excr.1999.4763; Dey R, 2000, J BIOL CHEM, V275, P31520, DOI 10.1074/jbc.M004053200; ESTORNELL E, 1993, FEBS LETT, V332, P127, DOI 10.1016/0014-5793(93)80498-J; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; Graff C, 1999, J INTERN MED, V246, P11, DOI 10.1046/j.1365-2796.1999.00514.x; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; HOWELL N, 1988, SOMAT CELL MOLEC GEN, V14, P185, DOI 10.1007/BF01534403; Irwin MH, 1999, TRANSGENIC RES, V8, P119, DOI 10.1023/A:1008925419758; Kenyon L, 1997, P NATL ACAD SCI USA, V94, P9131, DOI 10.1073/pnas.94.17.9131; King M P, 1996, Methods Enzymol, V264, P313, DOI 10.1016/S0076-6879(96)64030-0; Kwong LK, 1998, ARCH BIOCHEM BIOPHYS, V350, P118, DOI 10.1006/abbi.1997.0489; Levy SE, 1999, TRANSGENIC RES, V8, P137, DOI 10.1023/A:1008967412955; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; Marchington DR, 1999, NAT MED, V5, P957, DOI 10.1038/11403; Moraes CT, 1999, MOL BIOL CELL, V10, P3345, DOI 10.1091/mbc.10.10.3345; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Seibel M, 1999, BIOL CHEM, V380, P961, DOI 10.1515/BC.1999.119; SEIBEL P, 1995, NUCLEIC ACIDS RES, V23, P10, DOI 10.1093/nar/23.1.10; Silver L. M., 1995, MOUSE GENETICS; TAYLOR RW, 1993, BIOCHIM BIOPHYS ACTA, V1181, P261, DOI 10.1016/0925-4439(93)90030-5; Trounce I, 2000, NUCLEIC ACIDS RES, V28, P2164, DOI 10.1093/nar/28.10.2164; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Verneau O, 1997, J MOL EVOL, V45, P424, DOI 10.1007/PL00006247; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wallace DC, 1999, AM J HUM GENET, V65, pA18; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231	33	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31514	31519		10.1074/jbc.M004070200	http://dx.doi.org/10.1074/jbc.M004070200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10908563	hybrid, Green Published			2022-12-25	WOS:000089762700106
J	Nicolas, E; Beggs, JM; Taraschi, TF				Nicolas, E; Beggs, JM; Taraschi, TF			Gelonin is an unusual DNA glycosylase that removes adenine from single-stranded DNA, normal base pairs and mismatches	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME-INACTIVATING PROTEINS; POLYNUCLEOTIDE-ADENOSINE GLYCOSIDASE; POKEWEED ANTIVIRAL PROTEIN; ESCHERICHIA-COLI MUTY; RICIN A-CHAIN; EXCISION-REPAIR; DEOXYRIBONUCLEASE ACTIVITY; DIVALENT-CATIONS; RNA; MECHANISM	We reported that plant ribosome inactivating proteins (RIP) have a unique DNA glycosylase activity that removes adenine from single-stranded DNA (Nicolas, E,, Beggs, J, M,, Haltiwanger, B, M,, and Taraschi, T. F, (1998) J. Biol, Chem. 273, 17216-17220), In this investigation, we further characterized the interaction of the RIP gelonin with single stranded oligonucleotides and investigated its activity on double-stranded oligonucleotides. At physiological pH, zinc and p-mercaptoethanol stimulated the adenine DNA glycosylase activity of gelonin, Under these conditions, gelonin catalytically removed adenine from single-stranded DNA and, albeit to a lesser extent, from normal base pairs and mismatches in duplex DNA, Also unprecedented was the finding that activity on single-stranded and double-stranded oligonucleotides containing multiple adenines generated unstable products with several abasic sites, producing strand breakage and duplex melting respectively. The results from competition experiments suggested similar interactions between gelonin's DNA-binding domain and oligonucleotides with and without adenine. A reexamination of the classification of gelonin as a DNA glycosylase/AP lyase using the borohydride trapping assay revealed that gelonin was similar to the DNA glycosylase MutY: both enzymes are monofunctional glycosylases, which are trappable to their DNA substrates, The k(cat) for the removal of adenine from single-stranded DNA was close to the values observed with multisubstrate DNA glycosylases, suggesting that the activity of RIPs on DNA may be physiologically relevant.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University	Taraschi, TF (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, JAH 229,1020 Locust St, Philadelphia, PA 19107 USA.				NIAID NIH HHS [AI-41761] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041761] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAILLY V, 1988, NUCLEIC ACIDS RES, V16, P9489, DOI 10.1093/nar/16.20.9489; Barbieri L, 1998, MOL MICROBIOL, V29, P661, DOI 10.1046/j.1365-2958.1998.00911.x; Barbieri L, 1997, NUCLEIC ACIDS RES, V25, P518, DOI 10.1093/nar/25.3.518; Barbieri L, 1996, BIOCHEM J, V319, P507, DOI 10.1042/bj3190507; BARBIERI L, 1994, NATURE, V372, P624, DOI 10.1038/372624a0; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; Berdal KG, 1998, EMBO J, V17, P363, DOI 10.1093/emboj/17.2.363; BETTER M, 1994, J BIOL CHEM, V269, P9644; Bjelland S, 1996, FEBS LETT, V397, P127, DOI 10.1016/S0014-5793(96)01166-0; Brigotti M, 1996, BIOCHEM MOL BIOL INT, V40, P181; Chen XY, 1998, BIOCHEMISTRY-US, V37, P11605, DOI 10.1021/bi980990p; David SS, 1998, CHEM REV, V98, P1221, DOI 10.1021/cr980321h; Day PJ, 1998, EUR J BIOCHEM, V258, P540, DOI 10.1046/j.1432-1327.1998.2580540.x; DIANOV GL, 1991, MOL GEN GENET, V225, P448, DOI 10.1007/BF00261686; Glassner BJ, 1998, P NATL ACAD SCI USA, V95, P9997, DOI 10.1073/pnas.95.17.9997; Gluck A, 1996, BIOCHEM MOL BIOL INT, V39, P285; GOODHEAD DT, 1994, INT J RADIAT BIOL, V65, P7, DOI 10.1080/09553009414550021; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; HABUKA N, 1991, J BIOL CHEM, V266, P23558; Harrison L, 1999, J MOL BIOL, V290, P667, DOI 10.1006/jmbi.1999.2892; HELENE C, 1975, NUCLEIC ACIDS RES, V2, P961, DOI 10.1093/nar/2.6.961; HUANG QC, 1995, BIOCHEM J, V309, P285, DOI 10.1042/bj3090285; Ishchenko AA, 1999, J BIOMOL STRUCT DYN, V17, P301, DOI 10.1080/07391102.1999.10508363; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; Krokan HE, 1997, BIOCHEM J, V325, P1; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; McFail-Isom L, 1998, BIOCHEMISTRY-US, V37, P17105, DOI 10.1021/bi982201+; MCGRATH MS, 1989, P NATL ACAD SCI USA, V86, P2844, DOI 10.1073/pnas.86.8.2844; Nicolas E, 1997, FEBS LETT, V406, P162, DOI 10.1016/S0014-5793(97)00267-6; Nicolas E, 1998, J BIOL CHEM, V273, P17216, DOI 10.1074/jbc.273.27.17216; Nicolas E, 1997, BIOCHEM J, V327, P413, DOI 10.1042/bj3270413; Noll DM, 1999, BIOCHEMISTRY-US, V38, P6374, DOI 10.1021/bi990335x; PERENTESIS JP, 1992, BIOFACTORS, V3, P173; POVIRK LF, 1988, BIOCHEMISTRY-US, V27, P380; Putnam CD, 2000, NAT STRUCT BIOL, V7, P17, DOI 10.1038/71211; RAY T, 1995, ELECTROPHORESIS, V16, P888, DOI 10.1002/elps.11501601149; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TELTOW GJ, 1983, ANTIMICROB AGENTS CH, V23, P390, DOI 10.1128/AAC.23.3.390; Tumer NE, 1997, P NATL ACAD SCI USA, V94, P3866, DOI 10.1073/pnas.94.8.3866; Verdine GL, 1997, CHEM BIOL, V4, P329, DOI 10.1016/S1074-5521(97)90123-X; VESNAVER G, 1989, P NATL ACAD SCI USA, V86, P3614, DOI 10.1073/pnas.86.10.3614; Wang P, 1999, NUCLEIC ACIDS RES, V27, P1900, DOI 10.1093/nar/27.8.1900; Wang YX, 1999, CELL, V99, P433, DOI 10.1016/S0092-8674(00)81529-9; Waters TR, 1998, J BIOL CHEM, V273, P20007, DOI 10.1074/jbc.273.32.20007; Williams SD, 1998, NUCLEIC ACIDS RES, V26, P5123, DOI 10.1093/nar/26.22.5123; Williams SD, 1999, BIOCHEMISTRY-US, V38, P15417, DOI 10.1021/bi992013z; Wright PM, 1999, J BIOL CHEM, V274, P29011, DOI 10.1074/jbc.274.41.29011; Wyatt MD, 1999, BIOESSAYS, V21, P668, DOI 10.1002/(SICI)1521-1878(199908)21:8<668::AID-BIES6>3.3.CO;2-4; Zharkov DO, 1998, BIOCHEMISTRY-US, V37, P12384, DOI 10.1021/bi981066y	50	32	34	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31399	31406		10.1074/jbc.M004505200	http://dx.doi.org/10.1074/jbc.M004505200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906135	hybrid			2022-12-25	WOS:000089762700092
J	Nikolaishvili-Feinberg, N; Cordeiro-Stone, M				Nikolaishvili-Feinberg, N; Cordeiro-Stone, M			Discrimination between translesion synthesis and template switching during bypass replication of thymine dimers in duplex DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM VARIANT CELLS; IRRADIATED HUMAN-CELLS; XERODERMA-PIGMENTOSUM; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; MISMATCH REPAIR; N-2-ACETYLAMINOFLUORENE ADDUCTS; POSTREPLICATION REPAIR; METHYLATION ANALYSIS; PYRIMIDINE DIMER	The goal of this study was to determine whether bypass replication occurs by translesion synthesis or template switching (copy choice) when a duplex molecule carrying a single cis,syn-cyclobutane thymine dimer is replicated in vitro by human cell extracts. Circular heteroduplex DNA molecules were constructed to contain the SV40 origin of replication and a mismatch opposite to or nearby the dimer. Control molecules with only the mismatch were also prepared. Heteroduplexes were methylated at CpG islands and replicated in vitro (30 min). Following bisulfite treatment, the nascent DNA complementary to the dimer-containing template was distinguished from the other three strands by methylation-specific polymerase chain reaction. Cloning and sequencing of polymerase chain reaction products revealed that 80-98% carried the sequence predicted for translesion synthesis, with two adenines incorporated opposite the dimer. The fraction of clones with sequence predictive of template switching was reduced when extracts deficient in mismatch repair or nucleotide excision repair activities were used to replicate the heteroduplex molecules. These results support the conclusion that lesion bypass during in vitro replication of duplex DNA containing thymine dimers occurs by translesion synthesis.	Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Cordeiro-Stone, M (corresponding author), Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Lineberger Comprehens Canc Ctr, 517 Brinkhous Bullitt Bldg, Chapel Hill, NC 27599 USA.	uncmcs@med.unc.edu			NATIONAL CANCER INSTITUTE [R55CA055065, R01CA055065] Funding Source: NIH RePORTER; NCI NIH HHS [CA55065] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baynton K, 1998, MOL CELL BIOL, V18, P960, DOI 10.1128/MCB.18.2.960; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cleaver JE, 1995, METABOLIC MOL BASES, VIII, P4393; Cordeiro-Stone M, 1999, J MOL BIOL, V289, P1207, DOI 10.1006/jmbi.1999.2847; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; CORDEIROSTONE M, 1979, BIOPHYS J, V27, P287, DOI 10.1016/S0006-3495(79)85218-2; Cordonnier AM, 1999, MOL CELL BIOL, V19, P2206; Ensch-Simon I, 1998, BIOCHEMISTRY-US, V37, P8218, DOI 10.1021/bi972460j; FEIL R, 1994, NUCLEIC ACIDS RES, V22, P695, DOI 10.1093/nar/22.4.695; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P407; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; FUJIWARA Y, 1976, MUTAT RES, V37, P91, DOI 10.1016/0027-5107(76)90058-0; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Gibbs PEM, 2000, P NATL ACAD SCI USA, V97, P4186, DOI 10.1073/pnas.97.8.4186; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; KoffelSchwartz N, 1996, P NATL ACAD SCI USA, V93, P7805, DOI 10.1073/pnas.93.15.7805; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LEHMANN AR, 1972, J MOL BIOL, V66, P319, DOI 10.1016/0022-2836(72)90418-4; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; MAHER VM, 1976, NATURE, V261, P593, DOI 10.1038/261593a0; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; McDonald JP, 1997, GENETICS, V147, P1557; MENEGHINI R, 1981, BIOPHYS J, V33, P81, DOI 10.1016/S0006-3495(81)84873-4; MENEGHINI R, 1976, BIOCHIM BIOPHYS ACTA, V425, P428, DOI 10.1016/0005-2787(76)90007-1; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; MYHR BC, 1979, MUTAT RES, V62, P341, DOI 10.1016/0027-5107(79)90089-7; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; RAIZIS AM, 1995, ANAL BIOCHEM, V226, P161, DOI 10.1006/abio.1995.1204; RENBAUM P, 1990, NUCLEIC ACIDS RES, V18, P1145, DOI 10.1093/nar/18.5.1145; ROBERTS JD, 1988, P NATL ACAD SCI USA, V85, P7064, DOI 10.1073/pnas.85.19.7064; ROBERTS JD, 1993, METHODS MOL GENET, V2, P295; SHAY JW, 1992, EXP GERONTOL, V27, P477, DOI 10.1016/0531-5565(92)90003-I; Svoboda DL, 1995, P NATL ACAD SCI USA, V92, P11975, DOI 10.1073/pnas.92.26.11975; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; THOMAS DC, 1995, J BIOL CHEM, V270, P21226, DOI 10.1074/jbc.270.36.21226; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; THOMAS DC, 1994, P NATL ACAD SCI USA, V91, P7752, DOI 10.1073/pnas.91.16.7752; UMAR A, 1994, J BIOL CHEM, V269, P14367; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; WANG YC, 1991, P NATL ACAD SCI USA, V88, P7810, DOI 10.1073/pnas.88.17.7810; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; Washington MT, 2000, P NATL ACAD SCI USA, V97, P3094, DOI 10.1073/pnas.050491997; Washington MT, 1999, J BIOL CHEM, V274, P36835, DOI 10.1074/jbc.274.52.36835; WATERS HL, 1993, J INVEST DERMATOL, V101, P744, DOI 10.1111/1523-1747.ep12371686; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191	60	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30943	30950		10.1074/jbc.M005225200	http://dx.doi.org/10.1074/jbc.M005225200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10913440	Green Published, hybrid			2022-12-25	WOS:000089762700031
J	Smits, VAJ; Klompmaker, R; Vallenius, T; Rijksen, G; Makela, TP; Medema, RH				Smits, VAJ; Klompmaker, R; Vallenius, T; Rijksen, G; Makela, TP; Medema, RH			p21 Inhibits Thr(161) phosphorylation of Cdc2 to enforce the G(2) DNA damage checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CDK-ACTIVATING KINASE; CELL-CYCLE; NUCLEAR EXPORT; PROTEIN-KINASE; 2 POINTS; LOCALIZATION; MITOSIS; P53; 14-3-3-SIGMA	The cyclin-dependent kinase inhibitor p21 is required for a sustained G(2) arrest after activation of the DNA damage checkpoint. Here we have addressed the mechanism by which p21 can contribute to this arrest in G(2). We show that p21 blocks the activating phosphorylation of Cdc2 on Thr(161). p21 does not interfere with the dephosphorylation of two inhibitory phosphorylation sites on Cdc2, Thr(14) and Tyr(15), indicating that p21 targets a different event in Cdc2 activation as the well described DNA damage checkpoint pathway involving Chk1 and Cdc25C. Taken together our data show that a cell is equipped with at least two independent pathways to ensure efficient inhibition of Cdc2 activity in response to DNA damage, influencing both positive and negative regulatory phosphorylation events on Cdc2.	Univ Med Ctr Utrecht, Dept Hematol, Jordan Lab, NL-3508 GA Utrecht, Netherlands; Univ Helsinki, Haartman Inst, FIN-00014 Helsinki, Finland	Utrecht University; Utrecht University Medical Center; University of Helsinki	Medema, RH (corresponding author), Univ Med Ctr Utrecht, Jordan Lab, G03-647,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	R.H.Medema@lab.azu.nl	Medema, Rene H/E-2981-2013; Smits, Veronique A.J./R-2302-2019; makela, tomi/B-3734-2009; Medema, Rene H/G-5415-2011	Smits, Veronique A.J./0000-0002-9160-4525; makela, tomi/0000-0002-4869-8044; Medema, Rene/0000-0002-6754-0381				APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hitomi M, 1998, ONCOGENE, V17, P959, DOI 10.1038/sj.onc.1202005; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LI Y, 1994, ONCOGENE, V9, P2261; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Smits VAJ, 1999, FEBS LETT, V457, P23, DOI 10.1016/S0014-5793(99)01002-9; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Winters ZE, 1998, ONCOGENE, V17, P673, DOI 10.1038/sj.onc.1201991; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131	39	176	179	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30638	30643		10.1074/jbc.M005437200	http://dx.doi.org/10.1074/jbc.M005437200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10913154	hybrid			2022-12-25	WOS:000089577900099
J	Williams, LJS; Lyons, V; MacLeod, I; Rajan, V; Darlington, GJ; Poli, V; Seckl, JR; Chapman, KE				Williams, LJS; Lyons, V; MacLeod, I; Rajan, V; Darlington, GJ; Poli, V; Seckl, JR; Chapman, KE			C/EBP regulates hepatic transcription of 11 beta-hydroxysteroid dehydrogenase type 1 - A novel mechanism for cross-talk between the C/EBP and glucocorticoid signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT/ENHANCER-BINDING PROTEIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; RNA POLYMERASE-II; NF-KAPPA-B; MINERALOCORTICOID ACTION; TISSUE-DISTRIBUTION; GENE-TRANSCRIPTION; RAT HEPATOCYTES; KNOCKOUT MICE; EXPRESSION	Glucocorticoid action within individual cells is potently modulated by 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD), which, by interconverting active and inert glucocorticoids, determines steroid access to receptors. Type 1 11 beta-HSD (11 beta-HSD1) is highly expressed in liver where it regenerates glucocorticoids, thus amplifying their action and contributing to induction of glucocorticoid-responsive genes, most of which are also regulated by members of the C/EBP (CAAT/enhancer-binding protein) family of transcription factors. Here we demonstrate that C/EBP alpha is a potent activator of the 11 beta-HSD1 gene in hepatoma cells and that mice deficient in C/EBP alpha have reduced hepatic 11 beta-HSD1 expression. In contrast, C/EBP beta is a relatively weak activator of 11 beta- HSD1 transcription in hepatoma cells and attenuates C/EBP alpha induction, and mice that lack C/EBP beta have increased hepatic 11 beta-HSD1 mRNA. The 11 beta-HSD1 promoter (between -812 and +76) contains 10 C/EBP binding sites, and mutation of the promoter proximal sites decreases the C/EBP inducibility of the promoter. One site encompasses the transcription start, and both C/EBP alpha and C/EBP beta are present in complexes formed by liver nuclear proteins at this site. The regulation of 11 beta-HSD1 expression, and hence intracellular glucocorticoid levels, by members of the C/EBP family provides a novel mechanism for cross-talk between the C/EBP family of transcription factors and the glucocorticoid signaling pathway.	Univ Edinburgh, Western Gen Hosp, Mol Endocrinol Grp, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland; Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland	University of Edinburgh; Baylor College of Medicine; University of Dundee	Chapman, KE (corresponding author), Univ Edinburgh, Western Gen Hosp, Mol Endocrinol Grp, Mol Med Ctr, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.		Poli, Valeria/A-9215-2012; Seckl, Jonathan R/C-3555-2013	Poli, Valeria/0000-0002-3739-3966; Chapman, Karen/0000-0001-7777-6817				AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAKKER O, 1991, NUCLEIC ACIDS RES, V19, P1213, DOI 10.1093/nar/19.6.1213; BALMAIN A, 1982, NUCLEIC ACIDS RES, V10, P4259, DOI 10.1093/nar/10.14.4259; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Breed DR, 1997, ENDOCRINOLOGY, V138, P5527, DOI 10.1210/en.138.12.5527; Brown RW, 1996, BIOCHEM J, V313, P1007, DOI 10.1042/bj3131007; Cappelletti M, 1996, CELL DEATH DIFFER, V3, P29; Chapman KE, 1997, BIOCHEM SOC T, V25, P583, DOI 10.1042/bst0250583; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; Gotoh T, 1997, J BIOL CHEM, V272, P3694, DOI 10.1074/jbc.272.6.3694; Jamieson, 1997, Stress, V2, P123; Jamieson PM, 1999, J STEROID BIOCHEM, V68, P245, DOI 10.1016/S0960-0760(99)00037-0; Jamieson PM, 1999, J ENDOCRINOL, V160, P103, DOI 10.1677/joe.0.1600103; JAMIESON PM, 1995, ENDOCRINOLOGY, V136, P4754, DOI 10.1210/en.136.11.4754; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; Kotelevtsev Y, 1999, J CLIN INVEST, V103, P683, DOI 10.1172/JCI4445; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LOW SC, 1994, J MOL ENDOCRINOL, V13, P167, DOI 10.1677/jme.0.0130167; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; Matsuno F, 1996, J BIOCHEM-TOKYO, V119, P524; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MOISAN MP, 1992, MOL ENDOCRINOL, V6, P1082, DOI 10.1210/me.6.7.1082; Napolitano A, 1998, J STEROID BIOCHEM, V64, P251, DOI 10.1016/S0960-0760(97)00200-8; NYE JA, 1990, P NATL ACAD SCI USA, V87, P3992, DOI 10.1073/pnas.87.10.3992; PARK EA, 1993, J BIOL CHEM, V268, P613; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; RAJAN V, 1995, J STEROID BIOCHEM, V52, P141, DOI 10.1016/0960-0760(94)00159-J; Ramos RA, 1996, MOL CELL BIOL, V16, P5288; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Seckl JR, 1997, EUR J BIOCHEM, V249, P361, DOI 10.1111/j.1432-1033.1997.t01-1-00361.x; SIERRA F, 1993, GENE TRANSCRIPTION P, P125; Voice MW, 1996, BIOCHEM J, V317, P621, DOI 10.1042/bj3170621; WALKER BR, 1995, J CLIN ENDOCR METAB, V80, P3155, DOI 10.1210/jc.80.11.3155; WALKER BR, 1992, CLIN ENDOCRINOL, V37, P483, DOI 10.1111/j.1365-2265.1992.tb01478.x; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	53	100	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30232	30239		10.1074/jbc.M001286200	http://dx.doi.org/10.1074/jbc.M001286200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10906322	hybrid			2022-12-25	WOS:000089577900045
J	Epinat, JC; Dvorin, EL; Gilmore, TD				Epinat, JC; Dvorin, EL; Gilmore, TD			Envelope-dependent transactivation by the retroviral oncoprotein v-Rel is required for efficient malignant transformation of chicken spleen cells	ONCOGENE			English	Article						v-Rel; retroviral oncogene; transcription factor; malignant transformation; NF-kappa B; envelope sequences	VIRUS STRAIN-T; ONCOGENE; DOMAIN; ACTIVATION; SEQUENCES	The retroviral oncoprotein v-Rel is a chimeric protein that has 11 helper virus-derived Envelope (Env) amino acids (aa) at its N terminus. Within these N-terminal Env aa of v-Rel there are three aa substitutions compared to the Rev-A helper virus Env, These aa substitutions have previously been shown to impart a number of unique properties onto v-Rel, including increased transforming and transactivating ability. In this study, we have analysed the sequence requirements for the Env aa to influence several properties of v-Rel, Phe residues at aa 3 and 9 are critical for an N-terminal transactivation function of v-Rel, and the analysis of several Env mutants demonstrates that transactivation ability parallels the transforming ability of v-Rel, Substitutions of conservative aa, such as leucine and tyrosine, for Phe 3 and 9 are tolerated for transactivation in chicken embryo fibroblasts and for transformation of chicken spleen cells. In contrast, the substitution of 10 Phe residues at the N terminus of v-Rel does not enable transactivation, indicating that a distinct structure surrounding Phe-3 and Phe-9 is essential for v-Rel function. We also show that the addition of the v-Rel Env aa to the N terminus of human c-Rel can enable it to activate transcription. Taken together, these results indicate that Phe residues at positions 3 and 9 have been selected for their ability to enhance the oncogenicity of v-Rel by increasing its ability to activate transcription.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.			Dvorin, Evan/0000-0001-5037-2783	NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHAT GV, 1990, ONCOGENE, V5, P625; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Chen CL, 1999, MOL CELL BIOL, V19, P307; Epinat JC, 2000, ONCOGENE, V19, P599, DOI 10.1038/sj.onc.1203376; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KEWALRAMANI VN, 1992, J VIROL, V66, P3026, DOI 10.1128/JVI.66.5.3026-3031.1992; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; Sambrook J., 2002, MOL CLONING LAB MANU; SARKAR S, 1993, ONCOGENE, V8, P2245; SMARDOVA J, 1995, ONCOGENE, V10, P2017; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	16	3	3	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 29	2000	19	28					3131	3137		10.1038/sj.onc.1203651	http://dx.doi.org/10.1038/sj.onc.1203651			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918567				2022-12-25	WOS:000088019200001
J	Leethanakul, C; Patel, V; Gillespie, J; Pallente, M; Ensley, JF; Koontongkaew, S; Liotta, LA; Emmert-Buck, M; Gutkind, JS				Leethanakul, C; Patel, V; Gillespie, J; Pallente, M; Ensley, JF; Koontongkaew, S; Liotta, LA; Emmert-Buck, M; Gutkind, JS			Distinct pattern of expression of differentiation and growth-related genes in squamous cell carcinomas of the head and neck revealed by the use of laser capture microdissection and cDNA arrays	ONCOGENE			English	Article						oral cancel; tumor progression; oncogenes; tumor suppressor genes; biomarkers	APOPTOSIS; DISEASE; CANCER	Although risk factors for squamous cell carcinomas of the head and neck (HNSCC) are well recognized, very little is known about the molecular mechanisms responsible for this malignancy. Furthermore, the ability to investigate gene expression profiles at different stages of tumor progression is usually limited by the remarkable heterogeneity of these neoplastic lesions. Here, we show the successful use of laser capture microdissection (LCM) to procure specific cell populations. The 5000 cells from representative sets of HNSCC and their matching normal tissues are sufficient to extract RNA of high integrity for the synthesis of labeled amplified cDNA probes which can then be hybridized to these membranes arrayed with known human cancer-related cDNAs. Furthermore, when compared to normal tissues, we demonstrate a consistent decrease in expression of differentiation markers such as cytokeratins, and an increase in the expression of a number of signal transducing and cell cycle regulatory molecules, as well as growth and angiogenic factors and tissue degrading proteases. Unexpectedly, we also found that most HNSCC overexpress members of the wnt and notch growth and differentiation regulatory system, thus suggesting that the,wnt and notch pathways mag contribute in squamous cell carcinogenesis. This experimental approach may facilitate the identification candidate markers for the early detection of preneoplastic lesions, as well as novel targets for pharmacological intervention in this disease.	Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; Wayne State Univ, Div Hematol Oncol, Detroit, MI USA; Prince Songkla Univ, Fac Dent, Dept Oral Biol & Occlus, Hat Yai, Thailand	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Wayne State University; Prince of Songkla University	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Bldg 30,Room 212, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BARTKOVA J, 1995, CANCER RES, V55, P949; Desai SB, 1999, J IMMUNOTHER, V22, P186, DOI 10.1097/00002371-199905000-00002; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Granville DJ, 1998, LAB INVEST, V78, P893; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Liu YL, 1996, GENOMICS, V31, P58, DOI 10.1006/geno.1996.0009; Mao EJ, 1998, J ORAL PATHOL MED, V27, P297; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33; Peterson LA, 1998, CANCER RES, V58, P5326; Shelly LL, 1999, J CELL BIOCHEM, V73, P164, DOI 10.1002/(SICI)1097-4644(19990501)73:2<164::AID-JCB3>3.0.CO;2-0; Simone NL, 1998, TRENDS GENET, V14, P272, DOI 10.1016/S0168-9525(98)01489-9; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59	15	238	271	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3220	3224		10.1038/sj.onc.1203703	http://dx.doi.org/10.1038/sj.onc.1203703			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918578				2022-12-25	WOS:000088019200012
J	George, SJ; Allen, JWA; Ferguson, SJ; Thorneley, RNF				George, SJ; Allen, JWA; Ferguson, SJ; Thorneley, RNF			Time-resolved infrared spectroscopy reveals a stable ferric heme-NO intermediate in the reaction of Paracoccus pantotrophus cytochrome cd(1) nitrite reductase with nitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOSPHAERA-PANTOTROPHA; DISSIMILATORY NITRITE; STOPPED-FLOW; PSEUDOMONAS-STUTZERI; ELECTRON-TRANSFER; OXIDE; BINDING; CYCLE; RECONSTITUTION; DENITRIFICANS	Cytochrome cd(1) is a respiratory enzyme that catalyzes the physiological one-electron reduction of nitrite to nitric oxide. The enzyme is a dimer, each monomer containing one c-type cytochrome center and one active site d(1) heme, We present stopped-flow Fourier transform infrared data showing the formation of a stable ferric heme d(1)-NO complex (formally d(1)Fe(II)-NO+) as a product of the reaction between fully reduced Paracoccus pantotrophus cytochrome ed, and nitrite, in the absence of excess reductant, The Fe-(NO)-N-14 nu>(*) over bar * (NO) stretching mode is observed at 1913 cm(-1) with the corresponding Fe-(NO)-N-15 band at 1876 cm(-1). This d(1) heme-NO complex is still readily observed after 15 min. EPR and visible absorption spectroscopic data show that within 4 ms of the initiation of the reaction, nitrite is reduced at the d(1) heme, and a cFe(III) d(1)Fe(II)-NO complex is formed. Over the next 100 ms there is an electron redistribution within the enzyme to give a mixed species, 55% cFe(III) d(1)Fe(II)-NO and 45% cFe(II) d(1)Fe(II)-NO+. No kinetically competent release of NO could be detected, indicating that at least one additional factor is required for product release by the enzyme. Implications for the mechanism of P. pantotrophus cytochrome cd(1) are discussed.	John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Oxford	Thorneley, RNF (corresponding author), John Innes Ctr Plant Sci Res, Dept Biol Chem, Colney Lane, Norwich NR4 7UH, Norfolk, England.			George, Simon/0000-0002-4864-5479				Allen JWA, 2000, NAT STRUCT BIOL, V7, P885; Averill BA, 1996, CHEM REV, V96, P2951, DOI 10.1021/cr950056p; Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; BRAY R C, 1973, Biochemical Society Transactions, V1, P1067; Cheesman MR, 1997, BIOCHEMISTRY-US, V36, P16267, DOI 10.1021/bi971677a; Cutruzzola F, 1999, BBA-BIOENERGETICS, V1411, P231, DOI 10.1016/S0005-2728(99)00017-1; Ding XD, 1999, J AM CHEM SOC, V121, P128, DOI 10.1021/ja982979i; Ferguson SJ, 1998, CURR OPIN CHEM BIOL, V2, P182, DOI 10.1016/S1367-5931(98)80059-8; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; GARBER EAE, 1982, J BIOL CHEM, V257, P8091; George SJ, 1997, J AM CHEM SOC, V119, P6450, DOI 10.1021/ja971088s; HILL KE, 1978, J BIOL CHEM, V253, P489; JOHNSON MK, 1980, BIOCHEM J, V189, P285, DOI 10.1042/bj1890285; Kobayashi K, 1997, BIOCHEMISTRY-US, V36, P13611, DOI 10.1021/bi971045o; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4028, DOI 10.1021/bi991912k; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4243, DOI 10.1021/bi000192a; KOPPENHOFER A, 1998, THESIS U OXFORD; MOIR JWB, 1993, EUR J BIOCHEM, V212, P377, DOI 10.1111/j.1432-1033.1993.tb17672.x; OZAWA S, 1995, INORG CHEM, V34, P6362, DOI 10.1021/ic00129a022; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; PARR SR, 1977, BIOCHEM J, V167, P447, DOI 10.1042/bj1670447; Rainey FA, 1999, INT J SYST BACTERIOL, V49, P645, DOI 10.1099/00207713-49-2-645; Richardson DJ, 1999, CURR OPIN CHEM BIOL, V3, P207, DOI 10.1016/S1367-5931(99)80034-9; Scheidt WR, 1999, ACCOUNTS CHEM RES, V32, P350, DOI 10.1021/ar9700116; SILVESTRINI MC, 1982, BIOCHEM J, V203, P445, DOI 10.1042/bj2030445; SILVESTRINI MC, 1990, J BIOL CHEM, V265, P11783; SINGH J, 1973, BIOCHIM BIOPHYS ACTA, V333, P28; Thorneley RNF, 2000, PROKARYOTIC NITROGEN FIXATION, P81; TIMKOVICH R, 1982, ARCH BIOCHEM BIOPHYS, V215, P47, DOI 10.1016/0003-9861(82)90277-6; Wang YN, 1996, J AM CHEM SOC, V118, P3972, DOI 10.1021/ja9538647; WEEGAERSSENS E, 1991, J BIOL CHEM, V266, P7496; WHITE AJ, 1995, BIOCHEM J, V306, P843, DOI 10.1042/bj3060843; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; WILLIAMS PA, 1995, NAT STRUCT BIOL, V2, P975, DOI 10.1038/nsb1195-975; WU WS, 1987, J AM CHEM SOC, V109, P3149, DOI 10.1021/ja00244a050; YAMANAKA T, 1963, BIOCHEM Z, V338, P62; YU NT, 1986, METHOD ENZYMOL, V130, P350; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	38	59	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33231	33237		10.1074/jbc.M005033200	http://dx.doi.org/10.1074/jbc.M005033200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10922371	hybrid			2022-12-25	WOS:000090104600010
J	Homori, K; Miyata, T; DiRuggiero, J; Holley-Shanks, R; Hayashi, I; Cann, IKO; Mayanagi, K; Shinagawa, H; Ishino, Y				Homori, K; Miyata, T; DiRuggiero, J; Holley-Shanks, R; Hayashi, I; Cann, IKO; Mayanagi, K; Shinagawa, H; Ishino, Y			Both RadA and RadB are involved in homologous recombination in Pyrococcus furiosus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; DNA STRAND EXCHANGE; HYPERTHERMOPHILIC ARCHAEON; ESCHERICHIA-COLI; RECA PROTEIN; ATP HYDROLYSIS; IN-VITRO; SACCHAROMYCES-CEREVISIAE; GLUTAMATE-DEHYDROGENASE; BREAK REPAIR	RecA and Rad51 proteins are essential for homologous recombination in Bacteria and Eukarya, respectively. Homologous proteins, called RadA, have been described for Archaea, Here we present the characterization of two RecA/Rad51 family proteins, RadA and RadB, from Pyrococcus furiosus, The radA and radB genes mere not induced by DNA damage resulting from exposure of the cells to gamma and UV irradiation and heat shock, suggesting that they might be constitutively expressed in this hyperthermophile, RadA had DNA-dependent ATPase, D-loop formation, and strand exchange activities. In contrast, RadB had a very weak ATPase activity that is not stimulated by DNA. This protein had a strong binding affinity for DNA, but little strand exchange activity could be detected. A direct interaction between RadA and RadB was detected by an immunoprecipitation assay. Moreover, RadB, but not RadA, coprecipitated with Ajc, a Holliday junction resolvase found in P, furiosus, in the absence of ATP, This interaction was suppressed in the presence of ATP, The Holliday junction cleavage activity of Hjc was inhibited by RadB in the absence, but not in the presence, of ATP, These results suggest that RadB has important roles in homologous recombination in Archaea and may regulate the cleavage reactions of the branch-structured DNA.	Biomol Engn Res Inst, Dept Mol Biol, Suita, Osaka 5650874, Japan; Biomol Engn Res Inst, Dept Biol Struct, Suita, Osaka 5650874, Japan; Univ Maryland, Inst Biotechnol, Ctr Marine Biotechnol, Baltimore, MD 21202 USA; Osaka Univ, Dept Mol Microbiol, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan	University System of Maryland; University of Maryland Baltimore; Osaka University	Ishino, Y (corresponding author), Biomol Engn Res Inst, Dept Mol Biol, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.	ishino@beri.co.jp						BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; BIANCO PR, 1998, FRONT BIOSCI, V8, P570; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Davies AA, 1998, CURR BIOL, V8, P725, DOI 10.1016/S0960-9822(98)70282-9; DEHENESTROSA ARF, 1991, MOL GEN GENET, V226, P503, DOI 10.1007/BF00260664; DIRUGGIERO J, 1995, APPL ENVIRON MICROB, V61, P159, DOI 10.1128/AEM.61.1.159-164.1995; DiRuggiero J, 1999, J MOL EVOL, V49, P474, DOI 10.1007/PL00006570; DiRuggiero J, 1998, NEW DEVELOPMENTS IN MARINE BIOTECHNOLOGY, P193; DiRuggiero J, 1997, J BACTERIOL, V179, P4643, DOI 10.1128/jb.179.14.4643-4645.1997; Diruggiero Jocelyne, 1995, P97; DONOVAN JW, 1994, GENE DEV, V8, P2552, DOI 10.1101/gad.8.21.2552; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Hayashi I, 1999, NUCLEIC ACIDS RES, V27, P4695, DOI 10.1093/nar/27.24.4695; HOLDEN JF, 1993, J BACTERIOL, V175, P2839, DOI 10.1128/JB.175.10.2839-2843.1993; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; Karthikeyan G., 1999, Journal of Molecular Microbiology and Biotechnology, V1, P149; Katagiri T, 1998, GENE CHROMOSOME CANC, V21, P217, DOI 10.1002/(SICI)1098-2264(199803)21:3<217::AID-GCC5>3.0.CO;2-2; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Kil YV, 2000, J BACTERIOL, V182, P130, DOI 10.1128/JB.182.1.130-134.2000; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; Komori K, 1999, NUCLEIC ACIDS RES, V27, P4167, DOI 10.1093/nar/27.21.4167; Komori K, 1999, P NATL ACAD SCI USA, V96, P8873, DOI 10.1073/pnas.96.16.8873; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; LAUDER SD, 1991, J BIOL CHEM, V266, P5450; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Masson JY, 1999, EMBO J, V18, P6552, DOI 10.1093/emboj/18.22.6552; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; MORIMATSU K, 1995, EUR J BIOCHEM, V228, P779, DOI 10.1111/j.1432-1033.1995.0779m.x; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Olsen GJ, 1997, CELL, V89, P991, DOI 10.1016/S0092-8674(00)80284-6; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Radman M., 1975, MOL MECHANISMS REPAI, P355; Rashid N, 1996, MOL GEN GENET, V253, P397, DOI 10.1007/s004380050337; ROBB FT, 1992, BIOCHIM BIOPHYS ACTA, V1120, P267, DOI 10.1016/0167-4838(92)90247-B; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; ROSSELLI W, 1990, J MOL BIOL, V216, P335, DOI 10.1016/S0022-2836(05)80325-0; Sandler SJ, 1999, J BACTERIOL, V181, P907, DOI 10.1128/JB.181.3.907-915.1999; Sandler SJ, 1996, NUCLEIC ACIDS RES, V24, P2125, DOI 10.1093/nar/24.11.2125; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Seitz EM, 1998, GENE DEV, V12, P1248, DOI 10.1101/gad.12.9.1248; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Spies M, 2000, EUR J BIOCHEM, V267, P1125, DOI 10.1046/j.1432-1327.2000.01108.x; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; TRENT JD, 1994, J BACTERIOL, V176, P6148, DOI 10.1128/jb.176.19.6148-6152.1994; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; Uemori T, 1997, GENES CELLS, V2, P499, DOI 10.1046/j.1365-2443.1997.1380336.x; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Woods WG, 1997, MOL MICROBIOL, V23, P791, DOI 10.1046/j.1365-2958.1997.2651626.x	72	21	29	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33782	33790						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10903318				2022-12-25	WOS:000090104600084
J	Reiter, CD; Teng, RJ; Beckman, JS				Reiter, CD; Teng, RJ; Beckman, JS			Superoxide reacts with nitric oxide to nitrate tyrosine at physiological pH via peroxynitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; AMYOTROPHIC-LATERAL-SCLEROSIS; PROSTACYCLIN SYNTHASE; OXIDATIVE DAMAGE; URIC-ACID; HYDROGEN-PEROXIDE; NITROGEN-DIOXIDE; SOLID ARGON; INACTIVATION; DISMUTASE	Tyrosine nitration is a widely used marker of peroxynitrite (ONOO-) produced from the reaction of nitric oxide with superoxide. Pfeiffer and Mayer (Pfeiffer, S., and Mayer, B, (1998) J. Biol; Chem, 273, 27280-27285) reported that superoxide produced from hypoxanthine plus xanthine oxidase in combination with nitric oxide produced from spermine NONOate did not nitrate tyrosine at neutral pH, They suggested that nitric oxide and superoxide at neutral pH form a less reactive intermediate distinct from preformed alkaline peroxynitrite that does not nitrate tyrosine, Using a stopped-flow spectrophotometer to rapidly mix potassium superoxide with nitric oxide at pH 7.4, we report that an intermediate spectrally and kinetically identical to preformed alkaline cis-peroxynitrite was formed in 100% yield. Furthermore, this intermediate nitrated tyrosine in the same yield and at the same rate as preformed peroxynitrite. Equivalent concentrations of nitric oxide under aerobic conditions in the absence of superoxide did not produce detectable concentrations of nitrotyrosine. Carbon dioxide increased the efficiency of nitration by nitric oxide plus superoxide to the same extent as peroxynitrite, In experiments using xanthine oxidase as a source of superoxide, tyrosine nitration was substantially inhibited by urate formed from hypoxanthine oxidation, which was sufficient to account for the lack of tyrosine nitration previously reported. We conclude that peroxynitrite formed from the reaction of nitric oxide with superoxide at physiological pH remains an important species responsible for tyrosine nitration in vivo.	Univ Alabama, Dept Anesthesiol, Ctr Free Radical Biol, Birmingham, AL 35233 USA; Univ Alabama, Dept Biochem & Mol Genet, Ctr Free Radical Biol, Birmingham, AL 35233 USA; Univ Alabama, Dept Pediat, Ctr Free Radical Biol, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Beckman, JS (corresponding author), Univ Alabama, Dept Anesthesiol, Ctr Free Radical Biol, Birmingham, AL 35233 USA.							AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; Ara J, 1998, P NATL ACAD SCI USA, V95, P7659, DOI 10.1073/pnas.95.13.7659; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; Beckman JS, 1996, METHODS NITRIC OXIDE, P61; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BOHLE DS, 1994, J AM CHEM SOC, V116, P7423, DOI 10.1021/ja00095a062; BRUNELLI L, 1995, ARCH BIOCHEM BIOPHYS, V316, P327, DOI 10.1006/abbi.1995.1044; BUTLER J, 1982, J BIOL CHEM, V257, P747; CELIO XC, 1999, ARCH BIOCHEM BIOPHYS, V372, P285; Crow JP, 1997, J NEUROCHEM, V69, P1945; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; Daiber A, 1998, NITRIC OXIDE-BIOL CH, V2, P259, DOI 10.1006/niox.1998.0186; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; Estevez AG, 1998, J NEUROSCI, V18, P923; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Estevez AG, 2000, FREE RADICAL BIO MED, V28, P437, DOI 10.1016/S0891-5849(99)00261-0; Estevez AG, 1998, J NEUROSCI, V18, P3708; Ferrante RJ, 1997, ANN NEUROL, V42, P326, DOI 10.1002/ana.410420309; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; Fukuyama N, 1997, FREE RADICAL BIO MED, V22, P771, DOI 10.1016/S0891-5849(96)00401-7; Goldstein S, 2000, J BIOL CHEM, V275, P3031, DOI 10.1074/jbc.275.5.3031; HADDAD IY, 1994, AM J PHYSIOL, V267, pL242, DOI 10.1152/ajplung.1994.267.3.L242; HADDAD IY, 1993, AM J PHYSIOL, V265, P555; Hooper DC, 1998, P NATL ACAD SCI USA, V95, P675, DOI 10.1073/pnas.95.2.675; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; Kelm M, 1997, J BIOL CHEM, V272, P9922; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; Klebl BM, 1998, FEBS LETT, V422, P381, DOI 10.1016/S0014-5793(98)00053-2; Kooy NW, 1997, CRIT CARE MED, V25, P812, DOI 10.1097/00003246-199705000-00017; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250; Koppenol WH, 1996, METHOD ENZYMOL, V269, P296; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KRAUSS M, 1994, CHEM PHYS LETT, V222, P513, DOI 10.1016/0009-2614(94)00381-5; LO WJ, 1995, CHEM PHYS LETT, V242, P147, DOI 10.1016/0009-2614(95)00702-6; LO WJ, 1995, J CHEM PHYS, V103, P4026, DOI 10.1063/1.469588; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; Mehl M, 1999, NITRIC OXIDE-BIOL CH, V3, P142, DOI 10.1006/niox.1999.0217; MILLER MJS, 1995, GASTROENTEROLOGY, V109, P1475, DOI 10.1016/0016-5085(95)90633-9; PACE MD, 1993, FREE RADICAL BIO MED, V15, P337, DOI 10.1016/0891-5849(93)90080-E; Pfeiffer S, 2000, J BIOL CHEM, V275, P6346, DOI 10.1074/jbc.275.9.6346; Pfeiffer S, 1998, J BIOL CHEM, V273, P27280, DOI 10.1074/jbc.273.42.27280; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; PRYOR WA, 1995, FREE RADICAL BIO MED, V18, P75, DOI 10.1016/0891-5849(94)00105-S; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; Sawa T, 2000, J BIOL CHEM, V275, P32467, DOI 10.1074/jbc.M910169199; Shin JT, 1996, ARCH BIOCHEM BIOPHYS, V335, P32, DOI 10.1006/abbi.1996.0479; Skinner KA, 1998, J BIOL CHEM, V273, P24491, DOI 10.1074/jbc.273.38.24491; Skinner KA, 1997, ARCH BIOCHEM BIOPHYS, V342, P282, DOI 10.1006/abbi.1997.0114; Smith MA, 1997, J NEUROSCI, V17, P2653; Souza JM, 1999, ARCH BIOCHEM BIOPHYS, V371, P169, DOI 10.1006/abbi.1999.1480; Strong MJ, 1998, BIOCHEM BIOPH RES CO, V248, P157, DOI 10.1006/bbrc.1998.8930; Tsai HH, 1996, J PHYS CHEM-US, V100, P15087, DOI 10.1021/jp961091i; TSAI JHM, 1994, J AM CHEM SOC, V116, P4115, DOI 10.1021/ja00088a072; TSAI JHM, 1994, THESIS U ALABAMA BIR; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; Viner RI, 1996, FEBS LETT, V379, P286, DOI 10.1016/0014-5793(95)01530-2; Viner RI, 1996, FREE RADICAL RES, V24, P243, DOI 10.3109/10715769609088022; Worle M, 1999, CHEM RES TOXICOL, V12, P305, DOI 10.1021/tx990013u; Yamakura F, 1998, J BIOL CHEM, V273, P14085, DOI 10.1074/jbc.273.23.14085; Zou MH, 1998, BIOCHEM J, V336, P507, DOI 10.1042/bj3360507; Zou MH, 1996, FEBS LETT, V382, P101, DOI 10.1016/0014-5793(96)00160-3; Zou MH, 1997, BIOL CHEM, V378, P707, DOI 10.1515/bchm.1997.378.7.707	70	325	335	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32460	32466		10.1074/jbc.M910433199	http://dx.doi.org/10.1074/jbc.M910433199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10906340	hybrid			2022-12-25	WOS:000090003800013
J	Wang, N; Silver, DL; Costet, P; Tall, AR				Wang, N; Silver, DL; Costet, P; Tall, AR			Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; SCAVENGER RECEPTOR BI; CORONARY HEART-DISEASE; KNOCK-OUT MICE; TANGIER-DISEASE; CELLULAR CHOLESTEROL; CASSETTE TRANSPORTER-1; SR-BI; ATHEROSCLEROTIC LESIONS	Mutations of the ABC1 transporter have been identified as the defect in Tangier disease, characterized by low HDL and cholesterol ester accumulation in macrophages. A full-length mouse ABC1 cDNA was used to investigate the mechanisms of lipid efflux to apoA-I or HDL in transfected 293 cells, ABC1 expression markedly increased cellular cholesterol and phospholipid efflux to apoA-I but had only minor effects on lipid efflux to HDL. The increased lipid efflux appears to involve a direct interaction between apoA-I and ABC1, because ABC1 expression substantially increased apoA-I binding at the cell, surface, and chemical cross-linking and immunoprecipitation analysis showed that apoA-I binds directly to ABC1. In contrast to scavenger receptor BI (SR-BI), another cell surface molecule capable of facilitating cholesterol efflux, ABC1 preferentially bound lipid-free apoA-I but not HDL, Immunofluorescence confocal microscopy showed that ABC1 is primarily localized on the cell surface. In the absence of apoA-I, cells overexpressing ABC1 displayed a distinctive morphology, characterized by plasma membrane protrusions and resembling echinocytes that form when there are excess lipids in the outer membrane hemileaflet, The studies provide evidence for a direct interaction between ABC1 and apoA-I, but not HDL, indicating that free apoA-I is the metabolic substrate for ABC1, Plasma membrane ABC1 may act as a phospholipid/cholesterol flippase, providing lipid to bound apoA-I, or to the outer membrane hemileaflet.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA	Columbia University	Wang, N (corresponding author), Columbia Univ, Dept Med, Div Mol Med, 630 W 168th St, New York, NY 10032 USA.		costet, philippe/A-5314-2010; Tall, Alan/AAT-8528-2021	Silver, David/0000-0002-7289-9890	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056984, R01HL022682, R37HL022682] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56984, HL22682] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; Arai T, 1999, P NATL ACAD SCI USA, V96, P12050, DOI 10.1073/pnas.96.21.12050; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BOVET P, 1989, ATHEROSCLEROSIS, V80, P41, DOI 10.1016/0021-9150(89)90066-X; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; Chinetti G, 2000, CIRCULATION, V101, P2411, DOI 10.1161/01.CIR.101.20.2411; Connors TD, 1997, GENOMICS, V39, P231, DOI 10.1006/geno.1996.4500; Costet P, 2000, J BIOL CHEM, V275, P28240; Croop JM, 1998, METHOD ENZYMOL, V292, P101; Duverger N, 1996, SCIENCE, V273, P966, DOI 10.1126/science.273.5277.966; FERRELL JE, 1985, BIOCHEMISTRY-US, V24, P2849, DOI 10.1021/bi00333a006; FIELDING CJ, 2000, BIOCH CELL BIOL, V271, P451; Fournier N, 2000, ARTERIOSCL THROM VAS, V20, P1283, DOI 10.1161/01.ATV.20.5.1283; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; HAYEK T, 1995, J CLIN INVEST, V96, P2071, DOI 10.1172/JCI118255; Hirano K, 1999, CIRC RES, V85, P108; ISHIDA BY, 1987, J LIPID RES, V28, P778; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SCHAEFER EJ, 1980, ANN INTERN MED, V93, P261, DOI 10.7326/0003-4819-93-2-261; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SUNE A, 1988, BIOCHEMISTRY-US, V27, P6794, DOI 10.1021/bi00418a022; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; WALTER M, 1994, BIOCHEM BIOPH RES CO, V205, P850, DOI 10.1006/bbrc.1994.2742; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200; Xu SZ, 1997, J LIPID RES, V38, P1289	47	488	506	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33053	33058		10.1074/jbc.M005438200	http://dx.doi.org/10.1074/jbc.M005438200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10918065	hybrid			2022-12-25	WOS:000090003800092
J	Wariishi, H; Nonaka, D; Johjima, T; Nakamura, N; Naruta, Y; Kubo, S; Fukuyama, K				Wariishi, H; Nonaka, D; Johjima, T; Nakamura, N; Naruta, Y; Kubo, S; Fukuyama, K			Direct binding of hydroxylamine to the heme iron of Arthromyces ramosus peroxidase - Substrate analogue that inhibits compound I formation in a competitive manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPRINUS-CINEREUS PEROXIDASE; AROMATIC DONOR MOLECULES; BASIDIOMYCETE PHANEROCHAETE-CHRYSOSPORIUM; RAY CRYSTALLOGRAPHIC ANALYSIS; NUCLEAR MAGNETIC-RESONANCE; HORSERADISH-PEROXIDASE; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; LIGNIN PEROXIDASE; HYDROGEN-PEROXIDE	The interaction of hydroxylamine (HA) with Arthromyces ramosus peroxidase (ARP) was investigated by kinetic, spectroscopic, and x-ray crystallographic techniques. HA inhibited the reaction of native ARP with H2O2 in a competitive manner. Electron absorption and resonance Raman spectroscopic studies indicated that pentacoordinate high spin species of native ARP are converted to hexacoordinate low spin species upon the addition of HA, strongly suggesting the occurrence of a direct interaction of HA with ARP heme iron. Kinetic analysis exhibited that the apparent dissociation constant is 6.2 mM at pH 7.0 and that only one HA molecule likely binds to the vicinity of the heme. pH dependence of HA binding suggested that the nitrogen atom of HA could be involved in the interaction with the heme iron. X-ray crystallographic analysis of ARP in complex with HA at 2.0 Angstrom resolution revealed that the electron density ascribed to HA is located in the distal pocket between the heme iron and the distal His(56). HA seems to directly interact with the heme iron but is too far away to interact with Arg(52). In HA, it is likely that the nitrogen atom is coordinated to the heme iron and that hydroxyl group is hydrogen bonded to the distal His(56).	Osaka Univ, Grad Sch Sci, Dept Biol, Toyonaka, Osaka 5600043, Japan; Kyushu Univ, Dept Forest Prod, Fukuoka 8128581, Japan; Kyushu Univ, Inst Fundamental Res Organ Chem, Fukuoka 8128581, Japan	Osaka University; Kyushu University; Kyushu University	Fukuyama, K (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol, Toyonaka, Osaka 5600043, Japan.		Nakamura, Nobuhumi/C-1972-2013	Nakamura, Nobuhumi/0000-0002-5373-2972				Abelskov AK, 1997, BIOCHEMISTRY-US, V36, P9453, DOI 10.1021/bi970387r; AKIMOTO K, 1990, ANAL BIOCHEM, V189, P182, DOI 10.1016/0003-2697(90)90104-H; ANDERSEN MB, 1991, ACTA CHEM SCAND, V45, P1080, DOI 10.3891/acta.chem.scand.45-1080; ATOR MA, 1987, J BIOL CHEM, V262, P1542; BAEK HK, 1989, BIOCHEMISTRY-US, V28, P5714, DOI 10.1021/bi00440a003; BAEK HK, 1992, J AM CHEM SOC, V114, P718, DOI 10.1021/ja00028a046; Berg R, 1940, BER DTSCH CHEM GES, V73, P172, DOI 10.1002/cber.19400730303; BRUNGER AT, 1992, XPLOR VERSION 3 0; Davey CA, 1996, BIOCHEMISTRY-US, V35, P10967, DOI 10.1021/bi960577m; DEPILLIS GD, 1989, BIOCHEMISTRY-US, V28, P7947, DOI 10.1021/bi00445a059; Doyle WA, 1998, BIOCHEMISTRY-US, V37, P15097, DOI 10.1021/bi981633h; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FREAR DS, 1955, ANAL CHEM, V27, P1664, DOI 10.1021/ac60106a054; Fukuyama K, 1997, J BIOL CHEM, V272, P5752, DOI 10.1074/jbc.272.9.5752; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; GOLD MH, 1989, ACS SYM SER, V389, P127; Henriksen A, 1999, J BIOL CHEM, V274, P35005, DOI 10.1074/jbc.274.49.35005; Henriksen A, 1998, J BIOL CHEM, V273, P2241, DOI 10.1074/jbc.273.4.2241; Henriksen A, 1998, BIOCHEMISTRY-US, V37, P8054, DOI 10.1021/bi980234j; HIGASHI T, 1990, PROCESS PROGRAM INDE; Ignatenko V. E., 1994, Proceedings of the Third International Symposium on Corrosion and Reliability of Electronic Materials and Devices, P392; Itakura H, 1997, FEBS LETT, V412, P107, DOI 10.1016/S0014-5793(97)00751-5; Johjima T, 1999, P NATL ACAD SCI USA, V96, P1989, DOI 10.1073/pnas.96.5.1989; KJALKE M, 1992, BIOCHIM BIOPHYS ACTA, V1120, P248, DOI 10.1016/0167-4838(92)90244-8; KUNISHIMA N, 1993, PROTEINS, V15, P216, DOI 10.1002/prot.340150213; Kunishima N, 1996, FEBS LETT, V378, P291, DOI 10.1016/0014-5793(95)01458-6; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; LAMAR GN, 1995, J AM CHEM SOC, V117, P411, DOI 10.1021/ja00106a047; MORISHIMA I, 1979, J BIOL CHEM, V254, P2814; Ozaki S, 1998, J AM CHEM SOC, V120, P8020, DOI 10.1021/ja9714696; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4331, DOI 10.1021/bi00013a023; PIONTEK K, 1993, FEBS LETT, V315, P119, DOI 10.1016/0014-5793(93)81146-Q; POULOS TL, 1993, J BIOL CHEM, V268, P4429; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SAKURADA J, 1986, J BIOL CHEM, V261, P9657; SCHONBAUM GR, 1973, J BIOL CHEM, V248, P502; Schuller DJ, 1996, STRUCTURE, V4, P311, DOI 10.1016/S0969-2126(96)00035-4; SHINMEN Y, 1986, AGR BIOL CHEM TOKYO, V50, P247, DOI 10.1080/00021369.1986.10867369; SMITH AT, 1992, EUR J BIOCHEM, V207, P507, DOI 10.1111/j.1432-1033.1992.tb17077.x; Smulevich G, 1996, BIOCHEMISTRY-US, V35, P10576, DOI 10.1021/bi9605898; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; Tsukamoto K, 1999, BIOCHEMISTRY-US, V38, P12558, DOI 10.1021/bi982925l; WARIISHI H, 1992, J BIOL CHEM, V267, P23688	44	15	16	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32919	32924		10.1074/jbc.M004223200	http://dx.doi.org/10.1074/jbc.M004223200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10915789	hybrid			2022-12-25	WOS:000090003800075
J	Blackburn, MR; Aldrich, M; Volmer, JB; Chen, W; Zhong, HY; Kelly, S; Hershfield, MS; Datta, SK; Kellems, RE				Blackburn, MR; Aldrich, M; Volmer, JB; Chen, W; Zhong, HY; Kelly, S; Hershfield, MS; Datta, SK; Kellems, RE			The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice - Differential impact on pulmonary and immunologic abnormalities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; S-ADENOSYLHOMOCYSTEINE HYDROLASE; GENE-THERAPY; REPLACEMENT THERAPY; CELL-DEATH; 2'-DEOXYADENOSINE; DEOXYNUCLEOTIDES; INACTIVATION; LYMPHOCYTES; ONTOGENY	Adenosine deaminase (ADA) deficiency results in a combined immunodeficiency brought about by the immunotoxic properties of elevated ADA substrates. Additional non-lymphoid abnormalities are associated with ADA deficiency, however, little is known about how these relate to the metabolic consequences of ADA deficiency. ADA-deficient mice develop a combined immunodeficiency as well as severe pulmonary insufficiency. ADA enzyme therapy was used to examine the relative impact of ADA substrate elevations on these phenotypes. A " low-dose " enzyme therapy protocol prevented the pulmonary phenotype seen in ADA-deficient mice, but did little to improve their immune status. This treatment protocol reduced metabolic disturbances in the circulation and lung, but not in the thymus and spleen. A "high-dose" enzyme therapy protocol resulted in decreased metabolic disturbances in the thymus and spleen and was associated with improvement in immune status. These findings suggest that the pulmonary and immune phenotypes are separable and are related to the severity of metabolic disturbances in these tissues. This model will be useful in examining the efficacy of ADA enzyme therapy and studying the mechanisms underlying the immunodeficiency and pulmonary phenotypes associated with ADA deficiency.	Univ Texas, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27707 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27707 USA	University of Texas System; University of Texas Health Science Center Houston; Duke University; Duke University	Blackburn, MR (corresponding author), Univ Texas, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA.	Michael.R.Blackburn@uth.tmc.edu		Blackburn, Michael/0000-0002-1394-9966	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046207] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61888] Funding Source: Medline; NIAID NIH HHS [AI43572] Funding Source: Medline; NIDDK NIH HHS [DK46207] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73, DOI 10.1016/0033-0620(89)90015-7; BENVENISTE P, 1995, J IMMUNOL, V155, P536; Blackburn MR, 2000, J EXP MED, V192, P159, DOI 10.1084/jem.192.2.159; Blackburn MR, 1996, J BIOL CHEM, V271, P15203, DOI 10.1074/jbc.271.25.15203; Blackburn MR, 1998, J BIOL CHEM, V273, P5093, DOI 10.1074/jbc.273.9.5093; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; Bollinger ME, 1996, NEW ENGL J MED, V334, P1367, DOI 10.1056/NEJM199605233342104; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; CARSON DA, 1986, EXP CELL RES, V164, P273, DOI 10.1016/0014-4827(86)90028-5; CHURCHILL PC, 1982, J PHARMACOL EXP THER, V222, P319; COLEMAN MS, 1978, J BIOL CHEM, V253, P1619; Cronstein Bruce N., 1997, P285; DONOFRIO J, 1978, J CLIN INVEST, V62, P884, DOI 10.1172/JCI109201; FREDHOLM BB, 1988, TRENDS PHARMACOL SCI, V9, P130, DOI 10.1016/0165-6147(88)90194-0; FUKUNAGA AF, 1982, ANESTH ANALG, V61, P273; GIBLETT ER, 1972, LANCET, V2, P1067; Hershfield M S, 1985, Prog Clin Biol Res, V198, P305; HERSHFIELD MS, 1979, J CLIN INVEST, V63, P807, DOI 10.1172/JCI109367; HERSHFIELD MS, 1995, CLIN IMMUNOL IMMUNOP, V76, pS228, DOI 10.1016/S0090-1229(95)90306-2; HERSHFIELD MS, 1979, J BIOL CHEM, V254, P22; HERSHFIELD MS, 1993, PEDIATR RES, V33, pS42; HERSHFIELD MS, 1987, NEW ENGL J MED, V316, P589, DOI 10.1056/NEJM198703053161005; HERSHFIELD MS, 1995, METABOLIC MOL BASIS, V1, P1725; HIRSCHHORN R, 1980, NEW ENGL J MED, V303, P377, DOI 10.1056/NEJM198008143030706; Hirschhorn R, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P121; Huang S, 1997, BLOOD, V90, P1600, DOI 10.1182/blood.V90.4.1600.1600_1600_1610; JACOBSON MA, 1997, PURINERGIC APPROACHE, P585; KIZAKI H, 1990, J BIOL CHEM, V265, P5280; KNUDSEN TB, 1992, TERATOLOGY, V45, P91, DOI 10.1002/tera.1420450109; Kohn DB, 1998, NAT MED, V4, P775, DOI 10.1038/nm0798-775; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MIGCHIELSEN AAJ, 1995, NAT GENET, V10, P279, DOI 10.1038/ng0795-279; MITCHELL BS, 1985, ANN NY ACAD SCI, V451, P129, DOI 10.1111/j.1749-6632.1985.tb27103.x; MORGAN G, 1987, CLIN EXP IMMUNOL, V70, P491; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; RATECH H, 1985, AM J PATHOL, V120, P157; Tourigny MR, 1997, J EXP MED, V185, P1549, DOI 10.1084/jem.185.9.1549; ULLMAN B, 1978, CELL, V14, P365, DOI 10.1016/0092-8674(78)90122-8; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673; WEINBERG K, 1993, J CLIN INVEST, V92, P596, DOI 10.1172/JCI116626	41	82	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32114	32121		10.1074/jbc.M005153200	http://dx.doi.org/10.1074/jbc.M005153200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10908569	hybrid			2022-12-25	WOS:000089858900077
J	Che, FS; Nakajima, Y; Tanaka, N; Iwano, M; Yoshida, T; Takayama, S; Kadota, I; Isogai, A				Che, FS; Nakajima, Y; Tanaka, N; Iwano, M; Yoshida, T; Takayama, S; Kadota, I; Isogai, A			Flagellin from an incompatible strain of Pseudomonas avenae induces a resistance response in cultured rice cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT-PATHOGEN INTERACTIONS; HOST SPECIES-SPECIFICITY; HYPERSENSITIVE RESPONSE; DEFENSE RESPONSES; POSTTRANSLATIONAL MODIFICATION; SALMONELLA-TYPHIMURIUM; PHYTOALEXIN PRODUCTION; N-ACETYLCHITOHEPTAOSE; MICROBE INTERACTIONS; DISEASE RESISTANCE	The host range of Pseudomonas avenae is wide among monocotyledonous plants, but individual strains can infect only one or a few host species. The resistance response of rice cells to pathogens has been previously shown to be induced by a rice-incompatible strain, N1141, but not by a rice-compatible strain, H8301. To clarify the molecular mechanism of the host specificity in P. avenae, a strain-specific antibody that was raised against N1141 cells and then absorbed with H8301 cells was prepared. When a cell extract of strain N1141 was separated by SDS-polyacrylamide gel electrophoresis and immunostained with the N1141 strain-specific antibody, only a flagellin protein was detected. Purified N1141 flagellin induced the hypersensitive cell death in cultured rice cells within 6 h of treatment, whereas the H8301 flagellin did not. The hypersensitive cell death could be blocked by pretreatment with anti-N1141 flagellin antibody. Furthermore, a flagellin-deficient N1141 strain lost not only the induction ability of hypersensitive cell death but also the expression ability of the EL2 gene, which is thought to be one of the defense-related genes. These results demonstrated that the resistance response in cultured rice cells is induced by the flagellin existing in the incompatible strain of P. avenae but not in the flagellin of the compatible strain.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Natl Inst Agroenvironm Sci, Tsukuba, Ibaraki 3058602, Japan	Nara Institute of Science & Technology; National Institute for Agro-Environmental Sciences (NIAES) Japan	Che, FS (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Nara 6300101, Japan.	fsche@bs.aist-nara.ac.jp	Isogai, Akira/O-8897-2017; Nakajima, Yoshihiro/M-6935-2018	Isogai, Akira/0000-0001-8095-0441; Nakajima, Yoshihiro/0000-0002-7422-730X				AGRIOS GN, 1997, PLANT PATHOL, P93; AMBLER RP, 1959, NATURE, V184, P56, DOI 10.1038/184056b0; ARLAT M, 1994, EMBO J, V13, P543, DOI 10.1002/j.1460-2075.1994.tb06292.x; BABA A, 1986, PLANT CELL PHYSIOL, V27, P463; BAKER CJ, 1993, PLANT PHYSIOL, V102, P1341, DOI 10.1104/pp.102.4.1341; BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; BOLLER T, 1995, ANNU REV PLANT PHYS, V46, P189, DOI 10.1146/annurev.arplant.46.1.189; Che FS, 1999, PLANT CELL PHYSIOL, V40, P1036, DOI 10.1093/oxfordjournals.pcp.a029485; CULVER JN, 1991, MOL PLANT MICROBE IN, V4, P458, DOI 10.1094/MPMI-4-458; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; DIXON RA, 1994, ANNU REV PHYTOPATHOL, V32, P479, DOI 10.1146/annurev.py.32.090194.002403; Doig P, 1996, MOL MICROBIOL, V19, P379, DOI 10.1046/j.1365-2958.1996.370890.x; EBEL J, 1994, INT REV CYTOL, V148, P1; Felix G, 1999, PLANT J, V18, P265, DOI 10.1046/j.1365-313X.1999.00265.x; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; GABRIEL DW, 1990, ANNU REV PHYTOPATHOL, V28, P365, DOI 10.1146/annurev.py.28.090190.002053; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GILBERTOGONZALEZ R, 1980, BIOCHEMISTRY-US, V19, P4299, DOI 10.1021/bi00559a023; Greenberg JT, 1997, ANNU REV PLANT PHYS, V48, P525, DOI 10.1146/annurev.arplant.48.1.525; Guerry P, 1996, MOL MICROBIOL, V19, P369, DOI 10.1046/j.1365-2958.1996.369895.x; He DY, 1998, MOL PLANT MICROBE IN, V11, P1167, DOI 10.1094/MPMI.1998.11.12.1167; He SY, 1996, PLANT PHYSIOL, V112, P865, DOI 10.1104/pp.112.3.865; HE SY, 1993, CELL, V73, P1255, DOI 10.1016/0092-8674(93)90354-S; HE XS, 1994, J BACTERIOL, V176, P2406, DOI 10.1128/JB.176.8.2406-2414.1994; HEATH MC, 1991, PHYTOPATHOLOGY, V81, P127; HUET JC, 1995, MOL PLANT MICROBE IN, V8, P302, DOI 10.1094/MPMI-8-0302; IINO T, 1969, BACTERIOL REV, V33, P454, DOI 10.1128/MMBR.33.4.454-475.1969; Joys Terence M., 1992, Biomedical Letters, V47, P371; JOYS TM, 1988, CAN J MICROBIOL, V34, P452, DOI 10.1139/m88-078; JOYS TM, 1985, J BIOL CHEM, V260, P5758; KADOTA I, 1991, Annals of the Phytopathological Society of Japan, V57, P268, DOI 10.3186/jjphytopath.57.268; Kadota Ikuo, 1996, Annals of the Phytopathological Society of Japan, V62, P425, DOI 10.3186/jjphytopath.62.425; KALMOKOFF ML, 1988, J BACTERIOL, V170, P1752, DOI 10.1128/jb.170.4.1752-1758.1988; Kamoun S, 1998, PLANT CELL, V10, P1413, DOI 10.1105/tpc.10.9.1413; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; Keller H, 1999, PLANT CELL, V11, P223, DOI 10.1105/tpc.11.2.223; KELLYWINTENBERG K, 1993, J BACTERIOL, V175, P2458, DOI 10.1128/JB.175.8.2458-2461.1993; Kombrink E, 1995, ADV BOT RES, V21, P1; KUCHITSU K, 1993, PROTOPLASMA, V174, P79, DOI 10.1007/BF01404046; KUWAJIMA G, 1988, J BACTERIOL, V170, P485, DOI 10.1128/jb.170.1.485-488.1988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McCabe PF, 1997, PLANT J, V12, P267, DOI 10.1046/j.1365-313X.1997.12020267.x; Minami E, 1996, PLANT CELL PHYSIOL, V37, P563, DOI 10.1093/oxfordjournals.pcp.a028981; MOENS S, 1995, MICROBIOL-UK, V141, P2651, DOI 10.1099/13500872-141-10-2651; Namba K, 1997, Q REV BIOPHYS, V30, P1, DOI 10.1017/S0033583596003319; NAMBA K, 1989, NATURE, V342, P648, DOI 10.1038/342648a0; NEWTON SMC, 1991, MOL MICROBIOL, V5, P419, DOI 10.1111/j.1365-2958.1991.tb02124.x; NISHIYAMA K, 1979, Annals of the Phytopathological Society of Japan, V45, P25, DOI 10.3186/jjphytopath.45.25; Panabieres F, 1995, MOL PLANT MICROBE IN, V8, P996, DOI 10.1094/MPMI-8-0996; PERNOLLET JC, 1993, PHYSIOL MOL PLANT P, V42, P53, DOI 10.1006/pmpp.1993.1005; Ricci P., 1997, PLANT MICROBE INTERA, V3, P53; Ryerson DE, 1996, PLANT CELL, V8, P393, DOI 10.1105/tpc.8.3.393; Scofield SR, 1996, SCIENCE, V274, P2063, DOI 10.1126/science.274.5295.2063; SHIBUYA N, 1993, FEBS LETT, V329, P75, DOI 10.1016/0014-5793(93)80197-3; SOBERON X, 1977, GENE, V2, P95; Stocker B A, 1994, Int Rev Immunol, V11, P167, DOI 10.3109/08830189409061724; SWEIGARD JA, 1995, PLANT CELL, V7, P1221, DOI 10.1105/tpc.7.8.1221; Tang XY, 1996, SCIENCE, V274, P2060, DOI 10.1126/science.274.5295.2060; TURNER JG, 1974, PHYTOPATHOLOGY, V64, P885, DOI 10.1094/Phyto-64-885; Umemoto N, 1997, P NATL ACAD SCI USA, V94, P1029, DOI 10.1073/pnas.94.3.1029; Wang H, 1996, PLANT CELL, V8, P375, DOI 10.1105/tpc.8.3.375; WEI LN, 1986, NUCLEIC ACIDS RES, V14, P8227, DOI 10.1093/nar/14.20.8227; WEI ZM, 1992, SCIENCE, V257, P85, DOI 10.1126/science.1621099; WIELAND F, 1985, J BIOL CHEM, V260, P5180; Wilson K., 2001, CURR PROTOC MOL BIOL, V71, P27, DOI [10.1002/0471142727.mb0204s56, DOI 10.1002/0471142727.MB0204S56]; Yang YO, 1997, GENE DEV, V11, P1621, DOI 10.1101/gad.11.13.1621; YOSHIOKA K, 1995, J BACTERIOL, V177, P1090, DOI 10.1128/jb.177.4.1090-1093.1995	67	99	109	1	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32347	32356		10.1074/jbc.M004796200	http://dx.doi.org/10.1074/jbc.M004796200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10922369	hybrid			2022-12-25	WOS:000089858900108
J	Law, PY; Kouhen, OME; Solberg, J; Wang, W; Erickson, LJ; Loh, HH				Law, PY; Kouhen, OME; Solberg, J; Wang, W; Erickson, LJ; Loh, HH			Deltorphin II-induced rapid desensitization of delta-opioid receptor requires both phosphorylation and internalization of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-MEDIATED INTERNALIZATION; SIGNAL-REGULATED KINASES; G-PROTEIN; SOMATOSTATIN RECEPTOR; BETA-ARRESTIN; ADENOSINE RECEPTOR; MAMMALIAN-CELLS; TRAFFICKING; RESENSITIZATION; INVOLVEMENT	Similar to other G protein-coupled receptors, rapid phosphorylation of the delta-opioid receptor in the presence of agonist has been reported. Hence, agonist-induced desensitization of the delta-opioid receptor has been suggested to be via the receptor phosphorylation, arrestin-mediated pathway. However, due to the highly efficient coupling between the delta-opioid receptor and the adenylyl cyclase, the direct correlation between the rates of receptor phosphorylation and receptor desensitization as measured by the adenylyl cyclase activity could not be established. In the current studies, using an ecdysone-inducible expression system to control the 6-opioid receptor levels in HEK293 cells, we could demonstrate that the rate of deltorphin II-induced receptor desensitization is dependent oil the receptor level. Only at receptor concentrations less than or equal to 90 fmol/mg of protein were rapid desensitizations (t(1/2) <10 min) observed. Apparently, deltorphin II-induced receptor desensitization involves cellular events in addition to receptor phosphorylation. Mutation of Ser(363) in the carboxyl tail of the 6-opioid receptor to Ala completely abolished the deltorphin II-induced receptor phosphorylation but not the desensitization response. Although the magnitude of desensitization was attenuated, the rate of deltorphin II-induced receptor desensitization remained the same in the S363A mutant as compared with wild type. Also, the S363A mutant could internalize in the presence of deltorphin II. Only when the agonist-induced clathrin-coated pit-mediated receptor internalization was blocked by 0.4 M sucrose that the deltorphin II-induced receptor desensitization was abolished in the S363A mutant. Similarly, 0.4 M sucrose could partially block the agonist-induced rapid desensitization in HEK293 cells expressing the wild type delta-opioid receptor. Taken together, these data supported the hypothesis that rapid desensitization of the delta-opioid receptor involves both the phosphorylation and the internalization of the receptor.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Law, PY (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA.			Law, Ping-Yee/0000-0002-5364-1093	NIDA NIH HHS [DA00564, DA07339, DA11806] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA000564, R01DA007339, P50DA011806] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; Appleyard SM, 1997, J NEUROCHEM, V69, P2405; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; Bastepe M, 1997, MOL PHARMACOL, V51, P343, DOI 10.1124/mol.51.2.343; Beaumont V, 1998, J BIOL CHEM, V273, P33174, DOI 10.1074/jbc.273.50.33174; Capeyrou R, 1997, FEBS LETT, V415, P200, DOI 10.1016/S0014-5793(97)01124-1; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng ZJ, 1998, J BIOL CHEM, V273, P24328, DOI 10.1074/jbc.273.38.24328; El Kouhen R, 1999, J BIOL CHEM, V274, P9207, DOI 10.1074/jbc.274.14.9207; FANTOZZI R, 1981, MOL PHARMACOL, V20, P8; Hasbi A, 1998, J NEUROCHEM, V70, P2129; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; Holtmann MH, 1996, J BIOL CHEM, V271, P23566, DOI 10.1074/jbc.271.38.23566; Ko JL, 1999, MOL BRAIN RES, V69, P171, DOI 10.1016/S0169-328X(99)00094-7; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; KOOVER A, 1997, J BIOL CHEM, V272, P27605; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; LAW PY, 1994, J PHARMACOL EXP THER, V271, P1689; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Pak Y, 1996, MOL PHARMACOL, V50, P1214; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; Palmer TM, 1996, J BIOL CHEM, V271, P15272, DOI 10.1074/jbc.271.25.15272; Palmer TM, 1997, BIOCHEMISTRY-US, V36, P832, DOI 10.1021/bi962290v; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PEI G, 1995, MOL PHARMACOL, V48, P173; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; Roth A, 1997, J BIOL CHEM, V272, P23769, DOI 10.1074/jbc.272.38.23769; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Wang CH, 1998, BIOCHEM BIOPH RES CO, V249, P321, DOI 10.1006/bbrc.1998.9080; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1999, J RECEPT SIGNAL TR R, V19, P301, DOI 10.3109/10799899909036653; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	38	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32057	32065		10.1074/jbc.M002395200	http://dx.doi.org/10.1074/jbc.M002395200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10893226	hybrid			2022-12-25	WOS:000089858900070
J	Michel, YM; Poncet, D; Piron, M; Kean, KM; Borman, AM				Michel, YM; Poncet, D; Piron, M; Kean, KM; Borman, AM			Cap-poly(A) synergy in mammalian cell-free extracts - Investigation of the requirements for poly(A)mediated stimulation of translation initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(A) BINDING-PROTEIN; HUMAN RHINOVIRUS RNA; MESSENGER-RNA; POLY(A)-TAIL-PROMOTED TRANSLATION; SACCHAROMYCES-CEREVISIAE; POLY(A)-BINDING PROTEIN; INTERNAL INITIATION; CAP STRUCTURE; HUMAN EIF4G; TAIL	The 5' cap and 3' poly(A) tail of eukaryotic mRNAs cooperate to stimulate synergistically translation initiation in vivo, a phenomenon observed to date in vitro only in translation systems containing endogenous com petitor mRNAs, Here we describe nuclease-treated rabbit reticulocyte lysates and HeLa cell cytoplasmic extracts that reproduce cap-poly(A) synergy in the absence of such competitor RNAs, Extracts were rendered poly(A)-dependent by ultracentrifugation to partially deplete them of ribosomes and associated initiation factors. Under optimal conditions, values for synergy in reticulocyte lysates approached 10-fold. By using this system, we investigated the molecular mechanism of poly(A) stimulation of translation. Maximal cap-poly(A) cooperativity required the integrity of the eukaryotic initiation factor 4G-poly(A)-binding protein (eIF4G-PABP) interaction, suggesting that synergy results from mRNA circularization. In addition, polyadenylation stimulated uncapped cellular mRNA translation and that driven by the encephalomyocarditis virus internal ribosome entry segment (IRES), These effects of poly(A) were also sensitive to disruption of the eIF4G-PABP interaction, suggesting that 5'-3' end crosstalk is functionally conserved between classical mRNAs and an IRES-containing mRNA. Finally, we demonstrate that a rotaviral non-structural protein that evicts PABP from eIF4G is capable of provoking the shut-off of host cell translation seen during rotavirus infection.	Inst Pasteur, CNRS URA 1966, Unite Genet Mol Virus Resp, F-75724 Paris 15, France; INRA, CRJJ, Lab Virol & Immunol Mol, F-78352 Jouy En Josas, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Kean, KM (corresponding author), Inst Pasteur, CNRS URA 1966, Unite Genet Mol Virus Resp, 25 Rue Dr Roux, F-75724 Paris 15, France.		Borman, Andy/H-3663-2019; Poncet, Didier/AAV-6583-2021	Borman, Andy/0000-0003-0585-5721; Poncet, Didier/0000-0001-7689-0175				BANERJEE AK, 1980, MICROBIOL REV, V44, P175, DOI 10.1128/MMBR.44.2.175-205.1980; BORMAN A, 1992, VIROLOGY, V188, P685, DOI 10.1016/0042-6822(92)90523-R; BORMAN A, 1993, J GEN VIROL, V74, P1775, DOI 10.1099/0022-1317-74-9-1775; Borman AM, 1997, RNA, V3, P186; DASSO MC, 1989, NUCLEIC ACIDS RES, V17, P6485, DOI 10.1093/nar/17.16.6485; De Gregorio E, 1998, RNA, V4, P828, DOI 10.1017/S1355838298980372; DOEL MT, 1976, CELL, V8, P51, DOI 10.1016/0092-8674(76)90184-7; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Gebauer F, 1999, EMBO J, V18, P6146, DOI 10.1093/emboj/18.21.6146; Hoshino S, 1999, J BIOL CHEM, V274, P16677, DOI 10.1074/jbc.274.24.16677; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; IZUKA N, 1994, MOL CELL BIOL, V14, P7322; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JACKSON RJ, 1994, MOL BIOL REP, V19, P147, DOI 10.1007/BF00986957; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; LIEBIG HD, 1993, BIOCHEMISTRY-US, V32, P7581, DOI 10.1021/bi00080a033; MOLLA A, 1991, SCIENCE, V254, P1647, DOI 10.1126/science.1661029; Morley SJ, 1997, RNA, V3, P1085; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; Piron M, 1999, J VIROL, V73, P5411, DOI 10.1128/JVI.73.7.5411-5421.1999; Piron M, 1998, EMBO J, V17, P5811, DOI 10.1093/emboj/17.19.5811; PONCET D, 1993, J VIROL, V67, P3159, DOI 10.1128/JVI.67.6.3159-3165.1993; Preiss T, 1998, RNA, V4, P1321, DOI 10.1017/S1355838298980669; Preiss T, 1998, NATURE, V392, P516, DOI 10.1038/33192; Proweller A, 1997, J BIOL CHEM, V272, P6004, DOI 10.1074/jbc.272.9.6004; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; Wei CC, 1998, BIOCHEMISTRY-US, V37, P1910, DOI 10.1021/bi9724570; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7	35	119	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32268	32276		10.1074/jbc.M004304200	http://dx.doi.org/10.1074/jbc.M004304200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10922367	Green Published, hybrid			2022-12-25	WOS:000089858900098
J	Dhe-Paganon, S; Shigeta, R; Chi, YI; Ristow, M; Shoelson, SE				Dhe-Paganon, S; Shigeta, R; Chi, YI; Ristow, M; Shoelson, SE			Crystal structure of human frataxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PROCESSING PEPTIDASE; FRIEDREICHS-ATAXIA; YEAST; IRON; MATURATION; HOMOLOG; ASSOCIATION; DEFICIENCY; DNA	Friedreich's ataxia, an autosomal recessive neurodegenerative disorder characterized by progressive gait and limb ataxia, cardiomyopathy, and diabetes mellitus, is caused by decreased frataxin production or function. The structure of human frataxin, which we have determined at 1.8-Angstrom resolution, reveals a novel protein fold. A five-stranded, antiparallel beta sheet provides a flat platform, which supports a pair of parallel alpha helices, to form a compact arp sandwich. A cluster of 12 acidic residues from the first helix and the first strand of the large sheet form a contiguous anionic surface on the protein. The overall protein structure and the anionic patch are conserved in eukaryotes, including animals, plants, and yeast, and in prokaryotes. Additional conserved residues create an extended 1008-Angstrom(2) patch on a distinct surface of the protein. Side chains of disease-associated mutations either contribute to the anionic patch, help create the second conserved surface, or point toward frataxin's hydrophobic core. These structural findings predict potential modes of protein-protein and protein-iron binding.	Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Univ Cologne, Dept Internal Med 2, D-50931 Cologne, Germany	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; University of Cologne	Shoelson, SE (corresponding author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.		Ristow, Michael/O-9858-2014	Ristow, Michael/0000-0003-2109-2453	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007260] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK4312, DK07260] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BLASS JP, 1976, NEW ENGL J MED, V295, P62, DOI 10.1056/NEJM197607082950202; Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275; Branda SS, 1999, J BIOL CHEM, V274, P22763, DOI 10.1074/jbc.274.32.22763; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHAMBERLAIN S, 1988, NATURE, V334, P248, DOI 10.1038/334248a0; Chasteen ND, 1999, J STRUCT BIOL, V126, P182, DOI 10.1006/jsbi.1999.4118; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; *COLL COMP PROJ 4, 1994, ACTA CRYSTALLOGR D, V50, P7608; Cossee M, 2000, HUM MOL GENET, V9, P1219, DOI 10.1093/hmg/9.8.1219; Cossee M, 1999, ANN NEUROL, V45, P200, DOI 10.1002/1531-8249(199902)45:2<200::AID-ANA10>3.0.CO;2-U; De Michele G, 2000, NEUROLOGY, V54, P496, DOI 10.1212/WNL.54.2.496; Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601; Gordon DM, 1999, HUM MOL GENET, V8, P2255, DOI 10.1093/hmg/8.12.2255; Gray JV, 1997, NAT GENET, V16, P323, DOI 10.1038/ng0897-323; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Knight SAB, 1998, J BIOL CHEM, V273, P18389, DOI 10.1074/jbc.273.29.18389; Koutnikova H, 1998, HUM MOL GENET, V7, P1485, DOI 10.1093/hmg/7.9.1485; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; La Fortelle Ed, 1997, CRYSTALLOGRAPHIC COM; Lodi R, 1999, P NATL ACAD SCI USA, V96, P11492, DOI 10.1073/pnas.96.20.11492; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352; Wong A, 1999, HUM MOL GENET, V8, P425, DOI 10.1093/hmg/8.3.425	30	171	178	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30753	30756		10.1074/jbc.C000407200	http://dx.doi.org/10.1074/jbc.C000407200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10900192	hybrid			2022-12-25	WOS:000089762700003
J	Haldrup, A; Simpson, DJ; Scheller, HV				Haldrup, A; Simpson, DJ; Scheller, HV			Down-regulation of the PSI-F subunit of photosystem I (PSI) in Arabidopsis thaliana - The PSI-F subunit is essential for photoautotrophic growth and contributes to antenna function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL-PROTEIN COMPLEXES; CHLAMYDOMONAS-REINHARDTII; THYLAKOID MEMBRANES; BINDS PLASTOCYANIN; ELECTRON-TRANSFER; CYTOCHROME C(6); HEAT-STRESS; BARLEY; IDENTIFICATION; POLYPEPTIDES	The PSI-F subunit of photosystem I is a transmembrane protein with a large lumenal domain, The role of PSI-F was investigated in Arabidopsis plants transformed with an antisense construct of the psaF cDNA. Several plant lines with reduced amounts of the PSI-F subunit were generated. Many of the transgenic plants died, apparently because they were unable to survive without the PSI-F subunit. Plants with 5% of PSI-F were capable of photoautotrophic growth but were much smaller than wild-type plants. The plants suffered severely under normal growth conditions but recovered somewhat in the dark indicating chronic photoinhibition. Photosystem I lacking PSI-F was less stable, and the stromal subunits PSI-C, PSI-D, and PSI-E were present in lower amounts than in wild type, The lack of PSI-F resulted in an inability of light-harvesting complex I-730 to transfer energy to the P700 reaction center. In thylakoids deficient in PSI-F, the steady state NADP reduction rate was only 10% of the wild-type levels indicating a lower efficiency in oxidation of plastocyanin. Surprisingly, the lack of PSI-F also gave rise to disorganization of the thylakoids, The strict arrangement in grana and stroma lamellae was lost, and instead a network of elongated and distorted grana was observed.	Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, DK-1871 Frederiksberg C, Denmark; Carlsberg Lab, Dept Physiol, DK-2500 Copenhagen, Denmark	University of Copenhagen	Scheller, HV (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, 40 Thorvaldsensvej, DK-1871 Frederiksberg C, Denmark.		Scheller, Henrik V/A-8106-2008; Scheller, Henrik/AAH-4770-2020	Scheller, Henrik V/0000-0002-6702-3560; Scheller, Henrik/0000-0002-6702-3560; Haldrup, Anna/0000-0002-2348-7072				Allen JF, 1997, PHYSIOL PLANTARUM, V100, P863, DOI 10.1034/j.1399-3054.1997.1000412.x; ANANDAN S, 1989, FEBS LETT, V256, P150, DOI 10.1016/0014-5793(89)81737-5; ANDERSEN B, 1992, PHYSIOL PLANTARUM, V84, P154, DOI 10.1111/j.1399-3054.1992.tb08778.x; ANDERSON JM, 1986, ANNU REV PLANT PHYS, V37, P93, DOI 10.1146/annurev.arplant.37.1.93; ANDERSSON B, 1980, BIOCHIM BIOPHYS ACTA, V593, P427, DOI 10.1016/0005-2728(80)90078-X; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; Baena-Gonzalez E, 1999, PLANTA, V208, P196, DOI 10.1007/s004250050550; BASSI R, 1992, J BIOL CHEM, V267, P25714; BASSI R, 1987, EUR J BIOCHEM, V163, P221, DOI 10.1111/j.1432-1033.1987.tb10791.x; BENNOUN P, 1982, P NATL ACAD SCI-BIOL, V79, P4352, DOI 10.1073/pnas.79.14.4352; BURKEY KO, 1993, PHOTOSYNTH RES, V36, P103, DOI 10.1007/BF00016275; Burrows PA, 1998, EMBO J, V17, P868, DOI 10.1093/emboj/17.4.868; Catala R, 1997, PLANT CELL PHYSIOL, V38, P1382, DOI 10.1093/oxfordjournals.pcp.a029133; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Croce R, 1998, BIOCHEMISTRY-US, V37, P17355, DOI 10.1021/bi9813227; Durnford DG, 1999, J MOL EVOL, V48, P59, DOI 10.1007/PL00006445; FARAH J, 1995, EMBO J, V14, P4976, DOI 10.1002/j.1460-2075.1995.tb00180.x; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Haldrup A, 1999, PLANT J, V17, P689, DOI 10.1046/j.1365-313X.1999.00419.x; Hippler M, 1999, J BIOL CHEM, V274, P4180, DOI 10.1074/jbc.274.7.4180; Hippler M, 1997, BIOCHEMISTRY-US, V36, P6343, DOI 10.1021/bi970082c; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; Hippler M, 1998, P NATL ACAD SCI USA, V95, P7339, DOI 10.1073/pnas.95.13.7339; Hippler M, 1996, EMBO J, V15, P6374, DOI 10.1002/j.1460-2075.1996.tb01028.x; Hippler M, 2000, J BIOL CHEM, V275, P5852, DOI 10.1074/jbc.275.8.5852; HIYAMA T, 1972, BIOCHIM BIOPHYS ACTA, V267, P160, DOI 10.1016/0005-2728(72)90147-8; Horton P, 1999, AUST J PLANT PHYSIOL, V26, P659, DOI 10.1071/PP99095; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; JANSSON S, 1991, MOL GEN GENET, V229, P67, DOI 10.1007/BF00264214; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; Jansson S, 1992, PLANT MOL BIOL REP, V10, P242, DOI 10.1007/BF02668357; Jensen PE, 2000, J BIOL CHEM, V275, P24701, DOI 10.1074/jbc.M000550200; KANA TM, 1992, J PHYCOL, V28, P304, DOI 10.1111/j.0022-3646.1992.00304.x; KAY R, 1987, SCIENCE, V236, P1299, DOI 10.1126/science.236.4806.1299; Klukas O, 1999, J BIOL CHEM, V274, P7351, DOI 10.1074/jbc.274.11.7351; KNOETZEL J, 1992, EUR J BIOCHEM, V206, P209, DOI 10.1111/j.1432-1033.1992.tb16918.x; Knoetzel J, 1998, FEBS LETT, V436, P339, DOI 10.1016/S0014-5793(98)01158-2; Lajko F, 1997, PHOTOSYNTHETICA, V33, P217, DOI 10.1023/A:1022160213152; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; Martin M, 1996, PLANT CELL PHYSIOL, V37, P293, DOI 10.1093/oxfordjournals.pcp.a028945; Naver H, 1996, J BIOL CHEM, V271, P8996, DOI 10.1074/jbc.271.15.8996; Naver H, 1999, J BIOL CHEM, V274, P10784, DOI 10.1074/jbc.274.16.10784; NAVER H, 1995, PHYSIOL PLANTARUM, V95, P19, DOI 10.1111/j.1399-3054.1995.tb00802.x; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; Sazanov LA, 1998, FEBS LETT, V429, P115, DOI 10.1016/S0014-5793(98)00573-0; SCHELLER HV, 1990, PHYSIOL PLANTARUM, V78, P484, DOI 10.1034/j.1399-3054.1990.780326.x; Schmid VHR, 1997, P NATL ACAD SCI USA, V94, P7667, DOI 10.1073/pnas.94.14.7667; SHEN WJ, 1989, NUCLEIC ACIDS RES, V17, P8385, DOI 10.1093/nar/17.20.8385; SHUVALOV VA, 1986, BIOCHIM BIOPHYS ACTA, V850, P319, DOI 10.1016/0005-2728(86)90187-8; SIMPSON DJ, 1980, CARLSBERG RES COMMUN, V45, P283, DOI 10.1007/BF02906180; Sonoike K, 1996, PLANT CELL PHYSIOL, V37, P239, DOI 10.1093/oxfordjournals.pcp.a028938; TEICHER HB, 2000, IN PRESS PHOTOSYNTH; Tjus SE, 1998, PLANT PHYSIOL, V116, P755, DOI 10.1104/pp.116.2.755; Tjus SE, 1999, PHOTOSYNTH RES, V60, P75, DOI 10.1023/A:1006283618695; Varotto C, 2000, PLANT J, V22, P115, DOI 10.1046/j.1365-313x.2000.00717.x; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; WYNN RM, 1989, PLANT PHYSIOL, V91, P445, DOI 10.1104/pp.91.1.445; WYNN RM, 1989, BIOCHEMISTRY-US, V28, P5554, DOI 10.1021/bi00439a032; XU QA, 1994, J BIOL CHEM, V269, P3205; ZAMBRYSKI P, 1983, EMBO J, V2, P2143, DOI 10.1002/j.1460-2075.1983.tb01715.x; Zhang H, 1997, PLANT PHYSIOL, V115, P1525, DOI 10.1104/pp.115.4.1525	63	80	88	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31211	31218		10.1074/jbc.M002933200	http://dx.doi.org/10.1074/jbc.M002933200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10900198	hybrid			2022-12-25	WOS:000089762700066
J	Lock, LS; Royal, I; Naujokas, MA; Park, M				Lock, LS; Royal, I; Naujokas, MA; Park, M			Identification of an atypical Grb2 carboxyl-terminal SH3 domain binding site in Gab docking proteins reveals Grb2-dependent and -independent recruitment of Gab1 to receptor tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; PLECKSTRIN HOMOLOGY DOMAIN; PROLINE-RICH PEPTIDE; C-MET RECEPTOR; SCATTER FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL MORPHOGENESIS; ADAPTER PROTEIN; T-CELL; SIGNAL-TRANSDUCTION	The Gab family of docking proteins is phosphorylated in response to various growth factors and cytokines and serves to recruit multiple signaling proteins. Gab1 acts downstream from the Met-hepatocyte growth factor receptor, and Gab1 overexpression promotes Met dependent morphogenesis of epithelial cells. Recruitment of Gab1 to Met or epidermal growth factor (EGF) receptors requires a receptor-binding site for the Grb2 adapter protein and a proline-rich domain in Gab1, defined as the Met-binding domain. To determine the requirement for Grb2 in Gab1 recruitment, we have mapped two Grb2 carboxyl-terminal SH3 domain binding sites conserved in Gab1 and related protein Gab2. One corresponds to a canonical Grb2-binding motif, whereas the second, located within the Gab1 Met-binding domain, requires the proline and arginine residues of an atypical PXXXR motif. The PXXXR motif is required but not sufficient for Grb2 binding, whereas an extended motif, PX3RX2KPX7PLD, conserved in Gab proteins as well as the Grb2/Gads-docking protein, Slp-76, efficiently competes binding of Grb2 or Gads adapter proteins. The association of Gab1 with Grb2 is required for Gab1 recruitment to the EGF receptor but not the Met receptor. Hence different mechanisms of Gab1 recruitment may reflect the distinct biological functions for Gab1 downstream from the EGF and Met receptors.	McGill Univ, Ctr Hlth, Dept Biochem, Mol Oncol Grp H5 10, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Dept Med, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Dept Oncol, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University	Park, M (corresponding author), McGill Univ, Ctr Hlth, Dept Biochem, Mol Oncol Grp H5 10, 687 Pine Ave W,Rm H5-10, Montreal, PQ H3A 1A1, Canada.	morag@lan1.molone.mcgill.ca		Royal, Isabelle/0000-0002-7548-1182				Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GOUDREAU N, 1994, NAT STRUCT BIOL, V1, P898, DOI 10.1038/nsb1294-898; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Harmer SL, 1999, J BIOL CHEM, V274, P12183, DOI 10.1074/jbc.274.17.12183; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; KOMADA M, 1993, ONCOGENE, V8, P2381; Korhonen JM, 1999, J BIOL CHEM, V274, P37307, DOI 10.1074/jbc.274.52.37307; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Liu SK, 1998, ONCOGENE, V17, P3073, DOI 10.1038/sj.onc.1202337; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Matsumoto K, 1993, EXS, V65, P225; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; Qiu MS, 1998, BIOCHEM BIOPH RES CO, V253, P443, DOI 10.1006/bbrc.1998.9795; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; RAMOSMORALES F, 1995, ONCOGENE, V11, P1665; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359; ZHU H, 1994, J BIOL CHEM, V269, P29943	63	145	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31536	31545		10.1074/jbc.M003597200	http://dx.doi.org/10.1074/jbc.M003597200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10913131	hybrid			2022-12-25	WOS:000089762700109
J	Jeon, H; Shipley, GG				Jeon, H; Shipley, GG			Vesicle-reconstituted low density lipoprotein receptor - Visualization by cryoelectron microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT COMPONENT C9; GROWTH-FACTOR PRECURSOR; CYSTEINE-RICH REPEAT; LDL RECEPTOR; FAMILIAL HYPERCHOLESTEROLEMIA; ELECTRON-MICROSCOPY; 3-DIMENSIONAL STRUCTURE; MEDIATED ENDOCYTOSIS; CYTOPLASMIC DOMAIN; INSULIN-RECEPTOR	The low density lipoprotein (LDL) receptor is a key protein for maintaining cellular cholesterol homeostasis by binding cholesterol-rich lipoproteins through their apoB and apoE apoproteins. The LDL receptor is a transmembrane glycoprotein of M-r similar to 115 kDa; based on its primary sequence, five distinct structural domains have been identified (Yamamoto, T., Davis, C. G., Brown, M. S., Schneider, W. J., Casey, M. L., Goldstein, J. L., and Russell, D. W. (1984) Cell 39, 27-38). As a first step toward providing a structural description of the intact LDL receptor, the receptor has been purified from bovine adrenal cortices, reconstituted into unilamellar egg yolk phosphatidylcholine vesicles, and imaged using cryoelectron microscopy (cryoEM). CryoEM has the advantage of providing images of the reconstituted LDL receptor in its frozen, fully hydrated state. LDL receptor molecules were visualized as elongated, stick-like projections from the vesicle surface with maximum dimensions similar to 120-Angstrom length by similar to 45-Angstrom width. In some of the images, a short arm (or arms) was visible at the distal end of the stick-like projections. The LDL receptor was labeled via accessible free cysteine residues, probably including that corresponding to Cys-431 of the known full-length sequence of the human LDL receptor. The accessible cysteine was demonstrated using a maleimide-biotin streptavidin conjugate and confirmed by labeling with monomaleimido-Nanogold. Images obtained by cryoEM showed that the extracellular stick-like domain of the reconstituted LDL receptor was labeled by Nanogold. This combined cryoEM-Nanogold labeling study has provided the first low resolution structural images of the reconstituted, full-length bovine LDL receptor.	Boston Univ, Sch Med, Ctr Adv Biomed Res, Dept Biophys, Boston, MA 02118 USA; Boston Univ, Sch Med, Ctr Adv Biomed Res, Dept Biochem, Boston, MA 02118 USA	Boston University; Boston University	Shipley, GG (corresponding author), Boston Univ, Sch Med, Ctr Adv Biomed Res, Dept Biophys, 715 Albany St, Boston, MA 02118 USA.			Shipley, G./0000-0001-9603-5555	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL026335, R01HL057405] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 26335, HL 57405] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; Bieri S, 1998, BIOCHEMISTRY-US, V37, P10994, DOI 10.1021/bi980452c; BISHOP RW, 1992, J LIPID RES, V33, P549; Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; BROWN MS, 1979, J CELL BIOL, V82, P597, DOI 10.1083/jcb.82.3.597; CHRISTIANSEN K, 1991, P NATL ACAD SCI USA, V88, P249, DOI 10.1073/pnas.88.1.249; DALY NL, 1995, BIOCHEMISTRY-US, V34, P14474, DOI 10.1021/bi00044a025; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DELOOF H, 1986, P NATL ACAD SCI USA, V83, P2295; Dirlam KA, 1996, PROTEIN EXPRES PURIF, V8, P489, DOI 10.1016/S1046-5928(96)90129-1; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; EYTAN GD, 1982, BIOCHIM BIOPHYS ACTA, V694, P185, DOI 10.1016/0304-4157(82)90024-7; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; HOFFER MJV, 1993, BIOCHEM BIOPH RES CO, V191, P880, DOI 10.1006/bbrc.1993.1299; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Jeon H, 2000, J BIOL CHEM, V275, P30465, DOI 10.1074/jbc.M002582200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE LY, 1989, NUCLEIC ACIDS RES, V17, P1259, DOI 10.1093/nar/17.3.1259; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARAZZITI D, 1988, BIOCHEMISTRY-US, V27, P6529, DOI 10.1021/bi00417a050; MEHTA KD, 1991, J BIOL CHEM, V266, P10406; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; North CL, 1999, BIOCHEMISTRY-US, V38, P3926, DOI 10.1021/bi9821622; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; Saxena K, 1997, BIOCHEMISTRY-US, V36, P15940, DOI 10.1021/bi971579p; SCHNEIDER WJ, 1985, METHOD ENZYMOL, V109, P405; Simmons T, 1997, J BIOL CHEM, V272, P25531, DOI 10.1074/jbc.272.41.25531; Springer TA, 1998, J MOL BIOL, V283, P837, DOI 10.1006/jmbi.1998.2115; STANLEY KK, 1985, EMBO J, V4, P375, DOI 10.1002/j.1460-2075.1985.tb03639.x; TOLLESHAUG H, 1982, CELL, V30, P715, DOI 10.1016/0092-8674(82)90276-8; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; Woldin CN, 1999, J BIOL CHEM, V274, P34981, DOI 10.1074/jbc.274.49.34981; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	44	23	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30458	30464		10.1074/jbc.M002583200	http://dx.doi.org/10.1074/jbc.M002583200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10889196	hybrid			2022-12-25	WOS:000089577900074
J	Ling, SZ; Woronuk, G; Sy, L; Lev, S; Braun, AP				Ling, SZ; Woronuk, G; Sy, L; Lev, S; Braun, AP			Enhanced activity of a large conductance, calcium-sensitive K+ channel in the presence of Src tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; SPONTANEOUSLY HYPERTENSIVE RATS; PROTEIN-COUPLED RECEPTORS; FOCAL ADHESION KINASE; SMOOTH-MUSCLE CELLS; ION CHANNELS; ACETYLCHOLINE-RECEPTOR; TRANSMITTER RELEASE; GABA(A) RECEPTORS; CYSTIC-FIBROSIS	Large conductance, calcium-sensitive K+ channels (BKCa channels) contribute to the control of membrane potential in a variety of tissues, including smooth muscle, where they act as the target effector for intracellular "calcium sparks" and the endothelium-derived vasodilator nitric oxide. Various signal transduction pathways, including protein phosphorylation can regulate the activity of BKCa channels, along with many other membrane ion channels. In our study, we have examined the regulation of BKCa channels by the cellular Src gene product (cSrc), a soluble tyrosine kinase that has been implicated in the regulation of both voltage and ligand-gated ion channels. Using a heterologous expression system, we observed that co-expression of murine BKCa channel and the human cSrc tyrosine kinase in HEK 293 cells led to a calcium-sensitive enhancement of BKCa, channel activity in excised membrane patches. In contrast, co-expression with a catalytically inactive cSrc mutant produced no change in BKCa, channel activity, demonstrating the requirement for a functional cSrc molecule. Furthermore, we observed that BKCa channels underwent direct tyrosine phosphorylation in cells co-transfected with BKCa, channels and active cSre but not in cells co-transfected with the kinase inactive form of the enzyme. A single Tyr to Phe substitution in the C-terminal half of the channel largely prevented this observed phosphorylation, Given that cSre may become activated by receptor tyrosine kinases or G-protein-coupled receptors, these findings suggest that cSrc-dependent tyrosine phosphorylation of BKCa, channels in situ may represent a novel regulatory mechanism for altering membrane potential and calcium entry.	Univ Calgary, Fac Med, Dept Pharmacol & Therapeut, Smooth Muscle Res Grp, Calgary, AB T2N 4N1, Canada; Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	University of Calgary; Weizmann Institute of Science	Braun, AP (corresponding author), Univ Calgary, Fac Med, Dept Pharmacol & Therapeut, Smooth Muscle Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	abraun@ucalgary.ca	Ling, Shizhang/J-6114-2014; Lev, Sima/AAP-7880-2020	Ling, Shizhang/0000-0002-6856-3577; Lev, Sima/0000-0002-2108-3330				Akhand AK, 1999, J BIOL CHEM, V274, P25821, DOI 10.1074/jbc.274.36.25821; ASANO M, 1995, J PHARMACOL EXP THER, V275, P775; ASANO M, 1993, BRIT J PHARMACOL, V108, P214, DOI 10.1111/j.1476-5381.1993.tb13465.x; BIELEFELDT K, 1994, J PHYSIOL-LONDON, V475, P241, DOI 10.1113/jphysiol.1994.sp020065; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BULTER A, 1993, SCIENCE, V261, P221; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHENG HC, 1992, J BIOL CHEM, V267, P9248; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; Cui J, 1997, J GEN PHYSIOL, V109, P647, DOI 10.1085/jgp.109.5.647; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; Hall SK, 2000, J BIOL CHEM, V275, P3749, DOI 10.1074/jbc.275.6.3749; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HARTZELL HC, 1988, PROG BIOPHYS MOL BIO, V52, P165, DOI 10.1016/0079-6107(88)90014-4; Holmes TC, 1996, J NEUROSCI, V16, P1581; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; Hu XQ, 1998, J BIOL CHEM, V273, P5337, DOI 10.1074/jbc.273.9.5337; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; KUME H, 1992, P NATL ACAD SCI USA, V89, P11051, DOI 10.1073/pnas.89.22.11051; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; KUME H, 1991, AM J PHYSIOL, V261, pC1204, DOI 10.1152/ajpcell.1991.261.6.C1204; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; MCCOBB DP, 1995, AM J PHYSIOL-HEART C, V269, pH767, DOI 10.1152/ajpheart.1995.269.3.H767; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; PALLANCK L, 1994, HUM MOL GENET, V3, P1239, DOI 10.1093/hmg/3.8.1239; PELZER D, 1990, REV PHYSIOL BIOCH P, V114, P107; REINHART PH, 1991, J NEUROSCI, V11, P1627; ROBITAILLE R, 1993, NEURON, V11, P645, DOI 10.1016/0896-6273(93)90076-4; ROBITAILLE R, 1992, J NEUROSCI, V12, P297; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; VALENZUELA CF, 1995, MOL BRAIN RES, V31, P165, DOI 10.1016/0169-328X(95)00048-W; Vogalis F, 1996, AM J PHYSIOL-GASTR L, V271, pG629, DOI 10.1152/ajpgi.1996.271.4.G629; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zamponi GW, 1998, CURR OPIN NEUROBIOL, V8, P351, DOI 10.1016/S0959-4388(98)80060-3	53	76	80	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30683	30689		10.1074/jbc.M004292200	http://dx.doi.org/10.1074/jbc.M004292200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10893418	hybrid			2022-12-25	WOS:000089577900105
J	Tong, XK; Hussain, NK; Adams, AG; O'Bryan, JP; McPherson, PS				Tong, XK; Hussain, NK; Adams, AG; O'Bryan, JP; McPherson, PS			Intersectin can regulate the Ras/MAP kinase pathway independent of its role in endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; NUCLEOTIDE EXCHANGE FACTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; RECEPTOR INTERNALIZATION; SIGNAL-TRANSDUCTION; PHENYLARSINE OXIDE; ADAPTER PROTEIN; EPS15 HOMOLOGY; BETA-ARRESTIN	We previously identified intersectin, a multiple EH and SH3 domain-containing protein, as a component of the endocytic machinery. Overexpression of the SH3 domains of intersectin blocks transferrin receptor endocytosis, possibly by disrupting targeting of accessory proteins of clathrin-coated pit formation. More recently, we identified mammalian Sos, a guanine-nucleotide exchange factor for Pas, as an intersectin SH3 domain-binding partner. We now demonstrate that overexpression of intersectin's SH3 domains blocks activation of Ras and MAP kinase in various cell lines. Several studies suggest that activation of MAP kinase downstream of multiple receptor types is dependent on endocytosis. Thus, the dominant-negative effect of the SH3 domains on Ras/MAP kinase activation may be indirectly mediated through a block in endocytosis. Consistent with this idea, incubating cells at 4 degrees C or with phenylarsine oxide, treatments previously established to inhibit EGF receptor endocytosis, blocks EGF-dependent activation of MAP kinase. However, under these conditions, Pas activity is unaffected and overexpression of the SH3 domains of intersectin is still able to block Pas activation. Thus, intersectin SH3 domain overexpression can effect EGF-mediated MAP kinase activation directly through a block in Pas, consistent with a functional role for intersectin in Ras activation.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; NIEHS, Lab Signal Transduct, Res Triangle Pk, NC 27709 USA	McGill University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	McPherson, PS (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	mcpm@musica.mcgill.ca		O'Bryan, John/0000-0001-5386-1080	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090091] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams A, 2000, J BIOL CHEM, V275, P27414; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Budd DC, 1999, J BIOL CHEM, V274, P12355, DOI 10.1074/jbc.274.18.12355; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Guipponi M, 1998, GENOMICS, V53, P369, DOI 10.1006/geno.1998.5521; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HERTEL C, 1985, J BIOL CHEM, V260, P2547; Hussain NK, 1999, J BIOL CHEM, V274, P15671, DOI 10.1074/jbc.274.22.15671; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; KATO Y, 1992, P NATL ACAD SCI USA, V89, P8507, DOI 10.1073/pnas.89.18.8507; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; Okamoto M, 1999, J BIOL CHEM, V274, P18446, DOI 10.1074/jbc.274.26.18446; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; Ramjaun AR, 1996, J BIOL CHEM, V271, P24856, DOI 10.1074/jbc.271.40.24856; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; Roos J, 1999, CURR BIOL, V9, P1411, DOI 10.1016/S0960-9822(00)80087-1; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Sorkina T, 1999, J CELL SCI, V112, P317; Tong XK, 2000, EMBO J, V19, P1263, DOI 10.1093/emboj/19.6.1263; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; Zhang JS, 1999, CURR BIOL, V9, P1458, DOI 10.1016/S0960-9822(00)80115-3; Zhao H, 1998, J BIOL CHEM, V273, P12061, DOI 10.1074/jbc.273.20.12061	54	68	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29894	29899		10.1074/jbc.M004096200	http://dx.doi.org/10.1074/jbc.M004096200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896662	hybrid			2022-12-25	WOS:000089439800097
J	Walter, L; Nogueira, V; Leverve, X; Heitz, MP; Bernardi, P; Fontaine, E				Walter, L; Nogueira, V; Leverve, X; Heitz, MP; Bernardi, P; Fontaine, E			Three classes of ubiquinone analogs regulate the mitochondrial permeability transition pore through a common site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOSPORINE-A; COENZYME Q(10); INDUCED DEGENERATION; LIPID COMPOSITIONS; CELL-DEATH; APOPTOSIS; ISCHEMIA; NEURONS; BRAIN; DYSFUNCTION	To identify the structural features required for regulation of the mitochondrial permeability transition pore (PTP) by ubiquinone analogs (Fontaine, E., Ichas, F., and Bernardi, P. (1998) J. Biol. Chem. 40, 25734-25740), we have carried out an analysis with quinone structural variants. We show that three functional classes can be defined: (i) PTP inhibitors (ubiquinone 0, decylubiquinone, ubiquinone 10, 2,3-dimethyl-6-decyl-1,4-benzoquinone, and 2,3,5-trimethyl-6-geranyl-1,4-benzoquinone); (ii) PTP inducers (2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone and 2,5-dihydroxy-6-undecyl-1,4-benzoquinone); and (iii) PTP-inactive quinones that counteract the effects of both inhibitors and inducers (ubiquinone 5 and 2,3,5-trimethyl-6-(3-hydroxyisoamyl)-1,4-benzoquinone). The structure-function correlation indicates that minor modifications in the isoprenoid side chain can turn an inhibitor into an activator, and that the methoxy groups are not essential for the effects of quinones on the PTP. Since the ubiquinone analogs used in this study have a similar midpoint potential and decrease mitochondrial production of reactive oxygen species to the same extent, these results support the hypothesis that quinones modulate the PTP through a common binding site rather than through oxidation-reduction reactions. Occupancy of this site can modulate the PTP open-closed transitions, possibly through secondary changes of the PTP Ca2+ binding affinity.	Univ Grenoble 1, Lab Bioenerget Fondamentale & Appl, F-38041 Grenoble 09, France; F Hoffmann La Roche & Co Ltd, Discovery Chem, Div Pharma, CH-4070 Basel, Switzerland; Univ Padua, Sch Med, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, Sch Med, CNR, Unit Study Biomembranes, I-35121 Padua, Italy	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Roche Holding; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Fontaine, E (corresponding author), Univ Grenoble 1, Lab Bioenerget Fondamentale & Appl, F-38041 Grenoble 09, France.		Fontaine, Eric/ABA-8853-2020; Walter, Ludivine/S-4456-2017; Bernardi, Paolo/C-3656-2008	Fontaine, Eric/0000-0002-5204-9477; Walter, Ludivine/0000-0001-7214-0676; Bernardi, Paolo/0000-0001-9187-3736				BEAL MF, 1994, ANN NEUROL, V36, P882, DOI 10.1002/ana.410360613; Beal MF, 1998, BBA-BIOENERGETICS, V1366, P211, DOI 10.1124/jpet.112.192138; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; Bernardi P, 1996, J BIOENERG BIOMEMBR, V28, P131, DOI 10.1007/BF02110643; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; BROUILLET E, 1994, NEUROSCI LETT, V177, P58, DOI 10.1016/0304-3940(94)90044-2; Crestanello JA, 1996, J THORAC CARDIOV SUR, V111, P443, DOI 10.1016/S0022-5223(96)70455-5; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; EDLUND C, 1994, J NEUROCHEM, V63, P634; EDLUND C, 1992, BIOCHEM CELL BIOL, V70, P422, DOI 10.1139/o92-065; ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3; FAVIT A, 1992, J CEREBR BLOOD F MET, V12, P638, DOI 10.1038/jcbfm.1992.88; Ferrand-Drake M, 1999, NEUROSCIENCE, V90, P1325, DOI 10.1016/S0306-4522(98)00559-4; Fontaine E, 1999, J BIOENERG BIOMEMBR, V31, P335, DOI 10.1023/A:1005475802350; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; GENOVA ML, 1995, BIOCHEM J, V311, P105, DOI 10.1042/bj3110105; IMBERTI R, 1993, J PHARMACOL EXP THER, V265, P392; KALEN A, 1989, LIPIDS, V24, P579, DOI 10.1007/BF02535072; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Leist M, 1997, BIOCHEM BIOPH RES CO, V236, P1, DOI 10.1006/bbrc.1997.6890; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Matthews RT, 1998, P NATL ACAD SCI USA, V95, P8892, DOI 10.1073/pnas.95.15.8892; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; SODERBERG M, 1990, J NEUROCHEM, V54, P415, DOI 10.1111/j.1471-4159.1990.tb01889.x; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TAKEO S, 1987, J PHARMACOL EXP THER, V243, P1131; VINOGRADOV A, 1972, ARCH BIOCHEM BIOPHYS, V152, P646, DOI 10.1016/0003-9861(72)90261-5; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339	35	127	140	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29521	29527		10.1074/jbc.M004128200	http://dx.doi.org/10.1074/jbc.M004128200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10889201	hybrid			2022-12-25	WOS:000089439800046
J	McCloskey, DE; Pegg, AE				McCloskey, DE; Pegg, AE			Altered spermidine/spermine N-1-acetyltransferase activity as a mechanism of cellular resistance to bis(ethyl)polyamine analogues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; SUBSTITUTED POLYAMINE ANALOGS; L1210 LEUKEMIA-CELLS; BREAST-CANCER CELLS; SPERMINE N1-ACETYLTRANSFERASE; TUMOR-CELLS; ANTITUMOR-ACTIVITY; GROWTH-INHIBITION; LUNG-CARCINOMA; IN-VITRO	To develop a model system to investigate mechanisms of antiproliferative action of bis(ethyl)polyamine analogues, intermittent analogue treatments followed by recovery periods in drug-free medium were used to select an N-1,N-12-bis(ethyl)spermine-resistant derivative of the Chinese hamster ovary cell line C55.7. The resulting C55,7Res line was at least 10-fold resistant to N-1,N-11-bis(ethyl)spermine and N-1,N-11-bis(ethyl)norspermine. The stability of the resistance in the absence of selection pressure was greater than or equal to 9 months, indicating that a heritable genotypic change was responsible for the resistance phenotype. Polyamine transport alterations and multi-drug resistance were eliminated as causes of the resistance. Spermidine/spermine N-1-acetyltransferase (SSAT) activity and regulation were altered in C55,7Res cells as basal activity was decreased, and no activity induction resulted from exposure to analogue concentrations, which caused 300-fold enzyme induction in parental cells. SSAT mRNA levels in the absence and presence of analogue were unchanged, but no SSAT protein was detected in C55,7Res cells. A point mutation, which results in the change leucine156 (a fully conserved residue) to phenylalanine, was identified in the C55,7Res SSAT cDNA. Expression of wtSSAT activity in C55.7Res cells restored sensitivity to bis(ethyl)polyamines. These results provided definitive evidence that SSAT activity is a critical target of the cytotoxic action of these analogues.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	McCloskey, DE (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA.	dem15@psu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026290] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-26290] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASU HS, 1994, CANCER RES, V54, P6210; BASU HS, 1993, CANCER RES, V53, P3948; BASU HS, 1993, ANTICANCER RES, V13, P1525; BASU HS, 1990, CANCER RES, V50, P3137; BERGERON RJ, 1988, J MED CHEM, V31, P1183, DOI 10.1021/jm00401a019; BYERS TL, 1989, AM J PHYSIOL, V257, pC545, DOI 10.1152/ajpcell.1989.257.3.C545; BYERS TL, 1990, J CELL PHYSIOL, V143, P460, DOI 10.1002/jcp.1041430309; CASERO RA, 1989, CANCER RES, V49, P639; CASERO RA, 1990, BIOCHEM J, V270, P615, DOI 10.1042/bj2700615; CASERO RA, 1995, CANCER CHEMOTH PHARM, V36, P69; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1991, J BIOL CHEM, V266, P810; CASERO RA, 1994, CANCER RES, V54, P3955; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; COLEMAN CS, 1995, BIOCHEMISTRY-US, V34, P13423, DOI 10.1021/bi00041a020; Coleman CS, 1996, BIOCHEM J, V316, P697, DOI 10.1042/bj3160697; DAVIDSON NE, 1993, CANCER RES, V53, P2071; EDWARDS ML, 1990, J MED CHEM, V33, P1369, DOI 10.1021/jm00167a014; Gabrielson EW, 1999, CLIN CANCER RES, V5, P1638; Germann U A, 1993, Semin Cell Biol, V4, P63; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; Ha HC, 1998, CANCER RES, V58, P2711; Hazlehurst LA, 1999, CANCER RES, V59, P1021; HYVONEN T, 1994, BBA-MOL CELL RES, V1221, P279, DOI 10.1016/0167-4889(94)90251-8; KRAMER D, 1995, J BIOL CHEM, V270, P2124, DOI 10.1074/jbc.270.5.2124; KRAMER DL, 1993, J CELL PHYSIOL, V155, P399, DOI 10.1002/jcp.1041550222; Marverti G, 1998, INT J CANCER, V78, P33, DOI 10.1002/(SICI)1097-0215(19980925)78:1<33::AID-IJC7>3.0.CO;2-Y; MATSUI I, 1981, J BIOL CHEM, V256, P2454; McCloskey DE, 1999, J BIOL CHEM, V274, P6175, DOI 10.1074/jbc.274.10.6175; McCloskey DE, 1996, CLIN CANCER RES, V2, P441; McCloskey DE, 2000, CLIN CANCER RES, V6, P17; MCCLOSKEY DE, 1995, CANCER RES, V55, P3233; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1989, BIOCHEMISTRY-US, V28, P8446, DOI 10.1021/bi00447a026; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1989, J BIOL CHEM, V264, P11744; PEGG AE, 1992, BIOCHIM BIOPHYS ACTA, V1171, P106, DOI 10.1016/0167-4781(92)90148-S; PERSSON L, 1988, CANCER RES, V48, P4807; PILZ RB, 1990, J BIOL CHEM, V265, P8880; PIZZORNO G, 1988, CANCER RES, V48, P2149; PORTER CW, 1985, CANCER RES, V45, P2050; PORTER CW, 1991, CANCER RES, V51, P3715; PORTER CW, 1988, ADV ENZYME REGUL, V27, P57; PORTER CW, 1993, CANCER RES, V53, P581; SAAB NH, 1993, J MED CHEM, V36, P2998, DOI 10.1021/jm00072a020; Salvatore C, 1999, ANTI-CANCER DRUG, V10, P663, DOI 10.1097/00001813-199908000-00006; SEPPANEN P, 1981, EUR J BIOCHEM, V118, P571, DOI 10.1111/j.1432-1033.1981.tb05557.x; SEPPANEN P, 1981, BIOCHIM BIOPHYS ACTA, V674, P169, DOI 10.1016/0304-4165(81)90375-5; Webb HK, 1999, J MED CHEM, V42, P1415, DOI 10.1021/jm980603+; Wyler B, 1997, BRIT J HAEMATOL, V97, P65, DOI 10.1046/j.1365-2141.1997.52649.x; Zagaja GP, 1998, CANCER CHEMOTH PHARM, V41, P505, DOI 10.1007/s002800050774	52	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28708	28714		10.1074/jbc.M004120200	http://dx.doi.org/10.1074/jbc.M004120200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10887189	hybrid			2022-12-25	WOS:000089330700051
J	Adamkewicz, JI; Mueller, CGF; Hansen, KE; Prud'homme, WA; Thorner, J				Adamkewicz, JI; Mueller, CGF; Hansen, KE; Prud'homme, WA; Thorner, J			Purification and enzymic properties of Mot1 ATPase, a regulator of basal transcription in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; RNA-POLYMERASE-II; CROSS-LINKED DNA; GENE-TRANSCRIPTION; CRYSTAL-STRUCTURE; TBP-BINDING; GLOBAL REPRESSOR; FAMILY MEMBER; IN-VIVO; HELICASE	The 1867-residue Mot1 protein is a member of a superfamily of ATPases, some of which are helicases, that interact with protein-nucleic acid assemblies. Mot1 is an essential regulator of RNA polymerase II-dependent transcription in vivo and dissociates TATA box-binding protein (TBP)-DNA complexes in vitro. Mot1-(His)(6) was purified to apparent homogeneity from yeast extracts. The preparation efficiently dissociated TBP TATA complexes, suggesting that no other protein or cofactor is required. Mot1 behaved as a non-globular monomer in hydrodynamic studies, and no association was detected between differentially tagged co-expressed Mot1 constructs. ATPase activity was stimulated about 10-fold by high ionic strength or alkaline pH, or by deletion of the N-terminal TBP-binding segment, suggesting that the N-terminal domain negatively regulates the C-terminal ATPase domain (Mot1C). Correspondingly, at moderate salt concentration, Mot1 ATPase (but not Mot1C) was stimulated greater than or equal to 10-fold by yeast TBP, suggesting that interaction with TBP relieves a conformational constraint in Mot1. Double- or single-stranded TATA-containing DNA did not affect ATPase activity of Mot1 or Mot1C, with or without TBP. Mot1 did not exhibit detectable helicase activity in strand displacement assays using substrates with flush ends or 5'- or 3'-overhangs. Mot1-catalyzed dissociation of TBP from DNA was not prevented by a psoralen cross-link positioned immediately preceding the TATA sequence. Thus, Mot1 most likely promotes release of TBP from TATA-containing DNA by causing a structural change in TBP itself, rather than by strand unwinding.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Thorner, J (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Rm 401,Barker Hall, Berkeley, CA 94720 USA.	jeremy@socrates.berkeley.edu	THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X; Mueller, Christopher/0000-0002-4119-2729	NIGMS NIH HHS [GM21841] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021841, R37GM021841] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMKEWICZ JI, 1999, THESIS U CALIFORNIA; Ashraf SI, 1998, CURR BIOL, V8, pR683, DOI 10.1016/S0960-9822(98)70435-X; Auble DT, 1999, MOL CELL BIOL, V19, P412; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Auble DT, 1997, MOL CELL BIOL, V17, P4842, DOI 10.1128/MCB.17.8.4842; BENTON BM, 1994, J CELL BIOL, V127, P623, DOI 10.1083/jcb.127.3.623; Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Chang MP, 1997, NUCLEIC ACIDS RES, V25, P4861, DOI 10.1093/nar/25.24.4861; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CHENG S, 1988, J BIOL CHEM, V263, P15110; CHENG S, 1990, THESIS U CALIFORNIA; Chicca JJ, 1998, MOL CELL BIOL, V18, P1701, DOI 10.1128/MCB.18.3.1701; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; Citterio E, 1998, J BIOL CHEM, V273, P11844, DOI 10.1074/jbc.273.19.11844; CLELAND WW, 1967, ANNU REV BIOCHEM, V36, P77, DOI 10.1146/annurev.bi.36.070167.000453; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Cross RA, 2000, CURR BIOL, V10, pR124, DOI 10.1016/S0960-9822(00)00309-2; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; Goppelt A, 1996, NUCLEIC ACIDS RES, V24, P4450, DOI 10.1093/nar/24.22.4450; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Guzder SN, 1996, J BIOL CHEM, V271, P18314, DOI 10.1074/jbc.271.31.18314; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; HANSEN K, 1996, THESIS U CALIFORNIA; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; INOSTROZA JA, 1992, CELL, V70, P477; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; JONES EW, 1991, METHOD ENZYMOL, V194, P428; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; Kim J, 1996, J BIOL CHEM, V271, P18405, DOI 10.1074/jbc.271.31.18405; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; Kim S, 1997, P NATL ACAD SCI USA, V94, P820, DOI 10.1073/pnas.94.3.820; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; Li C, 1998, MOL CELL BIOL, V18, P3771, DOI 10.1128/MCB.18.7.3771; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Marians KJ, 1997, STRUCTURE, V5, P1129, DOI 10.1016/S0969-2126(97)00263-3; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; McKay LM, 1999, NUCLEIC ACIDS RES, V27, P3064, DOI 10.1093/nar/27.15.3064; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; Mermelstein F, 1996, GENE DEV, V10, P1033, DOI 10.1101/gad.10.8.1033; MOORE D, 1999, CURRENT PROTOCOLS MO, V1; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; NAEGELI H, 1992, J BIOL CHEM, V267, P7839; PARVIN JD, 1995, NATURE, V373, P724, DOI 10.1038/373724a0; Patikoglou G, 1997, ANNU REV BIOPH BIOM, V26, P289, DOI 10.1146/annurev.biophys.26.1.289; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Peterson CL, 1998, COLD SPRING HARB SYM, V63, P545, DOI 10.1101/sqb.1998.63.545; PIATTI S, 1992, CHROMOSOMA, V102, pS107, DOI 10.1007/BF02451793; POON D, 1993, J BIOL CHEM, V268, P15325; POON D, 1994, J BIOL CHEM, V269, P23135; Reece RJ, 1997, BIOESSAYS, V19, P1001, DOI 10.1002/bies.950191110; Reinberg D, 1998, COLD SPRING HARB SYM, V63, P83, DOI 10.1101/sqb.1998.63.83; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sauer F, 1997, CURR OPIN GENET DEV, V7, P176, DOI 10.1016/S0959-437X(97)80126-8; Sherman F., 1986, METHODS YEAST GENETI; SPIELMANN HP, 1995, BIOCHEMISTRY-US, V34, P12937, DOI 10.1021/bi00040a004; STARR DB, 1995, J MOL BIOL, V250, P434; TOMIC MT, 1987, SCIENCE, V238, P1722, DOI 10.1126/science.3686011; Travers A, 1996, CURR BIOL, V6, P401, DOI 10.1016/S0960-9822(02)00507-9; Wade PA, 1996, MOL CELL BIOL, V16, P1641; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; YANCEYWRONA JE, 1992, NUCLEIC ACIDS RES, V20, P6713, DOI 10.1093/nar/20.24.6713; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895	81	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21158	21168		10.1074/jbc.M002639200	http://dx.doi.org/10.1074/jbc.M002639200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10887203	hybrid			2022-12-25	WOS:000088230600028
J	Ahmad, M; Shi, YF				Ahmad, M; Shi, YF			TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention	ONCOGENE			English	Article						apoptosis; thyroid cancer; Fas; TNF-alpha; TRAIL	DEATH RECEPTORS; CYTOCHROME-C; LIGAND TRAIL; PROTEIN; EXPRESSION; MODULATION; INHIBITOR; CASPASES; MELANOMA; PATHWAY	To determine whether the apoptotic machinery of thyroid cancer cells is functional and could be activated for tumoricidal purposes, we examined the apoptosis induced by the cytokines TNF-alpha, Fas and TRAIL in thyroid cancer cell lines, NPA. and SW579. Interestingly, out of these cytokines, only TRAIL was able to trigger significant apoptosis, The tumoricidal effect of TRAIL was further enhanced by CHX, suggesting the presence of CHX-sensitive inhibitor(s) of apoptosis in these thyroid cancer cell lines, The anti-apoptotic proteins like FLAME-1, Bcl-2 and Bcl-xL are believed to be such CHX-sensitive inhibitors in various types of cancer cells. We, however provide the evidence using NPA and SW579 cell lines that these proteins were not affected by the CHX treatment in thyroid cancer cells. The apoptosis of thyroid cancer cells,vas mediated by the classical activation of caspases that in turn activated the DNA Fragmentation Factor (DFF-45). To elucidate the role of individual caspases in TRAIL-mediated apoptosis, the inhibitory effects of several general and specific tetrapeptide caspase inhibitors were studied. The inhibitors of caspase-1, -6, -8, and -9 as well as general upstream inhibitors of apoptosis could dramatically inhibit TRAIL-induced apoptosis in thyroid cancer cells. Caspase-2 and -3 inhibitors, on the other hand, had no significant effect. When the cells were treated with either agonistic Fas antibody (CH11) or TNF-alpha, no apoptotic changes mere observed, The apoptosis induced by agonistic Fas Ab could be seen only after a prolonged exposure (24 h) to CHX, whereas TNF-alpha had no effect even in the presence of CHX. The efficacy of TRAIL nas also tested on other types of thyroid cancer cells like ARO, FRO (anaplastic carcinoma) and TPC-1 (papillary carcinoma) and compared to that triggered by other death inducing cytokines Fast and TNF-alpha. Again TRAIL tvas more potent in triggering apoptosis than Fas and TNF-alpha. Since TRAIL is effective in selectively killing thyroid tumor cells without affecting normal thyrocytes and also does not cause organ toxicity and inflammation in vivo, its potential for the treatment of thyroid cancer seems very promising.	King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res, Lab Mol Apoptosis & Canc Therapy, Riyadh 11211, Saudi Arabia	King Faisal Specialist Hospital & Research Center	Ahmad, M (corresponding author), King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res, Lab Mol Apoptosis & Canc Therapy, 226,MBC-03,POB 3354, Riyadh 11211, Saudi Arabia.		Shi, Yufei/ABG-5228-2020	Shi, Yufei/0000-0002-6999-0191				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bretz JD, 1999, J BIOL CHEM, V274, P23627, DOI 10.1074/jbc.274.33.23627; Burow ME, 1998, CANCER RES, V58, P4940; Cerutti J, 1996, CLIN CANCER RES, V2, P119; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FARID NR, 1994, ENDOCR REV, V15, P202, DOI 10.1210/er.15.2.202; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Griffith TS, 1998, J IMMUNOL, V161, P2833; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Knauf JA, 1999, J BIOL CHEM, V274, P23414, DOI 10.1074/jbc.274.33.23414; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Rudin CM, 1997, ANNU REV MED, V48, P267; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shi Y, 1996, BRIT J CANCER, V74, P1336, DOI 10.1038/bjc.1996.546; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tung WS, 1996, MOL CARCINOGEN, V15, P5; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Zhang XD, 1999, CANCER RES, V59, P2747	31	46	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2000	19	30					3363	3371		10.1038/sj.onc.1203679	http://dx.doi.org/10.1038/sj.onc.1203679			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918593				2022-12-25	WOS:000088198100004
J	Berns, K; Hijmans, EM; Koh, E; Daley, GQ; Bernards, R				Berns, K; Hijmans, EM; Koh, E; Daley, GQ; Bernards, R			A genetic screen to identify genes that rescue the slow growth phenotype of c-myc null fibroblasts	ONCOGENE			English	Article						c-myc; cell proliferation; cell cycle	CELL-CYCLE PROGRESSION; E CDK2 KINASE; ACTIVATES TRANSCRIPTION; RESPONSIVE GENES; IN-VIVO; S-PHASE; TRANSFORMATION; EXPRESSION; INHIBITION; PROTEINS	The c-myc gene is frequently over-expressed in human cancers and is involved in regulation of proliferation, differentiation and apoptosis, c-Myc is a transcription factor that acts primarily by regulating the expression of other genes. However, it has been very difficult to identify bona fide c-Myc target genes that explain its diverse biological activities. The recent generation of c-myc deficient Rat1A fibroblasts with a profound and stable growth defect provides a new system to search for genes that can substitute for c-myc in proliferation. In this study, we hale attempted to identify genes that rescue the slow growth phenotype of c-myc null cells through introduction of a series of potent cell cycle regulatory genes and several retroviral cDNA expression libraries. None of the candidate genes tested, including SV40 T-antigen and adenovirus E1A, caused reversal of the c-myc null growth defect. Furthermore, extensive screens with high-complexity retroviral cDNA libraries from three different tissue sources revealed that only c-myc and N-myc rescued the c-myc null slow-growth phenotype. Our data support the notion that there are no functional equivalents of the myc family of protooncogenes and also suggest that there are no c-Myc-activated gents that alone can substitute for c-Myc in control of cell proliferation.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA	Netherlands Cancer Institute; Netherlands Cancer Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.			Bernards, Rene/0000-0001-8677-3423	NATIONAL CANCER INSTITUTE [R29CA076418] Funding Source: NIH RePORTER; NCI NIH HHS [CA76418-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RALSTON R, 1991, NATURE, V353, P866, DOI 10.1038/353866a0; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803	36	52	53	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2000	19	29					3330	3334		10.1038/sj.onc.1203639	http://dx.doi.org/10.1038/sj.onc.1203639			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918589	Green Published			2022-12-25	WOS:000088019300011
J	Hinoi, T; Yamamoto, H; Kishida, M; Takada, S; Kishida, S; Kikuchi, A				Hinoi, T; Yamamoto, H; Kishida, M; Takada, S; Kishida, S; Kikuchi, A			Complex formation of adenomatous polyposis coli gene product and Axin facilitates glycogen synthase kinase-3 beta-dependent phosphorylation of beta-catenin and down-regulates beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; WNT SIGNALING PATHWAY; MOUSE FUSED LOCUS; F-BOX PROTEIN; XENOPUS EMBRYOS; NEGATIVE REGULATOR; FUNCTIONAL INTERACTION; PHOSPHATASE 2A; APC; TRANSCRIPTION	Adenomatous polyposis coli gene product (APC) functions as a tumor suppressor and its mutations in familial adenomatous polyposis and colorectal cancers lead to the accumulation of cytoplasmic beta -catenin. The molecular mechanism by which APC regulates the stability of beta -catenin was investigated. The central region of APC, APC-(1211-2075), has the beta -catenin- and Axin-binding sites and down-regulates beta -catenin. Glycogen synthase kinase-3 beta (GSK-3 beta) phosphorylated beta -catenin slightly in the presence of either APC-(1211-2075) or Axin(Delta beta -catenin) in which the beta -catenin-binding site is deleted, and greatly in the presence of both proteins. The enhancement of the GSK-3 beta -dependent phosphorylation of beta -catenin was eliminated by the APC-binding site of Axin. Axin down-regulated beta -catenin in SW480 cells, but not Axin(Delta beta -catenin). I, L cells where APC is intact, Axin(Delta beta -catenin) inhibited Wnt-dependent accumulation of beta -catenin but not Axin-(298-832)(Delta beta -catenin) in which the APC- and beta -catenin-binding sites are deleted. These results indicate that the complex formation of APC and Axin enhances the phosphorylation of beta -catenin by GSK-3 beta, leading to the down-regulation of beta -catenin.	Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Japan Sci & Technol Corp, PRESTO, Hiroshima 7348551, Japan; Kyoto Univ, Fac Sci, Ctr Mol & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Hiroshima University; Japan Science & Technology Agency (JST); Kyoto University	Kikuchi, A (corresponding author), Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.			Takada, Shinji/0000-0003-4125-6056; kishida, shosei/0000-0003-0405-851X				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Dale TC, 1998, BIOCHEM J, V329, P209; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; GLUECKSOHNSCHOENHEIMER S, 1949, J EXP ZOOL, V110, P47, DOI 10.1002/jez.1401100105; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Itoh K, 2000, MOL CELL BIOL, V20, P2228, DOI 10.1128/MCB.20.6.2228-2238.2000; Jho EH, 1999, BIOCHEM BIOPH RES CO, V266, P28, DOI 10.1006/bbrc.1999.1760; Kawahara K, 2000, J BIOL CHEM, V275, P8369, DOI 10.1074/jbc.275.12.8369; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kikuchi A, 1999, CELL SIGNAL, V11, P777, DOI 10.1016/S0898-6568(99)00054-6; Kikuchi A, 1999, CYTOKINE GROWTH F R, V10, P255, DOI 10.1016/S1359-6101(99)00017-9; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kodama S, 1999, J BIOL CHEM, V274, P27682, DOI 10.1074/jbc.274.39.27682; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; PERRY WL, 1995, GENETICS, V141, P321; PIERCE SB, 1995, DEVELOPMENT, V121, P755; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1997, CANCER RES, V57, P4624; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shibamoto S, 1998, GENES CELLS, V3, P659; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yanagawa SI, 1997, J BIOL CHEM, V272, P25243, DOI 10.1074/jbc.272.40.25243; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	58	104	113	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34399	34406		10.1074/jbc.M003997200	http://dx.doi.org/10.1074/jbc.M003997200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10906131	hybrid			2022-12-25	WOS:000165095300055
J	Tamir, Y; Bengal, E				Tamir, Y; Bengal, E			Phosphoinositide 3-kinase induces the transcriptional activity of MEF2 proteins during muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; CELL-CYCLE WITHDRAWAL; SKELETAL-MUSCLE; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; MYOGENIC DIFFERENTIATION; IGF-I; RETINOBLASTOMA PROTEIN; KINASE PATHWAY; ENHANCER	The activity of phosphoinositide 3-kinase (PI3-K) is essential for the differentiation of skeletal muscle cells by largely unknown mechanisms. Here we show that inhibition of PIS-K activity by the pharmacological agent LY294002 affects early processes of myoblast differentiation including the transcriptional activation of myogenin, Previous studies indicated that transcription of myogenin was dependent on MyoD and MEF2 proteins. We find that expression of a dominant negative form of PI3-K or growth in the presence of LY294002 inhibits cellular activity of MEF2 but not of MyoD. Evidence reveals that whereas MEF2 transcriptional activity is inhibited, its DNA binding activity remains unaffected. Recent studies demonstrated that phosphorylation by p38 mitogen-activated protein kinase (MAPK) induced transcriptional activity of MEFS proteins. We show that the phosphorylation of MEF2 occurring during muscle differentiation is prevented if the activity of PI3-K is inhibited. However, our results also indicate that p38 MAPK is not affected by PIS-K in muscle cells. Nevertheless, p38 MAPK. can substitute for PIS-K in the induction of MEF2 and muscle transcription. Together, these findings indicate that PI3-K affects skeletal muscle differentiation by inducing phosphorylation and transcriptional activity of MEF2 proteins in a parallel but distinct route from p38 MAPK.	Technion Israel Inst Technol, Fac Med, Rappaport Inst Res Med Sci, Dept Biochem, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Bengal, E (corresponding author), Technion Israel Inst Technol, Fac Med, Rappaport Inst Res Med Sci, Dept Biochem, POB 9649, IL-31096 Haifa, Israel.							BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Blaeser F, 2000, J BIOL CHEM, V275, P197, DOI 10.1074/jbc.275.1.197; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; Engert JC, 1996, J CELL BIOL, V135, P431, DOI 10.1083/jcb.135.2.431; FLORINI JR, 1990, J BIOL CHEM, V265, P13435; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FLORINI JR, 1987, MUSCLE NERVE, V10, P577, DOI 10.1002/mus.880100702; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; FLORINI JR, 1989, AM J PHYSIOL, V256, P701; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kumar S, 1999, BIOCHEM BIOPH RES CO, V263, P825, DOI 10.1006/bbrc.1999.1454; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Musaro A, 1999, MOL CELL BIOL, V19, P3115; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Ornatsky OI, 1999, NUCLEIC ACIDS RES, V27, P2646, DOI 10.1093/nar/27.13.2646; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; QUINN LS, 1994, J CELL PHYSIOL, V159, P387, DOI 10.1002/jcp.1041590302; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; ROSENTHAL SM, 1995, P NATL ACAD SCI USA, V92, P10307, DOI 10.1073/pnas.92.22.10307; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; Yang CC, 1998, NUCLEIC ACIDS RES, V26, P4771, DOI 10.1093/nar/26.20.4771; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zhao M, 1999, MOL CELL BIOL, V19, P21	56	84	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34424	34432		10.1074/jbc.M005815200	http://dx.doi.org/10.1074/jbc.M005815200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10896679	hybrid			2022-12-25	WOS:000165095300058
J	Cartwright, JL; Gasmi, L; Spiller, DG; McLennan, AG				Cartwright, JL; Gasmi, L; Spiller, DG; McLennan, AG			The Saccharomyces cerevisiae PCD1 gene encodes a peroxisomal nudix hydrolase active toward coenzyme A and its derivatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTT MOTIF; 3-OXOACYL-COA THIOLASE; PROTEIN; FAMILY; SEQUENCE; IMPORT; PURIFICATION; EXPRESSION; SIGNAL; YEAST	The PCD1 nudix hydrolase gene of Saccharomyces cerevisiae has been cloned and the Pcd1p protein characterized as a diphosphatase (pyrophosphatase) with specificity for coenzyme A and CoA derivatives. Oxidized CoA disulfide is preferred over CoA as a substrate with K-m and k(cat) values of 24 muM and 5.0 s(-1), respectively, compared with values for CoA of 280 muM and 4.6 s(-1) respectively. The products of CoA hydrolysis were 3'-phosphoadenosine 5'-monophosphate and 4'-phosphopantetheine. F- ions inhibited the activity with an IC50 of 22 muM. The sequence of Pcd1p contains a potential PTS2 peroxisomal targeting signal. When fused to the N terminus of yeast-enhanced green fluorescent protein, Pcd1p was shown to locate to peroxisomes by confocal microscopy. It was also shown to co-localize with peroxisomal thiolase by immunofluorescence microscopy. N-terminal sequence analysis of the expressed protein revealed the loss of 7 or 8 amino acids, suggesting processing of the proposed PTS2 signal after import, The function of Pcd1p may be to remove potentially toxic oxidized CoA disulfide from peroxisomes in order to maintain the capacity for beta -oxidation of fatty acids.	Univ Liverpool, Cell Regulat & Signalling Grp, Liverpool L69 7ZB, Merseyside, England; Univ Liverpool, Ctr Cell Imaging, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England	University of Liverpool; University of Liverpool	McLennan, AG (corresponding author), Univ Liverpool, Cell Regulat & Signalling Grp, Life Sci Bldg, Liverpool L69 7ZB, Merseyside, England.	agmclen@liv.ac.uk	Zhang, Ning/F-1387-2014; Spiller, David G/I-3645-2012	Spiller, David Geoffrey/0000-0003-2502-6787				Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BOCHNER BR, 1984, CELL, V37, P225, DOI 10.1016/0092-8674(84)90318-0; Bucovaz ET, 1997, BIOCHIMIE, V79, P787, DOI 10.1016/S0300-9084(97)86938-6; Cartwright JL, 1999, J BIOL CHEM, V274, P8604, DOI 10.1074/jbc.274.13.8604; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; DEHOOP MJ, 1992, BIOCHEM J, V286, P657, DOI 10.1042/bj2860657; delCardayre SB, 1998, J BIOL CHEM, V273, P5752, DOI 10.1074/jbc.273.10.5752; Dunckley T, 1999, EMBO J, V18, P5411, DOI 10.1093/emboj/18.19.5411; ERDMANN R, 1994, YEAST, V10, P1173, DOI 10.1002/yea.320100905; ERDMANN R, 1994, YEAST, V10, P935, DOI 10.1002/yea.320100708; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Gasmi L, 1999, BIOCHEM J, V344, P331, DOI 10.1042/0264-6021:3440331; Gaudon C, 1999, EMBO J, V18, P2229, DOI 10.1093/emboj/18.8.2229; Geraghty MT, 1999, P NATL ACAD SCI USA, V96, P2937, DOI 10.1073/pnas.96.6.2937; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; JACKOWSKI S, 1986, J BACTERIOL, V166, P866, DOI 10.1128/jb.166.3.866-871.1986; Kim JS, 1998, INT J BIOCHEM CELL B, V30, P629, DOI 10.1016/S1357-2725(97)00142-8; KING MT, 1985, ANAL BIOCHEM, V146, P173, DOI 10.1016/0003-2697(85)90412-9; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P4847, DOI 10.1093/nar/21.20.4847; MATHEW N, 1995, BIOCHEM J, V311, P717, DOI 10.1042/bj3110717; McLennan AG, 1999, INT J MOL MED, V4, P79; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; OSUMI T, 1992, BIOCHEM BIOPH RES CO, V186, P811, DOI 10.1016/0006-291X(92)90818-6; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; Safrany ST, 1999, J BIOL CHEM, V274, P21735, DOI 10.1074/jbc.274.31.21735; Sekiguchi M, 1996, GENES CELLS, V1, P139, DOI 10.1046/j.1365-2443.1996.d01-232.x; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; VALLARI DS, 1988, J BACTERIOL, V170, P3961, DOI 10.1128/jb.170.9.3961-3966.1988; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; Xu WL, 2000, BIOCHEM BIOPH RES CO, V273, P753, DOI 10.1006/bbrc.2000.2999	33	55	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32925	32930		10.1074/jbc.M005015200	http://dx.doi.org/10.1074/jbc.M005015200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10922370	hybrid			2022-12-25	WOS:000090003800076
J	Honda, S; Kashiwagi, M; Miyamoto, K; Takei, Y; Hirose, S				Honda, S; Kashiwagi, M; Miyamoto, K; Takei, Y; Hirose, S			Multiplicity, structures, and endocrine and exocrine natures of eel fucose-binding lectins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY CHROMATOGRAPHY; SPECIFICITY; MARKERS; SERUM	Lectins, a group of proteins that bind to cell surface carbohydrates and play important roles in innate immunity, are widely used experimentally to distinguish cell types and to induce cell proliferation. Eel serum lectins have been useful as anti-H hemagglutinins and also in lectin histochemistry as fucose-binding lectins (fucolectins), but their structures have not been determined. Here we report the primary structures and the sites of synthesis of eel fucolectins. Eel serum fucolectins were separated by two-dimensional gel electrophoresis and sequenced. cDNA cloning, based on the amino acid sequence information, and Northern blot analysis indicated that 1) the fucose-binding lectins are secretory proteins and have unique structures among the lectins, exhibiting only weak similarities to frog pentraxin, horseshoe crab tachylectin-4, and fly fw protein; 2) there are at least seven closely related members; and 3) their messages are abundantly expressed in the liver and in significant levels in the gill and intestine. The lectin-producing hepatic cells were identified by immunostaining; in the gill, exocrine mucous cells were stained, suggesting that serum fucolectins derive from the liver. Using primary culture of eel hepatocytes, the message levels were shown to be increased by lipopolysaccharide, suggesting a role for fucolectins in host defense. SDS-polyacrylamide gel electrophoresis analysis showed that eel fucolectins have a SDS-resistant tetrameric structure consisting of two disulfide-linked dimers.	Tokyo Inst Technol, Dept Biol Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Univ Tokyo, Ocean Res Inst, Nakano Ku, Tokyo 1648639, Japan	Tokyo Institute of Technology; University of Tokyo	Hirose, S (corresponding author), Tokyo Inst Technol, Dept Biol Sci, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.		; Takei, Yoshio/R-2368-2017	Honda, Shinji/0000-0002-1584-4156; Takei, Yoshio/0000-0003-3004-8905				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Baldus SE, 1996, GLYCOCONJUGATE J, V13, P585, DOI 10.1007/BF00731446; BEZKOROVAINY A, 1971, BIOCHEMISTRY-US, V10, P3761; DANGUY A, 1988, Biological Structures and Morphogenesis, V1, P93; DCruz OJ, 1996, FERTIL STERIL, V65, P843, DOI 10.1016/S0015-0282(16)58224-7; Gabius HJ, 1998, BIOTECH HISTOCHEM, V73, P263, DOI 10.3109/10520299809141120; GERCKEN J, 1994, COMP BIOCHEM PHYS B, V108, P449, DOI 10.1016/0305-0491(94)90098-1; HAYASHI S, 1985, B JPN SOC SCI FISH, V51, P765; HAYASHI S, 1998, CELL TISSUE CULTURE, pA23; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; HOREJSI V, 1978, BIOCHIM BIOPHYS ACTA, V538, P299, DOI 10.1016/0304-4165(78)90358-6; Iwamatsu A, 1996, J BIOCHEM-TOKYO, V120, P29; JONSSON B, 1944, ACTA PATH MICROBIO S, V54, P456; JUDD WJ, 1980, CRC CR REV CL LAB SC, V12, P171, DOI 10.3109/10408368009108729; KATAFUCHI T, 1994, EUR J BIOCHEM, V222, P835, DOI 10.1111/j.1432-1033.1994.tb18930.x; KELLY C, 1984, BIOCHEM J, V220, P221, DOI 10.1042/bj2200221; KONAMI Y, 1991, J BIOCHEM-TOKYO, V109, P650, DOI 10.1093/oxfordjournals.jbchem.a123435; LeshkoLindsay L, 1997, DEVELOPMENT, V124, P169; MATSUMOTO I, 1974, BIOCHEMISTRY-US, V13, P582, DOI 10.1021/bi00700a028; Saito T, 1997, J BIOL CHEM, V272, P30703, DOI 10.1074/jbc.272.49.30703; SEERY LT, 1993, P ROY SOC B-BIOL SCI, V253, P263, DOI 10.1098/rspb.1993.0112; Sengupta Susmita, 1997, Indian Journal of Experimental Biology, V35, P103; TAKEI Y, 1988, COMP BIOCHEM PHYS A, V91, P293, DOI 10.1016/0300-9629(88)90419-7; Wagner M, 1988, Acta Histochem Suppl, V36, P115; WATKINS WM, 1952, NATURE, V169, P825, DOI 10.1038/169825a0; XU XF, 1994, EXP PARASITOL, V79, P399, DOI 10.1006/expr.1994.1102	26	84	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33151	33157		10.1074/jbc.M002337200	http://dx.doi.org/10.1074/jbc.M002337200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10924498	hybrid			2022-12-25	WOS:000090003800104
J	Johnson, BD; Chadli, A; Felts, SJ; Bouhouche, I; Catelli, MG; Toft, DO				Johnson, BD; Chadli, A; Felts, SJ; Bouhouche, I; Catelli, MG; Toft, DO			Hsp90 chaperone activity requires the full-length protein and interaction among its multiple domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; C-TERMINAL REGION; ATP-BINDING; IN-VIVO; MOLECULAR CHAPERONE; ESTROGEN-RECEPTOR; TYROSINE KINASE; IDENTIFICATION; HYDROLYSIS; HSP70	Hsp90 is an abundant and ubiquitous protein involved in a diverse array of cellular processes. Mechanistically we understand little of the apparently complex interactions of this molecular chaperone. Recently, progress has been made in assigning some of the known functions of hsp90, such as nucleotide binding and peptide binding, to particular domains within the protein. We used fragments of hsp90 and chimeric proteins containing functional domains from hsp90 or its mitochondrial homolog, TRAP1, to study the requirements for this protein in the folding of firefly luciferase as well as in the prevention of citrate synthase aggregation. In agreement with others who have found peptide binding and Limited chaperone ability in fragments of hsp90, we see that multiple fragments from hsp90 can prevent the aggregation of thermally denatured citrate synthase, a measure of passive chaperoning activity. However, in contrast to these results, the luciferase folding assay was found to be much more demanding. Here, folding is mediated by hsp70 and hsp40, requires ATP, and thus is a measure of active chaperoning. Hsp90 and the cochaperone, Hop, enhance this process. This hsp90 activity was only observed using full-length hsp90 indicating that the cooperation of multiple functional domains is essential for active, chaperone-mediated folding.	Mayo Clin & Mayo Grad Sch Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; CNRS UPR 1524, F-75014 Paris, France	Mayo Clinic; Centre National de la Recherche Scientifique (CNRS)	Toft, DO (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD009140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046249] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 09140] Funding Source: Medline; NIDDK NIH HHS [DK 46249] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; Bartha BB, 1998, BIOPHYS CHEM, V72, P313, DOI 10.1016/S0301-4622(98)00114-8; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CHADLI A, 2000, IN PRESS P NATL ACAD; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; Chen CF, 1996, MOL CELL BIOL, V16, P4691; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Felts SJ, 2000, J BIOL CHEM, V275, P3305, DOI 10.1074/jbc.275.5.3305; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; GUPTA RS, 1995, MOL BIOL EVOL, V12, P1063; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Maruya M, 1999, J MOL BIOL, V285, P903, DOI 10.1006/jmbi.1998.2349; Meng X, 1996, J CELL SCI, V109, P1677; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Scheibel T, 1997, J BIOL CHEM, V272, P18608, DOI 10.1074/jbc.272.30.18608; Scheibel T, 1999, P NATL ACAD SCI USA, V96, P1297, DOI 10.1073/pnas.96.4.1297; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Toft DO, 1998, TRENDS ENDOCRIN MET, V9, P238, DOI 10.1016/S1043-2760(98)00060-5; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; Yue L, 1999, GENETICS, V151, P1065	45	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32499	32507		10.1074/jbc.M005195200	http://dx.doi.org/10.1074/jbc.M005195200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913439	hybrid			2022-12-25	WOS:000090003800018
J	Mio, K; Carrette, O; Maibach, HI; Stern, R				Mio, K; Carrette, O; Maibach, HI; Stern, R			Evidence that the serum inhibitor of hyaluronidase may be a member of the inter-alpha-inhibitor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN PH-20; MAJOR THERMAL-INJURY; EXTRACELLULAR-MATRIX; TRYPSIN-INHIBITOR; SOLUBLE HYALURONIDASE; PLASMA HYALURONAN; MARKED INCREASE; ELEVATED LEVELS; MESSENGER-RNA; HEAVY-CHAINS	A study of the uncharacterized serum inhibitors of hyaluronidase, first described half a century ago, was undertaken. Activity was measured against bovine testicular hyaluronidase using a microtiter-based assay and reverse hyaluronan substrate gel zymography, The predominant inhibitory activity was magnesium-dependent and could be eliminated by protease or chondroitinase digestion and by heat treatment. Kinetics of inhibition were similar against hyaluronidases from testis and snake and bee venoms. The inhibitor had no effect on Streptomyces hyaluronidase, indicating that inhibition was not through protection of the hyaluronan substrate. Inhibition levels in serum were increased in mice following carbon tetrachloride or interleukin-1 injection, inducers of the acute-phase response. Reverse zymography identified a predominant band of 120-kDa relative molecular size, with two bands of greater and one of smaller size. The predominant protein was tentatively identified as a member of the inter-or-inhibitor family. Inhibition was also observed using either purified inter-cu-inhibitor or an inter-or-inhibitor-related 120-kDa complex. Inter-cu-inhibitor, found in the hyaluronan-rich cumulus mass surrounding mammalian ova and the coat of fibroblasts and mesothelial cells, may function to stabilize such matrices by protecting against hyaluronidase degradation. Turnover of circulating hyaluronan is extraordinarily rapid, with a half-life of 2-5 min. Prompt increases in levels of serum hyaluronan occur in patients with shock, septicemia, or massive burns, increases that can be attributed, in part, to suppression of degradation by these acute-phase reactants, the inhibitors of hyaluronidase.	Univ Calif San Francisco, Sch Med, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Dermatol, San Francisco, CA 94143 USA; Lion Corp, Life Sci Res Ctr, Kanagawa 2560811, Japan; Univ Cincinnati, Vontz Ctr Mol Studies, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Lion Corporation; University System of Ohio; University of Cincinnati	Stern, R (corresponding author), Univ Calif San Francisco, Sch Med, Dept Pathol, San Francisco, CA 94143 USA.	rstern@itsa.ucsf.edu	Mio, Kazuhiro/L-7488-2018	Mio, Kazuhiro/0000-0002-1655-8231	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029894] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011912] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-29894] Funding Source: Medline; NIDCR NIH HHS [P50 DE/CA 11912] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AUSTIN CR, 1948, NATURE, V162, P63, DOI 10.1038/162063a0; Balazs EA, 1998, WENN GR INT, V72, P185; BALDUYCK M, 1989, BIOL CHEM H-S, V370, P329, DOI 10.1515/bchm3.1989.370.1.329; BERG S, 1988, SCAND J CLIN LAB INV, V48, P727, DOI 10.3109/00365518809088752; CAMAIONI A, 1993, J BIOL CHEM, V268, P20473; Carrette O, 1997, BBA-PROTEIN STRUCT M, V1338, P21, DOI 10.1016/S0167-4838(96)00184-7; CASTILLO GM, 1993, FEBS LETT, V318, P292, DOI 10.1016/0014-5793(93)80531-X; CHEN L, 1992, J BIOL CHEM, V267, P12380; Chen L, 1996, J BIOL CHEM, V271, P19409, DOI 10.1074/jbc.271.32.19409; Cherr GN, 1996, DEV BIOL, V175, P142, DOI 10.1006/dbio.1996.0102; Csoka AB, 1999, GENOMICS, V60, P356, DOI 10.1006/geno.1999.5876; CSOKA AB, 2001, ENCY MOL MED; Csoka TB, 1997, FEBS LETT, V417, P307, DOI 10.1016/S0014-5793(97)01309-4; Csoka TB, 1998, GENOMICS, V48, P63, DOI 10.1006/geno.1997.5158; Csoka TB, 1997, INVAS METAST, V17, P297; Delpech B, 1997, J INTERN MED, V242, P41, DOI 10.1046/j.1365-2796.1997.00172.x; DORFMAN A, 1948, J BIOL CHEM, V174, P621; Ellis IR, 1998, CYTOKINE, V10, P281, DOI 10.1006/cyto.1997.0294; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; FERRARA JJ, 1991, J SURG RES, V50, P240, DOI 10.1016/0022-4804(91)90185-O; FISZERSZAFARZ B, 1968, P SOC EXP BIOL MED, V129, P300; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; Fries E, 1998, WENN GR INT, V72, P149; Frost GI, 1997, BIOCHEM BIOPH RES CO, V236, P10, DOI 10.1006/bbrc.1997.6773; Frost GI, 1997, ANAL BIOCHEM, V251, P263, DOI 10.1006/abio.1997.2262; Furuya T, 1997, BIOL PHARM BULL, V20, P973, DOI 10.1248/bpb.20.973; GMACHL M, 1993, FEBS LETT, V336, P545, DOI 10.1016/0014-5793(93)80873-S; GRAIS ML, 1948, J INVEST DERMATOL, V11, P259, DOI 10.1038/jid.1948.95; GUERRA F, 1946, SCIENCE, V103, P686, DOI 10.1126/science.103.2684.686; GUNTENHONER MW, 1992, MATRIX, V12, P388, DOI 10.1016/S0934-8832(11)80035-1; HAAS E, 1946, J BIOL CHEM, V163, P63; Heckel D, 1998, HUM MOL GENET, V7, P1859, DOI 10.1093/hmg/7.12.1859; HELDIN P, 1989, BIOCHEM J, V258, P919, DOI 10.1042/bj2580919; Hunnicutt GR, 1996, BIOL REPROD, V54, P1343, DOI 10.1095/biolreprod54.6.1343; HYMAN LJ, 1955, SURG GYNECOL OBSTET, V100, P515; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; JONES CP, 1989, THROMB RES, V55, P791; KAKEGAWA H, 1985, CHEM PHARM BULL, V33, P5079; KAKEGAWA H, 1988, PLANTA MED, P385, DOI 10.1055/s-2006-962477; KAKEGAWA H, 1985, CHEM PHARM BULL, V33, P3738; KINOSHITA T, 1989, BIOCHEM BIOPH RES CO, V165, P1229, DOI 10.1016/0006-291X(89)92733-2; Knudson W, 1996, AM J PATHOL, V148, P1721; KNUDSON W, 1989, BIOL HYALURONAN, P151; KOLAROVA M, 1977, NEOPLASMA, V24, P285; KREIL G, 1995, PROTEIN SCI, V4, P1666, DOI 10.1002/pro.5560040902; KUPPUSAMY UR, 1990, BIOCHEM PHARMACOL, V40, P397, DOI 10.1016/0006-2952(90)90709-T; KUPPUSAMY UR, 1993, PHARMACOL TOXICOL, V72, P290, DOI 10.1111/j.1600-0773.1993.tb01652.x; KUPPUSAMY UR, 1991, EXPERIENTIA, V47, P1196, DOI 10.1007/BF01918384; KUSHWAH A, 1978, INDIAN J EXP BIOL, V16, P222; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Li MW, 1997, BIOL REPROD, V56, P1383, DOI 10.1095/biolreprod56.6.1383; LIN Y, 1994, J CELL BIOL, V125, P1157, DOI 10.1083/jcb.125.5.1157; Lokeshwar VB, 1996, CANCER RES, V56, P651; Madan AK, 1999, ONCOL REP, V6, P607; MATHEWS MB, 1952, ARCH BIOCHEM BIOPHYS, V35, P93, DOI 10.1016/S0003-9861(52)80053-0; MATHEWS MB, 1955, PHYSIOL REV, V35, P381, DOI 10.1152/physrev.1955.35.2.381; McClean D, 1942, NATURE, V150, P627, DOI 10.1038/150627a0; Meyer MF, 1997, FEBS LETT, V413, P385, DOI 10.1016/S0014-5793(97)00936-8; MOORE DH, 1949, J BIOL CHEM, V179, P377; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NEWMAN JK, 1955, J BIOL CHEM, V217, P31; ONARHEIM H, 1991, SCAND J CLIN LAB INV, V51, P693, DOI 10.3109/00365519109104582; ONARHEIM H, 1992, CIRC SHOCK, V37, P159; ONARHEIM H, 1991, J SURG RES, V50, P259, DOI 10.1016/0022-4804(91)90188-R; PERREAULT S, 1980, J REPROD FERTIL, V60, P461, DOI 10.1530/jrf.0.0600461; POGREL MA, 1999, INT J ORAL BIOL, V24, P75; PRIMAKOFF P, 1985, J CELL BIOL, V101, P2239, DOI 10.1083/jcb.101.6.2239; Salier JP, 1996, BIOCHEM J, V315, P1, DOI 10.1042/bj3150001; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P435, DOI 10.1016/0968-0004(90)90282-G; Scott J. W., 1989, Circular - Agricultural Experiment Station, University of Florida; SJOBERG EM, 1990, BIOCHEM J, V272, P113; SNIVELY GG, 1950, J CLIN INVEST, V29, P1087, DOI 10.1172/JCI102340; Spicer AP, 1997, J BIOL CHEM, V272, P8957; Sun LK, 1998, KIDNEY BLOOD PRESS R, V21, P413, DOI 10.1159/000025893; SZARY A, 1975, Archivum Immunologiae et Therapiae Experimentalis, V23, P131; TOLKSDORF S, 1949, J LAB CLIN MED, V34, P74; TONNESEN HH, 1989, INT J PHARM, V50, P91, DOI 10.1016/0378-5173(89)90132-4; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; TOOLE BP, 1984, ROLE EXTRACELLULAR M, P43; Tschesche H, 1998, J PROTEIN CHEM, V17, P549; WEIGEL PH, 1986, J THEOR BIOL, V119, P219, DOI 10.1016/S0022-5193(86)80076-5; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WOLF RA, 1984, AM J CARDIOL, V53, P941, DOI 10.1016/0002-9149(84)90529-0; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YUKI H, 1963, J BIOL CHEM, V238, P1877	86	49	58	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32413	32421		10.1074/jbc.M005428200	http://dx.doi.org/10.1074/jbc.M005428200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10908571	hybrid			2022-12-25	WOS:000090003800007
J	Park, JK; Keyhani, NO; Roseman, S				Park, JK; Keyhani, NO; Roseman, S			Chitin catabolism in the marine bacterium Vibrio furnissii - Identification, molecular cloning, and characterization of a N-N '-diacetylchitobiose phosphorylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLOBIOSE PHOSPHORYLASE; CELLVIBRIO-GILVUS; CASCADE; OLIGOSACCHARIDES; DEGRADATION; CHEMOTAXIS; EXPRESSION; TRANSPORT; MECHANISM; GLUCOSE	The major product of bacterial chitinases is N,N'-diacetylchitobiose or (GlcNAc)(2). We have previously demonstrated that (GlcNAc)(2) is taken up unchanged by a specific permease in Vibrio furnissii (unlike Escherichia coli). It is generally held that marine Vibrios further metabolize cytoplasmic (GlcNAc)(2) by hydrolyzing it to two GlcNAcs (i.e. a "chitobiase"). Here we report instead that V. furnissii expresses a novel phosphorylase. The gene, chbP, was cloned into E. coli; the enzyme, ChbP, was purified to apparent homogeneity, and characterized kinetically. The DNA sequence indicates that chbP encodes an 89-kDa protein. The enzymatic reaction was characterized as follows. (GlcNAc)2 + Pi reversible arrow GlcNAc-alpha -1-P + GlcNAc K'cq = 1.0 +/- 0.2 REACTION 1 The K-m values for the four substrates were in the range 0.3-1 mM. p-Nitrophenyl-(GlcNAc)(2) was cleaved at 8.5% the rate of (GlcNAc)(2), and p-nitrophenyl (PNP)-GlcNAc was 36% as active as GlcNAc in the reverse direction. ALL other compounds tested displayed less than or equal to 1% of the activity of the indicated substrates including: for phosphorolysis, higher chitin oliogsaccharides, (GlcNAc)(n), n = 3-5, cellobiose, PNP-GlcNAc, and PNP-(GlcNAc)(3); for synthesis, (GlcNAc)(n) (n = 2-5), glucose, etc. (GlcNAc)(2) is a major regulator of the chitin catabolic cascade. Conceivably GlcNAc-alpha -1-P plays a similar but different role in regulation.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Roseman, S (corresponding author), Johns Hopkins Univ, Dept Biol, Mudd Hall, Rm 214,3400 N Charles St, Baltimore, MD 21218 USA.		Keyhani, Nemat O/I-8150-2013		NIGMS NIH HHS [GM51215] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V1; BASSLER BL, 1991, J BIOL CHEM, V266, P24268; BASSLER BL, 1991, J BIOL CHEM, V266, P24276; BOCHNER BR, 1982, ANAL BIOCHEM, V122, P100, DOI 10.1016/0003-2697(82)90257-3; Bouma CL, 1996, J BIOL CHEM, V271, P33457, DOI 10.1074/jbc.271.52.33457; Chitlaru E, 1996, J BIOL CHEM, V271, P33433, DOI 10.1074/jbc.271.52.33433; COMB DG, 1960, J BIOL CHEM, V235, P2529; DAKHOVA ON, 1993, BIOCHEM BIOPH RES CO, V194, P1359, DOI 10.1006/bbrc.1993.1974; FOSTER AB, 1960, ADV CARBOHYD CHEM, V15, P371; HOROWITZ ST, 1957, J AM CHEM SOC, V79, P5046, DOI 10.1021/ja01575a059; Keyhani N, 2000, J BIOL CHEM, V275, P33110, DOI 10.1074/jbc.M001717200; Keyhani NO, 1999, BBA-GEN SUBJECTS, V1473, P108, DOI 10.1016/S0304-4165(99)00172-5; Keyhani NO, 2000, J BIOL CHEM, V275, P33102, DOI 10.1074/jbc.M001045200; Keyhani NO, 2000, J BIOL CHEM, V275, P33091, DOI 10.1074/jbc.M001044200; Keyhani NO, 2000, J BIOL CHEM, V275, P33084, DOI 10.1074/jbc.M001043200; Keyhani NO, 2000, J BIOL CHEM, V275, P33068, DOI 10.1074/jbc.M001041200; Keyhani NO, 1996, J BIOL CHEM, V271, P33425, DOI 10.1074/jbc.271.52.33425; Keyhani NO, 1996, J BIOL CHEM, V271, P33414, DOI 10.1074/jbc.271.52.33414; Keyhani NO, 1996, J BIOL CHEM, V271, P33409, DOI 10.1074/jbc.271.52.33409; KITAOKA M, 1992, BIOSCI BIOTECH BIOCH, V56, P652, DOI 10.1271/bbb.56.652; Liu AM, 1998, J FERMENT BIOENG, V85, P511, DOI 10.1016/S0922-338X(98)80071-8; MATHEIS G, 1984, INT J BIOCHEM, V16, P867, DOI 10.1016/0020-711X(84)90145-9; MIEYAL JJ, 1972, ENZYMES, V7, P515; PERKINS SJ, 1977, CARBOHYD RES, V59, P19, DOI 10.1016/S0008-6215(00)83289-9; Reichenbecher M, 1997, EUR J BIOCHEM, V247, P262, DOI 10.1111/j.1432-1033.1997.00262.x; ROSEMAN S, 1956, ANAL CHEM, V28, P1743, DOI 10.1021/ac60119a028; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SOTOGIL RW, 1984, CHITIN CHITOSAN RELA; VOET JG, 1970, J BIOL CHEM, V245, P1020; VOGEL HJ, 1989, METHOD ENZYMOL, V177, P263; WOOD WA, 1988, METHODS ENZYMOL, V161; YU C, 1993, J BIOL CHEM, V268, P9405; YU C, 1991, J BIOL CHEM, V266, P24260; Zechmeister L, 1939, ENZYMOLOGIA, V7, P165; Zechmeister L, 1939, ENZYMOLOGIA, V7, P170; Zobell CE, 1938, J BACTERIOL, V35, P275, DOI 10.1128/JB.35.3.275-287.1938; [No title captured]	38	60	64	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33077	33083		10.1074/jbc.M001042200	http://dx.doi.org/10.1074/jbc.M001042200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913116	hybrid			2022-12-25	WOS:000090003800095
J	Taguchi, T; Ogawa, T; Inoue, S; Inoue, Y; Sakamoto, Y; Korekane, H; Taniguchi, N				Taguchi, T; Ogawa, T; Inoue, S; Inoue, Y; Sakamoto, Y; Korekane, H; Taniguchi, N			Purification and characterization of UDP-GlcNAc: GlcNac beta 1-6(GlcNAc beta 1-2)Man alpha 1-R [GlcNAc to man]-beta 1, 4-N-acetylglucosaminyltransferase VI from hen oviduct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-V; GLYCOPROTEIN-SYNTHESIS; CDNA CLONING; UDP-N-ACETYLGLUCOSAMINE-ALPHA-3-D-MANNOSIDE BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFE; MOLECULAR-CLONING; RAT-KIDNEY; CELL-LINE; EXPRESSION; BETA-1,4-N-ACETYLGLUCOSAMINYLTRANSFERASE; LIVER	A new beta1,4-N-acetylglucosaminyltransferase (GnT) responsible for the formation of branched N-linked complex-type sugar chains has been purified 64,000-fold in 16% yield from a homogenate of hen oviduct by column chromatography procedures using Q-Sepharose FF, Ni2+-chelating Sepharose FF, and UDP-hexanolamineagarose. This enzyme catalyzes the transfer of GlcNAc from UDP-GlcNAc to tetraantennary oligosaccharide and produces pentaantennary oligosaccharide with the beta1-4-linked GlcNAc residue on the Man alpha1-6 arm. It requires a divalent cation such as Mn2+ and has an apparent molecular weight of 72,000 under nonreducing conditions. The enzyme does not act on biantennary oligosaccharide (GnT I and II product), and beta1,6-N-acetylglucosaminylation of the Man alpha1-6 arm (GnT V product) is essential for its activity. This clearly distinguishes it from GnT TV, which is known to generate a beta1-4-linked GlcNAc residue only on the Man alpha1-3 arm. Based on these findings, we conclude that this enzyme is UDP-GlcNAc:GlcNAc beta 1-6 (GlcNAc beta1-2)Man alpha1-R [Glc-NAc to Man]-beta1,4-N-acetylglucosaminyltransferase VI. This is the only known enzyme that has not been previously purified among GnTs responsible for antenna formation on the cores of N-linked complex-type sugar chains.	Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; RIKEN, Wako, Saitama 3510198, Japan; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan	Osaka University; RIKEN; Academia Sinica - Taiwan	Taniguchi, N (corresponding author), Osaka Univ, Sch Med, Dept Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	proftani@biochem.med.osaka-u.ac.jp	Taguchi, Tomohiko/I-5014-2019; Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Taguchi, Tomohiko/0000-0003-0464-6370; Taniguchi, Naoyuki/0000-0001-5889-5968; 				BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BROCKHAUSEN I, 1989, J BIOL CHEM, V264, P11211; BROCKHAUSEN I, 1992, CARBOHYD RES, V236, P281, DOI 10.1016/0008-6215(92)85022-R; CAMPION B, 1989, EUR J BIOCHEM, V184, P405, DOI 10.1111/j.1432-1033.1989.tb15032.x; DAGOSTARO GAF, 1995, J BIOL CHEM, V270, P15211, DOI 10.1074/jbc.270.25.15211; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; INOUE S, 1997, GLYCOPROTEINS, V2, P143; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Minowa MT, 1998, J BIOL CHEM, V273, P11556, DOI 10.1074/jbc.273.19.11556; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; NISHIKAWA A, 1990, BIOCHIM BIOPHYS ACTA, V1035, P313, DOI 10.1016/0304-4165(90)90094-D; NISHIKAWA Y, 1988, J BIOL CHEM, V263, P8270; Oguri S, 1997, J BIOL CHEM, V272, P22721, DOI 10.1074/jbc.272.36.22721; OPPENHEIMER CL, 1981, J BIOL CHEM, V256, P799; PARENTE JP, 1982, J BIOL CHEM, V257, P13173; Raju TS, 1998, J BIOL CHEM, V273, P14090, DOI 10.1074/jbc.273.23.14090; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; Taguchi T, 1997, BIOCHEM BIOPH RES CO, V230, P533, DOI 10.1006/bbrc.1996.6013; Taguchi T, 1998, ANAL BIOCHEM, V255, P155, DOI 10.1006/abio.1997.2465; YAMASHITA K, 1982, J BIOL CHEM, V257, P2809; Yoshida A, 1999, GLYCOBIOLOGY, V9, P303, DOI 10.1093/glycob/9.3.303	27	20	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32598	32602		10.1074/jbc.M004673200	http://dx.doi.org/10.1074/jbc.M004673200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10903319	hybrid			2022-12-25	WOS:000090003800032
J	Clyde-Smith, J; Silins, G; Gartside, M; Grimmond, S; Etheridge, M; Apolloni, A; Hayward, N; Hancock, JF				Clyde-Smith, J; Silins, G; Gartside, M; Grimmond, S; Etheridge, M; Apolloni, A; Hayward, N; Hancock, JF			Characterization of RasGRP2, a plasma membrane-targeted, dual specificity Ras/Rap exchange factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; RAS SIGNALING PATHWAY; BINDING DOMAIN; FACTOR SOS; ACTIVATION; PROTEIN; GRB2; RECEPTOR; SHC; COMPLEXES	Ras proteins operate as molecular switches in signal transduction pathways downstream of tyrosine kinases and G-protein-coupled receptors. Ras is switched from the inactive GDP-bound state to the active GTP-bound state by guanine nucleotide exchange factors (GEFs), We report here the cloning and characterization of RasGRP2, a longer alternatively spliced form of the recently cloned RapGEF, CalDAG-GEFI. A unique feature of RasGRP2 is that it is targeted to the plasma membrane by a combination of N-terminal myristoylation and palmitoylation. In vivo, RasGRP2 selectively catalyzes nucleotide exchange on N- and Ki-Ras, but not Ha-Pas. RasGRP2 also catalyzes nucleotide exchange on Rap1, but this RapGEF activity is less potent than that associated with CalDAG-GEFI. The nucleotide exchange activity of RasGRP2 toward N-Ras is stimulated by diacylglycerol and inhibited by calcium. The effects of diacylglycerol and calcium are additive but are not accompanied by any detectable change in the subcellular localization of RasGRP2. In contrast, CalDAG-GEFI is localized predominantly to the cytosol and lacks Pas exchange activity in vivo. However, prolonged exposure to phorbol esters, or growth in serum, results in localization of CalDAG-GEFI to the cell membrane and restoration of Pas exchange activity. Expression of RasGRP2 or CalDAG-GEFI in NIH3T3 cells transfected with wild type N-Ras results in an accelerated growth rate but not morphologic transformation. Thus, under appropriate growth conditions, CalDAG-GEFI and RasGRP2 are dual specificity Ras and Rap exchange factors.	Univ Queensland, Sch Med, Dept Pathol, Queensland Canc Fund,Lab Expt Oncol, Brisbane, Qld 4006, Australia; Queensland Inst Med Res, Bancroft Ctr, Queensland Canc Fund, Res Unit, Brisbane, Qld 4006, Australia	Cancer Council Queensland; University of Queensland; Cancer Council Queensland; QIMR Berghofer Medical Research Institute	Hancock, JF (corresponding author), Univ Queensland, Sch Med, Dept Pathol, Queensland Canc Fund,Lab Expt Oncol, Herston Rd, Brisbane, Qld 4006, Australia.		Clyde-Smith, Jodi/R-8910-2016; hayward, nick/AAV-8802-2020; Grimmond, Sean M/J-5304-2016; hayward, nicholas k/C-1367-2015; Grimmond, Sean/K-3246-2019	Clyde-Smith, Jodi/0000-0001-9798-9924; Grimmond, Sean M/0000-0002-8102-7998; hayward, nicholas k/0000-0003-4760-1033; Grimmond, Sean/0000-0002-8102-7998; Hancock, John/0000-0003-0542-4710				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Bergman L, 1999, GENOMICS, V55, P49, DOI 10.1006/geno.1998.5625; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Byrne JL, 1996, ONCOGENE, V13, P2055; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kedra D, 1997, HUM GENET, V100, P611, DOI 10.1007/s004390050562; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; Sturani E, 1997, EXP CELL RES, V235, P117, DOI 10.1006/excr.1997.3660; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Wittinghofer F, 1998, NATURE, V394, P317, DOI 10.1038/28492	46	104	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32260	32267		10.1074/jbc.M006087200	http://dx.doi.org/10.1074/jbc.M006087200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10918068	hybrid			2022-12-25	WOS:000089858900097
J	DeLong, CJ; Qin, LY; Cui, Z				DeLong, CJ; Qin, LY; Cui, Z			Nuclear localization of enzymatically active green fluorescent protein-CTP : phosphocholine cytidylyltransferase alpha fusion protein is independent of cell cycle conditions and cell types	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CTP; PHOSPHATIDYLCHOLINE SYNTHESIS; ENDOPLASMIC-RETICULUM; HELA-CELLS; IDENTIFICATION; TRANSLOCATION; BIOSYNTHESIS; HEPATOCYTES; EXPRESSION; CYTOSOL	To address the recent controversy about the subcellular localization of CTP:phosphocholine cytidylyltransferase alpha (CT alpha), this study was designed to visualize green fluorescent protein (GFP).CT alpha fusion proteins directly and continuously under different conditions of cell cycling and in various cell lines. The GFP.CT alpha fusion proteins were enzymatically active and capable of rescuing mutant cells with a temperature-sensitive CT. The expressed GFP-CT alpha fusion protein was localized to the nucleus in all cell lines and required the N-terminal nuclear targeting sequence. Serum depletion/replenishment did not cause shuttling of CT alpha between the nucleus and cytoplasm. Moreover, the subcellular localization of CT alpha was examined continuously through all stages of the cell cycle in synchronized cells. No shuttling of CT alpha between the nucleus and cytoplasm was observed at any stage of the cell cycle. Stimulation of cells with oleate had no effect on the localization of CT alpha. The GFP.CT alpha lacking the nuclear targeting sequence stayed exclusively in the cytoplasm. Regardless of their localization, the GFP.CT alpha fusion proteins were equally active for phosphatidylcholine synthesis and mutant rescue. We conclude that the nuclear localization of CT alpha is a biological event independent of cell cycle in most mammalian cells and is unrelated to activation of phosphatidylcholine synthesis.	Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University	Cui, Z (corresponding author), Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA.			DeLong, Cynthia/0000-0002-6823-8619	NCI NIH HHS [R01-CA79670, CA-09422] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009422, R01CA079670] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P26, DOI 10.1016/0005-2760(87)90214-1; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; DAVIS RA, 1979, J BIOL CHEM, V254, P2010; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; GEORGE TP, 1989, BIOCHIM BIOPHYS ACTA, V1004, P283, DOI 10.1016/0005-2760(89)90075-1; GOSLIN K, 1989, J CELL BIOL, V109, P1621, DOI 10.1083/jcb.109.4.1621; Houweling M, 1996, EUR J CELL BIOL, V69, P55; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Jack DB, 1996, MOL MED TODAY, V2, P271; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; Northwood IC, 1999, J BIOL CHEM, V274, P26240, DOI 10.1074/jbc.274.37.26240; PELECH SL, 1983, J BIOL CHEM, V258, P6782; SWEITZER TD, 1994, ARCH BIOCHEM BIOPHYS, V311, P107, DOI 10.1006/abbi.1994.1215; TERCE F, 1992, BIOCHEM J, V282, P333, DOI 10.1042/bj2820333; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; WANG YL, 1993, J BIOL CHEM, V268, P5512; WANG YL, 1993, J BIOL CHEM, V268, P5899; WANG YL, 1995, J BIOL CHEM, V270, P354, DOI 10.1074/jbc.270.1.354; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WAWRA E, 1983, MOL CELL BIOL, V3, P297, DOI 10.1128/MCB.3.3.297; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; Yang JL, 1997, BIOCHEM J, V325, P29, DOI 10.1042/bj3250029	30	50	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32325	32330		10.1074/jbc.M004644200	http://dx.doi.org/10.1074/jbc.M004644200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10918057	hybrid			2022-12-25	WOS:000089858900105
J	Mould, JA; Drury, JE; Frings, SM; Kaupp, UB; Pekosz, A; Lamb, RA; Pinto, LH				Mould, JA; Drury, JE; Frings, SM; Kaupp, UB; Pekosz, A; Lamb, RA; Pinto, LH			Permeation and activation of the M-2 ion channel of influenza A virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; M2 PROTEIN; A VIRUSES; TRANSMEMBRANE DOMAIN; PROTON MOVEMENT; LIPID BILAYERS; MOBILE BUFFERS; PH; HEMAGGLUTININ; AMANTADINE	The M-2 ion channel protein of influenza A virus is essential for mediating protein-protein dissociation during the virus uncoating process that occurs when the virus is in the acidic environment of the lumen of the secondary endosome. The difficulty of determining the ion selectivity of this minimalistic ion channel is due in part to the fact that the channel activity is so great that it causes local acidification in the expressing cells and a consequent alteration of reversal voltage, V-rev. We have confirmed the high proton selectivity of the channel (1.5-2.0 x 10(6)) in both oocytes and mammalian cells by using four methods as follows: 1) comparison of V-rev with proton equilibrium potential; 2) measurement of pH(in) and V-rev while Na-out(+) was replaced; 3) measurements with limiting external buffer concentration to limit proton currents specifically; and 4) comparison of measurements of M-2-expressing cells with cells exposed to a protonophore. Increased currents at low pH(out) are due to true activation and not merely increased [H+](out) because increased pH(out) stops the outward current of acidified cells. Although the proton conductance is the biologically relevant conductance in an influenza virus-infected cell, experiments employing methods 1-3 show that the channel is also capable of conducting NH4+, probably by a different mechanism from H+.	Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Howard Hughes Med Inst, Evanston, IL 60208 USA; Forschungszentrum, Inst Biol Informat Verarbeitung, D-52425 Julich, Germany	Northwestern University; Northwestern University; Howard Hughes Medical Institute; Northwestern University; Helmholtz Association	Pinto, LH (corresponding author), Northwestern Univ, Dept Neurobiol & Physiol, Hogan Hall,2153 N Campus Dr, Evanston, IL 60208 USA.			Pekosz, Andrew/0000-0003-3248-1761	NIAID NIH HHS [AI-20201, AI-31882] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020201, R01AI031882, R01AI020201] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENZ R, 1983, BIOPHYS J, V41, P381, DOI 10.1016/S0006-3495(83)84449-X; BURCKHARDT BC, 1992, PFLUG ARCH EUR J PHY, V420, P83, DOI 10.1007/BF00378645; BYERLY L, 1986, J PHYSIOL-LONDON, V376, P477, DOI 10.1113/jphysiol.1986.sp016165; Chizhmakov IV, 1996, J PHYSIOL-LONDON, V494, P329, DOI 10.1113/jphysiol.1996.sp021495; CIAMPOR F, 1992, VIRUS RES, V22, P247, DOI 10.1016/0168-1702(92)90056-F; DUFF KC, 1992, VIROLOGY, V190, P485, DOI 10.1016/0042-6822(92)91239-Q; Frazier CJ, 2000, BIOPHYS J, V78, P1872, DOI 10.1016/S0006-3495(00)76736-1; Gandhi CS, 1999, J BIOL CHEM, V274, P5474, DOI 10.1074/jbc.274.9.5474; GRAMBAS S, 1992, VIROLOGY, V191, P541, DOI 10.1016/0042-6822(92)90229-I; GRAMBAS S, 1992, VIROLOGY, V190, P11, DOI 10.1016/0042-6822(92)91187-Y; GREGORIADES A, 1981, J VIROL, V40, P323, DOI 10.1128/JVI.40.1.323-328.1981; Hay A.J., 1992, SEMIN VIROL, V3, P21, DOI DOI 10.1016/J.BMC.2015.06.030; HOLSINGER LJ, 1994, J VIROL, V68, P1551, DOI 10.1128/JVI.68.3.1551-1563.1994; HOLSINGER LJ, 1991, VIROLOGY, V183, P32, DOI 10.1016/0042-6822(91)90115-R; IRVING M, 1990, BIOPHYS J, V57, P717, DOI 10.1016/S0006-3495(90)82592-3; JAMESKRACKE MR, 1992, J CELL PHYSIOL, V151, P596, DOI 10.1002/jcp.1041510320; JUNGE W, 1987, BIOCHIM BIOPHYS ACTA, V890, P1, DOI 10.1016/0005-2728(87)90061-2; KURTZ S, 1995, ANTIMICROB AGENTS CH, V39, P2204, DOI 10.1128/AAC.39.10.2204; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; Lin TI, 1997, J GEN VIROL, V78, P767, DOI 10.1099/0022-1317-78-4-767; Mould JA, 2000, J BIOL CHEM, V275, P8592, DOI 10.1074/jbc.275.12.8592; PANAYOTOV PP, 1992, VIROLOGY, V186, P352, DOI 10.1016/0042-6822(92)90096-8; Pinto LH, 1997, P NATL ACAD SCI USA, V94, P11301, DOI 10.1073/pnas.94.21.11301; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Ruigrok RWH, 2000, VIROLOGY, V267, P289, DOI 10.1006/viro.1999.0134; Sakaguchi T, 1997, P NATL ACAD SCI USA, V94, P5000, DOI 10.1073/pnas.94.10.5000; Sakaguchi T, 1996, J CELL BIOL, V133, P733, DOI 10.1083/jcb.133.4.733; SCHROEDER C, 1994, J GEN VIROL, V75, P3477, DOI 10.1099/0022-1317-75-12-3477; SHIMBO K, 1996, BIOPHYS J, V70, P1336; Stewart AK, 1999, J PHYSIOL-LONDON, V516, P209, DOI 10.1111/j.1469-7793.1999.209aa.x; SUGRUE RJ, 1990, EMBO J, V9, P3469, DOI 10.1002/j.1460-2075.1990.tb07555.x; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; TAKEUCHI K, 1994, J VIROL, V68, P911, DOI 10.1128/JVI.68.2.911-919.1994; TOSTESON MT, 1994, J MEMBRANE BIOL, V142, P117; WANG C, 1995, BIOPHYS J, V69, P1363, DOI 10.1016/S0006-3495(95)80003-2; WANG C, 1994, VIROLOGY, V205, P133, DOI 10.1006/viro.1994.1628; ZHIRNOV OP, 1992, VIROLOGY, V186, P324, DOI 10.1016/0042-6822(92)90090-C; Zhu GY, 1998, J NEUROSCI METH, V81, P73, DOI 10.1016/S0165-0270(98)00019-3	38	132	135	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31038	31050		10.1074/jbc.M003663200	http://dx.doi.org/10.1074/jbc.M003663200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10913133	Green Published, hybrid			2022-12-25	WOS:000089762700044
J	Proenza, C; Wilkens, CM; Beam, KG				Proenza, C; Wilkens, CM; Beam, KG			Excitation-contraction coupling is not affected by scrambled sequence in residues 681-690 of the dihydropyridine receptor II-III loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; CALCIUM CURRENT; RYANODINE RECEPTOR; ACTIVATION; CHANNELS; MYOTUBES	A peptide corresponding to residues 681-690 of the II-III loop of the skeletal muscle dihydropyridine receptor alpha(1) subunit (DHPR, alpha(1S)) has been reported to activate the skeletal muscle ryanodine receptor (RyR1) in vitro. Within this region of alpha(1S), a cluster of basic residues, Arg(681)-Lys(685), was previously reported to be indispensable for the activation of RyR1 in microsomal preparations and lipid bilayers. We have used an intact alpha(1S) subunit with scrambled sequence in this region of the II-III loop (alpha(1S)-scr) to test the importance of residues 681-690 and the basic motif for skeletal-type excitation-contraction (EC) coupling and retrograde signaling in vivo. When expressed in dysgenic myotubes (which lack endogenous alpha(1S)), alpha(1S)-scr restored calcium currents that were indistinguishable, in current density and voltage dependence, from those restored by wild-type alpha(1S). The scrambled DHPR also rescued skeletal-type EC coupling, as indicated by electrically evoked contractions in the presence of 0.5 mM Cd2+ and 0.1 mM La3+. Furthermore, the release of intracellular Ca2+, as assayed by the indicator dye, Fluo-3, had similar kinetics and voltage dependence for alpha(1S) and alpha(1S)-scr. These data suggest that residues 681-690 of the alpha(1S) II-III loop are not essential in muscle cells for normal functioning of the DHPR, including skeletal-type EC coupling and retrograde signaling.	Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Anat & Neurobiol, Ft Collins, CO 80523 USA; Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Physiol, Ft Collins, CO 80523 USA	Colorado State University; Colorado State University	Beam, KG (corresponding author), Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Anat & Neurobiol, Ft Collins, CO 80523 USA.			Proenza, Catherine/0000-0003-4324-6206				ADAMS BA, 1989, J GEN PHYSIOL, V94, P429, DOI 10.1085/jgp.94.3.429; ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; Casarotto MG, 2000, J BIOL CHEM, V275, P11631, DOI 10.1074/jbc.275.16.11631; Dulhunty AF, 1999, BIOPHYS J, V77, P189, DOI 10.1016/S0006-3495(99)76881-5; El-Hayek R, 1998, BIOCHEMISTRY-US, V37, P7015, DOI 10.1021/bi972907o; ELHAYEK R, 1995, J BIOL CHEM, V270, P2211; GARCIA J, 1994, J GEN PHYSIOL, V103, P107, DOI 10.1085/jgp.103.1.107; Grabner M, 1998, P NATL ACAD SCI USA, V95, P1903, DOI 10.1073/pnas.95.4.1903; Grabner M, 1999, J BIOL CHEM, V274, P21913, DOI 10.1074/jbc.274.31.21913; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; Zhu XS, 1999, FEBS LETT, V450, P221, DOI 10.1016/S0014-5793(99)00496-2	16	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29935	29937		10.1074/jbc.C000464200	http://dx.doi.org/10.1074/jbc.C000464200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10915779	hybrid			2022-12-25	WOS:000089577900004
J	Hayakawa, A; Kitamura, N				Hayakawa, A; Kitamura, N			Early endosomal localization of hrs requires a sequence within the proline- and glutamine-rich region but not the FYVE finger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN; BINDING; GROWTH; DOMAIN; MOTIF; EEA1; ACTIVATION; VACUOLAR; HOMOLOG	Hrs is an early endosomal protein that is tyrosine-phosphorylated in cells stimulated with growth factors. Hrs is thought to play a regulatory role in endocytosis of growth factor-receptor complexes through early endosomes. Early endosomal localization of Hrs seems to be essential for Hrs to exert its function in the endocytosis. Hrs has a FYVE finger domain that binds specifically to phosphatidylinositol 3-phosphate in vitro, The FYVE finger is a likely domain that mediates membrane association of endosomal proteins. In this study, we examined whether the FYVE finger participates in early endosomal targeting of Hrs. Hrs with a zinc binding-defective FYVE finger was still localized to early endosomes. In addition, the N-terminal FYVE finger-containing fragment of Hrs showed a cytosolic distribution in mammalian cells. These results indicate that the FYVE finger is not required for the localization of Hrs to early endosomes, Furthermore, by analyzing a series of deletion mutants of Hrs, we identified a sequence of about 100 amino acids within the C-terminal proline- and glutamine-rich region as a domain essential for the targeting of Hrs to early endosomes.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Kitamura, N (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Dept Life Sci, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.							Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Komada M, 1999, GENE DEV, V13, P1475, DOI 10.1101/gad.13.11.1475; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; Lohi O, 1998, FEBS LETT, V440, P255, DOI 10.1016/S0014-5793(98)01401-X; Lohi O, 1998, J BIOL CHEM, V273, P21408, DOI 10.1074/jbc.273.33.21408; Mao YX, 2000, CELL, V100, P447, DOI 10.1016/S0092-8674(00)80680-7; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Peterson MR, 1999, CURR BIOL, V9, P159, DOI 10.1016/S0960-9822(99)80071-2; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; SUEMORI H, 1990, CELL DIFFER DEV, V29, P181, DOI 10.1016/0922-3371(90)90120-L; Takata H, 2000, GENES CELLS, V5, P57, DOI 10.1046/j.1365-2443.2000.00303.x; Tall GG, 1999, MOL BIOL CELL, V10, P1873, DOI 10.1091/mbc.10.6.1873; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Webb GC, 1997, MOL BIOL CELL, V8, P871, DOI 10.1091/mbc.8.5.871; WEISMAN LS, 1992, J BIOL CHEM, V267, P618; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525	27	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29636	29642		10.1074/jbc.M002696200	http://dx.doi.org/10.1074/jbc.M002696200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10889197	hybrid			2022-12-25	WOS:000089439800062
J	Sorgine, MHF; Logullo, C; Zingali, RB; Paiva-Silva, GO; Juliano, L; Oliveira, PL				Sorgine, MHF; Logullo, C; Zingali, RB; Paiva-Silva, GO; Juliano, L; Oliveira, PL			A heme-binding aspartic proteinase from the eggs of the hard tick Boophilus microplus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YOLK DEGRADATION; POLYACRYLAMIDE GELS; RHODNIUS-PROLIXUS; BOMBYX-MORI; IRON; IDENTIFICATION; SENSITIVITY; HEMOGLOBIN; ALIGNMENT; PROTEASES	An aspartic proteinase that binds heme with a 1:1 stoichiometry was isolated and cloned from the eggs of the cattle tick Boophilus microplus. This proteinase, herein named THAP (tick heme-binding aspartic proteinase) showed pepstatin-sensitive hydrolytic activity against several peptide and protein substrates, Although hemoglobin was a good substrate for THAP, low proteolytic activity was observed against globin devoid of the heme prosthetic group. Hydrolysis of globin by THAP increased as increasing amounts of heme were added to globin, with maximum activation at a heme-to-globin 1:1 ratio. Further additions of heme to the reaction medium inhibited proteolysis, back to a level similar to that observed against globin alone. The addition of heme did not change THAP activity toward a synthetic peptide or against ribonuclease, a non-hemeprotein substrate. The major storage protein of tick eggs, vitellin (VT), the probable physiological substrate of THAP, is a hemeprotein. Hydrolysis of VT by THAP was also inhibited by the addition of heme to the incubation media. Taken together, our results suggest that THAP uses heme bound to VT as a docking site to increase specificity and regulate VT degradation according to heme availability.	Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Ciencias Biomed, Dept Bioquim Med, BR-21910590 Rio De Janeiro, Brazil; UNIFESP, Escola Paulista Med, Dept Biofis, BR-04044020 Sao Paulo, Brazil; Univ Fed Fluminense, Inst Biol, Dept Biol Celular & Mol, BR-24001970 Niteroi, RJ, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal Fluminense	Sorgine, MHF (corresponding author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Ciencias Biomed, Dept Bioquim Med, BR-21910590 Rio De Janeiro, Brazil.		Logullo de Oliveira, Carlos Jorge/G-3436-2013; Juliano, Luiz/D-7204-2012; Zingali, Russolina/G-4862-2012; L. Oliveira, Pedro/A-9438-2010	Juliano, Luiz/0000-0002-5589-2822; Zingali, Russolina/0000-0003-3156-6923; L. Oliveira, Pedro/0000-0003-0307-354X				AFT RL, 1984, J BIOL CHEM, V259, P301; Ascoli F, 1981, Methods Enzymol, V76, P72; Braz GRC, 1999, CURR BIOL, V9, P703, DOI 10.1016/S0960-9822(99)80312-1; DeCarlo AA, 1999, J BACTERIOL, V181, P3784, DOI 10.1128/JB.181.12.3784-3791.1999; FAGOTTO F, 1995, J CELL SCI, V108, P3645; FAGOTTO F, 1990, ARCH INSECT BIOCHEM, V14, P217, DOI 10.1002/arch.940140403; FAGOTTO F, 1991, DEV GROWTH DIFFER, V33, P57; Filippova IY, 1996, ANAL BIOCHEM, V234, P113, DOI 10.1006/abio.1996.0062; GARESSE R, 1979, EUR J BIOCHEM, V99, P253, DOI 10.1111/j.1432-1033.1979.tb13252.x; GUTTERIDGE JMC, 1988, BIOCHEM J, V256, P861, DOI 10.1042/bj2560861; HAGEDORN HH, 1979, ANNU REV ENTOMOL, V24, P475, DOI 10.1146/annurev.en.24.010179.002355; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; Henikoff S, 1999, BIOINFORMATICS, V15, P471, DOI 10.1093/bioinformatics/15.6.471; Hirata IY, 1995, LETT PEPT SCI, V1, P299, DOI DOI 10.1007/BF00119771; IKEDA M, 1990, INSECT BIOCHEM, V20, P725, DOI 10.1016/0020-1790(90)90087-B; KACZMAREK E, 1987, BIOCHIM BIOPHYS ACTA, V914, P275, DOI 10.1016/0167-4838(87)90286-X; KUBINOWA M, 1998, BIOCHEM BIOPH RES CO, V249, P38; KUNKEL JG, 1985, COMPREHENSIVE INSECT, V1, P83; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Logullo C, 1998, PARASITOLOGY, V116, P525, DOI 10.1017/S0031182098002698; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCINISZYN J, 1976, J BIOL CHEM, V251, P7088; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Mendiola J, 1996, EXP PARASITOL, V82, P27, DOI 10.1006/expr.1996.0004; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; NUSSENZVEIG RH, 1992, ARCH INSECT BIOCHEM, V21, P253, DOI 10.1002/arch.940210402; Oliveira MF, 1999, NATURE, V400, P517, DOI 10.1038/22910; OLIVEIRA PL, 1995, J BIOL CHEM, V270, P10897, DOI 10.1074/jbc.270.18.10897; Otto BR, 1998, J EXP MED, V188, P1091, DOI 10.1084/jem.188.6.1091; Ponka P, 1997, BLOOD, V89, P1; Raikhel A.S., 1990, P147; ROOSELL R, 1991, INSECT BIOCHEM MOLEC, V21, P871; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCHACTER BA, 1988, SEMIN HEMATOL, V25, P349; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; TAKAHASHI SY, 1993, J BIOCHEM, V114, P267, DOI 10.1093/oxfordjournals.jbchem.a124165; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUITSUI K, 1982, ANAL BIOCHEM, V121, P244; Uzel C, 1998, SEMIN HEMATOL, V35, P27; VINCENT SH, 1989, SEMIN HEMATOL, V26, P105; VINCENT SH, 1985, J BIOL CHEM, V260, P4521	43	60	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28659	28665		10.1074/jbc.M005675200	http://dx.doi.org/10.1074/jbc.M005675200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10896678	hybrid			2022-12-25	WOS:000089330700044
J	Gandarillas, A; Davies, D; Blanchard, JM				Gandarillas, A; Davies, D; Blanchard, JM			Normal and c-Myc-promoted human keratinocyte differentiation both occur via a novel cell cycle involving cellular growth and endoreplication	ONCOGENE			English	Article						epidermis; mitosis; cell size; flow cytometry; cell fate; endoreduplication	EPIDERMAL STEM-CELLS; TERMINAL DIFFERENTIATION; PATTERN-FORMATION; DNA-REPLICATION; TARGET GENES; IN-VITRO; EXPRESSION; APOPTOSIS; PROLIFERATION; INDUCTION	The relationship between cell cycle and differentiation in human keratinocytes is poorly understood, It is believed that keratinocytes suppress DNA replication and cell cycle arrest in G0 before they initiate terminal differentiation, However, a temporal separation between both events has not been established. Moreover, c-Myc promotes keratinocyte differentiation without causing cell cycle arrest. To address these paradoxes we have analysed cell cycle control during normal and c-Myc-promoted differentiation. Continuous activation of c-Myc or initiation of terminal differentiation results in a block of G2/M, cellular growth, endoreplication and polyploidy. Keratinocytes abandon G1, continue replicating DNA as they differentiate terminally and become polyploid. In fact, simply blocking mitosis with nocodazole resulted in increased cell size, terminal differentiation and endoreplication. This indicates that terminal differentiation associates with defective cell cycle progression and provides a novel insight into c-Myc biology.	CNRS, Inst Genet Mol, F-34293 Montpellier 5, France; Imperial Canc Res Fund, FACS Lab, London WC2A 3PX, England	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Cancer Research UK	Gandarillas, A (corresponding author), CNRS, Inst Genet Mol, F-34293 Montpellier 5, France.			Davies, Derek/0000-0002-6977-4181				ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; BATACSORGO Z, 1993, J EXP MED, V178, P1271, DOI 10.1084/jem.178.4.1271; BenBassat H, 1997, CANCER RES, V57, P3741; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Dang CV, 1999, MOL CELL BIOL, V19, P1; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DOVER R, 1987, J INVEST DERMATOL, V89, P349, DOI 10.1111/1523-1747.ep12471751; EDGAR B, 1995, CURR OPIN CELL BIOL, V7, P815, DOI 10.1016/0955-0674(95)80065-4; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; FUCHS E, 1993, J CELL SCI, P197; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gandarillas A, 1999, EXP DERMATOL, V8, P71, DOI 10.1111/j.1600-0625.1999.tb00350.x; Gandarillas A, 2000, EXP GERONTOL, V35, P53, DOI 10.1016/S0531-5565(99)00088-1; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; Grafi G, 1998, EXP CELL RES, V244, P372, DOI 10.1006/excr.1998.4213; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; HALL PA, 1989, DEVELOPMENT, V106, P619; Harvat BL, 1998, J CELL SCI, V111, P1185; HASHIRO M, 1991, BIOCHEM BIOPH RES CO, V174, P287, DOI 10.1016/0006-291X(91)90518-C; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; Hawkins NC, 1996, DEVELOPMENT, V122, P281; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HOFFMAN R, 1989, BLOOD, V74, P1196; Hudson DL, 1996, INT J CANCER, V66, P457, DOI 10.1002/(SICI)1097-0215(19960516)66:4<457::AID-IJC8>3.0.CO;2-V; Hulskamp M, 1999, INT REV CYTOL, V186, P147; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; JACK EM, 1990, HEPATOLOGY, V11, P286, DOI 10.1002/hep.1840110220; JACKSTON LA, 1999, CELL, V98, P779; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Judware R, 1997, ONCOGENE, V14, P1341, DOI 10.1038/sj.onc.1200955; KARTASOVA T, 1992, MOL CARCINOGEN, V6, P18, DOI 10.1002/mc.2940060105; KIRK D, 1980, CELL BIOL INT REP, V4, P83, DOI 10.1016/0309-1651(80)90013-2; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; LAVKER RM, 1983, J INVEST DERMATOL, V81, pS121, DOI 10.1111/1523-1747.ep12540880; Li Q, 1999, MOL CELL BIOL, V19, P5339; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Martinez LA, 1999, ONCOGENE, V18, P397, DOI 10.1038/sj.onc.1202300; MEYEROWITZ EM, 1994, CURR OPIN GENET DEV, V4, P602, DOI 10.1016/0959-437X(94)90079-I; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Morasso MI, 1996, J CELL BIOL, V135, P1879, DOI 10.1083/jcb.135.6.1879; NAKATANI S, 1992, ARCH DERMATOL RES, V284, P349, DOI 10.1007/BF00372038; Neufeld TP, 1998, CURR OPIN CELL BIOL, V10, P784, DOI 10.1016/S0955-0674(98)80122-1; ORMEROD EM, 1990, FLOW CYTOMETRY PRACT, P69; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PENNEYS NS, 1970, ARCH DERMATOL, V101, P323, DOI 10.1001/archderm.101.3.323; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PINKUS H, 1966, ARCH DERMATOL, V94, P351, DOI 10.1001/archderm.94.3.351; REGNIER M, 1986, J INVEST DERMATOL, V87, P472, DOI 10.1111/1523-1747.ep12455517; REISS M, 1987, CANCER RES, V47, P6705; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Solari F, 1996, J CELL SCI, V109, P1203; Traas J, 1998, CURR OPIN PLANT BIOL, V1, P498, DOI 10.1016/S1369-5266(98)80042-3; Waikel RL, 1999, ONCOGENE, V18, P4870, DOI 10.1038/sj.onc.1203040; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; WATT FM, 1988, P NATL ACAD SCI USA, V85, P5576, DOI 10.1073/pnas.85.15.5576; WATT FM, 1991, J CELL SCI, V99, P397; WATT FM, 1981, J CELL BIOL, V90, P738, DOI 10.1083/jcb.90.3.738; WATT FM, 1993, DEVELOPMENT, P185	66	68	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2000	19	29					3278	3289		10.1038/sj.onc.1203630	http://dx.doi.org/10.1038/sj.onc.1203630			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918584				2022-12-25	WOS:000088019300006
J	Lyu, RM; Germano, PM; Choi, JK; Le, SV; Pisegna, JR				Lyu, RM; Germano, PM; Choi, JK; Le, SV; Pisegna, JR			Identification of an essential amino acid motif within the C terminus of the pituitary adenylate cyclase-activating polypeptide type I receptor that is critical for signal transduction but not for receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; SITE-DIRECTED MUTAGENESIS; PROTEIN-COUPLED RECEPTOR; CARBOXYL-TERMINUS; FUNCTIONAL EXPRESSION; CYTOPLASMIC DOMAINS; PEPTIDE RECEPTOR; SPLICE VARIANTS; A RECEPTOR; CELLS	The pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 (PAC1) receptor is a G protein-coupled receptor and class II receptor member. The receptor domains critical for signaling are unknown. To explore the role of the C terminus, truncations of 63 residues(Tr-406), 53 residues (Tr-416), 49 residues (Tr-420), 44 residues (Tr-424), and 37 residues (Tr-433) were constructed and expressed in NIH/3T3 cells, and immunofluorescence, radioligand binding, adenylyl cyclase (AC) and phospholipase C (PLC) assays were performed. I-125-PACAP-27 binding (K-d = 0.6-1.5 nM) for the Tr-406 and Tr-433 were similar to wild type Hop and Null splice variants (K-d = similar to1.1 nM), Although internalization of ligand for both the Tr-406 and Tr-433 mutants was reduced to 50-60% at 60 min compared with 76-87% for WT, loss of G-protein coupling did not account for differences in internalization. Despite similar binding properties Tr-406 and Tr-416 mutants showed no AC or PLC response. Addition of 14 amino acids distal to HopTr(406) resulted in normal AC and PLC responses. Site-directed mutagenesis indicated that Arg(416) and Ser(417) are essential for G protein activation. The proximal C terminus mediates signal transduction, and the distal is involved with internalization. Two residues within the C terminus, Arg(416) and Ser(417) conserved among class II receptors are the likely sites for G protein coupling.	VA Greater Los Angeles Healthcare Syst 111C, Gastroenterol & Hepatol Sect, CURE, Vet Affairs UCLA Digest Dis Res Ctr, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles	Pisegna, JR (corresponding author), VA Greater Los Angeles Healthcare Syst 111C, Gastroenterol & Hepatol Sect, CURE, Vet Affairs UCLA Digest Dis Res Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK052274] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 52274-01, P30 DK041301] Funding Source: Medline; RRD VA [I01 RX000194] Funding Source: Medline; BLRD VA [I01 BX004560] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); RRD VA; BLRD VA		AKIKO IK, 1997, J BIOL CHEM, V272, P6882; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BURNSTEIN ES, 1998, J BIOL CHEM, V273, P24322; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; CHEUNG AH, 1989, MOL PHARMACOL, V35, P132; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; FINDLAY DM, 1994, MOL ENDOCRINOL, V8, P1691, DOI 10.1210/me.8.12.1691; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; Go WY, 1998, AM J PHYSIOL-GASTR L, V275, pG56, DOI 10.1152/ajpgi.1998.275.1.G56; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Holtmann MH, 1996, J BIOL CHEM, V271, P23566, DOI 10.1074/jbc.271.38.23566; HUANG ZM, 1995, MOL ENDOCRINOL, V9, P1240, DOI 10.1210/me.9.9.1240; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; NAKAMURA M, 1995, J BIOL CHEM, V270, P30102, DOI 10.1074/jbc.270.50.30102; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; Pisegna JR, 1996, J BIOL CHEM, V271, P17267, DOI 10.1074/jbc.271.29.17267; Pohl M, 1997, J BIOL CHEM, V272, P18179, DOI 10.1074/jbc.272.29.18179; Prado GN, 1996, J BIOL CHEM, V271, P19186, DOI 10.1074/jbc.271.32.19186; Roettger BF, 1997, MOL PHARMACOL, V51, P357; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; VARRAULT A, 1992, MOL PHARMACOL, V41, P999; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Wu V, 1997, J BIOL CHEM, V272, P9037; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N; ZHU X, 1994, MOL PHARMACOL, V46, P460	42	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36134	36142		10.1074/jbc.M004612200	http://dx.doi.org/10.1074/jbc.M004612200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10908567	Green Accepted, hybrid			2022-12-25	WOS:000165382000070
J	Oram, JF; Lawn, RM; Garvin, MR; Wade, DP				Oram, JF; Lawn, RM; Garvin, MR; Wade, DP			ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER-1; TANGIER-DISEASE; CELLULAR CHOLESTEROL; A-I; REMOVAL; PHOSPHOLIPIDS; FIBROBLASTS; MUTATIONS; EFFLUX; CELLS	Lipid-poor high density lipoprotein apolipoproteins remove cholesterol and phospholipids from cells by an active secretory pathway controlled by an ABC transporter called ABCA1, This pathway is induced by cholesterol and cAMP analogs in a cell-specific manner. Here we provide evidence that increased plasma membrane ABCA1 accounts for the enhanced apolipoprotein-mediated Lipid secretion from macrophages induced by cAMP analogs. Treatment of RAW264 macrophages with 8-bromo-cAMP caused parallel increases in apoA-I-mediated cholesterol efflux, ABCA1 mRNA and protein levels, incorporation of ABCA1 into the plasma membrane, and binding of apoA-I to cell-surface ABCA1, All of these parameters declined to near base-line values within 6 h after removal of 8-bromo-cAMP, indicating that ABCA1 is highly unstable and is degraded rapidly in the absence of inducer. Thus, ABCA1 is likely to be the cAMP-inducible apolipoprotein receptor that promotes removal of cholesterol and phospholipids from macrophages.	Univ Washington, Dept Med, Seattle, WA 98195 USA; CV Therapeut Inc, Palo Alto, CA 94304 USA	University of Washington; University of Washington Seattle; CV Therapeutics, Inc.	Oram, JF (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055362, R29HL053451] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53451, HL55362] Funding Source: Medline; NIDDK NIH HHS [DK02456] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASSMAN G, 1995, METALOLIC MOL BASES, P2058; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Costet P, 2000, J BIOL CHEM, V275, P28240; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; ORAM JF, 1983, J CLIN INVEST, V72, P1611, DOI 10.1172/JCI111120; Oram JF, 1999, J LIPID RES, V40, P1769; Oram JF, 1996, J LIPID RES, V37, P2473; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sakr SW, 1999, BBA-MOL CELL BIOL L, V1438, P85, DOI 10.1016/S1388-1981(99)00041-4; SERFATYLACROSNIERE C, 1994, ATHEROSCLEROSIS, V107, P85, DOI 10.1016/0021-9150(94)90144-9; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647	17	453	480	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34508	34511		10.1074/jbc.M006738200	http://dx.doi.org/10.1074/jbc.M006738200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10918070	hybrid			2022-12-25	WOS:000165095300069
J	Wixler, V; Geerts, D; Laplantine, E; Westhoff, D; Smyth, N; Aumailley, M; Sonnenberg, A; Paulsson, M				Wixler, V; Geerts, D; Laplantine, E; Westhoff, D; Smyth, N; Aumailley, M; Sonnenberg, A; Paulsson, M			The LIM-only protein DRAL/FHL2 binds to the cytoplasmic domain of several alpha and beta integrin chains and is recruited to adhesion complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; ZINC-FINGER; SIGNAL-TRANSDUCTION; CYSTEINE-RICH; SKELETAL-MUSCLE; CALCIUM-BINDING; INTERACTS; TAIL; IDENTIFICATION; SEQUENCE	LIM proteins contain one or more double zinc finger structures (LIM domains) mediating specific contacts between proteins that participate in the formation of multiprotein complexes. We report that the LIM-only protein DRAL/FHL2, with four and a half LIM domains, can associate with alpha (3A), alpha (3B), alpha (7A), and several beta integrin subunits as shown in yeast two-hybrid assays as well as after overexpression in human cells. The amino acid sequence immediately following the conserved membrane-proximal region in the integrin alpha subunits or the C-terminal region with the conserved NXXY motif of the integrin beta subunits are critical for binding DRAL/FHL2. Furthermore, the DRAL/FHL2 associates with itself and with other molecules that bind to the cytoplasmic domain of integrin alpha subunits. Deletion analysis of DRAL/FHL2 revealed that particular LIM domains or LIM domain combinations bind the different proteins. These results, together with the fact that full-length DRAW FHL2 is found in cell adhesion complexes, suggest that it is an adaptor/docking protein involved in integrin signaling pathways.	Univ Cologne, Fac Med, Inst Biochem 2, D-50931 Cologne, Germany; Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands	University of Cologne; Netherlands Cancer Institute	Aumailley, M (corresponding author), Univ Cologne, Fac Med, Inst Biochem 2, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	aumailley@uni-koeln.de	Geerts, Dirk/K-8260-2015	Geerts, Dirk/0000-0002-6386-8187; Smyth, Neil/0000-0002-3734-2149				Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; Chan KK, 1998, GENE, V210, P345, DOI 10.1016/S0378-1119(97)00644-6; Chan KK, 2000, J CELL BIOCHEM, V76, P499, DOI 10.1002/(SICI)1097-4644(20000301)76:3<499::AID-JCB16>3.0.CO;2-4; Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Dogic D, 1999, MATRIX BIOL, V18, P433, DOI 10.1016/S0945-053X(99)00046-3; Dogic D, 1998, J CELL SCI, V111, P793; Eigenthaler R, 1997, J BIOL CHEM, V272, P7693, DOI 10.1074/jbc.272.12.7693; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; Fimia GM, 1999, NATURE, V398, P165, DOI 10.1038/18237; Genini M, 1997, DNA CELL BIOL, V16, P433, DOI 10.1089/dna.1997.16.433; Haas TA, 1997, PROTEIN ENG, V10, P1395, DOI 10.1093/protein/10.12.1395; Hagmann J, 1998, J CELL SCI, V111, P2181; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hobert O, 1999, J CELL BIOL, V144, P45, DOI 10.1083/jcb.144.1.45; Hodivala-Dilke KM, 1998, J CELL BIOL, V142, P1357, DOI 10.1083/jcb.142.5.1357; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Kaapa A, 1999, EXP CELL RES, V250, P524, DOI 10.1006/excr.1999.4533; KASSNER PD, 1994, J BIOL CHEM, V269, P19859; KAWAGUCHI S, 1994, MOL BIOL CELL, V5, P977, DOI 10.1091/mbc.5.9.977; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Konrat R, 1998, J BIOL CHEM, V273, P23233, DOI 10.1074/jbc.273.36.23233; Kowalski K, 1999, J BIOMOL NMR, V13, P249, DOI 10.1023/A:1008309602929; LaFlamme SE, 1997, MATRIX BIOL, V16, P153, DOI 10.1016/S0945-053X(97)90003-2; Laplantine E, 2000, J CELL SCI, V113, P1167; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; Mastrangelo AM, 1999, J CELL SCI, V112, P217; Morgan MJ, 1999, BIOCHEM BIOPH RES CO, V255, P245, DOI 10.1006/bbrc.1999.0179; Morgan MJ, 1999, BIOCHEM BIOPH RES CO, V255, P251, DOI 10.1006/bbrc.1999.0180; Morgan MJ, 1996, BIOCHEM BIOPH RES CO, V225, P632, DOI 10.1006/bbrc.1996.1222; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; OTEY CA, 1993, J BIOL CHEM, V268, P21193; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; PerezAlvarado GC, 1996, J MOL BIOL, V257, P153, DOI 10.1006/jmbi.1996.0153; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Pomies P, 1997, J CELL BIOL, V139, P157, DOI 10.1083/jcb.139.1.157; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Retta SF, 1998, MOL BIOL CELL, V9, P715, DOI 10.1091/mbc.9.4.715; Rietzler M, 1998, J BIOL CHEM, V273, P27459, DOI 10.1074/jbc.273.42.27459; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; Roof DJ, 1997, J CELL BIOL, V138, P575, DOI 10.1083/jcb.138.3.575; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; Sondermann H, 1999, CELL ADHES COMMUN, V7, P43, DOI 10.3109/15419069909034391; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Thomas SM, 1999, J CELL SCI, V112, P181; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Vallar L, 1999, J BIOL CHEM, V274, P17257, DOI 10.1074/jbc.274.24.17257; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wixler V, 1999, FEBS LETT, V445, P351, DOI 10.1016/S0014-5793(99)00151-9; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Zhang XA, 1999, J BIOL CHEM, V274, P11, DOI 10.1074/jbc.274.1.11	66	117	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33669	33678		10.1074/jbc.M002519200	http://dx.doi.org/10.1074/jbc.M002519200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10906324	hybrid			2022-12-25	WOS:000090104600069
J	Coburn, CT; Knapp, FF; Febbraio, M; Beets, AL; Silverstein, RL; Abumrad, NA				Coburn, CT; Knapp, FF; Febbraio, M; Beets, AL; Silverstein, RL; Abumrad, NA			Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL ACYLTRANSFERASE; TRIACYLGLYCEROL SYNTHESIS; MEMBRANE-PROTEIN; CARDIAC MYOCYTES; BINDING PROTEIN; RAT HEPATOCYTES; UP-REGULATION; METABOLISM; TRANSPORT; ADIPOCYTES	The transmembrane protein CD36 has been identified in isolated cell studies as a putative transporter of long chain fatty acids. In humans, an association between CD36 deficiency and defective myocardial uptake of the fatty acid analog 15-(p-iodophenyl)-3-(R,S)-methyl pentadecanoic acid (BMIPP) has been reported. To determine whether this association represents a causal link and to assess the physiological role of CD36, we compared tissue uptake and metabolism of two iodinated fatty acid analogs BMIPP and 15-(p-iodophenyl) pentadecanoic acid (IPPA) in CD36 null and wild type mice. We also investigated the uptake and lipid incorporation of palmitate by adipocytes isolated from both groups. Compared with wild type, uptake of BMIPP and IPPA was reduced in heart (50-80%), skeletal muscle (40-75%), and adipose tissues (60-70%) of nub mice. The reduction was associated with a 50-68% decrease in label incorporation into triglycerides and in 2-3-fold accumulation of label in diglycerides, Identical results were obtained from studies of [H-3]palmitate uptake in isolated adipocytes, The block in diglyceride to triglyceride conversion could not be explained by changes in specific activities of the key enzymes long chain acyl-CoA synthetase and diacylglycerol acyltransferase, which were similar in tissues from wild type and null mice. It is concluded that CD36 facilitates a large fraction of fatty acid uptake by heart, skeletal muscle, and adipose tissues and that CD36 deficiency in humans is the cause of the reported defect in myocardial BMIPP uptake. In CD36-expressing tissues, uptake regulates fatty acid esterification at the level of diacylglycerol acyltransferase by determining fatty acyl-CoA supply. The membrane transport step may represent an important control site for fatty acid metabolism in vivo.	SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Oak Ridge Natl Lab, Nucl Med Program, Oak Ridge, TN 37831 USA; Cornell Univ, Weill Med Coll, Div Hematol & Med Oncol, Dept Med, New York, NY 10021 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; United States Department of Energy (DOE); Oak Ridge National Laboratory; Cornell University	Abumrad, NA (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.				NHLBI NIH HHS [1R29 HL58559, HL42540] Funding Source: Medline; NIDDK NIH HHS [DK33301] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058559, R01HL042540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033301] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abumrad N, 1998, J LIPID RES, V39, P2309; ABUMRAD NA, 1984, J BIOL CHEM, V259, P8945; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; AMBROSE KR, 1987, EUR J NUCL MED, V12, P486, DOI 10.1007/BF00620471; Antozzi C, 1997, CARDIOVASC RES, V35, P184, DOI 10.1016/S0008-6363(97)00141-7; Baillie AGS, 1996, J MEMBRANE BIOL, V153, P75, DOI 10.1007/s002329900111; Berk PD, 1999, J BIOL CHEM, V274, P28626, DOI 10.1074/jbc.274.40.28626; Binas B, 1999, FASEB J, V13, P805, DOI 10.1096/fasebj.13.8.805; Bonen A, 1999, AM J PHYSIOL-ENDOC M, V276, pE642, DOI 10.1152/ajpendo.1999.276.4.E642; Bonen A, 1998, AM J PHYSIOL-ENDOC M, V275, pE471, DOI 10.1152/ajpendo.1998.275.3.E471; BURKHOLDER TJ, 1994, J MORPHOL, V221, P177, DOI 10.1002/jmor.1052210207; COLEMAN RA, 1992, METHOD ENZYMOL, V209, P98; DEUTSCH J, 1994, ANAL BIOCHEM, V220, P321, DOI 10.1006/abio.1994.1344; DOUMAS BT, 1971, CLIN CHIM ACTA, V31, P87, DOI 10.1016/0009-8981(71)90365-2; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fukuchi K, 1999, J NUCL MED, V40, P239; GREEN HJ, 1984, HISTOCHEMISTRY, V81, P67, DOI 10.1007/BF00495403; GREENWALT DE, 1985, J CELL BIOL, V100, P397, DOI 10.1083/jcb.100.2.397; GREENWALT DE, 1995, J CLIN INVEST, V96, P1382, DOI 10.1172/JCI118173; Hamilton JA, 1998, J LIPID RES, V39, P467; Ibrahimi A, 1999, J BIOL CHEM, V274, P26761, DOI 10.1074/jbc.274.38.26761; Ibrahimi A, 1996, P NATL ACAD SCI USA, V93, P2646, DOI 10.1073/pnas.93.7.2646; Knapp F F Jr, 1996, Q J Nucl Med, V40, P252; KNAPP FF, 1986, J NUCL MED, V27, P521; KROPP J, 1992, NUCL MED BIOL, V19, P283; Lee K, 1999, TRANSFUSION, V39, P873, DOI 10.1046/j.1537-2995.1999.39080873.x; Luiken JJFP, 1997, J LIPID RES, V38, P745; MAYOREK N, 1989, EUR J BIOCHEM, V182, P395, DOI 10.1111/j.1432-1033.1989.tb14844.x; Memon RA, 1998, AM J PHYSIOL-ENDOC M, V274, pE210, DOI 10.1152/ajpendo.1998.274.2.E210; Memon RA, 1999, DIABETES, V48, P121, DOI 10.2337/diabetes.48.1.121; Pelsers MMAL, 1999, BIOCHEM J, V337, P407, DOI 10.1042/0264-6021:3370407; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Poirier H, 1996, EUR J BIOCHEM, V238, P368, DOI 10.1111/j.1432-1033.1996.0368z.x; RESKE SN, 1985, EUR J NUCL MED, V10, P228; RICHIERI GV, 1995, J LIPID RES, V36, P229; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SORRENTINO D, 1989, J CLIN INVEST, V84, P1325, DOI 10.1172/JCI114301; SPITSBERG VL, 1995, EUR J BIOCHEM, V230, P872, DOI 10.1111/j.1432-1033.1995.tb20630.x; STALS HK, 1994, FEBS LETT, V343, P99, DOI 10.1016/0014-5793(94)80615-2; STUMP DD, 1993, AM J PHYSIOL, V265, pG894, DOI 10.1152/ajpgi.1993.265.5.G894; Tanaka T, 1981, Methods Enzymol, V71 Pt C, P334; Tanaka T, 1997, J MOL CELL CARDIOL, V29, P121, DOI 10.1006/jmcc.1996.0257; Tontonoz P, 1999, CURR OPIN LIPIDOL, V10, P485, DOI 10.1097/00041433-199912000-00002; Torizuka K., 1991, JPN J NUCL MED, V28, P681; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Zakim D, 1996, P SOC EXP BIOL MED, V212, P5	49	498	515	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32523	32529		10.1074/jbc.M003826200	http://dx.doi.org/10.1074/jbc.M003826200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913136	hybrid			2022-12-25	WOS:000090003800021
J	Landriscina, M; Prudovsky, I; Carreira, CM; Soldi, R; Tarantini, F; Maciag, T				Landriscina, M; Prudovsky, I; Carreira, CM; Soldi, R; Tarantini, F; Maciag, T			Amlexanox reversibly inhibits cell migration and proliferation and induces the Src-dependent disassembly of actin stress fibers in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; FACTOR-I; TYROSINE PHOSPHORYLATION; SUBCELLULAR-LOCALIZATION; FACTOR RECEPTOR-1; DNA-SYNTHESIS; C-SRC; BINDING; RELEASE; PROTEIN	Amlexanox binds S100A13 and inhibits the release of fibroblast growth factor 1 (FGF1). Because members of the S100 gene family are known to be involved with the function of the cytoskeleton, we examined the ability of amlexanox to modify the cytoskeleton and report that amlexanox induces a dramatic reduction in the presence of actin stress fibers and the appearance of a random, non-oriented distribution of focal adhesion sites. Correspondingly, amlexanox induces the complete and reversible non-apoptotic inhibition of cell migration and proliferation, and although amlexanox does not induce either the down-regulation of F-actin levels or the depolymerization of actin filaments, it does induce the tyrosine phosphorylation of cortactin, a Src substrate known to regulate actin bundling. In addition, a dominant negative form of Src is able to partially rescue cells from the effect of amlexanox on both the actin cytoskeleton and cell migration. In contrast, the inhibition of cell proliferation by amlexanox correlates with the inhibition of cyclin D1 expression without interference of the receptor tyrosine kinase/mitogen-activated protein kinase signaling pathway. Last, the ability of amlexanox to inhibit FGF1 release is reversible and correlates with the restoration of the actin cytoskeleton, suggesting a role for the actin cytoskeleton in the FGF1 release pathway.	Maine Med Ctr, Res Inst, Ctr Mol Med, S Portland, ME 04106 USA	Maine Medical Center	Maciag, T (corresponding author), Maine Med Ctr, Res Inst, Ctr Mol Med, 125 John Roberts Rd, S Portland, ME 04106 USA.		Prudovsky, Igor/GVU-1521-2022; Landriscina, Matteo/K-1092-2016; Tarantini, Francesca/I-6332-2012	Landriscina, Matteo/0000-0003-0591-9799; TARANTINI, FRANCESCA/0000-0002-1390-2965	NHLBI NIH HHS [HL32348, HL35627] Funding Source: Medline; NIA NIH HHS [AG07450] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032348, R01HL035627] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Carreira CM, 1998, J BIOL CHEM, V273, P22224, DOI 10.1074/jbc.273.35.22224; Chan AY, 1998, J CELL SCI, V111, P199; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; Cramer LP, 1999, CURR BIOL, V9, P1095, DOI 10.1016/S0960-9822(99)80478-3; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Garfinkel S, 1996, J CELL BIOL, V134, P783, DOI 10.1083/jcb.134.3.783; Gimona M, 1997, J CELL SCI, V110, P611; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Ishikawa R, 1998, J BIOL CHEM, V273, P26991, DOI 10.1074/jbc.273.41.26991; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; Kilby PM, 1997, PROTEIN SCI, V6, P2494; LaVallee TM, 1998, J BIOL CHEM, V273, P22217, DOI 10.1074/jbc.273.35.22217; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; MAKINO H, 1987, INT ARCH ALLER A IMM, V82, P66, DOI 10.1159/000234292; Mandinova A, 1998, J CELL SCI, V111, P2043; Mulholland J, 1997, MOL BIOL CELL, V8, P1481, DOI 10.1091/mbc.8.8.1481; Nelson W J, 1991, Semin Cell Biol, V2, P375; Osterloh D, 1998, CELL CALCIUM, V24, P137, DOI 10.1016/S0143-4160(98)90081-1; Oyama Y, 1997, BIOCHEM BIOPH RES CO, V240, P341, DOI 10.1006/bbrc.1997.7476; PAVALKO FM, 1991, BIOCHEM SOC T, V19, P1065, DOI 10.1042/bst0191065; PERIN MS, 1991, J BIOL CHEM, V266, P623; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Sheetz MP, 1998, TRENDS CELL BIOL, V8, P51, DOI 10.1016/S0962-8924(98)80005-6; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Tarantini F, 1998, J BIOL CHEM, V273, P22209, DOI 10.1074/jbc.273.35.22209; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; Wicki R, 1996, BIOCHEM BIOPH RES CO, V227, P594, DOI 10.1006/bbrc.1996.1551; Winkles JA, 1996, AM J PATHOL, V149, P2119; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1993, J BIOL CHEM, V268, P9611; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	39	36	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32753	32762		10.1074/jbc.M002336200	http://dx.doi.org/10.1074/jbc.M002336200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10921913	hybrid			2022-12-25	WOS:000090003800053
J	Meriane, M; Mary, S; Comunale, F; Vignal, E; Fort, P; Gauthier-Rouviere, C				Meriane, M; Mary, S; Comunale, F; Vignal, E; Fort, P; Gauthier-Rouviere, C			Cdc42Hs and Rac1 GTPases induce the collapse of the vimentin intermediate filament network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; ACTIN-CYTOSKELETON; RHO-FAMILY; INDEPENDENT PATHWAYS; PROTEIN-KINASES; TYROSINE KINASE; LIVING CELLS; DYNAMICS; PHOSPHORYLATION; MICROTUBULES	In this study we show that expression of active Cdc42Hs and Rac1 GTPases, two Rho family members, leads to the reorganization of the vimentin intermediate filament (IF) network, showing a perinuclear collapse. Cdc42Hs displays a stronger effect than Rad as 90% versus 75% of GTPase-expressing cells show vimentin collapse. Similar vimentin IF modifications were observed when endogenous Cdc42Hs was activated by bradykinin treatment, endogenous Rad by platelet-derived growth factor/epidermal growth factor, or both endogenous proteins upon expression of active RhoG. This reorganization of the vimentin IF network is not associated with any significant increase in soluble vimentin. Using effector loop mutants of Cdc42Hs and Rac1, we show that the vimentin collapse is mostly independent of CRIB (Cdc42Hs or Rac-interacting binding)-mediated pathways such as JNK or PAK activation but is associated with actin reorganization. This does not result from F-actin depolymerization, because cytochalasin D treatment or Scar-WA expression have merely no effect on vimentin organization. Finally, we show that genistein treatment of Cdc42 and Rac1-expressing cells strongly reduces vimentin collapse, whereas staurosporin, wortmannin, LY-294002, R-p-cAMP, or RII, the regulatory subunit of protein kinase A, remain ineffective. Moreover, we detected an increase in cellular tyrosine phosphorylation content after Cdc42Hs and Rad expression without modification of the vimentin phosphorylation status. These data indicate that Cdc42Hs and Rad GTPases control vimentin IF organization involving tyrosine phosphorylation events.	Ctr Rech Biochim Macromol, CNRS, UPR 1086, F-34293 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Gauthier-Rouviere, C (corresponding author), Ctr Rech Biochim Macromol, CNRS, UPR 1086, 1919 Route de Mende, F-34293 Montpellier, France.		Fort, Philippe/M-9498-2015; Vignal, Emmanuel/B-6985-2009	Fort, Philippe/0000-0001-5997-8722; GAUTHIER-ROUVIERE, Cecile/0000-0002-8364-3882; Comunale, Franck/0000-0001-8838-2151; Vignal, Emmanuel/0000-0002-2585-119X				AEPFELBACHER M, 1994, P NATL ACAD SCI USA, V91, P4263, DOI 10.1073/pnas.91.10.4263; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chou YH, 1997, CURR OPIN CELL BIOL, V9, P49, DOI 10.1016/S0955-0674(97)80151-2; CiesielskiTreska J, 1995, EUR J CELL BIOL, V68, P369; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; Djabali K, 1999, HISTOL HISTOPATHOL, V14, P501, DOI 10.14670/HH-14.501; DRABEROVA E, 1993, J CELL SCI, V106, P1263; Dutartre H, 1996, J CELL SCI, V109, P367; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; GYOEVA FK, 1991, NATURE, V353, P445, DOI 10.1038/353445a0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HIRATA K, 1992, J BIOL CHEM, V267, P8719; Ho CL, 1998, J CELL SCI, V111, P1767; Inada H, 1999, J BIOL CHEM, V274, P34932, DOI 10.1074/jbc.274.49.34932; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; Jeffcoat Sheila, 1995, Cytobios, V82, P81; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Kosako H, 1997, J BIOL CHEM, V272, P10333; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LAMB NJC, 1989, J CELL BIOL, V108, P2409, DOI 10.1083/jcb.108.6.2409; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; Mukai H, 1996, J BIOL CHEM, V271, P9816, DOI 10.1074/jbc.271.16.9816; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Prahlad V, 1998, J CELL BIOL, V143, P159, DOI 10.1083/jcb.143.1.159; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Schliwa Manfred, 1993, Trends in Cell Biology, V3, P377; Sin WC, 1998, MOL CELL BIOL, V18, P6325, DOI 10.1128/MCB.18.11.6325; SOELLNER P, 1985, P NATL ACAD SCI USA, V82, P7929, DOI 10.1073/pnas.82.23.7929; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Valgeirsdottir S, 1998, J CELL SCI, V111, P1973; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; YANG HY, 1992, CELL MOTIL CYTOSKEL, V22, P185, DOI 10.1002/cm.970220306; YANO H, 1993, J BIOL CHEM, V268, P25846; Yoon M, 1998, J CELL BIOL, V143, P147, DOI 10.1083/jcb.143.1.147	49	53	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33046	33052		10.1074/jbc.M001566200	http://dx.doi.org/10.1074/jbc.M001566200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10900195	Green Published, hybrid			2022-12-25	WOS:000090003800091
J	Xu, Q; Li, YH; Cyras, C; Sanan, DA; Cordell, B				Xu, Q; Li, YH; Cyras, C; Sanan, DA; Cordell, B			Isolation and characterization of apolipoproteins from murine microglia - Identification of a low density lipoprotein-like apolipoprotein J-rich but E-poor spherical particle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID BETA-PEPTIDE; ISOFORM-SPECIFIC BINDING; DIFFERENT PLAQUE TYPES; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; IN-VITRO; MESSENGER-RNA; CELL-DEATH; EXPRESSION; PROTEIN	Amyloid A beta deposition is a neuropathologic hallmark of Alzheimer's disease. Activated microglia are intimately associated with plaques and appear to facilitate A beta deposition, an event believed to contribute to pathogenesis. It is unclear if microglia can modulate pathogenesis of Alzheimer's disease by secreting lipoprotein particles. Here we show that cultured BV2 murine microglial cells, like astrocytes, secrete apolipoprotein E (apoE) and apolipoprotein J (apoJ) in a time-dependent manner. To isolate and identify BV2 microglial particles, gel filtration chromatography was employed to fractionate BV2-conditioned medium. Analyses by Western blot, lipid determination, electron microscopy, and native gel electrophoresis demonstrate that BV2 microglial cells release spherical low density lipoprotein (LDL)-like lipid-containing particles rich in apoJ but poor in apoE, These microglial particles are dissimilar in size, shape, and lipoprotein composition to astrocyte-derived particles. The microglial-derived particles were tested for functional activity. Under conditions of suppressed de novo cholesterol synthesis, the LDL-like particles effectively rescued primary rat cortical neurons from mevastatin-induced neurotoxicity, The particles were also shown to bind A beta, We speculate that the LDL-like apoJ-rich apoE-poor microglial lipoproteins preferentially bind the lipoprotein receptor, recognizing apoJ, which is abundant in the choroid plexus, facilitating A beta clearance from the brain. BV2 cells also secrete an apoE-rich lipid-poor species that binds A beta. Consistent with the role of apoE in A beta fibril formation and deposition, this microglial species may promote plaque formation.	Scios Inc, Sunnyvale, CA 94085 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA	Scios; University of California System; University of California San Francisco; The J David Gladstone Institutes	Cordell, B (corresponding author), Scios Inc, 820 W Maude Ave, Sunnyvale, CA 94085 USA.							ARAUJO DM, 1992, BRAIN RES, V569, P141, DOI 10.1016/0006-8993(92)90380-R; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; Bitting L, 1996, J BIOL CHEM, V271, P16084, DOI 10.1074/jbc.271.27.16084; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; BORGHINI I, 1995, BBA-LIPID LIPID MET, V1255, P192, DOI 10.1016/0005-2760(94)00232-N; BURKEY BF, 1992, J LIPID RES, V33, P1517; CHAO CC, 1994, MOL CHEM NEUROPATHOL, V23, P159, DOI 10.1007/BF02815409; CHOIMIURA NH, 1992, ACTA NEUROPATHOL, V83, P260, DOI 10.1007/BF00296787; Chung HY, 1999, J BIOL CHEM, V274, P32301, DOI 10.1074/jbc.274.45.32301; Cole GM, 1999, J NEUROSCI RES, V57, P504, DOI 10.1002/(SICI)1097-4547(19990815)57:4<504::AID-JNR10>3.0.CO;2-H; CORDER EH, 1995, NEUROLOGY, V45, P1323, DOI 10.1212/WNL.45.7.1323; DAVIS JB, 1992, BIOCHEM BIOPH RES CO, V189, P1096, DOI 10.1016/0006-291X(92)92317-Q; DESILVA HV, 1990, J BIOL CHEM, V265, P13240; Dickson DW, 1999, AM J PATHOL, V154, P1627, DOI 10.1016/S0002-9440(10)65416-8; Fagan AM, 1999, J BIOL CHEM, V274, P30001, DOI 10.1074/jbc.274.42.30001; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; GRIFFIN WST, 1995, J NEUROPATH EXP NEUR, V54, P276; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Hammad SM, 1997, J BIOL CHEM, V272, P18644, DOI 10.1074/jbc.272.30.18644; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; JORDANSTARCK TC, 1994, J LIPID RES, V35, P194; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LADU MJ, 1995, J BIOL CHEM, V270, P9039, DOI 10.1074/jbc.270.16.9039; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Mackenzie IRA, 1998, NEUROLOGY, V50, P986, DOI 10.1212/WNL.50.4.986; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Matsubara E, 1996, BIOCHEM J, V316, P671, DOI 10.1042/bj3160671; MAY PC, 1990, NEURON, V5, P831, DOI 10.1016/0896-6273(90)90342-D; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MessmerJoudrier S, 1996, EUR J NEUROSCI, V8, P2652, DOI 10.1111/j.1460-9568.1996.tb01560.x; Michel D, 1997, J CELL SCI, V110, P1635; Michikawa M, 1998, J NEUROSCI RES, V54, P58, DOI 10.1002/(SICI)1097-4547(19981001)54:1<58::AID-JNR7>3.0.CO;2-G; Murphy GM, 1998, J BIOL CHEM, V273, P20967, DOI 10.1074/jbc.273.33.20967; Nakai M, 1996, NEUROSCI LETT, V211, P41, DOI 10.1016/0304-3940(96)12716-6; Overmyer M, 1999, ACTA NEUROPATHOL, V97, P383, DOI 10.1007/s004010051002; Reardon CA, 1998, J LIPID RES, V39, P1372; Rogers J, 1996, NEUROBIOL AGING, V17, P681, DOI 10.1016/0197-4580(96)00115-7; ROZEMULLER JM, 1989, J NEUROPATH EXP NEUR, V48, P674, DOI 10.1097/00005072-198911000-00009; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; Sasaki A, 1997, ACTA NEUROPATHOL, V94, P316, DOI 10.1007/s004010050713; Saunders AM, 1996, LANCET, V348, P90, DOI 10.1016/S0140-6736(96)01251-2; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Sheng JG, 1996, NEUROPATH APPL NEURO, V22, P334, DOI 10.1111/j.1365-2990.1996.tb01112.x; SHENG JG, 1995, NEUROPATH APPL NEURO, V21, P290, DOI 10.1111/j.1365-2990.1995.tb01063.x; Sheng JG, 1996, NEUROBIOL AGING, V17, P761; Stone DJ, 1997, EXP NEUROL, V143, P313, DOI 10.1006/exnr.1996.6360; Tornqvist E, 1996, NEUROBIOL AGING, V17, P695; Weisgraber K H, 1986, Methods Enzymol, V129, P145; WOOD PL, 1994, NEUROREPORT, V5, P977, DOI 10.1097/00001756-199404000-00031; Zlokovic BV, 1996, P NATL ACAD SCI USA, V93, P4229, DOI 10.1073/pnas.93.9.4229	56	59	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31770	31777		10.1074/jbc.M002796200	http://dx.doi.org/10.1074/jbc.M002796200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10918055	hybrid			2022-12-25	WOS:000089858900033
J	Allal, C; Favre, G; Couderc, B; Salicio, S; Sixou, S; Hamilton, AD; Sebti, SM; Lajoie-Mazenc, I; Pradines, A				Allal, C; Favre, G; Couderc, B; Salicio, S; Sixou, S; Hamilton, AD; Sebti, SM; Lajoie-Mazenc, I; Pradines, A			RhoA prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERANYLGERANYLTRANSFERASE-I INHIBITOR; GTP-BINDING PROTEIN; SWISS 3T3 CELLS; BOTULINUM C3 EXOENZYME; ADP-RIBOSYLATION; EXCHANGE PROTEIN; GAMMA-SUBUNIT; MEMBRANE ASSOCIATION; RAS TRANSFORMATION; PHOSPHOLIPASE-D	The importance of post-translational geranylgeranylation of the GTPase RhoA for its ability to induce cellular proliferation and malignant transformation is not well understood. In this manuscript we demonstrate that geranylgeranylation is required for the proper cellular localization of V14RhoA and for its ability to induce actin stress fiber and focal adhesion formation. Furthermore, V14RhoA geranylgeranylation was also required for suppressing p21(WAF) transcription, promoting cell cycle progression and cellular proliferation. The ability of V14RhoA to induce focus formation and enhance plating efficiency and oncogenic Ras anchorage-dependent growth was also dependent on its geranylgeranylation. The only biological activity of V14RhoA that was not dependent on its prenylation was its ability to induce serum response element transcriptional activity. Furthermore, we demonstrate that a farnesylated form of V14RhoA was also able to bind RhoGDI-1, was able to induce cytoskeleton organization, proliferation, and transformation, and was just as potent as geranylgeranylated V14RhoA at suppressing p21(WAF) transcriptional activity. These results demonstrate that RhoA geranylgeranylation is required for its biological activity and that the nature of the lipid modification is not critical.	Univ Toulouse 3, Ctr Lutte Contre Canc Claudius Regaud, F-31052 Toulouse, France; Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Yale Univ, Dept Chem, New Haven, CT 06511 USA	UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Yale University	Pradines, A (corresponding author), Univ Toulouse 3, Ctr Lutte Contre Canc Claudius Regaud, EA 2048,20-24 Rue Pont St Pierre, F-31052 Toulouse, France.		Lajoie-Mazenc, Isabelle/M-4636-2014; Pradines, Anne/M-3935-2014; FAVRE, Gilles/K-9189-2014; ALLAL, Ben C/I-8146-2014; Sixou, Sophie/O-1322-2018; Couderc, Bettina/P-1576-2014	Pradines, Anne/0000-0002-2449-678X; FAVRE, Gilles/0000-0002-2344-1883; ALLAL, Ben C/0000-0002-4207-2219; Sixou, Sophie/0000-0001-7525-7538; Couderc, Bettina/0000-0002-4530-5508	NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER; NCI NIH HHS [CA67771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; AEPFELBACHER M, 1995, BIOCHEM J, V308, P853, DOI 10.1042/bj3080853; BARON R, 2000, IN PRESS P NATL ACAD; Berton M, 1997, BBA-MOL CELL RES, V1355, P7, DOI 10.1016/S0167-4889(96)00111-5; BIFULCO M, 1993, J CELL PHYSIOL, V155, P340, DOI 10.1002/jcp.1041550215; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COX AD, 1993, J BIOL CHEM, V268, P11548; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; COX AD, 1994, J BIOL CHEM, V269, P19203; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; FENTON RG, 1992, J CELL BIOL, V117, P347, DOI 10.1083/jcb.117.2.347; Ghosh PM, 1999, ONCOGENE, V18, P4120, DOI 10.1038/sj.onc.1202792; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORI Y, 1991, ONCOGENE, V6, P515; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kanaho Y, 1996, J LIPID MEDIAT CELL, V14, P223, DOI 10.1016/0929-7855(96)00529-9; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; Kranenburg O, 1997, J CELL SCI, V110, P2417; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; Matsuda T, 1998, BIOCHEMISTRY-US, V37, P9843, DOI 10.1021/bi973194c; Menager C, 1999, EXP CELL RES, V249, P221, DOI 10.1006/excr.1999.4481; Miquel K, 1997, CANCER RES, V57, P1846; MIURA Y, 1993, J BIOL CHEM, V268, P510; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; Mondal MS, 2000, BIOCHEMISTRY-US, V39, P406, DOI 10.1021/bi991856n; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Myung CS, 1999, J BIOL CHEM, V274, P16595, DOI 10.1074/jbc.274.23.16595; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERONA R, 1993, ONCOGENE, V8, P1285; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SASAKI T, 1993, J BIOL CHEM, V268, P23959; SCHMIDT RA, 1982, J CELL BIOL, V95, P144, DOI 10.1083/jcb.95.1.144; Seabra MC, 1998, CELL SIGNAL, V10, P167, DOI 10.1016/S0898-6568(97)00120-4; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Strassheim D, 2000, J BIOL CHEM, V275, P6699, DOI 10.1074/jbc.275.10.6699; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1995, ONCOGENE, V11, P39; UEDA T, 1990, J BIOL CHEM, V265, P9373; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055; Zeng Q, 2000, J BIOL CHEM, V275, P21444, DOI 10.1074/jbc.M000453200; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	67	86	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31001	31008		10.1074/jbc.M005264200	http://dx.doi.org/10.1074/jbc.M005264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896672	hybrid			2022-12-25	WOS:000089762700039
J	March, ME; Lucas, DM; Aman, MJ; Ravichandran, KS				March, ME; Lucas, DM; Aman, MJ; Ravichandran, KS			P135 Src homology 2 domain-containing inositol 5 '-phosphatase (SHIP beta) isoform can substitute for p145 SHIP in F-c gamma RIIB1-mediated inhibitory signaling in B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-GAMMA-RIIB; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE 5-PHOSPHATASE; PHOSPHOTYROSINE-BINDING DOMAIN; FOCAL ADHESION KINASE; PHOSPHATASE SHIP; ANTIGEN RECEPTOR; MULTIPLE FORMS; SHC; ACTIVATION; ASSOCIATION	The inositol 5'-phosphatase, SHIP (also referred to as SHIP-1 or SHIP alpha), is expressed in all cells of the hematopoietic lineage. Depending on the cell type being investigated and the state of differentiation, SHIP isoforms of several different molecular masses (170, 160, 145, 135, 125, and 110 kDa) have been seen in immunoblots. However, the function of the individual isoforms and the effect of expressing multiple isoforms simultaneously are not understood. Some of these SHIP isoforms have recently been characterized at the level of primary sequence. In this report, we investigated the function of the recently characterized 135-kDa SHIP isoform (SHIP beta), which appears to possess the catalytic domain but lacks some of the protein-protein interaction motifs at the C terminus. By reconstituting SHIP-deficient DT40 B cells with either SHIP beta or the better-characterized p145 SHIP alpha, we addressed the function of SHIP beta in the complete absence of SHIP alpha. We observed that SHIP beta had enzymatic activity comparable with SHIP alpha and that SHIP beta was able to reconstitute F(c)gamma RIIB1-mediated inhibition of B cell receptor-induced signaling events such as calcium flux and Akt and mitogen-activated protein kinase activation. SHIP beta was readily phosphorylated in response to B cell receptor cross-linking with the inhibitory receptor F(c)gamma RIIB1 and SHIP beta also interacted with the adapter protein Shc. During these studies we also observed that the SHIP alpha or SHIP beta interaction with Grb2 is not required for F(c)gamma RIIB1-mediated inhibition of calcium flux. These data suggest that SHIP beta, which is normally expressed in B cells along with SHIP alpha, functions comparably with SHIP alpha and that these two isoforms are not likely to be antagonistic in their function in vivo.	Univ Virginia, Hlth Sci Ctr, Beirne B Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA	University of Virginia; Ohio State University	Ravichandran, KS (corresponding author), Univ Virginia, Hlth Sci Ctr, Beirne B Carter Ctr Immunol Res, Bldg MR4,Rm 4012F, Charlottesville, VA 22908 USA.	kr4h@virginia.edu	Lucas, David M/E-3555-2011	March, Michael/0000-0001-9173-6862	NIAID NIH HHS [AI-43425] Funding Source: Medline; NIDDK NIH HHS [F32 DK09774-01] Funding Source: Medline; NIGMS NIH HHS [GM-55761] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055761] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aman MJ, 2000, MOL CELL BIOL, V20, P3576, DOI 10.1128/MCB.20.10.3576-3589.2000; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Astoul E, 1999, J CELL BIOL, V145, P1511, DOI 10.1083/jcb.145.7.1511; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Carver DJ, 2000, BLOOD, V96, P1449, DOI 10.1182/blood.V96.4.1449.h8001449_1449_1456; Coggeshall KM, 2000, CURR TOP MICROBIOL, V245, P213; Coggeshall KM, 1998, CURR OPIN IMMUNOL, V10, P306, DOI 10.1016/S0952-7915(98)80169-6; DAmbrosio D, 1996, IMMUNOL LETT, V54, P77, DOI 10.1016/S0165-2478(96)02653-3; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Damen JE, 1998, BLOOD, V92, P1199, DOI 10.1182/blood.V92.4.1199.416k16_1199_1205; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; DeuterReinhard M, 1997, MOL CELL BIOL, V17, P2559, DOI 10.1128/MCB.17.5.2559; Drayer AL, 1996, BIOCHEM BIOPH RES CO, V225, P243, DOI 10.1006/bbrc.1996.1161; Geier SJ, 1997, BLOOD, V89, P1876, DOI 10.1182/blood.V89.6.1876; Gold MR, 1999, J IMMUNOL, V163, P1894; Harmer SL, 1999, J BIOL CHEM, V274, P12183, DOI 10.1074/jbc.274.17.12183; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; Hashimoto A, 1999, J BIOL CHEM, V274, P11203, DOI 10.1074/jbc.274.16.11203; Helgason CD, 2000, J EXP MED, V191, P781, DOI 10.1084/jem.191.5.781; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; Jacob A, 1999, J BIOL CHEM, V274, P13704, DOI 10.1074/jbc.274.19.13704; Jefferson AB, 1997, J BIOL CHEM, V272, P5983, DOI 10.1074/jbc.272.9.5983; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, J BIOL CHEM, V272, P10998; Liu QR, 1998, J EXP MED, V188, P1333, DOI 10.1084/jem.188.7.1333; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Lucas DM, 1999, BLOOD, V93, P1922, DOI 10.1182/blood.V93.6.1922.406k21_1922_1933; Mason JM, 2000, J BIOL CHEM, V275, P4398, DOI 10.1074/jbc.275.6.4398; Mikhalap SV, 1999, J IMMUNOL, V162, P5719; Okada H, 1998, J IMMUNOL, V161, P5129; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Rohrschneider LR, 2000, GENE DEV, V14, P505; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Sieg DJ, 1999, J CELL SCI, V112, P2677; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; Tridandapani S, 1998, MOL IMMUNOL, V35, P1135, DOI 10.1016/S0161-5890(98)00097-2; Tridandapani S, 1997, IMMUNOL TODAY, V18, P424, DOI 10.1016/S0167-5699(97)01112-2; Tridandapani S, 1997, MOL CELL BIOL, V17, P4305, DOI 10.1128/MCB.17.8.4305; Ware MD, 1996, BLOOD, V88, P2833, DOI 10.1182/blood.V88.8.2833.bloodjournal8882833; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	49	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29960	29967		10.1074/jbc.M003714200	http://dx.doi.org/10.1074/jbc.M003714200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10900203	hybrid			2022-12-25	WOS:000089577900008
J	Mucke, M; Lurz, R; Mackeldanz, P; Behlke, J; Kruger, DH; Reuter, M				Mucke, M; Lurz, R; Mackeldanz, P; Behlke, J; Kruger, DH; Reuter, M			Imaging DNA loops induced by restriction endonuclease EcoRII - A single amino acid substitution uncouples target recognition from cooperative DNA interaction and cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; MEMBRANE-PROTEIN COMPLEXES; MODIFICATION SYSTEM; NAEI ENDONUCLEASE; ESCHERICHIA-COLI; SITES; BINDING; ENZYME	EcoRII is a type IIE restriction endonuclease characterized by a highly cooperative reaction mechanism that depends on simultaneous binding of the dimeric enzyme molecule to two copies of its DNA recognition site. Transmission electron microscopy provided direct evidence that EcoRII mediates loop formation of linear DNA containing two EcoRII. recognition sites. Specific DNA binding of EcoRII revealed a symmetrical DNase I footprint occupying 16-18 bases. Single amino acid replacement of Val(258) by Asn yielded a mutant enzyme that was unaffected in substrate affinity and DNase I footprinting properties, but exhibited a profound decrease in cooperative DNA binding and cleavage activity. Because the electrophoretic mobility of the mutant enzyme-DNA complexes was significantly higher than that of the wild-type, we investigated if mutant V258N binds as a monomer to the substrate DNA. Analysis of the molecular mass of mutant V258N showed a high percentage of protein monomers in solution. The dissociation constant of mutant V258N confirmed a 350-fold decrease of the enzyme dimerization capability. We conclude that Val(258) is located in a region of EcoRII involved in homodimerization. This is the first report of a specific amino acid replacement in a restriction endonuclease leading to the loss of dimerization and DNA cleavage while retaining specific DNA binding.	Humboldt Univ, Fak Med, Inst Virol, Charite, D-10098 Berlin, Germany; Max Planck Inst Mol Genet, D-14159 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Reuter, M (corresponding author), Humboldt Univ, Fak Med, Inst Virol, Charite, D-10098 Berlin, Germany.							AGGARWAL AK, 1995, CURR OPIN STRUC BIOL, V5, P11, DOI 10.1016/0959-440X(95)80004-K; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Behlke J, 1998, BIOCHEMISTRY-US, V37, P11989, DOI 10.1021/bi980914m; BICKLE TA, 1993, MICROBIOL REV, V57, P434, DOI 10.1128/MMBR.57.2.434-450.1993; Bilcock DT, 1999, MOL MICROBIOL, V31, P1243, DOI 10.1046/j.1365-2958.1999.01266.x; Christ F, 1999, EMBO J, V18, P6908, DOI 10.1093/emboj/18.24.6908; Colandene JD, 1998, P NATL ACAD SCI USA, V95, P3531, DOI 10.1073/pnas.95.7.3531; GABBARA S, 1992, J BIOL CHEM, V267, P18623; Huai Q, 2000, EMBO J, V19, P3110, DOI 10.1093/emboj/19.12.3110; JO K, 1995, SCIENCE, V267, P1817, DOI 10.1126/science.7892605; Karpova EA, 1999, IUBMB LIFE, V48, P91, DOI 10.1080/713803460; Kim JJ, 1998, J BIOCHEM MOL BIOL, V31, P149; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; KRUGER DH, 1995, FEMS MICROBIOL REV, V17, P177; KUPPER D, 1995, PROTEIN EXPRES PURIF, V6, P1, DOI 10.1006/prep.1995.1001; MERELO JJ, 1994, NEUROCOMPUTING, V6, P1; Morgan R, 1998, APPL ENVIRON MICROB, V64, P3669; Nobbs TJ, 1998, J MOL BIOL, V281, P419, DOI 10.1006/jmbi.1998.1966; OLLER AR, 1991, BIOCHEMISTRY-US, V30, P2543, DOI 10.1021/bi00223a035; PETRAUSKENE OV, 1994, BIOCHEM BIOPH RES CO, V198, P885, DOI 10.1006/bbrc.1994.1126; Petrauskene OV, 1998, FEBS LETT, V425, P29, DOI 10.1016/S0014-5793(98)00184-7; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; REUTER M, 1993, ANAL BIOCHEM, V209, P232, DOI 10.1006/abio.1993.1113; Reuter M, 1998, J BIOL CHEM, V273, P8294, DOI 10.1074/jbc.273.14.8294; Reuter M, 1999, J BIOL CHEM, V274, P5213, DOI 10.1074/jbc.274.8.5213; Rudnick J, 1999, BIOPHYS J, V76, P1725, DOI 10.1016/S0006-3495(99)77334-0; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Siksnys V, 1999, J MOL BIOL, V291, P1105, DOI 10.1006/jmbi.1999.2977; SPIESS E, 1988, METHOD MICROBIOL, V20, P293, DOI 10.1016/S0580-9517(08)70057-6; TOPAL MD, 1993, NUCLEIC ACIDS RES, V21, P2599, DOI 10.1093/nar/21.11.2599; TOPAL MD, 1991, BIOCHEMISTRY-US, V30, P2006, DOI 10.1021/bi00221a038; VINOGRADOVA M V, 1990, Molekulyarnaya Biologiya (Moscow), V24, P847; WENTZELL LM, 1995, J MOL BIOL, V248, P581, DOI 10.1006/jmbi.1995.0244; Wentzell LM, 1998, J MOL BIOL, V281, P433, DOI 10.1006/jmbi.1998.1967; YOLOV AA, 1984, FEBS LETT, V167, P147, DOI 10.1016/0014-5793(84)80850-9	36	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30631	30637		10.1074/jbc.M003904200	http://dx.doi.org/10.1074/jbc.M003904200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10903314	hybrid			2022-12-25	WOS:000089577900098
J	Scott, IC; Imamura, Y; Pappano, WN; Troedel, JM; Recklies, AD; Roughley, PJ; Greenspan, DS				Scott, IC; Imamura, Y; Pappano, WN; Troedel, JM; Recklies, AD; Roughley, PJ; Greenspan, DS			Bone morphogenetic protein-1 processes probiglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOLLAGEN C-PROTEINASE; PROTEOGLYCAN-II DECORIN; MAMMALIAN TOLLOID-LIKE; GROWTH-FACTOR-BETA; DERMATAN SULFATE PROTEOGLYCANS; HUMAN ARTICULAR-CARTILAGE; COMPLETE CDNA CLONING; GENOMIC ORGANIZATION; TARGETED DISRUPTION; FIBROGENIC CELLS	Bone morphogenetic protein-1 (BMP-1) is a metalloprotease that plays important roles in regulating the deposition of fibrous extracellular matrix in vertebrates, including provision of the procollagen C-proteinase activity that processes the major fibrillar collagens I-III. Biglycan, a small leucine-rich proteoglycan, is a nonfibrillar extracellular matrix component with functions that include the positive regulation of bone formation. Biglycan is synthesized as a precursor with an NH2-terminal propeptide that is cleaved to yield the mature form found in vertebrate tissues. Here, we show that BMP-1 cleaves probiglycan at a single site, removing the propeptide and producing a biglycan molecule with an NH2 terminus identical to that of the mature form found in tissues. BMP-1-related proteases mammalian Tolloid and mammalian Tolloid-like 1 (mTLL-1) are shown to have low but detectable levels of probiglycan-cleaving activity. Comparison shows that wild type mouse embryo fibroblasts (MEFs) produce only fully processed biglycan, whereas MEFs derived from embryos homozygous null for the Bmp1 gene, which encodes both BMP-1 and mammalian Tolloid, produce predominantly unprocessed probiglycan, and MEFs homozygous null for both the Bmp1 gene and the mTLL-1 gene Tll1 produce only unprocessed probiglycan. Thus, all detectable probiglycan-processing activity in MEFs is accounted for by the products of these two genes.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Shriners Hosp Children, Joint Dis Lab, Montreal, PQ H3G 1A6, Canada; Shriners Hosp Children, Genet Unit, Montreal, PQ H3G 1A6, Canada; McGill Univ, Dept Surg, Montreal, PQ H3G 1A6, Canada	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; McGill University; McGill University; McGill University	Greenspan, DS (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA.	dsgreens@facstaff.wisc.edu	Imamura, Yasutada/AAI-3078-2020	Greenspan, Daniel/0000-0001-8096-7446; Imamura, Yasutada/0000-0001-6264-1709; Pappano, William/0000-0003-2848-2219	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043621] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR43621] Funding Source: Medline; NIGMS NIH HHS [GM46846] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON SR, 1992, BIOCHIM BIOPHYS ACTA, V1132, P225, DOI 10.1016/0167-4781(92)90019-V; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; Blader P, 1997, SCIENCE, V278, P1937, DOI 10.1126/science.278.5345.1937; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; CHOI HU, 1989, J BIOL CHEM, V264, P2876; Clark TG, 1999, DEVELOPMENT, V126, P2631; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; DREHER KL, 1990, EUR J CELL BIOL, V53, P296; FISHER LW, 1987, J BIOL CHEM, V262, P9702; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hocking AM, 1996, J BIOL CHEM, V271, P19571, DOI 10.1074/jbc.271.32.19571; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; LI W, 1992, ARCH BIOCHEM BIOPHYS, V296, P190, DOI 10.1016/0003-9861(92)90562-B; MORRIS NP, 1975, J BIOL CHEM, V250, P5719; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; ROUGHLEY PJ, 1989, BIOCHEM J, V262, P823, DOI 10.1042/bj2620823; Roughley PJ, 1996, BIOCHEM J, V318, P779, DOI 10.1042/bj3180779; SAWHNEY RS, 1991, J BIOL CHEM, V266, P9231; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; SCOTT JE, 1981, BIOCHEM J, V197, P213, DOI 10.1042/bj1970213; Suzuki N, 1996, DEVELOPMENT, V122, P3587; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; TOROK MA, 1993, BIOCHIM BIOPHYS ACTA, V1173, P81, DOI 10.1016/0167-4781(93)90247-B; UITTO J, 1976, BIOCHEM BIOPH RES CO, V71, P60, DOI 10.1016/0006-291X(76)90249-7; WEGROWSKI Y, 1995, GENOMICS, V30, P8, DOI 10.1006/geno.1995.0002; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YEO TK, 1995, J VASC RES, V32, P175, DOI 10.1159/000159091; ZHAN Q, 1995, INVEST OPHTH VIS SCI, V36, P206	50	117	129	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30504	30511		10.1074/jbc.M004846200	http://dx.doi.org/10.1074/jbc.M004846200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10896944	hybrid			2022-12-25	WOS:000089577900080
J	Deguchi, M; Iizuka, T; Hata, Y; Nishimura, W; Hirao, K; Yao, I; Kawabe, H; Takai, Y				Deguchi, M; Iizuka, T; Hata, Y; Nishimura, W; Hirao, K; Yao, I; Kawabe, H; Takai, Y			Papin - A novel multiple PSD-95/Dlg-A/ZO-1 protein interacting with neural plakophilin-related armadillo repeat protein/delta-catenin and p0071	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; JUNCTION-ASSOCIATED PROTEIN; TYROSINE KINASE SUBSTRATE; DOMAIN-CONTAINING PROTEIN; BETA-CATENIN; POSTSYNAPTIC DENSITY; DESMOSOMAL PLAQUE; MULTIGENE FAMILY; BAND-6 PROTEIN; DELTA-CATENIN	A neural plakophilin-related armadillo repeat protein (NPRAP)/delta-catenin interacts with one of Alzheimer disease-related gene products, presenilin 1. We have previously reported the interaction of NPRAP/delta-catenin with synaptic scaffolding molecule, which is involved in the assembly of synaptic components. NPRAP/delta-catenin also interacts with E-cadherin and beta-catenin and is implicated in the organization of cell-cell junctions. p0071, a ubiquitous isoform of NPRAP/delta-catenin, is localized at desmosomes in HeLa and A431 cells and at adherens junctions in Madin-Darby bovine kidney cells. We have identified here a novel protein interacting with NPRAP/ delta-catenin and p0071 and named this protein plakophilin-related armadillo repeat protein-interacting PSD-95/ Dlg-A/ZO-1 (PDZ) protein (PAPIN). PAPIN has six PDZ domains and binds to NPRAP/delta-catenin and p0071 via the second PDZ domain. PAPIN and p0071 are ubiquitously expressed in various tissues and are localized at cell-cell junctions in normal rat kidney cells and bronchial epithelial cells. PAPIN may be a scaffolding protein connecting components of epithelial junctions with p0071.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, Exploratory Res Adv Technol, Takai Biotimer Project, Kobe, Hyogo 6512241, Japan; Tokyo Med & Dent Univ, Dept Med Biochem, Bunkyo Ku, Tokyo 1138519, Japan	Osaka University; Japan Science & Technology Agency (JST); Tokyo Medical & Dental University (TMDU)	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Kawabe, Hiroshi/U-7325-2018; Nishimura, Wataru/R-9215-2019	Nishimura, Wataru/0000-0002-8068-1277; Kawabe, Hiroshi/0000-0001-5650-8696				Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Hata Y, 1998, NEUROSCI RES, V32, P1, DOI 10.1016/S0168-0102(98)00069-8; Hata Y, 1996, J NEUROSCI, V16, P2488; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; HATZFELD M, 1994, J CELL SCI, V107, P2259; Hatzfeld M, 1996, J CELL SCI, V109, P2767; HEID HW, 1994, DIFFERENTIATION, V58, P113; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Ide N, 1999, BIOCHEM BIOPH RES CO, V256, P456, DOI 10.1006/bbrc.1999.0364; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Kurschner C, 1998, MOL CELL NEUROSCI, V11, P161, DOI 10.1006/mcne.1998.0679; Levesque G, 1999, J NEUROCHEM, V72, P999, DOI 10.1046/j.1471-4159.1999.0720999.x; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Mertens C, 1996, J CELL BIOL, V135, P1009, DOI 10.1083/jcb.135.4.1009; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Paffenholz R, 1997, DIFFERENTIATION, V61, P293, DOI 10.1046/j.1432-0436.1997.6150293.x; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; Shimizu K, 1996, J BIOL CHEM, V271, P27013, DOI 10.1074/jbc.271.43.27013; Shiratsuchi T, 1998, BIOCHEM BIOPH RES CO, V247, P597, DOI 10.1006/bbrc.1998.8603; Sirotkin H, 1997, GENOMICS, V41, P75, DOI 10.1006/geno.1997.4627; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SRIVASTAVA S, 1998, NEURON, V22, P179; STADDON JM, 1995, J CELL BIOL, V130, P369, DOI 10.1083/jcb.130.2.369; Stahl B, 1999, J BIOL CHEM, V274, P9141, DOI 10.1074/jbc.274.14.9141; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tanahashi H, 1999, NEUROREPORT, V10, P563, DOI 10.1097/00001756-199902250-00022; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	48	53	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29875	29880		10.1074/jbc.M005384200	http://dx.doi.org/10.1074/jbc.M005384200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896674	hybrid			2022-12-25	WOS:000089439800094
J	Bortnick, AE; Rothblat, GH; Stoudt, G; Hoppe, KL; Royer, LJ; McNeish, J; Francone, OL				Bortnick, AE; Rothblat, GH; Stoudt, G; Hoppe, KL; Royer, LJ; McNeish, J; Francone, OL			The correlation of ATP-binding cassette 1 mRNA levels with cholesterol efflux from various cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; TANGIER-DISEASE; SULFONYLUREA RECEPTOR; ABC TRANSPORTERS; MESSENGER-RNA; LIPID EFFLUX; MACROPHAGES; GENE; FIBROBLASTS	Studies show that lipid-free apoA-I stimulates release of cholesterol and phospholipid from fibroblasts and macrophages. ATP-binding cassette 1 (ABC1) is implicated in this release and has been identified as the genetic defect in Tangier disease, evidence that ABC1 is critical to the biogenesis of high density lipoprotein. We quantified levels of ABC1 mRNA protein, and cholesterol efflux from J774 mouse macrophages rt exposure to a cAMP analog. Up-regulating ABC1 mRNA correlated to increased cholesterol efflux in a dose- and time-dependent manner, mRNA levels rose after 15 min of exposure while protein levels rose after 1 h, with increased efflux 2-4 h post-treatment. In contrast to cells from wild-type mice, peritoneal macrophages from the Abc1 -/- mouse showed a lower level of basal efflux and no increase with cAMP treatment. The stimulation of efflux exhibits specificity for apoA-I, high density lipoprotein, and other apolipoproteins as cholesterol accepters, but not for small unilamellar vesicles, bile acid micelles, or cyclodextrin, We have studied a number of cell types and found that while other cell lines express ABC1 constitutively, only J774 and elicited mouse macrophages show a substantial increase of mRNA and efflux with cAMP treatment. ApoA-I-stimulated efflux was detected from the majority of cell lines examined, independent of treatment.	Pfizer Inc, Div Cent Res, Dept Cardiovasc & Metab Dis, Groton, CT 06340 USA; Med Coll Penn & Hahnemann Univ, Dept Biochem, Philadelphia, PA 19129 USA; Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Philadelphia, PA 19104 USA	Pfizer; Drexel University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Francone, OL (corresponding author), Pfizer Inc, Div Cent Res, Dept Cardiovasc & Metab Dis, 118B-206B,Eastern Point Rd, Groton, CT 06340 USA.	omar_l_francone@groton.pfizer.com	Eckhardt, Erik/G-1567-2010; Bortnick, Anna/V-5983-2019	Hoppe, Kenneth/0000-0001-5950-6813	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07443, HL22633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; BERNARD DW, 1991, J BIOL CHEM, V266, P710; Bielicki JK, 1999, J LIPID RES, V40, P85; BIELICKI JK, 1991, BIOCHIM BIOPHYS ACTA, V1085, P7, DOI 10.1016/0005-2760(91)90225-7; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Christian AE, 1997, J LIPID RES, V38, P2264; Cole SPC, 1998, BIOESSAYS, V20, P931, DOI 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J; Demolombe S, 1996, TRENDS PHARMACOL SCI, V17, P273, DOI 10.1016/0165-6147(96)10037-7; Fournier N, 2000, ARTERIOSCL THROM VAS, V20, P1283, DOI 10.1161/01.ATV.20.5.1283; FRANCESCHINI G, 1991, ATHEROSCLEROSIS, V88, P99, DOI 10.1016/0021-9150(91)90073-C; Francis GA, 1999, BIOCHEMISTRY-US, V38, P16315, DOI 10.1021/bi991742b; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; GLOMSET JA, 1968, J LIPID RES, V9, P155; HARA H, 1991, J BIOL CHEM, V266, P3080; Hatch F T, 1968, Adv Lipid Res, V6, P1; HUANG YD, 1995, ARTERIOSCL THROM VAS, V15, P1746, DOI 10.1161/01.ATV.15.10.1746; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Jain MK, 1998, J BIOL CHEM, V273, P5993, DOI 10.1074/jbc.273.11.5993; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; Johnstone RW, 2000, TRENDS BIOCHEM SCI, V25, P1, DOI 10.1016/S0968-0004(99)01493-0; KLANSEK JJ, 1995, J LIPID RES, V36, P2261; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Kozyraki R, 1999, NAT MED, V5, P656, DOI 10.1038/9504; Kritharides L, 1998, ARTERIOSCL THROM VAS, V18, P1589, DOI 10.1161/01.ATV.18.10.1589; Lafleur RL, 1998, INFECT IMMUN, V66, P4087; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Li QQ, 1995, BBA-LIPID LIPID MET, V1259, P227, DOI 10.1016/0005-2760(95)00165-4; Li QQ, 1997, BIOCHEMISTRY-US, V36, P12045, DOI 10.1021/bi970079t; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCLOSKEY HM, 1987, BIOCHIM BIOPHYS ACTA, V921, P320, DOI 10.1016/0005-2760(87)90033-6; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; MENDEZ AJ, 1991, T ASSOC AM PHYSICIAN, V104, P48; Mendez AJ, 1997, BBA-LIPID LIPID MET, V1346, P285, DOI 10.1016/S0005-2760(97)00031-3; MENDEZ AJ, 1994, J CLIN INVEST, V94, P1698, DOI 10.1172/JCI117515; MENDEZ AJ, 1995, J BIOL CHEM, V270, P5891, DOI 10.1074/jbc.270.11.5891; Mendez AJ, 1997, J LIPID RES, V38, P1807; Oram JF, 1999, J LIPID RES, V40, P1769; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; ROTHBLAT GH, 1982, J BIOL CHEM, V257, P4775; Rothblat GH, 1999, J LIPID RES, V40, P781; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sakr SW, 1999, BBA-MOL CELL BIOL L, V1438, P85, DOI 10.1016/S1388-1981(99)00041-4; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; Tsujita M, 1996, BIOCHEMISTRY-US, V35, P13011, DOI 10.1021/bi960734h; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; von Eckardstein A, 1998, J LIPID RES, V39, P987; WALTER M, 1994, BIOCHEM BIOPH RES CO, V205, P850, DOI 10.1006/bbrc.1994.2742; YANCEY PG, 1995, BIOCHEMISTRY-US, V34, P7955, DOI 10.1021/bi00024a021	58	260	267	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28634	28640		10.1074/jbc.M003407200	http://dx.doi.org/10.1074/jbc.M003407200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893411	hybrid			2022-12-25	WOS:000089330700041
J	Odajima, J; Matsumura, I; Sonoyama, J; Daino, H; Kawasaki, A; Tanaka, H; Inohara, N; Kitamura, T; Downward, J; Nakajima, K; Hirano, T; Kanakura, Y				Odajima, J; Matsumura, I; Sonoyama, J; Daino, H; Kawasaki, A; Tanaka, H; Inohara, N; Kitamura, T; Downward, J; Nakajima, K; Hirano, T; Kanakura, Y			Fall oncogenic activities of v-Src are mediated by multiple signaling pathways - Ras as an essential mediator for cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; CYCLIN D1 PROMOTER; C-MYC EXPRESSION; HEMATOPOIETIC-CELLS; TRANSCRIPTION FACTORS; STAT3 ACTIVATION; GENE-REGULATION; LEUKEMIA-CELLS; 3T3 CELLS; TRANSFORMATION	Tyrosine kinase oncoproteins cause simultaneous activation of multiple intracellular signaling pathways. However, the precise mechanisms by which individual pathways induce oncogenesis are not well understood. We have investigated the roles of individual signaling pathways in v-Src-dependent cell growth and survival by inhibiting one particular pathway. v-Src induced constitutive activation of signal transducers and activators of transcription 3 (STAT3), phosphatidylinositol 3-kinase, and Res in murine Ba/F3 cells and led to factor-independent proliferation. Dominant-negative mutants of STAT3 (STAT3D) and phosphatidylinositol 3-kinase (Delta p85) inhibited v-Src-dependent growth by similar to 60 and similar to 40%, respectively. Moreover, dominant-negative Res (N17) induced severe apoptosis, which was accompanied by down regulation of Bcl-2 and activation of caspase-3. Although cells overexpressing Bcl-2 or caspase-3 inhibitors remained viable even when N17 was expressed, the growth was reduced by similar to 85%. During N17- and STAT3D-induced growth suppression, expression of cyclin D2, cyclin D3, c-myc, and c-fos was suppressed by N17, whereas that of cyclin D2, cyclin E, and c-myc was suppressed by STAT3D, Thus, v-Src-activated Ras and STAT3 are involved in distinct but partly overlapping transcriptional regulation of cell cycle regulatory molecules. These results suggest that the full oncogenic activity of v-Src requires simultaneous activation of multiple signalings, in which Ras is particularly required for survival.	Osaka Univ, Sch Med, Dept Hematol Oncol, Biomed Res Ctr, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Mol Oncol, Biomed Res Ctr, Suita, Osaka 5650871, Japan; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Tokyo 1080071, Japan; Imperial Canc Res Fund, London WC2A 3PX, England; Osaka City Univ, Sch Med, Dept Immunol, Abeno Ku, Osaka 5450051, Japan	Osaka University; Osaka University; University of Michigan System; University of Michigan; University of Tokyo; Cancer Research UK; Osaka Metropolitan University	Matsumura, I (corresponding author), Osaka Univ, Sch Med, Dept Hematol Oncol, Biomed Res Ctr, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Kitamura, Toshio/AAA-2071-2021; Hirano, Toshio/C-8194-2009	Downward, Julian/0000-0002-2331-4729				Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BOS JL, 1989, CANCER RES, V49, P4682; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; CHEN SY, 1994, ONCOGENE, V9, P2691; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; GouilleuxGruart V, 1996, BLOOD, V87, P1692; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Haefner B, 1997, BIOCHEM J, V328, P649, DOI 10.1042/bj3280649; HIRAI H, 1985, BLOOD, V66, P1371; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Matsumura I, 1998, MOL CELL BIOL, V18, P4282, DOI 10.1128/MCB.18.7.4282; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WHITE MA, 1995, CELL, V80, P535; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; Zhang Q, 1996, P NATL ACAD SCI USA, V93, P9148, DOI 10.1073/pnas.93.17.9148	56	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24096	24105		10.1074/jbc.M001606200	http://dx.doi.org/10.1074/jbc.M001606200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10918073	hybrid			2022-12-25	WOS:000088564200094
J	Kumar, LVS; Rao, CM				Kumar, LVS; Rao, CM			Domain swapping in human alpha A and alpha B crystalline affects oligomerisation and enhances chaperone-like activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; SITE-DIRECTED MUTATIONS; DESMIN-RELATED MYOPATHY; MOLECULAR CHAPERONE; MISSENSE MUTATION; EXPRESSION; GENE; DISEASE; LENS; FILAMENTS	alpha A and alpha B crystalline, members of the small heat shock protein family, prevent aggregation of proteins by their chaperone-like activity. These two proteins, although very homologous, particularly in the C-terminal region, which contains the highly conserved "alpha-crystallin domain," show differences in their protective ability toward aggregation-prone target proteins. In order to investigate the differences between alpha A and alpha B crystallins, we engineered two chimeric proteins, alpha ANBC and alpha BNAC, by swapping the N-terminal domains of alpha A and alpha B crystallins. The chimeras were cloned and expressed in Escherichia coli, The purified recombinant wild-type and chimeric proteins were characterized by fluorescence and circular dichroism spectroscopy and gel permeation chromatography to study the changes in secondary, tertiary, and quaternary structure. Circular dichroism studies show structural changes in the chimeric proteins, alpha BNAC binds more 8-anilinonaphthalene-1-sulfonic acid than the alpha ANBC and the wild-type proteins, indicating increased accessible hydrophobic regions. The oligomeric state of alpha ANBC is comparable to wild-type alpha B homoaggregate. However, there is a large increase in the oligomer size of the alpha BNAC chimera. Interestingly, swapping domains results in complete loss of chaperone-like activity of alpha ANBC, whereas alpha BNAC shows severalfold increase in its protective ability. Our findings show the importance of the N- and C-terminal domains of alpha A and alpha B crystallins in subunit oligomerization and chaperone-like activity. Domain swapping results in an engineered protein with significantly enhanced chaperone-like activity.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Rao, CM (corresponding author), Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India.	mohan@ccmb.ap.nic.in						Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; BENNARDINI F, 1992, CIRC RES, V71, P288, DOI 10.1161/01.RES.71.2.288; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Datta SA, 1999, J BIOL CHEM, V274, P34773, DOI 10.1074/jbc.274.49.34773; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; DEJONG WW, 1988, J BIOL CHEM, V263, P5141; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; Der Perng M, 1999, J BIOL CHEM, V274, P33235, DOI 10.1074/jbc.274.47.33235; Derham BK, 1999, PROG RETIN EYE RES, V18, P463, DOI 10.1016/S1350-9462(98)00030-5; Djabali K, 1997, J CELL SCI, V110, P2759; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; Kumar LVS, 1999, J BIOL CHEM, V274, P24137, DOI 10.1074/jbc.274.34.24137; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; Muchowski PJ, 1999, J MOL BIOL, V289, P397, DOI 10.1006/jmbi.1999.2759; NGO JT, 1989, GENOMICS, V5, P665, DOI 10.1016/0888-7543(89)90106-7; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; QUAXJEUKEN Y, 2000, P NATL ACAD SCI USA, V39, P1420; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RAMAN B, 1994, J BIOL CHEM, V269, P27264; RENKAWEK K, 1992, ACTA NEUROPATHOL, V83, P324, DOI 10.1007/BF00296796; Renkawek K, 1999, NEUROREPORT, V10, P2273, DOI 10.1097/00001756-199908020-00009; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P155, DOI 10.1007/BF00296185; SCOTTING P, 1991, FEBS LETT, V285, P75, DOI 10.1016/0014-5793(91)80728-L; Shroff NP, 2000, BIOCHEMISTRY-US, V39, P1420, DOI 10.1021/bi991656b; Smulders RHPH, 1998, INT J BIOL MACROMOL, V22, P187, DOI 10.1016/S0141-8130(98)00016-6; SMULDERS RHPH, 1995, EUR J BIOCHEM, V232, P834, DOI 10.1111/j.1432-1033.1995.834zz.x; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9	38	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22009	22013		10.1074/jbc.M003307200	http://dx.doi.org/10.1074/jbc.M003307200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10896951	hybrid			2022-12-25	WOS:000088363800037
J	Hakak, Y; Hsu, YS; Martin, GS				Hakak, Y; Hsu, YS; Martin, GS			Shp-2 mediates v-Src-induced morphological changes and activation of the anti-apoptotic protein kinase Akt	ONCOGENE			English	Article						shp-2; src; akt; cbl; transformation; apoptosis	TYROSINE-PHOSPHATASE SHP-2; PHOSPHATIDYLINOSITOL 3'-KINASE; PHOSPHOTYROSINE PHOSPHATASE; TRANSFORMED FIBROBLASTS; PROTOONCOGENE PRODUCT; FOCAL ADHESION; P85 SUBUNIT; RAS; 3-KINASE; CELL	The protein-tyrosine phosphatase Shp-2 is a positive modulator of the Ras/mitogen-activated protein kinase pathway and a putative substrate of the transforming non-receptor tyrosine kinase v-Src, To characterize the role of Shp-2 in cellular transformation and signaling by v-Src, we expressed v-Src in normal and Shp-2-deficient mouse embryo fibroblasts. Expression of Shp-2 was found to be necessary for morphological transformation by v-Src: Shp-2+/+ cells became rounded or spindly upon v-Src expression, whereas Shp-2-deficient cells remained relatively hat, v-Src-induced reorganization of the actin cytoskeleton and the formation of podosomes were compromised in Shp-2-deficient cells. Shp-2 deficiency also reduced v-Src-induced activation of the anti-apoptotic protein kinase Akt. The reduced activation of Akt in Shp-2-deficient cells correlated with a reduction in the association of the p85 regulatory subunit of PI3-kinase with the adapter protein Chl. Activation of PI3-kinase by v-Src may be mediated by the association of the adapter protein Cbl with the p85 subunit, Since activation of Akt is dependent on PI3-kinase, this suggests that the effect of Shp-2 on Akt activation may be mediated, at least in part, by its effects on the interaction between Pw-kinase and Chi, The defect in activation of the Akt survival pathway also correlated with enhanced sensitivity of Shp-2-deficient cells to an apoptosis-inducing agent. These results implicate Shp-2 in v-Src-induced cytoskeletal reorganization and activation of the Akt cell survival pathway.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Cell & Dev Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Martin, GS (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Cell & Dev Biol, 401 Barker Hall 3204, Berkeley, CA 94720 USA.				NCI NIH HHS [CA17542] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA017542, R37CA017542] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DombroskyFerlan PM, 1997, ONCOGENE, V14, P2019, DOI 10.1038/sj.onc.1201031; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fincham VJ, 1999, J CELL SCI, V112, P947; FRAME MC, 1994, MOL BIOL CELL, V5, P1177, DOI 10.1091/mbc.5.11.1177; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; HIRAGA A, 1992, EUR J BIOCHEM, V209, P195, DOI 10.1111/j.1432-1033.1992.tb17277.x; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Maegawa H, 1999, J BIOL CHEM, V274, P30236, DOI 10.1074/jbc.274.42.30236; Manes S, 1999, MOL CELL BIOL, V19, P3125; Mayer T, 1999, ONCOGENE, V18, P2117, DOI 10.1038/sj.onc.1202537; Oh ES, 1999, MOL CELL BIOL, V19, P3205; PENG ZY, 1995, ONCOGENE, V11, P1955; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Saxton TM, 1999, P NATL ACAD SCI USA, V96, P3790, DOI 10.1073/pnas.96.7.3790; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	67	68	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3164	3171		10.1038/sj.onc.1203655	http://dx.doi.org/10.1038/sj.onc.1203655			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918571				2022-12-25	WOS:000088019200005
